<SEC-DOCUMENT>0001193125-14-027049.txt : 20140130
<SEC-HEADER>0001193125-14-027049.hdr.sgml : 20140130
<ACCEPTANCE-DATETIME>20140129215027
ACCESSION NUMBER:		0001193125-14-027049
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20140130
DATE AS OF CHANGE:		20140129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-193648
		FILM NUMBER:		14558637

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d662896ds1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>FORM S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As filed with the Securities and Exchange Commission on January&nbsp;30, 2014
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Registration Statement No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM S-1
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:2px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Its Charter) </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1591613</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code and telephone number, including area code, of registrant&#146;s principal executive offices)
</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Scott Koenig, M.D., Ph.D. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>President and Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and telephone number,
including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Richard E. Baltz</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold &amp; Porter LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>555 12<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT> Street NW</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Washington, DC 20004-1206</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(202) 942-5000</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Steven D. Singer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lisa Firenze</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 World Trade Center</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY 10007</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(212) 230-8000</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the public: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">As soon as practicable after this Registration Statement becomes effective. </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1">(Check one): </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CALCULATION OF REGISTRATION
FEE </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of Each Class of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Securities to be Registered</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to be<BR>Registered(1)</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount&nbsp;of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Registration&nbsp;Fee(2)</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Common Stock, $0.01 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">$90,000,000</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">$11,592</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock the underwriters have the option to purchase. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Calculated pursuant to Rule&nbsp;457(o) under the Securities Act based on an estimate of the proposed maximum aggregate offering price. </FONT></TD></TR></TABLE>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically
states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#cc062a">The information in this preliminary prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these
securities in any state where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registration File No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>PRELIMINARY PROSPECTUS </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g97j81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are selling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The selling stockholders identified in
this prospectus are offering an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. We will not receive any of the proceeds from the sale of the shares being offering by the selling stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#147;MGNX&#148;. On February &nbsp;&nbsp;&nbsp;&nbsp; ,
2014 the last sale price of our common stock was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our common stock involves risks that are described in the &#147;<A HREF="#toc662896_2">Risk&nbsp;Factors</A>&#148;
section beginning on page&nbsp;11 of this prospectus. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:18pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds before expenses, to the selling stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;margin-left:8%;border-bottom:0.5pt solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We refer you to &#147;Underwriting&#148; beginning on page 154 of this prospectus for additional information regarding total underwriter compensation.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also exercise their option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from the selling stockholders, for 30 days after the date of this prospectus.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares will be ready for delivery on or about February &nbsp;&nbsp;&nbsp;&nbsp;, 2014. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Leerink&nbsp;Partners</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="98%"></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Stifel</B></FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Wedbush&nbsp;PacGrow&nbsp;Life&nbsp;Sciences</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Roth&nbsp;Capital&nbsp;Partners</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of
this prospectus is February &nbsp;&nbsp;&nbsp;&nbsp;, 2014. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_3">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_4">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_5">Market Price of Our Common Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_6">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_9">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_12">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_13">Certain Relationships and Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_14">Principal and Selling Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_15">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_16">Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_17">Material U.S. Federal Tax Consequences for Non-U.S. Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_18">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_19">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_20">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_21">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc662896_22">Index to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not authorized anyone to provide you with information other than that contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. We
are offering to sell shares of our common stock, and seeking offers to buy shares of our common stock, only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the
underwriters have taken any action to permit a public offering of the shares of our common stock or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. You
are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information and consolidated financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the following summary together with
the entire prospectus, including our consolidated financial statements and the notes thereto appearing elsewhere in this prospectus and the matters discussed in the sections in this prospectus entitled &#147;Risk Factors,&#148; &#147;Selected
Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before deciding to invest in our common stock. Some of the statements in this prospectus constitute
forward-looking statements that involve risks and uncertainties. See &#147;Special Note Regarding Forward-Looking Statements.&#148; Our actual results could differ materially from those anticipated in such forward-looking statements as a result of
certain factors, including those discussed in the &#147;Risk Factors&#148; and other sections of this prospectus. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &#147;MacroGenics&#148;
&#147;the company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MacroGenics, Inc. and its consolidated subsidiaries. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. Some of these product candidates include therapeutics in the emerging field of immune oncology and are designed to
promote tumor destruction by either enhancing or restoring the body&#146;s immune system to destroy cancers. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148; which are drugs
designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with global
pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms that can be applied in combination with one another to custom design an
antibody or antibody-derived molecule that is optimized to treat a specific disease. These technologies are described below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <I>Dual Affinity Re-Targeting, or DART, platform</I> enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure,
and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells. We have created over 100 DART-based molecules, or DARTs, which we believe improve upon the human immune system and have more potent immune
properties than the parent antibody molecules from which they are derived. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Fc Optimization platform</I> enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular
cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells. To date, we have successfully incorporated our Fc Optimization technology into our two lead oncology product candidates and have
pre-clinical data demonstrating that these antibodies have substantially greater ability to kill cancer cells than similar antibodies that have not been Fc-optimized. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Cancer Stem-like Cell, or CSLC, platform</I> provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the
differentiated cancer cells derived from them. Using this platform, we can create antibodies or antibody-derived molecules that specifically target and destroy CSLCs, potentially enabling us to address the large, unmet medical needs of many cancers
that are difficult to treat. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We utilize one or more of our technology platforms for engineering and optimizing
our antibody and antibody-derived product candidates. Many of our cancer product candidates are derived from our library of over 2,000 purified antibodies. We believe our approach allows us to take advantage of the enhanced properties of an
engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune disorders more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness of antibodies
include the following: enhancing the body&#146;s immune system; targeting multiple antigens on the surface of the same target cell; increasing the strength of the binding of an antibody to its antigen targets; and reducing the likelihood of an
unwanted immune response to the antibody or antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases and to improve
clinical outcomes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into strategic collaborations with Les Laboratoires Servier and Institut de Recherches
Servier, or collectively, Servier, Gilead Sciences, Inc., or Gilead, Boehringer Ingelheim International GmbH, or Boehringer, and Pfizer, Inc., or Pfizer, among others. Under our current strategic collaborations, we have received approximately
$106&nbsp;million in non-equity funding during the three year period ended June&nbsp;30, 2013. Under these agreements, we believe we are likely to receive over $100&nbsp;million of milestone and other payments subsequent to June 30, 2013 and by the
end of 2015, assuming all of our collaboration programs advance as currently contemplated. Between June&nbsp;30, 2013 and December&nbsp;31, 2013, we received a total of $22&nbsp;million from our collaboration partners. As of December&nbsp;31, 2013,
we had $116.9 million in cash and cash equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Product Candidates </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. We also have several proprietary product candidates in
pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. In addition, we intend to use a portion of the net proceeds from this offering to advance two pre-clinical DART-based oncology
product candidates to IND submission and commence Phase 1 clinical trials in 2015. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination therapy, depending on disease characteristics,
current standards of care, and overall safety, tolerability and efficacy of specific regimens. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g97i90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2 positive, or HER2+, patient populations than those treated with current HER2 therapies, as
well as improve the outcomes for patients who would be eligible for other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American
Society of Clinical Oncology, or ASCO, and the November 2013 Chemotherapy Foundation Symposium demonstrated that anti-tumor activity had been observed at a range of doses tested, including the lowest dose level, even in patients who were heavily
pre-treated (frequently including with other anti-HER2 agents). We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and we plan to commence a Phase&nbsp;3 potential registration clinical trial in advanced
gastroesophageal cancer in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on T&nbsp;cells. We have engineered MGA271 to utilize the same Fc Optimization enhancements that we
incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumor cells and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is designed to destroy all of these components of the
cancer in addition to reducing its inhibitory properties on T cells. We expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional expansion cohorts using MGA271 as
monotherapy in other tumor types in 2014, as well as combining MGA271 with other therapies for certain tumor types. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. MGD006 pre-clinical data was presented at the 2013 Annual Meeting of the American Society of Hematology, or ASH. We expect to commence a Phase 1 clinical trial in the second quarter of 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial in
the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Collaborations </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our product candidates and technology platforms, including: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment, and may be
eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for, and successfully commercializes
MGA271. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to
obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada,
Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if
Servier exercises all three of its options and successfully develops, obtains regulatory approval for and commercializes a product under each license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead for the research, development and commercialization of up to four DART-based
molecules. The time period for Gilead&#146;s exercise </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining
programs. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive an additional $7.5 million in grant fees for each of the remaining two DART-based molecules if any are selected by Gilead.
We are further eligible to receive additional pre-clinical, clinical, regulatory and sales milestones and royalty payments. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received three annual maintenance payments, including a $4&nbsp;million
payment received in the fourth quarter of 2013. Also in the fourth quarter of 2013, Boehringer&#146;s selection of a development candidate triggered a $5&nbsp;million milestone payment to us under the agreement. We have the potential to earn
development, regulatory and sales milestones and royalty payments for each of the DART programs under this agreement. Boehringer provides funding for our internal and external research costs under the agreement. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestones and royalty payments for each DART program under this agreement. Under this collaboration, one DART program is currently being pursued and completed our research obligations under this program in January 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and commercialization of antibody-based therapeutics for the treatment of patients with cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a
Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect to have results in late 2014. We plan to commence a Phase&nbsp;3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the
second half of 2014. We are currently enrolling three dose-expansion cohorts in a Phase 1 clinical trial of MGA271 as a single-agent in the treatment of 45&nbsp;patients with solid tumors. In addition, we are currently optimizing multiple DART
therapeutics as candidates for clinical development. We anticipate that we will begin Phase&nbsp;1 clinical trials of MGD006, our first DART candidate, in the second quarter of 2014, and MGD007, our second DART candidate, in the second half of 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and
access to the development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
enter into additional collaboration agreements with biopharmaceutical companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and
commercialization rights in key markets. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies and our DART molecules. Our goal is to identify and further develop new clinical
product candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates, through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We currently manufacture the drug substance for all of our product
candidates at our manufacturing facility, which we intend to expand in order to increase our production capacity. We intend to build on our technology platforms, methods and know-how that together comprise our capabilities in order to expand our
product pipeline. Our goal is to file one or more new investigational new drug applications, or INDs, annually for the next several years. With the net proceeds from this offering, we intend to advance two previously undisclosed oncology DART-based
product candidates to IND submission and to initiate clinical testing in 2015. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Factors </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves substantial risk. You should carefully consider all of the information in this prospectus prior to
investing in our common stock. There are numerous risk factors related to our business that are described under &#147;Risk Factors&#148; and elsewhere in this prospectus. Among these important risks are the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our clinical trials may not be successful, and clinical results may not reflect results seen in previously conducted pre-clinical studies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not have adequate funding to complete development in some areas, and may be unable to access additional capital on reasonable terms or at all to
complete development and begin commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our current or future collaborators may not adequately support development in designated areas, or they may elect to change their strategic or business
priorities, and these changes may have an adverse impact on us, our development plans, or our business; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter unexpected regulatory changes that delay or impede our development and commercialization efforts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to obtain adequate protection for the intellectual property covering our product candidates or develop and commercialize our product
candidates without infringing on the intellectual property rights of third parties; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product reimbursement may be challenging for us due to recent and proposed changes in healthcare law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter manufacturing and distribution challenges; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to recruit or retain well qualified personnel who are necessary for us to conduct our business. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Corporate Information </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of the state of Delaware in 2000 under the name MacroGenics, Inc. Our principal executive offices are located at 9640 Medical Center Drive, Rockville, Maryland 20850
and our telephone number is (301)&nbsp;251-5172. Our website address is www.macrogenics.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">DART<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the phrase &#147;Breakthrough Biologics, Life-Changing Medicines&#148; and the MacroGenics logo are our registered trademarks. The other trademarks, trade names and
service marks appearing in this prospectus are the property of their respective owners. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by the selling stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares by us</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares by the selling stockholders</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock to be outstanding after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds of this offering to fund approximately $10 to $15&nbsp;million of additional clinical development expenses for MGA271, including additional
Phase 1b dose expansion cohorts as monotherapy as well as in combination with other therapies; approximately $20 to $30&nbsp;million to fund research and development expenses for two additional, previously undisclosed, oncology product candidates
based on our DART technology; approximately $5 to $10&nbsp;million to expand our manufacturing facility, which should enable us to increase our production capacity; and the remainder for working capital and general corporate purposes, which may
include other research and development programs, in-licensing or acquiring other products or technologies. We will not receive any of the proceeds from the sale of shares offered by the selling stockholders. See &#147;Use of
Proceeds.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider carefully before investing in shares of our
common stock.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Select Market symbol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;MGNX&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock to be outstanding after this offering is based on 25,188,987
shares of our common stock outstanding as of December&nbsp;31, 2013 and excludes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,208,199 shares of common stock issuable upon the exercise of outstanding options to issue common stock, as of December&nbsp;31, 2013, at a weighted
average exercise price of $5.04 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,395,218 shares of common stock reserved for future grant or issuance under our stock option plans, as of December&nbsp;31, 2013.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus reflects and assumes: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise by the underwriters of their option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock from us and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from the selling stockholders. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial data for the periods presented and should be read together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes appearing elsewhere in this prospectus. The consolidated statements of operations and
comprehensive income (loss) data for the years ended December&nbsp;31, 2011 and 2012 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following
summary consolidated statements of operations and comprehensive income (loss) data for the nine months ended September&nbsp;30, 2012 and 2013 and the balance sheet data as of September&nbsp;30, 2013 have been derived from our unaudited consolidated
financial statements and footnotes included elsewhere in this prospectus. We have prepared the unaudited consolidated financial statements on the same basis as the audited consolidated financial statements and have included all adjustments,
consisting only of normal recurring adjustments, which in our opinion are necessary to state fairly the financial information set forth in those statements. Our historical results are not necessarily indicative of the results we expect in the
future, and our interim results should not necessarily be considered indicative of results we expect for the full year. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:119pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,025,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,083,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,463,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,025,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,083,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,412,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,908,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,039,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,419,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,473,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,328,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma basic and diluted net income (loss) per share reflects the automatic conversion of all outstanding shares of our preferred stock upon the
closing of our IPO, assuming all such shares of preferred stock had been converted to common stock for all periods in which such shares of preferred stock were outstanding. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:22pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:49pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;adjusted(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;As adjusted&#148; consolidated balance sheet data give additional effect to the automatic conversion of all outstanding shares of preferred stock into an
aggregate of 16,955,790 shares of common stock upon the closing of our IPO and the net share exercise of Series D-2 preferred stock warrants into an aggregate of 116,270&nbsp;shares of common stock and the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting the underwriting discounts and commissions
and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the following risk factors, as well as the
other information in this prospectus, before you decide to purchase our common stock. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our
common stock could decline and you may lose all or part of your investment.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business and the Development and
Commercialization of Our Product Candidates. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical
drug development is expensive, time consuming and uncertain and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive
regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries
until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to
the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to
obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after
product approval, if any, subject our company to administrative or judicially imposed sanctions, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the products, manufacturers or manufacturing process; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">civil and criminal penalties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizures, detentions or import bans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voluntary or mandatory product recalls and publicity requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">total or partial suspension of production; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">imposition of restrictions on operations, including costly new manufacturing requirements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to approve pending BLAs or supplements to approved BLAs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of pre-clinical
studies and clinical trials that will be required for regulatory approval varies </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory
agencies can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a product candidate may not be deemed safe or effective; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may change their approval policies or adopt new regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the
particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses
for which we may market the product. These limitations may limit the size of the market for the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If clinical trials for our
product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product
revenue. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently enrolling a Phase 2a clinical trial of margetuximab in patients with metastatic breast
cancer and anticipate commencing a Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We have initiated a Phase 1 clinical trial of MGA271 that we expect to complete by the
end of 2014. We expect to commence a Phase 1 clinical trial of MGD006 in the first half of 2014 and expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. The commencement of these planned clinical trials could be
substantially delayed or prevented by several factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial
programs, including some that may be for the same indication as our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to obtain sufficient funds required for a clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical
research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The completion of our clinical trials could also be substantially delayed or prevented by
several factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">slower than expected rates of patient recruitment and enrollment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of patients to complete the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of efficacy during clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of our clinical trials by one or more clinical trial sites; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend
clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing
or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to
that site, or us, due to a number of factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for
the clinical development of any of our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or significant delay in completing
clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not
satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no products approved for
sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future
collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient
safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer
significant setbacks in subsequent registration clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not
necessarily predict final results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising
results in earlier clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the design of a clinical trial can determine whether its results will
support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We
do not know whether any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials
or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials. In addition, any of these regulatory authorities may change
requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other agencies&#146; approval. In addition, any
of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S.
regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our products in development are based on new technologies, such as Fc Optimization, bi-specific DARTs and CSLCs. Given the complexity of
our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. It is possible that the
validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory
approval path and requirements may not be clear, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the products that we develop would adversely affect our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress these
product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at&nbsp;various cancers
and autoimmune disorders, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical
development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face
difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there
is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have limited financial and managerial resources, we focus on research
programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications
may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize
their full market potential. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to market any products outside of the United States, we must establish and
comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one
country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign
regulatory approvals could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country
to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to
obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and
we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our
ability to realize the full market potential of our products will be harmed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may seek fast-track designation of margetuximab and may
seek fast track designation for some of our other product candidates. There is no assurance that the FDA will grant such designation and, even if it does grant fast track designation to margetuximab or one of our other product candidates, that
designation may not actually lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek fast-track designation of margetuximab and may seek fast track designation and review for some of our other product
candidates. If a drug is intended for the treatment of a serious or life-threatening condition or disease, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if
we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Moreover, even if we do receive fast </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it
believes that the designation is no longer supported by data from our clinical development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may seek breakthrough therapy
designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates
will receive marketing approval in the United States. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may apply for breakthrough therapy designation for some of
our product candidates. The FDA is authorized to designate a product candidate as a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease
or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
clinical development. For products designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of
patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA are also eligible for accelerated approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the
FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product
candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later
decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain orphan product designation or exclusivity for some or all of our product candidates. If our competitors are able to obtain orphan product exclusivity for their products
that are the same as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000
individuals annually in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, if a product candidate with an orphan drug designation subsequently
receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency, or EMA, or the FDA from approving another
marketing application for the same drug for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria
for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. In the
United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a
major contribution to patient care. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our product candidates may have undesirable side effects which may delay or prevent marketing
approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product
candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or pre-clinical development. While our clinical
trials for our initial product candidates to date have demonstrated a favorable safety profile, the results from future trials may not support this conclusion. The results of future clinical trials may show that our product candidates cause
undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the
FDA and other regulatory authorities with restrictive label warnings or potential product liability claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our
product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require us to take our approved product off the market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote the product; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the product may decrease significantly; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to litigation or product liability claims; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community, and third-party payors our revenue generated from their
sales will be limited. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commercial success of our product candidates will depend upon their acceptance among
physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations or warnings contained in the approved labeling for a product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the standard of care for the targeted indications for any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations in the approved clinical indications for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">demonstrated clinical safety and efficacy compared to other products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of significant adverse side effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales, marketing and distribution support; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability and extent of reimbursement from managed care plans and other third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of market introduction and perceived effectiveness of competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the degree of cost-effectiveness of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular
diseases; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse publicity about our product candidates or favorable publicity about competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">convenience and ease of administration of our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential product liability claims. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these
products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing our products is complex, highly regulated and subject to several risks, including:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing biologics, such as margetuximab, MGA271, and our other product candidates, is extremely susceptible to product loss due to
contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the
manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural
disasters, power failures and numerous other factors. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving
quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product
candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and
commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing
applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product
candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory
compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no marketing,
sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization.
If any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function
to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is
sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our
products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to certain of our existing and future product candidates, we have entered into collaboration or other
licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly
marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable
to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations
with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face
significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing
therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently
be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research
institutions. Many </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have
extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also
have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to
accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection
and/or FDA approval or discovering, developing and commercializing products in our field before we do. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specifically, there
are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as
biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single
recombinant molecule. Amgen, Inc., or Amgen, is in late-stage clinical development of cancer product candidates which work by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells. In addition, other
companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche Ltd., or Roche, and Xencor, Inc. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain
approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking
to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even if our product candidates achieve
marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, or collectively, ACA created a new regulatory scheme authorizing the FDA to
approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a previously approved biological product or &#147;reference
product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years following approval of the reference product. The FDA may not approve a biosimilar product until 12 years from
the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such
product containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. Furthermore, recent legislation has proposed that the 12 year
exclusivity period for each a reference product may be reduced to seven years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller and other early stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid
technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete,
less competitive or not economical. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market
acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by
future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot be certain that
reimbursement will be available for any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a
limited basis, we may not be able to successfully commercialize any of our approved products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which
expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based
on average sales prices for physician-administered drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and several foreign jurisdictions are
considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in
the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to
the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In March 2010, the ACA became law in the United States. The goal of ACA is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private
insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively
affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. We also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the
promulgation of detailed regulations implementing the statutory provisions, which has not yet occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If any product liability
lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and
will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials,
patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or
eventual outcome, liability claims may result in: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for our future approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of clinical trial sites or entire trial programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">increased regulatory scrutiny; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant litigation costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to or costly settlement with patients or other claimants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product recalls or a change in the indications for which they may be used; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of management and scientific resources from our business operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to commercialize our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if
we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer
perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our
financial condition or results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently hold $15 million in product liability insurance coverage in the
aggregate, with a per incident limit of $15 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance
coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product
liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and
collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing regulatory requirements for drug approvals in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with non-U.S. laws and regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. currency exchange rates and currency controls; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing foreign operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods
and fires. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no
products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of September&nbsp;30, 2013, our accumulated deficit was approximately $172.5&nbsp;million. We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize
any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and
likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to
accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA, to perform trials in addition to those that we currently
expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities
for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never
succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our
failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also
cause you to lose all or part of your investment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional funding, which may not be available to us on acceptable terms,
or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical studies and clinical trials, is expensive. In order to obtain
such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond this contemplated offering to complete the development and
commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our liquidity
requirements, based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and cash equivalents and a significant portion of the $100&nbsp;million in collaboration payments we
anticipate receiving through 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007, MGD010 and two additional oncology product candidates based on our DART technology through 2015, assuming all of our
collaboration programs advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our
product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future funding requirements will depend on many factors, including but not limited to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and characteristics of other product candidates that we pursue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be
required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need and ability to hire additional management, scientific, and medical personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing products that may limit market penetration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which
we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or
private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale
back or eliminate one or more of our development programs or our business operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common
stock in this offering, restrict our operations or require us to relinquish substantial rights. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that we
raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a
common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring
dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant
licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back
or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering, and from our initial public offering and may not use them effectively. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management has broad discretion to use our cash and cash equivalents to fund our operations and could spend these funds in ways that
do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the
price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited
further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code. The limitations apply if an ownership change, as defined by Section&nbsp;382, occurs. Generally, an ownership change occurs when
certain stockholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to
Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of $64.2 million and research and development tax credit carryforwards of
$21.8 million available. Future changes in stock ownership, may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit
carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax
credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Dependence on Third Parties </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our existing therapeutic
collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or
distribution. Accordingly, we have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Servier, Gilead, Boehringer, Pfizer and Green Cross Corp., or
Green Cross. These collaborations also have provided us with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic
collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not perform their obligations as expected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue
or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing
priorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products,
which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such product or products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of
which would be time-consuming and expensive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue
further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements with Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified
notice period. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our therapeutic collaborations do not result in the successful development and
commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
under these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology
platforms. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our program collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the
collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and
biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among
other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. These factors may include the design
or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such
product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and
industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborations are complex and time-consuming to negotiate and document. In
addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable
collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope
of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to
obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential
collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with
third parties for specified periods of time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials
may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect
to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have
the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs
will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote
sufficient resources to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we
develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we
comply with standards, commonly referred to as current Good Clinical Practice, or cGCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and
confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our product candidates and harm our
business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure of our third party contractors to successfully develop and commercialize companion diagnostics for use with our
product candidates could harm our ability to commercialize our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to develop companion
diagnostics for our product candidates, where appropriate. Companion diagnostics are used to identify patients who could potentially benefit from our therapeutic product candidates. We expect that, at least in some cases, the FDA and similar
regulatory authorities outside the United States may require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or
commercializing diagnostics and plan to rely in large part on third parties to perform these functions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to outsource
the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and
commercialize these companion diagnostics. Our contractors: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not perform their obligations as expected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may encounter production difficulties that could constrain the supply of the companion diagnostic; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not commit sufficient resources to the marketing and distribution of such product; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may terminate their relationship with us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third
party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate
or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical testing in the future and expect to continue to do so for commercialization. This reliance on
third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a manufacturing facility located in Rockville, Maryland. We manufacture drug substance at this
facility that we use for research and development purposes and for clinical trials of our product candidates. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our
DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such candidates. We do not have experience in manufacturing
products at commercial scale. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate engagement of contract manufacturing organizations in 2014 to supplement our
clinical supply and internal capacity as we advance pre-clinical product candidates into clinical development. We expect to use third parties for the manufacture of certain of our product candidates for clinical testing, as well as for commercial
manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to enter into long term supply agreements with several manufacturers for
commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates.
Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for
the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully
manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves,
including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement
third-party manufacturer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to
meet our manufacturing needs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these factors could cause the delay of approval or commercialization
of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required
commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any
such new source approved by the FDA or any other relevant regulatory authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Intellectual Property
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be
materially harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court
decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not
allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some
cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or
that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our
patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent
protection from our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent
protection may be of insufficient scope to achieve our business objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy depends on our ability to identify
and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all
jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not
ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may
have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek
approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of
proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to
achieve our business objectives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent position of pharmaceutical or biotechnology companies, including ours, is
generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly
and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to
the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought
in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the
United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the
breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of
the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad
to protect us against third parties with similar technologies or products, or provide us with any competitive advantage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become
involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even after they have issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If
our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive
business position, business prospects and financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are examples of litigation and other adversarial
proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment
that their product or technology does not infringe our patents or patents licensed to us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our
collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of
our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or
licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or
administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own
patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties
from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to make the inventions covered by patents or pending patent applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to file patent applications for these inventions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies that are patentable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may
have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these
patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and
enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and
results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.
Invitrogen, Inc., for example, has asserted that we are required to obtain a license for use of a cell line. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such
litigation or proceedings include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third
parties or to obtain a judgment that our products or processes do not infringe those third parties&#146; patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to
participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our
collaborators will need to defend against such proceedings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or
misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific
personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our
collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will
order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to
license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry
participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For
example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we
may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful
conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter
significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more
effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the
marketplace. Patent litigation and other proceedings may also absorb significant management time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with our
obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment,
royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements which grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271.
These licenses typically include an obligation to pay an upfront payment, yearly maintenance payments and royalties on sales. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their
respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to
negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary
information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These
agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#146;s relationship with us be kept confidential and not disclosed to third parties. Our
agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all
circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade
secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use
technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual
property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#146;s assignee. Such assignment or
license may not be available on commercially reasonable terms or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adequate remedies may not exist in the event of unauthorized use or disclosure of our
proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to
enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and
proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at
research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their
former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over
the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured
by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we
have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents
covering each of our product candidates, our business may be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depending upon the timing, duration
and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the
Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review
process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension
could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our
competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Legal Compliance Matters </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our
operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental
contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#146;
compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate
coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted
in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal
healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback statutes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for
payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed
healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and
regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to
scrutiny if they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and
services reimbursed by private insurers. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free
trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label
promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by
governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#147;fraud and abuse&#148; laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements and insider trading. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk of employee fraud or other
misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial
information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of significant fines or other sanctions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Employee Matters
and Managing Growth </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate
qualified personnel. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are highly dependent on the research and development, clinical and business development
expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment letter agreements with our executive
officers, each of them may terminate their employment with us at any time. We currently maintain $1 million in &#147;key person&#148; insurance coverage for Dr.&nbsp;Koenig. The loss of the services of our executive officers or other key employees
could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage
our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers
and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and
commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, we had 162 full-time employees. As our development and commercialization plans and strategies develop, we
expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their
attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure,
give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other
projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could
be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability
to effectively manage any future growth. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Our Common Stock and this Offering </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our stock price is likely to be volatile and the market price of our common stock after this offering may drop below the price you pay.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should consider an investment in our common stock as risky and invest only if you can withstand a significant
loss and wide fluctuations in the market value of your investment. You may be unable to sell your shares of common stock at or above the public offering price due to fluctuations in the market price of our common stock arising from changes in our
operating performance or prospects. In addition, the stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical,
biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate or decrease
below the price paid in this offering include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or discontinuation of any of our development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issues in manufacturing our product candidates or future approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146;
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition from existing products or new products that may emerge; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments or disputes concerning patents or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of technological innovations or new commercial products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or
capital commitments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in estimates or recommendations by securities analysts, if any cover our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern over our product candidates or any future approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">future sales of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the structure of health care payment systems in the United States or overseas; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of any of our product candidates, if approved, to achieve commercial success; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic and other external factors or other disasters or crises; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments
under commercialization or licensing agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions and market conditions for biopharmaceutical stocks; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overall fluctuations in U.S. equity markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of
our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>An active trading market for our common stock may not be sustained. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we closed our initial public offering, or IPO. Prior to the IPO, there was no public market for our common stock.
Although we have completed our initial public offering and shares of our common stock are listed and trading on The NASDAQ Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock
does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they
would like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our
shares as consideration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insiders have substantial control over us which could delay or prevent a change in corporate control or result
in the entrenchment of management and/or the board of directors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After this offering, our directors, executive
officers and principal stockholders, together with their affiliates and related persons, will beneficially own, in the aggregate, approximately [&nbsp;&nbsp;&nbsp;&nbsp;]% of our outstanding common stock. As a result, these stockholders, if acting
together, may have the ability to determine the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation, or sale of all or substantially all of our assets. In
addition, these persons, acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delaying, deferring, or preventing a change in control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entrenching our management and/or the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impeding a merger, consolidation, takeover, or other business combination involving us; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure requirements
applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to
delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will
be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We cannot predict whether investors will find our common stock less attractive because we will rely on these exemptions. If
some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an
&#147;emerging growth company.&#148; We could remain an &#147;emerging growth company&#148; until the earliest to occur of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to the prospectus
filed with the Securities and Exchange Commission on October&nbsp;11, 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial
time to corporate governance standards. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public company, we will incur significant legal, accounting and other
expenses that we did not incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls
and disclosure controls and procedures, retain a transfer agent and adopt an insider trading policy. As a public company, we will bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with
our obligations under the securities laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, regulations and standards relating to corporate governance and public
disclosure, including the Sarbanes-Oxley Act and related regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Select Market, have increased legal and financial compliance costs and will make some compliance
activities more time consuming. We are currently evaluating these rules, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. We intend to invest resources to comply with evolving laws, regulations
and standards, and this investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards
differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with our IPO, we increased
our directors&#146; and officers&#146; insurance coverage which increased our insurance cost. In the future, it may be more expensive or more difficult </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make
it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the corporate governance standards of the NASDAQ Global Select Market, a majority of our board of directors and each member of our
audit committee must be an independent director no later than the first anniversary of the completion of our IPO. We may encounter difficulty in attracting qualified persons to serve on our board of directors and the audit committee, and our board
of directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If we fail to attract and retain the required number of independent directors, we may be
subject to the delisting of our common stock from the NASDAQ Global Select Market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions of our charter, bylaws, and Delaware law
may make an acquisition of us or a change in our management more difficult. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain provisions of our restated
certificate of incorporation and restated bylaws that became effective upon the completion of our IPO could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including
transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our
common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could
prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">allow the authorized number of directors to be changed only by resolution of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison
pill&#148; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at
stockholder meetings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit who may call stockholder meetings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our
restated certificate of incorporation and restated bylaws. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, because we are incorporated in
Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock,
from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock
appreciation for any return on their investment. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently intend to retain our future earnings, if any, to fund
the development and growth of our businesses. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our
common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A significant portion of our total outstanding shares of common stock is restricted from immediate resale but may be sold
into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Sales of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the perception in the market that the holders of a large number of shares of
common stock intend to sell shares, could reduce the market price of our common stock. After our IPO in October 2013, we had 25,020,288 outstanding shares of common stock. This includes the shares sold in the IPO, which may be resold in the public
market immediately and the remaining shares are currently restricted under securities laws or as a result of lock-up agreements but will be able to be resold as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus.
Moreover, holders of an aggregate of 15,504,104 shares of common stock, which includes 15,130,610 shares of common stock issuable upon the conversion of all our outstanding shares of our preferred stock have rights, subject to certain conditions, to
require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Certain of the holders of such registration right may not elect to sell any
shares in this offering, and certain of the selling stockholders identified in this prospectus that have registration rights may not register all of the shares that are eligible for registration rights, and therefore those holders could require us
to file additional registration statements covering their shares in the future. We also filed a registration statement on Form S-8 to register all 1,920,168 shares of common stock that we may issue under our equity compensation plans, and, they
therefore can be freely sold in the public market upon issuance and once vested, subject to the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result in additional dilution of the percentage ownership
of our stockholders and could cause our share price to fall. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, we have options to
purchase 3,208,199 shares outstanding under our equity compensation plans. We are also authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to 1,395,218&nbsp;shares of our common stock,
pursuant to our equity compensation plans. We plan to register the number of shares available for issuance or subject to outstanding awards under our equity compensation plans after the completion of this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and
trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for our common stock will depend on the research and reports that
securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade
our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which
could cause our share price or trading volume to decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus includes forward-looking statements within the meaning of federal securities laws. Forward-looking
statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these
statements appear, in particular, under the headings &#147;Prospectus Summary&#148;, &#147;Risk Factors&#148;, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business&#148;.
Forward-looking statements can often be identified by the use of terminology such as &#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;,
&#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;, &#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current
expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results
to differ materially from those matters expressed in or implied by forward-looking statements: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to develop and commercialize our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ongoing and planned clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial
objectives; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance and clinical utility of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our commercialization, marketing and manufacturing capabilities and strategy; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant competition in our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic, political and other risks associated with our international operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to receive research funding and achieve anticipated milestones under our collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our intellectual property position; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss or retirement of key members of management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure to maintain effective internal controls. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Consequently, forward-looking statements should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee
future results, events, levels of activity, performance or achievements. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their
option to purchase additional shares from us and the selling stockholders in full, we estimate that the net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million after deducting underwriting discounts and
commissions and estimated offering expenses payable by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will not receive any proceeds from the sale of shares by the
selling stockholders, including if the underwriters exercise their overallotment option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are undertaking this offering in
order to increase our liquidity and raise capital to further develop our pipeline of product candidates. We intend to use the net proceeds of this offering as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $10 to $15 million to fund additional clinical development expenses for MGA271, including additional Phase 1b dose expansion cohorts as
monotherapy as well as in combination with other therapies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $20 to $30&nbsp;million to fund research and development expenses for two additional, previously undisclosed, oncology product candidates
based on our DART technology; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $5 to $10 million to expand our manufacturing facility, which should enable us to increase our production capacity; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remainder for working capital and general corporate purposes, which may include other research and development programs, in-licensing or acquiring
other products or technologies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our expected use of net proceeds from this offering represents our current
intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts
that we will actually spend on the uses set forth above. Due to the many variables inherent to the development of oncology and autoimmune therapeutics at this time, such as the timing of patient enrollment and evolving regulatory requirements, we
cannot currently predict the stage of development that our product candidates will reach using the net proceeds of this offering. Based upon our current operating plan, we anticipate that the net proceeds from this offering together with our
existing cash and cash equivalents and a significant portion of the $100 million in collaboration payments we anticipate receiving through 2015, will enable us to fund clinical development of the above product candidates through 2015, assuming all
of our collaboration programs advance as currently contemplated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount and timing of our actual expenditures will depend
upon numerous factors, including the results of our research and development efforts, the timing and success of pre-clinical studies, our ongoing clinical trials or clinical trials we may commence in the future and the timing of regulatory
submissions. As a result, our management will have broad discretion over the use of the net proceeds from this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation
investments, including short-term, interest-bearing, investment-grade securities, certificates of deposit or government securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_5"></A>MARKET PRICE OF OUR COMMON STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock has been listed on the NASDAQ Global Select Market under the symbol &#147;MGNX&#148; since October&nbsp;10, 2013. Prior
to that, there was no public market for our common stock. The following table sets forth for the periods indicated the high and low intra-day sales prices per share of our common stock as reported on the NASDAQ Global Select Market: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:108pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year ended December&nbsp;31, 2013:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth quarter(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:111pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year ending December&nbsp;31, 2014:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">First quarter (through January&nbsp;28, 2014)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Represents the period from October&nbsp;10, 2013, the date on which our common stock first began to trade on the NASDAQ Global Select Market after the pricing of our
initial public offering, through December&nbsp;31, 2013, the end of our fourth fiscal quarter. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A recent
reported closing price for our common stock is set forth on the cover of this prospectus. Computershare Trust Company, N.A. is the transfer agent for our common stock. As of February&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014, there were
&nbsp;&nbsp;&nbsp;&nbsp; holders of record of our common stock. The actual number of common stockholders is greater than these numbers of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name
by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_6"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid any dividends on our common stock. We currently intend to retain any future earnings to finance the growth and
development of our business, and we do not anticipate that we will declare or pay any cash dividends on our common stock in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors
and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any future indebtedness and other factors the board of directors deems relevant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates our capitalization at September&nbsp;30, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis as of September&nbsp;30, 2013, without giving effect to the shares issued or proceeds of our IPO; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma basis to reflect the conversion of all of our outstanding preferred stock into an aggregate of 16,955,790 shares of common stock and the
net share exercise of Series D-2 preferred stock warrants into an aggregate of 116,270 shares of common stock immediately prior to the closing of our IPO; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (the last reported
price of our common stock on the NASDAQ Global Select Market on February&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This table should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this
prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of September&nbsp;30, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;
Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share data)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.01 par value per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-1: 26,874,792 shares authorized, issued and outstanding, actual; no&nbsp;shares authorized, issued and outstanding, pro
forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-2: 7,364,582 shares authorized, issued and outstanding, actual; no&nbsp;shares authorized, issued and outstanding, pro
forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B: 71,401,237 shares authorized, issued and outstanding, actual; no&nbsp;shares authorized, issued and outstanding, pro
forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C: 110,952,217 shares authorized, issued and outstanding, actual; no&nbsp;shares authorized, issued and outstanding, pro
forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D: 30,000,000 shares authorized, 14,446,227 shares issued and outstanding, actual; no&nbsp;shares authorized, issued and
outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D-2: 75,000,000 shares authorized; 63,681,176 shares issued and outstanding, actual, no&nbsp;shares authorized, issued and
outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01 par value; 425,000,000 shares authorized, 2,124,624 shares issued and outstanding, actual; 425,000,000 shares
authorized, 19,196,684 shares issued and outstanding, pro forma; 425,000,000 shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as
adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of September&nbsp;30, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;
Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share data)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock, at cost, 14,381 shares actual, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(172,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(172,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares of our common stock to be outstanding after this offering are based on 2,124,624 shares of our
common stock outstanding as of September&nbsp;30, 2013 and exclude: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,750,000 shares issued in our IPO in October 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,208,199 shares of common stock issuable upon the exercise of outstanding options, as of September&nbsp;30, 2013, at a weighted average exercise price
of $5.04 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,395,218 shares of common stock reserved for future grant or issuance under our stock option plans as of December&nbsp;31, 2013. For additional
information regarding our capital structure, see &#147;Management&#151;Employee Benefit Plans,&#148; &#147;Description of Capital Stock&#148; and Note 5 of the Notes to our Consolidated Financial Statements.</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statements of operations and comprehensive income (loss) data for the years ended December&nbsp;31, 2012 and 2011 and
the consolidated balance sheet data as of December&nbsp;31, 2012 and 2011 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following selected
consolidated statements of operations and comprehensive income (loss) data for the nine months ended September&nbsp;30, 2012 and 2013 and the balance sheet data as of September&nbsp;30, 2013 have been derived from our unaudited consolidated
financial statements and footnotes included elsewhere in this prospectus. The unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements and, in the opinion of management,
include all adjustments, consisting only of normal recurring adjustments, which management considers necessary for the fair presentation of the information for the unaudited periods. Historical results are not necessarily indicative of future
results, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. The following data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and the consolidated financial statements and related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:119pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,323</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,944</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,025,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,083,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,078,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,463,798</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,025,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,083,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,412,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,908,859</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,039,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,419,588</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,473,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,328,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:66pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,&nbsp;2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,976</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related
notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled &#147;Risk Factors&#148; and
elsewhere in this prospectus, our actual results may differ materially from those anticipated in these forward-looking statements. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising
product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance
the development of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development.
Additionally, we have several proprietary product candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. In addition, we intend to use a portion of the net proceeds from
this offering to advance two pre-clinical DART-based oncology product candidates to IND submission and commence Phase 1 clinical trials in 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and we plan to commence a Phase&nbsp;3
potential registration clinical trial in advanced gastroesophageal cancer in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules and is over-expressed on a wide variety
of solid tumor types. We expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as
combining MGA271 with other therapies for certain tumor types. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes CD123, the Interleukin-3 receptor, or IL3R, alpha chain which is expressed on leukemia and
leukemic stem cells, but not on normal hematopoietic stem cells, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the second quarter of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33, expressed on gastrointestinal tumors, including more than 95%
of human colon cancers, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, business planning, raising capital, developing our technology platforms,
identifying potential product candidates, undertaking pre-clinical studies and conducting clinical trials. We have not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
generated any revenues from the sale of any products to date. We have financed our operations primarily through the private placements of our convertible preferred stock, collaborations and
government grants and contracts. From inception through September&nbsp;30, 2013, we have received $151.3 million from the sale of convertible preferred stock and warrants. In October 2013, we received $84 million from the initial public offering of
our common stock, net of offering discount and expenses. During the three year period ended June 30, 2013, we received an additional $106&nbsp;million of upfront, milestone and other payments from our collaborators. Between June&nbsp;30, 2013 and
December&nbsp;31, 2013, we received a total of $22&nbsp;million through our collaborations and government grants and contracts. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we anticipate that
the net proceeds from this offering, together with our existing cash and cash equivalents, including the net proceeds from our initial public offering, and a significant portion of the $100 million in collaboration payments we anticipate receiving
subsequent to June 30, 2013 and by the end of 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007, MGD010 and two additional, previously undisclosed DART-based oncology product candidates through 2015,
assuming all of our collaboration programs advance as currently contemplated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through September&nbsp;30, 2013, we had an
accumulated deficit of $172.5 million. Due primarily to upfront fees paid by our collaborators, we realized a profit of $6.7 million and $8.4 million for the years ended December&nbsp;31, 2011 and 2012, respectively. We have recognized income of
$2.9 million for the nine months ended September&nbsp;30, 2013. We expect that over the next several years we will increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;16, 2013, we completed our IPO, in which 5,000,000 shares of our common stock were sold at a price of $16.00
per share. Additionally, the underwriters of our IPO exercised the full amount of their over-allotment option resulting in the sale of an additional 750,000 shares of our common stock at a price of $16.00&nbsp;per share. We received net proceeds of
$83.8 million from the IPO, net of underwriting discounts and commissions and other estimated offering expenses. Upon consummation of the IPO, all outstanding shares of preferred stock automatically converted to common stock at the applicable
conversion ratios then in effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Strategic Collaborations and Licenses </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations that provide us with significant additional funding in order to continue development of our pipeline and to extend our technology platforms and
on-going programs. Our collaborations have allowed us to speed up the progress of our on-going pre-clinical and clinical stage programs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment, and may be
eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate
to be $30 million, based on the number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a
$20&nbsp;million option grant fee. In addition, we will be eligible to receive up to approximately $1&nbsp;billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of
its options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, including $5&nbsp;million upon IND acceptance for each </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of MGD006, MGD007 and a third DART molecule. In addition to these milestone payments, we and Servier will share Phase 2 and Phase 3 development costs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:11%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its
territories. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead for the research, development and commercialization of up to four DART-based
molecules. The time period for Gilead&#146;s exercise of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining
programs. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive $7.5 million in grant fees on each of the remaining two DART-based molecules if they are selected by Gilead. We are
further eligible to receive up to an additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to approximately $240 to $250 million per remaining program in additional clinical, regulatory and
sales milestone payments if Gilead exercises both remaining options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are
also eligible to receive tiered royalties on the net sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. In the fourth quarter of 2013, Boehringer nominated a bi-specific antibody therapeutic
candidate generated by our DART technology for pre-clinical development. This formal selection of a development candidate triggered a $5 million milestone payment to us under the agreement. We have received three annual maintenance payments,
including a $4 million payment in the fourth quarter of 2013.We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement.
Boehringer provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. From the commencement of the collaboration through September&nbsp;30, 2013, we have received
$39&nbsp;million under this agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5 million and have received milestone payments and funding for our internal and external research costs under the agreement. We are
eligible to receive technical, development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the
program. In addition, Pfizer is required to pay us mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we completed our research obligations under this program in January
2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Green Cross.</I> In June 2010, we entered into a collaboration agreement with Green Cross for the development of margetuximab. We granted Green
Cross an exclusive license for all indications for all pharmaceutical forms of margetuximab in South Korea. Under the terms of this agreement, we received an upfront, nonrefundable payment of $1.0 million and are eligible to receive clinical,
development and commercial milestone payments up to $4.5 million as well as royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab in South Korea. In addition, Green Cross purchased $2.0 million of our Series
D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue consists of collaboration revenue, including
amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreement with our strategic
collaborators, including Servier, Gilead, Boehringer, Pfizer and Green Cross. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other educational institutions on behalf of the U.S. government,
primarily with respect to research and development activities related to infectious disease product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and
Development Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses consist of expenses incurred in performing research and
development activities. These expenses include conducting pre-clinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and
development activities. We capture research and development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in
research and development expenses: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related expenses such as salaries and benefits; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related overhead expenses such as facilities and other allocated items; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense to employees and consultants engaged in research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of laboratory equipment, computers and leasehold improvements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to consultants, subcontractors, clinical research organizations, or CROs, and other third party vendors for work performed under our
pre-clinical and clinical trials including but not limited to investigator grants, laboratory work and analysis, database management, statistical analysis, and other items; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid to vendors and suppliers for laboratory supplies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to compliance with regulatory requirements. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows a summary of our research and development expenses for the years
ended December&nbsp;31, 2011 and 2012, the nine months ended September&nbsp;30, 2012 and 2013, and from our inception in 2000 to September&nbsp;30, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="border-bottom:1px solid #000000;width:119pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>From<BR>Inception&nbsp;to<BR>September&nbsp;30,<BR>2013</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">410.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is difficult to determine with certainty the duration and completion costs of our current or future
pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed
in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical
trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including
competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of
each product candidate&#146;s commercial potential. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and
intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income (Expense) </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense) consists of interest
income earned on our cash equivalents, offset by interest expense and other expense, including changes in the fair market value of the preferred stock warrant liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
management&#146;s discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States
of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the
date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and
evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material
revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that
the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and judgments we used in preparing our consolidated financial statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these
agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies, (ii)&nbsp;rights to future technological improvements,
(iii)&nbsp;research and development activities to be performed on behalf of the collaborative partner or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborative partner. Payments to us
under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments
based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic
territories. We follow the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605-25, <I>Revenue Recognition&#151;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue
Recognition&#151;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of
accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue
recognition criteria are applied to each of the separate units. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, we had the following two types
of agreements: 1) exclusive development and commercialization licenses to use our technology and/or certain other intellectual property to develop compounds against specified targets, which we refer to as exclusive licenses; and 2) option/research
agreements to secure on established terms development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by us during an option period, which we refer to as
right-to-develop agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exclusive Licenses </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified antigen target, and may also include deliverables related to
rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases we may have an option to participate in the co-development of product candidates that result
from such agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the
terms of the agreement, provide that we will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally consistent with what other third parties would charge,
(ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant us an option to participate in the development and commercialization of products that result from such
agreements. Royalty rates may vary over the royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights. We may provide technical assistance and share any technology
improvements with our collaborators during the term of the collaboration agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not directly control when any collaborator will achieve milestones or become liable
for royalty payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the units of accounting, management evaluates whether the exclusive license has
stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the
collaborator and the availability of technology platform and product research expertise in the general marketplace. If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then
determine the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration
agreements, recent pre-clinical and clinical testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the
likelihood that technological improvements made will be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value.
Prior to the adoption of Accounting Standards Update, or ASU, No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, we determined that our licenses lacked stand-alone value and were combined with other
elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which we refer to as our period of substantial involvement. The determination of the length of the period over which to defer
revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Historically, our involvement with the development of a collaborator&#146;s product candidate has been significant at the
early stages of development, and lessens as it progresses into clinical trials. Accordingly, we generally estimate this period of substantial involvement to begin at the inception of the collaboration agreement and conclude at the end of our
substantial involvement. We reassess our periods of substantial involvement over which we amortize our upfront license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product
candidate under a single target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining portion of the upfront fee until
there is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, we would recognize as revenue any portion
of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license
has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue related to research and pre-clinical development services that represent separate units of accounting as they are
performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. We recognize revenue related to the rights to future technological improvements over the
estimated term of the applicable license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically perform research activities and pre-clinical development services,
including generating and engineering product candidates, on behalf of our licensees during the early evaluation and pre-clinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials
produced or services performed as revenue from collaborative research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our license agreements have milestone payments which
for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing
approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at
risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;our performance to achieve the milestone, or (2)&nbsp;the
enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and
investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of
substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we did not
contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no
continuing performance obligations, assuming all other revenue recognition criteria are met. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Right-to-Develop Agreements
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and
commercialize in specified geographic territories product candidates developed by us under agreed upon research and pre-clinical development programs. The product candidates resulting from each program are all directed to a specific target selected
by the collaborator. Under these agreements, fees may be due to us (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program, (iii)&nbsp;upon the exercise of
an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv)&nbsp;some combination of all of these fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborative partner. Options are considered substantive if, at the inception of a right-to-develop
agreement, we are at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall
objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed
on the collaborator as a result of exercising the options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure a
development and commercialization licenses to a product program are considered substantive, we do not consider the development and commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop
agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, we have deferred the upfront payments received and recognize this revenue over
the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any
substantive option fee is deferred and recognized over the life of the option, generally 12 months. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to
the development and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
commercialization license. Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee to the development and
commercialization license and apply the multiple-element revenue recognition criteria to the development and commercialization license and any other deliverables to determine the appropriate revenue recognition, which will be consistent with our
accounting policy for upfront payments on exclusive licenses. In the event a right-to-develop agreement were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was
classified as deferred revenue, at the date of such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure
development and commercialization licenses to product programs are not considered substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue
recognition criteria to determine the appropriate revenue recognition. All of our right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for
development and commercialization licenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense and related Accrued Expenses </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to
obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our
vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to CROs for services performed on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to investigative sites for services performed on clinical trials; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid for professional services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Expenses related to clinical trials performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated
accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We will adjust accordingly should the estimates vary from the
actual expenses. However, we do not anticipate that our payment of actual expenses will differ materially from our estimates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income
Taxes </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax
basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is
recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset
will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold,
the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax
expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recorded deferred tax assets of $78.1&nbsp;million as of December&nbsp;31, 2012, which have been fully offset by
a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
tax assets are primarily comprised of federal and state tax net operating loss, or NOL, carryforwards and research and development tax credit carryforwards. As of December&nbsp;31, 2012, we had
federal NOL carryforwards of $100.9 million, state NOL carryforwards of $64.2 million and research and development tax credit carryforwards of $21.8 million available. These federal NOL carryforwards will begin to expire at various dates starting in
2023. We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another
Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance.
As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in
increased future cash tax liability to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, <I>Compensation&#151;Stock
Compensation.</I> Prior to our initial public offering, or IPO, the fair value of stock-based payments was estimated, on the date of grant, using a Black-Scholes model. The resulting fair value was recognized on a straight-line basis over the
requisite service period, which was generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates that include the following: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair Value of Common Stock&#151;</I>Prior to our IPO, there was no public market for our common stock, and so our board of directors had
historically determined the fair value of our common stock. Since 2007, through the date of our initial public offering, the board relied on contemporaneous valuations to determine the fair value of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Volatility</I>&#151;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical
volatility) or is expected to fluctuate (expected volatility) during a given period. Prior to our being a publicly traded company, we had historically identified several public companies of similar size, complexity and stage of development and
calculated the historical volatility using the volatility of those companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Dividend Yield&#151;</I>We have never declared or paid dividends. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Risk-Free Interest Rate&#151;</I>We have historically used the United States Treasury rate for the week of each option grant during the year, having
a term that most closely resembles the expected life of our options. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Term&#151;</I>This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term
of ten year and we have estimated the expected life of the option term to be seven years. We use a simplified method to calculate the average expected term. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Forfeiture Rate&#151;</I>The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on
an annual basis before becoming fully vested. We estimate the forfeiture rate based on historical turnover data with further consideration given to the class of the employees to whom the options were granted. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumptions used in the Black-Scholes option pricing model for the years ended
December&nbsp;31, 2011 and 2012 and for the nine months ended September&nbsp;30, 2013 are set forth in our consolidated financial statements included within this prospectus. The stock-based compensation expense includes stock options granted to
employees and non-employees and has been reported in our consolidated financial statements as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:119pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">354</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">393</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2011, we exchanged outstanding options to purchase 1,921,894 shares of our common stock with exercise prices ranging from $1.88 to $4.69 per share, for new
options to purchase the same number of shares of our common stock with an exercise price of $0.94 per share, which we deemed to represent the fair market value of the shares of our common stock as of December&nbsp;31, 2010. The exchange was
implemented because one of our product candidates, teplizumab, did not meet the primary efficacy endpoint in a Phase 3 clinical trial and our collaboration with Eli Lilly&nbsp;was subsequently terminated. We recognized compensation expense of $2.1
million related to this modification as of the exchange date. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has historically estimated
the fair value of our common stock relying on contemporaneous valuations. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American
Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, or the AICPA Practice Aid, and considered many objective and subjective factors to determine the
common stock fair market value each valuation date. The following factors, among others, were considered: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our financial condition and operating results, including our projected results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stage of development and business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial condition and operating results of publicly-owned companies with similar lines of business and their historical volatility;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">External market conditions that could affect companies in the life sciences and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prices of our preferred stock sold to outside investors and the rights, preferences and privileges of our preferred stock as compared to those of
our common stock, including the liquidation preference of our preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any recent valuations prepared in accordance with the AICPA Practice Aid. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dates of our valuations have historically coincided with our year end and would therefore not always fall on the same dates as when
options have been granted. However, we have historically granted the majority of our equity awards on an annual basis coinciding with the beginning of each calendar year. Therefore, our board of directors has historically used the valuation closest
to the grant date of options granted in determining the exercise prices. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We considered several types of approaches in the preparation of our valuations as follows:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Market Approach&#151;</I>The market approach values a business by reference to guideline companies, for which enterprise values are known. This
approach has two principal methodologies. The guideline public company methodology derives valuation multiples from the operating data and share prices of similar publicly traded companies. The guideline acquisition methodology focuses on
comparisons between the subject company and guideline acquired public or private companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Income Approach&#151;</I>The income approach values a business based upon the future benefits that will accrue to it, with the value of the future
economic benefits discounted back to a present value at an appropriate discount rate. This approach uses two methods to value an investment. The discounted cash flow analysis forecasts future revenues and free cash flow, or net operating profit
after tax from continuing operations, associated with those revenues. The capitalization of earnings analysis uses a single year&#146;s estimated free cash flow and converts it into a value in one step by dividing free cash flow from operation by a
capitalization rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Asset Approach&#151;</I>The asset approach considers the underlying value of a company&#146;s individual assets net of its liabilities. This
approach uses the most recent balance sheet as a basis for determining value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we also
considered several types of allocation methods as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Current Value Method&#151;</I>This method allocates the enterprise value of a company to its conversion value. The method assumes that each
preferred stockholder will, at the valuation date, exercise its conversion rights in the manner that is most beneficial. If the conversion of a class of preferred stock into common stock would result in a value less than the total liquidation
preference of that class, that class is considered to be &#147;out of the money&#148; and would not convert. On the other hand, if the value of the common stock would be greater than the liquidation preference of that class, the preferred stock is
considered to be &#147;in the money&#148; and would convert. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option-Pricing Method&#151;</I>Under this method, each class of stock is modeled as a call option with a distinct claim on the enterprise value of
the company. The option&#146;s exercise prices would be based on a comparison with the enterprise value. The method assumes that a formula, such as the Black-Scholes model, would calculate the fair value when provided with certain values, including
share price, expiration date, volatility and the risk free interest rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Probability Weighted Expected Return Method&#151;</I>Using the probability weighted expected return, or PWERM method, the value of a company&#146;s
common stock is estimated based upon the analysis of future values for the company assuming various possible future liquidity events like an IPO, sale or merger. Share value is based upon the probability-weighted present value of expected future net
cash flows, considering each of the possible future events, as well as the rights and preferences of each share class. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates our stock option grant information from January&nbsp;1, 2011
through the date we became a public company, including the estimated fair value of our common stock on the date of grant. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:38pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Options&nbsp;Granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Exercise&nbsp;Price(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;Fair&nbsp;Value&nbsp;of<BR>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;9, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;16, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,571</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;15, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;7,&nbsp;2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;10,&nbsp;2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;8, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;14, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">313,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;13, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;19,&nbsp;2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;8,&nbsp;2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;6, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">337,282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;8, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;19, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July&nbsp;19, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">206,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;18,&nbsp;2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;9,&nbsp;2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">429,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the absence of a public market for our common stock prior to October 2013, the exercise price per share was the estimated fair value of common stock and
represented the determination by our board of directors of the fair value of our common stock as of the date of each grant, taking into consideration various objective and subjective factors, as discussed more fully herein. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2010 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach was best suited to use for the December&nbsp;31, 2010 valuation. We&nbsp;focused on determining the market value of our total capitalization. The market value of
non-operating assets was added to determine the market value of the total common equity. We used the option pricing method as the allocation method. We utilized a long-term forecast that represented our best estimate of expected performance.
We&nbsp;determined that a 14.71% cost of capital would be appropriate. We developed a long-term model that projected our product candidates&#146; performance and potential commercialization over the next twenty years. We assumed that we would
continue development of additional product candidates in our pipeline and generate revenue through commercialization of our product candidates or through collaborations. This normalized cash flow was then discounted back to a present value at the
above mentioned cost of capital. The cost of capital utilized was 14.71%. The Company&#146;s capital structure did not contain any debt; therefore the weighted average cost of capital did not contain a cost of debt. We noted that the capital
structure of 100% equity and 0% debt was comparable to the median capital structure of the guideline public companies of 99.6% equity and 0.4% debt. We determined the cost of capital utilizing the following inputs: (i)&nbsp;yield on a 20-year
Treasury bond of 4.13% derived from the U.S. Federal Reserve website; (ii)&nbsp;market risk premium of 5.18% based upon Morningstar&#146;s publication &#147;Stocks, Bonds, Bills, and Inflation: Valuation Edition 2010 Yearbook&#148;; (iii)&nbsp;an
unlevered beta of 1.00 based upon an analysis of betas of publicly-traded guideline companies, debt-to-equity ratios and tax rates; and (iv)&nbsp;a small stock premium of 5.4% based upon stocks in the 10th decile, including companies with market
capitalizations ranging from $1.0&nbsp;million to $214.1 million from Morningstar&#146;s publication &#147;Stocks, Bonds, Bills and Inflation: Valuation Edition 2010 Yearbook.&#148; The total market value of our capital stock, based upon a
discounted cash flow analysis, on a minority interest basis was approximately $74.0 million. We added free cash in the amount of $43.5 million and determined that the market value of total equity, on a marketable minority interest basis was
approximately $117.5&nbsp;million. Using the option pricing method approach, this value was then allocated among the preferred and common stock and we applied a discount rate of 30% to account for the lack of marketability of our common stock. We
concluded that the fair value of our common stock was $0.94 per share at December&nbsp;31, 2010. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2011 to November 2011 </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15,
2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011, with each option having an exercise price of $0.94 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we
conducted of our common stock as of December&nbsp;31, 2010, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances most likely to affect the value of our
common stock that occurred between December 2010 and the grant date, and whether those events and circumstances were part of the assumptions used in the December 2010 valuation. Our board of directors determined that there were no other events and
circumstances that occurred between December 2010 and November 2011 that were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock
at January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15, 2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011 was $0.94 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2011 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach
was best suited to us for the December&nbsp;31, 2011 valuation. We&nbsp;focused on determining the market value of total capitalization. The market value of non-operating assets was added to determine the market value of the total common equity. We
used the option pricing method as the allocation method. We utilized a long-term forecast that represented our best estimates of expected performance. We determined that a 15.46% cost of capital would be appropriate. We developed a long-term model
that projected our product candidates&#146; performance and potential commercialization over the next twenty years. We assumed that we would continue development of additional product candidates in our pipeline and generate revenue through
commercialization of our product candidates or though collaborations. This normalized cash flow was then discounted back to a present value at the above mentioned cost of capital. The total market value of our capital stock, based upon a discounted
cash flow analysis, on a minority interest basis was approximately $61.6 million. We added free cash in the amount of $48.2 million and determined that the market value of total equity, on a marketable minority interest basis was approximately
$109.8 million. Using the option pricing method approach, this value was then allocated among the preferred and common stock and applying a discount rate of 30% to account for the lack of marketability of our common stock. We concluded that the fair
value of our common stock was&nbsp;$0.94&nbsp;per share as December&nbsp;31, 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2012
to November 2012 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;8,
2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13, 2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;8, 2012, with each option having an exercise price of $0.94 per share. In establishing this exercise price, our board of directors considered
input from management, including the valuation we conducted of our common stock as of December&nbsp;31, 2011, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and
circumstances most likely to affect the value of our common stock that occurred between December 2011 and the grant date and whether those events and circumstances were part of the assumptions used in the December 2011 valuation. Our board of
directors determined that there were no other events and circumstances that occurred between December 2011 and November 2012 that were indicative of a significant change in the fair value of our common stock. For example, although we entered into a
collaboration agreement with Servier, the cash received offset cash used in operations between January 2012 and November 2012, and thus the value of the Company had not been altered significantly from December 2011. Based on these factors, our board
of directors determined that the fair value of our common stock at January&nbsp;8, 2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13, 2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;08, 2012 was $0.94 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2012 Valuation </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We used the PWERM method to allocate the equity value to our common stock in the December&nbsp;31, 2012 valuation. For the various
scenarios, we utilized a combination of the market approach (e.g., consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical
development) and the income approach (e.g., projected future cash flows) to determine the value of our business and ultimately the fair value of our common stock. The market approach was used to determine the fair value of the IPO scenarios as well
as the merger or acquisition scenario and the income approach was used to determine the fair value of remaining private. We utilized the following probability-weighted scenarios to determine the equity value of our company: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by second quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by fourth quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the middle of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we incorporated IPO scenarios as this strategy was considered a possibility based on
our stage of development and current market conditions. We believed that a second quarter 2013 IPO was unlikely given the tremendous effort required to file a registration statement and our lack of need for additional cash and therefore applied a 5%
probability to this scenario. We determined that an IPO either in the fourth quarter of 2013 or first quarter of 2014 was somewhat more likely due to the progression of our lead product candidates and therefore applied a probability of 15% to each
of those scenarios. We determined that the likelihood of a merger or acquisition was low based on the timing of availability of key clinical data and assigned a probability of 10% to that scenario. We determined that given our relatively low need to
raise capital as a result of our collaboration agreements and anticipated milestone payments, the scenario most likely to occur would be to remain a private company and therefore assigned a probability of 55% to that scenario. We concluded that
after applying a discount rate of 25.0% for lack of marketability, the value of our common stock as December&nbsp;31, 2012 was $1.50 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2013 to March 2013 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of
directors granted options to purchase common stock on January&nbsp;6, 2013 and March&nbsp;8, 2013, with each option having an exercise price of $1.50 per share. In establishing this exercise price, our board of directors considered input from
management, including the valuation we conducted of our common stock as of December&nbsp;31, 2012, as well as the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances
most likely to affect the value of our common stock that occurred between December 2012 and the grant date and whether those events and circumstances were part of the assumptions used in the December 2012 valuation. Our board of directors determined
that there were no other events and circumstances that occurred between December 2012 and March 2013 that were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that
the fair value of our common stock at January&nbsp;6, 2013 and March&nbsp;8, 2013 was $1.50 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March&nbsp;31, 2013
Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the market conditions for IPOs of biotechnology companies, we determined that obtaining a valuation of
our common stock on a quarterly rather than annual basis was warranted in 2013. In the first of our quarterly valuations, we used the PWERM method to allocate the equity value to our common stock in the March&nbsp;31, 2013 valuation. For the various
scenarios, we utilized a combination of the market approach (e.g.,&nbsp;consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of
clinical development) and the income approach </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(e.g., projected future cash flows) to determine the value of our business and ultimately the fair value of our common stock. The market approach was used to determine the fair value of the IPO
scenarios as well as the merger or acquisition scenario and the income approach was used to determine the fair value of remaining private. We utilized the following probability-weighted scenarios to determine the equity value of our company:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that the possibility of a fourth quarter 2013 IPO or a first quarter 2014
IPO were equal, given that only two biotechnology companies had successfully completed IPOs from December 2012 to our board meeting in March 2013. Therefore we applied a 20% probability to each of those scenarios. Additionally, the value assigned to
the FPO scenarios was increased as a result of the higher market values that were reflected by IPOs completed in March 2013 trading at premiums to the offering price. We determined that the likelihood of a merger or acquisition was low based on the
timing of availability of key clinical data and assigned a probability of 15% to that scenario. We determined that given our relatively low need to raise capital as a result of our collaboration agreements and anticipated milestone payments, the
scenario most likely to occur would be to remain a private company and therefore assigned a probability of 45% to that scenario. We concluded that after applying a discount rate of 20.0% for lack of marketability, the value of our common stock at
March&nbsp;31, 2013 was $2.63 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from April 2013 to June 2013 </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on June&nbsp;19, 2013, with each option having an exercise price of $2.63
per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of March&nbsp;31, 2013, as well as the objective and subjective factors outlined
above. At the grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between March&nbsp;31, 2013 and the grant date and whether those events and circumstances were
part of the assumptions used in the March&nbsp;31, 2013 valuation. Our board of directors determined that there were no other events and circumstances that occurred between March&nbsp;31, 2013 and June&nbsp;19, 2013 that were indicative of a
significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at June&nbsp;19, 2013 was $2.63 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>June&nbsp;30, 2013 Valuation </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In this quarterly valuation, we again used the PWERM method to allocate value to our common stock as of June&nbsp;30, 2013. For the various scenarios, we utilized a combination of the market approach
(e.g., consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical development) and the income approach (e.g., projected future
cash flows) to determine the value of our business and ultimately the fair value of our common stock. The market approach was used to determine the fair value of the IPO scenarios as well as the merger or acquisition scenario and the income approach
was used to determine the fair value of remaining private. We utilized the following probability-weighted scenarios to determine the equity value of our company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that the possibility of a fourth quarter 2013 IPO was more
probable than in previous valuations. This is due primarily to the recent market for biotechnology IPOs. We assigned a 32.5% probability to that scenario. While we determined that this was the most likely scenario, we assigned a 22.5% probability to
an IPO in the first quarter of 2014. We determined that the likelihood of a merger or acquisition by the third quarter of 2015 was relatively low based on the timing of availability of key clinical data and assigned a probability of 15.0% to that
scenario. We determined that given our relatively low need to raise capital as a result of our collaboration agreements and anticipated milestone payments, the scenario where we would remain a private company was more likely and therefore assigned a
probability of 30.0% to that scenario. We concluded that after applying a discount rate of 15.0% for lack of marketability, the value of our common stock at June&nbsp;30, 2013 was $4.69 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants in July 2013 </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on July&nbsp;19, 2013, with each option having an exercise price of $4.69 per share. In establishing this exercise price, our board of
directors considered input from management, including the valuation we conducted of our common stock as of June&nbsp;30, 2013, as well as the objective and subjective factors outlined above. At the grant date, our board of directors considered the
events and circumstances most likely to affect the value of our common stock that occurred between June&nbsp;30, 2013 and the grant date and whether those events and circumstances were part of the assumptions used in the June 2013 valuation. Our
board of directors determined that there were no other events and circumstances that occurred between June&nbsp;30, 2013 and July&nbsp;19, 2013 that were indicative of a significant change in the fair value of our common stock. Based on these
factors, our board of directors determined that the fair value of our common stock at July&nbsp;19, 2013 was $4.69 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>August&nbsp;31, 2013 Valuation</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we again used the PWERM method to allocate value to our common stock as of August&nbsp;31, 2013. For the various scenarios, we utilized a combination of the market approach (e.g. ,
consideration of pre-money IPO value indications from companies in the pharmaceutical and biotechnology industries with similar product candidates and at similar stages of clinical development) and the income approach (e.g., projected future cash
flows) to determine the value of our business and ultimately the fair value of our common stock. The market approach was used to determine the fair value of the IPO scenarios as well as the merger or acquisition scenario and the income approach was
used to determine the fair value of remaining private. We utilized the following probability-weighted scenarios to determine the equity value of our company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that given where we were in the IPO process and the recent activity of
IPOs in our industry, the possibility of a fourth quarter 2013 IPO was much more probable than in previous valuations and therefore assigned a 60.0% probability to that scenario. While we determined that a fourth quarter 2013 IPO was the most likely
scenario, we assigned a 15.0% probability to the scenario where an IPO is completed by the first quarter of 2014. We again determined that the likelihood of a merger or acquisition by the third quarter of 2015 was relatively low based on the timing
of availability of key clinical data and assigned a 15.0% probability to that scenario. We determined that given our progress in the IPO process, the scenario to remain a private company through the end of 2015 was relatively low and assigned a
10.0% probability to that scenario. We concluded that after applying a discount rate of 12.5% for lack of marketability, the value of our common stock at August&nbsp;31, 2013 was $7.51 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants in September 2013</I> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on September&nbsp;18, 2013, with each option having an exercise price of
$7.51 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of August&nbsp;31, 2013, as well as the objective and subjective factors
outlined above. At the grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between August&nbsp;31, 2013 and the grant date and whether those events and
circumstances were part of the assumptions used in the August 2013 valuation. Our board of directors determined that there were no other events and circumstances that occurred between August&nbsp;31, 2013 and September&nbsp;18, 2013 that were
indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at September&nbsp;18, 2013 was $7.51 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Determination of Initial Public Offering Price </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2013, we selected underwriters for our IPO. The midpoint of the preliminary range for our IPO as determined by us and the underwriters was $15.00 per share. In comparison, our estimate of the fair
value of our common stock was $7.51 per share as of the August&nbsp;31, 2013 valuation. We note that, as typical in IPOs, the preliminary range was not derived using a formal determination of fair value, but was determined based upon discussions
between us and the underwriters. Among the factors that were considered in setting this range were our prospects the general condition of the securities markets and the recent market prices of, and the demand for, publicly traded common stock of
comparable companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the difference between the fair value of our common stock as of August&nbsp;31, 2013
and the midpoint of the estimated price range for our IPO was the result of these factors as well as the fact that the estimated IPO price range necessarily assumes that the IPO has occurred, a public market for our common stock had been created and
our preferred stock had converted into common stock in connection with the IPO. The estimated IPO price range therefore excluded any discount for lack of marketability of our common stock and any consideration of the preferences of our convertible
preferred stock, which we factored into the August&nbsp;31, 2013 contemporaneous valuation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, from the time of the
August&nbsp;31, 2013 valuation, to the time we determined our IPO price, our product candidates continued to progress through clinical and pre-clinical development, including achievement of additional partial responses in our margetuximab Phase 1
clinical trial, and further discussion with the FDA regarding our development plans for a potential Phase 3 clinical trial of margetuximab in gastroesophageal cancer; we received a $10 million milestone payment for dosing a first patient in the dose
expansion portion of our MGA271 Phase 1 clinical trial; we have generated additional supportive pre-clinical data for multiple proprietary as well as partnered DART-based programs; and finally, other clinical-stage oncology companies, including
those with differentiated technology platforms, had gone public during that time. Further, those companies have continued to increase in market value that continued to raise the estimated enterprise value when we used the market approach in our IPO
assumption. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;25, 2013, we and our underwriters agreed upon an estimated price range for our IPO, the
midpoint of which was $15.00 per share. On October&nbsp;8, 2013, we and our underwriters further refined the estimated IPO price to $16.00 per share. In comparison, our estimate of the fair value of our common stock was $7.51 per share as of
September&nbsp;18, 2013. We note that, as is typical in initial public offerings, the estimated price range for our IPO was not derived using a formal determination of fair value, but factors including our prospects and the history of and prospects
for our industry, the general condition of the securities markets and the recent market prices of, and the demand for, publicly-traded common stock of generally comparable companies. In addition, at the time these awards were made, we and our
underwriters had not yet agreed upon a definitive proposed price range for the initial public offering. Specifically, we believe that the difference between the fair </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
value of our common stock as of September&nbsp;18, 2013 and the initial public offering price was primarily the result of the following factors: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We commenced preparations to launch a roadshow for this offering; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The August&nbsp;31, 2013 contemporaneous valuation used a probability weighting of 60% that the IPO would occur in the fourth quarter of 2013. However,
our discussions in September 2013 with the underwriters took into account positive overall market conditions and the market for initial public offerings particularly for biopharmaceutical companies, and confirmed our and our underwriters&#146;
expectations that we would complete our initial public offering during the fourth quarter of 2013; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the month of September, and subsequent to our last valuation, the NASDAQ Biotechnology Index had increased by more than 6.3%.&nbsp;During that
time, there had been five biotechnology IPOs, including Five Prime Therapeutics, Inc., Acceleron Pharma, Inc., BIND Therapeutics, Inc., Ophthotech Corporation and Foundation Medicine, Inc.&nbsp;Of these, all but one had traded significantly higher
than their IPO price, representing an average increase of 36%.&nbsp;In addition, the average equity market value of biotechnology companies at IPO was $295 million for those companies that went public from January&nbsp;1, 2013 to August&nbsp;31,
2013 (excluding Intrexon, which is deemed to not be comparable).&nbsp;In the subsequent period beginning September&nbsp;1, 2013 and ending September&nbsp;26, 2013, the average equity market value of biotechnology companies at the time of IPO was
$408 million for companies that went public, representing an increase of 38% over those that went public in the prior 8-month period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The estimated initial public offering price range necessarily assumed that the initial public offering has occurred, a public market for our common
stock had been created and that our preferred stock converted into common stock in connection with the initial public offering, and therefore excluded any discount for lack of marketability of our common stock, which was factored in our valuations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of our IPO, all outstanding shares of our preferred stock were to convert into common stock, thus eliminating the superior rights and
preferences of our preferred stock as compared to our common stock; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The completion of our IPO would provide us with access to the public company debt and equity markets. Those projected improvements in our financial
position influenced the increased common stock valuation indicated by the initial public offering price. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>JOBS Act
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107 of the
JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or
revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this
extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have not yet filed an annual report on Form 10-K, to which many of the exemptions available under the JOBS Act relate, we
continue the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including
without limitation, (i)&nbsp;providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Section&nbsp;404(b) of the Sarbanes-Oxley Act and (ii)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of
(i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the
date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Nine Months Ended September&nbsp;30, 2012 and 2013 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Revenue </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the nine months ended September&nbsp;30, 2012 and 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:120pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:69pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Increase/(Decrease)&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in collaboration revenue of $8.3 million for the nine months ended September&nbsp;30, 2013
compared to the same period in 2012 is primarily due to the conclusion of the teplizumab clinical trial-related reimbursement from Eli Lilly. Aside from reimbursing us for the continued monitoring expense of one on-going trial, Eli Lilly&#146;s
participation in the development of teplizumab concluded in the first quarter of 2013. Grant revenue decreased in the nine month period ended September&nbsp;30, 2013 as compared to the same period in 2012 due primarily to the completion of grants to
study H5N1 influenza virus, small pox and West Nile virus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the nine months ended September&nbsp;30, 2012 and 2013:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:123pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the nine months ended September&nbsp;30, 2013, as compared to the same period in
2012, our research and development expense decreased overall by $4.7 million. This was due primarily to the reduction in spending on teplizumab-related clinical development as we ended trial enrollment and began closing down the trials during this
period. In addition, we significantly reduced our Cancer Stem-like Cell (CSLC) related activities. These decreases were partially offset by an increase in spending on MGA271 and our various DART-based product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our general and administrative expense for the nine months ended September&nbsp;30, 2012 and 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:123pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase/(Decrease)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense for the nine months ended September&nbsp;30, 2013 was $0.7 million
higher than the same period in 2012 primarily due to an increase in professional fees and other expenses incurred in preparation for public company operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Years Ended December&nbsp;31, 2011 and 2012 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research
and Development Revenue </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the years
ended December&nbsp;31, 2011 and 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:67pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase/(Decrease)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration revenue was $12.6 million higher for the year ended December&nbsp;31, 2012 compared to the
year ended December&nbsp;31, 2011 primarily due to two Servier collaborations signed in late 2011 and late 2012. Grant revenue decreased as our contract with the U.S. government to develop a monoclonal antibody for the treatment of West Nile Virus
ended in September 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2011 and 2012:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:68pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase/(Decrease)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenditures in research and development increased by $4.3 million overall from the year ended
December&nbsp;31, 2011 to the year ended December&nbsp;31, 2012. This was due to the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending in support of the MGA271 Phase 1 clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending on toxicology related studies and increased efforts on our DART-based product candidates as a result of additional collaborations;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite ceasing enrollment on teplizumab-related clinical trials, we continued to follow the patients for an additional 18 months and closed down the
trials in late 2012. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These increases were partially offset by: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completion of our contract with the U.S. government to study West Nile Virus that resulted in a reduction in spending; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduced spending on our CSLC efforts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a
comparison of our general and administrative expense for the years ended December&nbsp;31, 2011 and 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:65pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase/(Decrease)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in general and administrative expense of $0.7 million is due primarily to reduced patent
filing and related legal expense, which was partially offset by an increase in the amount of bonuses paid in the year ended December&nbsp;31, 2012. Additionally, we realized a savings from a consolidation of personnel from three to two facilities in
Rockville, Maryland. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash Flows </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table represents a summary of our cash flows for the years ended December&nbsp;31, 2011 and 2012 and the nine months ended September&nbsp;30, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:89pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:115pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2011&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2012&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2012&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;2013&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by (used in):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net increase (decrease) in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Activities </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and perform toxicology studies. The differences between the year ended December&nbsp;31,
2011 and 2012 were primarily due to the upfront fees received from our collaborators. The primary difference between the nine months ended September&nbsp;30, 2012 and 2013 was due to the receipt of upfront fees and accounts receivable due from our
collaborators, including the achievement of a $10.0 million milestone from Servier in the third quarter of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing Activities
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities in all periods was primarily due to the acquisition of additional lab equipment
needed to further our research and development activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing Activities </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other than stock option exercises, we had no financing activity in the nine months ended September&nbsp;30, 2013 or 2012 and in the year
ended December&nbsp;31, 2012. However, during the year ended December&nbsp;31, 2011 we sold 18.4&nbsp;million shares of Series D-2 preferred stock to our collaborators for net proceeds of $12.0 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since our inception through September&nbsp;30, 2013, we have raised an aggregate of $560.7 million to fund our operations. Of this total amount, we have received $151.3 million from the sale of preferred
stock, $354.9 million from our collaborators, including payments in the form of upfront, milestone and annual maintenance payments and reimbursement for research and development services performed, and $54.5 million from government grants and
contracts. As of September&nbsp;30, 2013, we had $33.6 million in cash and cash equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;16, 2013, we
completed our IPO, in which 5,750,000 shares of our common stock were sold at a price of $16.00 per share, inclusive of the underwriters&#146; overallotment option. We received proceeds of $83.8&nbsp;million from the IPO, net of underwriting
discounts and commissions and other estimated offering expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our existing cash and cash equivalents, we
expect to continue to receive additional reimbursement from our collaborators for research and development services rendered, additional milestone payments, annual license maintenance payments and grant revenue. However, our ability to receive these
milestone payments is dependent upon our ability to achieve certain levels of research and development activities and is therefore uncertain at this time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we
are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as
well as additional clinical trials and pre-clinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our
efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing
cash and cash equivalents, and a significant portion of the $100 million in collaboration payments we anticipate receiving through 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007 and MGD010 through 2015,
assuming all of our collaboration programs advance as currently contemplated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Contingent Liabilities
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents future minimum operating lease payments under noncancelable operating leases as of
September&nbsp;30, 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:38pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1&nbsp;to&nbsp;3&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:38pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3&nbsp;to&nbsp;5&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:62pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than&nbsp;5&nbsp;years</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating Leases</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current obligations and contingent liabilities are limited to the operating leases at our three
facilities, including two in Rockville, Maryland and one in South San Francisco, California. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with an Asset
Purchase Agreement with Tolerance Therapeutics, Inc., or Tolerance, entered into in June 2005, we may be required to give Tolerance additional consideration as follows: (i)&nbsp;a maximum of $10.9&nbsp;million if certain milestones are met,
including the initiation of Phase&nbsp;3 trials and the filing of various regulatory product license applications; (ii)&nbsp;36,135 shares of our common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired
from or patented by Tolerance or other product fees earned by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2008, we acquired Raven Biotechnologies, or Raven.
The Raven purchase agreement provides for certain contingent payments that are based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a
onetime payment of $5.0 million to the former Raven stockholders upon the initiation of patient dosing in the first Phase&nbsp;2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the
Phase&nbsp;2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain cost reimbursements) we may receive for
each license of a product candidate derived from the Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for licenses executed after July&nbsp;16,
2018. There is additional contingent consideration of one time payments of $8 million and $12 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven cancer stem cell program. At our sole
discretion, each payment can be made in cash, common stock or a combination thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The contractual obligations table does
not include any potential future payments we may be required to make under our Asset Purchase Agreement with Tolerance or the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of the events requiring payment under
that agreement, the amounts to be paid by us are not fixed or determinable at this time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never entered into any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange
Commission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Loss Carryforwards </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of
$64.2&nbsp;million and research and development tax credit carryforwards of $21.8 million available. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another
Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance.
As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in
increased future cash tax liability to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, FASB issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common fair value measurements and disclosure
requirements in U.S. GAAP and International Financial Reporting Standards, or IFRS. The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRS. Consequently, the amendments change
the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The
adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The amendments in ASU No.&nbsp;2011-05 require that all nonowner
changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and
its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of comprehensive income. This amendment is effective for fiscal years
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We evaluated all ASUs through the date the consolidated financial statements were issued and believe that the adoption of these will not
have a material impact on our consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures about Market Risk
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.
As of September&nbsp;30, 2013, we had cash and cash equivalents of $33.6 million, of which $26.0 million was invested in money market funds. Our primary exposure to market risk is related to changes in interest rates and our current investment
policy is to invest principally in deposits and securities issued by the U.S. government and its agencies and money market instruments. We do not believe that our cash and cash equivalents have significant risk. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_11"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. Some of these product candidates include therapeutics in the emerging field of immune oncology and are designed to
promote tumor destruction by either enhancing or restoring the body&#146;s immune system to destroy cancers. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148; which are drugs
designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with global
pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of these collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms consisting of: (1)&nbsp;our Dual Affinity Re-Targeting, or DART, platform,
which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells; (2)&nbsp;our Fc
Optimization platform, which enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy
targets such as tumor cells; and (3)&nbsp;our Cancer Stem-like Cell, or CSLC, platform, which provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them.
These versatile technology platforms can be applied in combination with one another to custom-design an antibody or antibody-derived molecule that is optimized to treat a specific disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antibodies, which are proteins produced by specialized cells of the body&#146;s immune system usually in response to foreign substances,
such as bacteria and viruses, or to cancer cells, serve as the primary resource for our product candidates. Many of our cancer product candidates are derived from our library of over 2,000 purified antibodies. Our antibodies are targeted to more
than 70 different antigens, or components of the foreign substance that induce the production of antibodies, expressed on the surface of cancer cells. In addition, we continue to generate new antibodies for our library using our proprietary CSLC
lines and soluble protein antigens. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initially select a specific antibody based on its functional properties related to a
disease target as well as its distribution on tissues in the body. We then utilize one or more of our technology platforms for engineering and optimizing our product candidate. We believe our approach allows us to take advantage of the enhanced
properties of an engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune diseases more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness
of antibodies include the following: enhancing the body&#146;s immune system, targeting multiple antigens on the surface of the same target cell, increasing the strength of the binding of an antibody to its antigen targets, and reducing the
likelihood of an unwanted immune response to the antibody or antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product
candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination
therapy, depending on disease characteristics, current standards of care, and overall safety, tolerability, and efficacy of specific regimens. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g97i90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2+ patient populations than those treated with current HER2 therapies, as well as improve the
outcomes for patients who would be eligible for other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American Society of Clinical
Oncology, or ASCO, and November 2013 Chemotherapy Foundation Symposium demonstrated anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated
(frequently including with other anti-HER2 agents). We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and we plan to commence a Phase 3 potential registration clinical trial in advanced gastroesophageal cancer in the
second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on
T&nbsp;cells. We have engineered MGA271 to utilize the same Fc Optimization enhancements that we </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumors and CSLCs, as well as on the supporting tumor vasculature and underlying tissues. MGA271 is
designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate
additional dose expansion cohorts in additional tumor types, including in combination with other therapies, in 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. MGD006 pre-clinical data was presented at 2013 Annual Meeting of the American Society of Hematology, or ASH. We expect to commence a Phase 1 clinical trial of MGD006 in the second quarter of
2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial of
MGD007 in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We pursue a balanced approach between product candidates that we develop
ourselves and those that we develop with our collaborators. Under our current strategic collaborations we have received approximately $106&nbsp;million in non-equity funding over the three year period ended June&nbsp;30, 2013. Under these agreements
we believe we are likely to receive over $100 million of potential milestone and other payments subsequent to June&nbsp;30, 2013 and by the end of 2015, assuming all of our collaboration programs advance as currently contemplated. Our collaborators
include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment upon dosing the
first patient in the expansion cohort of our Phase I clinical trial of MGA271, and may be eligible to receive up to approximately $415&nbsp;million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier
exercises the option, obtains regulatory approval for, and successfully commercializes an MGA271 licensed product. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the
number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize
DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option
grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options and successfully
develops, obtains regulatory approval for, and commercializes a product under each license, including $5&nbsp;million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestones, we and Servier will
share Phase 2 and Phase 3 development costs. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead for the research, development and commercialization of up to four DART-based
molecules. The time period for Gilead&#146;s exercise of one option has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for each of these remaining
programs. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive an additional $7.5 million in grant fees on each of the remaining two DART-based molecules if any are selected by Gilead.
We are further eligible to receive up to an additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to approximately $240 to $250 million per remaining program in additional clinical,
regulatory and sales milestone payments if Gilead exercises both remaining options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the
agreement. We are also eligible to receive tiered royalties on the net sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received three annual maintenance payments, including a $4 million
payment received in the fourth quarter of 2013. Also, in the fourth quarter of 2013, Boehringer&#146;s selection of a development candidate triggered a $5&nbsp;million milestone payment to us under the agreement. We have the potential to earn
development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement. Boehringer provides funding for our internal and external research costs and is required to pay
us mid-single digit royalties on product sales. Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is
required to pay us mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we completed our research obligations under this program in January 2014.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently manufacture all of the drug substance for research and development efforts for all of our
product candidates in-house. Drug substance for all of our clinical trials is manufactured using current good manufacturing practices, or cGMP, at our manufacturing facility, located in Rockville, Maryland. We contract with vendors to provide fill
finish manufacture of drug product. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. We intend to use a portion of the net proceeds from
this offering to expand our manufacturing facility, which should enable us to increase our production capacity. In addition, we intend to enter into agreements with contract manufacturing organizations to supplement our clinical supply and internal
capacity as we advance additional pre-clinical candidates into clinical development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and commercialization of antibody-based therapeutics for the treatment of
patients with cancer, autoimmune disorders and other complex diseases. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We&nbsp;intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a
Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect to have results in late 2014. We plan to commence a Phase&nbsp;3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the
second half of 2014. We are currently enrolling the dose-expansion portion of a Phase&nbsp;1 clinical trial of MGA271 as a single-agent in the treatment of 45 patients with solid tumors, including: 15&nbsp;patients with melanoma; 15 patients with
prostate cancer and an additional group of 15 patients with other solid tumor types. Servier has indicated that it intends to evaluate MGA271 in up to 75 additional cancer patients representing additional types of cancers beginning in the first
quarter of 2014. We intend to assess and prioritize future indications for MGA271 clinical trials based on data from these cohorts and determine the best path forward to potential commercialization. We intend to use a portion of the proceeds from
this offering to conduct additional MGA271 Phase 1 dose expansion cohorts in additional tumor types, including in combination with other therapies. In addition, we are currently optimizing multiple DART therapeutics as candidates for clinical
development. We anticipate that we will begin Phase 1 clinical trials of MGD006, our first DART candidate, in the second quarter of 2014, and MGD007, our second DART candidate, in the second half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and
access the development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with
biopharmaceutical companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies. We believe that such linkers and drug conjugates can be combined with the selective
targeting properties of our DART technology and the enhanced immune activities of our Fc Optimization technology. Our goal is to identify and further develop new clinical candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates,
through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We intend to build on our technology platforms, methods and know-how
that comprise our capabilities in order to expand our product pipeline. Our goal is to file one or more new investigational new drug applications, or INDs, annually for the next several years. With the net proceeds from this offering, we intend to
advance two previously undisclosed oncology DART-based product candidates to IND submission and initiation of clinical testing in 2015. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immune System and Antibodies </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The immune system, composed of both
innate and adaptive elements, defends against invading pathogens such as viruses, parasites, and bacteria, and provides surveillance against cancers. The adaptive immune system includes: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B cells, which mature into plasma cells and produce antibodies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Helper T cells, including those that enable, or help, the B cells to produce antibodies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytotoxic T cells, which can destroy tumor cells or cells infected with viruses. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">T cells and B cells (and the antibodies derived from the mature B cell) of this adaptive immune system respond to small structural
differences found, for example, on a cancer cell. This normally imparts exquisite specificity on these individual immune components. As a result, billions of different structural variants can be recognized by the adaptive immune system, but each
individual T cell or B cell or antibody can only bind and respond to a single structure or molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the
following illustration, the antibody is a Y-shaped molecule that has two identical variable regions at the tip of the arms of the antibody (Fab region), which bind to antigens, and a constant region (Fc), as its opposite end that binds to
F<I>cy</I>Rs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Monoclonal Antibody Structure </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g79f34_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An antibody&#146;s structure is amenable to engineering either the variable regions to improve its
strength of target recognition or affinity, or the constant regions to modify its engagement and collaboration with other components of the immune system, or both. The two variable region arms naturally target the same antigen; however, they can be
artificially engineered to target two different antigens, allowing the creation of a bi-specific antibody. The Fc region can bind, recruit and activate immune cells to amplify the immune response to targets bound by the variable region of the
antibody molecule. The Fc region can be modified to enhance the engagement with other immune cells and increase the potency of the immune response. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Therapeutic monoclonal antibodies are typically derived from natural antibodies and are obtained from immune cells of mammals that have been immunized with a desired antigen and are all clones of the
unique parent cell. The antibody&#146;s ability to bind specifically to a target or antigen is also referred to as its specificity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Using this mechanism, antibodies can tag foreign substances for attack by other immune system cells or neutralize the targets directly. In treating diseases such as cancer, researchers find
antigens specific to cancer cells and create antibodies that bind those antigens to use the body&#146;s immune system to destroy these cancer cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Monoclonal antibodies are typically produced in mice and although they are relatively easy to generate, they can have drawbacks as targeted therapeutics. The major drawback is that a mouse monoclonal
antibody is recognized by the human immune system as a foreign target and therefore, the immune system attacks the antibody, rendering it useless against its intended target. Many advances have been made to genetically engineer and humanize
monoclonal antibodies. In addition, fully human antibodies can be created, which also significantly reduce newly generated immune responses in patients treated with monoclonal antibodies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer is a broad group of diseases in which cells divide
and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is
disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will
become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it may be incurable. Cancer cells that arise in the lymphatic system and bone
marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland,
breast, lung, colon and skin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer is the second leading cause of death in the United States, exceeded only by heart
disease, and accounts for almost one of every four deaths. The American Cancer Society estimates that in 2013 there will be approximately 1.6&nbsp;million new cases of cancer and approximately 580,000 deaths from cancer. The National Institutes of
Health estimates that the direct medical cost of cancer of all types, including solid tumors, in the United States in 2010 was approximately $125 billion and according to IMS Health the amount spent in the United States on drugs to treat cancer
exceeded $23 billion in 2011. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Solid Tumors&#151;Incidence and Therapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about selected solid tumor types for which we are developing, or may develop, therapeutic
product candidates. The estimated U.S. annual incidence and five-year relative survival rates are based on information from the American Cancer Society in 2013. Relative survival compares survival among cancer patients to that of people not
diagnosed with cancer who are of the same age, race and sex. It represents the percentage of cancer patients who are alive after a designated time period relative to persons without cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Solid Tumors </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Five-year</FONT><BR>Relative<BR>Survival<BR>Rate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prostate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">238,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">~100</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">sipuleucel-T (Provenge); radium 223 dichloride (Xofigo); docetaxel (Taxotere); abiraterome (Zytiga)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breast</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">ado-trastuzumab emtansine (Kadcyla); trastuzumab (Herceptin); lapatinib (Tykerb); docetaxel (Taxotere); paclitaxel (Taxol, Abraxane); capecitabine (Xeloda); anastrazole
(Arimidex); letrozole (Femara); exemestane (Aromasin)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228,190</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); erlotinib (Tarceva); crizotinib (Xalkori); pemetrexed (Alimta)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Colorectal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,820</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); ziv-aflibercept (Zaltrap); cetuximab (Erbitux); panitumumab (Vectibix)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Melanoma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,690</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">vemurafenib (Zelboraf); ipilimumab (Yervoy)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bladder</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,570</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">doxorubicin hydrochloride (Adriamycin); cisplatin</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kidney</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,150</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); axitinib (Inlyta); everolimus (Afinitor); temsirolimus (Torisel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pancreatic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,220</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">gemcitabine (Gemzar); erlotinib (Tarceva); protein-bound paclitaxel (Abraxane)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ovarian</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">paclitaxel (Taxol); topotecan (Hycamtin); etoposide (Etopophos); docetaxel (Taxotere); gemcitabine (Gemzar)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gastroesophageal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,600</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">capecitabine (Xeloda); trastuzumab (Herceptin)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the marketed therapies listed above, there are many generic chemotherapies and regimens
commonly used to treat these cancers. Although the various marketed therapies and regimens provide benefits to some patients when given as monotherapies or in combination with other therapies, each has efficacy and adverse event limitations and none
of them are successful in treating all patients. The level of morbidity and mortality from these cancers remains high. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Hematological Malignancies&#151;Incidence and Therapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about the hematological malignancies for which we are developing, or may develop, therapeutic
product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Hematological Malignancies </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:32pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:46pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Five Year<BR>Relative<BR>Survival&nbsp;Rate</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:99pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute myeloid leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">daunorubicin (DaunoXome); doxorubicin hydrochloride (Adriamycin); cyclophosphamide; cytarabine; vincristine sulfate</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Myelodysplastic syndromes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,673</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Highly<BR>variable</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">decitabine (Dacogen)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute lymphocytic leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,070</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">dasatinib (Sprycel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hairy cell leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,199</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">cladribine; pentostatin; rituximab (Rituxan)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Currently Available Cancer Treatments </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. A cancer patient often receives
treatment with a combination of these methods. For patients with localized disease, surgery and radiation therapy are particularly effective. Systemic drug therapies are generally used by physicians in patients who have cancer that has spread beyond
the primary site or cannot otherwise be treated through surgery. The goal of these therapies is to damage and kill cancer cells or to interfere with the molecular and cellular processes that control the development, growth and survival of cancer
cells. In many cases, drug therapy entails the administration of several different drugs in combination. Over the past several decades, drug therapy has evolved from non-specific drugs that kill both healthy and cancerous cells, to drugs that target
specific molecular pathways involved in cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cytotoxic Chemotherapies </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The earliest approach to pharmacological cancer treatment was to develop drugs, referred to as cytotoxic drugs, which kill rapidly
proliferating cancer cells through non-specific mechanisms, such as disrupting cell metabolism or causing damage to cellular components required for tumor survival and rapid growth. While these drugs have been effective in the treatment of some
cancers, cytotoxic drug therapies act in an indiscriminate manner, killing healthy cells along with cancerous cells. Due to their mechanism of action, many cytotoxic drugs have a narrow dose range above which the toxicity causes unacceptable or even
fatal levels of damage and below which the drugs are not effective in eradicating cancer cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Targeted Therapeutics
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next approach to pharmacological cancer treatment was to develop drugs, referred to as targeted therapeutics,
including monoclonal antibodies, that target specific biological molecules in the human body that play a role in rapid cell growth and the spread of cancer. Included in this category are small molecule drugs as well as large molecule drugs, also
known as biologics. With heightened vigilance and new diagnostic tests, targeted therapies (including monoclonal antibodies such as Herceptin, Rituxan and Avastin as well as small molecules such as Nexavar and Tarceva), have resulted in improvements
in overall survival for many cancer patients. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Next Generation Antibody-based Therapeutics for Cancer </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While targeted antibody therapeutics have been highly successful in treating various cancers, the therapeutic effects of many such
therapies are often relatively transient. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to distant organs. The significant need for improvement in the
treatment of cancer through antibody-based therapies is driving the growing focus on next-generation antibody-based therapies. Opportunities to create next-generation antibody based therapeutics lie in several technology advances including:
antibodies that target multiple antigens, Fc-optimization, and ADCs. Multi-specific antibodies and ADCs have the potential to increase efficacy for cancer treatments and reduce systemic toxicity. Fc Optimization may enable modification of the
antibody to enhance the immune system&#146;s response and augment the therapeutic potential of the antibody, and may increase its half-life, which can potentially lead to less frequent dosing (a competitive advantage for injectables) and a lower
cost of goods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Growth of the Biologics Market </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Over the last 20 years, recombinant biologic therapeutic drugs, including monoclonal antibodies, the largest subclass of recombinant biologics, have had a dramatic impact on cancer therapy. The
improvement of engineering technologies, efficacy and safety of biologic drugs have driven significant market growth, with worldwide sales in 2011 of $157 billion according to data from the IMS Institute for Healthcare Informatics. Data from La
Merie, a business intelligence firm, indicates that therapeutic antibody products represent approximately 52% of total biologic drug sales, with 2012 global sales of approximately $65 billion, an increase from approximately $22 billion in 2006.
Approximately 40 antibody product candidates have been approved by the FDA and international regulatory authorities since the first approval in 1986, and the three largest selling cancer drugs are monoclonal antibodies, Rituxan, Herceptin and
Avastin, which had 2012 worldwide sales of approximately $7.1 billion, $6.3 billion and $6.1 billion, respectively. Today, more than 300 monoclonal antibodies are in various stages of clinical development. According to a 2010 statistical analysis by
Tufts University, antibody product candidates have shown a 2.5 times higher probability of successful clinical development as compared to small-molecule drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Platforms for Creating Next-Generation Antibody-based Therapies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design highly targeted antibody-based product candidates. Our antibody-based platforms consist of: DART, Fc Optimization, and CSLCs.
Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having: (1)&nbsp;multi-specificities; (2)&nbsp;increased abilities to interact with the body&#146;s immune
system to fight tumors; (3)&nbsp;capacity to bind more avidly to antigen targets: (4)&nbsp;increased potency; (5)&nbsp;reduced immunogenicity; or (6)&nbsp;the ability to target cancer cells which are resistant to standard treatments. Moreover, these
technology platforms are complementary and can be combined. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>DART Platform: Our Proprietary Approach to Engineer Multi-Specific Antibodies </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use our DART platform to create derivatives of antibodies with the ability to bind to multiple targets instead of a single target
found in traditional monoclonal antibodies. Our current DART product candidates are bi-specific. An example of a bi-specific molecule is illustrated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g77g14_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because cancer cells have derived ways to escape the immune system, we have created DART molecules
which improve upon the human immune system, by creating alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific
and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are multi-specific and capable of targeting multiple antigens or epitopes (i.e., specific part
of antigen bound to the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bi-specifics and their inherent short half-lives, as well as the inefficiencies in manufacturing these
compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This results in a
structure with enhanced manufacturability, long-term structural stability, and the ability to tailor the half-lives of the DARTs to their clinical needs. This engineered antibody-like protein has a very compact and stable structure and enables the
targeting of multiple different antigens within a single recombinant molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The DART platform has been specifically
engineered to accommodate virtually any variable region sequence with predictable expression, folding, and antigen recognition. To date, we have produced over [100] different DART molecules and have completed numerous <I>in vitro</I> and <I>in
vivo</I> proof of concept studies on most of these molecules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our DART platform may provide a significant advantage over current biological
interventions in cancer and autoimmune disorders by enabling a range of modalities, including those described below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Redirected T Cell Activation and Killing</I>. In this version of the DART molecule, we are
enabling the cancer-fighting properties of the adaptive immune system to: (1)&nbsp;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&nbsp;enable the recruitment of all
types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right), and (3)&nbsp;trigger T cell
activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body&#146;s T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T
cells that are normally generated to kill a cancer cell. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact
structure of the DART protein makes it well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:2px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center">


<IMG SRC="g662896g18q24_g.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Modulation of receptor signaling. </I>In another configuration of the DART molecule, we have
taken advantage of the two (or more) different specificities engineered in a DART structure to bind not only to particular cells involved in autoimmune processes, such as autoimmune B cells, but also to usurp the immune checkpoint signaling pathways
programmed within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a checkpoint inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on the
immune system&#146;s B cells. Using a single DART molecule, we not only target two receptors with a single molecule, but also promote the interaction of these two receptors to interrupt the autoimmune response. This is critical because interruption
of the autoimmune B cell response cannot be achieved merely by using two separate antibodies. In this particular example, the activity of an immune checkpoint molecule, CD32B on B cells, is captured to curb a destructive immune
response.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center">


<IMG SRC="g662896g73g29_g.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Simultaneous targeting of multiple pathologic factors, such as cytokines and growth factors
and their receptors.</I> Targeting multiple soluble proteins or receptors that are important to the perpetuation of an autoimmune disease or generation of a cancer may create therapeutic synergies within a single DART molecule. Examples of this DART
include the targeting of different inflammatory cytokines, such as TNF-a, IL-1, and IL-6, involved in the pathogenesis of autoimmune diseases or those receptors contributing to the growth of cancers such as members of the EGFR family including
EGFR1, HER2 and HER3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g662896g85w60_g.jpg" ALT="LOGO">
</TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.40em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>Targeting multiple epitopes on a pathogen for enhanced neutralization and/or clearance.
</I>Infectious agents with slightly different genetic sequences or structures may perpetuate disease. Sometimes multiple variants may infect one individual and may evade the patient&#146;s normal immune responses. Creating DARTs that eliminate
multiple infectious variants of a virus or multiple toxins produced by a bacterium could be an advantage for prevention or treatment. Examples of this include targeting the major genetic and serological forms of dengue virus, the cause of a major
viral disease transmitted by mosquitoes, quasi-species of HIV, or different bacterial toxins derived from pathogenic clostridium species.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g662896g37d02_g.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we have the ability to tailor a DART molecule&#146;s valency (number of binding sites), the
strength by which the binding sites attach to its targets, and its half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is incorporated in a DART, changes can be included that can modulate the DART&#146;s
engagement with different immune cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have developed proof-of-concept pre-clinical data and are developing specific
product candidates using this technology, including MGD006, MGD007 and MGD010, among others. We have been able to produce DART molecules in both bacterial and mammalian expression systems. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To enhance the body&#146;s immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with
immune effector cells. Such interaction enhances the body&#146;s immune ability to mediate the killing of cancer cells through ADCC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ADCC </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g04y47_g.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Fc region mediates the function of certain antibodies by binding to different activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the
activating Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and with a reduced affinity to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, we have been able to impart a more effective immune response, and improve effector
functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have established a proprietary platform to engineer, screen, identify and test
antibodies&#146; Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. These mice can be used for <I>in vivo </I>testing of antibodies
that incorporate Fc domain variants, including those antibodies intended for cancer therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have successfully
incorporated our Fc variants in our lead product candidates, margetuximab and MGA271. We have pre-clinical data demonstrating that these Fc variants have substantially improved the antibody&#146;s therapeutic effects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer Stem-like Cell Platform: Our Proprietary Approach to Discover Cancer Targets </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our CSLC platform provides new approaches to discover and identify cancer targets that are unresponsive to current cancer therapies.
Cancer stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth and metastasis and are refractory to much standard chemotherapy. Therefore, the ability to
specifically target and destroy CSLCs could potentially address an unmet medical need in many hard-to-treat cancers today. Using our CSLC platform, we can create antibodies that target and kill CSLCs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building on our expertise in growing stem cells from normal tissues using proprietary media and culture conditions, we have produced
CSLCs from primary human tumor tissues. These CSLCs have been generated <I>in vitro</I> from a range of solid tumors and many have demonstrated tumor growth and differentiation <I>in vivo</I>. We believe that this technology holds great promise in
creating the next generation of oncology therapeutics that target both differentiated tumor cells and their precursor cells which traditionally have been resistant to conventional chemotherapy and radiation therapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy has been to generate CSLCs from a range of primary tumors, including those derived from the colon, lung and ovary. We
analyze and characterize the CSLCs for the following: (a)&nbsp;ability for self-renewal, (b)&nbsp;ability to form tumors <I>in vivo</I> that differentiate with the expected histological characteristics, and (c)&nbsp;genetic and protein stem cell
marker expression profiles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have created novel antibodies that target antigens on both CSLCs and bulk
differentiated tumor cells, which are derived from the CSLCs. In addition to their value for identifying potential immune-based therapeutics, other opportunities include their use in small molecule compound screening and diagnostic applications.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have generated over 2,000 monoclonal antibodies that we have screened by immunohistochemistry, or IHC, for lower-binding
to normal, non-malignant tissues. Many of these antibodies have been characterized for binding to primary tumors and cancer cell lines and we are developing the most promising of these antibodies into product candidates. This collection of
antibodies is selective for both validated and novel cancer targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have utilized our CSLC technology to generate or
characterize the antibodies we use in our MGA271 and MGD007 product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product Candidate Pipeline </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates
in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We expect that the net proceeds of this offering will enable us to advance two additional oncology DART-based product
candidates into clinical testing in 2015. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Margetuximab: Fc-Optimized Antibody for HER2-expressing Solid Tumors </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab, or MGAH22, is an Fc-optimized, monoclonal antibody that targets and binds to the HER2 protein on cancer cells and is
intravenously administered in order to kill tumor cells or inhibit tumor cell growth. We are developing margetuximab as an improved, more potent, anti-HER2 treatment for a variety of HER2-expressing tumors such as breast, gastroesophageal and
bladder cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An important mechanism of anti-HER2 monoclonal antibody action is the mediation of ADCC. In ADCC, the
anti-HER2 antibody binds to tumor cells and then recruits immune cells, such as macrophages, through their Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R-mediated mechanisms play a critical part
in the effectiveness of targeted tumor antibodies including anti-HER2 antibodies. Therefore, we have optimized the important Fc region of MGAH22 and thereby improved the cell-killing properties of margetuximab, compared to current anti-HER2
therapies (including trastuzumab). Specifically, we increased binding to activating receptors and decreased binding to the inhibitory receptor on immune effector cells. As a result, we believe margetuximab has the potential to be effective in a much
broader population than the approximately 25% of breast cancer patients treated with trastuzumab today and may overcome resistance in populations who no longer respond to trastuzumab. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The HER2 gene and receptor have an important role in normal cell growth and differentiation. When the HER2 gene has multiple copies,
which is referred to as gene amplification, it results in increased HER2 protein production. This causes cells to multiply in number and grow more rapidly than normal cells, contributing to the formation of cancer. HER2 gene amplification and
protein over-expression occurs in approximately 25% of women with breast cancer. The level of HER2 protein on tumors can be detected by IHC and is scored as 0, 1+, 2+ or 3+, where 3+ indicates the highest expression of HER2 positivity. Fluorescence
in situ hybridization, or FISH, testing is a method used to determine the number of HER2 gene copies that are in a tumor cell. Breast cancer patients with HER2 gene amplification and protein over-expression have a more aggressive disease, greater
likelihood of recurrence, poorer prognosis, and decreased survival compared to patients with HER2-negative breast cancer. Currently, anti-HER2 therapies are only approved for treating approximately 25% of all breast cancer patients whose tumors
overexpress HER2 at the 3+ level, or if 2+, when accompanied by HER2 gene amplification. As illustrated in the figure below, this population of 25% of breast cancer patients represents 60.5% of the 42% of all patients who are HER2+. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g74d12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to study several patient populations in which we believe margetuximab, because of its
optimized structure, has the potential for particular benefit. The first populations being tested include breast and gastroesophageal cancer, but there is also potential to explore other HER2-expressing cancers such as bladder, ovarian and colon.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initially presented data from our Phase 1 clinical trial of margetuximab at ASCO in June
2013. We continue to explore additional intermittent dosing cohorts and expect to complete this clinical trial in 2014. We are currently enrolling an exploratory Phase 2a clinical trial in patients with metastatic breast cancer whose tumors exhibit
expression of the HER2 protein at the 2+ level by IHC and lack evidence of HER2 gene amplification by FISH. We plan to initiate a Phase 3 clinical trial in patients with HER2+ gastroesophageal cancers with HER2 protein expression at the 3+ level by
IHC or 2+ level by IHC with documented gene amplification by FISH that have progressed after standard first and second-line therapy. We expect to begin enrollment in this clinical trial in the second half of 2014 and anticipate that enrollment of
such a trial should be concluded in approximately three years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments for HER2-expressing Solid Tumors </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of breast cancer is largely based on the stage, grade, hormone receptor status and type, and includes surgery, radiation
and drug therapy. Cytotoxic chemotherapies are a mainstay of metastatic breast cancer treatment, irrespective of hormone and HER2 status. Patients who have no detectable cancer after surgery are often given additional drug treatment to prevent
recurrence. This is known as adjuvant therapy. Some patients receive treatment before surgery to shrink the tumor. This is known as neoadjuvant therapy. While anti-HER2 therapies have initially been tested in patients with metastatic cancer, often
as single agents, benefit has been shown in the much larger population of patients treated earlier in adjuvant and neoadjuvant settings. We expect that this paradigm will also be true for margetuximab, but in a larger population. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of gastroesophageal cancer is based on radical surgical resection of the tumor, which when carried out at an early stage
of disease may be curative. When surgical resection of the tumor is not possible, or the tumor recurs or metastasizes, chemotherapeutic agents are utilized. The incidence of gastroesophageal cancer has been declining steadily since the 1930s, yet it
remains a major cause of cancer death in the United States and a greater problem in the rest of the world. Gastroesophageal cancer is the fourth most common cancer in the world (989,000 new cases diagnosed in 2008) and the second most common cause
of cancer-related death in the world. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Several drugs directed at HER2 have been approved for the treatment of early and advanced stage breast cancer and advanced
gastroesophageal cancer. Most patients treated with existing HER2 therapies, such as trastuzumab (Herceptin), pertuzumab (Perjeta), lapatinib (Tykerb), and ado-trastuzumab emtansine (Kadcyla, also referred to as T-DM1), will either fail to respond
or become resistant to continued treatment. In addition, existing HER2 therapies are not effective in the treatment of patients who do not highly over-express HER2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of Margetuximab </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab is an
Fc-optimized, monoclonal antibody believed to mediate its therapeutic activity against HER2+ tumors by a combination of mechanisms including: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Modulation of the receptor signaling resulting in growth retardation or the induction of apoptosis, or cell death; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADCC and improved binding to immune cells to enhance destruction of HER2+ tumor cells; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presentation of antigens by cells such as macrophages that engulf the tumor cells, digest them, and display the tumor antigens to other cells of the
immune system including T cells. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R mediated mechanisms play
a critical part in the activity of several antibodies including anti-HER2 antibodies. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R sequences will differ among people and a single amino acid difference in an
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R can significantly alter an antibody&#146;s Fc binding properties. Clinical data shows improved outcomes in metastatic breast cancer patients who have a higher binding form of an activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD16A, in response to treatment with chemotherapy plus trastuzumab. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below shows the difference in progression-free survival between patients treated
with trastuzumab who have the higher-binding form of CD16A and those who have the lower-binding form of CD16A. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g03z41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowing that approximately 80% of subjects express the lower-binding
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, we specifically optimized the Fc domain of margetuximab to enhance binding to the lower-binding form of CD16A. We believe margetuximab will have greater activity than trastuzumab and may overcome
resistance in populations of patients whose tumors do not respond, or no longer respond, to trastuzumab. In addition, the optimized Fc domain of margetuximab imparts reduced binding to the inhibitory
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD32B, a feature expected to further enhance the activating properties of margetuximab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have conducted <I>in vitro</I> and <I>in vivo</I> pre-clinical studies that support the superiority of margetuximab compared to trastuzumab. In these pre-clinical models, margetuximab exhibits enhanced
anti-tumor activity against HER2-expressing tumor cell lines in <I>in vitro</I> ADCC assays and in human tumor xenograft models in human CD16A+ transgenic mice. We have also demonstrated superior effects of margetuximab over trastuzumab in <I>ex
vivo </I>studies using patient samples from the Phase 1 clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of Margetuximab </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the pre-clinical laboratory studies conducted with margetuximab, we assumed that margetuximab would have clinical benefit in
patients with tumors not currently thought to be targets for trastuzumab therapy, including those whose tumors express the HER2 protein at less than 3+ levels by IHC and lack evidence of HER2 gene amplification by FISH. We also assumed that
margetuximab benefits would extend to patients bearing the lower-binding form of CD16A. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 2a Metastatic Breast Cancer
Study </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We submitted an IND in January 2010 for margetuximab for the treatment of HER2-positive carcinomas, including
breast cancer. We are currently enrolling a Phase 2a clinical trial to determine if margetuximab has sufficient activity in patients with metastatic breast cancer who are not currently considered candidates for trastuzumab therapy to further
evaluate margetuximab in this patient population. We are enrolling patients with metastatic breast cancer whose tumors exhibit expression of the HER2 protein at the 2+ level by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
IHC and lack evidence of HER2 gene amplification by FISH. This group of patients represents an unmet medical need which may be addressed by margetuximab. Margetuximab will be administered as a 6
mg/kg intravenous, or IV, solution weekly on Days 1, 8, and 15 of each 28-day cycle. If fewer than two partial or complete responses are observed in the first 21 patients evaluable for response at the first tumor re-evaluation on day 22 of cycle 2
of treatment, no additional patients will be enrolled and the trial will end. If two or more responses are observed at the first tumor re-evaluation on day 22 of cycle 2 of treatment, we will expand the clinical trial to include a total of 41
patients evaluable for response. If five or more partial or complete responses are observed in these 41 patients, then we will consider margetuximab to have adequate activity in this patient population to justify additional clinical development. We
are conducting this clinical trial at six sites in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Anticipated Margetuximab Clinical Trials
</I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to file a separate IND for margetuximab for the treatment of patients with HER2+ gastroesophageal cancers with
HER2 protein expression at the 3+ level by IHC or 2+ level by IHC with documented gene amplification by FISH in the first quarter of 2014. We plan to commence a 425&nbsp;patient, randomized Phase 3 clinical trial to evaluate the addition of
margetuximab to standard cytotoxic chemotherapy (irinotecan or paclitaxel) in the third line treatment of patients with advanced gastroesophageal cancers which have progressed after standard frontline and second-line treatment of advanced disease.
We have selected the CRO and intend to commence patient recruitment in the second half of 2014. The primary analysis will compare the overall survival of patients randomized to chemotherapy plus placebo to the overall survival of patients randomized
to chemotherapy plus margetuximab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Anticipated Phase 2 Development </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate conducting exploratory clinical trials in patients with other HER2 expressing malignancies. The design of these clinical
trials will be informed by the results of the ongoing Phase 2a clinical trial in metastatic breast cancer. If the results of that clinical trial are positive, then we will pursue a population of patients with HER2 2+ or 3+ tumors. Such a population
would represent approximately one-third to one-half of patients with metastatic bladder cancer, and smaller proportions of patients with ovarian cancer, endometrial cancer, and colon cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Study Results </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 clinical trial is an open-label, multi-dose, single-arm, dose-escalation study conducted to define the safety profile and pharmacokinetics, or PK, of margetuximab and to begin to explore the
antitumor activity of margetuximab in patients with refractory HER2+ tumors. We enrolled a total of 34 patients in the dose escalation (0.1 to 6.0 mg/kg) and expansion (6.0 mg/kg) phases of the trial. This patient population was heavily pre-treated
with prior therapies, including 19 patients with other prior anti-HER2 therapies. In the absence of dose limiting toxicity, an additional cohort of patients was treated at the top dose. We expect to complete this clinical trial in 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the dose escalation and expansion segments of the Phase 1 clinical trial of margetuximab, a dose of 6.0 mg/kg has been
well-tolerated in patients with refractory HER2+ tumors who were treated weekly for four weeks. Approximately one-third of patients received additional cycles of margetuximab treatment. Using margetuximab as a single agent, tumor response was
observed even in patients who had failed prior therapies including other anti-HER2 treatment. Responses to date include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unconfirmed partial response in one patient with mucoepidermoid carcinoma of the salivary gland treated at 1.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 3.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 6.0 mg/kg; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with a gastroesophageal junction tumor treated at 6.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unconfirmed partial response in one patient with colorectal cancer at 6.0 mg/kg; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">four patients with times to progression exceeding five months. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we are exploring intermittent administration of margetuximab as a more convenient dosing regimen. In this portion of the
Phase 1 clinical trial, a patient with breast cancer experienced a confirmed partial response at 10.0 mg/kg (administered every three weeks) with a time to progression currently exceeding five months. We are currently enrolling patients who are
being administered margetuximab at 15.0 mg/kg every three weeks and intend to enroll additional patients at 18.0 mg/kg every three weeks. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Evidence of activity was seen at doses as low as 0.1 mg/kg weekly, to which a patient with metastatic breast cancer whose tumor had progressed after two prior anti-HER2 therapies (trastuzumab and
ado-trastuzumab emtansine) experienced stability of disease and time to progression that exceeded nine months. The maximum percent reduction (below baseline) or increase (above baseline) in the size of target tumors at any time from patients treated
with different doses of margetuximab is shown below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g61o14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most frequent adverse events observed in patients participating in the dose escalation portion of
this trial were infusion reactions, which we observed in approximately 27% of patients on the day of infusion. Most of these events were mild or moderate in severity. Institution of pre-medications has reduced the incidence and severity of
infusion-associated adverse events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We assessed the <I>ex vivo</I> ADCC response of peripheral blood
mononuclear cells, or PBMCs, obtained from subjects in the dose escalation portion of this Phase 1 trial. Each patient sample was divided and exposed separately to margetuximab and trastuzumab. Margetuximab outperformed trastuzumab in <I>in
vitro</I> ADCC assays, reducing the dose required to achieve equivalent cell killing and increasing total cell killing. The concentration of drug required to achieve a half maximal effect (EC</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">50</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">) on ADCC was much lower for margetuximab (mean 3.5 <U>+</U> 1.0 ng/ml) than trastuzumab (mean 40.7 <U>+</U> 17.1 ng/ml).
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGA271: Fc-Optimized Antibody for B7-H3-Expressing Solid Tumors </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271
is a humanized, Fc enhanced, monoclonal antibody that targets B7-H3 expressing tumors and is intravenously administered in order to kill tumor cells or inhibit their growth. We are developing MGA271 to treat multiple solid tumors such as melanoma,
glioblastoma, prostate cancer, and breast cancer. We believe that targeting B7-H3 using MGA271 has significant potential to treat a variety of solid tumors because it incorporates multiple complementary mechanisms of action in one molecule. These
potentially include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhanced ADCC through Fc Optimization; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Targeting of both CSLCs and tumor cells; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opportunity to differentially target tumor vasculature and underlying supporting tissues; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Potential for enhanced anti-tumor immunity by blockade of T cell inhibition (inhibiting the inhibitor). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 has been engineered to have enhanced binding to CD16A. MGA271 also exhibits reduced binding to CD32B. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initiated a Phase 1 clinical trial of MGA271 in patients with B7-H3 tumors in August 2011. We have completed the dose escalation
portion of this trial without exceeding a maximally tolerated dose, or MTD. We commenced an expansion phase in the third quarter of 2013, in which we are enrolling patients and treating them at the highest dose tested during the dose escalation
portion of the trial. We expect to complete the first three dose expansion cohorts of this clinical trial by the end of 2014. We plan to initiate additional dose expansion cohorts using MGA271 as monotherapy in other tumor types in 2014, as well as
combining MGA271 with other therapies for certain tumor types. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of B7 Family of Immune Regulators, Including B7-H3, in Cancer
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The B7 family of cell surface molecules consists of structurally related protein ligands that bind to receptors on
lymphocytes and regulate immune responses. B7 homolog 3 (B7-H3) is a novel member of the B7 family of immune regulatory molecules. This family of molecules is an area of interest across the pharmaceutical industry, and is being explored by companies
including AstraZeneca PLC, or AstraZeneca, Bristol-Myers Squibb Co., or Bristol-Myers, GlaxoSmithKline plc, or GSK, Merck&nbsp;&amp; Co., or Merck, Merck KGaA and Roche. The chart below describes our understanding of various B7 immune regulator
targets and current marketed products and clinical stage product candidates addressing such targets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B7 Immune Regulator Family </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="39%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:81pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Antigen-Presenting&nbsp;Cell</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:21pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>T Cell</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:30pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Function</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:107pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Product or Product Candidates</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 (B7-1) or CD86 (B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CTLA4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ipilimumab (marketed by Bristol-Myers)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-CTLA4 (AstraZeneca, Phase 2)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 (B7-1) or CD86 (B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD28</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD-L1 (B7-H1) or PD-L2 (B7-DC)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD1</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Merck, Phase 3)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Bristol-Myers, Phase 3)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1 (Bristol-Myers, Phase 2)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD-L2/Fc fusion (GSK/AstraZeneca, Phase 1)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1 (Roche, Phase 2)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-1 (AstraZeneca, Phase 1)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD-L1 (Merck KGaA, Phase 1)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7RP1 (B7-H2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">ICOS</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMG 557 (Amgen/AstraZeneca, Phase&nbsp;1)</FONT></P></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 (MacroGenics, Phase 1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H5 (VISTA)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H6</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKp30</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our own analysis of fixed tumor microarrays representing more than 700 samples across various tumor
types including glioblastoma, thyroid, gastroesophageal, breast, pancreas, prostate, melanoma and ovarian cancers, we saw B7-H3 expression in approximately 70&#151;99% of tumor samples, with high expression (2+ or greater by IHC) in most of these
tumor types. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3 inhibits T cell activation and cytokine production. Other examples of inhibitors of T cell activation
include the immune check-point regulators PD1 and CTLA4. Anti-PD1 and anti-CTLA4 (e.g., ipilimumab) antibodies have shown therapeutic effects in patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer and are being tested in
individuals with several other types of cancers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-Clinical Development of MGA271 </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have evaluated the ability of MGA271 to mediate ADCC activity across multiple cancer types expressing varying levels of B7-H3 as
determined by flow cytometry. The cancer types tested included melanoma, lung cancer, prostate cancer, breast cancer, bladder cancer, and renal cancer cell lines. MGA271 mediated ADCC activity against all tumor lines that express B7-H3 at detectable
levels. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 exhibited anti-tumor activity in mouse models when administered approximately one week
after tumor cell implantation (as shown below), or after tumors were allowed to become fully established (approximately three weeks after implantation when tumors were approximately 300 mm</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in volume). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Tumor Efficacy of MGA271 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>in a Pre-clinical Model of Renal Cell Carcinoma </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g01c75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a renal cell carcinoma tumor line were implanted subcutaneously in immunodeficient mice that expressed
the lower-binding form of human CD16A. MGA271 was administered intravenously weekly at the indicated dose levels as shown by arrows above. All dosages of MGA271, including 0.1 mg/kg, inhibited tumor growth when compared to both control groups,
vehicle or lgG. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A repeat dose Good Laboratory Practice, or GLP, toxicology study was conducted in cynomolgus monkeys to
determine the potential toxicity of MGA271. MGA271 was well tolerated when administered by IV infusion at four weekly doses of up to150 mg/kg. The no observed adverse effect level was considered to be 150&nbsp;mg/kg. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of MGA271 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to complete the first three dose expansion cohorts of a Phase 1 clinical trial by the end of 2014. We plan to initiate additional expansion cohorts with MGA271 monotherapy in other tumor types
in 2014, and a combination of MGA271 with other therapies in certain tumor types. We submitted an IND in March 2011 for MGA271 for the treatment of patients with refractory B7-H3-expressing tumors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:3%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Trial </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 trial is an open-label, multi-dose, single-arm, multi-center, dose-escalation clinical trial. This trial includes patients with B7-H3-expressing tumors, such as prostate cancer, pancreatic
cancer, melanoma and ovarian cancer, and tumors whose vasculature exhibits B7-H3 expression, such as glioblastoma, renal cell carcinoma and ovarian cancer. The clinical trial began with a dose escalation segment in which patients were treated with
increasing weekly doses of MGA271 from 0.01 mg/kg up to 15 mg/kg. We have not seen any dose limiting toxicity, and we initiated an expansion phase in the third quarter of 2013 at a dose of 15 mg/kg. During
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the expansion phase, we are recruiting an additional 15 patients to each of three cohorts that represent a distinct patient population determined by histology: 1) patients with melanoma, 2)
patients with prostate cancer and 3) patients with any B7-H3 positive tumor other than melanoma or prostate cancer with the limitation of a maximum of five patients with any single histologic type such as colorectal adenocarcinoma or histologic
subgroup such as sarcoma. In addition, Servier has indicated that it intends to evaluate MGA271 in up to 75 additional cancer patients representing additional types of cancers beginning in the first quarter of 2014. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We enrolled a total of 26 patients in the trial through the dose escalation portion, with 15 different types of tumors. Ten patients
received additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment. The most frequent adverse events in the trial were mild or moderate infusion reactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because anti-cancer monoclonal antibodies are target specific, the presence of the target on tumor cells is usually required for the
desired biological effect of the antibody. An immunohistochemistry based companion diagnostic for MGA271 would detect the presence of B7-H3 on the cellular membrane of tumor cells. A positive result detecting B7-H3 on the cellular surface is
currently required for trial eligibility and we expect it will be required for identification of appropriate candidates for MGA271 treatment should the product candidate be approved. We are working with two third party vendors for the development of
the companion diagnostic, and we plan to contract with a vendor for future commercialization based on the results. We plan to have a companion diagnostic ready for incorporation into potential Phase 3 trials and are working with a collaborator to
develop it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD006: DART-Based Molecule for Acute Myeloid Leukemia </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGD006 is a humanized DART molecule that recognizes both
CD123 and CD3. We are developing MGD006 for the treatment of hematologic cancers. The primary mechanism of action of MGD006 is its ability to redirect T cells which express CD3 to kill CD123 expressing cells, such as leukemic cells. We plan to
initiate a Phase 1 clinical trial of MGD006 in patients with relapsed or refractory acute myeloid leukemia, or AML, or in patients with untreated AML who are not candidates for standard induction chemotherapy in the second quarter of 2014.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of CD123 in Acute Myeloid Leukemia </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CD123 has been reported to be overexpressed on malignant cells in a wide range of hematologic malignancies including AML and myelodysplastic syndrome, or MDS. Overexpression of CD123 is associated with a
poorer prognosis in AML. AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells, or LSCs, which generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123
expression, which is not present in the corresponding normal hematopoietic stem cell population in normal human bone marrow. CD123 is also expressed by plasmacytoid dendritic cells, or pDCs, basophils, endothelial cells and, to a lesser extent,
monocytes and eosinophils. The anti-CD123 component of MGD006 is based on a humanized version of 7G3, a mouse monoclonal antibody directed against CD123. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of MGD006 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a targeted therapy for CD123
expressing cells, we believe that MGD006 will have fewer side effects than conventional chemotherapeutic agents which broadly target rapidly dividing cells including cancer cells, normal hematopoietic stem cells and certain immune cells such as
activated lymphocytes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, because CD123 is expressed on the LSCs that perpetuate this disease, MGD006 will be
targeting the source of the disease, and potentially deliver more durable remissions. This would represent an advance in AML therapy, because the LSCs that sustain this disease are generally resistant to the chemotherapy
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which is the standard approach to disease treatment. The resistance of LSCs to chemotherapy may be due to the fact that they are a rare, relatively dormant, cell type within the leukemic cell
population and, therefore, are less susceptible to the primary mechanism of action of chemotherapeutic agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development
of MGD006 </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2013, one of our academic investigators presented data from a pre-clinical study at the 55th
Annual Meeting of the American Society of Hematology. The pre-clinical study investigated the ability of MGD006 to redirect T cells against CD123-positive AML blasts. Investigators demonstrated that MGD006 binds to both human CD3 and CD123 to
mediate target-effector cell aggregation, T-cell activation and proliferation. MGD006 induced a dose-dependent reduction of primary AML blast survival <I>in vitro</I> and <I>in vivo</I>. Notably, a short course of treatment with MGD006 in mice
engrafted with an AML patient sample induced a greater than 97% elimination of AML blasts from the peripheral blood and significant clearing from the spleen and bone marrow 6 weeks after AML cell infusion. The results of this study provide a strong
rationale for the clinical development of MGD006 as a novel molecule for the treatment of patients with AML. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our own <I>in
vitro</I> experiments, we have demonstrated that MGD006 is able to mediate T&nbsp;cell killing of CD123-expressing cells. In an <I>in vitro</I> model of T cell-mediated killing of AML cells, addition of MGD006 led to destruction of AML cells derived
from leukemia patients. Three leukemia cell lines expressing CD123 were exposed to MGD006 or a control DART protein in the presence of T cells. Dose-dependent increases in cell killing were observed following treatment with MGD006. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart below, primary AML PBMC samples were incubated with a phosphate buffered saline, or PBS control, a DART protein control or
MGD006. Treatment with MGD006 resulted in a dose-dependent decrease in leukemic blast cell number counts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AML Blasts
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g50h21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We performed pilot toxicology studies in cynomolgus monkeys. Complete depletion of CD123-expressing
pDCs, an indication of activity in healthy animals, occurred at doses as low as 10 ng/kg/day. Importantly, this effect was reversible as pDCs were observed in peripheral blood a few weeks following cessation of dosing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No significant infusion reactions were observed at the lowest starting doses studied,
including the pharmacologically active dose levels (10-30 ng/kg/day). Administration of MGD006 at higher doses was associated with acute infusion reactions, which typically decreased or disappeared with subsequent dosing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD007: DART-Based Molecule for Gastrointestinal Cancers </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGD007 is a DART protein in which the first specificity
is for the glycoprotein gpA33 and the second specificity is for CD3. MGD007 also contains an Fc domain which provides for an extended serum half-life compared to basic DARTs. gpA33 was identified through immunizations using our proprietary CSLC
lines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing MGD007 as a potential therapeutic agent for the treatment of colorectal cancer. Other tumors of the
gastrointestinal tract, such as pancreatic and gastroesophageal cancers, may also be potential indications for development. In a survey of normal tissues examined, the gpA33 antigen was expressed almost exclusively in the intestinal epithelium. It
was present in more than&nbsp;95% of human colon cancers, and in approximately 50% of gastroesophageal and pancreatic cancers. Studies by others with a radiolabeled monoclonal antibody against gpA33 demonstrated preferential binding to tumors over
normal colonic mucosa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have conducted pre-clinical <I>in vitro</I> and <I>in&nbsp;vivo</I> proof-of-concept studies with
MGD007 or a basic DART form of MGD007 without the Fc domain. In addition, we have completed the <I>in vivo</I> portion of a GLP toxicology study in cynomolgus monkeys. We are planning to submit an IND in 2014 and commence a Phase 1 clinical trial
for MGD007 in the second half of 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development of MGD007 </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results of <I>in vivo</I> experiments shown below demonstrate that a gpA33 x CD3 DART is able to mediate T&nbsp;cell killing of
gpA33-expressing cancer cells: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g25i12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a colorectal cancer line and activated human T cells were implanted subcutaneously in immunodeficient
mice. A gpA33 x CD3 DART was administered intravenously daily for four days at the time of tumor implantation. Inhibition of tumor growth was observed at all dose levels tested when compared to animals treated with a control. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Oncology DART-Based Product Candidates </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have an active discovery effort and we have generated multiple un-partnered product candidates, which are in various stages of
research and pre-clinical development. Several of these undisclosed product candidates are based on our DART technology, and are directed toward various oncology targets, both novel and validated. We intend to use a portion of the net proceeds from
this offering to advance at least two of these programs to IND submission and commence Phase 1 clinical studies in 2015. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010:
DART-Based Molecule for Autoimmune Diseases </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Autoimmune diseases including rheumatoid arthritis, or RA, Crohn&#146;s
disease, systemic lupus erythematosis, or SLE, and multiple sclerosis, or MS, collectively affect more than 20&nbsp;million people in the United States. Autoimmune disease involves self-tissue destruction by T cells and antibodies due to lack of
self-tolerance. Anti-inflammatory therapies, such as TNF (tumor necrosis factor) inhibitors, have been able to improve diseases like RA; however, it has become increasingly known that, in addition to T cells, B cells play an important role in many
common autoimmune and allergic disorders by initiating and amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections
(e.g., rituximab, or <I>Rituxan</I>), or exhibit a delayed onset of action and limited efficacy across patient populations (e.g., belimumab, or <I>Benlysta</I>). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To address limitations of existing B cell targeted therapies, MacroGenics has developed a novel CD32B x CD79B DART, called MGD010. In pre-clinical studies, this DART modulates the function of human B
cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 exploits this mechanism and triggers this
inhibitory &#147;immune checkpoint&#148; loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. Studies in SLE patient B cells and humanized
mouse models have demonstrated that MGD010 can block B cell activation in the absence of B cell depletion. To advance this program to the clinic, we recently performed studies in non-human primates with MGD010 demonstrating a favorable safety
profile and pharmacological effects on targeted B cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart below, treatment with MGD010 prolongs survival compared
to a PBS control or a single dose of rituximab in a mouse model of graft versus host disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010 in a Chronic Graft
versus Host Disease </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Transplantation) Mouse Model </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g74m92.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Immunodeficient mice administered human PBMCs by injection were treated intravenously either with MGD010 at 5.0 or
10.0 mg/kg or PBS control every four days (9 total doses) or with rituximab at 5.0 mg/kg for one dose. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Teplizumab: Fc-Modified Antibody for Type 1 Diabetes </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is a humanized, anti-CD3 monoclonal antibody being developed for the treatment of Type 1 Diabetes, or T1D. Teplizumab has been
engineered to alter the function of the T cells that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of T1D by addressing the underlying
disorder, rather than merely using insulin replacement therapy. In 2007, we entered into a collaboration with Eli Lilly. During the clinical development of teplizumab, Eli Lilly provided financial, manufacturing, and commercial support to us while
we conducted our Phase 3 clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, we published the results of Prot&eacute;g&eacute;, a Phase 3 clinical
study of teplizumab in T1D, in <I>The Lancet</I> and follow-up data in <I>Diabetes</I> in 2013. The primary clinical endpoint of this trial, a composite of glycated hemoglobin, or HbA1c, and insulin usage, was not met. HbA1c is a form of hemoglobin
that reflects average plasma glucose concentration over prolonged periods of time. When T1D is poorly controlled, the glucose and consequently, HbA1c levels rise. Insulin use was measured as units used per day. Subjects were required to have a low
HbA1c level (&lt;6.5%) and low daily insulin usage (&lt;0.5 units per day). Similar numbers of patients in the 14 day teplizumab regimen and placebo (insulin only) achieved this endpoint. Although this trial did not meet its primary clinical
endpoint, an exploratory, post-hoc analysis suggests that teplizumab, when used in a full dose regimen, may preserve insulin production by beta cells in the pancreas, as measured by C-peptide, and increase the percentage of patients requiring very
low doses of insulin compared to those on placebo. Preservation of insulin production as measured by C-peptide, relative to standard of care, is now recognized as an acceptable primary endpoint by the FDA. The findings suggest that future studies of
immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta cell function (measured by C-peptide) and preservation of glycemic control at reduced doses of insulin, particularly in children, if
intervention occurs soon after diagnosis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is currently being evaluated in a Phase 2 clinical trial, called At
Risk, for the prevention or delay of onset of T1D in patients determined to be at very high risk for developing the disease. This clinical trial is being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, or NIDDK. In
2011, Eli Lilly terminated its collaboration with us to develop teplizumab and pursuant to the terms of the agreement, we reacquired the commercial rights to teplizumab. We are actively seeking a collaborator for further development of teplizumab.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The At-Risk study is being conducted under an IND filed and sponsored by MacroGenics, pursuant to IND 102,629 filed on
December&nbsp;23, 2009. The clinical study is being conducted by NIDDK at TrialNet clinical sites. NIDDK, in conjunction with TrialNet, prepared the clinical protocol and is responsible for training and monitoring the clinical sites. MacroGenics
officially transferred these sponsor responsibilities to NIDDK in its initial IND submission. Under FDA regulations, MacroGenics remains responsible for submitting the appropriate documents to the IND, including but not limited to, IND Annual
Reports, expedited reports, revised clinical protocols provided by NIDDK, and new clinical investigator information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Collaborations
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our therapeutic programs. These therapeutic collaborations have
provided us with approximately $106 million in non-equity funding during the three year period ended June&nbsp;30, 2013. Under these agreements, we believe we are likely to receive over $100&nbsp;million of milestone and other payments subsequent to
June 30, 2013 and by the end of 2015, assuming all of our collaboration programs advance as currently contemplated. Key terms of our collaborations are summarized below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier MGA271 Agreement </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to
obtain an exclusive license to develop and commercialize the Fc engineered antibody we designated as MGA271 and certain other Fc engineered antibodies that also bind the B7-H3 receptor, collectively referred to as the MGA271 licensed products, in
all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment upon dosing the first patient in the expansion cohort of our Phase I
clinical trial of MGA271, and may be eligible to receive up to approximately $415 million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for and
successfully commercializes an MGA271 licensed product. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of MGA271
licensed products at percentages ranging from the low double digits to the mid-teens, subject to reductions in specified circumstances. Under specific circumstances, Servier may defer payment of certain milestone payments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Plan</I>. Under the agreement, we are responsible for conducting research according to an agreed upon research plan during a
specified research term. The activities under the research plan include the generation of data by us that the parties have agreed will be included in a data package, or MGA271 data package. We will continue conducting the current Phase 1 trial of
MGA271 under the research plan. Under the agreement, Servier may conduct separate development and clinical activities under the research plan, subject to our approval. The term of the research plan begins on the effective date of the agreement and
ends on the earlier of November&nbsp;24, 2015 or the expiration of Servier&#146;s option under the agreement. In general, during the research term, each party is responsible for the internal and external costs it incurs to conduct its activities
under the research plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I> . Under the agreement we are obligated to supply cGMP produced MGA271 licensed
products to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials according to a clinical supply agreement negotiated between the parties. Servier is obligated to pay for such supply of MGA271
licensed product under the clinical supply agreement at our fully burdened manufacturing cost. Prior to exercising its option, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier exercises its option,
upon its request, we are obligated to enter into negotiations to execute a commercial supply agreement for MGA271 licensed product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Generally, Servier may exercise its option at any time after the effective date of the agreement until ninety days after Servier&#146;s receipt of the MGA271 data package which shall
include results from completed expansion cohorts from the Phase 1 clinical trial. In the event Servier exercises the option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the number of different indications
represented within the patient population in a planned expansion cohort in our Phase 1 clinical trial of MGA271. If Servier elects not to exercise the option, it will lose all rights to develop and commercialize MGA271 licensed products and we will
be entitled to develop and commercialize MGA271 licensed products throughout the world exclusively or with a third party or parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>License/Exclusivity </I>. If Servier exercises the option it will receive an exclusive license to develop and commercialize MGA271 licensed products in all countries of the world other than the United
States, Canada, Mexico, Japan, South Korea and India. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and
commercialize MGA271 licensed products under the agreement, there are additional obligations regarding exclusivity and noncompetition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to these provisions, in the event that we seek to grant rights to a third party to develop and/or commercialize certain DARTs that bind the B7-H3 receptor outside the United States, Servier
has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights within a specified time period, subject to specified exceptions, we will have
the right to enter negotiations with a third party for the same rights. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>.&nbsp;If Servier does not exercise its&#146; option, the
agreement terminates upon the expiration of the option. If Servier exercises the option, the agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent related to an MGA271 licensed product, the regulatory
based exclusivity period or 12 years after the first commercial sale of any MGA271 licensed product. The agreement contains customary termination rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier DART Agreement </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In September 2012, we
entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART
molecule, collectively referred to as the DART-licensed products, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. Under the terms of the agreement, we received a $20 million option grant fee. In addition,
we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all of the options and successfully develops, obtains regulatory
approval for and commercializes a product under each license, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestones, we and Servier will share Phase 2 and Phase 3 development
costs. Under the agreement we are also eligible to receive royalties on the net sales of DART licensed products at percentages ranging from the low double digits to the mid-teens, subject to reductions in specified circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs</I>. Under the agreement, we are responsible for conducting research according to an agreed upon research plan for
each option target during the specified research term. Each research plan and its activities are considered a research program. The activities under each research plan include the generation of data by us that the parties have agreed that will be
included in a data package, or the Servier DART data package. With our consent, Servier may conduct separate development and clinical activities under a research plan. The research term for each research program begins on the effective date of the
agreement and ends on the earlier of September&nbsp;19, 2016 or the expiration of the applicable option. In general, during each research term, each party is responsible for the internal and external costs it incurs to conduct its activities under
that research plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I> . Under the agreement we are obligated to negotiate a clinical supply agreement with
Servier regarding the supply of cGMP produced material to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials for each DART licensed product. Servier pays for such supply of each DART licensed
product under each clinical supply agreement at our fully burdened manufacturing cost. Prior to exercising one of its options, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier exercises an option,
then upon Servier&#146;s request, we are obligated to enter negotiations to execute a commercial supply agreement for DART licensed products subject to that option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Under the terms of the agreement, each option may be exercised by Servier within ninety days after Servier&#146;s receipt of the applicable Servier DART data package. In the event Servier
exercises an option, Servier must pay a specified license grant fee for exercising that option. The respective license grant fees are $15 million for the MGD006 option, which becomes exercisable upon completion of our GLP toxicology study, and
additional amounts related to MGD007, and a remaining DART molecule, which become exercisable after a significant portion of the Phase 1 trials for each of these programs is completed. If Servier elects not to exercise an option, it will lose all
rights to develop and commercialize DARTs that bind such option target and we will be entitled to develop and commercialize DARTs that bind the former option target throughout the world exclusively or with a third party or parties, subject to
Servier&#146;s right of first negotiation, as described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses/Exclusivity.</I> If Servier exercises an option it
will receive an exclusive license to develop and commercialize DARTs that bind to the option target for that option, and pharmaceutical products that comprise or contain such DARTs, in all countries of the world other than the United States, Canada,
Mexico, Japan, South Korea and India. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and commercialize DARTs under each
license, under the agreement there are additional obligations regarding exclusivity and noncompetition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to these
provisions, in the event that we seek to enter into a transaction under which we would grant rights to a third party to develop and/or commercialize certain product candidates in Servier&#146;s territory that bind an option target in exchange for
certain consideration, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights within a specified time period, we will have
the right, subject to specified exceptions, to enter negotiations with a third party for the same rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and
Termination.</I> If Servier does not exercise any option, the agreement terminates upon the expiration of the last to expire option. If Servier exercises an option, the agreement will terminate in its entirety with respect to such DART licensed
product upon the later of the expiration of the last-expiring patent related to a DART licensed product, the regulatory based exclusivity period or 12 years after the first commercial sale of a DART licensed product. The agreement contains customary
termination rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gilead </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I><B>.</B> In January 2013, we entered into an agreement with Gilead for (i)&nbsp;the research, development, manufacture and commercialization of DARTs that bind to a first pair of specified
targets; (ii)&nbsp;an exclusive option for an exclusive license to research, develop, manufacture and commercialize DARTs that bind to a second pair of specified targets in North America, the European Union, Norway, Iceland, Turkey, Australia and
New Zealand; and (iii)&nbsp;separate exclusive options for worldwide exclusive licenses to research, develop, manufacture and commercialize DARTs that bind to third and fourth pairs of targets to be subsequently identified by Gilead and accepted by
us within a specified time period after the effective date of the agreement, which we collectively refer to as the Gilead licensed products. The time period for Gilead&#146;s exercise of the option to the second target pair has expired. At present,
Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights to each of these remaining programs. We received an initial $7.5 million license grant fee for granting Gilead a license to the
first target pair, and are eligible to receive an additional $7.5 million in grant fees for each of the remaining two DART-based molecules if they are selected by Gilead, up to an additional $20 to $25 million in pre-clinical milestones across each
of the three remaining DART programs and up to $240 to $250 million per remaining program in additional clinical, regulatory and sales milestones payments if Gilead exercises both remaining options and achieves all of the requisite milestones under
each option and license. Under the agreement, we are also eligible to receive tiered royalties on the net sales of Gilead licensed products at percentages ranging from the high-single digits to the low double digit, but less than teen royalties
subject to reductions in specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs.</I> During specified research terms, we are
responsible for conducting research according to an agreed upon research plan for each pair of targets for which Gilead exercises its option. Each research plan and its activities are considered a research program. Upon approval by the joint
research committee, Gilead may conduct separate development and clinical activities under a research plan. The term of the research plan for the first target pair has already begun. The research terms of the research plans for the third and fourth
target pairs can begin only after Gilead&#146;s exercise of the options for such target pairs. The term for Gilead&#146;s exercise of the option to for the second target pair has expired. Gilead has fixed time periods to exercise its options for the
third and fourth target pairs and we may decline to accept Gilead&#146;s selection of the third and fourth target pairs under specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During each research term, Gilead will reimburse us for all internal and external costs we incur to conduct our assigned activities under that research plan, subject to specified limitations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses.</I> Under the agreement, we granted Gilead an exclusive worldwide license to research, develop, manufacture and
commercialize DARTs that bind to the first pair of specified targets. Upon initiation of each of the research terms for the third and fourth target pairs we will grant Gilead a worldwide exclusive license to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
research, develop, manufacture and commercialize DARTs that bind to the corresponding target pair. Gilead did not exercise its option with respect to the second target pair. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pre-clinical Milestone</I>. Notice by Gilead to pay the pre-clinical milestone for each target pair category must be provided to us
within specified time periods. Upon providing notice to pay a pre-clinical milestone for a target pair category, Gilead will become responsible for all research, development and commercialization activities with respect to licensed products within
such target pair category in Gilead&#146;s territory for such target pair license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified
exceptions, during the term of the agreement, other than with respect to the research and development activities pursuant to the agreement, we may not, directly or indirectly, research, develop, manufacture or commercialize a product that binds to
both targets from any target pair category covered by the agreement in a country where Gilead has been granted a license for such target pair. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent related to a Gilead licensed product, the regulatory based
exclusivity period or 12 years after the first commercial sale of a Gilead licensed product. Gilead has the right to terminate the agreement at any time with respect to one or more selected target pairs or in its entirety, upon prior written notice
to us. The agreement contains customary termination rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Boehringer </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010 we entered into a collaboration and license agreement with Boehringer to discover, develop and
commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, we granted Boehringer an exclusive, worldwide, royalty-bearing, license under our intellectual property to research, develop, and
market DARTs generated under the agreement, or the Boehringer licensed products, throughout the world. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the agreement,
we received an upfront payment of $15 million. We subsequently received three annual maintenance payments including one in the fourth quarter of 2013. Also, in the fourth quarter of 2013, Boehringer&#146;s selection of a development candidate
triggered a $5 million milestone payment to us under the agreement. We have the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement
in the case of full commercial success of multiple DART products. Boehringer also provides funding for our internal and external research costs and is required to pay us mid-single digit royalties, on a licensed product-by-licensed product basis, on
worldwide net sales, subject to reductions in specified circumstances. We have the option to co-promote certain DART products in the United States and may elect to co-fund Phase 3 clinical development in exchange for an increased royalty rate on net
sales. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I> Under the agreement, Boehringer is entitled to select up to ten pairs of targets for which we would
generate DARTs that bind to such targets. Several of the targets were identified in the agreement. Subsequent target pairs are selected according to a process which permits us to decline to accept such target pairs under specified circumstances.
During the research term of the agreement, we are responsible for generating pre-clinical DART candidates that bind the accepted target pairs and generating data according to specified criteria which will be presented to Boehringer as a data
package. If Boehringer accepts a pre-clinical DART candidate it will be responsible for subsequent development and commercialization of such pre-clinical DART candidate. We have the right to co-fund a portion of the Phase 3 clinical development in
exchange for an increased royalty rate. We also have the right to co-promote up to two DART products that are developed under the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Purchase.</I> Boehringer purchased $10 million of our Series D-2 preferred stock in January 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified exceptions, during the term of the agreement, other than with respect to Boehringer licensed products, we agreed not to research, develop or commercialize any
product using our DART platform that is directed to a target covered under the agreement. Subject to specified exceptions, we further </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
agreed not to grant any third party rights to research, develop or commercialize any product using our DART platform that is directed to a specified number of specific targets identified in the
agreement, until a specified time period or the date on which neither of the identified targets has been selected as a target subject to development and commercialization under the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent
related to a Boehringer licensed product, or 12 years after the first commercial sale of a Boehringer licensed product. Boehringer has the right to terminate the agreement at any time with respect to one or more selected target pairs or in its
entirety, upon prior written notice to us. However, it must maintain research efforts during a specified time period of the agreement. The agreement may also be terminated by either Boehringer or us in the event of an uncured material breach by the
other party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pfizer </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010, we entered into a research collaboration and license agreement with Pfizer. Under the agreement, we granted Pfizer a non-exclusive worldwide, royalty-bearing license and
received upfront and milestone payments and funding for our internal and external research costs under the agreement. Under the terms of the agreement, we received a non-refundable, non-creditable $5 million upfront fee. In addition, we are eligible
to receive up to approximately $210 million per Pfizer DART molecule, as defined in the agreement, in technical, development and sales milestone payments if specified net sales thresholds are reached. We are also entitled to receive royalties from
Pfizer at percentages ranging from the mid-single digits to the low-teens on net sales of any Pfizer DART. Under this collaboration, one DART program is currently being pursued and we completed our research obligations under this program in January
2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I> Under the agreement, we are obligated to construct Pfizer DARTs that bind to a first and second target
identified in the agreement that are each expressed on cancer cells. During the research term of the agreement, which expires on October&nbsp;13, 2013, we conduct pre-clinical development of the Pfizer DARTs in collaboration with Pfizer according to
an agreed upon research plan. Under certain circumstances, Pfizer has the right to substitute the second target during specified periods. Pfizer has exercised those rights at various times during the specified periods which have now expired.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product Development.</I> Upon expiration of the research term in October 2013, Pfizer will use commercially reasonable
efforts to develop and obtain regulatory approval for each Pfizer DART in both the United States and other specified countries. In addition, Pfizer will use commercially reasonable efforts to commercialize a Pfizer DART in each country where Pfizer
has received regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement, Pfizer has sole responsibility and authority
for commercialization of Pfizer DARTs at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> Pfizer has the exclusive right to
manufacture Pfizer DARTs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I> Under the Agreement we granted Pfizer an exclusive, worldwide license to use,
develop, manufacture, and commercialize Pfizer DARTs. The license includes the right to sublicense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>.
Subject to specified exceptions, until October&nbsp;3, 2015, we agreed not to research, develop, commercialize, manufacture, or grant any third party rights to research, develop, commercialize, or manufacture, (i)&nbsp;a Pfizer DART that binds to a
cancer target for which a Pfizer DART is under development in the agreement; or (ii)&nbsp;product candidates based on an antibody that we have supplied to serve as the basis for generating a Pfizer DART that is in development under the agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will terminate in its entirety upon the later of the expiration of the
last-expiring patent related to a Pfizer DART licensed product, or 12 years after the first commercial sale of a Pfizer DART licensed product. We or Pfizer may terminate the agreement in the event of an uncured material breach by the other party.
After a specified period, Pfizer may terminate the agreement for convenience upon prior written notice to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Green Cross </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In June 2010, we entered into a Collaboration Agreement with Green Cross Corp., or Green Cross, to grant Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 trials
and commercialize margetuximab in South Korea. Under the terms of the agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if Green
Cross commercializes margetuximab. We are also entitled to receive royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab by Green Cross in South Korea. In addition, Green Cross purchased $2.0 million of our
Series D-2 Preferred Stock in January 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Development.</I> Initial development of margetuximab under the
agreement is being conducted according to a Phase 1 development plan that has been agreed upon by the parties. We hold the clinical trial application for the ongoing Phase 1 clinical trial conducted in South Korea. Based upon an amendment to the
agreement, Green Cross is responsible for all of its costs to conduct the Phase 1 development plan up to a specified amount and, we are responsible for all of our own costs to conduct the Phase 1 development plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development of margetuximab under the agreement after completion of the Phase 1 clinical trial will be conducted according to a Phase 2
development plan. In that regard, Green Cross is obligated to use best efforts to initiate a Phase 2 clinical trial with margetuximab in South Korea within a specified period of time after the completion of the Phase 1 trial. The costs of conducting
the Phase 2 trial will be the responsibility of Green Cross. After completion of the Phase 1 trial, Green Cross has the responsibility for submitting clinical trial applications to the Korea Food and Drug Administration, or KFDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Green Cross shall have the option to participate in any additional studies to the extent such studies are required by the KFDA to obtain
approval of margetuximab in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement Green Cross has sole responsibility
and authority for commercialization of margetuximab in South Korea at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> We are
responsible for supply of margetuximab that is used for clinical development by Green Cross in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I>
Under the Agreement we granted Green Cross an exclusive license to conduct specified Phase&nbsp;1 and Phase 2 trials and commercialize margetuximab in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Consideration.</I> Under the Agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if
Green Cross commercializes margetuximab. In addition, we are entitled to receive royalties which are determined by a formula that allocates the cost of commercial supply and third party royalties against net sales. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>. The agreement will terminate in its entirety upon the later of the expiration of the last-expiring patent
related to margetuximab, or 12 years after the first commercial sale of margetuximab in South Korea. The agreement may also be terminated by either Green Cross or us in the event of an uncured material breach by the other party. The agreement may be
terminated by us immediately in the event Green Cross participates or actively assists in a legal challenge to one of the patents exclusively licensed to Green Cross under the agreement. Either party may terminate the agreement in the event of a
change in control of the other party upon 30 days prior written notice to the other party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent
protection intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and/or other aspects of the inventions that are important to our business. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business
that are not amenable to, or that we do not consider appropriate for, patent protection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to continue to expand our
intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our technology platforms and ongoing development of our product candidates.
Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules
in a variety of therapies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend significantly on our ability to obtain and maintain patent and other
proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of
our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen,
and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office filings for any applications by third parties that may infringe on our patents. To
date, we have not identified any potential infringement of our patents by third parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A third party may hold intellectual
property, including patent rights that are important or necessary to the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to
commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third
parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to
invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application
can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable
patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors.
Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because patent
applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially even longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries,
we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. We are participating in post-grant
challenge proceedings, such as oppositions, that challenge the patentability of third party patents and may have to participate in such proceedings again in the future. Such proceedings could result in substantial cost, even if the eventual outcome
is favorable to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent portfolios for our most advanced programs are summarized below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>. We own our margetuximab patent portfolio, which includes one issued patent and one pending U.S. patent application.
Our issued patent relates to the composition of or methods of making or using margetuximab and covers Fc engineered HER2 binding antibodies. This patent will expire in 2025. Related </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Patent Cooperation Treaty, or PCT, and national patent applications filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire
in 2025. Our current pending U.S. application relates to the composition of margetuximab. If issued, this patent will expire in 2029. We filed related PCT and national patent applications in a number of other countries. Any patents resulting from
these patent applications, if issued, also will expire 2029. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain issued patents and pending U.S. patent applications for
our Fc Optimization platform portfolio provide additional intellectual property protection for margetuximab. We own three issued patents in this portfolio, two that relate to compositions of matter and one that covers methods of use. In addition, we
have four current pending U.S. patent applications relating to compositions of matter, methods of using, and methods of making. The issued patents and any patents resulting from the pending patent applications, if issued, will expire between 2024
and 2030. PCT and national patent applications filed in a number of other countries are pending. Any patents resulting from these applications, if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271. </I>We own our MGA271 patent portfolio. This portfolio includes two pending U.S. patent applications. One of these pending
patent applications claims MGA271 variable domains that bind to the B7-H3 receptor. Both pending patent applications cover the composition of or methods of making or using MGA271. In addition, related PCT and related national patent applications are
pending in several other countries. The U.S. pending patent applications and national patent applications, if issued, will expire in 2031. MGA271 is also covered by the same patents and patent applications from our Fc Optimization platform portfolio
that cover margetuximab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006.</I> We own our MGD006 patent portfolio. This portfolio includes two U.S. pending
provisional patent applications that claims general composition of or methods of making or using MGD006. Any patents resulting from this application, if issued, will expire in 2034. We expect to file PCT and national patent applications in other
countries in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of
matter, methods of using, methods of making also cover MGD006. These patents, if issued, will expire between 2026 and 2031. In addition, related PCT and national patent applications filed in a number of other countries are pending. Any patents
resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. We own our MGD010 patent portfolio. This portfolio includes four pending U.S. patent applications. Each patent application
claims compositions of matter, methods of using, and methods of making. If issued, any patents resulting from these applications will expire between 2022 and 2034. In addition, related PCT and national patent applications in a number of other
countries are pending. Any patents resulting from these patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Three pending U.S. patent applications for our DART platform portfolio claiming compositions of matter, methods of using, methods of making also cover MGD010. Any patents resulting from these U.S. patent
applications will expire between 2026 and 2031. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire on the same dates as
our corresponding U.S. patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>DART Platform.</I> We own our DART platform patent portfolio. This portfolio includes
seven pending U.S. patent applications, each of which claims compositions of matter, methods of using, and methods of making. Patents resulting from six of these U.S. patent applications, if issued, will expire between 2026 and 2031. The remaining
application, which relates to certain mutations incorporated into our DARTs, if issued, will expire in 2032. In addition, related PCT and national patent applications in a number of other countries are pending. Any patents resulting from these
patent applications, if issued, will expire on the same dates as our corresponding U.S. patents. A PCT application in our DART Platform patent portfolio also relates to a particular binding component of our DARTs. Related national applications will
be filed in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fc Optimization Platform.</I> We own our Fc Optimization platform patent portfolio. This
portfolio includes three issued U.S. patents that cover the compositions of antibody Fc regions with certain mutations that affect their binding to Fc receptors. These patents expire in 2024. Related national patents have issued in a number of other
countries or are pending. The issued patents and any patents resulting from the pending patent applications, if issued, will expire in 2024. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Cancer Stem-like Cell Platform.</I> We own our cancer stem-like cell platform patent portfolio. This portfolio consists of one issued U.S. patent that will expire in 2028. Related national patents have
issued in a number of other countries and will expire on the same date. In addition to patent protection, we will also rely on the use of trade secrets to protect our cancer stem-like cell platform. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries
in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However,
the term of the U.S. patents may be extended due to delays encountered during prosecution which are caused by the USPTO or by delays incurred due to compliance with FDA regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Regulatory Review Process </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Hatch-Waxman Act permits a
patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the
remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a
patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to
any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be
granted, and even if granted, the length of such extensions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Trade Secrets </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our
proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to
our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to
execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the
individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived
by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases
our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render
under such agreements or grant us an option to negotiate a license to use such inventions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also included in our trade secrets
are hybridomas which express antibodies that bind to proteins which are or may be expressed on cancerous cells, including cancer stem cells. The antibodies produced by each hybridoma are unique and may have properties that are absent in antibodies
expressed by other hybridomas. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
These properties could confer advantages and capabilities to product candidates developed with antibodies that exhibit such properties. We closely control and monitor access to the hybridomas and
the antibodies they produce. Before receiving such materials, our collaborators, prospective collaborators and all other parties are required to execute material transfer agreement or other agreement which contractually limit their permitted uses
and dissemination of such materials. In many cases our agreements with other parties granting access to and use of our biological materials require them to assign or grant us licenses to inventions they invent as a result or their use of the
materials or grant us an option to negotiate a license to use such inventions </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In-Licensed Intellectual Property </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into patent and know-how license agreements which grant us the right to use a certain technology related to biological
manufacturing to manufacture margetuximab and MGA271. We anticipate using this technology for future product candidates. This licensor has a business dedicated to licensing this technology and we anticipate that licenses to use the technology for
our future products will be available. The licenses typically include an obligation to pay an upfront payment, yearly maintenance payment and sales royalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into a research evaluation agreement for a technology related to biological manufacturing that we anticipate using to manufacture certain DART products. This licensor has a business
dedicated to licensing this technology and we anticipate that licenses will be available to use it to manufacture quantities of the DART products for clinical and commercial uses. The licenses may include an obligation to pay an upfront payment,
yearly maintenance payments, milestones and sales royalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In establishing our Fc Optimization platform, we entered into
patent license agreements which grant us the right to use technologies to generate mutant Fc regions. The licenses include obligations to pay a yearly maintenance payment, development milestones and sales royalties on products we develop and
commercialize that include mutant Fc regions generated using the patented technologies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a manufacturing facility located in Rockville, Maryland. This facility has been used to manufacture all of the current
clinical supply for margetuximab and MGA271 to date. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. We intend to use a portion of the net
proceeds of this offering to expand our capacity at this location, or possibly elsewhere. For our Phase 3 clinical trials for our antibody product candidates and for commercial sale quantities of such candidates, we anticipate that we will need to
obtain additional manufacturing capacity through contract manufacturers to be able to supply the quantities required. We intend to screen multiple manufacturers to provide the drug substance for commercial purposes for some of our product candidates
prior to the filing of a BLA. We currently rely on and will continue to rely on contract fill-finish service providers to fulfill our fill-finish needs for our current and future product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our product candidates are biologics and are manufactured in disposable bioreactors in CHO cells in accordance with current Good
Manufacturing Practices, or cGMP. We expect to continue to develop product candidates that can be produced at our manufacturing facility and at contract manufacturing facilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate cell lines internally that serve as the source for our biologic drug substance. These cell lines are then sent to a vendor
where they are expanded and banked, and are available upon our request to use in developing drug substance. All other manufacturing materials used in the production of drug substance are readily available in the ordinary course of business from a
number of standard biotechnology vendors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generally expect to rely on third parties for the development and manufacturing
of our companion diagnostics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commercialization </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not yet established a sales, marketing or product distribution infrastructure because our lead product candidates are still in clinical development. We generally seek to retain commercial rights
in the United States for our clinical product candidates for which we hope to receive marketing approvals and have done so to date in our collaborations other than our Boehringer, Gilead and Pfizer collaborations. We believe that it will be possible
for us to access the United States oncology market through a targeted specialty sales force. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to receiving marketing
approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists
who are the key specialists in treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for
any of our product candidates that obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also plan to build a marketing and sales management
organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing
educational initiatives with respect to approved products and establishing relationships with thought leaders in relevant fields of medicine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect that our collaborators for any companion diagnostics we may develop in the future for use with our product candidates will hold the commercial rights to these diagnostic products. We expect to
coordinate closely with our diagnostic collaborators in connection with the marketing and sale of our related product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with
competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research
institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major
pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In
addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen is now in late-stage clinical development of cancer product candidates which work by targeting antigens
both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent
antibodies, including Roche and Xencor, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have significantly greater financial, manufacturing,
marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key competitive factors affecting the success of all of our therapeutic product
candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of
reimbursement from government and other third party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other
regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be
affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be
approved prior to margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug
therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in
combination with or as an adjunct to these therapies, our product candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis.
Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to currently marketed therapies, there are also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety,
dosing convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our lead product candidates are approved for the indications for which we are currently undertaking clinical trials, they will compete
with the therapies and currently marketed drugs discussed below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I> . Irrespective of HER2 status,
metastatic breast cancers are often treated with cytotoxic chemotherapies such as anthracyclines and taxanes, as well as capecitabine. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. In addition, there are
several approved therapies specifically indicated for the treatment of early and advanced stage breast cancer and advanced gastroesophageal cancer that are HER2+, including Herceptin, Kadcyla, Tykerb and Perjeta, and each of those drugs targets
HER2+ tumors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I>. The most common treatments for solid tumors are various chemotherapeutic agents, radiation
therapy and certain targeted therapies including monoclonal antibodies such as Herceptin, Avastin, Erbitux and Vectibix, as well as small molecule agents, including, Tarceva, Sunitinib and Sorafenib. No therapies are approved specifically for the
treatment of tumors associated with the expression of B7-H3. Yervoy, which targets CTLA4, an inhibitory molecule on T cells, is currently indicated for the treatment of melanoma and marketed by Bristol-Myers. In addition, there are several
antibodies in development that target other members of the B7&nbsp;family or their associated checkpoint receptors. These include anti-PD1 molecules by Merck, Bristol-Myers and AstraZeneca, and anti-PD-L1 molecules by Bristol-Myers, Roche and Merck
KGaA and a PD-L2 Fc fusion protein by GSK and AstraZeneca. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006</I>. The most common treatments for AML are various
chemotherapeutic agents, radiation and stem cell transplants. No therapies are approved specifically for the treatment of AML associated with the expression of CD123. We are aware of a monoclonal antibody currently being developed by CSL Limited
which targets CD123. In addition, StemLine Therapeutics, Inc. has treated patients in a clinical trial with a recombinant protein composed of IL-3 linked to a truncated diphtheria toxin payload. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I>. The most common treatments for gastroesophageal tumors are various
chemotherapeutic agents, radiation therapy, monoclonal antibodies including Herceptin, Avastin, Erbitux, Vectibix, as well as small molecule agents. No therapies are approved specifically for the treatment of tumors associated with the expression of
gpA33. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. Current B cell targeted therapies for autoimmune diseases include Rituxan and Arzerra for the treatment
of rheumatoid arthritis and Benlysta for the treatment of SLE. In addition, several other therapies are available to reduce inflammation, including nonsteroidal anti-inflammatory drugs such as Advil and Aleve; corticosteroids such as prednisone;
disease-modifying antirheumatic drugs such as methotrexate and hydroxychloroquine; immunosuppressants such as cyclosporine; and other drugs which target a variety of processes involved with inflammation such as Actemra, Kineret, Enbrel, Remicade,
Humira, Simponi, Cimzia, Orencia and Xeljanz. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation and Product Approval </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among
other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes
for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Approval Process </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The Food and Drug Administration (FDA) subjects biologics to extensive
pre- and post-market regulation. The Public Health Service Act (PHSA), the Federal Food, Drug, and Cosmetic Act (FDC Act) and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, civil penalties, or criminal penalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The PHSA emphasizes the importance of manufacturing
control for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of
shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction, or spread, of communicable diseases in the United States and between states. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process required by the FDA before a new biologic may be marketed in the United States is long, expensive, and inherently uncertain.
Biologics development in the United States typically involves pre-clinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical
trials to establish the safety and effectiveness of the biologic for each indication for which FDA approval is sought. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required may
vary substantially based upon the type, complexity, and novelty of the product or disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-clinical tests include
laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal
regulations and requirements, including good laboratory practices. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a
proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans.
If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the condition under investigation, all under the supervision of a qualified
investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define
the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each
protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes
that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also
be submitted to an institutional review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other
conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or
be combined. In Phase 1, the biologics initially introduced into healthy human subjects or patients, and the biologic is tested to assess pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible,
early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer treatments, initial human testing may be conducted in the intended patient population. Phase 2 usually involves trials in a limited
patient population to determine the effectiveness of the biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an
acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites.,
These Phase 3 clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit FDA to evaluate the overall benefit-risk relationship of the biologic and to provide
adequate information for the labeling of the biologic. Trials conducted outside of the US under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of product licensing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial
design and trial results in FDA public databases. These requirements are subject to specific timelines and apply to most controlled clinical trials of FDA-regulated products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA review and approval of the BLA is required before marketing of the product may begin in the United
States. The BLA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls and must demonstrate the safety and efficacy
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the product based on these results. The BLA must also contain extensive manufacturing information. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission
of most BLAs is additionally subject to a substantial application user fee, as well as annual product and establishment user fees, which may total several million dollars and are typically increased annually. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#146;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such
applications for standard review biologics are reviewed within ten months from the date the application is accepted for filing. Although FDA often meets its user fee performance goals, the FDA can extend these timelines if necessary, and FDA review
may not occur on a timely basis at all. The FDA usually refers applications for novel biologics, or biologics which present difficult questions of safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other
experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA,
the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic is manufactured. The FDA will not approve the product unless it
verifies that compliance with current good manufacturing practice, or GMP&#151;a quality system regulating manufacturing&#151;is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe and effective in the
indication studied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or
a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those
deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. The FDA approval is never guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it
continues to be safe, pure, and potent. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. The approval for a biologic may be significantly more limited than requested
in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions be
included in the product labeling. In addition, as a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the biologic outweigh the potential risks. REMS can include
medication guides, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a biologic can materially affect the potential market and profitability of the biologic. Moreover, product
approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the biologic&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not
maintained or problems are identified following initial marketing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After a BLA is approved, the product may also be subject
to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release by the FDA, the
manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also
perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products.
After approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fast Track </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Fast Track program, a provision of the FDA Modernization Act of 1997, is designed to facilitate interactions between a sponsoring company and the FDA before and during submission of a BLA for an
investigational agent that, alone or in combination with one or more other drugs, is intended to treat a serious or life-threatening disease or condition, and which demonstrates the potential to address an unmet medical need for that disease or
condition. Under the Fast Track program, the FDA may consider reviewing portions of a marketing application before the sponsor submits the complete application if FDA determines, after a preliminary evaluation of the clinical data, that a fast track
product may be effective. A Fast Track designation provides the opportunity for more frequent interactions with the FDA, and a fast track product could be eligible for priority review if supported by clinical data at the time of submission of the
BLA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act (Affordable Care Act) signed into law on March&nbsp;23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009. That Act
created an approval pathway authorizing the FDA to approve biosimilars and interchangeable biosimilars. Biosimilars are biological products which are &#147;highly similar&#148; to a previously approved biologic product or &#147;reference
product&#148; and for which there are no clinically meaningful differences between the biosimilar product and the reference product in terms of the safety, purity, and potency. For FDA to approve a biosimilar product as interchangeable with a
reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biosimilar and the reference biologic may be
switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex,
structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. To date, no biosimilar or interchangeable biologic has been
licensed under the BPCIA framework, although such approvals have occurred in Europe, and it is anticipated that FDA will approve a biosimilar in the relatively near future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product. A biosimilar application may be filed four (4)&nbsp;years after the approval of the
reference biologic. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be
licensed by FDA until the end of the exclusivity period. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics
submitting under the abbreviated approval pathway for the lesser of (i)&nbsp;one year after first commercial marketing, (ii)&nbsp;18 months after the initial application if there is no legal challenge, (iii)&nbsp;18 months after the resolution in
the applicant&#146;s favor of a lawsuit challenging the biologics&#146; patents if an application has been submitted, or (iv)&nbsp;42 months after the application has been approved if a lawsuit is ongoing within the
<FONT STYLE="white-space:nowrap">42-month</FONT> period. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by FDA, in fact, will be readily substituted by pharmacies, which are governed by state pharmacy law.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advertising and Promotion </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once a BLA is approved, a product will be subject to continuing post-approval regulatory requirements. For instance, FDA closely
regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities
involving the internet. Failure to comply with these regulations can result in significant penalties, including the issuance of warning letters directing a company to correct deviations from FDA standards, a requirement that future advertising and
promotional materials be precleared by the FDA, and federal and state civil and criminal investigations and prosecutions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to
some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be
implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adverse Event Reporting and GMP Compliance </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance
to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, manufacture, packaging, labeling, storage and distribution procedures must
continue to conform to current cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to
periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality
control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals if a company fails to comply with regulatory
standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Companion Diagnostics </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA regulates the sale or distribution, in interstate commerce, of medical devices, including IVDs. IVDs are a type of medical device that are intended to detect diseases, conditions, or infections,
or the presence of certain genetic or other biomarkers. If safe and effective use of a therapeutic depends on an IVD, the FDA generally will require approval of the companion diagnostic, at the same time that the FDA approves the therapeutic. The
FDA previously has required <I>in vitro</I> companion diagnostics intended to identify the patients most likely to respond to a treatment to obtain approval of a premarket approval application (PMA) simultaneously with approval of the biologic. A
required companion diagnostic has the potential to delay approval of the biologic and create barriers to patient access. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics intended to treat a rare disease or
condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity
of the biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to
receive FDA approval for a particular product to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same
disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different biologic for the same disease or condition,
or the same biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate seeking orphan drug designation for margetuximab, MGA271, MGD006 and MGD007. Such designation would be sought in those
populations that are being, or will be, studied to treat a disease or condition that affects fewer than 200,000 individuals in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United
States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human
Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>International Regulation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations in the United
States, a variety of foreign regulations govern clinical trials, commercial sales, and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for
FDA approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pharmaceutical Coverage, Pricing, and Reimbursement </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend
in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the
medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement
adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our headquarters are located in Rockville, Maryland, where we
occupy office and laboratory space under a lease that expires on March&nbsp;31, 2018. Our manufacturing facility is also located in Rockville under a lease with the same landlord that expires on December&nbsp;31, 2014. We have an option under each
lease to continue the respective lease for five years under the same terms. We also sublease office and laboratory space in South San Francisco under a lease that expires on December&nbsp;31, 2018. We are seeking to sublease a substantial portion of
this space. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, we had 162 full-time employees, 126 of whom were primarily engaged in research and development activities and 35 of whom had an M.D. or Ph.D. degree. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
are not currently a party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_12"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides information with respect to our directors and executive officers as of December&nbsp;31, 2013. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:35pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position(s)</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Research</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kathryn Stein, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Product Development and Regulatory Affairs</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Clinical Development</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanford Stewart, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Clinical Oncology Research</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Risser</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Business Development</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lynn Cilinski</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Controller and Treasurer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Directors</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith (1)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz (1)(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D (2)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D (1)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Audit Committee </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Compensation Committee </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Nominating and Corporate Governance Committee </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Koenig has been our President and Chief Executive Officer and a director since September 2001 and was one of our co-founders. Prior to joining us, Dr.&nbsp;Koenig served as Senior Vice President
of Research at MedImmune Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the
National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr.&nbsp;Koenig currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation and of
the Children&#146;s Research Institute of Children&#146;s National Medical Center, and serves as a Board member of the Biotechnology Industry Organization (BIO) and Children&#146;s National Medical Center. Dr.&nbsp;Koenig received his A.B. and Ph.D.
from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. We believe that Dr.&nbsp;Koenig&#146;s detailed knowledge of our company and his over 29 years in research and the biotechnology industry provide a
valuable contribution to our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Karrels joined us as Vice President and Chief Financial Officer in
May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life sciences companies. Prior to joining us, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director
of Finance, where he was responsible for the company&#146;s financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr.&nbsp;Karrels spent 11 years in the Investment Banking Group at Merrill Lynch,
most recently serving as a Director in the Global Healthcare Group. Mr.&nbsp;Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Bonvini, Senior Vice President, Research, joined us in June 2003. From 1985 to 2003, Dr.&nbsp;Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is
responsible for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982
to 1984, Dr.&nbsp;Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr.&nbsp;Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty
Certification in Clinical Hematology from the University of Genoa, School of Medicine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stein joined us as Vice
President, Product Development and Regulatory Affairs in May 2002 and has served as a Senior Vice President since 2006. From 1980 to 2002, Dr.&nbsp;Stein was at the FDA, including serving as Director, Division of Monoclonal Antibodies in the Office
of Therapeutics Research and Review at CBER from 1992 to 2002. While at the FDA, Dr.&nbsp;Stein worked on all regulatory aspects of therapeutic proteins and monoclonal antibodies and was a leader in policy development at FDA for these products. Many
currently marketed monoclonal antibodies were approved under her leadership. Dr.&nbsp;Stein received her Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine of Yeshiva University and her B.A.&nbsp;in Chemistry from Bard
College. Dr.&nbsp;Stein commits half of her time to us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Wigginton joined us as Senior Vice President, Clinical
Research in August 2013. Dr.&nbsp;Wigginton was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine-Clinical Oncology at Bristol-Myers from October&nbsp;2008 to August&nbsp;2013.
While there, he led the early clinical development of the Bristol-Myers&#146; Immuno-Oncology portfolio including anti-PD-1 and anti-PD-L1. Prior to joining Bristol-Myers, Dr.&nbsp;Wigginton was the Director of Clinical Oncology at Merck Research
Laboratories from May 2006 to October 2008, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, Dr.&nbsp;Wigginton held several positions at the National Cancer Institute
Center for Cancer Research (NCI-CCR), including Head of Investigational Biologics Section, Pediatric Oncology Branch. Dr.&nbsp;Wigginton received his M.D. and B.S. in Biology from the University of Michigan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stewart joined us as Vice President, Clinical Oncology Research in July 2008. From 2005 to 2008, Dr.&nbsp;Stewart served as Vice
President, Clinical Research at Raven Biotechnologies, Inc., which we acquired in July 2008. From 2001 to 2005, Dr.&nbsp;Stewart was with Corixa Corporation, most recently as Vice President, Clinical Research. Dr.&nbsp;Stewart was with ALZA
Corporation in 2001 and from 1998 to 2001, he was with Genentech, where he was Clinical Scientist on the Herceptin project and guided post-marketing clinical development, including the adjuvant breast cancer program. Dr.&nbsp;Stewart trained in
Medical Oncology at Stanford University, and served as a member of the faculty of the School of Medicine at Vanderbilt University for more than twelve years. Dr.&nbsp;Stewart received his M.D. from Baylor College of Medicine and his B.A. degree from
Rice University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Risser joined us as Vice President, Business Development in May 2009. Prior to joining us,
Mr.&nbsp;Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson&nbsp;&amp; Johnson, where he worked from 2003 to 2009. Before Johnson&nbsp;&amp; Johnson, Mr.&nbsp;Risser started and built a
consulting practice that provided counsel to emerging life science companies in the United States and Europe. Earlier in his career, Mr.&nbsp;Risser held venture capital and investment banking positions with BA Venture Partners and Lehman Brothers
Holdings Inc., respectively. Mr.&nbsp;Risser holds an M.B.A. from Stanford University and a B.A. from Yale University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Cilinski, Vice President, Controller and Treasurer, joined us in October 2003. Prior to joining us, Ms.&nbsp;Cilinski spent a
year as a consultant to various companies providing services to the government. Prior to that, she spent more than 20 years with Covanta Energy Inc. (formerly Ogden Corporation) where she held the position of Corporate Controller for four subsidiary
companies that provided services to the federal government. Ms.&nbsp;Cilinski holds a B.S. from Strayer University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Costa has served as a director since June 2009 and became chairman of the board in September 2013. Mr.&nbsp;Costa served as
President and Chief Executive Officer of Novartis U.S. Corporation, a pharmaceutical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and consumer health company, from October 2005 to August 2008. From August 2009 to August 2012, Mr.&nbsp;Costa served as chairman of the board of directors of Amylin Pharmaceuticals Inc., a
publicly held company, and currently serves as a director of two privately-held companies. Based on Mr.&nbsp;Costa&#146;s diverse experience in the pharmaceutical industry, ranging from successful product development, launch and commercialization
and his extensive senior management experience within the industry, the board of directors believes Mr.&nbsp;Costa has the appropriate set of skills to serve as a member of the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Galbraith has served as a director since July 2008. Mr.&nbsp;Galbraith is a Managing Director at Five Corners Capital Inc.,
general partner and investment manager of the Ventures West venture capital funds. He has served in this capacity, and in a similar capacity with the predecessor manager and general partner of these funds, since 2007. Mr.&nbsp;Galbraith has over 25
years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr.&nbsp;Galbraith has served as a director of Celator Pharmaceuticals, Inc., a
publicly held company, since July 2007, and has also served as a director of Tekmira Pharmaceuticals Corp., a publicly held company, since January 2010. In addition, Mr.&nbsp;Galbraith serves as a director of several privately-held companies. Based
on Mr.&nbsp;Galbraith&#146;s depth of experience in the biotechnology industry, ranging from executive officer to director roles, the board of directors believes Mr.&nbsp;Galbraith has the appropriate set of skills to serve as a member of the board
of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Hurwitz has served as a director since October 2004. Mr. Hurwitz is a managing director of Precision
Bioventures, LLC, a consulting and advisory firm, and a director of the general partner of Alta BioPharma III, L.P., a fund affiliated with Alta Partners, a venture capital firm. He was a director at Alta Partners from 2002 through December 2013 and
continues to serve as a consultant to that firm and as a board representative of several of its privately-held portfolio companies. The board of directors has concluded that Mr. Hurwitz should serve on the board of directors due to his financial and
scientific expertise, as well as his deep understanding of the biotechnology industry, which the board of directors believes makes him an important resource for the board of directors as it assesses both financial and strategic decisions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nadav has served as a director since June 2013. Dr.&nbsp;Nadav is a Managing Director at TPG Biotech, the life
science venture investment arm of TPG, a global private investment firm. Dr.&nbsp;Nadav joined TPG Biotech in 2007 with a focus on global pharmaceuticals and biotechnology investments. Prior to TPG, Dr.&nbsp;Nadav served as Business Development
Director at Eisai Pharmaceuticals in New Jersey for four years, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this, Dr.&nbsp;Nadav worked for Johnson&nbsp;&amp; Johnson Development Corporation, the venture
capital subsidiary of Johnson&nbsp;&amp; Johnson, and for Neurim Pharmaceuticals. Based on Dr.&nbsp;Nadav&#146;s business experience and scientific expertise, the board of directors believes that Dr.&nbsp;Nadav has the appropriate set of skills to
serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky has served as a director since 2000. Dr.&nbsp;Oronsky has been
a general partner with InterWest&nbsp;Partners, a venture capital firm, since 1994, focusing primarily on life science companies. Dr.&nbsp;Oronsky serves as a director of Tesaro, Inc., a publicly held company, as well as several privately held life
science companies. The board of directors believes that Dr.&nbsp;Oronsky&#146;s experience in the life sciences industry as a venture capitalist and his service on the boards of directors of other public and private life sciences companies provides
him with the qualifications and skills to serve as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stump joined our board of directors in September
2013. Dr.&nbsp;Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc. from November 1999 until his retirement in December 2012. Dr.&nbsp;Stump also serves as a director of Sunesis Pharmaceuticals,
Inc., a publicly held company, and as a director of Dendreon Corporation, also a publicly held company. The board of directors believes that Dr.&nbsp;Stump&#146;s medical training and 23 years of experience in research and development and operations
in the biotechnology industry qualify him to serve as a member of our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Composition and Election of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Board Composition </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently consists of
seven members. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our restated certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our board of directors. Our restated certificate of incorporation
and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy
on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the terms of our restated certificate of incorporation and bylaws that will become effective upon the closing of this
offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. Upon the closing of this offering, the members of the classes will be divided as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I, whose term will expire at the annual meeting of stockholders to be held in 2014; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class II, whose term will expire at the annual meeting of stockholders to be held in 2015; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class III, whose term will expire at the annual meeting of stockholders to be held in 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I shall consist of Messrs. Koenig, Nadav and Oronsky, Class II shall consist of Messrs. Galbraith and Stump, and Class III shall
consist of Messrs. Costa and Hurwitz. At each annual meeting of stockholders after the initial classification, the successors to directors whose terms will then expire serve from the time of election and qualification until the third annual meeting
following election and until their successors are duly elected and qualified. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class
will consist of one third of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in control or management of our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will
further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the
competitive landscape. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Independence of the Members of the Board of Directors </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director Independence </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable NASDAQ rules require a majority
of a listed company&#146;s board of directors to be comprised of independent directors within one year of listing. Under applicable NASDAQ rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, the board of directors has affirmatively determined that all of the members of our board of
directors, except for Dr.&nbsp;Koenig, are independent directors within the meaning of the applicable NASDAQ listing requirements. In making its determination of independence, the board of directors
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
considered the relationships of our directors, other than Mr.&nbsp;Costa, with certain of our principal stockholders. Our board of directors does not believe that these stockholder relationships
interfere with these directors&#146; exercise of independent judgment in carrying out their responsibilities as directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board
Committees </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has an audit committee, a compensation committee and a nominating and corporate
governance committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our compensation committee currently consists of Messrs. Hurwitz, Costa and Nadav. All members of the compensation committee are independent directors, as defined in the NASDAQ Global Select Market
qualification standards. The functions of this committee include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and, as it deems appropriate, recommending to our board of directors, policies, practices and procedures relating to the compensation of our
directors, officers and other managerial employees and the establishment and administration of our employee benefit plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exercising authority under our employee benefit plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and approving executive officer and director indemnification and insurance matters; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advising and consulting with our officers regarding managerial personnel and development. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our audit committee consists of Messrs. Hurwitz, Galbraith and Oronsky. All members of the audit committee are independent directors, as
defined in the NASDAQ Global Select Market qualification standards. Each of Mr.&nbsp;Galbraith and Mr.&nbsp;Hurwitz qualifies as an &#147;audit committee financial expert&#148; as that term is defined in the rules and regulations established by the
SEC. The functions of this committee include: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our independent auditors and with internal financial personnel regarding these matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-approving audit and non-audit services to be rendered by our independent auditors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending to our board of directors the engagement of our independent auditors and oversight of the work of our independent auditors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financial statements and periodic reports and discussing the statements and reports with our management, including any significant
adjustments, management judgments and estimates, new accounting policies and disagreements with management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls and
auditing matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financing plans and reporting recommendations to our full board of directors for approval and to authorize action; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administering and discussing with management and our independent auditors our Code of Ethics. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both our independent auditors and internal financial personnel regularly meet privately with
the audit committee and have unrestricted access to this committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our nominating and corporate governance committee is comprised of Messrs. Galbraith, Nadav and Oronsky. All members of the nominating and
corporate governance committee are independent directors, as defined in the NASDAQ Global Select Market qualification standards. The functions of this committee include: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying qualified candidates to become members of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting nominees for election of directors at the next annual meeting of stockholders (or special meeting of stockholders at which directors are to
be elected); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting candidates to fill vacancies of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to our board of directors our corporate governance guidelines; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing the evaluation of our board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has adopted a code of
conduct and ethics that establishes the standards of ethical conduct applicable to all directors, officers and employees of our company. The code addresses, among other things, conflicts of interest, compliance with disclosure controls and
procedures and internal control over financial reporting, corporate opportunities and confidentiality requirements. The audit committee is responsible for applying and interpreting our code of conduct and ethics in situations where questions are
presented to it. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the members of our compensation committee at any time has been one of our officers or employees. None of our executive officers
currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Compensation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our named executive officers for the year ended December&nbsp;31, 2013 include our principal executive officer and two other officers:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., President and Chief Executive Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels, Vice President, Chief Financial Officer and Secretary; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D., Senior Vice President, Research. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2013 Summary Compensation Table </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents the compensation awarded to, earned by or paid to each of our named executive officers for the year ended
December&nbsp;31, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:42pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards&nbsp;$(2)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:58pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nonequity<BR>Incentive Plan<BR>Compensation(3)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation&nbsp;$(4)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">456,065</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,520,830</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,825</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,255,720</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Chief Financial Officer and Secretary</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">306,748</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">800,763</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123,296</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,825</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,234,632</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President, Clinical Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,649</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">801,106</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,215</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237,464</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,293,433</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Wigginton joined us in August 2013. This represents the prorated portion of his $365,000 base salary that was paid for the portion of 2013 he was employed by
us. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the grant date fair value for awards granted during 2013. The grant date fair value was computed in accordance with Financial Accounting Standards
Board Accounting Standards Codification Topic 718,<I>&nbsp;Compensation&#151;Stock Compensation</I>. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the performance bonuses paid in 2014 for performance during 2013, as discussed further below under &#147;Narrative to Summary Compensation
Table&#151;Nonequity Incentive Plan Compensation.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect $3,825 in 401(k) matching for each of Dr.&nbsp;Koenig and Mr.&nbsp;Karrels, and a $237,464 new hire bonus paid to Dr.&nbsp;Wigginton.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Narrative to Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual Salary </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We review compensation annually for all employees,
including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual
performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board
of directors has historically determined our executives&#146; compensation. Our compensation committee typically reviews and discusses management&#146;s proposed compensation with the chief executive officer for all executives other than the chief
executive officer. Based on those discussions and its discretion, the compensation committee then recommends the compensation for each executive officer. Our board of directors, without members of management present, discusses the compensation
committee&#146;s recommendations and ultimately approves the compensation of our executive officers. To date, our compensation committee has not engaged a compensation consultant or adopted a peer group of companies for purposes of determining
executive compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective upon the closing of our IPO, our board of directors approved salary increases for each of
Dr.&nbsp;Koenig and Mr. Karrels. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonequity Incentive Plan Compensation </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our bonus plan motivates and rewards our executives for achievements relative to our goals and expectations for each fiscal year. Each
named executive officer has a target bonus opportunity, defined as a percentage of his or her annual salary. Following the end of each year, our board of directors determines bonuses. Material considerations in determining bonuses include
achievement of an executive&#146;s corporate objectives for the year; the executive&#146;s handling of unplanned events and opportunities; and the chief executive officer&#146;s input with respect to the performance of the company, our executives
and our financial performance relative to our plan. Based on these factors and in the sole discretion of our board of directors, we approved the bonuses in the table above for our named executive officers in December 2013 for the fiscal year ended
December&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specific achievements and performance considered by our board of directors in determining bonuses for
the fiscal year ended December&nbsp;31, 2013 included: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of margetuximab, including Phase 1 data presentation at ASCO and initiation of activities related to the planned Phase 3
gastroesophageal cancer study; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of MGA271, including completion of enrollment of the dose escalation portion of the Phase 1 clinical trial and initiation of the
dose expansion portion of the study, which triggered a $10 million milestone by our collaboration partner, Servier; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing our existing DART collaborations with Boehringer, Gilead and Pfizer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finalizing IND preparation activities for MGD006; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating GLP toxicology studies for MGD007; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completing IND-enabling pre-clinical activities for MGD010; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accessing public market through an initial public offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining a minimum cash balance throughout the year and ending the year with more than $35&nbsp;million in cash and cash equivalents.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of our IPO we implemented a new nonequity incentive plan that will provide guidelines for
target bonus amounts, performance goals and determination of the amounts of nonequity incentive compensation ultimately awarded in the discretion of the compensation committee of our board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long-Term Incentives </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Stock Option and Incentive Plan, or 2000 Plan, our 2003 Equity Incentive Plan, or 2003 Plan, and our 2013 Equity Incentive Plan, or 2013 Plan, authorized us to make grants to eligible recipients
of non-qualified stock options, incentive stock options, stock awards, and other forms of award, such as stock appreciation rights. Although the 2000 Plan, 2003 Plan and 2013 Plan provided for a range of types of awards, our equity grants to our
executive officers under those plans were only in the form of stock options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically grant equity incentive awards at
the start of employment to each executive and our other employees. Through 2013, we have not maintained a practice of granting additional equity on an annual basis, but we have retained discretion to provide additional targeted grants in certain
circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We award our equity grants on the date our board of directors approves the grant. We set the option exercise
price and grant date fair value based on our per-share valuation on the date of grant. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to our executives typically
vest 12.5% six months after the date of grant with the remainder vesting in 14&nbsp;equal quarterly installments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, options to purchase 3,208,199 shares of common stock at a
weighted average exercise price per share of $5.04 were outstanding. As of December&nbsp;31, 2013, 1,395,218 shares of common stock remained available for future issuance under the 2003 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please see &#147;&#151;Employee Benefit Plans&#148; for information relating to additional current and future benefit plans. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We paid Dr.&nbsp;Wigginton a $237,464 new hire bonus upon his joining the company on August&nbsp;16, 2013. Other amounts shown in the &#147;All Other Compensation&#148; column in the Summary Compensation
Table relate to 401(k) matching contributions made to Dr.&nbsp;Koenig&#146;s and Mr.&nbsp;Karrels&#146; 401(k) accounts, consistent with the matching contributions offered to all of our employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employment Arrangements </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Please see &#147;&#151;Amended and Restated Employment, Severance and Change in Control Agreements.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards at 2013 Fiscal Year End </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table
lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:48pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:72pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B># Exercisable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:72pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B># Unexercisable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price&nbsp;$</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:80pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Expiration&nbsp;Date</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/7/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2017</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/16/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/15/2017</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2020</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,987</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/9/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/9/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/10/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/9/2018</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,314</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2020</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,913</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/8/2021</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.94</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,496</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/9/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10/9/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/19/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7/18/2023</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest and become exercisable with respect to (i)12.5 percent of the underlying shares six months after the grant date and (ii)&nbsp;the remainder of the
underlying shares in 14 equal quarterly installments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as discussed below, during and prior to 2013, we did not pay cash compensation to any non-employee director for his or her service
as a director. We reimburse our non-employee directors for reasonable travel and other expenses incurred in connection with attending board of director and committee meetings or otherwise in direct service of our company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to our IPO, In connection with his service as a director, Mr.&nbsp;Costa received
$25,000 per year. In addition, with his election as a director in June 2009, we granted Mr.&nbsp;Costa an option to purchase 49,435 shares of our common stock. In 2013, Mr.&nbsp;Costa exercised the option in its entirety. Following our IPO,
Mr.&nbsp;Costa will be compensated for his board service according to the director compensation program discussed below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
September 2013, our board of directors approved a director compensation program that became effective upon the completion of our IPO. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under this director compensation program, we pay our non-employee directors a cash retainer for service on the board of directors and for service on each committee on which the director is a member. The
chairman of each committee receives higher retainers for such service. The fees paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member are as
follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Member<BR>Annual&nbsp;Retainer</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Chairman<BR>Additional<BR>Annual&nbsp;Retainer</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Board of Directors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nominating and Corporate Governance Committee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in
connection with attending our board of director and committee meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, under our director compensation program,
each non-employee director elected to our board of directors subsequent to our IPO receives an option to purchase 13,849 shares of our common stock. With respect to each non-employee director serving on our board of directors upon the closing of
this offering, each of these options will vest as to 33.33% of the shares of our common stock underlying such option annually, beginning on the first anniversary of the grant date, subject to the director&#146;s continued service as a director.
Further, on the date of the first board meeting held after each annual meeting of stockholders, each non-employee director will receive an option to purchase an additional 6,924 shares of our common stock. Each of these options will vest in full on
the one year anniversary of the grant date, subject to the non-employee director&#146;s continued service as a director. The exercise price of these options will equal the fair market value of our common stock on the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This program is intended to provide a total compensation package that enables us to attract and retain qualified and experienced
individuals to serve as directors and to align our directors&#146; interests with those of our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amended and Restated
Employment, Severance and Change in Control Agreements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dr.&nbsp;Koenig </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, we entered into an employment agreement with Dr.&nbsp;Koenig. Dr.&nbsp;Koenig is employed &#147;at-will,&#148; which
means that he has no definitive term of employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Koenig&#146;s employment agreement includes non-competition and
non-solicitation provisions that will prohibit him from competing with us, soliciting our customers or employees, or hiring our employees for a period of two years following the end of his employment with us for any reason. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Koenig is eligible to receive severance benefits in specified circumstances, as set
forth in the employment agreement. Under the terms of the agreement, upon execution and delivery of an irrevocable release of claims against the Company and subject to his continued compliance with the non-competition and son-solicitation
provisions, Dr.&nbsp;Koenig will be entitled to severance benefits if we terminate his employment without cause or if he terminates employment with us for good reason within 12 months following a change in control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, Dr.&nbsp;Koenig is entitled to specified accelerated vesting of options related to a change of control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following definitions are used in the employment agreement: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Cause&#148; means: (a)&nbsp;a failure to substantially perform the duties with us (if the failure to substantially perform is not cured, if
curable, within thirty (30)&nbsp;days after receipt of written notice from the board of directors that specifies the conduct constituting Cause under this clause (a); (b)&nbsp;willful misconduct, or gross negligence in the performance of duties to
us; (c)&nbsp;the conviction or entry of a guilty plea or plea of no contest with respect to, any crime that constitutes a felony or involves fraud, dishonesty or moral turpitude; (d)&nbsp;commission of an act of fraud, embezzlement or
misappropriation against us; (e)&nbsp;a material breach of the fiduciary duty owed to us; (f)&nbsp;engaging in any improper conduct that has or is likely to have an adverse economic or reputational impact on us; or (g)&nbsp;a material breach of the
employment agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Good reason&#148; means the occurrence of any of the following events (without Dr.&nbsp;Koenig&#146;s consent): (i)&nbsp;material adverse change
in functions, duties, or responsibilities that would cause executive&#146;s position to become one of materially lesser responsibility, importance, or scope or (ii)&nbsp;a material breach of the agreement by us. No resignation will be treated as
&#147;good reason&#148; unless (a)&nbsp;Dr.&nbsp;Koenig has given written notice of such event to the us within ninety (90)&nbsp;days after the initial occurrence, (b)&nbsp;we have failed to cure the condition constituting &#147;good reason&#148;
within 30 days following the delivery of the notice, and (c)&nbsp;Dr.&nbsp;Koenig terminates employment within thirty (30)&nbsp;days after expiration of such cure period. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Change of Control&#148; means: (a)&nbsp;any person (excluding our employee benefit plans) is or becomes the &#147;beneficial owner&#148; (as
defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, as amended) directly or indirectly, of securities representing more than fifty percent (50%)&nbsp;of the combined voting power of our then outstanding securities;
(b)&nbsp;we consummate a merger, consolidation, share exchange, division or other reorganization or transaction with any other corporation unless our outstanding securities continue to represent at least 50% of the combined voting power immediately
after the transaction; or (c)&nbsp;liquidation or winding-up of our company or the consummation of the sale or disposition of all or substantially all of our assets; or (d)&nbsp;during any period of 24 consecutive months, individuals who at the
beginning of such period constituted our board (including for this purpose any new director whose election or nomination for election by the stockholders was approved by a vote of at least two-thirds of the directors then still in office who were
directors at the beginning of such period or whose appointment, election or nomination was previously so approved or recommended) cease for any reason to constitute at least a majority of the board of directors. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the schedule of severance benefits Dr.&nbsp;Koenig would
receive in the event of a qualifying termination. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:35pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scenario</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:80pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salary Continuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continuation of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:62pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Health Benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceleration of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:67pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unvested Equity</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 months of base salary and target bonus (55% of base&nbsp;salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">50% of the shares with respect to which the stock option&nbsp;is&nbsp;not vested</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination occurs within Two Years Following a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 months of base salary and target bonus (55% of base salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">100% of the shares with respect to which the stock option is not vested</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, upon the occurrence of a change of control (irrespective of whether Dr.&nbsp;Koenig&#146;s
employment terminates), each outstanding stock option held by Dr.&nbsp;Koenig that was granted by us to him prior to the IPO will become fully vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mr.&nbsp;Karrels </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2013, we entered into an employment
agreement with Mr. Karrels. Mr. Karrels is employed &#147;at-will,&#148; which means that he has no definitive term of employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr. Karrels&#146; employment agreement includes non-competition and non-solicitation provisions that will prohibit him from competing with us, soliciting our customers or employees, or hiring our
employees for a period of 18 months following the end of his employment with us for any reason. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Karrels is eligible to
receive severance benefits in specified circumstances, as set forth in the employment agreement. Under the terms of the agreement, upon execution and delivery of an irrevocable release of claims against the Company and subject to his continued
compliance with the non-competition and son-solicitation provisions, Mr. Karrels will be entitled to severance benefits if we terminate his employment without cause or if he terminates employment with us for good reason within 12 months following a
change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Karrels is also entitled to specified accelerated vesting of options related to a change of control.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Karrels&#146; employment agreement contained the same definitions of the terms &#147;Cause,&#148; &#147;Good reason&#148;
and &#147;Change of Control&#148; as those defined in Dr. Koenig&#146;s agreement, discussed above. The following table summarizes the schedule of severance benefits Mr. Karrels would receive in the event of a qualifying termination. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:35pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scenario</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:80pt"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salary Continuation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Continuation of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:62pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Health Benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceleration of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:67pt"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unvested Equity</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Absent a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months of base salary and target bonus (35% of base&nbsp;salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">50% of the shares with respect to which the stock option&nbsp;is&nbsp;not vested</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination occurs within Two Years Following a Change in Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months of base salary and target bonus (35% of base salary)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 months</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">100% of the shares with respect to which the stock option is not vested</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our employees, including our executive officers, are entitled to various employee benefits. These benefits include the following: medical and dental care plans; flexible spending accounts for healthcare;
life, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
accidental death and dismemberment and disability insurance; employee assistance programs (confidential counseling); benefit advocacy counseling; a 401(k) plan; and paid time off. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension Benefits </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any qualified or non-qualified defined benefit plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-qualified Deferred Compensation </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any
non-qualified defined contribution plans or other deferred compensation plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>401(k) Plan </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our employees are eligible to participate in our 401(k) plan. Our 401(k) plan is intended to qualify as a tax-qualified plan under
Section&nbsp;401 of the Internal Revenue Code of 1986, as amended. Our 401(k) plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory limit, which for most employees is $17,500 in 2013.
Participants that are 50 years or older can also make &#147;catch-up&#148; contributions, which in 2013 may be up to an additional $5,500 above the statutory limit. Employee contributions are held and invested by the plan&#146;s trustee. Our 401(k)
plan also permits us to make discretionary contributions and matching contributions. We match participant contributions up to 1.5% of a participant&#146;s annual compensation, subject to statutory limits. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2000 Stock Option and Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Plan is administered by our compensation committee and provided for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code, non-statutory stock
options, restricted stock, and other stock-based awards. Our employees, officers, directors, consultants and advisors were eligible to receive awards under our 2000 Plan. Upon an acquisition of us, the exercisability of options or the vesting of
restricted stock awards issued under the 2000 Plan will be accelerated. In addition, the Board will make appropriate provisions for the continuation of awards by us or substitution of awards by the surviving or acquiring entity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, under our 2000 Plan, there were options to purchase an aggregate of 23,657&nbsp;shares of common stock
outstanding at a weighted average exercise price of $0.83 per share. The 2000 Plan has expired, and no further awards may be issued under the plan. Any shares of common stock subject to awards under our 2000 Plan that expire, terminate, or are
otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under our 2013 Stock Incentive Plan, or the 2013 Plan, up to a specified
number of shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2003 Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2003 Plan is administered by our compensation committee and provided for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code, non-statutory stock
options, restricted stock, other stock-based awards and cash awards. Our employees, officers, directors, consultants and advisors were eligible to receive awards under our 2003 Plan. Upon an acquisition of us, the exercisability of options or the
vesting of restricted stock awards issued under our 2003 Plan will be accelerated. In addition, the Board will make appropriate provisions for the continuation of awards by us or substitution of awards by the surviving or acquiring entity.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, under our 2003 Plan, there were options to purchase an aggregate of 2,566,252&nbsp;shares of
common stock outstanding at a weighted average exercise price of $1.52 per share. Upon the completion of our IPO, the 2003 Plan was terminated, and no further awards may be issued under the plan. Any
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares of common stock subject to awards under our 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or
resulting in any common stock being issued, will become available for issuance under the 2013 Plan, up to a specified number of shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2013 Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;18, 2013, our board of directors approved the MacroGenics, Inc. 2013 Incentive Plan (&#147;2013 Plan&#148;) and it was subsequently approved by our stockholders.&nbsp;The purpose of the
2013 Plan is to assist us in attracting, retaining and providing incentives to employees and directors and consultants and independent contractors by offering them the opportunity to acquire or increase their proprietary interest in MacroGenics and
to promote the alignment of their interests with those of our stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Awards and Eligibility</I>.&nbsp;The 2013 Plan
provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&nbsp;No new awards will be granted under our 2000 Stock Option and Incentive Plan.&nbsp;All employees, non-employee directors,
consultants and independent contractors of the company are eligible to receive awards under the 2013 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administration.</I> The 2013 Plan is administered by our compensation committee, unless the board of directors appoints another
committee or person(s) for such purpose.&nbsp;With respect to awards granted to non-employee directors, our board of directors serves as the &#147;committee,&#148; unless the board appoints another committee or person(s) for such purpose.&nbsp;The
committee has plenary authority and discretion to determine the eligible persons to whom awards are granted (&#147;participants&#148;) and the terms of all awards.&nbsp;Subject to the provisions of the 2013 Plan, the committee has authority to
interpret the plan and agreements under the plan and to make all other determinations relating to the administration of the plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Subject to the 2013 Plan.</I>&nbsp;The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan is 1,960,168&nbsp;shares.&nbsp;The number
of shares of common stock reserved for issuance will automatically increase on January&nbsp;1 of each year from January&nbsp;1,&nbsp;2014 through and including January&nbsp;1,&nbsp;2023, by the lesser of (a)&nbsp;1,960,168 million shares,
(b)&nbsp;4.0% of the total number of shares of common stock outstanding on December&nbsp;31 of the preceding calendar year, or (c)&nbsp;the number of shares of common stock determined by our board of directors.&nbsp;All of the shares available for
issuance under the 2013 Plan are eligible for issuance pursuant to the exercise of incentive stock options.&nbsp;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited,
or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards.&nbsp;However, any shares that are withheld (or
delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The maximum number of shares of common stock with respect to which an employee may be granted awards under the 2013 Plan during any calendar year is 1,225,105&nbsp;shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Options.</I>&nbsp;The 2013 Plan authorizes the grant of nonqualified stock options and incentive stock options.&nbsp;Incentive stock
options are stock options that satisfy the requirements of Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;).&nbsp;Nonqualified stock options are stock options that do not satisfy the requirements of
Section&nbsp;422 of the Code.&nbsp;The exercise of an option permits the participant to purchase shares of common stock from the company at a specified exercise price per share.&nbsp;Options granted under the 2013 Plan are exercisable upon such
terms and conditions as the committee specifies.&nbsp;The per share exercise price of options granted under the 2013 Plan may not be less than 100% of the fair market value per share on the date of grant.&nbsp;The 2013 Plan provides that the term
during which options may be exercised is determined by the committee, except that no option may be exercised more than ten years after its date of grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Appreciation Rights.</I> The 2013 Plan authorizes the committee to grant stock
appreciation rights (&#147;SARs&#148;), which may be granted in tandem with an option. SARs are awards that provide for the payment of cash and/or shares upon exercise, based on the appreciation of the shares above the base price established as of
the date of grant. The per share base price of SARs granted under the 2013 Plan may not be less than 100% of the fair market value per share on the date of grant. SARs may be subject to such terms and conditions as the committee may determine,
including terms that condition the payment or vesting of the SAR upon the achievement of one or more performance goals as described below. The 2013 Plan provides that the term during which SARs may be exercised is determined by the committee, except
that no SAR may be exercised more than ten years after its date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted Stock Awards.&nbsp;The 2013 Plan
authorizes the committee to grant restricted stock awards.&nbsp;Shares of common stock covered by a restricted stock award are restricted against transfer and subject to forfeiture and such other terms and conditions as the committee
determines.&nbsp;Such terms and conditions may provide, in the discretion of the committee, for the vesting of awards of restricted stock to be contingent upon the achievement of one or more performance goals as described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Units (&#147;RSUs&#148;).</I>&nbsp;RSU awards granted under the 2013 Plan are contingent awards of common stock or
the cash equivalent thereof.&nbsp;Pursuant to such awards, shares of common stock are issued, or the cash value of the shares is paid, subject to such terms and conditions as the committee deems appropriate.&nbsp;Unlike in the case of awards of
restricted stock, shares of common stock are not issued immediately upon the award of RSUs, but instead shares of common stock are issued or the cash value of the shares is paid upon the satisfaction of such terms and conditions as the committee may
specify, including the achievement of one or more performance goals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Awards.</I>&nbsp;The 2013 Plan authorizes
the grant of performance awards. Performance awards provide for payments in cash, shares of common stock or a combination thereof contingent upon the attainment of one or more performance goals (described below) established by the
committee.&nbsp;For purposes of the limit on the number of shares of common stock with respect to which an employee may be granted awards during any calendar year, a performance award is deemed to cover the number of shares of common stock equal to
the maximum number of shares that may be issued upon payment of the award.&nbsp;The maximum cash amount that may be paid to any participant pursuant to all performance awards granted to such participant during a calendar year may not exceed
$3&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Stock-Based Awards.</I>&nbsp;The 2013 Plan authorizes the grant of &#147;other stock-based
awards&#148; (including the issuance or offer for sale of unrestricted shares of common stock) covering such number of shares and having such terms and conditions as the committee may determine, including terms that condition the payment or vesting
of other stock-based awards upon the achievement of one or more performance goals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Dividends and Dividend
Equivalents</I>&nbsp;The terms of an award may, at the committee&#146;s discretion, provide a participant with the right to receive dividend payments or dividend equivalent payments with respect to shares covered by the award.&nbsp;The payments may
be either made currently or credited to an account established for the participant, and may be settled in cash or shares, as determined by the committee.&nbsp;Payment of dividends and dividend equivalents may be contingent upon the achievement of
one or more performance goals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Goals.</I>&nbsp;As described above, the terms and conditions of an award may
provide for the grant, vesting or payment of awards to be contingent upon the achievement of one or more specified performance goals established by the committee.&nbsp;For this purpose, &#147;performance goals&#148; means performance goals
established by the committee which may be based on satisfactory internal or external audits, achievement of balance sheet or income statement objectives, cash flow, customer satisfaction metrics, achievement of customer satisfaction goals, dividend
payments, earnings (including before or after taxes, interest, depreciation, and amortization), earnings growth, earnings per share, economic value added, expenses (including sales, general and administrative expenses), improvement of financial
ratings, internal rate of return, market share, geographic expansion, net asset </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
value, net income, net operating gross margin, net operating profit after taxes, net sales growth, operating income, operating margin, comparisons to the performance of other companies, pro forma
income, regulatory compliance, return measures (including return on assets, designated assets, capital, capital employed, equity, or stockholder equity, and return versus the company&#146;s cost of capital), revenues, sales, stock price (including
growth measures and total stockholder return), comparison to stock market indices, implementation or completion of one or more projects or transactions (including mergers, acquisitions, dispositions, and restructurings), working capital, or any
other objective goals that the committee establishes.&nbsp;Performance goals may be absolute in their terms or measured against or in relationship to other companies comparably, similarly or otherwise situated.&nbsp;Performance goals may be
particular to an eligible person or the department, branch, affiliate, or division in which the eligible person works, or may be based on the performance of the company, one or more affiliate, or the company and one or more affiliates and may cover
such period as the committee may specify. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Capital Adjustments.&nbsp;</I>If the outstanding common stock of the company
changes as a result of a stock dividend, stock split, reverse stock split, spin-off, split-up, recapitalization, reclassification, combination or exchange of shares, merger, consolidation or liquidation, or the like, the committee will substitute or
adjust: (a)&nbsp;the number and class of securities subject to outstanding awards, (b)&nbsp;the consideration to be received upon exercise or payment of an award, (c)&nbsp;the exercise price of options and the base price of SARs, (d)&nbsp;the
aggregate number and class of securities for which awards may be granted under the 2013 Plan, and/or (e)&nbsp;the maximum number of securities with respect to which an employee may be granted awards during any calendar year.&nbsp;In the event of a
merger of the company or certain other types of transactions, the committee may cause awards to be vested in whole or in part, be assumed by a successor or be cancelled in consideration of a cash payment equal to the fair value of the cancelled
award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Withholding.</I> The company is generally required to withhold tax on the amount of income recognized by a
participant with respect to an award.&nbsp;Withholding requirements may be satisfied, as provided in the agreement evidencing the award, by (a)&nbsp;tender of a cash payment to the company, (b)&nbsp;withholding of shares of common stock otherwise
issuable, or (c)&nbsp;delivery to the company by the participant of unencumbered shares of common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Termination and
Amendment; Term of Plan.</I>&nbsp;The board of directors may amend or terminate the 2013 Plan at any time.&nbsp;However, after the 2013 Plan has been approved by our stockholders, our board of directors may not amend or terminate the plan without
the approval of (a)&nbsp;our stockholders if stockholder approval of the amendment is required by applicable law, rules or regulations, and (b)&nbsp;each affected participant if such amendment or termination would adversely affect such
participant&#146;s rights or obligations under any awards granted prior to the date of the amendment or termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless
sooner terminated by our board of directors, the 2013 Plan will terminate on September&nbsp;18, 2023. Once the 2013 Plan is terminated, no further awards may be granted or awarded under the 2013 Plan.&nbsp;Termination of the 2013 Plan will not
affect the validity of any awards outstanding on the date of termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee Stock Purchase Plan </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;18, 2013, our board of directors adopted and our stockholders approved our 2013 Employee Stock Purchase Plan, or 2013
Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share Reserve</I>. The 2013 Purchase Plan authorizes the issuance of 245,021 shares of common stock
pursuant to option rights granted to our employees (or to employees of any of our designated affiliates) to purchase shares of our common stock. The 2013 Purchase Plan is intended to qualify as an &#147;employee stock purchase plan&#148; within the
meaning of Section&nbsp;423 of the Internal Revenue Code. As of the date hereof, no shares of common stock have been purchased under the 2013 Purchase Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administration</I> . Our board of directors will administer the 2013 Purchase Plan or
delegate administration to a committee. The 2013 Purchase Plan is implemented through a series of offerings of option rights to purchase shares of our common stock to eligible employees. Under the 2013 Purchase Plan, we may specify offerings with a
duration of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of common stock will be purchased for employees participating in the offering. We
have not yet determined when we will commence offerings under the 2013 Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Payroll Deductions</I>. Generally,
all regular employees, including executive officers, employed by us or by any of our affiliates may participate in the 2013 Purchase Plan and may contribute, normally through payroll deductions, a percentage of their earnings, not to exceed 20%, for
the purchase of common stock under the 2013 Purchase Plan. Common stock will be purchased for accounts of employees participating in the 2013 Purchase Plan at a price per share that is at least the lower of (a)&nbsp;85% of the fair market value of a
share of our common stock on the first date of an offering or (b)&nbsp;85% of the fair market value of a share of our common stock on the date of purchase. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Limitations</I>. Unless otherwise determined by our board of directors, employees must satisfy the following service requirements before participating in the 2013 Purchase Plan: (a)&nbsp;be customarily
employed for more than 20 hours per week, (b)&nbsp;be customarily employed for more than five months per calendar year and (c)&nbsp;have been in continuous employment with us or one of our affiliates for at least two years. No employee may receive
option rights to purchase shares under the 2013 Purchase Plan or any other stock purchase plans we may offer that accrue at a rate in excess of $25,000 worth of our common stock (valued based on the fair market value per share of our common stock at
the beginning of an offering) for each year such an option right is outstanding. Finally, no employee will be eligible for the grant of any option rights under the 2013 Purchase Plan if immediately after such rights are granted, such employee has
voting power over 5% or more of our outstanding capital stock measured by vote or value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes to Capital Structure</I>.
In the event that there is a specified type of change in our capital structure, such as a stock split, appropriate adjustments will be made to (a)&nbsp;the classes and maximum number of shares subject to the 2013 Purchase Plan and (b)&nbsp;the
number of shares and price per share of common stock subject to outstanding option rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transactions</I>. In
the event of a merger or other certain corporate transactions as set forth in the 2013 Purchase Plan, the board may in its discretion, with respect to, any then-outstanding rights to purchase our stock under the 2013 Purchase Plan (a)&nbsp;cancel
the option rights and return participants&#146; accumulated payroll deductions without interest, (b)&nbsp;continue the option rights without change, (c)&nbsp;substitute similar option rights for the outstanding option rights, or (d)&nbsp;use the
participants&#146; accumulated payroll deductions to purchase common stock immediately prior to the transaction and terminate participants&#146; option rights immediately following such purchase. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with Management and Others </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since January&nbsp;1, 2011, there has not been, nor is there any proposed transaction where we were or will be a party in which the amount involved exceeded or will exceed $120,000 and in which any
director, executive officer, holder of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the compensation
agreements and other agreements and transactions which are described in &#147;Management&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Policies and Procedures for Related Party
Transactions </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the written charter of our audit committee adopted March&nbsp;24, 2005, our audit committee of
the board of directors is responsible for reviewing and approving, prior to our entry into any such transaction, all related party transactions and potential conflict of interest situations involving a principal stockholder, a member of the board of
directors or senior management. In addition, our company policies require that our officers and employees avoid using their positions for purposes that are, or give the appearance of being, motivated by a desire for personal gain, and our policies
further require that all officers and employees who have authority to initiate related party transactions provide a written report, on an annual basis, of all activities which could result in a conflict of interest or impair their professional
judgment. All such written reports concerning related party transactions or conflicts of interest are submitted to, and reviewed by, our Chief Financial Officer and our audit committee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_14"></A>PRINCIPAL AND SELLING STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates information as of December&nbsp;31, 2013 regarding the ownership of our common stock, after giving effect
to the sale of common stock offered in this offering, for: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person who is known by us to own more than 5% of our shares of common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our directors and executive officers as a group; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each selling stockholder. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of shares beneficially owned and the percentage of shares beneficially owned are based on 25,188,987&nbsp;shares of common stock outstanding as of December&nbsp;31, 2013. Percentage ownership
of our common stock after this offering (assuming no exercise of the underwriters&#146; over-allotment option to purchase additional shares) reflects our sale of shares in this offering. Unless otherwise indicated in the footnotes to the table, and
subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially owned by them. In accordance with SEC rules, if a person has a right to acquire beneficial
ownership of any shares of common stock, on or within 60&nbsp;days of December&nbsp;31, 2013, upon exercise of outstanding options or otherwise, the shares are deemed beneficially owned by that person and are deemed to be outstanding solely for the
purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for any other person. Except as otherwise indicated, the address of each of the persons in
this table is 9640 Medical Center Drive, Rockville, Maryland 20850. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:134pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Prior to the Offering</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;Shares<BR>to&nbsp;be&nbsp;Sold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:91pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Before</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Offering</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with TPG (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,208,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with Alta BioPharma Partners&nbsp;(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,013,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with InterWest Partners (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,908,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with MPM BioVentures (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,780,955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Caisse de d&eacute;p&ocirc;t et placement du Qu&eacute;bec (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,313,315</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ventures West 8 Limited Partnership (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,270,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Named Executive Officers:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D. (8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz (9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,013,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D. (10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,908,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D. (11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith (7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,270,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa (12)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,435</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D. (13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,155,829</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels (14)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jon Wigginton, M.D. (15)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (15&nbsp;persons)&nbsp;(16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,990,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Selling Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>All Other Selling Stockholders (17)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates ownership of less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,208,762&nbsp;shares of common stock held of record by entities affiliated with TPG. TPG Biotechnology Partners, L.P., a Delaware limited partnership,
whose general partners is TPG Biotechnology GenPar, L.P., a Delaware limited partnership, whose general partner is TPG Biotechnology GenPar Advisors, LLC, a Delaware limited liability company (&#147;Biotechnology GenPar Advisors&#148;), and
(ii)&nbsp;TPG Ventures, L.P., a Delaware limited partnership, whose general partner is TPG Ventures GenPar Advisors LLC, a Delaware limited liability company (&#147;Ventures GenPar Advisors&#148;) are collectively referred to as the entities
affiliated with TPG. The sole member of each of Biotechnology GenPar Advisors and Ventures GenPar Advisors is TPG Holdings I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A, LLC, a Delaware limited liability company,
whose sole member is TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation. David Bonderman and James G. Coulter are officers and sole shareholders of
TPG Group Holdings (SBS) Advisors, Inc. and may therefore be deemed to be the beneficial owners of the securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. Messrs. Bonderman and Coulter disclaim beneficial ownership of the
securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. except to the extent of their pecuniary interest therein. The address of each of TPG Group Holdings (SBS) Advisors, Inc. and Messrs. Bonderman and Coulter is c/o TPG Global,
LLC, 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,013,509&nbsp;shares of common stock held of record by entities affiliated with Alta BioPharma Partners. Alta BioPharma Partners, L.P., Alta BioPharma
Partners&nbsp;III GmbH&nbsp;&amp; Co. Beteiligings KG and Alta Embarcadero BioPharma Partners III, LLC are collectively referred to as the entities affiliated with Alta BioPharma Partners. The directors of Alta BioPharma Management Partners III,
LLC, which is the general partner of Alta Biopharma Partners III, L.P., the managing limited partner of Alta Biopharma Partners III GmbH&nbsp;&amp; Co. Beteiligungs KG, and the manager of Alta Embarcadero Biopharma Partners III, LLC, exercise sole
dispositive and voting power over the shares owned by the entities affiliated with Alta BioPharma Partners. Edward Hurwitz, one of our directors, Farah Champsi and Edward Penhoet are directors of Alta BioPharma Management Partners III, LLC and
managers of Alta Embarcadero Biopharma Partners III, LLC. These individuals may be deemed to share dispositive and voting power over the shares held by the entities affiliated with Alta BioPharma Partners. Each of these individuals disclaims
beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. The principal address for the entities affiliated with Alta BioPharma Partners is One Embarcadero Center, Suite 3700, San Francisco, CA 94111.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,908,716&nbsp;shares of common stock held of record by entities affiliated with InterWest Partners. InterWest Partners VIII, L.P. (&#147;IW8&#148;),
InterWest Investors&nbsp;Q VIII, L.P., and InterWest Investors VIII, L.P. are collectively referred to as the entities affiliated with InterWest Partners. InterWest Management Partners VIII, LLC (&#147;IMP8&#148;) is the general partner of the
entities affiliated with InterWest Partners and has sole voting and investment control over the shares held by the entities affiliated with InterWest Partners. Harvey B. Cash, Philip T. Gianos, W.&nbsp;Scott Hedrick, W. Stephen Holmes, Gilbert H.
Kliman and Arnold L. Oronsky, a member of our board of directors, are the managing directors of IMP8. Each of the managing directors share voting and investment control with respect to the shares held by the entities affiliated with InterWest
Partners. Dr.&nbsp;Oronsky disclaims beneficial ownership of all shares held by the entities affiliated with InterWest Partners except to the extent of his pecuniary interest therein. The address for these entities is c/o InterWest Partners, 2710
Sand Hill Road, Suite 200, Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,780,955&nbsp;shares of common stock held of record by entities affiliated with MPM. MPM BioVentures II, L.P., MPM BioVentures II-QP,
L.P., MPM BioVentures GmbH&nbsp;&amp; Co. Parallel-Beteiligungs KG, MPM Asset Management Investors 2000B LLC and MPM BioVentures IV Strategic Fund, L.P. are collectively referred to as the entities affiliated with MPM. MPM Asset Management II L.P.
is the general partner of MPM BioVentures II, L.P. and MPM BioVentures II-QP, L.P. and the special limited partner of MPM BioVentures GmbH&nbsp;&amp; Co. Parallel-Beteiligungs KG. MPM BioVentures II LLC is the general partner of MPM Asset Management
II L.P. Ansbert Gadicke, Luke Evnin, Nicholas Galakatos, Michael Steinmetz and Kurt Wheeler are the investment managers of MPM BioVentures II LLC and MPM Asset Management </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Investors 2000B LLC and share voting and dispositive power over the shares held by MPM BioVentures II, L.P., MPM BioVentures II-QP, L.P., MPM BioVentures GmbH&nbsp;&amp; Co. Parallel-Beteiligungs
KG and MPM Asset Management Investors 2000B LLC. MPM BioVentures IV GP LLC is the general partner of MPM BioVentures IV Strategic Fund, L.P. MPM BioVentures IV LLC is the Managing Member of MPM BioVentures IV GP LLC. Ansbert Gadicke, Luke Evnin,
Todd Foley, Vaughn Kailian, Jim Scopa and John Vander Vort are members of MPM BioVentures IV LLC and share voting and dispositive power over the shares held by MPM BioVentures IV Strategic Fund, L.P. Each individual identified in this footnote
disclaims beneficial ownership of the shares except to the extent of his respective proportionate pecuniary interest in such shares. The address for the entities affiliated with MPM is 200 Clarendon Street, 54th Floor, Boston, MA 02116.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,313,315&nbsp;shares of common stock held of record by Caisse de d&eacute;p&ocirc;t et placement du Qu&eacute;bec, or CDP. An investment committee has
voting and dispositive power over the shares held by Caisse de d&eacute;p&ocirc;t et placement du Qu&eacute;bec.&nbsp;The members of the investment committee are Pierre Pharand, Claude Lafond, Anne-Marie Laberge, Manon Hamel, Fran&ccedil;ois
Libotte, Michel Paquette, J&eacute;r&ocirc;me Marquis, Martin Garand and Mohamed Kortas. Each committee member disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,270,174&nbsp;shares of common stock held of record by Ventures West 8 Limited Partnership. Kenneth Galbraith is General Partner and Senior Vice President
of Ventures West 8 Management Ltd., the general partner of the stockholder. Mr.&nbsp;Galbraith, one of our directors, along with the other partners of Ventures West 8 Management, Inc., have sole voting and investment control over the interest owned
by Ventures West 8 Limited Partnership and disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address for Ventures West 8 Limited Partnership is Suite 400-999 West Hastings Street, Vancouver,
BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (6)&nbsp;above. Mr.&nbsp;Galbraith is a General Partner of Ventures West Capital Ltd., and as such Mr.&nbsp;Galbraith may
be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Galbraith disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Mr.&nbsp;Galbraith&#146;s
business address is c/o Ventures West 8 Limited Partnership, Suite 400-999 West Hastings Street, Vancouver, BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nadav, a member of our board of directors, is Managing Director of TPG Biotech. Dr.&nbsp;Nadav has no voting or investment power over and disclaims beneficial
ownership of the securities held by TPG Biotechnology Partners, L.P. and TPG Ventures, L.P. Dr.&nbsp;Nadav&#146;s business address is c/o TPG Global, LLC, 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (2)&nbsp;above. Mr.&nbsp;Hurwitz is a director of Alta BioPharma Management Partners III, LLC and , and as such
Mr.&nbsp;Hurwitz may be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Hurwitz disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Mr.&nbsp;Hurwitz&#146;s business address is c/o Alta BioPharma Partners, One Embarcadero Center, Suite 3700, San Francisco, CA 94111. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (3)&nbsp;above. Dr.&nbsp;Oronsky is Managing Director of the general partner of the entities affiliated with InterWest
Partners, and as such Dr.&nbsp;Oronsky may be deemed to share voting and dispositive power with respect to all shares held by these entities. Dr.&nbsp;Oronsky disclaims beneficial ownership of such shares except to the extent of any pecuniary
interest therein. Dr.&nbsp;Oronsky&#146;s business address is c/o InterWest Partners, 2710 Sand Hill Road, Suite 200, Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stump was appointed to our board of directors in September 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 49,435 shares of common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;53,265&nbsp;shares of common stock, (ii)&nbsp;641,208&nbsp;shares of common stock owned jointly by Dr.&nbsp;Koenig and his spouse, of which
Dr.&nbsp;Koenig has shared voting and dispositive power, (iii)&nbsp;53,265&nbsp;shares of common stock held by the Scott Koenig Family Trust, an irrevocable trust, of which Dr.&nbsp;Koenig&#146;s spouse and brother-in-law are co-trustees, and of
which Dr.&nbsp;Koenig may be deemed to have shared voting and dispositive power, and (iv)&nbsp;408,091 shares of common stock issuable upon the exercise of options exercisable within 60 days after December&nbsp;31, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 80,231 shares of common stock jointly owned by Mr. Karrels and his spouse, and 73,235 shares of common stock issuable upon the exercise of options
exercisable within 60&nbsp;days after December&nbsp;31, 2013. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 21,306&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after December&nbsp;31, 2013.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 973,620&nbsp;shares of common stock and 1,107,377&nbsp;shares of common stock issuable upon the exercise of options exercisable within 60 days after
December&nbsp;31, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock held by selling stockholders not listed above who, as a
group, own less than 1% of our outstanding common stock prior to this offering. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_15"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our securities and provisions of our amended and restated certificate of incorporation and bylaws that we
expect to become effective upon the closing of this offering is only a summary. You should also refer to the copies of our restated certificate of incorporation and bylaws which have been filed with the Securities and Exchange Commission as exhibits
to our registration statement, of which this prospectus forms a part. The description of common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering in accordance with the terms of the
amended and restated certificate of incorporation that will be adopted by us immediately prior to the closing of this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our authorized capital stock consists of 125,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of
undesignated preferred stock, par value $0.01 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue 125,000,000 shares of common stock. At December&nbsp;31, 2013, 25,188,987 shares of common stock
were deemed outstanding and held of record by 154 holders. Under our restated certificate of incorporation and bylaws, holders of common stock do not have cumulative voting rights. Holders of shares representing a majority of the voting power of
common stock can elect all of the directors. The holders of the remaining shares will not be able to elect any directors. The shares of common stock offered by this prospectus, when issued, will be fully paid and non-assessable and will not be
subject to any redemption or sinking fund provisions. Holders of common stock do not have any preemptive, subscription or conversion rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Holders of common stock are entitled to receive dividends declared by the board of directors out of legally available funds, subject to the rights of preferred stockholders, if any, and the terms of any
future agreements between us and our lenders, if any. We presently intend to retain future earnings, if any, for use in the operation and expansion of our business. We do not anticipate paying cash dividends on our common stock in the foreseeable
future. See &#147;Dividend Policy.&#148; In the event of our liquidation, dissolution or winding up, common stockholders are entitled to share ratably in all assets legally available for distribution after payment of all debts and other liabilities,
and subject to the prior rights of any holders of outstanding shares of preferred stock, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue from time to time up to an aggregate of 5,000,000 shares of preferred stock in one or more series
and to fix or alter the designations, preferences, rights and any qualifications, limitations or restrictions of the shares of each of these series, including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption,
including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or designations of a series without further vote or action by the stockholders. The issuance of preferred stock
may have the effect of delaying, deferring or preventing a change in control of us without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with
voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. We currently have no preferred stock issued or outstanding, and we currently have no plans to issue
any shares of preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the ability to issue preferred stock without the expense and delay of a
special stockholders&#146; meeting will provide us with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. This also permits the board of directors to issue
preferred stock containing terms which could impede the completion of a takeover attempt, subject to limitations imposed by the securities laws. The board of directors will make any determination to issue these shares based on its judgment as to the
best interests of our company and our stockholders at the time of issuance. This could discourage an acquisition attempt or other transaction which stockholders might believe to be in their best interests or in which they might receive a premium for
their stock over the then market price of the stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Takeover Provisions </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. Subject to exceptions, Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a
&#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years from the date of the transaction in which the person became an interested stockholder, unless the interested stockholder attained this status
with the approval of the board of directors or unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the
interested stockholder. Subject to exceptions, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of the corporation&#146;s voting stock. This statute
could prohibit or delay the accomplishment of mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. Our amended and restated certificate of incorporation and bylaws, upon
completion of this offering, will include a number of provisions that may make it more difficult to acquire control of us. These provisions could deprive stockholders of the opportunity to realize a premium on the shares of common stock owned by
them. In addition, these provisions may adversely affect the prevailing market price of the stock and are intended to: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enhance the likelihood of continuity and stability in the composition of the board and in the policies formulated by the board;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage transactions which may involve an actual or threatened change in control of us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage tactics that may be used in proxy fights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">encourage persons seeking to acquire control of us to consult first with the board of directors to negotiate the terms of any proposed business
combination or offer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares or that
is otherwise unfair to our stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Classified Board of Directors; Removal; Filling Vacancies and
Amendment</I>. Our restated certificate of incorporation and bylaws provide for the board to be divided into three classes of directors serving staggered, three-year terms. The classification of the board has the effect of requiring at least two
annual stockholder meetings, instead of one, to replace a majority of members of the board. Subject to the rights of the holders of any outstanding series of preferred stock, our restated certificate of incorporation authorizes only the board to
fill vacancies, including newly created directorships. Accordingly, this provision could prevent a stockholder from obtaining majority representation on the board by enlarging the board of directors and filling the new directorships with its own
nominees. Our restated certificate of incorporation also provides that directors may be removed by stockholders only for cause and only by the affirmative vote of holders of 75% of the outstanding shares of voting stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Voting Rights.</I> Cumulative voting for the election of directors is not provided for in our restated certificate of incorporation,
which means that the holders of a majority of the shares voted can elect all of the directors then standing for election. A director may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes that all
of our stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our
directors then in office. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Delaware General Corporation Law provides generally that, unless otherwise specified in a
corporation&#146;s restated certificate of incorporation or bylaws, the affirmative vote of a majority of the shares entitled to vote on any matter is required to approve such matter. Effective upon the completion of this offering, our bylaws may be
amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Special Stockholder Meetings</I>. Our restated certificate of incorporation provides that
special meetings of the stockholders for any purpose or purposes, unless required by law, shall only be called by the Chairman of the board of directors, a majority of the entire board of directors or the Chief Executive Officer. A special meeting
of the stockholders may not be held absent a written request of this nature. The request shall state the purpose or purposes of the proposed meeting. This limitation on the right of stockholders to call a special meeting could make it more difficult
for stockholders to initiate actions that are opposed by the board of directors. These actions could include the removal of an incumbent director or the election of a stockholder nominee as a director. They could also include the implementation of a
rule requiring stockholder ratification of specific defensive strategies that have been adopted by the board of directors with respect to unsolicited takeover bids. In addition, the limited ability of the stockholders to call a special meeting of
stockholders may make it more difficult to change the existing board and management. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advance Notice
Requirements.</I>&nbsp;Our bylaws require advance notice by a stockholder of proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide
that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less
than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary of the preceding year&#146;s annual meeting date. The notice must contain certain information specified in the bylaws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Written Consent</I>. Our restated certificate of incorporation prohibits the taking of stockholder action by written consent without a
meeting. These provisions make it more difficult for stockholders to take action opposed by the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amendment of Provisions in the Amended and Restated Certificate of Incorporation</I>. Our restated certificate of incorporation
generally requires the affirmative vote of the holders of at least 75% of the outstanding voting stock in order to amend any provisions of the amended and restated certificate of incorporation concerning: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the removal or appointment of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the authority of stockholders to act by written consent; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the required vote to amend the amended and restated certificate of incorporation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">calling a special meeting of stockholders; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">procedure and content of stockholder proposals concerning business to be conducted at a meeting of stockholders; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">director nominations by stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These voting requirements make it more difficult for minority stockholders to make changes in the amended and restated certificate of incorporation that could be designed to facilitate the exercise of
control over us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Undesignated Preferred Stock.</I> Our restated certificate of incorporation provides for 5,000,000
authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender
offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors
could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder
group. In this regard, our amended and restated </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of
preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have
the effect of delaying, deterring or preventing a change in control of us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Options and Warrants </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, options to purchase a total of 618,290 shares of our common stock were outstanding, and up to 1,341,878
additional shares of our common stock were reserved for future issuance under our 2013 Plan, which will become effective upon the signing of the underwriting agreement in connection with this offering. For a more complete discussion of our stock
option plans, please see &#147;&#151;Employee Benefit Plans.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a fourth amended and restated registration rights agreement, dated September&nbsp;19, 2008, which we refer to as the
registration rights agreement, with holders of our preferred stock. Upon completion of this offering, the holders of 15,504,104 shares of our common stock, or their transferees, will be entitled to certain rights with respect to the registration of
such shares, or registrable securities, under the Securities Act of 1933, as amended, or the Securities Act, as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Demand Registration Rights.</I> The holders of shares representing at least 40% of the registrable securities issued or issuable upon
conversion of our Series A-1, Series A-2, Series B, and Series C preferred stock collectively then outstanding may request that we register all or a portion of their shares of registrable securities, provided that the reasonably anticipated
aggregate price to the public of such public offering would exceed $5,000,000. In addition, the holders of shares representing at least 40% of the registrable securities issued or issuable upon conversion of our Series D and Series D-2 preferred
stock collectively then outstanding may request that we register all or a portion of their shares of registrable securities, provided that the reasonably anticipated aggregate price to the public of such public offering would exceed $25,000,000.
Upon their request, we must, subject to some restrictions and limitations, use our best efforts to cause a registration statement covering the number of shares of registrable securities that are subject to the request to become effective. The
holders of registrable securities may only require us to file a maximum of one registration statement in response to their demand registration rights, provided, however, that such obligation will be deemed satisfied only when a registration
statement covering all shares of registrable securities that are requested to be registered has become effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Piggyback Registration Rights.</I> In the event that we propose to register any of our securities under the Securities Act, the
holders of registrable securities are entitled to notice of such registration and are entitled to include their registrable securities in such registration, subject to certain marketing and other limitations. These registration opportunities are
unlimited, but the number of shares that may be registered may be cut back in limited situations by the underwriters. The holders of registrable securities waived their registration rights in connection with this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Form S-3 Registration Rights.</I> The holders of shares of the registrable securities issued or issuable upon conversion of our Series
A-1, Series A-2, Series B, Series C and Series D-2 preferred stock then outstanding may request that we register all or a portion of their shares if we are eligible to file a registration statement on Form&nbsp;S-3 and if the reasonably anticipated
aggregate price to the public of the public offering would exceed $1,000,000. In addition, the holders of shares of the registrable securities issued or issuable upon conversion of our Series D preferred stock then outstanding may request that we
register all or a portion of their shares if we are eligible to file a registration statement on Form S-3 and if the reasonably anticipated aggregate price to the public of the public offering would exceed $5,000,000. The holders of registrable
securities may only require us to file one registration statement on Form S-3 in any twelve month period, provided, however, that such obligation will be deemed satisfied only when a registration statement covering all shares of registrable
securities that are requested to be registered has become effective. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are generally obligated to bear the expenses, other than underwriting discounts and sales
commissions, of these registrations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NASDAQ Global Select Market Listing </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#147;MGNX&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our common stock is Computershare Trust Company, Inc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future sales of our common stock, including shares issued upon the exercise of outstanding options or warrants, in the public market
after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair our ability to raise equity capital in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2013, based on the number of shares of our common stock then outstanding, assuming (1)&nbsp;the closing of this
offering, (2)&nbsp;no exercise of the underwriters&#146; option to purchase additional shares of common stock, and (3)&nbsp;no exercise of outstanding options or warrants, we would have had outstanding an aggregate of approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. Of these shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, including the 5,750,000 shares sold in
our IPO, and all of the shares of common stock to be sold in this offering, and any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable in the public market without restriction or further
registration under the Securities Act, unless the shares are held by any of our &#147;affiliates&#148; as such term is defined in Rule 144 of the Securities Act. The remaining shares of common stock are &#147;restricted securities&#148; as such term
is defined in Rule 144 or subject to lock up agreements in effect in connection with the initial public offering or entered into in connection with this offering (as described below) and will be available for sale in the public market as follows:
(i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares available for sale on or about April 7, 2014 due to lock up agreements in effect in connection with our initial public offering; and (ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares available for sale on or about 90 days from the date of this prospectus upon expiration of the lock-up agreements referred to below, subject in some cases to applicable
volume limitations under Rule 144. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Rule 144 as currently in effect, any person who is or has been an
affiliate of ours during the 90 days immediately preceding the sale and who has beneficially owned shares for at least six months is entitled to sell, within any three-month period commencing 90 days after the date of this prospectus, a number of
shares that does not exceed the greater of: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1% of the then outstanding shares of common stock, which will equal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
immediately after this offering; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume during the four calendar weeks preceding the sale, subject to the filing of a Form 144 with respect to the sale.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales under Rule 144 by our affiliates are also subject to certain manner of sale provisions and notice
requirements and to the availability of current public information about us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A person who is not deemed to have been an
affiliate of ours at any time during the 90 days immediately preceding the sale and who has beneficially owned his or her shares for at least six months is entitled to sell his or her shares under Rule 144 without regard to the limitations described
above, subject only to the availability of current public information about us during the six months after the initial six-month holding period is met. After a nonaffiliate has beneficially owned his or her shares for one year or more, he or she may
freely sell his or her shares under Rule 144 without complying with any Rule 144 requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are unable to estimate the
number of shares that will be sold under Rule 144, since this will depend on the market price for our common stock, the personal circumstances of the sellers and other factors. Prior to the offering, there has been no public market for the common
stock, and there can be no assurance that a significant public market for the common stock will develop or be sustained after the offering. Any future sale of substantial amounts of the common stock in the open market may adversely affect the market
price of the common stock offered by this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with our IPO, we, our officers and directors and the holders of substantially all of our common stock and securities convertible into or exchangeable for our common stock agreed that,
subject to certain exceptions and under certain conditions, for a period of 180 days after the date of our IPO prospectus, we and they will not, without the prior written consent of Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, dispose of
or hedge any shares or any securities convertible into or exchangeable for shares of our capital stock. Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated may, in its discretion, release any of the securities subject to these lock-up agreements
at any time. Sales of shares by our executives officers and directors as well as any other employees who participate as selling stockholders in this offering will be permitted during the lock-up period but only pursuant to the registration statement
of which this prospectus is a part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we, all of our officers and directors, and all of the
selling stockholders have entered into lock-up agreements with the underwriters, subject to specified exceptions, that we and they will not, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, make any short
sale, or otherwise dispose of or hedge any of our shares of common stock, any options or warrants to purchase shares of our common stock, or any securities convertible into, or exchangeable for or that represent the right to receive shares of our
common stock, without the prior written consent of Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, for a period of 90 days from the date of this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any employee or consultant who purchased his or
her shares under a written compensatory plan or contract is entitled to rely on the resale provisions of Rule 701, which permits non-affiliates to sell their Rule 701 shares without having to comply with the public information, holding period,
volume limitation or notice provisions of Rule 144 and permits affiliates to sell their Rule 701 shares without having to comply with the Rule&nbsp;144 holding period restrictions, in each case commencing 90 days after completion of our IPO.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a registration statement under the Securities Act covering the shares of common stock that we may
issue upon exercise of outstanding options reserved for issuance under our 2000 Plan, 2003 Plan and 2013 Plan. Accordingly, shares registered under such registration statement were available for sale in the open market following its effective date,
subject to Rule 144 volume limitations and the lock-up agreements described above, if applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_17"></A>MATERIAL U.S. FEDERAL TAX CONSEQUENCES FOR NON-U.S. HOLDERS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a general discussion of the material U.S. federal income and estate tax consequences of the ownership
and disposition of our common stock by a beneficial owner that is a &#147;non-U.S. holder.&#148; For purposes of this discussion, a &#147;non-U.S. holder&#148; means a beneficial owner of our common stock that is not, for U.S. federal income tax
purposes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States
or any state or political subdivision thereof; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate, the income of which is subject to United States federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority
to control all substantial decisions of the trust or if the trust has a valid election to be treated as a U.S. person under applicable regulations issued by the U.S. Department of the Treasury (&#147;Treasury Regulations&#148;).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discussion is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and
administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations, changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein, possibly with a retroactive
effect. In addition, the Internal Revenue Service (the &#147;IRS&#148;) could challenge one or more of the tax consequences described in this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion below is limited to non-U.S. holders that hold our shares of common stock as capital assets (generally, property held for investment) within the meaning of the Code. This discussion does
not address all aspects of U.S. federal income and estate taxation, including the Medicare contribution tax, that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#146;s individual circumstances nor does it address
any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules under the Code applicable to particular
non-U.S. holders, such as: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">brokers or dealers in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">tax-exempt organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pension plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insurance companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">controlled foreign corporations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">passive foreign investment companies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain U.S. expatriates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a partnership, or any entity treated as a partnership for U.S. federal income tax
purposes, is a holder of our common stock, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. A holder that is a partnership, and the partners in such
partnership, should consult their own tax advisers regarding the tax consequences of the acquisition, holding and disposition of our common stock, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Prospective holders are urged to consult their tax advisers with respect to the particular tax consequences to them of acquiring, holding and disposing of our common stock, including the consequences
under the laws of any state, local or foreign jurisdiction. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the section entitled &#147;Dividend
Policy,&#148; we do not anticipate paying any dividends on our common stock in the foreseeable future. In the event that we do make distributions of cash or other property on our common stock (other than certain pro rata distributions of our common
stock or rights to acquire our common stock), those distributions generally will be treated as dividends to the extent paid from our accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds
our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described below under the heading &#147;Gain on Dispositions of Common Stock.&#148; Any such distribution would also be subject to the discussion below under the section titled &#147;Withholding and Information Reporting
Requirements&#150;FATCA.&#148; Dividends paid to a non-U.S. holder of our common stock generally will be subject to withholding tax at a 30% rate, or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of
withholding under an applicable income tax treaty, a non-U.S. holder must provide an IRS Form&nbsp;W-8BEN (or successor form) certifying its entitlement to benefits under the treaty. Non-U.S. holders are urged to consult their own tax advisors
regarding their entitlement to benefits under a relevant income tax treaty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The withholding tax does not apply to dividends
paid to a non-U.S. holder that provides an IRS Form&nbsp;W-8ECI (or successor form), certifying that the dividends are effectively connected with the non-U.S. holder&#146;s conduct of a trade or business within the United States (&#147;effectively
connected dividends&#148;). Instead, effectively connected dividends will be subject to regular U.S. income tax as if the non-U.S. holder were a U.S. resident, subject to any applicable income tax treaty providing otherwise. A non-U.S. corporation
receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; currently at the rate of 30% (or a lower rate prescribed under an applicable income tax treaty). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit
against any excess amounts withheld by timely filing an appropriate claim with the IRS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gain on Disposition of Common Stock
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder generally will not be subject to U.S. federal income tax on gain realized on a sale or other
disposition of common stock unless: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the gain is effectively connected with a trade or business of the non-U.S. holder in the United&nbsp;States, and if an applicable tax treaty so
provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the
manner applicable to U.S. persons, subject to an applicable income tax treaty providing otherwise and if the non-U.S. holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable
income tax treaty, may also apply; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the non-U.S. holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other
requirements are met, in which case the non-U.S. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source
capital losses of the non-U.S. holder, if any; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are or have been a &#147;U.S. real property holding corporation,&#148; as defined below, at any time within the five-year period preceding the
disposition or during the non-U.S. holder&#146;s holding period, whichever period is shorter. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not,
and do not anticipate becoming, a U.S. real property holding corporation. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; if the fair market value of its U.S. real property interests (as defined in the Code and the
applicable Treasury Regulations) equals or exceeds 50% of the aggregate fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. Even if we were to become a U.S. real property
holding corporation, gain on the sale or other disposition of common stock by a non-U.S. holder generally would not be subject to U.S. federal income tax, provided that the common stock is regularly traded on an established securities market and the
non-U.S. holder does not actually or constructively own more than 5% of the common stock during the shorter of (1)&nbsp;the five-year period ending on the date of the disposition or (2)&nbsp;the period of time during which the holder held such
shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Information Reporting Requirements and Backup Withholding </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such
holder and the tax withheld, if any, with respect to such distributions. Unless a non-U.S. holder complies with certification procedures to establish that it is not a U.S. person (as defined in the Code), information returns may be filed with the
IRS in respect of the proceeds from a sale or other disposition of common stock and the non-U.S. holder may be subject to U.S. backup withholding (currently at 28%) on payments of dividends or on the proceeds from a sale or other disposition of
common stock. The certification procedures required to claim a reduced rate of withholding under a treaty will satisfy the certification requirements necessary to avoid the backup withholding tax as well. Generally, information reporting and backup
withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office or broker. However, for information reporting purposes, dispositions effected
through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors
regarding the application of the information reporting and backup withholding rules to them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Copies of information returns
may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amount of any backup withholding from a payment to a non-U.S. holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund or
credit against the non-U.S. holder&#146;s U.S. federal income tax liability, provided that the required information is furnished to the IRS. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Estate Tax </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual Non-U.S. holders and entities the property of which is potentially includible in such an individual&#146;s gross estate for
U.S. federal estate tax purposes (for example, a trust funded by a non-U.S. holder individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the common stock
will be treated as U.S. situs property subject to U.S. federal estate tax. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withholding and Information Reporting Requirements&#150;FATCA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Foreign Account Tax Compliance Act, which is commonly referred to as &#147;FATCA,&#148; will impose a U.S. federal withholding tax of
30% on payments of dividends on and gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; the foreign entity undertakes
certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the
foreign entity is otherwise exempt under FATCA. Although this legislation is effective with regards to amounts paid after December&nbsp;31, 2012, under final Treasury Regulations issued on January&nbsp;17, 2013 and IRS Notice 2013-43 released on
July&nbsp;12, 2013, withholding under FATCA will only apply (1)&nbsp;to payments of dividends on our common stock made after June&nbsp;30, 2014 and (2)&nbsp;to payments of gross proceeds from a sale or other disposition of our common stock made
after December&nbsp;31, 2016. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits for such taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prospective investors should consult their own tax advisors regarding the possible implication of the FATCA rules on their investment in our common stock, and the entities through which they holder our
common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_18"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, and Leerink Partners LLC are acting as representatives of each of the
underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us, the selling stockholders and the underwriters, we and the selling stockholders have agreed to sell to the underwriters, and each of the
underwriters has agreed, severally and not jointly, to purchase from us and the selling stockholders, the number of shares of common stock set forth opposite its name below. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><U>Underwriter</U></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of&nbsp;Shares</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.60em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leerink Partners LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush Securities Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roth Capital Partners, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:3.60em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the selling stockholders
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of
legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve
the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commissions and Discounts
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The representatives have advised us and the selling stockholders that the underwriters propose initially to offer the
shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering,
the public offering price, concession or any other term of the offering may be changed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the public
offering price, underwriting discount and proceeds before expenses to us and the selling stockholders. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:34pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:54pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Without&nbsp;Option</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:43pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>With&nbsp;Option</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to the selling stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us and the selling stockholders. We have also agreed to reimburse the underwriters for certain of their expenses, in an amount of up to $25,000, incurred in connection with review
by the Financial Industry Regulatory Authority, Inc. of the terms of this offering, as set forth in the underwriting agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Option to
Purchase Additional Shares </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the selling stockholders have granted an option to the underwriters, exercisable for 30
days after the date of this prospectus, to purchase up to additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the
underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>No Sales of Similar Securities </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the selling stockholders and our
executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 90 days after the date of this prospectus without first
obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">offer, pledge, sell or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sell any option or contract to purchase any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">purchase any option or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">grant any option, right or warrant for the sale of any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lend or otherwise dispose of or transfer any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">request or demand that we file a registration statement related to the common stock; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such
swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for
which the person executing the agreement later acquires the power of disposition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nasdaq Global Select Market Listing </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares are listed on the Nasdaq Global Select Market under the symbol &#147;MGNX&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Price Stabilization, Short Positions and Penalty Bids </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our common stock. However, the representatives may engage in
transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, the underwriters may purchase and sell our common stock in
the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than
they are required to purchase in the offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short
position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the
price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close
out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after
pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the
offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the
underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of
raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on the Nasdaq Global Select Market, in the over-the-counter market or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock.
In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Passive Market Making </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in the common
stock on the Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through the completion of distribution. A passive market
maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits
are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriters and dealers are not required to engage in
passive market making and may end passive market making activities at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electronic Distribution </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such
as e-mail. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Relationships </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Affiliates of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated have passive limited partnership interests in certain holders of our common stock, which, in the aggregate, account for less than
one percent of our common stock. Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have
received, or may in the future receive, customary fees and commissions for these transactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the ordinary course of their business activities, the underwriters and their
affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers.
Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in
respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation
to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to the public in that Relevant Member State other than: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares shall require the Company or the
representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member
State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an
exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the
Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied
in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the
expression &#147;2010&nbsp;PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer
subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article
49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom,
any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Switzerland </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This
document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing
Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise
made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this document nor any other offering or marketing material relating to the
offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market
Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in
collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the Dubai
International Financial Centre </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules
of the Dubai Financial Services Authority (&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other
person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the
prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the
contents of this prospectus you should consult an authorized financial advisor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the
Australian Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the
&#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt
Investors&#148;) who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to
one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the
date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the
offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains general information only and does not take account of the investment objectives, financial situation or
particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to
their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong
Kong </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document,
other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has
been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong
(except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948,
as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall
mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Singapore </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
&#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_19"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the issuance of the shares of common stock offered by this prospectus will be passed upon for us by Arnold&nbsp;&amp;
Porter LLP, Washington, District of Columbia. Legal matters relating to the sale of common stock in this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_20"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ernst&nbsp;&amp; Young LLP, independent registered accounting firm, has audited our consolidated financial statements at December&nbsp;31, 2011 and 2012, and for the years then ended, as set forth in
their report. We&#146;ve included our financial statements in this Prospectus and elsewhere in the Registration Statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc662896_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed a registration statement on Form S-1 with the Securities and Exchange Commission under the Securities Act with respect to
the common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information with respect to us and our common stock, please see the registration statement and the exhibits and schedules filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit
to the registration statement. The registration statement, including its exhibits and schedules, may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, N.E., Room 1580, Washington, D.C. 20549,
and copies of all or any part of the registration statement may be obtained from such offices upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC
also maintains an Internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the site is <I>www.sec.gov</I>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:7%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and,
in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and on
the SEC website referred to above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc662896_22"></A><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MacroGenics, Inc.</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_2">Consolidated Balance Sheets as of December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013 (unaudited)</A>
and September&nbsp;30, 2013 pro forma (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_3">Consolidated Statements of Operations and Comprehensive Income for the years ended December&nbsp;
31, 2011 and 2012 and the nine months ended September&nbsp;30, 2013 (unaudited) and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_4">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the years ended December&nbsp;
31, 2011 and 2012 and the nine months ended September&nbsp;30, 2013 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2011 and 2012 and the nine months ended September&nbsp;30, 2013 (unaudited) and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin662896_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. as of December&nbsp;31, 2011 and 2012, and the related
consolidated statements of operations and comprehensive income (loss), stockholders&#146; equity (deficit) and cash flows for the years then ended. These financial statements are the responsibility of the Company&#146;s management. Our
responsibility is to express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the
standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were
not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all
material respects, the consolidated financial position of MacroGenics, Inc. at December&nbsp;31, 2011 and 2012, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted
accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;8, 2013, except for the last
paragraph of Note 4, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as to which the date
is September&nbsp;26, 2013 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_2"></A>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro Forma</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,569,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,397,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,281,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,662,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,927,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,953,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,469,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,680,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,975,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,739,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,798,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,652,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,123,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,298,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,289,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,728,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,265,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,378,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,360,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,801,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,888,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,237,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,956,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,812,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,164,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,984,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,024,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 convertible preferred stock, $0.01 par value&nbsp;&#150; 26,874,792 shares authorized, 26,874,792&nbsp;shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $27,000,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro
Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 convertible preferred stock, $0.01 par value&nbsp;&#150; 7,364,582 shares authorized, 7,364,582&nbsp;shares issued and
outstanding at December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $7,000,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro
Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS&#151;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro Forma</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value &#150; 71,401,237 shares authorized, 71,401,237 shares issued and outstanding at
December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $31,000,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro Forma)</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value &#150; 110,952,217 shares authorized, 110,952,217 shares issued and outstanding
at December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $45,000,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro
Forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred stock, $0.01 par value &#150; 30,000,000 shares authorized, 14,446,227 shares issued and outstanding at
December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $9,400,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 convertible preferred stock, $0.01 par value &#150; 75,000,000 shares authorized, 63,681,176 shares issued and outstanding
at December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013; aggregate liquidation preference of $41,500,000 at December&nbsp;31, 2012 and September&nbsp;30, 2013 (unaudited), and no shares outstanding at September&nbsp;30, 2013 (Pro
Forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value &#150; 425,000,000 shares authorized, 1,049,030 issued and outstanding at December&nbsp;31, 2011,
1,098,914 issued and outstanding at December&nbsp;31, 2012, 2,124,624 issued and outstanding at September&nbsp;30, 2013 and 19,196,684 at September 30, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS&#151;(Continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2013</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro Forma</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock, at cost; 14,381 shares at December&nbsp;31, 2011 and 2012 and September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,449,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,334,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,569,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,345,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172,528,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172,528,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,048,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,048,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,680,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,975,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,975,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_3"></A>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:89.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:119.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1.00px solid #000000; width:56.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2012&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1.00px solid #000000; width:56.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,054,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,645,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,283,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,015,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,152,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,744,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,207,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,826,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,027,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,128,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,088,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,432,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,924,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,233,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,868,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,187,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,640,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,322,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,957,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,620,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,565,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,556,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,249,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,461,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,571,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,908,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,039,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,473,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,328,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_4"></A>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series A-1 <BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series A-2 <BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series B <BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Convertible</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series D <BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:40.75pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Series D-2 <BR>Convertible<BR>Preferred Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:39.55pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:39.50pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Treasury Stock</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:27.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Additional<BR>Paid-In<BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:34.00pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:35.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Total <BR>Stockholders&#146;<BR>Equity<BR>(Deficit)</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:17.35pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:21.05pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,253,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">452,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,202,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(190,551,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,634,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Issuance of convertible Series D-2 stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,427,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,049,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,449,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,334,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_5"></A>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:89.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:116.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,459,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,551,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,713,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(965,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,271,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,312,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,444,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,940,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(466,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,275,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,810,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,935,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,968,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,757,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,581,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,281,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,988,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,036,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,036,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,085,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,342,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,475,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,767,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,173,957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,876,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,451,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,569,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin662896_6"></A>MACROGENICS, INC. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Nature of Operations </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its
proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its
understanding of disease biology and immune-mediated mechanisms may address disease-specific challenges which are not currently being met by existing therapies. The Company creates both differentiated molecules that are directed to novel cancer
targets, as well as &#147;bio-betters&#148; which are drugs designed to improve upon marketed medicines. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Principles of Consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics West, Inc. All
intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is
available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal
antibody-based therapeutics for cancer, autoimmune and infectious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in accordance with U.S. generally accepted accounting principles (GAAP) requires the Company to
make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements,
management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue
recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical
experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the Company utilizes estimates and assumptions in determining the fair value of its common stock. The Company granted stock
options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. Management uses contemporaneous valuations in estimating the fair value of its common stock. The board
of directors has determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and the historic prices at which the
Company sold shares of its preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim consolidated balance sheet as of September&nbsp;30, 2013, the consolidated statements of operations and
comprehensive income and cash flows for the nine months ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
September&nbsp;30, 2013 and 2012, and the related interim information contained within the notes to the consolidated financial statements have been prepared in accordance with the rules and
regulations of the Securities and Exchange Commission (SEC) for interim financial information. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring
adjustments, necessary for the fair presentation of the Company&#146;s financial position at September&nbsp;30, 2013 and results of its operations and its cash flows for the nine months ended September&nbsp;30, 2013 and 2012. The results for the
nine months ended September&nbsp;30, 2013 are not necessarily indicative of future results. All references to September&nbsp;30, 2013 or to the nine months ended September&nbsp;30, 2013 and 2012 in the notes to the consolidated financial statements
are unaudited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Balance Sheet Presentation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet as of September 30, 2013, reflects the automatic conversion of the outstanding shares of Series A-1,
Series A-2, Series B, Series C, Series D, and the net share exercise of the Series D-2 convertible preferred stock warrants into shares of common stock as though the completion of the Company&#146;s initial public offering (IPO) had occurred on
September 30, 2013. The shares of common stock issued in the IPO and the net share exercise of the Series D-2 preferred stock warrants of any related net proceeds or cash received from the net share exercise are excluded from such pro forma
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of
purchase to be cash equivalents. Cash and cash equivalents consist of certificates of deposit and investment in money market funds with commercial banks and financial institutions. Cash equivalents are stated at amortized cost, plus accrued
interest, which approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors
including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of
December&nbsp;31, 2011, December&nbsp;31, 2012, and September&nbsp;30, 2013, as the Company has a history of collecting on all outstanding accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is
required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit card accounts. Amounts classified as restricted cash on the consolidated balance sheets are $582,171 at December&nbsp;31, 2011
and $404,850 at December&nbsp;31, 2012 and September&nbsp;30, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair market values of the financial instruments included in the financial statements, which include cash equivalents and money market
accounts, approximate their carrying values at December&nbsp;31, 2012 and 2011, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with Accounting Standards Codification
820, <I>Fair Value Measurements and</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Disclosures</I> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value
measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following
three categories: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1 &#150; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2 &#150; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets
or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3 &#150; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&nbsp;&#150;
e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective
judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities subject to fair value measurements as of December&nbsp;31, 2011, December&nbsp;31, 2012 and
September&nbsp;30, 2013, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:164.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair Value Measurements at December&nbsp;31, 2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quoted&nbsp;Prices&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Active&nbsp;Markets&nbsp;for</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:64.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identical Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant&nbsp;Other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:63.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Observable&nbsp;Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unobservable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:47.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,049,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,049,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,800,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,631,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:164.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair Value Measurements at December&nbsp;31, 2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quoted&nbsp;Prices&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Active&nbsp;Markets&nbsp;for</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:64.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identical Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant&nbsp;Other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:63.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Observable&nbsp;Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unobservable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:47.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:166.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fair Value Measurements at September&nbsp;30, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quoted&nbsp;Prices&nbsp;in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Active&nbsp;Markets&nbsp;for</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:64.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identical Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant&nbsp;Other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:63.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Observable&nbsp;Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Unobservable</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:47.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Inputs</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:24.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Level 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,522,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,522,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,974,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,974,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, the Company transferred its money market funds from Level 2 to Level 1 because
the inputs are now based upon a quoted market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level 1 securities primarily consist of restricted cash, cash
equivalents and money market funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company determines the estimated fair value for its Level 2 securities using the following methods: quoted prices for similar
assets/liabilities in active markets, inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.) and inputs that are derived principally from or corroborated by
other observable market data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s preferred stock warrant
liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC 820 as of December&nbsp;31, 2011,&nbsp;December&nbsp;31, 2012, and September&nbsp;30,
2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:66.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,&nbsp;2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,663,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total unrealized gains (losses) included in earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to estimate the fair value of the preferred stock purchase warrants, the business enterprise value
was established based on a discounted cash flow model (income approach). The Company utilized an option pricing method to value the shares using a contingent claims analysis, which applies a series of call options whose inputs reflect the
liquidation preferences and conversion behavior of the different classes of equity. After the equity value of the business enterprise was determined, the total equity value is allocated to the various equity instruments such as preferred stock,
stock options and preferred stock purchase warrants. Key management estimates relate to the time period to liquidation and conversion behavior of a particular class of stockholders. The business enterprise value includes assumptions related to
product approval, market penetration and costs to develop the product. Significant changes to these assumptions would result in increases/decreases to the fair value of the outstanding warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The total unrealized gains (losses) on the preferred stock warrants included in earnings is included as a component of other income (expense)
in the consolidated statement of operations and comprehensive income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents,
and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2011 and 2012, and the nine months ended
September&nbsp;30, 2013, all of the Company&#146;s grant revenue was related to contracts and research grants received from U.S. government agencies. Collaborations with Les Laboratoires Servier and Institut de Recherches Servier (collectively,
Servier), Boehringer Ingelheim GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc. (Pfizer), and Eli Lilly&nbsp;&amp; Co. (Eli Lilly) account for all other revenue. All outstanding receivables are due from Gilead, Pfizer, Boehringer, Eli
Lilly, and U.S. government agencies. The following table represents the percentage of all significant revenue earned in the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Nine&nbsp;Months&nbsp;ended<BR>September&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant accounts receivable balances as of
December&nbsp;31, 2011, December&nbsp;31, 2012 and September&nbsp;30, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE="border-bottom:1.00px solid #000000; width:66.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;ended<BR>September&nbsp;30,<BR>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation
are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following
estimated useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter of lease term or useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, <I>Property, Plant and
Equipment</I>. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by
a comparison of the carrying amount of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the
fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the
lower of the carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2011 and 2012, and September&nbsp;30, 2013, the Company determined that there were no impaired assets and had no assets held-for-sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Deferred tax assets
and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to
reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The
Company&#146;s policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics
to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to the Company&#146;s technological platforms, such as its Fc Optimization
and Dual-Affinity Re-Targeting, or DART, technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and
(iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development
activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements
include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification
(ASC) Topic 605-25, <I>Revenue Recognition&nbsp;&#150;&nbsp;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, the
Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value
to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the periods presented, the Company had the following two types of agreements with the parties identified below: 1) exclusive development
and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) Option/research agreements to secure on
established terms, development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by the Company during an option period (referred to herein as right-to-develop
agreements). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are no performance, cancellation, termination or refund provisions in any of the
arrangements that contain material financial consequences to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Licenses </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the
Company may have an option to participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Generally,
exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at
negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an
option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises
any co-development and co-commercialization rights. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In determining the units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements
to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the partner and the availability of technology
platform and product research expertise in the general marketplace. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated
selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company&#146;s previous collaboration agreements,
recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be
made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value. Prior
to the adoption of Accounting Standards Update (ASU) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, the Company determined that its licenses lacked stand-alone value because it did not have
vendor-specific objective evidence of selling price (&#147;VSOE&#148;), and were combined with other elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which the Company refers
to as the Company&#146;s period of substantial involvement. In making the determination of the length of the period over which to defer revenue for contracts entered in to prior to the adoption of ASU No.&nbsp;2009-13, significant judgment and
estimation is used by the Company and can have an impact on the amount of revenue recognized in a given period. Historically, the Company&#146;s involvement with the development of a collaborator&#146;s product candidate has been significant at the
early stages of development, and lessens as it progresses into clinical trials. Accordingly, the Company generally estimates this period of substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involvement to begin at the inception of the collaboration agreement and conclude at the end of the Company&#146;s substantial involvement. ASU No.&nbsp;2009-13 amends the criteria for separating
and allocating consideration in a multiple element arrangement by modifying the fair value requirements for revenue recognition and eliminating the use of the residual value method. The selling prices of deliverables under an arrangement may be
derived using third-party evidence (&#147;TPE&#148;), or a best estimate of selling price (&#147;BESP&#148;), if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within
the license agreement was sold on a standalone basis. Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating
the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate
pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables.
Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return relative to the delivered item,
delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate
units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in
determining whether a deliverable is a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In determining the separate units of accounting, the Company
evaluated whether the exclusive license had standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination included the research and development
capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considered whether or not (i)&nbsp;the collaborator could use the license for its intended purpose without the receipt
of the remaining deliverables, (ii)&nbsp;the value of the license was dependent on the undelivered items and (iii)&nbsp;the collaborator or other vendors could provide the undelivered items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company reassesses its periods of substantial involvement over which the Company amortizes its upfront license fees and makes adjustments
as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company&#146;s technology to develop an alternative product candidate to
the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining period of substantial
involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred
revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upfront
payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological
improvements, research services and the manufacture of pre-clinical and clinical materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue related to
research and pre-clinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable
is probable. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company typically performs research activities and pre-clinical development services,
including generating and engineering product candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research
materials produced or services performed as revenue from collaborative research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s license agreements have milestone
payments which for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate
initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing approvals
for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At the
inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of
whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company
evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone
consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Non-refundable
development and regulatory milestones that are expected to be achieved as a result of the Company&#146;s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the
milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of
substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><I>Right-to-Develop Agreements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize
in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a specific target
selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program,
(iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered
substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in
evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront
consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization
licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop agreements entered into prior to
the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, the Company has deferred the upfront payments received and recognizes this revenue over the period during which
the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is
deferred and recognized over the life of the option, generally 12 months. Subsequent to the adoption of ASU No.&nbsp;2009-13, the Company&#146;s evaluation of whether the option is substantive is consistent with pre-adoption of ASU No.&nbsp;2009-13.
How the Company determines the selling price of the option is the only difference between pre and post adoption of ASU No.&nbsp;2009-13. Post adoption of ASU No.&nbsp;2009-13, the selling prices of deliverables under an arrangement may be derived
using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves
management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions
related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management
considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of
accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is
considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling
prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of
accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the
Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management&#146;s best estimate. Management&#146;s determination of selling
price includes such factors as stage of development, market potential and cash flow models used during the negotiation with the collaborator. There have been no option license exercises to date for any period presented. Upon exercise of an option to
acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee to the development and commercialization license and apply the multiple-element revenue recognition criteria to the development
and commercialization license and any other deliverables to determine the appropriate revenue recognition, which will be consistent with the Company&#146;s accounting policy for upfront payments on exclusive licenses event a right-to-develop
agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company&#146;s
right-to-develop agreements have been determined to contain substantive options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to
secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the
multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses,
including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, the cost of acquiring and manufacturing clinical trial
materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2012, the Company adopted FASB&#146;s Accounting Standards Update 2011-05, <I>Presentation of Comprehensive
Income</I>. ASC 220, <I>Comprehensive Income</I>, requires the presentation of the comprehensive income (loss) and its components, as part of the consolidated financial statements. Comprehensive income (loss) is comprised of the net income (loss)
and other changes in equity that are excluded from net income (loss). Comprehensive income (loss) equals net income (loss) for the years ended December&nbsp;31, 2011 and 2012, and for the nine months ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Stock-based payments are accounted for in accordance with the provisions of ASC&nbsp;718, <I>Compensation&nbsp;&#150; Stock Compensation</I>.
The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance
condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the
Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend
yield, expected volatility and the expected life of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Income (loss) per share is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to
each class of common stock and participating securities based on their respective rights to receive dividends. In the event that the Board of Directors shall declare a dividend payable in cash or other property on the then-outstanding shares of
common stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock shall be entitled to receive the amount of dividends per share of Preferred Stock that would be payable on the largest number of whole shares of
Common Stock into which each share of Preferred Stock could then be converted. Therefore, the Series A-1, A-2, B, C, D and D-2 are participating securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is determined by dividing the net income (loss) allocable to common stockholders by the
weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per share is computed by dividing the net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income (loss) allocable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive
effect of the Company&#146;s stock option grants and the if-converted method is used to determine the dilutive effect of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:89.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:115.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic income (loss) per common share</B>:<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,466,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,944,149</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted income (loss) per common share:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,466,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,944,149</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,334,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,445,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,025,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,908,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted net income (loss) per share
because their effect would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:89.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to Purchase Series D-2 Preferred&nbsp;Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,885,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were included in the calculation of diluted net income
(loss) per share: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:68.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to Purchase Series D-2 Preferred&nbsp;Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pro forma Net Income (Loss) Per Share</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pro forma net income (loss) per share is computed using the weighted-average number of common shares outstanding and assumes the
conversion of all outstanding shares of the Company&#146;s <FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> A-2, B, C, D, and D-2 convertible preferred stock and net share exercise of the Series D-2 preferred stock warrants into shares of
common stock upon completion of the Company&#146;s IPO, as if they had converted at the beginning of the period. The Company believes the unaudited pro forma net income (loss) per share provides material information to investors, as the conversion
of the Company&#146;s <FONT STYLE="white-space:nowrap">Series&nbsp;A-1,</FONT> A-2, B, C, D, and D-2 convertible preferred stock and net exercise of the Series D-2 preferred stock warrants to common stock occurred upon the closing of the IPO, and
the disclosure of pro forma net income (loss) per share thus provides an indication of net income (loss) per share that is comparable to what will be reported by the Company as a public company. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended</B><br><B>December 31,<BR>2012 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months<BR>Ended</B><br><B>September&nbsp;30,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) used to compute pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,512,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares, used to calculate net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,083,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,517,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,373,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add: Pro forma adjustments to reflect assumed weighted-average effect of conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,955,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,955,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in calculating pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,039,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,419,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,473,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,328,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The calculation of pro forma net income (loss) per share for the nine-month period ended
September 30, 2013 excludes 116,270 shares of common stock upon the net share issuance of the Series <FONT STYLE="white-space:nowrap">D-2</FONT> preferred stock warrants because their effect would be anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards Adopted </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2011, the Financial Accounting Standards Board (FASB) issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common
fair value measurements and disclosure requirements in U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP and
IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years,
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The
amendments in ASU No.&nbsp;2011-05 require that all nonowner changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement
approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of
comprehensive income. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended
December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all ASUs through the date the consolidated financials were issued and believes that the
adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:68.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,951,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,003,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,172,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,910,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,603,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,831,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,893,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,607,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,643,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,379,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,339,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,174,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,287,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,469,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&nbsp;31, 2011 and 2012 was
$1,147,300 and $959,930, respectively, and $722,496 and $834,615 for the nine months ended September&nbsp;30, 2012 and 2013, respectively. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Stockholders&#146; Equity (Deficit) </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1 and Series A-2 convertible preferred
stock (Series A preferred stock) for $1.00 per share resulting in net proceeds of approximately $34,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2004,
the Company entered into a series of transactions raising $30,261,672, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B convertible preferred stock (Series B preferred stock). In connection
with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure but remained unissued at December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2006, the Company raised $44,898,754, net of related offering costs of $101,246, from the sale of 110,952,217 shares of its
Series C convertible preferred stock (Series C preferred stock). In connection with the Series C preferred stock offering, 10,003,300 shares of common stock were allocated to holders of Series B preferred stock as an anti-dilution measure but
remained unissued at December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company issued 12,466,039 shares of its Series D convertible
preferred stock (Series D preferred stock) in exchange for all of the outstanding capital stock and convertible notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently, in March 2011 a settlement was reached with the former Raven
stockholders bringing the total Series D preferred stock issued in connection with the Raven acquisition to 14,446,227 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;19, 2008, the Company raised $24,843,211, net of related offering costs of $156,788, from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (Series D-2 preferred stock). The Company also issued preferred
stock warrants for the purchase of 2,875,327 shares of Series D-2 preferred stock. The preferred stock warrants are exercisable at any time prior to September&nbsp;2018, but expire upon an IPO, and have a stated exercise price of $0.65 per warrant.
On May&nbsp;16, 2010, the Company exercised a put notice to Lilly in accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708
additional shares of Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2011, the Company raised gross proceeds for $12,016,500 from the
sale of 18,427,388 shares of its Series D-2 preferred stock. Issuance costs associated with the sale were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Due to certain
provisions in the Series D-2 convertible preferred stock warrant agreement, these warrants are required to be classified as a liability. Management believes that the circumstances requiring cash settlement of the award are remote. The Series D-2
preferred stock warrant liability is recorded at fair value, which is adjusted at the end of each reporting period using the Option-Pricing Method, with changes in value recorded as &#147;Other income (expense)&#148; in the accompanying consolidated
statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Holders of the Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are entitled
to vote, together with the common stockholders as one class, on all matters as to which common stockholders are entitled to vote. In any such vote, each share of Series A, Series B, Series C and Series D preferred stock shall entitle the holder to
the number of votes per share that equals the number of shares of common stock into which each such share of preferred stock is then convertible. For so long as at least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
four&nbsp;million shares of each of the Series A, Series B and Series C preferred stock remain outstanding, the holders of each of the Series A, Series B and Series C preferred stock, each voting
as a separate class, shall each be entitled to elect two members of the Board of Directors of the Company. The holders of a majority of the common stock, voting as a separate class, shall have the right to elect one member of the Board of Directors
of the Company. The holders of a majority of the common stock and the holders of at least 66 2/3% of the preferred stock, each voting separately as a single class (and on an as-if-converted basis to common stock with respect to the preferred stock),
shall be entitled to elect all remaining members of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dividends are noncumulative and accrue on the Series A-1,
Series A-2, Series B, Series C, Series D and Series&nbsp;D-2 preferred stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and are payable when and as declared by the Board of Directors. Dividends must be declared so that
the Series A, Series&nbsp;B, Series C and Series D preferred stock are paid in like-kind and participate equally to those of the Series&nbsp;D-2 preferred and common stock. No dividends have been declared and none are accrued at December&nbsp;31,
2012 and 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are initially
convertible into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio of certain series of preferred stock is subject to change in the event specified dilutive transactions
occur. These dilutive events are considered to be the sale of common stock at a per share price less than the applicable preferred stock conversion price. There are no anti-dilution protections for the Series A-2 preferred stock and no adjustment to
the Series A-1 preferred stock conversion price is made if a common stock issuance is at a price per share greater than the conversion price of the Series C preferred stock. The conversion price shall be $12.39, $18.77, $6.95, $7.70, $12.20 and
$12.20 for each share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. The Company has reserved 17,129,782 shares of common stock for the potential conversion of the Series A-1, Series A-2,
Series B, Series&nbsp;C, Series D and Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each share of Series A-1, Series A-2, Series B, Series C, Series D and
Series D-2 preferred stock automatically converts into shares of the Company&#146;s common stock upon closing of a firm commitment underwritten public offering of common stock registered under the Securities Act of 1933 which generates net proceeds
to the Company of at least $40&nbsp;million. The holders of two-thirds of the Series&nbsp;A-1, Series&nbsp;A-2, Series&nbsp;B, Series C, Series D and Series D-2 preferred stock, voting together as a single class, but separately from the common
stockholders, shall have the right to elect to convert all outstanding shares of Series A-1, Series&nbsp;A-2, Series&nbsp;B, Series C, Series D and Series D-2 preferred stock into shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In liquidation, the holders of Series D-2 preferred stock are entitled to receive $12.20 per share prior to any distribution to the holders of
any Series C and Series D preferred stock. The holders of Series C and Series&nbsp;D preferred stock are entitled to receive $7.70 and $12.20 per share, respectively, on a <I>pari passu </I>basis, prior to any distribution to the holders of any
Series B preferred stock. The holders of Series B preferred stock are entitled to receive $6.95 per share prior to any distribution to the holders of any shares of Series A preferred stock. The holders of Series A preferred stock are entitled to
receive $12.39 per share prior to the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with preparing for the Company&#146;s initial public
offering, the Company&#146;s Board of Directors and stockholders approved a 1-for-18.7739 reverse stock split of the Company&#146;s Common Stock. The reverse stock split became effective on September&nbsp;26, 2013. All share and per share amounts in
the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to
additional paid-in capital. In addition, in September 2013, the Company&#146;s Board of Directors and stockholders approved an amendment of the Company&#146;s restated certificate of incorporation to, among other things, change the definition of a
designated public offering to remove the per share price requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Shared-Based Payments </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2000 Stock Option and Incentive Plan (the 2000 Plan) allowed for the grant of awards in respect of an aggregate of 130,725
shares, which was increased to 150,297 shares of the Company&#146;s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other performance
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (the 2003 Plan), and it was amended and
approved by the Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company&#146;s common stock. During the year ended December&nbsp;31, 2006, the
maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 460,746 shares to 2,512,390. During the year ended December&nbsp;31, 2008, the maximum number of shares of common stock authorized
to be issued by the Company under the 2003 Plan was increased by 745,716 shares to 3,258,106. During the year ended December&nbsp;31, 2010, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was
increased by 532,654 shares to 3,790,760. During the year ended December&nbsp;31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 545,970 shares to 4,336,731. As of
September&nbsp;30, 2013, a total of 46,176 shares were available for issuance under the 2003 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Stock options granted under the 2003
Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subsequent to
September 30, 2013 the Company implemented the 2013 Incentive Plan (&#147;2013 Plan&#148;). The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares
of common stock initially available for issuance pursuant to awards under the 2013 Plan is 1,960,168&nbsp;shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Exchange
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2011 (Exchange Date), the Company modified certain outstanding options with exercise prices of $1.88 and $4.69
(Original Options). These Original Options were canceled and replaced with options having an exercise price of $0.94 (Replacement Options), reflecting the current fair market value of the Company&#146;s common stock on the Exchange Date. Original
Options submitted for exchange were replaced on a one-for-one basis with Replacement Options. Additionally, the Replacement Options retain all terms and conditions of the Original Options except for the reduction to the exercise price as described
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Total compensation associated with the Replacement Options consisted of the grant-date fair value of the Original Options for
which the requisite service period is expected to be rendered (or has already been rendered) at the Exchange Date, plus the incremental cost associated with the modification of terms. The incremental compensation expense was measured as the excess
of the fair value of the Replacement Options over the fair value of the Original Options re-measured as of the Exchange Date. A total of 1,921,894 Original Options were exchanged for Replacement Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following stock-based compensation amounts were recognized for the years ended
December&nbsp;31, 2011 and 2012 and the nine month periods ended September&nbsp;30, 2012 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine&nbsp;months&nbsp;ended</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:65.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">353,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">284,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">628,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">393,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><I>Employee Stock Options </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in
the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended<BR>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine months<BR>ended&nbsp;September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:71.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2013</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53% &#150; 58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.18</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.24%&nbsp;&#150;&nbsp;2.05</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected average life of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market value of common stock at:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50&nbsp;&#150;&nbsp;$7.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected Forfeiture Rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Common Stock&nbsp;&#150;&nbsp;</B>Given the lack of an active public market for the
Company&#146;s common stock, prior to the IPO on October&nbsp;10, 2013 the Company&#146;s Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous
valuations to determine fair value. In the absence of a public market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the
common stock at each grant date. The factors include: (1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the status of strategic relationships with collaborators; (3)&nbsp;the significant risks associated with
the Company&#146;s stage of development; (4)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (5)&nbsp;the Company&#146;s available cash, financial
condition and results of operations; (6)&nbsp;the most recent sales of the Company&#146;s preferred stock and (7)&nbsp;the preferential rights of the outstanding preferred stock. The contemporaneous valuations were performed in accordance with
applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as
Compensation</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility</B>&nbsp;&#150; Volatility is a measure of the amount by which a financial variable such as a
share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not maintain an internal market for its shares and its shares are not traded publicly. The Company has been able
to identify several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of these companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Expected Dividend Yield</B>&nbsp;&#150; The Company has never declared or paid dividends
and has no plans to do so in the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>&nbsp;&#150; This is the U.S. Treasury rate for the
week of each option grant during the year, having a term that most closely resembles the expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Expected
Term</B>&nbsp;&#150; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company
uses a simplified method to calculate the average expected term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Expected Forfeiture Rate</B>&nbsp;&#150; The forfeiture rate is the
estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of
the employees to whom the options were granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Equity instruments issued to non-employees are accounted for under the provisions of
ASC&nbsp;505-50,<I> Equity Based Payments to Non-Employees</I>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services required are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Information with respect to stock options granted to employees and non-employees from January&nbsp;1, 2012 through September&nbsp;30, 2013 was
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number of<BR>Options&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Estimated&nbsp;Option<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/08/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/14/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/13/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/19/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/08/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/06/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/08/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/19/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">07/19/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/18/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the Plan during the period then
ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="86%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:37.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:59.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average&nbsp;Exercise<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:62.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average<BR>Contractual&nbsp;Term<BR>(in Years)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,885,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,883</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,025,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, September&nbsp;30, 2013 (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,877,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2012:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,620,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,734,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2013:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and Expected to Vest (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding and options exercisable as of September&nbsp;30, 2013 is
approximately $17.4 million and $12.2 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted for the years
ended December&nbsp;31, 2012 and 2011 was $0.94. Total cash received for the options exercised was $46,826 and $53,225 for the years ended December&nbsp;31, 2012 and 2011, respectively. The total fair value of shares vested in the years ended
December&nbsp;31, 2012 and 2011, was $374,684 and $400,236, respectively. As of December&nbsp;31, 2012, there was $636,308 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the 2000
Plan and 2003 Plan. That cost is expected to be recognized over a weighted-average period of approximately four years. As of September&nbsp;30, 2013, the total unrecognized compensation expense, net of related forfeiture estimates, was $1.5 million,
which the Company expects to recognize over a weighted-average period of approximately four years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Income Taxes </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2011 and 2012, there was no current provision for federal or state income taxes due
to the taxable losses which resulted or use of legacy net operating loss carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s
deferred tax assets (liabilities) were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal U.S. net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,825,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,330,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,493,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,521,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,507,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,039,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,194,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,218,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,924,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,379,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,515,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,790,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,090,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77,302,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,090,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax asset/(liability)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely
than not to be realized. In assessing the likelihood of realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference and
carryforwards; (iii)&nbsp;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax asset is not more likely than not to be utilized
due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in 2012 is due to the fact the Company generated book and taxable income in the
current year; therefore, the net deferred tax asset amount decreased, although, the Company generated significant orphan drug credits which increased the net deferred tax asset. The increase in the orphan drug credits offset by the current year
income amount resulted in a net current year increase to the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has reported book losses from inception
through December&nbsp;31, 2010. The net operating loss carryforwards of approximately $100.9&nbsp;million for U.S.&nbsp;federal and approximately $64.2 million for state will expire in various years beginning in 2023 through 2030. In addition, the
Company has U.S. federal tax credits of $21.8 million which will expire in various years beginning in 2020 through 2032. During the nine months ended September&nbsp;30, 2013, the Company corrected an immaterial error of approximately $1.2 million
related to state net operating loss carryforwards. The correction of the immaterial error resulted in a reduction to the state net operating loss carryforward deferred tax asset and corresponding valuation allowance. The immaterial error and the
related correction of the error had no effect on the balance sheet, statements of operations and comprehensive income (loss) or statements of cash flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The use of the Company&#146;s net operating loss and tax credit carryforwards in future years
are restricted due to changes in the Company&#146;s ownership and tax attributes acquired by the Company in a purchase. As of December&nbsp;31, 2012, $10.6 million of the Company&#146;s net operating losses are limited for use over the years
2013&nbsp;&#150; 2027 in which a range of such amounts could be utilized on an annual basis of $0.2 million to $2.1&nbsp;million. The remaining $90.3 million of net operating losses is not limited and can be offset against future taxable income.
Additionally, despite the net operating loss and credit carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax
rate to the net income is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:89.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States federal tax at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,350,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,926,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (net of federal benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(512,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,056,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,895,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(496,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,991,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense/(benefit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The change in unrecognized tax benefits, for the years ended December&nbsp;31, 2011 and 2012, were as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2011</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2012</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,246,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases as a result of expiration of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2011 and 2012, of the total gross unrecognized tax benefits, approximately $1,105,256
and $1,140,067 would favorably impact the Company&#146;s effective income tax rate, respectively. Although, due to the Company&#146;s determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance
would be recorded, therefore, zero net impact would result within the Company&#146;s effective income tax rate. The Company&#146;s uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute
carryforward amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2012 and 2011, the Company has not recognized any interest or penalties
related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within
the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s U.S. Federal and state income tax returns from 2001 to [2011] remain
subject to examination by the tax authorities. The Company&#146;s 2001 through 2007 years remain open for examination, even though the statute of limitations has expired, due to the net operating losses and credits carried forward for use in
prospective years. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Lease Exit Liability </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based
company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven was considered a development-stage enterprise as defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the acquisition, the
Company issued 12,466,039 shares of its Series D convertible preferred stock in exchange for all of the outstanding capital stock and convertible notes payable of Raven. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company undertook restructuring activities related to the acquisition of Raven. These restructuring activities included reductions in
staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with these restructuring activities, as part of the cost of acquisitions, the Company established a restructuring liability
attributed to an existing operating lease. The terms of the operating lease extend through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Changes in the lease exit liability for
the years ended December&nbsp;31, 2012 and 2011 and the nine months ended September&nbsp;30, 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="70%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:45.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exit Liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,054,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(466,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at September&nbsp;30, 2013 (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,607,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Future principal payments to be made under the lease agreement for the next five years and thereafter as of
September&nbsp;30, 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="54%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Twelve Months Ending September&nbsp;30,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,808,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,315,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">616,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,607,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The purchase agreement provides for a specified total of certain contingent milestones that
are based on the achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0&nbsp;million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical
trial of any product derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue
(excluding consideration for research and development and equity) received by MacroGenics for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from $8.0&nbsp;million to $12.0&nbsp;million
dependent upon a specified level of sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The contingent
consideration will be accounted for as additional purchase price and recorded as incremental in-process research and development expense when it is deemed probable that the contingencies will be attained. For the years ended December&nbsp;31, 2012
and 2011 and the nine months ended September&nbsp;30, 2013, no additional amounts have been recorded. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration and License Agreements </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Les Laboratoires Servier </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the development and commercialization
of MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement,
Servier made a nonrefundable payment of $20 million to the Company. The Company is eligible to receive up to $30 million in license grant fees, $47 million in clinical milestone payments, including $10 million received in the third quarter of 2013,
$140 million in regulatory milestone payments and $208 million in sales milestone payments if Servier exercises the option, obtains regulatory approval for and successfully commercializes MGA271. The Company concluded that the license grant fees are
not deliverables at the inception of the arrangement. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still
recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. In the event Servier exercises its option to
continue development of MGA271, Servier must pay a license grant fee. Under this agreement, Servier would be obligated to pay the Company from low double digit to mid-teen royalties on product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that the option is substantive and that the license fees for this option is not a deliverable at the inception of the arrangement as there is considerable uncertainty that the option
would be exercised and the additional fee to be paid upon exercise of the option represents its estimated selling price (i.e. no substantial discount was given). The Company&#146;s substantive performance obligations under this research
collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement and participation on an executive committee and a research and
development committee. The Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company&#146;s technical expertise and committee
participation. As such, the initial upfront payment was deferred and is being recognized ratably over the initial 27-month period, which represents the expected period of development and the Company&#146;s participation on the research and
development committee. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2011 and 2012 the Company recognized revenue of $0.9
million and $9.1&nbsp;million, respectively, under this agreement. During the nine months ended September&nbsp;30, 2013 the Company recognized revenue of $18.9 million, including a $10.0 million milestone payment related to dosing the first patient
in the expansion cohort of the Company&#146;s Phase 1 clinical trial of MGA271. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012, $10.0 million of revenue was
deferred under this agreement, $9.1 million of which was included in current liabilities and $0.9 million was included in long-term liabilities. At September&nbsp;30, 2013, $3.1 million of revenue was deferred under this agreement, all of which was
included in current liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company entered into a second right-to-develop collaboration agreement with
Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by the Company as MGD006 and MGD007, as well as a third DART molecule, in all countries
other than the United States, Canada, Mexico, Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable
payment of $20 million to the Company. In addition, the Company will be eligible to receive up to $65 million in license grant fees, $98 million in clinical milestone payments, including $5 million upon IND acceptance for each of MGD006, MGD007 and
a third DART molecule, $300 million in regulatory milestone payments and $630 million in sales milestone payments if Servier exercises all of the options and successfully develops, obtains regulatory approval for, and commercializes a product under
each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although
sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue
recognition at that time. Under this agreement, Servier would be obligated to pay the Company between high-single digit and mid-teen royalties on net product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The
Company&#146;s substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement
and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the pre-clinical development represent a single unit of accounting, since the license does
not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation. As such, the initial up front license payment was deferred and is being recognized ratably over the initial 29-month period, which
represents the expected development period. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2012 and the nine months ended September&nbsp;30, 2013, the Company recognized revenue of
$2.0&nbsp;million and $6.5 million, respectively, under this agreement. No additional milestones have been recognized under this agreement through September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012, $18.0 million of revenue was deferred under this agreement, $8.6 million of which was included in current
liabilities and $9.4 million of which was included in long-term liabilities. At September&nbsp;30, 2013, $11.6 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities and $3.0 million of which
was included in long-term liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Sciences, Inc. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2013, the Company entered into an agreement with Gilead for the research, development and commercialization of up to four
DART-based molecules. The time period for Gilead&#146;s exercise of the option to one target pair has expired. At present, Gilead retains a license to one and options to two of the original four programs. Gilead has exclusive worldwide rights for
each of these remaining programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company received an initial $7.5 million license grant fee for the first DART-based molecule. If
Gilead exercises its option with respect to the two remaining DART-based molecules and successfully develops, obtains regulatory approval for, and commercializes a product under each option and license, the Company may be eligible to receive
additional license grant fees of $7.5 million on each of the two remaining options to DART-based molecules, up to an additional $20 to $25 million in pre-clinical milestones across each of the three remaining DART programs and up to $240 to $250
million per remaining program in additional clinical, regulatory and sales milestone payments. The Company has determined that the other licenses are conditional deliverables, which are substantive options that were not granted with a substantial
discount. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone
(assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Gilead also provides funding for the Company&#146;s internal and external research costs
under the agreement. Additionally, Gilead would be obligated to pay the Company high single digit to low double digit, but less than teen royalties on product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Gilead and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include a license to its technology and research and development services. The Company concluded that the deliverables
do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of standalone value for the license and research and development services, the combined unit of accounting (the upfront payment and the
expected research and development reimbursements) is being recognized ratably over a period of 21 months, which represents the expected development period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the joint committee as a
deliverable, it would not have had a material impact on the accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Receivables of $1.1 million as of
September&nbsp;30, 2013 relate amounts due to the Company from Gilead for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company recognized revenues of approximately $5.9 million under this agreement for the nine months ended September&nbsp;30, 2013. No additional milestones have been reached under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $4.4 million of revenue was deferred under this agreement, all of which was included in current liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer Ingelheim International GmbH </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2010 the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to
ten DART-based molecules which span multiple therapeutic areas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DARTs generated
under the agreement, or the Boehringer licensed products, throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, the Company received an
upfront payment of $15 million. The Company subsequently received two annual maintenance payments through September&nbsp;30, 2013 and a third annual maintenance payment subsequent to September&nbsp;30, 2013. The first two maintenance payments were
solely attributed to the passage time. Because Boehringer has the option to cancel the program after the second anniversary of the agreement, the third maintenance payment will be recognized over the remaining obligation period. The Company has the
potential to earn milestone payments of approximately $41 million related to pre-clinical and clinical development, $89 million related to regulatory milestones and $83 million related to sales milestones for each of the DART programs under this
agreement in the case of full commercial success of multiple DART products. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered
substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer also
provides funding for the Company&#146;s internal and external research costs and is required to pay the Company mid-single digit royalties on product sales. From the commencement of the collaboration through September&nbsp;30, 2013, the Company has
received $39.0 million under this agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of the Company&#146;s Series D-2 Preferred Stock in January 2011.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to
be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional
period is not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company concluded that the undelivered element of
research and development services had fair value. The Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not represent a separate unit
of accounting. The Company concluded that because the drug candidate has not yet been developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the
Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a combined unit of account and recognized over the
expected obligation period associated with the research and development services through September 2015, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint
committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the organization period for the research and development services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Receivables of $246,375, $355,568&nbsp;and $146,150 as of September&nbsp;30,
2013,&nbsp;December&nbsp;31, 2012, and December&nbsp;31, 2011, respectively, relate to amounts due to the Company from Boehringer for reimbursement work performed under the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $6.9 million, $11.7&nbsp;million, and $8.9 million under this agreement during the nine
months ended September&nbsp;30, 2013 and the years ended December&nbsp;31, 2012 and 2011, respectively. One milestone payment of $2.0 million was recognized under this agreement through December 2012. No additional milestones have been recognized
under this agreement through September&nbsp;30, 2013. A milestone was earned under this agreement subsequent to September&nbsp;30, 2013. See Note 12, Subsequent Events, for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012, $14.0 million of revenue was deferred under this agreement, $5.0 million of which was included in current
liabilities and $9.0 million was included in long-term liabilities. At September&nbsp;30, 2013, $10.3 million of revenue was deferred under this agreement, $5.0 million of which was included in current liabilities and $5.3 million of which was
included in long-term liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer, Inc. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2010, the Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. The Company granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5 million and has received milestone payments and funding for the Company&#146;s internal and external research costs under
the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive milestone payments of approximately $17 million related to pre-clinical and clinical
development and $195 million related to commercialization and sales milestones for each DART program under this agreement. The Company has determined that each potential future technical and development milestone is substantive. Although sales
milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition
at that time. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART
program is currently being pursued and the Company completed its research obligations under this program in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated the research collaboration agreement with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research
collaboration include an exclusive license to its technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon reaching
regulatory approval. As such, the manufacturing services are not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company determined that it had fair value of the undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and
development services) and therefore does not represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not yet been developed, the license is of no value
to Pfizer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without the Company agreeing to provide the research and
development activities for the other party). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a
combined unit of accounting and recognized over the expected obligation period associated with the research and development services through January 2014, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The $5 million upfront payment received by the Company is non-refundable; therefore, there is no right of return for the license. The Company
is recognizing revenue associated with this non-refundable up-front license fee through January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company and Pfizer have also
agreed to establish a joint research committee to facilitate the governance and oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined
that it was not a deliverable because it is a participating right and not an obligation of the Company. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the
accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on
January&nbsp;1, 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Receivables of $501,794, $896,285,&nbsp;and $936,010 as of September&nbsp;30, 2013,&nbsp;December&nbsp;31, 2012,
and December&nbsp;31, 2011, respectively, relate to amounts due to the Company from Pfizer for reimbursement work performed under the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $3.2 million, $5.5 million, and $5.2 million under this agreement during the nine month
period ended September&nbsp;30, 2013 and the years ended December&nbsp;31, 2012 and 2011, respectively. Included in the 2012 revenues are milestone payments totaling $500,000. No additional milestones have been recognized under this agreement
through September&nbsp;30, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013 and December&nbsp;31, 2012, $58,000 and $1.3 million of revenue was deferred
under this agreement all of which was included in current liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross Corporation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s anti-HER2
antibody known as MGAH22, or margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Green Cross made a nonrefundable payment of $1.0&nbsp;million to the Company. The Company is eligible to
receive clinical development and commercial milestone payments of up to $4.5 million. The Company has determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on
net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the two companies collaborate under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the collaboration agreement with Green Cross and has determined that it is a revenue arrangement with multiple
deliverables or performance obligations. The Company&#146;s substantive performance obligations under this agreement include an exclusive license to its technologies and participation in a joint steering committee. The Company concluded that the
license does not have value on a standalone basis and therefore does not represent a separate unit of accounting. Likewise, Green Cross could not sell the license to another party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The $1 million upfront payment received by the Company is non-refundable; as such, there is
no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $100,000 under this agreement during each of the years ended December&nbsp;31, 2012 and 2011,
and $75,000 during the nine months ended September&nbsp;30, 2013. No additional milestones have been recognized under this agreement through September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2012, $750,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and
$650,000 was included in long-term liabilities. At September&nbsp;30, 2013, $675,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and $575,000 of which was included in long-term liabilities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eli Lilly&nbsp;&amp; Co. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly to jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the
Agreements, Eli Lilly acquired the exclusive rights to the molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreements, Eli Lilly made a nonrefundable
payment of $41.0&nbsp;million to the Company. In May&nbsp;2008, Eli Lilly paid the Company a milestone payment of $50.0&nbsp;million and in May&nbsp;2010, Eli&nbsp;Lilly paid an additional milestone of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2010, Lilly notified the Company of its decision to terminate the agreement after review of one year of clinical data from
the PROT&Eacute;G&Eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the study. During the year ended December&nbsp;31, 2012, Eli&nbsp;Lilly satisfied its obligation
related to the cost of monitoring patients under the PROT&Eacute;G&Eacute; and ENCORE trials. The Company&#146;s obligations continued through September 2012, which represented the follow up period for enrolled patients and the Company&#146;s final
reporting of the trial&#146;s results. There is no additional clinical trial activity under the Eli Lilly Agreements as it relates to such trials. In February 2011, the Company reacquired the commercial rights to the molecule from Eli Lilly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Receivables of $244,542, $558,516 and $351,357 as of September&nbsp;30, 2013,&nbsp;December&nbsp;31, 2012, and December&nbsp;31 2011,
respectively, relate to amounts due to the Company from Eli Lilly for reimbursement work performed under the above mentioned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2013 and the years ended December&nbsp;31, 2012 and 2011, the Company recognized revenue of
$673,927, $31.2&nbsp;million and $30.9 million, respectively, under this agreement. No additional milestones were recognized under this agreement through September&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commitments and Contingencies </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company leases office and laboratory space over periods extending through January&nbsp;30, 2018. Several of the leases contain rent
escalation clauses. Rent expense for the years ended December&nbsp;31, 2012 and 2011 was $3.1 million and $3.2 million, respectively. The Company incurred $2.4 million of rent expense for each of the nine-month periods ending September&nbsp;30, 2013
and 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under noncancelable operating leases at September&nbsp;30, 2013, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="54%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Twelve Months Ending September&nbsp;30,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,460,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,385,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,486,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,035,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,390,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Product Milestone Payments and Royalty Agreements </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (Tolerance) entered into during June 2005,
the Company may be required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications;
(ii)&nbsp;36,135 shares of common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be
paid under the Asset Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional considerations have occurred during the years ended December&nbsp;31, 2012 and 2011 or during and the
nine months ended September&nbsp;30, 2013. Additionally, certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no other revenue from product sales is being generated by the Company.
</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Employee Benefit Plan </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the 401(k) Plan) for its employees under
Section&nbsp;401(k) of the IRC. Under this 401(k) Plan, all employees at least 21 years of age are eligible to participate in the 401(k) Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to
government maximums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as
determined by the Board of Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $225,195, $217,097 and $194,498 for the years ended December&nbsp;31, 2012 and 2011 and the nine months ended September&nbsp;30, 2013,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, the Company completed its IPO, in which 5,000,000 shares of the Company&#146;s common stock were
sold at a price of $16.00 per share. Additionally, the underwriters of the Company&#146;s IPO exercised the full amount of their over-allotment option resulting in the sale of an additional 750,000 shares of the Company&#146;s common stock at a
price of $16.00 per share. The Company received net proceeds of $83.8&nbsp;million from the IPO, net of underwriting discounts and commissions and other estimated offering expenses. Upon consummation of the IPO, all outstanding shares of preferred
stock automatically converted to common stock at the applicable conversion ratios then in effect. Subsequent to the IPO, the Company had 25,020,288 issued and outstanding shares of common stock and no outstanding shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2013, Boehringer nominated a bi-specific antibody therapeutic candidate generated by the Company&#146;s DART technology for
pre-clinical development. This formal selection of a development candidate triggered a $5.0 million milestone payment to the Company under the October 2010 agreement described in Note&nbsp;8, Collaboration and License Agreements. In addition,
Boehringer paid an annual maintenance payment of $4.0&nbsp;million to the Company in the fourth quarter of 2013. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g662896g97j81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P>
<P STYLE="font-size:60px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:30%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P R O S P E C T U S </B></FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:30%">&nbsp;</P></center> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>BofA
Merrill Lynch </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Leerink Partners </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Stifel </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Wedbush PacGrow Life Sciences </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Roth Capital Partners </B></FONT></P> <P STYLE="margin-top:60px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>February &nbsp;&nbsp;&nbsp;&nbsp;, 2014 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Expenses of Issuance and Distribution </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable in connection with the sale and distribution of the securities being registered. All
amounts are estimated except the SEC and FINRA registration fees. All of the expenses below will be paid by us. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:14pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Item</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing and mailing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and registrar fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under Section&nbsp;145 of the Delaware General Corporation Law, we can indemnify our directors and officers against liabilities they may incur in such capacities, including liabilities under the
Securities Act of 1933, as amended, or the Securities Act. Our bylaws that we expect to be effective upon the closing of this offering (Exhibit 3.4 to this registration statement) provide that we will indemnify our directors and officers to the
fullest extent permitted by law and require us to advance litigation expenses upon our receipt of an undertaking by the director or officer to repay such advances if it is ultimately determined that the director or officer is not entitled to
indemnification. Our bylaws further provide that rights conferred under such bylaws do not exclude any other right such persons may have or acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our restated certificate of incorporation that we expect to be effective upon the closing of this offering (Exhibit 3.2 to this
registration statement) provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&#146; fiduciary duty of care to us and our stockholders. This provision in the restated certificate
of incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to
be subject to liability for breach of the director&#146;s duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law, for actions leading to improper personal
benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities under any other law, such as the
federal securities laws or state or federal environmental laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our restated certificate of incorporation
provides that we shall indemnify our directors and officers if such persons acted (i)&nbsp;in good faith, (ii)&nbsp;in a manner reasonably believed to be in or not opposed to our best interests, and (iii)&nbsp;with respect to any criminal action or
proceeding, with reasonable cause to believe such conduct was lawful. The restated certificate of incorporation also provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&#146;
fiduciary duty of care to us and our stockholders. This provision in the restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-
monetary relief will remain available under Delaware law. In addition, each </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us for acts or omissions not in good faith or involving intentional misconduct, for knowing
violations of law, for actions leading to improper personal benefit to the fiduciary duty of care to us and our stockholders. This provision in the restated certificate of incorporation does not eliminate the duty of care, and in appropriate
circumstances equitable remedies such as injunctive or other forms of non- monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director&#146;s duty of
loyalty to us for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases
or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. The restated certificate of
incorporation further provides that we are authorized to indemnify our directors and officers to the fullest extent permitted by law through the bylaws, agreement, vote of stockholders or disinterested directors, or otherwise. We intend to obtain
directors&#146; and officers&#146; liability insurance in connection with this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, concurrently with this
offering, we will enter into agreements to indemnify our directors and certain of our officers in addition to the indemnification provided for in the restated certificate of incorporation and bylaws. These agreements will, among other things,
indemnify our directors and some of our officers for certain expenses (including attorneys fees), judgments, fines and settlement amounts incurred by such person in any action or proceeding, including any action by or in our right, on account of
services by that person as a director or officer of our company or as a director or officer of any of our subsidiaries, or as a director or officer of any other company or enterprise that the person provides services to at our request. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement (Exhibit 1.1 to this registration statement) provides for indemnification by the underwriters of us and our
officers and directors, and by us of the underwriters, for certain liabilities arising under the Securities Act or otherwise in connection with this offering. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Sales of Preferred Stock</I></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we issued and sold
18.4&nbsp;million shares of our Series D-2 preferred stock to three investors at a for an aggregate purchase price of $12,016,500. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No underwriters were involved in the foregoing sale of securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were issued to investors in reliance upon the exemption from the
registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the Securities Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All
purchasers of shares of our common stock described above represented to the Company in connection with their purchase that they were accredited investors and were acquiring the shares for their own account for investment purposes only and not with a
view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities
had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Stock Option Grants</I></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Between January&nbsp;1, 2011 and
December&nbsp;31, 2013, we granted options to purchase an aggregate of 1,407,765&nbsp;shares of common stock, with exercise prices ranging from $0.94 to $7.51 per share, to our employees and directors pursuant to our 2003 Stock Plan. As of
December&nbsp;31, 2013, 1,366,244 options to purchase shares of our common stock under this plan had been exercised for aggregate consideration of $1,171,708, options to purchase 252,008&nbsp;shares had been forfeited and options to purchase
2,589,909&nbsp;shares of our common stock remained outstanding at a weighted-average exercise price of $1.51 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Between October 9, 2013 and December 31, 2013, we granted options to purchase an aggregate
of 618,290&nbsp;shares of common stock, with exercise prices ranging from $16.00 to $26.00 per share, to our employees and directors pursuant to our 2013 Stock Plan. As of December&nbsp;31, 2013, no options to purchase shares of our common stock
under this plan had been exercised or forfeited and options to purchase 618,290&nbsp;shares of our common stock remained outstanding at a weighted-average exercise price of $19.06 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item&nbsp;15
were issued pursuant to written compensatory plans or arrangements with the Company&#146;s employees and directors in reliance on the exemption provided by Rule 701 promulgated under the Securities Act. All recipients either received adequate
information about the Company or had access, through employment or other relationships, to such information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of the
foregoing securities described in sections (a)&nbsp;and (b)&nbsp;of Item&nbsp;15 are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15
included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each
purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus as
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the city of Rockville, State of Maryland, on January 29, 2014. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL MEN BY THESE PRESENTS, the undersigned hereby constitute and appoint Scott Koenig, M.D., Ph.D. and James Karrels and each of them, his true and lawful attorney-in-fact and agent, each with full
power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, or any related registration statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that each of said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ James Karrels</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary (Principal Financial Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Lynn Cilinski</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lynn Cilinski</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Controller and Treasurer (Principal&nbsp;Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Paulo Costa</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kenneth Galbraith</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Edward Hurwitz</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Eran Nadav, Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Arnold Oronsky, Ph.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ David Stump, M.D.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">David Stump, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 29, 2014</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., Attorney-in-Fact</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restated Certificate of Incorporation of Company (incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form 8-K (001-36112) filed on October 18,
2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October
1, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.3 to the Company&#146;s Current Report on Form 8-K
(001-36112) filed on October&nbsp;18, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Fourth Amended and Restated Registration Rights Agreement by and among the Company, the Founders, and the Investors, dated September 19, 2008 (incorporated by reference to Exhibit
4.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September&nbsp;4, 2013)]</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Arnold &amp; Porter LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on
September&nbsp;4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2000 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994)
filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994)
filed by the Company on October 1, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on October 1, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between Red Gate III LLC and the Company, dated May 31, 2011 (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated March&nbsp;26, 2013 (incorporated by reference to Exhibit 10.9 to the Registration Statement on
Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated December&nbsp;2, 2004 (incorporated by reference to Exhibit 10.10 to the Registration
Statement on Form&nbsp;S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated January&nbsp;31, 2006 (incorporated by reference to Exhibit 10.11 to the
Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated June 1, 2011 (incorporated by reference to Exhibit 10.12 to the
Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement by and between Amgen SF, LLC and Raven biotechnologies, Inc., dated November 21, 2006 (incorporated by reference to Exhibit 10.13 to the Registration Statement on
Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration and License Agreement by and between Boehringer Ingelheim International GmbH and the Company, dated October&nbsp;18, 2010 (incorporated by reference to Exhibit 10.15
to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between the Company and Gilead Sciences, Inc., dated January 3, 2013 (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1
(File No. 333-190994) filed by the Company on October 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16.1&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to License Agreement by and between the Company and Gilead Sciences, Inc., dated October 1, 2013 (incorporated by reference to Exhibit 10.16.1 to the Registration
Statement on Form S-1 (File No. 333-190994) filed by the Company on October 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration Agreement by and between the Company and Green Cross Corp., dated June 30, 2010 (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1
(File No. 333-190994) filed by the Company on October 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated January 19, 2011 (incorporated by reference to Exhibit 10.18 to the Registration
Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated December 13, 2012 (incorporated by reference to Exhibit 10.19 to the Registration
Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to
Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated November 24, 2011 (incorporated by reference to
Exhibit 10.21 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October&nbsp;4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated October 13, 2010 (incorporated by reference to Exhibit 10.22 to the Registration
Statement on Form&nbsp;S-1 (File No. 333-190994) filed by the Company on October 4, 2013)</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated August 9, 2012 (incorporated by reference to Exhibit 10.23 to the
Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.24&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 2 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, effective October 13, 2013 (incorporated by reference to Exhibit 10.24 to
the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 20, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.25+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 (File No.
333-190994) filed by the Company on October 1, 2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.26+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.27+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Employment Agreement between the Company and James Karrels</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Company (incorporated by reference to Exhibit 21.1 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4,
2013)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Arnold &amp; Porter LLP (included in Exhibit 5.1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included on signature pages hereto)</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-7
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>d662896dex1027.htm
<DESCRIPTION>EX-10.27
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.27</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.27 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (this &#147;Agreement&#148;) is entered into as of the &nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013, by and between MacroGenics, Inc., a Maryland corporation, including its successors and assigns, (the &#147;Employer&#148; or &#147;Company&#148;), and James Karrels
(&#147;Executive&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the promises and the respective undertakings of Employer and Executive set
forth below, Employer and Executive hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Employment</U>. Employer hereby employs Executive, and Executive
hereby accepts such employment and agrees to perform services for Employer, for the period and on the other terms and subject to the conditions set forth in this Agreement. Executive&#146;s Start Date shall be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and shall be considered the Effective Date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Employment at Will</U>. Executive is employed &#147;at-will&#148; which means that Executive&#146;s employment is not for any defined
term and may be terminated by either Executive or the Company at any time, with or without cause, for any or no reason, subject to the notice provisions herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Position and Duties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.01. <U>Service with Employer</U>. Employer hereby employs Executive in an executive capacity with the title of Chief Financial Officer and
Executive hereby accepts such employment and undertakes and agrees to serve in such capacity. Subject to the overall policy directives of the Board of Directors (the &#147;Board&#148;) and applicable law, in Executive&#146;s capacity as Chief
Financial Officer, Executive shall have such powers, perform such duties and fulfill such responsibilities as are typically associated with such position in other similarly situated companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.02. <U>Performance of Duties</U>. Executive agrees to: (i)&nbsp;devote substantially all of Executive&#146;s business time, attention and
efforts to the business and affairs of Employer while employed; and (ii)&nbsp;adhere to all Employer&#146;s written employment policies and procedures as shall be in force from time to time. Executive shall report directly to the President and CEO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.03. <U>Outside Activities</U>. During the Term, Executive shall not: (i)&nbsp;except as set forth below, accept other employment;
(ii)&nbsp;except as set forth below, render or perform services for compensation to any Person (as hereinafter defined) other than Employer; (iii)&nbsp;serve as an officer or on the board of directors (or similar governing body) of any entity other
than Employer, whether or not for compensation; or (iv)&nbsp;engage in any other business, enterprise or activity that will require any effort on the part of Executive that, in the sole discretion of Employer, could reasonably be expected to
materially detract from the ability of Executive to perform Executive&#146;s duties to Employer pursuant to this Agreement; <U>provided</U>, <U>however</U>, Executive may engage in the activities described in clause (iii)&nbsp;or (iv)&nbsp;above if
prior to engaging in such activity, Executive has disclosed such activity to the Board and received written approval to engage in such activity from the Board. Executive may engage in personal investments without disclosure to or written approval
from the Board provided Executive is not required or expected to serve as a board member, advisor or consultant and Executive shall, at any time, own beneficially less than 2% of the outstanding securities of any issuer and such personal investment
shall not otherwise interfere with Executive&#146;s performance of duties hereunder and/or the provisions of Executive&#146;s written agreements with Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.04. <U>Executive Representations</U>. Executive represents that Executive is not subject to any restrictive covenant, confidentiality
agreement, or any other agreement that would prevent Executive from accepting employment with Employer, and based on the information provided to Employer by Executive, Employer accepts such representation. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Compensation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.01. <U>Base Salary</U>. Employer shall pay to Executive an annual base salary for all services to be rendered by Executive under this
Agreement of $312,300 (the &#147;Base Salary&#148;), which Base Salary shall be paid in accordance with Employer&#146;s normal payroll schedule, procedures and policies (which schedule, procedures and policies may be modified from time to time) and
subject to applicable deductions as required by law. Employer shall review Executive&#146;s salary on an annual basis and may, in its discretion, consider and declare from time to time increases in the Base Salary that it pays Executive. Any and all
increases in Executive&#146;s salary pursuant to this section shall cause the level of Base Salary to be increased by the amount of each such increase for purposes of this Agreement. The increased level of Base Salary as provided in this section
shall become the level of Base Salary for the remainder of the term of this Agreement unless there is a further increase in Base Salary as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.02. <U>Annual Bonus</U>. Executive shall also be eligible to receive, in addition to the Base Salary, an annual bonus having a target amount
equal to 35% of Executive&#146;s Base Salary (&#147;Target Bonus&#148;), with the actual amount being determined by the Compensation Committee of the Board in its discretion taking into account the Company&#146;s performance and Executive&#146;s
individual performance. In order to receive a Target Bonus, Executive must be employed by Employer on the date the bonus is paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.03.
<U>Accelerated Vesting of Certain Options Upon Occurrence of a Change in Control</U>.&nbsp;Upon the occurrence of a Change in Control each outstanding stock option held by Executive that was granted by the Company to Executive prior to the date of
an initial public offering of the Company&#146;s common stock shall, to the extent not previously vested, become fully vested. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, &#147;<U>Change of Control</U>&#148; means: &#147;Change of Control&#148; means, and shall
be deemed to have occurred, if: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any Person, excluding&nbsp;(i) employee benefit plans of the Company or any of its
Affiliates, is or becomes the &#147;beneficial owner&#148; (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, which Rules shall apply for purposes of this clause (a)&nbsp;whether or not the Company is subject to the Exchange Act), directly
or indirectly, of Company securities representing more than fifty percent (50%)&nbsp;of the combined voting power of the Company&#146;s then outstanding securities (&#147;Voting Power&#148;); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Company consummates a merger, consolidation, share exchange, division or other reorganization or transaction of the
Company (a &#147;Fundamental Transaction&#148;) with any other corporation, other than a Fundamental </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
Transaction that results in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity) at least fifty percent (50%)&nbsp;of the combined Voting Power immediately after such Fundamental Transaction of (i)&nbsp;the Company&#146;s outstanding securities, (ii)&nbsp;the surviving entity&#146;s
outstanding securities, or (iii)&nbsp;in the case of a division, the outstanding securities of each entity resulting from the division; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the stockholders of the Company approve a plan of complete liquidation or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or the consummation of the sale or disposition (in one transaction or a series of transactions) of all or substantially all of the Company&#146;s assets; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) during any period of 24 consecutive months, individuals who at the beginning of such period constituted the Board
(including for this purpose any new director whose election or nomination for election by the Company&#146;s stockholders was approved by a vote of at least two-thirds (2/3)&nbsp;of the directors then still in office who were directors at the
beginning of such period or whose appointment, election or nomination was previously so approved or recommended) cease for any reason to constitute at least a majority of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.04. <U>Participation in Benefit Plans</U>. Executive shall be entitled to participate in all employee benefit plans or programs offered to
other senior executives from time to time (to the extent that Executive meets the requirements for each such plan or program), including participation in any health insurance plan, disability insurance plan, dental plan, eye care plan, 401(k) plan,
life insurance plan, or other similar plans (all such benefits, the &#147;Benefit Plans&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.05. <U>Expenses</U>. Employer shall
reimburse Executive for all ordinary and necessary business expenses reasonably incurred by him in the performance of Executive&#146;s duties under this Agreement, subject to the presentment and approval of appropriate itemized expense statements,
receipts, vouchers or other supporting documentation in accordance with Employer&#146;s normal policies for expense verification in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.06. <U>Vacation</U>. Executive shall be entitled to no less paid vacation than the other senior executives, pursuant to Employer&#146;s
standard vacation policies, and shall be guaranteed a minimum of four weeks of paid vacation per year. Executive may carry over up to a maximum of 200 hours of annual leave (including sick pay) at any time, and any unused vacation time beyond that
will be forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.07. <U>Total Compensation</U>. Executive shall not receive any other compensation or benefits other than as provided
in Sections 4.01 through 4.06 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Payments Upon Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.01. <U>Voluntary Resignation without Good Reason</U>. Executive may terminate Executive&#146;s employment by providing Employer with 30
days&#146; advance written notice. If Executive terminates Executive&#146;s employment (other than for good reason or by reason of Disability) (i)&nbsp;Employer shall pay to Executive the Accrued Obligations (as defined below),
(ii)&nbsp;Executive&#146;s participation in the Benefit Plans shall terminate as of the Termination Date, and (iii)&nbsp;Employer shall have no other obligations to Executive under this Agreement, other than those provided in this Section&nbsp;5.01.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, &#147;<U>Accrued Obligations</U>&#148; means: (i)&nbsp;Executive&#146;s earned and
unpaid Base Salary through the Termination Date; (ii)&nbsp;reimbursement for any reimbursable business expenses incurred by Executive through the Termination Date in accordance with Section&nbsp;4.05; and (iii)&nbsp;Executive&#146;s accrued but
unused vacation time as of the Termination Date. The amounts payable pursuant to clauses (i)&nbsp;and (iii)&nbsp;hereof shall be paid no later than sixty (60)&nbsp;days following Executive&#146;s Termination Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For purposes of this Agreement, &#147;<U>Termination Date</U>&#148; means: the effective date of Executive&#146;s
&#147;separation from service&#148; as defined in Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.02. <U>Termination by Employer For Cause</U>. If Executive is terminated for Cause: (i)&nbsp;Employer shall pay to Executive the Accrued
Obligations, (ii)&nbsp;Executive&#146;s participation in the Benefit Plans shall terminate as of the Termination Date, and (iii)&nbsp;Employer shall have no further obligations to Executive under this Agreement, other than those provided in this
Section&nbsp;5.02. For purposes of this Agreement, &#147;<U>Cause</U>&#148; means: (a)&nbsp;Executive&#146;s failure to substantially perform Executive&#146;s duties with the Company (if Executive has not cured such failure to substantially perform,
if curable, within thirty (30)&nbsp;days after Executive&#146;s receipt of written notice thereof from the Board that specifies the conduct constituting Cause under this clause (a)); (b)&nbsp;Executive&#146;s willful misconduct, or gross negligence
in the performance of Executive&#146;s duties hereunder; (c)&nbsp;the conviction of Executive, or the entering by Executive of a guilty plea or plea of no contest with respect to, any crime that constitutes a felony or involves fraud, dishonesty or
moral turpitude; (d)&nbsp;Executive&#146;s commission of an act of fraud, embezzlement or misappropriation against the Company; (e)&nbsp;Executive&#146;s material breach of the fiduciary duty owed by Executive to Company; (f)&nbsp;Executive&#146;s
engaging in any improper conduct that has or is likely to have an adverse economic or reputational impact on the Company; or (g)&nbsp;Executive&#146;s material breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.03. <U>Termination by Employer Without Cause or by Executive for Good Reason</U>. If Executive is terminated by Employer without Cause or by
Executive for Good Reason: (i)&nbsp;Employer shall pay to Executive the Accrued Obligations, (ii)&nbsp;Executive shall be entitled to receive the Severance Benefits (as defined below in Section&nbsp;5.05 and subject to the conditions described
therein and in Section&nbsp;5.06), and (iii)&nbsp;Employer shall have no further obligations to Executive under this Agreement, other than those provided in this Section&nbsp;5.03. For purposes of this Agreement, &#147;<U>Good Reason</U>&#148; means
the occurrence of any of the following events (without Executive&#146;s consent): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a material adverse change in
Executive&#146;s functions, duties, or responsibilities with the Company which change would cause Executive&#146;s position to become one of materially lesser responsibility, importance, or scope; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a material breach of this Agreement by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no such event shall constitute &#147;Good Reason&#148; unless (a)&nbsp;Executive
shall have given written notice of such event to the Company within ninety (90)&nbsp;days after the initial occurrence thereof, (b)&nbsp;the Company shall have failed to cure the condition constituting Good Reason within thirty (30)&nbsp;days
following the delivery of such notice (or such longer cure period as may be agreed upon by the parties), and (c)&nbsp;Executive terminates employment within thirty (30)&nbsp;days after expiration of such cure period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.04. <U>Termination by Employer due to Executive&#146;s Disability</U>. If Executive&#146;s employment is terminated by reason of Disability
(as defined below): (i)&nbsp;Employer shall pay to Executive the Accrued Obligations, (ii)&nbsp;Executive&#146;s participation in the Benefit Plans shall terminate as of the Termination Date (except to the extent Executive is eligible for continued
disability benefits under the applicable Employer plan), and (iii)&nbsp;Employer shall have no further obligations to Executive under this Agreement, other than those provided in this Section&nbsp;5.04. For purposes of this Agreement,
&#147;<U>Disability</U>&#148; means Executive being determined to be totally disabled by the Social Security Administration or Executive&#146;s inability to engage in any substantial gainful activity by reason of any medically determinable physical
or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.05. <U>Severance Benefits</U>: &#147;Severance Benefits&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The payment to Executive of the Severance Amount in substantially equal installments over one year (with the first payment
commencing on the first payroll date that occurs at least 28 days following the Termination Date), in accordance with Employer&#146;s payroll practices in effect as of the Effective Date (&#147;Severance Period&#148;), provided that in the event
such payroll practices change, in accordance with such new payroll practices, but only if any such change in payroll practices does not result in a payment being accelerated or delayed by more than thirty (30)&nbsp;days. Severance Amount means the
sum of Executive&#146;s Base Salary and Target Bonus in effect immediately prior to the Date of Termination provided that Target Bonus shall be included in the Severance Amount only if the Termination Date occurs upon or within two years after a
Change in Control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The continuation of Executive&#146;s participation in the Company&#146;s medical, dental, and
vision benefit plans at the same premium cost to Executive as charged to Executive immediately prior to the Termination Date for a period of twelve (12)&nbsp;months immediately following the Termination Date, or if earlier, until Executive obtains
other employment which provides the same type of benefit; <U><I>provided</I></U>, <U><I>however</I></U>, that (a)&nbsp;it is understood and agreed that such continued medical, dental and vision benefits may at the election of the Company be provided
by Executive electing the continuation of such coverage pursuant to COBRA with the Company reimbursing Executive for COBRA premiums to the extent required so that Executive&#146;s premium cost for the coverage in effect for Executive prior to the
Termination Date is substantially the same as immediately prior to the Termination Date, and (b)&nbsp;if the Company determines, in its reasonable judgment, that providing medical, dental, and/or vision benefits in accordance with the preceding
provisions of this Section&nbsp;5.05(b) would result in a violation of applicable law, the imposition of any penalties under applicable law, or adverse tax consequences for participants covered by the Company&#146;s medical, dental, and/or vision
plans, the Company may terminate such coverage (or reimbursement) with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
respect to Executive and instead pay to Executive taxable cash payments at the same time and in the same amounts as the Company would have paid as premiums (or as COBRA premium reimbursements) to
provide such coverage.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) With respect to each stock option granted by the Company to Executive that is outstanding as of
the Termination Date and is not fully vested as of the date of the Termination Date, Executive shall become vested as of the date Executive provides the Company with the Irrevocable Release provided for in this Section&nbsp;5.05 within the period
prescribed therein with respect to 50% (100% if the Termination Date occurs upon or within two years after the occurrence of a Change in Control) of the shares with respect to which the stock option is not vested as of the Termination Date.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.06 <U>Required Delivery of Irrevocable Release; Compliance with Section&nbsp;6 Obligations</U>. Notwithstanding the
provisions of Section&nbsp;5.05, as a condition to entitlement to the Severance Benefits, Executive must provide to the Company an Irrevocable Release not later than the sixtieth day after the Date of Termination. In the event Executive fails to
provide an Irrevocable Release to the Company within such sixty day period, the Company will immediately cease to pay or provide any further Severance Benefits, no accelerated vesting of stock options pursuant to Section&nbsp;5.05(c) shall occur,
and Executive shall be obligated to immediately repay to the Company all previously paid or provided Severance Benefits. &#147;Irrevocable Release&#148; means a confidential separation agreement and release of claims, in form and substance
substantially similar to the attached Exhibit A that has been executed by Executive, delivered to the Company, and become irrevocable by Executive. In addition, in the event that Executive breaches the obligations under Section&nbsp;6 of this
Agreement at any time during the Severance Period, Executive will cease to be entitled to any further Severance Benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Promises
and Covenants Regarding Confidential Information and Goodwill; Inventions and Assignment; Restrictive Covenants</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.01.
<U>Confidential Information and Goodwill</U>. In consideration of Executive&#146;s promises and covenants contained in this Agreement, including Executive&#146;s promise and covenant not to disclose Confidential Information, Employer will provide
Executive with Confidential Information. In further consideration of Executive&#146;s promises and covenants contained in this Agreement, including Executive&#146;s promise and covenant to utilize the Goodwill exclusively for the benefit of
Employer, Employer will allow Executive to receive Confidential Information concerning the Company&#146;s customers, labs, vendors and employees and, to the extent required to fulfill Executive&#146;s duties, the Company will permit Executive to
represent the Company on its behalf with such persons. To the extent that Executive&#146;s duties involve sales or customer relations, the Company will permit Executive to utilize the Goodwill in Executive&#146;s sales efforts and will provide sales
support to Executive similar to that which it provides to its sales representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.02. <U>Duties</U>. While employed by Company,
Executive shall perform the duties required of Executive hereunder and shall devote Executive&#146;s best efforts and exclusive business time, energy and skill to performing such duties; not make any disparaging remarks regarding Company to any
person with whom Company has business relations, including any employee or vendor of Company; use the Goodwill solely for the benefit of Company; and not interfere in such Goodwill, either during or following Executive&#146;s employment with
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.03. <U>Delivery of Company Property</U>. Executive recognizes that all documents, magnetic
media and other tangible items which contain Confidential Information are the property of Company exclusively. Upon request by Company or termination of Executive&#146;s employment with Company, Executive shall promptly return to Company all
Confidential Information and Company Property within Executive&#146;s possession and control, and shall refrain from taking any Confidential Information or Company Property or allowing any Confidential Information or Company Property to be taken
from Company; and immediately return to Company all information pertaining to Company or Company Property in Executive&#146;s possession. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.04. <U>Promise and Covenant Not to Disclose</U>. The parties acknowledge that Company is the sole and exclusive owner of Confidential
Information, and that Company has legitimate business interests in protecting Confidential Information. The parties further acknowledge that Company has invested, and continues to invest, considerable amounts of time and money in obtaining,
developing, and preserving the confidentiality of Confidential Information and that, by reason of the trust relationship arising between Executive and Company, Executive owes Company a fiduciary duty to preserve and protect Confidential Information
from all unauthorized disclosure and unauthorized use. Executive shall not, directly or indirectly, disclose Confidential Information to any third party (except to Executive&#146;s attorneys, the Company&#146;s personnel, other persons designated in
writing by the Company, or except as otherwise provided by law) or use Confidential Information for any purpose other than for the direct benefit of Company while in Company&#146;s employ and thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.05. <U>Inventions and Assignment</U>. Executive agrees that he will promptly disclose to the Company any and all Company Inventions and that
Executive hereby irrevocably assigns to the Company all ownership rights in and to any and all Company Inventions.&nbsp;During Executive&#146;s employment or at any time thereafter, upon request of the Company, Executive will sign, execute and
deliver any and all documents or instruments, including, without limitation, patent applications, declarations, invention assignments and copyright assignments, and will take any other action which the Company shall deem necessary to perfect in the
Company trademark, copyright or patent rights with respect to Inventions, or to otherwise protect the Company&#146;s trade secrets and proprietary interests. The term &#147;<I>Inventions</I>&#148; means discoveries; developments; trade secrets;
processes; formulas; data; lists; software programs; graphics; artwork; logos, and all other works of authorship, ideas, concepts, know-how, designs, and techniques, whether or not any of the foregoing is or are patentable, copyrightable, or
registrable under any intellectual property laws or industrial property laws in the United States. The term &#147;<I>Company Inventions</I>&#148; means all Inventions that (a)&nbsp;relate to the business or proposed business of the Company or any of
its predecessors or that are discovered, developed, created, conceived, reduced to practice, made, learned or written by Executive, either alone or jointly with others, in the course of Executive&#146;s employment; (b)&nbsp;utilize, incorporate or
otherwise relate to Confidential Information; or (c)&nbsp;are discovered, developed, created, conceived, reduced to practice, made, or written by him using property or equipment of the Company or any of its predecessors. Executive agrees to promptly
and fully communicate in writing to the Company (to such department or officer of the Company and in accordance with such procedures as the Company may direct from time to time) any and all Company Inventions. Executive acknowledges and agrees that
any work of authorship by Executive or others comprising Company Inventions shall be deemed to be a &#147;work made for hire,&#148; as that term is defined in the United States Copyright Act (17 U.S.C. &#167; 101 (2000)). To the extent that any such
work of authorship may not be deemed to be a work </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
made for hire, Executive hereby irrevocably assigns any ownership rights Executive may have in and to such work to the Company. This Agreement does not apply to any Inventions Executive made
before Executive&#146;s employment with the Company. To clearly establish Executive&#146;s rights, Executive has listed on Exhibit B any Inventions, whether or not patentable or copyrightable and whether or not reduced to practice, made by him prior
to Executive&#146;s employment with the Company that are owned by Executive (&#147;<I>Prior Inventions</I>&#148;), together with the approximate dates of their creation. If no such list is attached, Executive represents that there are no Prior
Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.06. <U>Other Promises and Covenants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) During Executive&#146;s employment with Company and for a period of 18 months following termination of employment for any
reason or the Severance Period (the &#147;Non-Competition Period&#148;), Executive shall not either directly or indirectly, on Executive&#146;s own or another&#146;s behalf, engage in or assist others in any of the following activities (except on
behalf of Company): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (whether as principal, agent, partner or otherwise) engage in, own, manage, operate, control,
finance, invest in, participate in, or otherwise carry on, or be employed by, associated with, or in any manner connected with, lend such Executive&#146;s name to, lend Executive&#146;s credit to, or render services or advice to a Competing Business
anywhere in the Geographic Area; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) provide or develop any products, technology or services that are the same or
Substantially Similar to the products, technology and services provided or developed by the Company or any of its Affiliates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) induce or attempt to induce any customer, agent, supplier, licensee, or business relation of the Company or any of its
Affiliates to cease doing business with the Company or any of its Affiliates, or in any way interfere with the relationship between any customer, supplier, licensee, or business relation of the Company or any of its Affiliates; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) on behalf of a Competing Business, solicit or attempt to solicit the business or patronage of any Person who is a
customer or agent of the Company or any of its Affiliates, whether or not Executive had personal contact with such Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) During Executive&#146;s employment with Company and for a period of two years following termination of employment for any
reason (the &#147;Non-Solicitation Period&#148;), Executive shall not either directly or indirectly, on Executive&#146;s own or another&#146;s behalf, engage in or assist others in any of the following activities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) solicit, encourage, or take any other action which is intended to induce any employee, independent contractor or agent of
the Company or any of its Affiliates to terminate Executive&#146;s employment or other business relationship with the Company or such Affiliate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) in any way interfere in any manner with the employment or other business
relationship between the Company and/or any of its Affiliates, on the one hand, and any employee, independent contractor or agent of the Company or such Affiliate, on the other hand; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) employ, or otherwise engage as an employee, independent contractor or otherwise, any individual who was an employee,
independent contractor, agent or was otherwise affiliated with the Company or any of its Affiliates from the period beginning one year prior to the date on which Executive became employed and continuing through the expiration of the Non-Solicitation
Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that nothing set forth in this Section&nbsp;6 shall prohibit Executive from owning, as a passive investment, not
in excess of five percent (5%)&nbsp;in the aggregate of any class of capital stock of any corporation if such stock is publicly traded and listed on any national or regional stock exchange or reported on the Nasdaq Stock Market.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.07. <U>Definitions</U>. For purposes hereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>&#147;Affiliate&#148;</I> means, with respect to any Entity, any Entity that, directly or indirectly through one or more
intermediaries, controls, is controlled by or under common control with, such Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>&#147;Agreement&#148;</I>
means this Employment Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>&#147;Company Business&#148;</I> means the research, development, testing and/or
marketing/sales of pharmaceutical products or processes that are, rely on, target or rely upon (a)&nbsp;CD3 (when targeted individually), (b)&nbsp;HER2, (c)&nbsp;B7-H3, (d)&nbsp;CD123, (e)&nbsp;gpA33, (f)&nbsp;CD32b and CD79b (when jointly
targeted), (g)&nbsp;any other undisclosed target either being developed by Employer or the subject of a collaboration between Employer and a third party, or (h)&nbsp;any effort to develop diabodies similar to the Company&#146;s &#147;DART&#148;
technology including DART conjugates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>&#147;Company Property&#148;</I> means all physical materials, documents,
information, keys, computer software and hardware, including laptop computers and mobile or handheld scheduling computers, manuals, data bases, product samples, tapes, magnetic media, technical notes and any other equipment or items which Company
provides for or to Executive or which otherwise belongs to the Company, and those documents and items which Executive may develop or help develop while in Company&#146;s employ, whether or not developed during regular working hours or on
Company&#146;s premises. The term &#147;<I>Company Property</I>&#148; shall include the original of such materials, any copies thereof, any notes derived from such materials, and any derivative work of such materials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>&#147;Competing Business&#148;</I> means any other Entity engaged in the Company Business, other than the Company and
its Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>&#147;Confidential Information&#148;</I> means the trade secrets and other information of Company,
including but not limited to (i)&nbsp;the customer lists, customer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
contact information, customer purchase information, pricing information, strategic and marketing plans, compilations of customer information, names of employees, contracts with third parties,
training, financial and marketing books, sales projections, internal employer databases, reports, manuals and information including information related to Company, its Affiliates or its customers, including those documents and items which any
employee may develop or help develop while in the employ of the Company or any of its Affiliates, whether or not developed during regular working hours or on the premises of the Company or such Affiliate; (ii)&nbsp;the identity, skills, personnel
file information, performance appraisals and compensation of job applicants, employees, contractors, and consultants; (iii)&nbsp;specialized training; (iv)&nbsp;source code, scripts, user screens, reports or any other information pertaining to the
internal information technology or network of the Company and/or its Affiliates, including the proprietary database system commonly referred to as the Office System; and (v)&nbsp;information related to inventions owned by the Company or any of its
Affiliates or licensed from third parties; and unless the context requires otherwise, the term &#147;<I>Confidential Information</I>&#148; includes the original of such materials, any copies thereof, any notes derived from such materials, and any
derivative work of such materials. The term &#147;<I>Confidential Information</I>&#148; does not include (1)&nbsp;information that was or becomes generally available publicly other than through disclosure by Executive, or (2)&nbsp;is required to be
disclosed to any governmental agency or self-regulatory body or is otherwise required to be disclosed by law. Unless the context requires otherwise, the term &#147;<I>Confidential Information</I>&#148; shall include the original of such materials,
any copies thereof, any notes derived from such materials, and any derivative work of such materials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>&#147;Entity</I>&#148; means and includes any person, partnership, association, corporation, limited liability company, trust, unincorporated organization or any other business entity or enterprise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>&#147;Geographic Area&#148;</I> mean those states in which the Company or any of its subsidiaries conducts business or
in which its products are being sold or marketed at the time of the termination of Executive&#146;s employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
<I>&#147;Goodwill&#148;</I> means the value of the relationships between the Company and its agents, customers, vendors, labs, and employees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>&#147;Substantially Similar&#148;</I> means substantially similar in function or capability or otherwise competitive to
the products or services being developed, manufactured or sold by the Company during and/or at the end of Executive&#146;s employment, or are marketed to substantially the same type of user or customer as that to which the products and services of
the Company are marketed or proposed to be marketed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.08. <U>Acknowledgements Regarding Other Promises and Covenants</U>. With regard to
the promises and covenants set forth herein, Executive acknowledges and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the restrictions are ancillary to
an otherwise enforceable agreement including the provisions of this Agreement regarding the disclosure, ownership and use of the Confidential Information and Goodwill of Company; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the limitations as to time, geographical area, and scope of activity to be
restricted are reasonable and acceptable to Executive, and do not impose any greater restraint than is reasonably necessary to protect the Goodwill and other legitimate business interests of Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the performance by Executive, and the enforcement by Company, of such promises and covenants will cause no undue hardship
on Executive; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the time periods covered by the promises and covenants will not include any period(s) of violation of,
or any period(s) of time required for litigation brought by Company to enforce any such promise or covenant, it being understood that the extension of time provided in this paragraph may not exceed two (2)&nbsp;years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.09. <U>Duty to Give Notice of Agreement</U>. During employment by Company and the period of any post-employment obligation applicable
hereunder, Executive shall provide written notice to any prospective employer of Executive&#146;s obligations under this Agreement, and shall provide a true copy hereof to such prospective employer at the outset of any communications about
employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.10. <U>Independent Elements</U>. The parties acknowledge that the promises and covenants contained in Section&nbsp;6 above
are essential independent elements of this Agreement and that, but for Executive agreeing to comply with them, Company would not employ Executive. Accordingly, the existence or assertion of any claim by Executive against Company, whether based on
this Agreement or otherwise, shall not operate as a defense to Company&#146;s enforcement of the promises and covenants in Section&nbsp;6. An alleged or actual breach of the Agreement by Company will not be a defense to enforcement of any such
promise or covenant, or other obligations of Executive to Company. The promises and covenants in Section&nbsp;6 will remain in full force and effect whether Executive is terminated by Company or voluntarily resigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.11. <U>Remedies for Breach of Agreement</U>. Executive acknowledges that Executive&#146;s breach of any promise or covenant contained in
Section&nbsp;6 will result in irreparable injury to Company and that Company&#146;s remedies at law for such a breach will be inadequate. Accordingly, Executive agrees and consents that Company, in addition to all other remedies available at law and
in equity, shall be entitled to both preliminary and permanent injunctions to prevent and/or halt a breach or threatened breach by Executive of any such promise or covenant, and Executive waives the requirement of the posting of any bond in
connection with such injunctive relief. Executive further acknowledges and agrees that the promises and covenants contained in Section&nbsp;6 are enforceable, reasonable, and valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.01.
<U>Governing Law; Arbitration </U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement is made under and shall be governed by and construed in accordance
with the laws of Maryland, without regard to its conflicts of law principles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) With respect to claims by the Company against Executive related to
Executive&#146;s threatened or actual breach of Section&nbsp;6 of this Agreement, each Party hereby irrevocably agrees that all actions or proceedings concerning such disputes may be brought by the Company in (a)&nbsp;the United States District
Court for the District of Maryland; or (b)&nbsp;in any court of the State of Maryland sitting in Montgomery County, provided that the United States District Court lacks subject matter jurisdiction over such action or proceeding. Executive consents
to jurisdiction of and venue in the courts in the State of Maryland set forth in this Section, and hereby waives to the maximum extent permitted by applicable law any objection which Executive may have based on improper venue or <I>forum non
conveniens</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Except to the extent provided for in subsection (b)&nbsp;above, the Company and Executive agree that
any claim, dispute or controversy arising under or in connection with this Agreement, or otherwise in connection with Executive&#146;s employment by the Company or termination of his employment (including, without limitation, any such claim, dispute
or controversy arising under any federal, state or local statute, regulation or ordinance or any of the Company&#146;s employee benefit plans, policies or programs) shall be resolved solely and exclusively by binding, confidential, arbitration. The
arbitration shall be held in Rockville, MD (or at such other location as shall be mutually agreed by the parties). The arbitration shall be conducted in accordance with the Commercial Rules of the American Arbitration Association (the
&#147;<U>AAA</U>&#148;) in effect at the time of the arbitration, including the Expedited Procedures. All fees and expenses of the arbitration, including a transcript if either requests, shall be borne equally by the parties. Each party is
responsible for the fees and expenses of its own attorneys, experts, witnesses, and preparation and presentation of proofs and post-hearing briefs (unless the party prevails on a claim for which attorney&#146;s fees are recoverable under law). In
rendering a decision, the arbitrator shall apply all legal principles and standards that would govern if the dispute were being heard in court. This includes the availability of all remedies that the parties could obtain in court. In addition, all
statutes of limitation and defenses that would be applicable in court, will apply to the arbitration proceeding. The decision of the arbitrator shall be set forth in writing, and be binding and conclusive on all parties. Any action to enforce or
vacate the arbitrator&#146;s award shall be governed by the Federal Arbitration Act, if applicable, and otherwise by applicable state law. If either the Company or Executive improperly pursues any claim, dispute or controversy against the other in a
proceeding other than the arbitration provided for herein, the responding party shall be entitled to dismissal or injunctive relief regarding such action and recovery of all costs, losses and attorney&#146;s fees related to such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.02. <U>Entire Agreement</U>. This Agreement and the documents referenced herein contain the entire agreement of the parties relating to the
employment of Executive by Employer and the ancillary matters discussed herein and supersedes all prior agreements, negotiations and understandings with respect to such matters, including, without limitation, any term sheet between the parties
hereto with respect to such matters, and the parties hereto have made no agreements, representations or warranties relating to such employment or ancillary matters which are not set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.03. <U>Withholding Taxes</U>. Employer may withhold from any compensation and Benefits payable
under this Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.04. <U>Golden Parachute Limit</U>.&nbsp;Notwithstanding any other provision of this Agreement, in the event that any portion of the
Severance Benefits or any other payment or benefit received or to be received by Executive (whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (collectively, the &#147;<U>Total Benefits</U>&#148;) would be
subject to the excise tax imposed under Section&nbsp;4999 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) (the &#147;<U>Excise Tax</U>&#148;), the Total Benefits shall be reduced to the extent necessary so that no portion of
the Total Benefits is subject to the Excise Tax; provided, however, that no such reduction in the Total Benefits shall be made if by not making such reduction, Executive&#146;s Retained Amount (as hereinafter defined) would be more than ten percent
(10%)&nbsp;greater than Executive&#146;s Retained Amount if the Total Benefits are so reduced.&nbsp;All determinations required to be made under this Section&nbsp;7.04 shall be made by tax counsel selected by the Company and reasonably acceptable to
Executive (&#147;<U>Tax Counsel</U>&#148;), which determinations shall be conclusive and binding on Executive and the Company absent manifest error.&nbsp;All fees and expenses of Tax Counsel shall be borne solely by the Company.&nbsp;Prior to any
reduction in Executive&#146;s Total Benefits pursuant to this Section&nbsp;7.04, Tax Counsel shall provide Executive and the Company with a report setting forth its calculations and containing related supporting information.&nbsp;In the event any
such reduction is required, the Total Benefits shall be reduced in the following order: (i)&nbsp;the Severance Amount (in reverse order of payment), (iii)&nbsp;any portion of the Total Benefits that are not subject to Section&nbsp;409A of the Code
(other than Total Benefits resulting from any accelerated vesting of equity awards), (iv)&nbsp;other Total Benefits that are subject to Section&nbsp;409A of the Code in reverse order of payment, and (v)&nbsp;Total Benefits that are not subject to
Section&nbsp;409A and arise from any accelerated vesting of any equity awards.&nbsp;&#147;Retained Amount&#148; shall mean the present value (as determined in accordance with sections 280G(b)(2)(A)(ii) and 280G(d)(4) of the Code) of the Total
Benefits net of all federal, state and local taxes imposed on Executive with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.05. <U>Compliance With
Section&nbsp;409A</U>. This Agreement is intended to comply with the requirements of Section&nbsp;409A of the Code (including the exceptions thereto), to the extent applicable, and shall be interpreted and administered accordingly.&nbsp;If any
provision contained in this Agreement conflicts with the requirements of Section&nbsp;409A of the Code (or the exemptions intended to apply under this Agreement), this Agreement shall be deemed to be reformed to comply with the requirements of
Section&nbsp;409A of the Code (or applicable exemptions thereto).&nbsp;Notwithstanding anything to the contrary herein, for purposes of determining Executive&#146;s entitlement to the Severance Benefits under Section&nbsp;5 hereof,
(a)&nbsp;Executive&#146;s employment shall not be deemed to have terminated unless and until Executive incurs a &#147;separation from service&#148; as defined in Section&nbsp;409A of the Code, and (b)&nbsp;the effective date of any termination or
resignation of employment (or any similar term) shall be the effective date of Executive&#146;s separation from service.&nbsp;Reimbursement of any expenses provided for in this Agreement shall be made in accordance with the Company&#146;s policies
(as applicable) with respect thereto as in effect from time to time (but in no event later than the end of calendar year following the year such expenses were incurred) and in no event shall (i)&nbsp;the amount of expenses eligible for reimbursement
hereunder during a taxable year affect the expenses eligible for reimbursement in any other taxable year or (ii)&nbsp;the right to reimbursement be subject to liquidation or exchange for another benefit.&nbsp;Notwithstanding anything to the contrary
herein, if a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment or benefit under this Agreement is due to a &#147;separation from service&#148; for purposes of the rules under Treas. Reg. &#167; 1.409A-3(i)(2) (payments to specified employees upon a
separation from service) and Executive is determined to be a &#147;specified employee&#148; (as determined under Treas. Reg. &#167; 1.409A-1(i)), such payment shall, to the extent necessary to comply with the requirements of Section&nbsp;409A of the
Code, be made on the later of (x)&nbsp;the date specified by the foregoing provisions of this Agreement or (y)&nbsp;the date that is six (6)&nbsp;months after the date of Executive&#146;s separation from service (or, if earlier, the date of
Executive&#146;s death).&nbsp;Any installment payments that are delayed pursuant to the provisions of this section shall be accumulated and paid in a lump sum on the first day of the seventh month following Executive&#146;s separation from service
(or, if earlier, upon Executive&#146;s death) and the remaining installment payments shall begin on such date in accordance with the schedule provided in this Agreement.&nbsp;To the extent permitted by Section&nbsp;409A, each payment hereunder shall
be deemed to be a separate payment for purposes of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.06. <U>Amendments</U>. No amendment or modification
of the terms of this Agreement shall be valid unless made in writing and signed by both Executive and Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.07. <U>Severability;
Reformation</U>. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable Law but if any provision of this Agreement is held to be invalid, illegal or unenforceable under
any applicable Law or rule, the validity, legality and enforceability of the other provisions of this Agreement will not be affected or impaired thereby. If any provision of this Agreement is found invalid, illegal or unenforceable because it is too
broad in scope, too lengthy in duration or violates any Law or regulation, it shall be reformed by limiting its scope, limiting its duration or construing it to avoid such violation (as the case may be) while giving the greatest effect to the intent
of the parties as is legally permissible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.08. <U>No Waiver</U>. No waiver of any provision of this Agreement shall in any event be
effective unless the same shall be in writing and signed by the party against whom such waiver is sought to be enforced, and any such waiver shall be effective only in the specific instance and for the specific purpose for which given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.09. <U>Assignment; No Third Party Beneficiary</U>. This Agreement is a personal service contract, and shall not be assignable by Executive.
This Agreement shall be assignable by Employer to any successor to the business of Employer, without the written consent of Executive; provided, however, that the assignee or transferee is the successor to all or substantially all of the business
assets of Employer and such assignee or transferee expressly assumes all the obligations, duties, and liabilities of Employer set forth in this Agreement. Any purported assignment of this Agreement in violation of this Section&nbsp;7.09 shall be
null and void. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns, and no other Person shall have any right, benefit or obligation hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.10. <U>Counterparts; Facsimile Signatures</U>. This Agreement may be executed in separate counterparts, each of which will be an original
and all of which taken together shall constitute one and the same agreement, and any party hereto may execute this Agreement by signing any such counterpart. A facsimile signature by any party on a counterpart of this Agreement shall be binding and
effective for all purposes. Such party shall subsequently deliver to the other party an original, executed copy of this Agreement; provided, however, that a failure of such party to deliver an original, executed copy shall not invalidate
Executive&#146;s or its signature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.11. <U>Notices</U>. All notices and other communications relating to this Agreement will be in
writing and will be deemed to have been given when personally delivered, three (3)&nbsp;days following mailing by certified or registered mail, return receipt requested, and one (1)&nbsp;Business Day following delivery to a reliable overnight
courier or immediately following transmission by electronic facsimile. All notices to Employer shall be addressed and delivered to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">9640 Medical
Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Matthew D.
Keiser </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Arnold&nbsp;&amp; Porter, LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">555 Twelfth Street, NW </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Washington, DC 2004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(telephone) 202-942-6398 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(fax)
202-942-5999 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address and facsimile number as designated by Employer in a written notice to Executive. All notices to Executive shall be
addressed and delivered to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">James Karrels </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">9640 Medical
Center Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Rockville, MD 20850 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to
such other address and facsimile number as Executive has designated in a written notice to Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.12. <U>Interpretation</U>. The
headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.13. <U>Cumulative Remedies</U>. The rights and remedies of the parties hereunder are cumulative and not exclusive of any rights or remedies
any party hereto may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.14. <U>Expenses Relating to this Agreement</U>. Each party shall pay its or Executive&#146;s own
expenses incident to the negotiation, preparation and execution of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Executive and Employer have executed this Employment Agreement as of the date
set forth in the first paragraph. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;EMPLOYER&#148;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MacroGenics,
Inc.</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Edward Hurwitz</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chairman of the Compensation Committee</P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7">&#147;EXECUTIVE&#148;</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">James Karrels</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Employment Agreement by and between &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&#147;Executive&#148;) and MacroGenics, Inc. (the &#147;Company&#148;), in order for Executive to receive the Severance Amount therein, Executive is required to enter into this Separation Agreement and General Release (this &#147;Release&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein contained, of other good and valuable consideration, the
sufficiency and receipt of which are hereby acknowledged by the Parties, it is agreed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. As of the Termination Date, and at
all times forward, Executive will not hold himself out to any person or entity as being an employee, officer, representative, or agent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. In exchange for the considerations provided for in this Agreement including the receipt of the Severance Amount, Executive hereby
completely, irrevocably, and unconditionally releases and forever discharges the Company, and any of its affiliated companies, and each and all of their officers, agents, directors, supervisors, employees, representatives, and their successors and
assigns, and all persons acting by, through, under, for, or in concert with them, or any of them, in any and all of their capacities (hereinafter individually or collectively, the &#147;Released Parties&#148;), from any and all charges, complaints,
claims, and liabilities of any kind or nature whatsoever, known or unknown, suspected or unsuspected (hereinafter referred to as &#147;claim&#148; or &#147;claims&#148;) which Executive at any time heretofore had or claimed to have or which
Executive may have or claim to have regarding events that have occurred as of the Effective Date of this Agreement, including, without limitation, those based on: any employee welfare benefit or pension plan governed by the Employee Retirement
Income Security Act as amended (hereinafter &#147;ERISA&#148;) (provided that this release does not extend to any vested retirement benefits of Executive under Company&#146;s 401(k) Safe Harbor Plan); the Civil Rights Act of 1964, as amended (race,
color, religion, sex and national origin discrimination and harassment); the Civil Rights Act of 1966 (42 U.S.C. &#167;&nbsp;1981) (discrimination); the Age Discrimination in Employment Act of 1967 (hereinafter &#147;ADEA&#148;), as amended; the
Older Workers Benefit Protection Act, as amended; the Americans With Disabilities Act (hereinafter &#147;ADA&#148;), as amended; &#167;&nbsp;503 of the Rehabilitation Act of 1973; the Fair Labor Standards Act, as amended (wage and hour matters); the
Family and Medical Leave Act, as amended, (family leave matters), Article 49B of the Maryland Code (discrimination), any other federal, state, or local laws or regulations regarding employment discrimination or harassment, wages, insurance, leave,
privacy or any other matter; any negligent or intentional tort; any contract, policy or practice (implied, oral, or written); or any other theory of recovery under federal, state, or local law, and whether for compensatory or punitive damages, or
other equitable relief, including, but not limited to, any and all claims which Executive may now have or may have had, arising from or in any way whatsoever connected with Executive&#146;s employment or contacts, with Company or any other of the
Released Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive acknowledges, understands and agrees that Executive has been paid in full for all hours that Executive has
worked for the Company and that Executive has been paid any and all compensation or bonuses which have been earned by Executive through the date of execution </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Agreement. Executive acknowledges, understands and agrees that Executive has not been denied any leave requested under the FMLA or applicable state leave laws and that, to the extent
applicable, Executive has been returned to Executive&#146;s job, or an equivalent position, following any FMLA or state leave taken pursuant to the FMLA or state laws. Executive acknowledges, understands and agrees that Executive has reported to the
Employer&#146;s management personnel any work related injury or illness that occurred up to and including Executive&#146;s last day of employment. Executive acknowledges, understands, and agrees that Executive has no knowledge of any actions or
inactions by any of the Released Parties or by Executive that Executive believes could possibly constitute a basis for a claimed violation of any federal, state, or local law, any common law or any rule promulgated by an administrative body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. To the extent permitted by law, Executive agrees that he will not cause or encourage any future legal proceedings to be maintained or
instituted against any of the Released Parties. To the extent permitted by law, Executive agrees that he will not accept any remedy or recovery arising from any charge filed or proceedings or investigation conducted by the EEOC or by any state or
local human rights or employment rights enforcement agency relating to any of the matters released in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. Older Workers
Benefit Protection Act /ADEA Waiver </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.01. Executive acknowledges that Company has advised him in writing to consult with an attorney of
his choice before signing this Agreement, and Executive has been given the opportunity to consult with an attorney of his choice before signing this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.02. Executive acknowledges that he has been given the opportunity to review and consider this Agreement for a full twenty-one days before
signing it, and that, if he has signed this Agreement in less than that time, he has done so voluntarily in order to obtain sooner the benefits of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.03. Executive further acknowledges that he may revoke this Agreement within seven (7)&nbsp;days after signing it, provided that this
Agreement will not become effective until such seven (7)&nbsp;day period has expired. To be effective, any such revocation must be in writing and delivered to Company&#146;s principal place of business by the close of business on the seventh
(7th)&nbsp;day after signing the Agreement and must expressly state Executive&#146;s intention to revoke this Agreement. Provided that Executive does not timely revoke this Agreement, the eighth (8th)&nbsp;day following Executive&#146;s execution
hereof shall be deemed the &#147;Effective Date&#148; of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.04. The Parties also agree that the release provided by
Executive in this Agreement does not include a release for claims under the ADEA arising after the date Executive signs this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Executive shall promptly turn over to the Company any and all documents, files, computer records, or other materials belonging to, or
containing confidential or proprietary information obtained from, the Company that are in Executive&#146;s possession, custody, or control, including any such materials that may be at Executive&#146;s home. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Executive acknowledges that, during the course of Executive&#146;s employment with Company, Executive has acquired or been exposed to the
Company&#146;s confidential information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and trade secrets, including, but not limited to, business plans, marketing plans, financial data, proprietary technology, and customer and client lists and asset information (&#147;Confidential
Information&#148;). Executive agrees hereafter to maintain the confidentiality of the Confidential Information, to refrain from disclosing any Confidential Information to anyone, to refrain from using the Confidential Information on his own behalf
or on behalf of anyone other than the Company, and to comply with any confidentiality or non-disclosure agreement Executive has executed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. The Parties agree that they will keep absolutely confidential, and not make any future disclosures to anyone except that the Parties may
disclose this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.01. to enforce this Agreement; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.02. to an attorney; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.03. tax advisor or attorney in connection with a tax matter; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.04. to the United States Internal Revenue Service, or state or local tax authority upon its request for tax purposes; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.05. as required by court order or otherwise required by law or in response to valid legal process; provided that the Parties may make
disclosure to attorneys, accountants, tax advisors, and family members only if such persons agree to keep the information confidential; and provided further that before providing information pursuant to a court order or other legal requirement, the
Party providing such information shall promptly notify the other Party, and to the extent possible will comply with the court order or other legal requirement in ways that preserve confidentiality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. Executive agrees that Executive will not publicly make or publish any adverse, disparaging, untrue, or misleading statement or comment
about the Company or any of its officers, directors, employees, or agents. The Company agrees to instruct its directors, officers, and senior management not to publicly make or publish any adverse, disparaging, untrue, or misleading statement or
comment about Executive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. Executive agrees to answer questions that the Company may have from time to time regarding matters that
Executive worked on and to cooperate with the Company, upon request, to assist in the investigation, prosecution or defense of any claim, grievance, investigation, or audit by or against the Company. The Company agrees to reimburse Executive for any
reasonable and necessary out-of-pocket expenses he incurs as a result of such cooperation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. This Agreement shall not in any way be
construed as an admission by the Company of any acts of unlawful conduct, wrongdoing or discrimination against Executive, and the Company specifically disclaims any liability to Executive on the part of itself, its employees, or its agents. This
Agreement shall not in any way be construed as an admission by Executive of any acts of unlawful conduct, wrongdoing or discrimination against the Company, and Executive specifically disclaims any liability to Company on the part of himself or his
agents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. This Agreement shall be binding upon Executive and upon Executive&#146;s heirs,
administrators, representatives, executors, successors, and assigns, and shall inure to the benefit of the Company, and its representatives, executors, successors, and assigns. This Agreement shall be binding upon the Company and upon the
Company&#146;s assigns and shall inure to the benefit of Executive and his heirs, administrators, representatives, executors, successors, and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. This Agreement and its Exhibits sets forth the entire agreement between the Company and Executive and, except as expressly provided for in
this Agreement, fully supersedes any and all prior agreements or understandings between the Company and Executive pertaining to the subject matter hereof, except that Executive&#146;s obligations in Section&nbsp;6 of the Employment Agreement between
Executive and the Company shall remain in full force and effect. In reaching this Agreement, neither the Company nor Executive has relied upon any representation or promise except those set forth herein. If any provision, or portion of a provision,
of this Agreement is held to be invalid or unenforceable for any reason, the remainder of the Agreement shall remain in full force and effect, as if such provision, or portion of such provision, had never been contained herein. The unenforceability
or invalidity of a provision of the Agreement in one jurisdiction shall not invalidate or render that provision unenforceable in any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. This Agreement cannot be amended, modified, or supplemented in any respect except by written agreement entered into and signed by the
Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. This Agreement shall be governed by the laws of the State of Maryland without giving effect to conflict of laws principles,
and Executive consents to exclusive personal jurisdiction in the state and federal courts of the State of Maryland for any proceeding arising out of or relating to this Agreement. The language of all parts of the Agreement shall in all cases be
construed as a whole, according to its fair meaning, and not strictly for or against any of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. Executive acknowledges that
he has read each and every section of this Agreement and that he understands his rights and obligations under this Agreement. Executive acknowledges that the Company has advised him in writing to consult with an attorney of his choice before signing
this Agreement, and that Executive has been given the opportunity to consult with an attorney of his choice before signing this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. This Agreement may be signed in counterparts, each of which shall be considered an original for all purposes, and all of which taken
together shall constitute one and the same written agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company, has caused this Agreement to be executed
by its duly authorized officer, and Executive has executed this Agreement, on the date(s) set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Executive</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/Date</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MacroGenics, Inc.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">/Date</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF PRIOR INVENTIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:15.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Brief&nbsp;Description</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No Inventions. [initial if none]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional sheets attached. [initial if additional sheets, and state how many]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d662896dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;23.1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consent of Independent Registered Public Accounting Firm </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;8, 2013, except for the last paragraph of Note 4, as to which the date is
September&nbsp;26, 2013, in the Registration Statement (Form S-1) dated January&nbsp;30, 2014 and related Prospectus of MacroGenics, Inc. for the registration of shares of its common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Ernst&nbsp;&amp; Young LLP </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McLean, Virginia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;29, 2014
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g662896g01c75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g01c75.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1'D4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!7P```<`````&`&<`,``Q
M`&,`-P`U`````0`````````````````````````!``````````````'````!
M7P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#T@````!````<````%@`
M``%0``!S@```#RP`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!8`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U-[`]CF'AP(/S65C]/Q^F9^/5BOMV7BTO;9=99]$,V-:+K7^UD_N?
M^I-2[U?2?Z&WUMI]/?.W='LW[?=LW+)QOVQ]OQOVJ<??%OIC%]3;$,W>IZSO
M_1:2F_9U+'KR+,=S;M]-7K/(IM+-NOT+VU^@^WV_S++/55=GUAZ:]S6@WR]S
M6MG'O$EQ]-OTJ?H[_8@Y;<L=5O>W$N=CC#);E-S#76;/?^K#!]3TZ;=OO^W^
MG_Y[652W-;0RNVK-;L`#KKNI5B2!_A+*7GW.C<_TZO\`P-B2G9_YQ]+VS-_&
MX@8]Y_=]NYE+F;OTC?SEJ+G6XV0&V4MKSWD;+&,.<W>36VIWI;C=ZC/Z18R_
MW^E9Z5=G^%K4,/#R,S,(L'4\1A_3-L=E,<*G-(%F+96UUMC/M+7^IZ;_`%Z/
M1_2464O24]*DDDDI22222E))(7VG'^T_9/5;]I+/5%,C?Z8.SU=GTMF_V[DE
M)54??>WJE.,"WT+*+;'-VG?OK?0QL6;]NS;>[V>C_P!<3NZEBUOR66%U8Q`P
MVO<UP;^D$L])\?IG?F[:OS_8LO$RLK,^L5=YFO%9B9%;*C'\X+<7U-W^DMKV
M[+O\'C/_`%?]-D?:OLR4_P#_T/2*.J57B]]=5OI4;OTI#8>6%S;!4S?ZWTF>
MWU:JO5_P/J5JIC=3Q^I9^-9CLN8VH6M<;JGU:N#"-OK5M_ZO_P`P;I5%C.O=
M9O=4YC,AU!K>6.`?Z=7HO.][0UWN'YCOH*YDC_*>$8_-NUCRK[[?^_I*<C/.
M(/K#EFQ_3A<WISB6W5/=D^G^D_GK/4]-^%N:YUE3&>ML_P`]96%?TP.!J?T0
M$`0<>BQQCW:-H:[W5_\`?_TWYZZRW!RGY=F0S/NJJ?3Z3<=K:BQC_=^L-+ZG
M6>I[OSG[$!G2NI@Q9U>^QO<>G2T_'=74W\[^QL_[<24Y&59@,K#2.D.-FRNR
MO)>YK7M-..YM?K6-L]7V?S3W5>_'^SU_F*W]6<+IA#LNAF&Z[&<_&KOPR^16
M[T[W4Y3+BZRF]MG_`&FM?;]G9_QBN7=*S[:K*_VBYH?6UC6BFDUA[1[K?2L8
M_=ZK_<^O?_Q>Q%P,'.QKWV9&;]I98T;JS4RO]*(:^T/K]^QS6^RJSU/3_P!*
MDIOI)))*4DDJG4>H5X%55M@&RRZNDN<]K`WU#LW_`*4MW_\`%,_2V?X-)3:<
MYK&ESB&M:)<XZ``=RLJH]1S>H_;L9U56`*#52;6/=98\O:]U[6MMJ9]E]-NV
MK=^EL_G/YCT_4AC867G9>3?FA[>G66,LQL:QSBYX:QC?UBAWMQZ?4;ZK,7Z=
MC_Z7_H*R6Y]^9F_L_"FNG87V]0$%LM=Z5F/B@_SF0S_"7?S./_PEWZ))30&)
MD9G7,RDY8N](T^J*Z32,4^F?YNXOL^U9N779[+/^\ZC_`$=EU7K;3.GU5Y--
MU3C6S'I=CUT-#16&N-;MWT/5W-]!C6_I?3_D*&#T_P"QWWN8YOV>P5BJL-=N
M;M#O4=;<^RSUWVO=OW^G6_\`TOJJZDI__]'M^F546_6#ZPM+0X7?9F6G5I(]
M%U?IN^A_6]5G^D_X-$Q>C]-Z3GXM73Z12VQMNX;G.)VMK:W^=>]Z?I^S]L]:
MKI<_[4/0+B\5^G[JW>AZ18/M7M]WJ,R'>G_W&^G8EBU]6KS\4=4OIOL+;=AH
MK=6``VO?N:^ZS=[OY'_7/]*E.M;8VJMUC@XM:)(8USW?V:ZP][O[+5C9G7G5
M6BNF[''TBYM[;J[&`#U0RRG8]W]'JRK/4L]'_`;*5N))*:'1L^S/Q77O?4\>
MHX,-(>!MAI:'_:&L?ZGN]_M5])))2DDE%[V5L=8\AK&`N<XZ``:DE)37NZEA
M4LL/JML=4\5.JK(>_P!4@/;1Z;/=ZSF.W^G_`*/])_-JN[$KO#<[K+:HQR+J
M*;-KJ\<L]S<ASW^QV8W_`+D_]I_YK&_P]^31Z=>RW,S,FBM^7GNNA['^RO%!
MKIVX[[W,VLM=0,>S+9C_`&F_UOT=GZ.I7,CHS\UV/;FWBVW'OKR&-V#TFFL[
MOT-+R[]([_N1:ZVZO_`>BDIA3??U?)RL>UCL;!QW,:&>YEMX>QEVZS<ROT,?
MW[/08[U[-GZ?T/TF-;HLP\2NUMS**V6LK]%EC6-#A4#N]!KP-S:=P_F_H(R2
M2E))*H_-M;U&O!^SN+;&.L%\C9M9M;9N_.W[[:O8DI__TN_Z?CY&/U+JV?=4
MZNK(=6:V>UY=Z+'5&VOTGO?^E8VO]"^MBAC=2'4.H8KQC9.*&-M!;E5&HF6U
MGV!SO=M6P2`)/"I7N#NIX9:0X!MP)&L&&:<?]_24WDDD/(R<?&J-V3:RFIOT
MK+'!K1.@E[X:DI(DN4QO\9'0LD7OJ98:\>]^/O<^BL.V_1MK^TY-#_3M_,]F
M]-U+Z],Q/L1;CULISK#6W)NR*F,8`TV^M9[O2<SV_P#<FO\`\FE/29W4,/I]
M/KY=HJ82&MT+G.<?HU55,#K+K7_F55,]18^3T_J'UB-#LZL8'3:;F7LQ7@/R
M;=F[^D/:[T\*I^[^8J]:]]?\]=1^EQU@_5WJVV[J6?9T_-S\UF==75D6UO=L
MK+*G;,=K:7.PZ?=_,MK]1_\`A/\`@]+K'UNZEC#`;CX-M+LK*KIO=9C9%NRE
MX>;'U[*Z&>NUS6;6>I_UBQ)3T>'3ATOR&XHVGU!ZS`7;0\5UAHK8[]'6WT?2
M_F/T?_7-Z+=DX]$&^UE0,D;W!N@^E]+]U<ETWK/0/M'4-@S:,@9`^T9%MOI^
MK9L;6+]C[:\5GMK]'9Z5=?Z+^;3]:SS=5@_9\RYP^W8P=-F#[F.?[JQ^D9N]
M7]W\])3TPZEB>I<Q[C7]GGUGO]K&Q'TWN]K-V[>S?].O](LT/MMZVW,QL&R[
M$%!(R8I8#?N%;=C<CT<UWZMO_3;_`+)Z:H=-S.E_MCJMCV9-^33=0;'95F.:
MF/-#/2LPV-M932YU#6^K9M]5%;]<L=_UA'36.K=3]C.00+*3^D%HI#!D"_T=
M^W_`?3_PB2FSBT=4=U?.L9B-P:7"KT,JWT;'.W-W98IHQ6LN8[U6L]1^9EV_
M\%4KM.!TVCJ3;WO];JII<P6VO!M-.YKK-E3=E;*?5]/^9I8Q9=/UOI?U+J.+
M8['IKP?0A]]U=31ZK7/>U][+<G>_<WV;::T7$ZG3F?6'&:W+Q[G'#N>RK&'J
M-VFW':]_V[?M?[F5[*FT5_X7_K:4_P#_T_4WL:]CF/$M<"'`]P="LJGI73NF
M]1Q6X..S'%@M+]C8D@5\NVG_`,^?^8:ZR<RG//5:7,N=ML%GH%M`>RD!C-[<
MB_U&_P`]8-]7M_X-)3K+E[?J/@Y_U@ZCU3K`&;C9+J'X>*Y[]E9JJ%%K[:/;
M4][W?1^FMS[-U*?Z8V)X]$<3_7_<0K*^JL?4P96_U7%I>V@%K88]^^S],W8S
MU&?R_P#1?\*DI'@_5CH.#5=31A4^E?<_(<Q[&N:'V1O%;7-_1U^WV5M^@B7?
M5WHEUF+:_#J#L*WU\?8T,#;(V[]M>UK_`.VB_9NI3_3&Q_Q(\1_+_=57+LZG
MC/IK]:RXW.#=U6+O:V7-JW6N%OZ)FZYEWO\`\!1D)*2XW0>EXS\I[:6V',O=
MDV^H&NA[FLK=Z?M]C-M+$^3T/"O=CEALQ?LUS;P,9YJ#RP/9Z5VSZ=#O4_25
MJ?V;J<_TQL?\2/Y/_"?UU7RG]2QK*&&]]HOL#":L;>&`S[[7"S]$SW5^_P#X
MS_K24DQ^@X6/=E7-=<YV9:+[`;7@!P8RB&>F6>S94WZ>]5NJ?53IW41BAQ?5
M]ERJLJ02XO-1)])SK-SFM?\`OL_2*[]FZI']-;,?Z$<P/^$_>W*MU"[J6"RM
M_JVY/J6!FS'QO4<`2YQ>^+&[&;/;ZG[Z2D6)]5.GX^;G93W/N;FNK<*GO>17
MZ;/2]KC8YS]_\Y[_`,]6/^;W3/VFWJ3F%]S<<X@8\[V>F;!D3%FY_J>HWZ6]
M&^S=4C^FMGQ]$>'_`!G[ZK9]O4L*MEOJV9`=8&;,?&%C@"=V]S18WVMK;LW_
M`.D_,_P:2DE'U>Z31G9><W'8ZW-]+U0YK2T>BTU5>FW;[?8Y2KZ#TRGJK>JT
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MK0]K'LL:#K#JW"VMW]E[5\LI)*?JI)?*J22G_]DX0DE-!"$``````%4````!
M`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O
M`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``
M````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!7P'``P$1``(1`0,1
M`?_=``0`./_$`(H``0`"`@(#`0$````````````("0<*!08"`PL$`0$!````
M`````````````````!````8#`0`!`P,"`@4'!PT!`@,$!08'``$("1,1$A05
M%@HA%R(8,2-X&3DR)"77.)BX5K97ERC864%1<;$S0S0F)[=8*7DZ$0$`````
M````````````````_]H`#`,!``(1`Q$`/P#?XP&`P(Q]C*)0U\WVK*XOTBIY
M)%7\7<+)DM^)Z[A=J?L."5ZF/E\[7*(7/4#I'7%&;%&A4`X8R1G$%[V83KY0
MAP-4,KT.]9TW/$=?I_U@CJ>Q89Y0]+>OAKO(N>Z$)47`P,MUM4;YSYIGR-?$
M0L+0W.E4@1*GHR,HV"2A?9:E2!6ZT45\@3"H3TG[3M3JNL;-?+)"R4Q9?J?/
MO-M7PJHK.K4KC%(/#^-3[PW?!,^$F,MQ3,F6<MP5CS]S\KC_`.@N2<"9!HTT
M@8@MFY@[PMZW^I)KR7T!QI+^4+*C-"LG1#-^NW54UPH)1`7RQ'6M$HP*:J7N
MJ!G7A?F55]23U`C?L*WO8=!$6,8688#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_T-_C`8#`Q_:=5US=
M]>RNI[;AK%85;3IK$QS&%2=$!QC\E9S#BCS6MX;S?H4M;SC"`[&4/Z@,UKZ"
MUL.]ZV&([LXMY'Z145NIOWFRE;A-I\T1E8:L.NHQ*"H.6:8T&J$$?3NC<H3H
MF=4./H-G(=!VC/TC)T84+18=:#]2'COE1LZ'<.M6_GBGTG33H@-;7"]28%'@
M6:I3GL26+'F"EOX/ZJ%>HBR,MK,5`,"I&VAVD$9M.(1>PK?K*>.\S][[W;'6
MK;&K@N!^9E?Q!J=9V"$!:[/:T_5U@NI%A5T;#IO,51\'7C=1)"]O)+,[@6)#
MP'("@A+&8%V6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P(]]0V#T!5M-R&:<R<ZH.J[?;E[`2PTHXW-&Z"(D;
M>X/*)"_+@V9+H[)V!I-CS2H-7:)/2_\`/-$;)+$$P0?J%:WE-Z<]:>D0'2>S
MGSN;.9.=$@K+C;;=(.PX3=+@[VK5\](@;[7@:O:ZF@,H0D?GIG0S]8-,_"^U
MNUHOY=*"AX%UN!__T=_C`8#`8#`8%)%7V.;//?&^VHZN[+@P:X\T*_@Q#K/X
M\A8VFQ"DO54]>/WO6JE$\NQT@@:@QZVB+6J2T1PEJ)0'X-```PP+M\!@8OM:
M[J9H>.I9?>-NUA3,37NI#&BD]K3Z*UW'5CTJ3*UB5G2O4O=F=M/=5"-"<:!.
M`P1HRR3!:#L(!;T&0&MT;'ML;GMD<4+NS.Z%(ZM+LU*T[@V.C8O(+6(7%N7)
M!G)5R%<E.":2<4(19I8]"#O>MZW@=>?+#@$7E,'@\EG4.CLULY6_M];0]\DS
M(TRBPE\58E,HDZ*#Q]P6IW:6+(W&41SBO+0%*!HT!0SSM`*!L>@]L0G<(L%"
MYNL"F<4F[8RR:30IX<(A(FB2H&F8PIZ6QN8Q-R6,RM80ADT3D+:H0.:`T0%2
M!:0:0>`!@!`T&,%74G.J"G'KH5SNBNVFC8W(I'$G^UWB2M[1!&>21&SG&EY(
MT.$B<S4C<F5-=JM*AA']P]!$Y%_$#8M[#O8=\G]IUU59,1/L:8L<.)GL^BE6
M0PQ]6!1@DEB3E<)MA\.:A#UO2E]D2\&R4I.OZFCU]-?UP._X&%*AZ4YTZ"43
M)'0E^TK=RNNG-*RV"EJ&TX-92B"/"X3@%$TS,B&/ST9%W-8)H5Z*(7:(-,VF
M-^T._C']`S7@<*SR*/R+]5_0'UF??T-Y71U[_1G-$Y_H\@;/B_46)T_"//\`
MT]Y;_F!\Z8[[#RONU]P=?76!UJSK4KJEX8XV):TQ8X%!FA?'&QUE4D5A;V5N
M72Z3,\.C9"Q:9K9:?;M)W]$B*$+Z!^92#[MZUOZX'?\``8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%#G\<7_AMB_P!K?M;_`,2UA_\`
MTX%\>!__TM_C`8#`8#`8%)M968TV#[X7LU-<=L9C,K3S+@$!=5D\K6;U^UR-
MS2=7V"\'O5=.,Q8V9+8T'V6[A3E/S,)8T*%A!Y)*@8B3-!"[+`8&F?[8_P`;
MKK7ME@I!SYU[CN"^WZMWJ=;?H5WG<29U96M%./VIK3Y5+E6U,M+<P+RC(]L#
MJD6(Q@5)0)]IC2A)Q$J0M#\[_%^R>/\`G_F.`S?T>[A<)=2[7'U<GKJK;>BS
M=S"H=D3^?)G*!QF%3*GW66*ZN"<J$VB"J6I5+@DT,X)3?\P4R<)<^I?/MVV_
M3-5VMRE%&29==<@=#U7TGS[&']\9XBU3E8QN9T)MBKGR8NZI`0QQJR*/FTC0
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MN\8ERCW+373E@WPPW#T1S5%:K:YC;%WD7#7Z6_%-9W1!+(OJJG-LOJY+`:P3
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M'.#8BT:E#!D:\U_5*44)=E;V,P6(.22&D.;(E99-H=F"O.,]4=65[WA`[AG'
M4%8MDLGCVVTK$$]'Q1<'3<H3Q94L_4$R$+1H:``AAN'X#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`H;_CB_\-K?^G_M;=K?Z?\`:6L/
M`ODP/__3W^,!@,!@,!@4C57<-?6G[WWXRP=Y6NKE4'FE`JQL!.LC4JCP&>:H
M.K9^_JFQ&HDK*T)I(D`U/R4P+@UC6MPQ&"+`>(PLP``NYP&!K,>L_P#(",XV
MJ74YX]J277?+H19*N)79&;QY-[GI^*Q*+`+<6S]Y--K2RF(%5ZA(V3%$F;3`
M">#?SMN9!B/9@`#V(,S\&^ZE<W3S35M@]=06YZDOVP0.#JY5A4'!WHE9$/8&
M1P>U:>"%H)XR<Y3".2U7(XP!(YC5-K@H0Z_."26,?QB&(+*^V.G)3S"U\R+H
MK'F"1&WEVIS5S&^AD`G$);-%[LF1D=?I"T_IRE*(;^TI"_O1Z.V--\F_]8`>
MOZ8%7JSWX@-P1&4-W(?/MAR*T5ML<P4)6$DO62TO&*)5V1V!:<PJRI5\X<ZB
MN2W+9C2!I'7KZ\O#`NC37)TJ5`2B5IVY6X)<#)"3U5FU?^<O8O8%@'4=?5D<
ML6RHIT,<I6)7]SW$E4[?B*5;83%+&C_43"BG-?NB21W2WJ'=6G->&O<>-(6)
MCQ'F'(TX9CDO=U^<>1:M(9V]4;)?'4%RO-U/M;5QYTM@US2X4Y1591RQ+)FC
M[KJZS*D0,Z^$"=#TAR4E]6+'GYV[].2&*E1R)*'5XS[=\Q36TZXK:&5'T[)F
M:TG#G-@BMNMT)K0BKA2WK7F,/5O.\/7F.MO-L_2/=C5Z6>B`,,?&@:GI-LIS
M4HDIJ98>$<^=/Y!]=V7SY4MS7#Q_T]6SA8%2=6]!R<J%H*PL>!5[S_R)*TD9
MLZZ'B4J;,B<F/AB5<\HFT!0&+]8/?]*$:="<5I(J6!EE\]?%$RE]`P2M:3L>
MF+!?.X>2J`O&L^GXU"!RM!3'65&6Q;T"L&$.-(W38T,$L?T$&+_%&<[GJVU6
MB6(W)L*-#]F@EQZ<]4W?QGS&IONE(!6$\,CECU''YZ"SI/)V5.Q0NQ;2AM:*
M'2+L479%:B92C]3F*<!*12YLB1,3LU6-0H$0!"J"(D>]0[L?>Y#:S)KFJ!\C
M[]!)IYB@=2ULK)Z'1]`PSD+_`#5'VB<`]=JOW&I7!2D51S;<4F*=$WQA</RC
M?O`A$'=+A]J:@J2ZY_1B3E#MNV)%`K4GE(%R*IX#1[O$)K;=8T(P]03F`PQ;
M*>@X>]J'EBH9]W(A#<&]M2G)D2@DHXQ7HE.>'(5O[6\QW%TASYS-5M:WS-)7
MT=$JEG$1DZ,BB&6.1N-W%S=OK%@=YG')5?,?N!,RL]+:_+<7-LBSHT:<_P#H
ME*J5.?\`S3`@_,/;2?4Q)Z@O&R&M!)>0^I>UNR*4HB/PB##?K;F=4\]5\SU3
M1_\`:HT<GBC>XS+H_K"-.JE$=(1`0!8WU&6,U`G*$L"%E-3^J=/W)VP\\*Q*
MG;V#9<8_NJ5,IDN/Y\'`H2JI9CJMRL`B6M3-T`[W*R)DKW=,=96Q<;$=-L@<
MEAAK4I6MJ16O("SW`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z
MY+99%8#%9'.9S(V.'PR'L;K)I9+),ZHV..1J.,2,]S>7U^>G(],WM30U-Z8P
M]0H/,`424`0A"T'6]X&O=_&*NRH[/\^I?%*^L>'R^4P'JCIUTFL99'M$KD45
M:;.O"?S&NGA]8PF_JC:S3F-C&J:E9I84ZX*=0`D8S$R@!0;&F!__U-_C`8#`
MAYWAV5`N".8YUTO8;4KD39%W.%1=BBR)[8(P=*)K8\T88!#&11*96L;HQ$V<
MZ0R(@US=G`X"1K;"E"LS[]$_&(*MIS[L'1&NX9*XYRPR7E)47-MS]I=#-'.?
M7=)7+7].\F4?9I=:2BRH9<4;1ZBMW2M6N$>>1'4134(O]-<2CUA(DFQ&!FBO
M/96%6;U'&ZIC%&2E5S'-NF7KB>&]B`GL3,CCWUDQ4=N_5%>&58`G4H01!PBR
M=0VH9!M:/:I^3&)=H0%!$I"&-.8NKN;.N?:ZS9US%=E=7K#XWY<U[#W^25K)
M$4E9VB4D=9V,\'L"]8A&86G="FMW2J!$BW]VBCP"^GT%K`OOP&!TBR*W@=PP
M&8U9:4189[7-@QUUB4TALF;R'1@DL;?$AB%U:'5`HT(I0E5I3A!W_H$'?T$'
M81:UO0=P(()2DDIDY)2=,G*+(3D$%@*(()*#]A1))16@EE%%%AT$(=!UH.M:
MUK`Q5;E%U7>R:NTEJQ;<I(JFVX!>L"+_`%R1LGZ#:E7.@GJ"RG[XX[LXW33$
MYF;-_!6[4-RK_DJ$YH/\.!3OQQX55OSW5%B<_7G=DGZ<YZFD.KZ.MM)GE6K6
ML&C<T@$U>)LGOUE1J+_LA37=^."Y0V$!>*Y-KYK0$,J825K*."$T`6%1CSLY
M`C%$7YS3_;%\F5/]0R61S+H!DMVW[MN^36E*Y7$XA!WB1R6S;DL>=VB-XW&8
M`RD)%!#R28W&-I!Z39"@'RX&.7[R:X<E4'CD!DL&N.0-\1DLRE$9E;UV!V2Y
MVZRGV'6C#34[CJ"]5M_&W6574NJZ+-S(X17]P;C"M"C*"8@%L/UP._LWF]Q5
M'9`Q2>/T:VL3K%[`Y^M"-A9YA8K:T,<TY7J-71%!.+5'$4P(CJ)NKNIEQC.0
MV%I0M:PO[3EB=2I``\(<)7_E[PO6+<^LD1H\1<<D57="TBNB4BLZXIO#$M.]
M5RJ)S>_*MC\-G%@R.+1.`S^5PI`N$U-2-&B;3OR?T\M(%<NTI#&;YY`\9ET]
M,*SKB*3.#2E\DC%8\6N9]N>_+?M6#V]7].R*C:9L`B;VK;<FF4E0TG`I*H2Q
MN,N3H?%V\._H6@#]=[P,XVAY^\W7=S35O)5O([:FU+5)'JXCK*TI.A[XK9^D
MQ-5-3*VPQ=9,HINQ:X?+(<&Y3'T;GO\`6#E2?]:3E.`2@JRB32P_+"_.3C^`
M7RV],QVMI.;=+2J(=T<HE%VWS/&O]XEU(RT.JM-7!9U9TBKYQNM\J!@3,3M.
M5#4;,'A%L[\YR4&*5)AH=F4\(\IK)VMLM35?R39QNRP>BECW^^+'!\]R6GSD
M3R5/)C^G%S`+27^N\^IPQ_\`3PIPM27Z?G)TQ+EO:S`K#WX:_L+HJ27+RWU[
M9/*,17P"LZUBD(JU':!TDB\'I;D%JY1JVO7J5.O0@X!:4`CHHPS2LT<IA3K,
M#G=I3EE2-,4`&P!.![\I^'YWSOSGS';=-H;6K3EZGG.EZP22)\D[(<EC\DJU
M/4DP?'(N$/<71KYG)HZ3M7MW&7M>W/8].C>:D<2RE0`P%R_Y+.G+_:M@]417
MJVR%4'L&P+DL&1TB1JS4Z:?+K39V!HCK3=+Y(KUF,`LTJH0LYJQD>RH6S3%:
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M<#RQ@4B&(0@DI6_CG6U8=.L]O1RZ[!(Y]B73LH[8A'(!<?AI<"C_`%7*Z/+H
M198BBPA-QUC/$>:HJH7KV]B&I*)(>UHE`SS2OD3G!QD`LJN;!]Z;F:H'/X3-
MG.MO,"O8'8K;$94PR5P@4W2=:6,[K(9-4;.O6*(K*DS2\)%1C<N"0L`F5$F[
M+T`T`MA=%@,#1:_DH3OWDBH>;1U0ZRV"115-;Y+95'E_/NR?WL[QPG5=[CG^
M9$$;88JVIU29M'H30$HQ61^68Y_%L(=?482L\();[XR+AEJ<I<"FYF:.X9^2
MI??26P^S@=/[;RC&+0D_QN<-DPAPM,#8_P!'^Y9HO8MFZ^@/ZX%J_N@3T8]\
MJ4W77+%QV50UN7+V?S;3S59M62:11%_CY$]?GIJ+/='>-*4JX41+>?PS71,8
M/216D*$2?H10Q!V%&K)W-ZC=$S5W[-JG5\P2369YS]_0>D.1/Q)"NA3;?W&5
M:\=))?:#?2JU0IB,NM`75UOV4S1PQ6A6.+FV1IN1[).T(2'8?E_SN."UGLSD
M?BJR>\NAY1TAKCNO8MT7`.Z+UZ0OTJ*3B3W+/>B)4TUGT3`*AC7'_6D2Y[H:
M5*G%CCDF)C#2K?647Y!`TOQEAR4][<F=C\R>;=76OV#T=Q[Z(0VSA41?LKDE
M\S&G:EK-IY$O!JC5_7'T7&D#HJA/2MEW3"HF@0LD7<'%\0NJV5F+`")0IUZL
M86/EQ!&Z>AOH=8W^=?LZAN.>9J<W![GFKQUK<$@KU+U7TH_([1F0J?BUM.MC
MTE6L4YQIPYN9DB=I8$XH^Y330&_:90UI1I0E9XU]JP&Y^(N!ZZFEZN=I]33;
ME,V:S,F4.DNF=@/+G41\!BER/$[EKLG<?CD,;E]D,R5:%U7@7J%"\/QA-T`W
M985=\&=KSZ$=1JK$Z-Z"OY4H9H_Z'D>E=;3]]MZ>TMS'-V?T%@]2<!H(!7*@
MI\8*B=);6CZJ;T"&*)"T[XP%C=591^DRIP3A9+QMT)'7+UT]-J(WUI.;H3:K
MKE>3P"KIS.TKS'ZNF4>E'4K-T%!*CAC&RQV*Q1N@"13"$3UHA(:[JMC;SG=:
MO5B_(V%>EV^F7JQ%73H"2U[(^6"8-!RO9Z<P2+RSF.TWN2)X=Y-WJV1R.Q%Z
MEC-T+'T#X\]!PR6IT>W,EJ2@0B;?D3IS#3AG`#NU6>UMN/W:G3::W9E255\E
M\L0?JZ:R^O'AEC;):TR24)5]6S*.QZI7]ZN@ZR+0FV]2:2N<G%JOV-G;D+*A
M+0G+_P`\1Y01;76OV)P!97FY*WG:L$TZ9YMO&X>]+`E+7)7^NN;)'VAZ!\63
MVVK;E%:H9"A22(VCT]AEUXU;TL3%LC8:6X';$W(%28X+)O+7TBZ2[8[2Z>@E
MCS&CFJG:O;+I;H-535'F&(W`YOE>]63&GVZ8QUM471-[-E%51JMXJT:D#V_Q
M:'[%,)5I$G1A(2EB-#8+P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!'
M\_K'EA,_'151TM0">4)W<R/J(X?<E=E/Q#\2MVW&LAS..2!<"W<IQ#L@2;9>
MCM':^S8?N_I@2`P&!3[U%V!<=^7%-O/3S@=6XF_(^WMY?4/73LSDR>G.%(K(
MR3]EIC$NE):2R^K)"W%B%%X4`6DZ,8MN+R<G1I323`P/<;'`^):KC7E'P!`V
MBYNU^QHY-WF;R.[3#K,6$0^7@7,M[=\=\S1<A7K)JA7+G%2G2)7;0?W<_&D,
M#2FTD)VD3AAO^*GSK7M#>:DB5Q5`2HETWZEZ(16!,CDQ)+K+#:GL-VJ2)_-L
M.SCD;4WQR)`-(0_,:2G5+%9H-_<H-$(-E[`__];?XP&`P&`P&!3'!76`.7O3
M<!,*<8>O<VORYKUNGQ466,BI<W3$'6UCGJ$$P+:33%"23`:STHQE+=!5:3C*
MWO7V;!@7.8#`Q?=-SU?SO5,]O"ZIHT5Y5581M?+)U,WT:C],8&)M!H2A282B
M3JW!<I.&,!*=*E)/5K%)A9!!1IQA98@R"UNC8]MC<],CBA=V9W0I'1I=FM6G
M<&QT;%Y!:M"XMRY(,Y*M0KDIP323BAB+-+'H0=[UO6\#!/375?/7&U9ZN3IN
MTF&GZQ_=$<AHIC)"'90UE2.6+-H6-`?IF;G14G*4F@&,Y0,H*9(G*,//,*)*
M&8$."D':G*L5OQRY@DUY09AO%FI1UZ+?86[+53>7'J28U0TKU8,BE:A(7#(^
MTM>B]J#P+'$A44A^BL16DN]';#",/]6_/Z=5C<5T1[HAK%5U#0QOL6RYF]P6
MU(FTM\%>52Q`R2Z+_NR"LBNR(X_N"`29N51HIV)<%(RB4XC33R0&!V6S/3'A
M2G45`NEE='0R+-/4+#"Y72#TJ02I:QRJ)6,<R)H++G5Z:F!<U0.)2I5(T92-
MTD1S2A.--V7HW[RS0@#JYGK%Y]HK<LNC7WHAMAUCT^WVB[6*WS^`6Q7D<CS3
M2[N4PV6[!L*<P./5V\M4:=U!*?\`);W540L,4$Z2C/T<5L825IE[Y\OMOAG8
MU.$Q::@MZI(VVPNZ$C"J1/\`(Z=.='&81]G1*WUM;Y&V1M0\O9RX:,PE-\B@
M0!G%[$45]@=,J'N;D^^KJLGG>H[ICDUN2I"I"HFT+0M\D1&ITD0E94#F:^.O
M3LR-T;G;;"9TI*97M2PK',AG=S0(U@B%(PE[#T5'W5RS>][VES55%F*I=<E+
M'2]-94;)KVSVEGCJR`RML@\Q0%SY^A;57;\Y,$K>"$1Z9M=EA_R;&((!`*-$
M`)<8$$GOS(X&D\ZF=CRGEBK)3++!>I?)):=)VM;(V)PDMA+H^Y6!)4T/>W!=
M#V:13Q;%D`GM>A0)ECOI/]JLPT`S`B#LM)=W<Y]!6.&JJYD;ZLF:L'2B^/)W
M"*O:-DF,7Y/N^,\YW'-HG*RTRJ*O44;+>EB5K0'@6!.<OM..3E"()-'H.8I#
MAKDSFZ>R&SJ0HZ(5Y.I*UR)@6O[0)X4G-L;F$X469+(O$D;LZ.#;!(G);!4[
M>5[4R$M[>K<`%'FDB&45L`2PP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!`?T
M-Z`ZYYKI-3:G)O-5>=(+(DCEDLM1ML*[2Z;30^O8?%G&2+WQG^Z)R0R7.:G;
M>,H*4LQ,,O[=;UHW[_\`5AB?R@[+ZW[LH5#T/T;R]6_.E>V5$:XG_/;C!+NW
M;#A8<3F2!_7/9\I83HE&U<"61T"-LV4$TY2-;^HF!^,G\78C@M0P&!J@R+S%
M\]'_`/D.D5`\\;<]N562/R.G'0;[7BNM8Z9#G6[%'<,4BYUFK6#:3]-.EID<
M=%"':K9?W?BG"+_Y._I@;7V!2[T)U%=7;-JV+P?YQ3,Z$`KE\(AO;7?2)(4X
MQ?G`)XDXI%0_.JH85#;8'8BUG4#TM.#H337A0]#6&_K(R$R4.U6S/*4\C.=Z
MGYDY!IL-C]%WE)W2'\O<])'14?/.B+L<"$:ZP+FNRP3R5;L>QQY*;^Y+%G;X
M;]$Z(KZ&*`#,2E8&>^"^)A\J1F<6#:\R)N[L[HYW;9[UKT>J;PHUMAS-$A_`
M889#TAA11D4I&I&4>F6'L!("$S>V$?+LH*E0HV((,?QQ?^&UO_:V[6_\2UAX
M%\F!_]??XP&`P&`P&!3-!X!`X3[S6ZXPR$Q*(N$]\NJ]F<Y7Q>-LS"LFDP6=
M<60VJY7+%+4B2'R*2JVUK2IS%ZS9RH9"8LL1GVE@UH+F<!@:DWN#XA]D=95]
M&*SX-O*\7>-V!-I-+^BV#J?T.ZMEU7JFQ`XM3Y7\(B--S&26+7IC(GE)ISGH
M1J$H;2:S-P$>]:$9H(9^\L?&OH&L>3(76W?G2/8S5<E8/:Z&Q0GF[U![7::I
M74RR(F85;I$L-8+!@\9@PXL@-/CQ;.U("4!;8T)#0?09Y@0!9]Z;<0+N_*?I
MRE!CAYD(8^JJ.M"XFB8.3TV$R>EH:YNQ=G19@-96"0&'RQ^C+P<G0$J0I49A
M@OH<J(#_`(L"E6#_`,?WIY\KTUHZ%Z0K"7V_8/*'<7+=NW@Q:FCH^#C]D51Q
MQSYQSMA8WF,LW[C9856/*I[O-$RM>V';DDD7_AG+]*S5H`RS-/,OU?Z(FQ:"
MV;\H.D*/E4RY*F-F5K";WO;K>N4TAYA>[3M1P>*DY]O6@*JK6OX=9=NI:R).
M@Q:X3(WL<96;,5+S#0IC@]3)Y=>C4-YMY6X6=C^0NBN-^8;JFDW=8G*NB+OH
M&:]#P&"7,HM#CZ%6JK9.1[^8FJ&5@:<D4O\`%F\LPAR71]H)*=MI$ZH*P+.V
MCE_H5G[`Z_[A?&BD;0L9[K&K^=^(ZM>K-G<*B<*HV'.9%C6"9:%@):8G"B(S
MFW;J6[=EHFF+28"%#&F1.!2<,)QA08X\SZ^[4Y3KOD_A*Y:?J35>\]<B',M@
M]`UC94RG$3D$^CTHB4-J*-0X<SJZH7?3S)8RW2AXD;=MJ6$L)1#5K3D;M<`)
M@15YI\T^[>8IW7\CC#CR;+D'(K+WA%^7UDILJWB7^[&[O/MJ'=$2EZZ*&W43
M]*I7UE5L>5M[>BCZF9E.LD5!/,4(TGR@,"5O./%'1E2^@%FWZF7QJF.7)4EZ
M1<WJF(-U_P!1]!,U\VQ<USL,^CEY22A[G@L3ISEB8MC$A<S75%!5KPG6.CV>
M4$_:4O0AA6'=O\>%ZMYUOR9+&7F598EOE>SLB3RQX?[(*7FV7V)=#1:WG9*W
M]6AKTXS1G,ZHUX5NHBP'ZCKLXC.9RG<9QIV@B7!Z=[8H[O\`[.Z33\'6G?/2
MK<V=N1SF6ZT<`41]-%Y;+:[H^!598$BL&?\`/29ONN)6`^Q$#?%3V^W7)3#X
MXLDHU,9:$;D>4G"P>]_#RVEW^[A;:'E]-ND$X/YVB]<3FKK=?YVQ0OK2:M?2
MO*UUR]DN$F.06<#,KJQ%%22*5+5)I;B9J<E,OY#2O;AKM%ACCQ+YVMJN>_\`
MK2W+MY"GT$G5A1SI,C71,G@CI6Z=OCKUW/.Y_&ZGD),DY_BBRV9[9;!(DD@+
MEC3:-I-Q,4C3,UJ%:0:5(5@;5F`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(S
M]H_]CSK+_9GO7_\`:Z5__)@1*\0O^$1YT_[)U1_^;:;`M-P&!16L_P#^F./?
M_P"%<R_\?L$P.5MOH.YO3"Q9ER5P#8SY4_.%:3,Z#]J>A,0-$E<R%K4(H<EY
MFXC>]IU;?([M5@%^+)9N'0FB!I#?N3;6.QJ4@(2FM.PN3/'WCB.-$"K1-%H+
M%U+15'///%5M9R^P;UNR8;5`A-60=#H+B^S>V+4D11AZ]U7#5K#S!*W9T4""
M6I4:#K/!W'MD1"83CN#L\]EE7?/0S&G9I(%I4D.T1Y9HT+@5((AQY3*]/O\`
M`-A\'7?:ID+VG`$^7R71K@I-/`6D$`+/\"AS^.-_PVQ?[6_:W_B6L3`OCP/_
MT-_C`8#`8#`8%)M95#5]7^]][/5=0&*0AUMWS-@%F6<NC+.C:#YW8"WJZP6%
M=,Y,)&65ITDBYH8D:<Y49K9IH$X=B%O>M[P+LL!@:T_:'\@&M8!T7"^?>2[H
MXR5"20FWY%<UB=0*^D6:*1.85].J\A++6#&FJ*K9.]J90\[DKNNVH&0<W#3-
M)NOG),T4%4'9>'?Y"O+=GL5ML78U_<SUU:L`OQRK"'G4@1>S]6EFP'^WM72A
MDL%@7SJOFZ2H@*Y5,G9F.*7ID8@FL^S-%Z+&$P86*>I7?ZWS;YF1=!ME&O'1
M#JY6M`:O;JQ8)D5!WES/F@W0PU8V.QL5F/YCFB1,YVTB`*/6W!4(LCYR/OV8
M$(93CWRH6(7W/(<W5A))OS57O$LXZ^<.G(G)DZTR0NT%JRD;V<*8AU8GQX@I
MV>U=.=)05T`ZJ9&A3DK)`6E4)R2RC580Y[?KS9,9K"^WNQ><^=!=!5@?1D*@
MW(U(>AE97K>3Y?G0MC(*LKWGF[8^@J6(.%`6"*6/:,*LX*64M1:8#@>4I.+;
MS-C#RLSV.EL<Y*XR[6JSDM/;=+]1*Z-BTJ:O\P31"[=A%M719,?JDRCZHJ]9
M6+V[W]:<$EJQW"Y(?EBQ(D[&H-`=]H3OQPR>O]"NM&SMZTN,R^#X?-W&'458
M/1$,?ZQ[`:'B3R.O4=FE5=2'[_BE@T35L%J=_NIT&I6_@CF3PH:6YD=C"=.8
MTJ<M:$U^(NE@]D\B\Z]5!AFZZ#?M3Q*T`P44BU+1134J;2G#3(*3!8XR%\VA
MT9]FU&F]'HS>OK\0/]&!CKF[L:4WIU1VYS+*J&=Z>.Y"=:<*8Y2]V'%I@MN"
M+7&CL9='YL3'8BE6-\#:%R"O]+4"12[KW4U`Y$[<$S6M+/0EA%^1^[OG3$72
M4-LCFMWM:>''S,U]DN^4.F'&$)HQ6-KJZ2MNQ")RSU8X1);652V<G*:)$_%+
M!MS>X+$Z7Y1JC-D!"1T/]+^49WTC-N7HY()Z=8->-ERN\LD;G4MC1^IV]!SR
M]L,6NY61:[_'&R%.2"LY=)4#.ZJTRHY&2Z*2TVCA&""'80!H'VJW(;'Y8B/1
ME?-=<H.V:+E/0'.37%&></-E25GFW5H:NY@@)$&+*>G%_?I9SJ[M\XDKP6%O
M0-A)*Y2-.D;TXS`!8CS;Z+\R]96[-J7I1RL=ZDT%A@K$6/4AJ&QX/!Y#!_[D
M2VHTLIA,PF,=9&F7,;I8,`?F]$I1"-)7#9%HR!&%D#'@3JP&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P*?O=/N^!^?GF_=]G3>*OLV5VNUN?-\#C#&J(;MKY
MS<$/EK<D5.SPH3+B6=EC\?;'%R/-^`X1VT@4X`_(>$00J<\&O;WEYW\T^?Z5
M>:UZI47!S3&&#G]T@U-\I=(]+[FPH:Q-`T$RC4IHVI)?#VPAX9%VU)S0[KF]
MV1"2*-:*4$;2*E86\?[V3]46[10GS1]:YO\`>H^!,KWQK_:U$I^97^*A.^?H
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MU!.PN'P(]]0U[T!:5-R&&<Q]%(.5;?<5[`<Q76XTS&[](CB!O>D2Y^0AK.72
M*,,#L;(6E.:AT<>J_P"9Z/V<6`1@`?0*UO*;S&ZT\W@NL#G/HBV=-\ZJ]V7)
M6VE@<>0FE5[3:MHSU//7VP]6@UVQ/I2O(_/4NA?Z.:7^#H+CK9?Q:3E`P+K<
M#__1W?ND.HN>N0*O<[HZ;M^$4I6+4K3MATKG3P4UI%KRL(6*D,>84>M'.DFD
MS@E;E!J=L;B%2\\M.8(LD02Q[T%1P?Y+/D>$Q,X+;GM]J@"U6:D1VZZ\G=0(
M:P4?8%3HI4&0&U-^8%&H4)1DZ,$D#H`];$;HLH(S`A<U3%U5)T56,1NFBK%B
M5L51.T2IPB$^@KTDD$9?DZ!S7,CEI$XH3#"=JVA[;52%:G']IZ-<F.3G@+.*
M&`(<9?O0%.\N5-*KTOZ>M%95+"#8^7*9N^E.)S8SF2J4,L*CI1Y30C<7`PQV
ME<C0H2M%D#WLY2'6]:U]1:")DL]:O.>#5_3%IRWJJ!L4!Z"-E`JGD:QMF?X\
MA;(3+!0:82IT2DQ@QPA<"BTMUI`OD+Z2VL20\PO1JL.C"]B#*C?W[QPZ]0F\
M8-M^0I9TN26I^M9)PO0S37%#%R9NOBZ65::OV,MG;?"#@/)\?)<QOB=HW^88
MD"GULS`@95]/5M5GOA?C[`8JDCCO</FA7]FV2M3*W%29*IVLZJGL<42)8%P6
MJRTJDUDCJ%-LM,$DC0$X/H7]?NWL+ML!@0'ZK\_H=U):M:7<3?\`U)S?:]85
M]8%5-4WYALJ.5\\/M>V3(X!+I)%I/N2P.=IU[9N25JTJR?@+2CT:3_K!&:T#
M0`[MQKQC"^+(I:L=BEGW;<CQ=5S.U[V-8O0,P8YO8DAGKO7]=5F<:H>X_$H8
M@VV)HI5K2225M'LP`P&"V8+0M!"'?NA^:*XZ<;:H:;+$_?@T[?55]$Q<AB7(
M40%LZI]Y-?(NAD!:]K=2G*+JE9P@KD@`DF*"M_:$XO\`TX$`:K\-N!:EKF,5
M$RQ"</U9QR`]C5DMA\LEQ;@AET/[;4U05:2"4.#>S-+^-3$HQ24;8HDJ;U;>
MJ96EN*ULQ0J`6J`'5_\`<3<F2F;P^;=`VCU)UQ^RTU7-#=%>F;*ALXBKG%*5
MCUYLU5PV5)X_64.>I6P0UVZ#?7PD3@N4+E+X6D4*U*@)0RC0Y!O\1>=(B\U.
MXT]>_5]&,M#6'>EDT97];3*H%5;4X^]"R=5*IXGKF%6/1U@,\82HE3FO1M!Y
M`-.38UN:U&6J^!4:`030;.*83'9?U]9D0LZYH?;O9SG`5E@6VQOT,-FT%::K
MB)$-KB(5,%[@3Q%HW%(>VC<#TJ=P;'8T:]Z<%)QIIBCZ@#$/(7GV\<;OU.1"
M!].7;,>8>?\`GF1TQ6U*V,\-#FJ5/\KFL8>`RR9.T08X/&7U'5\.@B1FB11C
M*-P2`?'D:A:;HXD`0R327#,8H_JSHSKALO+H2<3/IU"TMM@02P9#7#A5S6BB
M3NL75NGB+/'*MBTH;`5>R.JYD9=JGE<+]*7G!6[6*?B5%A'U_P#&_E"1P"55
MNN?;F`P3"BNU>>G4Y-+XR6YEP3O#IEJZNN94B4#@QQ!4B:;,:"B(^H&4,E$T
M;$0I)6G;THT%=9OAWU.3<'H')H5U35%4PSO1VZA06.^,52MLOM605MTO;\?D
M!<14R=ZCK-,H6MK&HCY`TMYJ*5N;<I>5B14!"A(3A("%I=[>4_+%\W!1-Z.>
MK!KRR>7X17\&YZ>:MD#)'"*C;JVLJ-V-'EL6;G2+2!"8K/31TR-KDZT"QK6Q
M=T6HC4FQFEGE!%+R1\L;[\ZK&NEYF5SU3*Z[M1B5#?(S`J\;44FL.UC;:G4Z
M07#-K`=HJUV(B&QP^9',J:.K'R5)_E5*5@E_R;"$07KX#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`QE<ER5;SS5LYNRZYPPUO5=;,"N336:R97M*T,;0EV6#[
MQ_&`Y4N7K51I:9$B3%'+5ZTXI,F*-/-++&%(!/+$C]Q$[);O?E<3RK?/1$I<
M'WF3A5SDDFK^P;J"L0N37'.G.LWF$.<=E\2<5+$Z;5P^"-CDG&Q_+^6XJU1I
MFB=!;+R!Q1RWP/40**Y'J!CIBK_W$[2U4P-3I)I&N>)0^!2$N,@D<LFSW)IC
M)G<Y&WIDH#W%P4F$(DI"4K8$Y!)8`E/@,#J<ZG4,J^%RRQK%E#%"8'!8\[RV
M9R^3.29HCT9C3"A/<GE]>G1:84E;VUM;TQAIQI@M!``&_P"N!3)SS!9=ZF7;
M7W??0,:?(UQC3K\7,/-KG&5(E;2HL-ZT5K33Z`77&CS"3CGZ0MQH_P"US&Z$
M?_EYC4?K'P@7.`#L"\?`8#`8#`__TKZNVH+Z_73T9:[#3K]3=?<N5]/(VY5,
M_2WD:L^@9[#T40Y4+M=/?E;*K`M`E+,+!FG1PGJI360B/:<V!H<"G=,+Z&".
M&%C=6]S46@KVE(?U5T/S!475\GK"K!V_14ANRKHS*HW<,JBS+J8P=+"'B;JW
MT!B2;*E;>F2_<I,&(O181F[_`,6PF5#H3#*[CZ2)5_$8Q!(JA5/"Y#&8<P-4
M9CR-;('A?(GY8E9F1*A;$ZM[D#JJ7JS`%Z&I6*33C-B-,&+811]"J96=!<JS
M:IT=./%[Z?I/5#X97T8OI;S3+35-=6O#+,8I+$;B;D*M7%Y+"I3#4#LET$Q'
MM4-'LG\DG8];V&N7(_+CUM<(/)'29B@W2=A]-^?G8/GD_-EX=**I&\\B0+H/
MHDBR*BE\MN!TKQ4^=)N]5UXZFIGMP1H"G9<Z,J#2;YDZ<@0@DW0GEGUY573M
M?5R[-D)>>9*K]/9UZ7)>L5MG&'VS,&]]Y&'0K!S\&JPL9[XC=3)B\CV[.*IX
MTU#CK62$`CCP%IS@D'S)S#4G*_MA9L,IXFR2F*1^75>RUV_N=>UYW^^&/BKK
M2QFDXY+*K]L>S)4UMXT;43O2%*M)0A-T8;HG1QIHQA?;@,#4`_D1=J>V5'\8
M3-SJCFB(<W5$=.C(U974//73DANVV(U7!ZLQ+''/](!1M+.]$M\Q6:)(6OZ5
M0]&(##P(M*49IY)YX33\U>N?<ZS.,*`F-Y>?E$3>:O\`$42@^Q;/[%=N:K#G
M$;V<(J-S>9TBT\G7"1$9#(&#1"M2`+HF_,&/\@+>WA."F`$EO<2=]21#E6HX
M]QS;+U2U\W)V-SG2,/FS)MCT<6OL)^=D34UN`I"WN+7N/N<C3(0.)9@`@4(M
M&D&"^(PS6PI%0>M_?MZS60]G4<"7,=;2OSE[E_LAR>YQ!<N:%G2'&54\>2FT
M+&5Q`Y`-_E+A%>C>@IA#$992P8W%%"-%_8'YQ:&'H<_2AWBS#<G,/.7;/775
MUN=$;X^A]8=$P>P:3Z]<4;/=\MM)[NZZ*9HGGFL6ZPJ0M&$4-3$X>38"J5+A
M,IH&+>TB/[MJC@[++O2>S+=Y5\TD@N])SREZ.&V0GI&Y*NG$QIBGJ3CS[RU<
MZ*"]>7GVTS7!`FN4`2O<-AYH6:&A?&A8X/TH2)T+4I,)7_CA/YJU8B[TG[Y'
M%_2+I"KN5N:J7)+O*<6_9=2OE2U!U)T]+`6`PPNGFVP:V*K&-Q7G.C4Y0B_U
M\]X$VNDI:B%92D"4XI4$R/(+L^(]#\)<)?OWHF&6ITQ:',J&<2]&;.(V]6')
MGR!$Q%GMEU=VIK5#4END3D<U;$[N4,HHY(I6EA,`'>]_0(F^<_0TU>?3[KZ@
MY[T-,.B%CFU]/77"U\`Z]JOH3F>KZN;NQSXE6E4O-01*LH]-.:[SA]=2AD:M
M-;E)9`4X@:GHS7PC)T22$4K"]K_1B+1VSK/8Z=XL<ZVAE0]T]),K4XK+P23E
M547GSVR5R':<5=32'@Z/:L2RQ/S>[,*PD6FYK`F4Z5$*A'$DE!(:N_;&PGKK
MOT$B<^(YRC?+GG[$>Q9+93<@<3M=$GF\R2MIBT/0MOZI;Y.W\ZUDI;LZ&;3P
M@E&RB2I6T:L\]Q0J5`0[9>LNS^"^H?-ZJ[;G+N^2+K3F-HE/4CQ<LBL1XHCG
MRY^M^Z6.;2^:RJ%-3N4N*60LV:"J2#[&>U-38K=&DA<O2-Q9H30LJ\F/4&[_
M`$4NSHU!(TO.#-3=2M2A(T1V`*W`ZZ([8)ETVG"@1*:?J-M2)2]L;'7$`:G<
M]]W$HTF<5\G+2D%%&-RLH87OX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&#>C^
MCZ8Y)I><]`=`3EKKVJZ\:]N<@D#GL9AAAAA@4S6Q,;6E`:Y2&42%R-*1-C8B
M*.6N"PXL@DL9@]:V%7]+\ZW3Z%7)`NW>\86]5C1==.*2:<.>>LN"7I=!70)A
M@V+I[LAD3*%;)(>EUS?LM3'8H(Q8V5FG4?'L1S[M6I+"[+`8#`ZY+99%8#%9
M'.9U(V*'PN',3K)I;+),[(V.-QJ-L:(YS>GY^>7,],WM3.U-R8P]2H/,`422
M`0ABT'6]X&AC5])K?4C^08<K!/.G]^95FU2H]"HY1U]3>?I:\Z4KNMYU#ZQ2
MO47I23/SJF14-9739B=_:6N1-B#]0BZ<T9*-*E4(0!#?N`6`H`"RP!+++"$L
MLLL.@E@`'00@"``=:T```Z^FM:_IK6!YX#`8#`8'_]/?XP/GT<4<[67*;#GC
M]#/*SS+MV$-_??1Z-/<_9%S1EK[88437T]*Q*TUL1HZ3&.::PX$$6RFXO](;
MC%2%.B.`D.T>%6M#Z"^`P&`P*2*NK-/7WOC?CL1-K*EN[,\T*_GQ[;/YNZRY
MJA!ZOJJ>L@XK6B%RV(,+@1>F72LMI3"VF*7*E!P-:V=O6@NWP&!'+I_J'F'E
M*N#9SU;;U:U'73ZLW$R%5E.Z!&CECDYI%(AQ1D8E`5#A,75<W%'"$W(DRL\Q
M.`P6R_C"/>@R#3URU/T%7$7M^CK'AELU=-$1CA%9]`9`VR>+O:<A6>@6@1NS
M4I4)MJVQQ2')%B<6PGHUA!A!P"SBC"PAZ+>L^E:ABR.:WU8=75="DLDCZ!#+
M+>EL2A463RYS7:2Q=$D?IFX-C23)%[B/1:`L!VE1I^]!)T(7]-AQX+#H!FM=
M!2Q<YIUJO)-"GNR6JIP2>%(;7(KE[D&R)+/D$#TM*EQ4*=Y4B$!<Z%)=(5#@
M3O1IHC@_T#"->=3>>$H9[-L*I^C.,)!'Z5"9*[EG%>6]1[LT5*`Y*]H39)9T
MEC<A4(H$$U$!Q)$L=3DGW%:4@V/[?EU@<Q/+CX.B[E56[0M3D>.N]]*$CQ2'
M[]G%-M#E<RN4&-!B%SJK]P.B=38JB1'.J`11[1^8)6-21L(A[,+^H>AMZYX%
ME$WLRCVCIWC^161&5$\<+DJ!MNFF'B<1]7703$MFK[-@"62J'YI400#$(M^-
M=4A8FS2/85>ROAWH(=UJVMN8I)(XYU+2S164C7RJID\$A-M5HZ-C[$W6HG:2
MZG1B."K8TX+(3IBE4D"G7+ES66$QY$A0_DGG@0(M$![PW5RM!E-Y..K:Y]AZ
MNGMM;_TLM#/*XCRBK-OY#B[,SW>:G3LD-A&WM*4K4IE+^)-^26$XPL0M:&+`
M[57SO1=R05DL&JW*IK5K*9M#YJ.3>OEL/G,$E;"^O)JF2_HDDCAKI'WUG>9$
MC,&N^`XTE0M)$(W[C`;WH(7/GD)YY2B:2^>2NA%\O>IO,+(GCTW2^Z>@)7!T
M<ON.TXI=5L/<2K.0VFY5O`#[*L:$MJU]`PM3:2Z)R1H%`#$!ZA*:$PKRGU)5
M#"UMEWDICS/$=.L&@)[R\QM1)CECO8MA1B$P.)I6QK:'IZ=E,EL>0M21(D(3
MG?<M.+']NOMV,(13XDXXX`J-2IO;C6-Z6?E,L_Y^;YH*Y+HMUIC<6@=X34^Q
MJIKY-:MA35GKV,,]\M;R8X-K`0WHC79,+8@CT45L(6*X#`8#`8#`8#`8#`8#
M`8#`8#`8#`ZE/9S%:P@\RLF=O!$>A%>Q.1SB92!22K4IV.*Q)G6O\A>#TS>G
M5KE!+8T-YQXBR"C3AA!O0`B%]-;"I^G_`.0!Y`WW:=?TI4O9\7EUG6I+F."0
M&+%UG>;.=(I;)5Q+8QLI#G(:O:61&>Y+U!9)8U*DDK[Q:UL>L"P'J;JNC^,Z
M?>;POZ7_`+5AK<XM4=:$3>W+Y#,)Y.)&IVAB==5Q#&5.KD,ZL&6K]?"WM;>0
M<H,^TPT?QIR3SBPKSYVY5O#KNXX]W5Z014B/BASR3(^)N"7!:BDD)Y52E`'^
MD7==)2?YX]879#JE/$,E3K\EO@1)@B&P>UXAJ$H7,8#`8&-;AN*KN?JQFMT7
M5.XW6=5UTQJ)%-9S+7`IK8F!I3#+)^92H-W]YRI8K.+3)$Q(3%2U6<4G3EFG
M&EEB"FR(U+;/K_,8Q=G5T*E%.>;\%EJ&8\Y\9R]"I9)UV&X,XBU<4OWLJ.J1
M!4LM0I5P`.$2K!46';B/0'"1`,(`F1'!_=I4J'^2U%4*%,0C1(_"25I4:-*2
M6F2I4J;OF!DITR9.2$!9"<@H&@@`'6@A#K6M:^FL"]S`8#`8#`8'_]3?XP/G
M\0*DXUT%TM(+5K/S>\0J8CC!UY8$+?(AU!U1;C1V.T2JK[U>(Q*GF4P9ML1@
M;(U/GMP9A.3:V*6803/R2#0EJ$IY0C`^@/@,!@,"DVL8$Z0KWNO9Q<;/L:Q"
MI[YFU_,FMIGJB'GM=8MRGJ^PFL,`KD,5AL56IX,C.;1K2BW@]Y=/RUA^QKA%
M;**)"[+`8&L=Z$>1O53E>?.O6W-_2?;/2DBJ&5WC^NU(_P#5U05'9L%CUY-3
M`B,>>3K1F5$ND"KTZ/"8?P79I>2!FO;$<!*0YHA%&[5!V'SO\5+YJ.L)O(KK
M[E[EH:P[CZ`L>_W>DZ!Z5KU\AL+)G"EEVWL=@3!3SXWM5HVLK2,H3Y2_-+6Q
MM#DO/'I,CT$O:I2$]/7[B*0^@?/5/<\-T=*D<-7];T');I3C>VID4MU%M3F]
M-]I/C:<[JDFEKLU1UY&:F3)MF+#C=:^$`AZP*.(YXW^E%NL;U.^AWF'M/5]U
M\.=\\B67;I$^1KF.-MFZBXUY]Y#;'50Q.KC)EC)<A=)SB;2`]K(7[:U4T7Z5
MIBSS=-X@R?,.,_5OHQ8&C2^;JPYNY0G2_CQJEM67=OB^Q:EK"&\_2:U;ILJH
M(25R:S5A>5@<N324P"M(DW,,B>%,A&C='8U2I3)#5'P!QKAP3WWOEOC+@N[>
M+T70]-<V6F[,MM7E5UE<U-=IW7SKSK=^I[R!54)-NJTF"75-7,G:4C(;)-@=
MU,A3(HZ)K*T3MQ-6EA:(Y<AS"4]D=M=?W/R7%+AA[!4$+YLY$YXTJI!>"YHD
MY/S3<G0UMRQMFSR57;9+;,MI,R-[>9(EJ%>0UPH!AX`"5@U@>'DX\='T'2/&
MGGS=W*4VKF64IQK^9;5FK)G#Y1`XT]0:3Q2NJZCC4]0`^5Q.1.EQ@')'5(F"
M])W-I01@T:Q'K2M,/85\]!<$]@6#;WJ2JJ7B=)7-?7M<O!-]5N4ELKFV-1?I
M9^XMZ?361;K3(F:-3E4Y1V3].(G]PEB!RDS<G`<YI!`?CDJQ1K>PE&S</==D
M^</0M7L;&\U!=W3'H^7U8DK.M+B2PB44E2%C^A-5W#/H(EM^!2]F:$$J;*!9
M'I6ZCC3H`@]<M4HV\Q28,`CPK6ZAY!]#^)^?NB;AK6>=7JV/<,]%:R=D[CUY
M<5S+6JFWCLZA0>=*F-,"JSY9+XVZ1_G=1*MKGA@$TO32U"5EN[HUF*#E.@RY
MYW1V6=*K^':"<(MT>XUO2'6/6_?G1UA7&V62"LI1.ZAF9D(Y)K>@)W*K9N\V
M6TC')[9B=VC!"R7.ZY2"K!+57R&&B/&$4[;YO]+.'.?>EU<]*G"R%7#TU`1T
MFXQ"YY2TP*B*QL+U-NVU+7J*RHU25GP-\)B]^0&?-,J>YF0^QE2!H=#XXXO[
M<8WHF]2&RCXZ[_\`ZU^5@C4WXXJRXE*B79[Z92+T-P29^)LJ:%2"8.R5RF=B
M+2HC,GP*AUBGWO;IH425MH@J!@V'`LPP&`P&`P&`P&`P&`P&`P&`P&`P&!JT
MUSW5S?R+Z[^^=@V5.D3V[.J+RL@M7U%7BAOFETWK;3?1MM18--4K6[6NV_3V
MS#Y8YI6PY"F#H#4<H^5R-1IBSCRPL5Y3Y!N:]K4B?H#Z4LS,;T,R[<E_+'*S
M8Z_N"I>"85(2A@TC2&$[*:+-ZDD;4(G4MG*@@>DQY06]D`C0IPB."X'`8#`P
M9T;TC2_)E/RZ]K_G;37U:PI%^2YO#GLPU6XKSON`TQF,,R4)SK*IC(UNM)6M
MH;R5#@X*S`$D%#&+6MA5O3G.%T^CUD0KL/T(@;I6O/L/7,TXXT\X989H\4.>
M41IREBZ2[-:R/^BI?T(N2F!/88>=M2S5\C4?$<`]\$K/*"[O`TYY;[0^9,2_
MD#G7O(.I6-NJB&^7D[Y$DLOW7MP*"6SHM%VQ&9BJK034CKL]]4K@1ME5*OSR
M4IC2+16P!5;,V$&PW&,!@,!@,!@?_]7?<>I+'(X)H#(G]E81/[VBC3!IY=D+
M7M\D;F`\QNC[1I<H3[<GM>6E-$2D)^\\W18M@#O[=_0-*FE?'WIJM+AD3U8W
MBMQQT:M<NK[(MEMZ?MKN!Z47*?#9C=#I.XV[3)I1M8V"32J%,;@64`:=N;25
MY:0O1R/\@:@Y0&ZO'I+'9:UEOD4?V63LAJMS;RGB/NJ%Y;#%[&ZK6)[1`7MQ
MZA()6SO;:H1JBM#V-.J(,),T$PL0=!S>`P&!255\.FD5][;W6RRVI19J&7>:
M$#D\,9Y)'*_8DU4Q53UC82)/6T:50>*QEPD4>;UR)0L*6OQKJ]",6C`:L&46
M2`L+M<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"`_HU.^X:
MLYUD%I\+CY4%-:S12JP;)1=9,]NO,7<:NAL$D\B=D$'3T](HV[:GRAV;48$_
MYZC3=M.([0]@']@M!@+Q^Z&]#>N.<XIT_P!K)N,FN`WQ659V70+#RVP7BQ2]
MF;Y0D>G"3([A+MB8S!FTM(2&->D`650:7HS\KY3!:T3O89R[-]`85RV[1>F8
M!"))TWV?:[6L6TCR'52I`.P)4E*-&@U/;$>5@A,E*48SNFM@=9D_[);DX"C@
MI@+5)0D^!JF^,G\9KO/BGTSK?M#J"X*240^HP6-)OK7$SF$_FUHS&RJ\ED(,
M:W$<K@$3(;6](9-U*UU<E`C%*@]($I*2+\G\U*&]K@,!@4V^Z795F<1<%S&V
MN?[OKZINE`2:*):4B4WB:.?K[U=/UQ$EE-60V#"1NSV[R(Z+.*AR*4(D9H$9
MB`L2LQ,A&H4E!$7QYI'H;T!J?EWU&]1[`0W3:P6IRG?'](-D98HG2]!,KFY.
M*!GO%7"&`O\`2)??LS9R-*FQZ7"4"C;,>E"C+3N/SF%!LF8#`8#`8#`8#`8'
M_];=OZBY,YQ[3J=PH_J6HXM<U7N+FB>]QF4%KBA-C^VD+$K=)(X^,RUKD<4D
MJ!(Y*227%L6)%Q1*DXL)N@&F!$%(1'\?'QQ'/Y!#G.>W3)44<+CJ21\UO?=M
MIJ8K'&QT&U)8TSOD62SU)8B!K>3=DEHB5CG]%&U`0$_7ZE:"%]E%T13O,U3P
MNBZ"KN,U145>(%3;#8%$$/Z<Q,:=P=%KZZ&$E;&8>J<'E]=%2]<K/,-5+ERH
MY0H,,.-,&(,M8#`8%)%71JR8_P"^5^*Y]9J.PFF2^9]?OM;-*:"-D--K*"&]
M5SQ&F@"QR;W9R-GBE,^(UJ[]84EHSQ@6A3[)^A&C#`NWP&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(`^I?0E/<Q^?G6%FW?-D$%AQU)V#!&
M]P6$+EZIXFMC1=UA<(BS(TM:5<Z.KO()*])R``))$$@K9BD\124@\\H*$O)S
MT`N3I_SFXSXL\O&).MMZJ>?ZXKGJCKVXX._)*`XU<VII/;71H:(\\IV9=T7?
M:M&@_+C[`T_)&]!4I53LY%I?R"0AL)<9<'T]Q>R2Q?&ELIM*];:7I)%T)U%;
MKIN6WO?,M2)2TB9QFDM4!UMOC+$F!I.QQML`C8&)'K1:1*`8SS3@FS@,!@5H
M]?\`H4"I+#;^3.5JZ'U;WQ,V@IVC]$L+OIIAU/Q9<2(9%S=56,64J;:;J9NT
M,LPDH_[GZ2&F$I&E(<,_YR0C([>>PZNH3KOKSK6QM=5]^2ODR^V9WNMU:/TF
MOZ/B;A54N_(I;DJN#SE2*GZJ;BE)I!ZL'W2*3G&J%SLJ,-6&D`#/GB%_PB/.
MG_9.J+_S;38%IN`P&`P&`P&`P&!__]??XP/FR3NEG>J.XK]XY5]#>:49;>D9
MC'JVO+KS?94%66^YN[3Z..?7A5A6%3YSLYV(AZV;`)&V%B8UY6V]"J:TIIB[
M1&]'@#Z3>!`+TSUU:X\@6##>-:\E\^N"S'"-5JO/KR=UI7EAU]5<R>2&RW[*
MKI^MJ:5Y#-65&J[&X!C>CW=()._J4:O>QEIC"QAH]Q5BMPOC6H8)T32G8L!C
MT!X=]+(]YS,3)JV99,5GID+T`ECA13PP[I5\EKNWSR.1>0-4>8E4GTB,.1M3
MRI0_*W*$"Y4%J'.C-?QWJ!!%UE-5U;]'T/IM81-U/I+9<(Z@UY1H^'BP-:98
M][&920*O46JJ:!,*<M6,W<Y/-$`L:H1&MA:'S(U]5-7MA9Q'6DYY^GLW'Y<U
MZ.,NW.M56-4<530[_-G8P$R-]CUEW)=CPMDOZP!68-2G<TZ7:8PHL)&AEC--
M"^[`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8''NCHV,;8XO3V
MXH6AF9T"MT=G9T5D-[8UMB`@Q6N<7%>K&2E1(4*4D1IQQHPEE%@V(6]:UO>!
MK0]@5])/Y&<4?.;Z<7F5%YH5[.3W=[[7<(Y^ORKIZ]*\->&-KC?*$35OK,VN
M=!0=S<%`GV>.`34DC<2-M[&#9252X#"?'CMY"5%X^T--*EKRQ)9;\OM&:DSF
MS++E36AC07E>V-@6..L\<AS8M=$D:CS&VA,&$LU:XK#UBM088JV5M.G3!;M@
M,!@4IV-V=>_><TD_-_E:^,S+`8L\*HIT5Z:O3,EEU.54O2F;(=ZPY18E(P,_
M2/0))>Q"6.`#MPR(EB*VK4JUBDA,6$_.1.+:'XFKYQ@U,LCPI>)<\#EUMV[8
M#VHF]W7S8RO0QO-FW393F`+S-YH]*SSCA#'HE"BT<(A`E1I`EIP!CSO[D6X>
MRJM0U;5?8UF\A-JW4G:[&6UO!*\G!EFPV51U3'%\0?2ITWJ3VM`!.L-&`U`>
MG,%LT7W_`';T4(L,>^9'`%E^=]5+:4DW9EG]3UFR1VO8E3$3L&`U_"T%(QF#
M)9$C5,\850]-^L/I$G(=D03Q.BI2(C345LG[=F';&%FN`P&`P&`P&`P&!__0
MW^,#Y^_#J.;M\RG+7"(M_&CK^&-W>O2")NK_`-#W%?)/1^`H0]-RT8XJOE#.
MU,9<Q>FDLWZ0EP5[/4*&\3>'9^R0%!`'T",!@,!@4D5<.X1^^%]AM)/6J=B+
M\T:^!3PX`ME*MW55AKJN>B1J+*+D:!$C0SS<CVX@-*:Q*6_\$*883?E&8`(7
M;X#`8#`8&*KOMMDH>H+)N:2LDHDC'6<.?)DY1R$H$+M,I`F8T1RS;)%&IS<V
M1O<I&["+"0B3G+$P#U)H`;,#]?K@8LXQZB;NQN9*PZ8;ZZG%1-%F,RUX3PJR
MRFY%*60IM=%[.MTXD(U1PDQ&ES8?\?Y1:15LL/W#(*T(.L#HT+]+?/RQ(#8E
MJPWLCG9\K6I38JGL>=DVE%TT3B:F<-I[K#$[B^KUZ1O$?*2$B@I``H9@E:Q*
MH2%Z$J3GDEABJO/5SG&V.E()SK7D4NJ2(;(E[E6$5OT$/CK12"FXV7FT'6SS
M3BW4@FK3<C5/66BS@.:[2B'%M:!8/]-4K2G((TH0]]D>J?.U6](KN>9/%K=V
MUQ^P$].3?HAO8X2?S[`;O6<ZS;JQ)3DD>5%A)++/F7]C((H>%2ALBSBQ->U:
M,A>X)5!^RP!E_A?M2-=Z4HEON"T]<U205Y6I"(J&YS*7_69:VJF-K>POK4CI
MFY;D2-B%/IV"D4)G90VNJ9>2<2:D!LH6!-#`8#`8#`8#`8#`8#`8#`8#`8#`
M8'2;&LB`5#!939UI3.-5[7<)9U4@ETVF+T@CT8CK,B#H2AQ=WES/3HD24&Q:
MUK8QZV,8M!#K8A!UL*3&V.6[[5.*"564SSVA?)%(K2NL&J!U`\0*[?1HM.8>
M$F:78C*5H9+5G("E00`]AB0])GB=(Q@<G7X$!J-&$+TH^P,438F2+19D:(U&
M(TT-L?CD<C[:C9F&/L3,B);FAD96AN)3-[4T-3>F+(3)B"RR2"2P@`$(=:UH
M.7P&!'BR^M>7Z=@,KM"S.@:?AL`@S,JD$HDKK8$8"B;&M$'0AC^(AP/6+E:@
MP0"DR5,6<K6*#"R""S#C"P""JG]O]+^Q9J@<\06=Q]Y5.9>RD=>#-=:YZP]`
MXJJ+#LQ58JE,:BEW-7+$N3_ZL+$G&CFDP9CC/S36Y$M`0$+IZYK>`U#!8O6-
M6PV-5Y7<(:$D?B,)AS,@CT8CK,B#L*=N9V=L)3HT24&Q;WL(`Z^\>]B%]1"%
MO8=VP&`P&`P&`P&`P&`P&!__T=_C`^>ATF\4#1ELE6/"NKO!OH>2D]:URP.]
M`4GY7<Q2GIXYIF=\,L4D6Z_5(=.;M-;,@A#R)<;LYP;3UND2@XM>%7HDL\/H
M7X#`8#`I,K%7;BOWNO8%G1^N6)D2>9M?I:E.@DRDTL=7VMB^KK`$B?+%32&"
MPM+$IPJ?AK@&M3::]("$8$XPN)Q@S`%A=G@,!@,!@>L8`F@&68`!A9@1EF%F
M!T(L8!:$$0!EBUO1@!!W]-ZW_3>L#`_3D"L.P>8>@:OI!SCD5M><T5:<!J5Z
MD:YT8XG&)[)H"^QV#N[TOCK,_/#6PL;^N3'J#$2!4H*(*W\1(QZ"'85I4OX>
M\W5]51,,L>R+IMNS&<JA2ZVZ`*DC13MLT03S%4:^EZ*(I!XI)BK]#$BX)$GY
MUV=M2F7ZD*EV5">0+RC?@"'867R`C,5N&Q[JB7671K)+'^5]`6=4HAME&.FJ
M#NCJANAC)?-QQ`]PJ$TV73:2QV';:FH,BTZ-L<:W1:2@2EB-`:6',K?).%;Z
M!M7H!AZ-NZ/.<VL"ZKPKZ#[9*4D\'IOHB_Z4BW/UC7*S-\TJN0J[`7J:KC9K
M.B9I2<\,;>@=W`HA,#9I0R`DSPQP]7G"%9SV`022R"9N5L7-,K]LR6OS%7\0
M_7[(F[7%X^Y*&6#51#X%74(CB".PQK1(VQI:DQ!127[Q[,.-.-&$UL!@,!@,
M!@,!@,!@,!@,!@,!@,#!71_2=*<EU!*[TZ`GK/7E;Q!+\JYV=!C,7.KD<`S]
M*BT59$X#G>6S.1*`?CMC0WDJ%[@J$$H@H8]_3`JSKGF^Z_3>=Q7IKT&@3S57
M*41>T4PY1\WI3\/Y+T)*:C=HAT#WFU)%ZUIE=KF""%4T5N;^0Q0H/V@7:6NO
MY0]!>#@,!@1*[$[2I3B2M4<^MI7('I\E3R1#ZCINN64R9W;?%CK_`+0L]:TU
M7:,XETF4N<S1A^H0;*2(2=[4+#TZ8`S@AIZ^(OD/5;I["^D%G]:\W5_!9SS&
MOY^N:I.42)`DM.M.?95V@58%U1E(8^)$S1&IA+*'B\2)9T(0HE;(D7KSE*/8
MSD#<L"&]_@,!@,!@,!@,!@,!@,!@,#__TMUSK6$]2SZHCX_Q]=\#Y^N0<B9%
MA%AV-5Q=O1PJ-I1J!/K-N'F/+&`2YS",K1*G9PO@T6+_``[V+ZZ#21K'HJ1U
MWVTQ-B/J3C5J`CZ);ZJD7:,,\)XG#Z%>K=.L(A@D4*1=8LSJE6()&[3@@;<)
M_P#M_2].(PJ_SQ)P[4A#Z!6`P&`P*1JLDMF2#WOOU+8%8(:[;(UYI0)AK1V1
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MK7[6WQMN-W*3USN$P"-6G^<K00PZ^D/JQ8\-AK'TA`.SAK9"GZZ#**.X\K:2
M1.KDO1T#HF*MW$<5@UW\G3VP;D-YYL2Q;R5/[I,[)EK/']O]>$!<V>/:1JD"
M@)!=Q3;J!TYSX\I1777>MI1JL4-W5GUS)*5K3J:,V?T)T?0?)X&2DD228U&D
M:+++Y_O7I:3_`*ON?_(EASDMCI6UCF6@,&,\([\T1ST#9.FZ<5=2&>@*:RN6
MGU*W7Y:3"S]/S^BGOC6CO-&)P56"!L<::Y73O6EZ=7]NV(LE2@AB1S&PDCE'
M1"$D3@0DDF!</XM$V+OBD3K;@.IDMD2?H;IR4OS1V`S7LRV]'H^^W7+5M3,!
MG^8%B8)@ZL+;28XT`M4D+&U#6?E%E#^8M266%L^`P&`P&`P&`P&`P&`P&`P,
M,="7&=0%.3BX$]1W/>QT)0(5P*GY[AZ">W',OS7EM:!(X-$'-_BZ)]7H0..U
MAY0UQ&P(DQQ@=B$$(!A6SPI[,5[W[;C_`%/6_$7HM5J>%RZR*XL"U[WH*#0^
MGJZM.J"2QS.J9W,(M<DY4QJR6]2<!+MI/1:4`5&`+-T5]VMX$V>P^T:5XDK(
MFP[;6OKN\R1W2Q"I:>KQIW,+LOBR'4Y.D8JSIBNDJA.ZS:8NZQ64'XRMEI41
M0MJ%AZ=,`PX`0PYOXTNR_P"X(GW9Z9(V%5<L46">N7.,X^]`EE$\.I!C4@;9
M"8M`8)EN7JU8V&A$\3DTC\9J4[$F8"TR8DDW87!X#`X5]D4?B[>)UDSZS1QK
M":62)R?G1$TH`GG[W\)(UC@>G3:--%K>@A^_ZB^G],"N_K;TB@%(K8;37/+$
MEZ^[/N8I<&D.9:KEC(<L<$2(W2=TLNWIJ08Y,5,4E%3!"$OD+QLH"@9)B=`6
MJ4`,`4'1>>>`;3KQRL?L:^[`KGH[U)G5>2EDAUIR]EE)'.'.07-I6J(I0?/4
M"*<-2:#\_L,D5:+>70@9,SEY!BE4XJOG4:3DA"?D;C#VYIOOR^.O;7G?E<Y1
MOLU]Y=;^IH_7K'UL:]LU>\SQJ0P=I+H!')'!$@8IF^165+!*#9$O>D(W`))@
M"B"0#(-#8\P&`P&`P&`P&`P&`P&`P&!__]/>&Z1OF.\QTG/+WEL/M">1BND3
M8YOT9IN"N=DV*H:US^TLBQR9(4S"`Z/*6.D.>W%Q^'ZB3-:50H^T>BOMV&H_
MS50%*=ZE*>0>8O=2`S#S7?+N<[B=?.YYY_KR%];-R8?0YW1\DI@,MLHV+7R"
M(IK4-,4:?S68\XDL7X>R3R0Z,&&ZE@,!@,"DRLI=,I1[WWLBE=3R:M$,1\S8
M!&8:\O\`(H$_);6BQ'5]@KR+'C:6%RB1.,=8%KBN/0@1/Q+8\@.0F&#2!(,)
M-,"[/`8#`8#`8'7V2*Q>,G/ZB-QMACRB5OQ\KE)S(T-S4=)92K0MK6JDD@,0
M)R!O#^H;6A(F,6*-F*!DIB@;'L)8-:#L&`P&`P&`P&`P&`P&`P&`P&`P&`P/
M`9@"@#,-&`LLL(S###!:"6``-;$(8QB^F@!"'7UWO?\`36L#43\U_2JEJ$A/
MI9':B_#ZVZ:Z`]O?0M=RWS'14NC$AFUS)9A)HDOBMC+'=(X+6:O^<RD>M.#Q
M8;EO4>;F@!B@H:L[X4IX72\;\'S:,V4H[9[IF;'?7?,Q95#:D<V5.XE4CR1"
MWU$06YT7R1$7M6XFQ2-`)+_'>9.=O<DEIFC#EQX0'&$;"TK`8'3+"L2`U+"Y
M%9%IS>)5O7L0;S'>53B=2)IB<1C;66862)>^R)]5H&EK2?,<`'R'F@#\@PAU
MO8A:UL-:#TSNR>^P7#/2=+<C\W"=>.]UV[6)+N]^G&^6U;7CT34.T%G-ZGCB
MJ3&YMMR[)$>MC^RT4J6%QV$A,3*"-JW,@[99@9^_C/\`$-*<J^6_/%HPB,LY
MUO=55^RW3<=FC:DQ,JDHY0>X.\/AQKD/:A:7%:^CJXE$C1A."E$K_*7:*`>M
M.^H;"F`P&`P&`P&`P&`P&`P&`P&`P/_4W>.HGGI&/4+8;MR)#JWL#HY.@:2Z
MOBEPOCI'*T<799(VA$ZJ9>[,IZ5V):V>.*5J[XDQA9RDQ,`D`M;,UO0:_KMX
M0])=UW1`^C_7#J^H)'+Z]EK!-8E47#7.5<5>TQYVB3B@<F%N5]263"WWHN<0
MG[DNB#V=<%-O1110RE8#=:$`-H+`C+V/);5A_,]LR:E'F11ZS&9A0*XV\0^A
MW+IR7H@AD#06^"B-%-<Q@*FPI2;'#%9;<G&Z%)TRT1:I02K((-1GAJO1#VG]
M";=YQ:7B$V/SQ"+FYB\^^R>^^FEDMI1X<A6TY\L]+/M/1KF&4U\.=QU3SO/Y
M%`V+:^6@2*7):B?%Z`M!^,C4?7`FK1OJGUQ;W4-<62,ZO&;DNSO2>7>8Y/+:
MFM'35TQ9QCG*#C?B;HI1;NY&2I6KPSAH4(G-F-CY+6DC@TX]"_*-&K*#._,5
MY2:^O:^S)/)^;>@N8EC/Y<5Y'R(=T8WU*W2M_2%]:6*X!E3&33]NW&PCCB@U
M<-*`2IP2K?R4IOW)@E_&88%]^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&!7CZSR>NHKYF]U'VK,7B"P^1\P7#70WZ-I!N4I'(;0A;M7,+8HDS`6MVW^6
M2J92E"V-C=M0F`O6JRDYAI99@C`A0#_&R\!NH/,.W[`ZUZCL*LRI%;/.;?6$
M<I6NU\CD3I%29M**[LN0CL][?8O%VEMFD.7P5,TZ1,QCTW&F*59@%XP`)V:&
MX9@>!A@"@#,,&`LLL(C###!:"6``-;$(8QBWK0`!#KZ[WO\`IK6!41/O4<ZV
MYI(J)\P*DWW3<4><QQV<7`DD/[1X8H!X_P"8%JO[M]*%)71MFLF8@.Y*LV'0
M)-))&H(*/+,TA&7L00_M=>6P[1FD;OKTZMT?=UU1UP)D4'JUTC88AQ+S\][!
MLTO5.<UC6NS1*9&Q&*34Q,QFI[](E9)1)P-(#`Z+"&=_2&.=IS'FB2UEP[`N
M?IK,K-:Y56<Z37Y.)=`V6.UO,X))HXN>X>=#XX^Z<).WN:]+LLA6(A,$C[]_
M0P7T"$(\^-5.>A7,_-,,Y=[4@'-$7AG/E5UE6-*RBCK'FTVE<T)CB-W;Y&XV
M&AD478F5HV!,G;A)MH3-[&::?H1?VZ"+`N(P&`P&`P&`P&`P&`P&`P&`P&!_
M_]7?XP-/;F_U:]#J0Z<D/GM/A\)=&6D;T_837%%UD^C$&07^VP"9V6O61BKY
M(S-D6.8)':T#950T29E1EM+D,HE,CVU%G@V,\-PG`Q%>%%UET97ZVK[<9'1^
MAJ]T8WHU*QS&;5\])G>-.J5[8W)IF%=2.)S%D7-[FD+,":B7D"%H.P"WL`A!
MV$*GCQS\TGV#U57+IR?"SX=3::6H88TD2.Q$!BMKGTQ;+!G#'8;H@F:9XN*.
MR^;,Z=S<FZ7J7U"M6%_>:4/8A_<&9F;SXXWC_3JOL9FHJ-M_1*QQ=7P4[(=Y
M;^`FE#["VVNGZ;-E?CD(ZT9I^^P1J):%T@2,Y#TK0:&4<J&`TW0P@G5EFD6'
M[WWXUDP>S8<*L_-*!5^>X6%"G&(M4X.0]6SYX%+:T6N`M@FD!4A>=)B79-K2
M<U8G4%:_Q%;P+N,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"E6P/R/0O
MTKC-/)!_G\A^7$FB=Q7,J*`(UGM?T#>F33W1E4A7!3ED.+5R]7[\&:/8$RPT
M!4H>65*L3_(C%]@758%;W37IM2E%V*+G&JHW-^P>SUJ4@]KY+YN1H)9/8^0N
M$@)0R2[Y8J6(Z[YRKTHYY1#5/4Q<FS04BD)Z8A9K_!L(\$<(=6]UFE27U-MI
M%'*:7;*6MGG!RC+I3':4$A,$6N1MG5%ZI-QRR>F7A)]Q1;@QH],4$_-1Z&6D
M7E"^086[P"OH'5,,CE=5A"HK74`B#:2S1.$0>/M,5B<9:4^Q;(;6*/,B1"TM
M*$H1@A:*(*`#ZBWOZ?7?]0[C@,!@,!@,!@,!@,!@,!@,!@,"HWHN>]H4=U?)
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M3[INZD8E`10T7R+P-B5MT6@5*R"-&*`A]%_`8#`8%)M96K#[(][[V9HMN5?G
MU7YF5_7<Q!)J\L*")RY,DZNL!\,_;*Z<Q:.()]&S6Q[3C)?&$US9%`Q#+*5C
M-*-``+LL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@08]$NMG'CKFEZG4(C
M89]?=C2B,4/RO5GT'LVT^E;84GL=7Q+80;!]&=`J+4/;T9LPK1#`T+C=#ULO
M6!$92W<_>27G$EJ"XNG76`7#:;1/"G>\HHQ"F_1=_P#;%Y[5.4]M:I*K;V=X
ME=N6:ZVQ+`KFEHTW.):)N*0I5NPH$PAA"AGQ0@/M5Z7M'1$B[9]+>CJ8HFI[
MFE_+5BU1`(Y6M?\`1$CLNM%$9>;%C":QFR%))#1!,<6K$;<O<6K[WU3L:U$0
M<C#\IXPV^N9.2.<>-Z]#5_-%1Q*J(F<M$[/FF%(<HDDTD)H=@52VQ9J[J'&8
MV/,EP/IH]W?%S@XG!UH(SMA"'00D9@,!@,!@,!@,!@,!@,!@,!@,!@,#'UEU
M15MTQ-5`KCK.`6S!ERE"M70NRX;'9Y$U:QL4!5-JM5')0W.S,H5(%80F$F#)
MV(HP.A!WK>M;P*!_XU5$4?&.'E=N1JFJJCUKK>B^R((ML]CKR(--A*X.V])2
MTENABF:-[0FDA\40$,*`!+<)3M&4%$0$)>M$EZ"&QS@?_]??XP/GV</3&P&2
M;SAAAO1O\>GGF#-_?'1R='SYV2XPJ1]MU^WJ.FY6K41(B<*F-A6V@J,+4B'#
M7O\`/=?R4!Z%.!>$*<*5&'T$\!@,!@4D5;;]?6A[X7ZQPAY5NSG4'FC7]9V`
M0ICLG8RV:9H^JI[(E+6C5R%F:DDD3%M,A2&?G-9BUOV,P103MFE&@`%V^`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!K[?R(Z?FR;A.\.R*LZX[8YNL[F&I'
M!QB4>YIZ5G%,5I-USO,HNF`LM*(10PC<K6M)"PX"102I1*"RS=@&,P`0!`%*
MW"B?K?H_L1S=>'7?H?LBJ.56U;#Z&[S])+WF=[<[UMT#;<.B\>ZVN:"/FTK3
M);Q>((SQ8F&U_"(T>-E3_J3P_.3RC)=DX3@V,8KR+5/GE%K$[QMUDZ8]'^U&
MN.($LRN]LK?^\O3LA;'MU0,"NON7Z-BXD47IVMTJI_4*11R*E(@%-FU)C@K6
MA)V;H($^%?1L^:+1[4I:R^$/1BBE75GHQVWVA7=E7MR#8-7TXRUA;+FR2>'1
MV?6!(A$H8U8ZY"RG%;;PEJ48U>P$DK#1F!UL-G?`8#`8#`8#`8#`8#`JN5\K
M>A)W2G6-E-O>FV.FK5I+4(YRK3<!;)#JA[+,?Y4Y-TZ-:75$6Q/6X<%S*/`<
M(9JB1%K/TQR!I&S-IAH8-(X;]4P4?PW!0>EAB&R:1DCXZ],3?47.>S;?C3C"
MVIHC,,+=W5J`\S[]@K4RQ"%W?RTBN0:7:?7`O]62DE8%X>!&'LVD)YTES#<=
M'5E:CE2<YL6,DLK!9[3IXVOC)Q+RUN:O1.F1Z9%6@O3<A.;S-F[6M^BE8OSF
MYU1_.V*PA7OSXZ2_N7Q#-#.W)RK9.8DB9/:L=/)GI95^*")6_2)8Z2?8+.,T
MA<7AL=$[:,ID''6;021E*VURC7X40;@S7Q?R'='-=E=232TNFY+?;)>=@L,L
M@D<D)<J`"LFQIBC2QJ&MOV[S1]0G)C=HBT90U9#E(!H6U,8O?7$PSXDP6#X&
M/;2MBKJ/@S]9]RV)"*IKF+)M+)'.[#E#-#HFR)AC"668YO[^L0-B3\@X6BRP
MC-T(TT00`UL8M:P-:GU/Z*O#U\X(Z'Y5\O>+[KZ4A5JHH:V'=73IVA/,-#.:
M6*V7#9P,=%*+]>89++^4J5</4-YZI&A:HXE#]R@MV5"T4F4!"C^+5Y#^AWG+
MTGTU/^S.?/[.1*PJ/88?#W;^Z]'V'^KR-%/FQ[4MWX%5V5.7)!HMM3C-^942
M01O[?MT/8]ZU@;M^!__0W^,#Y_/25H5K1EK%6)"NW?$/H>1$=9UU'G?GRD_,
M_GB4].'LTTOAEB<AU7ZE`J<W2:V5!$KR)<;LY>V'+=(5!I:\*OX2SP^@-@,!
M@,"DJK[AJVU/>V]V>N9]%YLZU#YGP2L;/01MT3NBF"6$V=96$]KX9)2TXA[;
M)"C:7M(>:F,^A@"U`-[U_BU@7:X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`@
M;VKZ,\U\+MS.W6>^N\ON.:MKDY5;S?5C:"8WI9R5I)6*75W8H@6K1IV"$,*-
MN5*'64/JEJC32G2'#5+R]E_8(-(WTM>?;/WMJXYTYIJ5P=N2X/*S1O%,TE)H
MFBJ!V?$2A,WM1(.B9_+8#OMF?1%[TYDOBB%LNZUCIJ%,-K7.ZDXQ86&VUX+\
MH]-<3^7_`#WSKUH)"BMN'&S]Q,AR%U:I#NMHS+9Y()5'X$ODS$O<V20N;00\
M#./-1J#DB8:G\0DPTM,$TP+BL!@,!@,!@,!@,!@,!@,"LOU?Y:CO2G)=CNSW
M:W0]5N5$U[;-P1!;S_=<OIL]TE<;K21J6@F:#BBDC<J8TBA/H8$I_P#]F(8]
M@$'[Q_<$9?X_5`)*[\^:*Z#7W'T;;-@];T=2MEV5N];PFMMQ]BE"-C>U)YM:
MLTL6+"((D>390;I>!,+8UNDB0)HQZ3%?:%YV`P-.>6^+_F5+?Y`YU$R#EIC<
M*IF7EY.^NY+$!6%<"<ERZ,6]L1J'*K,&ZI+$(?$ZX<<>E27\`E46TAT;L84N
MC-!&$-IGHSJGG#D6!'V=TU==<4C!R]J24KS8,G;F(;XO2I1K1LL3:CSMO4QD
MAJ<O>R6MJ3+'%1OZ:*)&+>M;"N0/8W??:`!H.!.7!\[5`Y%Z*)[3]!XU)83I
MS:U*S1&Y)0_&S2J;+BL$"MA5%NC(XS5;!FA3O[0FDG@V(`@[_67DA1O[[8+T
M[*G5B^BG2#">G<F6R.K#6%ZKJO'C24DI691O,T8:F.@*@;]KRORTHTK(L>DJ
MC[3-N9AH=&8%K>`P&!__T=H?W7MZUZ%\J>J[9I"8R>!6G$"*9/B,JAS\HC$B
M0*G;H:I&%<D0/R46CFX#TT.JE">/Z;`),I,"/0@BWK80?K1Q[EC5ML,^;/XO
M?(-5RUPEB-8^W/%NW>*RIU'_`-6>TZQ^F6G6.\Y-\J=G-&:(:\P)2L*I6>5K
MZ#^06A8&RC@8ENZR)'4];ODVB%.V5?TH0*F)M8JGJ4<&33:4.4A?FU@3:2N5
MF32O8&R,S4-RTM='!S>$:9`V)E!_U,$6$H84MHOY"W.$AI.NKH@_.'5$[*=:
M=O#HV\(2P,%5I)1S10?-ULBI&X[.GATCM-C89F@:I^`T+6AB:M[<7-N1JU(B
M4PDIQ`0DY#/7BC9]U$S\_P`9K"YEU;R:]GSE&*]8Z000%$R+J:-TR"_GFF4*
M'<ZU;9!Y-=;$$AZ4QLAG5/)"A"4<+X!GX&(*4O2DK\]O+!E-$W)5=TQAI\JZ
MZC[I(JEL&)6.Q-CZ3UQ9;B<QN#M#G=Y;D3N4WN*<_:8PP)^B3BQ[#]HP[$%X
M.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P.KS6;PNM8G(9]8TOC$!@L2:U3Y*II-
M7]JBT3C+*A+V:M=Y!(GQ4A9V9K2%Z^XU0I.+*+U_40M:P-8GL_W/GUC'QNJ/
M/=BE;"W6T:K9ZPZ!<*A<K&OGHPPC;@F7G^>_(#SME<;/CC:H1&?DVO81D=JM
MJTB6Z"8ZG$E$FARO$WA`ZS%R?KL](#%CNJLMW02J7\L&68ON"0VBZ(#6IP9'
M3T!ZD^-G>>J7YC7LZ`TB!Q]-'J88E;<$:%E7`/,%L-G5E96>-L[3'8ZTMK!'
MF!M0,K$Q,J!(UL[*SM:0I`V-+2V("B43<UMR(DLD@@DLLHDH&@AUH.M:P.4P
M&`P&`P&`P&`P.ES>Q8)6S6WO,_ES!#FQV?V>+-*R0.:9N*=))(%6D;,Q-NE!
M@!KW5Q.WOXB"M#'L`!F?3XRQBT'7=7I3`I"GBFK5K[<A5L&Y2E:PRUCV>ICH
M60,G$[D"_,^(Y%J+BTZ;$$6_HV;_`"__`,/_`*W`[!"+&@=E-[FZU_,(],$#
M+(7V)O*A@<TKD%IDT8=%3+(8^Z!3FC,;G=H=$)I)Y!P2S0"!]=Z^W>M[#NV`
MP-33^4)ZT-_+G(J^A^3>JH`P]6RZSVN!7!6T700&TI:S4-+*\LEMGK+.FE^C
M4V:*S.?%JIJ"F,6::GTT.]C0#V`)XM!"?^,]Z->FTWX<D=:1#DIP[<@M!3M@
MIRJI(*[^;N:V"H(4S0&,'M=<NQ;E&TTYF):(M6->)Y-1/BX85&B=F#$#[0AL
M<AZM]:S1!**\C:U(--WH!9[CZ45R2WDC'O[0&+CF_GEU7E(RA;T(T1"52<$&
MM[`48+Z`$'+GW_[`&D'E(_-3D1&K,+,`E5K?3B5K4:50,.PD*5:--P"D4JTI
M!@M",*+-*,,`'80B#O>MZ#YZ]VVY[#NGN=,7Q99O3-0V@MZO4\Q[L"G'*W+"
MK2M*8?NDFYR6UO6S_-8A%T<TYW87\!;FB:G9I1-#H4F+,5(0:&,&@^C!SEY<
M\OT!/DU[21/.NH>J@$B`LZQZQERNZKM(&(TXWXH.M?228=3;.F`H$G3M\+9X
M^C)1Z"3L`@ZWO86-X#`8#`8'_]+???X\P2MI5L$H8F>2L*_X/SV1_:T3PT+?
MQ51*U+^6W.)"E&I_&6)BSB_O`+[#0!'KZ;#K>!S.`P(F]Q4-<G3O+]J4-1'2
M#AR98%FLZ>,@O5E@8K$D,1C:U>FU+DT<9"YQ7BEO?)'&]*6TEU3NJ9:U?E;5
M)1!4E$C`%/#UX36FMKJ,0:+=C5'5AP^'+/\`-FTC:PXI6,T:E?'5C3=BF@6.
M"1=_ZKE"RO[I;C`/Z99,7-SE1;T*0&+%37M>3M2>&=:I\8TE2=$QF6L%_MQO
M)$![1E/?\"Y8_L>@3RAGZ0DW/VJ'3J7&]]V.I0N5;Q,*]R?6AG30QO6I7!:`
ML;B:2E)#@>=-Q.D(1[J6[%Z4C=51%.T^7=<%SJ.U:SQ%@*;9DIZNL%8($M:(
MFF1@1R8]@4H3=Z6%A5B1C(%OZEB+WL+P<!@,!@,!@,!@,!@,!@,!@,!@,!@,
M"LGLCU%IGEV2+Z4@,?=>G^N@1A3+BN;:O?&!H/@\03D%'*+,Z/MR4*$E7<O4
MXVZ4IS%<AERY)O:<\)J-(NT$80AK[QJ"]P^TDZ1RMQET"M:K8_(!J$%Q/\&?
MS_+#G]R;E0&M21RQSC.B662>IO0L57)UVB[#L4M-4[.L*.`WMZP!J46!LO<=
M^?U`\6I9(]P1');"N^Q]$FW+T[<;W^_>@K?5IP)"TI,MGBQ.0-NBK44@3E-L
M<9R&R.-1*<&DJ$L6A#&$X,!@,#HME6?6U,PE^LRW["@U4UO%2$ZJ46#94M88
M-"(VF6N"-J1J7Z62AP:V)G3JG-P)3%"4GEA,4'%EAW]XPZV%/GEG>3"?/[T@
M$^]AN3_0R>6A,M3&EZUJ.[:=F$QKZ#L*!U428I%&X=)%KZH2&)UB7\DE,E$W
M(2VW2@.P#5'ZT%WN`P&`P(`*_3?D%NNOHR@G*:S!'/N4ZP';MU%!J:T7-OC<
M.1*70MZ/($R1%S<W%<TH4*=<466E^Q[0.))[,-S+*7;1ABTOV4X3%5?+-Q'S
M6?)H?U_+'6#5*/\`M)8#@J,F$<;4BR2QQS,9V5S:%[PTNCB0UI2&14\&2%<(
MS;%IU2I5BE,&>/0#F;EWJ#G"01_L!M?G&DJG<DO03\./.4P3*&T51MKP_*W%
M4Q0PM>OFZ`J.C<`#9S&]TV:(P!Z-.%S3H%*<*1:6[/\`XZ]^=U5K,:>NVSY9
MUK+X(P<F0=K'7OH*SA6,,OBB>IXVQNSY+JR:D["%3$MB3:5N;ND:@JQF/BG_
M`*7!IU+"]_COB7GWA&N'^J><HV]1B&26P9=93FWO,KD$HWJ02]Q&L/*0:>EJ
ME,T-;4W@3H$Y24LH9Y*4*E:8K<3UBU2&$^D?43G"A[`-H"#IIWUAUL:5L2'D
M_E2/EVK;C;L1J<@+C9ZE*M102BXPE-6$F*G*9N[(26D'LXL)^@[#L(^!YI]'
M^Z?HO[3NW_(KS\Y;"=_DXXCG"A==4E:C=$&_HO0/;6V]N=$?W_8<E<&BLVYF
M2*4I_P!GZT?O7W;"P2B^+.3.::Q34U1O/555[6Y*TEV5QQLB3:OW('Y.28F!
M*)B\O93F_P`WEXR#1!,=WA6N<SM"W]YXOKO`S]'HG%HBF/112-,$81JE'Y2E
M)'F=O9DIZKXRR=*3T[:G2E&G?"4$.Q"#L7VAUKZ_36!V'`8#`8#`8$=.INEX
M=R13CY=D[A]O3V/L3BQM1D8HZKI3;]A."M_<B6Q)MMAT22J7`Q(F,.^12I-V
M4F(+#O[A_<(`1!##@;V%YA]'9F]PWGZ`]1M0&2.R.1&36U>?)A`JT6[B<F:8
MG(HZW6$?^I1<V7M3R\``8V&*"E6OA.UH.Q$F!"%K6!__T]_C`8#`8#`8%,T'
M@$$A/O-;KA#(5$H@X3WRZKZ9SE=%XVS,*R:3!9UQ8[8KEDL4M2)(?(Y*J;6M
M*G,7K-G*AD)RRQ&?:6#6@N9P&`P&`P&`P&`P&`P&`P&`P&`P*L_8WJSI3B+A
M:Q.H.7G#E1/,ZD7)I)*FWKARE+=#957Z5FD'ZG$JZU%9O7RAVNI]D.FLIA;E
M#F64Y_10E*+-6&I2]AJY\Y^W?I[Z*4NW!M">4?SM'[CE#I"JDJOS;K>7SGTR
MZ-61H*Y-.8W4T<L6YK4A7-M=MQ(MC>+5EQ#.1'`)]'(=GB$(TD+C.//$(M^C
MC8M[<C40@]-'RA%9K?YR5++I!.*U?K"&N.?_`.Y7?W1$A/\`[C]^WP6[*"1J
M?UD\,&;E*01*%$M1&`^@;';0TM4?:FMA86QN9&-E;D;2RLK0B3-K2T-+8F*1
M-S6UMR(HE(WMR!(2`HDDH`2BBP!`'6@ZUK`Y'`8#`8%6OM'T#!^:_,WK2R)@
MNI83HGJJ0HZUBM\LT*EL$L"U`I1.4%APZ_G@%+%83JM>6T!Z=IVG4C-$GV;H
MO[2A""&BE_&<](W:$]K7T"=\B%V^RRB'WGT,6=QOQ!#K!OJL)_85DU"U.IL;
M'7S,EL6&\WL[`[.#41&V+Y6QN5.R4HE%\9@A`#>.-]P?-U@6)FFUK@L3G=_,
M,_'6,O37,'4?/!K.J"L/;SD[L[VW3<5BZ3:96E.`<9I>,@GX#OO,U\)OV!*:
MM_0S@>XA)"ZI[9Y,L54M`0(ANAG1%22)VT)06`PI.>T-DM4.B19]#-:$0:2`
MXL7^$0="UO6!+\LP!H`&%C"868$!@#"Q:$6,`M!&$8!A_H8`0=_76]?TWK`]
MF!6'Z$J;"YMJB?=)\L<0T'TK9XF)V*N\%CS=@J4:>CHDRS6QI$XC=E4+E)LS
MWM_V8(;.'\82M4O$I'LT1?TP(U>3DSG7<G.]66ST-YS<S\[4:GK^#3WD!9";
M'8[:5.<8G496,3\B<8FI@3"OA`B(LU-A2K2I4H_5`&%@.*$-($S`O(5*DR%,
MI6KE*=&B1D&JE:Q4<!,F2I4Q8CE"E2H.$`HA.06`0AB$+00@UO>]_3`^>YYX
M_P`CZ&2[UA[3LZ#<1=`V7(/2,OD2'5A4M<2J!O<_C\@Y@IRR8DI3K-/IT5CC
MJCESA("U(U0UJ!.S-Q!ZA0(82MAV&T3KFGT?[I^U?VG=O^17G]RV$[_)QQ'.
M5"ZZI*UF?`;IEZ![:_3VYT1_=]AR5P:*S;F9(I2G[!^M'[U]VPL?YMY1YPX_
MKXBKN9J9@M,PDLT"M:V0YF*2KY$Z!+^(3_,I(J&LD\YE!Y?UT<Z/"U<XG_\`
MWAPL"0F`P&`P&`P&`P&`P*'/XXO_``VM_P"UMVM]?^\M8F!?'@?_U-_C`8#`
M8#`8%)57T]5M5^]M[O-<0&,0EUMWS/@=G6>OC;4F;%$[L)SZQL)E7S.2F)P@
MVYR%8TLB0@U29]3!EIP:WO?VZP+M<!@,!@,!@,!@,!@,!@,!@,#IL@L.`1)8
M4VRN<P^,N!R4"XE#(9,R,RTY$8<<06K*2N2U,>-(,],86$S6MAV,L6OK]0[P
M*[.@_3&,,=AF<Q\5P(WN/L=6B0JU=:5I)4".I:.:'@@U2VSSJN]@`=(=3,3$
ME)V<F;OJOE3W]2BFYK._(`;H-4'V0H9PZS$1SS?'<5#6=VV"<QDWH3HFZ;/5
M\U>5OF-'!1^52]LYPJ,2V1&-9_3EV/+,F1I_UM/,K&>HDS."Y6B94(1C3A.;
M^+%PDCX=EG6C<1VUYF=@J[,BU8+UP.*K[)OBQZ[%$WN7I4X)(YA8HR8QP&3%
M2'0A`&DWM0YI"M:%]"?J,-QW`8#`8&N?[S^W5L>-B[FU7%N:H'><.O\`264G
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M8]A^XL.]!E_`BU97#O%=T*1K+BX_Y<MA6</8S55E<_U/.E!@]F!/$(P^4Q%T
M-,WL\H(_K]?KL0=;_P!.OK@0],\.?,1$I.<8!SHZ4:[&%G!3NW-]Z=$<XJ6\
MXPD\HM2C2TG:\%:]&IQ*C#`%FIC"-F&F;&6+Y3=##^E>64GB:XYWI[U`]3JW
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MPH"]-;-44=<EB<#>^'"`$I:1O1H0[%O8=;#L-CK`8#`KZ]&+A[>H>DU%J<65
M7SU:BN"-LVFEP-U^SR:PHEKK^'Q)?(C%<)*AS(Y"?'X\UN-`(E2H2@#K0-!^
M_9@A%!B;R/ZM[<[6Y[:^D^L*?YXJ:`6]"*RL3G4JD9S-Y7('N-2Q!(E\F_N:
MTRYK3)HPO;"@L_X):-6LT<)0JT9]FBBA&A:]@,#7S?\`W:FK'U(Y\BD^2_HF
M]7"BBSS9B*--+!2YKJ^TPRV(761EOM211:9"4R%*92H)3E*!J@%_(>#6QZUO
M[]!L&8#`Z;.[$K^KH\HEUFSJ&UU$T1@2EDGG4F9(C'DIQA9IH"U+U(%S>VD#
M&62,6@B-UO>@[W_HUO`HF]$OY!G%7.'/]K.G+70E-=']$,FHDQ19IK[]WW75
ML,7S2:L,-4SNT)?2[9)(ZFCM?M[PH=CFG3LD<7L]$!L2[+4*RS`!A/PO?K5Y
MAL=+Y[2J0OMAUY9'/MQ]]PQVM3GU=RQTO3\A>>K%-<SF"WC2H[-M9$V1BWW>
M4ZE<`6&+&]P,:DS@4>G&$LO2<-G?`__5W^,!@,!@,!@4C553U>U9[WWZ]P=F
M6M3E;WFE`K.L!0LDLJD('F:N'5L_8%3HC325Z=TL;2#:V!*6%`U@1-P!%[,`
M0$PPP8PNYP&`P&`P&`P&`P-87^1Q[4=.>09/*`N;(KS9,UU['6_J5,MYQNU9
M,])DM?`KO]+=8J17\_K9J0-@#9<:4N&N7*5!QHT^DY&@`4&8$&_-7^5],;WJ
M:R'/KSGVM=VLR3Q&VPLRE;?YBYGJG]GJ69M5'&3ER[@[=BTF0.Z5;^:,+@W$
M+&<PO1)(QDG:,%@3%EO\F>(,:X*5LH;F4L*DH:M*IE7KGY]J2241&SP&?JYE
M%SSH(I`Y'&D;^!(0-8,P`RQCV5]^]:#JA'\D"=S+X$T/JSAB(*]DFN)^Y'U;
MV;<ZLI$`9));<X1_GGR_F"QD<Q#5`&)0-2I;=?&,H)XQB+V(/`'LOZ(2Y.1J
MN&7ER2NBLHTQL:*U\Y?<J]%+Z6(`S/U!I6"YDH]F5LK640(P:E.J4Z7%"T,L
M)(0_40>YT]!_6N8C7DI2>A8@(O2=K:3:>_CT=:?"]'*0%G&KR5G4_<L0_0'!
M.<ITFT<Y(P-(=E;,'O9>A#&&DS_(&O#H&X>UV%OZ.GMZS">P&FXFTJV7H'F2
MM.4I?`!OCH^OY,;:*VK6T;A1'Q9S8U3>\DN*QYTJ4+7-4'24DH`!G!L<>5O5
M?4]F^4=)<7>0'%72:4R+JED?[[[:;0<B59)FV4S?1DKF"7E1_G5SUG$+.N12
MUO)#*ED;^8%\@<=2MABI"M<#$:@@,`>^G440YA\[*Z\PXUP'*./)%*[;BMT.
MX+>M[C?H&Q)V@9DL@,F=FV`Z4]=EQVTU6E:DE/2`53)S"VJW]O*=&PI:-&)2
MCP(L?Q2[M[UA5K]007B/G3FR^!O,0KZ0V..[K+34Z]0IJ;UTA:D"V+2YKCLK
MFCHTR-S4)@NR$AN7("SD*,P84YINC3`V];KZ,_DMLP/K3?G3Y\/HOQ41OT'U
M'(YGOYS%"HE4G^DF<N=0_*27HH[?^+XPE?703#C!;`6$8G;I'^0N>G$LOJI;
MLH$XPHG9C5Q9P-QQTNV)DY_P-NUJ62SGUGLR0_G%J]&&@3BC*D18A@4'%Z2!
M&3L/SH+JM.2(QBZS[,_D85D@2!3!<'"%^6<+I:(,X5*[>UNG.2<W<6WR[&)$
MAY"=-HPI]-.$(0A)CSR%&_H'Y4MH^)!JH#=T!ZH^ETM++6ID[BP]5]4^E/.+
M(:Y?*J;#37=B1,/-K.U&MCN<(U6()*4IK.T`!OXZ;Z$B#5]_D<U_YM"D7,:_
MS1LNF9Y!AUG;4FL=R@G3C3>S\&0Q]^AK<D03EQLN\I9:D15_HZLK]%;E";07
MD9A_Z:2>:4L^P+]OXM_<7(7(_FS9=5=3=E<R4Q)HEU9;SC'8?:EZ41"Y:IB`
MX+5ARUTC;$FLQW=IG'5\N3.VF]P3%'!<A!%I((\KXOH%F?H9_(/XEJ;CV_IS
MQOV1SO9/2D5AR9QJ9D+99=;D->I*-^9B%#(X[A:EA:OSE#&H4?9LQY)TW&F%
M*CR5!(-IE`52<$_R1[,D?85?5YUIV=QK<'/4AJ&P9)-GKEKC/O)++8;9;`)D
M*C\',#.ZVB\AV-6)T$J$YHV!\;-I42A,H"A//1*=AL,?[\OS'_\`3M/_`/NG
M=B_]0.`_WY?F/_Z=I]_7_1_[)W8O_4#@/]^7YC_U_P#UVGW]/]/_`+)W8O\`
MU`X#_?E^8_\`Z=I__P#/_P!D[L7_`*@<"H3V<]9>3[WYNKBM^4^N^NJOO>8W
MS$H?"9G20>R.2VB*F2&.2\MUFET29KY]632Q:KA32B-<3XE&4RJ1.[B4DTF+
M"4!0<4&#?$WTJI'E%?TY5?<??/7W1EOQTRH`I+)G[MW'TQ2<RBK^RREZ1/=4
M5Y8W/*"X:'E3>YB5MDD2OB?2-Y_#0JFQ0H(T:$D+J[9]Y//".5;9+_!K_$FG
M+-`I<YP85H\W]@16NCIJB8'`^(HIH_&46C,;8ZX2(*9.J$29I4,LS["-".$6
M`04043_)F[*>9IQD\W?_`+N=?3W1-APIDMB+\\03O*QNA*2B<E2'N^RGB-M,
M6ED7=K!>F](8E9FF.'RQ0J<Q`+-)*)"H/(#8L6^OE++"=+:WY3].+F:#=G"1
M/\`\W.M6M@<B$PME*5#<[6G6M;)%.D[B`249>A:4:/`/_5[+`(S0>:/THO&6
M@VGK;R(],7QU,4;3I=6$R\@4<P#,(3:6K/RGJS^NF98C`6CW_JC1(1)E*CZ$
M%F;-^H0AQY'7GJJ]FE@8?'AOC91HDX='V]Z'4)&=)_R3-Z^1874L#O@P!:$C
M6MJ?AT>,)F_M)">'ZF8%('O7UEZ!UY0G.K3U_%>+>7^9KEZ<C<5M.#0/KGJ>
MR9S/8`AC4K7.$/MQ?6'-E,2Y;1"5T+;ULN*@RU3)7%*-*E(3!)&M,*#'/@YT
MMVU/73M*IO.5SX`N3DZBK`J)+#:UGUV=PU[!:W#-X(^A<77G8ZUJ=NZ]8U5L
MWDD/5J3F&3Z$C1/:5P$SCTE,$8<&PJKZ&]@8V2$AT\SN6;!4IE`D:IUK#TD=
M&XASV'YOL=FIBLWBZ(&HFHS[`Z^-2X?EA^_6_BW_`(M!#\B/M+TN1G`!)?&.
MRU!)9AI*T^NNX^,)/]1A";\*AI+GD[J42U`:,(/N$I_`4``/Z_!O>OMV&FI8
MON]83;W=,O2=F4I6/HJLARGCQ3Q_+%/(2*FQ\7,O1C6I>(`IN5!U:^WJ_7L\
M2=H!(!R5B@JUH3+ONVE)5QDDU0:&Y&4I]OK>/*,`U><_$D3=R#-&`<UU[=PW
M'%]#.^,`A)&P')=3G.I)0-F:T%8YI!:$'6]_7[OM`7YM='V.9I7U#ZR=RV",
M)OU+B_-PZFX@@8$AGRB/0B'1\&'<AP-&#ULH\R;#5EAU]NS1Z^GVAVZ!^+_F
M'!9";,5?(E>V].%.]F*YUTXXS'K"8G+!F%GGN0)#TK);4<$+B>J*^01J49&P
MC$+[?MT+>L#.76L]Y0Y.Y,F[E>]7)%W,"5N;(#+*J@U$.5JQYT89PY)(H".J
M*A@L4?4ZV-+C7,)2H)J'2$!0OH9OZ[`$05M^/W5GC?8$LL*I?+JFGFM760M"
MR?6$]HN9+;KMGDR."N3?$2VU[MB91<"%:.(+9#I,V,BAT"6@^=2%&G+WL_6P
MOTP/_];?XP&`P.J3B<PJLHC([!L:6QN!02'-"Q_EDSF+VV1J+1EC;R]GKWA]
M?WE2C:VEM2$AV(TX\T!8`Z_KO6!'F>=W\6U=%:0G%E]4T+7L0Z40LCK0<AFU
MH1&+-=ML\B:FA[9WR#*7MT0A?6)2U2%O.$M*^J4D*]+HPP`E!.AAVM/UMRZK
MZ#5<FI>A::4=-H634B6T(18L5-M=*T_I87[9Y\(`Y[?RS@1X87(1&R-*`M@P
M+-EZ3#";L*U:UK1G@'OA>KNTO]B/!EE^9->3QU03FRIW8+5&W13U7/F52SUV
MW31^?4U<PHS3,%4!A9M(V=.M4*#B$Q6SAZP+L,!@,!@,!@,#"=\](4)RW`EU
MH]&7%7=*0%`(1(Y/8\J:8NWJUNB#5);0SZ<E1*A_?E11(OQV]"6H7*1:T$HH
M8MZUL-;BZ?Y+,+M)!.2O/Z%L*:H80Z*8O8?HMV<&34_R37+V)&%6D;X#7:1N
M-O;I"SU:083$$':F]HD*H0BS1)MHOE4%AH1>K]P03H6UH];23I>^NJ[2>T<K
M'8=Y=`/T`CYTU(3/#$7$V2J.7ZT)F`>5ZX90.+F:W,C_`"HQS6EZ.--9V$02
M$R\)->-78M&\\Q*<PVPKQONII^]6:SRJ)%UOP3R-VM$CFU*P$H"EPS+QC;E:
M\%F7[D*(`1^WU8&Y1H)0CB1':T:`-A];[I4C2K4,N`^W\S&H<]E+'6&B\2H.
MSRY,K`H$D*-5FMR^AX>:D-0?:>5K>UAX0??_`*_[A!3@#D8!_(4[&MEK+-YF
MZTH.X),UE`,21WJ'F_A#CENE/XB1$;\;VOG7N+%YR`2TY<2%8-GC!>P;VH$F
M*UM.,D`69\[]7_R:>@/F<62G_%$B.;^'X78RVK3D`$I1JQR1B6.1M$]#]$I`
ME$'-8RS"R1F"^06@@$,0#@EA-1W*_DB+&@!+,J\2F-Y&D$%2K5$=TOJ0I4,*
MCZB0%_\`0^PZ)^\O0!G!.#L18AB*WH>BP!\\3^1T^]W*.[H_#?1"T.6+*O\`
M@-)1!MV3R;'9ZSP>%0]_>))+(]&7QRL6NH$^/TC/`]&.6S"C'9*G2KRBM*"S
MM'IR@NAXM]TO0@/(G,/FQY?<KT-?-ZLO,L(B;99E*(;8?-T*\F;VQ+Y!>$*G
M="4_33!8^E8C'-R>E#Z^PO;RLTM='1R&8K).#B?0/PH]K9AR79TYD"3F.5M*
M92P=(W!5\&LZ=7/VS?MI1F-R!G=9K;MP36D8X79TVK^)3%X`U16*R)HAJ-($
MY,Q,BI8:7I4&*/`[R`ZVZEH)UZ6?>:O/"3TW((^AK*C7'LVHYRIDTC;XI/[&
MDLHLJ$K:!=J_EZAU*EDI4,VY5('!6[JD;4D;D9H&]H1A`&P,A_CT76X#3[3V
M'PQSB8$PEU&[\TUIZ=,[JC=`I0)3&]O3I_6.!-"=(J!OZ*%Z4E$M4Z)"$8?C
M,-+V'.)/X^/=2!<D&P>]_:M:,)"X9Q<+JA?T^BB;6VFC.V<SQQMMKO6Z#6\@
M[9NS=FK#7$_2G8C-"T#>R\"6]:^0G:T$3'$.7NWZ(24W\=*A2'*V>DW;12)*
M7H.OR=63$+-4*W$P80[&LT<4>9_7Y-CV+8L#^V5Y*=YS%*0FC'O'W=%1)DZH
M1)JNO*%.%MS-*&%,I4CK^,U6J6MQ`M!V-(::+8_IO[3"][^[0:EGLEX5]2PR
MU8:=<G?]^];+I/3]M6'"+0G/(/35C,)5K,]C5$VGT>\N7.VNEUT#6V%#I0]R
M)"ZFL:5`%1&PH%.M!6EK$@9F\FO%[O)!6%PO5%3<U37$4Z)>VF+ODDO;NGS<
ME5KB9ZRJQZU84*@;[RK*'PJ/$/#L8SHW1X:$*LYR:EI?U+(3E&F!)CTTYZ]1
MJYXGOI)83'WZB@K^@B5<NSJZ>KM"=:4V4QVG9D,K=4RRVOK%YGY[MN=I)`DF
M?Z<A^]Q+-3N)H3U:DE*G^<T*7O.#C'TK\K>[H&NLF&=G\JV!<\`NZ(1YQY\Y
M@J3L6=3>'0Y)#I6_D,<+4.5D1:1H"WHEN&\!1_"L;4_PJ"UFP&_8,-I[?I5T
MK3Y)VYGZ;)V1X0#$49%.^?`7NRE!EI](2C=.,AG=3S*L8T@+"W*"5X]EI"0A
MT(P\824FP%%AW>O/:N]'LU687U]_'SM4"'01"C3EVI>O&<]<COD-%IG:XW<]
M86H8!W4?@*$P/F$`LH1A"@[910P@&$QZV]1>R;$6ED13SJJB\$IOVF$+.1O4
MOCN[!+DHB3E05K<DL3_+Z8H2J$&RU1&S-DB&E^48]%B++`<&6%'JI*8WM,58
M_EAZN0M2(LO\TUCYRKF[FQ,IVE&<9I,KYZO*UUZU'\I!Q8#?Q"S-_8#[RB]G
M$A&%=?JU[)^5>N47J.=8T9V3)W/<J0.]<U',.8.L.2+*9+KA2%SEM:2F*7?8
M<(JA)5TD;7)N*&4[L+VL>T*)6,6T"E.-2G&$;_$[V9\]7JE)\?37*'>3QUM*
MU\9G'6K9!ZYZ4[_LNP)F82Y1*.RY^Z(6'3V3JX<C9V0HEK)E:UA3M?Y9B9*6
MH'I8K-"X";>B_5DG@<BD56>0?3AT+1L3L?*Y'V=</(7(T`:&!*B<Q2!TEJ&0
MW39\\2Q!M;2-G+CSX[HO\+1P]A^W1?SAH.^0O0_8BWUPK^J&*2\D3]GJB:6<
MFHCGKH/N&1CX:IR5.7[BC$`2\?21NG]Y$2R4,!DT.88(",-D[<C&QW5&%%`U
M\[LA#Z$_[Q]L_P#^.GEE_P!]#K3_`-PG`X&1VU[&0YK.?I=2ODM%F-+]/RGF
M1]S=2L;4F^H!BU\[DY\(I49&]A`+?^(>OZ:W@0/LOV=O6HMB)G5X>`"%T+4!
M1BC;'ZA7M-9CM2,TP@)((5".))%+#!C4$B*#]J(7U-U]FO\`'_AP-;/W[[^Z
MA]$.?J)JV-5-`Y<2U6E,YX@EW()/H?)VM<SPVFIM*9HW.IE]\4<RUO,&A/`V
MQPD)JMF<I"K:FN/+U!Q*5'L\_8=:_C6=;]R\',/2T<@7F/U'V8T6PCYQGRD^
M#RMPB0ZT@ZIDM53`'M'$93''QJ<&JTFUS4+&Q8FVV:7(V\)FS5)'XNR@V_85
M[#]!N!`=V-XD>K444B3EB$5#:YIB?)0*A&"T<5M2]7)7)PDI9.M"T;HC[Q;W
ML/Q:_P!.P[#,_:)1""CQ+_)+VM>SR0D"TDAG#K9,SC]J!?0`25$<N)Q;=B+#
MK>S/N/#\>M?U^F]AUL/G%W#ZERHWT5FG4B&JXW%;21_W;KD$9G'$?(29_B+K
MN^Y.[P9GE%6.%9NJ%SLYEKQ`U1]\DZ\T4[1KSEZ,EP.0IP$+`^B_/O<^`U\P
M:DCCYJ^SCBUZ*V<H.1^<UG-!2``E(D"4+DMF;M%6QN-7N&@DD%FJ`&#&:6+>
MM%F`&(($2S^516"%S7H(]Y_=6Q`M$:H)TLZMD%1<LEA/1%$%KT:XEXE<^4HG
M!&XFB^XK[3/HB+&HWL(M?#@9&AWO=/KH2EEUVI\8:E6#<E*0!_0'M/$3%QWX
MC?I0,DJ$U_S"N>S@JSU1>TZM.K4IQ`)-+&$`_KLH(]>AG=?JZOX\FJ^E^Q_+
M9LFL_D585-7;5Y^S*5WMT'*97=DP8*SA;#"IM:LNBD!@:27RF4%IE,E$UA61
M]OT)<@4Z7!)V6$$_XD!O=%.W_:'-U_S&T(I0DPJSH.X:UIZ2-4#F$*E%HTIT
M%7M`W[+$-@ZE#E/*_DL$G\@*;%30D2B:9&>L5+E!@3D2<Q4&_+@?_]??XP&`
MP(>>@->J[8XPZ-K9MH8[IA]FM:NL?B=-IR:C-4/TV7'I2X1(B3+SF5?UD@-K
M:7?@R<*Q:[)E2';-^0W!/<BDB<T-9V9\#^AC[SU2\53<)S"2R9S\$G7QXDD)
MF=R<B-Y5&7TD-J-$'I!P=T%^2EJ?Z3?@-:AP1&Q]0XR\)L52A5,*4:@G80D1
MS[YP]H5QU/6M>RNIG!RKBK_6"Q?0U9W@=8M*F)9M4D@XI#2#)3*2")9`;=7[
MZ?9DXE-#V%7%VYE*:60"A*OWLQ.`H)1\K<WH^9O:NSX@BNKHZ\`/_E[7LJ'(
M^F+B?;HE[48HZPL-KVQ,,@?R25+1%RM-85!:`O6BBU1YQFOZFBP+^L!@,!@,
M!@?'D8OY`7JZY=*-\LD/H5;M;0IYN@#P^ELJ,4RKJO(H\33\AU$PU5*F^1;D
MD4AK.J,&A8W`*X:E*F+3'?,(0ON"6/4$YZ'[)D7]V^?.>;N.Y]4!6(3O1[U0
MNAG@TUNA(0M3K!%-5\VQ(JPHKG>OPD)?A(AM,*620KTYNTBIR<"3]-H`]U*>
M,G1';AT1=WM^Z'[2C\:8S45?QOD:K2.>>/H>Q'N9KF_PR$=5]=1ZD:6@R).]
M+#U"@JL:UL-M7KCCE8-J##/E4!S'J[X-6GQAS3$INVUQQM72UC0RZQ9NP1OI
MZ3S2_6RO8VT-XPBF4PO6QJACEQ256X.!J8MMK"HD*4)Z`X0CQ;$GTJ"^;^.C
MY2OV^'W5Q?.O>LN8[%DEA;ELHB_''97.<GKR9QR3Q..NE>3M_88E"K3=*^F(
MV`PQG6-#PM*7!$S;/^(O1VRB@O@?/':.S)$-NL/T/]5+!;]C(,);W[KTII;2
M!D",&$W]+@U;Q%M6J/O,^H3512@TO[=:+$#6Q:V$5Y5_&"\WYT(0YO)NJ)B(
MPK1`Q2JY6B0B&5\PE7Q#V[P!9L1>E(MF?;O>P_?O8OI]?ZX'5&#^)EXV,8AJ
M3ZPNEZ=?U`]P*>EE]SIE7)!G;",)"$F%GQ5I1I4PM;V5HI,$0/NWK[OMT'00
MEA!/!SC2ID)Z"G[8[_J`)J-0D(-K#T(ZQA8T03DJ9'\J4AFLU.AV(DE$GT$)
MI)I.])R@C`(`=!P/GI?R&>*D]&^D\UBE>]'+K^9W(JFX>MD_2?:U7VK?\;L*
M3QA.89&[466%.VFR(C$6%'M,<!X?TA#"TMBI/M0XEA%K00V[_!/R1XSE/F=0
M]E)I39L5Z.?5$[*N^S^,_1CH%@0?OQIL"6MB)N4J.:NC3:3!($=8JFI$K"B2
M",TE.^HA;&;LT82F]*?'*\9QR/84`X*Z:[==+[GQ[1$-&]$>I?;2ZKFNO'50
M9JQ37F+.]@31CG(GV-%&LVFI>DVC,+<QGF;'I/\``<%1G\9WS5ZAM;AY-8]Q
M];=?T_SE8OY<JY-;.6>TK$KY+&PI9U847M=MEM/F,RV$L*A5-V(+LB-2A4DN
M!BI6-:4(0PZ$&RB1Y@64TE*PQKUK]6&HU43]OU=;4Y>G2?2DL)WXZG[)]R/)
M5I!8!&_ZPI*H2!."'7W;^[01:#V+>*/1<@8=Q_V?O418@[TI!-.->#9`8$81
M?ZL3<9%*.KL*8`@"W\NCPJ]CWH/V;+^@M##UM_,'KBTB^XCU>H^0_<3HHPN;
M>9C`L)`,.PB"I2?LCK6O32E`]ZW]_P`HSR]ZWK[0!WKZ[#R/BON,T)TI3=>/
ME=.!E%:3'GO?,?6-?+#OA"6$#F>>T=6SU"H5+/M$(T@I&D)`,7^K%]NOLP-?
MG^0/ZB^KG`_+#?3UK2+B2#6)UFF?X5!ISR-,.C4-T1&.0]3&5]A6`TI)^PH6
M>((G%O<R60H0'92XI3GO9J,XTQ&,\`6!^9GHUZU>EW&]8]'TA7WF:!*(;G7]
MAK;*NGI<N=!LR![2L\FU)JY@G/I<5@2N4:&1(DB5%(GHDEI=T@?J$6QZ+#OG
M?$L]8HUQMT1)>FJ-\B;8H^.5N[2"<UBK*Z^N0=@ELAJ9T88<TUFI@<<32>32
M*4I$*5H`:XH"TSH:G4#4$A*V8$-5K^,]:?33MU)T*PT%Q7P6@O9>_P!FVFRV
M3T'!K9I0R`(5[O&&.T>:ZBL>KJOLH,!1LJ9<F/1QY4W[/;T`%H0Z,*$<7@;N
M*KH'V%BI(4KSYM<GV<J3'B(4O-2>CSZRHG$)OS'$*VR/VQQ?$E21(D+V!.?^
M0X_.(X.S"RMEB^@0Q[*NC^QYTWB2W]X/6!8#,F1C_(2LO27G]=1)2<DTE6Z%
M)&6R;5KA6O+-&E`:D*(3C/6&%!T,H@?QZV$-+&;_`#JDQA^K=_C0=*I#CE*=
M0M?&WSAX]G#T$L]6,9:K;]S[<<]DBL@Q>J-$H3)S#C];$,TXG16_DV&)6BN_
M$^&`_4SN'O6SC$Q4%0A)?HO0_LY32%M>-%E:2(4*KGA8[15<['%-`%I`"@+$
M9HD83#OJ,OZ8%/\`[(R#R[G]'5`7'>X/3KI.NHET*WS2Z>>K>O6Y29`WU.52
MEY,ZN?TX9Z)UH4W*K5C$\>F=N(T4K=G0E$^K""T)AFTHDH8B\0[@Y(HY+?<Z
MJCTWL_RVJFR*WY?;F:$39R\Z^DK[MJQ(8]=#?W7(?V!/SG+IZ7%ZWDDU)U&W
M)TB,9?'=D>?D4`4MZ%#I$%M?1W<T%D="7Q%VK^1TZV<DD-06@QHZZ?\`@:@`
M.]@%O$,?$14&<)%&Z"B"8DV3[4_I_P"2D2(A%!/T,.@B#]VPUB><^IZKMBQN
M5Z7B\M<*XD--6MP4\H+1Y;\M:`8NA4K/`F(L_I*P'BP*\KVW[[ELNYZ=DY8&
MLXYN=RYL:4:XKFT(_L3##;4-.IJ7JOFDK/\`RI.T&=XV4X&H7-HZ9YN@,A1J
M!!>@AVUQ$'"\4.:1?BZ$3\199>ORP`3"^H"PD!V)AY#I`EP_=54?QA++M=9H
M7QD2+O*^^/WQ\.4$M(R=;<DEY]0]1R_8/E7A*"<),H!LL@LW6_F2DE`">-8-
M'I/#D`D7.'DYYA\8A"G7%@427JYT.+&688C3D%:C/-7$Z-,7O82/F&1MW^)0
M46`(CDYFOMV%0_\`('B?K1(>#W!PO&@>+.B]I9B>7#HWR7S9VC<UIT28XP:>
M%2V]_P"Z1MDQ^.5RTP&$$J$XW=XBBUN4+'`K0DY.P!-`$:OXQ?-O?TNY)LB2
M5-<SUP0I=WN"F@D=A^<I<[:^EZP/87E?5-F0V\+%G4%:[+(CIS@^-IB5J3JD
MS4DTB.-.'^HEZT&S6FXJ])35!07CV@N`+?K8Q'ZBW$_#[.[F;^,>B@%.$BJJ
M;-A)6C=A$/6T!@Q!U]`B!O?W:#EM>?/4;\,1T_\`8OT&<CR`%E-G]NX5Y_U0
MF))^XP:C3HD9N*78EX4&#V'XS1_&,H.MA_Q:WK[0^?-:/B)V^^>V4GHW5&R^
M>-\AD<B[%/0O]R\EMMP3[CHGHI%6\EMQ;*&MD8J.9+<E3H\;4EM^X]HY&X*P
MC&WGDDF#&&_[_NII%_\`%1];/^\M5W_N]X']_P!U/(O_`(J/K7_I^O\`VEJM
M_P#=[P,:37POHVT0F;MKL;TFM9:H`06M73KK-4Y?F`3*3%2,L;2CA3='4A"(
MT>]E%)D1!)>_\00_?L0MA4AZ4_Q4J'EO+=AK>(R;7F/6VGR(.=?$7%:T04Q)
MS_*G#".P1R-X=HY'CT6U,,$X'!.`H--/6ED@V6()@A`"*/\`$0XA[(K*S)?T
MQ9XFG_*JWU7U+1%8I4\H87=<UW4Z]`<\-]J$@:"56GYM:5HN;-?&/XS$!PR!
M'`V48>+:@-]/`__0W^,!@,!@,!@4EU?`':$^]M\.+E:5DV05//,^!S)J:I^?
M##6RL&Y9UA8+<57E<@B4*B*Q/!$!K8-42%X.>77\I6?LQ<87\9907:8#`8#`
M8#`^/C1?E\_3/V8;^6WJ@O19GYW3=!:6'S%/SW,6/HN&4/(Y\[16I.CI_'I3
M5+@@A<!<9.G1+G1X<V4*`AN`KUKZGD[#@?3BH[R,X*H^6I[3'2VKUO<H#88J
MZ)ZNE$FZ@O%4Y-.OHD>6^<W2Z3`^%N(?IK?TCI#,F#KZ!`2$.OMT%EF!#CH_
MSVX>Z^E+)-^G^5J1O:8QJ/ABC#)[*@;+)GQJC07%<[EL2-R7IQJ0-1+HZ*5!
M9'W;++.4&B#K6S!;V'8N:N).1N-@3,OE;G2HJ`#8HH\.=?VNAK5$QRT42"]Z
MC.GXUM(*,<@,(9(X?B:,WO1&UI^PZULT?U"4N`P&`P,'3#F/FRPI&XS"?\]T
M=.):[_AZ=I3,*G@4FD;I^`A3-:#3B]O3`M<UOX3:B)3D_*:+XR"@%A^@0AUH
M,APF`02M&$F*5Q"HE7\63'J52>-PF.,T48"%2TW9RQ20SL2-`WDGJC=[&:,)
M6A&"W]=[WO`C%V7Y_P#)WH%%8=".M*U=K-C$"D*R511J;+5N*K0MSZM;AM"E
MP4*J?L"`+W<6V\P10"UIJ@HK[Q;``(A;WL,,\9>/OG?Y\V$YVGR%0SO4DV>(
M6YUZXK]WIT3/VU1#W=Y9)$XL_P"UK0MJ:Q,GYWJ.(E&E!:("DL9/T`8$(QZ&
M%F.`P&`P*C?2GRK=/2/2R-2/N3J^AZ9D5:M]<3R@J=<J_)JNP`H)2]2<<HD[
M;)X>].JN0KMN25(=O2O2?\9J2_86`83!&A(WAKCV<\<0J3PJ8=B=']=)WE<P
MF1Q?T0XPEP55VT,#1^DEL$/'$HE'5)3:X%_8-0!4<I!H1!7P@)WLX1P97ZIY
MW.ZCJ%SJ0B^^CN:S7)X8W@%J<K6*BJRWVS]$7!6";&V7.49ER(EG>0?4A<0-
M"9\Y&]ZUL`M:%H*W^,_$:O\`B"X@V[6G?GIS-D[G9\\N>P:DM?HV`2&F+CM&
MS&U8@FDXMV&1RD(@JFLF>U*DM>>N-6EJC7!(G.,,'LK0=A==@,!@,"A+^0/P
MMV-Z-\M0;ESEU-$Q1)\GA\UN@^1W8;3YBX,,1)C:QCBA)_9VU29Q$SY6XG/"
M])LUH,(7,3<,LPS8]B)"-?\`'-\P>[_*QKO&H>B4E>&4S9Z6.3]O/BE]*[("
MT76R?CQQW5QB""IBO2XLSSR('%?JBA0[NQ_WQ]M*+U]-FF;#8GOERLEHI6UG
M*G88JL2U4=?RLZO(.@G;!6*^4S#3,K"Q,R&PY3'Y9&84N6+Q`"0YN#6X(DAO
MVF')S2P[`(-#OSK\4N_.-/1**=;M?FK=<?9F6>P95`%#MZO\KO;G6[.^-+W%
M.@'.YWEIYX<73H5CG3;)#E)38UM427(DQ1J;\A:H/+6)P^@]@,!@0#[QX%0]
MZ1R)Q%ZZV[5YCC4?;YZSR1GY"N&,U4AMAFL%`QM;BS6P1(JYL`$K:V9`S&E(
M$X=)BB@.BW1H3OE#\08_\\_+Z+^<:-1&ZZ[![HO.M"8*SU_$:=Z<N""V+5M9
M,[`L+4M*FLHY&:D@)\.7)DNAH]A3J?PS$AGVC($(LD906>8'YE28M:F4I#A*
M`%*DYZ8T:54J0*@%G@$4,29<B-3K$9X0B^H#23`&EBUH0!:%K6\"A%1_&H\N
M3I*9,`1SIE-)A-AS"4^D]B=(">DT>.<`NNXZ2]J;#4O'Z$!P`$[28:@8-F@T
M8+[C/\6!>Y&X\V1*.Q^*L8%93+&&5KC[06X.CH^+RVMF0D-K>6M>GQ8Y/;PK
M`D3AT8J6*#U:@>MC.,,,$(6PYO`8$4.Q.,J3[GJQLIV^2[!'#VB:M-@-XZVM
M&?5*_DR-E:7]C1F&R*NWZ/.JYL_3),K`8A4F'(S#!EFB*^8DDPL(?\;>)/!G
M!UK,UQ<Z1ZZ&"5Q]%*4C4WR/HJZ)A"B3)FD4HI&X*H(_3%5$71Q7D+CQ?*K1
MG_8>9M0'6E`"S0!;?@?_T=_C`8#`8#`8%)-712?QGWQOQ9-;5<+):Y7YH5](
MZ^9U\0BD8#54,.ZJGB`JND2^,HT:J8(4;PB5KBW-U^1R%M=LD8QEDE[P+ML!
M@,!@,#KLMC+?-(I)H<[*'=*U2R/O49<U3`].L;?D[>_-JIK6GLDB8U:!Z8'<
ME.J$),M1GDJDIV@F$C`8`(M!0N@_C><3H)NLLDCH/T9_?KDT-\;>)EKMNSD\
ML>HPU+1.*"+NLI1`2R)9'DBTTPPM*)5\9)A@QEZ`/?W8&P5@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__TM_C`8#`
M8#`8%)-71NRV'WPOQ78%F-]@-4D\T*_?*V9D$#10S=90,SJJ?(4L$6N*5]>C
MYXM3O*)8N&\J`HC3=+M$:3@+(!L07;8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_]/?XP&`P&`P&!25
M6"2W4OO;>XK2?ZW>F=7YG0-34B>`1&419S8JS,ZRL,+<S6,KD,VF"65SLAZ`
MM,.<VPEE0&IC2"PH"S"QFFA=K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_U-_C`8#`8#`U)8%U#=SI
MZMDLZKIZV5/0JKV%N[EQ]X966\]:K1O\T8CQBY3^)72+G--^3&6!,5(DK1(D
M$X_2TZYZ<'(Q")R,`!0$L,EIE'L-KV%ERI%%?-PVX@^;L'2G!4S3J,BJ]U6'
MJ*R#&D\MP+KP^4`L@Z4?E?D)-D[;0-NBA@/&;L8=!-F5VC[X1F?U5"D=!>:,
ML:[)<)>@>+`CE@]5'0VJ@Q>*+)*@6V*<O@2%Y1H9@J1_I388@1K]B<C"P':)
M+'HS`]]EV5[X0!G8'9IHGS)LLQYL.M8.O:H)8?5:ATC;58$Z886XV([IGN`L
MP1PJN4[YMY?AI1*5J=G1J#R4YVRM@V'+3^<^\T)@<UF;=4/EU/5\1B4DE"&"
MPRP>MU<QF:MA9EKJEB<42.=;M;<JDLC4)`I$!:A2F)&J.+"886'>QZ#D(M*?
M>211B.2!?5_E7%5KZQ-#RMB\@LCK<+]&U;FWIEQ["]A;:T<6[3NS''"3J=)U
M!Y/S%B^PP8?H+8=4J2SO?&S8"T3-^H/S.J)U=%TD1J8!9-A]3D3%F#'Y.\QU
M*M<BXQ!)&RZ1R1(T`=$`BEA@A-RT@1FBS=C*`'L@ME^^$Q=K.;'.B?,J!E5Y
M8AL&:7276'U64W6<U!A<+EQ-BP`YG@+L:IA)ZN6G,VC%H$:T+LS+BQ)PE@*,
M-`ELOWO46R^5J91/F2E9&BNXK.$MMGV'U7JN'UVD4EF$?6UTU*2X`9(136*I
M(N0Y.!9R`I$%"\HMDJ#31'EDAC>T.I?:VJ[YYBY^>:N\OG24=4.EN-,->F:P
M>LS8[&#*>K=79K\IF)ZJNTK@C1NC4CVD1#2)U6QK3``,T4#?WZ#(MF6;[WU\
MV1ER:J(\S++,D%C5S`U;7`;`ZN5N,::YY,&B*NEBOP'FOF<DF#5TB<QO#X:2
M,Y62V)#A$$*#0A*&'(V5/_>JOZYL">-5,^7]DN<)A,JES;7,#L+K-9.)\OC3
M"X/*.%0Q(\5RSM*F5RI0B`@;BU2M*F&L/+T8<4#8AZ#M#8^>\*]M;ERFOO)]
MI4K4*16H:UUF=>"6MIZ@@LXUO6"25<K1B5(QF;+,V4887L8=_:,6OIO`Z%3]
MH>^%I5O%I\^T'YH4\[2-&K4+*VLZP.JDD[BAB9R6(`HY$GCD"D3(6I5%I`J`
M?C+5`-D'%[^[Z_4.@\Z\L[WQG*FQDKO0GF;7/[#LAY@;8HFEB=3%IK%9VQG8
M'='94&.88(]Z509]_71I4PUGX:\*M"I+.3%;+U]P>22SO>Y5;D@K$=$^9B1D
M8JZAL\*MI5/^K@5L_.DLDTZCRFN6-:&OQ/JJ<1-)"RG-U+$A`C(0/;=L)XS#
MA%@#PD=G>^3%9%:0-)0GF=)&B?(ITL>K*9+$ZGW!:S'#D#.L;$4Z/701"^DJ
MYVH=1IV<*!"O",U&?^0(@.@#&&/>CNIO:WFA%3*^6U=Y?R`F[>BZ=YKCX8K8
M'6:DQFEMT2`<=CTAD&G.NVL)$4:EH?O7F$;/4@*WKXR31?X<#)%MV5[XUE6$
M^L1CHKS)MQVA$2?)0AK&M[#ZJ4S^=GLB`]P_;$,1R*`Q]G725U"1LI$G/6I]
M*#Q!+T+[A!U@9$_4?=O_`,CO)3_UE=B_]5&!C:H;.]\K/K:(S]^H3S.I]VE+
M:)R5UK9=A]3IIY$_JJ4DD(),FC,$DC(D<#TQ(#]E%+3]E`-"$S[3=#+`'A7-
MH^^,\.L0IUH/S1K@,&LJ05^UGSFP.JTQ=B-+(A9EB:RX1^BP)Y&H@;^:[#3H
MC%ND:X9R)1]Z<`-%B,#]#-97O@ZV=/J]4T5YE,C1#(Q7DD:K-=;#ZKU`9^HG
M*N=I'2-0]4C@*I[,D->?LP@Q[*6HD9993XWB(&?HPS10>#W9OO<T6?7U>)Z)
M\SGMIG$9L20.5G-5@=7F0"OU4%40A.UQJ:*U5?)GE*_6&&7GF,@$J)44:!D7
M[/,(V`G1P>JR[1]\*_*@YK50?FC9@IA94+@#@1`K`ZJ4FPAIE:\U&X67+/UR
M!,I:>!PLL'Y#J:F$I7`)WKX$YX]Z!@=)ZLZ9]LN2.;KMZ;F]8^7<HB%%5S)[
M-DD?AMA=:*Y2[,L5;C7)>B84SO7#0V&N1B8D7Q_D*B"M[U_B&'7UW@2"_4?=
MO_R.\E/_`%D]B_\`U?VI_I@8ZJ2RO?"S*Q@=A/M%>951N\SC#1)'"LK(L/JM
M-/H*I=DA:L<8F"6/0"0,B60M?RZ+5%)EJDLLW6PZ'O>M[P/SUG:/OC8!<X-=
MZ#\T*S%#[*F<`;B)[8'524V;M,57%(T%EQ/3'`WLM1`YH4/\AJ-5;3+ADZW\
MZ<@>M@P/;'K.]\7RRK(@"RA/,V.-4";($Y,UE/5A]3_L.R]S1&_GN*&"J6Z"
MKWH;C`U3%HAY*<$2`18UJ81'SE&_)H/8\65[X-=GP.O$M%>9+VTS&)V+*'6S
MFVP^J]0"`'01PK]O;(Q+EBV`HWG4FL,4Z--9$Z%$K"<0Q.1AXB`D!V8'JL2S
MO?*#**\)::#\S;'#.;)8H&ZGPBP^IS":Z9WAO>EZNRIN)^@K*(B#,`V@"=6-
M#I:O_(7)]%)3`[&(`+>L[WRK"MY7/6&A/,ZX'>.(B%B*MJTL3J91.94,U>D1
MF(HX1)X+&F,Y8F(4"4#"H7)P[))']N]C^T(@[7*)?[IQ:-2*3JX+Y/K$T<8G
M=^4HT-C]A#6*B&=`H<#DZ,LRK"RQJCRT^PEA$(.MBWKZ[U@8XYTOSVYZ3Y]H
MKHN(UQY8,44OVG*PNJ,,<HL7K=/)6>/6G"6.<LS5(2&VM7-N)?&]N?2R504Z
ME00$\`M%F&!^@]AS=:V;[YS]+,E+O0GF;6FHO9,W@;61/+#ZF3J9LT0YX,:$
M5EQDEB@KX+4%FOPB4M`UOXB\Y)]IIJ8K0P?<'C&K1]\9!9-FP!70?FC&FFOD
M<#4M%E/M@=5%02S39DVNK@YHX"I10):^*E,#-;2TSQ^<B0@`>L)TG&?KY!%A
M^A797O@EMA@K4-$^9*IC>Z[ETY/MI-8?58ZY8G:+26$,"6NWE0*``D2>:RQ)
M,#G-L++;S$1R%E7[&H+-+++-#USVSO>^%.E8-S=1'F;/2;$L9/`W9TAL_P"K
ME+?6+6?#YC*A6-8`W2OFP])!DZV*D,XS40%BO3F\(@:(^(1II0?RV[-]\JR@
M#S-6*A/,VWG-H4L!)%?UO8G4RB9/)3Q(VEB6*VLJ302.-!I$<1.1CHLT-6`[
M:)&=\(#3_C),#N[O(/>!L:G1R(KWRA=CFYN6KB6IML?L`;BYFI$QIY;>@"?5
MI!`UBT96BRM#&`.QCU]=ZU_7`Z[7$\]ZY[7<#G#M37E[6SM,X7%I6YUW.;%Z
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M#1>P]\YLKWPA[S5[2UT3YDSPNQK#U!G5UB5B=5C:ZP:0P6<S4ZQ;!4/,`:-H
M844HAI3-]Z,*M::\/+>06G'HX8RP_/;UH^^-80!VFK%0?FC;SHVN$80IJ_K.
MP>JE4R>`R.6,D94+6XB1P*/,_P"#&DKP-U<3#EA7Q-J(\8-&&!"6,.W2F5>\
ML=C,CD"&K_*N5K6)A=WE%%X]9'6^WZ2*VQO4+4["R!<JT;VX3N\'$:3IM*%!
M!.SC`_>8`/U%H/PP2;>\\SA$,E[E4?EQ`G*512/21?!IA8O6A$LABY\9T;HJ
MB<I(:*X=FDJ1QT]4)(N"E5JDX51)FBSC`?0>PX2JK-][[(A^I2\T1YF56O\`
MW5849,AMB6!U<DDY9$%L*409#)M%L5?/;8;&Y\@CA3\QG`4"&H9'-(::`HT8
MR@!)G@WI+IBXIIV#3O5\.H^+VORE<M?UJK7\^.\_>Z[E#78G/U57PU.J)99#
M6S2,2Q"ALXM"HT)*07H],9H&A!#HP8?_U=_C`8#`8#`X4N.Q\I\/DY3$S%25
M4ATUJ9"6UH@OBEK"82=IN/=@$:7FH-&IP"T2(S9>A`#OZ?4.L"I)C]<6-[[(
M#ST7S]+4]"*^MICP$U]9&3R(C8U79D%IY5=3[5RFK"R=R=#%3F-N5M2*0;6#
M$ID"0Q+M"`H(U(0N'P&`P&`P&`P*R>UO1"6\6V-449>>-;KM2N[KM:GZ+A%Q
M02QN<4#(YW-<\A7,$<KM%7\PMZ/6\Y.B$I`-<K4D,(VXE``T\2@)2<\906;8
M#`8#`8#`8%>E,>B5?VOT)WS1LBKJP*/:_/UIK-_L6S;F"R1*-R^+V"3="Q18
M$90_J"M:W5DT-=++%R9Y<AI=.C<J+6%$`2_$<<'Y_-CT1A_I/5-MVU"JJL2H
MFFK;_DM'Z8;/`W)92^$-=?5A:+#,SV=`8,Z-%22(6NVF[;%F]+D!X323]?>'
M>!8G@,!@,!@,"M&[/1-QH/M?GKE*?\L6\DK_`*:GBBI:JZ81RJIW2(22S$U<
M?W+7-R&L&::N=O$0QD;2S4#D_N+2VIT;BF.^A1J,(%A@9`X-[I8^[XWT))6.
MG[4I/?/_`$U+^:7B)W,A:F6?+7B(5[5E@*)`[Q9J7.6XAM<DM`@G38K4&+TH
MD^_R0DFB&G)"=V`P&`P&`P*T>\/1-QX/E%/'2OEBW['I"Q;"J>LY9?L*E-3$
M,<$F-SSI7`(;&&NMW>:I[>LB2)W),6L<D[4R?C)FY60,E2I/V<F(#%5$>P%<
MWUWU-^%F"E+"9U\5FW25:I[%6RBNW17J7<KJH8BL5TG%3,,B<K"JVKI2IF1(
M89)GD@I))]_%\)10E``Z"X/`8#`8#`8%??H[W6K\^*(/ODRC7BZ(TRZD3E,0
M(+=I.HB8W'(I%W26NIB!1;TTC;C/INZ-;0H_1(Q&T+L[NYB8\(`%B`7HX,/5
M9ZN1BYNU!<:P;GJRBW)LB=3S*73J:61SO7CA$&JWZ):K[8B55&3&W&GH*3KF
M-A>"6UZ!'XT[@:7+1FE(RR0;.P+9<!@,!@,!@1MZRZ4CG)M&RNY7^//<X<T*
MR-Q"NZPB>R136W[<L*1MD(JJIH4F/^X*B3S^<OR%N(%]I@$P#AJ3=:((-V$*
ME)+[@RIAXEY+]`6_A2?2;G;H%'5YMDO#1>E5ERFJGJU+?+IQFA-?5^O(2SWH
M";DOIH%NTB%K9$YK<>49I1K9:X*(/__6W^,!@,!@,!@5$1GR2AT;Z\-Z'!?-
MC+:=(ZUG?>[)RD9'(.G@Z#L.Q*<%2K]:BZ?E-0K`=&-*PN3DYH6'YR$R9\<!
M*!&FDZ&F-"W?`8#`8#`8#`A;<7'J.[^ON4^F)M/E:J'\AL]N/->4>5'OJR.U
MW6FRM\*2W'*)`>_FI')77E>[=&]A;_TC1J%:]*%P%H1:"5@32P&`P&`P&`P*
M:77R?D%D=#=[6+?'2""R*(]"(/`JNM^AXQ3SS5<D;:XIL$]14\P,-WQV[5[R
M0N9&:P5:5^5A9R=2((`[^)&`1A0@SQYY^<L4\]1=2!BERW';J;I?H5PO,T-O
M3N;SAQAY2B&Q>)I&(UXFLREZZ72LP#`,UUE2@1#L]D?@I5>AE-:380L>P&`P
M&`P&!4K,O.B\I3Z=L'H>#LA";&H=$F"LJ^YUE_.#!-&^K:M4I&0RX6.K[#/L
MUJU#YM=C^WJ5#K+@,!T@);CR6@)QC8FTG-#OO`G#UT\<R_J:0V'T[%[Y:^I[
MWE'2LD96?GS^T"J.6[,X[`H=(%S:\!N*QM*XH?&:X;BB&P24LPA3LT[:D81Z
M+`%EN`P&`P&`P*E>W/.B\NL.M.8>E89V0AJB+<J(CGJO:%E_.##=]>ZN=S<'
MI.\7JJ`YV9"$RVP$\(7IF=@,<$3EJ*#(/<6H29<L,-"&.J"\=P4CWZY=RG]'
M*Y6J46)U'8FH^"H62-6K,M]/[:`G5[>/0".9.#S<-1TNG9DQ<'CIK*VHV'\-
M&(KZ[3:V8%U^`P&`P&`P*Y/2OA*2^@U+@HQ+:E8UW#'-NG+?*T]F\P0CI38E
MTLBYT38I]7`I;*X@LJFVJ[;75U_19`WGFFIQ.IN]DB$`H0`C8J\>"7R\.0)U
M*NA$\AJWBJ24--*R9!T+"4'34NE//5$-M-1,%O=CIW\4XL*(OCJF4R%Z:SF4
MD3DI6;1FJ-I2$X2@NNP&`P&`P&!&+JGCSGWM*'0R!]$Q*22N/5W9+1;T)'$;
M5MRFY'&;'88Y*HFSR=JF=*SJO)D2I1L$W=$^BOU#:47Y/WB*$864,L*<&KP+
M?*^@_`D!I;OVW(%'O/EKD[M5S)+*FKVZ8H[W7,G^2NSS>BV'6>X/<?02IK;Y
M&)#'D?Q*$$4"6-2T!1JU*D\T/__7W^,!@,!@,!@,!@,!@,!@,!@:^/?O,W15
MB>IO`$]AO;=D5&H5?Y@/[&06*0Y`IJ>OO[=4_&Y)+/[P0M1)B%706K>?E"M$
M\_5QB_XL9VD0MOX2].:\JPV#L!@,!@,!@,"DCU\Y9M#H9PY8<T76]Q417<:Z
M;YM:(K#*(0Q^+2@JZ)/;`6A/<TLL-^+E/[L;X-'EY(8_%OTE&UDN>E*QQ-=`
MFI$R`+A:^:YJQP:(,UC2YKL">-4=:6^7SEDB?[$:Y?(4:(DATD2.&:?Y27&"
MGE46)1^$!P5%)Q#V``_MT'6!W+`8#`8#`8%+_O55-D6GYP=!CB=]S*E81`ZW
MF<]L=FK9M(03JVM1UM(60N#[LD]R$=!H`"1ATLD*9$V*'"0)R2D05J%+M86L
M"S+G:M['J&HHG6EH7,[=`22&)SV));,GCB>.SB4Q9`I-)B9MB"1.[JW2BPDC
M``@AY?4Y3:4]K2S%GX*49HBM!F[`8#`8#`8$=NIJ6G'0M,2:FH1>$LYYU/1)
M6*8V57;.U.%F):\6F"*FK#7#T]F&-<"F,H9QC0IY&-$YJ&<HXT](GTMTG5)@
MAEXP5'8E0>=W++7+;VEEWP^7<^4-8U:D6*T(C)]5C3/JEB<KD-9K+`0+R@V#
M!X_*'51J+?F-:5S8V413:>K<"DR<TH+5L!@,!@,!@8WMZ-6!,ZQF\2JRR`4[
M84CCRYGBUI"A[;/SH`Y.`-)M2AOA[RY-C(^/+2G&8:A+7&&H0+`EF*"%1(1I
MC@JQ\;>9+!YNJ:VFTWJ*WKUJ9UZ8[,8F>(WZ)#.;`B$XJ_L^^ZJ=)DQV\D.8
MW!2QV?'86B=7UC7M:P&I8<N<T2M(6O4(A!<M@,!@,!@,!@,#_]#?XP&`P&`P
M&`P&`P&`P&`P&!A:<41"I_<%&W:^'/H)ES]NS-P4IO7ID[(=_=:+)8C)_P!P
M(34*A0X?&U(P;2?$<1\)WU$+[]?X<#-.`P&`P&`P&!BZTZDBUO(X4WRHUV*(
M@EGU_;;+^D*B$8QRFM9$EDT=+7B/2*]'M1CBE#I22'18S2M[T$P&_P"N!E'`
M8#`8#`8#`PST/1D+Z:I"SZ`L4]]30:VX@ZPF4*(RN3-C^2SO!/PJAM*]8@<T
MJ1:$'_(&8G.!K?\`I!O`S-@,!@,!@,!@,#&=,U5&J*IZJ:0A1KJ=#:<K6"U5
M$CGU40N>SHS7L6:XBPF/*Y,D0I5CH8U-!.U!I9!)9AWW""6'6_MT&3,!@,!@
M,!@,#&E457&J=C#K$8F8ZFM3O95S6HJ&\*R5BS4FO6X)S=TU+)-(2(BP-1,R
ML)P`A*V'9A"$))8QFC#LT89+P&`P&`P&`P&!_]'?XP&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P-7*M?2'JN0>MUX<T7_UE#>4-5]T#)8ISCP/8')A
M.D/;'-3<RB(AMEU5UT_S./[*M^QE^Q'H&HM0)$%8`M.6C5Z$J3HP_;S9_(6F
MR[F6VNB>P^,+1KMDA_<Q?(L.=:U*@@V!W72>TGV$M,7=DC_<CX\ZL:I&ML)U
M+E!7Q,[@L."-K^TH6P%!.7HSVQH'FZQNJJ>>J@O*=VIS=?''7,T6@E=M$3>'
MOH:[>WZO46G3L)JDMPE+462J3LS:M`YC=A(0EB2"_%_+,&44,*\N0/;*?)>M
MNHV#JZMNCH56UF>BW-W%E*P2RXW7+&Z\D3>VJ.5.K5%+++8'M0-5')]/8\K&
MA=4BUY3&DG%*@G`3GEZ$%UW//=T2ZRI7J>X*@BDG98[S]<_15$QF23`MF/8[
M8>>?4I2%TLV"B87IQ_4*R>I7I4B0F*!I5BC]./$,DK0@X&N/SSZK^HM8\4>?
MWJ/T==5'='<R];7XQ47=?/[5STDJ"RZ5:);:$\JYEL:MK1C<\<FVQ')O=(1M
M6J;G%C0%&%*0I`?U$)P2A<W*?8V,U]UE$N4[)Y!Z8KI=;=@7+4M`6!*G*@DS
M5<%D4ZQJGH#6FA""YU]G0.-6P!($$)>)`SMZ>0@7H#R@@(//,2!S/,GLOSUU
MD^<`QNJ(%9ZY][T@G1MB)&Y61%RE//<>YD4+(Y.3;O2`D`G!L$\V2D%&V?;>
M2N+5K];,$(HG6A""W[`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__2W^,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"@#IC@=3,^Q.5K0[Q]5XTXT17_
M`'6U]!<6<J3NJ.>:2G*SHC]R+WFF*5B/0ADC03NW&2).CHG1H(RE9QN[ZE)*
M*5G*3@)3DX1.F'F!S<Z<G=JU:^^O%2MO,=W]XGW'0$I5LW/!#/R-V=JZ'"=2
M*!.EFJK(`3<\U<)((AB/BZY4P."<E.:2626>>8+0<18/E/3+C*[\U=/L_!%O
MH+87;'FY<L?N*4QKG&+3"H^ZJ-K2>M?,<6,YR3V$TL+\ON*N)*N,A\#5%HW!
M<TMI1I(WC1)Z@T,;]F<+5A3W`7L.DE'=<2[+ZWO^U^8YD^N"N2\ZT%.JF[6C
M:>$I*?9=$AL-JBM9+9)("].3.R*A-;L3$-;;TYCH?H2U4%X_F11],5+Y/\Y4
M36]K5[.JZ8.>76+S"WJWGT2L*O72QG84D-Z&E#'/(XZ.44=4:&YW*2".&6K-
M`E/),).,V849O`I]YE\I.?ZPYYX>1]&^S<(Z7\VN>KPCDZY+KEI:.:J4Y]LJ
M_P!/8,T=XBW22[6V;SQQOO0;`<WH".,@>?J>N*-3ZT,)(R-!C^FO+SSVAWH!
M5$O:/7/DR;VK47H#9][PBD4S?R[OK&963.'EX73.AKJM]OME7==Q2Z+R(:4M
MM+/;$:AI*+6$'-AYJA.<@#*WB?SG0,(]6/6V](59%6+3IE8$UA_+-41R^J=L
M&6M-$?W?62[IN=LE=UY,I*\Q*I';IAP;4"#:A*W_`*<I2;1JBM*Q_8$-K3`8
8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g662896g03z41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g03z41.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0\^4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!)P```=X````&`&<`,``S
M`'H`-``Q`````0`````````````````````````!``````````````'>```!
M)P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#*$````!````<````$4`
M``%0``!:D```#(4`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!%`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U&\6NIL;2X,M+2*WD2`Z/8XC^LN:SLOKN#15<[JE&27YM3"UM3=HJ
M>'M.,[;;5MW.^A;O6ET?J>;G9F8RUK?LM#S738*GU;G->^NUM3[;;/M-=&ST
MWW^E1^D^@LDT=&L]`8'3K<4OZ@'/]:A]8-OIY3O79ZXV_O[;F?GVL_TB2GH:
M>K],NIKO9E4[+6A[?TC#HX;A]%[F_P":I_M+IW_<JG_MQO\`Y)8>)@].Q^J?
M9LC$Q;,?J)==BO>RMK_4#*[+ZZZ75MWLL_293_2LN?Z_VC]'74MC]B]'_P"X
M&-_VRS_R*2FVQ[+&!];@]CA+7-,@CR(4ES70.N?5_`Z>[#NS\/$LHR<MAQWV
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MV57?^>UT72Z!1AMK%+L>'.)K>_U7:N<=[[=S]SK?YSZ2HYN`U[[[!B9+GN?.
M^K(VD_S3?4I8Z]K*W;6^WV5_S/\`@_YQ)3E8^'U7(R&,:&U!SB\F[IC&U!FT
M;6.=]I]1OO:__A?TJT\;HV10R]V<_%RF>F[TA7BMJ<UWN=+G;[=_[K/H*%?3
MF#J=5XZ=EM+"PC)LRR]HAC6?I*'95V_9]!_Z-_[ZV<G^CV_U'?D24__0[;H#
MFOZUUL#&QJFT7LKKNIJ8RQP<SU+69%E;GNMVV^[W_P#J.J69^UA?A?;CCFO[
M>STC3O#MFS(C>+-S76[O2_\`!?ZB?H%E?[2ZQC-]2:;VN+K+3<'!X<0ZMSVL
MLJ8S:ZGT??75Z7Z-9N.>C-OQF]/S;\I_[28VT7OL):\597Z#](UG\VQMOZ-_
MT'U?Z6MB2G2^L'37'I&::656.K:Z_%K->XMN:&NJ=7[VU[_5K]N[V?Z7]'ZB
MTL/J>#G2,6T6.:QECFP6N#+"\5/<QX:]OJ>E;M_J(]U3;JG5/^B\08_VK*Q+
M,FK-JLM>'LR*JZ#ZET.#V_:;O9C%OI/?_@_4KM]>[_"?T=)3L*I;_P`IXW_$
MW?\`58ZMJGGX%F4ZJRG+MPK:MP]2D5.):_;N8YN53DL^DQCO8W>DIN)++_9/
M4O\`R[S/^V\/_P!X4OV3U+_R[S/^V\/_`-X4E-CJ#BPXUL.(KM)<6M<^)JN8
MTN;4'/V[WM0W]1<:[`PEMA814XX]Y`?'M<]NQNYF[^4A_LGJ7_EWF?\`;>'_
M`.\*7[)ZE_Y=YG_;>'_[PI*06Y_5]SO1LI#=QV[\7*)V>[9NVEOO^@I79_42
MYQIL8UO+&NQLB>&>US]OT=_J_P"#_FT^8WJ>'BLJJOS<VU[G$Y%=>*7M&FUC
MZG-PZ=G[FQO_`!JJ79G7198&5Y_Z8->T"C%+:FEPW"MQR/=8UHV/;;9=]/U_
M3V)*2OSNMEYV74-9[8'V3*+N/TOOG;[G_0_1_P">M&[/QWTO8T6ESFD`>C;R
M1_Q:Q[\KZQ--@:W,V@N(=7CXQ(:T.T;NRW>KN_,]G^C_`.$6ATO,ZB7MQ\K'
MR+"Z7.RK655,:V/T;2RJU[G/?M_-9^C_`,+Z:2G_T>V^K[(ZUUTM86L]:IH<
M6O`<0PESFW/:VJWZ;6?H_4]+\_\`P2:ZSK#KL0=0QZ,=@Z@P5>C8737LR-KW
M2QNYVE/M_1?G_N>\?U=QFN^L/7,ZMYV.N%.UA=Z9>T?I7.W,]*RZO8VOVWVO
MH_34^G1^C4)P#D8HQ^IVYSQU)N^NVT.V/V9>[&:P-8[;7^E_0N^A]G_X%)3T
MZP>L-]+IV8YS26XSF6N:6A_LKM;EU/$VX_MKVV?SEU7I_P`Y_@OTF\JENQN1
M;ZC'NKLK9]%KG"6FS=]`._D)*28^?@Y3G,Q<BJ]S`USVUO:\@/'J5.=L+MK;
M:W;Z_P!]B.LW(Q+,B^K*PGFBVEME0=93NTL-#G?SQJL^CC_F/_ZA+'R<UO5?
ML618U[74/R&M%1:1^EV,9ZP>ZK]#6[T_H^I;_/?R$E.DDDDDI22&RT/LLK@@
MU$`DQ!D!VYL?YJ>ZZJBI]USVU55-+[+'D-:UK1N>][W>UK&M24Y/UF=D%G3<
M;&MLIMRNH8[`ZH@';679V0'[FO\`T?V;$N]G_?/T:V&N:X2T@B2)&NH.UW_2
M7/8@S.MY#NNXQ;556PU=%;E5$MVO+?M?4[*-V/D;LMC?L^'^DJ_5?TW_`&NL
MK0C]6^H/+A;C])+"YCX&/;+W`/:\O_3^W9ZK_3_G?]+^C24]*'L)+0X$CD`Z
MC_7:I+`P.@YN+G49/I],8*QM>^C$?7:&0^:Z;'9%NSW/_P"G:M])3__2].Q\
M+#Q76OQJ*Z'7NWW.K8UA>[]^TL`]1^OTGK#LRKK[\1MG3W83:^H,:QYB'PS)
M_2ZMJ=L]NUNW?_/?\8NC6=E4NZB]]$78;\*YEE.3#"U[MN[=4'^KOK_2/JLW
MUI*=%)9W[.ZG_P"6MW_;5'_I%5\6KJN0ZQIS,O'](QNNIQ@'ZN'Z/8Q_[O\`
MTTE.RJ74,+*R',MQ,D8ES&/K%GI,M/Z0UND>I[F[74_1W>G9_A/\%Z=/,IZK
MBUM>,W+R2YP;LHIQBX3^>[U&5^QJL?L[J?\`Y:W?]M4?^D4E(.H8_7JL/+OQ
M\XV6L9=912RAFXGVV8]#-SG;G,]-]+7/_G/7_2?X-7*NK=/L96X7-FS9`UYL
M)8P<?OMVJAB,ZKDW9%1R\W'^SNVBRZG&#+=7LWXY8Q^YGZ/?[]G\Y6EU!G5<
M'']=N7FYIF/2Q:<9UG#G;HM94W;[=OTDE,\S,+J+[\*]U)M-0JOKH=E`$@NW
MV8U0]78YOZ/_``?^#50Y_46RX9]CO4KVU-=TO)(%FT,]:S9[_P"=999Z?L6@
MSIW42-XZG<POAS@::`9@#WQ3]+:-JKXC.JY3[F'+S<;T7%FZ^G&#;(+V;Z-C
M'[F>S?[OS+*TE->[J?4ZWO;]K+6-<8=^R\IY#6'W&Q[+&5V>T;?4JK]_J?HZ
MZU?Z9G9!N^R95K\FXMW"QN';CL`'^DMM-E/Z3_![7J&37U3"#+_M.5GAKB78
M]5>."0UK[(=N93[7[/2]C]_J6,6NDI22222G_]/U5)?*J22GZJ27RJDDI^E/
MK&,DXM(QG9#+?4=M.,U[SN]&_P!+UVU/J_0>OZ7TW>GO]/>LIC/K@*<DWW9#
MV^CD;&FK%:_U/3;]F<Q^'D66;?5W^DST_5]3^=7@"22GW;&K^N'J.]#(S=A8
M[2ZBB0W=E>D&_:<K])D[_;_@OU;]EOR?YO(KLGL^MX=?NMRRT,/J!]=`#AM'
M\P[%N=?6[^D,9]F]6_\`H]G_``5G@R22GZEQ?5&+3ZY)N]-OJ$@`ET#?+6%S
M?I?NHJ^54DE/U4DOE5))3]5)+Y5224__V0`X0DE-!"$``````%4````!`0``
M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````
M!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!)P'>`P$1``(1`0,1`?_=
M``0`//_$`*H``0`"`@(#`0$````````````)"@<(!08!`@0#"P$!````````
M`````````````!````8"`0("!04'#`D0!`\``0(#!`4&``<($0D2$R$Q%%D*
MU!67&!E!(M466)@:46&V%S=WMSAXN#EY\'$R(R25)]<H@9&QP=%",T0E1;4F
M=I;61Z%72#KA0U/3-%0U566%-D9F9VD1`0````````````````````#_V@`,
M`P$``A$#$0`_`+_&`P&`P&`P&!A_37(#2G(>$G;)H[:%,VI`UBU3=(L4M29Q
MI.,86WUMVHPGJY(+LS&*VEHEZD9)=$W0Q#E$!P,P8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`QCNS]QK;?[V-]_8K*_K#@05]MCL\]K?9O;IX"[
M(V#P+XR6^^[!X5<6+Q=[;/:NK\A.VBWVS1E%GK+8II^NW,N^EIJ9?KN7*QQ$
MRJRIC#U$<#=7[$+M$>[IXG?1'6_DV`^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]
M$=;^38#[$+M$>[IXG?1%6@_V&V`^Q"[1'NZ>)WT15OY-@/L0NT1[NGB=]$5:
M^38'G[$+M$>[HXF_1%6ODN!X^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]$=;^38
M#[$+M$>[IXG?1%6_DV`^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]$5:^38#[$+M
M$>[IXG?1'6_DV`^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]$=;^38#[$+M$>[IX
MG?1%6_DV`^Q"[1'NZ>)WT15OY-@>?L0NT1[NCB;]$5:^38'C[$+M$>[IXG?1
M'6_DV`^Q"[1'NZ>)WT15OY-@![(7:(Z#T[='$[KZP_R15KU_<_XL'HP-+M7=
MNK@K4^Y?S%XH5KBCI&$XV;-[;G".[[!TG'4.(;:YN%P8<ON8KQE8I^M)H!'R
M$LV=Z]A%"+'()@-%-Q_^*+T#_]"_Q@,!@1J=W&`LDUP&Y#O:KR%VOQQE:GKN
MU7)O;=-VN$HMSGG%;@WTHRJ*=ODH>4F8*,F7S<A71X=1C)JH`9-)RD!C#@0)
MS-B+R9U;V@M+;PW+L5YJ&W]MCDQO"^JPN]-A4!];=ZZGUQK5S0IVYW>DW*MV
M.P3=-7FW,@BR?OEDCN!\Q5%3I@14ZVWEO7D?QAY3[:Y%;WWHVW%PEX,Z6V!P
MNE";TVA2G_XTN;V^CV>ZC0U>MT`RV59KVS:I,'"LLA*-UVP>61,`,/4+7O*K
MFKW(-%:0XF6#BGV_W7-N?V5J&H6';DVILI2D.*?:'=1A'KAFXK[*JS;UPM*/
M7*JQG!E$DB&ZI^#Q>G`K*=I;NT[VX&\,>25]E^#=MVE36O*S>5^VN\J&PJDS
MEM?S,S=W:]DK*-;DG2=CF"5IRLJFJ\*S*B4J0G/T*`]`NI<`^8M=Y]<4-3<K
MZI2+)KF`VQ$O)6.J%L=,7LY%(M)!S'^%VZC>C)<%S-A4(<@=!(8,#<G`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`QCNS]QG;G[V-]_8K*X&IW:=_H
MLNVG_(`X;_S==<X&_P#@,!@,!@,!@,`/J_L_LZX%9+O\;NVMI;>O`"]:@V]8
MJ)-:.@^4W*"8H$=?K%5*EN<VC0T1=HG4&P(.%EXQG;6^Y:I!VJHP[5X57J^F
M#^S@"@"`A#!5.ZGS.X_!RDW%7]ULWULY:;?XF;;L)KY-V_<%=XJ:^W'0.6.V
M)O7FI]9>3=V<$YU>)->Z[L+A"+>LX]VB!G;47#A!PT#.F]>Z1N7D'NKB#$[2
MW)KF)K=.MW"K:TC5M8:LN<90;&[LVF$+1NG8,SMF>GF4Y0@K&U996$-399L#
MV,;)`FX\3GJX`.H<=>^GRFHNRN&^AHQU7ZSIF,1T%3]F+6[74@^K+FL7FKTS
M]L&?8[*D)^UV,DA09Z==]',I)Q2;9PF*"K=^4O0`D_X&]WC:.P[5<8CECR(T
M.-7MW&&X[1J:C2I1VJW>N=H06V;#K^)UNI,#;I9.RO+!2VS:</[2D@Y`QRF1
M*F@(E$(3Z-RCW!)SO;9ING.4UBUSJ]LR83^^U:WM#7D!6%;W>>36P+=M]S<F
M\S5EY!5V=15<RJCI^J<6JY/`8I!*`AO1SOYZ;)U]W$][[=XQ<C%+WKB_:ZTO
MQE94IEMR2-K"NGVQ4'T:\W55X%O-E@VDOJVPJJOI-ZT2(X(8J7C.`@&!@WCA
MW5^4W&?5VJ]%Q_(YG/K4Z8GRUNQ[+I5NY$3/):RCN)&NRU.V!M.:M[=UHJIL
MJ`*\RQDUE#F4]!BF%'^\B&7.8W=?YC3M>V$SHW,RATFJSC[8D_#L=.ZO9N-G
MZWB=&<I=15F)8Q-XBKHM(74-EZOL4Q-+I%C&YI")AA:I$.DL[55#@=6]S#=6
M@MP<AKMKOE+J^SZ\WEO_`'.H[;[0TU/R2[%[#\8ZS9:-O$[6I65.X,864O<:
M6,/7V,:9$YO.3("CCIT#;GMG\[C<M^>7$"_[%OT?);SM'$CE9KW9(*P<913V
M>(I>\ZW*Z;<QU2;-HMZA'O(R3G7<<9VS8O'+03KJ-4#&,&!;+P(LJ=_39\B_
MZK+A?_.TY[8'_]&_Q@,!@8/W[QMT9RDI'[6W(+6M>VI10DFTN%:LI'AXWYR9
M@8K9T)&3MFJ8Z0*&Z`)Q*("/4,#664[4G;OF-7UO2[[BEK4=9TZV2]WJU6:#
M8HY&#LU@8QD;.R$=)1TXTF6Z4S'PS5%TV!S[(X30*"B1@#TAVR^=MK@GLRR:
MXMEVXP:MF9W4T1"0%`=%B',6VA(*LK)N*_#+1<,]CHF;C(9PD51LA((.TDE`
M\12@81$0W:22303301331023(DBDD0J::2290(1,B90`I$R%``*`!T``P*('
M93.E=]5]R!I'-%))EIKEMO9QLR/5;BJDZKU]N=H!%@DQ.4P3K60CT%DW3<"G
M*9,PE.`E$0P)R^*G<6J.IN26C^VY%<<]V2BFP8A].5;9U'J==;Z&U95&<',R
MB4587"<JQ?P2""T)[,FBV8G236>($#H!A\(3\8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8&,=V?N,[<_>QOO[%97`TO[8]JK='[1W;PN-QG8NL56L
M]NSB'-V&Q3;U".AX6(CN-VNW+Z2DG[HZ;=FR:-TS'44.8"E*`B(X'T_:Y]K_
M`*]?K\<5?[7[<U+Z?K_\Z>G`\_:Z=K_\OCBK],U,_"F!F/2/.SAER2M3BCZ`
MY/Z2W#<6L:M+N*SKS85>M$TC%MA`J[\\=%O7#@K1$3!XC^'PEZX&URGC!,XI
M`45/`;RP.(E()^@^`#F*4YBD$WK$`$0#[F!#70>[?$7"P4&CR.L$:[L%.[<E
M(?D'5GEI$'.DZ3QL8N9&=O+@%HQ%66:6-K[/[`D<C85C+"!3#X?2&`*!WEMC
MP>KKK*;MU#72[8L6N-5;GXO4>%F'E>5W;3]][KEM-Z\JC="3;O7*-F@91D@O
M*JM_:"@U=$5!,H>C`L#Q3AX[BXUU(,PCW[E@S</F`*>;[$[6;IJ.68*^$GF>
MS+&$GB\(=?#UZ!@??@,"';N8\T],<3]Y\'J5N;C;2-QU'D=;KY6+EL^U0];E
MU="4BJ2^JX)U=EFDY`2JKVM-;%MIBM*B59LFPCF[EV<3`D(8&`^.'<1[9FW]
M::(L6P./6LM?7G<##6*EE@('CXTOU%TY*;QVO:M/Z4B-K[2A-??BG0'6TK35
MU$8<)A5B9V<X`0#`("(95U)R][=UZX8V[G!?^*T/I?4='V9L_6D^E?.+;-M8
M`?:ZW1;--$?14,C257\X22EZT'M"35-52+?'68.P2=M7"28=>JO<1[,5TW!#
MZ+@*?K9;9,Q/P%14AG/%-=BA!7.T1R$E7J9:I-YK]&/K%LER+>2A'O5$7)W1
M#H>#S"&*`<E3N>G:*O[1X%/U!!3UI9;#9:O/K./X932^V5[8_K,Q<TDV>M4]
M;FM[N)2JM>>R"SY-J9JBU:J*'.!2B.!A[2G<`[8)F.ZX[<_'_3&C7NKKMNEY
M'%/QG;,:M<:#0+(S9KV&N3JVO&4/8[F]<3*9Y**9'7?-W2X%4*)S8'&;R[G7
M:XK7'N?V=HO1.OMI;#""L4K6]=N.*DA&/8P:G98:NS[S9R/[7"C[6D`S=RQ2
M>W2J3=`ZABE*81,&!,O0]!\<;;1Z;:G''/1;1>S56O6!=JEJFB*)-EIF(:22
MC=-0]>*91-$[D2E,(`(@'7I@=K^K%QK_`">M'?1-0OP!@!XQ\;.G\7K1WT3T
M+\`8'WUOCOH"G6=M=ZCHS3U6N;-H+!G;JYK*E0EH:,!%<PLFT_&0C660:&,Y
M4'RRJ@3JH;T??#@9BP(LJ=_39<B_5_19<+O[?\;3GM_Z,#__TK_&`P&`P.,E
M)J&A$4W$U+1D0@LJ"*2\H_:QZ*JQO[E)-1VJD0ZION%`1$<#\WD_!1ZK%!_-
M1#%:3$H1J+R29ME9`3=/"#%-98AW8FZAT\L#=>N!R^!2+^&&;'>*=\%L11-,
M5>35G`%%1$I"B5_LP_WP^H/[GI_;P,V;![NUQX,=QS@MQ?L]UUM0.*.[6=OG
M]]6NZ1JWM\:]<MKC#U0[*RGD6S2%;*6&`C40$R*H&,Z.`B'4!*%O:.EXJ73*
MO%2+*03\I!43,W*+CPIN4BKH&4!(YC)@JB<#%\701`0'`Y+`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8&,=V?N,[<_>QOO[%9;`T5[=6M:+N3LX<!M4
M[/K4=<M=[#[;O$RHW2J2P+#&6&MSG&K7K&6B7P-EF[CV9ZT6,0_@4(?H/H$!
M].!KS^C>]DO\@C7_`*__`%@;O_VMH=,`/PWO9+Z#TX$:_P"OW/\`*#N__.A@
M;-\4>T/VX^#VR%MO<5N+=0U!LEQ!OJVK:XFR;$G'_P`R27@]O8)I6VY6!B@F
MZ!,`.8B13B`=.O3T8$D>!$[O7M*:1V-;.4&U]<2\QK;<G+FLUFA[7MC@X3L,
MC2X^>82EM2J5>`C`8&Q7>/9"U?/O:%?,(;[X@@'3`SSM7MT<7]Q[+XG[7N56
ME3V?AHD=KJ%.*E4XZ(<QA(QA'Q<-=&)&*A['$U]U&(OV"(*-P0D">=]]U$N!
MO0'7KZ?];^S^P<#S@!_LZX&I?([A1H/E=9:19-VUU_:!H>NM_P"K(R$^<"MH
M&1IW):H0=(V>SF696QW+ETX@Z\W!BNDL@JR7`52B)_")0U!UOV4N%6JC:K:U
M(FW4*WK2,THQE:4[V*=S4=QON.=]F=G:/L6Z8HL,DI<9[75ZFE)!FHBJP;JJ
M(HE<I+D2`N!GK[.+CQ]7_9G&$Z^PU=.;/W+<MWO:TM:T5C52TWW:+[<EDB:6
M]4B#+Q56=;#EGC\K5<7:I3NU0\X0$.@8+E.RGP9?\D;GRB:U:V0FP]C6U.\7
MF/BY:O'KD_9D696B4HF,O5)6U5MPF;QK":'E8X3KJF,<3?>@4.DZF[#_``@T
M3&M4=0R.\M>62-N-<NL+L&I["B(*[PDA6ZA9:`FQCI",IS6+"*F:5:W<;(D6
M9K+/$3`H=3VCQ+&#*%P[./"R^PSV`N,%?;%&R#7;#9T25MY'RQU=RR47,6^0
M4<N8A5=>2+)PZ"S550QQ3,!O,!4#&`0Z.MV.^%:U/K5+*YW#'LH*)M-;DI*N
MW"MU"0NU1MLVQLDE4;LWI](@8&7@49R-1<(%29-G!#E^^5.`B`A+C7H-C6(&
M$K<6"A8ROP\9"1Y5S>8N#&)9(L&@++`4@*J@@@7Q&Z!U'T]`P.9P&`P&!%E3
MOZ;/D7_59<+_`.=ISVP/_]._Q@,!@,"M_P!^+3$Q=;!IS:EI:ZNV%HC5>B>4
MI;;IG8?(5'2#U?8T]7ZN.M-NUA@M(QAKI*ZZ=1KD$D$3*+I+NTP(0PJ8%;^&
MF+=?N,O(F>YE6ZV(\G>/W;5XP6_ARA;]@66'MM?O4S:E#QUQUW'J3+%Q/WB=
M`6J+DY4G*JR'A*9,`'`NL[6W+S>UIQ"X[V_C1QKKO*/=<W1-:!L.H7W::NI`
MCE'E&AW4[.+3(UBT*.I'YY.H51N9`@^(1$3=?1@4U.S/VE-X\L*AR0YG0/._
M='$"7;\L]MN=I\>M71*T]2[7+4&YRLQ)5VQSZ=\JB,ZQ55.YCA47BU2^083`
M0?%X,"5CDSV9M?=V"1K=:L6_OVE;G1$6LG"V2'T<VO%P)'5]RY56;H7)YM"L
M,V<7(R4Z"ZC+YM4."J)3@OTZEP(1.'';XWG:N5G<ZU7L_O+<H.*%"X<[TA=6
M+[PDY6R,V&YI:4L5CJT-(S",IMN!CHB36;P3<Z+=!V^Z)+AT,"9`,(3NM_AN
MN7SM!%TV[_?.5=NY237;N$8>P*)+MUB%4253.7?PE.DHF8!`0]`@/7`_;]&R
MYC>_WYU?XDL/^?[`?HV7,;W^_.K_`!)8?\_V`_1LN8WO]^=7^)+#_G^P'Z-E
MS&]_OSJ_Q)8?\_V`_1LN8WO]^=7^)+#_`)_L!^C9<QO?[\ZO\26'_/\`8&@\
MUQAY>]L/O/\`:=T?8NYORGY84/D9L-_)6V!V-.6>O0/L4($O'C"OX$VQ;BPG
MF3PP%5,"W@*4Q0#PCZ\"^5@,!@,!@,!@,!@,!@,!@,!@,!@,#&.[/W&=M_O8
MWW]BLK@:2]M2[5+6W:"[?%_OMABZG2J=VYN(UBM-FFW)&41`P<5QMUX[D922
M=J?>-V;-LF8ZAQ]`%#`^O6W=X[9NX;U6-9ZSYHZ/M]\N<LU@JM68JRJ_.4Y,
M/5`2:1S$KEDW14<N53`4A1.'B,/0/3@=MWMW/.W]QCO[S5N_.66GM7;#CFC1
MY(U"SV$Z$TQ;/DO/:*.VC9JZ]F%PB('*4X@82"`].@AU#9'1N_-,\E=>QNU]
M";(JVU=<R[IZRCK=3Y`LE#N7D><J;UH"P%(=)RU,<OC3.4IP\0#TZ&`1#+BG
MF>6?R@**O@-Y8',)2"?H/@`YBE.8I!-ZQ`!$`^Y@0S4?N[0EHM59UU,:Q0K.
MQ8"U<D&?(VLOK27QZ6HO'1DM(2-V\X\:D>91M[8S<(Q%4C3SE%1#Q!X>HAB+
MC9W6M^[*WEI;1FP=9:AA)+<^N:UO:/EI&P;%KTTVUELJ];)@Z+`0]<B:!<8M
M];H^K4).0>JR4I$,UC/R%2,(E-T"?G^S_;P&`P-*N:'*>V<56?':7@]6$V'`
M;EY7\<>-UOFU[6QKJ.O&/(+<-)T_&6=&/4;O9*RR+24NI'"31!,B(IM%?.71
M$R?C#`/';N+3FX.=O(+AS?=?5+4@ZOF-CQFJS3]GMA-E[PB=>.:![;?ZE5Y"
MBQM2>T$K.X+@Y<LYQV[:.$$2F;^6MYI`^#3W<T7V7RQ-HF2U$:!UK;-E\N=/
MZHV4WM"4G8)J\<)K;-T;<QKI3_8&Z%8K\C8J?,!!.&[U\J[;MT3N$FQEO`4.
M@ZK[I3Z'U8UWOR.ISM.A;PY#;#TEQ3K.E:M,W?8%J5UU==O5-Z6TQ:B[)!O(
MS#?6'M+?RS@F45O+,/7H.!GC5'=?X>[IN&J:-0+)<I.;W*RA7E,\^F/F;,33
M3EVP(QEW2RW_`"7(QTDP7;.TCE$4%T3%$1Z=<#5?F!WF@XA[$VJE8=#KVG26
MJ-GU/0<S=XFY-4+L\W/>J&PN]:9-*6ZCTV'XCF"5;M74B>2!RB<QC%:G*7J(
M:_;F[]UYT3%!!WCBC'FVK$WBM0=KAX/9ZDO2658N5&C=@UN4B["WJOSXK*NX
M61\E8'<8TC6CM,05>%3$%,"5SASRMN'(?8O*6C7"L0]>-I.[:]2JJL0\,\&2
MI&T=?,;S71EEBF5;*3<>515%<Z!S-U.A3$$0'K@;ZX#`8#`BRIW]-GR+_JLN
M%_\`.TY[8'__U+ZEJN50HL4I.W:U5NG0:1RI*S-JG(RO12:AP$2IJ2,NZ:-"
M',!1$`$_4>F!@VJ\RN)-WG'-;J7)71L_/M'(M%8F-V?3UGIG0K';`@V1^=@,
M\5,JD)0!'S!'IU#T"&!LH0Y5"E.0Q3D.4#D.00,4Y3``E,4P"(&*8!Z@(>@0
MP/;`P=M_C1Q_W^^J,ENO4%#V@^H;MP^I[BYP#.;/`.7AFQW9V(.R'(4CD[-(
M5$S`9,XIE$2B(!@?!?N*?&O:=LIUZV)HW65QM^OBM"4NPSM1B'LE74F`D,P0
MCESMO[VV8&3**"1@,FB)0\`!TP,_E*4I0*4`*4H`4I2@`%*4`Z```'H``#`K
M1_#71Q)CB+S+B%%#(IRO.WEA'*+$`#'2(^O<ZV,H0IOO3&3*KU`!]`B&!N3K
MBQ.M%[@NBT-7)>ZJ0XS%:13:(JB<&YY!(QG;HC1);RSJ>PE`H!Z.O7`B^^)>
MC&V^.U3,5_26LU);=5EWYJ*[7FC:]IKAY>W"*$=;XYU,6)K"Q02LJ9D[EVB:
MBZWF&(*Q>H@'J"TUJYNNUUGKMJ[240<MJ-4D'""Q!36071K\>FJBJ0P`8BB:
MA1*8!]("&!WO`8#`8#`8%2WO`_\`O`/86_[56W_I&6P+:6`P&`P&`P&`P&`P
M&`P&`P&`P&`P,8[L_<:VW^]C??V*RN!HMVZ=:T3<?9QX"ZJVA5XN[:ZV%VWN
M)=2NM1FDCKQ%DK<UQKUZRE8>11342449OFBIDS@!BB)1]88'%Z[[)G:CU+>J
MGLS7'!C1]1OE%GHVSU&SQ<3+EDH&?B')'<;*L17F5T0<LW*93D$Q#!U#U8'<
M-]]HOMK<H=F3FY>0/#O3^U-I65-@C/W:SQ<FM-2J<8V38L"O%6DJU14]E9I%
M3*/@`0*4/U,#:7CIQET'Q*ULVU!QMU95M/:R:2TC.MJ;3VJ[2'3EY8&Y9*1\
MMRX=+&<O"M$P.83CU`A?5TP,[8$7>].U1H':%CY)[(I9Y/6NW>5]<J='W#>6
M*HRA)&D04^QF)N+A85SX&L)(VULR]F>O$A\U5,WIZ].F!N?1N..J]<[,D]M5
M*'=1MNE=0ZVT:X.#Y0\8GKS4\A:)*EQC:.$H(H.&#FWO?&L`^)4IB@(?>A@9
MUP&`P-0^6_"O4_-&&U[`;:G=GQ$9K&\P6RJPCK>]OJ08+Q5)Z`M-/L4D=DW<
M"_?T^R5EH^C#&Z>S.2&,'7Q#@8QL7;-XY7"^;#V?;9+<-COE]UUL35S"RRFT
MY]63U=4MK+QCG83?3KE$$%=?/K2M#-!<.6HBKT;IE*)2EZ8'>M>\!>-FL.0=
MPY*U2K2Z.Q+A(;!FS-'U@?OZ;6;#MM^UEMK6.FU98?8:].;)F&QG<RND(B[<
M.%S]"^:8!"/N4[.$O;JU0=67/D'-'T[JKES9^2>N8*H-G54M-7@[G+[@L5AH
M\=9&9SJMEC3>U1,@Z*`^!)H!1`?%@;]:Z[=?#C5,=16=(TE78F2UO76E<J%J
M*M(JVN*;,TW?ER!9@[SS%9I1T^6<G<F()SN53*#Z1P,+2O9[X0V292E[A3;C
M=DAKD-!R4%;K].SE>L,M7JDC1X6_V&,<J=);8T=7&R:*<NH?SP,0I^GB#K@=
M3D>R;P6E8=K&R->V8]DBN9/YWN#C9<VO=+7!R\.UK[RG6J=6(HI+U$8%DFR(
MS$A`(W+X0-]W`V@XJ\1(_C-=N1]N8V$DLWWC>*E+P<*@S%HUH]&U[2V5(I%/
M1.<QU'@Q$0U$IE1'[[J'ZF!N?@,!@,"+*G?TV?(O^JRX7_SM.>V!_]6?/F'V
MW."/.'N#3U+YA<J-L7B_3.HJ+L?67"4=HKZ_H-;UX5=]K]Q9J[7XTZ'X^!8K
MC1)AV]26\URW<.%#``(E*(!")OO0OPZ-!WS=M`%X<\BZM7=*;59Z/V=RZTN2
MY1%#UGN05(B-<U>3O+-91<'\#)S31%\X2`I6[A4>OH`!$+?'!GB.KPETB;12
M.[MJ[V@(VY3\[3K!N"33F[74ZI+-XM*-U^E-`8[J6AJ^JP6507<F,X.=V?Q#
MT`H`&Y&!UBTW:F49FA(W6W5BGQ[IP5HV?6F?BJ^S<.S^DC5!U+.VB"K@P>HA
M3"8?U,#YY785!@EX)K-WBH0[FT"F%9;RMEA8]>Q"J!12""1=O45)<5`,'A]G
M!3KU#I@=OP*VGPRW\5OEM_+_`.4?\(DQ@2C\=I6.9<AMV,GCQNV=2TNY0C4%
M5`(J]70DY1=9-`@_W9R(@)A`/4`8&%^7=!V"QF-PQVMMWJ:(VMNVAO(#5FU8
MZ)4DU-<S#^:A@&P/4S@=/P)MXI9(1`HF("OC`.I0P(>G7`'O#<<YC6FU.1/Q
M";>OZF3V=KZ,D_QRBR1,/;1E9]H=.G-EYABU8.G]F8H+HII'.!!)XSG$J9#F
M*%N.,E(R:8-96'D6,M&/4@69248[;OV#M$1$H*M7C515NX2$Q1#Q$,(=0P/N
MP&`P&`P*EO>!_P#>`>PM_P!JK;_TC+8%M+`8#`8#`8#`8#`8#`8#`8#`8#`8
M&,=V?N,[<_>QOO[%97`U%[53QK']J?MN/GKA)JT:=OKATX<N5C`1)!%+CGKH
MRBJAA]!2$*'41P-P0V]K#I_^N:Y_C!+_`'<!^V_J\>O_`%ZKGZ@_\HI?[N!R
MD/L2C6!\G&0EIAI-^J4YTVC-XFJN<B8=3F*0OI$"!Z\#N>!"[6^\-6[;K[F#
ML1GJ-K`0/%<]Z@$S2NVZ=,V>XW>L3Y:A!1:VNH9$MGK\3:;,Z;I-G"IC"J4Y
MO"`F#`RGQ$[BEKY&;NL?'BU:7@J3>]:5^(6VA)(;8KBB[*SOJE5+4]9UO6;Y
MN6\OZVP"V(M#R*A@3(Y3,0P=>F!*?@,!@:<<N^7B'$Q;CN:0U1==B1.^^2FE
M..+NPUIS%L836DAO#9U-U16K3:G4D?QN&A;+>&@D9-R"X<HI.#%$OE>D/36_
M+U*_<RM\<.WVIKM2YO2NIM8;D87RQN8LD#LBG;.N6RZ&PD:Q%MCJ239FRLFJ
MY5(%G`@#DB93D*`#@?MK'EXPV)RKY&\6GFLKC2I3CW3]=WD;K8W$:6%O]:V$
MYL\>SEJY&MC*2#6/:2=0?)%5<"'M!$P4*``/3`U6U)W2JBKK>P[NY,LJ]I73
MUIW;?-/\<;#''L%EE-L+:]N6TJA,+C&,F3QRG(NSZT5<-DD4^ADU>@^D`P-I
MJ'W`>'VS)Z@5>C[PK=AL.T&,-)4>,CX^QK&GFT\!_FT$'I848Q%8ZJ9TCD57
M(9)5,Q#@4Q1#`TRY2=Y36'$_9>QJU?=.7J1U?K&[U[4=BW##3D"=@&Y+=1FU
MZK-#0J"I/GTR,FS?(-AD_%[,BX5`#!T`1P,:3_?"@ZJYJ58M?&6R4W8<YLZ-
MUW8X"Y;>H5>J='9V'7C#9E4M4SLAPR5KJC*PUY^!$V_A342=$%(QNOIP)#^+
M?*>6W]LGE'KB>J495W_'S8=4KL<YB9?YZ:V:IWFFM;?69\7I/\%46<MU%2B9
M`10.4A3$]`X&Z&`P&`P(LJ=_39\B_P"JRX7_`,[3GM@?_]:9#OC;"X]W[=&M
MN*K7BQN3=G-&L:2=<F->;GT%L;5FD-H\:Z`>[S5*@+O"[(VC9*K&69FXNU=?
ME=5TBZY#MTS^:D";HQA"#/B#J_CA=Y;5O+?N9H[UD..?+:]P^SJ'R<U[;KM&
M<;=Y;@BK*E39-CR]TK6BNV^MMJDNU939R4L=N6&M$@T.Z(L`+D*F']#3`8%3
M#XD;YSE=S<*JU6%=435H6U?RYFQHW)"Z1NO]"2-?C:G3T7UD/8I:4BF2NX*\
M\=(FK+0ICKJJ'5$I>@#@07U>WZQO?&CDR[VW:[&?:6L>W!QF/P-#;UK5CMBG
MO7XW*-W4_IUL$JD6RVR2M!3(E4C0<N%614_&7P>G`NP;OM/<9K_#KCG)<*M:
M:IV=R`=T?68;+A]\W%>D1S-%2BPZD^\%\#=PJM._/@J`HD8H"`]>OIP(SOA8
MEK0XX6<BG%W9Q\==5N;7(96WL(EP+N+8VA6X/5+`SC78@474>VEA5(BIT#QI
ME`?NX$J<G4XBI<TJ:E#IN"%F'#V=>@NN9<3/Y*$FEG)R")0\M(QQ^]+ZBX&8
M^4L1KY@SK5]N=3E[>XCGR,*UC(^1.U;F1.9P^$7B!"&!PD90@E,'4.H#TP(M
MN\CQMU3W1^W'-:95?OZ1LNL3#O;W'.O/Y)Y!L9/=5-HVQZ)18JQ22#!TW3K#
M]2YO$U`5$I2G!-0P]"8&^7::X_;=XK=N7B7Q]WT5!+<&L=8)0=]1;SI;,BVF
MG$_-RXM"SI#J$DC-6DDDF90IC%\91`HB`!@2(X#`8#`8%2WO`_\`O`/86_[5
M6W_I&6P+:6`P&`P&`P&`P&`P&`P&`P&`P&`P,8[L_<:VW^]C??V*RN!IQVNX
M5C8^TQVYX"3*H:/F.WEP_CGI45!15,V=<<==)*@FJ`"*9Q(8>@_<P,R_4OTA
MZ0]@L?I]?_6!Q^KU_P#D<#Q]2[1__P!0L?H__D+C_P":P.YT/C7K#7-C;VFM
M-)E*6:)+H(G>3"SM#RW)`(KXD3)E`1$`]'I]&!G[`B-LG:II"%=I&O-?2E=C
MZ#)<ME>37(%Q8J\BK>-EQZ4XK;X[7S&QQB"2Y81I;/*6!-X=1($D@`H`/IP-
MW]2<6=7Z>VEO'<,!&-GM\WO>/QVL5@D8N,4F(D35ROUQ2O0LR5O\YMZ^JC7$
M%S-O-!,5Q$PEZ^G`V3P&`P-(N;?#$.:%<U7676ZMAZ?8ZKVQ1=TQYZ"C$*JS
M%]U9<JML'6DK)#*)*`'XG7"J(/$"DZ%4.8P'`0Z8&*IKMVS\GR(W7R5C^76]
MZU?MRZ#C^//G0!:VT"C4ZMRMULM(>51P=HLHE+4VV[$FI)J=4IP,N^,4_4I2
M@`90HW"M.F\P]P\O5MT[#L4IN.E06O9O6LHC$DIL94ZHO./*I%QBB"19`"0+
MVROU4C&-U,9R;Q=0`,",N1[3_)>ST?3VEY#=]>I6M]"<TKMO_65CHI'J5XA]
M<WZ?WG9Y6#`T@DLQ/864AM)HBF)@%%1)NIU]88&\VF^TYQ&T:EK!_28*WHW3
M4L$UBZK=G-UGU)(DHW<2,BI97D85Z2$<2CF<EG#TX"@*8JJ=.@@`8&%M@]E/
M0VXI=\\W+MK=NRH:QEK5CO5<F["R18W7<%1I3.BP6Y995FS362MS6+8I*B1+
MHV,Y(!_#]S`_*<[+NJ[/JZW:NL>^=S3S':,[&/=PSLP:M24WL6O0$"SJU<JB
M[AY%JA7VD+7&96J3AEY;@2F$PCU'`VJX<\2)GC5L3E-:Y"7BWD%N*[Z^#7D-
M'"Z57K6M-5:^8T&FQ4NY=>ES,%8MS"L<OWH]`'UX&^F`P&`P(LJ=_39\B_ZK
M+A?_`#M.>V!__]>3+O9PHV#D<2=Y1=FC97-?CW1JW78?4?)CB]LB?A=R1T1+
M1+69N-"OE1IY75TGH>/O:[\[-H@D6/*BH"PF%910,#JU/[ZNDH?2U4XL<:^R
MQSFNE0I\#&T>N:/D]$O*E1H2'9%%!JSD9&0K-@CF"2<E_P`*N[03\:YS*G.!
MQ'J%B#@CMWE;O/1RFQN8''>(XM[)F+K8`K>H6%I1N,I#ZW2:1!JP^M\RS=.H
MXUK?NU7HN$VHE1(B1+[PAQ.4`W/P,4[4T7IK>#**CMQ:NHNS6,$]&1AFMVK4
M58D8M\<"%.Z8%DVRX-5CE(4#&)TZ@`=?5@<=/<=-"VF4IDW8].:UFI?722"-
M$D9*FP3IW446OA!LE`+*LC'C$V_A#P%2$I2]/0&!F8"@4.@!T#[@````?VNF
M!6U^&6_BN<MOY?\`RB_A%F,"47>T1LR(Y`0&QZ127EG"!B6WLPF;*JQRKA1B
M\8*I+B@N@OU3(Z$?O3%](!@<E5N2&U)3952U]?M=UZOA87?0Q%VDH#TC;V=T
MH5RV(YDW"(`)VXEZB4?1UP,4=U7C%;-^\5]V16O=BI:MLLEJ6P4R#GT(MRNK
M$R=E*_A4)1%:/DHU=#R#SX&$4Q!0`*(@/7IT")WL0ZN[O/&]IRAI7+6Y/MTZ
M(H^HX2%X4S-XO$<$=<[/5WMK*FTBV(2$S8X.!F`%NU=KR"I5FQ44@3(H'42!
M(#V&NYIM?NO\+K1R9W%0->ZXM4'R`O.I&L#K0MD+`+0=7I^N+&RDG`6F<GY$
M95=S<UTU1*N5'RTB>$A1\0F":S`8#`8$*/=.[(6D.ZOL+2VS-F;SWOIBSZ-@
MYJ$J;O2[^G1JRI9N2"27?.7EDJT^];O4%`\!#-U$0\`CU`1P(VOT2G1'O&^X
MG](>O?\`P!@/T2C1'O&^XG](>O?_``!@/T2G1'O&^XG](>O?_`&`_1*=$>\;
M[B?TAZ]_\`8#]$HT1[QON)_2'KW_`,`8$,??![-\+VE.-^A.1NF.;/,O95GN
MW,'5ND9"!VCL"#4KS6OV2A[9O;N5:%JM=KT@,NA(ZW:HD\:QD/(75\1!-X#%
M#^C=T_L'[OZ^!YP&`P&`P&`P&`P&`P,8[L_<9VY^]C??V*RN!J=VG?Z++MI_
MR`.&_P#-UUS@;_X#`8#`8#`8#`8#`=<!@,!@,!@,!@,!@,"+*G?TV?(O^JRX
M7?SM.>W^K@?_T+\\M*Q<#%R<Y.23"&A(9@\E9F8E7C>.BXF+CVZCN0DI*0=J
M(M6#!BT2.JLLJ<J:21!,80*`C@:)\?.X]PHY##MN1UGM[7C.(U!>J_KFW6V:
MN&NXJLO[-;GDJSJK:"L#&UOV,JE9GD,N2/\`&=)1Z<`!$AQZ@`;^X#`8#`8%
M;3X9;^*YRV_E_P#*+^$68P+)>!H3MH/]+_4/ZGS8AZ/5_O9H!_M^O`V_V+2F
MFQ:5.TQ\[<,&LZ@W06=M2IF<(@W?-GQ13*J4R8F,=L!1ZAZA'`UPV1QNIP4R
MJ@]MT_7H/6E84CE5F"K0IGH*N@=O))T+GRTB.'3Y8Z@@!B$`3]```Z``0G]C
M>Z\5>&_)[EQV0^-E?VU8&O'=BPY8RN^=EVZK3?[84AMRK:,)+P#.`K%;A&M<
M1J,;;X-@W$%G/MGLCA53P*"/C"SM@,!@,!@,!@,!@,"I9\8W_1T\4?ZRG1?\
M!G)[`MIX#`8#`8#`8#`8#`8#`QCNS]QG;?[V-]_8K*X&IW:=_HLNVG_(`X;_
M`,W77.!O_@,!@,#&-5W3IV\VB;I%*VUK*X72LBI^,M1JU\JU@M%?!)44%?GN
M`B91W*Q/E+_>&\]%/H?T#T'`Y:O;,UO;;%8ZA5=@TBS6NG*()6ZL5^V04U8:
MLJY%0&R=CA8Z0<R4&HN*1_`5TDD)O"/3U#@=X'U?=_U/7@=;@KE4;0]L<96K
M37+#)4Z8_%ZW1\'.1DN]JM@!FVD!@[&UCW3A>$F`8/$5O9G14EO*5(?P^$Q1
M$.R8'6['<*E3DX56W6BNU=.QV*'J%>4L4W&PI)ZV6!<6L#5X8TDZ:EE+%..@
M%)FR0\;ETI]ZF0P^C`XB%VCK*R7"PZ\KVQ*)/;`J**;FV4:&MU?E+C6&RITD
MTG%AK+&07FH5!0[@A2G<H)%,)R@`_?!@?M$;(UW8+98*%`WZE3=ZJ2*+BU4N
M)M4')6RLH.?)]F7L-<9OUIB%17\\G@,Y13`_C+T$?$'4,9:5Y+ZKW]8-KUO6
M\HO*2&FK42FW5431:C)&<,XEVJC9DO&RDB*OLSJ$<I*@L5!0BB8E$OB`P%#8
M(?4.!T-[M/6,9;3Z_DMCT-A?$H9>QJTE[;Z^UMR=>:I&7<SQZVO(DF20K=$@
MG.Z%'R"$`1$P`&!U?ZQ7'T*Y%W']O73@5";FSUF&M0[/I7XN2]D34!)2OQ<X
M,W\V2$V14P%,T25.N!A`/!UP.LW[EEQTUPSO1YS<.N7DYK>$6L=QI4->Z;(7
MJ$AFYFP.'[^JC/(2;%JW3=D444<%13(F/B$P!TZAG6#F(^PPT1/Q2Y749.1<
M?,QKHATE".(^4:I/6:Y%$3JHG(JW6*8!(8Q1`>H"(>G`Y7`8#`BRIW]-GR+_
M`*K+A?\`SM.>V!__T;</=LXV[?Y>]N#ESQPT'*EB=P;1U:K%4859=&!1FI2+
MGH2R+4Y>;=.6;*);7N.A5X15PX63;(IR`F6,"0&'`IAT;BUS_P!KV_EOQ#TY
MV:=C<+*-RPV-V^I![89DS*M:#X\)<-6!$]DVJ!NHQS2O;#-L"R"YDVBL3(O7
MAC+&]+]8XJ&#^BG@,"OC\0O#:W)QGILJ1SL`>4M]MT?Q_P")\91]FWJE>9L#
M:4S")/IZ5K]2G8EG:(^IL8XKQP+HBPMD`,)0`IC`(0T\K:'?*.;GG2-A[DV\
M;8G;%X$<9K9QB=EVA:H]Q%;.E7[%:S;/*W9R+4ML=VRR'59^-TFX150\*8%Z
MX%G_`&SOOFS1N(O'C8_&'B:;F1N:XT;6K^^TA[M_6^EE(H)FCP\I-6)>=V=8
M:W$O%QEW"A3-DEC+>(1'P],"+CX6F0GI7ACR/E+5`_BM:)'F]R(?62LA(,Y4
MM<GWER?N9B!^=(Y5Q'R7S1(**-_:$%#HK>7XR&$I@$0LV8&HV\./-IV;>XBZ
MUJXMZLZB(I%BV4]F='>)KIK.%!<(N&[I`4NI%_#ZNOKP.@_5JW[_`.OV1_7^
M^F/]7_G/`Q[MC1^XZEKRSV"P;B?V"&CFB)I"&44D_!((N'S5F"1O/?*I^$JC
M@INABB`^'`A:[8O'YYJ'OQ<O^1M\VMH^`B.5'%^FT/0^L)#9]>CMW;'FJA7]
M+.;VM5]62:[*S3\316.D9-U*.H])V@V:.6RIC%`502"V]@,!@,!@,!@,!@,"
MI9\8W_1T\4?ZRG1?J_>,Y/8%M/`8#`8#`8#`8#`8#`8&,=V?N,[<_>QOO[%9
M;`TP[8R4XMVCNW>E654D+"IV[>(1(998Q"I)R1N-^NP:'4,H4Y`(5;IUZ@(=
M/N8&?]41'))E,RBFT9J%?Q!X1TG%IL%V*BA)D3$%LJH"#)N<$P+UZ]1$/UL#
MB]90G*1G;F*^R)V">U4K.3*\;LG$>=<79X]P2-,4J+!%40(^%,3=#=`#]4,#
MD->P_)9M??:K[-PCNC>.2'V5HX8G=>`YSC'!X46**O4A.GB^_P#]?`VB'U>C
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M9E`V+R"OD^\YH7";0U*ORFAJ)IA3C+&)U-MKD\F$%L^K62J,O:[199%5C%_.
MJCH\8S:2L.\:%9II!(-W7-$;0W5#<0YG2_&-UR`V+H[F=QHWT6>CKCJ2ERFN
MJ)IS?VI=G[)814EM.[TP%I38U1IBS!!-B9<#JMRE<BDF8AC!KG4M(\FJYW).
M2'-T.`<I#M:7HC8NHN-5=HVW>-]:CM\/K19H;:-UV%MVPCLAU9&VP=I72)1C
M8-.0B48VNL$UEG:AUW1U4P^#C%VZ]]ZI[HFWN22#6R5#0SA]RYM$9(6^>T_*
M3FQKKR:V>ROQV\6IKE,;VOKZN2)G#J,3MZ@/8ALBU8H(^!(RHA'ZVLN\(+CS
MH+1.@ZSR,AM]-^XYNBE\L&.H)N?T7<=D5Z\['Y5V^LN#[4DU*O%#`R,4LQ>M
MY)21;MT140'STCF(.!(9QFXT]W>LV?CE=]Z[Q7L$/3ZO75-N:Z6W1)2,A87\
M6XE5CP4I['$'J5BG58<S)F^D1=BW>O$U5Q.8#>,0T=YM=N#G_P`M[CM:R5;C
MK":OO.U]J:QWA&[8F-W:S?.Z'4:WI>'JENXTR#RORJMI?NY>PM'+(7+)L>OK
M)+^>9<"]0P.`V_VRN;%YXX\@:=2N)Y->R>X+5KEU1=4Q6S>+CR.IZU&UQ`U*
MQS5OG9EW(HUBN[`FXXSA=S291O9@1(`J??&\`!DJ[\..2O'R]<IMKEU/,QW'
MO8_%_9;?D.E9)+3^TFUQV>XU!%4RCQW'B+J19C?,6Q&U)E(N2:,B0Z293F*H
M(]0"P]PW@;75^)O&NN7@7'XW0FC]8QM@3>`J#MO(M:=$I*LW15R$63=,@`$E
M"F*`E.00^Y@;*8#`8$65._IL^1?]5EPO_G:<]L#_TK9O>)G.3=:[8W-"?X=+
MVAIR)A],RK^C/J,9ZG>HZ.0E(D^P)2BJQBB4PC>8O6H3#B&4CS?.*<FD@9H`
MN02*(4)]"\R..5*:\S.+7;7WQS1V5M;E1O3MC3_$A>PN]FFWU/W2GMG<[RJ=
M;!M,5'5V)C%&EMFGC"113,=I*)F*#47;0GM)0_J!X#`Q7>=(:@V;;M97W8>M
MJ==;GIF>>VG5%ELL$QEY?7=ED67S<\GZB[>)JGA)==A_>1<(>%7RQ$`,`".!
MA/=W;_X5<D=GTS=.]N,VH]I;4H!F)JM>+;56<A.,BQ;DKV+;OEP\M.>9Q;P@
M+-4)`CI%LJ`'3*4P=<#;U---(A$TB%333(5---,H$333(`%(0A"@!2E*4.@`
M`=`#`K;_``RW\5SEM_+_`.47\(LQ@62\!@,#`?*'T:&V(/J_Y.C/V01'^S@5
M"MI:DM[WX@WLLW.EU2Y3=>;ZQVW.7>ULXUV]K%<=-(S=+:18R$VSCT(R%\F)
M%F)D'3D5E3/D2@`^>BF8+N.`P&`P&`P&`P&`P*EGQCG]'3Q1_K*=%_P&<GL"
MVG@,!@,!@,!@,!@,!@,#&.[/W&=M_O8WW]BLK@:G=IW^BR[:?\@#AO\`S==<
MX&_^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!%E3OZ;/D7_59<+_YVG/;`_].W
M-W9H_>\GVY>6K7C')[QA^0!-7+OM2O.-Q'2FZ!N<5/0<G%LJ8E'KMI1;YU,S
M,UD2,U"/3Q*SDK<?/%/`K[\..ZAS^I`::@]E?#A<HB[P?0M(H.YN5$95+/6I
MZ[RZ+6.@;)L^V3%AX\2%M=K3AT324B$K9'BAUE%!5>*=?,$+C6`P&`P&!6T^
M&6_BN<MOY?\`RB_A%F,"R7@,!@=/O=+B]A5*9IDTX?-HN=100>+Q:K=!^0B#
MQN^*+91VV?-R&,JU`!\21_O1'[OIP*Y>ZN(E-YRTL>)=FV9N+2"%IVE7+`UV
MYHZV,ZM?V"52C[0W)4GRCR$E49FI61S)I+.V@BV`'K-JOXA\GP"&P7;G[$E(
M[=>ZY3=%8YN\U]TN).G3516HNU]D1CRB*A-)E2"8D86.AF_SE)Q)>JC(QSE!
MNY`BH=1+T$(]NSEIK;^A>^[W=-6SM[Y&;.U#6:=`RU/NNZYNT61D]D]CSNO;
MZ5NTFGC9I6'#AFM*R;%B+5,B@LH\Y.AA25$`MUX#`8#`8#`8#`J6?&-_T=/%
M'^LIT7_`9R>P+:>`P&`P&`P&`P&`P&`P/CD8]C+Q[Z*DVB#^-DV;J/D&+I,J
MS9XQ>H';.VCA(X"15!PW4,0Y1]!BB(#@1>_8A=HD?7VZ.)WT1UK[@^C_`(MU
MZ8'G[$+M$>[IXG?1%6ODV`^Q"[1'NZ>)WT15OY-@/L0NT1[NGB=]$5;^38#[
M$+M$>[IXG?1'6_DV`^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]$=;^38#[$+M$>
M[IXG?1%6_DV`^Q"[1'NZ>)WT15KY-@/L0NT1[NGB=]$5;^38#[$+M$>[IXG?
M1%6_DV`^Q"[1'NZ>)WT15OY-@/L0NT1[NGB=]$5;^38#[$+M$>[IXG?1'6_D
MV`^Q"[1'NZ>)WT1UOY-@/L0NT1[NGB=]$5:^38#[$+M$>[IXG?1%6ODV`^Q"
M[1'NZ>)WT15OY-@/L0NT1[NGB=]$=;^38#[$+M$>[IXG?1'6_DV`^Q"[1'NZ
M>)WT15KY-@/L0NT1[NCB=]$5;^38&1JMVHNVS2*)M'5M1X1\<J[KO=C.HQ^V
MJ=$ZV@FE?V&PH-G;W.F-+7'IMP2ED*S:VB4@T*H'1%T0IR^D.H!__]26GNN<
M[+9P![PO![=%WBN5-UXL(<1]WPM[UWH"+F[C"S%]L%F>L:[)35$6M57I,K)Q
MITF:AG#M472"2:9D^O@(`!IIVI/B`H;74?NC67++7O<?VO>]T\Z-SWK2MCGM
M:/\`8D70M#;.EZNCJJ@O9BW;,2DZC%4XR#P1A8UNXC(I)7PM1.`F*`76L!@5
M9N_H[M%FY3\(]925/X^;4TTRTIR]W?:-1<L-AWV@<?KS;=4Q6OG4&G8DZ#!S
MKFXV]C#R+\(.+?D(P.[5%10Q?"!@"%O9VRM6<NM:<OM[W_6#?1ULTQV[.,>P
MNWEIQS:I@[C0%DE;,#<DQH[SG390]BG+"T\L5FR8*+-3ID.D`!U$+?V[MW<_
MM6<.>.=RXC<1([F?O>>H^LR['HMPW;1M&K1(/*+#NYZQN[)L.5BX^0D1FE%"
MJ-B*BMXQ$>F!&=\+'(6.6X6<BI6XP"55N$ES:Y"O[75T)%M,(UJR/+@^<SD`
ME+,3JLI5.'DU56Y7*)C)+@GXRB)3`(A9PP&`P&!";4YZBP%4VVYD7IHS:!9:
M+7UO),TYI"69+I2KGYX5C)B+2]GBU/9?0)E54C&#T%ZC@;Y<8]XQ%HK%-H4W
M+S<OL(T;./7KR2*\?`Z;MIN9.V47F7CEPLY7"-13`?$(]!#PAT````A!W5W:
MNXSQM[UFK."^U.-^I"<..56V:G2.-FU7`2;;84O4VL12T-C6E!S"7V99NUX>
MUVM1MY,G#QOWB28I`8H*'.%G[`8#`8#`8#`8%2CXR)9)OVX^*[A=0B*"'<ET
M<LLJH8")I)):)Y/G44.8>@%(0A1$1'U`&!/_`/:0\!/7]<;CH`>C_P`UJ@`A
MZNH?_:?I`>H8'G[2+@)^6+QT^E:H_A/`\AW(>`@^KF+QT^Y_YK5'[OJ_YSP'
MVD/`0?\`VQ>.GKZ?NK5'UA_^9X'C[2+@('H'F+QT^E:H_A/`?:1<`_RQN.GT
MK5'\)X`.Y%P$'T!S%XZ?2O4?PG@>0[D/`0?5S%XZ?2M4?PG@/M(>`GY8O'3T
M!U_=6J/X3P/'VD7`/\L;CI]*U1_">!Y^TAX">C_3%XZ>GU?Y5ZC^$\#Q]I%P
M$]'^F+QT]/J_RKU'^U_]YX'G[2'@)Z/],7CIZ?5_E7J/ZW_XG^O@/M(>`@#T
M^N+QTZ_OK5'\)X#[2'@)Z/\`3%XZ>GU?Y5JC^$\!]I#P$_+%XZ>GI_YK5'[O
MJ_YSP//VD'`4?_;%XZ?2O4/PG@>OVD7`/\L;CI]*U1_">`^TBX!_EC<=/I6J
M/X3P'VD7`3T].8O'3T?_`-K5'\)X&XT9*QDU&,IF(D6<G$23-&0CY-BY1=,7
MK%RD5=N\;.D3'16;K)&`Y3E$2B4>H>C`USLW-+B73J=8=@V?D5J&(IE38/Y2
MR6-Q=X12-AF$7(*1,@Y>J-W2ITDVLFD9N;[WJ*P>``$WHP/D+S9XK*[7INC4
M=TU=QMK8%?J]JJ-';HS;B6EZ]=$)1W5)7JA%'9L6LZVA'9V_M*J)CD0,(ATZ
M=0YC8'+WC+JG;]!T)LC==#IFXMI.XF/H%`GI8&4[9G]@4DT*_'L"F3%H5_/N
M(5XFP155(J]4:K%0*<4S@4,-'[H?;V2@+Y:%.7FE2P&LI2'AKQ+&M:(,X%[8
M$+BZAA4/Y/\`A[*0::[GUDW;4%V@I0C\_F`1HN*8;=UG95(N4W>J[6+"TF9;
M6DRTKMX29I/!:5^=?1+6>2B'$HHW3BG4BA$OD%G"+=94[7S2E6!,Q@*(=%W9
MR7T7QTH:>S=Q[&AZA2G$[!UAC+%;RUC7EK'99-&%@(&"A*I'SL].S$M*."((
MMV;5=4YQ_N?0.!EEG881\E&JH2*!#RS1F]8,WHGC9-5O(("Y:>9$R)6LFV74
M2`PBBJB14@E,4Q0,40`/W/-PJ95CJ2\6F1LO[,X,>0:%*@X\(G]G6,94`27\
M(=?`;H;I]S`_09>*``$9./`!*B<!%ZV`!(Y_^CF`?,_N5_\`>#ZC?<ZX&+-6
M;_T[NNGM[]K.^1%CJ#N5GX9I-*)2,$DZD*O*NH2=3;-K&RB'KA!A*,E41<$2
M%!0Q!%,YB^G`X>G\H>/NP+3'4VC[9J-OGI>J3-X8)5M\I,QBM6K]@<569E5+
M"Q06KS4K"PM%6ITE71%Q42/T((%,;`S1\]PP>RB,M&='H)"R'V]K_A8+B<J`
MM?[[_A`+"F8">#KXA*/3U8')X#`8'__5OB;%V)1M246V;.V;:X.C:^HD%(V>
MXW"SR#:)@*Y`1*!W4C+2LD[.DW:,FB!!,8YA`/0'W<"'ZO?$3=GZTVF'I\#S
M!J+^>GIII7XENE#60$'DF_=D9-$DW9HH&_EN'*I0*IXO`("`]>F!-K@,#"NZ
M.-^@.1L9"PV^],:SW%%UR2"8K[/8],@;<C"R0>#Q.HOYZ8NS,3KE3*54$Q*5
M8A0*<#%#I@=>N/$/BML.P4:U7KCCI&VV+62+-KKV9G]94^3?4UG&F(:-95Y5
MU$*#&L8TZ13-T$^B2!B@9,I1`!`-BBE`H`!0``#H``'H```.@``>H```P*VO
MPRW\5SEM_+_Y1?PBS&!9+P&`P&!J?OK4>M(?4NP9N,ID(REFL*L[;OT&PE<(
MN#.4/$JF;QB!5#`<?3T^[@:;Q%8<:\T74MY5>9D6=MEOGFN%2330%!B@I9+#
M&F=(&,10PK>0B`_?%$.HX&)>8'/'5FA>;_:-T-LGC54-P;$Y7+3#&E;SL"%?
M-:M'2Q&]$A7TM6E)&$=OR'G9"VHG=`V=,P`C?Q@!E"IA@3B+RD8U=-F+F18M
MWKP>C1FN[;HNG0@(%$&S=10JJX^(0#[T!](X'W8#`8#`8#`8&G7-O@;QC[A^
MJ:_I7E=0U=B:[K&PHK:,-"HSDO7SM;I"URV5..E!>PKIFZ4*A!W611\HQA3-
MYWB$!,4H@$7'Z+QV7_R7GWTF7[\-X#]%X[+_`.2\^^DR_?AO`?HO'9?_`"7G
MWTF7[\-X#]%X[+_Y+S[Z3+]^&\!^B\=E_P#)>??29?OPW@/T7CLO_DO/OI,O
MWX;P'Z+QV7_R7GWTF7[\-X#]%X[+_P"2\^^DR_?AO`?HO'9?_)>??29?OPW@
M/T7CLO\`Y+S[Z3+]^&\!^B\=E_\`)>??29?OPW@/T7CLO_DO/OI,OWX;P'Z+
MQV7_`,EY]])E^_#>`_1>.R_^2\^^DR_?AO`?HO'9?_)>??29?OPW@/T7CLO_
M`)+S[Z3+]^&\!^B\=E_\EY]])E^_#>`_1>.R_P#DO/OI,OWX;P'Z+QV7_P`E
MY]])E^_#>![%^%Y[+Y3%,/%QX<"F*(E-LR_B4W00'PFZ3@#X1]0]!#T8$Z%"
MUI2-8ZZJ^IZ-`-J_KZF5>/IE:K;99VJUBZU%L"1C&+27=+KO3I(,DP)XCJ&4
M'UB/7TX$2'.WMF0$[QEVYJG@CQIXX4O8^^H"O:[O=QFE1HAXJ@PLC'N'(1SF
M,KM@5>R4I$).V*@E!LH<79EUE53@(&#KK'M_<L;%S9JW(:/O\%Q2J,+I&;UI
MLY_I;:UNV)-;Y?J:>4UIJ('^MKO18K6U0-H68?.9UK(BF\<.WY$402.W5<C@
M=!Y+\!N>W)O>455]@737MHXVZ;UK9&W'*^S-V<0&S&?)N3T!;:'!\KMQ5BJZ
M^+'VZWT>[VM=2MQ<6O%,X;S!?"9PN5)-$,-53LR[9O.N(6O<A:AI!*SJ:UXE
M\4*`-(N-RE:[Q9XZ<5]0;[HL[L:O`+*C*;+VMN1YO^VM/F.1:/*\BTL*02?M
MK=)XU6#/6N^WOSSIG;*VYQ/<[[K;C=%DOII6G3<=9IF#;!1',K7I;8-=D-GP
ME68W8LSMB73G71YAT@_G&WSL51T^<NO,.4-!-8=I?9K7E#I+7.WX*]W36DKR
MJ:\IK[2FO[=4[QBXU5C4>MMFITS5FLMFW=5@C:G5UN-VA57(MP2.K(-'*G@%
M-(3%#8O87`GFARI[BV]M^HNU=,:YH.[-1L]-[,LERV=#6L];TEKIQ85&U(U:
MT;LZ58*3L?8.PE6#V9<K*'!K&/$DB")OO@T?LW:1[AD?:].Z[.@TMHW45I_;
M[4N^M_/-*34[K363FO'V9L?:Q(%&Q1NPMLW^95EV\(V:HM2-$2M!6`"@.!N2
MS[3'/VMVZHU2.W=1+/I^!B-)O)NR3=^V"6]3,EIG7%HC(BGH0RL6N@G`N-AS
MB+Q=\I)>:Y9MDTU$1,7K@8>K'8[YJ(V'5L%<]A:FL%$IY81VYM!-F;;C+#$Q
MS>C6Y"9UM$4.'9QM.5KT[L>S!)2,DL=9Z\(D`>`!*`X'OJ[L?\MM.ZS?0]+=
M:AAW!F/&R#MFKZWNO;-7J^ZZKK5_M.?VY"66Y,J^M*UI78MFN\4JL+9H!%X^
M'!L<X>8;QAD2F]E#EG%2.GG]PWE%SKK3$[QD-1@C-F;32A:?7*?NBU[PW=%Q
M#!VZ04GR'6FFU7@5)4BROS&BH4X)`J)`"TI_K_J?_#Z?3@><!@?_UK8_>/T-
M:.3G;#YF:*I%%L6RKQL#43IC2*55))"+G)JZ14]!V*IBU<.2F160C+!#MW;A
MJ/A]N;(*-@,4RH&`*V_$^^\V:4PT7J2Q?#*\5W<S08_7]-M6VFS76K6P(+5]
M"+AY'8#IF^U%.S<?)^-N9Z<',LX6*M_=.3&ZGP+O.`P.%E[)7:^"`S\]"P@.
M1.#89>48QH.!3Z>8"`O5T?-$GB#KX>O3KZ<#YG5QJ+$T<1[:JXS/,`4T05U.
M1C<TH!Q`I!CBJNB"^`QAZ!Y7BZC@=CP*VGPRW\5SEM_+_P"47\(LQ@62\!@,
M!@85Y&?N(;)_[.J_K?\`&6V!K#I*;E+MQX9:_P!>(0KZYU922)*EL[!):/8I
M3ECGY%H\9"]169K/4VS@ABB)3E*;T"'7`T4Y']G!+N"[;T-M_E=M?;5&M7%)
MZ]<::>Z=M-4KJH!,3-=EY,5GL1&+/HX4EJDS*B)!3,0AC`'ZP:.]VC5.R8[O
M\=EK:-"F=R2<!?;*Y@MCUN)E["XUC7X?6%TK4DWDU82/`L3&.9B/MSX\FLY$
MP.D&*/7H"(]0MJX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`X>PS
MT558"<L\Z[(PA*Y#R<],OE`,*;.*AV2\A(.S@4!,)&[1N<X@`"/0,"M1Q&[X
MFP%M41E>Y$:0N-BW_;1H%HU4U83VL*O%;3J>\W>W+72'#=S(VQK&T:'J&NM7
M.WKY><59G!EY"I@\:P%P,EZ\^(>TG;XE9U8=%;-I<PT@:UM60KCZ3J4K)L.-
MSG3V]MWWWD`J>'F'K16EZ[IF@Y(CH$E#JNI!_'MFY5%7:13!E2([O3K<G;*Y
MS\X*II#96A3:'U;LF1TZMM1E"2+;85O/JPE@UBK#!7I238R"WX]SL=#233S?
M"VDO&B)Q`!,`:S.N]O8M9TG4#??-)V/KO8VDKYO77_*>IH5W7UVF]I3W'#C?
MQ]G)&,K\E!7]M`TQSLS='+>DQ#0R8O?9)\RK!P1!`JCD@>NZN]MM^'NNM9"J
M\=;?%PNI+ORO5Y3:\BKAJ>UNGM,XS:R@1MDA#W^.M;NEF@X/8FQ8M$3-GAGC
MITS5:)D%?JD(98UE\0II+<.Y+;KNA<;N0#JC:YCKL\V)MZ1859K6*L%&K<M,
MSKM['I3[B<;Q$1-03N(>.5D$BIOR%`H'(<I\#Z>1/=]N"?`2V;6I>I+YH[DW
M<Z)JZR:@UW<8^(LK@(C>5BJ56UK8W%@B'CZC-9&9DK07RXUV]([0(4JCA(A#
M!@='^W`<O+8SD(W6.PG+C7\;(:\ON@8UGKBP3]QW/+[J<:9J#>#VE%["/6"-
MU7T:N[-[*BZ9&3(J)G*8)CU#J&[N_<ZMNFG$+H#3%TI^ZY*3J]2LTW:;!K16
M!TK/VK;*6NXE=XDM:A/L$'Q(U^X`L*1Z";9/S#"`!@=FK_?%7U'0ZM(;,UQL
M'>"<X,O?;9L:O1=!U[!ZTU:]W&.G:DZEHE]>Y->;&4D&*[QD=F<[E\V`QA;I
M"7PX&]G$7NJ4WEILW:%2B=26NC4376IV^[B;.G;-1IB*E-=25CM]<@Y.0AJQ
M8)>;JDC+C0Y)ZDRDT&SKV`B2PD\*I.H:0<5.[1R:M6N=9WW;.II[9%[Y86RW
M)<:='5K5,?H&.0UU1VQ;/,;#+O#;6U_Q4V-6'-2L<*FF[2:Q11DG'E)%5`QO
M+#AMY=^I^_T_9VG'72-Q;<@&MK'6"K"?KS?8D1K?9ZO(\^E86G6:NU*PLG=D
MM5TKE6LDY$1;-XFLNW8(F.8A5TQ$)3.UYR#W5RFX@5+>6\SU=>R7"\;99UM]
M6:J\H:LC0ZALBRTJMN[70GECMZE'NW_5U9.2B_G5\+1=/PG.145$4PD+P/_7
MM@=Y?8G(;5/:^YF[`XJI6!3>U=U(JK3'%3CEI6S1#1]8Z_%W6QU]DW1<+GEZ
MO07TK(MSE3.9)5J50"CX.@A2I=.>&_%[5W$'E#VTNZ;R0Y&=R&^['TNVNNCI
M3:\KLY?:[BTS<0AL^$V%IPK<]BJ#2*:.WRX!,KOS*G0*4ABJG*H`?TCL!@5U
MN^GIJ,L-AT#R*GGG$:ZUSC;KKD#8YKCGRJVO/:M1W`A,1=3$B]!=PK!V60LM
M=^:#%1*N8A//=IE](F`,"OCMW;&K.4FO^9^ZMFZS;Z+O,'V[^,ES[>NF;-.2
M#2PZEL$I9"IM_P!HYM)N&DC*7!].H%*JLQ1%TNB8GF)E`<"W9OFY]QZL\,N.
M,OPCU5K?;?(-[2-8!LF#W=:T*>S:(+42&5GWRCR1D8L59L)LR@*IF4\8&Z]0
MZX$:_P`+"O:G7"KD.YO+%C&79SS8Y!KW&.C%RNHV.M*MO>J6!A'N2G4*X8M)
M8RR:*@&,!TR@("/7K@6<\!@,!@?#)1K"78N8R49MY"/>)BBZ9NTBKMG"0B`B
MFLD<!(H01`/0.!H]Q,:H,KQO]DR1(W;-;6Y:M6Z)`32001EYM)!!(A>@$(D0
MH%*`>@`#`YWCFM/P.Q-HUZ[23UM*2TL=_6H6;DU57J\65Y+.#.(UBY7.H5J#
M4H&ZD*`>$/UL"+SNX=X*V]M/G#VW-533G6\'QGY*RNPB<AKA<HF7<SM4K]9G
M*##LYFMRT?)H-HLD>G:UEW`+-'0+`F4H"GZ38$\%1V/0;ZBT<4NYUBT$>P$'
M:&Z4'.QLBY&N69BA)U^;59M7"KI".F6#@BK94Y"D63,`E$0'`[K@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<18(&(M,#-UBP,492!L<1)0,W&.?'
M[/(Q$NS6CY)@OY9B*>2\9.#IF\)@'PF'H(8&J5F[?W"VY0ZM?M/&S5T[#JLJ
M;'&8R$""J1(_7T*\K=,8-Q\\%&K*!@9)PT223,0@H+J%4`P'-U#G8#A%Q'K$
MHYF8/CUJ]E(NM$I<872PUEHZ3<<?$O/ZZA6:/?:6BE(6(Z4(JS%/P+I&\"GC
M(```<G`</>,U7TC(\;X+3509:/F)!O*R^N!0>NH"6D&LM$33=Q*`]>.7L@*$
MA`LA*"RRA02:I(]/)(5,`Q'O?MQ\7-Y47;557U_!TFQ;A8;%:678U=@*]+6L
MCG;5LUW=-ER2"-RB[+`J2%VF]4P`O5SM!<D3C4?956RB22B8==X_]KGB#H#3
M#33#37B&QF!XK;$59K5L!./<6:X-MX['4VMM!K*EK;&MP#&+L=O%$0:,639%
M!BR;-@`2)#X@R9%]OKA=!V?8=QAN.6MXJP;6C;!$W]W'1CEDWL;&UI*HV5)Q
M%MW:<2R4G4W"H.E6R"*JWG*^(P^8IX@RQLSCAHS<NKF&D]H:QK%TU/%I5U&/
MH4PT44KK1*I"T-6"(LT%T/`$"=@B9MT$?*,D4P>D`$`QY7>"W$&HN*\ZK''O
M7$"O5!K1J^I%PPLPC5*>YD'M;63(BN4BKF+?RSER554#J*.ESK*&.J83B'!N
M^W?P@?R];GWO&'4KF<J+3V*NRRU;2/(1S<)-],EZ.Q5%9RNG)R2ZI%5A45(9
M4P%,`>C`YIQP6XDK0;FNIZ)H36,<1-?A`11B$UB(1U2D'DQ5VZ;=\+QDHA`S
M#]5V@DLDJ@+@PF4(?U8&#^&_:[XY<,&6_$J<-@N\GR3=+)[2D[@WJ[`DC6?8
MY"-84V.BJ37*K%QT`RCI1R40!,ZRBKA4_C+XBE*&RMLXA\9+S6]44^W:1H$_
M6-&KME]1PLA")JLJ#[&W:LTV]?(4Q3-V"K5B@FLU,)V[DB*8*D/X"]`Q'HCM
MV<8M$5.1K,;18NXN97D'9N3[^RVV,C%9QUMZ?EIZ186-PM&-(]!PK4F-A681
M0*$.#5F4A0#Q%`V!MIKS7-(U156E'UU6XZI5)A(V*6904215-@VD;;9)>X6-
MTD1958Q3RUFGGCM0`-T!1<W0`+T``[M@?__0M'\R;!W2J_M/=TAQU-QAA>,<
M;P[D'VO;3N.9C8U]'\JR7EL*PW894Z#1KK<FO!7\Q5PH5F"WA\8^+K@5S-5Z
M[[K^A>7.HY&=JW9=UKMO<\Q$V6,7K;/6L5L2Y5.1D45W\Y1$V?\`<'DVA5!8
MN&14@<G#H@8P@(8%YS`8&*=F:*TONCYD#;FJJ!LK\671WM?&[U2%LAH9RH*1
MU58TTJS=&:^<9`@G`G0IQ('B`>@8'Q6;CQH:YS53L=MTUK"QSM$*@G3)69H]
M<D'M82:^$6B,(NYCE#QZ#42`*2:?A(F(`)0`0P,Q``%``````]``'H``#T``
M?K`&!6U^&6_BN<MOY?\`RB_A%F,"R7@,!@,!@1V\>+Y3J;LW>32T3\?"N)J]
MOD(M)X<Y3/E2SLP0R:'@(<#"!U2^OIZ1#`R%/0C&K\JX"\SMIA&J,U'.(F(A
MCKG4EG#A:,7BR)@B0#`B473\@AXNG4!'I]W`S+MCCAH/>KR`D-S:?UYM![5B
M/$:XZN]6BK$M")R*K5=\G&GDFZXM2/%F*)E`+T`XIEZ^H,"OGV[Z_9(/XA_O
M")&AYV*H3?1W'",J":C&095-)LPBZPW18UTITDXDJ+)%(Z94VWH3*4Q0`.@A
M@6=\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0P=]_N/L.VOP"V7
MLJ"G&\=O#8[5QK#1#(JR821;A/M3I/K4U0-U4%&EQ!U7GF^$2$=^S%-Z#X&;
M^T%S?:=PKM]\?N2BK]H\N4Y64ZOM1)H)`)'[5J*:,5=F9D2CXVX'D2@X2*8`
M,9NNF?\`N3`(A)A@,!@,!@,!@,!@,!@,!@?_T;;/=XX]NN57;4YA:$9;(@=1
MO+[J9V5K?K5*IPE6AEJS-PMQ3:V:75512CZ[8C5X(U\J8W0K5XIU`W]R(5'-
ME\!-K;5M=COO,/:O#JK]S[E3?^&K?A7K^G;D9PD%QTXQ:&?1A7$]J)X@";(Y
M=CP#,J3:/2*D991!0Q!$S@XX']`+`8'7[1;:K2(9U8[I9J_4:\R\`/9VT3,=
M`0S3S#>!/VJ4E7+1BW\PWH+XSAU'U8&/;5R&T/1I&GQ%QW+K&L2FP!0"D,9N
M\5R.<6LKH"BU5@DW,@F,BW<^,`353\2:@B`%,(B`8&82F*8H&*(&*8`,4Q1`
M2F*(=0$!#T"`A@5M?AEOXKG+;^7_`,HOX19C`LEX#`8#`8$9W)[7%2I=\UQ*
MUV-%B_M%G?R$RMYIU/:G9Y-DZ,KX3B(%ZK.CCT#]7`R/R3@J+6=BT7:,U8$H
MI[&/6CAS#MVB[V3FR,738Z:R*93`FDDW(7P"/ZIPP-HM8[1KFV8)Q8*R#XK%
ML_4CE/;D!;J^>FDDJ;PEZCU+X50].!$-QT[F)]B=XOG#P"ND#J^DQ>E*'JI_
MK"QIKHLMA;.G;!'Q\K-Q;HZX)J2Q(UI+@=-!,3BB1+Q=/OAP)P<!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4"?BR.$/(2T:[GN?7(#>\*EKVBWV
MJZ9XX<<:9'/%6->B;4$Y(.[%<IR25*W>VN;2KZKAT=F3PE$R:)?[VD&!)O\`
M#1<#.5W!C2&M[878U=V?Q'YIZ>I&^I^BOSK0ESX][RDZ='.74A#HKE.RL]9N
ML4FWB7A$/`Y358LW!@\!%?$%K_`8#`8#`8#`8#`8#`8#`__2M[]U'BVXYJ=O
M3E9QD9WZ+U>]VAK)9NQODZ[*PKU??U:;A[PR5L[TZS=-I5GKJLD;2:ACE*1@
MNL(CT#`I\T?@W,\Z=><K>3>U.3G"S9_-ZS<A^%FL(FVZUV`V@M:<+-6:=L",
M=!P=#EB@T8-Y[9L;7CMT(YD/@54:_>F\:JO4/Z`^`P*N?Q+C#=VP],0^M(W2
MFY;WQDKNL=K;:VU9];0J$I!#L6N,XAAJ6!NRHR+1PTJ\>\?OI)V)2*>,4"!T
M'`@PL=LJEKTUS*0W]57E7W+9.V-P_@.%E>V1$$1NKB>9.HMLT_:@35*Z60L[
MJ?2*NH:/.5R*0E%3H'HP+AV]U.X_"\,.."'!J"U1,\@F]&U>TV.TWO)GCHU!
MHA1(9.=,"ZA3F4FRS15`4`WWW7K]W`C:^%@-:C\*>1![TG'HW<W-CD&:Y)1)
M_,BTK4-O>C84HP_^_CTY<5@1'[J8%P+.6`P&`P&!H)S.431LVFUE3E322F'J
MBBAA`"D*1W%B83&$0`I0#KU$?0&!N!_DZOKG_P#;%J<L41'H(,915JB<Y0$P
M=?-,DF8_0!]0".!J-=&;S57(.*O*\=(5S436,;(2#V.(9"OA*.6[]L4JK%LH
M1)1P=8Z0"(IB/40].!%Z\F^TC7.]7J>?2UK9ICGKR+I<S:JUM+PR#BHLC0<8
MA5$6Z[110J#*77BH@")*%*)2`7J/I'`L;8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`I<_&@;&DC\6^'/'&#,=W+;KY`RLTA%(G**CE[2(2,A805
M$?[L?:7FP%$TA]7B`P8%MKC9K^.U3Q\TGK6)*9..H^K:/6FB9R%3.1**KL>U
M`ADR")2&*8@@(!Z/1@9LP&`P&`P&`P&`P&`P&`P/_].V%WE=(6#DAVP>9>E*
MIL:M:KL=ZU.HTA+C<K.PIE3)(Q-EKU@;5FQ6J3=,X^#AKZI$!`.'"RGED3DS
M>(IP'P&"F9K7C[W">2%PY,\8-5=JAMQ*UES+N_;SGIRYQ<[6D=":-K_$&#;D
MLEMH<C75%XBWQFR99495DM&NGYB(+#T,Z.?S\#^C3@,#YW+5L]06:/&[=VU7
M(*2[9RBFN@ND8.ADUD52F34(;]00$!_4P.$=T^IOUX]T]JU<>N8DJ9(MP[A(
MQPO&IIB`IDCUEFQU&14Q`!*"8E`.GHP.QX%;3X9;^*YRV_E_\HOX19C`LEX#
M`8#`8&)]FZ8I.VOFK\<&KUQ\S>T^Q`T?N&7A]J\KS1/Y"A/,_P"!#IU]6!J9
MQ/AV-=W-N.!C2*$CXA)W'M"JJ'45!NUG$$D@.H<?$H8"E]8CZ<#>Z?K-?M<>
M>)LL/'SD8HJFJ=A)M4W;4RB)O&DH**P&()TSAU`?N#Z<"KAO3C%&(]\[C?RZ
MLFV>-V@]$<;*+:*T^87RWUK6T]8)9\HH]8Q]=9R?S3&SAE!DA%9=1WYJ!"_W
M!P$.@66Z)O'2NTH^9EM9;@U=L:*KI1/8).B;`J=NCX(A43.#'F7E?EI!M&%*
M@03B*YB`!`$?4'7`Z+&<P>),U,,Z]#<I..DM/R+TD;'P<9NW6C^8?2*BGDIL
M&<8ULRKUR]45^]*D0ACB;T`'7`V+P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&!0[[LCH_/GXFO@%Q!KYTY"M\8BZ^LUX*45'D6VD8-V\WO-.9`B8*II
M"=LC&Q*Q1#P@KX4S]!$0P+X)"%3(5-,H$33*4A"%#H4I"@!2E*`>@`*`>C];
M`]^O^[@,!@,!@?@Z=-63=9X]<MVC1NF95PZ=+)MVZ"10ZF4675,1)),H>L3"
M`!@>Z2J2Z2:Z"B:R*R9%45DCE42524*!TU$U"")#IG(("`@(@(#U#`_3`8#`
M8#`8'__4M==Z&E5O8O:UYK4JVVC7M(@[#IYTS7N6U5+`C0JJ^)/P+J&L4ZO5
M6,I8&XPTTW;N&BC9LX43>IHF%,Y0$HA71T5?N^7QAXY:ZN]H[G';(G>&''EC
M0:)<=D)3==V&ZC*7!$B8=C6I>R1&MY"<>W,\'Y+5%LJH$HJJ)`$OF#@7$M([
MUT_R2UK7=PZ)V%6MHZSM:2B\!<*J^]MC'H(G,DX0.4Y$';)ZU4#HJW<)I+I"
M(>(@=0P,M8&$-R<E>/7'9*NJ[XW9J_3Z=N?FBZO^V-=J_436!\F9$BR$0G-/
MV9WWLQG!/.,F`D1`Y?&)0$.H<;L+EAQBU+/4:K[.Y!:<H-BV;[(.OX6V;%JL
M)(V])_Y?L#N!:OY1%1\P?F6(5!P0/(6.<I2'$Q@`0S^0Y5"E.0Q3D.4#D.00
M,4Y3``E,4P"(&*8!Z@(>@0P*VWPRW\5SEM_+_P"47\(LQ@62\!@,!@,!@:#\
M:OXP.]_1_P`9E/N>O_K$E_KX&_&!!ES![??#'N;[Z?U[FO0U+%%:/9.F5$DX
M79-RU<X;IS9VCAZA)/*E88).7,HL/4OG^88O3H7I@9=XD=H/ML\*:3O&N\=:
M:^KE1WY534';"\ONJ[W)*3KZZ+A'YN;2UCM<F>OKG(Y.)5&JB"WB'J`]0#`U
M&I7PS_91J5DA=B534UL^=J-/1-I92OUG-P24?&RL._0DX]Q()JWY=B=`KMN0
M3)K@*:A?O3`("(8'0>U-M>ZW'O8=\*D2>P9VT4"D/>.R5!KKNPN9>N5QLH2_
M,7`5UD=RLR8IJ-F*!#B@`>(J90'U!@69\!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@8_VOLVHZ7UCL';M^DDXBDZSIMCO-IDE#)E!K!U>)=3$B9(%#IE5=
M';M#$13`?$JJ8I"]3&`,"DG\,'0K9S9[@'<*[O&SHX5!M-QL6OM</#=?9$I.
M[S);7;6T>U5(`(-(:NMH5NU,GZ$@.JF'3H(8%ZS`I`:RV*GRJD>+&XX#;.VY
MSO!;2[GK)?8^K8FX7PB/#OC'JSDA<&.PJ!?]9%6:5&K:;K7'6H),7"<F@12Q
MRTTF)//.H()AVNJ]]CFSN/C93[7I>;J=BVU%\/[%?-BJHZR9'A3<IN2?/_6G
M&'BKILJ:T*=BG+ZHUK:)"4E&S$5A>&0\;\IS$4!,)&^YAS>Y/<"Z;Q'TA9>5
MT'4M@;(B-\7S;G,.;T93Y=A(HZN@9N[PNJZ5JAM$*5)K8;:YD6$%%)F(J^48
MLC*G.N\,HN8(TK9WNN=DOKNETN6V'"\9MUP?%)#>\1/2>F8"YN^:NV;Q$ZZL
M6KM-Z=KLI67L&QCEF6R4D)%2.2,])[*`^>D/F'P,G:?[O_-W;7)NOUVT;7JF
MMTXS9.U:3N_B0VT["O9;56ON/&A2[!V'LRP[2>QRLY'O=@7]LX80K05P34CA
M\QOXU$Q/@?#R#JW(:S=I?MAZ&1NTU"7/F%MFS[DW7`KU[\9):_5:S25VY-RM
M?>E>^8\;1Z<9--6JS0H>4Z35*D<@D#PX&)=3]WGG.WU\U6TMM+6>R(V<T6UC
MDM75K1M?A:IPOW/8=L1VN-/:NEWL;!M)2S2SF#27<2<<]<.#HD*)B$0*4,"X
M_H:L;9J.K:O"[RV83;FT4F@.+9<T:O7:<Q<R3HI5EF$7!5B/CHUM&1BAA20,
M8AEU$R@94YS"(X&8<!@,!@,#_]6V7WB>,VU^8W;-Y?<;=''9?MK;-UFW:4QE
M(.DV3:<D*[;*W<'%7,\6_O#-:V1U>7C$55!*DFJ[*8YBD`P@%&2Z\,>:07VX
MI:@[->P]6<8[E:.,%BV9Q!@=[Z[V#$RTIQ)?V1SL68N44:?>.4W>SS3QT&`*
M-@,Y%`ZIO:U5/.5"VQ\/9J+9>L^+.^K'=-$V/BY2]T<NMM[9TQQXM+8K"5UK
MK:?;5QJP:C$D3;!#-WSZ.6(FU%NV\LK<#`GY9B"(3X8%<CXCZ7IJO$2S41_O
M+CIJ&W7/6=\11@=OZ\>VO9&TJDRD*NM*TS1]D;N?#4K6\E!:D$Y&<BNH91(2
MH@4AC`$!.U+O5G>ON:L+NZC3NMMN[X[8_#VJ<*]=[+:2$IL&1G(US&1K.J4!
M\[C4'3F[-9MN5V[!J1)9(BI3'$```P+<.]J#W&I;AAQPK'"#:6L]/;_A*/K!
MIL:8W34V]PCUFK"B0S2=C`9/XZ4*C,$F4C^-04_%U`?2&!&Q\+"C:6W"KD0V
MO+YC*75MS8Y!M[A)1C<&L;(6E*WO23[Z/;%33(W8NI8JJB28%*!$S```'3I@
M6<\!@,!@,!@1MT%*TT'EW+P"RZ+=M='<Q)O$$!(X!U$.A>R$>4ZATRF14!9L
M!A`OJ$/6(8$DF!B+8NEJ9LF,<Q\FV-%+/'C=X[E(9-LVDW1V_P#P9'#DZ"AE
M"=.G4!Z^K`Z;'\9:7':_FM=(RMA/#SLFUE7;I1T@+]-=H42ID04!OY94C`/I
M`2C@?O6.-E-JE-N5*82M@6C+J@DA)+N7#<[QN5+P]#,SD;%(0P^'T]2FP(?.
MW-RFXP2/<S[AW$:EZNA-9[=TTYUY%RNR)RW5[\;.0*8HSWF$9P"<=$R3P:<F
MU$YO`=Z9))V43B0!`1"8^V\K.+M`L$A4[WR2T'2K3$J%1E:U;=PZ\K=@C%CD
M!0J4A#3-B9R+)0R9@,!5$RB(#U]6!VV?W=I>J4J)V5:-NZPK>NIX698._3]^
MJD/2IH9%%1S'A$VJ1EFT%(B^;HG41\E<_FD*)B]0`1P/EUSOS1>X7DG':DW3
MJ;:4A"MD7LPQUSL:GW=Y$LW"ID&[N3;5F9DUF#9=8@D(HJ4A3&`0`1'`Y2@;
M@U)M<TZ35NTM<[*/5W2#&S$H%WK-Q-77KH70-F<Z6NR<B,0Z<"R6\M-QY9S^
M2?H`^`W0,BX#`8#`8#`8#`8#`8#`8#`8#`8#`8#^U@4[OBON?,]7]3:O[7O'
MQTXG>0/,&Q5MO<J_7UBK2S/7J\^W85BK."H&4.U=WZV@D;PG\LY&C(#CU17`
M1"?KM2<&Z]V[N"FB.,<25!:<J]82F=A3"2?@&>V/:#FG+E)F\?58$E)IZJ5$
MAA-Y2)2D`>A0P)!4IF'6<)M$96-5=*KOFR39)\U4<*.8L2%DVZ:)%14.O'"H
M4%R``F1$P>,`ZX'#PL'20?OK'78BJA)O'+QM(SL*PB`?NG:3@Z4@@]E&*7GK
MN4G:9BK%4.)BJ%$#>D!#`X^&A]:CY3.O1=&Z.6K&P(M85E`""[(7RCB-FDD6
M*7]]:C)('.@Y*`D\\@F*;Q@(@&E_./B_PMY/0E0DN6=C>(U2I68*''MH_<-H
MU_6IBQW>4BHA.C6F.JT_&,K.[FY+V9J6/>D5,8RO@`@`<0$-T8K6>O(2*JT'
M&4>J-8JCQ$7`T]D6!C#)5F'@V36-B(Z%$[8YHYJP8L44DBI"0"$2*`>H,#IN
MT;/J73$&ML*Y5E))O+V&N55T]K=`=VN?D)>ZS#.KQ2;IE6X:2F7+5P]DTTW"
MYR"B@@8QUC%3*80#I,WQKT#,<AZ?R2GT7#_:^M*VZU]1TI&[2YZE2F5F:D;N
MDX'7RLG^*L/89M@B"?M2;,CQ=`OA`PE#I@90FU-2:_KMVLTA'4V&AJ?%2%SN
MRK*)B`5CV,&P<S;F6E&;)N+@[ANS;*+)F.45#"'WG41P/VU%MN@;SU[5=IZR
MG4K#2[G#,9^!D`079KJQLBD"[-5S'NR(O8]5=$0.":R9%/"(#TZ"&!DO`8#`
M8#`__]:UKWII7D?"=K'FQ+<2EK@UWRPTZZ7J3O7P/?Q[90GXP0)=D/J>I%B$
MRWLS+5YIE9DLQ$)!%P0AVH@X*F.!1M=77M-:XUKPPOG:"Y4<SKCW6IG9^B&1
M:BM*[UD9:ZR\_-P;;;M?W%7K/6(W6JT<DT<R#=%K7W+AL_7*F3Q/69E%C!_3
M5P&!P$S5JQ8SM5+#6X&=48F,9D>9AX^4.S,?P"<S8SUNN+8QQ(41\`AUZ!^H
M&!X?U2K2;IB]DJS`2+V-`A8YX^AHUVYCRIB`IE9.'#<ZS0$Q`/#Y8EZ=/1@=
M@P*VGPRW\5SEM_+_`.4?\(DQ@62\!@,!@,!@:$S_`/'?JX_<_%I+T_J_X!,?
M[0X&^V`P&`P(5*OP%[6-9[B$MS)8ZKM1>;+V[24F783^^;A5AT;;,0CRN23A
MC4&-P+KPY'$(^51\#J,40(!O&0I5``P!AC?W:![%G(/D9L2][QXT2EMWQLW8
MD@\OTXEN?EY6V\W>IR3\J0=!&TW<,#4(TKF16](,FK=J7K]Z4"X&<MW<#.TC
M>M&:NX#[?TJ[E=(Z%EVO[6NM&U^Y$Q1JQ++(G9IJ*;`JNP(R\6`ZZ3H?--)3
M#T%##XS]3@`@'T<8.!G:9[5FV+;;N,VEGFEMGW2CH4^S30[`Y#;3._I;^3B;
M22(02V;L&_Q,8FYE(AFNH=HD@N8R!"G.)0\.!H=\/!P4VOPEY%]YR.G]'7;2
MW'VY\Q6,=Q*);3S+AA;-)TNT[U=TZ4ITI9)27L%FK+:@76OE3E7+AR=RJH=)
M5<[M!T5,+1.`P&`P&`P&`P&`P&`P&`P&`P&`P&!'5W/>Y+HWM><7;9R$W!(M
M7TZ9L^AM1ZQ;OVB-FVKL([431E?AVJSA)P6'9+JI+S#\I3$CV/4_0ZQT$5@K
M&_#O<!]W<V>2>P.^GW!V#R?MVRIN9D>+M:M*2_LZ"4@HJU6V9#03LHA$U&"B
M>D34D"@DV!H"SE)$R)V:H!:@[DNEMP\C.%FZ=#:*>'BMB[99U&E-ILE@0K)X
M"KRM_JW[8,PG,KB)T%V=`2D_*(D!EE51*0A1,8,"N9LOL@<PJLG;YSBI6Z+J
M[8K7=//RX:XOD-MB9AK+6-93G"28T)Q*IM4D%9UTA57M\V_;9&RV%=!)!7YP
M19N)-4WL;44`YS2O9WY;2E<M%:M&AJ7QCU3O#D[VP(W9^E*=R$)<)6-XB<,]
M?6*W[FDI_8-9&+4E-H[RW29B%B-#'2?R,FNH]5?/O(^=7(1\U71>ZMX=R???
M&_C!0J?7-J:9Y#]UF[USDO19JQ1D7J.IL.-]NT'V\]&R;*+I4/!:-U7H39Z\
M"FPADRO2.I6*6?P[0S5-5^Y#<6B=E[D1$Z$XPK67A[*7N]QG,S2=[Y)Z=V_R
M)XVRK";U9I/4LU2H6WQSC6E+JFN`";LL@B[L"BAIVY6Y8J\A++JO%_+*'?M9
M]O#N=0$E$U-UQDI,'1*%RZOG)>W3;CE)!JCR):U.7W7;-&:]K].C%I=E1:(N
M\M</'N4Y%1F9@1%$`9F2(HHW#AM']G?N/:NAZS6+J>H[&DJ=R&U]NB'O)-R3
M!XMGJJIZXV'?83C!6Z[;YZ>DJ[1]=\C9QHT:B4QDI=DH1\Y,`H%30#B8#L"\
MEJU7(]>,85=UL=E'\*RH7"Q[-DI1TA?*U+*WWE!M5P"<T1D]L3:P./F2/7.V
M.\=12!"(CY(`0`ZRU[2?<TG3;MM4KHRAUO;+_4/*&FM]J.>3$78;IR,V'O&^
MHEB;597H(*I4:M5K7!3-(A!Z:0<QJ(BFFFAZ6Y@F?[-7!O;?$B&WM:=J:IKG
M'1'9TIKF%I7'NF[(9;-BJM`:QIC:JNKM9;'#M4H&3NFPY1-1^LLU,`E0,4BR
M9%`\(!-O@,!@,!@?_]>W1W8G&^V/;GY9O^+LMNN&Y"1FKU934KOCK3%;_N-Q
M<8V?A7\?$4ZJ-5$GTF:P%;G82!V@*/6L6Y<N&R*RZ2:)PKM\)^Z'N_7KO3KF
M^?#2<TJMR;F8.H4C=_*JG\0IZKSESLZ[5C!7+9]ENKKCY`6Q9*UN4U9:23D)
M$XIG7434<+`3SCA<TP&!JER?YR<0N%C.HON5G(G5VB4;[)*Q5-)L"RMHEY8W
M34S8CX\9'`"\@XCXT7B(NW?E>RM`5(*RB8&`1#K>V.XOP5T58]85+;O*W25$
ML6YFD5):TC9J\193V>(G11+!SJ+ALJY:1U>F5'"9&LB\4;,G"ARD35,<0`0W
M,071<HHN6RR3ANX2370704(JBNBJ0%$ED54Q,15)4A@,4Q1$#`/4,"MU\,L`
MAQ;Y:]0Z?Z?_`"C_`(1)C`LE8#`8#`8#`CJW2CLJK<CV6Q:?K>T7%O&5]D@B
M>/KD\_BUEU$I%NLD9_&,ER`HB5<!$H#U#T=<#G/K*\B_R;K'_P!V;U^"_P!7
M`\_65Y%_DW63_NQ>?P7@/K*\B_R;K)_W8O7X+P,O:<VYM:]V)W%WC4LM18Q&
M/.Y1E'T/8V"*SDIP`&X*R[)N@8QB^D``WB_6P,N_M7ZZ^?AL_P")-;_&(77M
MXS7S2T^<1>^KVH7?E^9YX!_OO%UP/Q7U/K-U-FLCBB59>?/(%ESS"L.T-(&D
MRK@Y*^%T9,51=%7*!P-Z_$'7UX'M)ZHUI,RZD]*T6L2,RLNFY5E'<0S7>J.$
MA`4UC.#IF4,HF)0$!Z^C`]Y[5FN+2_-*6.D5J;D3)(H"^DHEH[<B@W(5-!+S
M5DS'!-),@``>H`P*X7P]_*CDMO7DEWG]/[]V%,W&!XO\RDM=:I@9QC"H.M?0
M"-UW[4'=60>QL>T>O&;1AKB-3`KE5P8JR"B@&\:RICA9[P&`P&`P&`P&`P&`
MP(<=#5"J<4NZU>>+&AX)#77'G=7!I/E&[TM6U#1NJJ!N:@;]9:KFK/JRA-RE
MKNNR;+JU]:_/S.&18Q[QY"-W9T#.E5U3!,=@,!@,!@,"+_N8]W'A[VLM8.;G
MR`N[>3V%*1SI?7.AJF_8/MI[$?)IF*V!E"F6$T!6S.O"1Q,ORI,6X=?"*JH%
M1,%2?A?P7Y>?$F\N8KN3]QV-DM9\%J-)D::0T8E[>R97ZN0\C\ZQU*IK20:-
MS.-=KNW`FL%G53!>=5\;=MZ/$=J%_P!K5;@*=7X6J52&C*[6:Y&,H6!@H9FA
M'Q41$QS=-JQCH]DV(FW:M&C=(I"$(4"E*'3I@<W@,#P/J'I@`_U?0/H_7#I^
MOU'U_P!K`\X#`8#`8#`8#`8#`8'_T)(._P![VD;-SKX'<$MB\_;EVW>)-]U7
MN/>F]MWZ^OZNM;%<Y>!<A!Z_H#ZT%D(E-JP1DH546S==5=DNXDC+.&CA9FS%
M(.+['W=UT)KAARCX:\K^YEKK>S717*-_0N(7(?=6S8LMZW]I*T,6R]<*G/S,
MK(/;@6`G4%DTWJ[YX<@2!6::I6K9JDF%NS`8%>3O_<D*M2=44;B4K64X6T<S
MXBVZXL?(V6U)<]FUO0&D(^0K"^RIQ=OKZE7BTR-DF1=M48F)29J(.G1/-6*!
M$?&4(-]]Q.J-),.>>AJ<VV-;X;F!V\^+FFNWO/KZFVPO);P6K,DUBAJ<)\ZU
M%O*UZQPTZFI(/VDF#-*/(;Q"KX0#`M-[\TIW$[%PUXZ:[X0\BM=<7=]T^E:R
MB]A6G:NNHK:$:\9PE&AXN;@4HV7K=L;(2))AN<3+@AXAZ#]^&!&K\+"SM$=P
MJY$1]XEVEANK'FQR#97"?CV9(^/F[0UM[U&?F&+!-!JDR9R4LFLLFB5-,J1#
M@4"E`/#@6<L!@,!@,!@,!@,!@,!@,!@,"FQH'D+(=N3OF:UX?U72-9U_2>Z!
M$;1Y.<LM@WB+VQ+;AN&W&L)R#M%7L%8<SUP&&@8@]ZJ#OSVR$2JR.:QR0@5,
MR;8S8+DW]GW?U/\`5Z^G`\X#`8#`8#`8#`8#`B4D?Z=JG#__`)*;)_M_QQ=4
M_P"Q@2UX#`8#`8'!V:(<3];L$"SF)*NNYN$E8AK8(90B4Q!.))@NS1F8I50#
M)IR46HL"Z!C`(`J0HB&!4MX<?"K:_B>1%MY6=SC?D_SOV4]NLG/56G622LDQ
M35F2$HNI6Y+:]CMJOXS;-E4HP$O,C11CX=!4!3%-VB!0`+;T3$Q<#%QT'!QK
M"&A8ADUC8F(BF;:.C(R-9(D;,H^.8,TT6C)DT;IE3223(5-,A0*4```P.0P&
M`P&`P&`P&`P&`P&`P&`P&!__T;HW(C@APOY;S5>LO)[BYHS?=AJ44Y@JS.;5
MUO6;G+0<*\=_.#F*C9":CW3IM'*OA%842G\L%3&,``8QA$,%0W9S[5%=EXR>
M@^WEQ"BYF&?-9.*D6NBJ"FZ82#%8CAH[;J?,H^6NW73*8HAZA#K@23X#`?V?
MV?K^G`?Z_P#NX#`K:?#+?Q7.6W\O_E%_"+,8%DO`8#`8#`8#`8#`8#`8#`8#
M`K^<Z=6=M^;[P?!;:.^.0-AUWS@JND[NQT;K!L3VBK7/7P+[(0=2TZ88XZ,<
MZ;)V.T%:^-XB+KV<YR%$&:@'">]S-0S)HW?O)>,:,77@!L]<OVJ#1R*I#*I^
MSN%5BHJBHF43%\)AZE#J'H#`,)R%E?-^:YB+DO(`#+^P2#1YY)1Z]!5]G64\
ML!Z?=Z8'P_CA4O,\K\:*[YOC\OR_GN,\SS.OA\'@]I\7C\7HZ>OK@?;(3L'$
M&2)*S,5&'7*8R))"19LC+%((`<R17*R0J%()@`1#KTZX!"=@W3->1;3,4XCV
MPB5R^0D6BK-N)0*)@7=)K&02$`,`CXC!Z!#`^5M:JN]<)-&=D@';I<W@1;-I
MB.7<+']/WB2*3@ZBAO1Z@`1P.?P&`P&`P(B]OR4+IWO'<<]N;%EFE5H.Y^!>
M\N-M.M,L<&=?5W%7]]Z9VNPI,A+K"5A'3-II(23N,36.3VHL.Z*01,3PB$N1
M#E4*4Y#%.0Y0.0Y!`Q3E,`"4Q3`(@8I@'J`AZ!#`Z98]DZ]J$2$]:;Q4Z]"&
M411)+3%@BH^/.JY5.@@F1VY=)HG.LLD8I0`1$3%$/N#@?HCL2A.;*UIK:Z59
MQ;7L8$RSK:$]&+3;J),F"I9)O&IN3.UF1DC`<%"E$@D'Q`/3TX"3V'0H6QQ]
M/E[G5XRURK5P^C:V^G(UK./V;0@G<N6L8LX(\711(`B)BD$.@#^I@=8@][Z5
MLQ$#U[:^OIHCF91KK8T;;81V5Q/.$C+H0Z`HO#>;(JHD$Q4B]3B4.O3I@=X@
M;76K0,L%<G8J<^899U`S(Q;U!Z6,FF/@]LBWAD#G*@^:^87S$Q'Q%Z^D,#KE
MLVUK&AV:CTRYWRK5FV[,E58/7U;F9EFQFKC+H(&<KQ]>CEE2NI-RBW()S%3*
M;PE#J.!D/KU]6`P.#L]FKU*KD_<+=-1E;JU6AI*PV2P3+Q&/B8."AV:TA*RT
MF^<'(@T81[)N=550X@4A""(CZ,#W:6*!?0+:TM)F-6K;R-1F&TZ5X@6*6BG"
M)7*$B5\<Y6_L2K<X'!03`42CUZ],#Y(FXU6=G;56(6PQ$I8J,[BF%RA&+Y!S
M)5A[.P[6P0S6;:)',M'+R<&]1=H%4`HJ-U2G#J40'`[)@,!@,!@,!@,!@,!@
M,#__TK_&`P&`P,!;^Y2<>^+4%`V/D'MVCZGB;3/,ZO6'-RG&40:PV&070;-(
MB&0<*E6DGZJSD@>6D4PAX@Z]`P,/[Y[C?"[C->J9K7=F^J71[G>&T5(Q$/(.
M5E5&4/-KIM8>>L2S5)9"LP4H[6(DW>/C(-U53`4IA'`W5:.VS]JV?,G"+MF]
M;HNVCINH55!RV<IE60<(JD$2*(K)'`Q3`(@("`A@5O/AEOXKG+;^7_RB_A$F
M,"R7@,!@,!@,!@,!@,!@,!@,!@0-]T_L*Z+[IF_M5\B-@;DVUJNZZOUHEJQC
M^UR]8,2.:\WM-FM*+I%VHW%\RE#N+@^14.53PG1,0/"'0WB##FPNT#8>6/'3
MBMPIW3L/D3KW4'%YNX_%K8M.V$]8[%LJ[6K/89H;8$RZ</$+(H<ZW1`PH)^R
M`82)>$AA+@?MVPNT-/\`;QV_L]]6[]R%O-3V_69'6]B<[2ORT_'Q%8-(^V(S
MD#'IG3096@QFJ8)/A*<Z22BA"E$#B.!']6_A@:TRW?%2+O?W-O\`$=ELA-\+
M];<)E'IJZUL)G*#IQ)"V$ZSA1BF4RBPI>(YA$WA]/3`WD[D'9TL/<2W[2+;>
MMA<C:#7M>0K374*KK#8;N&AWU20=D7^>Y*/<KN4%;(MXA%P\(4AG($)XRCX"
M]`Y6B]GN;X[\:N0?`[6>PN0MST=R$L+*3LFSK/?'3S9L$FM'P[%T2GV!%PW1
MA&Z`,!,H3R#@L81\7W,"/?3/:^X/]N7NO<0:C8N8G*&7V;8K227TIKZ\WV0G
M(J[6YK#/_#'SK5I'*M!B`$ZH=%C)$.<@!XNH=,"ZC@,!@,!@0Z<OZ94.9'<*
MT+P-W2Q?6#CC6>*6V^8VQ=;D>JQT'MN_P>X=2ZAU%$VUY&J-9Q2L41*QV*64
M8H.6Z;Z158BN*J*"B)PEJEJU'2M6DZ@!GD1$R4`]K8*03M6)D8V/>1RL6"D.
M_:]%XUZR;*=6RJ?0R)RE,7T@&!51[G79KO'DZ7H?!/3][ME04);G=@?6G9%>
MVE$5:WH4R4I-'K4A5.0ER-"US7L]^/M@F92<CVSZ2C94P*-4R&.B5,.0XL]M
M+FQ6=YT604U=1-(77CWMC:6P8SE%<'-:V<RNM06TBQT/QZTI4"05FC]FRNM*
M543*NI)C(#&MQ=-_&;JX7ZX'S;*[?G-'87<VM?)[9FD)F\U*II1TO\\4=YI^
M'975#7&@K)"4F>U#9+9>7FPZM>K)MVVO`&I.TV5:1;(H+O72P]3B&'8;M&<F
MYC1=9IT?J.SZ]V/JR[6RU\79I^.CZQ*4S6%6U]6XBLH[^<ZQA%ZU?-V6FTL'
M:<0Y;O6\BW;*`K)/!+]Z8)/(O67<3IO:RI5&K.O@I'(P^R:\MLFM:2=TV!V8
M\T\_F2K[!DHN8NENGJRXW1.M1.99\M*.!5.?S">`0*FF&G/;1T%MVU\_;KMK
MEK<=F7"P<(=)O:]`*V"\1UV2UO8-BV>0L_[6=NG(.,4A[/>:CK9)'YT.S7.;
MVI0`,H?H`8&#-4UOO/;LCKMR0U[8.0R.IME6MXE+U-;8.JD++<=02^\+`JNY
MXW5Z>=(AKRP0&MH)NS%Q.&;NU1EUC)(@9ND8`]XFD]VF\;CIO&.*NW)>/M.H
M=?:]E['/L]H:Z/7]62FT>1\_LB`3WC:G@-3;8=4+C.S;PJR<$1Y[;)B!5C]#
ME.8,L[`XY=X+?55W-I?:-2N;>ERL5N>GN):0V/3WL'L][OWE;3SJ2L;&PTZX
M<,Z1J;C;%.TV"+M)LH"JZI4DC`<IC!@?9W!;O`[WH'):D[:C=\#5W>FJ51D-
M<5W=FM(VF[*FYWG#J,]_1T_"Q,FR:P5;IG"O7$FP9HSKY)23=29_$4AUQ.N&
M2+%PI[M5/>[RJ6J5-[MJOMK;G+R=U)=83<&JH[9%=V.RD]-:3X<;(Y-[$GR*
MV.]:2HNH=>R]I0B&)'#A=>3%@N02@V2*$B.BM$]R9#N%UC>&UMC['4T?+[ZY
MJ)7&A*6>MDU9&Z)I&H]0Z9XP*,*4V3<23>?W!>8:3NYE"NCBQ(V\LZ2)W+D5
M@GJP&`P&`P&`P&`P&`P/_]._Q@,!@,"NC\2:_P!!1?#.K/\`8SS7[7:Z.V=9
MK:J&RH0:ML2C&=_K3Z]/*<N^:K2[1)I&H(G?G:*)AY`!YG4`#`B*YH[@U=.6
MKO`@\O%6DY'D_P!O?BW"\67C%^A(DW(@1ZRC8Z'UJ\3]H_&*5:V%(Q5&C,QE
M43E$PD+TZX%D[=?VC-0X2\98O@35M,2^]XO7NJ(B]Q'(!P^:0C"*8:_A&LL1
M$6TO#K#,MY1$Q#`=41]`^@1P(X?A83VI3A5R'4O:4:C>#\V.0AKDA#&,:(0M
M9[@]/84HH3J*F-&I2_G`@(G,/E`7TCZ\"SG@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,#P/J'_<Z_P#HP*E?=)K5ONOQ`_9DEZSKV;?5_7-NF26ZW142J[CFGM02
MT@"LP]:MQ!HDT:F#[Y<P``&#I@6U<!@,!@,").1_IVZ=_5)[)_GBZHP)6Y>6
MC8")E)V8>(1T1"QSV6E9!TH5)LQC8YLJ\?/'"IA`J:#9JB8YS#Z`*41P(HN-
M/>;X3[MXJ47DW>=Q:\TZ6Q1]/-;:-9+>P=35!L-[@'=OKE7F/(`IE99Q4FAW
MJH)D$J1$5^H]$3B`;&P/<BX.V6":VB(Y):Q<0#NP%JZ4NI/MF[+YX/0!VGY*
MBRXD!%$NOBC+"L;HD#,!4$WA].!UJY]R3C6GP]W?S&TK?:MOFA:8CI\CLE)G
MV2R,Q;XAHR=-:>@_,(HMY.7^=&OD>+T'(X3,'4#`(ARM?[E'#"3>2%;E.0>K
MXJ^UA[5("]T\+6P=/*E<;/(DKY*R[72/Y*[EE:P5C%3$$2D=IBF;PF]&!YG>
MYSP)K4&>RSW*34L5`IM9]X,H[M+!)H9*KV-6HS1"*BIT.NTLJ)V?EA]\=<HE
M*`C@=MI//_ASL>ZT;7='Y!:ZLMPV32&^QZ3#Q<ZV<K3U)=`I[/8FBA#>2$<J
M9$Y0.<Q>IBB'K`<#5A?N_<;6-FYC:]EIRM1.S.*M@N$/&T27N];@9#:#&H1-
M/4=341*3KV.@HF/5LET9QQCN7)01%4ASB!5"]0SC7>YIPGEY>XT^5Y#ZM@-A
MZPJD[:=L4QS<(E=YKUO49",A;DWFGS9=2/.K6IR8:M5Q24.'F.D>G7S2=0UC
MU7WH./&U+[L)A$K5UGIW7MDVRG*[JD;_`%6*@RZ\U!7]=*V+998*7>L)Z0@3
M7:]F@Q]B0<F;N&8F6\L%"`(9]D^[9VY(:G1M]DN6^H&U5EG=P9,9(]E;")UZ
M*M'-;,"K8.KENE'OYIBU`ZA"$4=/VR1!$ZZ93!V'D/SSK.BN3.C>)D+K&T;8
MV[NVC6_9J4=`W+5=)CJ;0:A=-?4):<FY':=VI:$L\FYZ^=&$;%>W2+E.,>'*
MCT3#Q![0G<^X#V(DPK"<H=5R+6"K&W;J^?(6%N+$].T1"5^Q[3M+%Z<2MI*!
MJ<)9V;A9T@91$Y%!$AC>$W0,$Z.[ONC^07,]]P[UWKS8DLNE8=K5B/W`V?T1
M_1'LMIFM0L[=C/H&.M3K8E7B$7\R6*9OY6(9LW\FD=)!0_0!$):\!@,!@,!@
M,!@,!@?_U+_&`P&`P.D7+6>M]BE8DV#KZD7HD898T:6Y52!LY8\S@"`X,Q+-
ML'P-#+@F7QBGX?%X0Z]>@8'`O-%:1D'%1=/]-ZJ?.:`0"4-T\U[47*])("HK
M%3J*RT0=2MD!8PG`&8HAXO3Z\#*N!6T^&6_BN<MOY?\`RB_A%F,"R7@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@0\=U?A9R4Y+5"KK<.=[7/C7MQ"P$>S^QJ.X
M!"3?PC9H*"4*NJ(@LBU4.;Q#Y?I,/K]&!'_Q+[7W=UT/L&F;OVIW3-S[M:U:
M0<+2.AK)XW\!:T%4SMTFTXI("+8[`/'Y@@7HH!BAT'`ZCO\`[5_>/W7L?<6X
MZ3W5=VZ7C+#8@EJ=IB#65;PL*R<D9)*Q,+[`;V5G',_[X<A1ZF'H/7TC@;+[
M<X&]T'<G#O56FJ_S^VUIO<NDVC,)#;<*1HG9=ZF/%I,GI;J_9_X2+EJY:@L@
M8O0IC+J>/J/3`]>V5P/[G7&:];@MW*KGAMSD=%3>IYBOZ_I]P>%?0L1=EQ.O
M'60A'@"<LBQ42*1(`$"&*H;Q_<P,*\/^UUW:*7R[H>V-[]TC?MGTG2KL%\F=
M7R+HCR.OT6QET7*6NIALIU8HP\TU6,@Z,0.J;<IO+Z'\.!(Z8Z<IWUV9XY1-
MZ%-[3TXQM0MA!7YA>7SEU5'U/:RHDZE9N+"SHLLLU3.('538JG`/"7K@2.[O
MU='[PTOM[2TM+RE>BMOZOO\`JZ3GX,Y4YN#C[_5):IO9>'4/T(G*1K:6,LW,
M/H!8A1'`BCV%V.N.ENDTINI[,V_J689URET2*>Z\F&43\SZ[I7&>(XN,*A&M
MP;^0T16HD>NK[4F!7"3B0<@F)2*"`AQZO85X<.9/<CYU)[$.VVYH"N<?D8IO
M.>QQE"AH+7,%JIW;:DU0\*+:XV.CUY".?.CE$5V9UD1ZD6.`AL'']J_0[3AP
M3A:K*S?[7K^^U2_V^;BHZ%KT]<I"KV>!L`,I@8=JV14;2;6NMV"QS"HK[*'A
M`W0"E`->)/L0<8)_5VR=66/8&W)V+N+=S"TR7>SC<DUJ*I/=HR^X)"!I#QLF
MBJFYD;O.NG+B06,9VKXR@8P^`,#H:OPZO"I.G62L1,]L>*?S6RX+8L7.%DFK
MPM<3@F_EDJ;*$<D&*=5Z0?&4?N2*E$RTBJ9P;J<1$0WZUKVUN,>OY38+U[3X
MVXL=@534M*<0,U$1C*'A*YJ"*78U^,A6D*C'ILV;N0<*/W"1`(D=T<3B41].
M!J*CV*N-JKZWKSNR=M6.)LMM7MT55Y638*UZGNI_9U!V=?T8)B"'437MSK&$
MC':RQCJIQC$J!!\(B&!R<YV/.-LY#M&)[YLYA+,&-R.WLK!^Q1E5[5>-\5SD
M%-W&8`43-IV27M]0BT!2=%41,R8I)&`2E``#U;]CSC@+"P,9[8&T[@I<8:3@
M[M)VF082TI<&EHY(!R2O1Y]VHB3VQQ=Y]!O$OS"4`/$MB)=!]6!JQO'L3V"X
M<K(^[ZOV<RKF@MK6RC6OEO$3<I-FL>U(*J<M)+DY):I9P#%L>`0J,LF+.&(;
MS""JW3(+HJA6;4F!+Y?N!6A=J\C[MR;V7`(W._V?CY5..=95EV$:NIJNIUZS
M[-MDA8]:R:[9>1JM[L,KLHPJRS0Z+M`L:U!,X>'`CEL?9#JE@MW;FIEGVA9M
MH\:^$\1O*(L--OSEN66NE.L52T%5M.Z5*VAV;:-6T_"'TX1U/1BX'),'*<J_
MB(\6(`;H<;^V3H[B_N&(WGKN0ET]BJ-.22>R;$LQBF\ON20Y*;Q<;YGI;8\J
MR01>S[RFV=R+2#\\RH,HXI42>$H8$D&`P&`P&`P&`P&`P/_5O\8#`8#`8#`8
M%;3X9;^*YRV_E_\`*+^$68P+)>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&!KKH?BWJ+CL[O,[0HN6?7C:,C'RNS=E7*;>6G85^?0R3I"&/9+)(#YS
MAM$HOERM6R)$6R'G'$B8"<PB&Q6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P/_UK_&`P&`P&`P&!5\J?9V[H_$2<V76NWEW'M6:^TALS9=RW%(UK=.CW-C
MM;"\;`G'T]8T&TC7'1&*D(@X>`FV\0><)"]3^G`[Q]2SXCCWJW$[\W&T_+<!
M]2OXCCWJW$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2SXCCWJO$[\W"T?+<!]2S
MXCCWJW$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2SXCC
MWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2SXCCWJW
M$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2SXCCWJO$[\
MW"T_+<!]2SXCCWJW$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2SXCCWJO$[\W"T
M_+<!]2SXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<
M!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2
MOXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2OXC
MCWJW$[\W&T_+<!]2SXCCWJW$[\W&T_+<!]2SXCCWJO$[\W"T?+<!]2OXCCWJ
MW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2SXCCWJW$[
M\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&T_+<!]2OXCCWJW$[\W&
MT_+<!]2OXCCWJW$[\W&T_+<!]2SXCCWJO$[\W&T_+<"?S2D'LVLZCUQ7MT6Z
M&OVVH:G04=L6ZUZ,6A8*TW!JP12G9R)B'!C+1K"1?%.HDB81,F4P`/JP,GX#
M`8#`8#`8#`8#`8#`8'__U[_&`P&`P&!79Y6]X#D7JG:W*>5TQJ#4%HXS<%MG
M:=U7R.E[R[M[?:<W/;*.R<SJ^N1AYME78]I4(F036`7K-Z+P_4H>7@6#J]-L
MK-`0=DC1.:.L$/&3;`RA?`H9E*LD'[43E_WIQ0<%ZA]P<#F,!@,!@,!@0[Z,
MY[\M-U\@^X!QX5XQT77&PN,M&HUIT74[9L-T_>7X^P6UE4J+K9MD@FKJ*K;*
MQ)0S=Y[/'MW"K!LY\LZJZA1,`>>V;STY*\G]U\V..?)W7.F8*^\/KKK^JN[]
MQYD[;*ZJM+B\5E>Q.()!U<'\F_"R5D"%2=E(MX2G\13)IF+T$)A\!@,!@0W=
MWGFUS-X#ZEEN1NB]8\;[MI'6M?KLILDFWK3=V&Q;=8K%>&]7;4#4\!55&+-6
M<-'.T72:[I1V*IE#E!MX43&,&!^</>BN/'+:_#K4NI-,05UG-OW;C3%<E5+<
M\ED4]"0G)ZU1M;U]#$"(>M#+7N8;I2SU%!SXDB-6:9SE$%@P+!.`P&`P."L[
MR5CJY.OX)&*<3+*)D'<6C./SQ<*H^;M556Q9:2327.QCO-*'G*@0PII]1Z>C
M`K5T7OL[/I_VARV^*CQQVG6>%>FJ?LJ$VKQ-MEEF-26:[W1P2/C-+35SGYBU
M1J]G)(N2^-^R530*@@J<R!#=4T@DH[7W-+8/-"B7BW["V7Q#NTA#&IAF]<XM
MR5U>O=?NYV+D9&:K>R1NMBFU7[YH<&R;*18)MF#WRW`I@8"E$`E)P&`P&!'W
MW)>;@\%^.K_8=7JS39&ZK=+)4W1VJG2[E$MXN9F;J:DU)$8\?G)O6*A4HI_+
M2CA$/[TW:@3Q$,J0V!!ONOX@;D'0..7"_;;;6/'O5[WDCQ@V)OVQWS<B6U)+
M3KB]T$JPH<?M>*U"682J.P+6#85F:DD^51!)=,#%$PAX@LG<5MMVK??&W1FZ
MKQ0GFK;AM/5].O5EUT_547>4N9LD*TDWU=<++$354/'+.!3ZF*!A`/3Z<#/V
M`P&!'OW/.=#'MY<2;AR(-!PUFL;>>I]%H\!8Y8\%7'EPOUCCZQ"NK)+)@!V=
M<B'$B#M^8ATU/94#@0P'$,".4W=HWP]U+QZA];6?A#R%Y(<J^4+/CWK68T^]
MV?\`M&4)JG65[+9)S9<3+VMQ>EW\`A'KIE00?L#.P6153(!/&&!(?VS>95RY
MJZ,OUMV;3ZU2=K:5Y#;AXS[0C*4XDG%*?774$LQ9OYZHC-.7LPA`3+&6;+(I
M.5UEDQ$P&./J`)$\!@,!@04<PN>//_C'S)XNZ$A-;<4[Y1N6G(`^OM:P[5WM
M`=QL=4UPK:;V'?K&5.>1JS)W6*D<ZA!\KV==V)2%*;H8N!S=.[@_,RM]UO67
M`;?^D]"M]?[\U!N'<NOYK3ENNEHV;J>GZU?.T8&=WH,NBA6TXF\+,_FQHHR9
MLTQEU_**J?RA*J$WF`P&`P&`P&`P&`P&`P&!_]"_Q@,!@,!@5\N2/9UW)M?=
M/)]+7F^Z-4.+O-W9FHMM<CJ3/4*8FMDI6/5QF:<A'T.S,[3&P+2,NS%@D@N+
MR/<J-2`(IB)AZX$_,)$,J_#1$#%I`WC(2,81$>@`B;R6,:U19-$0,/I$$VZ)
M0ZC^I@<I@,!@,!@,"!MOVZ.X[&\C.8W(RO<WN/U5MG+#5<5K--U`\:+863UR
M:A5B?KVJK'".I#<CUH[E(!2527D/-0\#TR(@0$?$`@&R?:\X,[PX&:ZF]6;'
MVEI79]=DW;JT.K)0=3VZD;%NFS)Q][9;=B;4MUJV5?75UGK"8P^(YBHBB`$(
M002(4@!*C@,!@,"&ON'=O'D_S'Y":#V92.1>H:YIK0B"5GA^.^XM-6?95&G]
MTMI%XO%[5LB=>V91D9Y]6HY5)**9O4G#=BN0S@A?-,!@#7OEYV%H;E'+1NS&
M7)S:^K=V6O?^@][;SE*C:;\WUC;Y;38(-SJ4?7:5T12HEC;L&Y4:[)`Y<JP/
M3JF!_3@6#&+7V%DR9`X<N@9-&[7VEZN=R\<@@D1$%W;A03*+NE?!XCG,(B<P
MB(CU$<#[,!@,#K-T86*5J5DC*C)Q<-:'\+(M(&5FHL9N'CY5PU439.I2'*X:
M&DV"2Q@%5`%4Q4)U+X@Z]<"ME.=A?9&\[%R\V#O?;6D-=VGD3QTC=!5VF\7M
M136O]51<O6;0UN%>W!>:[.7.P.[A:#S+),%&PKHI)H%$A3"`AX0WT[<W;KVG
MQ=W'N_DAOW8^MKGMO;VOM2:D1A],4)]KC74+3-1Q0Q[26<0LA.3SF3MUI>`#
MMVY,J0B(F,BD4$_"4`E_P&`P&!'7SQ[<6M.=Y:7-VK8&VM;[`U76MF0VL+;K
M+8%EI@P;W9]=+7IQU*M*_(1_SRS=-$$D7"!CE\]KXT1,!3C@0LR7P\>X*MK3
MC=1JIR&U9O(FG>-6T^.$W6.5>N+CL?6C%QM:=?2SK;^JZRCL)FZI5SJC1T1I
M'H&<N&Y6[=-/[TH"`A8?X9\>7'$_BUHOCBZN\ML=QIW7-;HJUUF@4(^GU()@
MDS,\]G46<&9MC"GT10\9P12`I.H],#9O`8#`CW[FG"%US[XOR6DH2YQVO+K%
MWG7NS:!;YJ!-:8*,MVM[9&6N+0GZZ#V/&7@Y8\;[*Z2!9,_DJF$I@,`#@13M
M.R)OYE8W'*N/WOIR%YO*<R:?RZ;DA=63D;QM:!2]=/=8M-6-Z.TN"=F;0DS`
MR"JSU^E)IN5G0$.(=2F\82T=NCAI)\)M'W"DVN[,-A;+V[O3;/(_;5HA8=Q7
MJT[V/M^;1E)IG5H1Y(2SZ-KL.R8M6;8B[I=4Q4!.8WWW0`WXP&`P/`^D,"-W
MZADO8>YHY[@6Q]EL;=!TG0K+27'O41:NJT_:N-+/B3&QK>_GUY9VVFYRSRI1
M!LJBS:*M&9S(F.H`]0#`7#WM]<PM`\R=M<IMQ\F-%[V6WI/3)=A3+C0MI@]R
M,]9,(>63U?IVA7ESM67KU-U]0[,NU?&8MX?R7@%7\12JJD53":#`8#`8#`8#
M`8#`8#`8#`__T;_&`P&`P&`P&`P&`P&`P&`P&`P&`P&!CZX;;U5KQXUC[_LW
M7U&?OFWMC)C<+G7*R\>,P5.A[6U;34DR6<-O.2,3S"%$OB*(=>H#@8XLO+CB
MQ3JO-W>R\CM'Q-1K@,1GK`XVC2SQD1\YN@91_M[E"95*V]M=#X$_%T\8@/3T
M%$0#/,;(Q\S'L9:)>M)*+DVK=_'2#!=)TR>LG*15FKMHY1,=%9NNB<#%.41*
M8H@(8'WX#`8&"(+DYH*R7O=FM8?:E5<W'CB-9#><<J[58LM8J7"!)9ZZC:K`
M_;MJVR<2$";VGRRNS'1(!O-`ABB`!EVNV6NVZ'9V&IS\+9X"0*H=A.5V58S4
M.^*DJ=!4S.3C5W+)R5-=(Q#"0Y@`Y1`?2`X'&0%^HMJDYF%J]TJ5DF:XN+:P
MQ,!8X>8DX%R"AT1;S+".>.'46N"J9B^!<B9O$40Z=0P.VX#`8&%9[D5H^K;K
MJ''*P[-J\1O&_P!6?76EZR>O#(V>QU6->.V+Z;BVGE"DNS;.V*R9A\8&$4C=
M`$"CT#-6!A3>O(O2?&2JP5WWQL*'UI4;)>*QK:'L,\C)'BU[I<EUVM:AG+F-
M8OBQOSFNV.4'+KR6B0A_?%2=0ZAF9%9)PDDX0436163(LBLF8ITU4E2`=-1,
MY?O3D.0P"40Z]0'`_7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__]*_
MQ@,!@,!@,!@,!@,!@,!@,!@,!@,!@5]/B%^#G&?=?!SDARGV/KQ.<WGHKC_)
M,=7W@DS-,'=9:H6=.4121:,'S9DZ`CV;<G`54SCU5$.O3I@0@W+B;Q7XC_#6
MT[G!0..NJ[EOG;W&'C#-['DMP14KL>L6F8L4I6I&3E'U7E9I*.(]4>O55"BG
MX`*)Q#ITP-Y[!S][IFU>>NL>W5P<L_$W3T5-\`-?<@?QGVEJJPV)O2'*=<JB
MLH6ILH>P%;N%G4S8V;%LU>MG+-HQ,JJ)%%4R`<(UE>_5WI(3@7$]QR=L'#IU
MJ[1G*J)XO;-U7'ZHM"-JWNN8TTK-765G5[(HTI*:*D6DQ;MH3V$3'7.[.`%3
M*U4"0[N6][[=FN.YGO#@9K/E/H[@90>,VD:C;Y?<.U^,NS>4-@W9O._4NJ['
MK&M64-0"R#>@Z\5JU]C$74J:/5>,%VKU<IGHJMF203@=G/F]L'N']O'0G*7;
M5)9:_P!IW!O<Z[L.!B8Z3BJZK9]?7FQ4EW/UEC,.'<DUA+,WA$7Y&ZJJHLU7
M"C8%52H@J<*>^JKE,;K^'][Y7,*S.ER[0Y.=Q/:D_:I!FJLS.U@F`Z<>UZLM
MO+644;QT`I<9))ND502)-52)%]!.HAWS@#S^GNS?Q?Y_\1MF3CR>EH7CMISE
M_P`)_P`93J`K=)/D_0*="&J+(JTB9ZZ9DV996;5`$#>)%&,=N#%'Q#T#A>SD
M\MG:OY)]R[9FY'%HV-<]0=KVN\K=KPLC*.RR$Q>K9,UO:DS#J)O3"5A(L2S"
M<>N'3J59)40'[[`W-K_=M[PVD==\`N>_).S<6MA<5N>.XHF@O.-U%UI(UF[:
M=KMRLRL!59")V,:<=NYN2.3RUA%R=^1,@^%5,3F'RP[-R#[H?>"M?(;N\T?C
M/LGBEKG4?;<FSV:,<W[4$U:=AVVNLV$2J2BMWA+`>MD!\+I59Q(N&7M!0`")
M"3U@&HO=@Y8=PWE+P*[4G+^$VUJ?5%,Y'[,T.]8:]J5:N$?8(;<CV;2B5YJ>
MLI+"NC-ZZ<S39-R:)\H%2HF.GYA^H8&7^;U/[C@=\GM9TN%W+QM-SB=<$;Q'
MV/=3W6MJ/I2)%39.X%9:PPFMTYA&7D7S>-(1)JW763;&<'\2A/`40$,BU#O>
M=S-QVG>5.\UZ9K>^\F^*/-Q#BMLO:U(U1.6*J5O51(=K.6??KO5T3-1J#U>J
MFDFK/R?&V8*'7(=1(O7`SCL;:BW<>[#G<"F;]S3X_<Z$*W7']PH&UM0Z7F^/
M=NHKB@Q-5O2$%M/4E@EIU_1]C1T\Q?(H*MS$2=0[E%0H_P!].80FU[0F[+)R
M([9O"K;MR=.7]PMG'_7RMJD7?A\R1L+*#;,)60+X55NJ+MTW,<GB'Q^$0\70
M?1@208#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_T[_&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&!IGW#-1ZYWUPHY'Z=VYN"OZ`UOL'7$C7[;N>V.8)G7-=1
MB[MDK^,<PXL\Y6H%-BV<()E/[4_:)CX^GFE$0'`C3Y"<&N+%\[%&N^%-JYX:
MMH'&BOZ2T?3H+G%+RNNB:PGX"F+P!ZU=$'\ELF*H+B*NI61"M?)LAD#"X**2
MZO0`.'-\?>$W%NA]T^D<F*;SBUI?=UPW`F`T?'<7XZ7UVZO4UK%B37Q6F]FK
M2*V"]M@U9^C`LO"H2%4CQ%^02O1`R8&",FQ=IGM[2':!VKQ2>=W7C_'Z'L_-
M+]N";Y;JV+2)=>U?8WSI*KAIM^[4W>E3B6+R'2R()JSZ#_S4Q/[)T`R6!OSO
M[M]L-G=T#<')KMW]U*E\-.>LMIBG4/F#IMIKG2G+27G*"QBJ.;75LN.BK?L*
ML675K]:N1E=(WE7")DW;)-H+;R2NW!GH36\==>[1U7IFD4/=6\YCDIM6":RH
MW7>$]2JEK>1O\M*S\M-`_P#Q#HJ*%3JC",:R*;!FR8E\I%HT3`1,;Q&,%/KA
M1QBT;>>%_?-X"VWDOK[4/"L_/BR;)U#S;8V6DW'CJVI>TX;7LZTJ$;ML+9"Z
M=D+5KJ-KL$RL,*2P-7L;)R9B+((*&,3`V^YV=MCM1;CWOVS;MR)[B?&[55AX
MOZDTY`,J'==H:8K4CR_U%6DZP&N9!N%@VK`RL;7IUW!K&8/XI&5;.2R*I$3*
M&`A\#<JU<*>"B_-CN7[MW-S)U%*%Y!\/V>K.3_':=N^N:I(Z)TX@2)"6V9?9
ME:^C/5:L/VK1$`>2T9&,D/-\0N#@8H8$=&I>SWQZUM%\+)CE+WMZOR([=FF]
MG*6C@SHRW%T'JVAVBZ/IQ=U5X-GR(C=I2:V]U&4R<019,&Z1SKE\#4K4O5(0
MW49<`>(*6R^]/8OM"-2K37,!FLCR*KB4SK$CSAJ@>*8-C*['3_;.6=L/`"":
MO6<2KY?`<`^Z!L#&/(#ML\--@]HO@CQ05[FNH]7U[3%AUV[XI\UUYK4SND;+
MOT)87#ROJU2M2FV(ZE[`<S<BL1)JQCK$Y4,LD`$,H(B00S[`\!ZM7NY!P1WM
MRA[FE/W'S8T;Q?MVMF.L;)4=2:FV5R/AI6U763=;6@M9P>P0F(6"ACS#ED=&
M,B9-L*C(QCNP."A0#HW$?MPEH^C^7%)[<G=KKD5LG87/"8Y`VS=&JM?:=WPR
MU19E:<T@)_CGLC7A=E3M<GB'CU6KYRE(.8I^FJ5NH#9,`*)@C?Y!<:]?\->U
M]W0XGCWRRKW<'YE\N-N5ZH<IMG:<C=5TVEZ1L5RL*`V.<VOJK3=ELM.XRZSK
M==C)()J2F7+5JQ5>@9=5%OX$B!:%[=&N-=:@X*\4-7:GO=1V?KZ@Z+UU5ZUL
M.B6"$M=3N3*(KC%J-@A;-7'DC"3S*15(8Y739=9-;KX@.;KUP-TL!@,!@,!@
8,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g662896g04y47_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g04y47_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-36AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YK87)R96QS:CPO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C
M.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR
M9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S`T>30W7V<\+W)D9CIL:3X*
M("`@(#PO<F1F.D%L=#X*("`@/"]D8SIT:71L93X*("`@/'AM<%)I9VAT<SI5
M<V%G951E<FUS/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N
M9STB>"UD969A=6QT(B\^"B`@("`\+W)D9CI!;'0^"B`@(#PO>&UP4FEG:'1S
M.E5S86=E5&5R;7,^"B`@(#Q)<'1C-'AM<$-O<F4Z0W)E871O<D-O;G1A8W1)
M;F9O"B`@("!)<'1C-'AM<$-O<F4Z0VE!9')%>'1A9'(](B(*("`@($EP=&,T
M>&UP0V]R93I#:4%D<D-I='D](B(*("`@($EP=&,T>&UP0V]R93I#:4%D<E)E
M9VEO;CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4&-O9&4](B(*("`@($EP
M=&,T>&UP0V]R93I#:4%D<D-T<GD](B(*("`@($EP=&,T>&UP0V]R93I#:51E
M;%=O<FL](B(*("`@($EP=&,T>&UP0V]R93I#:45M86EL5V]R:STB(@H@("`@
M27!T8S1X;7!#;W)E.D-I57)L5V]R:STB(B\^"B`@/"]R9&8Z1&5S8W)I<'1I
M;VX^"B`\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"CP_>'!A8VME="!E;F0](G<B/S[_[@`.061O8F4`9,`````!_]L`
MA``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1
M"`#U`2P#`1$``A$!`Q$!_\0`C0`!``$$`P$!`0````````````@&!PD*`P0%
M`0(+`0$`````````````````````$```!P`"`0,"!`(&!@4("P`!`@,$!08'
M``@1$A,)(10Q(A4602-187$R)!>!0C,E&`KPD7.W.*&Q8F,T>!EY@T6%M29&
M=K97*3D1`0````````````````````#_V@`,`P$``A$#$0`_`(972\6G1+?8
MKI?+))6J[6:37EK+.SCLSJ9E)-QX!5R^.IZ3@<"D*0I`*4B:92D(4I2@4`IS
M@.`X#@.!3J-NJ[BT/*2A8(I:W1\8C,/JZF[2-*MHQP?VTG2K8!]0%$?`B7^^
M0ABF,4"F*(A47`<!P'`<!P'`^"(%`1,(``!Y$1'P``'XB(C]`#@<8+H&$`*L
MD(B/@`!0@B(C^```#Y$>!R\!P'`^>0#QY$`\_0/Z_P"S^G@!$``1$0```1$1
M'P``'U$1$?H``'`_)5$SCX*<AA](&\%,`B)1_`P``_4H_P!/X<#]\#I2,E'P
M[![*RSYI&1D<V6>/Y!\NFV9LVJ!!46<.%U3%3333('U$1^OX!]?`<"FZ/H%,
MTF$+8:18&-@BQ5,W55:F.1PS<E\^6T@Q7(D\8.!*'J*54A!.00,7R4?/`K'@
M.!Q^ZEY]/N$]7J`GCUE\^L?P)^/]\?/X?CP.3@>\>JVI,5BJ56SD,VA4[*Y*
M>O3)#-ZTL!11LC@IF0"A75@,`D?G\-#`(>%!\\#P>`X#@?A0X)D.<0$0(4QA
M`/Q$"AY_C].!O/\`Q=?'Y5^E^6*6F1EF]OV;7(.OR-XL[,#A"Q,.5(\G#TVI
M$622<_I#`T@*CERJ!57[KPH)2)D123#*9P'`<"Q&F=7NN6R-';34<.RV[@^3
M.DN\G:3`.9<"G+Z3&;3I62<TR6`/P41<)G*(`("`@`\#2X^4_'.JV`=EG63=
M8&MC9A7(=)QJ,=(V=6S5JNVV7%)_&U6K+2!'$TW5B810BK\KEZZ!-5TFB4$S
M)*E$,:O`LYNZVM(9U*J8PBR6MQ3$,I[OH/+)Q92F.[/66[DAH]U.B(%!,CC\
MHD$WH`RGI#@5?G1[NI2*TKI`19;NK&(JV!.'1,W9HNE/)R(F2%15,'J2`E*Y
M]H01]\#^V`$\<"M.!8B)ZYYK"ZV]V5BTDB65Y]PZ(Q/(+'AVDV^!5.2GFZ)A
M^Y,[?-U1(**BAVR8B8Q"`(AZ0OOP'`XG"Z35NNZ7,8J#5!9RN8B2JQRHH)F5
M5,1%`BBZQRID$0(0ICF'Z%`1$`X%A\9[$4_;I*V1E9BK$P5JKG\SB58"1G(Q
MBK@[9F^(X2]1(]XY42./V+CTN"$*)OS>#^@+^\!P(?7B7[.(]CJE'5.-CE,O
M59F,/J]T:TZAO+4+$\MK\$1=,;.R5,4&*27GZ"0$@4*=<>!.2H6N;HEMK=WJ
M[ANTL50G8RR0#M['1\NU;2T.[3?1Z[J)EFSV*DD4W")1.@X1505#R4Y3%$0X
M&?O7>P.R:9UD^.B`D$7$\OW)B]PJN^,,@Q;'7&GZ%#Q5Y;5IHPH#5[5V<36[
M$C7EU44G#51BDEY,X6/Y3]7`L]>?CAQMN]Z@R\;$;#E<;M?;)AUJTS.KGJN1
M:K:8ED\1-(DLL)<\O8NJ[`S@,VRJ#B->IKKM5S`)TB@0/=#QZUT@ZG7O4>RE
M1R.-[4;'_P`)D(G"6G.HJ4SNJ7[;='=::\H[U_GLP^B)*(K=*I[5BL==%X@,
MA(&3*HD!2B8HA7+GXVNM+G3NT2M)E]/OF9=8HG(ZLYJ)MJQ"F62\[)IK8\O,
MQ)M>L\?'YU4J_GL:X19O$%$W#QU+(K)(J#^5,0JZB=6ND./C\@%<M;2V[76J
M=UJHFM0<[!6;(+3:<WJEG663E:?`6E@RF:VPVZLVJ.<)*R[8_P!@O&"W\)@8
MQC'"$'Q:Y=FNI]P7)[=5$;Q5<VS?5=>JN>65-M))6^9IB#4:;!SS--,&<RHV
M-)D=+(@D9NNY;%]28I>2"'C-NS6R]_M&R_'-QKCO2(1Y>G%AAJWU]RK-:]L\
M1'MZY8`/0J%,&9Q$<TJ'A9,7@S1W*3-)H#Q10QD/!PE]*_&CB3S3NCK%HEK6
M=5;LQH^JYKHE`GM0R?4+54GV>0,G-,92NZ1FS"0J"@RH,RE=-%45EFAOR&`A
MP,`!96W_`!Z]5>P^1T<,#L.KK)6/N;!](]-0W9G57D38G,['GD5-+KD/546R
MT"R9`U%=NP5=+./J!1.FJF50P4CB7QV=$9+L[%='^L$AV&I:E`T/6V^YW?3I
M7.Y\]ZK>6QC\9VR4IPRCX):"L#VS1(Q3)"5(LS;1JI')Q]21TSA(9'XZ.NMH
MV/J-6(>QW*CQ6ZZ%HV?Z+E#K<,0V/1*LUJ]+L-NJ5\@KIE:<E7TX2S$B"I.6
MSMH91JL()E./J`W`QJZQ5.O+K=ZQG>!26H%SH9ZL9W9K5JIJ^A/REH-<UZS:
M+A"LH(A&L+5WK$Z#EDT<^ITV,!P5$0\<#(U\B':70.N>U:QTER.F953.ME(I
M,%FT9F<IEM,E#6)&UYW$.W5^?V>2BQM2ER5D)LR[&31>)F2<-R+&!1453'#V
M]C^+S%<HS#3H">O4[`:SFO7HNL%U*R[/AS?/KSHB%?1LTCC\1AQ'*>OQ";Z-
M<"WC)5P<1=N$_7Z#$.F54)/W!0XV#L";U'#S\`]!`/(B`@4Z!1,3^H!]8^0_
MK'^G@:R@?@']@?\`FX'W@.!FW^)KX_>JW=2/NLQKFAW=[<<]EVY)C%8%PPJK
M-W6)$@#"VE6R)?>6*8B))PDNU<)L_P!/.S<(@4Z@@JD8X;D<9&LX>-CXB.2]
MB/BF+2-8H>M13V6;%NFU;)>XJ8ZJGMH)%#U&$3#X\B(CP.]P'`<!P-$SY4^F
M]VZJ=E;98'AIRPY9M5EG[U0+[+KKR3AU)S;U69L].L$LL9116S5Z1>J"F*QO
M<>1YD5P\F!8$PQE<!P'`<!P'`<``B`@("("`^0$/H("'X"`_T\#RHR"A(565
M7AXB-BEIR0-+3*L>S0:'E90Z*;<\@_%`A/N79T4BE$YO(CX\_B(B(>KP'`>?
MX?P_'Q_9Y\?]7G@.!+:M=V=VI[?JPC6G]8BE>GCJYN<?>I5\5G1RW^2-(6AI
M<!</E$)]F_(JHV`A"-1(W5,`#[@@H`5Y-_(?LL@?,$*_0<#SB!R#=VW8VDU3
M-LS/5Z^AIB:#HCY],(IV!T]FV<VY?+.'@+KBY.J<I2+$2322(%Z>H?<C/:JU
M[D*[';&M#T/L]9ZG<V5HE<+;;_C3*1CKE8KG9FTWCCJ;8'6D%WTZ<D4Y.=R1
MD0XCY!1,HG#QM8[TT2H;!HRG5?*<Q>8%J6>Y_5=AR[3\AC&.4[+>Z8,@\=:@
MEC\;."EGBZLF_`S!NT?D51]KW5/*I@$H6.H/>71\TTS1M#J.8==HR%U6@-<Q
MNN+H9&P;X=)TYA[!V+$U$9R;8QWB*Z`JJ.E7:JSHZJ@KBIZO`!87*]MTG$=8
MAMLRJ=)3-`K\S(S,4]C&#4(I`)?[I.3A%(14AX]Q6GS)ZHU48G**7VQ@('@2
ME,`2^=_)SOB5YI.@TV@=;,LG:=9Y"XO2YEB$#6&]_GYBN3U2FE]$7!X\EI]I
M*P-G?I*H)NFR?NN/>#PL1,Y`\(/D6VMA-X7)U.CX/GL1UPO5OO\`D])H&:*5
MJF0LK>856$L+-]%M[`HZEF+LCIPY]:KC[P7;@YS+F*"9"!9VO]M-FJ>>*YO6
M)6(@8T>QL7VH93T=%F3M41KD*T^UC'T7)*.U6B4(V\%4^S4;*^3E\"<2"8HA
M>NS_`"3]@9[1Z3K<%6<)S31*C9Y2YRMGS7(H:N2.FV:>KSFJV!_JCE9W(N+<
MVG:^^<(.6HG0;F,L98"@L!%"!2[;O/=H#6,MV+.,2ZO8]9\FGK'9H5IE6.)5
M*)L,U:85S`2KBY^U/N9B<:IQ[M3[1J5XW;,U3B=(A1$>!#&0>N).1D)1R8`=
MR<@]E')D`,B4KM^[5>KF0`IO4B4JZPB3P/DH>/K]//`GO;/DH[`WV@*TZ]U;
M!+I:U:,\S4=UL^-5V8WDE+?Q+B"=1J5^=+'(D]4BW:J8/BLP>%.J=4#@L8R@
MA1E_[Q:)JM#/5-)RSKC=KDI0&F8#O5AQZ,?[P%.CX[])CD"7921^R+.Q\<`)
M(2OV'Z@E_?*J!Q$W`2'?'=I-W:WKI.B^]<NJL7TZF?;K3HA/\H8<@$:+-"C,
MF]BX"`#ZWPB=$1'Z(!X+X"&'`<"3O4N8ZO,-9C8OMU2I^RY#8_8B7]DJUGL5
M=F\Z?*+@"%J,T@%TC6*!)ZO;D&PE,X20_GM_4=,45@W*>L'QM=-\#NE8WWKN
MG<&TF[K[@(>?8:M9;)5[15+0Q24]ITT7D7</8(1\G[#I#U`<A5DDEDQ`Q"FX
M&2+@.`X#@.!0^A9EG6M5M:GZC1JGH=5<+INU:_<X"+L<3]XB15)!Z1C*MG2"
M+UNFX4*FL0"JD`YO28/(\#08^0,F*LNWVT5SKY28.AY=2+'^Q(N)KJCI2*?S
ME52"-N$XV!R[>$12?6DCM-)-`2-RH()B0H")A$(:B(%`3&$"E*43&,(@!2E*
M`F,8PC]`*4`\B(_0`X'$W<-WC=!VT<(.VCI)-PV=-5DW#9R@J4#I+MUT3'26
M15(("4Q1$I@'R`\#FX#@.`X#P/T'Q]!_`?Z?']'`<#[X'P(^!\!^(^!\!_:/
MX<#YP'`<#H2LK&048_FII^TBHB+:JO9&2?KD;,V35$OJ47<+J"!"$*'^D1$`
M`!$0#@<C!^QE6#*4C'C:0C9%J@]8/V:Q'#1XT<I@J@Y;KIB8BJ2J9@$!`>!V
M^!&@EP[`F[#_`+3/28=#'S12CDDZ<RJY#1[?P!IHDXB4HDL;A\J5`(DZ8$*G
M^;R(`*XA)?@.`X#@6@W./U:3SN4;8W*MHJY_<,U"'4]A)Z[C2J_XUG#R#LWV
M<7)'\E,"RI3%%,AR`)#&`P!7=/;VII5H)M=Y*,E[<C'-R6"2AF9F,8ZD0+_-
M.U;',;T@4/!3&`"%4.`G*0A3`0`J3@<:JJ2"2JZZJ:"""2BRZZRA$D4$4B"H
MJLLJH)4TDDDRB8QC"!2@'D1\<#])G(JFFLD<BJ*R9%454CE42624*!TU4E""
M8BB2A!`2F*(@8!\AP/UP'`<!P'`W5O@[SO6J7TOAY_0[H]F*AH<X]M&/49R9
M)TA0*,*KAJ<S5^8HO$4[A,)KR`,/4+9FF)#)E*HNN7@9DN`X#@.`X'&LG[R*
MJ/K42]U,Z?N(G%-9/UE$OK24#ZD4)Y\E'^`_7@:)'R+?'7J72_1Y&:11G+YA
M=UGW2](TX4%'[UO(2RZSW]HZ`HU2$&5O35.<$7)BD0F"![J7A;WD$@@5=NIN
M\7O$M!L;G)]FKN7EKJJ5BU!O3;%!0L!'R"R+)%^$[),&;-=JHZ7335(F8Y54
MCF*;P03&`(Z8SF*609]#T5*>DK'^FF<+JR$@82(E7=G!59K#L1.J$5#(J>11
M;@<_I$QC"(F,/`NGP'`<#Z'CR'D/(>?J'GQY#^CS_#SP(YYYGFPU_8]'N5OT
M!A/TBS-VR<-!H-W*9R_;G-^DIHQZAQ;5[]NM#'0.9(ZXO_=$YO`^1`)%\",U
MUQ[2K%NE+T:)U25B*7"H&2D:TU/]HNP;HD3.YBXYNFDI&R[*U+IE!VJ\(99`
MH?E]7I3]`2:$?(B/@`\CY\!^`?U!Y\CX#@?.`X%MM:S"#U^C2E(GEG3-%X*3
MN/D62ARKQ<NT]1F#_P!@%"(ODD5#?S$%?)%""(?E-Z3E#OYIG\-EM'@:+`J.
M5V$(V,4SMXJ=1R_?.5#.9%^H4QC$;_=O%#'*BGX32*(%*'T\B%=<!Y_A_#\?
M'`<#Q;%8X*I0DC8[+*LX6#B4!<R$D^5!)NW3`0*4//U.JLLH8")ID`RBAS`4
MH"80#@>#GVCTS4J\E9J1,HR\894S=P7T';/XUX4`,9C*QZP%<L'8$,!@*</!
MR"!BB8H@/`KC@.`X#@6XUG.6^KT.;HSF<EZ\G+)IB61B%Q3."S<PJ((2+<!*
M63AUE0#[AJ8Q05*'X@(`/`_.19RAE&>UZC(RKZ;/$(',[DWRRZ@.'SH_O.P8
M-UU5OTV*25'TMFQ!]"28!^)A,(A<G@.`X%:9U;(VC7BLVR:I5:T>$A91!S-T
M*X-U%Z[;8<WE&3A'YD#I.F1GC-0X(.T3%69N/0L3R)/`AMFY5\8GQ<=U<@JN
MW8S5;M1H*W,C&7:TG2;`C(56P-@*E-U:<A[0YMT:PFX%]ZDEDO9]LX>E1,3(
MJ)G,&9+#LBKF!Y#G6,5%W*/ZUFM5BZE"OIM5JM+O&,4B"*;J369-6+15\X'R
M=0R:*1!,(^"@'TX%U>`X#@.`X#@<2R"#DGM.$4G"?K34]M9,BI/<14*JBIZ#
M@8OK25(!BC^)3``A]0X%O]>SF&U_*]&RNPHI+PNB4FS4V1(L0#D(WL,.[C!<
M``@/A5J=R"I#!]2G(`A]0#@:*O7/XRNX79.P/(FHYL[K%9A)R2KL]IVC%=U.
MD-7T))+1$J,8LX:*S%J5;NVY_*<4T=@`AX.<@?4`LSVYPB#ZR;W<,(A[R;1G
M>=M:[&VRU$B20C!>Z2$"QF[#%P\<#R062BX)633:%,LL=915)0QO3Y`H!&S@
M.`X#@.`X#@.`X#@.`X#@.!YLS#1-ABG\'.QK.7AY1LHTD(V00(X:.VZH>#)J
MI'`0^GXE,'@Q#`!BB`@`\#Q*11*EG-?:U>EPK6#AFICJ`@AZU5W+A4?*KR0>
MK&4=R#Q7Z>I54YC>```\%```*MX#@1NUTG9,U_S\<D6JY*1]UXL@2:91`BP`
MI]X:U@L87:T$+/\`]D".]+@'7CU?7T#P)(AY\!Y\>?`>KT^?3ZO`>KT^?(@7
MS^'GZ^.`X#@.!VF+%]*/F<9%L7DG)R+INQCHV.:KOI"0?.U2H-63%DU35=/'
MCI<Y2)I)D,=0X@4H"(@'`J^%S6]3E[JF:IU:?C;E=+3`TZ"A9R%DX9ZXG+%*
MMH>.;F:R35JX#R[=%]7Y?(%`1_AP-NC+_@0Z@5RBIPNHRVC:?>7/MK25U9V=
M]1FS1;T"!VE<K<&JHQ:1Q3#Y`7QI!P80\BH`?E`)F=0OCUS;I)8[:^Q;2==7
MIEX:H_N+-+Q.5^R58TXR$A(ZT1:K>M1$M&3C5F!FRB@+G*Z;&*58IQ21,F$^
M^`X#@.`X#@.`X#@?!\@4?2`"(`/I*(^D!$`^@"(`/@/]`\#!'2O@XS2V:;=]
MJ[9Z?8M=N6@WBRWR9I]+]^BT9N_LDZ\F%(YU*E6<W*=9LTG)4"&3<10"0@>4
MP#Z<#5NU+KMK^=VK4&CS)]-:U7/[A<HAU:%Z#;DZRTAJ_8Y");RCBPJQ!8I.
M-4;MTS%<F6]HY3`8#"`@(A87@.`X#@.!\,8I"B8YBD(7QZCG,4A"^1`H>HQA
M`H>3"`!Y_B/`^\!P'`<!P'`ZH/V(OQB@>LQE"LPD#1@.D!D0CS*F0*^%E[GW
M0,Q7*)/=]/H]0>//G@=K@.`X#@.`X#@.`X&P1\"G4Z$TG4KEVAN*+&1C<2=M
MZOGL.L*:YRZ/.Q8/7MJ<MC`<"%K-;=E38B8`\NWYE2"!VQ1X&VD[C(U^HU6?
M1[%ZJQ73=,E7;1NY49N4C`=)RU.LF<S==,Y0$IR"!@$/(#P.]P'`<!P'`<!P
M'`<!P'`<#5:^7;_F5XCH79[%A.%=9=/N.U,!D60:'OU#O6/8='KL0(5S(U1O
M/QD'<MF:LQ/Y%2+"/B5`$ATY%4A@\AERZ5UC>.RWQA9ZV[GVE.T;7VEPJ=M6
MFNB5Z*K\55DMRBY2;K=4A:S$-VC>+89_4;#',4TCF5=&79G47646.<XABAL'
M_+PR4!DUPE8?L.^O.P1E8>/ZA6FU(CZK39NPL$@<I0C]^]G9Z6*29*D9NBN!
MVY4%U2'4`Q"F`0U'M9["M,GTJG9J_HENF9*S.OM'J\>S$AF3A5T,<BQAD52>
MS8Y-J_*(/$4E4P;$#ZF$P^D`D4(>!\?]/[/]'`<!P+`]C,EM&QT9"M5:YK5-
MVVEFD@Y;*"J2(GT45$_2WE5F9/U%,T:</N6P)F]LRY`!0HCZ#IA>J$8.8J%B
M(M[*NYUY&QC%@[FWY4B/I=PT;)H+23LB!2HE</%""H<"AX\F_B/D1#U.`X#_
M`*>1^@!_#ZB/T_$>`X#@1R+UOKA=X+N8V*Q+O0;*K#7W+YPJW)-BD1HW<(R/
MOE<E@$&7J],88#-P5](@/MA[?`D;P'`<#A<_<_;./LOMOO/MUOL_O/=^S^[]
MHWVWW?V_\_[7WO3[GH_/Z//I^OC@1UP1'L0G(7[_`#Q=Q"K`DT<E82:(-A55
M44,"[ES"NV1DREJ!&YR)MDG*9G(*^KR)?08#!)#@.!\$0`/(CX#_`*!_Y1X%
M0R52ML+$,K!,U.U0\!)^O]-GI:MS<9"2'MB`'^QEWS%"/=^D1^OMJ&X&U-_R
M[E<MK#$NP=ID(Q9M2;5IM;1J$JH8`2F96O5MRRMQF:8_F.UCS.&"(K!^0ZX*
MI@/J2.`!L1<!P'`<!P'`<!P'`<!P'`B3W%[S]6^A.6O-<[2:S`9O7`(Z2KT.
ML<\I>+[,-T?=3K>>TF-*XL=PGW1S$("31`Z:/N%.N=%+U*%"$7;OXCL%^22`
MT&[]A+!H<W8]6C\3?9`E;VD."G5*C4V2J5VL>>YM6XQ1*/C9;69=B_2NDFNX
M=R,F@[19"N+2-9)E#,4R9-(YFTCV#9!DP8-D&3)FV2(BV:-&J1$&S9NBF!4T
MD$$2%*0I0`"E``#@6TW2[$S7%->T,ZI40HV97NVE4,(`!5:]6)251`!$0#U&
M5:E`/Z1$.!_-?4;(2!V+V2:MGD@S6/(-G3INDX<,I%T@HBZ>,UE2'5:N5TG"
MA#G()3&(<2B/@>!W.`X#@.`X#@.!'/LYFNA:AGZ$'G=D-#R#:99O9"(,Z_3&
MUD9D52!-)>72\.61H=P`.R$`?;6,3P8/65/@7KJ47,0=7@(>P3ZUIFXR*9LI
M6Q.$$VRTP]02`B[TZ*8`!14-]`$WYS@`&.(G$P\"H>`X#@.`X'&59$RJK<JR
M1ET"(J+H%5(9=%-Q[GVZBR(&%1)-?VC^@Q@`#^@WCSX'P')P'`N?B%0@="VG
M(,_M+B09UJ]Z?0Z7/O(E9!O*M(BU6B+@G[J-7=(.FR+ULW?F.D91)0@'*'J*
M8/H(;.G7[X.7^`=Q,MUH^H5_4</HDE+VD(:Q0JT+>T;&TAWJ-0;/F+5.2K,\
MQ8S;I)RHY(HR-ZFQ?#8/5^4-@"WK4]C5+`_OJE<:TB(AI&6M#NVC&I5:-K\2
MS6?2LC.K2_IBFD/'1[=19PJX$J*2)#&.(%`1X%+8U(XW-9E4IWK\\S>2QV?8
M*SM&E<B5K3G.9:,EWCE^O*U=U4!-7';.1D%UE3JM1,11<YS"(F$W`]&[ZEG&
M:Q%KG;[>*O4XRCT6?T^W+S4RR:*U_.ZJ@LYL=VDF9U1>H5F&2;G^X>>V**9@
M](F]7@.![]5M%>O%7K=UJ,PQL-3M\##VBL3\8L#B-G*]8(]O+0LQ'N"^"KL9
M.-=I+)'#Z&3.`_QX'O<!P'`<!P'`<!P'`Z$JU=OHR19,))Q"OG;!VU93#1!D
MZ=13MPW42;R39K)-W<<Y78K'!4B:Z2J)S%`#D,41`0_GK=H/A\[4=A?DCRG?
MYO3>Q/:[KA)?(#FW66[ZWV*AT8C1$F51L/[@U6Q5"D04'!5N!ZQP,G6WU2C)
M)E'Q3%[-MU3H-18JM'3@/Z''`<"WVLYQ`[#E^A939RG-7M&IECI<N*?D%DF-
MCB746LX0$!+X<-0<^XF/GZ'*'`UQ.IGP`KIOD;1W#O*3E@R?*@RRO,I!9,9A
MJT<K)-W-OO0I(KM$)!)(BIF,4F54I%?2+TI@$O`MQ\TO2SJ7U9RO)K1AN6HY
M[=KUI2\`[-&6:UOHA>LQ-4F)*3($'-S4I'H.CR(L?"R1$S%`#!]?6/`UVN!R
M$255*L=))50C9,JSDZ:1U"-T3K)MR*N#D*)4$CN%B)@8P@`G.4H?40#@<?`<
M#IR)Y!..?J1#=H[EDV3H\8T?N5&;!S(%1.+-N]=HI+JM6JS@"E44*0YBE$1`
M.!9?!9C;9FNS*VW5^+@I9*??)0GV8I(/'4<"ZP*E=1[8R[5)@S6`$V+@%14=
MMP`YRC]%%`OIP'`<!P'`<!P+$UOK#<Y+8=(U6CWV^*R4C5W-@DH2-B&%B;Q%
M;KK8BUA>SC)^DNB_J==;$360*1-!2.2]PXK>D#&X%7>C78WZD=9W<42_P<-K
M!1I)0/\`MFRUPBS'$/\`U21?/]'\`#>;%'_2PY;<FA0_ONZRX@KNQ`/XG!.+
MD&L\)/\`[/\`5_5P+N=>M6SUUO\`AC)>[PU+?'V3+A]_0A=9\WC/;O4$HH]D
M7-R0@FK5FS(05%53*`F0A1$3``>>!_2ZK]DKULBFT[5IZ%LL(]+ZV<Q7Y1C,
MQ3LG@!];:0CEW+1<O@0^I#B'UX&.'Y;*=V!U_J2XZX=<*(K<KCV=TW.<2N,F
M\?2,-3:%C$Y-A/[-:-%L,0RE):`I<MGE:?5U=PT9O78+SJ)46ZIQ`.!AZQ_J
M7WRJQ\GZ,6NC['B&!9_\EVJVJ8L?3O5M$I^1%Z2]B>N>Q[`QSBGZLT3HF@!0
MLL[!3QJRX*JS8/F2B[)-L*9O:<@$2'_2[NW9$,MTO8\X^1*>[`V+XDNU&&5_
M2L]UW4(.T5;LQD^N7^?Z]0&V2M3TFON&L->,U@X=4R3Q-W'6R=6;+/45WIC+
M$#W,]VK>YOO;1ZEH6Y[E39W.-!Q'!,X:*:?KCVI67L^W^-FD2L/U7T_.*7I3
M//HJIM^Q4L\N=EG)RK2CQS(LCQSYZ9BN((A7^*XS\I4IUNLL9-WSOO!:Y:+7
M\>]>V>I.8C:J78H*],^S\*/:K8<RV_0]XU".G_U3*G<FC/%HC"$H@PS-DZ;L
M4C@+?@7+L^4_(5EB]'KM<B>\^RPN*?(3V:@L8QBQWO>5:[KO6FP:/B`Y=<]%
M[6TO7:_=*H\RN&=6%]4WM^"QU.6B#23%\W.L5L`AMG<!P'`<!P'`L3V0[%Y)
MU8R><V#;-"J&74B,?0=?"Y7YY(QE,C[-;Y9K6ZBA9YB-CI5:"@WUBD6Z+I^H
MC]NR0.998Q$R&,`:VL)K'8._[Y-+9QL]VZ#?*W-1S72&'4S:-ELF^_&'\DU.
MBXAFW0M'62?M;Q[&QU;M<$R0*F[I2\'8ZR=3R]BW)"+.`#8`Z.=MX?N?@D;J
MA:=-Y9H==L]HRC>,5M*B:MKQ'>,YD`A=)S"P+)$31>J0LGZ'#%ZF4J4E$NVC
MP@%(X*4`F!P'`<!P,;W?#X^8_OE;,*;W?0Y&FY=DZUVEK#"UEBBI;K=*6<*N
MU9,X^7D`7BZ\Q:L(9P"KDS9XN)E@*FF3ZJ`&";Y&OCI9(=N>MO6'IAE#6*+9
M,."0D@37?K,VZL??;"SG=&TFUOCOWPHMV2S<KAVX,HHIZ4V[9,QS)(B%8?(]
MU'RSX_\`X_\`-L@IYR6#3-BVFKOM2TIXV(A,7+]D5:RS:T<S2]2AXFFPTRY:
MBQCRF,5,1!54RBYSJ&#`71J1;=,NE6SJ@P+ZU7B[2Z4%5:S%E34DIN4416=&
M;-$U%$R>EJR;*N7"AC%2;-45%E3$23.8`]'M[07G1K4S8SV$LU'BM!0K[&U2
M<-2;*EHQZS7I,/,=*7<E3:OWE!;OR@)T/UM%@+A$HK)>XB(*"%NV3UG(LVDC
M'.VS^/?MD7C%\S72<M'C1P0%4'+5RB8Z*Z"R9@,4Q1$!`>!V>!Y<W-Q%;B)&
M>GY%I$0T2U4>R4D^5!%JT;)!Y.HJ<?(B(CX`I2@)SF$"E`3"`"'X@I^$M$2Q
MGJY+,)N&DD2N&,E&N4W35PD8/]51,1]"A!^AR&`IR&`2F`!`0X'K\"D+??J=
M0F[%Q;9YI#_JK@[2):F3=O9.6=)D]Q5"+B(UL]E)%1%/\RGLHG!,OU-X#@=^
ML6NM72'1GZG-Q\]#K*+H%?1ZWN)IN6IO0Z:.DSE3<,GC4_T516(FJF/]XH<"
M_4_AVG5K'L_WN5K+I/*=+L%JJE9M2/E9I^XZ>\.RDXB5*4H#%NG9D5CLO<_*
M\3;+BF(BBH4H6G$A@#U"42E\@'J,'I+Y,(``>H?`>1$?`?U\"=/Q7=@,(R/O
M=GDEK6BTB$K1:QK=;L323?H3*IS25"G&'Z*[KD6G*2;Y=\]*5L+06QS*&-Z!
M*(_3@=WY$,#J6:Z+):CU(R?LG?NM=T>`\9.R=;]DH]<SFSR2JRJU,CK'K-6H
M;*<JZ_H.M%NFYUTVR0"U54$R:1U@[W0GX[^Q_=ZCZ5<H;(XNF5Z-DDJ93;KI
M.VMZ2VC;BS0;RDZZD*;4<GUZ1N<:RCY%JD9LF^A_"ZAR_<@8H^@,J'7[_E]]
MQI5UJ^B:5W$SB.EJ=.M)R&KF=]=6]RB%7#=L)0-)O=BNDW#2`(.%CBFFK7SI
M&$A#F+^*?`R)UGX5^KT9H45J]COF]2M^C52NC/LSN\'U)@7KH%"JG-)5GI;4
MNN[*<0.8@!Z)0\@80_$PC]>!7?RQW2WUOK_B>=TRTV"CG[%]W.F76^SW&KSD
MG7K+!9]I6Z55*]$B+%%NFLI$N['6(AQ#F<I+$5*E(G])@,(#P+!X)\H^Z[7W
M,ON8M^M"S'J91M[[*]=+1M?Z9>F"V73?6V%DG3S2]&T"<CF&2JUB]6"OO&*4
M"R7+,0J#ED\<JK)J+$1#\[1\F?8'_C^JG3KJYE>5:;`*2/69W9[1)J:;:W4I
MFFY,;=;KOKL-;,ZBG>84:JY/1*N@L5M/R(/["M+ME6"9D/3[P90H"N]6++IT
M;K=7@NO\_LU@B)T(?38",SJ5TZ;@:N\3J5F"-N<<@O:I*(KK\Y(Q_P"TY.BT
M6$&ROH,($X&M=M7R`][ZL/<*L5J!U)UG=0^:O%L)@NU#31L@9P.79?/ZKU:A
MY3KTWS9^J72Y.(FHZT/6AWB$>X1`MA,(N2@DIZ0ZZ783N%_E+\V/8E;:^T#%
M;KPM\H58PFUNMEPEY@U1=Y!=)Z#S>%JN#,Z\;9XFXYO%,2J-)J1,K#G%L<1%
M454@$/0P'M!HQ<-^0Y/M[W9[A]<,LP"7ZH.86&M%EP^?[[Q4[HV4&MTA7Z5;
MZCG-IIUBH?:.T3<2VH#6,_5YX[E@_:@X8F%5%,))=6;CW1S'2/A(;=K=,L]G
MV_L'E/=;'NQU<?6./D6[^.@JLCV`Q^1O4353HT5YL>5Q-+:P4Q,,6Q#F=2;]
M'W3D/Y.&QOP'`<!P,4?S`=Q#=/\`K5`/UH?'#1&U7USCU@NO9"G6S0.O5$A'
M.;Z!>GAM,H]*]N?NR]_"D!5:_"E79MY.P3;1)=P1+U$4#&Q\9W2/,-6GV\7*
MHUQ;%,!D<KN^O]'I>&0W/K7UE[[OZQ1=OCG'0;L#,VQ[>\I:9:G/IMKM4$5)
M&$;RKS[)`XH@J'`V;HR"@X1255AH:*B%9Z56G9Q6,CFC!29FW#9HR7F94[5%
M(TC*KLV""1W"PG6,DBF43"4A0`/5X#@.`X#@=$(N,+)J318YB6968HQ:TL#1
MN$FK&-G"[MO'*/P3^Z.Q0=.E52(B<4RJ*&,``)A$0Q;_`">?'C=>_$7E#:I:
MS`9V?+5KD])%6&KR,W'V"0M2-?;I.%9&,EV;B+_3F\(<@?X9UZ@<"(>GQX,&
MH;W!Z&=1<T[?=8XBI_+\;'--P'0*U"=J+A'9YJ+ZE]<M!2=DF&\]GFOT*FRF
M5YU?UG1VT.XB;Q/-Q;`H1T]620!>..$_DJE(X+W9[L83K7B:TC:]6LO;3/=4
MF"Q<BCV>ZXZ0C$Q59FVLFS9-(B97R0S$:U+Q3=$C./(5%5N@1FZ3$0PY;IBH
M]0MD1J4:W.WZ[;5+RDIB[PWJ%CFU_7%:5L^)NES>2-8A_P"59*L^L0`4!6:%
M\F1#@7=OO7C5LQRK)-BN]8?P-0VT;`O0E'K1VDX>14%]C]K+OO6@5NP;V<CA
M=:+2.<'#MFS4<@0$#)'.%_?C\^/"@?))L4UCNSQ<T\PZKTR5MVAO*_*+P,XS
MDET5X2@IP,XBDL$=.A97GWR0F3534;QJY#IG3,8HAS=XOBS:_%]+TBBYY(2]
MLP6WL7*U&NTZDT_<R]J8HMU+=#7MQ&,V$6O9UEE0>MUT$4$7+$X%33(+94I0
ML/UD+CJ&WTJP=B)2(A<!HH6/1]IDITZQ8Q/.:!5IJU3S)4C8?O'3N;_3$X]H
MW;^7+IX[211`55"`(2"Z.=;FU>D+3VFO<#*0]VU`9$F05:[D9C9<,Z[JR#B1
MI=>FE2A]I':3;(8R$E:G*(D]M4Q&OJ`B2@"&#CO7,/=9T'=-2PN3B:!C.K7:
MDU)A[K1_!N=YF*K&.:W8M'HJ4:R6>2\3:9Q,4P*R;*N)YO'@X`3_`%(H&Z#\
M9'4[!.YOQQ9I@4A\@NP[C3,VIM9I^R8IEXT'&FV6Z2\2"Z2-:M\;(Y,V[&1]
M@B;(^56:2$W-@I)"V%9+UHB8@!&2C_\`+FVO/>VF..+DQIF^]<F.BLK!;K=9
M[%,2\ZG5ZVHZL#:#N%%O,G(H+*V5:,0CEQC#/FQONA$Y4D_H4-C1#X^NL%=[
M`99V4S'-JUCNCYBC.QAO\KZ]!TZN7.NSU6F:NI#VNNPK!E&.58U"7%5H\2(D
MZ)Z/:.91'TD*$VN!QI(HH`8J*2:)3',H8J1"I@90_P!3G,!``!.8?Q'\1X')
MP'`CGVJZT4SMICDAC]UE[#6$!MV<:%6+E4%HYO;:1?\`)K_7-+H=MKCB6CY6
M.3D(BT5=L8Q5FZJ:S<RJ1B^E0>!YK_I3U#E--M^SR76C$7VKZ!!6"LWC07.;
MU56TVV$ME>5J-I8V&5-&BXE0LM47/&/U%A,J\CCBV5,=$1)P(.WWX7>LUV[*
M5CL(SLEQI$?59;K5,PF6TVN9'&PM3#J6R81^-5++;^KG#G7L=S%JWBD"R];K
M4]'1LN45B*E*1PL0X3/SWI+URRG9H3;L[H$73;!4,IM>.T*K5EC$U_/,^J^B
MZ>\V+57]/J,-&L&<;:-8OZK5[8'YSK*/!C6P$!+_`!`N`N0_ZX8#*15H@I+&
M,S?PUVU*+V^X1;NF0+AA9MB@Y"NRT/J$XU58F1D[W&2=1BW"$HJ!GB2T>W,4
MX"D00"UYN@O2(]RTG1#=3>OAKWL<3>X'5[<.4TW]PZ-"Z@!PT>+N<I^D_=V)
MC>@4-^JINC*%?>H?>`_D>![>D=*>H6PFDSZIUFP[0SS431(&8/<,SJ<\>4AL
MN5FELWC9`TC%KF=M:(I9)`8@JGJ"/!ZL"/H!0X"%"4OH#URS39<1U?,J;%YK
M"]=J!L],R3'*!`UJI9/59K?9ZI2^G:0VKT+#M'!KS.,:>C'`O[X-R,W3O^4*
MJYE`";/`<!P'`UUNX.2_(%6M_P"\;&B]0*WWEH/>FC9G0,(O]YT^B.<HZI)5
M:DM:VK2]TZY[`Z4JL_F,%HQG]Z/)UY@^DYE5\HS<%%8K44`SFX5B&7==<MJN
M28]G&>931ZPR]+2F994HVDTIG)O3B\FWL57HQ,B+7]4E555SF.95=0Q_4HH<
M_DPA=S@.`X#@.`X#@.!JU=`ZQ#YG1-\^-#>Z?$%VG#;EJ+W9ZS8FB,C!=G\A
M[`7ZX6RI]E6?WB?F[UK58F>/&32BX*N8N<8K,7(D.1(.!$C4<+MD#7(WX^)F
M>EQV;K['WKL;\&'8R7]V9F[?#TR$6DM+^-S1Y-PH5W99-M4T!AF+19;USE24
M8NTP^YA`(<+?"USWOGULL],OU9G*/)O7TG1],HLLC]EHW7K?<_D/MY:)<(N2
M`O%W3-+@U*X9JF`"/&OMG_,@X,`AEZZFZ/$_*ITWU[HOVP"!KG=#K:QKU4T"
M1BF#5@A.K,F;L^%=M,UBR$2`:1HK)N<9!HU`J3&1_4XHP))&2]82^^(_I?8^
MGG7F=:Z7$M8S8]*O$S,WA)LND\*QB*T\>5FEQ#=ZB<Z3E@,8U5E$C%'\98P"
M`&`0`)5=TNK57[B=>;QBMA.V82<FV+,42RKHBJ:H7^'(JM6K`3T$.K]L1P<S
M9Z0@"9:/<KI!]3^0#0IQ3JS+Z[V9N+#11@)K#>I6F2-5E3UV60L=)W#L/27X
M)KL(N7;E(SLF;Y)))%5=&]/M/)PI$#E_PZI2AD7OD.7M-J%@ZJIWS_*[!\[H
MIMM^2#L.,F,*QQ'K`U1=2:N;L;+_`+.)U'?&4:Y:HB41<QE;3>OP(8?:*8)O
M=4J&7M#IM+[R6S,TLOQ?-J$3'/BXZU.H).(+A/6@C=G%I;;.UU0@C$;!O47&
M-562)@%>O50C1J4PKK+J"$A?CM3#?_DQ[6=O,DBTVO7VA8-!=,+1I[3T(1'9
M/L32]/<7>R3->,W+[-K@^O4,NK5AG3B<%Y&3=M&ZATFBGI#8'X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@8M?F#W/(\MZ2Z_G.F;/;,2DNQ5!T#*JO:\^Q>[]@[U%
MQ:U0DY73;3&9;GJC6R.X*FYJUD7DK+@Z8MH)L(.CN"*E1(H'WXR-$[9S5*G,
MF[$DZP7FL8=5LMI-&WCKE>;DF^NZRM%AYE*N:]@FA0#:Y8AIL70Y2!EW[-S(
MNDERS:0HIID`0`,I/`<!P'`<!P'`<!P,5/R;],KYM$-0^U/5A**B^\O5$LQ.
MY&=^L$;#;EG,H"2^F]5=(?$]`+4K5XUI_NU=?U%@[&DT?)&2+]R)P@/)M,=^
M4KJ!"3]6F;1G$LYFF]HH5K22-$[/U([49/+*)HJN6_\`*>UW3L;OK-1C*LC>
MV209>ZB8#-G91$,+?ZAV4JUY[2]\MULM8DMLS76JKEWRE]7<QSM.G06=8JRJ
ML/6NO??C+&B#V2E=-@[#'1JLM9YPQ@,K#O7+4J"!8$0$)07QWI68WS*N\O5,
M&E@WC"8]=XTK<?()D@NS77FS`UE="P68?HB=J];VR*2)*U5Z8%"QUB;M7"?T
M4/Y#;7ZP=E,H[?8+FG8W$YT9_.M1KK>=AU5TOM9>'>%4493U4LT88QE86VU"
M=:N8R59*?S&C]JJD/GT^1#%A\PO=NYT>/K/0SJ[:%8+M1V5KLA(W'08D2K.N
MKG68CDT->MJ='`1!E>;,<RL#2$#>E1:945>%$"QY@.&%*SN8[J]D^3X-UNSU
M.UZ?<9*'POJKB[=<QG5WT641552DK(^'RN2MU](7-CN$VN/I19I.%UC@=4HB
M'G]9NEEHMVP[=U$1[&2_8/HIGNM4'7N^-MD*?`0Z':7Y':W#M!T/`*C?H@C2
M=NO5?.)F*A9*;AI$BJ<=*,$81-91/[D.!D\[*6?3NQ&N5GXW>K-B>5+5-2JR
M-L[,;77B$]74;JB[<&B9:QQZB1/M66TZ^FFM!45@;TF0]3B4,4K=H53@9\\*
MQ#,.MF/9S@V,55A2<MRJJQE.I=9CBC[,?$1B7I!1PN?RO(2LBY.HZ?/%C'</
M7BZJZQSJJ',(78X#@.`X#@.`X#@.`X#@.`X#@.`X#@:ZGRPR_6WL?V+<].>P
M&[ATDE<FZH3G8#-.SBFR5C-+#H;77IFW9AK>#P%+T6&/G.M96_HM#*>\L7C\
MCLIGL45%$$ON%@#(?\5%.JL=TRSC88&V:QH5@[;I-^V6CZ+N,55(#4KK=]CK
M]??#(66MT-LTI%9;PM4C(J'C8Z(3"/:14:V(D)P`5#!D<X#@.`X#@.`X#@.`
MX&O/WTRM[\>?8">^13,XIVKU/W25@8CY&<Z@FBRZ.<V<`;5^E=Z:O"M"F`%(
M-,Z$3I":!`.]A?8ECE.LS<J\"@^W63W,LK2.\G5B#@M`WK'Z5*0EBS8%F#RF
M=V>H=Q0)*:5UGM2AR.H:>"PPRIIBDOG!%T64Z5,H`9!VH40Q@XVI5,5MF99Q
ME4G.VKI7VMSF?[%_'5=IIN\)/4^B1#IFML7470$G:B[Z,MW6^PS)48T5SG$T
M,J5H94SAF<.!,?X^M@G^G'>/7<GJ7NRN"=F.N.]=P9?+A6!JQH?8'`5:,VN5
MKI1A]3>+C=OK5H0"::$3`GZQ')O"``J+@<(<=:+*^M>6V?O5NEF+/;%VO@6O
M9';[VX07,VKM3"N*3%,S&JM/*[J.SC&*`1..BV*?D5#IK.#`99<P\#ARB-W&
MTV&BZ/3DGU([P_(/E4V7K&_D&97A/C9^+!S(,6MX[3R)%!,S;]D^SBKE!*`2
M3_GIN'#-N"A$F#Y%0,IVC6C.OCDZR95BG7/,U+E?9E]&X5U$Z_L'8K6?:=IL
M!5W:;NRRIQ^[69%>JNK/>[(Y'TMF173I90IU$P$,I?QW=)4^F6031;Q9TM2[
M/[G8QUKMAN*C8476F:Y*-"(JLH8BP`XBLRSJ-],'5(H/0C'Q#8IO;*NNX,<)
M_P#`P+]E_D![X(?)-H'0SJ77^C,-'9YU;SWL3(7SMW:->K02J]RN<U3W5=B%
M\Z6<MUEF:[1NL1,S4IO9]TQE!'T%X$Q+E\J73_)=^K'4C3M,=NNQBHYA!:)%
MYEE^M:!G697/5QBX^CQ6AZ)6Z?,U;-6]WFI1$D26>>M%3(.$5%_:*H4XA5?R
M6]YXCX[^IER[%.:2]TZV$GZ;F^49BPD20Z^A:UI4^UK%'K"LP=N[+$QRL@Z,
MY>.`24.FS;*BF0RGH*(8\G'?SY-.H.^]-JC\CF.=/G6*=VM:A>OT#<.J5CU<
MUHP3;KHP4>T:K:&AIBCJ'N\#+.6ZK-21BA:D3.DJL'DI$DW`23E?G0^,F$U)
M+'Y3L"]9VY#;I[KM9G2^5ZRG3L]UJ#N#ZB)5G2+\>E%IE'"QV:-72B7$@^1;
MR""1G29_M0%;@0<T7_F,,$B]&^0G!?TNU8_;^M(NJ+AFR6;$>PFM46UZ$2FS
M_P"NV36Z-GV7(6',Z/0-#C"(>IT\,%@ARG?LE?9\"(2KBOFDZD85A/6-WVWW
MZ$GMQV;J5GW9A`,-P_<Y6$U2L60IF$A:\NI)*E-7!K'F>L'CQ2-?E2D(Z-;*
MNG2:""9C%"[6*?-3\;78C:,LP;'NPR5PO&UPZ\AF3U&@:3%T:US+*"_<\G06
M&AS52CJ;_F7"P/\`/?P)GI9%B?\`D+IINA!`0L+CWS`X]F'6M]MG<K>:W>H^
M4[%]GLVK^@];NK_:%Q1JY7<+MI8I_!7R/5H]EF*Y+U!DL4KV9??:0\CX$S-5
M<J*RHA?_`$'YF>@&<5G++7*:;>;%':YBD?V4@F>>X5MNB6"L]>9,XIM=LTVM
MTV@S$YE^<G.4X!(3J#$I_:4$A3@F<2AS]H/E]Z*]9XO.FMHW%N_L>XXT[W#)
MAHE%O^K1RN4N8P[B"V*VK9Y6K"E4<J=.U$R_K$F9JT,!5!]8%26,F'L?#SV@
MUKN?\;75OLWNKN`?ZQJU8N$G<7E6A4J[`KO(/3[Q4V)X^&0<O$61/TB`;@<"
MJ&*=4#'#P!O`!DMX#@.`X#@:>W>#LDKM?=?L-B78[N/UOZ_U?)-QI^?]5L8[
M??%`;LKAU\825(H)WEWCMQT""@W1+E,:G)2,4L$;*MF!$V+<S4ZZ:@*E#;VA
M6`Q4-$Q9BL2FC8Q@P,6,8DBXTHLVJ3<2Q\8D=1..8@*?\I`IC%13\$`1`//`
M]/@.`X#@.`X#@.`X#@>3/0,):8*:K%EB(V?KECB9&!L$#,,F\C$3<)+LUH^5
MB)6/=IJM7\;),'"B*Z*I3)JI',4P"`B'`UY(SH?\EW4%.P=?.E"W5S6>L*LQ
M+K=;K;V0T74*SHW4BK3RYWB&:3]?KE,N"&YYWF+]VK^UO1)Q<D$<1)@[,*:1
M%1"(W;WJU&]*K;\*76*-M;^]GS#+_D#2G[Q)LT8UW<KO;(?++QH%K&+;G50B
M&]AN]DD':#,AU"M$%2(@<_H]0A;JG."L^_U/=G*8Y&OQH?(^X.0GCU&*@TQ9
M0Q2^H0#U&`O@//T\\"*&<%4:_%!6`*<2JI=`3*%4((@)3&PATJ4Q1^@@8H&#
M_3P,T,5T][0K9E\>_=SI8UR:\WUG\;?7;K7LW7[9;1-YU7M'S&.JU8T.AV&A
M:9`5RW'IE^HEHEY`#)/HUQ'2D<]%,YD544Q.$O\`H]T4V:(WBR]Y>\[C.)/L
MH[JJV88/D^7RLU:\JZF8\_,B\M$34K19HF!D+=K&IRB95;39`CF7K:MT(]H4
MK0JGNAE^X#@8$-;^(ZF]J?EVUOLUVVZ]Y)N/5&6Z79=F.<H7YQ'6%[&[;6-'
MF)29<I4\QB/H\B=1DE$P?&'VC@K[9?(B8"AY&2=;?D/Z6=^^Y<_@N`X=NO6O
MO=O6.["ZV.X;87.+!UZA8.O0E(T2ISV;%J\U/Z*6%K<>X/6$8IP@W!042N%4
MRG6*D'Y[G?!W$7_J7M.<]7]MW`VZ6+2\9WG-)/M)V(V'<L_B=+P:ZRETK$,T
M97>:M)Z-!V0D\^8NW$8W%7P9J90JJ;8""%-67KY\H/R-]A.CS[NIUUP[IMU\
MZ6[I6NTMO0H^_-]YN._[/GL<^:T"'J$?#5F%:T'/6DK(+.G@2KI=\9NIZ"B=
M0H#P,.>0]:^]7>S!/D2Z78AD.%..M>U?-AV'G]2[0V;3_P!'O^+CF6^TBYW>
M/-E!Z\Y<W>0DHZ`C@@'D<_`R/O.F[I)(HI.`#+C>^E/?6N]N?F8;4+&*)H'7
MKY-^MS2,I^T.MLA:O8\\TC/>HUNQRJ4&9S:2C5Y6;&Z7B6104DP<-F,<P/\`
M<G5./K;E#L]._C8[29'V+Z):5H=0IC.LX-\'T=TAO[M"XPDR_A.QB5S@)5S`
MQ31NFJK(P(P[=P49AL/VQP]2?X'`#!9;KE\4/<3-NMWP)YS9:=18ZX=".UFH
M:SV5;1U\@G3:`I]MDM2>1[VOR39--.XOG;>RL@60:^I4#G`IO)2&,4+26SXT
MOD_@.@]5Z9U/':#?,]TWY".S>]]OL^8]BX/+9K3>MLWKJ>AYGDD5H@0MB;0\
M)KQW9_W)[;-9\U9,2-3$`'*Q0"M^P/QK]R+7VF>=MFW4"2N%/[%]/,KPC5>I
M>"?(Y8.I[KK_`&G+BR5?2I2VCTV$JM3W#"YRENDD19?8I?:.3K"FQ$H![X7-
M7^/;O%U2['YGL'2OK'@MSH&C?&'G/0*Z9#HO8Z99Q74Z<IDTXG6DPUO\]392
MV;;E\<,L*+I-HQ0F)@[0R@IMO4D/`RG?#IU>UCI=\;'5WK#N3&%C=4R6N7:&
MMK2NS3:PPI%Y;5;Y9XQ5A+M"E;NDG4'.-E1``\I'.*8_F*/`R8\!P'`<!P-2
M;8Z#\F\+VISW0#;UW4LL9LG<N]41*CY7NF#?\*-"BJ9W(KJ%,I=[@'QW3^E9
M];>D2+]<$6X/+:I=F*[=VU(HH5(X;;/`<!P'`<!P'`<!P'`<!P'`UQ/FB_\`
M&]\7?_Z0[Y__`+%Q3@0`KO\`X\*Y_P#+%^2C_P"[L9X$8*'_`/Y25S_Y?Q?^
MX%;@;D_0C_P+=+O_`'3>N?\`W/T[@2RX#@.!AA^8CY3KO\;=2R)OB^#L^R>Q
MZ9_FS>GN<N+,]K1:]@O7S/W>@[5I:[F,BIAX;]MQZC%-!,R14E3+J#ZC&3]!
M@EK=ODHZ591C/7[>=EWRD9+G/9RF-[MC\[<G;I!C:(Y3/D=-<LFSUBS>M"2C
M6K+`8K=0Y%7+D2MD"JN5$T3!"KLS\_?03#.M64=H,[T:*["T37-R;XE!MZ2Z
MF8"2CGL,]A_\U)J;9V&KEDX5;*Z_/-)-[&/FK1\\;.4?MP,"I3\".FI_.(G<
MZ]\B&D])]=ZA[?EG5CHO([QF;)%CN)ML+LT9+#'O/\RZA8(.CU1SD?H4*1`T
M8_+(G="F!C^A0X)!/GX_ODNZ,=J(V&S?(MJP][V+5RJO;=N.:YW'.JPS0M4]
M"0+C4;+%.7T<TAKBA#6U\=K)O6,A*JM%2`1XM[A1'@7%P_Y7OCK[([,EU^Q#
MM?FF@ZT]/9$X*L18V%HVN2E0,L%G)GUHF(.-J&C&A"-E5'`03^1]"*1U/]F0
MQ@"!?<_YT<`H>D8/A'3?;<-VG>+#W\P+J[MV?R#6W3!Z]GM[MTC4=/DZ;,1R
MU<KD[::;+_9-5EV+^5;QCER0KIN(G*`!DI)\BW2E3&E>P1.P-2'(4=K#KDK;
MOT^T`">Y#;DZ(&9'@1@`LP6C]T*E;^U]EZ?;'W_5]O\`S>!-;@.`X#@.`X#@
M.!\$0`!$1``#ZB(_0`_M'@8)&WQ$[BE?8"A?\;38W0^L=Q_^-R(Z^)]>JFGL
MQ-,2W-]V-1ICKL@6TC(N*6CKC]1V9Y^BA.JQH_IQW0I>5!#.YP'`<!P'`<!P
M'`<!P'`<!P-<7YH0$>[WQ=@`"(_M#OG^'U__`"+BG`@!7@$.^%;\@(?_`-8O
MR4?B`A_]78SP(PT,IO\`X4=<'TF\?_#^*/GP/_\``*W`W)>A'_@6Z7?^Z;US
M_P"Y^G<"67`<!P-<OL/\<_>'NE\F'8G>S;>_Z;XKF_6RJ=2NOEE1S'%-_<[A
M0-49R-P[)O#U"[2<NE06#FQK,X91RX:M)1^U;`1,2MRF]80^ZU?&OWVJ<)\2
M&&;5C#2VT7XU/D2[(MPO\E:,SDHRR=3#4B9>X+L1(%6V2$D4?W#-%8-8OV%)
MB+.P;&,@0I"J@'G=B/C'[M2'7[Y*4<_Z^-;%9K?\UU%[UXAG#.[YW$/-<P^G
M/L]DY=]5W2TX:%K4S-J1KKPSECL'2@H*>4C',F10+A]G.D/>#LUJ?R8;?&=6
M)C-C]P/ABSK#J!0)'1<F?2T7V(-9IF:G,=D)6+M:$0,]7FK@@+2A_8AE3B`)
MNC?P#P*/\?7?CLSMG7F(U+JI3^C-2Z8_&1V0Z6I:C#ZM0;]%[5I>\XLAD5<E
M*`QSHJ5AB\]J2RJMA.64:MG#1Z==$H*+'*H<.3K7TI[_`.DN?APZY:YTOCNJ
ME,^)ZWEMNF=D2:YE5LA-=6I]`DZ1#0V&5ZD2<E<S-M=D%TY:?6F&L<F@?R*O
MN*E*50(ZY_\`'?\`)9`81T@Z,R/0^IMX3HU\HE"[,6?M^SVC(CIZ_F*V^66W
M/+50ZFJ^1O(R9JI;P=6,LDHR=%;PS9!)NY<&*@@%TR]2[>__`.85F>H$#+Q$
MITX9;%7?FZO=)8+D>.*CO):')9#$PD^U(?[2,0M&SN$;,DR53]2[?T+%^A//
M`W%>`X#@.`X#@.`X%@^T'7FJ]K,(T#`[G8[Q3H.^M(8`M^:SQ*S?:G-UBRPM
MRJMGJLVLRDFK.8@+376;M(%VSALM[(I+)*)'.0P:FB5.8]-]EWDDIKOS==NL
M-ZF=DIS4^UG8',]TI..]<,FG+3)5[>[?&W',HRP5JW]A96H0MS;3FAK031O'
M+-GRPI1Z9?4B8-SYD]:R+-I(,7"3MB_;(/6;I$P'1<M721%V[A(X?0Z2R)P,
M4?X@/`[/`<!P'`<!P'`<!P'`<!P-8WYYLSC-<[:_&'29>T:'3V3NN]Y)$T[E
MMVE<^N"*D72\5<)-FMGA1"0;L'1A]+E$OY5T_P`IOIP,<6#8+!XEWJ]BOW[:
MK]^M?&%\BDE(GV75;#J"T0DP9Y&Q:A7E;$830Z#U9\(.4T?/OF(F8X?D`>!"
M.F=.:>[^-:"T4VT=KT9%;I(%S&M->QEX;T(CP,46F/T1*G)F_3$ZE[Q?9_30
M_D?:>4?[O`WNNA0^KHQTO-X`/5U.ZZ#X*'@H><?IP^"@'T``_@'`ECP'`<!P
M'`<!P'`<!P*%BLOS6"OEKU.$SZDQ&FWR.@X>[Z)&5:$8WBWQ%91,VKD79K6V
M8I3L['0#<XD9H.5U4FQ1$$RE#@5UP'`<!P'`<!P'`<##!VV^/7XWM-[#OI_L
M%O=RRR=[#/Z;+Z7U>8=OY;&,<[73<`:&HM8E]%PI&SPQ-'DY!"*C8)<60(A+
M)M6[5R5P8``0F'U+[\=:>W]AU2AX9(VY*5Q.7<P<C&7+.K5G36R5R+M%ISY*
M^Y<>S1D:VOF8FNM"F85.6C14;I2$6L@H"9@3`X3<X#@.`X#@.`X#@.`X#@.!
MKF?-2Z;5[N3\6%IG5THBLO#=T,Y;V"14(TAAO=TS?,Y"H5-216$C5"<L[2JR
M)F"!S%.Z,S4*GZCAZ>!"'.(^3O\`\A]BJM!9'N%IIGQ2=WD;-!0I@>.H&0U&
MPY5$9K&3?L>Y^F2%XDX)XG'(*^%G!6RBA""0@FX$):WHE)C/AR9V?]V0J<1%
M]&'-'7?+NT"F;7MMDKBC*4MPR]PSE.V)W7_=8QHE^[^\_E^WZA\<#=;Z<5R4
MIW4/JM49R,>PLU5NM^'5R8AI),Z,C$RD'F-7C)",?HJ?G2>L';4Z2I1^I3D$
M!X$D.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&![YTNK^%7C&8OM=KVF,LF3
MP^E7S&9>=+UIK?:&Y6BD=FY[/:>>GXY3IR0B7M3["/;W#PJ5(L[%<RT))/%A
M.DHDLH9,/`^&3JA/Y9:--VG3J)W$S>WS];FJID]?[D;/AUBO$UF5YU*<VG2[
MDPZ_X=`,(?KV,_KEB!9W$N9"4,"JA3D!H995(P;`'`<!P'`<!P'`<!P.E)24
M?#L'<I+/FD9&L$#N7K]^X2:,VC=,/*BSARN<B**1`_$QA`.!#.2[Z8K'S[R)
M2:V^6C&IP23LL5$LU8QZH`B"AVC=W),I([4H_P!U040]S\2@)?`B%9,.Y_7E
M\S7=GN;F/40046^PD:[/H/5A3()O8;E)'+-UW!Q#TE*50?48?Q_CP,97=7:*
M)W%SZ=PNY9+4;5BDTZ:.9*(T.%8S\K*O(MP+B*F&(&$Y:=)QZX`HV=L%0DFY
MA$4W*?DQ>!KQ[IV6U7XOI5ABG0VOU3K-2=$BF>@72[P5`JEGN6H6AG).&2;:
M1T"^Q]ML\JQJ3%%-#[9VX5%`KPP)`FDJ/N!?OKI=>N^M0>?]O;O\;&:2/9MY
M8IFSVKL11<O862J6;3H"R/VR>K1V#1=T3J,-H11:I*.95:L/G*DJ15TB<IC%
M]`3CE>Z</89]":N&VVBMV=)01:GT(;EF;U@<YO/ML"V>.K<>R)Y#QZ6P@0?Z
MP\<"8>6]Z-68%9K1UZ@-8KZ:B1UD7CN*L"R[;U%]U-"QPB_WR:YT@$"*+*+E
M*;ZB4P>0$,SF;:+6]3J,9<:NY%9A($$CAJKZ2OHF12`H/(F20`1%!\R4-X,'
MX&*)3E$2&*80KO@.`X#@.`X#@.`X#@.`X#@.`X#@.`X$0^^D=C\[U&VRJ[S7
M;U9LJN];9T"RL\RSE_JU_BUK[/Q%/K]NJ5+C*[;';J<HUFFF<RW>A'.BQ*C`
M'QB^EL(@&M;UXGZY\<_<FHV'0Z/3^O<Q>Y1_DCIMV'V+5/DG^9/NK45)!:)K
MJD'4LMG)ZM]>\>>6%G%3RZB2+E`6T<F*B"7D2`&X=P'`<!P'`<!P'`BEL';[
M+LM,\B&+D;Q;FPJ(G@J^ND9HQ<D^@I34X(*LF!DS>0.FF"[@HAX%,/QX&*W8
M>PFC;4Z`MED"1]>05!5C4H8RS>#;G*(^VN[*=0RTN^)Y^BS@3`4?]F1,!\<"
MQW`<!P+:ZECV9[57DZMJ-0B[=#MW1'S)-Z"[=]&/""3U.8J68K-92,57(0"*
M^PL0%D_R'`Q?IP*KJU5K-(K\95*=`Q58K4*@+:*@H5HFQC6")E#JG*@W2``]
M:JRACJ',)CJ*&$QA$PB(A[ZOA=(S=<`7;G#TG07*"R!RC_`Z*@&3,']H<"V$
MOAF0V!8[Z0RZG&>^H3&EHN!;0,J4X_7UA-5XD7)D4\_7U`L`\"X61,IG%ITK
MS/=?[`T.">K)&FX&K:8G86#LJ":B;9=M$;#`ZA`)NF8J>2@+8`4('MF,!1\@
M&3_,-6V^V_X?/.V^87"75$0;TCL=@:59M:H_3PBA:\CT"CUYXI_#UM85W_$1
M3#R``%[7>R=L*01+][]><INS4H_XB5R#L7%,7AR_Q.2L;13LR8-CA^/H&>6#
M\?S_`$#R%"S?R9=<L_!8^WMM!PE!K^5U)7B!AK3`-S@4PF!:RXQ9=4@$"?D'
MP91PF'@!$?``(@%D.[?RET#,.B6F]L>GFC8=M$E1;MA=0</9QY/66C59#7]?
MI>=NYNZ0U,DX6X%3A8*Q.Y!-JDJ@X7,S])0-]2"'S%OD^:V%QE&4.JU8.X.W
M6^BN-8OMLZ29',P&-YSELSJ5KS&B6NSQ>^:?%W:*_6I^K/&1FK9:7?*&BWS_
M`.W08ID,(7ZZH_))U^[DVFDU''H[11D[GUC@>TRREEKL5%M*95)_4+9CZ%#N
MYF=BDW$)J;*\4.;0<1I4UVP)Q:YR.C@4`$,1W5WYTM(O>U6R.VQIU\>XGG]0
M[UZ3O09#6-DB=/ZC9IU%T:Q4VEW357]MF+%3-.:;>A`E0CVM<3:O$)-P4GMG
M`ITR!-.G_./U<OU9=*4W--ZM.O+:EF&1U'KI58_(+AJU]LNR9]:=6H+NN2E0
MV.>R-K#JY[1YJ0F%).T1Z]>-$.FTBBW<E226"O''S']5XWLC2^L,]!:I6+Y9
M[?CN6V)S9&&>12.8[5N])97S/L@O-54T@^F+68T5)M6LK(P<%,UJ&E'K=J[D
MTSJ&%,(QWKY_,B#KUJ6PY/UG[*2<_#]5]&[4X;%:K4ZQGU1W>DY-;H2B:G(5
MZRQMUM3^/A<GGK(S<SZKADFX5AQ4>12,D0$P4"_UB^93&**FR-?\![/UU*HT
MC!KMV@F$:919:O=/FW8^9/!Y:RV]\QTE1XZ>2ZA"R#A.KMK&I&PBR3UZ5`I_
M0`=2[_-5U_I+_26R^(=F'T7GO:*3Z9L[LZKF44S-+]V(@IBXQT[2*AI.C;#3
MJ8T;Q<?3%'HR,X\AX]?[UJR154DU#,DPR\0DF,U"Q$R:/D(@9:+CY,8J6(U3
ME8P7[1)T,?)ILG3]D209"K[:P(KK)`H40(<Y?!A#U.`X#@.`X'CV*&)8Z_.U
MY21F(=.=AY.&4EJ[).(6P19)1DNQ-(P4PT$'43,,BK^ZU<I""B"Y2G+]2AP-
M./3.JMBZLVG8LXK3"SX17I:P-HE;(>B5DD.U/S3_`"$5JVV&7JU-U?L)VSNA
M1L/6;"-0G*PZ%P]:_:-H8WOM%Y!JK[21PSV?&QO%MDHBR=/=FSVIXWNW6:A9
M3-N<0HV@WW=$,;P;1&4]#X)1]7WRX)J-K[OR<#GKQU/BT<+-SM7#-RBHJ58Y
MBAE(X#@.`X#@.!CJ[<=JOVX61RO-)$!L2A#M+;9V2H#^WDE"B1:%BETS?2>4
M*/A=4H_X,H^D/YP^4@Q%V.4&"KECG2I"X/"0$Y-E0\',+A2*C'<B"0@3^8;W
MSM_`^/S#Y_IX&&+JU\CVU:KO%)SZ^P%,>UC1)?\`1T$:O7Y%A*U==6->.6KM
MJX_5'QY!@DN@478NBJ"1#UJ%,0"^.!FVX#@.`X$`];^17%,DV!#)GT=8;&$:
M^_2KY;(#[-6+ILJK[!4F";190B]A68G5$)'V#I@T$!(7WE"G3*$_"&3-Z#@8
M%$C@0X'3$!!1(P`8ITS>/`@<@^0'^O@:\?::$[V1?9=PL$EIDT]E9M9]DSW,
ME+46D?MY-V@9BPCHN*75:101J0(DE4'WE0YP,HJ91,Y3F#->QR^\O&+$UKWK
M5'$H=DS-+(UA/.:I%EDC-TC2*;`8N@C($8E=B<$O4X,H"8!Y,(\#L&PVK.@\
M35KV&Q_4!,69V70R(G\?4`,U@YV$:^`'^@@>/X<#C+UTPXQ_=>YK`SBP_P!Y
M:TK3%N5./GSY44M,I,&4'S]?)O(^>!.3HO6,<H6TQ\(3*\PCV5U8+0:"Z%"J
MC=9K.-0-(PJZ+E*)*NFJN=%5O]#?F,N7S^`>`RS]F^K.6]L,@<XAII)Z.I+J
MZY;?5/V3)-JY+EG,ATFK:G4B)OACWR1&!K/4&A727M>5FHJ)E,03`<H6[TSH
MUG&B]GZ;VXC=&W+*-7KM3JN?7`F0Z$E4:KM.=4B[/-"JE#UZ$<04PI/0$+9I
M5\8AH]>+>JM)%TT5<*-5C)<"TGQT?'U"]&G?;J>.G5I"V]ENU^O[&VG*XYG7
M(Q6/V&X3EBR+,E4)MNU0@DJ$WM$H<[".(,<60DG2Z9U#+G-P*?<_#UTZD*M0
M*9+,]*E8"A1_<^M';.KL5%>[9_WSEK18=^S*^/HZ'8O)FB.;-9PE(9LB=HXA
MY&.9N$EQ52.94.D'Q&8PIF-2SMWO7:AS-9AI5,U7%M@:W?-*YKF+VBC5"PT"
M+_8\[4,AKU>D64K2[7(Q\N%@BIQ>71=&,Z554`AR!7-2^,?':!O)>P]-U'?(
MNYRYLVD].B7]NIUF@-NN664>,SVOW[3Y"UY[.WP;;,5N$9)S:T#-03>85:)J
MN43G`PF"&?4/X+,KS+K@GF7:'1]*VR_3_576^I,^W9Z9,N<IR[--PM:UFT]A
MUVB9&LP<[25K@Y91BSAR^%ZJ@JP31;%1:@*)PD#/_#;UQMTHS?W#6NTMH83E
M3P^H;Y6I368E.N=M&'7*<6G<@>=CF$72(Y6QRE9%0C)56"5KQ9.-02:/2N$2
M>D0N=?/C%Q*[XCMF`-]#V^F4#L1O.T;]KR-8LE'>.;?.;\XE7.CTIZUNN=W"
MO!G[IQ*BK'MP8?J,4Y;MW#5ZFX1*KP)UYS0:SE.>T/+J6T<,*=FU,J]!J;%V
M_>2CME6:=",:]`M'4G(K.9"1<-XN.2(===1198P"<YC&$1$*SX#@.`X#@.!%
MCME4:W_DENMT9X%9=PT"2QF>HO[5R"7C\[W;1*VX,Y<M,[J&NI3E/GZD0TN_
M.[;KI3#;[!P)W2`"X`I3AJ>XKG4GTAVR2LSC1+QV3^4?8K:XO/7WXK\"[+:=
MM>?XC<9#.T\CAM7[[]B9ZQR5NTB+S*@^&\C+7!^SKT<V!PC`1RHK%<HAMW=7
M,^UG+.OF3T+>=8>;EM,!4F9-2U9XQ:1A+A>I!9Q+61W%1K)HR185IA)OU&<2
MB9,%DHQNW*J)U0.<P7[X#@.`X&/SMUVE<4<S[+,]<G1MZS9(MEL:7Y1K+1\W
M(NDQBS_ZT\[:+%.*H?1HF<!+Y5,'MAB3,8QC&.<QCG.8QSG.8QSG.<PF.<YS
M")CG.81$1$1$1'R/`X5T$72"[5RD1=LZ06:N4%`]2:[=PD9%=%0O^LFJD<2F
M#^(#P+'9UUAZ^Y+8#VK.<GJE5L@HK-TIMFB^=R#)NY1%NY0C%I1\_P#TM)R@
M82*`W!+UD$0'R`B'`ON!1,/@H"(C_``\C]`\C_U!P.)%9%PD"[9=%R@)SI@N
MV63<(BHF82JI@JB8Z?N)F#P8OGR4?H/`Y.!]*82F`Q1\&*(&`?Z!`?(#_H'@
M8K+Q\56<7/2+/=T]0M%?A;19Y&RN*@PK<2Z28FEGPR+^-93+J2][[-5RJKZ3
M'0,<A%``/[H"(93D44FR"#9`@)(-D$6R"1?[J2#=,J**9?/\$TB``?V<#F`Y
MR@)2G,4IO[P`80`W]H`/@>!^>`X#@=^)E'T'*QDW%KF:R</(LI6/<D\^I!]'
MN4G;57P`AY`BZ)1$//U#Z<#.7UZ[)UC<(H&:H(0-]CFQ3S59.MY*X(3TE4EH
M%14?<>Q:AQ_,4?*S8P^E3R'I4.$EN`X#@.`X#@.`X#@.`X#@.`X#@.!'W,>M
M6'=;J_=TNL>#8SDTU:E9VQR"%,ID#0F=QN4@=[)I/;K,5B%_59`KV9<B*SE4
MKI9),YA3*/@"\#649[UV6P7MWJ/:G:\X[8U3M+MFV9;F/5CH8IL4198[M,R0
MZWIU'>LAJU19W*T9=0>JV&[>W;WV,VAQ$1K\D<LZ1=D]3E9L8-ESK;VYZY=M
MJ_89WKYLV9ZV6DS!:S?D,ZN,7;B5"T%(I[T6_<,#$,JT65;K`R?E3!E))HG5
M;**$`1`)(\!P/#LU@CJG79RSRZH(QE?B7\P^4$0`0;1[91TJ!?5]!4.5/TE#
M^)A`.!KE6NRR-RL]@MLN8325DF)"9>>1^B:C]P=<K<G\`2:I&*D0/P`A`#@4
MTY<MF39R]>.$&C-FW7>/';I5-!LT:-4CKN73E=4Q4D&[=!,QSG,(%*4HB(^`
MX%B<H[083M]AGZKF&@,+-/5Q-5T\8$92<>9]&(J((+34&I),VJ<U#).')$S+
MH"8"F,`B`%,4PA?S@1D[@YUINJ]?[I2<DEB1EOD3Q3H&WWIHM>Q1$:^(\DJP
MSF`<-DXEU+E2(!55#`BH"8HG$I51.4('_&;B78')K[IR^E4ZU46EOZDS9(1U
ME**366M"5@350=0[<CQ=O[K-B1S[ZY"^%2+$\&,`AP,K%RO<%1VS5:7,X67>
MG.5HP9$34=K$2#^:N)55$DTFZ9A`HG,/U,(`'D?/@+3#V(CO?$"U5^+7^"@R
M;8KC^T40;F2`/'_I\"X]/U"L7)8S)H=>-DP^J<;)^RFLZ*`>3&9*I**(N1+_
M`!(`@H`?7T^/KP._=;["4=F561,9S(+E\L8AL<@/'(`/@53B;R5JU+]?*AP\
M"(>"@8?IP*=@=GI,THDW7<N(-VJ(%*G+)%3;>L?P+^H(G5:E`1_`5!3#@77*
M8IRD4(8ITU"@=-0ABG34(/U`Y#E$2G*(?@("(#P/O`<#&EWH[O73K1::A1<^
MJM?DYB?K2]GE)RW,Y9Q'-&IY-6-CF<.W8/HQ)^Y$S%<SDQU#%1`4B^GR8>!)
M_I+V1NFV9/7MG<-VM*NT=;+!$`M4U)!LT0=0#AN1O(1QWSAVY*#ILZ`%DS**
M)B;UD'R41#@;"?7'N+$:&9A2])49P%Y4]IK&RY0*V@K6N(@FFD3R/MQ,XN/C
M_#B/LKG'^2("()`$Z^`X#@.`X#@.`X#@.`X#@.`X#@.!`30^D\FXGMQVK*M9
M>-NTE_=,5,IU';*;3-;AL4I39S0).R==:;'#!5^TQ77/5I&AB:Q1",M]^"LP
M]=,G3=S[1BAK.:C3OD4Z)872>K_7ZC4'!=$E=3RWHC&=X58-)"ZZQ&]A=YL^
M@YWUQZ04MU*VJPML6ZNTK3II0+[>5AE6[>&<HL&9'!/?1#8JZ:=E,PJ>J6;X
MS):/["U?=NM='-8JNKV.M3O7+=O_`%Z;V9:L5SL;%[2TE;*VLD?99=0J#EE,
M.(V;C'8BT%D5)#R4,AETN=<SZM2ENMDBG%P40B55VZ.0ZIQ,JH1!NV;H)%.J
MX=NW"I4TDR`)CG,`<###V$[36K:'*\%%`ZK&=(K?R((BH`_G?:/ZDGME71,)
M%0$Q0.FS((H)"`"85#@!P"'5DLU<IT(_LUMGHBLUV+(FI)3DZ_;QD6R(JJ1%
M(7#QTHFB055E"D('GU&,(``"/`HG8Z"38<?T#.FDPG&A?Z=(0\=.H*JJM6RT
MBW(O&2`J,5`.[C#+E3,J5,P@NV,8H>H#?4,9_3/H+LF#[JVTV^SU(+!5R,LL
M.Q:5R6DY-]91G8I2.1=E1/&L$XZ/;F5]PZ;HWNB<@>"?0#\#,#P'`C+:MNL$
M+99N(81L(NSC)%=DBLY(^,NH#<0(<RADGJ2?J]T#!]"@'C@6'LMCD[7+N)J6
M4*=RN!2)I)`8K=HW3\@DU:IF,<4T4_(C]1$3&$3"(B(CP/!X'Z(<Z9R*)G,F
MHF8ITU$S&(=,Y1\E.0Y1`Q#E$/("`@(#P.R^?OI-TJ^D7;A\]7]/O.G:IUUU
M/04"$`RB@B80(4/`!^`!P.IP*XJ6AV>G'*2->BXCO5Y5B'PG78'#S^;V2^H%
M&:@A_K)"7^L!_#@7TC^PL*J)2RE>DV?GP!U&3EL_3+^'DP)J@S5$O]7U'@7=
MKMRK-K((P<LW=K$)[BK(WJ;OT">0`3*LU@(L!"F,`"8H&)Y'\>!1VI85D&UH
MQ2.JT""NOZ&#L(9>4!ZB\BROQ0,]39/HUXQ>(I.C-4Q.3UB01(`^//`J6@9W
M2,KK#2EYY6X^IU9BX>NVL+&"Y,U2=2*XN7SCUNUW+A19TN/J.8QS"(_U<"M"
MF.0Q%$SG343.51-5,PD4243,!TU4SE\&(HF<H&*8/J`AY#@9XNK^RDV/,V+Y
M^X(>W5P4H*VH^0!15\@B`M)D"`(B",VT*"WGZ%!<%2!_<X$C>`X#@.`X#@.`
MX#@.`X#@.`X#@.!;S0L\IUX1K<Q8\^J5_LF8V`-$RXEJ8L%3UK1HN&EXJ&L%
M?F'D?)+5::%E,NF7ZBW3,LBV=JAX,4QB&"`7QK=/=/P^,V3LMVR=0%C[U]Q+
MJ%_W^9K[XTW7,YJL']S$X_URSB86*517.<<IHIMDSD*0'\HX=NCB?UIB`7)^
M06R?I^7U:LIG]*MFMZ3A4H#X$[&OL'#I4!#S]2`_=M1'^OQP-=;NYV.F.IW7
M*V;E`U6)NLG7+%GT(C79N1?14<Z2NEVA*HZ<*OHY)9VFJP;2IEDP*40.H0`-
M^41X&*7Y>>P=$_=E(S@-;@BA0S$#0,R*+]*8K]LM<9&S=6LLNV^T*63AG57?
ME33=I^ZTC5#B58Z:KDI1"7_QW=GL:<8O_DM*;54;!I^+UZ[VZVUV/D',P-<S
M.&F7SH'L=8&;=U`7"*KC-3PNI#NWY6A3D1'P)/'`O`S^3;H,_5=I->T.=J"S
MJJ%R,<Z=D10=P[A)HJ1M$N%X%-&;LI`?HD4AF9EY9-4_MF;`H4Y2A=6![C=8
MK/3,MT*!V*MR--VF\K9EFDXBVG")6+06R+Q=U456JL2F^@IIHE'JBJG(I-`3
M`H>1#UD]06GL/R*]<*O^^EY>RHL&69WJ"SB\OI)99@SKEQLQ"KP$1)+FCUDD
MAD6YO<]\ICMD2`855">DW@(JUKM5@>M,-(OU0U*LR5>HKIY*WV3<*/X="JLW
M9G3]*0DPG&,8O^E.4$E!;NR$,@X]`@F8P^`X'3HO9?#-+C;9*TK08^6;T:*1
MG;4@XC)^#E(J"=(J+L9PT/8(F*E74/(D2,#=T@BH@N;P4AA,(`(1=#NC?]&V
MZUY+UZH^66)A5:3!6XUBUV]V#-U94THZ!B]9QS)M`3`*`Q=JI>GU>A0Z1A,(
M!X\<"W.E?(:]IFOZ?4TY?+(VM8YG@.)>$DXF_2MCT?7S0$J>2I5/L$>U:QD'
M%UBW-T&BCE^V(F\;`<Z:@&.44PO3C/<BGI8;0]%[`:YGBUDT%Q+N8EEGU*O+
M4[5O%,8YU.0)ZL5M8K"_7I#ERHC(2R281IP]`E/^)C!?NX]G\`H53IEXL^I5
MUK5]$;B\HDC'%D[`K;&2:)7#A["1E?CY26=LV21P%PK[`$;F'TJ"4_Y>!;&.
M[PXI+=@(;!HV6*_4LE0KD]7;PS.^<P<U8;8X9'K]+9LDH@SD7DE"R*#XCXRA
M60)J`F8Q5`$`"O8[MKUOEM#3RJ.URLN[PO.+U=K')IRX1CVT-C"FXK3"T'C2
MU5_/)*AZ!:HO3JBI^0`$WTX%^>N'9G#+#V'+CM?T>%E=)^WO\*\J+9O*_J+)
M]2DDE[$W>JJQZ;%I]D9N/MBHJ4KH4S^P*GH-X"O=O[:[`U['H=2NJ6/TS5M?
MA,[:ZMJ-AU.[R-%S3-JC+.R,ZZP>NX2,E)R7LUA453.DBB4I4DUDQ$#^5!2"
MX,SW#HF*T'.I'N`]KN!ZS<XZ?=/LN@I"<UIPW+5Y%VSF+!!KT:ORLL_HY62*
M+T9)PT;HM4G)4ES%5(<`"TNJ=RY^*W_)J9D\E0+CD.G=+.QG96*M:#9Q,*34
MYF,7^HT=Q"S3.4;-1K#T"_XQ`4165\B7W$C%$`#,=\%6W6K=\5S_`%2\DAFM
MOU_`JI?K$UKS1>.@BS*<VLV<A%,'+Q^X:M"DD0$B9UU3%\C^8>!G^X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@>+8[%"U*"E++8Y%O%0D,S5?2,@Z/Z$6[=(/J/T\
MF454,($3(4!.HH8"E`3"`"&";L/NLIN=R"4,DI'U6#!TRJ,.H!07;LW"B0N9
M*0,41`TG*BW3,H4!$B)"$3+Y])CG#$I\E.,:1V`Z@7O+<EKP6F]35NR>3C84
M9.+AP<,JUI-;GII;[^:>,(Y+[.)8JK>DZI3'`GI(!C"`"$8M<ZD[);+A\M$[
M&YY'R@]D^NV34'"))>3JWW=KL%;SMY&3T,V6>/BNJXFVL:#7R=Z+1!55-)0I
MC>@IBAUS]1MJ::=U:G(G/8YC`YW\76K]<KNX82U59)1FP62BH1<+45&R#]%6
M1*]GE51^]1(JQ(<3J'6+Y$PAY&/=-=@JI_AH-.9;"L"=58#3O^($HO:<X_9<
M[8:=Z(=PL5N\6_<S]W:/YGOQ_P!X8CK^<8P#^?@1YO/4?LIG6!LYYMF#26LN
M;?*?IO9N#S9"VUB/>W/([:@LPA'E>DROUH**=N0$50:.CHK)I^1,F`AZ#!'&
MQ=:NQ=[JG8Y[8LKC(B?V+MMU]V!A4&]QK<^R2HU;]@;6DZE57#1D\7@&1@1>
M)&(3[E8JH-RJI^DQ@N9V"ZIZEJ=Y[OGJ<5&0T-L&583&9W)KR4;'Q=GLN<3"
M<Q,UY^W;*'=Q**Z$>1M]PY0(CY.F/D2`80"J<2P)]:+!>)W5LMW>H34]D+#+
MWMJUW<J=IB[UDE,LY<D)4XRK)"NUBX"38E=M'3Q0A?3_`"01_.;P$6'/2_1L
M^[&V.WSW6R#[89HK2HZ+KJ*UMIU323G4E"+)R:S"TR!7#21CBI"F8"D.F(J>
M2*&+YX$I+;B&M6.X][+*C209M]TZT9W3<]9GG(%91_=(ZC2T?,UDRI'I2-3P
M\H[(V%TN"+98?!R'$@^0"VMPZY;=`V/K5HT16=+L*%0ZM0&'7VKXUJ=6SG1Z
MO8F"3-XNNRF)]08&=K,BL91N_117`3G1*?U&+Z?4'HQ&#ZEA=MZS:QE&#3=O
MA,^R?2LVG\6E-4J#^^T=_?+9(VIO.M;K)IQ]6F#+J/S)O!:@'VZ1A2*!RAZQ
M"["]%VR/[9YOLY<E;KUN\==(O'K\E5[E6TF^+V%Q9S3DG('^_!@O9X>":*^E
M`T<AZG*A/!`('CR$;JOUP[&K93C74R9R.-K\#E'8".TV8[%)76LNX*:K$#<9
M:UHR5=KS90;A^];`C(E:JD713*0"AZS`'GT!-?JWE%GSBP=GYVWUEG"/M*[*
MWJ]UB2(K$O'\Q29%%B$"].\CU7#EJW!4[GVVZYDU4A.<1(7UCY#B;Q78K!^[
M4QV6QC*S]AJSM&85_+]!S9G?H&BV^.FJJ=,*S,14I;SEA7L;Z&R7E,QA,014
M#P7^680JW<L([<W7L#F?:^8QS5D%;1UTF,9TG(>KO9.DTS2<PD4[[.3T&V4N
M]P;1M:O-3L]9?-RSC=F9,B<D4WI]:::?N!ZL#TMTBJ7+K&IG^13=+SG.^@?;
M;&9&O6C3JK>9ZDZ5L3N8E*C192TM5(E"S/)1]+F_QC%J$<V`13$X%2]1@RS?
M$]*7OICU]ZNUS1:M]I:Z-C</0-)J9)%@^=1YC./N))NQDHQVZB74A'JH)*)B
M151!02B3U!ZO64-HZGW"NWVN1EKJDFA+0<L@"[1V@/@0$!]*K9RD;PHU>-50
M$BJ1P`Z9RB`AY#@5-P'`<!P'`<!P'`<!P'`<!P'`<!P,=WR(.9)*F9VW0>ND
MHIW9Y0LDQ35,1J]<H1:;B-4=I%$"K&9BFL*?J\@4QQ'\0`0#7T[7]K*_U4K5
M3G)>J25S?7*:D8B,AXV69PYT214>1\]D73MVU>!]JD9=%+TD3,83J@/X!P/>
MZV=G\[[/51]8*6#^(F(%=NTM5.FS-AFH%=VF91HY!1J<[>2AI#VE`;NT_2!S
M)'(<B9RB7@2.X$3.\>UVG`.LE_O]`,S3T=Z^IF>9JO(,T9!@ROVGW*$HU<E'
ML<Y*9O(-H5Q-&>&04`4UOM_08!*(\#P]`[OXMC%XD,NO+S0)V0SMSFE5V34H
M"C??9IF=KTDC)G3T]'GVCMHG!.[6Z<I.3IL6;M&.1=IF<>P0Q?`47VT[)5.E
MMJQ$^S8;.G.6Z/J5;K]'A3V&RWJ^R3=^NQ@Z['@LT1<D8QK!RL=919)N!2G-
MZ_`%]06`QW7:SN%)1O\`4(^T1T$XF)N#13MT&:ORBKVNOU(J6,1B9R[]35O*
M(+-O<]?U604+X#T\#U-2TJKX[GUITZZJ/T:K3F",E-JQC(TB_3:+/VD<4[=D
M51(S@2.'I!,`&`0)Y'Z^/`A&!]W^P^+-8"2E;V^+/47,$M;22.0V)F-5J5H,
MS+7-$L1ECD)$4F=-()?;*K"5XIZO_9ORF\!=^U]C:92KY!TBQ5C3V#.Q6RNT
M2*T=2C/29>ZM]L016KL*WM2KE)1X,D=P1$'2#55FFX$4CJ@8I@*%)J]Q,H(V
MTN91A].?4O*VES6GM(94&06SR4?YZNBUM\%6K.=RDVDYB*=+>V4IRH(N3IJ`
MBH<2#P/-7[J9@$?!NHZE[?.RECBK%:XBHQ&5RRMP7SNLF:E>:@O"/'3([.A/
M_NR_8.E3E6?"!@21$Q1#@<=C[PX?!H1#F,;Z1?$9S*F&UQY\]S^5LP!FKMY(
MLGMCD/;5;?I"-?/%JC($=>T9#\I"^M0?0`6NG>\T!2]DO@3@6:U86UPO'=7J
MTMG^?O+$X@HR[+2JU@NMQEFYT%(RL),#L@]+@0.FH(E33.8%``)%W#LQ1*-9
M*_"SU=TU.OV.9IE>8Z>WHKY3+2S6@ILCU%B>U*N$%'(2AI)!,R[9LNW;+*`F
MJ<AP,!0\5/MQEZ^A1N?-X?2%_P!8N5UH47>B4Q0N<O;+FK99WHS=&S+2*2@L
M:,@V4-(NA;`B0$S"05"E$0#PXOM'5=AA[/5\E=W*H7N?RFYW_&+1<:21A!7>
M.KZ2K-"X4XD@N]1FHIC-';"H@]1:KJ-5BJE2$@^H`R"=$-HO.^XAFFG2RJ:D
M):*'!RLF#LAU7#.T*-2MI>+BW8G!4[5M*MEQ$JON`DEZ"AX$0X&/7Y&GO962
M[$M(^#8Z/^QZM&567S,U"96IS%)2:B`N74^LM"MU&W[R0G"K)"8WE1!!)(I/
M!3#Z@S&==Y_1;3A^96'6HXT5HLK5VCFS,U6BT>\%R"JZ+1Y*1JZ2*D;,24<D
MBY=M_24$7"IB@``'@`R_?'DK:E;/?6Z,F[+2F4,Q</HDWA1BI99!X"<>[0`_
MD6CHL<P<`J*?I]TOH`_GTE\!E8X#@.`X#@.`X#@.`X#@.`X#@.`X$(.^]:?S
M.-QTRR;F73J=NCI23,3ZF;1CYF_AE'(AX^J2;U^W`X_ZI1]7X`/`UVNT/66I
M]HJ&RJ%AEI"MRD!**SM4LL8W;/%8J559*L5DGK%SZ"R,._04*#A$JJ*@BF0Q
M5"F('D//ZJ]5:CU8J,Q!P<R_M-BM3QC(VNTR+1LP,]6CFRC=C'1;!N988Z%8
MBX6.FDHLNH914QSG$1`"A*3@0V[^9'<]HZKWZLYO&'G-(K,S0-6S^OIJHH*V
M.UY/>8&],:V@LY60;)N9]M#K-$14.0GO+$\B`?4`U[^ZD8Z>=\M9T2(IT#&O
M+):*',3^=ZIG\/>I1U86E.JS-PI&D67$8X)Q%HD**)?N0;."@LD/N"(`$A^T
M.5[CH-,I0O5+;>XF1[`,],>P-:IU;=6O&J!^QY-I%4XE:1M%87TIY"6.0$#O
M4Y5B[1,;W1]8%]`!</#ZKV'KF1T=T^80V?%SV*U]BVPJMTVKPSC1XUPDY#('
MDLY6L<S'YY:RO@%Y(MDG[I!9=R(N%?(GX%>6/&-"UWJ:KBNMWMF.FW"B1,7>
MKU&0C-9@C9`E&$X^49PS$\0S<MF9VH,RBF*!50)[H`'GP(>#I/5'_,+_`(D_
M_P`>'B?^(7,\ISH?]P?>?M3_`"Q^Z`)<?]ZH?K/ZR#G_`&/\CV/`_G/YX%!V
MWI$^M>P*:<ZTV,7:DU/,=3C4)JA'F[K!GSHD.E_E]7[DO:4F\'G<D$6=<&C:
M/(L5TL)E%%2E$#!Z*'3V[-L\V'#8_<D6^(Z2UT\*Y57&<L7-DJDIJ,PI..SR
MEO">16GX:N2;MPHT;I-V:BOO?S51`H!P('FF^P!-RAU*MH16>BMJH;K0[/)T
MJ'G4'E-1FB-TBLX4'$4FTE8MZB9Z@J98P`/T4,9/SY"2*O3_`%"LZ>RS_&KM
M(YYFT/TWCL3=:;/4Z*NC:SJO[W..+/#F9FEHE2*MJK264DVSA$11;F.!!*H3
MZ`%Z%>DT.UKFN5.`O3R-A-*ZP9]UHC$WD(1^[K;&@1\M'H6MTNG)-23+F3+)
M^L[4"-BIF*(`H("'@*2MO0UU;KTULSS58U6-;S&(3;/]=SX\_;JV?&VM>8FK
M%-LBUL;M:Q1K4$(=VZ:(,1<?=KCZECD`0,%DLBQ':HW?)B6GLB>D8Z!IF\(Z
M?-VZMP*D55<IT9>P"G,9GJT?>55IBW6!HX9H&00K;0_L"*3@_H2]0A??,.J<
MUUFJUKEZNWSS2).HY1=*SG3>KXO#539+2_>1XD@6EIT,UG=H2SY44$FR_L-F
M*;SS[JX^2``AF0Z09@7&.H?7C+SJH+R50S&!96-9L!?;/;GA5I6VD$Q!,"AF
MUB?N4?7Y'U%3`?/CQP)5$55(`@150@#^($.8H#Y_I`!`!X'X$1$1$1$1'ZB(
M_41_M'@9CN@U<9QF-O[`F)#OK3;955V<O]Y-"&*C$LVIO^S%%57_`.FX$X>`
MX#@.`X#@.`X#@.`X#@.`X#@.!1>C?MC]@W/]Z>@*G^V9K]PB<""(17V"_P!W
M[0*"!1<^UY]KZ@/N^GQ]?'`UQE00!54&IUU&H*J`U4=IIHNE&P',#<[I%)5=
M)%R='P*A2J'*4XB`&,`>1#\<!P'`H23_`,K_`-Y1?ZQ_EP.C?9K_`*&$N-6"
M[_9>V'O?IHO`&P@S]OQZO:_+Z/ZN!`]?_;K^?1Y]];S[?CV_/NG\^WX\`*?G
M\/'T\<#BX#@.`X#@4*E_EG^^G7L?LC_,K[%'[SV_T;]X?8>%/9]WQ_O/T^CU
M>?\`7]'][\OC@5UP'`<!P'`EK@`R_P"W)4')2?HOZF(Q9S'/[_W7M$_42IIB
M3T"S$?0/J]7GW?4'C\1X%^^`X&9_H9[W^0Y?<\>W^];/]M]1'RCY8^OSY```
:?N?<_#S_`-?G@31X#@.`X#@.`X#@.`X'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g662896g18q24_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g18q24_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG,3AQ,C1?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`-4`E@,!$0`"$0$#$0'_
MQ`"#```"`@("`P$`````````````"0<(!@H$!0$"`PL!`0``````````````
M```````0```'``$#`0,("00`!04!``$"`P0%!@<(`!$)$A,4.2$5%G9WM[D*
M,4%7E]=8F-@:(C(C%W%"0R0846&Q<B89$0$`````````````````````_]H`
M#`,!``(1`Q$`/P"^/A-\)OB[Y6^+OB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.N
MX;7]#K,:LM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?XX_A7_D7J'[T=]_B
MOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??X
MK]`?XX_A7_D7J'[T=]_BOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^
M*_0'^./X5_Y%ZA^]'??XK]`?XX_A7_D7J'[T=]_BOT!_CC^%?^1>H?O1WW^*
M_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??XK]`?XX_A7_D7J'[T=]_B
MOT!_CC^%?^1>H?O1WW^*_0'^./X5_P"1>H?O1WW^*_0'^./X5_Y%ZA^]'??X
MK]`?XX_A7_D7J'[T=]_BOT"Y.5_@X\5><\X/%?DU+XBUJ#SWD-L'**L;)6T=
M!V1TWN\%G_#K7=/I\>[>/]&=RD82%O=98R!#L%VJBAVX)JF.B8Z9@8W^7'^"
MOP7^J&H_?[J_0.WZ`Z`Z`Z`Z`Z"(-8Y!85@PTPNV['F.2&T6SLZ502Z/>*W3
M#W.VOU4$6E=K)+!(L#34NLJY2#V+<%#E%0O<`]0=P4A+^7^],^1$W20XNEKG
M'RH\MY?Q]W+4[OJD-&Z37>6DS4G-LQ-Z_P`JAHJ9CV7'G9U7L#%1%F<SB#Q9
M_8VPBQ(FF(J`M(GDIY5:CP>SNXU7E?8=!W&T;GB#CGO4,^QTF66#QUYG:":1
M!:-EBEAH^&[9;:2RBM4J\;".)F8KULMD;&"M)"F5J[2<M@N/Q@UOR'[7L7"#
M#?\`Y;HM*[!<6MBY%\A-B@\`^?X[>(",Y<P>;X?02R&RY-D$O7KA)9=7Y%M,
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M5JU@$3!\D-6OFDZ-:ZP7BU*F?1.?X[;.2==+>]&JFO3&JR$??I&`0*QLURCZ
M0LTFI1BB9`50NEJ%`XM^+/C58M@Y!F?\KMET&M\<LYN$WH[.-6E>3^K\9X=X
MVP^ZS5(>!-T:MWFIQ,<BX?V=)FI(%2B&SA=9R[0;`<)W\<7DIR_G)2[.NZB*
MSD&O5VQNBV3,#VAG(.92(?>@T%<8%ZZ80+RQ,GK8H-7BA6WK:/$!(IV(H@8X
M,$U;1H+(,QT/5K.)@KV;TJS7>9*FHDDLM'5B'>3+ELW.L8J0.G2;,4T@,(`*
MARA^OH$$UGEKXLN7FXU3D]&;KK?"WE<%?KM(GWOTTL>0-=0K\`]=2]0I.R(Q
M+R3Q_7ZG5K#(K'9$>N4GX)+JMRK)MUCH]!1#+^,G('Q<WG,;)!0DK=.;MUKG
M(;+Z9!/Y&H6#&^1MUN)L^NNU>07DWRAC(VMZA2^+6:-(GZ1O:)?BO9B$L\BH
MQK3Y1DX(/0.>\3W(W3-IJ$Q5V\QI?)C"L_CI)+__`$8U-['5-ERMWF8N4K)Z
M.UXZY,S@&RX<9:&J\5CJ]/BZ(P,BU28,`?(MSOC`X;H#H#H#H%&\Y?B3>$?[
M?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H#H/`@!@$I@`Q3`(&*(`("
M`AV$!`?D$!#H$%Z+YG>$G$7;[I@><X<]D*77IMP:\7O"87/X2M.=)6742MC=
MM7$E*TC9WD4HBFB]E"N?4N\(HD4#@C[0P:Z?D3\B%M\@NLMI\T0ZIV1YPI+P
M^4T9TH15^V;22K;YUM=F7044:KVNPDCVX*II"*+!NF1NF900566!=CUF5ZF0
MOM5&ZB2I54ET1$JR1B_+W34*8AR#W[#W`0$!`!_5T%Z;!Y+^9LS@ERX\WG:9
MB^Y9=H)G6)9K;XJ*FK2UB6[QBZ*SC+I[LULB:+DD>5!8'3AT0[<YR=@$P"`4
MXJTLQBK#5Y]\Q4EHR)L-?G'T6FJ5JK*1\7+,I)W&IN%2*$;*OVK<R13F*8I#
M'[B`@';H-WC>_(?XK.17%6!A.15^A[7DG(!.NL[/BJI[4XN*)(BSP\E)0VEU
MFA.TY^&KM>G(Q/YU*Z5+&RC)%1,H/6R_LU0;7G[NB/J-4'67JU=;.%*Y#EHI
MJ2$86GEJB3%!&"1K*<*!8E&#;QR::;9-L!44TBE*0`````R_H#H#H#H%&\Y?
MB3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H#H$]>8?G+6^-/&F
M[YO1M*CH;DAIT>PK51@(2224N=:K<T^;HVF[+-V_M5Z\@VK0.4F+M?V)S/5D
MS-Q,=,PD#14;N&ZY#F05*H1(PD.;U"(@8/E$3&/_`*C>K]/J'OW_`$]^@]W*
MJ;,JAG/J0]DH*2I5"'*HFMZA(9,Z0E!0JA3@("`AW`0^7H/<AR*$*HF8IR'`
M!*8H@)3`/ZP$/D'H.$DLY4=NFZ[8"MTP[HJB`B54.X``#W[D/W`1'Y/T=NP]
M!RE2J"BH5`Q4U1(()&$O<I#=O](B7]8!T'HU3631(#@Y57';_E5*4`]0@(^G
MN(`'J])1[=^P=`X#Q-\A.?U1UZ-R;B7&NM6ICUXE*7G*KLY>ADM;AW;@J3^V
M/[+Z5CY:X-V$2.67J,_7*!/<GRG9/H-ZEJ9R9LW,]301>&02,[1;+*.6R3D4
MRBNFW<*H-55T"*]P(<R29C%`!$I1'L`??H#H#H%&\Y?B3>$?[?N:GX?N]=!'
M7Y<?X*_!?ZH:C]_NK]`[?H#H#H#H,5NMZI.:UF1NFBW"K4&G0YF)):V72P1-
M7K46:3D6D1&A(SLX[8Q;$7\L_0;(^U5+[5PL1,O<YR@(*5Y&^%+B%R>N^E[6
MA8-"IM\UJ/0F$)JI65A*TII:G"`*?3E"O/V+DTT6;2]B9PU^<$V2B?J,W!!1
M3VH`I#&/#)'\5];K^P<^=@PRL<<Z7I</&P\>E,RHJ[%97LFW:9^PDV<A$-6L
M%7I27.FXDF:BSI8&C98BHD:`LZ(#L.6?`7QM.+!<^:')W/(%K$UBJ*2.AN5I
M69BJ#/@@*+=C9;%5*TLT"QVXX*),VQR>H[TYTB'265!,Q0B34/"1PNVS7LLV
MBGD/0LR:0T0M;LKSE-LVHVJQ,=%L"4UY'R39R1>JHNV**991=B"AYAMZ3`9!
MR95TH"L?(;XD>+_'6VV'5!Y9U+CIDEL9R4G1\DLM1GM#NY[:@FLN\JM!CX6;
M0GIJG$740]FJHBNM%D7!-90Y"D4$-<AJ=V*KHKM),J9#F*V42,(>U+W.!5!`
MWJ-V$`*/80*/R]N@G[C+B55Y'<@,IQ.YZC'X[`:!:FL(YO4DU4>IM%UB*&9Q
M#)L!DVPSEC=$*QCSNE$F9'JZ8JF]/R&#]"SC'Q7Q7B'F<?E>(U1&O0:`INIF
M7=&*^M-QF@1*DO8K?/&33<S,PY`/TB!$4"=DD$TD2E3*%B>@.@.@.@4;SE^)
M-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT#M^@.@.@6]Y`>9;_CE7HRJ9Y;<
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MR%27D'BRSM1%,J8"1(`3`.PU[G[R/USBUD_$NXSAYW/LQGE'Z4JJX='L=HB(
M]L@VH]<M[U50P2<5GY#./<#&[F4`R'MO6=HB<0["Z>0'DY<\%P/CQ_V!-5BF
M\>U#.:S+5.9F82V3[Z.?KK4EW8IQF]2=J!G42J#")21,FF1(A5%`.J5,Q`KY
ML>ZZUR"N*5XVS1;!I-S1A(Z`:S%E>)+NFL'$I>R:,&35NDV9LV_K]2RPI)$%
MPY4475$ZISG$(A<K.TU&Y6[8%TSF[+G$WI%(O<`[A\OZ/2(CW^7]';H!5BFJ
M[1>>U737;@'L3HJF1,DH4PF273.3LHFLD<?44Q3!V,`#^D.@_0+\3O*:Z\N>
M'=6T314(DEUK%FL.83CN'(]20F#4U*+)'3;M)^\?KDE96'D&ZKL05%,[@QS$
M`A3`0H,IZ`Z`Z`Z!1O.7XDWA'^W[FI^'[O701U^7'^"OP7^J&H_?[J_0.WZ`
MZ"J>M;>6QRVY<7N/E]K+/F5`<<)O4:?'ST8ZEZS0I*UDG:KD5BT!1%H[CV;"
M8O$<=1%DL!W#QFP=*D1422/W!7''KQV77=-CEN3_`"<KFJ98-BJ->S33\)WA
M]@>X6_87D/D%?R?4K>O>J`E)4[/:%M\5%I0-CBXEFD[M<)`M5BC!-9%_&.0>
MW`5^%JT/'5^O1K2(AHEDSCHZ/9)`D@V9L&J+%FB7])S^Q:-R)@8PF,)2AW$>
M@UP?S#Y=1NC7B)C-`JUCN#>W6G2[2%=J4)*V*>F+168NL0D(DC%Q+5VZ429Q
MMP?&]0$[`97N80`.@UA-?P#=,">-XS8\?OV72<DF8\0G=JQ(P;*7."7MA)'2
MRJ(Q4FHFF(BH1!=0Z?8?6!>P]@B!J=P=`AG28)+_`"@H4H@)>X&$`,'8Q@#U
M`'?MW'H.1T'$.R04=HO#`;VR)1*00-V*(?ZNPF#M\HE]8]O_`!Z#E&$P%,)0
M`Q@*82E$>P&,!1]("/Z@$W0>L,C(22K-DJDW;OGSYNP0]Y=MF+3VKMPDW;G=
M/7:R;1@V!54/:++*%22(`G.8I0$0#=5\;G'S0_%O7)&D<AK\A:LTY!3%,LL'
M>:ZLX4RW&M5?QQH:3HEG5=K*#%-[T96/1CK0`(Q,F[9IM%RLW!V?OH/6Z`Z`
MZ`Z!1O.7XDWA'^W[FI^'[O701U^7'^"OP7^J&H_?[J_0.WZ"KW+CDM`\5LQ@
M]!LK0"0UDU'-<I=VN3E8ZMTG-2Z99VE8#2-)MTRDO#52D5477M%G3LH(+O3M
MF9CI"Z!4@*P\7'&K5+K8HSE/O]_K6TO:78=/C\5Y%U#:M2ODMK3.4DGF=7-Q
M`NISYB4@>,MG&H$L"5&DU+)!C=W;B7@A81;6)!P#\.@.@B/8=QQ/C_7F]XW#
M3:%ED"LY&&C9N\V&*@/G.0<@5Q\QP0/UTGDS*.2-04!FS(LNH5+U>@0)W`*_
M68_#7R:87?,TA[]G>X45T*;*8<TJQ1<K8\YM0).%*_/$204-,TNUQJA3+LS.
M44#+I`<HE4;J*$.&CUR_X&\EN%5U/7]3HDA)TMR5X\@-;JK5]-4&5B"3:T+&
M.)2::L_<JI-R*@(":,D#H.B&=)@0%"G(<P4M=)NSG;"V6*D0BG=P`_\`J)_Z
M?]/;TCW^0!^3N'Z>@8OXY_'Q?>>^NJQT7.PU8R;+Y.G2FSRDBX=DEGE;G9-Z
M(5RHM6")UU[).1T&]33744;-V0![8RAC@1(X/`Y\>!:H3=74OW!=HA4+G7H)
M)![BL]-/G5:OWS:V`A7E>M-@D'3NNW-X1/\`Y"O5S1K]8P"<[0_K5.&NAQ[X
MN7#7N5V><2=&^=L:N]KNCFF6Q&Q5Q=:>IJS",E):0]XK+MU''=.C-(LQ4`%8
MK=0RI%`4,E\HAN4<F,0TS$.&."\>\LGN1&I976]!I&><CIRC,X*]<CI3C&O`
M7%K8&5-CCPBJL@B2V*UZ.>(1;)Q+M:B+PC0#JI@H`4X@WW/IEI6XMX)_SNC*
M`VC>0+51U9J749!A$8\CQ[H2?&)_A,8ZJ,FK)<BU-E.X3?MHUH\:$;C*FE$$
MU$X\2AW<)=N8-FN.3O)]/G]2(V,\<[%+;D7F;6=W3]`Y)S5-K+-M%5&/J%0>
M6J@W_/+)7)B4L$PV5&7EU)ALQAVZY`,=$&F>/Y?=7'#;`C\F$KHEN2=-5:W\
M^B%CD[H]?,IV89Q<M/(1S=I[HYF:^@T=D0=I$E4$5R)R)0?E<]!<3H%&\Y?B
M3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H-8L[^`\D7DL7,$)LM;@*QG
M:,#%M[PWL67SE#R^C/D[%)Z/A.AY18[U1IYKMRNMUQ*\YAL=69.IBN2$8H1<
MH-/<"!LRQ<7&0<;'PL+',(B'B636-BHF+:-X^-C(YB@1LRCX]@T31:LF3-LD
M5-)),A4TR%`I0```.@Y_0'0:Y>X.G%[YU\H[3=1&1L^,SV?X_E3&1`%PSG+Y
M?'L^TIY(U1!4HDB7FHW.WR:TG(H`5Q((Q35FHH9*/(F0(]L6?LY:TQ.DUFP6
M?+MDK2!FU6VG-9!"!T.':F."QH62=.&C^%O=,<K%`SFO6)G*PCG])FP*>E0H
M=KR;Y.S>U\3-0XT<X_<:,$G#Q\I1.8N8P<ZMC3ZVTM\VL=42WO/&1[#;<26F
MIB)0;O7:9IBJ*BN=5-^P5]@R`-<#*N.LW?.0C?`;#:JS7Y<L:M-KR-<?H7MK
M-11*\E:F?T*D:^HYA9US+P#A-VW.JX;H`U,)S#[0`0,&VQP0P;CCXF:GJUDV
M/F=D"<+M[7.;/#R&F/:OB<E&0U>B+`Y;H*Q5DO4FO).GY+4!P(D!3D$GI]!A
M$.P9#IGY@+QDY^J+6`UJY[4\(J*2J>*9/?+;&I^DWI,H2UR<17:2[2`/E`6\
MFMZ@_P!O<>P=!;#BUR7X->0YFWVW$AI&AW/*YABC(FMM"2@-IR&?>L'01J4O
M%6B):7&K_.D:=P5F[0,:/D$2K`W76*13TA??H#H#H#H#H%&\Y?B3>$?[?N:G
MX?N]=!'7Y<?X*_!?ZH:C]_NK]`QSEY+YD.#Z'G>G[<EQ[CMGHVD9G%:D6<:5
MV3J+I_F=RG9FU1$N^408QCBEU"`DII5TX50;-F\><ZBJ8`!N@@K@7@3RHMKM
MR.NFF<>MTOW("#R]I`Z[QWRF.S^D2>*9U1HJM9JQAYE>Y:5:+0TF&Z*LNNHM
M8'<<DN\!)DDD@B4R@,0Z`Z`Z#7G\H/('QOUK39"=D.8<=B_-.@UYO3I1GF-+
MLW(`UC@8]^YF(O,^0N1T*.D4)"/C'LFZ6CSKR-=L<*9\L=F_117717!:_&;R
M-8OODHWHEF%7(M5=/W4;!P%O%2-K.D@W<*(MI/-;%)@V]NM+H)@X3@94K&P-
MR']`MUO2*H@PDQ1+[1-0O;N51%5)0OR&(<HIJI*IG#L8AR")3%,'80$0$.@4
M[R?\6=%T:1=Z-QTL#G"M+]E(G>5*-F[-!8U=S2+0[-^WD(:IOF<A0)&2:*&0
M,\AR'8F(H8'$<N!C&Z!%UVR.PXO>5*5J>9K9QHI4E%6J,XS9OC66/:_\0RU+
MO*0.F-Y@RE*'_,S=**H%[%<)('[D`.$)A-\IA$1_^XB/_P">@;EX/:!N^A<Z
MYMK@>KV;%WD!QVO4GHMYA*W6[C6P9N+)54\MK.D52U1[N.L<!.7!-XLBR;.8
MB9.V9OSL)%F(+J"&[SQ>VF=VO-WSV]5Z/I^MYS=;5D6TU&'<NWL%!Z=1'B;2
M7<UAZ_32?O*7<(EVQL,"JX*#D\',,Q7`JWM"@%C.@.@.@.@4;SE^)-X1_M^Y
MJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT%-?)-M=ALO)N0HSZWTBS5*EZ-4G^8Y1?Y
MSQ[[S2D=6S^"A/:V>-X][CH?$7DK7K9%2-P*B[2A[Q8VSH'!3)(@"XM2!L98
MKF-?QC)<[RNK1K&*A*+4X>OM6<<2139@LT:$&0=)EF)2<EQ-(21UG!S.WKQR
M914QE5U5!,H8)/Z`Z"M_,:U:'1>)/)^ZY(DY6U*H\?MALN=E9(^\O2W2#S^P
M25;68M?9J^^/D)9LD=%'TF]LJ4I.P^KH/S!(06YHEDY:O5I-.31),K3#ITH^
M>S[R8#YS>V*4D%CJ.)26GG3H[MTZ5.=5PNL90YC&,(]!RGK!G)M%V4@S;OV*
MQ0]X;.D2+MS@00.0QR*%,4#)'`#%-\AB&`#`("`#T%Y.+ODAUS%9*+SB=7F>
M3E`2,BQ9TAB\<6S?JBU+Z4B-Z1*-`DY2\L&I"@"</.`+CT@!&\BD7TI"&P]F
MVKTK5H]V[JKN6:RL01A]*J-<:[.433*(ZDVJ;UE'7[.+:QB;?4'[ELJ!T@>-
M2).2?ZT%%4^QQ#QK.4Y=LU(DZ7L-1KUQI0IJR3IO8BE13@U6B)CC8HJ=(LTD
M*G*1B114))-'+5=N!1'VI2]^@2O1N(O$JFZ4[ONAP7._E+PG7<D3-H?':F78
MR&2$9'<%E92P7&K9J#_D;FC8Q`!>9J4PVE(U)(XBWEC"95,-U3@9B/"C(<!K
M,UP0KM";8IK+"-T".OE+E7UL<Z@1\S*FQL]DOD\_E[7:Y)%N`H!\Y.U%F`E.
MV`B'H,D4.!PIEV^@/>5>ZP($/GNW\G9J:S"3;G34C[;3LQRK)\!6OL4JD8R;
MN%N=MR64=QKL@BE(17NKM(QT5TSF"\?0'0'0'0*-YR_$F\(_V_<U/P_=ZZ".
MORX_P5^"_P!4-1^_W5^@\\D>)_D4W7DK5;!)ZQQC9<96MS@F5NR:*E[=!V^Y
MY=6M!4LU4<H+WS)-H8TO3&D<[6;SKJKNH$+6V(BQ6<,TD4%D0=MT!T!T'@0`
M0$!`!`0$!`0[@(#\@@(#\@@(=!I4<H>(WBXN>]7F9X[9SS;DJ@WND^WO@<8K
MQQXIG'1W;VTFNC<F&.'Y!I.)MTW8V,CM)X-7%&JI/"*HL%2B4X)A8W`\>\!>
M>$9K:OQOW.%L#,Z8FF^:5*VC6(!18OH`5'<E4G^D\>VB7K$3";_VZ(=A$.Q>
MP=!L'<8]"X(2<0E!\/[9Q9^:U$2?_P`U@4CES`Z*91#TIO:U1SMG;-0@]NY%
MVY#@/Z0Z"JGD;9\/K-)UZNVV$NUIYFHP:ZV*M>,#B*9<J:_$JN0$9&1L3LQ*
MC5,85>F-\X'T,WT'=&`Y3H.78))"%&<JX4W.Z1<!-<XKG7M;E(XC9PWPRC1B
MM?P-L^:+"LQEM)8"H#S<;:D!4SKI/BM*<W=E,9G#"`)K=`R!J46X-$&)`;%:
M)MVK!NS3!!-HBW*5)HU9(-RD(W10(4I$DTP*4A0`"@```=`NO(^+7(S8Z[R:
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MV]REG"*GM`^4GI[A^CH-1O"7$<ID]*@(Z-5@G^>5V&S6XTUTW]TF\[O%$C&M
M:ME%M$4/_N(>?KLW'+(K)+%*94`*N03I*D4.&?6*U5^D0<C:K788NJUV(2*K
M)STU((Q<:R(H8$TBJNUU$R"LX5,!$DB^I590P$3*8X@40Z.O</[;S,,UF;1G
M$1BN,N0(NCIVBYQ`.^2-]CE.QBK913K9#N'>/Q#Y$>Z-BLR9I<2&!1I#$[IN
M@!N^*8-D_'BH$I.1U-.N19RLC3,J^DI6SW6XOF#1-BVF;]?;*]E;?=YM-HD5
M,KF2>.#(I@":()I`5,`^^Q;AE6`U9*X:S;V56BWSP(J`8`@]F+5<YXY!.A6J
M'385N_L]VLKD/]C*-:N%@`?6<")@8X`LNQ<M-/UB\`TT[#M[H/$M5F@HK4\#
MT/+XWD[I`*.%2O8W69.7N].<9337<>4HGAZ/-N+$Y!4R3F6;=E&A@>YPFY,<
M5-@I)<KXW1BV8AC$#!Q+WC]8Z,\RZX9M6%RKM:ZX)2W[=%N^JDB9FJ1O+Q2T
MA%N7!%2`Z,N54I0,.,T_^:_.LM?%48,(?BF:T^S]?N`;&:@W<MF*;_T?GD,A
M)01<=O\`7[J+7U?)Z.@N_P!`=`=`=`HWG+\2;PC_`&_<U/P_=ZZ".ORX_P`%
M?@O]4-1^_P!U?H+&\Z>-VR;O;*&PRODMF6*#<J1>\C4C=#HCRW72#?3@L+0\
MV#C#)06AYW-UOD!3*S7GH(+J*2+!-GV<*MP(U4*N#&HE9LXC&*K.2),MA;)$
M3E2+MG02'L2@D=T9PS`K5514Y!$XI@!?5W[`'Z.@[#H#H#H$Q\_\_P"(MPUA
M.JQ_%6-W3F=8ZA'V%W.4ZZ6C`5:%1CNG5>K5[Y![[FTG"6B(JYW<6Z;0D<FG
M.S\L9@NE'QYF[=RNW"N?'7@)1,CD8F^:M:K!R(UV%DGLO5)[1'TI.TG(%'RQ
MUDXO&ZG9'\VZ8*0Z*GNR%DG74S;ET2`)I!(IA0*%^%5`*5=PNJ4B:2:SITY7
M4*FDBBB0RSATY75,5-%%%,ICJ*'$"E*`F,(``CT"<.0WEQSR)T!G@O%./>[+
MI$L,HVE-<C*-=-#Q?/0BV*\A(KQ<70VZMHVVP-&+999-M"F0@B>Q,+F5+Z11
M,%7*O?\`&WEV6NUYVLE[WB?8E9O;QN+TM(T4T6\]"Y:_2*5;XVG-LZI"@J%,
MC#UZ-9LE"B4ZPN51%8P63(`J(D<)_P#(W5*!DG"?91!4HAW`R:Q/4FH40_0(
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M`5%\:SZ>M,M5K,1A&1!D%_F-@Q=OFK=T[.4P-2Z`Z`Z!,TV[:9MS=Y.TV^*H
M0=FY`3.::[C$M+J),D=.H56QRE9?8*=5'JYDV\K8\FN-1D'3^'1,9XW86-L_
M]E[)THH`<;5N05&RJ20J)D)G0-8DXU>7@L9SQ%A,:`^B6Q@37LD^1Z_C:_FU
M!9*F`'=ELSZ(@VW^WWDZPD1.%*KN]LFJRK%QR`>5._TL"*.%N,M-D;2C@K,Z
M@=F;;2;BC]$KER*LT9\BJAG",524'(%]WB'QDR/SA7=/&4&NU,]DCF=#BIAC
M$-*R@[CJL=O(EJC./^:$88C8C@L8V>$@R)1Q9!$4W*<>D"!0]C_Q=!>22W:X
M6:6(I<86F:!4"1S:$)E-XJ<7;,T3K[%(B+&)1K,R@\(D+1%,H`\`_OJG8?:*
MG*8Q1#I,YQ;@1IMP=1VC<>ZGQY>S:J(0ESXT7#3^/T,V?F.!3L[)#9U=X2`]
MF^'MZ'2K4R!#=RJE*!O:`#H>./$KCWQ9BY]'#Z,E"/[LM'R%RNTS8+%?-`O*
ML>@HE$GM&AW67L-NG6,6BY5]Q:JO3,F0+J>[))`H?U!(NR['GV!9Q8-6U"97
MA*=6S0[9VNQB)>PR\A+V2<C:O5JY7JY7V,G/6.S6JT33.-C8]DW7=/7SI)%(
MACG`.@K)&^1CC6\O[',)(^OU*Z/DJTT^:[G@NP5E-A<[C4IV\U3+):0DJ<E'
M16K66K5EZZCH%=5-](^R*FU*LJL@FJ$_X!R!SCDOGPZ5E[BP*P+>U7&CRC*U
M5:>IEB@[?0;$_JENK\O`6-BPD&KV'G8Q9$Q@*=%3T^I,YBCWZ";.@.@4;SE^
M)-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT#E;?58>]5.T4FQ)O5:_<*]-5:
M<2C923@Y!2'L$:YB9--C-0KMA,1#P[)V<$G31=%R@<0.DH0Y2F`-:Y1Y7?#U
MN>?4$J&5Y!Q3RJI;YJ,97,2)?%+[O643\A6X2LQ_)R2O#2&S%EH.-LP5"L34
MI9[%<-`?P9(F*]P4D5V#H-FUNNDZ;H.D#"=!RBDNB8Q#IB9)8A5$S"FJ4BB8
MB0P?(8`,'Z!`!Z#[=`=!&^IX[D^X5<U*V/-J1J-2,[1D2UZ^5B'M,4WDFQ%4
MVLHS:3#1VFQE6A%S@BZ1]"Z7K'T'#N/0(QY?FSVJYCI'&S@94\OX^EG'3,]L
MT&E4^*AT+59H9\10C5Z[A6/ODVVBB`JF20<^^'(Y`GL0]DEW4"H%<;Z34LE8
MH6%PTU#4X"IN1=J,U4H%K<K(T1<*,VQ';M-))H+SLDB=PHFGZS@*@D*)O2`=
M!CND6^V9\G9-9IZ&9V\LO-,7E0!=PLX09L')48]T"3LYW1COTQ$P?^0>W<![
M#T&+[S#)[!G#BG0-ZLN=RZTO%2S>?A6SGWE(8I90YF+PK*4BG"K)X17N().2
MB!R$$>X`)1";:6P4BZA68EQ89"VN(N"C8YU99@41EIQPU:IHK24H5#_C(]='
M*)E"_*(#_N,8>YA"XN%<K;OB+IJUE)<9G,6YTSSD-//!%O7H=,_KD)6$DG)^
M\,$>U]:QDC&]S.4H^HA1_P!90O?-TQ[SYI%K2L[VRY]QJGRTJ8P^3KB:5>U^
MP7*@WZJZC1.3$1*34=(!3HJ#M=/8.*E&/&#@LJT`[Z304;NFS1,.@-XV,_D]
M+'5[?N_(N[VAS*T*YS*$[-Y2S@I_6\MI%BH6=Z_+1%;R&"37M5.B;(HNRC0.
M%6]^:M5UHE8R!>@L+Q2XMT/B'ESK*L\F+/.0\C>+GHDD^L_T89"-EOLNI-SZ
M<!5Z)6:5GU&K0/U!,UAX&&C(UL)CG*B*RJRJ@65Z`Z!1O.7XDWA'^W[FI^'[
MO701U^7'^"OP7^J&H_?[J_0.WZ!+WF=QWD+H&3YM>>/.:YUH-JRRVA-M7!^.
MU<W[D-6IMR\B!KRV&-KP24H]4":D&8-I2:?QKT:TO[C/$26+%J(F#'^`_,"7
MSVSXIP[W1NUA=#UF/M4IG.7I:39]TW##FD50*QKZ%=Y5Z!:9N6M.DW+1JY:G
MU@>7^*8M<\93*@UMDY.H1B=T#P>@.@J'STTQSC?$7;]0;NYMFG2ZF$L_&N,5
M'TTZBADX]E)L&`)!W8G>LW9TSNS"1-FF8RQSD(0QRAKXY1H\+KN=U;1Z\TD(
M^(M+!5VU8RJ::;]F9J\<Q[ILM[`ZC=8$G30X$53,9-4G8Q1^7L`1[R0BMIE:
M;")XC=8VBS3:U1[BQ2K\J9E%ZX**Z2C9D"L?(E6.F\43540`J9G"1!(!P^4!
M##+9.NZI49NQDB9&UR$%"K/_`)HA6_:1G'C9$HG29M_4L*?O"W<XE#VADT^_
M8#B``(=+E=SEM!HT+;)JIR-*DI0'(+5^3]J9=(J#@Z"3M`5V[1T9F_(7VB7M
M4DU/2/RAV[&$,US[6*Y,34_7ZA88NP.ZW+-8^TQC,3JFCWS@RB!$Q<"F1,R@
MF04)ZD3J$!1(Q3#W*(=!\MUQ+0]9O69/(;3%JOFM><^TT"F$%X9.U)MY5O*I
M%5CTBC$SB3])J5DLA(=T$DC"<"G[F((;/G#/0@OF&5YNNH)I6DJK4R1*8WJ-
M[**(DI#*AW^4$SP;EN7_`/<AO_IT%K>@.@.@.@4;SE^)-X1_M^YJ?A^[UT$=
M?EQ_@K\%_JAJ/W^ZOT#M^@]3D(H0Z:A"J)J%,0Y#E`Q#D,`E,0Y3`)3%,4>P
M@/R"'0+!N_&_(?'1Q[YK<G.(^3UMOMK/%-'OT*M>7=MND6QC<VJUAN=.QNMM
MS3!IRD8)6YLKIRPIU<6CHEBL\7,U03.H'8.5X[^0N^:>&C9]R^L]=8<F*LUJ
MMGELDK>/O\XJL%19ULZ;Q6@Y3>W.@Z$RWG)KU((G%C.)*QSZ,704CY2.8OB'
M1Z"U&[\M^.W&=>`8[5ID=4)>TH/'E=KC:'L]NM<PPCE4$)"48U*DPECLJL2Q
M7<IIK._=/=DSG*4QP,(!T$*[5R)R/;>'N@WW%+O6=3I=A5)GLA*5UVG(-8M^
M_DXV/L4!:(U<B;^#EV<>_`CJ.?H(.D@<I^U2`J@=PU[LXTBVS6JZ9F#C(7M.
MS_.2LF-1NZ*"D?!3A"@@3W%HQ59LF9B+D5,JV^;_`&J*22)@5$IC%[AV6_7"
MOYK0)#1[0X?$AZT=H@LU8-?>W3U>7?-V#1%LD*B*17!W*I0]:AR)E)W[F#]8
M8%5[%'VZMP-KB/>2Q=BBF,U'>]H^[NRM'Z!'"`.$0,<$EBE-V,`&,'</D$0[
M#T'>^HWJ]7<?5W[^KN/?N'Z![_I[]!@4)$YIFD^8T.SJU3L&@SP/A:E<(,']
MNG&XG<B1JV7<`JZ4*98YO9(%`@'5,(%]1_E"6M,A]XEKED[[,;+6*[3(J9]_
MU2*F2&4D)V..LS*:-9'+&O?>&Y6!G(%(11H<KKV:@J"!0`H/[\>E45B\OM%L
M.[,HG;[4=)JP`P"DT;UM`T?[P8/_`"NWCEPJ!_U>R23Z"_\`T!T!T!T"C><O
MQ)O"/]OW-3\/W>N@CK\N/\%?@O\`5#4?O]U?H';]`=`"'?Y!^4!^00']?0>.
MP=P-V#N`"`#V^4`'L(@`_I`!$H=__#H%$^6V'T*N95&[S6=*F\_IV61KZ.NB
M%:T?DY4;#87=WLE2K=08Q5?P;D9QLJDTJ,T^]!WMIFTF<8FJ)R*I$,L)@['+
M+A7].\7BE@J]K)IC5I$3L`[T=(]D?M=`?9QIJ]4?7>-G+EI>RVFR1$DA6059
MR#^TS;M9H5/VJY5"F12!;PB(@`"(B`?H`1$0#O\`I[!^KH,$TN9H<!2)R1TN
M3@HBF`BBVE'MC316BBJ.ETTF*2K=9%R5RLH\$GLTP3.83!\@?)W`(H9)$<-&
MJT8FFYCE6;=RP<1B95H]>.62(HS<L56I3-CL%FYBF2,F/LQ((=ODZ"'9AQN!
MMAK;6!C:N;&@BS'LCYRND:=4>&2<&7]DGW]_1=-EB)>[$23,W42$XK'`?]@2
MZEB]&O%FJF@W*`0=26=NRRM8E'2B[5-%5)47GJ7.5P@W=,&+I`CD`6*=,BI0
M,';_`%=PF:LWBJ:)!R4QGUM@K(S0<R<*$U$.$Y2/8SK1'L9-QZ!*186:JZ2I
MB=_2JF("4PE,`]!:?CM">13C+XO][FF]H_[,Y)6[06!N,S$*>O=C5I'2;;1:
M.A9W5?7;1#VPUQB]FGMC-''(FDTC6Q^Q_9"(E#OL-Y&>6^@\L\MP[D\3C5I6
M-W[DUI/'YG?X#`]GQ34+/5L[XSOM\=;M6F3W1+IG(9\[L+<:JF<YS@ZDFZHH
M&$![)@_/H#H#H%&\Y?B3>$?[?N:GX?N]=!'7Y<?X*_!?ZH:C]_NK]`[?H#H#
MH#H*Y\IZ;L%YR)_#X@IGKZY-[#5I9]1=8;I#FNN4N-FVJUYR*YRAJK>'-:A[
M_5Q<L@DV\1(*LUS)F%!1+VA1"J'"NIV.'@N1N4<DF=&SRSZCN%F5K7'.EO;*
MEE=)I1L6R@[NL\>[+<F=8E-/JQFACS<U)0D1#Q<=99&2;)1[3W<QE0H;R'S/
M_H_1K94&YY&:C8IBG/0)_8D/*RD,\8J/FC0B9/9INI)-=%5F`E]!5EDN_8OJ
M[`"]Z'8Z?S0RF8"_Y-8Z_44K>1HWA;-(.6RLPZKPD63E&3V*^:G9`8/5%6KA
M,/\`258AR"8_R@`9O>-HRO!I3*<VETG4*%W=-JO3(V#BP-$0K!FJRB&BCTP*
MHIL8I!X\;MB@F"JH"?U"3TE,;H)7?N:O7GD::4=P,&^E7XPL.+]TQC5Y24<E
M.I\UQP+J(B^?+E3,())@8X@`]@^7Y0]+=-5FM5:P3=T=QT=48N(>+6-S*D!2
M,2AQ1%!XD[;^S5]X0735]E[$"&%43@0"B)@`0Q#B[4<UFZE!QO%F!3F:Y9IV
M2E(F,KJ,F\7=3PN$R21'K>7$S]@:.,V3242<^S2:-TR@/I3`!$&$>5;;\MOB
M63\&G)N">QZ[?Y2K6RX\.N4>[7?"KI<VZ:2CW/FF,:KG;.4C\YV!:V1JJT",
MH"2DB#8?<!`X`H`4J\$1>1"?)KD5'66P<I\CHZ->D[?=N&_,"PV77YVAU"S6
MQO2>'%LP_:[@$K<IBN?0S*;NQLA9:09G7<IQXMHPR)2OCAM3=`=`=`HWG+\2
M;PC_`&_<U/P_=ZZ".ORX_P`%?@O]4-1^_P!U?H';]`=`=`=!X,4IRF(8`,4Q
M1*8HAW`Q3!V$!#]8"`]`O?C]P`HG%_\`[3O>?K,M*WV9^GD?CNK[JYM]\G<N
MS>24>/LQP*-GINT3\_`8WG2RZ,?[E7E(<)",;)'<I*OBF=*!%$;KN*<GKC%\
M3^0:<A2>9L%57#QT[1SIS0(UY+H)RTPY;YZY&[ZA#S,::KL$YP8A2Q2:R<8X
M[K'1?(/F[(*/[/E%NQ:U2=.L)6H/0:KNZW,^S4)"SS18JH,9-N4PE4]B#S_2
MZ1]0J)*`8HB/<IC!2_'<^T$]/8J<F'%*T;0(FW2]@KLL2(BI)*K,7'NP,$(I
M^K$,?8+HK)**)F33*9)(R9!.84P$H=IK^`T3<97/9BVO9Y!WFT\:>A@@I-%H
MD[5.XCW:K.2(LV=>I$[F+1-[1(4ER@4Q0.`&^0+P8;Q[9<G+3-Y_8!1)3C5Y
M^[N2BT<UE6YV+DY&C6+48/N[18\FZ6^0#]_2FD<X?*4.@NM]&L*\:&3S=-P2
MM5?0^15JJMD?X/QR^F='H^E;9*0)$7"]:H<0_7;R3BOQ3QX$C/OF;21<MF95
M7*I%S)(I""C"\.-5\@?)C<^//(QKD/&[3LIM]2W?E;6LXCYOD]F>]L^058K]
M)S'=L'U*]3E$N/'W=\UHG'>2IT0RG8.2)4VTH\F(=KZWZ"J0;5Z3%D@Y</46
MC9)Z\3;(O'A$4RNW:3,%0:)NG(%]NY(U!=3V8',;T>LW;MZA[ARN@.@.@4;S
ME^)-X1_M^YJ?A^[UT$=?EQ_@K\%_JAJ/W^ZOT#M^@.@.@.@.@]%$R*IG24#U
M)J$,F<O<0]1#E$I@[@("'<!_5T"5]$\>^=\**->]VX98_I%]WY:]5^1B7K#0
M7HWBB9_+S,HSN$742(5J<>Z5`UYK;Y&P'@;`RLKNU3C9@K+J281S%)`.=C/.
MZ>;Y1ONH<^ZW2*72>(.(8:._RD?51MZU:Y%V]O<;CIV=)(5U>U1TW:ZMFMCS
M<DI$0@/"-;1,NF399P0$BD"?IW>_%YGTO,W.Z:=QCS>3K.GR^,33R_6"M41I
M#ZU7J_6[;8J6K&VM>)B$K36H"WQCJ0%-$3,"/4P6.F8>P!D=OY'^-5WN=?XS
M7'7.*:O("X_-1*]ES^Q4'Z=3#JQ1:<[7HYLW35!R$S8X59-Y',C*%>/VRJ:K
M=-0BA#&##>8O)!UPL;9?E^(85!KW+DQ";OGN&VP%(B`SIARFIN-6/1^/^4Z$
MW239/W9=QF*Z_C8]R#I(".VGL#&];E,0!!V&Y1HWE#E](J'_`&Y>-HM;_BOD
MFELN7W)#C*AD>^>-3R`4[78Q]-8MF=PH5+QB7!E%D>3,ZRJ+)^_;P[J)(G(/
M'4=+`#D-F7A1QSG^..'UZO:?)T.^<B9]JSD^1>ZTVFL:A([_`*1'M2PA--NH
M(MD'\K:9*O,&::ZCDRGLCIF31]"($(`6ZZ`Z`Z`Z!1O.7XDWA'^W[FI^'[O7
M01U^7'^"OP7^J&H_?[J_0.WZ`Z`Z`Z`Z`Z`Z!5O-3A?*:-EO&?B[@&95R#P*
M<YMY5K_*U!G+1<*U#(Z#=IKD5=5Y!I)/`FKO.ZQLU:A64@*8NGBWSDNX7[IE
M.<H+,J/CMYZ;?Q/96*K:"]XYZ%OVY>2+3^26!Z78KEFC"Q(\K]8E664V*V/J
M%6[=,S#[*<[J465.L.D4XJ>C)11!9VS.FDL`9WS-XD75+AMC_BAX[\3M3T'2
MXB*X9_1[G0O5\PJ.+4NP838LY0L&]V^_#=1OC#3:E4<O421BT(MS)O47C5DU
M66;"H)`='R`X<8GRAN>%W';6-JMR7'BY_P#9F>4I.Z6."SX-18KQ3FIZ58:K
M!/H]M8+GGJT:J,"Z7.)8\)%X`$."X@`6GZ`Z`Z`Z`Z`Z!1O.7XDWA'^W[FI^
M'[O701U^7'^"OP7^J&H_?[J_0.WZ#XN'#=HW7=.ET6S5LBJX<N7"I$6[=NB0
MRBRZZRABII(I)E$QC&$"E*`B(]N@QZKW:F7BO(6VEVZL6^J.@<F;6:KS\5/U
MYP5DJHB\%":B7;N-6!HLB<BOI5'V9BB!NP@/0<>GZ#0M"9*25!N]0O$<B"(J
MOZ?98:RLD@<>U]W%1U"O7J!`7]W4]'<P>KT&[=^P]!#W);E=C?$^M52PZS)6
M95_H=R99WF5"SZD6W3M0TZ]OX^1F4JM0,[HD1.VFRR2$)#O'SDR+?W=FR:J+
M.%$DR^KH*NV#RX\+:?:"UFYV#7J:1A4\CN5YM-IXZ[I"4G'8G<W4K'YBGN=J
M>T%.,Q=[892$=-3$LAHTK-=`P.3(E#U=!-*'/?C*]TCD?DL1;+38+[Q1HT+H
M.SP5;S#2[`XC8.P.[(PC&M0+$U1V?3)U:1JCQJ+&N!*+E=I^[B7V_J3*$'G\
MN?#XN$VGD04-_7H.;WG1<]V9FUXP[PZNF"SV11L7-Z:ON=,0H:DYEL-2X&<9
M/G;R62;HF;.B"B*IBJ%(#`DM+SU6(KT\-VJ[:)ME7<7:MO)";CXPDU4644TG
M7]D8)R*[59:&C(9^BZ=+@7V;5!4IU1(`@/00'R-YKX1Q@/FL=?']XMEPV,\Z
M?+,VQ7,[YN&EWN+JD6TG+?9*_1\O@;-.N:I4X9^W<2$F9(C)`KE$GM!57134
M"&T/*GPU/KBF./[=H<!+I:#G.1KW6S8CL%?R)AK6MTVJ7W.<NG=8E:6VHU5O
MUKKMWBQ:QDL\8N!>.R,Q`'8@B(3!CW-G#MMV[0N.M8#3:WKF=U1MH+NK:CCV
MF92K:\U>6J5H[;2\^<W^L0#>ZT->VPKAB219&4245*4Q?4DHFH8(UR'R<\1=
MKUJ.Q:IVR\Q-PLMUUC.<^?WO(=0H5#U:\X;+SL)K%4RS2K35(VA7JQ4IY67Y
MG3!C(J/#-VBRR22B22ARAU,;Y6.$T[AVX<AZUI4Y:,UX];2RX_Z*XKF>7N7L
M8:=,6VK4BM155J+6`-8[G&6^PW2.3AY&,;N6$FFX]HW5.0IC`&#6#S&<-Z_"
MU&<%ER6G$;AH\]BK:.K'$KD3/ST#NU:E'L5+X/<8!AG:DO4]G26CU5D:X]12
MD7;,"N4$U6YBJ"#/8651G8:)FV[:29-YB,82J#.9C7D-+M$9!JD[2;2L1(HM
MY"*DD"+`1=LNF19!4#$.4#%$`#L^@4;SE^)-X1_M^YJ?A^[UT$=?EQ_@K\%_
MJAJ/W^ZOT#M^@I-Y%>--_P"8'#K8>.>:76-H=HTEO4&9I6:=S,;"3-=A;[5[
M+<*+.2U>:R$Y#0NB52&>03MVV:O%&[>0.86S@@&04!;NN<&=]ROQU<D^.F65
M[-Z)!Z_D6E6G2X_&G.Y;;K=RY)Z)J-82F?FAXHPH[N5RRW8E&*P\ZG%0L=*(
M*KF/&,4T&Y4'`8IP6Q[G3QHPWD=O6;<4>/U'O_([9-MTIMQECJB[R1\U1AL]
MRC"^%5>KE>CIF`KF:Y\@O47UAOJLZ<L\E#NCKHLDI-99JF#`.6_%OD9K\]PI
MY$9!;<8B>4?$"V6FU*UK0V5T+@VCMM<R*4RG7JS\XP))6]T\I4I;WVORA6TD
MNU,V!%P@J1=02A2;</&WSJWFW\M$9O4>*-1I'D(X^<;,.Y/ST'!ZS-V_/(_)
MV&DP^D)835Y86L!,#;X#1EF<5(3\HDK'K(E=G:G'LW`)S<\4.?%5Y><H>1.0
MV/B;7XC0N']1XQ8$:VR.OV2QT^7QJ3U*SY!>M&A4ZRTA)EN_L>J+%G6#-[V(
MVCT3(*+'66*`52M7BGY86_@%/</YN,XDS5ZT&_:CH&G[#-;1RK).W+6=-K:7
MSAR@M<A4ZU4#W_2R7F3D7BM.E67T04CD(UBFHBU:@AT%C_(QXQ]AYNX#Q<QJ
M.U_/&=KX]PDI.V/9+M4I$MHU._Q61AG[&C2\)5`:QL3@F_2D@\+I\4@MZGD&
M"3)HB?OZDPFKDIQ3Y,S7(7C%S$XOS>`Q.TXOBVIX#=LMV0M[2QZR4'776=69
M^XJ%HHT2XM59G*1=,T9&9":*41E(Q91NL#4P$4*%3+7XQ^7>EZ#R,J-WU/CE
M$\:^6'*_C3ROVB3JD'I3K:3/\"J/'D9#,*#$3*A*95(.W:)@:"J<TYDI1^QA
MWATP;JN>RI`L+Q0X.;WE7/3D'S$T>=QVJ5[8LS-0)3.<BL^Q:`;2K2VU"7O$
M#KMPD=I%4^5/*]`2KF,;52J'4@0/(N%C*&%-`H!4&-\6G.UO6(?/T=JXSU>I
MX+R/YE\P>-<U`16H25YG]^Y!N.0AL?6UA^_:1\93J3D)^03MY(-H)&4=S;F.
M;I@JW2%43ABLCX*=8JN?Z!B.=<FV5SQ[6<7X*Y_<VVJ0S.H6N)M7"/D!0KG7
MYJIR&(TVGE*WLF)L)N#4DG:JEE"5^;G"L@L"7M4`M30O&#IF>YYC^1Q-_H#J
MF83Y4''-JESTI]+930[1ASUQ>;#]#]2M4DV>S%]W.*G=`<1WTCDGCP\I#QS,
M[QT9R!PZ!UO0'0*-YR_$F\(_V_<U/P_=ZZ!3_@YFO+DT\5G$5OQKS3QQSV(I
MUC0`H<MN.X<FJEJCQF.QZ*:6/;Z[0N/=UJ,:Z3L)GA&Y64H[(=F5$YS%4,=,
M@-?^D7GE_8[XC/ZD^9/]J70'TB\\O['?$9_4GS)_M2Z`^D7GE_8[XC/ZD^9/
M]J70'TB\\O['?$9_4GS)_M2Z`^D7GE_8[XC/ZD^9/]J70'TB\\O['?$9_4GS
M)_M2Z`^D7GE_8[XC/ZD^9/\`:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^(S^
MI/F3_:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^(S^I/F3_:ET!](O/+^QWQ&
M?U)\R?[4N@/I%YY?V.^(S^I/F3_:ET!](O/+^QWQ&?U)\R?[4N@/I%YY?V.^
M(S^I/F3_`&I=`?2+SR_L=\1G]2?,G^U+H#Z1>>7]COB,_J3YD_VI=`MCEO.>
M813G3XH%;YF'C49Z<WV?E0;#&%2W;E')4>7L"G"_94KPAJ\O,<=(J=KD(TST
5S]>+5B&,HX<31&R"Z:#4ZSA,/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g662896g25i12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g25i12.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[1#\4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!*0```5@````&`&<`,@`U
M`&D`,0`R`````0`````````````````````````!``````````````%8```!
M*0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#F`````!````<````&$`
M``%0``!_4```#D0`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!A`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))4.K6=7K97^RZF6O)=ZN^-&[3M<S=95NL]3;M9]#_264I*6ZXQ
MC\.K<T.VY>&YLB8(R<?W#^4M!<Q9=]:7M8WJV/CUX_VC$(?423O^U8WM^F_V
M_3]+]'[Z?2MM]&[U,6NP[I?3']7R+'=/R_4R&M9;E>H\5.BPVAK0W(W,VV?I
M/95LV)*=])<;]J^KUMV372W/OVW7LM;5N],/#\IU[K'5EK?Y_P!2G=E_Z?'_
M`.T_\WH]/R.G8'J7TU9SGVC;&1O>`VNRO&W>K:75U-]3)]:S?9_->M9_VF]B
M4]"DL5OUIQW5^I]BS&MFL$&KW?I'7USL:]SG;/LF[V?Z;']/^=2Q?K/5E5VV
MMP,VEE#'/L-]0J,MK;>^MK+'[W/:YWV;_P`,5_N?I$E.TDLJGZP4VV45C&R&
MG(8UX+F`!NX6NV6>[Z;&T?19_P!;5=GUNP+'FME&2+:PQ^12^IS;:Z["ZMM[
MJ#^E?6QS6>J^MNRNNW>DIW4E3Z5U3&ZKAMS,7=Z-GT"Z-00'!WM+OWE<24QL
M>&,<\@N#03#1),:^UH^DY1Q[V9%%=]<[+6A[-P+3#AN;+'>YJE9]!WP*K]+_
M`.3,3_B*_P#J&I*?_]#L>OU[>IXGVQUV53FVC&Q,;&?;CNI.WU;<JR_&R&.M
MV^E9_@/T?L_FO?ZG1@0(6!]:!<^_INRNZRO'R6Y%K:Z[;`]K`YH8'8]60WUF
MV/98QF1Z%7_=FM;XU$\>22FAUL@8=<F)R\,"?_#6.A_;\3]KNP_VHSU@T/\`
ML/Z+>)?L^EMW[7?S?I_SJ+UK^AU_^&L/_P!NL=7H$[HUXGO"2GEGY>;]HM;D
M?6'%K#<BX-QZ6-L<&@96S'L-;JK*[*:V/W[_`%'_`&C"_G/IU*RW(<:8_;;'
MM)<"T5_I''U\9FVO99Z^WW.P?T/_`'.I]/W^BM1G1ND5FPLPJ`;G.=:?3:2X
MO/J6;I'Y[_>C'`P2TM./5M(<"-C8AQ%CQQ^?8W>_^6DIYJO+!HD?60/<#3^E
M-6@)?FQO&_Z%NST[-_T/V=^F_G'I=-RP^JX_\X_M]@I<YEC*MC*Q]GK>VZWT
M_4KW>GMS/TG^%L_F_P#!KH_V;TZ(^RTQ[=/3;^9N]/\`-_,]2S9_74FX.$T/
M#**VBV?4VL:-V[Z>^![M_P"<DIPQE!N&''K[*OT%!^U65L:V#9<UMWZR[TM^
M5'V;8_\`2?H%2MS>I"`?K#B_:8.YK0!4^GUMLU/:U_IYF[U,/8S[0_\`F_\`
M"KJ6X.$P`,QZF@`-`#&CVMU8WCZ+57/0NC&@8_V*GT19ZS6;!`LD'U&?N.]K
M?HI*;6,2<:HE_JDL:38!`=I]./Y:3LBIN0S')/JV-+VC:X@M;&\[XV>W<U$:
MUK6AK0&M:(`&@`"K6?\`*>/_`,1?_P!7BI*;#_H.^!5?I?\`R9B?\17_`-0U
M5>HY5N8Z_I73K?3O8T#,R0"?098TF*7-]G[0=7M?34]_Z!EC,N[V>C3E'Z-4
M*>CX-37.>&8]30ZP[GF&-U>_\YZ2G__1[3ZVN(OZ*T.LKW]0K!LKL+!&RS]'
M9[F,L];^:^EZG^A6EU6KJ]@K'3+64D;_`%7/(U!;MKV-=1D>_?[]_P#@_P#0
MY/T%F_6@VORNET,LEK\ECWXP+6EX80XNW%S7O_-K]/\`F_TGJ6KH4E/+VX_U
MJ8*W]4RL:S&^T8GLJ:22XY6,3M]E.SW[_2_26[,?TZ;:[[_UQ=0L_K;FMPZM
MQ`G+PP)\3E8^BT$E*22224I))))2DDDDE(1D,.2[&VOWM8+"[:=D$[0/4^CO
M]OT%F9V1DW=:HP,1C@TX][<G-8YGZ#=Z#FAK'-M_6_YBRIEU?I>G9ZOZ7Z"G
MGYCF]0LP,*VL=4OQV.H8\%P8P/>RS*N96#^CJ]3]&RSTOM5WZOZK/YQA<?"H
MP\^FNEL&RO)MN?IN?8]^,ZVZR/SWN_\`2=?Z-)3:IQJ<7$;CT@BNIFUNYQ>[
M0<OLL+K+'_O/L=O4.E_\F8G_`!%?_4-1[214\AI<0TD-;$G3Z+9V^Y!Z:Q[.
MGXS+&FM[*F->QT2"&AKFG:7-24__TNX^LME%.5TJV['9E`Y(K].YSPQLC>W(
MKK&_&LRJ'L:ZCU:OM'_<3](MU8/UG;<;>E/IW/-.;6^RAH<\N80^KU-E;7_S
M+G^IZEGZ-G^D8K_5L7J&34QF#D?9G>\6.F)#FN:T#V/<UV__``G^"_X1)2NM
M?T.O_P`-8?\`[=8ZOKE7]*^L&+LMZAU4YE/VC$'IAC6RXY6/NTCV^H_==[?Z
M/ZGV2O\`0T>H_JDE*22224I))))2E6ZAG5X&(_)L:^S;#655C<][WD5TTU-_
M?ML<UGO_`$?^E?76I9UE56%D6WV>C574]UENXMV-:TN?9O9[F;&^[<U9O0-^
M?CXO5;'6BKT`S#KL?NWL>&/^WW,C=]HR8_1^I=?Z.+_H+<G*I24FZ?AOIZA?
M=E/;?F6UM+KMH:6L+[?3Q:OI;:*6M;^?^DM]2_Z=BM64Y!ZA3>W9Z-==C'@S
MOEYK=[?S?\"IC&K&4[*!?ZCF"LMWNV0#N'Z'=Z6_^7LWIGVW#,JI;M])['O<
M3.Z6%C?;^;_A4E);-VQVT@.@[21(!_JRW<AXEC[<6FVR"^QC7.VB!+AN]K27
M_P#5*.9ET8M1=:[W.!%=8U>\@?0JK'OL?_53=-<7=.Q7%I83362QT2/:WVNV
MRW<U)3__T_2[^E]/R<JO,R*&VY%#2RJQVNT%S+?:/H_SE5;E:2224Y_6W`8=
M4SKEX8T!/_:K'\%H*AUK^AU_^&L/_P!NL=7TE*22224I5\_,KP<.[,M_FZ&E
M[Y<UOM'TO?:YE;?[3U6R.I97[2'3,;"N<XU^J[.L;&*P'<T-]3=OOR/4:S]6
M9_@_\*LOJM.)9A7MS;_VKGUUV!U3!^A:=7[?L<W8>-M:[TJ<C/\`4N9_W)24
MW+!;U:IV5=6UW2_2%F-BO:X/ML!]1MV4U[1^B9L_5\?9<RS^D6_X&NK0Z=/[
M/Q@1!%3`0.-&@::-_P"I59[.IY.*YKOU:HUD;*BUU[]/S;#MQ<=SOY/K_P#'
M5I\+I=3,6D6G(#PQK7,LOL,$`#:=EKJG)*2W9K,?*<+[F,JV-+*X_2%[G.;[
M(<7V?0]M;*55>[J.7U"DUG[%C^C:)>P.O=[J/>QKBZO'_P"O,LL_X"M6:,/&
MIZ@^RO'#7^DUHOV@F-SW.K]8_I/SOHHSZKCF5W-<T5,8]CFD'<2\L=+7;MO^
M";^8DI:G"Q\<.=6TFUP]UKR76._K6/E_]CZ"6!_0<;_BF?\`4A'<UKFEKA+7
M""#W!3,8RMC:ZVAK&`!K1H`!P`$E/__4]522224\Y]9<9M-PZCD]0R:,9YQZ
M68]`#HL9>,D6#U2ZCW[/]#]H_P`'7;;^CQ%I?LG(W3^U,R(/MFB)_>_HVY:!
M`(@B1H=?$:A.DIS?V3DZ_P"5,PSQ_,::<#]5_M>]+]D9,`?M7,D1)_0:QX_J
MOYW\A:222GEVC`?]8'8-^;FY&1/V<5V.9Z8<RIF?O-=>RI[7TWM^GC?SOT_\
M"ME_2R['?0,JYC7`@%GIMV@F?8*ZFM]JL9=K<7%ORQ7ZCJ:WV[&[0YVUN[:'
M/+&;G[-OO>L2KZ]=#=6#8\L>Z/3`@BTFNC)G&<XL<ZO;EU>^^O'_`-+;Z5/Z
M1)3K/Z>]S"P9F0R6ELAS9U&V9]/\WZ?M0;J/L&%;D79N0^K%J+WESJP8J:76
M.]2QC/I[?<ZZW_MM9H^N^"_I;,]E+@Z:FVU6N92UCK:WY6S[3>68[_U>OU:O
M?^G]?%_[D*WTWZT](ZMD?9,8V.L<;&%KJS'Z)K'W[W:L;Z7VC'9;6_\`2UV7
MUUOK24CZ.\=3-N15GY9-!^S6AX8P;V[;W/%6Q];7[+/2=_A5?=TQ[LEE_P!M
MR1L8YGIAX##N,[G,V;'/;^\KH:&B``!Y)TE-%_2W/:]KLW)A\@$/#2T$;8:6
M,9_6_?65GWT_5UN&<GJ&;8PDM8QWI6-?Z;9=5:ZQC+O>SZ%OK?\`&6_Z3HTQ
M:TF2`3!$GP/(_!)3_]7U5)?*J22GZJ27RJDDI^JDE\JI)*?J/-_H=_\`Q;_^
MI*IV_P`V[^H__P`\UKYH224_1^+_`#G5/_#^/_[;]-4F?^*+&_\`"^?_`.?N
MFKYN224_522^54DE/U4DOE5))3__V3A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'``@`
M`0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`$I`5@#`1$``A$!`Q$!_]T`!``K
M_\0`I0`!``("`P$!`0````````````@)!PH!!08$`@,!`0``````````````
M```````0```&`@$#`@(#"`L("PH/``$"`P0%!@`'"!$2"2$3,11!(A5182,6
M%W<X.?!Q@9$RLG2V-[<*H;'10C1VN!G!<B5U-D8G5T@I>?'"5+0UM2966)CA
M4F*")$1DE)>GUQ@H>&D1`0````````````````````#_V@`,`P$``A$#$0`_
M`-_C`8#`8#`8#`8%#G(;C]I_7_FZ\>N^:A3$83;6Z:[R7@MGV]"9L:RMLBJC
MHZ;_`!=:.XAW,.:\T"-[A[3M6B"A_3O,;I@7QX#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]#?XP&`P&`P&`P&!4#RX_6N^*/^1\N_
MZC9G`M^P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__
MT=_C`8#`8#`8#`8%0'+G]:YXH_Y)RZ_J.F<"W_`^51\R1<HLUGC5)VY`PMVJ
MCA%-RX`G\(44#'!54"_3V@/3`^K`X,8I2B8P@4I0$QC&$`*4H!U$1$?0``,#
M@IBF*!BF*8H@!@,40$H@/P$!#T$!P/U@,#Y7;YC'D35?O&K))5=%JDH[<(MB
M*.7"A4F[=,ZQR%.NNJ8"D('4QC"```C@?5@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,"N[R,:]M+K1FP-R4[>6Y=4V#56OIR5B(O7,]!1=?FGZ2J:Z+FQ,I2N
M2[EZ='KVE]M=$`+]`C@9EX@:PE=?:CK<K-;<VMMF3O\`7*G<7[[:,U#3+B(>
MRU:C'+QC!FB8&#!K%F<*&.":@+&`QA^M@2LP&!__TM_C`8#`8#`8#`8%0'+D
M?^M<\4?WVG+K^H^8P).<X('G1.U&H)<';AK2IVI&P*J7)78T9\^B\@18+E;I
M19SC[*"Q'XD,?J'42>@8&HYR3T9YDGW-BJ/;V79MHV>O.UE:KW+6+F4;ZK:L
MD'C<QCL"L7"</&QS5,#"Z36+U,'7KW=<#8CY`4?S1R%^!QQ]VGH"(US^+-82
M086>%26G4YY&';IV-1\X6'\/[\L"AR&*`%[1#I@1^\CK[DE6.-W`NN\N[W+1
M^M9WD'%Q'/C8&A4K!!M6],+6)YW5&[IY6B*SD12Y*W)M499PW[2]I0ZB!3=,
M"*7(;GK<N,<,QI?C[VJY+J+7>I*)?N,%%NE%N6V)OG'?;KO>3IU^U77[E8V@
M3\)%T6%:E2;F`??3"11<B(MTNHA[(_-7R37;?]UHI;Q'PVMMK\C?+=Q%U_7H
MK3IRV'5[?BSI2\;&T;M(EI-ZV":D;'%(QB0*@5H_3[!3,941#`\+Q+YI^0R8
MU)QT:TS:H;7C=6^+2)Y1;&C9W4ZZ]TVKN.MN(JL/='O;$Z3;+L+'`2CHS*3<
M`47;M=FHKV]3C@8C=\T.4W)NHU.JVK8ZF]Z7&[-\;NWGVRJ/K68UO^3C;>PM
MYP1-G<>)!NS00-,(TN-1%1<Q^IVR:1@6'H?`W-<!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@1`Y^_H8<D?S73_P#%1P,V:,_H3T_^:Z@?S4B<#*>`P/_3W^,!
M@,!@0;\A=;5MW'*7@&DI?TI%W8(=5A5]8[B@-%7+8*J)'H'I\=L&P_\`T6/0
M624%ZLDG^&6(RZ%$`ZX&J#QDY)[=Y'ZJ\?\`Q+W/ROV_1ZA8]H\[(+=]Z0OC
M6MW-.P:,]E]KC5ZFVV[EPRL["CQ,L5TH^;+B20*W^MT*`@`8!CN8?)_?7'+>
ME^VSR\VSJRZ<'?%U5^1G&5["7="I#M_:X[XW35V6SK8T.1,-D#/1.NX*"!OT
M.@HH_`P%%10H"$HMA\M>3%KO>X^7<SOO9%%Y'Z&\D/CUXO:SXMQEH+&4N7U1
MMZFZ3=;%J<AJPX%<6)[M!S?IQ_\`.'(*B161P2$"IG$H6W[(L_*2>\O_`(XV
MW(#5FJ=?U://R_)K:5U[L>:N\M9&`:?L*:*UECI.JU]""<&BRI*F*BJX`%3&
M(`]`[A#8/P(UVKF)QBH]M?T2W;HI=?N,8^2C7U<D7;E&5;OW`D*@U,V^5,8R
MJQE2@7MZ@;J'3`D<W<(NVZ#IN?W$'**:Z"@`8H*(K$*HF<`.!3`!B&`?4`'`
M_A(QT=+LG,;*L&4G'/$_:=L)!J@]9.DA$#>VX:N2*(+)B8H#T,40ZA@=0%.J
M/?"'"JUONK(F-6SA!Q?=7C&`I3C!F^5ZQ0F*0`'V/;Z@`8&.FFV>/ZE[V!06
M=]U:38NFXM"^;,K19NN(V36T1:XQ61);[:S,LF[K;.:A@,NH]<^T51L;O.?L
M,`B&(8;F1P49:LE=V5_D%QX9ZD@Y=:HRM_B;C3FU:CIMTZ]]2N+/F;A,I'SY
MR;WBM@#O<=?<*4P#W8$@:"?5%OI\1:M9EH5@HMM!O;(2=IJ,"_K4^*Y_?;3[
M%[$IG8/US*DZ@X*)E"G*/J!@'H'=7F^4G655F;SL:VURC4RNM#OIRTVR880$
M#$LT^G<O(2LFNV9MB=P]`[CAW"(`'41Z8$:_]8'P<"#J-F5Y:\?&U>OJSQ"G
M3+S:M.91]@6CG9&+]./<NY5%,YV+Q0J:P")12.8`/TZA@9"L_*GC72MA4O5%
MMWOJFN[)V.@U=42E2UX@&=@M3=\!OL]:%CU7P*.TY,2"#42_Y48!!+O'`_KM
M3E)QOT78*]4]T[WU-JBR6ML1W7(78=\K=0?S#11Z,<1XQ1G9!B*K,7Y#(^[Z
M)^X`EZ]0P/6W#<NIM>S.N*[>=DTJISNWY_\`%?5D3/V.+C'^PK&9L5X6%J#9
MTY35GGXMEDS`FW`YA]Q,`]3D`0\4KRNXRH;/F-*+[]U$AMZOD64FM9K7^M)7
M>-!O%(SBY75;4D22J:J,*N1V<GM=Y6Y@4$.WUP.LU-S(XH;XLRE+TMR+TYM.
MVH1SB66KE#O]<LLRE&M#$(Y?*1T4_<N4VR!E"@<PE`"]0ZX'22_.GA_7&YG=
MFY$ZNJS4-E3VH$G%ILS2M(O-D59XG'6*K1JDX+`LH\AGZI47"C?W6Z:@]HJ=
M<#-6Q]NZNU!1)#9^T=@5&@Z\BV[=T^N=JGHZ'KJ*#SM^3.$H\<)-5A>=X>R4
MAC&5Z_4`<#%$YS3XC5I75R,_R4TI$*;M;,GNI"OMC5=$-ALI);Y6.?58QI'L
ME&,@[_`H+$$4U5_P93"<!+@2;*8IRE,4P&*8`,4Q1`2F*(=0,40Z@("`^@X'
M.!@7>?)C3'&\FOS[AMQ*J79UQ)1:=UCI&2-)3X13^==%.G&M72K5A&PL6X=N
MG*@%1001,8PA@9/HMXJFRZ75=AT6;:66F7:`BK35;`P]T&4W`3C)&1B9-H"Z
M2"X(/63@BA.\A#=IO4`'TP.MA-GT*Q7JY:SAK*Q>7V@,X&2M]7['2$G#QUG3
M=*0,BHFY013=,),&"Q4UD#*I@=(Q3"!@Z8'O<!@,!@,!@,"('/W]##DC^:Z?
M_BHX&;=&_P!"FG_S6Z__`)IQ/7^[@92P&!__U-_C`8#`#]_X8&%][\>-*\FZ
M*?6N^-<UK9M(-)-)DD!9V!'K1M+L4UTF<HT[NBC1^V1=*D(JF)3E*H8.O01P
M,&63QP\&;9IJH<?9WB_J%[IZ@RKB<IM&_%&-0AZY,O@,62E8M-!)-1L_E2*&
M*Z5*8#N2F$%!,`X'T7_QT\'=HO-3OK[Q?T[95]'PD=6=7%D*9$J-ZE6(=\E*
MQ-:CVX-RH#`1LJB1T@T.4R";DH*%*!O7`]+8.#7$:U<@H?E18N/NL9?D%`GB
M%XO:3ZL1Z]H;/Z\R&-KTM\X='JI,P,:86[-V8!<-D![$SE+Z8$+>6X?]:[XH
M_A_D?+L?_P`CIG[V!85OW2TAN^L1M=CML[,U$K'3"4J><U?.)0<M($3060&-
M?KJMG)5F!A5[Q)T`>\A1^C`JCOOAG:W'=-1OKS?VT9YA[;IW<K59I.-D-@%E
MHLB:E75@Y/[,*@5--8!`YE2G.3H`EP)KZ^X/V&B72M6]?EUR?M;>NR*;]2L6
M.\-75>FDTTU$_D)9FG&I"NQ4!3ZQ`,7KT#`K!_M%&X]BZXUKQ8J-"O$]3FVR
M-C;0):?LBXN*,U>Q55U>^?,I!_-HW#71%W55E9%&28,CSS(KUZW33]ISU$A0
MK/TTZY)[LY,ZVBN,-HYE[,_)K)>)VY4W:MCV+(UO7>O]33E*=6'E+)[[U[-7
M(YYV9VUKJ(<(HM@;R@N'/U"K)#U,L&>>./%?R.ZGY@0OD*V+QB@IMGR[M7,V
MN\F]6U2PLI?>;?46YXP;3QUI^R&UKF_R:NHG3!]+5VO,",53@DE8%BK^XF=4
MY`[31>@.3]$T9Y"I>S\?>4)&/(7?](LFI[S':^XV.>5:S=#7BU>G9ZRZN>2R
MNEX*M0+YJE$L31A$'Q6;I58"@8"G`),0W&_F]1_!UQ]X[ZUU]9M6\S:FXJ<7
MKAA0+DVA@UO-I;2>S4)==FRXR3Y@O$H1+D)"R1[87B"YE56Z).T0`H=SR#XX
M<H=K>+'BM7U]0W_8NVM0[:U7L_D#H2^W")D[EMM&E6M[(7R-3L+V1^P9OY]V
MH+^-;N%DD%4032'L[<"/W)C7^TMI[YU1O2F^*K:3_64SQ7Y-Z2<:6DH[2L4^
M;[`V.NBTJUBNK`MQ^Q*Y$2XF[UG2"CMV@BF)^SNZ%P/`;;X3\O(K7GC%X^QV
MG=I[%VAQVL7%RT[`F4F.JW?&R>+0)1=Y8'MUV<]DF&[$)754>_.WC6C4/DGI
MVZ9Q2/U-U":7DIT_MJ;YASM]BN$]GY@4G9GC'V7Q<B(>$/02U>&W-<=PM+-%
M%MLA=Y^*6KT`WA&JBJLBU0<KI$,`$()Q]`K5Y*>-#RB;&J&C*E4:S3[+9O&7
MP`XRU;2FP;Y9Y$\O<N8=8L%%WILBZZ!<,GZ1%9EJGI&`H'S5B3;I+MWKCH`)
MK*'*&;*KPGY8VCR(,^9MZT7<`TY:_(CK/<4GI5VE165AJ#2T\*-.U#\M2]QC
MI,U@F(35VQROX.8KRCD[!Y]G*+IMS"/>H%M?C^XPV72^^_)'<)[5,90V.S^2
M4=/Z=G4HV`;_`&S2`U)3XAP\A3Q9U7+")"PLER&14!$3*D,;LZ?6$-?:Q<<M
MW;*JTK)T7C58^0XOJQSTXI6EO!GK"3G7')"X\BIF<0OEG:VF6B58Z"DXARBX
M/*-@7<)ID+VD,`A@6N\I]<<E;)HKBY03<9=C;,C^#>U>-%CV3`M9*G2B7(RL
MUZBE96M>A1LK.,4),U-F@#N;R9VXN#%`Q,"N";XA\GX3C)P:XE;)X.;(M-%_
M':2WOOW86L6.L;5LNA5=MNZR;)UCQAKCZQW&!"LA'+2""TV_9+N$T&I1;M!Z
MG.?`LP\L_'+EYO"P1A^.*^^H"OT?@;R:L%*::IV:ZU^*_*R!:UB4XZP%A)'V
M*+^V9$)ELH*:2XG8G.D(+'[?B%3W,!ES2X<T"]:RL-OW.KK'<W-WA.YUP7:^
M]9A%+8;><X*;"O?+6$E=FNMDT^6KU6/R.@&SQRS6L,&@:2:IILQ50'V%`DQQ
M4*7G'2-,UG6L]M?=M?X3>,.;GVM\VPPE(>^;+Y;<UV=TJRHSK:PR<H@=]#Z_
MUS(/V/9(.D6C*UM026%$Z9C!71M%+GAP[XH:/T7R,<;,K>P+CLW4,>2Q'VN:
MEZOG-$TWBS/GA=81#:)V90&--L.F+C$J*230DTQ+/R8(K`9WU]G`O`\5CUM=
M.559O=!LVQKU06WB[XV0=KV!L]I),[E;KY);,V#,(O+8VDW\HY9V%T@1V\(B
M=RN)&*Z7MG,B*9A#8GP&`P&`P&`P(@<_?T,.2/YKI_\`BHX&;=&_T*:?_-=0
M/A_FG$X&4L!@?__5W^,"H3E%RG\JK?=UDTUP>\=-)NM0JR,1\[R?Y+[\A];:
MKF7LHR([5:4VA5MI([#LS>+[_:<.R&2*1<AB>WT[3&".[KD=_:'=0$_&?8_C
MZX4<EZDU$7$S5.,_)6TTK9J$>G]==2#3V]`(P4V\22*/MM4RF77/T*42]<"\
MS6UKE;U0*?<INF6'74S9J]%S,I1+85J6R5%^^:IK.H";!DLNT&0C5C"DH*9Q
M*82]0Z=>F![?`8#`8%0'+CK_`*UWQ1]/_`^7?W?^8Z9P+<)&5BX=`',M),(M
ML8X)%<2+QNR0,H;^"F"KE1),3FZ>@=>HX&-9/>6IXFUUVEOKU7"3UH;2+R(2
M)*L%&JB460IW/OO2.#-FJ@@;HF4Y@,H;J!>N![=K;ZF_<)-&-GKKUTN/:BV:
M34:Y<+&Z"/:F@BZ.HH/:`CT`!]`P/$;C>:/BJH27WZ_U?#TAE)LB)2^V7]7B
MJPUF'1^R/3)(VU9M%H2#HY.U(O>"B@AT*`X'1U_;7&EK882'JVS]'HVK8R,4
MUK43`WBB$G[RA'PAY"%;P$<PE/M"R)LJX<5VQ6Q%@(S,*A`!/UP,&5;R,<6+
MGR6Y,\2:U;Y^:W=Q,H#;9.VZW$TNRS*8UPT3$2\JA2%X=A(+7ZP5A.R1C>2C
M8M)R];/I)NU!,[@XIE#%E9\L/'6X:RVSL&MZSY<RUAT=>8_7NT-$M.*VW5N0
MU0GI>$_&:(<3FJ$H`\S$P4E5RFDBOW9T&J30HF5,F82E$)9Z3Y5:(W_I#5G(
MG7U_B?R5;G;L3:^F[4?\3',Q)/Y5S`I5P(RS#&ODK*6>8K,18]AECNDC%3`X
M"43!UV_.8''SC;I:0W]LJ_LCZW:2K*N1KZE-G>P)6UVZ4D30\13*9!T]*8DK
M1;9:7*+5NQ:$46,N`E$"]!Z!"NU>9_B?0V5+4O6O.8U/G+?7+M<WE&G>'V]$
M]AT.DZZ<I(76[;"I#6IO+#7JE7T5?F%GY4'#<6P&4*8P%'H&4+YY3N*&OYS0
MJ$BXVW-:]Y(.M>QNMN0-3TOL.P\=E9G;(F+K:!F-PLX3\5HZ<MY^A6[4JBJR
M'>47((`/7`[OE9Y+>-?#C8+'6^WF>ZI*</JF2WK97FJ-%[-W##:[TQ"6,:M.
M[0V([UU7[`XJU-@ICH1X[51,"!!*8P=#%ZA]^X/)7P\TC.<.82X;11>DYXS\
M-"\;IZJ1CRSU>V-;%^*"<#:Y.?C2'CZ]2YA_L&":-Y-T8C=1U+-R]>@G,0/'
M2GE7XF0O)*P\691QMQIL.O[.1TA^,`:7V"XU;-;N=Z_B-H1VGH#9K2&<520V
M1+4R>:NFD8*Z:S@5BE)W&$.H=WQ7\DVD^7VR[QJG6>M.4U;LNLE5F&PGFW.-
MFS]5UJFV!)DQDDZA9+%;(AE&Q%O>Q4DB[;QRYR.5FQP4*42]!P,$6OS(\*-1
M-I1Y.P.W8TKK9NW:\\0I.GY>ZO5X+3=I)3-D[XL#6C?:YX34D79"F;GF9`4E
MU!3$?9'I@3BWWS!T)QNX]..46S;7(IZ=3A(>P,)RJ5:S7.4G(^P,B2,)]BUR
MLQ<E-O5))FH"A>J)")DZF5,F`"(!E=KMO71]?5S:,I;82K4>TQ,1,14]<I1A
M569FLZQ+(QJ;E>:<LT&SQ=J83>T8_?\`5-Z>@X'PUO>^C[DZ*QJ&Y=4VIZ:L
MC=2LZWL.HSCHU-`ZB8VTK>,F'2HUD%$CE^?Z?*]2B'?U`<",?)WE_P`1:EQ%
MWKR5GK!J_D7JC1M2=VV9@J+8J/LDD[9D@*UIE)BE&3Z7B&MNO%G=-(J+*L8G
M>[>$`1[1'`[7C7S"T-MMMM:+81;/1]ITKMFP:"V)4+T[HU:5_*'K'5.M]F7I
MC4GD5..&UOJNOZWLIFW7D2%0*E\NL<4DVX)J*!U.P^7/$FUWSCWJJ4<4C=M;
MY#76P4>C7^KR.OMFZOA-DUVJ25TC:I8Y1A/2*\78+/#PSK[,]ALN"JJ78<R8
M&`1";D;!0L,98T1$1D69PFV17&/8MF8K),DO99I*"W33[TFJ(]J91]"%]`Z8
M';8#`8#`8#`8$0.?OZ&')'\UT_\`Q4<#-NC?Z%-/_FMU_P#S3B,#*6`P/__6
MW-^?&B=E<F>(NZM$:DO#C7EWV3"0<&VLK6QS=.<*5Y.XUV3O572ME::O)ZLF
MO=$824%\^U2459A)"KVF[1#`IEU7XE&7C^Y`:UYC+\A7D1`:PVILIYM?=N\^
M2.QW[*K<'/R8/(S7W'F<:;'FWE5FDJS?')G1)5RHW,T1[%/>54(!<"V_3WD[
M\>7(/8$1JG2',OCOM/9$^#D86DTK9M<G;%+?)IBLZ"/C&;M1=V*"11,8"`(]
M`ZX$[,!@,!@,"H#ER'7RN>*3IU_R/EU^Y_R'3/K^Y@69;/T[K+=$0R@-H4^+
MN4/&ORRC)C*?,E3;/RI*HE<I':.&JQ5`25,7^%T$##U`<"M>\>*FN6#83BSU
M*X5:DT[Y]BNRUZVH<A(QA&30R9EF<@^6N:;E\=^`&!50`3'ZWU0#I@31J'"[
MC%2IR#M5?TY4XRTU]PB^CYAI]L]S2222$@NVB#N6=IDZ&.82`<#]O7XB(=<"
MG/\`M#&H-S[>H_$^-U1JN^;%BH;86VW=^?TW5EHVZW@(>9U0_K#2,E*Y4M3[
M^E(][=#3*\?&R@TJ5)&NQ!Q\W&G(5<P0!TMXQ^0^^^14')Q?$35_$S6-!=^)
M+9IKANEM;9'?^F6'&.KNKG:]6\8;W%Z[;0%FE9^1ATJ]:W"CZ#&-^9*9PU<J
M&(@@$S-*>(+G?HS;FE.7<9RBU-?>1:6R>8]ZY`ZGL,"M3M%R#;F@PG9^[Q=/
MV;1M=,MZW)G6]DUJC+,4+$H"31E#+&8?(B5-NL'.JO%-S$UKQVYAZT6I_%FP
M0G*K<-6O+3C$KRNYBQ]&UY#1M:4B[9,)<M&=-3Y%6RW6^R-V<BHRD&:D61LV
M%IW^VJ8"AGRQ>+?D+:?$%K+QP6'9NI)K9;#\5X&Q;?<1]B;PNIJS'7Q2S(S&
MG6S*)9V"?O&MH,R;:N/I(\:JY?-TW+M4GUBB'IK[XW^0%I\=W%[C[69[0E)Y
M)\2KQKS8U*<LV]N<Z#N]BUI-/'*2-E3"#2M\0A>H]P*S]RFS>KLY%510I5PZ
M#@8[W?Q%\L6X=TZJY,-$/']5MLPN@MY<>K+6E=@;_F:'4H';#E(D7;X1\IJ-
M*7V%.P+45%EF+IO`M'"H$2!0""93`Q3LOPY<D'##@/J;5L[HU"J\,G.EI&,Y
M/67:.^8O:\8I191Q+[)CHCC!&0DUQZMJMX7?.$(^1E7Z3V,:+^V!NJ9.H3$Y
MK<0><5[Y3+[]XDS?&!,ETX+W;AA;GG(69V6R=TX]VV8VO+O9=;J="HUCCKNX
MC63,J:,4]DHE!=P;HHL5(![@KYW'_9_-Z;+I;W6=;Y=,M>4G1G`'CYPPXJ%B
MZG"S,E;9S4$S'[JL6Q-R.;33[#+:F4LG(ZE55X@M19$\FG"PB9%%S"F1`P9E
MH_B-Y+Q7-&,YZ6JW:0DMNR/+O7^ZKU13V[9MAU(XUF[XIZNTSM92ITR;J"5=
MK^[X+9==F9.J6%)@1X$2=L@Y>I`;V&P6<\2.*=\T-MCG=>;A.U61A^4>^V&T
M:.A7'4LXDX2O-M9UFEJM+.21BHUNVF!DH950I&JCI'V1*/N=PB4H4=-/&AS>
MV569D-6,-7:]F8]AR_X=;$8<CTMAU@\EJO96[I:]5G?VKG=7J%I:W95_!2W<
MDR5,R:NU/B]3$I@P+7]J\<>;3[AON3B1KEOQ>F(E74='T?HVPVZY[8J4BXK!
M:0E6;]9MIKQ%&N2;.=;OT?>B6<4W6;K)&[5UR"'40Z#?7!7>/*+@MQ?XX;8C
M>/[*[ZNW+QPNNV*XA-6V\Z?LU'TU8D7-EK\4[L6OHJ7GE[-`M^PK61B$&BBB
MADEC^UU.(4_\B/"'M31_''>=VTAK/2LK=FVM/*,P>4W0%1E&NSMDT[E1!DCM
M#ZTK[&'J57<V)*A,2&*K"BZ*V8]`3C4GIC`D<.NX/\7-\[&:Z7XT6?B9L77F
MIK3Y%#\QN6O)*9H$CJ^C<A*YQJU'KRU:HJY=2V_07&*QZ[K,[O9*L0S:`7IC
M)H^)4I62;J.`<.5E`[SG#XG>6^N'?DFY2:Z9UGD"IRLF^12,5IN`:7*Z7G6E
M'V?7]'HTZ\Z=JJ%2,5+:,M.4648;!CVWSR,W6&D05`K]9J+$P?OAGQBW1.L.
M$-$3XI;'U4YIWDRL7*3:FZIB@6*CUC8M9HFJ5W;B_+5:;T1QVE=0Q]DFEF=;
MAH!]58DKE5)PLV*H11100V]/V?1^W_LX#`8#`8#`8#`B!S]_0PY(_FNG_P"*
MC@9MT=ZZ4T_U^/Y+M?\`WO\`BG$X&4L!@?_7W^,"D'^T3MJ\\\3')%O8JK.W
M`JCC700,-#+IH-QMP[!KH55[:/>$&ZU*8SGLJ2Z2@@11@50HB'7J`1&\:.D^
M8=1WKI^=VGXGO%OQVI[6K@$IO#CP?1Z6W8<5(%N5%Q!(5&&4LA/M=3H#@A'B
MG0IA`ZI^G<(;.^`P&`P&!3CRQE8MSY:_%=&-I)@XDH]ARV._CT';=9ZR(OHZ
M9]D[MJFH9=L57I]43E+W?1@66[JWYJ3CQ5F]TW)=(NBUAW*-H5M+2PJE;K2;
MHAU&[0GLIJ'%10J1A#TZ>F!0?NS^TA:'U?R!=ZBJNJYC9--;S-?C";8AK+%L
MX%9M,*H)O9$K%X0CT$8DBPF4`2]3`4>F!;QK7R)<.=MVVMT*B;PJD_<[6L#2
M$@&AW?SCQY\HH]4:I"=L0@J$00.(^H?P<#V7*KF7H7AE5:_;M[626AF5KDY6
M*KD97:Q/W*Q3"\#`O;185V-?K+"2E5V-?KL:N]>K@E[;9NF)CB`=,"+L7YD.
M!4O>-8T!KLNTI3>UW6F&-<=O]7[!CJ]&NN0\>#_2Z%OL;R`1AZ>OL(3%;QQ)
M%9N99T(HA]<!#`\'JWRN-=L<X>3O#VOZ>=)L-45;;HZ(V@_M<?&PO(?:?'(*
M+%\A=9Q))!%LSK[S7-OV+',#NE7"B2A$G2Q_;30,.!@O7GF0V3L+C-R8W:QT
M=I./F.-.WHG6<].R')>OH<>["SDH)G..9JO[C4@B_:3N'4>$CW#-"/4/]HJ%
M2()@[C%";6L/)+JB3X'Z1YW[YB9?0M!VQ%U9>99RS5[8FU$>VNR*U:+<STM#
M,U4F=5=/BIKDE'!$&Z;)=-5;VP$P`'S\A?))KS6/%77W)/4=3GMTJ;RNU8UK
MH.GIHN*:KL*WW&8<PL&JN]L39L>'K!E6BBZCXZ1R_*@"B93@8.H15VMY,.;N
MH;UK/2\]P+J4GO"U:DVWO"U4R"Y$5]W%,=?:F=)@^4J%A4@D6UAGIAB)S-F;
MDK$_O%`AA#N`V!UE\\TJD1+\&[#0=+5^W:DYJO=4QU?+);8@X3><6KLIY),9
M*3B]0$9O7<S7]>.HXY9AX=VV(3M-[7N=/4)"\R_(!O307(4-"Z)XNM.0DC7N
M*-IY>W]1;9T70IAGKJFWY*CS<13X^4CUVEDMAE%R+-FIW#8%Q'L`W=TZA@_>
M_G!U/K)GP(N-#U[*[`U;R\H>OM[;1M[N61K[KC3QOV9?M3:EK.U;K%F0=_.E
M/L_<#&,6:D4(!`9/5`4$$>A@^"0\RDZV\A-IX/QV@X>>3B>0:?&^%GHC:$8O
ML-U:'6E*MN%O?9G6`QI9*)U(U):",'DT599-LJB<3%$2B7`D#P=YR<GN3FZ.
M0FM-L<8:)IZM\;+2;7M_ML#NMM?W1KZM6H2W1T=%PR-<BS.X=:$FB&4=^Z`)
MK$,3M$0ZX$-+OYJ]OU9A,NJ?QCB-HKQ[GD=M%TBCL!*HMXCC'H;9#C7*=L1<
MO8U^:<O=F=QSAPWCBD1;BF4.JQ>N!/CF+Y"R\;^&FMN6M(H$;>FNT934S*%A
MK=;F]`@(1CM-H1ZC,VRUKLY)K"1D"B?HY6.F*8#]/3UP,@27/74VJ^).L>5O
M(B<KE0K6P/Q)B1-JV4>;IKJMOO1S(04'4YRG1KE:V(2#T@I(.$&X%5.(```)
M@#`P?0?-=X\]B'L`16VI^';U;7&S]H3K^X:UOM0C6%?TNS&0VG'GD+!`,&I[
M51V7:H_BBF%\B4X=4^HX'FMQ^7#4SOACR@WYQA8VBY[1T]:JUQ^INO\`8.N[
MG0WLORGVVO5*_J+7;B$M,=!24J*\[L*&>2"+4143C53&$Q.H"`=7ICRXZN9V
M#E9KGE'.UVEWWBYN7;E`E5:7%V2<92VN](:HT?:K1MJ?9-V#I6E1MFN^SGD9
M#-7*AQ?+M2MVZBRY%"E#MV_EEUK?-F<7R:=82D[J#;W):P<2-F2=SIETU_=*
M+N5:@O[;3HYG"6J'B_G&JC]F@UD/I1^<3$.H^F!<"&!S@,#YW1UTVSA1J@#E
MRF@LHW;BH5$%UR)F,BB*IOJI`JH`%$P^A>O4<"JAAS3YINMX+\?E>$,`C?F&
MMX';<HW#D'1U&#6AS]PF*6A(D?@D#9P_++P+KJU*;W>PI3=.A@'`M?P&`P(@
M<_?T,.2/YKI_^*C@9LT;_0II_P#-=K_^:<3@93P&!__0W^,"J+S96G1-3\;W
M(![R/K^UK=JF2:U:O2]1TO/)UF^VN3L-IBHFNUMA-KHN&K&/FIQV@W>"N0R(
MM3G`X"7K@43^)3B;>]9<Q-/VUSXZ?(GH.K1<3*$:7S=G+!6^:MK+!:'!-@VE
MJ']CQJ+I,Z/:D@B!@!$P!T*/3I@;FN`P&`P&!1AR5TMJRH>:7QO[@K5(A(;9
MVSH3D_%7ZYM"."R]HCJWHV;"#:29C+G;J)QX''L$J93?=$>F!>*Z8LGZ((/F
M;5XB!BG]EVW2<)=Y?@;VUBG)W!]`_1@5Z;2\4G!/<VX7&^-@Z293.SG4E#RZ
M\ZE8+''(J/X%1%2+6&*CY1O%@"!T"B)02[3]/K`.!/IE7*_'>P9C"130[8A4
MT%6\>T262*0GMA[:J:0*%^H'3T'UP*6_-9P5Y`\WJEQQ8:,C(6=2U5?+[9+=
M`/K9&5*5D"6*CGK==,Q=3B7V&^AV[]=7[5;+*D.NR.*9"J=YB@$?M0>'WD+>
M=X.[[RLW'$UC7[8/'M>+-JG1\)6VM`W7L[AU5';^,0E4'C,DU1:K3]E-&2Z*
M#$"%E6@&3$$@`#@&?:#X+M"ZH>Z&V/K7;NWJMR7TW<]Q7B<Y%FFW=@L6SIG?
ME<OT/M=:<HMCE937,&I:):[)2BAF,<0#.HIL"Q5^@FP.RI'AW>Z\UKOVOUCE
MG;6FT>2U^JETVOL972FHG-1F6=-@GM=BJTTTHM'FH\6V68OCJN':!BNUG9$U
M1.'9VF#,1_%+J4?'_3?',38VP0TC%NV1-@R*AX\UHV57'%M<W&X5-RY2(@RJ
M\+;7SU9N)&*71DS/[:0=0[L#O+KXT*AL#A=K/B!9-P[$,ZTE*U>PZ?W?'-XA
MGL*E6*A22KVBRH-3)N8B5&!:G(U524*4CQ`G0_:(C@8%V-XC]E[5L.N=@W'R
M%;Z<;9J.O=E:DM&S(N@:PBINWZTVHZ3/9:S'L4&!HNGG(Q*=!L[13<N41.*@
M&$P%Z!V.SO#1KG80<;J$PW;=JCQOXU&U.ZJFE(ZET)],.934#XLI`O6^XWL:
M&P(%*9DTBKRJ3<X_-G$_:9,#B&!EWEWXVW7)_=##<M7Y/;7X]2+[CG/<5-@L
MM;0M4D']UTQ:;>6WV"&;6"RMG[FJS$@[3*D61:HJ.$"E`R?:?UP(_;*\!_"[
M;+/8T/=3WN0KTIQ7U%Q#T;"M+//PK/CMJS3E8G(ZNEK2,%-QC*\R3V[3(6=S
M]OH/$#RS9(WM]`$3![FF>'O7=/W!`\B4]RW9]O\`BN0FOM]2>VS5VN,K7:DZ
MMQ^UYQ]N6M;$^;#\V]HFT(:A#*237WO;2DGZATR=2@)@FSH+B=5=`WSE%>X:
MQS$^ZY3;5:;4M$?)H-D&U>?M:7"4L(J)40.91PT49PI51.IVF`YQ#IT`.H5-
M-_"O8=C5]U%7G=]JTW(5ZV\BM;LWVL48"PMMF\3MR;-=[$94B=2FDB+UF?2-
M(*-S/$N]5``'M(;J`X%@EOX1;)>:[MVLM:\M+WK:KODM=Q.NHIUK;6]^B=7U
M.B5LE;=5F.B[)'E1GV]G13*NY7=F]Y)8.I![1$N!YAAXN=.PG$7CKP^KUPN$
M;2>.NW-5;DAK"L2.>SUEL^L;<I=/;ET@3:Q[-E8YA=05DVQ"$;IG[4B@!0#`
MA[RB\+:=PX[;2JVF=F2LAM1S6^?CK7L?<RLXVKR5HYS,"HV.-G)!J5VJP85P
MJ8I,UBIF!4QP%;L+U'`P_P`+/%WR[JTSQGJ?(!/6=>XSZ%Y<7KF`WU^E+,)_
M;\_L*$T[#4?3"VR;55VYZU>)"*V9-S%D*\.X46:MHF*:F$PI)E1#U_,CPANK
M9"\T=K<8-DR3#D'RXF-O26Q(:R#'1-4V#3]H0FLF#'64K*`FZ,Q2UO-Z^<2]
M=D.Q-1-[-.TEQ]@_4H=+Q4\9_+:`C^'5*W0PUY6-7\>.8]IY3%9P\M#2.P6C
M.'UXZBJ-!726@$AB+U;)^_2`NW<FFH<4(]NDD<YS%*4H;(0?#]G[F!S@,!@5
MXQ7ZUZ\_]GSK+_2+VK_>P+#L!@,"E+S?<W(7BOQE7US^*B]LM7(9C.4N)(+W
M[.CH*.0;I+R4V^<>RN=<R)0`J:!"]3F'U$H!@2"\4G,>+YI<2JM=FE4<4Z5U
MZX0U-88=5V#]L>3J$##(IR,>]]E`5FDBR<)J``D*8AA,40].HA97@,#_T=_C
M`I@_M`ZMA2\4/)\E<E$8I=W&5-A*JC72V>1=UU]<(1M8(VNQPL)$R-HD(DZJ
M4<Z(F51J[,FJ4Z8E`P!4_P")K;'"F<Y-:2K6J>>'DQVO?0JZK:-U1R"C;XWU
M@X,U@&Y'3&P*2R2D252+(002ZG$O>7ZIOA@;?^`P&`P&!4!RY_6N>*/[[3EU
MU_\`P/F,"W_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8%>,5^M>O'_9
M\:RZ?^\7M7_!@6'8#X>HX$<^5W).G<2=$WC>MX9RLG#5!D048F%:+/)&7EGI
MA0BHQ!-$AQ3^;=B4HJ"':0.HC@:T-VXK[\Y\Z4WCY`>=JDW7*U`ZYL,IQDT"
MS<N81K58M0R:D?9)E!L#=<5E43`(`MW*N1'J?H3H&!L<<(]#:IX\\:=5TK45
M4;5.OR=2KEPE&Z*[IVXE++9:_%OYF8D'CU9PY<NWBYOB)NTA2E*4``.F!++`
M8'__TM_C`IBYCT#S#P6W+3>>(-PXQ[QT;9T(CV^-^^J^:!?5MU',R(OE(N\)
MD<MWC.2<IBM[:J0G*H;T'H`8$2(2+_M!6U)!&%C=#<`>%J"AC-'VUXE<NR[)
M&M5RBDY7@X)".8*BY%,PB0W?V@8`Z@.!L/:V@[56:!3Z_>;4-XN4/7HN/L]P
M%DG&_C).-VJ:<C+E8)?@VA'KD#'*F'\$!`,#VV`P&`P*@.7/ZUSQ1_R3EU_4
M=,X%O^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*\8KK_K7;Q]S_5\Z
MR_TB]JX%AV!%CE_R^U#PLT_-;=VW,D;-6I#M:Y7&JB9Y^X6!1,PL8*#9"/NN
M'+E4``Q@#M2)U,8>@8$%_&W,\R>3[G:W)?ENV9U[26W6\.EH[CI-Q#1ZVK]?
MCG;ERC:7[60;&.#B3;G3`#*@)EQ#O`"E`N!,SGPDDAPKY&HH)IHHHZKG$DDD
MB%32233(@4B::9``A"$*```````!@9RT=_0KI_Z/^2W7_I]S_P!$XG`RC@,#
M_]/?XP(&^2CE_,\&.(FPN057I\9>;A#R-.J-,K\_)JP]97M^P;5%4RN.K1*I
M"15C6H^6F4EGIRF(8K<ANABCZX%:?"SRK\E[_/Z$UER3K6A5]G;&Y@<@N+U]
M9:CD9M5"&3U;0(*ZP%QJ"<A*+.)*M?-2"C-Z[<("0_N(]@D,(]P;#V`P&`P'
M^Q@5`<N/UKOBD_DG+K^HZ8_PX%O^`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P*\8H?^M>O`?_Y\ZR_TB]J_WL#(G.'FQJK@OIE]M38S@TC+/USPFO:%
M'*IFL=^MJR!U&4/$L^IE_E4S`4SMR!#)MR&+W?7.F4X1UXSZXL7//26J=U>0
MWCCKUAL2MWR9OFHZ@YCWB_XM59\DA^+CF?AY59R3[550.?O17`P&(1,YR%.(
M@`6GH((MD46S9))NW;I)HH((ID21012*!$D44DP*1-)(A0*4H````=`P(B\_
M?T,.2/YKI_\`BHX&;-&_T*:?_-=K_P#FG$X&4\!@?__4W^,"LOS`[BU+HWQ\
M[ZNV[M(#R,U\YC(2H2&H??38HVV2NM@C:Q!MW<LHBL$$S:R\FBJH^`.]H4GN
M%$#%`0"B[P_<&=L\<^7E3V<\\0*''.OV2!L*#O=]EY<2V[GU"C[`T9NU`K=8
MG++/(MWLW\JB@JX;D]XR(=@J]GQ#<%P*V_*[.\8:OPWNUFY=WB^4_3D#*1<B
M\B=:7^PZ\N6R[("$@VK&L8B6JLE%3<@O:)1R3M:)K%(8Z)55>B:1A`-9?6=6
MOYM5>+/B!S*Y)6-EH[;;CF-LR_A&<@E2KP?V!&LK'IC3]SVU7K*!W<SK"M37
MS*C0T@($<D$O4Y"AU"$4?O#8V\>-N^K;R3Y+;5J-WX9^*2I[OX,R7Y7;!2Y*
MR[+/O[>4'"[9:MVTO'*;)M<TWHE9@O=6!X*S=9,O:8RA38$JMD;MVU;=A;JY
M7WG<.P*MSTTKY,O'-QYTOIUEL68A&R6H=BTK1"UTU^PTVE)-H^:@MHA=;&_D
ME3,5??.DH83`!#@`7(7";YJ2?F'\=Z'*2D\?*K2VJO,`NHWFF[1=IZQ2T9^2
M.Q$0/>&UI9MF#%V:&!$YP:"8OS(F`/J@&!L7X#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`"/3`8#`X'I]/T^G[?WO7`H,Y/>0OC=Q&\@>\=HW"YQ]L=TWA#KC
M7:=$IK]M*6>9V@3>^Q9D:`F"`K-8Z::1<JV=/O?,`LFRG<<HGZ)F"4T-PJU+
MRYW[I/R*;5;[&=.E-+4EY0..^RRM#5K5T_(($GAF',$9#W$K*V^=[5D5#>T#
MH!5$@'`H$"TTI2E*!2@!2E`"E*4``I2@'0```]```P.<"('/W]##DC^:Z?\`
MXJ.!FW1O]"FG_P`UNO\`^:<3@92P&!__U=_C`IB_M`A;4KXHN4+.I6&T0#F3
MB:M%3:5,KDY:+-:*E(VZ&9VND1$?`0\Z];NKC`JKQY72C<6K07'NKG32*<X!
M2%X=4/$TUY<Z.:\;VOF*B]UM:T];P<1R>&_AI*+,C`(IRD=92I-FM4!-DF`I
M-P33(Q[B!V%*3M#`W6L#&.V-)Z;WU6$Z3O'4VM=RTU*1;3"=3VI1JQL"M)RS
M--=%I*$@K7%RT861;).5")K`D"A"J&`!`#"`AAM7@5P<7UH.F5>''%LVH363
M\<1U=^0/5A=??C:)"I&M`4\M6"`+83HD!,SP&_S!D@[!/V^F!ZJY<1.*>Q9+
M6<Q?^-&@KO*:63:HZ>D+9J"@6%YJU!BH@LQ;Z_<RM?=JU!LR<-4E44V`H$26
M134(`'(02AVLKQBXWSVYH?D9.:`TQ,<@*\P2C('=TIK&EO\`;$-'HH*M$&D7
ML%U#*VM@DV:+J(I@DZ+[:*IR%$"'.40KSY<!_P!:YXI/Y'R[Z!Z_\QTQ]WJ&
M!;_@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#`_(-UR)8TPDAQO5TJG:F"Z[V
M9_+@TO3NO'@VK51=8D82A/&4F65,<G0HJF%+I\0ZX$9N"VX^9'("J0.V]UM>
M,<7J^U1<P,1$:J8[61OC29BYE[#_`.Z3BWRTA7U(U0[`Q^B1?=`#!Z]>H8%B
M.!C3:^Y-5:*J"U_W'L&J:TI;=_'Q:MEN,RTA(DLG*K@VCV!7+Q1,JKMVJ(]J
M9>INTIC"`%*80#3OU5X9=V0_EA9U*>V12'M(I5J@^9J]V;2DI)V2RZN>;GFG
M%;B!C'42FF6_3<_6U&LD*JIF2"8G<D6<=4TSANMX#`8$0.?OZ&')'\UT_P#Q
M4<#-NCOZ%-/_`!_HNU_\>G_JG$_<P,I8#`__UM_C`@+Y-IFG0'#3:DI?>76Q
M>#-70-6BR')75+"3D[Q1#*V.-3;I1#*'B9J46"?<&*Q5]AN*@)+FZ&(/U@#6
MNX!;Y9J>3#B_0M"^9;FQY-=<7"#V4.U=>7>%O58K6OE8J):+UNXVY:VTV.@9
MNJ'<**-U&R0I/TW!TE$U>PIRB&Z7@,!@,!@5`<N/UKOBC^'^1\NON?\`,=,_
M=P+?\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@=#:?^#%C_WAE_\`S>XP(5>,
M[]"W4'^UN'WO^.]BP)X',!2B8>H@4HFZ%`3&'IZCVE*`F,/3Z`^.!K71^I=P
M^8/F8YO^]:;;=;<!.+5O?1>O-86MHO#26YKY#/!;NY:>B%C%.+%5PV!1V<Q1
M2(V!-FD901<G$+0X@A2>5R[$(4I"$\>VLB%*0H$*0H<B]J`0I2EZ`4I2AZ=,
M"Q'`8#`B!S]_0PY(_FNG_P"*C@9MT;_0II_\UVO_`.:<3^W@92P&!__7W^,"
MA+RCT;R.0[K9FYJ/S;X<Z$X65:F1DI8ZUR'U#)W7[*<Q(.%I>1EW1F$C%2"+
MQQ[/RJ0%,I[@`4I>[IU"M[PR\K=I[WY@QU7C.>G"S9,&PJ\W,6O5FNN(MTX_
M;&O5<:BW1(]J$W:*=54YZ,C'ZZ2JWLJ+E*3H;MZ=!P-P[`8#`8#`J`Y<?K7?
M%'_(^7?]1TS].!;_`(#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z&T_\`!BQ_
M[PR__F]Q@0F\::R3?A1J9PX5(B@@C=%EEE3`1-))*ZV,ZBBAS"!2)ID*(B(^
M@`&!6;.\C>0'DIYWPNI>*-XLNL>)?%"\M);<NX:VNHT_*=:X.1_"U"/=%#V)
M&%>*-3MB(=3)J(&4<*`(&2+@;$Q"]I"%[A/VE*43B(=QA*`!W&$``!,(AZ_#
M`KTBOUKMX_[/G67^D7M3T]<"P[`8#`B!S]_0PY(A]/Y+I_\`BHX&;=&_T*:?
M_-;K_P#FG$!@92P&!__0W^,"E/S+&TCR5T!=.`*G([2^I^3.PV-(VCK"E;>L
M)("$MQZ%>(RR14=.*N$_ESUJP2<#\@ZZ&.8$U3#[9@],"-7'CC;Y">0W,#BC
MO7DIQIXA<5]7<4H^UR;"P\>KNSN=CVS+SD!^+C&OPYH:KP#6(ULJFN=V=LHJ
MLF!TDNT1,7U#9!P&`P&`P*6N4]TJ$OY?_&!4(JT0$E:ZQ&\K7-CK;&68NIR"
M;R.C9HS!>7BT%SO(Y%Z`=4C*D(!_\7K@72X#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`\1LJQ0-4H%PL%GF8VOP<;7)A>0EY=X@PCV:/R"Y>]PZ<'(DF43&``
MZCU$1Z!ZX&O=P:\AD'9F?'#@KIK63K>"]AB;P;?EJ92JD97-:4N:L-D$ZAGB
M;=;[0?+,G11,GW(`!50[#B?TP+VM`\=-.<8*`WUEI"E1U'J"$C(2ZC%F99PY
M?2LHN=R^D9*1>*+OI!XLHIT[U3F$I"@0O0I0``S=@5XQ7ZUZ\_<_U?.LO](O
M:N!8=@,!@0>YKZAY0;THDUJS2%ITM6:7>*G*5R\.=E,;>[GTU7RI/97KHUUJ
MX9D(F@7ZWO\`0>_X!TP,D\7:AR(HFOVE0Y`SNJ)Y[664'`5%YJII9F;4U>A8
M5C&)C.IV5N@J:446:F,(H]4^TP?3@28P&!__T=_C`UW?-#O/QKP]KJ.C^4G#
M:]\R.0MCJ1IK75-U=K.4F[G&P+B059-W2&P(XB9*P49),13]U02%,`F$`^(A
M"3Q$<1_)91N8%?VS`T7<?$#Q\FAY4DQQQY`[Q=[:MT\HZ0*:#5C8>0!TO7"(
M'$#%!)8J210Z=O4<#;]P&`P&`P*2N4&MJ!7_`#'>,O8<)3Z_%7J[1/*AA;K8
MQC6[>=L;*'T=-_9367D$R`N]18=WX(#B/8'PP+M<!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@4^>7R+K/(32#SA95MOUNF\AMFMD;S0:)*R*S-:\1--6</)&(
M=*-RF!JSD2HG*0RO0ASI].@],"$_]GKX0;/T16-D<AM@.X9K%[>BVE<J%?CE
MTGSPK.M3;Q&0EY!P1,`;"J^:G232`>HD+W#\<#9;P&!7C%?K7KQ_V?.LO](O
M:OT?>P+#L!@,!@,!@,#_TM_C`@_SYY/4W@IQXOO,&?U-^4Q76R5>9RR,,X@(
M.SH5F9L4?%23TMEE6;E=**@47QGJS9,%#JE2$J9#',&!Z[3?.OAYOYQ5(K4?
M)C1U[L]QAFLU"4ZL[-J<M;73=RQ1?G3+6T)()TKAHBK^%3.V(JF("!RE$!``
MEE@,!@,!@5`<N?UKGBC_`))RZ_J/F,"W_`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`QON&]R&L-6;`V)%5*;ODG3*G-V./IM<1%Q.V5Y%L%G3>&BD"D4.J\?JI
M@F0I2F,(F]`'`I5\>G%C:FSK%M'R3<R8-]';ZVI#V)CJ;74ZV6(;36L",7!(
MMDFS>`FXCY9T0ZA>PR2:A4_PA@`ZH@4+`/&=^A=J#_:W#^>]B_:P)Y8'\'+A
M%FV<.W!_;;M457"ZG:<_8BB0RBI^Q,IU#]I"B/0H"(_0&!1_#<[.*ZOD?LNT
MD]FN!H$SPTUUK*,LXZ_V<5@[O;/>>P9YS6R$-2RNBO4(>;:KF,9,$@(L'U^H
M"`!>/@,!@1AY+[=V]IBKR%YHFL:I?JI6X%_-VI>;O;NJ2C(&9R]B$8Q0K$VE
M(>ZD;KW&62Z#Z=/IP/8Z,NVT[_4T;-LVA5BA'EV\9*5UE7+BZMX/8:3C6K])
MR_6<U^!^1=E,X$HI%*J'IU[O7`S;@,#_T]_C`JN\T&V-=Z:\>6Z+ALO2--Y$
MPKIW1:I#ZEV&3NHMFNEPND)7*5^-@B)/;@HZRR3=PX,!B&!-(>TP#T'`I8X'
M<?=A\%N=G&>&Y;<"O'5KE_R/;W"(TCMGB)`/(R]ZWO<=7RSRE8G$I)NT!]!2
M$$FX3.]1*J)5DR]5>A@`X;?&`P&`P&!4!RX_6N^*/T_^I\N_ZCIC`M_P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!YRW6RNT2LSURMLNR@:S6(I]-3LQ(KIMF4=&
MQZ!W#ITX75,1,A$DDQ'U'UP*'.%FY^2'D8YN6'E7`6ZX:UX-Z///4/65/07<
MLF.ZIMP@JS>S,TQ-VMWS8GN%<G.8IOEB`BB3H<RI@"^>T@`5>Q@'P"`EP`/0
M```CG`=``.F!"OQG?H7:@_VMP_GO8L">>!P8`,`@(`("'00,'4H@/T"`_$!P
M.E"LUP!`0@(0.@@8.D4P#H8!Z@8!!#T$.F!W>`P&!&SF%Z<8-WC]R@3'I]'\
M%/`REJ7^BO6G^8%._F['8&0<!@?_U-_C`JZ\RVR]#:I\=N_K)R0TO/<@]7OX
MZOU%WJ.L2A*_-VVQ7&QQE<J#1A:3I+C45D+)(ME0E2IJJ1XE]XB9S%`HA1GX
MD^&V^=2\S-;[,V7XG>6.K(9E59^$KN[N3/DEUGR7BM(0DHR05(TJ6JX;6-)F
M4)"031(U]Q519VW)W%$0'N'`W$<!@<"(!\1#_N^G]_`"8`^(@'W.H].OH(^G
M7X^@#^]@.H=>WJ'=T$0#KZB`=`$>GW`$<"H'EQ^M<\4@_P#V3EU^]^0Z9_N8
M%O\`@,!@,!@,!@,!@,!@,!@,!@,!@,".\_R\XFU29EJ[:>4''>M6"!>+1\[!
M3^Z]:P\S"OVR@I.&,M&2-E;/8YX@J`E.DL0ARF#H(`.!G*$G82SPT38ZS,Q5
MAK\['LY>#GH.0:2\-,1,B@1U'RD5)QZSAE(QSYLH51%=$YTU$S`8IA`>N!4M
M9>6^LN<7++;?C9@-2J[AT36-=3<=R?W!'VES$PU0MBYUV["CQ`1R`'DE"/FA
MF+EPF\16+(`L1(ABLUSF"SG4NIM?:-UU5=4ZMK;&IT2F1:,3`0<>4?:;-4NI
MC'65.)EG;MRH85%EE#&454,)C"(CUP.^NCYDPJMA4?/6C),\)+)D4=N$6Q#'
M-'N.A`.L<A1.(_1@0H\9,E'+\-M1LT)!BX=IIV]11J@\;K.$R#=K"(&4125.
MHF40'TZ@&!/_``&`P&`P&!&SF'^B_O#_`#`F/XJ>!E/4W]%FM/7K_P"@%.]>
MG3_B['8&0,!@?__5W^,"E7^T*S$Q">)7E0XBKC&4E!Y#U6(L<K(PQ9MP^J$Q
M;X:/M5?KS12*ET$K;8(1=9I&+J)I)H/54SF70`/=(%,_A\V7XN97E7HJM<>/
M*CY7][;9)55VT!Q^Y&679)M-+E:UU`CV)GX!SJ]C46J=?0)VMT4YA5JD9,"I
M+*E`IC!NA8%<_ED@==V#Q_\`)AKL[;<_IRNL]57Z893U>VL?3KFPVF(H]E?U
M2CO+4@_BWK^,LTZBBFK$H.$U)02%0'O(8Z9PUDVUVX_[SXV>!K3?*+;U5E.&
M<YQNVL?=Q)'<0P-"?[MH.I:RI7:YM"UPUJ8E0M=.;/'3MI'R+M)RV>B)NSW/
MJB%9GXW5G9G&K=LSS0V]98^_<<O$;2MF^+Y[;=OVVJ6-*\N>16]H^J;,U"@%
MEB'-UV=*N:K4(<'R?SL@O&%00ZG2'J`2[VC:G]EW'NO>6W+Q,QOEMU?Y0?&E
MI[CS41V18(;9,5IRST+0YYZB4K4Z,\T:.-8[%8V2V/K"*46LTD5Q64=B(EZ8
M%Z-R;\X4/,-X[S\KYCBA)TA17F!^1U#CU6MO0EL:Q8ZCL0M_RE.MD6FP0[]^
M$(")5!BTVQ/F^X0+[?:`!L5X#`8#`8#`8#`8#`8#`8#`8#`8#`J@Y<:6TZ]Y
MC\"EGNIM9/5;CL'>2MN5=T.JN5;2JEKIBY24L1UHDYIM1-R85"F<BH)3CW!Z
MC@2&Y-SYY[7=_P"'O&#>&H]+<M[/IMX^U!69.1:1\C5*D@\9P+JQQ56@T7,Q
M#QK&)^8;,'C-DK]GN`(X32.5N8`#H_'9P1H?`/C_`!>KH!=O9-@V!9*T[FV6
M9N<DAL"^N4!*[=`NY[GQ*["`H=M%MU#"9)#N5/U<.'!U`GH'[/V_IP,0[ET!
MI3D-7V-5WAK"G;2KL9(%EHZ'N<,VF63*2*F*0/6J3DH^RX]L>WN*("(>@X'@
M].\+^*/'RRN;CI+C_J_6%I=QRD2YGJ=5V,1)JQBQP459&=($!3Y=4X`)BATZ
M_3@2;P/XN%TFJ"SE<W8@W1476/VF-V)(D%10W:0#'-VD*(]``1'`A:W\BW#)
MT^1BV^ZV2LDO\M[;`*;L8'8D=N/E&RQFYJ>55-LLY^H"I@!/N`0Z^@X$UP$!
M#J`]0P.<!@1LYA_HO[P_S`F/O_XJ>!E/4_\`19K3_,"G?3U_XNQWTX&0,!@?
M_];?XP(/^1:::5_B/LZ5>\O5>"K=M^+_`'\F48^"E%*")Y^/3!,K&R+MXE89
M\1^1^N<HA[_4OUNF!KC<*^45Z8>2KBMJBF^::\>2S6>SHC9*=]H%>J-&CV]-
MDX2(:NZ_.VY>NMY)%.JKJ&434/\`-MW)%Q3$I#E[Q*&XS@>%V)J_6FWZTM3-
MLZ[HNT*>X=-7SBJ;$J4!=JTN]8F,=D\6@K+'R<6JZ:',(I*&2$Z8B(E$,#%B
M_#OB.YU^;4SCBSQR<:K//A:CZT6TAK-77YK0`"`60U-/6#5PT^`#T^<%M\QT
M_P`?`]):N-O':]R.O)B[Z$TO<I?41T%-42MJU;1[#(ZQ4;&;';J:\?2T$[<T
ML[<[-$Q!C3-A(9(@AT$I>@??(Z#T7,;4B-Z2^EM32F[:_&C#0.XI'7-/>[3A
M(@4ET!BHC8+F'5ML;&B@Z5)["+LB7:H<.G0P]0K:Y<?K7/%'\/\`).77[XZ.
MF?IZ8%O^`P&`P&`P&`P&`P&`P&`P&`P&`P-?#RX^0+3W%[?/&N5:S3"X;8T:
MWW%;WFMX]4ZKM&2N6O6L/0FL^NB4Z<4SE9<"F5$P^Z1J`G*4>I0$,L>*+A'?
MZNYM'/GE^X5MW,GDFV^VS+3A1<.M1Z[ET6YXFFPZ:XJ!"O7D2BV36;HB!6#!
M%NR+V]BX&"[?`8#`8#`8$+(\1'R(6THCU`.&E!]!ZB`!^6O8GIT^'01,.!-/
M`8'Y,8I"F,<Q2%*`F,8P@4I2A\1$P]```#`I%\L/*^/C=9.]8:1V\R>[%457
M;7W7]:AT;>9Y3'27MR1IIZU;NTZV>/,4#E,HHF)^O3I@3PX"M]S!Q?UQ);UG
MQG+G.13:4:H#&M(S[!JZC1LC7(,R#1)(%%6T<@4YCGZF,*GQP)F8#`__U]_C
M`UA/)ISPOFA/)K4-`VOCCMCF]QJO'$.1LMCXL:VUM3MEHN;FVV$P".V#.05G
M;D!=E$(M`2`3+"FFHH40)W=!P,N>/WF5IRY<C*]0M:^%;?\`PREK=&RC)]NZ
M?XUZTUM7(>/;(%=J1TY9ZLH$L@SD5$BE*D'5,YRAW!Z!@;#^`P&`P&!4!RY_
M6N^*/^2<NOZCIC`M_P`!@,!@,!@,!@,!@,!@,!@,!@,"+O+SEOJ+A?IN<W)M
M^8*RC&`'9U^";&(><N%C41.=A78%F8P&<O71B]3&_@(I@)SB!0$<#3;M_`_D
MEY"N2>K>0NX6T1H.'YU;,M1JM`R"<H]LL%0J97HZ6/,_9RB9.JDA7A!-B"IT
M?=6*"@E32,4<#>KK4$UJ]<@*RQ5<K,:["14$S6>*BN\5:Q#%!@W4=KF]5G)T
M6Y1.8?4QNH_3@=W@,!@,!@,"%<=^L1MP_1_^S.@_UU[$]?OAT#`FF)BE`3&$
M"@4.IA,(`!0#XB(CZ``8$)][\\]':5E"TMF]DMJ;7=G^7BM5ZQ9GM5J=/%.A
M44GJ4?[K:(2.<P?7<G3+TZ],#`9-5<T^8(E>;PM#GBEIIST41U1KF1*ZVI9&
M"P]10N%N*`)5T#)%Z&0;%]THG,!@'T'`R7M3C1I/CMQ'W?$:GHD17%%=>S/V
ME/&2^?M$VL8B8JN9BQO/>E'JRYNIC`*@)B8?0H8$RM3#UU9K3I_Z@4[^;L=@
M9`P&!__0W^,#"ZO'O42V^6?)E2G,#;L8:^>:M:W@3K_:*5&?2K>:<P0)@I\N
M+<\BV*IU$O<`A\<#-&`P&`P&`P*@.7/ZUSQ1_P`DY=?U'3.!;_@,!@,!@,!@
M,!@,!@,!@,!@,")G,?F1J#A1J*6VGM683(<B2C:J5-HH0]@N,\<@@SB(=D`B
MLJ*JPE!13IVIE'J.!%/AY7=J\XM)P6U?(;HG7(/$]D*[)T%2G\(<9.EU<[5N
M,"\G6;D_09DQ@,</=+W'2[!.7KZ8&2.52::/+_QQ(HID322O6]$TTTR@0B:9
M-91Q2$(0H`!2%*'0`#T#I@6+`/4.N!S@,#$VX-CV#65>;SM?UC;-HK'=&1=Q
M%1.Q3>L&B:)EE)%P+]1-+Y8@%Z#T'KUP,4<=^3DKR"*WDVFDMATBH/V#MY&7
M&S'BAB)%5D\58K,D",UCN"N`<('#U*`?5P)88''7T$1]`#K\?O?3@:YMD\C]
MVJ/D"V`BPX^2EXM4736''X:W29Q.;<RC.L;`G[>C;8Q5J15$R,G&V5'ZIQ`J
M`]`.(#U#`FR73/,[E\<KOD+;AXTZ:<F!9'3>L9$RNP)QJ80`C:Y7`@E&/(<@
M""J"`]Q1-Z"(8$Z-*\;M+\>X0D)JFB0];*8H?.RY4"N[#++"`^XYE9QR"D@]
M<+"/4XF/T,/T8&<L"-G,/]%_>'^8$Q_%3P,IZF_HKUI_F!3O[E=CL#(&`P/_
MT=_C`8#`8#`8#`8%'O)K;6LK5YF?&MJVN7NL3>QM=Q'*20O5)C99JZL=393N
MC9HT.ZG8Q(YG$>C)%#JB*@%[_HP+PL!@,!@,!@,!@,!@,!@,!@>'V1'WV5I-
M@C]86*&J=[=,3IURPV"(-.P\8_$0]MP^B2G3%ZB4/B3N#K@402WD/WQQO<[=
MNG)_?^GYNL:;VU,ZI9:IINNDXS8NY9AA'-EVJ51$7ZSAA[CIX0JB@IF(F`>O
MJ/3`EQ!<2-1<^[;QTYV;VH.Q:W8(2DH/(+C_`+!=@I7(.06="ZCIB9@3D(FI
M(D*4JH`8@`H`E$P>G3`M=(0B9"ID*4B92@0A"`!2$(4`*4I"E``*4`#T`/A@
M4@\AJK5K7OZ)N5C\EAM?6C5-QNC[7E,&B5I<U#=S[(L3-0Q#.$16FA:1J)4A
M,?N,'3N'XX%Q>MECN->T==2W?C^=:I5]0]X^31C_`,<#'BFIALOR+8`09C-B
M/S'M$`"D]SH'H&![7`8'46#_`,@S?^]$E_XFM@19X(ATXMZT_P!K9OAU#XVN
M;^C]K`[/>7,C1FAG'V!/67\:-C.NJ41JFB)C:]B2SLW=[+9*MQ(NG[7W#^@G
M6(0"@/4?3`B6:"YP\RSG_&EV]X=Z(>F$OXO19R.=U6J,/U_!R;X0!&L$<I=.
MXA/KEZ^G00P.YX_\<=1<>N<\]4]959*,:L^']4E%91^X7EIV1F9K<ES:3,S(
MRSTRKEQ*2C6);)K*]0$Z:)2_#K@6B=/3I^S[W[V!S@,"-G,/]%_>'^8$Q_%3
MP,IZF_HKUIZ]?^3^F_S=CL#(&`P/_]+?XP&`P&`P&`P&!39RPA(9GY;_`!93
M+2(C6TO*L.6:,G*MV+9&1D$FVCIGY=)Z]33*Y<IH?X@',8"_1@7)X#`8#`8#
M`8#`8#`8#`8'P2DK&0<<\EYF18Q,5'MU'3^2DW:#%@R;(E$ZKAV\=*)-VZ"1
M`$3'.8``,"D[DOY=M26><G>*O#LETWQO^\1<U4(:T:ICOM"HZ\L$DS<L(^?D
M["H46[MG%2!RG661#Y9,@";W_3I@4;>'#@SO6^\[9B\<D-72LS6M&RUK#8,A
MLP1E$T]P]2?)B@1TY6++3R;L1<F7[5$^PQ3]1ZA@;PY2E(4I2`!2%*!2D*`%
M*4I0Z%*4````I0#H`8'Z']G[/V\"K3E3NOCY5^4W%^/LUYH<-(4BU;'<[`:R
M:C1!S"I3=+8A#K3A%&_>))%8WX$QN[O,/IZX%GR+A@BQ0<)*-VT?\NDH@<0*
MU;)MA2*=+H4X)%13!(0Z!T#H'T!TP,<V/>.F*@10]HVSK>O^T`B<DM=JXQ5*
M`?'\"O(E6']PHC@1XL7D<X35DZB+WD)27SI/J'RD`,K8W!S!_BIA"1KY,PB/
M_P`KI@1)Y$>2^MV[5-NB^*S#<\WLD69CP,XQT5-3M45(0!^>:R2\RT*DW:.&
MAC=5@2$Z?0!#`BOP3A?(SR&TVPKC3:45I+C_`/,24:TM+"LQ:6R'B7VFZ7FV
MU85(T2=,_<>.54Q=+G^H/H0H@&!<GQ^X>Z2XYM57-.KGVK=)(/=L>R+4J,_>
M;&_4$#NGLC//P5=%%PXZJ>TF)$B"/U2@&!*7`A7&_K$;=_\`TSH/]=>P\":F
M`P&!"/G-M"(K>FKWKDU<V#8+-?J1,M:^A3J#9K:S,X[TTBHOW\(P=M8Y4Y_X
M)53%$0]>G3`REQEVC!;(UC76\1#76%<T^OUFM3+6Z4R?ISD)-C7X\CD&2,\R
M9G?MB*`)?=2[B=0Z=<"10?O8#`__T]_C`8#`8#`8#`8%0'+C]:YXI/Y)RZ_J
M.F,"W_`8#`8#`8#`8#`8#`XZ_O\`_P`/3`J#Y7^8;2.D;U*:`T54[=RRY2-I
M-]6BZ@U#&/YL(.SL3J-GL5:96-9OU4'L2Z*`.FS5%=1'H8BQT#`(@'[K&@>0
MGD8XARM)\BU7<Z`G+!M$MH@J;INRO(>:;:]CTXI["P-V4.[E43/5WIW:#A#W
M5!]@J9C"5;J!0DE5>+^F.$.A[.QXMU/3.GI>+AQ60NNSBG)`KR"10*63V#:3
MRD7,O$![A[E#OD^@CT`>GI@1,X<N]TTS==S++<D^"M]A-Z[0E-CVZM:XLSA]
M?!D'\<DV/'4AH38,F15)(&I3?A6[DW3K^X%O]ALM<J$.\L-KGH:M0,<D*TA-
MS\FRAXEDD4!ZJ.Y%^LW:-R>GQ.<,"OFS>1*"M[QY6.(6K+QRJLZ"IF:UBIT>
MXCM1PKH?0AYK8KY`D4=,A_X1$1$3E#ZAQP*VM[\)-V<A>3O'^X<J[+2Z7-;B
ME)ROK5S3T8!7U5A:+!DL,>FO9I0JPS$W[CDB/OJHG]HJ8`41``Z!8NU\6FBW
MJH+W_8&^]G*CT]W\;=N6OVEOCU!1"*>QZ(E$1^`%`,#)]9\;_"RK*E7;:'J,
MNN40-[]I3<VE83!_C&4G%WIA$>GJ/TX$AZSH72E,`H535-`@.SIV_9=6AVO3
MH'0.@IM`Z8'M9>,C6<!-E:1[%J7[(DO1LT;H!_D2WT))D#`C+P0(4.+6M/JE
M#J6RCZ!T#_A7->H@'IU],"7^!_-55)%-1590B221#JJJJG*FFFFF43'44.80
M*0A"@(B(B```=<"L^,Y#Z`-SXLMB)O+3QX%YQ+HE?:S9-F4HT0YGB;COKP\(
MA)A-_)K2Y&KE)46Q3BL"2I#]O:8!P+-,!@,#@2E'U$`']L.N!P!0#KV@!>OW
M``/W\#]?#`8'_]3?XP&`P&`P&`P&!4!RX_6N>*3^1\NOW_R'S'][`M_P&`P&
M`P&`P&`P&!KS^9+RV[NX';)UCJ+1=)HSR7L]5+?+%;=BQDQ,QZD<,R^B6U>@
M8N+FX`H'.:/.9TZ.LH).\I"$*)1,8.BX(NO)1Y'+KIWFGN7?S#CWQBJMF):*
M3H;2!)!@.V1@GBL<]C[Y\Z\6<KTV;[5TUQDG4@99(1!NT;]Y'!`ONJFG]3T2
MTW.\TK6E#J5TV-(_:U^MM<J<'"V2YR0E1*+VSS<>Q;R4VN<R!3"+A13N4ZG'
MZYC&$,CX$2>4/)3CAJ>D6:`VUMS6=7EI6&>M(^NV9".NLDX?+ME/D/>UPBG(
MR<XW%QV]4C-A34#T$0ZX%!'!:S<Z-H7W8<WHK4G'(K8]KD',WL^YZFBJ9#TF
MP2;<B3=]6F[4C:V-0*P3*NC$MD!(3O\`PW3J.!;Q7?'#&WV897CFCN"[\K+@
MV6!ZUJTTX5J>E*\Y$0/[,'K:#719.443^@'=',"I0^NEUZX%CD!78"J1#*`K
M$)$UR"C42MX^&@XYG$Q3!N0``J+2/8HH-6Z0!]!"`&!7;O>4Y+V'?&G[=5.(
M]SL-8T=:KXZ++I[6TI&!>&%B@T(-@]A6,G=&[^-)WH^Z)'I$5`(;H)>[J&!8
MA6I&3EZ_"2LU`.ZI,2,4P>RE8?/8V2>UY^Y:I+.X9W(0SI]$O7,<N<R1U6RR
MJ"@E[B&,40$0[O`8&'=V[1BM64]:3E*OL>UEEP=0S9AK37UGV)+IN7+14J:S
MR,J[!^Z9L@$P`*R@%3`?3KUP(L\!=EE4U94]0R^MMV4RUUJ/G'TDYOVG[S3*
MT)'=ADGJ"#2S3D2UAW;P[9T0WLE5]SXAT]!P+",#\*)D5(=-0A%$U"&(HFH4
M#D.0X=#$.4P"4Q#!Z"`AT'`Q230>BTS$,GI?4R9DE2KI&)KFGD,FL00$BI!+
M#]2*D$`Z&#H("&!ED`Z8#`8#`8#`8'__U=_C`8#`8#`8#`\F\OE(C[.PI3^W
M5ME<)5`SF,J[J;CD)]^@4.HK-(E1R5\NGT#T$I!Z]/3`JLY<?K7/%)U_\#Y=
M??\`4='3'WL"W_`8#`8#`8#`8#`8%>7-V`\=-X=TVK\XXC44Q)1R"TY2D=BJ
M'CY5NS5<"W=C%RC-U'R)HU=PAVK-_>%NH8OUR#@>V+R\X3Z2U53W$'LS6M7U
MPC$-8^A5NFBU4*>&9E,U9LZS58))1VHU1(AV$(BA]`?=P,6EYQ[>V^W%'B9Q
M)V5=DW('39[%W6LVTYK-,P"'8]0.Y^U['.M1((#[9$&:I@'T'X=0Z,W%/FEO
MPYW/*+EHOKBK.C_A=0\2F3BFQYV2A0$[*5V=/HJV]\80$2'*5(4Q`/JFP,NU
M#@IHK0-;EICC[IS6+W<!&@JQ%YW4I.7!^^F`.!P>SUM>)SME8E4/]8YH\B0@
M/P*`8'1\=M=<MZ!L2[RES>\8)*H[.O\`(7RZ$I4]LYU:(A=ZR0:BQK;>7@FL
M8LD0S<H]72A1Z"/WL"P3`X$.N!\RCUDBH"2SILDMZ`":JZ1%!Z_#H4YP,/7`
M^D``/A^SZ?\`9P.<!@?A11-(@G5.1-,O\(ZA@(0/H^L8P@`!@?S1<MG'7Y=P
MBN`?'V54U0+][ZAC=,#^^`P.H+/P1W(,B3,29X+@[4&A9%F9R+D@]#MP0!85
M!7)]).G<'W,#M\!@,#QMTV)1-<L6TG?KA7:;'/'(,FCZR2S*':N78E[P;(+O
M544U5Q+Z]I1$>F!]=2NE1OL.G8*3982UP2JZS9.7K\DUE8X[AL8"N$2NV:JJ
M)E43#T,4!ZE'XX'I\!@?_];?XP&`P&`P&`P-$SE:VKTMS#YH-YY%VMY,B>9W
M@X7B")U)8NSV_&%JVU.I%&H!2'$&^GTJ6K8SSAFY?D!56.+SJH8F!9EROTGY
M+UO)?P-%'E7I!:8DY#E2YU18T^-]A-#:XA#ZQG'+N,N+0FQ%RV-](UWHQ06*
MNR`CG\+VF#ZF!8=^0'S$?^WKQ>_]TVQ__J_@8HW7K7SCT'7TG9M8\JN-&V[>
MT?PK9G2&G&2;A'#]K(2S1C)/"2#K;9T4RQ+!=1R8HAU.5(0#U'`RFAH/S&'1
M2.MSQXO)+'23,HD'$^QG!)4Q`%1/N#;_`$.!#"(=?IZ8!;0?F,(BJ=+GEQ>5
M6(DH9-(>)UC*"BA2&$A.[\KX]O>8`#KT],#%6CM;><C86KZO;MH\J>-&H+Q,
M-EUYO7CSC)-SKFO*D=+)(MUY1IMTB#@ZS8A%![0#M[^GT8&6OR`^8CI^GKQ>
MZ]!_Z)EC_?\`Z8/B&!AW76NO.;:+QN6OW'E%QIHM7HEMAX76]O<<9IN11VK`
M/JS'RTE9F3%';I5H9"*FG2L>*2HF,<Z`G#T'`S$.@O,.'_3UXO\`3T_Z)MDZ
M^O[6W_CUP,-S.N_.@QWC3M?1O)_C3*:LG:389^Q[@+QHF$6=5L\6[20AZBM`
MFVZ+UZM.MSF5*N4P$3`O00P,Q_D!\Q'_`+>O%[]SB;9/[O\`RO\`I@5/^0_C
M#S<<W'7%GY/[QI>Z8U!G'TRJO=9:;G-<0D9-VVSD:-H>5.]L]M1E)Z:6*5-D
M0BB1^XW:)1Z@.!/GB?XZ]AT:D5JZU=_K*FVN6C4%GI-A:M6M%T@7)3%$[`7T
M\<X,3ME4^A3-DD0Z?`>GQ";4_JSG/&5^<DXGD34YB6CH:3>Q5>9:\;-1EI!D
MP76CX=NY<N@3;&D729$0.?ZI!/U'T#`\IJ.@\^[[JS7%VV!O",U1>;91JM8[
M=K)U0HB8?:_LDW#,Y*:ILA*H+E;2#ZMR#E1FJLD`)J'1$Q?0<#O[GHWF,XJ-
MG24Y1I2ON04DD6)B-<,FKZ3%1HJ0635VW=?-M7+CKVD42^N4P@(>H8%;W#KB
M)RXIFSD'Z4SM73QTZ2M!!9[D[L%ZAG*22I%P:/HN?EW#%>56/UZ/E2_,"`=O
M=]&!:1^0[F"4.I.6[,Q@`>A5-7PW8(C_`/&,5UW=/VL##HTWR'AO0VNAVZR'
M5@:U:VTNYPID#\A^.JUADHMQKTU?%8'X.FT0S1?_`#744C$<`3IU#`KLY2\2
MN7%IW;;IEPYW/LQ:19T]JI>*2[N=2KY@@&S-=N6$A862181:K-8GMNE6Q>Y[
MV#[@F[NF!8AM>M^1.EDU6KK[9D5M(EVVY1Z1=08TN)@E-:ZZL9)-2R;5DR2C
MDAY)C3P:(`JQ2#YE8SD`*'U1P,Q#I_FP3U3Y04]0P?`JVM4P(/Q#J;VW/<'[
MF!C+<\7S=U!J;8^TU-^4ZR)Z]IE@MYX"/UV=-_,E@8UQ(C'-#BNH!'#OV.P@
M]!Z"/P'`B_L&N<R>1_!RH[%E=E/I&+W7K37%\5UQ1*W.5K8D82Y1$39TX5M8
MH)9)^T<Q?S@(N%"@0IP(8!Z=<#S/!;CYR[K,CL]>"NUSU0I.J03MVWVY'VFW
MLI$6;86:8UE"==F;PQ4R%ZKD1'\,<>\0^G`F#JBL>1.\P]C?7K9E8U8^BK[=
MJQ%1<E36DLXGZQ7+"^B:[>&JK%V9)NRN$6V3?H('_"))K`4_U@'`RB.G>:OT
M\I*J(?FS;_#_`.\_?P*3:GP1Y#,.3,1=VU3V=#S:/(^R[22VTY;VI>#;6BSS
M$@S?W5>"6<"W/6';5T#A.*4)\JV(8.A0[1'`N<6T/S96#TY?1R'0HE#V-=1)
M.O7_`!A]QNJ/<`8&!-I:@\BM9L6I(FG<@)Z_P]VOQ*U?9^*@:E$):OJQX:3D
M#W>3;/8H59ABG(LD6GRZ'X7O<@;U`!P/;R/$7FF])T)SFM"(BH*GX*N0#;H(
MCU[0$E>5'L^]]S`@+S3\>7(>Z0=!#9.Q[]RO:PMM&?BJ>,01>-@9-LT$B<R[
M080;--8ABF]L$U#]H_<P/NX5\+O)3IW4<G3]&\AM2\>M=J7^V6")UEM+CC/V
MRU1"\\Y;O'K@\\A?JPW=,':QA%`I&W1,H=O<(]>@2\'07F)^CGIQ>^]__$VR
M?W>NX.N!G'QD;JWAOOB?&7?D6[@)/;$/N3DMJV?F:Q6'U.@YYGI?D-LS4T#/
ML:[(R,JZ8)S4)36[D0%=0IC*"(#T'`__U]_C`8#`8#`8#`\JXHM)=VQE?75/
MJSF\QD>K$QMS<5^)6M<?%K^[[\:QL2K,TNT8+>^?O136*F;O-U*/4<"HSE9Y
MB]7\9MXW_7*N@]E[0I_'I;5R'([==55@4ZWHMSN>1-%5%L^82/\`NQ-.G+4P
MN7)&8E]IKU$P_1@7*LW;9^T;/F:Q'#1XW1=-5TQ[DUV[A,JJ*R9O@8BB9P$!
M^D!P/HZ?3].`P&`P&`P&`P&!4SKSRRZ.V->^<M-M>KMEZU@N!U$K^U+Y9-DP
MC2._&JK2\98IR-FJQ6U14DD"JMZT8[,RW0SCWDC$Z=V!W'!?R>PW,S:%AU!-
M\?\`9O'N\-]-57D31H[8C^$DR[$TE<)DL!$76*5A1$(Y1*4711<,U_PR)EB@
M(C@6G8`/V?L^[@,!^[@/A@,#CI\/O8'/3`8%27)/RF)<8N3VL-"[3XH;I::H
MW!MNIZ*JG),5JZ?7DQL&Z1@2+&,CZ\*BEBDXUNGWIN'!2%(0Z9PZ"!1P/-:<
M\QFI]J\H('CNPTKLFKZ]NNTMH:(U!OZ34A@U]L;:6E@*C=ZG"P[4?M:.08*D
M.DV<*_@7'LF[0`.F!<B(=?\`NC@<X'`@(_3_`'_\/W<!TP.<!@,!@,"LOR)^
M1=YX^*TVOLOQMV/N#6T;`DLM]O52LE2@(ZGQPSS:!^4096!P21M,_P![HB_R
M3),RGL&*/7J8`P(W;B\W6G=+['M%;8:#VG:-+Z>=\8VG)??$+]AQ51T)-\P$
MH29UHQGZ\Z[9F==`TN$<YES-0`6:CX"J=3@;`__0W^,!@,!@,!@,!@:T_,SQ
M8\P=L;]YDPFGI#4Y^.?D1E>.TQN:ZVV7D&E\U`MI%0K"5;UBM-TC-[0C9H`O
M8D(G(*"X]1],#9$A(IK`PT1!LN[Y*&BV$4S[Q[C_`"L<U19H=X_2;VD0ZC]W
M`[3`8#`8#`8#`8#`UJ)+Q\<^]T<FO)7:=M4[1E&U+Y`N/T'HX9VL[`E9ZQT$
MVK:=-UC7MA3AE&J82!;&YDDW$BB)@^6*02I]>N!(OQL\)>7FL.1*O(GEVVU5
M79;7O#BA<)]95_5\Z^L2=BJM3N;.[36Q;`[=I)%C'D](Q;8B+$H&%`@&[A^&
M!>9@,!@,!@,!@,`/W@Z_>P-?3D=Q0\B^V/)14^0DOKK06X^,>E',8AQTI%MV
M3-5D^O9F68LVMPW%)UMDU50L>Q&*;EVA%`N/M-4RE,7ZQAP,8\9/%#RNUSRA
MTRPV1+ZN'BQQ6Y1\BN4NH[=`RL@YV5>YG>B[AU'5&QU]9,&D,VJ1I!<JS@#F
M^:'M$H!@;+.`P&`P&`P&`P&!1KYE^$_(GG+5(/5.J=(Z&O\`!N*R[;0VUME;
M"M51N>C+V^FFRREQKD%$'^R+8V;1\:T6307(<PKI"7H!1P(.;@\.G-RSRW(S
M0,/<=4V_CGSQ>^/RS\DMTV.4?QVT*-9.(E7UG!;.&KU)%$6EC<;=D-6H/&JH
MF33CQ?G*(#VX'__1W^,!@,!@,!@,!@,#CH'[/W?3^[@<X#`8#`8#`8#`8#`8
M''7]O][]K_#@`'K]SI^WZ_X,#G`8#K^W^\.`P&`P&`P&`P&`P&`P&`P&`P&`
MP/_2W^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6AX1^5/G#SUY<[5@]6,N'%
M+T;H_E;9]"7_`(\[&L=MB>7GY+:7-H1=EW+&QP/?D74B@@=55!H1G\D"K55!
M8Z9BE,H&>>+OGPXS<@-X\T]4SL+;*'!<6)>R/J_<'-0NZZ5TUU0ZDI.7VTV!
MLYKS4*7)Q$FP=(MHYV8CAZB!#)E$1]0GPP\DG$.10XG.6^RE0;\V&[]UQZ66
MK\RBG;$(QD=\^.].HU`L$5NBF("+KL#K][UP*:>9GGZU<\V[QHU%P:V^E-V&
M8Y;Q^I]R*2>KY%]`6ZA1ZR\?:0UW9IZ%5AYHC*5;G1.YCE@<=P![?4I@,(6V
MI^5?A&KH1MR33VNH?5[S<Y./J#H*W.#8!VT:R?BF-1-6`9_;1799GZACBE[8
M$^OU[?7`PMY@^=F^.#VI>/$SQRK.M;)L;?W)K6W'^,+M="P'JT4.P_G&C*4=
MIU]_'2*?R\B5$5!ZG[$N_H03=,#!FC?)QROU!S0KW!OR;ZETOK^T[1U;9ML:
M3W=Q_F[5*:YMD12F[Q_;(2>B+3\U,QLU%QD<Y7$4Q`H$;"`$/WD,(9^H'G#\
M>^Q[%9:Q#;`V#%2<+JC8V[:_^-^G-CU%':.L]3UB1NE\LFIQGX!BO>4H.JQ+
MA\*39,%E6Z1C)D-TZ8$DH#R,<2;5'\.I.M;+">:\\4I9QQH&*A)=ZK=4*_&1
M\I8UWB*+0RD`A74Y1%)\9V"0-G!A3/T$IN@3BP&`P&`P&`P&`P&`P&`P/__3
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M$#S-(\;'E<6H?`+BG8^$NG:SK;@%RL9W"3Y)1N_];/K#O&C$GW@)72N40JC6
M8@D"Q1BNI!&3=A)+F.5-)IWE-@?VKO"27DO[0A9.)%=L$1-<-Z3?V/D>M>M8
MX#.V%1V?-P!HN+KDX=,YG#%*1G^YTDW,?M,X_"#T^&!=7YS>+'*/DYI[BTZX
MFZEC=U[`T)S"U-OV3H,CL6GZO),U[7JC^4<M$[3=I"/B&9GKPB3<Q@%99,%>
M\J*@%$,")R'#GRG<V>7[+G7R1U?I3A+9>-'&K<FN>&.EXW:\1R$EAWKL2HV"
M+@]F;:MM?@1IKFJQ$M+$]UB@W4%9N4I#-Q[#G7"'?#?QV^4:U<Y/&QO3F/H?
M:18CC7"\FZ9RBV1NWF'I[=\1=Y#;NE;9322NHM-4E1A&ZWU++2+INP3C&"2[
MQ8CPI7;<B#+YQP#P6<6;1!^3?E[JBP6YGL;CAX?;'M_0O#M=LX(];4Y]RIV;
M:-A62$6D"!_NE:*G5(M2,ETSB<T>].5+NZ%*(AN;!\/N_L^_@<X#`8#`8#`8
M#`8#`8#`_]3?XP&`P&`P&`P&`P&`P&`P&`P&`P&`P&!P/P_=#^^&!^2_PC?M
M!_&4P/W@?D?@?]W^*&!P'\+]P?XPX%!?!_\`78>5#_,+2?\`W^!?K]/_`,[_
M`+S`Y#X?NC_?'`YP*"/!5_Y?\M?_`&KO)O\`\:B,"_?`8#`8#`8#`8#`8#`8
$#`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g662896g37d02_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g37d02_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG,S=D,#)?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`+$`E@,!$0`"$0$#$0'_
MQ`""``$``P`#`0$!`0``````````!P@)!`4&"@,+`@$!````````````````
M`````!````<``@`#`PH%`@0$!P```0(#!`4&!P`($1()$Q0Y(2(5=G>7MUBY
M"C$6UQ@:UA=!(S,U,B0F-G)C=+2U-QD1`0````````````````````#_V@`,
M`P$``A$#$0`_`+Y>B;Z)WI=]K/2[ZG=@.P/4ZM:-L&C5N_/KI=7]]UZ'=SKN
M&U_0ZS&K+1M:T*%@VHM8.%:MP!NU2*8J0&,`G$QA#5#_`!R?18_(O3_O0WO^
MJW`?XY/HL?D7I_WH;W_5;@/\<GT6/R+T_P"]#>_ZK<!_CD^BQ^1>G_>AO?\`
M5;@/\<GT6/R+T_[T-[_JMP'^.3Z+'Y%Z?]Z&]_U6X#_')]%C\B]/^]#>_P"J
MW`XQ_P!NMZ)B;M!@ITBHR;YTDNNU9'U?=B.W*#442NED&YM9!99)L9PF"AB@
M($$Y?'P\P>(<G_')]%C\B]/^]#>_ZK<!_CD^BQ^1>G_>AO?]5N`_QR?18_(O
M3_O0WO\`JMP'^.3Z+'Y%Z?\`>AO?]5N`_P`<GT6/R+T_[T-[_JMP'^.3Z+'Y
M%Z?]Z&]_U6X#_')]%C\B]/\`O0WO^JW`?XY/HL?D7I_WH;W_`%6X#_')]%C\
MB]/^]#>_ZK<#.3M?Z'/I69UW@]*[):7U%K$%GG8;8.T59V2MHW_8G2%W@L_Z
M=:[IU/CWCU_HKN4C4X2]UEC($,Q7:J*'0!-0QT3'3,&C7[<?X*_1?ZH:C^/N
MK\#;?@.`X#@.`X&:7??L7V`Z;V7'.SD>UB[MT@J[U[3^Z5-CJLL\TK+:K:WT
M>WKG:>K33%1P_F*;D4@7RVZ$(U.H$`Z6D4?,9H<"!BUU_P!=TY+*/2^W&LS;
M/39[0[YZRW7]'<G\*TU:_F0EY3LGJ6%N*UJ$LSGYV,K<G8,*CDBE;J@RDD@9
MHF(9)-%+@>ZIW?;L%T]R7TJ-,[>]F]*F:SV0P/L;VF[36G8\UI]8:O+Q!]8\
MZELPZJ5-G7<Z@W=%<(7B<=2L?&F`M@DW<<\*HX534%LD%SNJ_J5=D[I9.@&)
M:MA=.L>A=GNI&;]B-&TYAH3'+H@]BMJY7NB4;%Z!+Q%CBKY:.O%4E8F:ND&X
ML\7/-X651=Q[)^!5"`&Y7`<!P'`<!P'`R-[R_$F]$?[?NZGZ?N]<".OVX_P5
M^B_U0U'\?=7X&V_`<!P'`<!P.#*1D;-QDC#3,>REH>78NXR5BI)JB^CY*-?M
MU&CZ/?LG)%&[MD\:JF3524*8BA#"4P"`B'`B&NL,/ZV8BT99O5J7G&)9O5WD
MA7ZGF%>AX6J0U>;J*OW*=8KE;;M(Q,CEX\,H)4$R^U<+B8PB<XB(<&F;_CNI
M15%3:S4?[WJ+>P!6Z?/)M#SKU&$)(MYM&0B$5)!%H0C9HL!O:G!-4AO(43";
MR\"-ZGU+Z:?W)SW9RF930B=BJJXDZW.7:$5DDEX"<L%1@(2;>C66\B6G1]VF
MZ*SCHU[,I1Y9=S%HILEG)D4_9`%PN`X#@.`X#@.!D;WE^)-Z(_V_=U/T_=ZX
M$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.`X#@9<]ZNRUXSC0,\S^A,K-!2<65KH:U
MR(\*SJLM[(LRV&H23%PT*TGFIV;-119(71#`HHD0J1S&*8H9+:;VWM&1X]9)
M2P*2$Q2*T6^/35F.(JLNY1U--"'DZZW.NJ9-K#%E'";M`RH^1DX\RWC_`,!#
MP6&Z4<'-&[`YNO+0$P\8I3L$>8C4B.V*CE!9BN1]&/T5D7!3(F42\!]HW53-
M[1,1*8H\"SG2^N=I'W=6$U2&[1Q4%A<JM,?[J8=+IS,K*6\S2IR$E*6Q^T&,
M&N1Q'%@=-Q3L#J1;NT%_%JFDJ0XD,'TC,GS*3:-W\<\:R#%VD59J]9.$G31R
MB?Y2+-W*!U$5DCA_`Q1$!X'*X#@.`X#@.!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_
M@K]%_JAJ/X^ZOP-M^`X#@.`X%4^VMGWNK4F$=X%%/Y2<<S2K>?\`HNM-[-),
MH4(]=4CMFU<G5(10'J9$Q\&SDQ@/\@%\OB(8!]GM2[&ZI"64DA8!5U*$@WD9
M5(ZTL/H6%A9PH`4QW%=009Q\=+JI>)16.W*)E")>W\R9/#@0-CL=I3#-*XPV
M22CIV_`V<_3SEHFU41,FLY548LWRC5%)@_D&C(Q$W"R29455"B(>;Y3F#]-5
MUZAXK76=HT"2=1<.]E6\&T.QC74FNH]6;N')4R-&9#'(@@S:**'-\@%(3P#Q
M$0`0_/5$]&LF6S">)61A"6^;90SV!E9#R!&O(U1RT?K(J`Z:/6I#OHTP@B==
M!0B9S`(@4?G%#Z#/3>TS;+;AU:JVVP$H[GZE7H=BCH[>)2C:I9"MF+5LYCV"
MAR1QGBT:Z*<B"K5I[N=H4GF,4Y?`P:*\!P'`<!P'`R-[R_$F]$?[?NZGZ?N]
M<".OVX_P5^B_U0U'\?=7X&V_`<!P'`<"B_>/8OY"SQQ7ZSJL/2;Q(MS+JUA6
M-&1G+75WY',6^9QKHC5V-:4$RACIOC`D'F1$A54S"!@#YJLRJ&P5RZZ?):)I
MA+[5;#)MWU"C54U4I"M-%'3]TNV=(F:))(E!LY10+Y%EP5!`%/$HF$.!+<@V
M?N#-/<GWN1$UO.Z\">8ZJ0>40*0?`0_X"`@/@`^/\?DX'!LE2JMQ:MF%MK<'
M9F+-ZE)-&4]&-)5JV?HD.1%XB@\253(X335,4#`'CY3"'\!X'?@4H%`H%*4I
M2@4I2@`%*4`\I2E*``4I2E#P``^0`X&B_0O4]MD-2/67^D,['2&5=+&0^8VB
MR*LY4[)H1(R$A2P<P,BBO_++-%3V[07K7VB!RB'S$@\H;=<!P'`<!P'`R-[R
M_$F]$?[?NZGZ?N]<".OVX_P5^B_U0U'\?=7X&V_`<!P'`AS=]]ROK9GKW3=>
MLO\`+M:0D8V"C4&D=)S]DM5IG%Q:U^FTJJ0320L5OM\^Z`2-(Z/;+N50*<_E
M!)-0Y`S\)ZD_4VXV.M&W_$=7Q*#1?`A5M7[&9K0QS>$D),R3=`E@MU2NVBI9
M.$B?RE!U:$X-D50"D47(L)2<"COJ?V#?-'73M/6N(IJ]?AWD'#US0'U2<1E.
MD8&1157>NFMOEXY!A=G"YTFXLSLQ78%:"8S7VOB98X5;:LI)W76+&?<ME9H\
M2P2F7D40Z#)67(V0&0<L$5!]HFR5?$.9,AOE]F(`/`\]>&MZ:9W/M<R7C#WY
MM#&+55;`0BD:K)IJI']F[*J;V`>V;@H1,5!]F502"?YH#P.[Q6,ODQ4:"EKS
MN%KUMD%F,5=IXJ/FJ\)*OGCHR2KL\&F[0(@C&D*HJ#<%/FIJ&*`@4W@%^.I'
MI_\`='K)M.C;%/7G-^P->5EE9;*:<IH]RIX-(63%^LX/%69*M2+2.D!C9`&!
M8IW'.X9\@0JHNVIP*/`O)H'J#-\PND7F=XP#3*KI-O@,U?9E3)R<H8O='L-V
MW:+PNS5RO25<L-EACESAS9(FPR#H'"@'KL@#@$B'152`(_AO5UZRR%;I%LD7
M4I#UV1;1!]'LB]=TL]3I4G.]:I;L[%5NI6-;,F;/5+0XI#5EXQS(K-XF$FW\
MZ8.546:H2]4/4LZHW71*)E,58M`:WN]SG\IIPTWC^GPQ*9=36;3Z8WI&F2C^
MK)1&=VY]:\=L+!LRE5VZCI9D`I>=-9$Z@1E:?5)S:&OG>G.*SFMJOUHZ291)
M:LX90%JS]H;7V%*C4'.PQ=2":L,>:NN<=E92/8RYY8&_O"[OP8D=')[,X:1T
M^QH7"I5:VM6RS-M::Y"6-NT<&(==JA-QC632;+&)\PRR";H"F$/D$0'PX'HN
M!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.!C!ZI2;B*VS
MI-;[+YDLW;NMXI,;*NA$D%";S>H*AI9D:2<*&!FSF;+1H6XP\.LIY#&=/CLT
MS"L]33.%9%4B*)KMG")%45TEFKILX2(JBN@L0R3AJZ;JE,FL@LF82*)G*)3%
M$0,`@(AP*[*Y%:,[EZK.8C,@[I50ET9<W570K)/A@DF@:7:RTTTS)=L27D.O
M<[.@W.D8\2T?5I05A%>&$P^W(&;?:WNFZ@-TG63R@Z%B![';9.1BLOM#^(K2
MM8@7<HU,W?Q,Y%R$E5='AW;ETJ*+V*D%V*:)2H*"BH42<"96/<SK%7:%#2=W
M[$T64NBCJZ14E3:%%VG1;<S<U9(BL&M,1M#@9=FP)<14!NW<'51;@NF8YQ(0
M1\@2)9?68Z2UIK*(Y#TYWG1(^[5&$C;I1]+ME3RO.V]HB#-7K&PUF=+.Z!J,
M:[8/1=I^T^CD_:HN3>4J8"8I@OGT&_<`9KMNI9YUOV["!ZYNKH]A\^R2ZU_1
MU-/SI]9%B)1E2HEK>2E1I%EJ4Q83IILHUX=L^8/'YTVZJ[=55(%0WUN^&Y'I
M-\R?4+W0*[:=`PR2M4OD5KEFAEY:@R=XKQZI;'D`J"A2-UINOG]W6$Q3AX%(
M8OE.0ABA#@="^G?\D$S8>ON?J45-XM(IUA5B\6BR/U\9;]>3O2)*O3F*[)C#
M1*`34`WG2:)$,02K%!4`[BH=+.KE#<P+^K8W6HZ4KDG7)V-FEG$W*SZD_4[/
MHEU@K%+S\Q*OYFQ6-M;=9LDBK(2"[IZ[=R[A1PJJ82B4.HL'0[J%9VLZVEL'
MI@*6F.UN(M,G%?2]?L-GBMXLK2W[#&62S5^4C+%/Q^A6%BBXD47;I9-4"`F`
M%2\2"%D:53:[G=0K-#J#%6,JM/@XVMUR-6D9274CH2':),8QC])33V1E7A6C
M1$B93KKJJ>4H>)AX'I^!D;WE^)-Z(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP
M-M^`X#@.!B?ZG7JN=(^M:EFZJ[#F4WVLNUDK#-?0,)K,%5)>LP,#-IHR5>3U
M*PWF5B:K7WLPDFF^CV:(OIA-,B3TK9-,S=<X?,%5?5*EZ/I4@2#Q.T$ZO.@;
M$@LULVRGU[<<R#VJH.@JFD3]9J:5UJ39N*8-H&?=OY1L!#$1G%$_9-RALWC&
M[9-V$J7\ZY!=(VWPR*I&LNU1!>/L56DCD`XPUQJ\BFVG:M,)@/\`T'B"?M`#
MS)"H00.(?OL>(Y+V"I3K/=GH4!H-3<*>\HL)QKYG</(E#_DS5;F&YD)>M3K4
MP`9)XQ707*(`'F$OB40PB['^FIKF*)OK/BAYG=,I:E4<*UM)LV':Z4P3`3F*
M,3'(M([58AFD'_6C46TV4A?G,G9O,J(9RL7S230,Y8+D<HIJK-UA(!RJ-G38
MXINF;UNJ5-PQ?-%2B19!8B:R)P$IRE,`AP)VZJ]?+=W+[$9AUYR^&/<9"P7N
MEO=!=1R)I.$SK,X6UQ$M=[K>WS4%FE>BH^"8+IM"NCIJR$DH@U;%465`H!_0
M1QB*ENM'99UUA9SD_.83JF76+8\`C[5.R=EELGG,VLM3K&OY%%V"==R,](YZ
MY;Z-7YNMM';A8\,)I1D@<L>FP;-0OWP'`<!P'`R-[R_$F]$?[?NZGZ?N]<".
MOVX_P5^B_P!4-1_'W5^!MOP'`<!P/YL'J7T2]YKZBG<BNZ6RD&5EMNX7+6:V
MYD@5_P#5F6Z`\))9U98%RKXEE(.,K::$$8R(G38O(A5F;R'1\O`HD_FX6*43
M1DY>+CUUA`J+=Z_:MG*YC#X%(@V55*NN<P_(!2%,(C_`.!:3K_UV[O7.UQ&C
M=4,%[3+V]N5-K%:7GV9V.LP#EF8Q5`BYNW:`PK>96JL+^/BHQDW+MB<H^8"%
M-X'`/HJJKKNIB68P]J]0CK8.,LC*&:O]DSRP5[0\WBTB>Q(UE=DA:-,VQYA?
MTB97Y[Y1S*5=%3Q!>18B9-$0G56:AF\*>SK34.A6D8KZ?4LRLJP2KJ4$"`._
MIP\\=R6*)#>Z_P#-][%;V'L_G>?R_+P,^+UU0ANY-TB-[Z_=7,XM4_6GR<G'
M[SOI$*EU]W!=LBHW3AK#DS^I6:;[)TM1$13+8%(N)31'RJ1,V<2>(!O[Z;>^
M5B;+=.LUMZGY[TF[(95`5NW73),F9U53&M(H\XL\A(?9L+MM5A:ZC;J$YG8U
MS'O&[]BTFJ_(`5H^2_YK=PY"4L]M4?V9[DK:S0UT)O$NK>:Z/B\/H#$_MX#1
M-TU:U4*0TN/I<FB8[*Q0.-UW*F,7(2#<QVAIZ;=L$SF<1;PB8:`\!P'`<!P,
MC>\OQ)O1'^W[NI^G[O7`CK]N/\%?HO\`5#4?Q]U?@;;\!P'`<#YZ_4^V7+-X
MTV1ZT,>KO7#>9#$5(H;]KW96IR=PKN<VVUPD=9D,VS"#J$I5+K-6P]6DH^1G
MG"5BA(V/1>-$#B]<G50:A7GKKN[CJJ*/\F^GET(>D:^`)S^!L'O7J^F*`^/M
M%`N=.UL95S\H^`NK4CXB/_4#Y1X&EE5]83$U!00UG$.S>-J^7_SLJOFK38:F
MV,`@!CDF<`G]0E?="A\OM',:U$`_B4.!(,QZI?5FW1;F"ZW2SOMKK#OVS`,7
MR]FNTG*XHJW(8'FWR5T9P</@]2]FY3,J[M'N;ETB8Q8]G(+@#<P9ZYWT'SY6
MYSNF[+6J2H$_96]U@NJN8GL37IMD5D1,=8)BO9K/+$87^\.')P</I9_'1L(K
M(%][8P$<N)E3AH4`**G*0I3*''R)ID*43&$"E`B:9"%`1\"E`"E*`?(```<"
MF!^O&8^HEV0>UYS-Z*ZQ+"\8U++M<T7%=6NN8,K/I6J73+)5I@H7W.)V#<7A
MG3(7-'4I;(8'+R+8NY"-;/DA<**(IA?W!9"[]9]:KG3;09MI<LSL-"E[#U-T
MD*Y5*C.EA,W^AF-UP?086CP];ISFTTB&F6,I`2T;&1I)N"]\(X;`\BG#M^%_
M^`X#@.`X&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C[J_`VWX#@.`X'RY
M]T,^L'5CLGNEJT2)F66'[MH9MDH6U)Q$I)T:)G;'5JQ"7;--(GXUF\;4*Q0]
MAK*CV)7E3-HZ4B'R239P9PS<($"N3G9<C:U=Q=1TVB.ZJV6;M#S4/9XFP-UI
M!X<$F$2P1@7,F]E)R27$$VK!JDL]=*B!$DCG$"\"9,SZX;QV#]WE[8-JZNXJ
MY\BR22K=JS[.Z-'G$#`+*->)/XWKW7I!'^#A^F]MYTS?,:1"OE5X&H&5Y'FN
M(U%"BY33XJEUE)PH_<M8_P!Y<R$W,+@'OEAM5@DW#ZP6ZSR)OG.9*3=.WRYA
M^>J(>``'FMN[#9-UY@XZ7TZR'92%A6694JCP$>[M&E:+*HE\3Q%`HD.1>>LC
MM/Q#VZQ$R,6)!]H[<-T@,H`96Z_K/:#L<=G[:4KG7_)F\HD[6P5PUE[K.ZM`
M%36*>`["Z-GM]SZ9AX65\Y#.:[29=NW\I10>RDFB=1#@7^ZX^I;)XV;.LGWC
M`<<RO$QD*_GM>TSK7(2,-FV6N9R1;0E62NV.V.#8.Z'09"<?HM#RT7+S+:,7
M<D.]20:BJ\2#0G<Y5M;NX_2S,J^";VT9Q+:WV0O:K8Q#+53,4L=T+"H4TH8!
M'W,+]H.K-T8](X`9\G!R)TO'W%82!>7@.`X#@.!D;WE^)-Z(_P!OW=3]/W>N
M!'7[<?X*_1?ZH:C^/NK\#;?@.`X#@5#[:]CK!B,;0:5F-5AKUNNV3DS7,RKU
MHD7T12(2/K4,I/7K3]&DXQJ\E4J%GT0*)G#9BF:0E9)\QCFXI'>>\H!G-GW5
M#/Z_JSKLAI+.KZSVAE&7N#C8G&>5*F-JA&G456-7,BI-?:GC\^@4E%S@+M5S
M*69\4?%_+NQ'Y`LU(R,?$1TC,S$BPB(>(9.9.7F)=\UC(F*C6:9EGDE*2;Y5
M!E'L&B)1.JNLH1),H")C`'R\#+/L;WMTV2K2[#II389\271>(PW97:(Z=B,A
M>F:J)INW&/U-..4M.NBDF8_N\ZJV;5+VI0,BK+$`Z7`KEG>&]FVHVS59GK)I
M^S6Z0D@KUWWFK:WENW7:WJMXXDX1DR8V"5R>[1E3:1ZP+-Z_`UUI&1X`)$V1
M#E,(A^,]K%1I+A)EJ#>[8H_5`HD9[KFN@XV0_G`IBBC+Z%6H&N/2B!@$#MGJ
MR8@("!A`0$0\Q:G3#L;&2'6["I>OZIK.X0KVB5^$I<FPN+6JQ-K1^A9G4KXZ
MKZ\BSJ6?Y_%OE)1T_?G;IN3MTVC457CA!$X?5UUYZX57K[#3ZC>P6G2M/T!W
M%S&N[;HKQG)Z1J4]#QQ8F(<3CJ.91D-"UZN1H"UA8&):,86&;&.5JV(=9PJL
M%A^`X#@.`X&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C[J_`VWX#@.`X&
M>'>7/-$3LV%]D<XID]IZF(AIE0T;-*BW0>WJ;R38F-2-8[/GL6X<M2V6XT&T
M9U!R`0I%".9>)!^@T%1\+5NL%)K!W(ST(]9OF%-UO8+V8P-6U#C,LT7./HM^
M<1(!=$NNMU&F5#,8]HJ`@Y-(N#2'S3%:LG:P`B8/&UN'9WPL5H?:E.`VNV1L
MRH]K_6V.7D6O5C+)!B=-W`3CV'7;A*]BKG&JD$%I.X$;M&;KR+14-'&+[8P=
MSJZRVN3REFM;AH1P'S")"Q8G8H-RN3BQ3\JH(E%=B@H1LDJ81,*228"'F`1,
M'IZ];)RL0\5`13KW2.AX^RL6Z:1"H'.XMS==E/S3HQ/*"TTXCE_=B+&_Z3=,
MA"@`%$3!S$NR[K7Y8ND4N]0]B@F+V0@H=&O2;.Q5&+"($\3(0)V1O>HE\J@(
M"1V5=(_MCF\PAY1)X!IKU3A4V>9(SIZEG]8>69^YD#KT2KUZK'FFA%#)MG]B
M:5IDQCCRXJ>U#Y"%$J?E\P%.)PX%">WOJ+ZOUUVK6<+BJ91G<]!Y1+=F,ZFG
M<?8)GWSK3FN&;!:]QM$S&-K'!,G]PI.TYC&5UN@#Z.:&)=(CVXE-[54P>5E/
M5X7A9*LRLIC;R,IUDF]LS.JJ3-FJ,0TNU_RS?NN_7D+E/W1>QJ1.*9>WNNPN
M_>U95G)+^YMP7\R9RHH/`F#K1ZIU:[+:[G6<0N%7VI5O1X%DI&:%/6:FN&C.
M[.</@=]4JB]=CGRTJZB/Y*E5A;3B!E&+TZ*1TBBBY*H0*43GK0W^3ROM+::L
MVPN@7.FW^FR?3J+V&OZ="0W:''-.L>AYUDT6P<6"P9PU4NU\T',W"SJSQ3][
M4*]6Y9M(.?;%:NO$/H;@GZLK!PTFO]'^WDHJ.?K?1+\LK%>U>-$7"GT9*$31
M))1_G4'V*X$("R?@<`#Q\.!VO`R-[R_$F]$?[?NZGZ?N]<".OVX_P5^B_P!4
M-1_'W5^!MOP'`<!P'`BS5;+0H.#]WT.$?34"]'P633J<I9(]#P`Q07=+,V#I
MM'J)@81*<QTU`_B7@82UFB05)?6C^7G<DZ83LZZD&Y)!0J@MVH.'0LD4_*DD
M<Y@;K@!CG#VAO`/'^'`BWLSU[B>RV8K9E.6FRTM`T[$6%O-5LR8NB.HD7!2-
MWC%P=)M(LE4G1Q`AQ`4ERIJE'S)@`A[65GX&E-*=0)$)Z9&:BFM4;.?E=/W+
M-JQ;0:K^4=E.@JJ\=%.!UCH@*GF,93P#P#@<+&\1S?`:BK1,MA'$%6UIE]/+
MM74M)3;A:6D$FK=RY4>RCARY$#(,4B%(`@0I2!X!XB(B%K\4W6ZN;0;),\<2
MTX^,1O7I%_%).WW^U4`^F2*62?A(0C52*E+*X%P;V:[@JB;=5/SK&$A114#7
M:`SZG5N&CX*-@8\[.-B7T(FM(()R<@YCY=Q[[.)2,D^*N]D33\@(N7YECG%X
MY,*BOF./CP.P>U"IR;!S%R-7KLA&/6TBR>1SV$C7;!VSF%T74NT<LUVRC==M
M*.FZ:CE,Y1(NHF4QP,)0$`Y:%?@6RB2K:$B&ZJ`$*@HA&LTE$2IL$XI,$CIH
ME,F!(M(K8/`0\&Y03_\```!P.IE:#19YHW83E+J4RQ:-$8]HRE:Y#R+1JP;^
M/N[%NV>,UD46B'C\Q(I0(7_@`<#U***+9%)NW220;H))HH((IE21112*!$DD
MDB`4B:29"@!2@```!X!P/TX&1O>7XDWHC_;]W4_3]WK@1U^W'^"OT7^J&H_C
M[J_`VWX#@.`X#@5#H.F;W9ZAN*VL4J#PB0K4U(QV<6&3D$7<.^B#MG`,Y)VY
M6=N47IV:R)/%TF1-%<5R^1#Q3,40RBDY:&7>J5M],HI2\ZRD`3:H/1;RKA!=
M)9)T\9*)>55%<I3'.FH'E,!B^8H?-'P"$NN.+U/KW59W,*Q>[)>!+9W]L>J7
M&2:2-@BS3S=DDBQ4.V(EXM"I1Y3@<Q?.=0YC&\!,`<#_`#<.Q^=4[L#FW7J;
MC9Y>\Z'!N9ZNR[.(1?PL9YE))HV:/G)%323)61+$N0,NFB+=`I2^V.4I_$H2
MDXO#%O>65$-'R)GKV.4D"R()@5@3R)*KE2`3?/5**:)@,H'S2*>!!^41\`EC
M*JRNVO*BM*ETJ#.V5RBM+VA)U,,6PG9',Y06EU8I-T)&I''B<14(5M[0WF5,
M4!$W`W&KZ3U"#B$9&8)8'Z<>U*\FTT&S9.5<`B3VK]-NT_\`+(IN3_.*4GB4
M`'_CP.XX#@.`X#@9&]Y?B3>B/]OW=3]/W>N!'7[<?X*_1?ZH:C^/NK\#;?@.
M`X#@.!G=VUS/NY=.P/6"P8#>LIC^N-7F7QNRN>:5'M7Z5LA'4G%E7?-F:M9E
M'4BZCZP#T(\J,A&BVD135.8Z?F``J9N[;*[?K*=[H5,;P_T8P5B8J59%6C6U
ME*W349`_;0Z148U!FD4%$FQBI>U,!SJ*B)C`5,*SY\P=J2EMN5FIZ%0FGJR:
M1W*CPQTEHY!#VKMT(N%CI-2^9$AEU0$J:GD`W@`%'Q"0(62K-F9L+577U?L3
M%\V4+%V:%6C99!VS!51)4C";9"N"K4%R'*<J:OD\X&`0\?'@>)VG6:YA69V?
M6;;%V.5KE119*RR55B`EY5!O(R+2,2<JE.LU:L(Q)X[3]X=.5D6R("`G/XB4
M!#3#'.O^8]BNJ56L[1S>:FCO.=U*WMID2C`W6$AK(QAYU6!?-!$T>]B7WLB^
MT:ND5R"FJ8`44#R'`+Q95G<3DN<T[-8)Y(R$13(-I!L7TLHDK(ND6H&_Y[LZ
M"2"'M%#G$?*0A2$#P*4```X$@<!P'`<!P,C>\OQ)O1'^W[NI^G[O7`CK]N/\
M%?HO]4-1_'W5^!MOP'`<!P'`_P`G(14ATE2$434(8BB9R@<AR'`2G(<A@$IB
M&*/@(#\@AP/#2U$@U1>/HB&A8^??,$88L^:-:.7D3$I(';@E&$<)*)H)H-SF
M!)`@$0]J?SG*8/,!@R8F.L-QNN57"<FFI8JHS=2N@2"0']SE%JXK&.&2QXQ!
MNB<S5U*(.E?<_%,$TTDO:F\"BF0X1IT8Z24:MT:>RC.9ZQ0M<JJJUD8N;$X+
M9G+J6LZRX+-7#HI(M)HS%6/(<I44@\H><?*8QA-P)FE<-U>@*1$J\I9[(U?N
M9*)DX=M$A9XQZU*]5B7L)88H[9TTD8"U1I_F@LF9NX;KB4X%,40X&OK$J963
M,J30&"16K<J3$$TT@9)@B0"-`22\$D@;E\">4OS2^'@'R<#E<!P'`<!P'`R-
M[R_$F]$?[?NZGZ?N]<".OVX_P5^B_P!4-1_'W5^!MOP'`<!P'`<"LG<C9K_@
M'6C7=4R.B0VJZ_6JE(K9/E4U96562TS05$A+7J7'O7CALI)3$LL!A:QC0WO\
MHJF#5J'MU4Q`,C6?KA'H654RV7[`7O84DIU/NW=JPZ)TZEXL,VA^KE,NT/3W
M.A3-5["3697BHV-/WN03=5,#S,HWD8==JDHY$PG1"?MQ]13KMTIE=.<0&5Z)
M9%5L!P/N/956*L'`UE/&]B[!0_7Y]+18R3E67CI/.%;`>QRT:HQ(C]'^)$5B
MJF]F0(GV7U4-GZU^H)OU0V2ATE;TY\1:=:*=HFPU5C/JZ9@-F['5.3GZ9N.M
M%._>P\IU^?VZ#?5J4>,FK96N*`T>KBJ@9<0#=UB^8RC%G)QCQK(QLBU;OH^0
M8N$7;%\Q=HD<-'C-VW.H@Z:ND%"G34(8Q#D,`@(@(#P.5P'`<!P'`<#(WO+\
M2;T1_M^[J?I^[UP(Z_;C_!7Z+_5#4?Q]U?@;;\!P'`<!P'`\%IN69IM-*F<W
MUZ@4[3J!82()SE,OE<B;5690&KA)XS.\AIIJ\8++,GB!%D%!)[1!9,JA!*<H
M&`*@:SZ9G476ZWIM6=T-]0XO5.J<5TJET,MFG%)8UWKI"V:<MS"BT6NL4EJC
M44RS-B="HNUC@561,5)03)ID*4(XT_TJ<)T*P]J='E)J_P!^T/LMUEO'5HL)
ML=YLMJQFAY58`AY>MY]4\]JSVEO:W1:Q=(%*3*G&2+27.=X]\'X'52.@$Q9;
MTBIM:N>LZ?I\BUTNW]B^MO7[KUOE,<0;,N*6AEB->O\`#/9&&I4^-BG4XZY_
M[ER2+EG*RTJ!8\B")CJ'!554+?U"H5;/ZI6J+1J[#5&ETV"BJQ4ZK78YK$0%
M<KD$Q0C(:#A8IBDBSCHN+CVR:*""1"II)$`I0``#@>BX#@.`X#@.!D;WE^)-
MZ(_V_=U/T_=ZX$=?MQ_@K]%_JAJ/X^ZOP-M^`X#@.!D1V)]1/:*AW?A.FO6_
MKQ&:_*5.(P:W;=8K1;?Y,8Q=<W709NM-F%7EG)20\=)U&C5"8L:[A^9P$FHW
M1BF+55TJHH@$/]^/6$D.O%I"O=9:]U_W%I"X7GNXR,];]I6@H[4C;AM4CU^Q
M/+^O9Z3`W`NAW>Q7J"DWD@X*8(]BPCP2$_M7`J-@V/K&N9C:GD5"0>F9O8;+
M)_SBV;PU9NM?F7C^1S2;;5736T4Q:2"S][_M_;'2<;,E*F)XMZH1!V"2Q@((
M?.*EZAG>(V\#G(Q5A''_`/\`O2OU-_N"^G\8^A/]FRH',7K)_MS[K_N-[0"A
M[;Z?]T]KX!Y??O'Y.!!].]3GNE1.O.*7&X:PXO\`=?4`Z77K.NH[B3KE+0!C
MZAE+[3S6,P"$<A"5N/;OQM6>;!`3JK%T5=J*-$>J$3*!W`'#4#O3HFLY[O\`
MZ=771?N_;NL].T#(^V4MLF[1Z6%0\I:;7@^9Y+(5.TV9SKM`M=&81IIR:?R$
MBQ;-6*+E-8Z0'2(4@D#)9YZTW:AY6.DVN35SDH:MX=EV7[;WN:T3!K+-TO=L
M^VOL+)8U`STY86-0M4-U\C6/6^H2.RLP>RD(@Z1DF:**JS<2I\">LU[9=QM:
M]2F\X$^[,[!G.)Z)W)[N=<*_:?<.N)LR;T[(.OU(OE"S[KN\4SBT:+$]IZW.
M6@;&5W;2NJO+5AH]!%&0<-SHIAJ)Z04SM&@=:Y_7=O[(ZKV!LMJV7>Z"R1T)
MAE,=#TZ&P?L-L./PIZNVS3-J&X]^M$!5F;B9/(+/RJ/D?,U(U3$R1@U=X#@.
M`X&1O>7XDWHC_;]W4_3]WK@5>_;V=@,&IGHY])JS<-MR.J62*J>F)R=?LNDT
MV"FXU1?=-1=H)OXJ4F6K]F=9HX35("B91,F<I@^0P"(;-?W4=8?S'8-][^??
MZAX#^ZCK#^8[!OO?S[_4/`?W4=8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_`%#P
M(PG[UZ?-LO\`6]8M-QZ;V74Z<U%E4=*G[#B<S?ZJR$79A:5RXR+QS8H-L)GZ
MX^S:N4B>*ZGR?/-XA4O3^NOI=ZSJ^(:=9-IQ2.B^O9*4.99#4M5PNIY'#.<[
MN)[_`$U9.$A6#6RL6,1<2MGYXMC+LX5\NP:B[9.`2`!"PE36].RC:^\W.J:7
MUI@M#7H\EG4<_B]4SB/B:S5+%>9/3;NTJ=<8SS:"KC[2=!D_IBS/6R!'L^_;
M-57JJPM4/($@?[H=#@_AHG4</_7XZQ_[MQO_`/:0@(#I7_</_?X@/_>?^X__
M`#N!P27[T_4F%$BDKITY3B\MFS67,8TECQ0C#.;&?WWSS]$9E>`WJ$V;Z2<>
M+J/*W7'VZGSOGF\0_+3+MZ>VU$@D]DMW336DZNZ<OJR33)_$;X2NO7@-@>/(
M(MI=RI8AT[!DC[11O[,ZGLB>81\I?`.T7U+H@Z976-=:+U(<QVDQK2&T6/7M
MV.+,K]$1\$G5F$5=6JD@9"TQK*LHDCD4'Q5TDV!`;E*"0`3@<5KH?0)D:/.R
MO/3YH>)N@Z1%':V;%FYHS1#0PUPU]CS)/2"RN@UX18#*)^5][F/L/:^S^;P/
M55O?NG5-BBP50VOK15(0KZ6DRP];T?+8**+)3TH\G)R0+'Q<RU:`^F9J1</'
M:OD]HX=+J*J"90YC"'??W4=8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_4/`?W4=
M8?S'8-][^??ZAX#^ZCK#^8[!OO?S[_4/`RF[K=A<!E/41]&.<C-QQ^1A:QN_
M<=U9)AAIE+=Q=>:R70W<8B.<SD@WFE&D2@_E7J+5$[@Z957"I$RB)S%*(?R+
MK+_WQ_\`_&E_]NCP.BX#@.`X#@.`X#@.`X#@.`X#@.`X#@=NP_[;._\`TS#_
'`/(H\#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g662896g50h21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g50h21.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0["4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!/0```;,````&`&<`-0`P
M`&@`,@`Q`````0`````````````````````````!``````````````&S```!
M/0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````#"4````!````<````%(`
M``%0``!KH```#`D`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`!2`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TCJ73?V@VIOVK(Q?1?ZDXS_3+M"WT[?:[?5[OH*OB=!&-G?;3U#-O
M=N>XTVW33+P9_0-8UK6LW?HF?X-6>H7=1J]+[#CMR)=^F#G!L,`_,W.;^D=^
M8JN)E_6*S/\`3RNGU481<_\`3"X.?M&[T9J'YS_;O]W_`*C2DW1W67]-HMNL
M?986D.>3J8+FR[8&M[*[Z0_>=]Y6#3UJOH_U>P\K+I<YKW>F65$/(>XV.Y?Z
M.YGL^G_T%7_\<'IDC]5R8[Z5_P#I5)3TWI#]YWWE+TA^\[[RL?H_UIQ>L9-F
M-BT6L?6SU'&W:T1.S3TW6^Y97^,KKO6>B=$QLKIEPQ;[<MM+[`UEDL-=]FW;
MD5O9].IB2GK?2'[SOO*7I#]YWWE>&?\`CC_7C_RU/_;&-_[SKL?\6GUJ^L76
M^HYM'5,O[7730Q];3757#B_:?=CU5N^BDI]"](?O.^\I>D/WG?>4IN_<;_G'
M_P`BE-W[C?\`./\`Y%)2O2'[SOO*7I#]YWWE*;OW&_YQ_P#(I3=^XW_./_D4
ME*](?O.^\I>D/WG?>4IN_<;_`)Q_\BE-W[K?\X_^124__]#MNE9='3&YS^HV
MNI&3U&WT7Y`<TN)97M8V6M;[?3>RKTOT3ZJ_T:T*.N]'R,O[%1EU690<YAI:
MZ7;F3ZC8_D;51Z'@,>[JAS<1K=_4;K*F6M8[VEM3!<SG^D>GZRU:L#!IL%M6
M-578)A[6-:X3S[FA)3R'U@>Q_P!3\`L<UX-[2"T@@@^O[@6KDEUWUA_\1^#&
MGZPWC_KZY%)3TWU!<UO5LDN(`^S\G^NU+_'$]COJYA;7`_K[.#/^!RDO\7__
M`"OD_P#A?_O[4_\`CC_\3>%_X?K_`//.4DI\B7H'^)QS6]8ZD7$`?9J^?^,*
M\_7H/^)O_ECJ/_A:O_SXY)3ZMZU7[[?O"7K5?OM^\+CO\9WUGZM]7,#"R.EO
M96^^YS+-[`^0&[A])>>?^.W]<_\`3T_]LL24^Z>M5^^W[PEZU7[[?O"X;_%=
M];>L_67]I_M5[+/LGH>CL8&1ZGVCU)V_2_FF+NX"2F/K5?OM^\)>M5^^W[PI
M0$H"2G__T>QZ3TV^RO/^SY?V>>IY%VZAPLD.#?T5P_1^FYEG\[18SV?S?OJ_
M2V7L3HV;1GC+MZID9#-SW'&?M%7OW>UK6C=LKW?H_P#U7Z<+#F]';:^G'_:+
M\W*?:X4L%)8US1L];TVV>OZ;:O2]?^=L_1I\/K/5,CJ(QK>DVX^,7/`RWO$;
M6[C6\U;=S?5CZ'_J/U4IP.OM+?J=@`O<\B]H+G1)(]?W'8UC=SER2ZWK[B[Z
MG8!+',)O:2'1()]?VNV.>W<N224]-]003U;)`);^K\B/WV^*7^.)I'U;PY<7
M?K[.8_T.5X`)?4$D=6R2`7?J_`C]]OBE_CB<3]7,.6EOZ^SF/]#E>!*2GR->
M@?XG`3UCJ4$C]6KU$?Z1WBO/UZ!_B<)'6.I0"?U:O01_I#XI*;_^.T$=(Z;+
MB[]8?S'[GD`O(%Z__CM)/2.FRTM_6'\Q^YY$KR!)3ZI_B-!/[;AQ;_1>(_[M
M^(*]3V._TCO^C_Y%>6?XC21^VX:7?T7B/^[?B0O4][O]&[_H_P#DDE*V._TC
MO^C_`.12V._TCO\`H_\`D4M[O]&[_H_^22WN_P!&[_H_^224_P#_TO4K+:JF
M[[7MK;+6[G$`2XBNMLN_.>]S6,0:^H]/LO.-7E4OR`7--+;&E^YL^HWTP[?N
M9M]Z+?CTY-3J;V"RI\;F.U!@[A_TE6HZ-TG&O&31ATU7B2+FL:'RX;7GU(W^
MYJ2GEOK%_P"(_!_\,-_]'KD5UO7V5L^IV`&-:P-O:T!H```]>&M#?S5R22GI
MO\7_`/ROD_\`A?\`[^U/_CC_`/$WA?\`A^O_`,\Y2;Z@M:[JV2'`$?9^#_7:
ME_CB8QOU;P]K0/U]G`C_``.4DI\C7H/^)O\`Y8ZE_P"%J_\`SXY>?+T#_$XU
MKNL=2#@"/LU?/_&%)3H?X[_^2>F_^&'_`/4+Q]>O_P".UK6](Z;M`'ZP_@1^
M8O($E/JO^(S_`+V__07_`-VUZI*\J_Q&M:[]MAP!_HO.O_<M>GVNPJ(]8U5;
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M553CD"RU[@UK@TM<YM=MU3'^HU^UOK55_P`M)3YV_P#Q9_5ECMC_`*P.;9#W
M>F14'D5FQEFVG^=?L?CWM]K/\%8MKZI?5#$Z7=DY?U?ZXS*+PVB]YKKN8(BY
MK6NHLK;O]_[RMVY-CG5OM_9CJ:'FS'<_*KWAX]1U5C8Q?2HM?LN=^C?9_A5N
M]'^TM%]65M]=AK-@8!M:]U53K*ZW-93ZE3'_`,T^QGJ;$E/.?6SZKMZUC8F-
M]8>LLJ#7N=3Z5`JW/%;K+?YRV_V,JKL>N:9_BM^J#VU.'U@(]>?1#O2:Y^T[
M'^FQY:]^U_M]J]'Z@76]1PL(D-JL;=:\[6N)-8KK8W],VQK6_K#]WMW_`-CU
M%*[HN)>QK+SZK*WBQC7,J(:\?1L9^A]KTE/+?4WZK8?1SF-^KG7*\AUPJ.5N
MK9=LV^MZ+?T5M7I/]UV]C_>I_6WZGLZY7@_\X>KMJ-=GHXYIH%8==D>FSTOT
MEM_TWT_HFK>ZE=7TW8]QS;C>2/U2EMCI:-WZ3T*=W[VSU%GV]?PQ&ZKJE[1!
M:6XS;1/BS]&[WM_D>_Z'^GH]5*>/_P#&L^J7M'[?=O>UMC:_T>_8[Z%GI?SF
MS^7L70_4_P"J-'1Z<RWZM=:KR69)8RVU]3;V;Z@Y];6NHNJ;_P!J?TON_P`Q
M=)3TS$R68V8"_<QN_&<ZNIKZQ8WW!GZ'=5N9[7L3YN-9BX.3?1DV,?54^QL"
ML#<UI<"YC:@UWT4E/__4]527RJDDI^JDE\JI)*?JI4.J?SF#]/\`I'^"^E_-
M7_\`0_?7S(DDI]IPOZ</^3/SOYO^E<?G?Z_T/U5V/2_Y_.^G_/-_G?I_S5/_
M`(%^Y_UQ?,J22GZ6ZG_RET_Z7%_\U_._19_[*_Z;_NS]B1/_`&+7S*DDI^FO
M_8M+_P!BU\RI)*?IK_V+5?J7_)N7_2OYFSGCZ)Y7S:DDI__9`#A"24T$(0``
M````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<```
M`!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`
M.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("
M`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`$]`;,#
M`1$``A$!`Q$!_]T`!``W_\0`O0`!``$$`@,!``````````````D!"`H+!@<"
M!`4#`0$`````````````````````$```!`4!`@4(#PX-#PD&!P$#!`4&``$"
M!P@1(0DQ01(3%%%A%187EQ@*<9$B5%6U5M97=[?7.#D:@:&QTB.3U-66MI@9
M67GPP=$R<B5UI49V)UC8X?$D-#5%E2:F-V>'IRB90F2DQ&6%-N9X4C-#TX9'
MDE-TA&F).HH1`0````````````````````#_V@`,`P$``A$#$0`_`,_B`0&,
M%D5O,\B\9-ZJP[+"Y+HMU;6+Q#+-Y7:QF=&*1_'-K6ZM792R)JZ-LRMD<EKE
MF2ZGDA>MPF*"9=1H;)YP(XQ@8Y54GHX`,I`AX[M7>&9W/_)3`A'RENU;R[5M
M]Y_AA>+*=HL1G6A1+<3QB>+`<:(X4ED-ES)ZB;77RP1K;N8(@-6O"*"O4J@2
M&D:D%RY"AU[DSO3LXV=>[+3(6W5R6,WL4,&]XEB]@LY<7%&TR`N+MZFU<,9D
M)-YKDJ5WC2AVTMAZT+]Q@9M@%-K*I18B0HD>*F1IBU#A;\0WVN=]NV!C_O#W
MV\;>W"Q@S&"WJ0[/P^!M4BMQ3L@CX-,:]:_9L9.O&FJE#N>3C>JY8T6ATBJ8
M@I"@HJ5S(%01*0N8"1+=?YHYON[,"UF.N6%ZF3?]"REW3UK-Z`U%9`LVWK0G
MK&N1ZW0:[%<%AD/M74C=#Z8*83?)<4FKK%-:V-63^JU42G7(0)FLI<OL=L*[
M<@W9R9N'W-+?F%PBVPG!VI/EY<M:4I"3)D^Q+`;+J6Z>>D'5/G9EI`TZ>:JE
M`<4LQGMB=D0P$NZ-D;K]TE@+(QPJ1<K98MR31/IJ>-,!03CH(C/!.IBJ0%ER
M1BIH($P#.<N71*55.H=J^$-:GT7<G>XN5ZT8!X0]J?1=R=[BY7K0@'A#VI]%
MW'L_T<7*]:,`\(:U/HNY.]Q<KUHP%?"&M3Z+N/O<7*]:,!3PAK4^B[C[W-R?
M6C`/"&M3P]EW)WN+E>M&`>$-:GT7<?>XN5Q]7_%'9P0#PAK4^B[C[W%RO6C`
M/"'M3Z+N/;_HXN5ZT8!X0]J?1=Q][BY6OE=J,`\(:U,_[[N/O<7*]:,`ED-:
MF?\`?=Q][BY7K1@'A#6I]%W)WN+E>M';`/"&M3Z+N3O<7*]:,!7PAK4^B[C[
MW-RO6CL@*>$-:GT7<G>XN5ZT8"OA#6I]%W'WN;D^M&`IX0]J?19R=[>Y?K0@
M*^$+:KT7<?>YN3ZT8"GA#6IE_?=R=[BY7K1@*^$-:GT7<?>XN5ZT8!X0UJ9?
MWW<?>XN5/Z#1@*>$-:GT7<G>XN5ZT8"OA#6I]%W'WN+E>M'9`4\(>U/HNX^]
MQ<KUHP#PA[4^B[D[W%RO(]2$`\(:U/HNY.]Q<KUHP#PA[4^B[D[W%RN/_P"D
M(!X0]J?1=R=[BY7K0@'A#6I]%W)WN+E>M&`>$-:GT7<G>XN5ZT8!X0UJ=O[;
MN/9_HXN5ZT=L`\(>U/HNY.]Q<OUH0#PAK4^B[D[W%RO6C`/"&M3Z+N3O<7*]
M:$`\(:U/HNX]G^CBY7K1@'A#6I]%W)WN+E>M'9`/"&M3P]EW'WN+E?0[4=8!
MX0UJ?1=Q][BY4^#_`.D8!X0UJ=O[;N/9_HXN5ZT8!X0UJ?1=Q][BY7K1V0#P
MAK4^B[C[W%RO6C`/"&M3Z+N/O<7*]:/7@'A#VH]%W'U/\W%RM/+[4=(#W>[M
M;3F.D]E%_F>A=D>5V@W!Y?1.R78KE<UVK<[SO3?,\UR>=Y'U3D\WYN`__]#/
MX@$!%<[-TG96Z>4#/R:OW?/*G(H.V#UNQ<"S^/\`>6XS*7L>;3..\0)THXQ&
MDUT.V+;?!]-0TT_630B2XXU@HCDZ0P2X=-`0<J0MD1-QTU,<K674#P^R#OW.
M_0N+-Q,0L2GKD3=HRMMS".UEW74;7'B8L"/:UCLE[I+G01%:9Y&5%0^L+@)E
M'325"D6)2&Y0=B@[C#%T:[Z)=IQWARM=I,1]XZWDNO9UP770U"S.0M_L8F01
M9EM[[7I1S;#-/UQ/\T,F%UA<H*.0@DN%:`#,J1,UI.BH#$W#N$S+?9Q>4W!D
M%<>UA(ME65MAB_<*YJ8?QYL7+--&5VQD.):9`;K.;+^(S>;3<:HFA4+#C6@4
MX!4,C%:`C==)F@.[<']U/8G!9\#7,:MS\B;YW`(6(8^+-OG9D:_6N\E*T&,]
MNU@9?:]C+:@,I@VZ3$]C$UJH$U54HEU-4%K*@RJ.<FF=-02=0$-.Y`^#9DA^
M<6SL]W5>X8"9:`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0
M"`0"`0"`0"`0"`0"`0"`0'__T<_B`0"`0"`0"`0$-.Y`^#9DA^<6SL]W5>X8
M"9:`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"
M`0"`0"`0"`0'_]+/X@$`@$`@$`@$!#3N0/@V9(?G%L[/=U7H"9:`0"`0"`0"
M`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`0'
M_]//X@$`@$`@$`@$!#5N0?@V9(?G%<[/=V7H"96`0"`0"`0"`0"`0"`0%K68
M69%A<$[+G;_Y(.55:ELD]PH+7-*Z.V5UV':%ARCBEDD"E&;Q(^I5ACC`U2J$
MD'.BB6VJ<I0$2_RH'<\^SI<'O#W:]:T!3Y4#N>?9UN#WAKMZ?>M`/E0.YZ]G
M2X7>'NUZUX#C]'C3.Z*$71$BNY-X@4\,*L2ESB6/>,T(:NFF55((9<$,5S2%
MKG/2F=2=11K+;5*6V`Y!\J!W//LZW!Z_\@]VMGD_XKP#Y4%N>?9TN%WA[M<'
M5U[5](!\J!W/7LZ7"[P]VOTVO`2[XEY;V0S<LNBW_P`>7$INFV3@4E9(3%=6
M;JRUCHQY#'I+*-%:.ODR*D%2$+7*4JJ@Y4U<,M8"Y>`0"`0"`0"`0"`0"`0"
M`0"`0"`0"`0"`0"`0"`__]3/X@$!$.XMZ"[K>;Q"Q&$UU\3+D6]8V4KDOJR<
M?+ZJ#D9ZF$^'%C\A3<#N6U"WZ0K'76V6`M$Z@))"D<"#K.4&P1^:I+\X*&')
M]VEO%WSO$F0W[O@XRJMGK+O=@"O9BO=;N_:!WJRV/0XPD$)"5+?LUVJ[X:AH
M>@(V8I%4B)<'D%>3.J50@4J@Z`O?OKVW9W(ZX3``Q]>SMQLL/DG8?$?(;*$B
MXFR30K;WMO\`!)8R.3*M`V?H<#A:C'J<::`X#X-$IDS1F05`8E4P^6'7K8W_
M`/;`=X-QUW`L,^V#AO=NK-`OCYE4:7&VII-S#&"C:>+HO&<.LDB>$<;71ULE
M;Q;#;@I@.8JJ9*<U(.@3ETT!<A@3O5#^7U["5B+DXWO''5Z7$Q*96>-A@U]U
M-5W%KCXKW`=I-FH3F5!&NHG9-%[DE=6(24$4S]6*TG`Y\JK;H$N"JM(Z$6D<
M6U9-1RDQ*0I&E4^53RTQ:M>2'(<V*"%,2K39+76<!#AN/%`@+C1D6.$=*"`F
M-XAG0.`,&9!K"'`&ODN"`C!"4USH$"%#JE5353.=-4IZR@)F.F$_/9;Z^%]-
M`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F$_/9;
MZ^%]-`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F$_/9;Z^%]-`.F
M$_/9;Z^%]-`.F$_/9;Z^%]-`8X?C4IDN)NEG?2&.")5W<[*SY-`M%=6DEI2U
MGR::ISTE`:Q*6NO%I+CEQZ<76@*S\G3R>.?4X90%8"FFNG#P\&SB_2@*;=9S
MEMX)2ELEK\WCT@*RZFO!LGQ=3J<&R`;?G<?5@-HYXL49+A[I6TU`@X`=<K@W
M/UIK%HHG+]NP/^355*<I0&09TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7PO
MIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[
M+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!
MTPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7
MPOIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH!TPG
MY[+?7POIH!TPGY[+?7POIH!TPGY[+?7POIH"O2RNFO22^FFNO/!Z::\G7]=P
M<K9Y,!__U<_B`0$$3-P9W@Q;>:7$SCNPY<2+NMV:HZ[=XV!+3FN^GNG&3&I3
M'4`@4%AL<"V@S/$NL^RDRHSN61E>NL[7RRI<8(G10'4%K3&P$RQPNNCDEO`[
M78[XX6ON&S\%WQCQ9O$W"Z=P7DV,BL@5-Y)J];R\5RF^HM9@DD]MD5_F`)E`
M@:E%.2IFQAS=`0>DP^4Y-SGFK<=]779+V>=@26.>8F76)>=N3"FE*#O[I;,N
M;9UJLE1O3:>WC?J0AD)6;=Q+H,XO6C*@ZF'6EI(54A0QA192H#@;:W!62KG9
M%K<.[NW1L^1P_P`5D[>6`6(>S/'=2G=]^RS[:=U6HU2K];:BBI2$V!+.]V!5
M4#HQ8^=I5#-`!<*F05-8\POQW;6[GRHL?D:PLC<LG'9JE<QYW<5K=V/:-`LP
MJNA?(OAAV[?20^5R]+N.NANMH5O*SI-M5+!*)`(9F8%%)BH42C0.582GY18A
MXZYHV\+VHR:ML5NE;\JN$G&`W3CA=S;!H6DZD2DF>Z<S%]N*E<P*1JM**AYA
M3G/;3.<I0$2&XNQTLVC8G7F:R2T1"+?9.=69+':Z:7<CMI!2FNT[OJB$WDF@
M2:[,<S0G)1,(&0HU0@XDJ.4)775.=4PF?[@-I_4R9^Z=W>1Z/=2`Q*<V<KKW
MVFRIO3;IB.XTBM%J.NA.0DN0ILW,F4FC)AJ87/FC8QD348S55K555/2?4@+5
M_#TR=]D(WU_,"?\`S]FV`IX>F3OLAF_K=?5U_P#S]L!Q]UYG9*.Y"-H)RZ;E
M2@#?-<X>;QXPDJH/-"T#2D6/A"5UA<J=$I5:2GK3K*`]AN9KY+MM$3T(M<]>
M404X&8(1U9-#J2F8IF((+RSAX06D0P+*8FFLY2\S*74@/L^'IDY[()OBT\Q7
MQ<'_`,;2`>'IDY[(1O\`_!7_`/.@+X-W7DO>"^.6UL;:W+=!IPLQP5."2JDS
M'/$>D]"0E`X6_L@D=`,A\V8`IGYFJ6NFD]D!E/=P&T\OX,F?NG=WV^@'<!M/
MZF3/W3N[[?0#N`VG]3)G[IW=]OH#'=\:$M0PFANIW:L-]%%(J-%[+-%Z3`BV
MX#U$@3"RHTBT='454V6G.JF7#.CE2XIR@-:E+9*<IZ:2X)_/X.M`/UTOF[)^
M1P3@*\.O%I/B\CC\N`\=DI;-=FW7BG.6R<OFP'E+ATU^9I+9UY=;;`)3GI.<
M]GZG7@*5=?;IMG*7#U.#7@@-FYXM1:5@.O=36K65Y#'.J(S^N6&(/0N.`C34
M&$LEZ0Z9`)ZL4+2Y,N.5$ISX]8"?/N`VG]3)G[IW=]OH!W`;3^IDS]T[N^WT
M`[@-I_4R9^ZAW?;Z`=P&T_J9,_=.[OM]`.X#:?U,F?NG=WV^@*]P*T_J9,_=
M.[OM]`4[@-I_4R9^Z=W?;Z`=P&T_J9,_=0[OM]`.X#:?U,F?NG=WV^@'<!M-
MZF3/W3N[[?0#N`VG]3)G[IW=]OH!W`;3^IDS]T[N^WT`[@5I_4R9^Z=W?;Z`
M=P&T_J9,_=.[OM]`5[@5I_4R9^Z=W?;Z`=P*T_J9,_=.[OM]`.X%:?U,F?NG
M=WV^@*=P&T_J9,_=.[NIIZ/0#N!6G]3)G[IW=]OH!.P-IY_P9,_=.[OM]`.X
M#:?U,F>/^$[NX_\`OZ`=P*T_J9,_=.[OM]`.X#:?U,F?NG=WV^@'<!M/+^#)
MG[IW=]OH#W.XA;+F.C]KIGF>A=C^1VQNG7HG9#LIS?+[-\OE=.\WR]>7IYG7
MD^9@/__6SH[D7PL_9XPA%;J7+9EOC+G3WPK-\%VKQ!$K6$NVC14']<!03Y'1
M0>?)LYEI)E441):T%20%8M<Y4TSG`<:QOR>L-EQ;(K>#'.YC:NK;LTK*2!)Q
MM@[2<*EEQ(YBI01SX>E(Q%2+`'`!J@1::*^9'#KTY%=,YAWU`(!`(!`("&G<
M@?!MR1_.+9V>[JO0$RT!@:[R+X<61FW^'`7S/V@1=D!9#`(!`(!`("2C='_#
MTLO^R='WL*D!G`0"`0&.!XU1\4H\/;SLIZ=*4!K#--FDI;-NR>OT=L`X^+9/
M3;LG+@X.K*<`G.>FSJZ;--O%Q\&V`K*?#K/KSZW6V0'CK+9.7#ME+77CZ_4@
M*S^CQ<'E^5`5Z^G6GU>'Y\H#:1^+#_%*6FV:?R@W/V?]]%X#(.@$`@$`@$`@
M$`@$`@$`@$`@$`@$`@$`@$`@$`@/_]>_'?77H=.0]YUG&E\8ZV>7V-8=V*A=
MK/Q&WH=E,9;CO%J7+MF01KEL"X+!=!5164QDOE&7*TY4330(8YPJ6"$"&##%
MGRPF&W+DD]5QWO9<`I:A@V8/W6RH?S^7F/;"_=N,AF$04A;=6D:Y(-KNJUR<
MF-ELHR:W&N03BZ%50(<)@D:!AA19F95U!,#`(!`(!`("&G<@?!LR0_.+9V>[
MJO0$RT!@:[R+X<61G\>0_2!%@+(8!`(!`(!`24;H_P"'I9?]DZ/O85(#.`@$
M`@,<#QJCXI1X>WG93TZ4H#6&[.'9Y.R`I*6FDN'76>OSY:]>`3X)RTXIZ=?J
M\''`5EMV\?\`4X)_-@*<$Y2E*74\B4^&?4XH!I*6G!/KSVSUXMOS(!MTX-O!
M*7#Q\<_F0&TD\6'^*4M-[85T/3L#6`R#H!`(!`(!`(!`(!`(!`(!`(!`(!`(
M!`(!`(!`(#__T)2O&.K?6PL;:I+R"8V,>-W=!N8=NP8N;D/<''.B\:U6[+>6
M&<;ELQ;D0NG@4!D'!>QYM4BW2ZRI5B%25`=4JJ!*ZZ9TA)QN;;A6[N98S(=R
M6.M"P[2XY!YD7>1\<!;>6P4;3(MS+0)35MF73+D&VXIU])4E@PY^RJ*,J2#`
M#4:$0,0,*BC24!+M`(!`(!`("&G<@?!MR0_.+9V>[JO0$RT!@:[R+7PXLC/X
M\!^5V`1H"R&`0"`0"`0$E&Z.^'I9?]DZ/O85(#.`@$`@,<#QJCXI1W^WG93T
MZ4H#6&::3G/33K2X]./3@\B`KKMTTXM>KY&V`IKMTGI/AGLX?*ZL`E.?#LE3
MKLEQSU@*Z3UVZ::3@*2UUGME^NV]:6FR`<F4M=);=-.&<!M)/%AYZ[I2TWM@
MW/\`3HO`9!T`@$`@$`@$`@$`@$`@$`@$`@$`@$`@$`@$`@$!_]&>;(7(;(_!
M7>#94W2NUB[E;E]B7DG:3'M,L2+81#&N@S+)J]J$%W$+G,)X6X&5"R:WUVY;
MQ7"ZH`JS*BUG0I!A5C2#+54AA=WNB$G)"BP=Z7SD8Q[CVDIO-E[?^\%B;(W<
M5#*A<:R>/#R4T3M`MLYRQHZHB-L=/4T]5/%T>@:HNDDSX)4OR2X05-(=](V\
M:PM7\J#&%J5?MF&LD"]3F+T6\Z4*$9.J[+(&55XMQ,4A@J$I3=#42R!@PHIX
M`U9HF"`+6)13*BK0&.>\:PORSN8\+/X_7Y9UQ[@LI)5'$I(**9&D(J-9$<DF
M<KNUJF#`019UM5.<]=!$903ZS!6@P)11.O6J4!1^[QW"RV&2*!B2^+]LQ`OR
MXUAF-LDRS9H74HZ[C4"BV_:"RK4!5)"*['L"'*M+3C0P1H[0('4%15*NF<P]
M!E[S'!NX-_';C.T\B6$I7@97;W2LM[LAT8D*:M<5J.W-3T=>,T!HJXI6[*!B
MB+1<H.*(FT`"S'E1(.O0/MXM;PK#[-%>>K8QKO:UKEN!@%"2LX$A+K,ES]39
M4SIA/2'FCESP!81=9"R=*"A%%<ISQ`Q73H&)5`7I0$-.Y`^#9DAUMXMG9[NJ
M].`F6@,#7>1?#BR,_CP'Z0(T!9#`(!`(!`("2C='ZRSTLO\`LG3*?W,*D!G`
M0"`0&-_XU3\4H\/;SLIP_NTI0&L-TE+3J3GU=FO%.7'K.`:Z<,]OS/(TZO#`
M)Z<.FWBV<?%+9`5T^?/;K.?!QZ=2<!2?4V\&G#I+Z.V<I0"4MFFR>S9/39II
MLE.`:::3G/JRG\WZ&V`VDGBP^OXI2TVO#W0KH>G9>`R#H!`(!`(!`(!`(!`(
M!`(!`(!`(!`(!`(!`(!`(#__TLEO>(9H[Q#&[)_&QA8J80#9*V.>34?*_=AX
M!NA$;PM3@3$!YCDF826E96(DF((V*41/6#"@?`'*JA<[,D7Y`X==<@N9W;E^
M,F\E+%NN\&3[$MG;=3=%XGI79]H6S?"!<0!)L<73&R"T@'FZFPM+B(>?P;@[
M,!GI`U@<@*@"50(=6NH0@WP9UXLT-Y\M&GWB'DK8^W&)*9EI8[!UT(V/CT+L
M&Y=^<B6@N,.XF7ES[O(R*"U&U;4VH%@##=JD9%'.U3[+&Q:)C2!F%K&$(]PL
M>#^$&2=WL;+V6'8&YSW363[,RZ//>WARWU;WN<95"LVW:&W!Y;#1T^YJXZIM
M<=Q$JRPQ@A,VKEZ:Q:#@U=,@^%=2R>2EZGMES8U,Q?OX3?N>^\VP%SELE>!9
MMJL!M!B8_)K4MB]W8I/2YP8`B0S')CTEMTTWSJ4(=#.!GS]18G0)3,?0.C$C
M!K,J[F/F+F`[?QRO&R\B,-26_"-7FO2YF6JM)@N,?*>W.03;L2I,Z[)\$DFO
MVJ^2O=)&(AR)&C`O04ZL<S3(J"'5`2R[H>VMWWEFW8"^BGC[=VQUO<6]QO8;
M=X71G=NW:U;`PH9/M>[;4=[C:353%XDG#NY)8R(S34QE(I0,2!J4@J*:Y3'T
MJ">G+VV&2UV+8EFUBQD&EXV7&H<!`^8?RLP"=Q2QA#+TBR.HM*&>/$0@Q#DZ
MJ9R&Y4YT2ITE+;K`1.;B=F7[(8C7?3#UZ6J?74C.7,1(=:T;M14=K<SM3;NJ
M1-RN<.D!]I`2>`X%8(4U05I"T+4B<B554I:P$TO:K?7V8F5WFS/OGP&$9O!P
M%<KF;?\`+KBD55U8%Z!TGE,DFS1RQP::$D3YT!+J/J=1.GD3E3R.?%VRUUVZ
M2"S.`0"`0"`0$A^ZP*KQW-ZT)9MK!)!6!*G+T144$:I>*%ITMQ2F)SR50J(]
M1CET2G3+^R*.3.>NW@F&9AVJWU]F)E=YLS[Y\`[5;Z^S$RN\V9]\^`=JM]?9
MB97>;,^^?`8\'C02%=%/W5+L,NNX;;<J13>RS5%:6EV[&;1JLQ6L*,@!Y*E;
MV7::*`:MM5'1Y\N7_*E`:U:7%*?#IUMG4V0%-9SG*>FDNK/AV];R8!+9KP;)
M:Z:ZSEY<I;("DI:<&V=6W;L_1IK`>77_`$=?9\R`?0_J=7J0%.']*<NI/K<6
MR4!LV/%JD&Z9[=4VL,->XS9;R14_KE4@IJE;<=Q&PA*5@O(6NM4I?")(60E6
MV5/1Z>3U9P$^/:K?7V8F5WFS/OGP#M5OK[,3*[S9GWSX!VJWU]F)E=YLS[Y\
M`[5;Z^S$RN\V9]\^`=JM]?9B97>;,^^?`.U6^OLQ,KO-F??/@':K?7V8F5WF
MS/OGP#M5OK[,3*[S9GWSX!VJWU]F)E=YLS[Y\`[5;Z^S$RN\V9]\^`=JM]?9
MB97>;,^^?`.U6^OLQ,KO-F??/@':K?7V8F5WFS/OGP#M5OK[,3*[S9GWSX!V
MJWU]F)E=YLS[Y\`[5;Z^S$RN\V9]\^`=JM]?9B97>;,^^?`.U6^OLQ,KO-F?
M?/@':K?7V8F5WFS/OGP#M5OK[,3*[S9GWSX!VJWU]F)E=YLS[Y\`[5;Z^S$R
MN\V9]\^`=JM]?9B97>;,^^?`.U6^OLQ,KO-F??/@/=[6KS<QR.ZLT>D=#YKG
MNY0/S?3NR//]+YCNB:\SV,_L?F>7KSGU7EZ?4X#_TYK?&/SMJD>SE@5QXW`R
M,9+V)&\F"286QJMBWKG/1=L0IXX/$++<4T$YUAN)K'3T&R(1HP,XPC]!M**=
M(J"!&IJ$F&%SNXP1;-H>.^2!6QUO+E669\\U;KAF+#73:R*S7'8U82[=6;0*
MK<`H"*ZW?2&0+HR.24ZC9D8N95#BF8.S+A!F`YUA-=`<==+2:CZ03S7>[9;[
MQ;"G43J46XZD5.<*$?J3CQ54(3/(ZL6-IYJHDI$@3(,Q`ZIACA45TZ54TSD'
M(H!`(!`0T[D#X-N2/YQ;.SW=5Z`F6@,#7>1?#BR,_CP'Z0(T_+@+(8!`(!`(
M!`24;H[X>EE_V3H^]A4@,X"`0"`QO_&J9Z;I-X3_`-.=E/3I2@-8;3+9+;+9
M.?!\W]6`KMTZOZGD:<,!3;Q]>>O!I+66S]6`KY'6_1Y4!3CE.7#/9MUX/(^9
M`>,MDY\.FV4O)UX)2VP'EP;9^1K_`%/)G`;23Q8?XI2TWMA70].P(#(.@$`@
M(2<J?&%]UGA;?%YXZ9!7L>+5NLP1RI=S(:99FZKI)DQ3A>@T!2"M-YJJ"2<E
M4#7*>H0U<I<$]L!;O\K`W)7\XVX'X.][_61`/E8&Y*_G&W`_!WO?ZR(#YJMX
MV5N6"*>9-I]^+D+1P&BFH!,*6`O$5,&ZJJZ*)T!&%)HDR(<Z**IU3F()1*<J
M9RX=)3`D^-E[E@\0+&E"_%R$0V+1RADPW8"\!LP5JUG+D"#IK1.$A)SEMUH$
MJEQ<,!]+Y6!N2OYQMP/P=[W^LB`?*P-R7_.-N!^#O>_UD0'?N+GC$NZKS(OW
M;G&BP=[GDZ+NW44U))92"I66NPV"2D=24!7<QX(PNN!J$$=.I"1T,P)*H<:B
MFNJB5,I\JJ4IA.#`(!`(!`(!`(!`(!`(!`(#_]25[>V7VON0R%4V!<FT^[J<
M%M;8LVZSWM(/?G+D6U5RE>SMSK#NNS]\5!PLH(H`>I;:NTW:X$PR%J($)(L"
M.'/EAT52"^S<'-%(;>!E"XAH=K$Y.N/>1^/L-?M5?99R+3WV*,DM!JCN5U7(
M7J0U$1Z)PK5FA&4^NBB9`LC%@ZI<OEZA-=`(!`(!`("&G<@?!MR1_.+9V>[J
MO0$RT!@:[R+X<61G\>`_2!&@+(8!`(!`(!`24;H_X>EE_P!DZ?O85(#.`@$`
M@,;_`,:IU_%)O#3A[N=E/3I2ZL!K#=)Z=2?#LX->OUH"D]NS6KATU_2XH#RX
M9;92Z\N&`3V\7!.7#Y'%`/*T_3GLEI`4GQ2TX-)Z^1UN'6`\OT:0&TB\6'V[
MI.TW%_*%=#T[`@,@Z`0"`T]WC+WQR667[KMSTB*P$#$`@$`@$`@)OO%O?CM<
M"/;`N#[B%T(#<=0"`0"`0"`0"`0"`0"`0"`__]68;>-[EG)[+',:XF1=JG%A
M(;:SW<^&SW)D<D;</1YOMNJV(ZDH*X;.2%9$2#10A;*ZQE4&*N=+H%G0L$*I
M!BRHJHHKD$G>ZRQ"NOAU:2^S:O0Y;)K[\O)E;=/(12(8](BPV+4LZ=PV\P$\
MPTFVW%LL4-H=!53:Y@W67IHYNFH[RI3G555`2;P"`0"`0"`AIW('P;,D/SBV
M=GNZKT!,M`8&N\B^'%D9_'@+T@18"R&`0"`0"`0$D^Z/^'I9?]FZ/O85(#.!
M@$`@,;_QJG2>Z4>$I\'=SLIZ=*4!K#)4[--O#MZ\M."76@*Z\$N"<Y<'E?I0
M%>MP_P!;CEL@*\&OEP'AK/39K+;+AE+@_2E`>74X]>MQ:<&NFR6L!337ATTU
M^;.?S)\4!M)/%A_BD[3>V%=#T[`@,@Z`0"`T]WC+WQR667[KMSTB*P$#$`@$
M`@$`@)OO%O?CM<"/;`N#[B%T(#<=0"`0"`0"`0"`0"`0"`0"`__6G4WB.]/N
M7BKE(ZK,(&5F[VM4F);99B\09-^C5TY74)%G`B`FACZZ"UT@ZD!DU)1I'K(S
M#KVE>1RI2KY4!W_N.%(Z[,><E+J*>1=KLE5*]^<M]KR*#KLX?=I]@,PX^T"V
MJ@/;!#J>8!95+%6I4'S@0-%$BX9<V'*F4JN7*032P"`]6L\2#-A$*SA6@\.%
M6.`2K,!4FQ@0IZ"C!%IUR&$"#G^NJE3.4N.`!GB0QHP1"-E13I2D*LV3#,!5
MFBM!BF=0%9@O37,4&D:F4YT3JE*54N#6`%3Q([TCH1PJ;Z(:%)&^BF`C'13H
M')Y\H8YJNOF30/*ERPZM*Z=9:R@/:@(:=R#LQMR1_.+9V>[JO0$RT!@:[R+X
M<61G\>0_2!%@+(8!`(!`(!`24;H[X>EE_P!DZ/O95(#.`@$`@,;_`,:IEKND
MWA*?LYV5].E*`UAVW@EIU^M\_6`:;?H]6?4XN"4!39K.?'+YG%Y4X#R@*2TX
M=-.KQ?U)P"?DZ;>MMV<$M>O`)3V;9;=)SGI^CAG`;2/Q8?XI2TWMA70].B\X
M#(.@$`@-/=XR_P#')99=97;GI$5G`0,0"`0"`0"`F^\6]^.UP(]L"X/N(70@
M-QU`(!`(!`(!`(!`(!`(!`(#_]>Z/?X7BP*(9J5V^1K3+C?WC"5;MD'2>4AE
MZIUK+9,I-4R)DZQ"]Q59P([E3'RF)J>!RI%`R4Z@ZJY4U5;-("=?<@N%\N3!
MI&,W'OWCWD6["-P'`EJ#[QN9Y=GLTC,HWVA7VL.*DHFI)5ROQ,%'K&/JP8%%
M)L$T7IE+ZGI(+/6T^65:[QE%YHI[)9166Q<'=8/5QKC/>MXB1YGM.\0F8ELF
M\DL-L-054`1V^X4UD(G]BIL@:E68(Q@3S5`M4!:3N8W<1PBR$,XJ9'CL)YW&
M;F!3PR,>N95O\F73>YC*%M&9<Y.`=0UU2"POK*`PU:@`,N<+&`)455$R-<I^
M9%VA9AD]>,W<2_N:^1*!=M=.9@VXWN6[PMKA0W4-_K)893QG=J9;E2:Z6RV$
M34@DYQVYO$TG6K+BF-,J,"?Y@,402FFBF506U(5\;Q-FT6*.5EF+H/Q3WDMW
M`]_<IY:-@D\UU=<Q8Q9ZUN0ZA:Y,>%MA3YDBVBEJSC3:QIMAU$R\@CIJFD&=
M=0LZ)!+IN4S#?;.>M@&Q8RX2V]+679W!^.>0F2X-%P%FX"*8S$7KRM=.%>#J
M&4%57!;US7,W5)>Z65G,N8$"+SG6%*0<M`R/,O+E9+VLM@7<.*UAD;(6XU;@
M3R([(7'D"QR8"$/2+,\KR5APQ:1!2LZ:92"TUJY6O%`1.;BA^7N,XC7?4%:Q
MP`;B5<Y,Q%9V)96X:"7+MYVJ5W%(VY&T!6<+5C'0$%7%%+4&?UH](<JY2EK`
M32=O%X=O\AOD?RF-?;_T39`81N\(-J)W,Z_YM82^PBF,\PZCB3TT!3Z$)V"2
M*>9Z>5HI+F=:)2GRJ92EM@+,H!`(!`(!`2([K`\L)V;UH3B`B=L:H'6Y>CH_
M9(JD=*Y3<4J:_P!L#M%9<#FPYSJ\U+;II*`S+NWB\.G^8W2?4[IC7^Q("G;Q
M>+V#/]IK6^Q(!V\7B]@S_::U_L2`QX?&@G+<)5W5#M*.2V4VJF57LLV)6K=N
MJ(N3H&H65"8)>1`@7#'JD-.<Y<J4]*=-L!K5N'79UO)_1K`-.K/7J]?Z/!`4
MX9[92\S.7]?R("L]9<&V?4GY/DRX(!KQ<>FL^I`)[)ZSZGE>1+KP%?FSX>MY
M7!P0&S7\6K<]Q4S=4VK*-ZUO;,F4OVY58:OV[H2-SHE:P7F(%T`\7$,!\U/9
MK.>E7%`3X3?%X>*QNO\`K,:\O^J0"3XO#QV-T_UF->?_`%2`2?%X=NMC=.I_
M*8U]O_1(#4?^,?'5A1WOV5!M=0^UY4&56_,PD=DBJMT6<D0M*F73R=-!<><Z
M9:ZTREI`080"`0"`0"`FG\7;.*J?OGL%3B&C=L*J`_'[431^R)9)Z=7596Y=
M%8?9$W166+<V#557K5*<I\G3AG`;>B3XO#QV-T_UF->?_5(!-\7AXK&Z_P"L
MQKR_ZI`4[>+P[/Y#/]IK7V?]$@*]N]X=?\QNSJ]TQK^5_:D`[>+P[?Y#>II_
M*8U]O_1-FD!3MXO%[!G^TUK_`&)`>7;O>#V#O]IC7^Q("G;Q>'9_(;Y/\IC7
MV<'_`#2`=N]X=?\`,;LZO=,:_E?VI`.W>\/L&_[3&OY7]J<<`[=[P^P;_M,:
M^SK?VI`.WB\/L&_[3&OU_P#FD`[>+P^P;K_K,:_7_P":0'N]N-U>8YSN.?5N
MA<_S'=";G]N=D.C=!YWHO(_M#^R>=_6__#_7;8#_T)/-\WF_DW9G(.X-KFEB
MU9FUMN$^UY5T-3.V]>/9V_:2^UQ/94U\ZP4LJCHRF7;DRBN)V%"-JU=`1<U+
MG9?4Y;0E,W(@8"CN][27#KR"(Y$N"]!9*O(]UM*1F6WDFW#[?K%9*@Z[,):&
MQR9$@F$;<JH=9>@,U1T_ZI.H6<Y540%\1[$#%E3N*)=Q1Q]M(?N>,O!.D9^&
MV.@F'0*X@!`Q@EH57%)U&Q%(,4*FJ0LZIU:RE/6`ZD=^[AQ%7;,WVL<T+1M>
MS[5R1;*DR[O*=I4E.9[H<[.<`Q:ETM>I>*%JC9-%<J0&*1,EPIT@2+F*^31*
MK2<@[4(X<8KIMP61=8CC_:LK<>VK?0&LPWF$T$J2^V$%J(=#::Y!,/3`F(')
MN-\.@F1$JY0I0O130%73333*0?5:^*N-K)N6\KR-*Q]LF_=*X!=0*O5])K22
M2[@<8"M52(L4*1RDOJ+V8KIY1R<I2F;GM%G7K.`]VS&,V/F.LW358NSEOK4U
M/=4[,NRMD-M/0Q%U1IYR88Q\0H%16($!,2OF@93D"%.NKD44\J>H=YP$-.Y`
M^#9DA^<6SL]W5>@)EH#`TWD7PXLC.L^0_2!%G`610"`0"`0"`DHW1_P]++_L
MG1]["I`9P$`@$!C?^-4STW2CPG/V<[*>G2E`:P[A\CROZL!2<M=DY[-.#7CZ
MO7@*];Y_%P[-O5@$^KLX-);..?7ZDX!ME/;QSEP<4]/H;(!P;)=?C@$Y3V\'
M6XM/ZT!M(_%A]/Q2EIM/9!N?Z=%]?GP&0=`(!`:>[QE[XY+++]UVYZ1%8"!B
M`0"`0"`0$WWBWOQVN!'M@7!]Q"Z$!N.H!`(!`(!`(!`(!`(!`(!`?__1R(<D
MM]A:3'/*=Q8@9!8JY%'"9U]+S52'8V;6J-QV<]+>DK)M&YQ%[)9$B1-!.PLN
M.9;4$(=,+\HPFR3*C1GZE7*4@O\`,"[CXT78M`Y7UBQ:1=LPPEJZ+H&<#7<5
MI3]EU%2?U24W!EUR=II\J2KYA1("D@J308=(0LR\Z*?_`'<X"]N`0"`0"`0$
M-.Y`^#;DA^<6SL]W5>@)EH#`TWD/PXLC?X\A?>^BP%D4`@$`@$`@)*-T?\/2
MR_[)T?>PJ0&<!`(!`8X'C5'Q2CP]O.RD_*6E&<!K#93UEK^CA@&DIZ3ZG!Q3
M^;KQ0#CXIZ;>OKM^=`4GKLG*>SATZOD=76`K*>O%IU-?U(!I^IKKU?+XX"G6
MUUG*7S>OMZ\!M)/%A_BE+3;-/Y0;G[/^^B\!D'0"`0&GN\9>^.2RR_==N>D1
M6`@8@$`@$`@$!-]XM[\=K@1[8%P?<0NA`;CJ`0"`0"`0"`0"`0"`0"`0'__2
MR(-^*)<XBUL3U8B=R";V-9*\+U`RN>>)[6I=.0+>9RE:IRE6$4:P)0L.Y"#6
M<C]J`)K8R9.@Q(*H'E3Y&LH#M[<JNC(%VXI/Q3OBJ7G<35"R5NZ2Q<=F1"'V
MNWM=>*P837'MHM7%2*Z`C918DMF5HJ#28HH,2(E@)"2Y6LYA+U`(!`(!`("&
MG<@?!MR0_.+9V>[JO0$RT!@:;R'X<61G\>0_O?18"R*`0"`0"`0$E&Z/^'I9
M?]DZ/O85."`S@(!`(#'`\:H^*4>'MYV4].E*`UALM-.#AGMTEIUN"<!2>DM>
M"75^9+9+39U8"OSM92\GC^A`.*<]DO)V<?'M@*P#]'Z4!326W9PZRV2V]?Y\
M!M(_%AOBD[3>V%=#T[`@,@Z`0"`T]WC+WQR667[KMSTB*P$#$`@$`@$`@)OO
M%O?CM<"/;`N#[B%T(#<=0"`0"`0"`0"`0"`0"`0"`__3F0WJ.^@R$P2RX)66
M83>QV7&,%;Q[.T<.X2G<-JN8TI(]H:'H13CB]6A&6F8&DLSIJ*AI@HM0P8P9
M<Q,(6K602U[M/,E9SKQ8:U]W&U6BT%\Z=#15A,9#^2[AMX<]2UVNXQ#A=330
M0!$<Q.ERR"&335/2RH@,YU3G171.87^P"`0"`0"`AIW(/P;,D/SBV=GNZKT!
M,M`8&F\A^'%D;_'D+[WT6`LB@$`@$`@$!)1NC_AZ67_9.C[V%2`S@(!`(#'`
M\:H^*4>'MYV5].E*`UANR>WJ:_U>M`4GMTGKIPREQ[9[.+9`)RX-NFS37CGP
M<$!6K@TZNS]2?EP#BZOSOH2@$NII*7S=9^3Y$!2J6LM-=O#^CK0&TD\6'V[I
M.TW!/^4&Y_!P?W:+P&0=`(!`:>[QE[XY+++]UVYZ1%8"!B`0"`0"`0$WWBWO
MQVN!'M@7!]Q"Z$!N.H!`(!`(!`(!`(!`(!`(!`?_U,[1^VDMA=*@F'<BWS0?
M5">26TXA)UM],6YD2+E(R3%\J3J4"X]16A5(TR#'Y$Z9UTRE+BE`?08=N6!:
MUO@-2VK*:K";1>H(0-":*"F-Y,YX(D33:#(I1++%@1SG8]/`!F-7*H6H,&BF
MJJ<J9:!#JX,]<F+5[UN_.-=VDVW4L9F!NQ;N9TL-)9Y(X:?ZA*V=\&E;PN8<
MS@/UTAA**PDBJU4R!>GHP4JBU4ZN<E7`6N[N+>4YM77R/P8;F3RY:QSVSWE&
M&]W\I;7-IA,OM:5K%+;`=:4L)C(/K\S(P[U1A[8N,H$(;,TT&)J8=<].1.`X
M#DIO9\R6+>S*B\-NU.V9#$/"O>"XNX./NSZPRY*-P;H$KF5M1.NW<`D^ZC-(
M[=4T9=N$0#1B@(=0`I8F)6+/EUP'0Y#?G9F,=C6'SKN!1:YUXE994[T8:WE@
MDMHUHS[MJG8,LF\3CMH:4K@A&*SCC//Q7LF;+JH8@=(98NH4UA:U!R@)`=V9
MGAFA<O+6UV.F6#IME<-.R4W5EJ]YFP%A@LBAC&;75O2Y;<8JW9X_0"9,TNLH
M0`>Y,4)3%Y`M=16KS/FZH"87*#+.Q6'%O"]TL@WCVDLDRMDFZ$K]B558Y:LH
M4B5%2W14@H<,T\Y(*KS4Z94RTVS@(B-QCD=9M3Q/O,Y"SNU27GG9F2]6\8FA
MN(3IS<==WU5;0C^@*2-(&9Q-.!B<BJ<A*-=*I2GL@)G?"'L]KIVW[>#_`,/N
MC[20&$9O!UE-<.9N0"RCF>F)J@]`QR9GFC!>0H4D)(#G/F#(0!@/6NB<M*J:
M9[("S2`0"`0"`0$B&ZO<".ULWK0KB\;Z"F$ZG+T@US!HUS?.MQ3"#G(`F`8,
MUZUU2EYFF?7@,R_PAK/2_A?P[/[@.C[20#PA[/;9]M_!LG_B^Z/M)`4\(>SW
MJOZ__A]T=73T$ZL!CP^-!7<MZ\]U0[41MN'LBIB7LLV8I+=B5PGJ`765"8]?
M/'TPJ7ER)5<$Z]9\6L!K5=FS3AEK*4M>ILX^I`5VRX--.*6G!UX"DI::[=9\
M/!Y'EZ0%?G[>MLZO4XH"FV4YSX9?/V<4NM`5TX]-O'^C@G.`I.4JM-G7^9\S
MJP&S9\6KN_;IH[JBUB*XG%V/4@']<P40KV(7#?(#%62]0=7/$4LR7GRI2X)5
MSGU8"?">0UGI<+O_`'@='VD@*>$19WU8?Y/NG[20%?"'L]/3_&_AX/\`%]T?
M:3K0&H_\8^<"0Y][[E0N()OIJ:<56_47,\P9+3$E2B%J:I\P<!+F*-O_`+5$
MH"#"`0"`0"`0$U'B[2ZDMG?/8*KJX;Z"EIS\?HIPUS!DSS5%=E;F`43Y@F"8
M,B3J%%IEYFBJ<M=>#@#;S^$/9[U7\>G_`(?='#_@2`>$/9[U7\&G\'W1Q\']
MY(!+(>ST]='?P</^+[H^TD!3PB+.^K#_`"?=/VD@*SR&L]+A=_[P.C[20%/"
M(L[ZL/\`)]T?:2`KX0UGM=.V_;P_W`='VD@'A#6>E_"_]X'1U_\`L3K0#PAK
M/>J_@V_W`='VDZT`\(:SW#VW]3^\#HX_^Y("OA#6?]5_[P.C[20%/"'L]/\`
MA?\`Y/NCK?\`8G7@'A#V>]5_4G_X?=''L]!(#W>[K:KF.D]M/U#H79#E]@W'
M_:?9+L1SW)[$<O\`NA]3Y.G*_P"5IR?-0'__U<_B`0$2SPW4J.^,YU/.9>R>
MOD9<JRPCUDU:V58C?K8*CCJLN\B^G%84R#43Z96P5]QDI#&*=>D3G75*5>FR
M`M@;6Y-4,:K97'.8T9#7)>-\VUBA<C$#")8NZJE`D/$*W]X''4><*VT#227F
M>5W(UZ#()DD=,2Z1,%)"*2ER!:M`[!GN,[/*%X$^XSGOU>IS,I?N/CI?B^EE
ME$VDU,6_>0V-3-1VPT;M/<:0$E`(\XU5ODU==(@:%E,^%.JO256P/58NX2QC
M;#S&FZ+C76N+8-ND<MREF,9W">3@;=63KS90W`U[\C-(V4`[*G)++=>"P7(4
M&=:4ZI1$%"\W*4X#O_!'=6L+"2X55UC-Z+IW_N"A8]LG$:U3ANA6E4"VFQ@M
MZMS<C9M"V@$@((,TG@+80`XYTQRC1B94&5<]*)0$FZ\VVZZ"4DYRH"*XT^0M
M(])!=2R*N2D,'^L%D64`#`$A:-=E7)UEK`0^[C<J5(XR9#DB1<`H3*;P_.8L
M5*%0@RY8J6`OBN`@%BY<*F@(```*B5-%%,I4TTRE*4I2@)G8#`TWD7PXLC/X
M\A^D"+PP%D4`@$`@$`@)*-T=\/2R_P"R='WLJD!G`0"`0&.!XU1\4H\/;SLI
MZ=*4!K#=O6X9Z3X_*G*`K/J[/F_JP%->#K]3;+RX"DI2G/76<YRG/CGLZT!6
M7'P\/]73R(!/AEY/Z4X!KMTX^'YFOS8#:2>+$?%*6F]L&Y_IT7@,@V`0"`T]
MWC+WQR667[KMSTB*P$#$`@$`@$`@)OO%O?CM<"/;`N#[B%T(#<=0"`0"`0"`
M0"`0"`0"`0"`_];/X@$`@$`@$`@$!#3N0/@VY(?G%L[/=U7H"9:`P--Y%\.+
M(S^/(?I`BP%D4`@$`@$`@)*-T?\`#TLO^R='WL*D!G`0"`0&.!XU1\4H\/;S
MLIZ=*4!K#9Z<'5XNKL^A`)<'#\WJP#;+K_HX-O!*4`EPSZLM/U9?1@'T/T?.
M@$I</!KQ^3+@V0%.+;IK+AG*<]=.'BVP&TE\6(V;I2TWM@W/].B\!D&P"`0&
MGN\9?^.2RQ_==N>D16`@8@$`@$`@$!-]XM[\=K@1[8%P?<0NA`;CJ`0"`0"`
M0"`0"`0"`0"`0'__U\_B`0"`0"`0"`0$-.Y`^#9DA^<6SL]W5>@)EH#`TWD/
MPXLC/X\A_>^BP%D4`@$`@$`@)*-T?\/2R_[)T?>PJ0&<!`(!`8X'C5'Q2CO]
MO.RGITI0&L-UTZO'/R./;`)<$N&6S32?Z<`V2ZTI?UO*@$M>MQZ^7Q0#7AUT
MX=/TY</'I`4X^#26NODSG+39IQ0%?Z^GD=?6`VD?BP_Q2EIO;"NAZ=E]?GP&
M0=`(!`:>[QE[XY+++]UVYZ1%8"!B`0"`0"`0$WWBWOQVN!'M@7!]Q"Z$!N.H
M!`(!`(!`(!`(!`(!`(!`?__0S^(!`(!`(!`(!`0U;D'X-F2'YQ;.SW=EZ`F5
M@,#7>0_#BR-_CP'Z0(L_H0%D,`@$`@$`@)*-T=/3/2R_7J=,O\F%2`S@(!`(
M#'`\:H^*4=_MZ64].E&`UANWK<.LN'@V:_-VP#@^?/9P:?JP'C5MUV;9?0X>
M#@GM@*REU=DYSUGIKP\,H"L^O*6G']'R-/)@*:SG+9MGK*?#II*>V6NG6@*Z
MRX)\?%.7T8#:1^+#_%)VFX/\X-S^#@_NT7@,@Z`0"`T]WC+WQR667[KMSTB*
MP$#$`@$`@$`@)OO%O?CM<"/;`N#[B%T(#<=0"`0"`0"`0"`0"`0"`0"`_]'/
MX@$`@(E]V!O-77O*&D4N>1QEJLY:1<8\G<V7@8OLQKD+!X^*X*48LVEUD-U$
M2UYH'31<`X:H$/<F55!725$^7*<@Z;O?OM6K9W(JXMN"^.;P>>/%B\EK!8DW
M_P`I"+\0DM'MQ>F_I8H.FD"%N1T,XK.MLL@5;2RRZ?I428A<V?D&$`-2'.NH
M.O&[XP+:DP[&PYWYCV^F'B!=,3-,&Q>5G;H@.`K<RK!9L.UU7;-&+8@)*<IM
M1+6T^WZX"@C"*INL\:(R#K#!D)RZ`N.P*WKIC,6]:;8:X.,CNQO>EP,06)G?
M9'LQ<!"N&1N5C._W:79J:YE`9'06]4RG645E9.Y]'%D<KHH-SG,>4P]!`F!@
M(:=R!\&W)#\XMG9[NJ[`3+0&!KO(OAQ9&:;?\>`_2!&G`60P"`0"`0"`DHW1
M_P`/2R^S_E.G[V%3;`9P$`@$!C?^-4RUW2CPE_ISLIZ=*4!K#=-.#79+9Q]7
MY\`E/9/7;.4MOZ7ER@*\,I]?A\KJ\<`ZNG#Q]?9`-=D^*?7ZOZD`ZT^'3R/*
MXX"FW379*>V6L]OSY\4!M)/%A_BD[2Z;/Y0;G^G1>`R#H!`(#3W>,O?')99?
MNNW/2(K`0,0"`0"`0"`F^\6]^.UP(]L"X'N'W0@-QU`(!`(!`(!`(!`(!`(!
M`(#_TL_B`0'HJ,E#L>>DE3*25)DC4DVH_0*(0I4.9KZ',Z&7%`,"$^D3IF)3
M1717.B4Y2JE/2<!C!V_P,RYPMN;D5O`V'8+&&UC]8V##]Q\L;B5A4CN^;'O[
M?5SO5(<-N;BW/25P^ADDQ*3W07)E3!2B8@Y5,G4-6?G25TJ#YKGW.F;-RK@W
M39#T>]@R&,^8N6V)^=64AY'D[Y7/:-TK1-ICJMYK66N(C5BI9]I/^Y#%`[$*
MALS082$X6<J@1ZZ9\X'`FSN"\F'4S;:8=7@NE:)/PSQ92]Y26Q]>#/*N8W>9
MY#9[-2ZC3;P-R4@X,514FFT(EY551J$)FA>RPA4`"NF@.J>@7Y;M/=U9762R
M*8F1^7;BLU)?Q]W<UKMV;9MO64%<IX@[K:6_?*,^U2[[^-.:@&M,>CF/-9-`
MDFDJ)DBE%`LZ:Y\O202@Y;X;6&S>MF6M'D,W5UR,@FX"#F`(MYY.ICGJ%=.H
M%H*C]F&BJHZI6%12-5*8<Q9AU<<H")?<58UVA1,2;PM0DW#$T9BYRYBL1NAF
MEI8.FB[:9]W5-!0RIH\9/"&SYDNG$@Z:QQJZQAJI3KKJJJG.<!-%X/%I?4Q^
M^2E]E0&$?O"$=.;V9M_T9)`Z,GI[R"!*@<NL288?8)'$Y/+$KKKJTJKGMG/6
M`LS@$`@$`@$!(ANL&^DNG-ZT*(MEI'$TY-RR,%^<%!Y<@VXIBT2YP*N@24^7
M3+@G`9EG@\VE]3/[Y*7V5`/!YM+ZF9_X24O)\]=6`>#S:7U,_ODI?94!CQ>-
M`VC83.W53M6V\B]!4J+VV:+TF.F'1I2"'6%&D6B=`PP@?FJ9=36`UJ^W3JSZ
MWS](!Q?J?I0#@E^I^EI`4TGIIK/YW!KLXI[=("DYZ:;./6?'/CXNI`>6NV74
MGMEU==.#RH"FS;I+@UEIIY<M(#9J^+5V?M^[MU3:M;7T.9U1&?URP:S'3#@/
M+#"6"](<N;`'HHER9<>D!/CX/%I?4S^^2E]E0#P>+2^IG]\E+[*@'@\6E]3'
M[Y*7V5`:D'QCY`2FOO?<J$5$+=#32:JWZ`"_.""\B52(6JJERQ:JZZM9SXYP
M$&,`@$`@$`@)J/%VT),<V^=P50UDOTM-4'X_0S9?G!`N=H#LK<L>B7.!54"4
MSD*%3/9.4]D!MY/!XM+ZF/WR4OLJ`>#Q:7A[6?WR4OLJ`KX/-IN'M9GK^Z2E
M]E0%/!XM+ZF?WR4OLJ`>#Q:7U,_ODI?94`\'BTOJ9_?)2^RH!X/%I?4S/_"2
ME]E=:`>#Q:7U,_ODI?94`\'BTOJ9_?)2^RH!X/%I?4S^^2E]E0#P>+2^IF?^
M$E+B_P#W4`\'FTOJ9_?)2^RH!X/-IO4S/_"2E]E=>`]WN$VPYCHW:[]1Z%V/
MY/3S_P#:G9+LMS6O2>5KT[S>NNO%P;(#_]//X@$`@$`@$`@$!#3N0/@V9(?G
M%L[/=U7H"9:`P-=Y%\.+(S^/(6O^`$;]*`LA@$`@$`@$!)/NC_AZ67_9NG[V
M%2`S@8!`(#'`\:H^*4>'MYV4].E*`UANNFV>R7'^EQ<<!26FW;Q\6S379Q[>
M&`KP>3]&`\9;>MU9RG*<^I*4]FD!76?*TV>7PRVZ<6NL!6?'MX?T]GE0%.#Y
MFV?'KLX-L^'24!M)/%A_BE+3;-/Y0;G^G1>`R#H!`(#3W>,O_')99?NNW-/\
M!%?TX"!B`0"`0"`0$WWBWOQVN!'M@7!]Q"Z$!N.H!`(!`(!`(!`(!`(!`(!`
M?__4S^(!`(!`(!`(!`0T[D#X-N2'YQ;.SW=5Z`F6@,#7>0_#BR,_CR'Z0(L!
M9#`(!`(!`("2?='_``];+?LW3]ZZK/B@,X&`0"`QP/&J/BE'?[>=E/3I2@-8
M;M\GK\&GS-9P%)2TUEQ3ZG%/3RX!LX^&<YSEPRZWT("LM-G%K+724OU)=>`I
M/K2VSV:[>#KSEM@*\>V4O+^;U.K`)>3K*?!+R8#:1>+#?%)VETX.Z#<_TZ+P
M&0?`(!`:>[QE_P".2RR_==N?-_:(K`0,0"`0"`0"`F^\6]^.UP(]L"X/N(70
M@-QU`(!`(!`(!`(!`(!`(!`(#__5S^(!`(!`(!`(!`0T[D#X-N2'YQ;.SW=5
MZ`F6@,#7>1?#BR,_CR'Z0(T!9#`(!`(!`("2?='_``]++_LW1]["I`9P,`@$
M!C@>-4?%*._V\[*>G2E`:PR4I2G/JZZSZVO7\B`;-LN#3J3EU)2UX=8"FLM-
M=NFO!+@VZ[=NW36`KLUX>';UI2E+AZVL`E/7;P<'#\^6G%`5TTGLEP\/Z6R`
MIQSGIIP;>*<O)UTGL@-I)XL/\4I:;@_S@W/X/W:+P&0=`(!`:>[QE[XY+++]
MUVYZ1%8"!B`0"`0"`0$WWBWOQVN!'M@7!]Q"Z$!N.H!`("U7-#,2SV!F/+UR
M=OR(Y@K9,(1'#7JF@C@+R_RUQ5+(Y"1-+,*"6"8U-FZ>7RAZ.31K/;/9`0+?
M*_MT)Y[R5[T*'[X4`^5_;H3SWDKWH4/WPH!\K^W0GGK)7O0H?OA0'RY^.'[H
MJ2G2G=%RHF%.6O925GFOV,I^HU#:55SNA(YKK+F__<_KYRXML!]3Y7]NA//>
M2O>A0_?#@'RO[=">>\E>]"A^^%`/E?VZ$\]Y*]Z%#]\*`F_P'SWL)O(;`ELD
M\;Q7>+;<R\'(QZ)OA!+MM=I7&K,C)5IK32JJL`R*Z*`4PQ)#3G7*<]92T@+U
M(!`?_];/X@$`@$`@/Q,&"Y0`8T:'!+%BP(A@P8,"T`@```T3$&&&&$JI#"!"
M#IG5555.4J92UG.`MML#F1BOE0HO5)QVOU;2\2I;D]2GO-/8SE)K!M#$%''*
MES8Q<*JD0TCFS!86@N?`D*1,543D&+5.4!<Q`0T[D'X-F2'6WBV=GNZKT!,M
M`8&N\AE.><61FS^'`?!+_L!%@+(8!`(!`(!`24;H_9GI9?\`9.CYO^+"IP0&
M<!`(!`8X'C5'Q2CO]O.RGITI0&L.ZWSH#QG/2?%PREUY2^9M@*3E.<]."4I?
M1V2V0#S,]G_LSX^+K;>*>D!Y</4GMV:0#C\B?E[./RX!/79MEU^+7BZ\!M(_
M%A_BE+3<'^<*Z'!^[9>`R#H!`(#3W>,O?')99?NNW/2(K`0,0"`0"`0"`F^\
M6]^.UP(]L"X/N(70@-QU`(!`8^?C0_Q+^4/_`.NMG]_R)`:A.`0"`0"`0"`V
MLGB??Q/*5_ZE[X<76:'EP&4I`(#_U\_B`0"`0"`M'S_9K^N-@?FQ;VU)8\=N
MB_,1\D&9;8FF#]&4C;^=%FWDALXLGF>6%T8Z.XCQ:D*OET\@2<IZRTU@,>_<
MS-P\^<Z<>[L6ZL]<.V]K\?\`<,X\X9W^./&U3KM&5+Y=(UX6JY%"WHJ>[$1O
M#.]S,MNM=6K.'BH1L`M2=HIJ&E,Q1*H,AK,*W^4MQ+4]B,2,B43&FYQ-7+J@
MS[7[2MR\9(ZA%`!ZCJ!2UG/520"'/U\CDF*9\X'.G9PSE`8T>ZCQ0WSB[CQ<
MA;8^\3;6.A!8RKR34UECO?!]@.!66G:>N*?-.:X!0VZ9$3Y5%>ZH)6=*%0@^
MB%@JI4`SG1*4!)OX'6_0_+'6J_`"LW]EP$=UT?%[=X%>.X#GN<_=Z6R%5X/!
M0DIKQ\MB&T$L$T<D5+E)"!$$]S%R1:F0!:B7)#HIIUEKIK.<!P+Y-!FC^4\9
MWX*+<]=<!3Y,_FC^4\9_X*+<]=D!7Y-!FC^4\9WX*+<]=<`^309H_E.V=^"B
MV_77`/DT&:/Y3MG?@HMSUUP#Y-!FC^4\9WX*+<]=<!VE9?<#[Q*P%Q$*ZEL=
MZBQ45YMN9R:0H&\/F8L@`=.*#$C/.)ZHXS1$;EEQZJ9<NBK3766DY2G`7^>!
MUOT/RQUJOP`K-_9<!9SE>W=_EC<Y,54%!WE[.NH#D;DRP[`KJDW\!;4T%[6(
MKR#4!#5RE_H1-6IJ0T.9*FD60U94*<Q):C4\87C>!UOT/RQUJOP`K-_9<!:[
MF!N<]ZKG79@]8')+>S6\=]L5%P(+H-HR5A3;MHG*UEM#BF4@Q2L-E;352@,`
M8:J=0<A945RGI5*<!$U\B^N+^4/1-G!IC[I]!^P#Y%[<7\H@B<&GP?9^OV`?
M(O;B[9?C#T3;P_[OL_7[`/D7UQ=-/QAZ)I_Z??\`S[`5^1?7&_*'HGX/O_GV
M`I+Q+ZXTN#>'HGX/O_GV`K/Q+ZXT^'>'HGX/O_GV`EQQ.W0F]?PELRC6"QXW
MM5NVG;%!4U973$93PFMPZ38)Y;'I,J(E:PXEI15!J1A:)3E34+.FG@E*4!<K
MX'6_0_+'6J_`"LW]EP%J.+3)W]V1'=N[.[SEDVOG:.]CNM*F37<!+45=NJ:V
M>C<P]$OII9+Y*8K=(^IR#Y\/S,]!*H"Z[P.M^A^6.M5^`'9O[+@(2LJO%(LA
M,T;XO+(O(+>1MIU75?HQ4=S+:;C40:Y,X*3+T%2]0**WGJGI).5`-$I3D$%1
M*<]LX"W;Y#TM_E`DKO%&_?"@'R'I;_*!)7>*-^^%`/D/2W^4"2N\4;]\*`?(
M>EO\H$E=XHW[X4`^0]+?Y0)*[Q1OWPH!\AZ6_P`H$E=XHW[X4!W]BYXHK?O#
MB_5NLEK![R!N->[MJE)25F4OJ>-A)S$DX\K("LV#PIA"<#V4$A0I$1ULR'*D
M<&NFFJN5<I2JIIG()P/`ZWZ'Y8ZU7X`5F_LN`LYS-;N_QQ5;=CUYN;RYG7C&
MN[DS:6P*DFMG`6U%`[*1KEBK@:A<I3Z`36:YHC3DD4U&9"4@!3D-+E#![-0O
M&\#K?H?ECK5?@!6;^RX"VO+;=#;V'-^Q3MQOR+WM-NG;:9\")0KC0TK":W#4
M.FZT52+JR?,)<;BRG*Y7FCI:BJ?-BT\N4IRGLG`0J_(>EO\`*!)7>*-^^%`/
MD/2W^4"2N\4;]\*`?(>EO\H$E=XHW[X4`^0]+?Y0)*[Q1OWPH!\AZ6_R@25W
MBC?OA0#Y#TM_E`DKO%&_?"@'R'I<_*!)7>*-^^%`3"83;E;>A[O6R0./.+6]
M@M^RK6`.I?>@:(L876_>9REP.?H79@U-:=2ZJJM00_8\+DA<[,,/3S,I:S@+
MNO`ZWZ'Y8ZU7X`5F_LN`BY[L>_\`NV;M0\-%`^-%_%L=L?@(,+D=J/<C[N/A
M><SV,Z)VE?P5YG^Y?.?5>E])V0'_T,_B`0"`0"`0'XA``@\YS((0/.BUCB\U
M12'SHXFG.#"<BF7+%$T\U5/6J?5@/V@/R"!"!IG0"$&#3.JJN=(=%-%,ZJYS
MJJKG31*4IU53VSGPP'SUQ>0VPDGEYR+*4WD-,`K-*2RN*)-)24\L'+40P>43
MXQ<F4`HEPUB5TTRZL!YI"RD.%,)+2`JIJXC*0%)I.5D@\54DP^6KUE08)'R0
MHQ4T!5.6RL.NJF?5@/I0"`0'$6Y<!AO%0="2T7LT72JLA4#0WHF-QR(RXH-!
M:%+4G`D=T$DPZ:,H"H(4KD+27-TA"S#G*J5/)VP''&S>VSSR2U!<:USF*MHZ
M6ZUQB*"H1<Z0(0*O)M&)%7"V!#4S5(/9M'-3YLR7E.8@5>RJ4IR@.:*#H;*2
M9)$E5Q(28<4M)IQ105T\F9/RJJIIIF2`,F`Q36M5<I2Y$JMLY=6`]56>S,0%
MA';JZ[6RC.!PS%I0$)57DM/65VH#D\]2C)9LT$>5*@N7+E2`#$G3K+7A@/G,
M&Y+`NHBFW';AXMY[H)%=6FR<56RJ%%8F3<3;/B)C@0S0Y0021=41U$"H(R!7
MR1`A):3EP0',A`01IA\Z#0),(20H4Q`Z:IABTS\R)1.J4YT5RUV52TGUX#]H
M!`<9-O1G$'&GLX\[&R2=RL6$.)36-KR66<:F4!GH,:3T,8U0IG"P4_UU8855
M-/'.`^V=/D4PL(<4CI1/)A<GG39TP"4+!<JJ5%/.#CUAA4<JJ<I2UG+6<X#V
M:*Z1*::Z*J:Z*Z95T5T3E53735*4Z:J:I3G*JFJ4]93ELG*`\H#@5R[GV_LX
MS%BXET':CLED($BTUAQKAB98@1F=-@$"=%55%`@H@IDX9##HHHIJKJJJEI*<
M!S,D<+*),HH$AJ3!,\6`.$S%'*E0.5-!4#@#4RJE35R1`JY52UE*>DX#CIU^
ML9->"+;Q1>C3(/\`<B6HKC=8QUQ(Y5X+Z*CU4TJZNBMD<X&M*B6EU5TR,F``
M!`@)SERZJ=8#ED`@/S#"#"Y4@PJ`^77.NOFZ*:)55U<-=7)TG57/CG/;.`_2
M`XTNO1G-<ZCISE=C9;J@XC4R+?(+JZEI)U=.RERIDT<J?-%QU,U*6WFP*:Z]
M.*`]QP.-OM-)-K[I749M(2?316?6G`J$D9))4""4A45FU)1'+$RU-8M=-,IU
MUTRG5.4N&<`H<;>$2B2Z&NHU:(I4E*TY9H5"-24H4'^3T&LDH4CS*&J3G+ES
M4PZZI":RY.NL!]F4Y3E*<IZRGME.6V4Y3X)RG`(#KNY=V+;V:;Y1UW1>*,R6
M^?<;<9Y!47!Z@`#SH=JJ`B-E!)4!T"C&E-:535```0=-55==6NFDISD'8-%4
MJZ::Z=M-5,JJ9Z3EK*J4IRV3TG+67%.4H#BPK]8P+U+6U&>C3"N,=;HKO)L`
M5Q(X;U-M,`_4ECN@LU:CDET=N@J=$RU9V@"9:D>4PYU\O9`<L@/Q$!"'Y,AP
M@Q:0ZZ10Y"44URH$HUY(E,JJ9RI$IUGI.6V4!^T`@.-*CT9R&M([;6G8VD=Q
M.'G.P""J+J6GK2YS.O.]ATLV:!/*?-<F?*YD.ODZ;8#[APZ33BHYY0-EB)(L
M',4R<.#A%BI<*G]<(.8'KH""#EKMG5.4H#]0A0APPQ@1`Q@1:*1`A0JZ1`Q*
M*I:TUAUT3G3715*>LIRGI.4!^D!P"Z5TK>62MZ[;KW8=Z*P;<,1''7G>\'$:
MZ&BH*07JHH$.GA]!*I43%&HHIIIIJK$$JE33*=54I3#FY4P"<+ES9:N8A<T`
M"9`$G16'.L$<.D0*N=`M-`E$Z@ZY3TJE*J7!/@T@.-JS]8R`ZFBQ5UZ--%>]
MP`W$*PF<K.)'374]PF@2*J3L%:+>.'`5=RAMA..@F%&HD"-(D`-16-R*:Z9S
M#ED`@/PZ*6UY71@.5S_2M>9#UZ3R.;Z3KR=>?YOS/+_7:;-=(#__T<_B`0"`
M0"`0"`0"`QY=\VLL)-RBW:97+]4"0=W`>N7<KPBE=T"G"MGZKJ`LX2JP"9>E
M0HEV%3V"?=?+D8%6*PDFFNFGGZZ9:0$=>4^<UFK4W'E9_#?-=F8.8,(F,%ZK
M[V&NA9P!MBL#)+*QJNU-25BSS(<#A1UA&=B,BE*PS(:6W*IA+8YKF2M1@:JB
MF06QO/>=[TI48%\;WNR^SILLZ<:F/NZGH-9`BQV820G&XK^KJ.W7K0^`CZ(8
M70DIQ(JA6HU)88Y>@`V8HIJHID#(*0?<?F3^16(JCOU%^WF9[Q3,@&;E=90%
MAV?>O:`IJ+<M]=)^6O3AKJ);(4T,-R2045*=(3>*F:*>Q58!L*8DJS8E`TP[
MPS@S,R\Q2NMD!8E^[Q5Y6VN7BUC/;ZYN)Z$OMRW1-P[P:\+W>2T.LIIQ(";`
ME#M)26!`6X4;Z5(,=.(!T&1:.10,8F%\>YK<K\<"QOC7>]4$5I7.6;R,ARNQ
MKR!$+CME^*.,R*J+R!T<6NL<`5&<`PI?D553JIF'I.<YZS@(/6C;=R7AQ=W`
M;':]KK;WJ>UZ%3-9POJWEX7*IM-AO.Y*HO7%%<"N^E5*17`?[+(*B7YT&J9,
M47G2@=,JJ=E<@Z!W@&-[NP]>5E\6\CK\6$-/UL[M>ZP"*[KU'7^I)*6_5NZJ
MJNMYLXY'B:I-R=U-KE5(-/;QXP741I\U.J9:J55(=(7J'KLL2U64.'^2RJ%:
MC**Z[YMAA#8I\X`Y!J*J>SZL0[B2.WPT"Y=AD2DH&HK%:H4.@K:J:I3*"5%5
M0U0PG2=``PGRW+PAE/N%O6&>@A4RM.W=X@_U!C&`)4]!J<SJ:386+HDRDZ9R
MHIF4<D@ZA:)4TRI%%G/;.<YP$ZL`@$!@:YBJ;>5,U,T$56/\YO"P=Z;B$6Q$
M0A#9V5[Q\99!)([E&M4D4B=F#-K)IM)VI3$)AS(Z2JF-/64!)9OY,OL%+^;N
M!\/)%R$`I<-N;ZF[<V[+"+EPK7!K-ZV"O)`+[;@#>7R+4HN"9:*32(/0)($Z
M1"ERA@!)[:H"[K.W-=Q-'="L')/#"]:%6JK,\>FFV+KM/L(\DKFEY606NXJB
MM*B`?2CXQ<2H4,2D2BK2NB<I\<!"#>K>>YIXZ(N0=H'QE-<9T(%N<\FI:.N[
M81.W[6NMVAN:QM%R!D,D]#B(38S8#[;C5%`51H"B70:9@!3UUU"]UL7$>V=%
MJ-U/AR^,ATG)EXWL>ZEEQDX^6NNLUPHQ&U=B5T123687<[+2TM%&,E'7T(B.
M6%+R,##4"RKG7+DP%LR7E]O$;K7YM`EIN;UP&"W;U[RV^>#P+;;K'MD*E,FV
M*`@'5A/7T8-2:AP4Z\T\4G(,H:-U#4E@Y^9HE5M@/N;MK(2\>1^\JW=3HOH]
M#5Q7XQ;/[S"S=;W4RA(HM.9#M;=`HV$-67I)Q<J4'7#1$M*9@6@.B5=>W24H
M#-"@$`@$!A'[[-:MS/,[>"(E^U,@5N!5@;8R>[@3W2=,DUU2OL:?P(;EHQX*
MUBT#*-Q)JLP:#5*936<Y$]*O,3@+OMY?EEC%=RY&[RME=^XZ8I8PV`RZ4K4;
MR,I<%)=S2M@Q[H`X]"*]KVS=A?=2,A-I53:W<>K$Z0"9-I4A95R&&ER*Y4A$
M!<QWV:8>Z`Q(<UTKMG6(;3-XDJNK#]"<UPW.V`US%\')@5147HEM,Z?)ANAG
M);2+EA2"D:!'H+HPH<R]<BXDM0R;]Z+F"_VKA/B'=S#&]Z<A`9)97XB6G0;Q
MM`FWGDFJ5LKYJ9U%/K;?H6R2FB*(0Y04$T7$J"KHJJ"IUUIG.4P@`O\`;T_-
M+'UMO"Q3PRHN$J$;5[P+.+'(*]5`MNF;=!U(]DK=LQ=M"$ZGFLHY9HDD\-Y/
M6JM3`H!!K.)X,J`Y52`F'6$H;,<SIS>N9NCL77K?5OY-"VSMP7WB65=S&DKM
M=R,=UN%'`&:EC4-/7F8G)R2)T=\JBL?*!S+@B#%4X(6O6<Y3J".^UN7^\@O/
M5A&XSN>=SVN5S7NEO&;+.-$;K+M<"1MTV\3#BNHLQ;8]1AHCBT/!8%2I`&U`
MU,P+04KJ#!Y$Y2JD%P&ZER&NIE)O*,&+R7J7J73<I;W/MT4AS.?HA<B8<1IK
MY?.5NA+1XL4#"*4**D73:13$PJ*`ZA:ISIIE+9`9AT`@$`@,%#>LJK2.YB;T
M-!N4I!`YO25MWX7W8B&;.G@WZ>J,.=HBG!K`)A82=2E3752K5N*HA0)2$-*4
MC_)KYN4PDXWT.5F&-[]U/EXVUZ_E9"Y>.CBJL>JHIE;N':L:67;7;B,HJ%MZ
MJ%0DU2-SE)/2U88U302J5$JH67+H%J$"\R'9.6>>JG;?Q>%U9G86WE;BT[K;
M6:LDG-.YC8&2G>E$G2GW=M?;5^I8LC81P@:/$.FJ2<;#$IJJ"&Y<ME5,IR"-
MK)K>&YGX9K&\2QW>F5-Q;DMRP&>N[)MS.]AI#8B!=],M)F'8=9O5?-NM1PED
M1+8;#K!46[21;ILZ6#*)H0W1Z:Z1APQ*0[%8-W']O`\5-VMA%<?)5)R?>^;N
M8-PKY9-G$-T,%Z$K>X785ORFYARRKV6K=I24`GN5P*"-;M)4*C0'.FE]95*`
M1:B=`,PPX0^\Q-X2Z;TN!S-S--^,)JGO&-7KN>6Y;E"9-M#3:;%A7M;T\Y9O
M<.I6:QT\M7&9M`Q<)!'/"#E"(A>8TP:Q!*YS#YN&V05Z<@-X9N6>[R_E"Z;W
ML=DMXP5C<2N,N%"!1S/%HV>MW:-$:JPZNQA<FGF7#V*'I!'&"!#D+(*FJ=/*
MY4YAFKP"`0'_TL_B`0"`0"`0"`0"`])13D]7(FTQ5(DU--/@"%3R>H%0#I$Z
M5&IG0,7-E#`8I<R`-1/2JBNFJF<N&4!Z)EM-PX62B1M`1#1-"%*#HA0PE$1B
MR,.GAR"(#)0`H%82>*2"ER0:@I43#IV4SE*`^U^CC_1QP'S@4=(`4C2R`E)P
M"P?+@E3JJ"1+!*1PJ7JJK+ES1Z@*DT.`!4).=%%=<Z:9SGI*`\3B(C*)Q.45
M!(3#R@D"UCI)XX0*&CJ6,)3.@05/-#@UC$A:Z)\FJH.JF<Y;-8#WQ@0C`(I<
M<.@8`<.L$8(2BFL,4(6F=`@8E%4IRJHKHGI.4^&7#`=#XYXSVBQ28ZU;>R:$
M?;+*6K@/>Y8B";75=<*)KDN$LB+[E"0:5<V;FAH(RJ,(*`G%N;)E)B52"#II
MGI`=^?H_JP'QQF^A&54%?&1DNM>+%1B)1=J3RDUHH3,2JI&+E528/3BX(DJI
MZT4B2IGQR@.F<=,8[.XK-)V,NR[=-M]'?5T']>5WUJ*TJN!3<%Q[F*_9IX.-
M15%DT<."CJ!J@.BBB54@@0`0PPZ:::92@._X!`?@:-%B)8P=.F`"9,F`,:-F
MS0P9<L5+%PZA1S!@<6J@(```*B=5==4Y4TTRG.<Y2E`1,3WO.$SI=RX<M&P<
MJ\GQF"IJ;*4;KXPX'929!,5+5RXU0:VVD>[-N[0+C:4I@CASD/)./CE:ZI;*
MZM)Z!R'\;19_9_NG;TW_`(6>='S_`.1'6`?C:;/_`,TW>F_\+/.CWDH"T3*[
M)/$+,&BUAZXF,N^?9CQLD[5![6GN19K=^;PBV;]8[A5DJI"5S:4L(MEZBP]"
MFD5S`$H-EC%-$O-!\BN7+@.(XK7$W;>&#@-/*P.[\WK#>?2HTZF:O/=P;O#>
M4O=Q.!+,+IATJAM2J>%NEA)#7E]QFQ#BDH%BI<X?&J^K"5TRIID%\U>]KLX'
M16*+BCO2@0@J*JQ!!-UKG-0'111*=5=5=55DM*:::9:SGKI*4!=5BEFCCCFJ
MS5IZX\W`[:RS47!FN^6PMMYS,.X=O'07IY8S<N!;E\I#>>K.6)42G50$>(@R
M&HE.H.==.V`NF@$`@$!8YEKG'B9BBXK9MN]ZDKN6[CV/&S=G[06PM*^+^7T<
M8Y2B8*BM,NV=KVL\7L"1*43F&*H2+`%I3^I\[.KS,!T,J;U.QJT1-)2SAYO/
MEA,.T<T<3E/=49OJ">;#E72)((R4-6.%+CARKHE/2JF<M9:\,![0.]ALR5""
M+E\2-Z.```'2$``!NK\Y`@00J*94T!A!AV1D&&'13+25-.DI2X(#]?QM%G^/
M$[>F3UXI;K/.CY_\B,!9-E??+#3+]?MR]7YC3OJF#<2U)%X(K+N/9#`7>%VM
M>I!M7!)DR+V:YA21K+"%%!#<15/!D+2,!6.#6'*HN*#5.JJ8>[BK>7=T84FU
MY3QMW>F])M\L.MG,%B.=8$W<6\B=2@N-JV9`RGM`F;J>%N%TN`,2H/&!C`Y8
M,`90.&1C)JH8<6L287F?C:+/Z?!.WIOD?BL\Z-9_[$=("GXVFS_#X)N]-XI?
M%9YS[>O_`)DH"OXVFS_\TW>FR_\`ZL\Z/TK)0#\;39_^:;O3?^%GG/[R4`_&
MTV?_`)IN]-_X6><_O)0#\;39_P#FF[TW_A9YT>\E`?+-;TVPQ]13E8[AMO.3
M:JDS'[%*9O=29NF%!+Z2'S9CL>=%L969)=(HER:^:JIE5+9/64!]3\;1:#9_
MNF[TSJ_%9YS_`$>XEI`/QM-H/YIN],_X6>=&WR/Y$IP%J^6>4^(F9C-8#2NM
MBOOBD,Y:6[C4OO:9\VOW=F\#MZ_K;W;926XT-NO9M+R-9?FA#I-%=RF5F7/%
MSA$0([5.L"8E`588=5XKO+=MX=7"5[RV:P+WMDKX.IKO%K/V]+ZW?N\MN#<*
MX@-QKEUWAN*N/,XZK<J2*I.Y^7(YI2554(B">-]$*%JA)$R10N`%_?XVBT'!
M+$W>F::?DM,Z.*4]DISLEPST@*_C:+/[/]TW>F<?!NL\Z/+_`,R4N/YL`_&T
MV?\`YIN]-_X6>='O)0'R5W?'8W,U'4'3<*P>\?MLQT(":@Z[@/[=G9OMMDLQ
M"`JIFHN5UKYNR4RZ0@(Y><QC1BJ57-A453E35/24PN-_&.8&]B^SGA:6+[">
M#IX6G9CM^1.Q?@X=N/<[[KG9#G^B=JW=`_:+7E\_V9_L+FND_4H#_]//X@$`
M@$`@$`@$`@$`@$`@$`@$`@$`@$`@([-[2IJJ1NW\O#:*J***?$M,?3I*22;&
M(*`!195DA(4J"QLO52,#4:33PH54Z9RGR!)RXX#H#,>^#AW?6Z.0W?C0WVVT
MG$UK668MW;2NIOE#32MX=>P#?0`GDI-\+H9$X0;PBB(=%#$G2$*//E"\J4ZI
M5!TA<.Y%_=V+::TBPF9&7QSYO5F6\+96HMHR<J'?;M'M4U;MNTI0K+[^)/6V
M5G4-WM>WA<B().A`!#/A5!RHD!6&)+E5!;8I;]C+<H_JL5BF)UA1\P6O>F[=
MB+DB';V/@GC^DKMNK?RN,EO%L+9:VRF^UQ!6424Z!D\8D6-`F*J:9#SERJJ0
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M;.Y!<FS5%0H#$I`$/)!(U6#2-.B8E0<])S@)H(!`(!`0OX*)R8^MY;O7[JNA
M.*JC^8#\L?8UH.(?GQ3:%;(K;JMRR;2?0*,*`3`,K8]1@>H*@.H6O3E:REI`
M300"`0"`0"`0"`0"`0"`0"`0"`0"`0'C+77CTTEU.OLTZW6ZL!A#]Q.S7;MW
M,NY/;OM#^5B>#=VL]J2+V.\';P??"Y[@/(Z'R^X;X2'^-W:=KVM]E?-="Y/F
M8#__U,_B`0"`0"`0"`0"`0"`0"`0"`0"`0"`0"`C@WO'Q;.7'M:!??0WH"XT
MI:*VE^\4VS9V\3,1;@VQN%9AGMQY,YP`5F$E=1SK529#E#,@A`3`-4ITRK#%
M"$#&!$IIK#KIKIE5(+-0]RU@4+;=7M<MM6^#Q0#QAI#("J_,L<H'L\;:T6_/
MS4V$4M"\7-=I1<%K";..Z5D0T,<E*4Y2YWG=):!SVWVZ6P(MK2PC"!991/.*
MW3D?;S1'RY[L7D=+]5WC<U*%0WTZ7T\5NX!Q=N(NKR6-6#,9<&/]%IGJ6D#/
M;`>N6W26"J2>L6H-6V+Q8P^.R`]V?;<1DWPO@VS4F/<<V:4'LQ'8JD+AT+3V
M9K@43E8XZ>J&30%0G)V<FFFF0?1>.ZEP@>%CK38]TVS=C.8-A'2HO:R2A;N]
M-ZF1<BU;L6)FNRZXS;LH5P"MR4XXI@GA@AY5J@H8@(DPYT\C24@YA9'=M868
MYNZT[^L]98!I/:RK&>]NV`YZ7O<=742C<N4L4.%_B.*A<>"B2?#D=R[1THXL
MK0*@KUB_K3--/F8"U&Z'QZ^+G_H!O;[J"=`3*0"`0"`AKW<OPZ]\C_ZE[->X
M[1`3*0"`0"`0"`0&$GBEOPLWTG'N_P!;W(FYJ)<3+B_`[#,[MIPJUMV&T0W2
M)>2X2G9.M`#;K$9:"UEP*QKO;JDJF3BH7,2-!`TT&9BA\L.0<SQ8WBV\,RU0
ML6,:WSDM<MG/$?'K*/)_)6]>.UC[+K^2]W4.S>0+GLNV;06.8QFVJQ;)LKLQ
MD:@P.<*MHT<,T<V#3*50M8D!V^D9R9)WV5-U_97%K>&Y-(;=R4R"S6M3=:\M
MXL5L5T+)`J6L.UT58;3-=C-=EFW!;>E8:*K48*C*1%%3#"D$).HS1(:4N0'3
M+4WBN\6R&RF=&[%4<JQ[9O['"XV8R(_\PK/VIM4C/>^J?8)M-P]:^0[%=S6?
M%N&%54NN6F;E+)B?.D[04K`+B%)USKI#H)F[VG>1938^Y'WG;V3JI8UT[NW#
M&PMXE-,9UL+1J3;R=NN_7>M$'.N7:3W8R%\8BTE%MML4$)*;HB)27',R'"%I
MJ#\V%V]K=[W=B\68Z@\;W7"S2L1CDR,J;.8A6^1<?;1XTN3&E4NV]6BA&QTW
M)]]W#)+E\SJC<QP+-81`FV$TL40BO,#5FJ*ZZZJ`S!H!`(!`(!`(##4_^^/_
M`/V5]?\`)W0'_]7/X@$`@$`@$`@$`@$`@$`@$`@$`@$`@$`@(W][S\6QES[6
M8?WT-Z`O5LO_`)G;3^UHQ/O62H"%;/LQ>R[F]3PJQ!:.5V16,]JKCXS9#W.=
MIG'9V-MH+ZJ[K?'TV38.J1ISM!YIIY/*2,SD,7%*SH%#EIK3K.<!!/?S?'93
M&\4+?8\*&;S;LO?E(R&R<3#&8*X,TK>2NI:'%D\9+M@A4832I)K&WQ<%R4A(
MBB`G$P`#X^O-A!SG5*`[;S2WG-][VH^[IN996YN;:<QKM[OB]M\[@,S!=>MI
M3<HQ=BV18H2H=KU+/<N(EG6*UEPL*:7R98`=1I3*Y\P6$JE.<@[C>@N75P$[
M<BNUQ[R3*A.<>?RZ58&0)C'&[+-;]JC)%'MJ?=!1Q6M3J;4\TA.@\,&#0JCF
M*#0`AD,6FDO1/S4!E[M])K04%$0ZU567JT9(34JM<7S(1U>6*DXF"3FJK1P`
MN4!-JZC,'GC(M`05(@U=54J*93E3((@;H:2WZ^+>L]/]P"]WNH)T!,K`(!`(
M"&K=R_#KWR/_`*E[->X[1`3*P"`0"`0"`0$:S/W2&![(<^++S1K.5B.G#4V^
MCMA%M5=;F53S;'N(84CK@I6*SBF)2["P)Y9.#D05&1D$@8,UB@4T"<FJD.*.
M/<UX1JK!M6S&LAW6M$X;'.1_.BS]Z;,WGN#;F_-OCMT5]0<C]3T:Z:*L4KQM
MNN-253$Q$T_TPB%0-7($(.=54YAQ4ON/<&"-N[+V_299&-TY85\W4N7;ZZ+1
MRBO>RKT%GY>N@G1<]SJ5T6>\4)T'#SM#(T4&*:10@::*JZ:**:1!)5!]!\[D
M7=^.JVUMK:M9@W#LJ%:E3N"J-6X%E;S7+9EX#8UVR,DVZ@3RNJ,XEAZW"#N"
M1IYI2K73:@/71.<@A`N55J'H7%W&F[SN*);T`2WK_8[:8UM639M:8=M+O7`9
M+&O#:BW2L77F<PK[-],6N9NJAHRP5H,2FI55FAZJ94C#"!RE3(.>N3=`83NG
M(\KDJHM:X!=9#?++NRIVD2[IO-,QX<MYK<I-*&Q+R.BRY12#:*U<MK)8=`95
M1$#_`%]$AJPZQ_JL!*!`(!`(!`(!`8:G_P!\>/\`_P!E?5__`([H#__6S^(!
M`(!`(!`(!`(!`(!`(!`(!`(!`(!`("QW>546K%P+RI#O:9>A*V`EH7%0Z3EN
M2)=4?10.OH]*4::B:<4$<JHK8"Y,K6``(;*T#52Y%0P<I\ND.FL(G!O'2&,M
MHD^[MH\5W4KDF(U06^[@\B;J,%SN5GR0R7:PI7"MT#B[<E'9#^K1.8[*DD]T
M.`E2<YSFS54H"/?>HNG"WNFV9_&8V)QD[J?::[^Y%).RQSW[8>T'I8?;MSL\
M;L+]>U;I&G3NRTNC<C7E^8U@.U,-G5B;W6T?P)K$[N[NC^#6B=K'<KRQO3VM
M^#MV=&YCM8_W+NYW_=[G.R_0?V\Y[E=DN.`Z8QS=.`O=18O@^V*PR[HW8',3
MM$Y.6&9W0.U;LW5X7G0YO3##M2[7>S/*Z3SO]BZ<KL7]3Y4!SNV+JQ([5=WO
MW.+$XG=J/=EN!^+VY>6.:/8WNK=CE3MT[1NV+"[7L5V,Z5T;LO\`M%S>O0N*
M`F.K=68\J*IT6'QFJ$E35.BFO+.Z=%%5>GF::JY865U4TSGPSE3.<NI.`C%Q
MI%NR>WN-W53-0@W&M?DUC(ET8OL:T*LK/VP:%8,)YUR>AA*NL[$2V[^=EVSS
MIY%2Z";9J*D%0>123%,5<JJ`G3@$`@$!`PSC=]$G>QY?J&$B`R'^PQVC9\KF
M0T;\.]Q6@827=_L"9FRURR-Q6(R+X.5>?DVCK2OI2TUTU+YCD5%%'E\JF`E0
M[:LQ?8)QH_"QNE_0N@*]M.8GL$XT]?\`WL;H_P!"Z`IVU9B^P3C1^%C=+^A=
M`5[:<Q/8)QI_"QNC_0O@';3F)QV)QI_"QNC_`$+I0%.VK,7V"<:/PL;I?T+H
M!VU9B^P3C1^%C=+^A=`.VK,7V"<:/PL;I?T+H!VU9B^P3C1^%C=+^A=`5[:<
MQ/8)QI_"QNC_`$+H!VTYB>P3C3UO][&Z/]"Z`=M68OL$XT?A8W1_H70%.VK,
M7V"<:/PL;I?T+H"O;5F+[!.-'X6-T?Z%T`[:LQ?8)QH_"QNC_0N@*=M68OL$
MXT?A8W2_H70%>VK,7V"<:/PL;H_T+H!VTYB>P3C3^%C='^A=`.VG,3V"<:?P
ML;H_T+H#CKK=N=P;<6*V/C_B2==W0Q:6^7=F8%Y$QN34JYRH!%63:1@ZK*=)
M$MRIB5!@@3K&Y$@Y5A<OG:`P\^QN3_8CF.W1H]V;\;ITWLIW,2O9/Y07V[]D
?>UGL#W7.PGXLWP"?VG[.=D>W;L1^W'8GLM^T<!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g662896g61o14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g61o14.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0S<4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!3````E\````&`&<`-@`Q
M`&\`,0`T`````0`````````````````````````!``````````````)?```!
M3``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"C\````!````<````#T`
M``%0``!0$```"B,`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``]`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TW.MQZ\:X7W_9F^E8]UK7!KV,:/TM[)W?S.[Z>U85&=3]LPF8.<_/
MH?=9N=:X/AX+:GAKFLJ=[&V/9L_F_P!)_-JST^S(NZCC691)M]/J#6[AM)K&
M3CMIV-+*G.;Z+:?=L0<@]1/4>F_M%M+;M[M,=SW,C=7L_G6,=N24WK[7G+O]
M3(OJKK-;&,H8'ZN;O<YP;3?9_;?[$FD.VQEYWNXFDCN&^Z<3V_2_.1[^FMNM
M?9ZC@+""6\00UU,M<PL=[JWH9Z/623ZA$\P7@:?R6V;4E(WV5L;O?F9K6S$F
MF()\?U1%IJ-QAF9E@C7WUAG_`)]QF)OV-7+G>HXN<9+B7S.OYWJ_RG)/Z-4]
MSGN>2Y_TC[M=-O\`I$E)OL-W_<W(_P#`O_2*I=2KZOC"MV$^S+:9%H=8RMPX
M]+T]F)?NW._G/W$?]C5_Z1Q(,@DO)&FW1YLW_13CI#14*?5)K#MX#MSM2-GT
MG/+_`**2FJQG6#9ALN=96+P_[46V-L](M'Z$5N&(SU?4_/?9Z7IJ^^Z]O3J[
MF.FW;67.+'62"6>I^BQ]K]SF;OH?0^G_`#:%^R6S419KCP*=#[=OT?S_`'<_
MGJR[$ILQ1BW#U*MH:Z=)VQ^YM_=24Y?[4ZBQYKL@EI<"YF'F.')#(VL<S]W<
M[U5/%ZV[<1F-L`<=M8KP\L&0-SI]6CZ*M#HG3&WV9#:8NN#A8X/>)WGU'Z;]
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M7_PJUZKZKM_IF?3<:WZ$0X<CW?%>7='(^RG7_O*I@?\`H;]%:>'U/*P^MOIQ
M[&MKR>L=0-S7"9V5UN9^<WZ7T4E/H22Y@_6)^'B`OLD5,PF0YI?KD6>@X^IZ
MKK[;?2_TO^%_G+$!W5ND-M>UW4\AI#\IKF>M=#1B[C?M>ZO\]OO^G^B_F\?U
M4E/7)+DV]7Z.;B'=3R&O:_%:X>L=N_,:+L)I8]S?;Z-?Z3_2+2QNOX>91Z^)
MF,N9%CAL:PD^@=EK6M]7Z5WTJO\`II*=I)46Y6ZTUC)&X6>E'IF"YS/79M=.
MW;Z?^$^AO_1_SB&>HT^EZGVQNS9O#A63HUPIL?\`]N>Q)3I)*D,D&WT_M+=W
MK&G;Z9^F&&_TIG_1>_>AC/J=6+!F-+376_=Z9XM=Z=3X_EN]FW\Q)3HI*B<Q
MHLV_:A.][(],\UMWW,G^K[E%N?60#]J!EM1_FG?]J'^GB_YWT/Y'\Y;Z:2G_
MT>UZ5:&]0I%CX-KNI^@S:X%X^U5/.KOW-OL_TGYB-0*7Y[7YV'5A6N9:\,<Z
MMQ)+JVONW,C<^QG\XIXN'?C]0K%UKWD5Y=AL:QPJ`R+Z[V-WO<^OU*F-:VMG
M_'/0^B6X=N0TXF9;G5BJP>K>27$A]>[EE7T$E-L8_0VL+0*`WTPP^YOT"[>T
M<_1<\J3J>CO?N<*7.W.Y+?I/$6=_SMJO))*:(KZ,&B/0#0T`:M^BT^WO]%,<
M?HQ=J*-VYW=L[K1^D[_X1BOI)*:0'20&PZF&06>YNGIRQL:_F;MJ&[%Z"Y@8
M]F.Y@!:`2V(LC_SYM6BDDIH-Q^B-(VMH!!#FP6\U^T?YB!?T7ZO7XS\=U-`K
ML8&NC;]`N]5OTMWTGN6LJ'["Z1#A]E9#M#S^_P"OX_Z7WI*<[-Z'TZIUF5C.
MK8\V6W7,]OZ1[JG5>F-NSW>W\]>?9[6,^KMS+`UKQTOIP()!]WVX[]1^=^^O
M5L3I73\.SU<:D5V;2PNDDP2'.^D7?G-4[L'$O#Q=4UXL#0^>X8=[/\UR2GS?
M)]'[??\`1C[9UOPX.,T5_P#2^@K.%Z1Z+@`;3.-T>(CF`VW_`-2KI>H_5&F_
M(;=B/]"3FV7`P9LS:?LSK-NWW;(W?SE:Q;L*SI^,S!L.YV&WI..YX@2ZKV..
MV7;4E/\`_]+U1TP=H!=&@)@3\=51P:>J>J,CJ)H]0,<PMQ]^W5S7-=-JOI)*
M4DDDDI2S\CJEU%CV?L[+M#';6OK%3FND-][)O:[;N?L][?\`P-6,_P!#[,[U
M_5]/2?L_J^I_9^Q_K'^8LW(;6:F&JS)91M?`?7EOLF?TON]6K)_<]/U/^L?X
M1)2=_6,AK2X=+S7$`^T"F9&WV:Y/YV[_`(OV*5G5<EEKJ_V9EOVN(#V>@6N`
M):'M+LEGM<W])[_W_P!_>L^]C?MP]2_(]?T*_H4YOI^GO_1[O2R/0^T;_P">
MW?K'I_SWZ)#J^V?M*_TR?6]=GJ[AG>EN@['5R?LGH>EM]M7Z#U?YU)3JCJMY
M<YO[-R]-T.BJ';1N;MW7M=^D^@S>WZ:'=UNVK=_DS-?L(G8RMTAV[:]D7;7^
MYGO9_.U[V>I7Z:KTUO\`=LOMC;;NW4Y7&YWJQNR/I[MWV?\`]E_S$*IC/V7;
MMMRCB^A7S5EBT-EL;?5O=F>MZ>_U?L_ZQ_I4E/0I+,Z4,CU[S<7;M-[8N].?
MS36_,/[O_<>OT_\`2+324I9W6NF/ZCC5U5.:Q[+J[BYTZ^F=[6^U:*22G__9
M`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V
M`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`%,`E\#`1$``A$!`Q$!_]T`!`!,_\0`O@`!``("`P$!`0$`````````
M``@)!PH!!08$`P(+`0$`````````````````````$```!@(!`@,#!`80#`X+
M"1$!`@,$!08`!P@1"2$2$S$4%4$B%A=187$8&5GP@9$R(S4V=M8WE[?7.*@*
MH;$S)"6U)E:V)W@YP='Q0G(T1497=RB8*7GA4K)SL[1E=4=G2()$A*2%E5B(
M&F+28X-49'159J;&AZ=H26DJ$0$`````````````````````_]H`#`,!``(1
M`Q$`/P#?XP&`P&!AG?G(32_%W6$_N;?VQ*UJ[6E9!`LO;+7(HQL<DX=J"DQ8
M(&5,!W<B^6^8B@F!E53>!0'`P%O3N1<*>-5#U5LO=F_*;1*;NR$C;-K&5E5U
M_P"ZBMRC&-DD+`S;((J."0J+&8;*+.3E*D@58OG,'7`^/;_<TX+:)=ZL9;/Y
M(:ZKBNYHR*GM?'&6*_;2U;FET&T9:G+I@#A"+J[IPY(0'[DR37S&Z>?K@3F:
M.VS]LV>LUTG3-V@DZ:.4%"J(N&RZ9545T5"")%$E4S@)3`/00'`A)W(-[[+X
MU<-MM[>U&6/:W>#<:[@6UIEH-2S1.LX+8&TJ7KZY;CE*VF=,M@8Z<J%H?VA5
MFJ8K9P6)\C@00%3`P!VLN2]IWTUY,5&V;OV'R!?:.VK#4YOL6^UCCW#H3+*:
MK"4^UD*C-\;6$-1;'6I5LJ1TD5=DE(QHJBU7.J<@B4+8\!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@?_]#?XP&`P&!3_P!]4M`<=MC?L/<=7S&U[-:*
MU8ZAI>%@==.]E2\+N:ST2Y1%1LK*,9LWRT"LP9N7J!98"%%D+D.ABF.`X%.'
M+GE;!W'M:<*N,L!QWV^I+[QT=6>/&T=V37'"R6F=XY5+6=5U_&;=<M:L:'4L
M+^6L#YL5E$))K-F[I7^N1$Q4.F!&C>5#A=5J<C*;0-![VV%K#F/VM-/\8>$<
MBZU!/O9<;]!.GL"[@+HV<-G"VM95>9=$?KJ.S(D*7Q\W0H#@;)N]-3<K:AP#
MH(:FY//>/NS..V@7MFO4FCK6`V6%_?4/6`OAK3M.PS$:6%1-)Q!@,Z2%=3]$
M'YH]`P(7<4N8')>B:$UQ+\F-B1?+)]R5T!HG?"1)RDP6NHZAQ&Y-4Q5BGM:?
M#(?X\TMT.DZE#E%TZ*B=9/J4R(%$0`)5:&YAUN$L=7UEKOCQK;5U<M5ICF+E
MG0T(RL1J+B4<IMEY(8B"KD6Q<._*;J)C`!C=.@C@6_\`Y/N_<\<#G`JK[KVX
M>0&L*3P[I_'':#+3=VY)\]='\:IG8;RG,;V:O4[8E1VK)RSMG6Y*0BVCYZD_
MJK,Y0,NE\TAB^8/-U`/+_>6]SO\`&U_R-:)_"G@/O+>YY^-K_D:4/^G]:77`
M?>6]SO\`&U_R-:)_"G@/O+>YW^-K_D:T3^%/`?>6]SO\;9_(UHG\*>`^\M[G
M?XVS^1K1/X4\!]Y;W._QMG\C6B?PIX#[RWN>?C:_Y&E#_A2P'WEO<\_&U_R-
M*'_"E@/O+>YW^-K_`)&M$_A3P'WEO<\_&U_R-*&']+:6`^\M[G?XVO\`D:T3
M^%/`?>6]SO\`&V?R-:)_"G@/O+>YW^-L_D:T3^%/`?>6]SO\;9_(UHG\*>`^
M\M[G?XVS^1K1/X4\#G[R[N>?C:P_YFE#_A2P./O+>YW^-L_D:T3^%/`?>6]S
MS\;6'_,TH?\`"E@/O+>YY^-K_D:4/^%+PP'WEO<[_&V?R-:)_"G@/O+>YW^-
ML_D:T3^%/`?>6]SO\;9_(UHG\*>`^\M[G?XVS^1K1/X4\!]Y;W._QMG\C6B?
MPIX#[RWN=_C:_P"1K1/X4\!]Y;W._P`;9_(UHG\*>`^\M[G?XVS^1K1/X4\!
M]Y;W._QM?\C6B?PIX#[RWN=_C:_Y&M$_A3P'WEO<[_&V?R-:)_"G@/O+>YW^
M-L_D:T3^%/`?>6]SO\;7_(UHG\*>`^\M[GGXVL/^9I0_X4L!]Y;W._QM?\C6
MB?PIX'637#WN>Q,/+2I>[."QHR,?R`(CPWHA`5%FU5<@D)PVB;R`H*?3KT'I
MUP)0]LK<^QN0O!/C9N/;DRUL.Q[UKF*F+=-LHU&':RDP?U$G+U&,;G508E7,
MGYO3*82EZ]`'`G=@,!@?&UD&#X5@8OF;P6Z@I.`:N47`H*A[4EO1.?TE`_[4
MW0<#A[)1T:1,\B_9,"+*`DD=ZZ0:D55$.H)IF743`Z@@'7H'4<#[<!@,#^%%
M4T4U%EE")(I$.HJJH<I$TDTRB9110YA`I"$*`B(B(``!@?DT=M'[9%XQ=-WK
M1P0%&[IHLFX;+ICU`#HKHF.DJ01#VE$0P/HP&`P&`P&`P&`P&`P&`P&`P&!_
M_]'?XP&`P&`P&!P(`/3J`#T'J'4/8/V0^P.!'[EI_%5Y,_Y/NYOWN;)@:Y%6
M_BY<$_EZ]O/A+]S]H>L#UP,KZ*_;GU;^OJM_VR0]OM#`V8L!@4]]W/\`3GM1
M_P#7"<3O\`]\X%PF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!"ON.
M;-NVF."'++:VMYU:L7R@:.O=GJ5A;D247AIR,B%EF$@B18IDC*ME@`Q?,`AU
M#`UL>+_=NYEZHD)_3T^X'D3M#9/(/A=IO2T'OBZ50ZE<6Y6ZUN\BG:+;LG4!
MYZ*&NI7JE&].+!`91I'*&,8ACB4,"?-5[UNU)G;W(VN3F@ZO6-.\<+;R-U!?
MMLRDM94X2H[0XUU-H_L5BLSI!JY76UU;K4W?-HULQ9+SA(\S-THB(+'*0,<5
MKOQ;;EM6WNY2F@Z3&GU%R"U[K3;5Y5?VYK1*=K'8U"/=X;9KFINP)LQ1NFH*
M+-<B31<S<CI-TJD5$%/*$Z^V)S!Y&<H-K<W:]NB1TR]J6G-VFJFLD]>24DI8
MFU=>P\;,1WQ*/D6;-PX@',<_(JW?+$(NJH<2"0``,"WI^_913%[)R3MNPCHY
MHY?R#YXLFW:,F3-$[AT[=.%3%20;MD$S'.<P@4I2B(CT#`TO-7=XK?&TI?N$
MNK-M&XQ>M^5'"'G1OC@8RE*%:*,XTI,<98C:!:97:K:IR"CH&YRFQ]%-XO8`
MNHEW)I-W")R&,0>@"%S'9_W1M+;=OYJ--D7R?NK:G6+BFA5T9QZ#LD&C:>)6
MLK584V!?*442S%BD5WBWM\ZZIC?+@7)7+]2%J_6W.?VL=8%<G9C_`,V/Q!_X
MJHO_`,.YP+/\!@=3/`H,',@CY_6&)D02]+S"IZ@LUO)Z?DZF\_FZ=.GCUP-'
M7MJVS?NK]T[ONS";V+4$&?%SDTK?+BEKO>ULA-:['KV]K))TZV;@J=YB$X2^
M7B0K#]).&:511R!HMO\`H@`/B`6/=[IS9[8V[5TC)3)9&D3LYR%4V9;;%4-X
M)ZS!_,<8)-*E6"_U32L5([`C51NKE!>%;>[F]&7!$%`!,JH@$:>.G)WNJUSC
MS36M4C]LPJ?&7M5ZZW`;6&TM8O;)L+<>[D9[8>O5F\_:'S;XKTD(:#8V-O$`
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MYBH>'>PO'">AT]:6.5=UY%^]>^LX;QYE'1&@HIK^H`%,%MO`/9O-/=O)[E5-
M;YO:45J/3L_7]:T;5T5KIS"P5CE)W7U&N,G?8RZS;..F9N+8R<FZ:-"`@0/(
M8P*`4Y?*`7%8#`8#`8#`8#`8#`8#`8'_TM_C`8#`8#`8#`C[RT_BJ\F?\GW<
MW[W-DP-<BK?Q<N"?C_\`X\N$P]?9X?4160Z_;#J&!E?1/[<^K?9^KJM^`?9^
M)H=>H>/7`V8L!@4]]W3].>U'_P!<)Q-_P#WQ@7"8'BFNR==/H&PVIE?J4\J]
M2>3,=:[(UM,&X@:Q(5PYDK"QL,PB_/'PKR"4(8KQ)RHD=J8!!0"B&!Z&%FX6
MRQ$;8*Y+QD_`S#-"0B)N$?M)6(E8]T0JK9]'23%5=F^9N$C`8BJ1S$.4>H"(
M8'AK1NC45(LGT/N>SJ%4;/\`1^.M8P=GMD'`R!:U+W")U[$3AF\J]:&+&RM\
MGV,,V5'H5Q*/$6J8F65(0P9-_)_I>WY<#\'3ILR;.'KUP@T9M$%73MVZ53;M
MFK9NF95=PX75,1)%!%(@F.<P@4I0$1$`#`Z6!MU4M0.1J]GKUD!D1FH\&!FH
MV8!HG(H"ZCSN1CW+CT"/VP>HB)N@*I_.+U#QP/,;8V_J_15(D]E;BOM7UM0X
M=Q&-)"TVZ6;0\0@^FI%K#PS`KAR<HN9*6E7J+9JV2`ZSA=4I$RF,(!@?+:MX
MZ5HDW3JS>=O:OI=EV&'FH%=MM^JM:GKN'JM4?[D8>:E6,C8Q!9ZB009I+"!U
M2%'Q,4!#VTU9ZW7%(9*PV&#@5;%,-:]7TIJ681:D[8'I%E64'#$?.$#2<P[3
M;J&2;(`==0I#"4H@4>@=Y@8[V3M[4VFH=I8MO[0UWJFOOWZ44QG-DW:M4:'>
M2BQ#J(QK23L\G%LG#]5-,QBHD.*ABE$0#H`X'O&;QI(-&K]@Z;/F#YL@\9/6
M:Z3EH\:.4BK-G35RB8Z+ALX1.4Y#D,)3E$!`1`<#JY^S5NJ,V\C:;#!UJ/>2
MD5!M'T_+,(9FZFIU^A%0<.W<R+ALBO*3,HZ2;-&Y3"JX74*FF4QS``AWF`Z_
MZ>`P&`P&`P&`P&`P&`P,!<H-"LN3NB=B:(E+O;=>Q.R(4*_,6BCFB2V)M$JN
MFZTBR:EG8Z6B56\NT2.U<$6;J%.W6.7IU'J`4PTO^;V:ZUS%PT+0^;7+>HQ=
M=O4'L^$90!]/1R49L2L-W36N71F*&M2'1L<$V>K)M'0#ZK<BI@()0,.!CV%[
M)_&K;%AVUORN=S#D/L*=>.KYJ_=NS8*\Z*L9%I6!:$K&RZ?L.;CZ.Z8EG(ED
MS!A--WI@=(D3!)P`>7I@8VTEV1.#6_Z0\BN/O<CW)MO7]1N$#8)-OK2WZ'MU
M=B[I'1KIM7922/"4-XT&70B3*IMCJB81;B(%ZDP+=^%7;4K?#/:^UMR->0&Z
MMVW3<4)"0MO?[7/25E7(0"H&C7YG57JM?>.WJ#<H(%,N=4"I%```.F!.;<L-
M6;'J#:M=NEH1H]/G]<7>$M=T<2$7$H5&MRU9DV$W9UI2;`86.2@8QPJZ,N[`
M6R0)>94!(!L#7\U[VD^/W)K55*?:R[JG([=VH=0M+%KJDO*A?=$7&H:Z;#17
M&N[938U2*H;MC605UQ-GC'S$?1$\0\`IR"BJ43!.KMC:0XY::=[Y)H7F]*\P
MY*;FZDRV1\6OVK[H^I,S4(=>JPJ+PFNXR-59JGA8PC!,[P#E%*.!)(0!$Q0"
MSZY?J0M7ZVYS^UCK`KD[,7^;&X@_\547[/\`O[G`L_P&!P8P%*8QA`"E`1,(
MB``!0#J(B(B```![<"OS6?<;X8;8W4XT'K"RVJU661LECI:%O@M$[@6TA9+I
M5$7:UKJ,5OE/7Y=-SE@@`8N".D232@%6041`QE2&(`2$Y)\A-`\6-22^YN1M
MR@:)K*MO(B.-+2T8^GG3V=GWZ,37JY5:Q!QLS9+5:IZ1<$08QD4R=OW2@]$D
MC=!Z!T.@N6&C^1M0F[S1E[A6&=>FT*A98C=&JMB:%N,)+.6S=_&1\G4]PU:E
MV`&LK'OT5V:I$%&SA-4/(<3>8H!DB_W;36HZG9+1L6<HM'J--B'5SLS^;/%,
M&,%"M!\CNQO6_D]1%JD8/*9<$Q^=X=1'`[^MV/7MHBX"V5:5J\M&72$8R5=F
MHU:..6Q0+]DG(,5V"Y?*J]8JL5RJE*'4`(;J(!@=D29IZ=?5DTY6M$JJ13H+
MR!'T66OI$]?W15%5T"H1I"^]'](Q1,'Z(/E'Q\,#]CHUA-Y'Q*B4`1^FT<N(
MF,.2.*\(Q*9,KQ>.9F`%BM2G.4%#)E\G40\P^.!_360K3M!P\9OH-RV9O7C9
MTZ;.6"R#:01+Y7Z#A9$YDT7B1`_1BF$#E#\\`8$?I;D%H>-WS2^+STK,]YO6
ML9[=E9\L)&K4AU6*]:8FHO5_CXJ@P)/N)N<1*W0*0RBY1,8INH=,"1"3^$))
MK0[=[%$F?03?.HM%TT+)@V,'I)O%F1#@[]`WE\I5#%\OAT`<#\/I16O<G4C]
M(H/X>P.1-\_^+1_N;-11P+,B;MU[QZ#<YW912`#F*(J!Y0\?#`_*<M<!74':
MLI)LT5VD1*3OPXKE`TJZC(=HH]D'#".%4KEX5!!(1'R%$`'IU'`BA#<_N,+[
MB8CS9G+P[HW']9F_=A8+E!2;2>,JRG'==3BFE3B4IJ>FI^4EV8HL8]@B[>O3
MF*5),QA\N!D#CYRST3R>H;78^I[9)+5]W87]3]TOE+N^I;6UL\48"OX%[2=J
M5ZG6UK((@;S`4S(`53$#IB<@@80D*$C'F>%CROF9GYT%W1&(.D!>';-5R-7+
M@K8#^L9!LZ4*FH<"^4BA@*(@(@&!\J\_!-6AW[J:B6S%-V#!1ZO(LT6B;X5B
MM@9G<J+%1*[%P8$P3$WG\X@7IU\,#ZQ?L0=)L1>M`>JE4,DS%PB#I0J0`94R
M;<3^J<J8#U,(!X![<#Z\!@,!@,!@?__3W^,!@>7M5VIU%8)RETM5>J<<LN5L
MB^L4PPAVJK@Q3&*@DN_70345$I1'R@(CT#`^JM6FM7*)0GJE/P]EA')U4V\M
M!2+24CESH*&17(D\9*K(',BJ02F`#=2F`0'QP*XN\38^1M'[>?(O9'&'>!./
MU]U?1++LB8O36DQ]TL[NI4^L3DL_J=+&7D&T14['9)A!@@:;7;20L(_WKT&_
MO)T%T`J6W_R0Y9[N<]N3C52^4^T^.I]C]N&Z<PML[>ULG4$=E[%V'KG2U7LM
M;AEYRT5N?8-*Z^L[Y1[.MV[4BCY`?3!1(@CU"`,!W%^?W+W3.TMJ-^6FP^/]
M@X-=N^E\ITH[64%08VO\A=Q?'IE!Z^VRRG:M-+36O99A7@1-%,5&2*AW!S=0
M'H.!L?\`*3E[+0W;B1V;,Z&W_M.9WWQBMQI=EH?7"%Y#7SZR:A>/'M@OJ+B?
M@RUJIMEY$QCN0]<2$3/T)\WQ"F/16Q`V5Q>X;2GT#V1KT:YPSXO:_&,V?64J
MM*S_`-"M0UN(+>*RU1DY4LMKRWII@ZA)(3)&?-!\XI)^S`D[HK]N?5WC_OYK
M?A\GZ9H=.H8&S%@,"GONZ?IQVH_;_GA>)OL_6)OC`N$P-51CPQY>L8;D%Q[B
M=56]#1G-79'([:>XGQBA'!55JIM#93R/@$$#)N%5!Y`5):%59"F!`6.G\\>A
M^N!D+0.M>XC2[[I*C!*[4T]4J)!:/;:XKR5*V[8]8'H\/K9%'8^OKU#U*39Z
MDB7LO>W#TCF1LK=66C"$:G8*>B!4C!C&DZ9YM2NV)':7T9YF2.UUN.>@:%M:
MV[E;NI.NMMLD[B^BKON*"T822(JV:ZW^IZ,E'J[>+32@R1#0JC(I5P=F$,V6
M,W<9N5TY;$H]>Y7ZGA;)3;ZQK,8K>-CW&2@K[&\F8:)K4[KZS7-H%%@G4]IM
M5[)L6%)9D@&4*X0174>O&QW)@F^]U?R/K'%CN":<CUMS;7<_2>W5_C<YV?LF
MZ2%_L5*MNKJ'Z[>/V@V3DKQ(13*[24SZ!Q%4Z(%4;%$K<A2$"/7!WC%R\XY<
M3.;2L/5EZ?R#MC%9AI-C*;8V'M8Z[ZC:M:0=:DHY;:\''(LC'EEE?AI!249J
M."E(L!42``A&ZT<;.1V^I33D,S6[@[_1E2Y:\'+_`"([VO\`L.M[7KE]K\G=
M4.0URK\RK*-;RQU=!0[V)<)>5<D0PF2KK19$B%(.!/?FUPJV5RWY81,(R<5&
MI:8L/$"S:XV/L.V:E^LV4;K/=U5*Q(U[5DFYMU;BJ%LI6-CU7*,L[;2Y6Z1?
M43:BHF!L#'RNGN9T7*W6_P`!:-_SMS6YHK0%`J%UMTC,:NK7'ZM:V0-4)B)I
MLB!X1A!/KL<WOTPH11\N(F3,J"74@A&Z"IG/RUP98&HVSGW6SVB&U'"\D9K9
M-@L$;.Q.SWF^*REL*5XVOY0KUI6*HWUDI(E<J5XB,(C&^11(@.@$X!/KG9Q<
MW7LXG#:@\?K(DQG->3FYFI]M[JI2?(V"K17W&C954@)3:T/=)(#6U.T3\@VC
MUGCQ5=;WAT"GIK&_0S!7/I&D<Y=<O^.='BV.\>.6F-5\=.)%<U-59.,W!?XR
MFO\`6K&QQ?*"H[73I3ZOZHLLI8):%49H2ET9$8H5E>+DH))DJ55``QAQ%VAR
MFW)($E76Q^0TMLRXAH2]Q^LY^[[)V%7++KR+Y40KC:>[X%A86C+6^NXT])EH
M^.^!P:!R-HXIU45BD$PF#/[_`(Y\_5HE&?+NKGB%@F./6T=AS4,VV[.MHUMR
M"@=IRP:PK,=&(LR%A8H::D@'P)J9)C*MC]7R;H>@@'?O(ON72V[=[R4K>MV5
M239,-]+T"`K]0VI-T:XT%YJ"9;Z9@ZZZ92"6AZ;;X^UDCG@R168689A-PV5,
MHFKU*'T;)UAS?U72MO5ZK;2YBW&$9)<,]HU-O9I;;^QK#M/8+VA;L;<CM,&V
M7J)>)W%INC6FPP-5<N'5:_L=69Y5N1-@$6_>,S!?Q0G4L^HM+>ST+)5N<>5.
MN.IFNS,L2?EX"6<0[-:1A96=3(FG-244\.=!=V4I0<JIF4```V!ZS`8#`8#`
M8#`8#`8&`N4M:WK<N/>UZCQGL]3I.\K157%?H%QNKZ;C(*JOIARVCY2PEDZ]
M#6.5CIZ'K[AVXB'!&#U-&63;'6051*H00J^[?>A]N<9],<I=$[?XT)4JA[+Y
M/;<#6M>XYVF0V$TC=</M-UU(T^[FMA0>O7X1,PXIH,(N572<R4O./1.^;M_.
M98X2([=\+O\`J87RDVA?>KGC%2JKJ^J\>0Y5536%0W[$O*_%2L3<*\Z::KA*
M]'S.OHF,:1!(U_*M22:SGW@/471`JF!9M@>,V*Y%G0+J["`G+4+:JSZP5JL1
MD#-62=\D6Z-\*@8:T.&M;EIA]T]-LV?J$:+K&*14?(8V!2]QHH'(ROZ_YZH6
M2@[SLTGS*V^]8:QW!LFCT/7^\W<K8.*T=KYQ?-\T&DR%>H^O]5ZVF-<1]?@I
M"&CF\B]1.@HYC5%#G?N`R-P(U3LIONB@[!GM$6_15>T_P6U_Q4LS:\1D'!/K
MGLRM3M/?NW=4:0<E*DL%'KB57?BTEE#I$<!*@*1.IU@(%M5R_4A:OUMSG]K'
M6!7)V8O\V-Q!_P"*F+_\.Y^Y@6?X#`Z*T09;/6K%6SNUV!+!!2\&=\U_VRS)
M+1[A@9VW^<3]';`X\Y/$/G`'C@:U''3@#W*-+;3XQZP730:<:^.T;OFG[-=U
M;E_;8_3G*S6UTC[O(:W9SG&LM(;FJ.SB3UK33G9I9=SYQ2]=%4_D(F(2ZY$<
M%]VW?AQP.B=`:BU!JC<7!?DGHKE#5^+]DVW:K7J&?^JEE;(.7U$7=,A5I>P(
M/UH6Y+N86P.HET5I*M4#*I@03*IA7;N'MP]S3>&D[!1[Q0ZG?:_;-ZWZV5>B
M<F^0M(Y<;GT?2IC3K:L5U"G;FWEJ:W42*8.=G*/GSL6$.XFHF&<IHQJQ'*8J
MF#KIGLU\N+@6=J,WKO2LNUO7`^J:/VK?MPVNE;8<26WZ-JZ%J].<Z5L3C6J&
MZ=4QB,S''1F&2LNZKKTI2/TVX.U5@`/3..RIN:\ZLV\Y2TIHG0VVPX-Z%T+Q
MX8P&RY"7CM=;`J4O)CR`81UDJE4@@K,9O&K)$CG<JU9'<"C)*D.'E*H)PQ);
M.S7S#G62-FIN@--:4TH?DQ1-E3';RHFQ=/7:F/H.L\9;/I69V6U+M[2EPXU2
M=YF-@SI9\8:6KKAGZ'5R1TE*IH*)AE-GV@.7U4M]03T4Q3H;MYP.9<9KGN[D
M5NRA;[O%/<5[4ENK&M(W3%GK&FJ1M#45WIT[;EH><>U]XVJ=DA$6[I1C[XCY
M3!#C</;`Y)ZFI%!?_>7:DIM+M6Q>#FHYSA[K;;KFQT;>M^U1]-E-D;_V?;J[
M18^*J#>_-GA6AUW;.0?.4UCFDS_.Z"&8W'86Y)W34RT+>-::);R,+Q^Y21^B
M=='V3)3<-QNVMM'<U1O6H*Y2;":O-RH-J+78AX0DJT(FBP65]-LD"9S=`^[D
MSVZ^X%7MJ[NY5/\`6&K4F.N^/'-:)86OCVM66&XMH0>Q>#-ZU1K5C(OZ_1&?
M(+8.TT-KO6;IZ+ZT)PD<9))S$M"JI>;`AGQ([>>X>2^@9!+5&BFS20HW)[45
M\Y)P\=#Z,UYI7D]5$>($YJ2B0VC(?9''QSJ)W9^.-BDSRME96RJ.TW5JG9"7
M;R'Q4S<4`LD#M-\TT-V\79&-HNLR470%8TM$UK:=GN^JK/O]G6ZQ!7>.N]'V
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M;]0,[LG,(NET_B<6YL+=.0.Z1>HO4B"(6R<`>VN\X[\IN0')+;%1K\]<+!6M
M34?2&QYVX&OVT(&D0&NF->NT'-2R4-7HEL\D9EJ4'+EJR1^(%3`_E(4?(`71
M8#`8#`8#`__4W^,!@:V/\X+@*8Q5XF[1V+#\;;]4*I9+_".M5\H;W>*_2;0^
MGH%NHRE:_7J#$2\Q)VN!!DH8KHZ*J"#154IB=3%,4+(NTC]$UN#FK9"C4/C[
MKFJR[RV2L/6N,=LEKIJ9)J_LDBN#V(G9QC'2IY%^8PJOD5D2'0=&.00ZEP)`
M\R.(.M^<6DY/0.V[+L^MT"=E6K^PEU3=EJ+,V)@A'2L8YJ\Y)(L9`)&I2S67
M/[XQ.GZ;@R:8F_.>(0AM'9#XAV[5&FM5RMTY-@;0J%LA-<;+9;QE6>V8N@WB
M(95^SZJ<7-&+`SG6LG!1Z3,8SW<H)MR^1,Y0$>H=GM'LB\$=GNM='^CNR==P
M]!UO7-.R52U9L>6IM5VIJFK/DI&+U[MV,00=FN=:]Z3,95,5&ZA_5/\`/#S8
M$XN3L1&P/$'D/"P[-"/BHCC=MN,C6+8@)MV;!CK&P-FC9(A?`J:""8%`/L!@
M:[56`?O<^"(C\G;PX3!U]O0?J*K(B'V?8.!E;1/3ZY]6^S]75;'P#_RDAU'I
M@;,>`P*>^[I^G/:C_P"N$XG?X![YP+?7+A)HV<.US"5%J@JX6,!3&$J2*9E%
M#`4H&,80(4?``$1P(":P[CFD-ORB-=H\3=96V2&Q#42$JY(EN$M+LDQD#.+P
M0/?!;Q]48MHM91RH[.@NWZ%(=,JABE$).;.Y#Z/TO+UB!VKM"H4.8N3@K>MQ
MUAE$F3J4.=RBQ*L4@@;W9D+Q<B7O"WIH>H/E\_7J&!A[3W-'76[-C\H:73&#
M]U7^*<NQJMXNWOD4=E)VX*^>RS\/$0B3LU@]V@X\R9`>*MB-G:X*D0.?TQ'`
MQGI;N8:`VG46MPMS.WZ)8S&L-8;MJZ&V(U%BK:]/[D2>FUU?(52`=3K91E/K
MQ;E(6JAR/VRB)O61(`@(AD68Y\<:6MALE+KE^CKO>*U0:AL]>MU]4A"OZ1=Y
M(D9!3<98)06-8<HK',)S$]\!0I0Z"7S"!1#+2_)G0;.8MM??[8I3";H4.YGK
MI'.YENBI6XIB"`R3R16-T;%3BA<I@Z\AS"W]0OJ`7S%ZAB>9[@W#J#1UV[<[
MTJ;MGM+;)M(T]W$A)R[=ULD*O,7`M>?FCV"YHD5H.$5537<@F@H*B(%./JDZ
MAG&M;XT]<&M\?5?85<G(_6+IVSO<A'NC+Q]<<,5I%!Z5V_!(&BR;5Q$.DU#H
MG5(51NH43>8HA@=3)<DM'1S)\Z#9M-=JLH.IV$&+>>8"Z<1U_9OWM"61*=4I
M03N*,8L+`YA`JP)B/7H'7`B/<.ZEQ:IT):!?S[M2_4RF4;8-FUND5N>7BJC>
MKS#4=G,*6`BIZ<X0C7$P#IT"3\XIMDC#T$WS<"2ZW+#2#GC]LWDM5[G'7G66
MI:1?KQ<']14^*/6C+6U=DK-:(LC$/27":;,8M0"('*4QSB7IX"`B&%=;]Q/C
M_=8BXCLSXSQ_FZ:?6*<_4-RMF$8_58;NK5CM.K'4:YB'<U#3I;M"5"7,BV;+
MJNDS1RQ54B#Y?,'TT/=G"?4;)S;&T?J#CV\O%_M%!062C:57)2YRE6FQ8/':
MB]1(L=2*4?G!81='3*V.KU7!)0P@(2:KF]M/6_8$[JRK;%K%AV%6&A7UAJD1
M(D?2<,U/Z8IK2)6Y3I-O5*J42`8X&,4P&`!#QP(OQO<<X[2U3TI;F4C,+M-Z
M(;"<U:.2:MUYF-2UK6).UV$;#&(.3NHL1C(E4$0.7J=7H7VC@8Z8=SRG/=)Z
M[W<IH?<C6(W)?]6:\T[7C+:]<3VP9C;=.G+W7G#,6=S<1E?:-*W`JK.@E5V2
MJ0G(3R"8WEP/6V#N1:I@]0ZRY`M]?;;FM'WU4K><V1'UA`L3K=T6YJZ]=-+;
M'/'S:<=.65N:K-CDC6ST3$1%8GF1$IS!FWD;RVU;Q=FM1,=K/1@X3;5DG:TU
MM;A9LC#5US!PGQM5>8%10'9TG2'S$RMTUE!,'B4`\<#UC?E!Q\=V6F5!MMNF
M+6+8D5'S=(CTY,#?26,EH]65BW,8[]/W%49"-1.LBF*I5%$RB)2CT'`^-QRO
MXY-:B[OBVWZ>6H,K,>G*3I7BRK1>S$9#)GB(XJ3<Z\LY+&D,Y$6I%B>[D.IY
MO(0Q@#&&Z.?'&_3+O7\*[OD+;K;LVQZDAJE3ZE*QTC,R<5N2TQ-:J]L0ZN$V
M9X$Q98KWS`KZBS-,ZB)%.F!^6Y>9#K3^[:%I`_'G<UVE-GKO6]'M-3)3#5F;
M5A(U"7LY2+2EICG[7Z-QS@%''K($\X`()><?#`_O07/?CKON`MTG&W>$J4Y0
M/I.YO%0M$U%M9ZK0]5FWT$_FY4B+I9JG'"[CS=3$4.).I0.!3&`!#WYN8W%T
MD36)L^\*"2/N=C<5"K'/+>1U.6AHXCFSN"8QQD0D3R3927;&42%(#$26*J/1
M/Y^!^Z7+WC*M7[-:B[KHB=>ILW&5RS2SF5]T:Q,U-JG0A62PNDD3JC,KIF3:
M'2`Z3DY#%3,82B`!VU>Y0\>;977=MKNX*-+5QA!L[(^EFLT@+9E"/YIQ7&D@
M[!0"*MDU9YJHT\IRE.5P7R&*`]`P,ZI*IKI)KHF!1)9,BJ1R_G3IJ%`Y#`(_
M(8H@.!!?87/O5VJ+MR2JFQ:CL2IQ/&K2##?%AN<C"-_@=RJ<A.6&LIM:(S0>
M+34S(GL-=59H^9LFFY74("1C@/4`QL'<D9I3<UJU_P`;MS1O):*LM9BF_'-U
M(ZU-<)2LV[7MOV=$[`9VE"ZJZ\&K(5RA3"3OS2H.6T@Q,U,EZJB0*!Y:"[OG
M'2=E(IJE7-@,XN2J8RJDH^812+AE=2M+8J?6BM>"3-8EIY.4I3^-%ZDU/$?$
MBIH`Z$RI.H6<T^>=6BJP%C>PCVMNIN*9R:T#(KL7,A$F>)%6!B]6BW+U@=V@
M4X`IZ2JA`/U`!'I@1EY4\NX/B\[U/#.Z+.WZP[AGI^`J\9%6?7]-9H+5J);R
M\@O*639%IJ-;9E.@Y(1%,77JK*"(%*/0<#$&Q.Y-K76FU;!K^P:ZV">L4/86
MK]-;,VBQ/57-:HFY=S4BN7O76OW,(6?^F<^K.1]TA6QI.,CG<2B\ED$SN`\B
MXI!]FA.X[J_D,^I5>I5.N"5SN%E/'KU5TYK#EQ6J@2KURX?6%.2L;-O(1.!-
M$VQBA[NFX4D`DE#LQ0]=)0A0G=<OU(6O];<Y_:MU@5R=F/\`S8_$'_BJB_\`
MP[G`L_P&!U\M*,X2+DIF16!"/B(]Y)OUQ*8WHLV#91VZ5\I`,8WIH(F-T`!$
M>F!1[K[N[;.L5FX^[$M_%A&I\,.5&ZYC1&E]WM]F1DQ??I6BYLS&K2UVU<C'
M)*P=>NSVH/BLU&[UVNB0$S+II^<>@3`Y&]Q77.G.(C/E-0JI;-J*7G8%&TSI
MC7:D3(4&P[#W#L[8+'6-(JK@MU9PZM9CW5G?>=R^>)D328HJ*D\X^0IPA%<>
M]7,<97FVM?<UN,TYK_=FK)OC^<*II*R?7+6;31.0ME-5:_;HFR)1,$LS4K<R
M@LV?LW;9!95PF4C7UQ4)U#*.D>\GHJT;UWIHW=SI?4\U3MS3-$U5(OJI>"05
MKJ\-J"G;4<KV*RN*^E`UZY-V,Z[,K$JN`<D1;AU+YAZ8&0DN]7V\G%*GKZCM
MV=<0<#/Z]KHHM-:W]]-S3_:X6;ZMU*W`,J^XEYQG<%*@_3:*()&`RB(%-Y1.
M7J'I>57/VWZRN/%?27&;1;O??(;ES";"O>OJ3;[(GIZMUG6&J8.`F[W<M@V&
MQ,%WU?5:&MD:S:L`9JO'+QP)/(4"&$`]2AW&=/TBY:FTGR193FC.16Q8F$1?
M:]>14K::I%WV0J![>\I$/M"`8.JA97*$:W6,BLV7%-7R`01*L(I@&+ZKWK^W
M9<(.?L<3N.>2BH2G0]\:+2VKMDPZUOK4]:T*-&.Z"TD:PW<W59>W.4X_T8\B
MZH.#=!+TZC@>WEN[5P<KUPU_0;)LR=K5PV*%0^&5^QZ\O,))P![_`&`*M24;
MLSDH)NO4%K-/"#=J5\5(3&,`CT*(&P,Z\7^:^@.8Q;VYT'/V.UQ.NY]S5[!8
M)"BV^KUY:>8/7L=)Q\#-6.(C6%C5BG[!5%R9D=8B*I?*80'`EE@,!@,!@,!@
M,!@,!@,!@?_5VV-X<^KM0=EVO5&DN$/*3DS9:(Z8L;9,5&"KNO-?MW,A$L9E
MLE7KWM"8K<)<P3:2!2+J1@N$4'!#HF/ZA#%`/;<9^:TMO:ZOM7["XM\B^->Q
MF$`YLWPW:=2:2%-?Q3-VS9.$XW9U.?3=(<2X+/2"5D9TFY42*<Y2B4AA`*L.
M[%M.9>[&U_LO1%?W+$[TXZ6NY:G%6S<(=C\CM0VVNWB!C)>==QL9"QCA-<K5
M6.;>ZSC413!0JK83?.$,"=/9RUXUU]PHKA/?+R]G;CL+:6PKFI>]/S.A7A+G
M<[Q-3ED1@M4SR#:0JE31DWBA8U(Q"@=J!#A^>P+4,!@.OY/R?+@1]Y:?Q5>3
M/^3[N;][FR8&N55OXN7!/V_YO/A-]S]HBL8&5=%>&YM7>'^_JM_VR0_T`P-F
M+`8%/?=T_3GM1_\`7"<3O\`]\C\N!<&(%,42F`#%,`@("'4#`/M`0]@@(8%+
M6XNV)<KO>Y7:^N[-2M976;V-*NA9UXDY`Q->H2OP\8R0BE(!1JN[NHR[5Q*O
M/7ZM7+EWZ9BB0O00R1RRX);9W1>[E8*-;-7O8O<W&V"XT;(<;6KK^=G:9%1,
MO:)!SL'6!V9#-F=FD6UL<>=)42$!XBW6\WZ'X!)#0/%9QI2J<F*[\9AI!SO/
M9MCNL7*M8OW9S'1<KJ/7NN8]C.G\A5)!XTD*@Y=G,41((.Q`/G"81"#L;VJI
MO5?$'1.BM&6Z`A-CU.JZ>J^^+A-N["Z#;L;KK6YZ@\A(N<=?%)NG5E.QNUY1
MBS:%232*H=+H'JF'`\]0NUGMFC:X2U@2\ZNDV$MQWUUJ:Q6A2%F23C2SZXV_
M,;$9/H83%ZK5Z5B98&BA%S`LF=$H@'E\`#KC]HJQJ.N1T:[LM/FFVSXG=2>N
M[[.2=N=V6M+[O?5IW88>9K(`%>=1B:5=(DHJ4YU%4R)``!T-@9IMW;IN33;L
M#M[6TEJE):J\C=`;HB:3/UQTUKKF*UWQCM7&J]1RX1:'E;2\FRN:TRQ63)T]
MY8($5'QZ@&7^)?#JY:0E^2T9:I"FQ^G]P.4PI^G:4K-2E8JTC(SFR9G8-P:*
MV9(7L2;8Q[NS.XATCJLFKN/562\HN3A@0+U#V7+Q0]AU.YVG>$19VL*\N<5-
MQY8F3#X_K^H1:4-Q.K3@CE0Z!%=.L!<E=*`'1R+M3R=.N![DW:FV0VK[NE(7
M'5LG`6[1NI]77*5EJ](GF&TKJO<T#LQ-Q$ID3,B\A;+$QBK)RDX'S`8X#XEZ
MA@2[7X/RB.G.X9JN$L-9AD^94+L*,J`Q\.=E%456Z\?X[4!%I-@T*DFY!*99
MG?K>@4HJ$/T_/]1P.EA^VKJJF5WB[!4:&KC174&^=?;LVQ*65*1M<IM1[0M!
M[7T_%H.)"=6?N#*Q+W8#=S'$6'T&:#4X$*50WF$(U6#M>;>92-JD*===138;
M+B.3>O;6TO\`6Y>0:U&E\A]EQM[1M=$20*H5"]5=LP%L?U/*@Z\Q?G`!0#`G
M?P_XA->+S[<+Y:1A+)(;&M\/+L+`E$D;V(D'!U&&J[-C.22A!<.W)OA0JF`I
M_3`3^`8$%*5V=Z_1:]QM6KTC2(C9>IVF[FFQKTQC9SWB]AM>B6"JM%&Z#AZL
MBU&-?S!'"W5,OG`@@7I@?)KWM5V5UQQXV\;MI0&AH6GZ(WGH#9MJ2URIL,Z.
MXHK4^HK9K>RK6#XQ(D=PMCL3R48ND19JI()E24*/^MP/4+\$.6,16N*NHF=V
MTE?]"<:W\M(*4&W,[9"FO3^!NCJ1TS(VI6"3!"5+K^JG;^LV4+Z4A,-BN51-
MX@(9CY#\$;G9;)K38VE;-7)BVTK;MIVW,5CD,ZGK[1I-]9JTO!*0M>:IIG6K
M,<S5<"HD1,IB$*4"_+@1=+VKN0!KCH-1[N>DOZ+INRZ<NK6**PFHTL3(T2`E
M65QKL%%,FY6[R+L<Y,*KM'#M;SLV71L4H%`,#XW_`&J-VJQ-+?,K]1F*&H=_
MW/8^HM'QTO<6.MJKK^^:<D=7V2K,K3Z"EJ1=J6!^>>8$5*L@P3<.&1#>FL(`
M'>&[5.QX&P5:!U[+Z1K>HV]CX4721:/X6S3UYI#KB/'56(4HNN+%(>HX)4[,
MUK95$%G1RKH'46`Q>BHX%GVUM%2VPM^\9]P,YQA'QVBWNSW4K$.&ZZCR<+?*
MHVKS0C%8GZ$@+%9#U%//^>*/0/'`K'MG:"EK/KMS2V^Q*G79*1HV^Z[*V"%K
MSEB]EY?:&Y->[:K"TLZ;%([>Q<<:CG8ORG,=0Z+PXI^T0$/?Z1[9LO2]EZ2V
MO9D=9QE@UO.;[L]E:1YK!>0G[9L_5U!UG5+:U<6Y`J3*6KK.E^=0I"%(*2@`
M4?.)A$(QSG;CY:4>KP4PI.Z[W-M67V3PACYAY*M)&2J<HKH3<-MMUOVC=862
M28(1L!/M;=ZPQ$:DH6.11,1(#^`8'?N>V=M^,V;QN:.I"&>PFP]X[BVKS`0I
M$:6)UPE27\C5+S3-:PB;Y9&6-'L[A6FID`%(_K.#NE3@0%/$-@TI0*4"%`"E
M*4"E````*`!T```.@``!@5,\A^`NYN2FVN2LM<MGZ\A=1[XXQ'XY1$9!5V;/
M?Z@$!9K%?*!<S2#M3X+(2,/=)XJSI`2@DLW;%('B(X'GW7`+DM);,>\KI'=.
MJS\NW%BJ4>UDD*?.DU&PU+6M2[#UDYIZ4.989\\O,2>S9&>.[$W1)X5%`H>B
M41$/GL':K4F]7:YUD-^KH%UE0+&=C:?HP#2Q6[<]MNDA=96QVN28@F^-1F#^
M?E/<XQ%4#)'=D4Z^9$N!8/Q6TO.<?](5+5UCM0W&7@C2:SJ43,^&/;_$I%P^
M3B(4)19Q)%A8E-8$6P+G.J"9?$<#''-GCO>^2VLSZWIA],HM9N*MM?GWFWZ0
MXN9H9I:(7X*G8*61KY5(ZRPY%E54S&.F10WD`Q@`N!%&7[7;:=VKQYE9:7H;
M_7_'T_'&:&VNXB?<;ZVU9.,=7A(^@_65/J/_`*+2+1>U5YI(NW@H+2"J"7NG
MG!(P]`ZF8[6\^^V33MMQ&QZM5[@.RW]KOJ=;KSZOPS*KH6F&F*?"Z[80BS)&
M/D*S#PIVXF>%40=.)1ZLH41%("A;A<OU(6K];<Y_:MU@5R=F+_-C\0?^*J+_
M`/#N<"S_``&!\C]BUE&+V-?HD<L9%HY8O6R@=4W#5VB=NX1.'RD514,4?M#@
M4[ZP[.].U[?]4N93D3MV]:"X_;+M.W="\;)YO!)4K7M\LRLVX1E%YML0)NRM
MJPYLCX\6W<]"-17\.OE#`DAN+@+%\@^(`<5MS[LV;=9IA:*UL"L;\/\`"8O9
M]4V-0KTTV#KNZ1`L$211)&GS<<W(D02>19L0R9_`XC@1AL79PKFQJ!O5OM[D
MSMG8V_-[S&DY*8Y%/8BMQ=EJS+CU8V5JU?`56J,2_1]E#1DZS]Z=)B(^^+J&
M.?H/3`[B=[-FG+C)K2]XVGL.SO97?EBY!V=19O$L1L-JMFCZ]I"P,%_=?]J,
M'L9`?$`%/YZ;I<Q0^84,#PFJ.R!JK6E+I=!7W#8IV"UQNO2&XJ6[;T*GUVQH
MAHAU;'-6JMFGXT3O;6Q=?2Q0JSAQY5"^B42%`3&P)E<R>"$9RJN^A]R57<>P
MN.V_^.+N^)ZSW!K=**?RC6L;2B(R&V%3IN"FR'B9N!L;:$9'$BOSD%6Q3DZ"
M(C@0YDNR52[/R1I_):_\G]V;%N-6E=86A<MR1A95W+7#6^L5=8*RA)8QR'A(
M>TLUU)%Y&,T$VWQ)4ZP"(C@=++]AG0TC0M7TYIN/:$5)Z9T7#Z:US;6S:%/)
M0;^N;>CMR5^_G:J![H\F8Z?C_0%L</=U6YQ\WB`8'OGO9Y@)O?\`K[DS<.0M
MMV!MN&AJ%";0G[WKZE6)/::&N+$2PUEXFQ<@5M1Y)J)/=O68%.8$?$.A@`<"
M>W#CBG4N&6D6>CJ38)JS0+*Z;%NJ<I8$VR<B9[L>ZS5VDFABM.B/NS%]-G21
M'\\*9`Z^/7`E-@,!@,!@,!@,!@,!@,!@?__6L7[[^MPI?)JL<@`Y]QE:=3FM
MZU6&7`A_O+:NL[S>0@9.;'Z4Z>C-'R3^]*S%F5?F;&,X@'[)5XB'54O0Q0"W
MCLOK/GO#5E+2>D^6^A'TQ?+!)+T3F7:K=<-GA[Q&P7DF868O#6.L1Z-))E`6
M!5FC;YY53`0>OF$(X][:4E8MSQ^BXOE5+Z#CMJ/)32>QJ]7*?=;K:'VJ=B6N
MD1]MN]82IKELE2Y1BJFU@C6&5$(]BC.&*`BL<A#!,;M24B$UEQDFM:UC:3K9
M]9U_O3>-2KP2+ZVR<KK^%A=C3S..UI)R=X,:SR#ZF-DRM%%G`B4XDZI"*0E'
M`LQP*PNX'W-J=P1L6J=?#J2X;JVAMN!V1=("GUNQU*E-&M$U%!%L>P["^M%U
M>LXGWJ(B#@=NP3`[EZ;YI.@X$6MB=^34%>A*A:=9\<][;DK*>@JGRAWQ(UY&
MNP+CCOHZVO!9M+5;XV<>$<SLB0$EEBL&/Z(LW1$Y3@`X%GG(*V0=]X5;TNM7
M>DDZ[;>,6T[#!ODN@D>1<QJV>?,5R^43!^B-URCT`1]ORX&O=5BB''+@EU`0
M\W;RX3&#J`AU`-%5DO4.OM#S%$/N@/V,#*FB?VZ-6]>OZNJW[`'KU^)H>`"/
M3[&!LQX#`A7SCX4UGG#K_6-+G=G[.T[,:>WG2N0>O=AZBDXN(NE>V#0X:V0D
M&[:/)>,EFA6Y&MQ=&,'H^;SE((#X"`A$[\%GNC\;-W'?W1J)^P0<!^"SW1^-
MF[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW
M<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[C
MO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_
M=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[H
MU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&H
MG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_
M8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!
M,!^"SW1^-F[CO[HU$_8)@/P6>Z/QLW<=_=&HG[!,!^"SW1^-F[CO[HU$_8)@
M<!VM-T_+W9NXZ'_\QJ'^P3`Y_!9[H_&S=QW]T:B?L$P'X+/='XV;N._NC43]
M@F`_!9[H_&S=QW]T:B?L$P'X+/='XV;N._NC43]@F`_!9[H_&S=QW]T:B?L$
MP'X+/='XV;N._NC43]@F`_!9[H_&S=QW]T:B?L$P'X+/='XV;N._NC43]@F!
M^+GM5[B=MW#1SW8NXVLW=(*MG"1]BT,2JHKD,FJF8/H)^=.0P@/VAP+">*W'
M2J\2^/FK..M(F;#8JOJFK,*K$3EK<-75BE6S$HA[[+N&39FT5?.#F$QQ323*
M(CX`&!(+`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_U[=>Z1P3V;M+
MG*\Y!ZA[<?*O>%G>:BHE0=\C.._=,I'"HSU"#<V(Y:<I1I%5"U)KUXCX!4>D
M5(U>>\%\I?,0YA"QGLYS]#><;KQ3ZU`\G:/>]9[JMU*W=K/EEO>2Y(;.UYL]
MI%5UV^@V&VGLW.LK-2G$*Z9NHY5DJFV,*RIO2*83"(1/[N-[[5>[+'&:2Y+<
M^+GQ$WQJI5!3X]IV6F(6[I5^6?Q%E^B5H!YKF[U>?JSV=KL=*%;'3]1%^P06
M*H42B4P28['D_K.S\%XZ8U0WN3ZK+;FWJW'8.Q+S)[&ONY9)EL^QM7^Y+;:I
M:LU!P[F=C+HC)*(DCVZ#3U_21+Z9"X%P6!KG][[M^\D^;=_X^NJQH:N<M>.U
M!JFUV\_H<=[1G&ZUP6Z[5`!"ZTW0C?GT<=><A*"HX676B47R/K'Z>=NZ`?*4
M(1S?:Y[KE`K=WJD?7=2<E[%S2X&ZWX:;ZVA-;DCJ(;CM-U1R[BPOJ\=(U--]
MM^!AZE(`EZ46BW?N5FH"!>A@$0NJYF<`./.QNWL?56[*I(;#0XO\<[L\UZ^:
MWK8M(%C:ZGJ5ZR1FUOH#;*L::1.M$IF!K(@Z:B`=#)"!C`(4M:`TWKG2/%KA
MY`:R@%:[%73AYQFV]96R]@LUC/(;"V=J.L6*[SJ;BU3,V[C6\S+'%0C!HHA&
MLB@";9NBG\W`E+HGQW/J[[(WFM@`?_*:'V0#VX&S%@,!@,!@,!@,!@,!@,!@
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MF4>#`L2R6?U^F3SR97?E=G`Q6PK`R],`6]/SDZA+?A!R$K?)K1S7:-,TW<M'
MTUU;[K!U2JW>E*Z]E)6"KUC?Q4=<6M4<L8U[%Q=L;M@>MR+MT5O35`3E`>N!
M,#`8#`C[RT_BJ\F?\GW<W[W-DP-<FK?Q<N"?_5Z<)OWAZQ@95T3^W/J[P_W]
M5O\`MD@'41\<#9CP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!__T=GK
M<O)+M<1?/BP0'*5+0NMN3?%_7.IK91-P[PEJ?57[Z!VVO>G;!AKR6L#YDO).
M*DO4E5'@@"@LCR*(D$@J"(A.3BS+<4;)3K?;N(MBU5;J1<=CV6T72SZELD5:
MX6;V;+IQZ]E?S$Q$R$DBK/K-_=?5(90!32],`*4O0,"G#OS2NZX1UQ;D]0.K
M5,R;*YE?0NN=6;#JE`VC9[E&W&CRC)<J5A?QCZZT@]98R<>[B&2HG5?OFISD
M.4O0`FUVH]OV_8NFM@0^W[K#+;LB-S;1L%GTN[V+6;YL[0E4N%TF9FAZYV82
M`?.E(>>@H%8C<R"I2^B9,R/43)FZ!:?@>5N-ZI.NX)Q:-@7&K46M-#HINK#<
M;#$UB#;*.%"HH)N):;=L6")UU3@4@&4`3&$`#J(X'22FX-2P9*FK-;1UU$)W
MU9LWHJDI=JU'DNCAX)"LT*F=W)HEL:SH5"@F5GZQCB8/*`]<#P/+,0'BIR8$
M!`0'C[N80$/$!_Q<V3V#@:Y=6\..7!/_`*O/A/XAX^S1%7#Q_-P,JZ*_;GU:
M'R_3JM^'R_IDA@;,6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/_]*T
MCGWO7AGI#GYS6?[!XO0/);EE;=1\"->:%U'M$:[*I;>N%TEMZQ,$VU%`/JPY
ME8NKUL')36Z4(Z<$.JD@D5-(Z("J%MG:EVW"['TGLRI!QOUSQ9V'I#=MIU5N
M'5^H5F#_`%H%_CX2MS:\]59:/9,"2#63AIEH54%2"Y151$B@^```5[]^N@Z;
MV%=^*%5V;OK6G&R7MK+:E;JNV-WT^(MVLJVNBV@;"J\AUG5DKTC3=JH*Q!#1
M$NF;TDD/>$_,"IDP$.\[+O`ZQZ;V%>>4'WS^@>2E$O-*E*9`[`T#!+1J>PK%
M([-MU]N<]L.7^D5B:STS6IRPJQ+`Y5A42:-^A_G=0`-C#`U2._C9K</-#@C3
MIAQQ\-IQCJ?E7L]Q7N6(R:O'JV;&HM(9O82.LL>TFJ^QEK<$,J]3@V[AP("[
M6\Y$E#E`HA4#L?<.FN3-9Y0;1Y(:[HFD)UGVF=96;@IJIZ[&&BJ9LT\Y+-EG
M?&R+E56T@-A?V%HU.V(Q(>0*DH0/$/'`VK>3$SS<9]LFN+:?JNG;-=W_`!6L
M*?(`-W3MN@W47`GTRN,V_J@UA!8[ZUE,9P()//*B)P)U'Q'`J!T$]V^\XM\.
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M920*Y\CI),Z`%P(I=X:U\DMFGB*!PSL5+=RVG:]=+UN*3KG&G4G,V_UZ=AAJ
MSB.U.\H.PHNSQ6N9NUT.6E9N-4<-F[V87B",6XF%?P"6W9UL>Y+/PGJ[_=R-
MG5LJ-]V>R@K';N.-8XE3-UHS2[S"5,N"_'VJUVK,M=!.0145@:JM`<'Z^H=1
M43^H8+3<#P>P-6:QVS%-8':FN:'LR#823698PNP*A7KE$LY=B83LI5I'6..D
MFC:2:''JDN0A54Q\2F#`^*T::U!=Y*GS-TU5K:WS&O'3=]0)6T4:L3\E1GS,
M4S-'E/?2L6[=5ETU,B04U&1T#D$H>40Z!@>&Y:?Q5>3/^3[N;][FR8&N15>O
MWN7!+['X/+A/U\1_UVB:N/0>H>/CU'`ROHD/\<^K?'_?U6_RO[)H>S[GVL#8
M?VSM6B:.UI=MN[.G4*S0->5Z0L]JG'":RY(^)CDO46.1NV35<.7"IQ*FDDF4
MQU53E(4!$0P(J\5>X-J3EA<[/K>$U_O;3>Q:[3JMLQG1^06MPUW/7'55W%V6
MI[-I0-9NQ1TW4YA5BJD("X1D62Q!3=M6ZG0HA.W`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8'_U+-^ZA?N)AN;VXEKSMS>G$/>6IZ9PJUR]V?QZWA7-=6/
M?VO.2%YV7')(6RHV9`(V9A^/:\8J^/)%,9TU:RZI1'RE2``M`[-'WOD7H_?%
M!XWMI26I.L>4FPJ=+;:L6P2;1L^^[@:M4>QSVV[#<B-VZ;V1FEI\K7TB`*:)
M&8``B838&#K;V<[AN;F'RVY!7/E1R5T-5MMV.AO:#"<8]OFHB,Q'P-7&,DW]
M\C%(&1*K,H/OT-N<I^GH=<"V[C!Q^0XR:A@M1MMI;;W(E!/)AX6][NMA;KL&
M1&7DG,B9M)SY6,=[RV8>\>BW+Z8>FB0I1$>G7`D)@.OY/^S@,"/O+3^*KR9_
MR?=S?O<V3`UR:M_%RX)_9_!Y\)OWB*QX8&5M$_MSZM]OZNJW\@!T_LDA[/#V
MX%Q_-R=XKVK3M\XX<F=PU+6,'NRDRL"<DS:8NNS:D<JHF!9>&"04*"JD9(HI
M*`/E$HF)Y1]N!`#B$/$'0.UIC<FS>X[KCD?MJ1U?0=`4N9E'5&HC"GZIHSEZ
MK`5F.@X6>F!DIN5E951P_?JK@+E<X>1%(H`7`O-162<))+H*$5163(JBJ0P&
M(HDH4#IJ$,'@8IRCU`?E#`_7\W`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M_]6:/>SYQQ>D><U\AWNO>&DT33.G..L@6D\A=1K6O87(USN&T;`83`U/8#:-
M=GJM<TI#1#5T[2,)A7%V8"_8P+Q.S?+5^=XH2,S7MP\?=R)26T+,ZD9/C)K@
M=8ZGJ<F>*KOK4J)A5&;)U).X='TS+OUB"HY%4!Z]```"*/>Q;VZVSW&UK!0V
M]]MZCKUBO3;<6K^-&]JWI&Y(V!6";'ITM,VQ_,Q[GR,#&7*,>;^J%6!00^:`
MX%@G:YCXF+X>T1G"4'<^M(XDS<#(U+?FU6.Y]E,14LDD=1:7OL<]?M9)J[4$
M5&J953"@@8J8]!+TP+#<"FWO(=PW8?"'1[:*XYQU=LG)Z\1]CL]0B;*W^(0%
M8UWK6--:-EWZT,B&*;X1&P;46;?S"4%)%X@0.O7I@5^[T[L7.1XA;)+C\TTQ
M#,.*7!/4G-CD<C=X&1E7&TRWV-0F7FNJ,=HL0E3,6-0<#[X?SB0XE``\,"U?
MEKS8T#5^WW,;2VWL""U@TY%\:[U]7[2?%\)INQVC4T@^;U]B+)F[ZN@4E$R`
M*GD+\X.H^W`I'TGM#7^V.,'#.8US:8VVQE5X6\5]:6)[%^\>C$WS7^GJU!7&
MLN?>4$#?$("6(**_E`R?G_.F,'C@23T5^W/J[KTZ?3JM_=_3)#\KK@1N_G'9
M`'=O'H!*`]-<V,>H@'L^/$\.H^S`UX:LF0+55/`@=;56^GS2B/C.,.GY@X'^
MFRC(NH?7*4PPCE99_%4DDBRB4!\JTD[8P0.6\>B/L!5ZLD"11^R8,#7:[=_.
M'D?M7??!P]HY%QV]6W-#0^TMM<A-*L*U$L$N(UJK<`E8(BML5(P32U>:PMD7
M^C+EK+@FX<.B^<H>8!P-EW^A@>?&VU4L_P#10UFKY;0+<'85L9F."?%J)0,#
MGX.+GXC[N)1`?/Z?EZ#[<#T&!\ZCMHBLBW6=-TG#GS>[H*+)IK+^0.I_12,8
M#J^0!\?*`],#Z`'K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_UML7N%<VM2<')OCA
M8MRZE/<M=[GV+-ZZNE_B*;(7:<UFUC*J\L$+-K5V$K4]*R\.Z?H"W7\ITA;%
M-YR%4$?*`23XF<EN/O*C6+G9/&UVN\H#:S25;<*.*%8==*!/QS9@Y?$""LL'
M7WRI?=WR/Z.5$R9_8!A$H@`5\]P>B]I;4,Q69GF)QXJ%ZM7(':\>^0;L-8+7
MR=E+?*'B*4KL&TE9E`D)7HT95BR=RCI1-%,7"28>8Y@*(3LX4H<68K3*M2X@
MU6"HVIZ)?MA4AQ3X"`5K+2OW>MVJ3C;NP4AUDTU$'(6)!<QC]/*KU\X"("`X
M$NL"KCN']I3BSW%H>7E-IU]S&[A2UU-:\HFUHV4F4'].8S#E%Z93X.RDF<;,
MH)O$"G,BY*<A_8.!!JU]@*$9QD-5=%<G+II6BW7CC2^*_**M,JQ"6HVZ]555
MR5RY)$RUC]]D:+894%7"8O&RB@I)KB4H=`#`MRY&:ZJ%2X3;IH\;"1ZD!1>,
M>SX*MMGK-L[^',X35DXQ8BAZZ1P16(BV+\XO0>N!K\TYHV9\<."Y6C9!JFKV
M^N%SI5-LBD@15TZT965G+E0J12%.X75,)CG'J8YAZB(X&7=$_MT:M^Q].JX'
MV?$91N/B`=/9XX$<?YQW^WAQZ'Y/JWLGM_\`/Q/#[N!KP57]5=5Z!U_NJK0`
M/M_W;8>/L]@=,#>F[CO<&M7`#5.@;-5=>P.P%]DOW==>-IZ2?QR48E"5-A+)
MN&YH\Q3JJKF6\@@;J``'AXX%+T'_`#@6T5:2F9JM</\`2\#+SZYW,W*0[R1C
MG\NN)Q,960=M$TEG9S'$3"*AAZF\?;@;6VC=AN]M:9U;M!]'(1#W8-"JUP=Q
M;1119M'N+!#M)-5FW56$5%$FYW(E*8W41`,#7MTAQKY;ZV[@^M9&9XUM["0O
M(3>]RWMRHLE3U986-PUO;F%HD=66>F['?3([8K-CKS%_&5A:$39%:$;,CG*8
M2'P-F;V_E?DZ#[>OA@:O/*[6/)"+[B-[N3GC%,[_`+-<^2/&J2X][&FJ6XN>
MNZ+Q:BJ-KR!O55K]K;7>OFT;=:+M1K:;&]5%BZ"=*^1\1ZB4@;0X?:_)_IX#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`__7V$^_K!<I'?';7%HX^N]V%J%*M%QE]MQ_
M'G:U7T_M!RX<4QRSU,^&Q62=K2LSK^*V`=(]AAV#U)](LU"E*!R%.40DUVG7
MW(RU:0V'M'?]9N5`C]L[54N>G-;["M];N]RIVMR4"B5U7XG*U.8GH2,:V2XP
M<I*-HM-TH9B1V('^<<<"''?/U]![G7XX:9J&D.6^V.1-S?6Z0HKCB5OK57&J
MPM*)4EH&QVN+MNQMU0]BU]-0`V)A#OTH55BLZ,]9HNDC)^B(F"?G:ST]-Z0X
M@TZF6S1NV-!7-6R7>P7*J[VWA3.1FW[!9YZSR4E+7^_[=H7EK5GG[PY7&14]
MW30*W!<$O23`GD`+%L!@,"/O+3^*KR9_R?=S?O<V3`UR:M_%RX)AX#T[>?";
MY/9_B(K`?E8&5M$^.Y]6_9^G-<\/'K^F3?\`,\,".'\XZ_;OX]>S]KFQ=0$.
MO7^SY/9[1ZX&O#5A_NKJGC_OJK0?8Z])R/#V?9_*P-IG^<1A_B"X:_;N=E_*
M_P`7T7@:HP^PP^("(F]@^WQZ_8$?'K@;SNT+Y==<]KWCG8:#:IVG3Q=>Z4:%
MF*[(+1D@5JXK3`J[<'*`E."2I0`#%]@@&!4E]]WREZC_`,H';`^'3QN,F'Y?
M7U!'`MIO>^-R5/L_7S>L'L.Q-]P06NE9:+O[M1I,SS:2^FD9'`\,>::2+1TJ
M#)<R8>LDH`%'P#P#`U?0[M/<;Z%#[ZN[?('ZG=;A[>GR_0D/'QP-J;LO<@-R
M<D.)<Q?]XWR3V)<&VV[97T)Z59PK%RG#1\/6'#-@"4'&1+,4T%WJI@,*7G'S
MCU,(=,#-/*#N7<?>*%WD:)=ZWN^\OJ=5(K8&XYG36IIW95<T!KR<>J,H:][F
MDHA5,]9K\D9JY62!LD_>"U9KKB@"*1CX$\H">B+1!Q%DK[]O*P<]&LIB(DFA
M_4;/XV1;INV3M`W@(IN&ZI3!UZ#T'Q`!P/WD9:+AT"NI>281;8ZR3<CB1>-V
M2!G"YP300*LY423%990P%(4!\QA'H`8'88#`8#`8'`F`!`.OB(CT`1`!'IXC
MT`>@CT^U@<C@,`.!^*[A!JBJX<KHMVZ!#*KKKJD1113('4RBJB@E(F0H>T1$
M`#`_I)5)=)-9!1-9%8A%4E4CE43524*!B*)J$$2'3.4>H"`B`A[,#^Q$"@(F
M$``.GB(]`Z?;$?9@?.9XT(Y29'<MR/5TE5T&9EDBNED$#$*LLDW$X*J))&5*
M!C``@43!U$.N!]/Y/S,!@<=?9]O[?VA_-'PP.<!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_T-E_O"\)-P<R8CBTOJC4.AM^
MI:5V[8KK<].<F)V18Z>N4%-4>0KC<9N"91\BA/2\1(.2.(\RZ9TV:P"?TU`,
M8N!C;L\\4N=W#%YM'56YM2\:-:<<;G=;MMBIUW2.P+++M-=V2R!6F+"@4JER
M<2C&P5*09Q2[E4R2Y`,[5,8J1"F`@!7WW9>0FH-W[,L^F=TW7MCW)YHK;LF%
M!J.^=W[TI%IIL`]JZ#9^XL+76Z<8DUNRD@L9$Y`562!F8.ANHB&!='V>FU,9
M\&-<MZ"GH-*M$G[W[HGQHNU[V#J8JPVV5%U\&LNR%W%K<OO7\WOA%CB1)SYR
MI_,`,"T/`A'S%[B/$O@6TJ+SD]LH]#3NYY`:^FUK=CLSA5G$J-$I67>H5R-D
ME(R%C%'R(.';@$T$A5+YC!UP,<[F[MW`'0CG5K?8F_H-L7<%9A[M4'D#%S=I
MC4:1.N&[6,NEHD*^PD&E1J:Z[HI1D)$[=L0>O4X>4>@24Y22#*6XC\C).-=(
MO8^1XY[>>L7C<Y56[IHZUI85V[A!4@B51)9$X&*8.H"`X&NI5_XN7!0/_P#7
MEPG'\S1-7`.G0?'KU^S[<#*^BOVYM7=?;].JYT^V/Q)#H'A@1Q_G'7[=W'L/
ME^KFQ?+_`.7R?+T^3I@:\%6_575!]@#:JT/3V>(S;#J/Y@>W`VF?YQ'XZ"X;
M>`]/IG90]GM_Q>Q?0`'KX=?9@:HP^SPZ]1`?D'[8=?`?]#V8&[?R#Z_@I..H
M#U_4+H_QZ^/ZG&7Y>!1OT]OM_)_2P+EMN]1[$NU/#K_BH6_?!AQ\?RL#3&#P
M$/:7J/7Y?;YA\.GR!T^U@;I'8%E8V#X$6Z9F'S6-BHO=-^?R,B^6(W9LF36N
M4]9RZ=+J"!$4$4BB8QC#T``\<#S7*RC\4^0&RMQW77?<QU;I"`Y/:IK&EN3-
M;9&H]T>W>B5(91I'DI<](VN)"ASCV`GGT:Y<G:R1#(N`.5,IR!U"X;CKL#C_
M`&.BQ5(X_;%I=\K&L(."J@)U"PQ\^$,R81R36+0D%&"RI4%EFK<#!YNGF\1#
M`K%[H&@[#L3?.D-B6_A]*<[M#0NCMZ:Z0TTPCJ?9$-;;UNLG1W%.V^\J=YDX
M^$>"[KD6]BDY4A5'$)T,H0R7K"80G9V[M1[;T+PEXX:@WK+K3.UJ'KIE#VY=
M>:6L:D<L:0D7L76?CSA58\J2GP3IK$E6`YB'(R`2&$GE'`F>(@`=1\`]O7Y`
M^Z/LP'7['3[?C[`^S@<X#K^3_4^7`UM^8';QY$<PN=VZ]^/UW=$UEH:DZM1T
M<\+`2SS:%LM-(9R-\EDM'V-O,Q[&FHVJSH-HN5=>DLJX1,*0D$HC@8IM=&[Q
M]81T?1&.U.6]LN]MU=J*Z#>HAMKU77\'OVP;(;J;BK.\),M:03K>I-?ZO8>G
M'1)0]YDGCE0X.#J^0I0BIQWY*=T[EY?=TUW5^Y^0$7;C1^K*CM):.9Z^GM7:
M+V%O/GXRC)"V:819PSE(:'I'ACJV73$S]Z]/(.947IR@*X#@2N=L.[RA?.7;
MB2VIROJ\7KB!O>O]"PT+J@FS8B_0CF.KE6U?L5M+L:RQC):[)OW3F=E'D:+U
MV4X*)J,TDD0(<.IM47W4]CL9JASM`Y*SU6MW&C4%#L%6OQJ_-5"F;%L4Q`-]
ME.)P\Q2DH?>ZB\,J[76D"&;C&>04EVPC@=79XOO95765]8U8^WJ_5=2[A2X[
M4IA5("+D+E=M((WV]V%WO:HUBL5F0D6;2,I*%9JL.9DU7.W9D=."H>)3E"37
M,_5&^K'QK[7>J-WZJW[SDIE=W0GMCF2E!Z\3>7.\QM`U'LIYKVG;*H:;EBQ4
MBY[:EQ@T7B;ORH"6&,NN4IBB7`@)6^,'<RT/1;$\I>M-HT*S0%6=L^/U/UM$
M,-@V'5-5W]RCO6[Y?C75]QK1=LG:15=>Z<@*_4G4F@=U%0SMT!2D%)$BA0D=
M<G/>;"W\E[?"RW(B!-2*[!5.@:CBJU'72#GZD_84N&>72DW5S7HVLVS;4(W"
M2D3J,E7)G4@H8%&Z"9"DP.CH;WO%LI35[EH7F+:4D+)R*LJ5#VRG5JTN%89U
MMX;1"FU=EPE7&M32REAKA&[RJG".<KIS95R.1,D8"!9_VAXSFFIJS95SYKW_
M`&[8;S<+)6C1E$VQ2EZ@?7CR)@#DN`U`SR'@W3ZL6:;?E.BD1$[-I[IY6ZRQ
M3"<0MUP.`'K]WY0^4.OLZX#K^3\GA@<X'`CTP'7['Y!#`=?#K@.O]#Y/#`=?
MR#@<X`!ZX#`XZX#K]GPZ_=_TO#`=?M#[?L8'.!QU_)_2_+'K@<]<!@,!U_-P
M..N!SU_)^3[F`P..OY/R>W`YP`#U]F`P'7^A@,!@/S<#CK^3Q^Y]C`YP..H?
MD_)UP.<#CK[0^Q@.O^G]KI]WV8'_T=ESO+;<Y!Z-UQIK8>BN0&I-$H?2F_4J
MZ.=PWA&C0,DG?:"_KU7M$>LHV=JV&7UA,K#,HQA"@#E1,@F,`$P/;]H":L\Q
MH'9"<CRK)S$I,+N>5A=8[C=6Y*[V.1K;2DT=:;:V.91;-0;NCW5S)N6S(P&4
M9LG"1#&'PZ!#+OGU/;%+9::VCI+5<Y(UUA;DK%M&0TKK"B6785DFHFT5!X@P
MV&K+Q#B4>:U>TE"9(\.F83>^^[E4,!!ZX%AG:JE-I6+BJE;=G5)W1$;IM';%
MOUK3I2/KL9-UO4D_>9B0UU%S;*JI)0B$@A6ED.I4P$Q2]`.(FZC@638%`'?B
MVGLLVL*%Q4HFD-KVRI\G3259WEN_5^NU=A2^J=-1,A#/[5"PD8U\KE6T7H2)
M,VQ1,5)),5%S`)DBX%1V]]4VG7,GR2KFG>)N_P"R:JYT]LS4O%'B<S-KAP>3
MI=VK*[ROJUS:S550XZ_Z+NBR*[A<?3\!.(^S`OYY4\5=H37;;C->M.1NUM)6
M'2/&&U?35UK1Q%^;8YH'3[MK)56U*2S=T*T*X68*$-Z0E4Z*FZ#[,"G+05!F
MM=<6N'4;/;)N&T'5BX=\9;TREKF=D9[686X:EK,K$:ZAO<4D4PJ=&9&*SC0.
M`K`B'SS"/C@2:TJB=SMS7#9-=1JHXN,&@FZ1Z>NU.L]23(Y0\W@"R!C`8O7_
M`%P8$`^]EJ&UZ1M/'>D7/=FQ>0$R2I7>4&_[14C5;2HVD;,FJWAQ-$MVK7W"
M+)\Q'YOF\OM$<"D^!;G<S\`U3<*LSNIZ%:INV_3WEF=S)LT$WC?S@)0<M#'!
M0G7J'G*'7`V+N\YJ.U:4X?\`#>EW+=6Q-^S/UJ;%G/I[M`\:K9P93-)BW32O
M^:*;MFOPJ"3`$6P>7S`3\\(C@:W/40`P]"CT$1`!Z].GF-\OR=<#<6ONMIZB
M=IK1#>:VK>MBG?%UY;V[NVJ,#.(Z+LL.U=L*2U]S12+]'*FFIZ#`!ZJ@D4/.
M(C@5'_8_)\N!9MO+6%CD>R%<Y9#;E]C6T,_=;2>0K-2."/G*ZI,(U\-/R0&0
M,H.OTI)\22`I1!Q[TW)\[R]0P-2<.OG#H`>T/'H/@(_9^Z&!LY]OO4EFVUV@
M]N-*SNG8NEQJ^T]L6B4>Z[4C$W-OC(ZBUI1Q4)X))NX(:!E`+Y5P3`JGE$>@
MX&L,5NCX#Z*9?'I^<+TZ=0\>G3VX&Q/V3-'7#>VH^0E3HN^]G<<92'VYK.TN
M[IJ,\2WL,Y%QE6FFCBFR1I5JZ;C`2JDDFNL!2@IZC5/H/3K@33L'(O>K>?GV
MR.U;D1%K/3;9!,)4Y2IHMY-T@D0H`7H4I4TP`/L8&6]'Q^]N5LM)T@W*O=6I
M%*R,+=/I#0Y*.5EI9O%S#5%U5Y`)9JY0"%ETG8@OY`!3H4.@AXX'4]S[4FW:
MUMWC_MF:Y`\N'/$69EY2C\C]8:7DI9JVJK1#7<PSHE_:I44C2[KN'^P56RCT
M$%_1\Y2"<OI^8,#M^`7'3E-M'@)7Z=?^4?*[4TP3>]WMVLMA6=\S5WU):"C[
M=-$UO6+\K8DI!=-&>JIVRRZ:QC.2%\H&-UZX$J>9,X_XA([MY^73?.]I;4M/
MU;"5!3C16%ZZ6CL;!:K-5Z-%WFO@^03=(6HDS-HJF477]W(4ZAA#H&!@[AC&
M6'F1PL@5:)S.Y9P\W6M^6A*T;.M*E/\`K0<R%&E6C&?U>[D8YHXK<S1/43\J
M;IGY@6*J?RGZA@6`$X_7LF\I;;@\EMP&JDCKP:4AI8ZT/]7D7,C'"R^GS(GN
MGQ$+."P^\=3*"EZH?G>F!A9OQ#V?+:!A]31G/OD6ZLT3L1:WN][QTG4G6PI:
M,!V]5/0)!PBQ4B@KJ)7)4O(4@+`5$O4>O7`RI4^+*]&Y$6O<]1V_<ZSKRTU%
M>$/QLKD158'4#"VNB1:;W9J+.*BFDBYNCPT>8RJZRAP.98PCUZ!@8T4X8;>/
MH2"TX'._DN2W1&P371WO(KFL?61-PXBGTH<BI\-^&C62^0>@%3!7YP_.P,MM
MN/-]0W9-;6/R:W&XJ\KKL*2VTVJO#?0"'F0C18#?V"8-`D`M`K#[QU,H*7JA
M[.F!BM]PWVX[T?!:E2YT<E&=IB-B.;L[W0W<UD-@S4,L]>NB:_D5#1PQWT80
M2=E1*!4P5]-$OCUZX&78O0%ZC^04_NA?DEMZ2I\SK9K16FAW:T..LX.;;M(E
MLIL2-3(T"3"U.5(Y14XF4%'U'2@^7V8&&?O+]O\`U"5W3H\\>3(VV$V(XN[S
M>7O58^LB?AEEA5)0)13X;\-&KH%'R%`J8*^7_78&8$N/E\3W;8=KFY,;A4J\
MWKLE)9Z:.M#?5_7YHL7\/-?XM,&82);0=?\`KD1.H*7K>/EZ8&'UN%VWU=+0
MVJR\\.3*-GB]F+WQSN)-U6/I]+P2QQ,77#]08WX>-30*/E*!4P6Z?Z[`S<CH
M:[I;OG]LFY%[:6JTSJWZOFFF#KQ'U?0<_P"C%I?69&I@T^(A<.L>H?J904?,
MY4'R^SH&"FO"G<;?1=?U$ISXY/.;7#;-5OKS=BKJK_6)/02B:)"ZWDSA&_#1
MJ20I"8`*F"WF./SL#.3G0EX7W18]II\CMMMJQ.:V4HK/3R2T1]`H";.W=HAL
M2+3%H,@%K(=R50!.H*7G2+\WVX&%PX9;?#3%=U9]_=R8&SP>ST[^]W`+JL?3
MV?@B*+G'6TF?X;\/&HG*J!1`J8+="!\[`S2GH6[DWA:=LFY&[:4JMAU6;7;'
M2YEHCZO:U/F1B$OK.ATP:?$2W(!C%#`8Z@H^9VK\WV=`PNRX9;?::`KNFE>=
MW)=Y<(3:R&Q7F]G#FL?65/U]%N[0-K"34+&A&#3%CN2J&*5,%O.D7YWMP,MO
M^/=]>;TG=N(\F=PL:I+ZZ>4AII1LM"AKR$FG+%VT3V#'$,S&2"TM%7!5DQ,H
M*/J)%^;TZX&+FW#K;:&E:_JH_.3DBXL\+L9*\.]Q*N:U]/YV%3D$WIM?22@1
MWP\:LJB04!`J8*^D8?G=<#*2_'R^*[QL6VB<F-PH56;UJ:B,]+IK0WU>U^;-
M&LF`;$BB"S^(EMA5FIG`"=04?66-\WIT#`Q.TX:[=;:`K.F5.=7)5U;X':;;
M8;_>RSFL_658X!#WL#ZQE5`COA?T-<>\%\Q2)@MU2+\[VX&5I#CU?7N\K-MM
M+DUN)C59[7;RD,=*MEH8->5N:=,G+1+8$0F9H,B6T-%5P63$Z@I>HF7J7I@8
MI^\UVY]1T!J3[^GDK]*H:_\`TR>;I]ZK/UA3T0+PCKZ"R9_AOPX:UZ1!1Z$3
M!7R&'YW7`RY][_>OKUL^W?OE-O!5)_7/T'8Z3!:'^KJMS7P]BR^L&(3]T&2+
M:A6:&<>8Z@I>JL?YO3I@8A?<--O.^/T)IA'G9R68W")V>M?W.^&SJLALR8@E
M0DP)K9^H:-&+&H(^_D\I2I@MU;)_.]N!F`=`WH=_63<OWR6W0J,[1E*DRT6"
MT/\`5K7I4Z"B(76*3]T^)A84S'`X"=04_,4/#`Q(IPWVX?258U.'.?DF2T0&
MP#7-]N4KFL_6!9(@SU-T%$EU!COAQJT1(@H@!$P5\AA\>N!E1#CW?$MUVG:I
M^3.XEJM8=9DH3#39UH;Z`5F=)%L(\VQX<@,_B`6TZ[,[D1.H9'UES_-Z=`P,
M/N.%VX%M"0VG"<\N33>VQ>UE-B.MY).JN&R)BOJ(NT0U>_4&-&-&FIF<E.4"
MI@L!DBCYL#-;C0EX6W_:MRDY';:0J%BH*=.C]$I+1`:TJ\N1BFT&]0R0M!DP
MLAU""L(G4%+U#>SI@851X7[A2TO7]6'YY<FE[/"[+-?'FX%'-7^GD]!F.Q-]
M74F<(T&`U0H-#@`$("O1<_C[,#-1]"7DVXK)LX.1^VRUJ=U6;7C+4@+1`T6O
M3PMTD?K-BB"T]_+<BG3%0#'.*/F./S<#"CKA=N!QHRMZB)SRY--K5!;--?GV
MZT758#8EB@C#*_XMY508T8[Z)`$BGT`B8+?UJG\[VX&;7.A;POOJW[B)R-VT
MWJ5FU\G2X[1R2T0&MZI,$:)MC7R#3%H,D6S**$]4144,EZ@CX=,##J'#?;B.
MCZQJ8W.CDFM:8#9R5^?[H4<UD=A62#3$@FUQ+J!'?#AJ2GD\0(F"WB/SL#*X
M\?+V.YK;M+[Y?<(5FR:M6U[':@!>&^@=5GE6S=N79D(3W/X@6X)'1,H4QSBC
MYU#?-P,4CPXVX.AH'3_W\_),+;#[#+=G>\`<UKZQIR&!^[=C0)%3X=\-&L&1
M<E0Z%3!7TTB_.Z]<#*;WCU?7?(2V;I2Y-;B9TZQZZ5I$?H5NM#!K*K32C)@U
M+L"%3,S&4+:$E69U@$ZHI>HN?YO3I@8Q:</-M-]'UC4JG.+D@ZM4!LA"\OMT
M+.:U]85DA4G#=8^O990L<$<-56(B9,P$3!7RJ&^=UP,C.>.FP%]TVK:A.4.Y
MV]8L.MW5&8:>27A0H59FW$4I'$V%#$%G\0+:FS@X.B"=04O6*'S>GA@8S5X;
M[<4T-6]/%YT<E$K;!W\UR>[Q(YK/UCV&(,]>N@HLJ<8X8P:T5)T5$`(F"OIH
ME\>O7`RHYX]7U?D%=MT)\F=Q-J?:];KT6+T.BM#!K.FS:L;',2[#KZ8M!E"V
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MT``Q2KPUVZIH>JZ?+SIY*)VVNWWZ8R&\".:S]8]HB?4\XT>94^&_#!K8A\WH
M1,%>GRX&5B\>KZ7>%LVU]\UN,:K9-?\`T,C]+BM#?5]5ICX5\.^G<*3W/XB6
MS>\?UUU.H*7K?)T\,#&#OAUMISI&GZG3YQ\D&MIK.PE[I);G1<UKZP;9#+2;
MQ^6@SAQCOAQJPBW=%;%!-,JOI(E^=UZX&8([0]W8\@)_<RW(O;,A4)G6;:AL
M]$NEHGZM(*<;DBR*;&C4B-0DPMCD8]0QQ.H*/5RIT+[,#__2O"[K.Y.#.S]M
MUG3G-2*Y%Z?::%?;!"MWA[Q[L>P=*[4B]S:@/4Y)_4[76X6YL!EJL,VFHBHN
M@R?,)%F/E`2'ZF#UW8]ONH*M7;_H#3\GR!W4UE[#,[@LW(6U<:C<>-'*O1B:
M=1XNJ4N+7CZRBXFG$/`-W#GW2.,#A<J[A50IC@7`Z3OR6O6U/;:$=73=/).A
MM[*:R4O8NN^->LS;/M6QM%34W45;O'.$QG*]]7Q)6=9Q<0%A17%TD61%JD7J
MXZ@$Q.S*&LOO+F*FG7&S6VNEMO[L/6J;MRKOJ7<M8L@V//D#6CJL2UFMTS%M
MZ:8HLTRO'QUS$2\QBI]?(`6OX#`=/#I[?R?:P(^\M/XJO)G_`"?=S?O<V3`U
MR*MX\<^"?VNWGPG]G_$15Q^Y\F!E?1/4=SZMZ^']W5;^Y^F2&!'#^<=?MW\>
MO'IUUS8O$/L_'R>`A[>@X&O%5AZVJJ>T`"U5KV^'^[C#I]SPP-IC^<1CTT%P
MU^7^[*S?O>Q?7^A@:HP^)3>/AX_<'H/V0^0.N!NW\A.H]J/CKT\!^@NC_;^M
MQC]K`HWZ^(^S[7VAP+E]NCT[$FT_^*A;]\&(^V&!IBAU$0#V^/C]K[7V?;[,
M#;C[1W^:/Y'_`"_W1;N]OZP:Y\F!J-E'Q`!\1Z_;`>OF$.GA]W`VK?YMO^IS
ME%XCU^DU*^Y^DJORA\N!T%F_5/:/US6'Y/#].7O^C@6!]M;]M"^>`?J%]O\`
M\O16!'7D?S_Y/Z^WELZE5:YQ;*O5JTO(R(:*U6ONU&[-)-$Q$CN5X]1=8P"<
M?$QA$<#*G!3FQR%W;R*K^O=B6N-EJN_KELD7+)K7(2-5.[BHP'3(X.V+)%P!
M2*^(@!NA@\!P)!=R+8O";;^G=P<(N0O)B"TS,7F)I2TZ"1$G=E@$8ZT5G8E=
M>)L96!FH)TA(+U]N"B2Z2J:C=0Q1+X^`8^[>.PNWWQMKAN/>F.64'M2X;:VM
M-W4R+TC>(6E[S=BQK5>+JE6K=9@*C5(<1C4_19,6S9N50QSB`G.8PA,CN"5/
M=EZX9<@ZGQU<R"&XYJ@O&E-+#R2</,O7'O3-62C(B75,F2+E)6&3<-T%_,7T
MU%`$#%'Q`*_.U]JVW5OD3R"O]`T=N;C7Q/G]6Z9K5:UENF17&:L&[JZE/!LN
M]PU9=VVYN*_&N&CIBS47][3+)+MC+@F'7S&"XG;3B]M=6;+=:M;M7>S6VO[D
MXUTT?`D+%S>D:[(GJ+9X"W1$S1:P%;E4\_S?((]?#`U\^VQ>]JV?DUQP3UU9
M^4MEJTAQ6LTSW#2<A879$=`P_)@S>ID@&-:#8T1',&%I1MZDN0S6MC\."*`H
MB`AY.@;)V!K*\5^X!M&X<Z]4Z\VIO/94_;]P[<Y.T:=T#7W>IX6DZ.2U+/6=
M"M5"[:S=4<VV4&ZE1C&#YM9QEB)2CER(`8Y/FX&S5@4.[`[B.ZHOF9-U0]WJ
M.M^/U(Y;T7B)]$%-,RFQ+=;+=9*E0+`I/WZY-;M!'U7#723O16=5<)L'2+HB
M!EE2JAU*`7Q8%/W+ON2;<T+?-_H:LX]UW:&I^'E%HNP>2ELG=C*U*T?#+J"T
M@M#:MKR=>DVDW,UFLI%D')G[ELBOZ@(I#YP$V!;!4K*PN-6KEMBP4"-LT)%S
MS`JH>54K269(OFY52CTZ*$27`#!]D!P*F.Z!W6T.W';=,5Q;5L1L%#9]6V?<
MWSN6N[ZGF:1NKVT,[>P<$#*HVHC^RSZ<MY&0.O=&8*$_15B%'S`%L%(M+:\4
MNHW1DW.T9V^KP%H:-5'#5VHV;3\4UE4&RCMBLX8N5$$W0%%1%0Z1Q#J0PE$!
MP,9[[Y*:5XQU:*N&[;LA3HF?GVU5K;=*(L%FL-HLKMLY>-X.L52IQ4[9[!)'
M:LU513:-%133()S^4H=<#V>K=IT;=%&@=D:WF%IZG65N=S$2;B'G*^Y6(DJ=
M!9-U"V2-B)V-<(+I&(=)TV15(8H@)<#W+IVU8MEWCURW:-&J1UG+ITLFW;-T
M4R^=159=8Q$DDB%#J)C"``'B(X'YL)!C*,V\A&O6DBP=I@JU>L'"+QHY2$1`
M%4'+<ZB*R8B`AU*80ZA[<#ZQ'H'LZ_\`9'I@<X#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8'_]/:<[JW<`><$:+JUY7M&U+>-PVA,WI.+BK_
M`+$AM84V`KVLZ<K>[K+.[%+P%B/*6$\&V%.)AFB`.I1UU*0Y0(8<#/W"/EW6
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M[>7";[?_`*!ZQX#\HX&5]$?MSZNZ]0#Z<UL?;X]1DV_AX_8P(X_SCH.N[^/?
M@/[7%C^7P_3]/[8>S`UWZM^JRJ?KJK70/G=0_LXP\?'I[<#::_G$G[0/#7[5
MSLH_F:]C/MA@:HQOSH]>G^N^7Q]IO#Y<#=OY"!_T4?'4/;_<+H_V_K<8^W`H
MV'V_9^U_H@/V<"YC;X"'8EVF'R_50K^^%#C@:8@>T!$?Z'^C]H?M8&W+VC_\
MTAR/_7#N[[?3^X"N>S`U&B^`AT$HB)AZ].H^P1Z>WK[,#:M_FVW3Z-\H1Z]1
M^DM)\.GV857J/7V>W`Z"S?JGM'3P_NFL7A[?'XR]Z=?N!@6!]M;]M"]_+_<,
M`=?E_3V+]N!5-S##_E.[MZ!_OZ?CTZ_+Z2`_E#@9T[7?\;^I>W]1]^^3P_27
M[OA^7@5B=\P"_A(]L]2E'K1]0>TO7_>'&^/V^@!@1F[;12_?Z<3@\I0'ZZJ9
MX@'0WZ9)_*`>'Y`P+X.]MS9Y5<9]^:QJFB=T6+6]>G-=.I>5BXB*J;]!Y)IR
M_NY7:BD_79=R50$?F]"J%+T^3`J&U_W6NX?*WZAQ4CRDNKN/E+O48R1:J5_7
M1".F$A88UF];*BE2DU"E<-UC$$2F*;H/@/4.N!L8]Z+G'R%X4U[CW(Z!FZS"
MNMBS^Q8^SFL=48V@KEM6XFKNXLC0CY9(K(Y%I583F+XG`0`?8&!0DEWUNX>@
M<PHW/520K*`=84]05]/UCF$`$QQ(Y`3'$/E'J.!L@\R.>^S^*O![27(^"JE.
MO=XOL1J[X\PLOQ6,@S/;?5F$M+/6B4&X17;"#Q<XII^82%*/3Y,"BQ#O_;B:
MV9>Z-^)?&)"WNDS).+0BA;B3RZ8]?,126(\*^4`P#X]3^/RX%^DCW&5]?=KI
MAW%MC:V)-N6FOZU<K#K:C2WPU-PO8M@QE#(RA96P@\%!)LK*D<"9QYQ,4ABA
MXB&!KAW'OV]N?8.Z(OD/=.UE)6/=D-(UZ6C]CR-THJEA)+5(B2=6E5U21A&[
M^2KA$"`Q<+IJJM0*'IF+TP-F[B)W&=?<IN%4ES<=T6SZPH<(I>SS59?O&5LL
M#-A0G1V\@\;GAT6B#XSHI!,FD4H&#V".!2#O/N1]BOD=?;#L;9:7*5P_V!!5
M2N;5KE7:[DI-%W)7J.^5DJ?#;5I=5ND3`7!E`/'!A3*ND!ED^B*XK(@"8!?;
MP=YX\;.<5'ML]QM5M?T5U3)1%.EF]IJ+RI'8K+PY7\:VC6CI5<SIHG')`7S%
M'YH@!?;@4@<O.XMV0>9%KI%BW3LKDDA.:QB;[28]77U7W#2$I.K7Y-I&7JJS
MXPD6F>2AY]O&IHJ"0R3@A.OI*D\PC@7"\`.?'"OE5#N]/</I*RF@="4>GPZ5
M?FJ5<*PTKU.:-@K=6CV+^V(^\2GNC6**D(F557Z$`RAC"(F$/[Y\<9]D[^<:
M1OFB[QJB&VEHJT7!\UJ^Y'5R9T&ZUK8-/>4VT0[NT:SE(_8FO;.R;KI.8R<A
M_.\:*IG(!?*H)BAEG@CJ+:6@>,FMM1;PV_';LVQ66<JI:;S'R,W)MY!61EWD
M@W9,GUH=O+-)L(5JZ3:).GIO>%R)`<X`8PA@8%[KNJMF;8T+JEC0]76O>].I
MG*#3>Q.0>B:/*0D?;=R<?:NI8AO='A&]CL=1A;"[-)/(V0&*7DV99)./,@!Q
M$X$.'0=JG3&RM4UGDI.3^I;1QPTWM;?;R\<<>--TD8-Y:-1Z\"H5R'E5)6-K
M=CMD-43W:V1[N2)"HR"WN!#AU*F*GEP,]=RW8%^U5P&Y9[&U98)BJ;$INE;?
M.U&RU],IYF$F630#-Y&-]1L[(5RV`1,4WIG\GY[IX8$$^QUR'W-O/7?(IAMG
M9D[N:/I.W(EOKG89;RCN6AFJD]K^K3CBJU/>Q]?:NEMF/Z[/O'9907<,F>+>
M',R(LLFB4XA=A:YOZ,U>R63W87OT?@9B;]S!3T1=_"H]P_\`=@6\B@)>OZ'E
M\WE-Y>O7H.!4#VI.[8'<I?["@WNJJ?KN6I%(H^P2*TK:\GL)G\-O$K8XHE6L
M#"U:TU5/QEPKBM>`[U2.:S$&8KM(I)#U>J0A<RLJF@DJNL<$TD4SJJG'KT(F
MF43G./3J/0I0$<"GCBIW29_DUNVAU)776C-9ZRW/#W2T:4C+3R4.?E/<J%4Y
M5Y%1^RG&A4-4EJJ58M2C!51-JTN#R3CT?(9PB/F,!`N+P*=V?=(EYWE>MI>+
MHVA:IJ5IR8L/$Z-N.WN2;F@;DVQM2D*P[/8OU):?;ZDL<#9X^E24ZW;$0D[/
M$O)E83`U(`%`Q@N(P*>>1/=%G=3\B;CJ"I:]T<SU]J&Z:GUSM+;W(WD>MHF-
MF]D;<A8JU1&M=.1$9JG9H6>TQ51FVKQ9::=0$>NY6!HDL)^JH!;\T7!TU;.@
M\@`Y;HKAZ2I5T^BR95`]-8@`18G0W@8/`P>.!5'S8[E<IQIV^KI:@4?3\G)U
M#5#7>&Y=G\C=XR>@M-ZSU_+6UG2*HT-8X'5NW)R=MESLKH6S5$L<W9M`3%5R
MX*7H`A9GKRV$OM`H]Y3"'*G<Z?6K6F%>GT+7``G8H5E+D^!6AJU8MK+#>5X'
MNL@F@B1XAY5BID`_E`(/<YN<,_Q:F]6ZZUUKNF7S9.T8395X<2^U=GKZ>TYJ
MO5NH6E><7O8NR+I&4K8]F%BU=6N/:M&,5"/G3E5<QS"DFD)C!)CC%NDO(;1.
MM]R%-KT_T[KS:9,IJG8Q-LZ\4.KYBG4J>PBURHJ66(.8HBDNK&,5A`>BB)#`
M)0#$/-[EX\XFT[6YJGKE/:^V-W[2K^F]14>1MJ6OZL_M\\@]D5I.ZWM2$LRE
M5J=>@HMV^>.$8R0<&2;B1)`ZABA@=WPDY-+\L-*?6>[=:-?OV=OL5-D7G';<
MC_>&M7#ZO`P%<S*W3.O]83K&3(+[RN8U]$(.6ABE$3*%4(;`^GFMRI9</-&.
M]KC2WFR+/*W2@ZOUQKUG--*S],]D[0M4=4*;!OK0^:2#.LQ*LG(@J[?J-W`-
MVR1S%24/Y2&#%O$#F)LO=.VN07&WD#IFLZ9W_P`=":\F+-'Z\V8\VWK:S4[:
ME?\`I#3Y^N6V5HNN)M!\4B2[9ZQ=11#(+("8BJA#E$`DOR4WK6N,>@MO<@KA
M'2<O6M/T*PWV8B(4$/BTHT@&*CL8Z.]Z.DV!V]4*5(ACF`A3'ZCX!@0FXH\\
MMT[4WQ#\>^2G&^JZ(N6Q./;+D[J5_0=T+;DA)>@+RT#%2M1NBK[7&MWE8V+6
M#69DHX*V2D8ER510$'8BE^B!9O+2K&#BI.;DEO=XV'CGDK(./*8_H,6#91V[
M6\A"F.?TFZ)C=``1'IT#`J1X?]SNS\I=R4RI2NN=$ZLH^X*#-[1T[6I;DN>:
MY436MF+U!"N;!LFC4-3L*HPKUS9+@Z(E'VZ2>11#$(Z3$Q^I0M_P*1M7=X4+
M]W(K/P(D=2TJ);1NS+SK"'M[+;LJXOA7U'U?$[*-9[!09K5M?J"=<L021HUF
MC&VR1F`=)^<S+T1$Y0NYP*-N0_>3^H'N+P7!AYIFJ3<5*671524N+K;K^N7I
MX]WG#S$HTGJ[3'NLW-'?5^E*Q((2)']LBW[DSI+W%%RH(HX%Y'41'Y/L_9\.
MGY7M'^E@4I=RKN\*=O?=>KM7*:DIUZC+MKZ<V)*2=FVK/T"<<MH6Z4ZGC5:)
M'Q>I[]`R=G=!;!>%4G).OQ1$6ARJ/""8#8%TC%XE(,F;]`2F0>M6[M$Q%4%R
M&2<I$63$B[959LN42'#H=,YTS!XE,("`X%3/=9[GKOMKPVD91IK*G;"^MM]M
M0KA:\;'LFN8F(;:KI;:Y+1C)Y5-5[9DY"QV\J_N$:0[%!FF[$@N5TD1,H0)I
M1W)B-D>'JG+LE472B4^/TIOOZ%#:*RJX%E%T5Y=U*W],47IZB"RJ306X2`K@
MQ()O5,8$P-T#_]39"[W4/L"RZ:U35X/A_KKF9KVR6F[P]UH.P*K7K(C6+D_H
MK]II6[D>3LG$.*I78&_+D6FY*/5]]2CR&3*`D4/@9,[.>O-HZ9XUV_26QZ?I
MRNL-4[8E*U1YS16L:]J&A7B#<T^FSLS8(^GUE15BX]RN$K(1I)8QC+RR+$BR
M@B;J(A@/N<:,['>M;U#[S[@W'37-NVMN5V:'C9=.@;`O]_MHUUAZBK@]?H!G
MDD=A%-.A5'0M@3()BE,?S&#J$_>W.MPX<<6*:MP/H26M^.1Y:T_16K)4NUT`
M&LF%@?!9'!ZY=&K2Q-SO)L%E!46)T6\WF*(E$!P)TX#`U0.YONOD%:.4?<3C
M*]RBWKH&$[?W!6D\D-#5C4.PW>NZ_9]KRKM]).IC:,3')II;6KAS1R;0(B5]
MYCQ(H8IDA`P@(6B<I.4^UX'MKQ%_)QPVYO2T[LXOVHM[2U6SK1?JY7G]/NW4
MG;+:A/S4&#:"1</U#G!J594`2.`$]@"%,&DME7*Y\;N"?TBT=LK6+R9XJ\8]
M0ZTC[R:L1[O<"]+U!5(QC:M<I(3RYIN$MB+A%PQ3`"N@373*JF10X$$)4T.-
MVW2-NUIN?1&S9NXU15A?5]=QS6&)<WU>BI-L15\WBG<J@HBS5=JIH%<*BF@"
MBA0$P=<",?>&A^1'*FU:KV<?B]L[2E9IT&ZICAUMZ5HT$E)S<[+$7CVT6LUL
MSQNX66\"%3$P*&./@4<"K,."/+:EW_7->LFG9&(M-IE8Z7I]5D;%56%AN+:)
M=-Y-Q]&HMU,).)01:MC"44RB`_9\!P+I.[<YY%\K-*:=01XB[CU!!Z-EI:P7
M"W;6>T.#K)6$A6V5?1%*1;6IXFB<'B/7HMZ?F`Q0+U,/3`H]G^"O*BJPU-L%
MGU:K7('8BL4C0IB:M%3C8ZXJSK4CZ'3K;IW,(I2YI-HL55'TA/YTS`8/`<#9
M&VW?]\S/"&@:*LO#K?&OOJKIU#0LVQ;6%);TA!.D1#9C(O!=M[.X>HLW)TO,
MD=1$@`40\W3`K6D-<[(BM?,-M2='DH_5LJ#?X9L5Y*5UO3)`7BQF[8K*P*RQ
M8YR=9=,2@!3B/4I@Z>`]`L6O<QR2MO;EN'$"O\+-_24_:J)\%B=A)$I9:*L#
MBP1]C2D_>1LX2@QPM&X@!P;CU$0'IY?'`UR(O@YRDF:98=CPVL1E-?U![*1U
MIO#&U5-Q58!_!D04F&<M.$F31S%Q&D73,L4Z@"0IR_9#`OF[?TOR+TQP(O\`
MHQ#AWNW99]LN;].578.O75"F**Y87.N1D&P6))'M2*S@C9U''%4R29P`/`.I
M@$,"BR%X!<O+$O<6U?T[(32VNUS-[\2,L-8>!35R(*/%$K**$N8D.=)JB=0W
MK"3RE(81\`'`N?[-TSOSBI2-L3B7%/;.\*YLV>BEX2QZ=E=?V&%;K5MLM%R3
M-X_7M3-'WQ)T`E$A!,)1*(&Z#@>G+&;!N6Q[W38#5-UD;[7G`V"WT)D6'?VZ
MGLK*X7D8T;'#LY-9U'`JDX``.<`(81`0'H8.H23XD;0VCJ&P7"X5OC!N7<K,
MZ;R@2J&N2U)V:OV&->1TE(1\NXD;$Q9MWS%,"%5;>H*Z8JE$2@`]<"#N[:UN
M#:G)&Y-&VD[S7M@7QV\ND;JB9<5L=@-X,R28J.U81G,N%'*")$Q,95$5$P*/
M7KTP/><,9/:FE^1TA88[0NPMIV36<5,P5UUQ0'E0>W2N.;.R,Q9J3$<]L#,D
M81$Z9Q."QB&$"B``)@$,"&/<PTER?Y+<QG.UF?'"^:T/N&.I=1H%'V'*TZ-N
M5EFJC66D5)-H:-:6!V63,8R'J%!`QQ*0P>;H(@&!A[BAQ<Y1Z'YFZ=E9_1%E
MGKCJRT0&S9K5,#/4]38[JL1;XJRKME7G<\W7])0$Q`JBGD3^41`/'`E]W>ZO
MR,Y2;*USM8W&/96EZY$5TE`2^MN5HT"I,6&3E2N&+6)4;65Z@Z5<"<"%3`WJ
M&,/@&!7!$\&.6NO=OZOKUFTQ*1MR>V&#M%>HKRP55G;[3&UZ7:RCX:]#.IE-
MU("+=BH!1(42]2CU'H`B`7$]Y&0Y"<N-?ZBG4^)6X-+5G2TO=Y:U6C;TA0H*
M!%O<&59BXPB#]K:GJ*:Q7D4)1*J)/,)R@3S"/3`I+LG`SEC3$Z:M;]2N:PGL
M!ZQ84-2>LE6BB7%[(I)NH]K7#/)A+XLJ\;J%,F"/G\Q3`/RA@7Q\\U.36^>#
M&L="->&6\Z$^U)%:]6L]VO"M%CZ:1I0JVTB95V#Y*T+KH-EE6HG3,LFF'D$/
M-T'PP*#Y?@[RA@*-#;.GM9#"ZYL1X\L!>I2T51C59H\L`?#2QDTYF$V#P7P`
M(I@0X^8`ZAX8%ZFU83EG>^ST\X!P/"/?2FP'6LJ=66M\54HY->JJ0.S8&_.9
M,K\+2,@$:M$19R)G]W_J@E$>A1$<#5T-VI><Q-?K[9-IY$-7-DI!9?8GTUIG
MT+22B9)U#RAS6,)L8SI'RS%=JK^B?,<)'3'YQ1#`V:^"3+E)IKM2V#B4XX8;
MMNU@OT+M%U7=@TI]K^8UX]8[&55=PD@WE@M::[AFDDKU5432,'_:]<#7/@>V
M5S4L4+:YVNZB).PNOG+V.O,Q$7&H/X^HOXIL5Q)-;$[;31THI=BW,"BI5A*)
M"^.!L,]D,W(_AIHW;K>1XB[?W+";CN<1::K;M/RNOK'63L8>O*0#M%636MC1
M)1T5\!@$$_.`>40,(&`0P*`FW:]YRVV[7ZK5[2#N8ME-?K.[I5HRT5-[/4Y.
M645D6066+;3"CJ(,JV6`0]8I?`>@],"Y3L:5GDAPYLF_;TZXO[&W;`76.@*.
M5SIB?U]9B0%CJLH]?RL=.JJVIHBS=$2?$Z)]14\>HATZ#@9)V51]T[.W_?HF
M*TU>X[8$^Z>WT^K7+J!5OD-79!PD5)](0;*875*T356(4RI/,EYC!\[Q#`S+
MP:M.T]);UN%@BM`[)W%-4ZN2E)N5&UU(4Z0M-2E)I_$ND%;`QD+(S3BR)?"#
MD,50P*><W0"B)3=`_;E!S'YY2FS-I7S7KG9^A]4U-_3:_-TVS3FJ&JFM[#(5
MJ)!.*M+D'<NC%2MI>&.^:MUG(JJHKE$"@'S0#^]:\H>XUI[9VH[;OX=N6K7-
MHFTVL73';_5\8MM`TE%NE8V*JJSY6';R[A854W"8).2^8A>H"/4`$)#\I>XG
MW%JC::P?4G#[ZNJ59#L:VP:<@A@&=CL-UD'((MHNO_!KQ[F^][!0I$T2^94Q
MQ]G3`Q%"]QGNT5W;VO\`6FQ^+>LV,C/2$;*.-=11F3#9-AI+202&QJTZ$D+P
MF=P^^&(KE;'$@I`J`";YI38%DMWY[2L/1K)([JXH[CTG1722-8?SVV)>D5F*
MDE+21Q%)1L=*1]ED")OEQ.)"@<R:@F4*).O0PE"(W%^B:"X&V>`G=<\>=[_3
M?85+B-*ZTE-M[GFM@3KK74:_6N$-JK5;:VV!9DVKQ9$WOQ&S%#U%#%*8ZABE
M+T"26VNY+N35U5D;9)]O7DRR@X?U59J;L)J-'P4=&H@8%9!R]:660.W;>'7S
M*D(7H/B(#X8%,%%W)H[C7<M9<JX;@1RVIU,BIFWR6A(:T\@9]WQSID]N\R#B
MW.M046PV9:IPAKN9L0_NS0!9D`.J"*08%ST]W,=CU"BQ5VNW!;D'18R3-76I
M)JW/M?1%:&6LSQDPB(U!ZI:1D%W<M(/DT&:0-O5654*'E#J/0*T2O]$[&Y3V
MG9M=X=<J'>U:!N:N\AMEZ3IF_P"T):TCM\0)&A8?;%YT?'V@];C;D(,FXN5O
M=FR3U1$AW2:JGSA"Q")[L[J4H-LV6RX@[UL=)H2TJVNMLILIK:=K]<<P:ADI
M9K)+?2Y!ZU=QZA1*LF=$IBB'@`X%+6_.?_:_Y';+G]KW70W,B#GK\77Q=LP^
MN=N/*!1]U(ZKE8R9UVGM>E5[8;:OVU2JO(=I[LN=!-SZ3=-(ZATR%*`7/:/[
MLI-\TE[;]&\*>3M_I-8?K5B0F8-#7ZC..DXF+CY!>,5,[N:2YEVT7(-E!\!^
M:J'CUP*A.4G<H[;/+JRLKQL71_,6I7A&DS>KY6XZ8VHKJ.<N.K+&X;NYW6MY
M5IVP(]I<*<_>-"+`V?HK&;*E\[<Z1C&$0LYXH=UNA;'I$3K+BQPNY,76I:6J
M53I3.*A3TI^I6ZQ`0[6!K#)V]E[L9Z\.E&1R:?JJJ**J"3S',)A$1#"G*CF/
MQIY(R=)-M?CWRIU_M#2LU/N*)L#5FUXS4FV=<R4\T0BK=$Q]IIM^8N?<)UFR
M21?L7(.6BWHD,)/.0I@#,_$?FYK35NLJAQOXK\-^25KK>LZV8L57&5CJ%QLK
M:#2>)D=S,Q,S]Z6D9$ZLG($]9954QC*KAX``^`1DYO\`=*X@[/\`?>/?*KBO
MRDJ-RUE<:Q<XI:NVB)UYM'5.PX5!E8ZG<*7>J3?XZ=J]E8MGR*R2S9R!5$5A
M35*=,QR"'\<#NYWQ3U<S4X[<5>,_+G8%DV%>;;L^7^EUNA=A[`O-]LR;%:TV
M::LMJO"SET]>(QB/F(4R2)`2^80!$W4/=\ZNZ!QIL56GN+W,KAWR7KB-B:UZ
MT#`*2U>JENAG<1+-9ZHW*K6JIWQC.5J?A)N-2=,GK-RDNDJG[1*)BB&#.&W=
M#X3:6N<S7M(<?^8.S-T\A[?5X^QWC:NPFNVMM[,L2#5E4Z/`/KA=[Z^=)QL0
MQ2191S!N+9DV)^=3`QCF,$FN<_>%T7I^E*Z8YM<)>25;IF_JE;H!2JV=A2Q:
MW.K(HL8NU-/5BKJ#A$B))Q`AC%43.452B4W4/`*QN*O>-[6_&>_#;M:Z;YNW
MO9DY3Z]I:NVK=&RWVX+%6-9QTDT4KFK:6\N^PI).MU%O)(MA!%`@++&12]=5
M3TR]`NRW/W=VFAZE"VS=O"WDO1*A;EBQL/)6!GKM1A,*.V0.O<RII7!?S@LR
M4`PE,7RB4?'`IHTKS_[7W'S;=<W#KG1/,YJZH+2\LM6Z^L&X9"UZDU&SV4]8
M2-Z;:TUW8-C2$+5FD\YBT!,@F!T&Y4BD0(D0`+@74W?NV+:WU,PWK>.%7)VN
M:BE&%9E6%[?M]>_!W,=<_<OHNZ)Z5R.X\DS\2;^EU(']4#KTP*98?N%=L6)Y
M#K<EU-!<P)JZ!M9]O2)JD[M$\CJ:N;FDJ@TH;O9L#K`;^E5&UN4JC,C,CE5%
M;TB")B%*?H8`N(+W@D5=&R7)-MPMY/O-(1$*[L+_`&"U:Z^5B$8=@L5!V]\G
MTR!R*:*Q@*/0G7K@4,;6[M7:$W7R#><D]@:'YG25PFI+54Y9ZK';#<P&K;G-
MZ15!UJJ7MVOX38$?#6!Q37H%<-DUP,W.N0IU4U!#`O=X\]XICRFUW([6T+PM
MY17W7D//RE4DK+&L=?H,&,W!Q\9)RC)8KJY(JE&/CY=NJ<0*(>10.G7`@SR@
MY'<+N7URB[QMS0_*XCUMKVQ:FGHO7^[&NN:_?]76V7A)VPT*_1M1O\9])JQ,
MR->:'6;G4)YRI^41\HB&!8MJKN1C::^U@=(\(^0UOKE*CHNO),*9]7;EE6XV
M/8I-(>,,"US2%))%@W(1(O4P^0H=1P*[.87./A]ROE:&SW=HGEQ5+9I.6O*%
M=D-9[3C=76B&6NT,G4;[!/Y6I7AH[<LYF':>Z.$Q-U*7S>F<AAZX&;:#S\XS
M6;C1;N)^M^$V]9WCM3>/UEH5WHT+,5Q5O7=`&JKNIVDTK/+;`"R)QI*V^626
M>%=B^`3B<JGJ=#8'_]6]3^<04R$F]1<6KK<W^BWFOM<;SEI6YZXY$[.NFN=;
M[.:R](DHJ+@ETZ"X;6.Q34=*'3=LTTA,#<Q#',`E$<"579-C:0TX8IR.NM=<
M<]:5&P[)M<Q&0W&'8MRV9KQYU90;)Q)/9J]O7M@86A19H*3IDH*8(D23$"!Y
MQ$0C9WJR[-K6UN&FT:,\Y'5F'J3S:T98KWQ4U]6KCM6O'GH*-3CVDBO;&SR(
M"E2RC82N&IDS',[(BH7IY1P+(^W+:;+<N*]+G+98^0-KFEY:UIN)ODW4(&C;
M<<IH6!^DW+,U^LL8Z(08(HD`C,Y$@%5J!#&$1$1$)U8#`@-R5[9/#/EOLN&V
MYO'5KNQ7F+B&%;DI"(NMUJ3*ZU.-D$I1E4-B0]7GHJ*O571?)%/[E)(KHB'4
MH@)1$N!FSE*P9Q?$?D;&QS9%E'Q_'/;S)BS;D!-!JT:ZTL2#=NBF'@1)%(@%
M*`>P`P*)ZKVY=D\L.-?:QV[1[A0HN&C.W/P>UI;&MVC9)].4EKKZW\9^4+"]
M:E<L2F3B[E87&K!KSU0XI_UHZ14`P^AY1"R&H\7.1)>>>M.7=N9<?V+5IQML
M.F=K*U!G9&UOL<[8+%!V9*38/'20)NXBON*P@W9I.C&,5)ZX-X&Z=0_#N9\&
M]H<R6>B)#5-\A:;9-.7*Q6!$MB4D$X_U;)"(PK:QM`8-GA',S4U$Q=-D'"1V
M[@PB0_0HC@1LV-VR^2.X=^:CVYLC8VH)7Z.+:':7.>0@)<+A$1O&C8EVM]2?
M:X5.D1E!2&TH^SH(V-,GHH$.DJ"8"F<H`$VNY1Q(N',WC[7]9T:QQD%/T_=^
MG]RI1L\\E(ZN79OJ^T)3Z])GY"&(I)1[*6``51<)$.9N];(*>4?)@5U;I[6'
M+O>6O=#4?8VW=(7F5U'I*;XZ2%PL-4E`=2%=OU%IT1;-N146T:(1T3LZLV2N
MKC#&;I(I^XK?/$J@FP+JMPZ]G[1HBU:VJ:4%-SSZFDKD46\*./@[]=!L@U(M
M,.6S9ZX344*CY_5*DH8JO0W3`I#<]J'E,;BCI#CJ>Z\?YYMHF>N]O@(JQP=B
M>U6PS&W(G<M:MC"TLP0].23I$9LEF[AW8I`LX>,UA5`OJ%$`MWJ?&A]5^$C3
MB0UO4BC)M..LEHQOL=J51.48OW]$>4]*VLR^<%4W<<X=`Z1#S`8#)E\>N!4+
MKGM4<P:EPMF>(LQM;2TI5%K!0+A6H)W&6"2@H*2TY"Z6C*[4W*ZK%J]FZ5M&
M=US,2DZW=^N9BG-$9MA%%`"@%MW"OCA.<:..$9J*QS40\L;RS[3N\T>HMUV%
M5KDIM2_6>]N*Y2V3DI5F==JY['[JS*8I>H(^;H'FZ8%5>J^U7RKUOI[E'Q]0
MW5KT=;\CHRXU5X_,E87<]&M9YI?'Y;V14S5!PG8)V;L<>TDV`KJLACFBHI=%
M%!ZA87V[N)%QXG4':;._OZ,-JVWMB6V=(US6,<[B]?T\KN'B(%I#5MH\316`
MJS6&*Z='\A?4=KJFZ>/7`C-J?M];_P!+<J]K;YJMETS)15BVYR$OE<<R<3/-
MKG:JQRTV;J:Z[$JFS)%F3RRB&HX;6:D?42@=1(A7Q0,4A$Q`0DCV_>+VS^+B
M?)R*O3/4T?7-N\C;7N^BQ.JVDJP:P3*VQ$%"OXB69R"238'0!5V[L54`_17#
MM<3=>A1P,5\A^&W(:^\X=5\L=526FH(FF*I<&M?2M3><=R5OE[;5EJR:-L;9
M@Q(1@TCO>!6(^17.N*902`H%,.!X[A'VV=C<:^4EVWI=KI1IF(/`[2KU74JT
M;)-K?=";;V_.[@DIC:4B]`$Y*2J;B9"+CQ*93]`3,?J'GZ8'I>7?`O=^Y.<.
MA^7&H-I5^H&UIK.,UP^8V(DB[5@"0VVFFTI.6KL4FV=Q,N?9$.W/6Y1-T"9F
MR'N[M$_KMDQ*'C=3=NW=\3SCB^5NR[3J11F:Z.MU3Z]0AYA*^K[`G^/H:*FM
M;M)V0)YSZE9*">8:H**"<7!NAB`(^;`R3W*N"6V.8,UQ_M>HMCPU&L&FYVSN
MB#8??CLV:EH9,6*=NBV[9J]:OIZME:&,BV=)&;N`/Y3"`8&`[OVS^16W^6.M
M^1.S+_J3R,+#I.R71W"1,Z>VP"G'IWL5.M1.MGSP@)1<9L>/NJ"D\F8R9`71
M7`A3%5+T"8?<OX?7/F?I/7=&HE@B(>=UKO[7.[0B+$_F(FO7=M2&-HCE*I+R
ML$FM)QA/6LJ<DV<)D.*3^-;FZ!TZ@$&>0O;`Y4\AX[4<7?MJZ6M;VB:GE./,
MO;INIR/Q8M+GF^IY62V]58]NU3C8#;C>S4-^FA[LF@W(R>$`!*(&#`LOYX\9
M[!RPXI;&T%5K2E6)NU,X+W&3DE7A8]\>!F8Z7-$S:S'S/2QLR1@**YTP$Y?/
MY@`>F!5OMOMA<PMLZ#TSJ*T;.T;;%-+1]UCZ^A;(*9=P+QKM[7%NUY9V\PT:
M,6R#YQJ=I8&QZT\%#WIP#50SDP**B;`NEUKJA367'RHZ82=-;HM3=6L:"FYM
M)5%8^S+QM="'#X\F'J+'CI-1/RN"AU,*)Q`/'`IMJ';6Y90O!_7O$=W+<9VT
M9J_;USWG"PC.%M"U%GYY[RH?<C*MKN:@ET/=2:^186J3A7"14AZ$;M3E)T$X
M8%GG$_C-*\?N(-2XWS5C9O)J.@=A-I6<K+96/B8R2V/:[=;GC2KM%?*JRAZR
MYMIFL>0?*)&[5/P#V`%=?%?MP<E>,%>V=!1L[H&SM-C58^NYJ-=1=B81\[6Z
MA%S:E)N$H0C5PF?8=CFK&L68<J)+%(BU;F3$QBCT"</;>XHV_AIQH8:8NL_7
M)R8+?=D7CR55LX3B(-OL"XRUM3@$Y!XBV?3BT6,H*:CU8A#N#`)O*`#TP(CZ
M*[=W(#0')[;V\ZO;--RT;<+EO0L0,G#3C:SVJ@<E^2X\A[Q]94BU3_LS9M=-
M7!Z_7A$5$`9ID$WE*'EP,\=N;ACL?B;(\HK%L29H:SCD'MN,V+&5:@LW7PVI
M(1=;2KBR"DR_91[N0))$;(J(-_2*DP2)Z9.OF,(AT6RN(O(62YS)\NM:/=,P
M8U75LW0ZVUG$)UP]M9[5-5!64):6S)DBG&FC8V#<'3>-UU5UU123$"I^;`\7
MV]^W)L+B-O396T+K;J+/1DE09O6E56JD9(,K+;X^P;IMFYW%RVB[>%*E)6R.
M<6<(M`Y!4_K=$Y_,'J=,".NW>UKR*O&[.5NRZT3C''UC<7*'2?(NFTF7@K"Z
MB)ASJG4>P-*2C?9;$C<6+^9MD7?#V-9TF0YBSK8@]1+T,`<;#[2F_;W6.+^O
MG^RM2R-;X[:ZC=$,IF8A9Y_/)Z\04T[:%M@5T''JIP^S&EIUL[8LS)B1)*'?
M`7S`8#`(2K[@_`?<G*7:/%S9NG-PL=;R^B9=V1XO.(.)'W=E*24&Z?V:'8"U
M?1DG8OA<4LR])ZF*!R.O,(@)0P,3J]N'D)>>:.M>4VT+GIY4L==M*[.NRT!$
M3IK=%3VBJ7>J+%5"@23TGE84R_,[<F^ET5#$`'22H%*8%`'`E9W'>(-XY=Z^
MU+%:]E*&A8=5[6F;U]'MHQ;J9H-IC+;H[<6BI1*5CVB:QS2U69[?-/12AB&*
M21BT@\!,!BA&RY<#.2<VV[?44WD=#2X\&=M4.4C[I-,K/],+!JK7M!K5,:QC
M=T!%#,;'9'#=\Z?@4X-C"FV*'7H?`F3W#>+MGYA\7+CH^GVAK4YZ9EJK.LW4
MBJ^;Q$I]&)MK,'KTTM&@9ZC%S!6_I*'3`QB>!@`>F!6EN/MB<Q=R:.TGJJ\;
M:T=?Y73%,V!KEA+W"L2JL?,0VZ]4,J%<;0^BV3)NR+;=92J9UZTX31*<Z(?H
MPE4.8<"9G//A7L+D3PAI'&+6#C6LA=:;8>/DE&W3;C.3>MXCZC['5[2>PPQH
MU-5^UM-@/4"QIERB4Q&4H[^=YA`!"/6LNW5R2H'(#<NZ&UKTE&GV0_WE%I*0
M<386=@EZERAW=#;>V,O<91,B:LQ/ZU:,UHFKF4,HF"/IBIY0`0P/CT#VU-M\
M?N'_`"QU0\F->V"_;?UU3J!58ZC,UZS6G336%'3HT+9[`=^F4/IA=6Z`/I=P
M("`N3F^<;VX&N=$=IKE9,UNT6J)?:4DZS07#R.NUC9[<KBT'57L2@162;34H
M!09LUF2:@"H`G'R^SV^&!LF=EWC_`';2/#39D/99&F6(-@['MENJ,M0+5'W"
M!F(5Y1:K7D5$96-$$"N"RT,X2.B/0Y#%^<`#X8&K4AVU><KAX\C$..UQ7DXL
MJ*DI'(.(1:0C".B>LU/),4I0SI@5RB/G3%4I`.7Q+U#`V$.PMQNW9HIUOY_M
M>A2%296$E>90SUR\BW[5^\BUURR31)>+>O4BNF)C`"J9C`8@^`@`X$!M[C_C
MJVN(_P!_UD_MBK\@8$^NT5T^^0N'VM/S@`'W;93O]+`HH[NO3\([RG'I[+?4
M_#[(_5A1/N]/`,#U79IZ?A"M)]/$!"Q]>OV?A"GY7L^3`SIW_/X]R/V/JDIO
M7[7^V>G3Y?;@5Y\$0_Y;7$4>H_QCM/B/3J'^_B('\W`LB_G9?[9'"7]96\?S
M1G-9^/Y73`U1M;C_`(QM>_K[IW^$<;^7@;X_?Y\>&_&+]=\2/A^LMH.!J.*_
MU!7IU#]"/U`>O00\AO'[`]<#<=[C/^8TU-X]/\6O#OQ_^#4/K@:<GC]KI^=Z
M]1Z=?L_FX&VY2P`?YNILX/8'U&7KV#]B=1P-`<G@4O\`L"_;^0!#VX&^[_-K
M0_Z*S=GR?\H+>0_<_P`5>L,"M]#J"20?_@T_'_W)?9]GIT^7`O4[.P?V(W6'
MR?$(#^BR5ZX&O!NT1^N/:W_&%;PZ^/A_9U]_H8$T^WA^I_GR/R_>';K_`/$B
M#[/9@?_6V">^I-U>CP/$3:4?9)1/D)0=NW=7CUK-GQU<\IV&U9B?H#F'O$1*
M:@:2]?6?IP=74][2D2OD#1BO10//U$@AD;L:%H,EQHVO>*W?WMPOVQN0]UM>
M\J\ZTZXX^(ZPVFI!U:-D:"PTPZ?2J]*;1T1'LUA`SMR+M1<RWGZF$I0Q7WI:
M=:-BWSBI48[6]VY-UE1394G-<2M7;T^H'8MY>M8R.1C=CQ=F<^A%6&(HWKG1
M=1BSA(WF?)KD`XI"`!-3M.:DY!:3X:4RC<CVDY!7-"SWR5KM'M%Y/LVTZWUS
M,VN4D:#K^R;`.`#:IFJ5EPW:+N@\Q3'3Z`8P!YA"RG`8#`C[RT_BJ\F?\GW<
MW[W-DP,4]M/_`#<O`$>@=?O)^*WL_P"(JAX$V,!@/;@,!@,!@,!@,!@,!@,!
M@,!T^3[G]#V8#`8#`=/;]O`8#`8''3_1_HX'.`P&`P&`P&`P&`Z?+\N`P&`P
M&`P'Y/R?FX#`8'G+A!*VFHVFLH2"T2M8JY-P2,JV#JXC%9>,=1Z<@@'4O59F
M=P"A/$/G%#`U^M2]J;F)KGB5N#B:_P!]:PL5-V;8CSC$\O7K&\6KYJ;-T2U5
M!`JZ<NT7DF6Q[%6GWTG0="L5)J_]-J)0*(F"U;@;QPMG&#1LA2+S(5!U;[;M
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M>H20[5^MZQ%[RW#/4_=6L-J%H%84U_=(ZBKV!5W`3<[8&KN*<&6EX>-8RL*^
M&GR*23UBHY:*+-5"%4$4S@`:Y_=U_P`X]RG`?`!MU3'K[/\`T7T7[GR#\N!Z
MKLS]?PA.DON63['_`.J%?D]O7KUP,Y]_X!^_L0^P.I::'Y?]<],"O/@CU^_:
MXB=.O7[XW3W@/R?W<0_B(=/$<"R/^=EA_C(X2_K)WC_;S6GRX&J+K?\`;&U[
MU_O[IW^$<;@;Y/?YZAPXXQ=/;]+XG_`MI\F!J-+?U)4/#^IJ"/7I[?(;[?3Q
MP-QWN,_YC/4O7_@VX=>SQZ_H%#^[@:<X].G0/9X^/VNH?9Z]>HX&VS3`_P#^
M=/9X?^HN]!]C_=U'`T""?G"_[$O](,#?=_FUO^:NW9X]>G(+>7L\?_17K#\W
MK@5OH]112_[V3_N0P+U>SMU^#[K_`/.,!T#Q^1DI[?D]N!KO[M\=Q[5`/^$.
MW]?N_'7WC_1P)J=O']3_`#X#_P#L.W7_`.)$^7`__]?84[XMWXTT&)XGV?D/
MMWDKH-[6+[M^ZZIVUQENVNJ!;XVZ5+3\R^&C%F+]3+F>7G=GLUPAX:'CDT',
MB^6^<)TTC$$/"]B[3,8SCMV;A2OG/NFWP^SK)";QXU<KMWZ;W'7V>S[?6-?W
ME'8SF=U5J:BMY:YR-+E(M-0%'!'$6?UF;A`#I@.!&/N7T7N!\A.5-:UOLOM=
M7OE#IG7%MV1;./>X^,?+R.XU2P5B3AH2.C6=NL\M9$&=4M$>5P[2>(2I$BRY
M5""P*4$%O,%X/;3UW:-6\3:53[CH?:'&V=8S%M7<ZGW!R$AN3UWA$WECD'*#
MQ_MR!D)*.FFLLB<'#=`BO5FBH5$P`)!#`GS@5G]RCG!OW@QK-3;>J.%TORDH
M53K=@N^Y+4GO/7VF(;5]1KJ\8DJJ5*U1\]/W2QRQ9`QFC".8B42H',JLGT*!
M@@MM3OSKQ4/%VK0G#*][LJ=,XO4CF%R=>S6TZKJJ8TAIBZK@1H$#!R\%/*[2
MNB31%PX+'MU8U)1)$!,NF!P$H6Q;YO\`6]A\'=S;!K[U,:]>^+FSK+`+.CIH
M*.(^<U5.2#/J4YP#U?1<%\P`(]!P/,=LYP@MVYN`I45DE11X5<5DE@35(H9)
M0NBJ(`IJ^01\APZ>(#T'[6!-[`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#I^3\GW<#CV?Z@C_2P*T;5P:VU*
M<S[#S&JV_P"EU"</K+ZJZE5R:5GIM,E=E+95)RQFOSY_NH(ZSO"0]?<LXM6'
MCJV=LO("X=B^]%-$0^O@;P"D^%\K>WTMM]GM-I*4J@:IUZW9ZZ)07=7UEKJS
M[.M\.VN#U*WVA._7A[+[3>%=2R:,2@9NW1(1F0PJ&.&HGW=.OX1[E/[/U750
M>OW-7T;K\H^SK^5@>K[-`]>X5I,/E_NDZ]1_\D*_)[`\<#.G?]_CV(]?9]4M
M-^Q\GO7R?;P*\^"/CS9XB^S^,=I_[/RWF('KX]1'`LA_G9?[9'"7]9.\?RO[
M.ZT]F!JCZW_;&U[^ONG>/R?JBC>H?+]G`WQ^_P`_Q-^,7Z[XG_`II]CQP-1M
M;^HJ>T1%(_V?^T'\T>@X&X[W&?\`,9ZFZ^/^+7AW[/'_`-[T/IT\?DP-.8/D
M^0?DZ_=]GL_HX&VW3.G_`-G4V?\`('U&7KY.O^[J/R8&@03\X7[/E+^9Y0P-
M]S^;6A_T5N[/;X\@=Y?;_P#17K#V!@5OI?U%'Y1]-/\`[DH#_3P+UNSK^D^Z
M_M24!]S_`&DI[?EZX&N]NSPW)M7Y/\85O^W[9U[]D`Z^.!-/MX_J?Y\>/7_D
M&[J#K]@/<B>'W,#_T-AKOQSO)Z&T?J-3CG$WB5:,+O9;+?!U'JK7.W]L1LC7
M*HXD]4O8&N;"K-N^#U=2_)IISLM$LPEF;3RB@NCYCFP)*=J38FZ=M:DW#LK;
M=&F-=1ESWA)36M:Q<J-3]>[(1JXT&@L9F1OD#3XN)`TC,7=E)N6KB4(K,*,5
M$@<*F(5$"AA?O%=P/>/`^)TE.:W4HE1I%IM#92^[$O\`1K1>V3MO'6NI,GNM
MH%&NRL8TK5@FZC+2DH62?E<(IHQ9R)I^H8,"8?;NY0W/F#H!YNVU0D?'0TUM
M':,3K&8C:W8*DWNNJ*]<Y6)U_=1K]G?/Y9DM8:\T1<',8Q$UC&%1--,ABD`)
MB7FI-K[3;/2GLS9Z\TM,)(P3F=I5AD:G;HA&2;*-5)"MV:(50E(&9:E4\[=T
MW.55%0`,40$,"@[G+VT>85GTOJ'BGQ>V,ZWAQA-?Y'8?)FN<S^1^V[?M3<A8
MUS!/:CJQSMMXRLUC8ZB/*18.Y*-;`B=R*7H>H"#AP0X8HWWVQ>>]YM.V;+J^
M*XMTYKS>X?T/B/R4J8V:Z#7^/<=3U5HI.TZ3\D*@M<X]&J.!318OBMQ!<I0#
MRE`3"%D?,[@5QBV%P"D=5[HU;7=NQG&3CK>W.K7=M*_.XKMFJFJ7S-I9&!F#
MR/\`*_,I$(J?/\Q.I"_-\,!V;.,6@N._;\XMSND]7UO74QO7C5QKVOMQ_`%>
M@O>]B3FD:8ZEK7-&>/'8'D7KAZJ<WI>FGYE#="AUP+4,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?Y
M]_=U'_I'N4X"(_JNJ@`'4/\`@OHG3H'AU`,#U79H'_I"M)AUZB(63H/V@B%?
ML]1Z_P!#`SIW_>OW]J`?^J2F_8__`#GQZ=?9TP*\^"(_\MKB)U\.G([3X?\`
M[\P_AX_9^V&!9'_.R_VQ^$OZRMX_V\UI@:HVMOVQM>A[>MZIW^$<8/V0P-\C
MO]?Q..,?7^^^*_P+:8&HVK_4E>H#_45/M?ZT0$/R@Z8&X[W&/\QGJ;_BUX=C
M\O\`^3T/`TYOE\>H]/L>WY/9U^[@;;-,'I_-T]GB'_`9>NG_`,_(_9P-`@GY
MPG^Q#^D&!ON?S:SI^"MW9U_^D%O(1^7P'5>L?M?)@5OH]021+[?T)/KX=?#R
M!]SVX%ZW9U_2;=7R_P!D8'\O^LE/ROEP-=_=G[<>U?D$-AV_V?\`GU[T^7`F
MIV\?U/\`/CP_]@W=7A_\")_0P/_1M![NW`[N+;_YA7O;G'2@6>UQZ&JM`UGC
MMM"L<I9'2KW1$C6++>YC?+-E1VK![%65_MAC.L6BKUV43((-"``'`"@0+C>U
M?HN=X^<9W-'M'&\W&JPN-@3\Y,UQ[O"2Y"V.\/W["%37V1;-CRS-@Z?V.P*-
MO271!(B:8-BB4H>;I@0H[Y#7D;!,-%;*T?L=.IQ\"K:H5S77VS]<4*LSUR>J
MPLO67-_AMJL92M76BH,X=XW=M&R))--1PF9%9(OGZABGLDK<Y+AN[>FWMXKW
MY73VQZZM,KJS6TJKLG3ZVR%]@VU6(B^/K6JB=A3*[4M?'CXR8CR&%())L8Q0
M#J(8&RO@,!@1^Y9!YN*_)<O4`\W'[<H=1\`#KKFQAU$?D`,"MK@-S4J],[37
M!?9KG3O(*881.H..&@E*Y`:QD).W.I>$U%5X=6],H--P59QK1XK%&4;RX#Z2
MJ*J9@+T.&!8,'*6OFW_(<?`UGN7XU'T92]GO8T)Z&L%V:;)P]&%:W#UO=%K&
M8K<4RM/+YQ4,4O7QP,4#W`*<&BXG?'U%<F_@\M?!H*=)^J*4^LAJ]!X5E\<>
MU/WKWIO61,;S^^";R>0!'I@9/9\K:\\WA*:++J_=24O%:V0V8I=5]?/DM<.F
M"\5&2I:ZRM8KBU<6XI)0J1F(%\X+I*$Z]28&+Y#N`TV.X^,.1!]$\G7$)(;,
M6U@2A--02J^T4'Z(2(C9'--!T#M&GG&-,4K\3>0QE$PZ?.P,L)\IJ^KOZ7X^
MAK+<Q9F'HY[TK>ST)Z76+IHFS5>#"L;>*_NCBQ&*D*8-0+YA5$"]?'`Q8?GY
M3B:-@][#HODT,1.W]37R-*#4,I]8S)ZF_!A\=D:I[U[TUK)CCYP>"82"G\[I
M@9+:<K:^[W?/:,+J[=:4M`:U3V:K=%]?/4]=/V"L5%RQ:Y&6H7`M7=N*G*%1
M%B!0."Z2A.O4@C@8D>]PREL="Q>_CZ$Y1K0\KM)QJI.BM=.2RVS&T@V:O79K
M.\J(.@=(4Q0K(2$D!-Y#*'(7I\[`SHKR4@T]\S>@OJ[VV>9@]=I['5O)*0\-
MK-ZQ5147"`CK=ZP-75I*!/*+("@<#B`=<#!:?<,IBFF(/=7U"<HRQ<YLA76B
M5.-IR6+L!E()"R`;#(5@77O+6I&%\``^$PD$4S^'S<#-2?)Z!4W%.:9#6NX2
MRD%JT-JK6XU$>!0GL>+9NY"L1ME]?W=W=/*X`OP\"^?SE,'7PP,(O.XA2F>C
M(C>YM!<IEX>8V:.KTJ4VTU++;':R!4)9<;(^J8.@=-Z>/P@Q0?B;R"=5(.GS
MPP,[J\E8-+?%DT$.NMMGF*UKU+8J]Y3I#PVM)%BJW]<(&(MOK>ZOK27\Z+,I
M0.!_#K@832[@E-5TC`;R#1')XD38-G$U<C2U-/RI=BL9`Y$C_223JOO7O+2G
ME]7H+\3>3S`(=/#`RJMRL@$=TRNDAU=NHTK$ZV5V8I<2:_>FU\[8(Q1I4:XQ
MM`+^[.+<=,OI%8@7SBN($ZX&*5.X)32:*B]]?4/R?-#RFP_JY3HY-/2AMDMG
MWO#ML$^\J?O7O3>K>=F(^^B;R>4Y!Z>.!F)WR@@6?(.Q<=S:UW$M-5S72VQU
M[\WH;U35L@Q1;-'(U^)N(+@T>VHX.P(5D4OG$Y3!U\,#$;7G_3G>CX#>A=%<
MFT8FP;)2UFC2E]0RB>QF#]51LF6Q2=5]Z%RSJ11=!U?"82!Y3>'A@96)RF@#
M[PEM%AK+<P2T1KX=AJW4U">AKETR"/-(_`&-J]?W9Q:?(7T_<P+Y_5^;UP,2
M+]P6FH:)A=]CH?D^I#S=_/KU*CI:>E3[*:/2.'K;X\_J7O0.FU8,=D(@\$WD
M$IR#T\<#-*/)>#7Y(6#C477.W2SM?H1;^ML,]'>%U*_9&1CE@@XR[BM[F\LO
M]D2E]T`@'\Z:@=?FX&%#]P>FET-![]^H;E`,-.[`^KY&C_4]*_66R>`"0C/R
M-1][]Z:5<?5Z`\$PDZ@/AX8&66W*JON=U3.D0U?NE.5A==AL96Y*T!\37KQB
M,:,G]'V%H%?W9S:O('I>Y`7S^M\WK@8L?=P"FL-(P>\CZ)Y.+Q,[L-QKE&EM
MM02JVQ6;UL\>LC3\C50=>\M*LJHQ$Q'@F$AB'(/3H;`RW&<HH"4Y`3O'I/6F
MXVLU`:X:[*6OKRAO4-7OF#IG#O"UZ,N!EO=7=L3"8*F=B!0."J*I>OS.N!AO
M\(53/J&KN_OJ%Y1?!K'L-?72%&^IV5^LN/>(*"D-@E:C[U[VRJIS!\UX)A(/
MV,#+Z7*BOJ[KL.D`UCN<LM7==DV,M<CT!Z&O)!D>*^*A7XNT>O[L]M14Q](6
M12^?U_F=>N!B!;N%4Q'2\-NL="<HCQ<SLQ?6*=.3T[*CL!F_0.)!L;ZL>]^\
MMZBH(?,?"82&^Q@9L1Y-0*V[I_1H:XV^66K^KAVHO=#T5X773Z/!&*6^C,9:
MA7]V>7/I+%*$>!0/YTE`Z_,'`P8V[B-+<Z-@-[!H'E,G$6#9BNL4:4KIN6+L
M=B_2215&R2=4]Z]Z9T\_K>4'PF\@G*(=/#`S@OR=@6^Z+%I0VMMP*2M<UN?9
M2UP2HKQ37\@Q(W=N1KL59P6!N\MI@:"0&(%`XG,4.OC@88+W!Z:;3-?W2&AN
M4`1=AV:75Z%/'3TJ&P&,@=1=,+')UCWOWEG4`%`1%\)O)T$/#QP,T)<G(%7=
MUHT<&MMP%EJMJP^U7%T-17H:[DX\B,0M]&(6T^M[L_N@A,%*$>4H'$Z*H=?F
M#@88:]P:FN]!0'($FAN3Z<-8-J(:H0HB^GY5/9S&17;.W06B3J`NO>F=*(5F
M)#2`F%,%#E+T\<#+4ARIK\?O&<T4?6.YW$O!:[>;&6NK2@O5]<O6+-@\?FK\
M=:@7]V=VI8K,4TV0%`YU3D+U\<#&#7GW3W6EH'=@:+Y-)14_L1+7"-.6U%*)
M[!8OE7Z4>%@DZN+KWAG5045`XO1-Y`3`3=.@8&3U^5,`WWA8]%CK#<ZDM6];
M'V6M=4J`^-KF18IQC&4&N1%K]?W5];CD?`D5B!0.*Y#DZ_-ZX&*FG<"ISO05
M;Y!$T1R=3A;-M)OJMO15M02J>SHZ0<$=G+9Y>H"Z]Z8TLGN@E-(&,)"F.4.G
MC@94D.55?C]X6;19]8;H7EJOKQ[L5S=6M`>K:ZDF+)BY?&@(:U`O[J_M*Q6H
MIILRE\YE3%+U\<#%?X0&G?4A`;S^HCD[\)L%^'7Z-+'4$H&QF+T':;/X[*57
MWKWEG61.IY@>";R>0!'I@99-RD@0WG9M$?5GN3XQ6-=#LAQ=PH+T=;R3'X<Q
MDOH]#VSU_=7]L%-^5,&0%`_K)G+UZEP,1R'<$IL?H"'Y!FT/R@<0TSLY?5Z5
M#:Z>E%MGM)!`LD8;(_IX.BNVU..,:8I'XG\AC*)AT^=@9?'E#`!ORQ\?_JVW
M$,Q6Z.K>7%Z"AO1UE(-$FZC@8:)M_K>ZOK$<$_*5J4H'$X@'RX&)3=P"G%TG
M6=X#HKDV,39[^;7S>F!J&4'8<:]*\39?'9BK>]>\L*P8ZGG!X8PD$@"/3`RD
MCRJKZ^ZK5I$-7[H)*U36A-FN;DI07I=>RD>>*CI;Z.0MH]<6TA;P3D02]Q*4
M#^NDH3KU+@8B<]PNF-M#0^_3:$Y1JPTSM-;5*5&0TY*J[,:2*+5XY&SOZB#H
M'3:EG]R$A9`3>0RAR!T\<#-3CD[`M]^6OC^.M]P*S53H9+^XO*5%>'UE*,CL
M$Y`(.$MX+`TD+*!%/3%H4H']4!+UP,*M^X72W&F:_ND-"\HR1=AV2;6B%/5T
MY*DO[!^06!?I%*5GWKWAG4C"_#H^,;R"*9_#YN!FD_)^`)N*QZ:^K7<1I2MZ
ML/M5>W%H;T:%(1Y&R3D:O$V7UO=WUT$JH%"/*4#B<!#KX8&%7?<+I;31M<WL
M;0O*-:(LNS!U@WI3?3DJILB/D"A+B-CEJG[T#IC4.L08`?&,)!%9+P^>&!3G
MS,MG!!;NT...V\^-:'O-LI&N[Q?MRS1=@.3WNT7^%N4?6(>MJ1%BB8&L1E?B
MM9)I+R"R;A%RZ451,5O[L950(_\`$3E+P^H_*>H[`UIP>GH:JS5OV51-;LJ$
MAL.W<CZ.ZIT;K9PGL#9]"=S+F)B:#=VFPQ!LKTZ-DT$U046!?H0,(]^!P\L'
M.<[AC!V$$FVIZ*0QUH=X!%1<-UG'1$Z22I3^D4_E4\?FG\,"N/B7+/:%RGXW
MW9]5+A+L:AO'6%@>1=<KDC*3TBWC+A%.56L1'`DD+V05(4032\P>8WAUP)^?
MSJC8K*R\AN-^OD*[;8YYK*BWU5_8)B$68U.R_39>@RS1.G31E!2GE81)B9*2
M`A2^Z+J)D-U$P8&L/K?]L;7OZ^Z=_A'&X&ZMWV][Q%@U=I+0J-)V2QF*<M5;
M6ZO$G4W336LLWE:>V33C(&VF5%K)3382]5FY2@8@>T<#6-5Z^DL'A_4CAT^S
M\PWL^SX8&TIW!>1\%*]LND<8D]>[7;3U<X_\,[ROLA[27B&GG[1Q&ZM=!#Q5
MZ,N+)Y8$_BY$S-0(!@425#_6#@:M_7H/CTZ?((#U]@]?8`^'C@;*&ON1\'(=
MF'<_&PFO=KMYR&XRW2T*;#<TIVCJ5VV5F$%0CF%V,M[FYF"@/04`)Y@-X8&D
MD3\X7_8E_I!@;MW\VQWI$DX:;FXYC2=D&FUKGO+:(;`"IN1U46/&C:S@_HT>
MZ`J#0+B"Q!5%AY//[OT/UZ#@1.1#]"2Z^/5,GR?_`'(>'W,"X/M0[6CZG-[9
MI3BJW>5=R5=<74DW!UU>1KC9K5X]8Z\(\E4U"IH6.3Z?UDT$/,X^00P*&MES
M*=DV-?)]!E(QJ,U;[')),9=H9C*,DWDN[6*WD61Q,=J]1`WE43$1$I@$,";7
M;ZDB-8[G)'F;.U3RO`W?7IN$$!4:-?A\8V6/[\N`@#87(+=$>H?/,40^3`__
MTMF7N4;VYVZ6WMQ</QJL/%ZNZ?E&.U)?9"&^[I9*NZLKVFT&UV291=DA(244
M3IE2KK%O)BZ;F*L1Z'E5`$A*(AECM3;^O_)_05SW9?=_Z=WTI<-NV8]>/H]C
M:&M)UI`LHJ`;-]>H.;K%P5JDG#18#OA7=L6PG(^*)`.02G$((]^)EIJO2G%3
M;6V]I<:::A3YF_PK"G\F]?[$VO4KF2QQ+(AUHJE:\:R#UI,0J[8@EDUD?33*
ML9$#>94`P+`^TW;:!=^%6OK#K*1TE*U!S-W=%B]X]T.VZWU@JX:VN4;OBQ%6
MNS1E8&;Q)VF<KLZJ8%5<@<Q>I1`<"R8?R=,#R5XOU&UE6)*Z['N56H-.AB(G
ME[7<Y^+K%<C".5TVK<TA-33IE&M`7<K$3)ZBA?,<X%#Q$`P/#6SD7H"A*4A*
M\;OU+3U-EG:$UVG9MAU.#/>AD!3*Q&I%DI9L-@*\,L0$C-?5*<QR@41$0ZAT
M/+(Y5.*?)<Y#%,0W'O<IBF*(&*<AM;V,2F*8/`2B`]0$/;@8K[:G^;EX`_Y$
M_%7]XJAX$V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@/R?D_,P&`P&`P&
M`P&`P&!QT#KU^7\G^E@<X#`8#`\#M:WGU_K#8MZ306<K4ZCVJSH-6Z"KEPZ<
M0<&^DF[5!N@FJLNLX7;%(4A2F,8Q@``P-3*I\FNZ+P?UEK';F^+/8'45R<I*
M3EFRV*6Y\@U*%=-?T*<V1:)@:W3Z?7'=4EMT/'K&`A*\955O'^[+.%'9S%\@
M!G/<?/SN27KB?NC:,#)U'CDSJ=QX-<>V]I3U!=K+:6&U.054XOVKD+L8S4RB
M:L1K[1;G<4LQ*=)H]%VM'*IBHFHG@>2OW<WYB:%N>TX2"JKN2L]QVIN>?I<G
M8];;/N<)N9KK':%2XW5>HZWA(]%-KJR+L;V+E;8]<.EU4F<?Z?D(KZ@G$)!;
M)V/S&AN`^W+%K^0OSWD9REYV6>A:P2;O)F"=5NB.ME.*RT&!DU(>85I->4KU
M4<G2=G:G3;D=E4\IO#J$;^*?<:YW0ULT3QV?L4.BZEBO^P[7R/2O,K.O*=]8
MNQ6MFUS5+5&4X7MJ=ZGJ%-$$I3W5`\DY4(!DTDA3`X?C<^][RPC:3!142QUT
MRW%9T>;%HB8LFJ-CV^,M:>B_JCK7'W76G8^"9%F[HEOO9=Z=Q+*QRC>*:HF:
M.RG3$[0`5#*UT[PG-R'O&W6</H&./(:\9[AI5CTV>AW]U,ZMNU!9P==US=[#
ML(D:G$VN`W;LJ3'X1'QZ!Q"OJD=>L(D5$`]&EW2^;M;V#5]=6ZEU"S/V6^=R
M42RFU[K"]*VRVUO6U'KTRR>5RI2R)&+.D.KHXDX8]@"267ZM$U@:F*IT`)X=
MJ+F+R3YI5/:>S=W5[7E4JJ,S"MJ'5ZPC9&]NJ;M<DHI8*O=4YR%BD%G,41)J
M!%4S**BJ94%"I]"@(6X8&*;CHO3>P;0PNUXUE2K5;HR`?U:/L<Y`1\A,-*[*
M>\>_0R3YPB=<K!;WM;YG7H05E/+T]0_4%2T9IRA6R0O=+UG2ZQ<I:!BZQ)6:
M%@6#":>U^%;M&D5$.'Z")5SLF35@@F0G7\X@F`]0(7H%2_<MV%R`I7*7B7'Z
MZU+-7W5<PY9N;N2IU5V^F;=8UMA5BO%J,K9V5/M+2)@H2DR;^<61E#L&+I%D
MHF5P5;TRF#&U.VAM>_=S?61J72+[6-$S$C7GE7I[_02]4U^\TZZXX72SVS8M
MJMC^KM5:[LNM<@64=%LF:[AN\%,Q2D2,D<5`#S'?UX)4'DY&<=MO[*W7:M2U
MO7%E'4**=5U0ZV<H^GM[6ZFPD!*3"B,_!-JS`L):+11<.G!_3$S@A"B94R::
M@4F[/['6D.+?(33^L;]S4MCRV3\I5;6LM`:`1?URFPJU[KU6K\K?ID^Q6RT%
M%V:X2S2,:';MWJHN%_,9,J93G*%W?\X!J,X;BQQ]K\%$S-D<0FP46"WP:'?R
M:PIL:NDS!RJVCT72B!%3)=0Z^`"/3K@:D2FN]ABBL'U>WT1!(_7^XRS>'0@^
M(A\*ZA[,#;U[D""[3L=ZM;.D5FSEOKGA\@X:N4SMW""Z*-$36;N$%2E51625
M`2F*8`,4P=!`!#`TX>OAT^3IT#QZ^`!\G@'7K[/;@;;%-'K_`#=/9P_^HN\_
MV]1^[@:!!/SI/E^:7^D'A^5@;[O\VN'_`**W=GVN06\ORNNJ]8#X!\F!6\B/
MZ"CX#XI$_P"Y#\GW,"]CL[&$(7=0=1\OQ*`-TZC[08J!U#Q]O3`UW]VB([DV
MJ/4>OUA6_P`>OC^GS[Y/;[,":7;Q$?H_SY\?_8/W4/VO!D3QZ?:P/__3O(_G
M$TYIF+U+QQ:[3H<79Y9W>-HR-7GK1N^:T-2XR%KFM'4ULFC3=H@.DA:)';5/
M;J0\;6P,F68<CY3*$!/Q"8?:4O&B-@U+E+/Z`KL1'5/[Y$K![8ZE;FMTH%ID
M&6EM1I()4J4CDDHIC'TV,]"$<,6WJ)M73$_50YC&Z!A'O#Q5"L=KTM2$>/7)
MOD5O+96OMNTFDUCCJOJZ%=0-2*ZIMHF+O)VC<$Y7ZM&2M-ME?AW<<1!<SE58
M1*H0S<QP,$L>U!J6U:=XA0,%?*)O37M\GKULBZ76$Y%2^KYC9SJRVRXRLQ)S
MDD;3<K+Z]81\VNX%PU;,5`])`Y04*53S!@6#7%_9HNJV&2IE>9VRV,8A\ZKE
M9D)LE;93TPBW.=A%.I]1E))PZ#UP!2&<F;K`D`^82&Z=,#4D[[=LY][IXU1]
M8W1P5OE8X_5:C;0V?N4-+;=USM:K$N-?C6K#4!+[89:4UA)DJ%?G9!6<?MF4
M5(JF6CVP$`_4X$"L[=5\U-,U[=RO+6D/]?WC879XT!5^`=+VXQ8/[C-[?00)
M%+M](!!/)]BO?9NQ>Y+II1SCX@9)5,#E*<!(`;7G(Z(YJ,^V?#QVKI724;>(
MWBG94-^_7M'7R5=.(='3;@DVA3C4M\S,WM@'*Y#SR`*-_4$GF#P,`AZKLXH<
MD4>WWQ6-OZ2TN_@U>,W&I329-2QUT8RC/5XZ2IOP9MLT]M>.FKR\$;"B#E2,
M*DQ$X'$A0`0``M*P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P/X4335(9-4A%$SE$AR*%*<ARF#H8IBF`2F*8/:`^`X'RN8V
M/>I)(O&#)VB@8#HI.6J"Z2)P*)`,DFJ0Y4S`0PAU``'H/3`_E2+C%6ZK16.8
M*-'"A5EVRC1N=NLJ3T_(JJB9,4U%"^B3H80$0\H?8#`_E2'B53HJ*Q<<H=N*
MHH'49-CG0%=3U5A1,9(12%94?,;R]/,;Q'QP/H]S:>5(GNK;R(*>L@3T$O*B
MMU$WJI%\O1-3S&$?,'0>HX'R&A(4RR3@T1%F<-R+)H+F8-!61(X$YER)*BEY
MTR+F4,)P`0`PF'KUZX&.TM&:B1VD7=*6OZN39Z="9:P0MY8EF$HUHL?:'UT:
MUUHIZ7E:L26B15>B"8%$RX@81ZE#H&2!B8H57*XQD>*ST4C/%A9MQ5=B@!00
M%RH*?G7%'RAY/,(^7IX8'`1$2#@CL(N.!VGZOIN@9-@<$]X'S+^18$O4+ZQO
M$_0?G#[>N!^C*-CXTBB<<P9,"*J&65(R:H-2*+'ZB950J!"`=0PCXF'J(X'V
MX#`8'`E*(@(E`1*/4HB`")1Z=.H"/L'H.!P!"@("!2@(!Y0$``!`/;T#P\`Z
MX$7N7W&5MRXT^.FY'9EVU=#.;O0;G*S-"0K2TS*&US:HR\P,(X-:(6=9(1IK
M7!1[M84DB+G]T*3S@F90I@C+>.V%1]G[AK.YMC;MW#<9V+?()6:-D7%40B;U
M4(6[5C9-*HTXFQKK9=G`TJ\U5!\R,Q.W<G!55%911(XDP/6]T)UR$9\4)Q;C
M7&6:1O2EUH;6P*TJO6FTW**UJYG4B7V5K$'04U=AOY5K#AX$KY1F?3,86OZ(
M`"`50\F=D<X;QQ\XXQNO-!\T=27RN:]ML9L)GK6CW&P661Y$2.O]=SN@TK-<
M')'LW:-/FEY*5;VF3D%3,&+Y!5O+*$42\0FYWS$U4^VY?4G)$4UD[GIM-4C4
M/(U(J6\P95"MPZ$\C<IP$"`(!X=/`,#1E#Y>@?:^[UZB'V`P-MJF=/\`[.IL
M_K[/J,O77_Y]1P-`<GYPO^Q+_2#`WW?YM;X]J[=G^4%O$/9_ZJ]8#^7[<"MY
M#KZ*(]?#TB=>O^P#QP+UNSL']AMU]0#],(`.H>'_`+R5\,#7@W:/7<FU>@_^
MD*WCX#]B<>_T?#`FEV\?U/\`/C_(-W6/_P`23^3V>T,#_]2?_?3[A%_K/(38
M/#N74XG1&EJ]KGCZ\+7>2G%>4Y-R=_LF]+1=(RU[?IC60=#0H@>,<%`,)$D<
M^8NAD5W2GG.)?(1,+4>Q%MCZQ^&MDJ["1UE::II#>E[U'0]EZDT5`<;:=M6F
M1455K%%W@FFJHS85FHS#IQ95VKPK%(J"ZK3U?G',<Y@K>VEQO[4&[NXQS3A>
M=$:VTI<=;R]0NE%EK1R\Y+:XL&P6%KK/J6C9M>:)[E@J'`5E)5,&";2!C6HI
M`!O5.?S=,"T[L@V>C6C@G!+:QIP5/7,/MC===H[MK=]I[`A[O68/9=BCXJ_P
M-AW);+O>U(JV-D2NTT7$DY01]02(""($*`6]X'RO6+*2:.&$BT:OV+M(R#MD
M];I.FCE$X=#HN&ZY%$5DCAX"4P"`X'2OJ;4)-2#5DJI6Y!6L+)N*TJ^@XMVI
M7G")0(DO!G<-5#1*R1"@!3-Q3,4`Z`.!B'EI_%5Y,_Y/NYOWN;)@8I[:?^;E
MX`_Y$_%7]XJAX$V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5W]U#3<+N[A#N&MV?9
M<5J*K5EK$[/M%]F8!]9V4-7=:2*-PF/["QS^->OG+IE%&21324]0RIB@4IA,
M!1#5NM/:FJU*T-3N0MHY6N8BI7^P1]3I=65XN[+4V?9+-*OEF,9!Q6N6]J5L
MKM^\%$RY2E1^:V`53="E$0"\Z9T0YK/8SV#J?5-E-OI2Q<?YI_1YRE5B38KW
M1O9';63CRQ5:6<R,HF[,BH)3(F.94IBF`0`0$,#0_)P(YM>F7KQ0WV'0@=1^
MK.T!T#IU'S",>'EZ=!Z]?9@;L_\`-^-3[.TWVS-RU3;%!M>N;*YW=NF;;05Q
MA'T#*KPSW6.NFS2329R"2*RC!TX8K$35`!*8R1@`?#`J=1_J*7CTZI)B/3_8
MA[`^V.!>MV=AZ0^Z_#_=&`'P_P#T%3[08&O!NW]N3:O7_A"M_P!OK_9YZ/CX
MA@33[>/ZG^?'L_B';J_\2('W/DP/_]7?<D:Q6I=P#N6KT'*.@3*B#F1B6#UP
M"1!,8B0+.6ZJGID,<1`O7H`B/V<#[H^+C(EO[I%1S&,:><RGNL>T;LF_J'Z>
M93T6R::?G-Y0ZCTZCTP*;^>NU^UU8OK,=\K]$4C>VT.-J]63-1K1K:$>['>M
M;=.1D%`O*=(692(;S%,7F)A$CAR9Z$:V,(BOY>@8$X.#6_-.<B^.]4O.BJ&Z
MUAKZ*?3U$8Z]<0=?KZ=0?4>6=5N4@V3&IO']7-'LGK`Y456"ZK95,`,0P@.!
M+[`8#`C[RT_BJ\F?\GW<W[W-DP,4]M/_`#<O`'_(GXJ_O%4/`FQ@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,#"/)+1=9Y-:$VWH"XO'D=6]N46?I,G(L$T%WL6299G1
M;2;=LZ`6KM6,>`FN""H>DMZ?D/\`-,.!6,P[.C.'U-7=70G*+8$.E3=AANFF
MO8^A4YM#5+<SNRNI:=ME>J:2Q&$96Y:!=GBBP"2Q635(YEDS^J8<"T?5&HJS
MHO2-.TO3`EEJQKNC-JC#&%P09QVVCH\Z'O`.>B:191ZL)E`,``4JI_#H`8%*
M5;H?,_[QC:O'5OJ;D4WO$OO?:5T:6:U[$9K6B7T:')2#OOU?L+P%P5LC:R7;
M3$L\BHWTE$4T56ZK?U4"BD?`L,X7:[VMJO@A&4G<I9UI<&++?\I'0EJL3FV6
MFHZVM&SMF6G35$LUC>/))U*6"AZBF8.'>'.Y<F(X9&3]9;R>H<-7-$/T%'_O
M2?R>/YP`^S@7J]G;])MUB(>/Q"!Z_E,E/#[F!KO[L$/KCVJ/B`_6%;_S?CKW
MQ_,_HX$T^WB']S_/D/E^\.W5_P"(DP/_UM_C`8&O!S+[=W+?F?SA9N-@3\9#
M\78HAST^UUMQ5T).GP05213%LK&/(%:PV.W.+U[BLJR=KJP#J+36*<I5O3$`
MM\X>ZQVCIG2,!K':Z>IAG::[E(>+DM-5LU-J4[7$'JOP6=<U,K5JU@+#)LA*
MJ_;M_40*Y,<2',`]<"15BL<!4(&7M%JFHNN5NOQ[J6G)Z;?-HR(AXMDD9=Y(
M24@\42:LF35$@G444,4A"@(B(!@:[?<Q[Q3:@VWC=JCASN:KRL/NB/VW<KOO
MW4]$5Y1C3JQIV)C'TK"0%,H[E\@_F'CN9;G>.'"B:,;'E464$/F@(1QVWW6N
M8-^:;2G^(N]--6&@\-.#]#Y>;+O,MK5PHGR6>V!P[7>56)BEUDG&NFA(V*71
M6^:*J3H?`/#K@6Y<N^<VH:AV\UMI[.&V00<D^-EW)4F%=H5SO!D9^T:E>O`9
M2QJA"3)8%DDM+D+[T]%!N!>HB?H4P@'U]F_D;K#??;\XL0NN7EE=/M+<:.-6
MLKX6P4BW5!NA;(?2-.;/48-W9H>*:VB**JT/Y'T<=RS4#H)5!`Q1$+3L!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@=#:H]Q+5>R130""[DX&8CVH*&\B8N'L>
MX;(@<X`;RD%10.H]!Z!@:J5,X67V^K7YA2-FZ#M;W4CY>&V@WA=G-W:NOY-B
M#HCIK:BA%D&+]$\>X`5#_H(B@H!3B)#=`M8[46NPK-'V/;XF^ZSV/4[7,-FD
M19=86U&W0RCV"34:2C1=XBU;`BX;+=/FB`^8H@<O4IBB(:S6[/'<FU?8'^,.
MW]1Z^'Z>O<":G;Q_4_SX'J/\0[=7C\O^TB?T<#__U]_C`8#`8'6S$/%6"*D(
M.<CF<O#2S1=A)Q<BW2=L)!BZ3,DX:.VJQ3HN&ZZ1A*<A@$I@'H.!55RQ[3&K
M=[S.HKGH^^3O#_8&GXK:%3A;%I6M4U!C)47=4"C6=F5N4KLU!R$*J>;B6Z?I
M.BI%<-UDRF*;V@(1@M7\WYTD6+K]3T[O[=6EJ)+Z(K?&KD!5ZTXKD@7D!J.O
MRZDR:-M4C,1#M]#S4HX<N$UGL>9!0$ES`7RB`"`6M\C:97*CPMWE3H2+:MX"
MH<9MIP<"R.BFH1BPA]6SS%B1'SD'RF30;E#J'3V8'C.V<V;M^W-P&,@@BB9?
MA7Q757,DDFD*RIM%403*JB0I?44,(^(CU'`F]@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,`/Y/E_H!XC@46H=NOE,O?.=TY].M1UVL\W#(T>P1K0+Y/R]6H\>
MSV&DVN%;EYN>6=PT^LK;&I$H%(WP-BF1<R2?F4*)0F-V[N*&PN*VKK?%[3F:
M:_O%XG*[(2D=KEC(1U%AF=*U[5M:PXPC236</2NIN-J:;]\)C`4'3DY2]0*`
MB&IGNWK]<>U1'_A"M_3J'M_LZ\#^E@34[>/Z0<^/9_$.W4/L\/\`:1/Z'3`_
M_]#?XP&`P&`P&`P(^\M/XJO)G_)]W-^]S9,#%/;3_P`W+P!_R)^*O[Q5#P)L
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_D_YP_\`L3?TAP-"G=G3ZX]J
MC\GUAV_[@_V<?=<":G;Q'^P'/D?'K]X?NK[O^TB?:P/_T=_C`8#`8#`A-RRY
M_P#'3AG+4:L;?E[:YNFQXJXV&H4JA4:SWRT2=8UY&DFK[9S1M:C7YFD%4H<W
MO#M=82`4G@7S&'I@1ZV!WIN`FO8NB3KC95HM$%=]9PVYU9BE:UOEI84C4DZ]
M".C]@[$6BH!<:;`*/.I3&>@FH4"&-Y/*41P)D<F9J+LG#WD'8(-ZA)0TWQMV
MU*Q4@V-YV[V/D-8V!RS=(F\/,FN@J4Q?M#@8][:?^;EX`_Y$_%7]XJAX$V,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?@Z61;-G#APLDW;H(*K+N%U"HH
M((I)F.JLLJ<0(FDD0HF,81```.HX&F!M/C!;I[81;1&;`T<K#;PV7<V6JGAM
MP4@I;H^1M#V.<,XGK*#YUV\D<&A_/Y2^]?H0")Q`N!,CB7QHO>D=A\G./FQ9
M_6D/NO>'#7:-2UMK5+859>V>;DY]BY/&F.Q:O5!9M%DHYPKZBHE'T$%%>GID
M,8`__]+?XP&`P&!Y2]1=GFZ;:(BEV-.GVV2@Y%E6[2M&HS*5?F7#91./EU(I
MP8B$B1BX,5043B!3^7H.!JD=TO@CSOVU+<9X+:+[9?).%I%7Y$N)/D3QEJU-
MU_N*$N5VIS&OZ^U<_A7-GB/)JVQO!6":52%0JY!*"WE(0.H1X-PX[BNO*'N^
MM6WAW)6ZW\U.V?JOB+"HZKDJ$UI^GMF51>1AE&5^27L2",'#(P[Y)\X=-`<-
MQ7(IY3&.(`(;)MYX$!N?B=H_CC==T;BUNEKS7$73+:]U!;0K+BYH*4]E69N'
ML2XMW7Q*)5225`I0Z?U0P]?'`RKPKX;5WA+K135%/VKM[950:(5F+J;+;%J^
ME`T6M5&O-*S!56IF]V;C'032,8I%!(?-XD#Q\,"8^`P&`P&`P&`P&`P&`P&`
MP&`P&`P&!'Y/E7QU5Y!N^*1=O4T.1;&LHW)SJ(\@=.W$K+E!LZ0EBM%$2H+(
MJ-7J2OD(H94$U`,)0+XX'ZZDY1\>]\7;<&N-.[;IVQ+QQ_LK:G;FKE:?G>O]
M?69VO,-$(>=#T2($=G>5]\B/I'5*55HJ01`Q!``SY@,#RUHO%-I(09KC:ZY5
M2V:?8U6NFL4S'PQ9ZSR:;A6.KT.:1<-PDII\BT5,BU1\ZRA4S"4H^4>@>IP,
M7;DW/K;0&O9K:>V[(%4HE>.Q++SOPF;F_=#23Y".9%^&UV-EI5?UGCDA.J:!
MP+YO,;H4!$`R2U<HO&S9VW/ZK=V@DY;J^0Y/4073*JD<2'*0Y/,F<!Z&`!#Y
M0`<#Z,#$-0WMJZ][9W#H^KV4DELW0K36[[:E<!A(MS5AKMJ'F9^@J'?.6J4<
M_P#CL5`.U0!LJJ*/I=%/((E`0QUR0YK<5N(7T2#DKNVG:A->EY!"H$M"DB"L
MZI%)D6DA9I1L>_4])@BL4RJAP*F0#`(B&!GBC7NF;-J%>O\`KRTP5UI-LC$)
MFM6JM2;67@YN,<@(HO(Z19**MW*(B`E'H;J0Y1*8`,40`,6W7E)H#7[./?63
M:%=]VD=L0&C4S0!GEP59[8LZBB4+29EO46DXY@)5R=$WG%\1NDW#Q6.F`@(A
MGP.@!X>S`\U;[I4-?5Y_;+W:*_3:O%%3/)V*T3$?`PD>594B"1GDI*.&K)L"
MJRA2%\YP\QA``\1P/#[MWIK'CQJZ>W)M:QDKVOZX$1\0F$F;R6446GY9A!PC
M6/CXM%R]DG<I*RB"*":)#G4,H'3`CPKW+."+3<)>/\MR;UI7]R_$HZ#6U_9)
M%Y7Y=E/RS-!]'UY\YEV+2'9SSM%RF!&9W(+G4."92B<0+@3C*8IRE,40,4Q0
M,42B!@$I@Z@("'@("'L'Y<#^L#RUXNE:UQ3K1?[G)?!JE2X&5L]EEA:/G_PV
M#A6:TA)O?<HQL]D7?NS1`Y_30145/TZ%*(]`P%)NE:V+4*W>Z=)!,56WPS"P
M5Z4]T?,/B$1)MR.F3L&4FV9R#;UD%`-Y%DDU"]>@E`<#U.`P.IGYR,K,)+V.
M;>(Q\-!1KZ7E7S@P%1:1\<V5=NW"AA$``J2"1A'[F!$[C/STXS\MY7X!I6YR
M,U8@UC4=QJ0,O6)ZOR2.N+X[>-*?95`DV2+7W:?%D=1!,JIEO2$IS$*!@P)'
M[,V'6=2:\N^T;JN\:4[7E5G+G:7D?'/)=XRKU<CEY68>(1D>DN^>F:1[5104
MTB&.($'H`C@?KKK85/VQ0ZALW7\VVLE'OE>B[55)]F"@-9B!FFB3Z-D$"JD3
M5*FY;+%,`&*4P=>@A@>SP&`P&`P&`P&`P&`P&`P&`P&`P&!ULRW6=Q$JU;-F
M+QPYCGR#=G)@8T:Z75;*II-I`I`,<S%=0P%5``$13$>F!K60W9JY)N6]$C;!
M<-"QD8VD9>"LB$'$V17Z(4W[ZU/E/$SFM0<)E+&W!=Z*D"YZ@FE[IZ:@"(E$
M,"44KV^^5-GY/PG(F>M>C&\E$3L!O`KF.C;*-A)N:A\3-P\6:KKUM+JE]Y2T
M[,DV2VL$F7S@N+MJL0A1%0#`'__3W^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@:>_<%XS<Q*IW*N7?<5XU<<MF[#V=QO)PZLVCTXBE6.0C]YUB
M5U59-<;MU[2EHYBM],'D*X?1CE\V:>L9F+03'*`AUP,#ZKX3<F.#]([@E*'C
M'OO;B^UZUVA8:\72FL-RMVE_V%8(O;=QYD;>;RVG3L-D[5JFLMF7-RK9H>O.
MC/3MG2"3@2H^;J'M^,O&[G1N`W`_6'):+YLT+1-,VCST7V4Z74W)JHL5JZK,
M(>U<=XW8$U.O362&J4M*-3)1!)E^JY71`Z`K*&`XB$/M977D[LE]R.NVJKAO
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M-MVY7JM$\2I[5U;)<)2&CH==&)AZ5(V%%9-S-)%*F1?SD!8H]0`(F[DUIS_C
MN,3#0BW&_G%:)_7]BYB.=$[349<J[;-UQ.N7IFWT95F,!K*:AUGD],0Y!?P]
MDM!W46=DF8B95C><I@_/D;I#G'([(WIM&"T5W""\U=A:P[5RG%;9VLJ9M&)U
M*UW90:_$L=_R&^IJ*.RJ+4E6K<D[:NU9]%=JT*H]2\R*PG$0NR[J_&;E-O[G
M%VWWG'R.;09:[`<G(2][FLVGW^V]5:S;6_6A8D#6^-!RPBF#RPD,LVB3/'20
M>^"02@H8OE$*G.3O#OE3Q&G^+O&+BIJ;EE>!XT1FC%J_R/HT1O\`L4'>?IEN
M:R3VZVL/#ZYE&VEM=,(%A*'-*)S#5V\7CEFQ$>A4#'$/OJ/$[D)IK9V\H/5V
MC^:,5?9;N^<==B2]D3KFX)?6=GXON[!+RMBM$79G'O=2FXIBZ<]9ITB8RK9K
MY".#@F!0P/@U-J;N9NYCF?<[\ORLK_(IUQ\[E,+8JM':1Y&/XC<SN>U=?T.-
MD?2MMN;,YT:1[7[62$<TQ&JQJ,LY5*+4`,83G`,<;\X%<T'NC=PZN0H/-[:-
M6VYVJ.%?([9D19Y';5SDIKGS7-GBGM:JPXR"ZSEOLB,HBRWOU.9"50J2:0BU
M#RI]`NJYUQ-=K_:AXSIUZ"VG7-75C=/#9[9X#=,=;HW9T15&>^*4+P+ZPOAU
M+9'KLI<Y%E0D#"8C8"B(^3RX%9W)33.Y[<][SG'6$X/\D-D;)YE\H-9V'C!M
MUAHNP!IB)C(]C30':2F^WS)M6:[$U8\<LY*JV=**JF2`A"B8_3`[9]JSG2RY
M?J.;91^<$[RFJ'/;CC&:*V;6(G:(\/6G!6$4I[?8*5JL44O]4K>#>0*$H$TW
M>@,HLY4`I0,<WEP,5R-`[CE7U;W"*%J+7/+[8TA;[CI6\SO)ZWZ[Y*T#;.S-
M66;E-*.MQ:/::DL<TS);K]1-1R9R*RNN#,PDJHD9NBJ#AP@4@6U\4-7<BZCV
MJ.:502L>[KW:YN)WZOQ_JEET[NG6%^J3&7U\C]'Z)KRK[BEK#MB<A4K&HH,2
MLX4.=1=51-$!\O40JVVCQCY_W&-VEL7X#SA97?2W&'@Q/<?X"LK[9AX5_N5C
M\*9;620J<65%E<+/%QIE4YAHJBN=J0#>L0@@(X%O_=#T5O?D9O'MVZ]@$.0R
M&E)IIR03Y+R.E9>[U-BT1-JBMO:)';#LU-6:*0C64NC'R,RN%DO>')#)$Z]3
ME$*';=5N</"CC-*<@9ZU<S*))['[/O)UAR!ONV;/L`[*F<EX7=^NM>\7H`7-
MW5^$:ZV8I2YH(R`CT/=)60:',+8BCDYE!#(&KMDR=8X4<J^,%.M5]@^9/,3E
M!J/BHWXWW,=OM9WC;#;8KC=(8J.2V]-S=L%/Z`MY^RK/_5Z%,8"F\I$TS"&6
M.2_$GE9I/N1LI'2NH.0LGP:U]J?@GJO:AM+UJUL;3L77VK4SPC>.IUJ@&A3S
M<;1Y!JW?6J/9*>N=CYA4^9U#`PIPWVG'WCF1MW;O)C:&S:]49[7_`#O2U@6W
MN-LN*1R994Q[8F4Q*EFG,S]49F6E]<1JL8#-BS(42&$5S`LCXAL;]DJ/M$;V
MN.'J-K3=).EM6Q[V&1>@H5PC4WKERZJ:1BJ_HA2IP"J`%`?87I@6J8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8'__4W^,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@.OR?+@<>SV>WV]/'Y>O],0P/X512734173(LBLF9)9%4A5$E
M4CE$ITU"'`2G(<IA`0'P$,",VG^%7$3C[=[3LO1W&C2&IM@W91XI:;I0-:U2
ML669^(.3O7Z3B7BHQL](U?/%#++(IG(BHJ83F*)AZX$G1P'Y/R>'RX#`8''M
M^V'7_5P'3[OM^UX^'_9P.<!@<?T>OR?)@/\`4Z]?]3[&!R.!X^^Z_HVTZA-T
M#9-1KM[I%D;$9V"IVR(8SU?F6R3A%VDA)14BBX9.TTG3=-0H'((%4(4P>(`.
M!Z2/8,XIBRC(UL@RCHYHW8,&39,J+=FS9HD;M6K=(@`1-!N@F4A"@``4H``8
M'U_<Z>SP^7\@!@`#V_;^W_J?9P`>W\GW1\<#G`8'C=A:[H.VJ58];[2I55V+
MKZX1JL/:Z1=H&,L]5L<4L8AU(^:@9EL\C))J*J93@15(X%.0I@Z&*`@&'-2<
M-.)6AHNNP^F>-6CM:,:A.O[16`I^L*?#NX&SR<<K#R5CBI%M$A),Y]]#K'9J
MO"*@Y.U,*(G%/YN!)02@(>4P`("'00$`$!#IT$!#IT$,"'T/V^N#->LNR;C`
M\1>.\/:MPQ,S`[.L$;J6E,Y6Z05D$!LD--O$(@BR\58S?.D&X"5%\</,N4YO
M'`E?"PD/6XB,K]>BX^#@H5BUC(B'B6:$?&1<<R1(W9L(]BU32;-&C5!,I$TT
MRE(0H``!@=G@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_U=_C`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`A?MSF=7M:<C*?QB@-8;&VIL&6UNCNB_+TIO
M!)06H=/O+FK0(R^W61L$O$$59RMF8OTT&;`';\Z$8[6]'TD3&P,`[+[OW#FB
MQM9GH2\$OE>D-KU/6]JEJZBN):?%6\L^$7L91HX22>3U$<JUMXFB_CR.4')D
M%`3,;R&Z!G"1[C?"R*L2M8?[\I:4BE52W!1Q[TH>'+%&@D[,#?XTFF:+&;^C
MZI7@L/6]\!N/G]/IXX'SZJ[B'&;<=RV/2J=8;-[]K-?5S::?R](M4/%/#[AC
M8Z2I'PAX_BD0=@_3DTBG``_0NOF-T((&$,_;[V\EH_7,AL!6%6GR,9.&COAJ
M#A-HHH:7?),@4!97J0`1]7S"'3Q]F!!/\)JPZ#_BID?`.O3X\SZ_E]4@Z8&5
MN27<"HW&6@ZFMU@UWL"^2^U:Y*W!K3]?HP[V8@ZC5JZTM%WM$FK,R<2R&*JT
M2[!14J:AG"_E$J*9S>&![9_S3H#/=O&?2Z50V"]4Y4:YL.RM=WY*#(A1$(ZO
M1$%.N8:5E'3A%4+`K%6)LM[NBFJ9,IP%3R>8O4)D8%%W<M[TL9V[]X5S3+S1
M,KLQ6P4)E=PG&-J80B38KR4?QH1XM73=510Z8L?,)^H`(&Z8&.N`W?CB></)
M*J\>VW'B8H"UEB9Z4+9GEPCI9!K\$:$<BB+%NV254%P!^@#U^;@61UGN`ZNM
M'+>4XE-*I>&LTT?7BM1NQG;2,+1)Z_:TBJ=.WRC1QB2)YPDO7H:^QBYEEFB;
M1<%C%25.9,X%#TG%OFE4>46P>1NLX>CV^D6SC-;*G5+JWLKNKR3.15ND1)34
M,ZB']5G)QJ10C6)4*[9N3(/F2OE(LD01`,"8SUS[FS=NQ*)P:MEW(D`>@G]!
M(ZOE`?D$WEZ8&I#>_P"=005*N]UIAN(E@?'I]OL]5%\7840B1\-<G'T.+PJ0
ML!,D#KW/S^41ZE\W3`N9[:O<N:=PW0>RMY,=0V"@DUW8Y*`-4FLBA;9J?/'1
M!Y4`B4H]!([A^\\OHHH``F.J8H![<#T3+N;ZPF.)NJ^4L#K':<HIN[;<%HG5
MFFC,8&.V7:-K6.VR=3CJJ<)&9;UN&.12$>NUW#Q\BW;M&JACG`0`!"7?&K?U
M(Y3:%U1R'UP632I6W*;%7&#:3;4&,U&IOTS$>0TPS`ZA&TM"R2*S1R0IC$!9
M$WE,8O01#\N26ZTN/6H++M9:!6LJ==5B$AAT':;)5S\5E6<6`E<+%,0@(B[\
MX]0\0#I@5>?AD(SIXZ0E?L?JGC_E_P#Q/3P'`G!RYYM5/AUH"-Y$WJAVZU4U
M4\.:=;U%W6B2,$TE44E_>"H6*9A?CCL`4,"+!A[Q(/#D$J*)Q\,#S.[^X9K#
M1O(F@\>9BE;!L;RU+Z#;6Z_UQC%+TS5*W*/:%ETUH(ET5>2;665-L+8E2?,4
M@8-G?N94@6<^DD<IQ"?P_9_TQ'Y/9]C`J`[B'=;8<"-C4O7[O3TCL4]PJSJS
M%D6=C9PQ&1&T@#$6ID'2*AU#&Z^;S!T#Y,##/#7O<1G+;D11M!HZ#EJ8K=$I
MQ0MB<VR/DD6'P:+6DA!1FBW(HJ"X(^0.@^`C@3[HO/S4.Q>8^R>&=9:N5KEJ
MLKJ-LUG?6"G1L6[ND?4*=?):F5FMO9Y"\6A]!U2],'+]VRC5H]F8YDU5BJ%,
M4`^/B!W!=5<RK3?:O1:M=JNK58&&O=5D;>TC$&6S=566S6VI5W953^'2+]PA
M!S$M2W8$0?D:OB)'2.=$I5`P)[X%'^V^\O%:LV=>=<J:.EI=2F61_7S2:=GC
MVQ'YF*A4Q<E0.B8Z15.O4`$>H8$T^$/-AIS*K&Q;(VH3^D$H$U%1*C1>21F%
MY/XG%KR?JH%:)E,4R0(>0"=!,81\,",4UWFM+PE/B;:YTGOLJ@V_D1!7BLN:
MY"1]DUA6.,&S2ZIVM?KG'/YQN*$+%65PW`C1`5I0Q7``+<#%.4H29V;S\UQJ
M_DG0..<G2;]+GNZFOV#S9T0SB5:#4)W:J]B0UY!V!9>30FA>68:N[,0[9HLB
MB4H>J<GF#`GC@,!@,!@,!@,!@,!@,!@,!@,!@,!@?__6W^,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,")&X.%FG-T;HIN_I]>[US9=3I;C6;V8HUN?5A
M"]:S7L)+:37U_9-B*HV2K-+,4[Q!$_D,DHX7`#^58X"$=:SVA.&M89&8(05[
ME$6\C7W$&>;O$A(+U>"J25N2J])KJQT2&CZ;`#>9(S9E\X"&6#J8?(7`_E7M
M`<+EIM>65K=V48N*X2"/5S7:0&K%D"55*DC<DXGT?*2YGK*)6QGP&ZB4.OEZ
M^.!)`O#75;/8MWV?!3&Q:S9-AI:?3M:==N;R.BY(VDFS&.IZAF!4%")G=0L8
MW82/00!ZT2`ANGMP/'V'8&JN7&S>4'"SU+3#VCC83CY9-A2R;1))@Y+N.'L5
MUI:<"[4,8'8I,JBN5X`@'IF,4`Z]<#PWX-C5W]^MR_\`B/\`][@9-WQP1T=R
M/IFK:9LT+<='4K)2+KTQ5[&YK$T\A7\.U@K#`2[QD0XO8&SQ;0J+YL(`54G4
M.H=<#SC7MX:497[C]L1O:]REE^,H6U+5$<IL=^M`Q;&[.C+3L9(1BK0Q9*.4
M9IMF221S`"3)DW2+X)]1">6!3WS[[-ND>X)MV!W#L?9&P:A-0%-:4MO'54D8
M:/68M)!Y(D<JB\`5/>#*/3%'IX>4`P/#<+^QEH'A/ONN[_HNTMF6BQ5R,FHM
MK$6,D06*52FFY6RZBPM2@MYTBEZEZ?+@3(L';CXZS^[++O\``=AP>PK-*?'U
MEZY>)")BHFR/)"GO;+88&-22,E&2]U:T*+8RZI3#[XQ;>D(%`QA$,G\>^(.J
M>-EPW'L"CN[G,W7>SZHN]A62[6,UAD9!"A-)QC4(QJ8&C)%JQA&MC>%)\PRJ
M@K"*AS"`=`D\[;E=M7+0XB4CINLW,8OYXI5DS)F$/M@!L#6:N/\`-?.*-SM]
MMN+[>FZ&SZW6>P6AXW;HP`MVSNPR[R8<H(>8OF%%%9X8I.OCY0\<"U7@1VWM
M9]O[2FP-(ZUOM[L,-L*:DIM]8)A=FPL42[DHH\492&=L"&(U<-4S^HBJ("8B
MI0'H/3`\C"=H_C'7]9Q&J8^S[W^C53GH^XT-5QMB36EM?WZ(V$.S8J_T]\+(
MOPFWL;"LX2*Z$AQ%@[7;B42*#@3WTOIZ@\?M4:]TGJR%+7]>:PJL33JE$>L=
MRHTAX=L5NB9RZ5_17CYR8!5<+'^<LNH<X^)AP.LWUIF#W]K"?U;8I*0B8FP*
MQ:KE]%^E[ZD,7)-9-($O6ZI]#JM0`W7Y!P*\_P`$%I7_`(0K]X]/];&_)_[G
MPZX$O^1W#K5?*?4D;I':[^Z*Z]0:?"YN%K5A&!2MT(JP3C7T'9!(U=&=QC]H
MF)#@F*2I/.82*%$>N!B5SVR^-,CM:B[AEQV3,VNAV.&LS1O*WZ4>P5@=4K;-
MQW7J=C;8I5,4YZ)TQL"]2#JK-U#`6+*<B8"<J90P+"`Z_F#^:'R8%8/.3M::
MEYVWJIWS8%[NU4D:C77%<9M*P6/,U<-G#T'IEW'O8"?U@.'0.GATP,3\5NRS
MHSBAO*H[VJ&RMB6&P4].7391<Z6,+&./B\>K'+"X%L7UA%-)83%Z?ZX,"15M
M[8_&6V[XMO(XZ>PJ[L^VS"]I4DJG=GD"R@;M*U_7E-M5XK31LV$T59[I1=71
M$)*+@H<CF,353\A16.;`\(_UWQ)[2U$V%R!B*W=?A%\NNM=<N6Y))>T.*Q%7
M;9CR.IE&I;)T"1:_0("W;'=+ILR"8$$U1^<($*`!.C?^[:?QOTQL;>FP`DC4
MO6%;=VFQA$-1?28QC,Z2:ON30#%%POYE@Z%ZAUP*Q)KM1Z"Y$R2F^D]B[&8(
M[A0C]CMV2:$:D1LUMT>TFFB/I*@*B0D;.R>8HCU*;J&!-3B+PQI'#ZOWJO4F
MSV2P-[Y+1LO(.)P6R;AFO&QRT:D5D9L'0H&26$W4?88`P(Y%[._$=>/:QTN]
MW)8B$OFT+]+.9W9\F]>6AUNNQM;CMBO69<K5'XK4KY;&:<B_8F`I%'1?,`A[
M,#V-ZX-<9-;6Q?ES<5]I6*9TK'6'9SEK(W61F8A\-1?6^^1#IY7#ID;RCFC_
M`$A?HP9#&`&;8Y4B]0*`X$TM)[;JV^M2:]W-20?A4MEU:+MU>"4;"SD`BY=`
M'#4'C41,*"X$'YQ>H]!P,HX#`8#`8#`8#`8#`8#`8#`8#`8#`__7W^,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"L_>_:9XB\AMXW?D3=&^Y('
M:6QXBF0EVF=9[XVOK)E8F.OHE>$J(24-2K3#QCA:'C72J::ADO/T4-U'Q'`Q
MA^!%X9?WR\L?D_\`;!Y$?P@?+@<_@1N&7]\G+#K_`)87(G^$#`?@1>&/A_=)
MRQ^W_P`L+D1X_P#]0,!^!%X8_P!\G+'_`)X7(C[?_P"W^`_`B\,>OZI.6/\`
MSPN1/\('R!@/P(O#+^^3EA_SPN1/\(&`_`B\,O[Y>6'_`#P>1'\(&`_`C<,?
M[Y.6/R?^V%R(_+_W_P#RX$0MK<.^SKI#9#_4>U.2W(JH;$BH%&RRE;><L^5C
MY6,B743*3[8TC(1-DD(AB_6@(9R_(R5<$>F9)^\`EZ)B','81/"#M+VME>U:
M!OKD=L&2UY";%FK#"U/F-R2D'Z1-60\5-W%J54UV28$<1[6>8@`G5!-0[HH$
M,;H?RA$+5E7[15J@G,IN"7YU\:WAJS6+U78G9O*CD/-.KO1KBC)N8*RTY+7.
MQ+@]F&X-(9TJ]1!N1:/20.HL4J91.`9IL''+M!M)*#84W>7(F_HK;'J5"NDO
M#\T>3+6!I+>VZ_N>R6<RM/+V5:$L+MM6::LX4C&3D[TB)_.<">7RF#^6.E.Q
MI)UN"MS#EOR'=P5EM_T&A5T>47,,7SRQ#$TJ?23^"_%`FVL.[A]D0#AO)K-T
MXQPG,M!2<']<G4+`_P`"-PP\.EDY8_9_CA<B?E]G^_\`\,#G\"-PQ_ODY8_\
M\+D1^S_`X_`B\,O[Y.6/L_\`IA<B/;]G]L#`?@1>&/3]4G+'[OWX7(G]G^`#
MLB\,OELO+$?_`*X7(@/_`./\!^!%X9?WR\L/^>#R)_A`P'X$7ACU_5)RQZ?8
M^_"Y$?T_I_@`[(O#'Y;)RQ'_`.N%R(#^A]/\#\OP'/!EP_@GDW]\5;$*]8X&
MU,8:X\HMZ6BO*359E6TU"NG\'-79Y&/P8R3--4I%4S%\Q`ZA@64[WTM2.1>G
MMB:-V2W?/*)L^M/:I:&T:_<1;]6)?^3URM)%F=-TS7ZI@)5"&`Q1#PP*T(WL
MNZ.AHV.AXKDESICXN)8M(R-8-.6^X4&C%@Q0(U9M&R)+(!$6[9ND4A"@``4I
M0`,"M_<%,[=>N=8;NV51N9G.O>0<=RMG.VJY0N:&QX1[5X95Y:8\TX:9V'=J
M?6YB.7D:3)L6?PUX]4DI)`&K4JJIA\H95A]"=M:3AX>5?=POF=5G\O`+V!2J
M6SEOO6%N4*DR1IRDO%SE=4F57C&<A%;]$HN&P>H;U7A03%0O4P!,B7[+&BK!
M%24'-\C^=$K#3+!W%RL8^Y;;A<,Y".?H':O&3M!2R"19LY;*F(<A@$#%,(#X
M8%H6G-45'1>K*%IZA-W;6F:WK$74JTW?/%Y!XC$1"!6[0CEZY.HX=+`F7YQS
MB)C#[<#)6`P&`P&`P&`P&`P&`P&`P&`P&`P/_]#?XP&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!K.<[_O-_PE^M_??KC^D_T[
MC/OQ_1^DGWL7I?>D[,^CGTG^(_W*_7C]27N'E]S_`$;Z/^Y^;]%ZX'K.V1^!
MP^CO(G[R3ZS/<OO2JS]=?TJ^G/Q7ZH^FPO>?+](?ZY^LKT_7^->3^O?3^&>;
MYOHX$38C\#9]5,/[G^$0^MCWJJ?5E[]]<?WX'U8?0&^?#/J@]]_K'ZAOJR^.
M^^_#OT'T?ZK_`&0]VP/<G_`C_6<?S_?$>]?1/37T&]Q^E/T)^KSZE=V?5[]&
M?@O]E/A_T$^DGZI/[,^KZ/NW]:>3`AQS'^][^^MX-?>*?6;],/?*#[Q]*/AW
MO_QG[V/MW_4=]!OK3_N/^GWWLWT>\WQ?^QWOWQ#UOZ_]+`W=O]+Q]G]'`YP&
M`P&`P&`P&`P.!Z=0Z]/EZ=>GV/'V^/LP--2M?>9?6)SJ^K/\(]]Z3]Z[HKXA
M]6_OGTF^KOZ\.=GTW^JOZ<_H/WI'N7Q'R>\_US\1Z^Z_UY[I@9C8?@`_OK=$
M?`/K4^M?Z3\`/J>]V^L3Z#?"?O<:C][Q[[](/ZX^KWZJ/HQ]-/BGSOC'PWXE
F_7?7`VR0_P!$?9]W^G@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g662896g73g29_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g73g29_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-S-G,CE?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`*@`E@,!$0`"$0$#$0'_
MQ`"````"`P$!`0$!````````````"08'"`4*!`,!`0$`````````````````
M````$```!P`!`@,#"0<#`P,%```!`@,$!08'"``)$1(3(10Y%79WE[?76+D*
M,975%AE9&B(R(T$D&%$T%V%",V0U$0$`````````````````````_]H`#`,!
M``(1`Q$`/P#>/9-[)O:[Y6]KOB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.NX;7]
M#K,:LM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?XX_97_`O4/K1WW[U^@/\
M<?LK_@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_''[*_X%ZA]:.^_>OT!_CC]
ME?\``O4/K1WW[U^@/\<?LK_@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_`!Q^
MRO\`@7J'UH[[]Z_0'^./V5_P+U#ZT=]^]?H#_''[*_X%ZA]:.^_>OT!_CC]E
M?\"]0^M'??O7Z`_QQ^RO^!>H?6COOWK]`?XX_97_``+U#ZT=]^]?H#_''[*_
MX%ZA]:.^_>OT!_CC]E?\"]0^M'??O7Z`_P`<?LK_`(%ZA]:.^_>OT!_CC]E?
M\"]0^M'??O7Z!<G*_L<=JO.><':OR6E\1:S!YYR&V#E%6=DK:.@[(Z0N\%GW
M#K7M/I\>[>O]&=RD82%O=:8R!#L%VJBIVX)JF.B8Z9@8W^G'^"OP7^:&H_;[
MJ_0.WZ`Z`Z`Z`Z#YGKQK',W<@^73:LF#9=X\<JCY4F[5JD==PNJ;_P"U-%(@
MF,/_`$`.@S/,<QN/J/%G1>8U+T.NZOAN;Y+;=EE+/F4Q&6I*0JM0HRVAO&\<
M+)T*9)IW6R)JHM7!D50]X3\X$`P#T&*:%W#]CSSBE(\V^=N1Y1BV(7:K8S<,
M-J6+Z?/ZUL+Y;<I>/B*-F5^8VBE9O14;]*.+1"$*[CY<T(@LZ<@Y7;MFAG9P
MHRU=Y"'O-LXTS6!(-H[/I:4[B<'R9JFC1<%)7&FV;A5QM/J85MC8J%=[/154
M1LDY"O#R<1*3,=(P[TGH+E,<1(#&.+_)UU;^&'#_`)`<DY.E9_H/(O,./DG)
M1,*E(QT`\U;=:Y79"&I=-B)!].3BRSZ6G@2;MC+NEDD4SJ*G]))50H;2Z`Z`
MZ`Z`Z`Z`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z!
M='-7N09#Q*A).$AWM(TS<T[70J&VRZ4UBE977ZA8M2KVAV>@RVY:C<'!JYB]
M$L$9ELR#>3D4EE';Q%%HU;KN'*)#`C/7>9O-C>=TXY6J70WO*<'VOCCQEV>D
M95EN/:%L--U]*X0#P.77$FZ9K6\P66L&KW()QLRC9>WWJ@1%/JRK6=;F5657
M.`-<[?/`NX<8\IY4<'[]DN((\'K3>MD?8:[J5AD1T>X9)R$E)Z8F<OV2JI4^
M*:MG^8UVP#6$)L9Z6>R<>T;E#TDFZ9C!&X;LWP2V"2'&+>.;7*3<>-E1J-7J
M6#9[;%,<K)L&CLYNE1O.8VDER@<T;SFFWO,'5%CF,1(6E218)1(.&J[%<CA0
M>@^N?[>O%O4(&OT"S\F]>MUUA<TY?8U7[F9/'ZN\39\T,XKF6:`^90>>8Q1L
MV+)UBNU=`*][I'HHI.5EC.0>&4#RA:?*/AAL-NJO%3.N-MS:T5EQRR7=J=1K
MS./R)N\]TR3XOS6%8'J9(MK'KDDY2G&GY$H*H-U#QZK_`-Z304]/TQ#'>C\J
MN2/;)PK-L6LT?-ZWNFF7Y22H]NVF_,=&H,'2WTDY0MU:/?'5OSVU.X;.IR1J
M<(C+6ES!)*2%Y051]5I'KM4P>5D]T<WO+J/=YAY0UI6=JL7)6-;-;DG?<\:V
M$&9"69G4[P#&)+98"*FTG#=%Z=LV.J1'S'23-YB%#O4J\4K2JM"WG.K?6+[2
MK&U%]7K?3)Z+L]8G60+*MS.X>>A'3V+DFQ7"!TQ.BJ<H'(8HCX@(`$IZ`Z`Z
M`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z"$:5I-"QS/[C
MJNI6V#H><Y]796V72XV1\E'0=<KL*T4>R<K)/%1\J:#9ND(^``8YS>!"%,<Q
M2B'G\TCNZZIO'!O:.4/&65SGC=6,FVV_46^VW3F2-^VW'Z1"##5C%!TCCK;U
M<XCLVT3D3J,ZP\Q;%*_(E0HCP9IZX56*=%L%0<)>'=_YPX]S/MMK@:%C^-=P
M&MVYGO4#6'<Q::R//?'K#'0-0YW<'=%A9%FK=.,^K/8AM:FK:2?,E4+!")G8
MF6:.UUU0V)Q(XRG[;!=/AH>V5B[;#M3G-+#LUBJM1FZ7F19.A50U;BEJ]1+!
M>-"LKR[VQNY<2=KL\U8)*9L#]X0RADDF[9%`)WQEY)<X(=ON#?E.YRJSOY:_
MIR>(RM!;E:15=I#M%\1_!2,81LRD5THLR#0S'WY1=\8ZR_O#E8I4PZ"3:#K<
M_+QDC-Z%<DV=<AVCB3DW$D]:0=9B6+1,57+Y\`&:1K=LV2*(F57$?*`>TW00
M*MV6OVZ$BK34)Z*LE=F&Y'T+8:_(MI.*D6WG,4CJ/DF*JJ"Q2*IB7S$-XD.4
M0'P,`@`76;N-Y[EEPSS&=5G(-?2=$]-E08<CYXVG[%Z9SM4%9)-&.DF+0S]R
MB9%!PX4:)NER&(3S'`W@&A&>RYIKE@KM:T'-:\[CFDTTFZX^N#:%L[2%MT8?
MU8.6:-Y*).E$2J"HF!L]2,59!4P>4Q?,)@"`<A.#L;>N/^_Y3A-H>99-\B)Z
M'FM(D'5BNB\9=ZHS4B(^QXTUE(J=2G,>SR]Y[&*58R]/*R<04>^6=LD#O!.=
M4,/\;+!K7;AB(;A5&<<IGE!R(OB5KY*2:^,Z?5H:IR%#:I5FM7>S2)-0;9_$
MYDWH[XL#3*W#M$5CW)RB$J?W1=:9.T!X%1L1+=5*Q;$X:PUPEGKT+825ZW1*
MT!:X(LU&MI(L-9X)R8[B%L,8#GT'K0XB=NY(=,1$2]!(>@.@.@4;SE^)-V1_
MI^YJ?E^[UT%=?IQ_@K\%_FAJ/V^ZOT#M^@.@YLO#Q%@C7D-/14;-P\@D*#^)
MEV+62C7R`F*847C%ZDLU<I"8H#Y3D,'B`=!C'1.`.$7SE'5>7;5.?HFJ-ZM,
M9ULS6G+0S>C<J,FD8"1BH[-.2E+F(:8@M(@ZC(ND7\.\421E6!VX-R.O=#"A
MT$KF^256IZJM5IM/3<Q%?;I0T,HQ7:0\`@A'(%9H-8N.:,SE2B6'H@BD5,$R
M>FGX$`"^'08OEI21L,M(3$FL9W)2;I=Z\7$O@!E%!$YQ*0OB":")`\"E#V$3
M*`?L#H,AXWR:<[!MFXY,VRRTP$%CSE%LRTQP\:2-8MROOI(]9)%1DE[JP7>*
M&%RQ(FY=BLS(8ZGHG#R"%\Z%1*YJ%%M^<7!LX>56\5^1K-@;-'2C%VK%RB`H
M.0:O4@%1HY*4?,FH`")3``^`_LZ#':/'/<<NO7&"F\<M$CZ5Q;R*-E&NA5.Q
M/EIFS6PTC.R,M)I2!#10$L!I5N^]-FH"[,L8Y,=8"C_I`0U9+Y[D=DT>NW>;
MJE%FM7I$8K_+$\_;1;RZUF'>JK@*S`#G-(M&1UW"OI+"GY4U%#^F8IC&\0EK
MFR5II.,*N\L,`ULLNU6>Q5;=S,:WGY5D@)RKNXV%7<DD7[9$R9@.=)(Y2B4?
M$?8/@%LTW3KK1%@-`S*P-!$/5B7XG?12P![/_:*G#W<_@'^]$R9__KX=!9^R
MX2PYOX=)3S!Z?)]_C:Q?J)F^R4Z;M5:LU-;6I-@VM=?3L=2F(.U(5"]QS%%M
M(H).3+-!]-^S%*19LW*(*UX[\D-GX57:7Q6UEM)>,G'6Y6>,T8+N:*D9*J16
M@3S):E*3.DM6TO%EEG3!\R0RK'J.TLFC7I691F+`-81?MHL@>E!!4%T$5RD5
M3*LDFJ":Z1T5R`H0#@19%0"J)*E`?`Q3``E'V#[>@_7H#H%&\Y?B3=D?Z?N:
MGY?N]=!77Z<?X*_!?YH:C]ONK]`[?H#H()IFFT3'*1.:1IEB:5&C5HC-:P66
M01>*QT,V?2#6+0>2)F+9VJU8E>O4BJKF*"*!#"HJ8B93&`,I:;RDHE^K3^O8
M??JW=6\M'*-IBYT2R1,^A"MG[<Q#-8]W$.GB:$UZ2GB<R@![MX^42BIX@0%>
M<7^.9>,])L--+J-]U4;#<I2Y*S%^<(JNX]U+)H%>,XY%%1<$4GCA$SER<3B*
M[I0RGE+X^'051R8;+:CLV?\`'VQ.I!OE!<LLFU:#6F3Y[%):P[:72&HM0I-B
M=L%FKQ_G\&Y<O)27C"*%0E')H])T"C4%$5@ALAQKRMNO'S>:0B&"7V"2%.M:
M-AD;!9]9(DG@'_82;&,BOY6O-97$H`YAY]A)1K@O[4BJ>50H3B!Y/V[*#H0?
M*^)BF%?!1)I'<G*!&/TLF?>H<$6XZ]4CKRLY@\NN<Q04?*+25144-X_*++Q*
MV`.S>.:F=5.SQ,`Q-!3+:=<K-*[)KW2*BB759N"0J'HI`:R"%C8J&5`C=TDL
M*+E11+T_$J@&Z#OT7C]E]JY`'YL5N3N+RY6O/4Z0,.J\9A6F#%FW;PCTZS!J
MT4>?*C=.)!%1,[M1L18AE2%$QBB`5/R3CN!<9L^;[WR'VG/J1I&2)-DJVQD]
M<@X51W\ER3J8B"RE,9NG%DE58J4>JJI$;II^KY_(J54G@7H-*XSR7X_<BV\L
MZPW8J)J`P/I&GF58EP/-PB;@XIMW$O7)!%A8(UFY4`2I+K-2(*F]A#B/LZ#<
MN!6ZPQ-Z@:\UFCM:_,/G`2<:Y.D9@J8&#A4JB15_8V>*JMTR`=,2F/["CYO8
M'0:-?\1\+GMQ8<BKA6YO0-1KSPLC0GFAWF[WBI93(_);>(7E<DS>RV"1SO,Y
MYXT0'UY.'BVDDJ*JOF<>"IP$-*]`=`=`HWG+\2;LC_3]S4_+]WKH*Z_3C_!7
MX+_-#4?M]U?H';]`M71.%FYT9R]M?!_E;>\<E#KN'RF,[`Y>;AQ^F%W"HN'#
M2/C[F>:N^:$>+',(GAGYVJ/CX),R@'09SMG,3D%6(&>POGOQ?KY(70X:4H4E
M9:!;VM2KMTC;!'+1#Y.E3%_?*Y=+33UL[%1NQ7N,/.E4$ODC"F`H`&/;)%NI
MO'<'M%JX\U1IK+S1APB_W;3V%VQ+1T'[1E+,,\T,MTRP[:S^72C1#`3+>N_9
M`^ERE*8X$-XA_%HGF;1C`I2F#"U,T1*8E7O>IP.G1JA"^T$&MEGJ5CNB-$Q+
M["G>2<L<`_:!O^H+MC\[U_*[?8];Y$V?3<<T&4MJZN8;+H]]S/1\5J4//*K&
MN><Z`Q>Z359&8RZU&&/5>%BVS!]#GAV;QJH55`2J!=V)<_,&U:\N\=E;YGT/
MK3!VG',AJ]O"UY%IKDY#'3<8WJ3B/AHZT+K%()CPSM)G.M1_T"W6*`+'#<QR
M>Q5%4@"4Y%$%T52`8JB:A3)K(+)'`2G34(82G(8!`P"("'AT"KN3/;1A[L=M
M>>+EQ3P'2(.5+8HZJ`T0>X[,RJ3M.15]Q@EH^5-ELF_>H`<74*V4CO6$5%HU
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MM<Z$N3;S3:$ZI.FTM?-[5(UA%/3(TS9TK(1HJ^NQC)`%%4G)0:-C+*LC""\>
M/E`WF(J00!M'0'0'0*-YR_$F[(_T_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_
M0'05UK$C5([/K,:Z1,18(!W'+1[FNSL>REHNP+/"BDVB'D7()+LW[=VMX>HF
MH0Y/3`QA#P*/0(`TGCE8'^=VBB8GJ$OE\3/(MG#.BSB"UWR^!GHF696&O3M*
MB))S_,&924%8(QNZ;?(KPD80Z8`>/5((E$/WX>8[M6/9_+U?=]=/KEJF[W*6
M%E,>^3$FE!Q,J1F52+1DI])"17!Q)$7>"EY"-VQEQ(D'E\>@\DG)[3+3R`Y$
M:WI.F++3$PPTK0:;4H:7\SMCF],I%SFZG`T^KQ[L#MX(C=K"@O('1(FN^DEE
MEUS',8H%"EGS)G)M%&$DU0?LE@*"K1VF5=`WIF`Z9O3.`@51(Y0,0P>!B&`#
M%$!`!Z#>W&[N([1Q]28UK032N[8ZR*DW(SG9=(NM4>.3`"@%3NTTN1M=8IDD
M'^B+GUBN0(`%0DDR@5(0?1A'(S%>3%0&[XE?X6[Q#90K6;9-%O=K+4I,?$JD
M-<:RY$DQ6Y1)0IB^1PD":HE$R)U2>!Q"2:KD.9;C3W="UJEPMYJKI0')(^80
M/[Q%R!"^"$S7I=HHVF*W/-/VHOF"[=TF(>P_AX@(>?;DQPDI?'70X=!SR68M
M,<D2JREAB'U?C=%Y/9O75/\`VTVQS]E:*@.JTIL8I@5D$TDII)(OB5G)G*<W
M0.7X!\%N']#0JO)[(-6?<J)>5BWZ>?[!*2E;=56N(R""D9/&I%2J<='15<LZ
MC=51D]6D?>IMDF=1L)T/.L0X7M=M9SFB<OWUHL=F:1$)4N,L/1;E*-FLE-%5
MN>D[0:5RFDF0@&4FY5LRK&G6%PW:"05@(]*```KE\P:\H_).1S1U):*?`-%^
M2(B/7*PM6R3=(XZT5BL]_P"-Y(R4AI4XE<4?^S*)$P2@%EC^H;P((@'02=ER
M.[C_`"2#T..F?9)G=7?B'N^K6>N7Y_263903%*]A;9HK.@S%](4"B)58:BOX
MU80]CTI1\>@U=AG$_8*Q9(72>1W,':-^O\4L+]M6X=>/QW#8I\LT6;'*CE^?
MHQQ;0DV*Y."0SKR02$?*IZ!#@42ANKH%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_
M!?YH:C]ONK]`[?H#H*9WQ2M$S.<+9!'P5!(D(5+R>]FL`>8T;[H!_9XE,4PJ
M_P#ZX*>/0+-Z#,:B/*9'E@BX1<U!WQ(=YUZ3AFH>(2ML3?T6RA@<HE!`D^Y,
M[DR$#_\`(HR!F<?854@>((][KO%?/JYL<7<\!>6M_N>TS2ELU+"J;2EM*8-H
M@Z1F\IMIX:%D(>8H#JSR#7T#%=.THJ;D4UEDP27!P<X<7*>$G`)=9DCN7-[4
M(J<6]+UZ?;:`7AZS!8P`*C,)'4:Q-R3GRF\2^9I.^WP$2G_8/0-!A>%';"PW
M/)79G&7Y9=*;4F"<I(Z1?K%)\@B`4RJ2#3W12Q3EPAW4E(/%DTFZ#-J4ZJQR
ME(7V]!:=KI_#W6,8K7(.$L-9Q6J5NOKNJ'R(SH\-C<[GL9[ZLS<PRCE6+9Q$
MA#'EVQV[JK3L?(QCUR44Q9'6$AN@@^+9_P`OM\C7+.>FXS'LC0DSH0_(8E#?
MU#==NIQD&ZC.<H_'^\(RD9A#R1$ZA%)JP&D!6(!74="($53,B#+,<P[+<#@G
M<%EM61@32[H9&U69Z\>V"^WR:4(!%[!H-]G%WUJNDXX`/:L_=*@D7P31*DD4
MJ903GR^N'_BAR1U5GQ?M/'#+Y#D1B[&[[)!:58[/7:Y7-=K]J_E5MI%)IN;U
MNPG/M>AYS8`!PDX2CVST(-G(NA7,4WJA4/#C8>)N`\>;/FM=@].O1;[,R]^V
MC_R*G<N:>I.3K5K`/E[?9$UTFDG6W:%?*+%RWB#IF2#_`$$2.444PW-B5CC=
M2JTI1;L[L>I8V@I`W/#F&3T7D?MVN8O9(=R5S6[!3-Q3QR%BI",@G)/4ASK#
M(.&0E%N+MVS,*``Y[AMONR:,-ESG:LQTZ-FZ*BW-!;79LMF<PKNL02@(`W<2
MU2FTVLA1]*9IKD^4X\$`C7?C[W'G*B<S5L&[N@.@4;SE^)-V1_I^YJ?E^[UT
M%=?IQ_@K\%_FAJ/V^ZOT#M^@.@X-EAJ_.0SUE9V+)_#@BHN[(](!DT4T$S*'
M<D4#P5;JH$`1!1,2G+^T!#H%*S:L/\J2JT*5=O`E=NU(WW]<%%THM,YS(*.U
MS`0`$&Y?,83?[0_:(^`CT$*J%TIN@0J-EHUJK]RKB[IVR3G*Q+LIN+4=QZYF
MS]J5ZP660]X:+%$IR"(&#V#^P0$04_1A.K?N3;J<]NC*\EM.:W\SC_\`IDCF
M#])''6BGG_YBUU'%!@E(<OL0%LJ<Z8>8ZHB%F*IE=H'9.$R.VJX>FHS<)E<M
ME@-[/(HV5*=)4#?L\!*/CT&3ICC]D.^6:PY?C7&NE:S?TER1]]F:T9;*\QS=
MP<Q%R*;+KM&)'`SE6Q_*N2`CR2]G7$I3%9)$_P"X(#3>*_;YH^!0%(/I%SLG
M(.[9^LN\SXU[>RDAEV)*NCBH,=AF=3TC-D@1CA.9-"?F7,Q:3E$P@^0(<4`!
M@JBG@59PNJ4I$DUG+EPNH!$TD4B&6<.7"ZI@(DBDF43G4.(%*4!$1``$>@5K
MN?<AC&;E*L<7JA8=>;J2KJ$M?(Z(HMAT3"\Q.T*<KYU"050>LKER"G&:Q!2*
MWK0A!(N0\KN6()3H"%+,>2/'_)LOV75LUG9SE5R+<JP%PU=K>8-]2]OLZPJ1
M]1C9V6H,U2Z]+T?)J"Q43;-V<#"FBXAOX%$3KK+.5`FELBJ[R'NG&9Q<*5.U
M!MRCXR[K2]?SYP[6BK$TH4.WS?0JV25=MDFJZ;JC7YV!8U=1$BB(SRH"F3UE
M$N@<+V^N/37#*1`5RB/))',*=$R]6B4;!+#.3LHH\EU9QQ[PY*1N1$C"0=F$
MHBDF4"&`B9/+XFZ"RN#"@7&J[COQURO!Y%<EM;NL(]\GE,OGF>2++C[EBJ1Q
M\?,PE,^QUA*(``B0?E$Q@_WB(AN#H#H%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_
M!?YH:C]ONK]`[?H#H/X(`("`@`@("`@(>("`^P0$!]@@(=`I_98Z`=WB_P`'
M'QI&$$Y<R4(XCT!40()'+$6$P9N'L,U3=KJK&3`G@4A3`)``/#H,N8)QYRKC
M325:!D<&[AH%U+.)V15DY5U-2TK+.$46OO<C(NQ`RIF[)LD@D4A2$(DF4/`3
M>8PAFKE]'<0HBYTF<UZXWG,]TO#$*EGTGA3FYEVG2V4:NJ>-IJ-2I<#:FVFH
M-)!T<(YI,13XC5557T#(D%<0".8UP6VS17DE)<AM7TVJ8:^4:J5G$W1L^@^1
M%AC"%4!=#;-?QV+@(BG0\N0Y/5K]9\\P4@"1U.$$RC4H-CI%&I>9U.%H>=5.
MO46DUQM[I!52J1+2$@HM`1\ZGNT>R322]=PH(G66/YEW"HBHJ<YS"80S-RTY
MV<;N%L(R=[/=D27">(D-.RJMG:2FC6PSE8K9L[3B%735I6*M[R<"KSTTO'PS
M4OB)G`F#R""Q9G:)7FT"B^CZMFTMF)C@X9<8L3T2.L=$!!(_J(&W*V1SEG8=
MGED!(`K1JS>,J2"A1`8YX8I7(A8%:F("=@X^0JJS1>NE(M'Q"D<U%G%@UB'"
ML7Z42@"#=`(MNJT,F@9$ONYDR@*0B02CT%3<B'[VM4B,U&MM7KG5,JN=&L..
MJQ`H%L[V]2-Q@JXSH,$NY<-"+HZJTEU:Z]8*K$9O6L@8%_`I`.0&2Y5GM[=W
MRT;WM3>*BM*L\$G2*=G<%*EL,'B.5(RP3QZ>6S$20;VZ_7"?21D;3,-TTV2R
M[-FR9`9HP(NY#:,G=-`PCC!R&VV*53;,8W+[4>AQRX'5=V'5'#16O9TE$H$,
M'I?*-V?LX\3&]JZBI2E*;R`(!O?!LMC\/Q'(<;BU"K,<LS6DT!%T4OE%\-3K
MD="+2*GL`3+R*[(RZAA_U'44,8?:(]!;'0'0*-YR_$F[(_T_<U/R_=ZZ"NOT
MX_P5^"_S0U'[?=7Z!V_0'0'09KY$9BYMD.RGJS"%?V:.=D(]]S(B20D(<R"Q
M3)CYC)B\.S7!,R9/]1P*)@+_`.G0)1V7E7`XSR$QCCK)TBS3]HUN32C'\C%+
MM$D<[5?/?<(G^:8I9-2236?J%.OZ9P;B5DF98HJ`'@`=IZTK3+G7Q_L%Q8QI
M5W^"[I2<9G7[9L!F^L2%FSJ=M5=C9%8GG1L]@R>)>J1Z!3@JX8LI0J0#_P`P
M&#:]NMU4S^L35UOEF@:53JVT,^L%JM4JR@J_#-"B!?6D9216;M&_G.($3*)O
M.JH($(4QS`40QC([!MG(4ONF&-)?`\<=@`+;_?JL0FNWB/.'M5PK'K8R].FQ
M3U(?%"U75IZHD$%&4"N04W0`O?8.VK"S5U1F(B%M5L3&==V-S<7%U2D]!NKY
M^5-RNGK%TM;O^;;'(MG3---L\.],@@W$Q4`:$,1!$/TU7&:IJEAH7%*$H6;S
M=\?6I:U[OMW\G0,O/Y=7(@8F6G:G0;@^CE9M"UE9*1S5TZ(NF5FXDD$@`%7"
M@)!J6>X%95'0\B7'+3M&.2C:+??R[%5#7[#*4I.43:+&BF[JFZ>AI%3:1BC_
M`,@+%:LFY2IB;R`7V>`51PHXLZX5.-U3FJYEK1LM*N4FKE]>>R5.1H5-:)Q2
M$:WOC&FY^P95YY?%U7;])I*2*SYRS:*>9J1H=0QC`P_@-I$1S(L^UU^TY/L>
M,J9!8&D0T"X,&T:C=FJ[J3:N7L>Y<,`,W<1YV*)EVZ0+D(F\2,"YO-T&T.4T
M/'OY7AGQEA!]&,OO(JH6R?CSE%P*F<<8XJ3WU^N]$0'U6SS2*558Y<3AY5#R
M@`;_`'>`AO;H#H#H%&\Y?B3=D?Z?N:GY?N]=!77Z<?X*_!?YH:C]ONK]`YRR
MV2`IM<G[?:Y>/K]7JL)*V2R3TJY39Q<)`0;%>3F)>2=K"5)K'QL<U4664,(%
M(F03#[`Z#"X]SSB&V3I3J;LNH5.-OD(ZML--7/CUO=1A8^@I3]/K#'3;9*6#
M.(]I2LPG)J_PR+*PRQF<2M[\4PKE*FN*0=:T=R#BM2FFF/K7/:7!-<:TJK9A
MJJS[!]L*7/Y.ZIMUJM:[5Z5"4&&S2:2=)F1LB_DAS><H>N`G(!@YL7R+8\O+
MU<\=XX;$-"C<Q<R;';[*:@7.+UCT&]YN6<(-\<5OU099\>"D[;FEEC5;6D><
M!JYBE$VS,#F2>)A]FC\6Z-G%.^6<JKP1RL<HO)71PY<O9VS7)PX`??;I:K1,
MKR%CM=M*!A]Z?/W+ARLV'P$X%2*7H,37[/J-J=7>TS0JW&6NLO'#%\K&R'KI
MF9R<8Y(\AYN)DF"[26K]@AWI"K,I%BX;/F:P`=%4AO;T&.MMQZKY_7V<A1R7
MG:.1RJ;MMQGKF[ZIHFY1U8N2!42+W&"K.DVB9JU<0IL6J=PO8GJ(*,?!-,78
M&6*FJ&KL;3U1+*Z&3<'D._UP*^W&_NX`K<L4M/F57,H+?W,B;(ZI&@I%7.@4
MJ!W`',F'D$O0<O1;597<O'Y+F"_IZ9:(EW.2$\2/4FFV39RR4,A.:=+Q2)3F
MDI0#D,SK45X>I-39BD`!00<F(&1,OEKQA&>:;K$MQ-V.`3!XX;LCWZQY[6WJ
M>?1<PLVH,,5S+6=[<;'H&C6*<6EY<`BA=R=JFU2^'IE;@0+@R/9^1EQW*_9Y
MIG&IWF.<UVO,9&OZ(-@^66LE+K%9&&*-(`DVBYX7_O*_D]P3*HQ%H8')?$X>
M4&+TK$+Y>F3:6C6C%A"NQ/[O*RKP$4ERIJG14.@V;D<O52%43,'F%,I1$/8(
M]!L#(L22SERO-2DN>9L"[52/3,V]=O&L6"ATE5$445#F4<*JJ(%$3G\`*``!
M2A[1$*9@S#HW<(O$J#@'$)QAXV5JA,D12\R;?1.2MR4O-U(13VE*^BZ!C-2.
M/[#E0F?#_:<?$-P]`=`=`HWG+\2;LC_3]S4_+]WKH*Z_3C_!7X+_`#0U'[?=
M7Z!PFCT"KZQGE\RR\,#RM*TJF6B@6^+(Y79GDJO<H-]7;`P([:G2<M3O(F16
M3!1,Q5"";S%$!`!Z!=L[VM:7=FE/C-+Y,\G=$B:[ELI@UCCYN4QF*'3,'D++
M0+.7)[Q)5/&*],_(QW><,47LC%.8R<DV[AX1R].#C_C#Y9KM49[,V*]6PG(#
M>(68TGD%1.15Y9P$=@<72[A;,O;RX9]'V_-DL0-GUL;0<Q*)2[F0D(U>;F9B
M*BW4B]=&C&0(A=7&#@'D/%+4MCUVAV&\S%IVIY-+V1"?/2X^(;H3FH7_`%UR
M"C2DTRH.+=--[9I4FDWF;&M-33>*!!@DZ(V2\APW$HFFJF=)4A%$E2&3434*
M!R*)G*)3D.0P"4Q#E$0$!]@AT%'ZI+M,OI:3>CY`IH-DL\JSJ53HM>A4&</(
MSDBBY70<W2P%C7433:5%-&2KJ2E7I3E101%-!)R\4;-5PS75."C>)<S%ZG;R
MC):_=D4U+O/-J_Z=:9I)+K.HZC9W$J2`.ZAFE:.L)&C$55UW*OF>.U%G2IC`
M%*ZYB^HP,%9Z\Q][A9B;@YN%JEXAF2TRQC9V2C73.%F$$DDA6]XCWZJ:Y4%2
M$4,*?@4!]@]`O_$>)G([CSFUGLG*3>]<B;E8GTA;+M;:)96L>REZI581-O"C
M-VZ>HZEO</H2$8.%`:"[109D5$$DBG,J<X3;CK0=DWV$HZ4D6_7ZF8]+.-4N
M;ZV3KBRR<EN-]*-ISC,UY&6<%=RS;CKEU@CG#U(A3%+99!+Q`%69R@#+,UX]
M6&XBN]LXR%2B&RXMRI.&)DYF063,(.`;-G@$!HW2$/+ZRA#`8WL*4P`(@&^X
M2'8U^(C8.-3%)A%,F[!H0P@)P1;)%2(90P%*!U3@7S'-X!YC"(]!U.@Q!P5/
M_-]-VG?%%O>S<C>2>NWZ&>&3\IU\^H\JTP3)U4SB'B9C)YIC\7)(@`B3P?F,
M7_<(B&W^@.@.@4;SE^)-V1_I^YJ?E^[UT%=?IQ_@K\%_FAJ/V^ZOT#M^@.@.
M@\_&K\2>5D_/[0M-XCJFL3T[S-@-0E-#KO+9&HP6R\1&FK-K)5<'J--?ZM3"
MYO*9OGYD(UXV79Q+-TO&KKH2#P\DN`AR1[>'+"Q5VKRE]L6H1.AT7AU>ZM(W
M#.>05AM=WTS5=!T59O0\DFV]PTK.:E<8C">/D*-<E+#).X!Y;']A.\3E$7+7
MWLH?!Q?X8=Q7->4G%K0-`E)-W1J558=CH@'UU\ZI\#2GZ?+)=]DIXQ34[-9;
M!(4)#2*$SCV:D9.13Y>`3<*SWC&MSN0]%G0'0+2[HE\M3?$J9Q[S&.0G=<Y;
M:A6<4I\*L8X(A7E#GLVESTN*8"9*J0])AG"4LK[/29O#"`^82]!>D;GNE<8<
M)H=(XXT"H['*U5RJYO49>=`=9A/WYS,A*3-UN4/8D:A<X9:_V:Z/S/S-9(K&
M-4*NHE[XV*1(0#NY3R>B-!FYJF7+*=LPC0:W`OK+-UC7J$X9P9H.)59MI66K
M>MTYY<,4N3)FX?I^)(VQ.'I4C`HJV2+YO*&36W>-X2$REQI4Y;KE"S#'$FF]
M264)9Y;;'HS2H2=,IFAPT.0E7BY>G/KS,4G1H"21AD)<[PK25264*1$BRB06
ME,=RCA"LK<*>XWL\99X)>LU2<A8JE:2O=8FTZ',#38"LPD.SH\D_F+^SMJHQ
MCN*8H/7\/+I':OT$%TE$RAQ<`YD<"J1E=!RG)]J:KT?+*W0LOJSF6KM\05DH
MYG=HWC]57J4S(TZ*9VKY;T=N,4>49`HS<R+=ZIZ@$:NS(A#;9WC>"5?K<-:8
M'1+=H$3.MKV\;O:9D>LR#*(CJ'CD5N;RQVLZM*0>UVBS%"LD0Y8SYVZD2NG*
MHK@M[JFY70"R$^YUPSCXR04N&N,:O8Z\VK2-GK"=;O=I70LU@L2-&=5.E2U7
MJ4G$Z]*UO1CGKLE_*BDP5A,IBU<^BL()]!M.@WNI:C1:9I=!FVUEHNA56OW:
MFV)FFY2:3M6M,4TG("8;)/4&SQ)"2BGR2Q2JIIJE*?P.4I@$`!77.7XDW9'^
MG[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z`Z`Z`Z`Z"J)/&:7-;/5-V
MEDY&1N]&HMFH%.2=NTU8"M1URE(F3M4Q$Q8M_,VLTZG`LV:[WU1-[BAZ)2E*
M=7SA:_01RXU6'O=1M5(L)':D!<JY.56<38/WD4^4A[#&.HB3(RE(Y9M(1KLS
M)X<$W""B:R)_`Y#%,`"`>?G5)+M2)P,/EN/U2\[3=[_KE/XZU*FYA:-KK#EM
M+:^IFM42T*OWYPT+%IYW4JEP-:)MK7#GD8I)"D/F+9<15D"F"^GTAVT\!OL[
M8H6<?O'E1YHW*Z:(_F;O=X^A97R`;Y'R(TG7+:A.69)O6[C*5&L62VRLQ#Q[
MR6<1TJ_1#T4%TV:)`HV]UOL\:=$9%3JIM]BS&\(9"7C!@CURXY#1C"BNLYE-
M.R6BV/2L\MC2"K3BW93INJS[9J_OB;8?YC=J)*K"[*3TPKM_(=I^"I6=UK)6
M^O[RWE([8LQLE@7UO9:9/3T#=,-P.KDK.E3^F.ZW)VVI7^D-LHK53(F12*:Q
MLC$JL3D:+B=P%P,IOLBU8]YTQ'5'ZH5'0[9(G>C.\C9HN?O;7%\B[9;B9/`H
M1KM6+RA@\L>A69^^K[96NQ<HS4?N72)HMF+4'E9=7*93LSSJHYPT!AGE6HE1
MKE#8E,^,5E3(.OQ\95V@&DQ&2,#:#:H$\7'_`#CY?^3_`%>/0+(YR_$F[(_T
M_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_0'0'0'0'0'0'0'0'0'0`^WV#^P>@
M2;-8)P-X#\CN+\S.;/.YHE"-IX^8YI:D],U5X]%-!OQXSI-WHLDO<?\`XOP3
M#V7)*0A86)63B85I+70SMP^,H(@(9JW%UVF]94T!.N7W3K=KO(W5)NMN=,;4
MKD7H$?4;C;\;ODU!::[8D5H$6MF=9R++9E2O66.D/<D(OP=MWQV)?>$@Y'%1
M]VD;?QCR^0U_4[1/W+1(FBOM,4W.8U2$O5ET2\:3(6QO#6](C5FQF922U?N-
M-UTU6J[U*3&>C9`'CU&.3?H!:U80[*M0?UM@WU>VV:6@UVUY96^S6GDO?/?W
MU5D<`NR#B9T"1CY2'?OH>+XST!\2,6>`=O6&+!4C<D5()'<A\MCX3]O?F!98
M3!.,^WVBGS.55J.J6N#0&NP6&6E,*I<6YXVNLB<Z5(3D11ZY!7AEG<PR72?E
MFB6;ROI-)JY*<[LX>A`A")D*FF4I$R%*0A"%`I"$*`%*4I2@!2E*4/``#V`'
M0*/YR_$F[(_T_<U/R_=ZZ"NOTX_P5^"_S0U'[?=7Z!V_0'0'0'0'0'0'0'0'
M0'0'08=V3@5D?(+D7#;YL$G;+9&UG-*CGL%D2%@G:_G3M2LZ:_UAQ-7J)@YA
MDVT9"0MS&N.T8R5168,W=8:KE(<YS@`5]"=I_AE7ZG'TZ-JVE!&QQY1%-Z]W
M#79.><0<K@#GB\-0=STC<'4FK2XO#W`0D?%@H5G')IE6;D37$ZIPZ6F]JG@Y
ML**J&@9$\F2G6U)RB="_Z!$+,'>OTW.,_M3V,7A[,Q6CGL?4,FK[.$62,52O
MECR*1PME1,H(1G4NU#Q@NT'L32D,)_*Y[8<QM&0KR$-8K3-U&@U+0,\R_&]"
MD<URN3LB>>U&]6'(LBA(9&;;L@=LSQ[=P'J^15)<-'Y#PQP##-`C]*SBK241
M9(+&*WQ]JA'-GGY*%IV15D\(Z;U"LPCY^M'1[63EJ\UD'RQB*.7,B55R90%7
M+HRP:HZ!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;[J_0.WZ`Z`Z`Z`Z`
MZ`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z!1O.7XDW9'^G[FI^7[O705U^G'^"OP7^:&H_;
M[J_0.N>N!9LW;LK=P[%JV7<`U:)^JZ<B@D=4&[9+Q+ZCA82^4A?$/$P@'0($
M[:O<EWOD#-2.I<IKSB]-R_3[!0\KSW"JI7;-+[%E'(C2;?>EZ;E=O+6X>3<5
MUBCFE4\LT>UG;R"$^V<KG)&Q_HIG"I^%_=JV36>2ZZV\Z94:MB9<IN>B:ACC
M'CIH,9=>-]ZNW+"N<7>+6$2-W2=35AT*ZV<3OGUF43@D$8^5\0`Z+`"^0&,<
M\N1-TOO;@YH:1P(M=@N.JY[%:EFD3/Y="2DC<8.YY?=_Y$V\F<,WD80]BO>?
M,(V=+%JL$W:*TRP(5L98Y0`03+JM]X!,;5P'99;RJY6O^#4WIW)O_P`AKPMR
M-YQJ/4=)9<78&3SUD]OSBQM](:V%:TG:O3PT>Y]S3LBRA#,TW:BJ!@K>Z[#R
M#8Y5VL+%H.@[F[Y4(;3E[I.DR>F<BZGS)T[BX_YEV>`RY\VX]1,='<>M"M>@
MX$#)349"[IHRS*"04.Y(DY]'Q"([UL#*PH]XV_\`%+DER$KU6K.2UG.XW([C
MN_(NSZ1?]5IO*VI#NO*^MQ$O*R5@PS*(:*M"='A4JV9FK)PJ+Q\BR0:%9"L#
M(.#G(#7*1VX^XI?"Z;,,QQ'5-VGN.&T6%;9>2&,KU8<WIEOH=:Q)_LK:)WG9
M<WJUP?+5]=.0.J\=3YGS:,<F0*U(D'8FN7?.O=NS;R_W-&N6S)N:->M%_J%E
MQ7+*3,HZMQ?A:Q?*E!WRG5`[LC^1TC3*WB*LA:XB>8I&(^=R;;W%,WH)`8,@
MZ[?.`+"_<#8_,N5?*IQP0F;-S#-M%Y9\C.<R[A'6([!\A?9TR;W]6Q!IZTZ6
M9="^0AV;E=DG8G#I/W0CP[AN(=^F9QN?(F%[0-/U&R\N(#E]I,[):ALVA2>O
M[QFLA7N"G%K3[+<JO(;=EU8M->S(FT\@8&>I%6DE):%&6=J3,BHX+ZK,P)!A
M34+;RTJ=:YWI5SD+9=:BJIBSLW(?=LEY!\HK149_8++W(,C_`/C0)B%>U.M(
M<8+]4N/KRSU^:K>?N7XL:LP565$I/<!6!CV2:ANCOLI]UA]$VW6)6?SI]S"0
MX[:C6KWLUYB']'7SN*M5#2XQZCJ+2-WRW46@/IA>':R<J*[WY<8/B-'"C1-N
M5,,^OMWT2,@MYRC@A>>7^S<?.2&><-./-)F4[7JEYGZ?RSU"VZ`[Y7GXO:QO
ML[&S$<:I<2:H\GI)4;"C78.V^X@FY9N%U4P"C-DT;FWJ&)<9,*A87DP_WOB7
M1.ZQE&D5.T[=LV.:/87N`T_&+5QEU>PW?"I^7::?M3;&;E#RT(P=3+F"LME]
M];'D2E445Z!K7&W'*M?.XCQ@T!+5>3&H5"V=M&B\K'%KG-HY$U&E:%O;70\Q
MJ+'2+)D*&BIYS6Y6R5)XX7?TT600R2[A85&)U2"KT'HCZ!1O.7XDW9'^G[FI
M^7[O70*?[''=T[:O&KM6<1<0W?F+C^8:S0ZSH#.XT2S2DFWG:^ZEMCT:PQR$
M@BA%.$2*.X67;."^4Y@%-8H]`V#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S
M_!.@SKB'<V_3Z<<G]TE\;Y=<<ZE.Z'\FDN5D6N>@6BT3C*$/)JP4*O9[A_,$
M^WK<`M-/#Q\8@Y2CF)W:QD$4S*G$P6[1.]7V1,PJ$!0,ZYL<8Z12:JP)%UVJ
MUA9]#P<.P(<ZON[&/95]%NB"BZIU5#`'G55.90XF.8QA"6_UY^SS_<"P']]3
M/\#Z`_KS]GG^X%@/[ZF?X'T!_7G[//\`<"P']]3/\#Z`_KS]GG^X%@/[ZF?X
M'T!_7G[//]P+`?WU,_P/H#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S_``/H
M#^O/V>?[@6`_OJ9_@?0']>?L\_W`L!_?4S_`^@/Z\_9Y_N!8#^^IG^!]`?UY
M^SS_`'`L!_?4S_`^@/Z\_9Y_N!8#^^IG^!]`?UY^SS_<"P']]3/\#Z!:_+?O
M#=L:^<ZNT_IU/YH8S/T+#-FY4V#7+.PE)4\90X2\<,-CSRIR<ZH>((=%K.7:
1?91J`D*<QG+D@"`!XF`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g662896g74d12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g74d12.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`)D%D
M;V)E`&3``````0,`%00#!@H-```3&P``7#L``'07``")VO_;`(0``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("
M`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\(`$0@`YP'!`P$1
M``(1`0,1`?_$`.X``0`!!`,!`0`````````````'!08("0,$"@(!`0$!`0``
M`````````````````0(0``$$`@`%`@8!`P4```````4#!`8'`0(`$"`P"!06
M$1(3%3870%"@(R(R)34F$0`!!`$"!`,#"`,,!0L$`P`#`0($!081$@`A$Q0Q
M(A5!,B,0(#!184(6!U(S)'&18G)#--0EM39VED"!4T144,&"DF-S@V2$-2:Q
MHV47E$4($@$```````````````````"@$P$!``(!!`,``0(&`@,````!$0`A
M,1`@,$%046%Q0)%P@/"!H<%@H+'1X?_:``P#`0`"$0,1```!W^```````&G<
MR$+K*F=HL4_"X#H%^F')E:8TDKE))&+>.\=HQ/+C+C)[(4)V+`*V9MG.````
M``````````8-%0*:5HE(ATM0E0M8G0_2!#MG0+Y+:+Q,?C,`A(O(AXR?(%*8
M<YU#-XJ8``````````!^$`F+Q%)22^#)$RS*@```````````````````````
M8U&E\U8$#@``OLV>'H%)1+E.T````````````````````1L>=TT\G4````*Z
M>SXAP[)D>7&#\/T'X<9^GZ<I\`^@<Y6"X#L@``````````PD/*60D`````;>
MS>:2P"%262;0`````#C**6\=,I)CZ6Z=H@\M"61+)Y,OBO@````&O<\F9:X`
M```!]'L?*P3.`1T7"9````````H!BT6T3"`:Z9<>E`IR9H6;+B]@```8KGC@
M+*`````!GZ>E<DL_0`1X7L32`````"$R`B80`#73+CTH`'(FV:S+D``%(/&>
M8E``````'JZ)T)R``!#!E"7$````#'TCDD```&NF7'I0`!3S:A<YQ@`&CT\X
MH`````!D4>MLN<J@``/TB$RY````(E(,)%```-=,N/2_ADHEP$8%AK:YT3<W
M<Y+`%%/#Z0^``````>CHS_)G```!&!.Y>@``!Q&#!,@```-=,N/2U4JY4$^U
MH12#J%=3?O9WP:OCRB``````%\'LQ/PO@```'Z1J92@``&+953G```!KIEQ[
M6;DLLE8L\^ULPLX_#8Q<[#`>9(TX``````&[HW$DN@````B`R[```,)24@``
M`#73+CTHOL[Q?J08M,`+V3?;8/%V8C@`V-'<.N0"8O@`[A[.02V````"%C+L
M[0`!9YC"2,````:Z9<>E%P'&<!T3@!Q%@)Z%K)1/!V6.`7V30?9>Y!Q:)8(!
ML\/0F2B#E->98)>Q/1DL?@!:A>Q*(`!C85`X@"&"S"LDV%5!KIEQZ4`4DX4D
M$D!9%29UF"YRR/`&`#/XH9(1$Y)A#IB2`>N,DDG0%M$2%BE,,D2_``<)12?`
M`#&<J``,;BSBMDKDH`UTRXIK<)?Z2&6&5<N<E=9#!?USF:>!XH@!S%\F7Q;Y
MB(40X`#V+%:)P!A"2J7\8\DMEBF6`!U2FD\``&,1508N%XD7E=(O)Z+!+L+4
M.":OPXSD(Y*0=-)46JGP7W<YIGB#,?P`5@F0IQ&Y;@`/643834##\EDM4K9#
MA?!E*<8+")<+]``,:BH'P=,LXIQTRBE8)-.^##4D::QN2\EC5+C(Q)P+%+C7
M,2YS#/)V:QP`````>GDS!)F/@C$O$PZ,@BKEGD_'R"%#,4^@`"'B.BO`AD_2
MT2XRTB="Z0=0POEM8N`'97JE@I?J]9,W+,FS2,>;P`````'HL-C)+8!89BD5
M$RM+K`!$1ER``#Y,'27"/2QB,213\,<B13,H^P6.872R,O>*46\7&=LC%-P%
ME3(9/#V4T`````WO&VLE<````'X6"9-@``&(9>@!$@(X)_*X<X`(1(\FK%2T
MRW2:B3%Y4V#6`>78U&`````&XPWCDF@````A$RZ*@```6:8MDG`C0ZQ^%?+V
M``!BH5J:[P!9IG+<RP`0">*LM4````&T(]"Q)````!UR/C*4````Q6.V58``
M```_#"N64E'6+IN<ZP`#3(>9X````&>!Z;"1````"!C(4U;&S8^P``"Y3%<E
M$[0````!1#$264%I-SLC/T``'FW-)8```!E">L<O@```$-&0YUC5J;*SZ*(8
M]%3)<+Q!<I?)A>7(7,`````0F62;)3E```.(\[9HM/P```E@]B)?1\```A8G
M8D\`%ID0$0GV<IG"``8Z$,DR'*```?!#I+!DJ`````:K#S7$3@``JI[4"]SD
M`!2B&C*,O,```````'`8S%HE#.(KA13[*R749.G:``````+`-'YIA(@``/:B
M7L5D%%(E+Z,E@``?);Q03K'V?!]'"<A]``^`?9\%5+J.X`````````4`U/F`
MIB\12<)ZS"%2K'P?IEL#\/P^S\/TMXHY=Y(AWP````````````#_V@`(`0$`
M`04"[\!NJ8&)@AY"@E@:EW"=XBRN8,8.U?9!*:0:OI'9$M$[7^";,\W<(18R
M:]0\2V$VL//RZS+@E\6GBMNH,9-'[PDLB4%^14/*Y)W[\(\.N)-T7GMA2**6
M=^_(A]NLRR7L-0-WO(%@\JL^21\"YG]D.Z=DDMGS"H,7&681QW;K8=)X7=;D
MR(6O4%KJEOE1/^:'HL0-<+TB"WB!FC1IQLC3(]-[!H&W@X=C2;4<P9^/`!NR
MD50AI$N7I?0L^!0@>`D;&$#6$W;T4#;2X=20EAP&HP6&&O*C!OV[ZG-3'$TK
M+27'9/1[)RO*86PECX]2@4[QI6OJ'+J@1Z@YS&BJ\8TI(<F$84,%82;:D&VH
MIQ1`Y6)LFB3!G_(.VK6T:R1\KZ5895\TJJ3W2\UZUSLQ\Q*@=\!+_IP_EJZ:
MO4/Z?/+=KZN$IOYIG7F91:%A33;J!2B21=Q"O,6P07%:V,'M"->X`/SIKHJY
M_I,KET<A`>U/+J2R/9===TMV18UX9)"F`^GJM;5:`>A/I.HSP)%08^RQ$@>N
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MS'Y&"E0WL6_:0JJ(C(I"8E9ON>-L`]^6;8ZF2RWPQCID<?3/-H9*MY"V[DLF
MS2-9;QQV4?\`3</YETC796/$ZYMD;-<]3]^S%L;GM!]:LT[OBC7_`+1KF*J[
M2`IU2=D^8.1)5B<&=J9S!<0J!CZ(37JN'\RZEV_UN*HM3:3YZ?,:S=A8GNU1
M"%K#GUANMQT99,FPUEU8S\.(RI[3EO9F4I2BHJ/!%12?7</YERU@[7Z#."AW
MQ/,=9.`AH4N$*<+)JYVJ^?ISP%S(D&@D?/Y>]GDQ[OAG7_H`;=7,DG?8EXIT
M4"1TTWD8+KWWU3T#K[RTWV+A_,N,L7N-4S!?.[B0G_5+DY"59ZLBQ)PL@LAG
M@%)'4(D35TW?-N7EK,?;55]V,@'TJD!#TM7US&PND>!]C&?AF"9^SGNNS7BS
MMLDDD@EV+A_,N%"3#&SDHU<.LF@3E8&>9C1ZY@818EU4=].5`27*POEYHR3)
M&?\`=\,X!]Q/&U,R.P.T6_XR9=;!;[[+NS</YER3:,/L[T,C[BWC`E1T\;[M
M7/.(&\Q><\KY,;'+AZ(M1?N-H\IV.M6DXJ>'PDE9%>;1*4=#=NL[<0./CJ<J
MB%#7;$+VK"TS[115T<(],@*:!`<08;C8OV;A_,N6"Q3#9T3)/N,/GNN5%%%M
M^6^^B>KQ^/+M(0<VDT/XDSO8A).;2+R,BJ+G,S&/E+9,JZQFU;!:.2Q:22)9
M_%9*)Z/%*`>\+'G:N3A_EIK\VX*[/O+IG=DF<0?:U)<XKY"T8SH7Z#S;#P#"
M'?KH=TVQOMM#M_A\_,A.P(QYBT@^S1K9`)XNT>M'^G*X?S+H=/V+#1L[7(<-
MHE.'W#:L%U.&E<PMILFDFBG3BN-8QTDEV#EE[C$N[#QM!WNU:2`.)0CLUB^H
MD$Q^SL>?B]#V44J>$Y4+Z\MS@EKPPKJ.,VJ=5QL,`5K.$3!-"/,4GG0IC&R5
M79SFONFQ]OBIT%ZS"F2Z=/B=FC"M561"+0X##6_*X?S)<R*;*MF\@(\-H',G
MG#:K17#HO"H.77M)9%HA8#Q70!*@$HQRJ?;Y"7!)KZ$CSV44WQ%F0HB?!URP
M*&4ZWC3U(LS48$\*JZI\_&]WZ^EJVS_X7D0:>KB2PZ3%'.#Z#Z/(`9"]B,M;
ME\L8F'D*Q'FOOA-O6&F4Z_Z;&Q\'G*2E4F;D,]DGK\R.3LS;T^8*QU`O-\AW
MQML&B^DPF&6T!(E"CBTH.E(=8XG'OM?'S:_-P\C`0DJE"026S2`Q]@^:LFK+
M''S8SFJ_^_XM<7D-9O0P=^@=_L4UOIK8$DP]+%')E_T>)+O5>F(%K](/R:3E
MR+($Y/A2&Z6,/;+FI,]:I:6HMAD_*2\)&M]?EWY2IWAC%XLS^WQGIM'/T`VV
M/ESQANAA<E(F`LKM+8FNIB51ML@WGX9R>(3F,#Q;5?5TUY2)C['+<2+3?<B+
M8&VKMZVE+4KND8-QUM&94D&5U5;1]BE/?H0QB4;NZBTSOR\MP&P>XNYX7.ME
MJUB7^)[QMKC;5G$`S19\+9DAIEC7+N-$'D0+N$8S'U6ZT!8?;<Y^;/*?:[.@
M6,8QCIL`7N9A8HCJ7%\CD)''GN84PRF-K_Y>/8@SZ257C&[(0S=L&W)=!%TB
MT16AI=G.DUG>\U&:<&I>Q9#5)D*^K[U%*:/I\Y;I;SN.X?`I4N5>4\WSI7_'
MFM%-GL8[GA"\^8"'^"4QYR8:_,`T`DS%PPU"%\Y!9*Y#=&^/N]B]6<8VQ$DL
MC->),\?L1L2>RH@\TVE#;>:K%D%HR<DS^0)H6!]L)Y3T&:Y4SKRD0!C)1(<2
MP5=MHN$:<.0X1;#`''$<MHK'6SG$9CZB2D;$*ZFHVW:-V;1N/9\6'$F\[A+Q
MHY'N^WX/.?@43Q]&RNU\==<5HED@WZYFA]AEW,O+QXDV%E>ICAK8HK+(213+
M,5$TU=>B:1E<T@$,('&,E8.7!B)!2P1XC%7;AK%6Q9F.XA0_:03WGY=5O[8F
MW;\+'GT[$(_X;0[4U7</$6C5!BUZY`$9R0+%B;QTUY%HJ.,NQL3;"MM8DSWP
M"`LX\VZIF(<A'[9RW>M^9PFH,90F,:1"-\[.@(^RH6<"DHX8[7B$\]+<,EU^
MG9'9552;I5^S6,NNS/@CUD[8/V91EW'[+V$8Y*JI-TJS`*G7_3Y5TGM*1O:\
M9W.6UV3G_%*NR13S.CLEF$3@XXIY<"B\CUL&!XU_84!X_84!X_84!X_84!X_
M84!X_84!X_84!X%RB,G%I&.4KIX@NBY1[9(<R+L!F[X`4VVUTUC,;4LASU^3
M/CWO'W'9I1[Z"V+%_P!"O8/FB"Y&-QX;%A$DB49F#$KXD`Q<AUKZ!_#]>P'@
MC"(.Q8^LKG#4C["#(BXQ6YA;]>P'C]>P'@7%XR#6SC&V"L8*0E808&'F/;G[
M`.\CL/A,BGC7331+3KWTT5TO[Q>5&[9QG&>N!./1SFTL?^9V_P!W46/D7I&*
MQ5A%&'09$)&V2@`O%&0<`0]LCZW=XAL<@9L%,>F15\W?OU92ZCJNF^BFG7G.
M-<8E*YM4!7B:#[MW/XPQZPMIA!Y5`BO4Q<>D?6-_EK?7;Y]>A\^9#&B"TDGN
M0,?$1@;_``%$TUDW55AT%%F-F!^%)FW8\)V+`5=_></^DK8L!1VTFC)WG1K9
M9?AM58YWE%!%LCW9)%H[+QEB^&&?FED!F<&<])578O2HY358=R($1XEHG*"\
MBX&5R@H[ZLYQKC8N)3VUED6WV1E\<<\(RH6YPC)=7/"!T@XPD5D:V$G<M5QI
M[OWX3;2W;A,;(L\)A"G&L;S\-8H-XQ$H_P`>S(C\R,:CC?*+=NVU_AE/M?H)
M37?B7)\G?'BJ?B2H]5GE>KSZ6R=92#?>',-T:9C,_:IQW,YES[=HG9AO@<-A
MP4R@ZEJO"'O#?A!M+\\(#))P@$*:X0CFR?",8'-M4@\+:;,$ZN2W%^R?I-O2
M_0_E_P#_V@`(`0(``04"_N=?_]H`"`$#``$%`O[G7__:``@!`@(&/P).O__:
M``@!`P(&/P).O__:``@!`0$&/P+Z?':VSNJ6QB9#>YC5SJ5V.2*4M#$QQ\SL
M)-?D9IS8%_-L.@W=%&QY6-773DJ\0;YV,9%#BW5FRGQWU*1C=8R\G,[GU!02
MI]X")#@U:15ZAY+PL<KFH/?KQ"S*LQVZM:TWK/?L'/Q6"^I?0$>.R`8MGD,.
M+82$43E$V$^3UVIJWQ36%0T%)<7$F9C=9D^K)./5I.PN:XMC7LC0[F[KIED5
M6L:,O;L(P!'IO5$U5).77^/FHNS=9.<@U`^-.C5ZF<0T!C9TJ0G202C?U=FI
M47;RXA?F/+LJ-N+V@["<#!H-`0MLRI"DE(/;9$6X`T]T=0MW,(!@-7*FYO&2
MGL\<R"#,Q?\`#Y)M6(^/7$D\;))O80"Q#T=W902F:9%W@ZJ&:O+35>+LL[&<
MIKKFFR&HQEN,205GK%E9WX62*=L)169*_I2H[][G/,Q!(U=W$6)=X[<Q+A:B
M1>VU,:QQ2/*IJZ+)6,YSC2LA!"M9)E:KPAA$D$*Q-43A^)TE!?62`A5%G-OA
M,KQTT&!=U_?P3R'GGCF;WZ]/IL$Y^[GIMY\97455_CT4>/4^+SJ+$[&E6=8Y
MK/N2]*55P)8+&)-!(&G-%&,WCS33GQ4XM:XM=P)ET98%;(=-QL@Y=LVM6Q[/
ML!WBW,,)MBC$>3'`)S_%6ISXP%UI0VN(Q[W,+2I/8BA45C26X:WU#J53G2+Y
M]M5$".+J:0T+O.-49JWB>HH%F,(:&]R*K+W>/R7W%=CRJD[2+!NI4RGDD:F\
M0YS([B#YI]7&16%5A>21[6MQ&!F=1%OH\&/'M:.?(9&]2_9[52BCPBO^(QRL
M,K=%:U=>,8QJ1BMR#([VC@WLN"2;C41($.8[IH2/WE^-]PJ:*10P^X,(7OM1
MWEXQ:H@0+:^I9^'9+:3L?IHU*LH\RN/&Z$Y\ZU-!6+'B`W[M)#4=JB;'NT3@
M]IVEND3\"@SRN<\48;[B"28^ND5D`;Y*.?;0I[4&1B^7S(J.5O/C\L[9K75]
M9DF45L+(@'KCV<^/52ZR1+,`,6N;*E/GA*UK?@-*[5%T1>/S.N,>L8X*['\S
MP>DQ^?,QJ>DF-67S!-M2RZ6<*'9RCB+N5C'#8]R>[XHO&`2$_,:O2+D]_>1[
M+-)WY:V=>V)7P*]3@!^#Y<QMGJR2-44F]JN1VO@G./\`F*ZYQS$30H=M,*LW
M'9,W\4L%+[?'5@0Y%J`M,R_'SV.20;<]NU-%XC976X[U<U+44TN;4#A'GK`=
M,[;U22.K"=DB2^OCD>5(^_=Y=J^"\878T\F+^:7XDS:/CDJRJZ@6-'ABD=/^
MJ9-1/NQK"R/<KMG55@--%=HG-:_&+#%KV%(MY3JVID$FXN5)=JE>^P9#?7Q;
M^1;PAF0:C8<P&!<_[VG/C&)>28I8T\O*LTF8?6."Z`^$4P26Z]UIZG)E,%"'
M5]$^Y$59"_#16<TKF1J2WDS;;*LGQ.!$)*H:QA9F*&0-@9UC<6\"L&DASD[8
M75ZYE71&<#(HWB5[&O41=O4&KFHO3)L<]F]G@NBJFO\`IU5W>3Y);TU#>VF2
M4N.R?18U9#NK8LHTB84T&ICVLY1$F/432R',8OLTY<8SB\>VLXTC#[&1:X_>
MO!53I4>7)63UVRX$Z`>IGQ3,E*UPWAYZ)HJ+Q2CEY-;),JJJ]I33AT^(,9-@
M9$136.RJ3'DIJR9O70<B,!AF#Y:JOFXP8A,BMI%9^7XZA:2K)!Q]'ME4T/LP
MF6Z'4LOF1Y>O4D1VR.B4GL1OEXG8^&XLKFGD3ITF%#MAURI61K`I3R*\18<*
M*62!Q3.74RO7GHFB<6&.Q<WS,.%3!6HPXD*56,B04MQF&<0+/TQ;DD('751`
M>9PVKXH[BTB'R&YDNM8>*02E%"QZL8$.'V*6%8@(M9418^I=NPSGH\A/'=KQ
MD4U]M;U]C>7.-Y!&GPG0T-26^+0NRKI$%#12C*-[/UPRH]K]=.7%=>$S.[_$
MP*XE3:7LJHQ&S=<P"R72]A*NQQ^145Y8Y':`?'"SILY:.\>,AR:-+EFEY'$H
MXDL)DBMC"2BA=D$D=D>.'8Z0WS/3W=WNHB<N+_.FFD%LL@K*BK-'*T"QHHJ=
M#((D14$AVD/UO/JY4Y<!RMM[<.6+ETG-(]<^-1JWU6;'='ECDVOI?KDR$K7?
M"$^3M%[.*8+\BOIU?CV86674]=*;5=**^U#.'-JW&!7AE'A%?8$=YG[TY(BH
MG%Q0BR2U+CUA36U'`K5J<4#)JH=OOZVEX"A'=SW1]_PNL=S43DY'\/BGL+7I
M$_+IGY;.Z;XS'^EC.*0V>UW;KI8]0*?]G_!XQ05[F=[;P\6+6R!`/68L$TB3
M4/:Z&05G$HP6M8QR#:T[0&;UVM\WBNM?DL;*+W&;BLI+.ACR*@=28;X5N0;I
MJ2`6E?.87>-FU--JM]Y%1R(O'Y.4M'`<Z@P::9EO82YP^X?0C$DKT\PO*2<^
MTM1L<NUO39S]FFF(SYDJ7')A^1@R6$R-T=DF5'CGCM!*ZHR+VZMD*OEVNU]O
M&9N6[NH)\TR'&\DDGB]@KZV?BXQ,@I`0\0K.F]1(K^JC^?&)S[[*KW([#$;:
MVM(DRQ%3B?,2VKUKGP9@Z^MA@[0`GN5FQK7:KS54XQNJ@YGE577XC>6U[0Q(
MZ4LF+#D64KNXXNUL*N7&,*F>]Z1-[%4:$7Q7GQ'HV9ID,:VC*`K,L$.F]7*>
M/)[AJRXJU?H\B.1/AD%VZ-(/DO/GQV3,GOTOWYE&SX^5]*F[XN31=J#D>F^F
M>C,AM8FB`0.WZU7B)DGXBO)+X65$S(421&H%4MU*B]K-?+LQ5`K8\4R<V`ZS
M0AU7:WPTCUD3,LEB^CYB3,\5EH&C*;&IT@L\TR+&1]7LL(<I]F75LKJZ>73[
MVY^&LRR_](F6]S;6ZS(.,VDNU->%$:41\B?1F=!GB(-S@R8O1(-Q'?9I$@@W
M]"%&!$#U'N(3I1Q-"/>1WF(_8SFJ\U_TE[+O.,9@G&BN?$6VB'GM1/\`R$4A
MIO[GDY\.:'(+"U5N[_VZAMM%5J+Y6OL(T`;M531%1=OVZ<*UE/G9VII\0531
MHQ=4UY(?)0D\OA[O#^MC><C:B_"44*@,YZ?6]KLA`@U_<5W"==,JJ]=->^I0
MDV^/CZ;8V'A]FO#60<^I`O?R1ENZ30+N_1_KR/7M557PT7G[.!RH4D$N,5-P
MI$4PS@(WZQE$YPWI^XO_`"@[\49#%!.V;Q4L1>^NS[DW,VUT=7%",GL(;I!_
MA<'BX#CL:FCKJP=M?:6%FK?885<![:Z&5/J>Z6W_`)G_`(FR^[M!/\83ICXU
M9S\=M5#[>M8J_8+G\_N\;OKBBD+IO+56,J"I-/NF2.4:&9_!=JB\#CY9"K\R
MA-T1QWM937*-\.4N$!8)=J?IQE>Y?%_`\GHXEK"B/D%B.#:Q6QRI(C[4,@GB
M*>/)$URZ;V/7[=%Y<3!>MU'4KC#C6`_4H>^!)-^ICS&];=%,7[K7Z*[A[1&$
M1PG;2M&1KU&[37:]&JJL=I]?_)1[W*+6-4UH.75.Y5(8NBJV/$CL1QY<HFG(
M8VN<O[G$BH_+UAL5I55XW6[^FN1SQ^9NX;TZ@:8;T7^25QT5/UJ<V\%DR3%D
M2#O<4QSD<4QB/7<\A2O5SR/<OBJ\U^B@5->)3SK*7'@Q`I_*2))6A$WVZ)O=
MS7V)Q&A1P]9F,THAH)C6M):7)]@F,7I(C5D6MO(1N[](G%<E_$URG>MO.R:O
M(Z#>MO9AW6$J0.Q&UI3#%+*NT)T+'Y<QKP5,KQ2GSN@-8Q[:5D57C5<N4`LH
M?.->9'CH(O0NYD-/]^KVI)9IRC)X\);TD>JGPK*W'D2SJTBHV5=`3II..^.]
MCEFATVO:_FG@Y.$>,,T2I;+>;0W-R$3K)R(CBO"*P:$@'Z<P.10*O/9KQ&(&
M?DC>VM#VVPF59',&>1(;M?'DMGV<KK5;?N0_YJ-?=8G$%69'DCVPY\R<49YL
M22VQ27NT@SG2(!#=A$5WP6!<%S=$U<O%?KE]]+;#+-?*;,B8NOJ@Y6[H!ENB
M8]">)M;K\%0=%SD3XJE\>(._*'RDC"FME]S35R/L2FW+"*98G:-`D'5-6B:S
MJHG/1>?$)'WE%)44&2R>K\;FA?-LG;NTDQGBR91UT(/+J!4<AY/85G$5"$QF
M0]M3([TC`VL-I;W_`'7M0J><L>I=_*;GD,GLUX9_5.,F?Z0XA&_B"UBM]>1?
M+#8_\,S%]((GC)TZS/\`8.X*[\-P#.'4MDL%&R+5Q[G70E4)951$8D1$YME/
M5F[VB;Q*5<3M9/;UD28-(-ACSWSIQW;9-1#2?;UK$D0O%Q3N`!Z>Z]5Y<3G/
MQ?)7]E%AR=`!J9#ICI6WJQ(+06Y%/*@*[0R>5GE7IN>FFL]2T^2Z0.QUZ%#.
MEK+[Y&Z=@R&P[Y7:J_0^B?"YZ\DUXG.D#NPMKI,&)(<[&,E5CSV"M2/V#VU+
MF6PD<[0I8JF$#^4<WB:A[4$?T^PBU,M9+#QVCL9VBQ(C7&$QIBGUY;-W/@PO
MQ)1(6-:CHI`G6T!I071M5#4%&XZ/'9F1-6`7XCT\$X7HW%67;/=5.Z=A$?I9
ML]^N7:5=)[?:']8GU<.4)1E1CW#>HWM?M(SDYCMJKH]J^*?Z.C9.VURB:%7U
M..A)M*YJ[VI/L2HCNRK6D;IK[Y7<F(NCE:2\RJR?,/YFQ(@]15U9'5=4B5T-
M%5D<*:)JO,A%3<]SG<_I).930*ZLQ`7[(YS7=,MY-8Y@='>XY8<17O5J^"O8
MO%%C*;25N-L9EU\BZ*PDU5+%QJ`]JIH[XR&DN;KRZ8G:>'RGR/#)@\?R$[NK
M8`<-7X[DRM1$Z>0UH]/VES6Z-G@V2Q^U2-^&LBJGPR4&5UK&K:XY,*PAF,5=
MK+"KE,T#<4LA4^')%R^Z]&/U8GTNCVM<G)='(CDU3FBZ+]2\,(^N@O(.2DT9
M'1([GCF(BM26QRCU;)1KE3>GFY^/$<OX:H.K#LBW40GH]=U(MP9=QK:._M]P
M+(KN;CMT*OU\1"1:>+%=!GS+2-VW5CM983]JS93AA(P9B258F[>CD73B+829
M4BIATQ9LH<F7E-U$A!=8?SKO'R+=D:3'Y>09]XA?<1O%:W$D_,3,O3!SQQEI
M[*_GT\KU#FXDW)LNMX=#>])>8'/FR>W3W-$T3B`VM;Z*"!!F1&ER'+17T^:2
M9NV3[2#%Q$@#3J]7_!5MCTM43>QZ<N(Z2?S-J7J&$^,_;@,'J23N>14L99DN
M!"?,8UR:($,:/Y4U$[FKJ2H#F$.8VRI+>R*<V+UHWM+63J6&UC6#+MV&2S<Y
M?JVIPBK-PZ8WEN9*QBS&KD3QV%B94!!.=]:L>GV<(EKAE/8-Y;C4V028)O#S
M=.OLJHX5W+X:S&Z?;PC+AMWB9%\5OJQ7045/'=;TQ;>I`/ZE,87+[>7`["GL
M8%K`-^JFULN/.B%Y(OPY$8A!/Y+[%^D2#!05AFEK'<^IKG^8$$"JX?JUGHJ+
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M+)\4NNJOJZ[I!I:3GX=G&`NGBJ_,Q+_"65_VWB7S%LJ.9.QZT=HKK"CE$KCF
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M.-.771*6N-KW$YC5T6?(1TEWW.DWR?.Q+_"65_VWB7SO7<8L7TMQY4.1C>K`
MM1L31L6\KE5H;*/M71%7:87B(C%Y\)3V01T.7A$YYJ=Y^I&LA"3XEAC\I[1K
M80T3F0>B'C>!&Z;7O^=,L[&0.)`KXQYDV49=HH\6,-QCF(OL8,;%5>)MX12A
MIHFZ!CE<]>4.K$]=A7CU5J39[OBG7GYEVZ[6-^F%>3`[+?,B-MBJY$Z@JM&[
M*J/KR=M<'4VB\T<5>,AS@O,5Q(](QW77RXO2E***<>YJ*@[><XTM/X)4^?%S
M6@"\UY0@>R;`$Y&+DF.;NK.IR:^1TN/S/#<O-IDV^#^(-O6F;(@6,84N*9JI
MYA%;N3715VO9X.3[KDT^CBX[CP`V&7VXB$A`/N["H@C78>^NWL\PZ^*Y=&#3
MXDDN@V>US9)B2I-M=63T/=7]AL=86DA/=1VQ$9%@1]=(\4>@@,Y)SU<OSL2_
MPEE?]MXE\\3VED19,4S)4*=#,^-.@2Q?JI4.2)4(`X]?%/%%5%U153C\+9.X
M(,OAQE,"2QK00\I@!T:^QA#3R`LH^J=Y%3DW7J#^&N@_FP/RUJI&V7>#9:9$
MX;E1XJ@1M($!5:O+U"6%SWIX],+?ND^FQ[&&,<Z+*F,D6KV[O@U$14//>YS>
M8]XF]-KO8]Z<0\7I%;&L<H/'Q2K1FC5APC`=ZI.&U$\J5U,$JM7P0JL^OB)7
MPQM%$@Q@Q(XV-1C6!`-!L1&IR3DWY^J<E3FG$K&5\M!E2R[W&^36AK[ABH3(
M*(>C&HT<C<DP#=>2.(B>'T22&`[^WL)#*W'ZAC]IK:WD(O;QF^U@!HU2&)X"
M"USE\.)4RRDMLLDNBMFY#;-8K&RI:-T'%AC57+'J:T:]*,/]!-R^=SOH,2_P
MEE?]MXE\O<NG:L=7XO*8(<F(Z4TMY8U\.3UHR(IA`&R4Y1N5$U=IX\7$(<B8
M@ZV7!A(\5I42GZR),\4B2[8$:'>$45'=H/\`:-=4Y\N(,R":4VPEV:P8X[!\
M*)&L@B"8DJ;#ZSQ.`"(YK&JI'*CG/V^]RXG5<AXB$A23@Z@2#(PB",\2$^&]
M_3W[-=CO.WP<B+\D>1%DF@6$&0.;6V,9=LF!.!S#)"O@NWP<U?*1BJUR*U53
MASY3!1,DIWC@9'7"5>F.6H]X;"&CO.M7:B3J@5==OF&JJ\;OF3[6P,V/`K(<
MJPFR'^Z")#"^1),[^"((U7C(,LG*_J7-B8X1/7<L2"WX-=!14Y;84$8Q)]>W
MZ:W_`#"G`TDW9%J:9S]-65<,G[8<?WV]W.3:NOB@45.+J[7S5F)C+B5)JB[7
MVCW#/E,X>J::L,P4)=/!T9WU_0E6L5&7E28-[0%]K;:KU,$/)%=TYX=\=R>U
M"\55Y%Y!LX092,]HB.;H8#OX<<R.8OVM^@<0CD8QC5>][ET:UK4U<YRKR1$1
M.).>2=5@=,]3A,=R(B`I.HK)]VK>>DK()`]&+XI$&W]-?H<2_P`)97_;>)?(
M9RQ9&R.()Y#D$]S8X9.SMRG<U%0+#=5NU7::[D^OC:.8=7D%!BZ-TU<*O,(\
M`7AX1SA8K?M3@I#SY#);9$<A7(@Q$257G,4#W=-C?C1Y!7KKXZKPP)GRYD('
M54>D9',$D5I9Q]I1AU8R.-7E<FNC&ZN7EP1[8EC/EG1\\KF@DRI!FF*N^814
M:\A$*=5U(OB[VZ\-:8;AJ\;2MW?>&_W7)]G+]]-/D@9=$1[P1&]GD4,>YRV.
M-F>CYC6B;IU9M8Y.ZC>W>Q6>!'<1YL0PY$26`,J+($[<(\>0-I0F&Y.3AE&Y
M%1?J^4]1'*HY^8SP4K-BZ$2N%^W6I/\`NGB`R._[)'TU/CE:W=-N;"-`!Y=R
M,4Y$:\SDU3X<<>KW?P6\1ZZC$WJ5%;`Q_'8Q%W=U;RNE75C2:^<N^:5"&7FO
M31[E\.*VG:_JOB1T[J0Y$ZDN<55-.F&5/>-)E/<YR^U5^AU3Q3FG&6XDOEBM
MECRFC9SVLK+Y7K-CCW.7R0K@14^S?]!5X5!.\$O+Y+X\\X=>K"QJ$U#WTEKD
M5%&\T?2.-=4^(9.!`CB8".`8P1P#3080!8@PB8GL8,;41/H<2_PEE?\`;>)?
M)D3"SBJRSJ:L,(81]P#JL!6%<AE20SHNC]HH?!53]SBJ,.$.&V"&,,W1Z[E>
MHCO([1#R3ZM1KN7@Y?;Q,,089+H[)ML`\B!#AND3F3VGJZU\49'H<"A>\143
M7D7716C1>'1Y`WF+_7_D</>`BV6-S:J.TNA1NV.E2$WZ>#-=.'03*6M1S*@F
M^)$0X4+6I;C)%Z3Y;"H$K;-'H[>OG'S3VMIQ"-UEBU/1*[EJA"VMK.:U^UQ&
M]7MYC%>FY=KE5OL^6SP>4_X^+.%)IMR\RXS9O,Z*%GUI33A&C:)[D?H?7\M%
MC0R;H^-T"2"LU_5V=Y(<8Z::Z<ZZ)$7_`%_36_Y@SA:Q:)BU%/N1%1UK,&U\
MP[>:.:Z)!<C47P7KK]7$.N35U3@<=EK-3S=,V4W$=PZL*\MJOJJ8CS:?^<;]
M7T>#7R(Y&R9,_$)SD]U0W`%FU;7<ON6<)=/X_P!!EF2*N^/",S#:7FCFMCU:
MME7AQ<O"9:F8S_T_T6)?X2RO^V\2^5LR0*4$W>B`(O<L<D]NJNF-CQEBMZ;8
M@-NK^HY$>Y$7WTT6IA*4<=R0B-4[DD&$*171IQMRB$+KN%U7:(UB*[3DFO$B
M&)UC&DZ5D@$:4GQTC3@4[V"<KHXHKY!RS3B34@T0[!M]U7*A0O'TE16O8Q"-
M,G1.QIXZM,WRF8^.5JH[[R+K\S%;[?TXKY[<<M^>B.JLD*""U2<].G$NDAR'
M*ONL$[Y?S!F.=NZ.12JAJ_P*%HZ-FGV;:_YN`VR29:4^28UE-Q?2F3:<1Z^;
M2KDO8QJ^#(>DZ0"1Z0#J.01=.HY=4TY?E:BNR7K_`)@$_+MDJV]2QI:R(_,4
M`2;&CU",]>0D0+W](KVJ'5J:JNO&--FDSCIWMA>UR8RP5',RJ5Z=+CP:JSKB
M1]L+T^\DE>T:/%UD</1&OY[<HK\>]6O\:QN5&B2K_L'OCP)9HT,DBMM)L-I*
M\,Z!,E]N_P`S=Q$\$U1/F@BQAN-(DF''CA8FKRF,]!B&Q/:Y[W(B<08<K1&T
M%*>UN2,7S2K(@W39R"ZBZN*>4_IA9JOW6I[.$EVJ-2]OY,C(;U6\T;8VCNNL
M5CN>H*\"M`/ZAL1/H[*:Q/CTIJR_C+KIM-46462YVOL_9D)^_P`".-=1F&PH
MU^MA&H]J_P"M%^=;VY%VLK:V9,U\>8`/(Q/^D]$3BBBF_G*P!S9J^UUA:.?:
M3U<OBYW=S'IK]GT6)?X2RO\`MO$OE%#2RGI$CJC@14F2.V"YI5.UP@=3IC5I
MUW\D][GX\/6;83IG4Z74[J6>1O[?J(#?U2.W=%"NV:^[N73QX1R2Y*.0D8K7
MH<B/:6$)0PR-=NW(^*%=HU^XWDG#BE(\I'KJ\A'*][U^MSG*KG+\JO(YK&-3
M5SWN1K6I]:N7DB<3JVN/(LI!@&CZ442;<'C'>-4&]?20RECD$]4<CG;=JIKJ
MG&,WY$VGMJ.MF2QJFBAG%BC[Z.YOW7QYF]CD]BM^3()[]=\V\MI;]=-=TF><
MSM=$:FNK_J^9`!6T=I92;2"2R@1:V$>PE28`9<B"24V+#8>0@62HKVZJU/#7
MP5%6@=&KXJ3/RXH<AIP`DP3M)%KK8EM'M76H7R!$60`N0E:GN;%VZHNBZXD0
ME%BCK/"DQ=E+>>F2_5^AB3P.JHTHZ62!-'=V[4*B#;O3ZN*VPK*&OO#UF0WT
MBE,:DL9ZUMQG*(2975SX<L3A%ENB%+&&BJ9KG%5B\UX>>)3EJH%].]/])QN+
M;1Z2SMXC(3SA'$?)F)-M?C@(5NYY-2,71-6\2O5J&VJGPA1I$H-G`DU\D,>8
M0@HTET66,,CMBE&K>IMV;N6NJI\P5U+#U*C#!LMC;D16%M"J\=0!4545=A6O
M/JG@H4U\>,;PIBZQ$>S+<D35?_;:F2GHL(FGLLKP?437DJ0G)\K&_I.:W]]=
M.,0JTC1$N+S,;ZAMHK8EL,$*LJP6A8TJ)-,Q(1Y9UA,W(A"::KY4XL\N?^$^
MI'F4T)D%*S)P-JUM+E]<2192I)4C600`3?\`L;]=47[.+S,Z^)B'3QVYMH#K
M&66Y;4Y5$@O""$7%XK&I/[BQEO<%&F?[Z)M1^O+'\<M["LJ,@N:ADZ57R+FL
M:ZHL'-C[*2:PDD<EEE*<?X(]FY_S;V(Y-R2J2W!I]I:^0UGCHFJ/5.,7E+KN
M-052OU\>HD(+">*N7WVK[?G'K6:JZ^M*.AT315<VTM8H"MT54UU#N\.>G#MJ
M(C=R[43DB-UY(B)R1$3YEK`DND)*IYF.09(VC%N(7*"'%7.C(X[7&&QT=>JO
M+9]O!YHZ;(C`9D/X7B]*/5.)96WJIZ?IPA^KH]HTF1W>8_1\O/C%V!BW?:9>
M1L:GM7UKAUJSW$F!]-D%>1#BF-+`*CM!N&W1-7(BHJE)#.R0P,DT,KA^#),9
M4:<*^'G&J\_EQ+_"65_VWB7S>I.F18;/TY4@4=O_`%BO8G">D5%Y<:^Z2#52
M6PW>U-+.:V'5\_\`ON$7TZHI&+]ZULUFRV?^AJ`GB/\`_P":G"+<978E]J@I
M(4*FC.^MCGR4N+#;_$.Q>&D=1Q[$[.;9%X63?&1WZ3'W!IO27ZMFW3V<-$$;
M!"8FU@QM1C&-^IK&HC6IQ9U2>%%F&4P6IX[0S[0F1QA_Q11;UC&_4U$^=,K1
MSX-:F2?E?^68Z*38&[2#(?0`J(V2UZS51P@*3(:V671[D$XD=4U0FQO&:V,:
MRIE#94T^#7V5]'<6IL[)$KA-F202XANIZA(CN,SNA;-ZHXZ(W?QDT_L\>.N$
MU]#DY#U]1&#47E[+Q6%CU[5#$"(*,>I__8'9R@1D8D18_>.&UC'Z<0/4YT:(
MX?YF83<$&57-1*VOBY`V;)5&)J@`.E,1VG/S<4,=S*?%I'K?YKQD6N+?E%5%
MR?"L8IZ3(I2S[&YGC&>8$H'.$_08VN>@]6^;/!RKBLMH_P#^OB`5:R86?%C2
M)F74!8=>DEX11EED,%96T+GIMW*J[T>U/EIY['!)-RI%R*QDL5=-)";(D=5?
M[G9PQM:Y/=W[E]O%OFTENA\QG=W`:YNTD;&H;>TQZ,OF=L<2&SN"-]AC/^6R
M,>QAQ1T1`):R)9F1HL!Y@AE!23).HP,1PC,7WN6NB\^,:!&)/>#&;^RRBK<Z
M4)_4G7(IC)'</:!$-$4<]^Q&[5\.:\$JI>29+^&H,FLM1QK2X@-KJ=U+9I;@
M*`JUP.U!W":$WN75G+5/'CU6HR.S?7%RJ=ET5^-759)J`Y!)8T,HT/\`8I\7
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MX6CF]G-E1=K_`'V]N=XM'Z<MR;>?S!M>][FA:K!-<Y503%>\JL&B\F-4I'.T
M3[SE7BNAW9G1ZLQ")*(R?#JGJC(Y2"$VRL`2H,!9!VM'U2C>QF[54XN*WTZ_
MKX2PL=GUU/\`CO&I0;6'8625Q;7\<1,>_#$YD4SU[>*R+US/<Y@W.(-S7=*L
MMK.3.A61/5QO[4<T%1&M<AA3!KCBQO58-J@H-<T'6?TSR+%&Z,:,CFSH98,N
MM='DE'V$Y=9<5J/78&0[I`WE8WQ78W7ZN'B:1Z"*K'$&CW(,CA[NFY[-=KE'
MO737PU7YF%.=N<@H,J%H1K?=ASI47;HFJ*S0?+ZT\>,:![85?Z<[GXN@%+%<
MJI]Q54?N_=\/E_-&K/5%N+A^89:L6(&"D^0,MJLF1C,I@]KEC[*B2U&F\NQK
M_'1>,*FU4]U7"BQ'-GPIU5^TA(L*('20(LV,4BE(-R(W8O3\?;Q.NH59.M11
MEF-CP&`'U[<L"1TAO@M5Y!$BR9#$>,G/R>9$U33BW6IDR:W(KO(FWUXV93&@
MM/+E6M;,,"M;-E17QX=?&"Y-ZJY3[5:O->,?&XMK/ABMQ+E+\;=,J;67`0!M
MI8B5DT-D"-W.WJCC&ZJIIIJF[BKDWQ\D#"KJ622OBR+J<F\I;Z;V`LB2/-<V
MVM(U0K-_6<1%U3?JJ<OED$7F@XT@BHGBJ,"]RHGV\N,3:[35:@#^7AH57%3Q
M1.:(_P"=@!/N-S.,-SOJ>>ML1"3Z_.1=/ES5;"5:-!$@8E'JPULV=`-WEHEJ
M]6LDPRA6.,\J.+K%W,:QC?,[1>*&&5(5G4.Q-DB;>LD2/VFV%*KX[WC7TM`N
M*YCR[1*1BE:BD7;IMXRB!7]K9[;V_.&%,A6:%JH$#&:R?%E/G]]T"55A.&Z.
M)@@L1IGJNYRZMXQJ\AMDPF7.302QPQA2!24QP\AS(_J+'*Y>I)`SJO\`=:C7
MM335%XHR622H0B87#-82ZN5.MK%8[[['PVMJ>*:H@+%O8U64JL8SN7\WZ+RY
MK.H)<JP`D\<6)*L.[NF?%*-KD+.M;6K.>'J[1)!);T:Y5TWZ;.`V/I<)X>TH
MT-5LJ[-M@2=:5\LD@@I/J#V"#$F"9J%0/?L56]3=H[C)I5C/2P&\]&2":/#L
M*^L1A:AI)3*R)83)SV";*54)M(OQ$5KM'M=Q59(.N2[G8RDGJ41B/[>[II?2
M=90!BZK`)/18[#1U?JQQ1(U_E7E%EXS#KHE9,"TH$KH0(#-ONJ,H`C%TC@>B
ML>QR;AO:K5YI\FS<F_:KMFJ;MJ*B*[;X[45?DM2R`N(2U]%98[9)6[EQ^0:=
M5MT8].BH2S'.733>CN?+@NB6#Q%O!Y'VI;2<6&&W';^N=S'BO.H8^^R\[FM1
M&N\%Y<5UA"2SBFJA$C0F!M[%D<40UF:V-#6/W'2)$++-YAJBM<-K&+Y6-1#I
M%$@DE2C33Z*Y>I*D:=8J[E717[4\.7R*B*BJW3<FO-NOAJGLUX_,)?8DO&V+
M_&2G<Y6_QD:]%_<7Y,^K=J-9'RZ_4"-1$3M3V4B1$Y(UC6_LI6\D31/9\T4K
MM8<WI;]8L\/<1#(0;Q.:46YBKHC]45%1S7:*BHJ<2(DB#12Z@P*<`Z*16HM3
M#90>H^DNB"&4<D9(RW$M5<I7*9TDBEWJ[7B58K)"Z=8WDZ_MY'1V/N)MC&DP
MSLL$$X;'QFQI\IHVL1G2[HJM5%=JA[&7TD,;8G3`SI@"((VA!'"S5RM"`+&L
M;JJKHG-5^;4`3;K!MKX#M%U5.I9'EIO3[JZ2/WN+&-S_`&++\S@IKIJC8N2V
M(FHJMY.7:GC\GV^S5=$U]FJ^Q.,X2[>&6"AIHMP,@\:N,;LILKHSD>!E=.?.
MFS:AK8+1"L4:H$?N9N79Q.R2FZZO%%CG"QT0@S=5TB(T@!@GBC=1[FE5C55$
M8J\]?;P>#:U-E3R(`IBS&'[$HPNC4<?(HHFDA2I`B&M:T^H6M7]8QS%T5.,4
M/$`V.V^99&.":Q''"P%(2RBL7IEV,)U$3?S7ERXJ)BPI+]<*R/(K0<BBO*H9
MY]6&,L,-=,L(@HYXA#F^(X/7T;SUX;DMG:T\QC28S-+"KZ0T+:&UL(L&77]Q
M)M;#KQ]MF-6O1@C(X>N[1=O#F_HN5O[RZ?+DLM?Y&AME;_WCX)A"_P#ND3C'
MH.FWM*2KCJG\(4(+'>Q/O)\ZDLM.51F.+3R+X;0>J#BR%5=4T;T9*Z^/"I]2
MJG[WR.E((:27B0#SHU$*\+7;VC<_WG,:[P^KBDIY#9+I-Z=0`>$;7@BZN:`!
M9SU(UP12YQ&1QJU'ZF(U%T3GPZO?>U+R&(2$Z,Z6'5[^JL,P5;N\&G^&_P!C
M7+HOCQ&BU<J'+9'L*V@;#KC1_P!A0D]E(WX>YK61:Z0G2?IR&J;?'CT)FB$[
M6L/UG3(&G4M$E$$)K.YVF:$$1SB.&XGBW:CN:H>U6WA2`B:;8,$D3BR2`BK-
M<(#5<FJK%3J(ON[/-KISXBRFHYK94:/*:UWO-;("PS6NTU3<U'\_E/D$=NF(
M7DI'Y$!J>3'KDZM&W(Q-\!UE@[1D]$Y#?MD?[;=QD@O069"632XP.!`DACR8
MNK9U\V7,>&41C7`@$+'(5&>=5Z>G/;IC[!RU]"@XRM>8,Z.J6!)8%I1123%%
M9."Z<0,8SNHT:M'JYO/<B\9&:K?-@AD6DVR63+],6E="!AD`$-XO,LULA^0P
MAL+NT^`U_@G/C')SPG=*F9%1Y`2*3HB+75)+<5@"*5J;&]2NJ58TR>95*UW%
M(&0UTOM,2)!/7A;&A'8/UK%94VB[ITQXCGM*RO.%KU48TTYJB+P1F.X_(I]9
MH&C@`'7USQ"<>/W,T4:&0XD$@]=P_AE)M73;JU_$:5(/*6>UL,!(9TK$@DUQ
M^0V5(.V.S>A/65&Y=A-J*WRIL5VM[,LQ6;%L&4*L+;.KUEF+&K.C.U2N<HF-
M'*U3P3^#Y-O&?3_NRLU[<'U*&MQ7&(3_`+J(KN_8=.2KX(GBBI\EA/V;0Y-3
MT]R)43R;A1_13HFB:;^M4J]R>/GU]OTMW'555(66RAL31J(B%K:V1R5.;O,5
M?'C.8?LC9S=%1$7RIZGT;1=&?<5SI>J_I+S]OR.:NNCFN:NUSF.T<FB[7L5K
MV.T7DJ*BI[.+"2_U"QD6=8M+)/;VMC:E]'59"NK0NFR"]",]THBNVZ.>KN:K
MP:GDC<L"0!D4@A&+'=T1J-6-&<+QG"K.DFCFN1R:>/$8[,C!Z789;!N)MY-G
M6%O*L"XFBQ#C;->=YV"K@,9'(5R]`,?5'\EXVRIT4A,=BR['X1R#%&B2H3HT
MDK2"T#(:V([16M5RCU3DBZ<5.D/KQ(-),IX(I#C$"^GN`#9+CR`'_7MD@:B?
M$373AM3$FVG8DET_=1[2VMKD25%1+[\59`%/G%'#_:Q"5":.<C6;>:::*Y?%
M55?W_ECTHU^)DM_0T*)KSZ4FP'+EJGMT;$@OU7V)PB)R1.2)]2)\[):\/Z\M
M3*)&^M),5O=1U;XZ/0P4T^WBLMF*BMLZZ%8<N7FEQAG(W3V*PCU14]BI\LFQ
MES+84QT6#&@$B64N,&L6#(66A@PPE9"F$-*1CW=R,S=PVZ(G`A+*EZ#A64'5
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MMK=Q][I"D:ZHJ0Y`J6H_@,W.?+QX@RBY]+<U=5W-XV.AV_=;&&[#L=9;8A()
MK$4MS$+TVA)%C$5$5W4WC4>WJ>7@DFG+!NY_6B`#7!L`C>\LH;I2,.Y.HZ*[
MT\1#(CVZJT:\N(XXP;&<V6&O-&-$B;PE2VB2)U:U'O*/S2HT5ZZ^X/EO5NJ:
MB='9+5DD$0D:26.H8BFL:I;>NC$>]R%::3%3PV^5VC7:*YNH"!@=5!Q)4VR(
MP!#CCLBX[3W3Q?SF.]B:W+54C4-M&W38YR\I]:R2X\V`I6+&C](YSG#80JI\
M4(!F4[#^I6`@M0K1(1SM6*YK7.3H28;88G_BG8CUT-'_``Q>1:HB2OB/%K('
M/8[R^5JL=S5%3BFGN8K29$:URI=R*CE#DMM-N8.J+X(.MF!8G\%J:\_DQ?,8
MXM7T5E(J)[VIYNQN1L+&*5?]E'FP=B?4Z1]O+Z3.*_5-16]=,V]3S?M$-P->
ME[$7M?>]O^KC\R@<]77E%-8B^T4C$J8:NU1--.O'>FGCR^9.JZV8"`><T<<D
MB0$IQ]DXK>^C[0F`1.]BHX*N1=6L>NG/14F8KZ`LAE]D&31YY*`M*Q]7BMB5
M^]8P;N_AA+)MHQ5"'XBNCM57/3>B<;\:I94`,2/5RRPS383R3ICID/N(D2-(
MFFI$+%B"4YW%50R936)X#3=6K>(B7"QF^HHWHZ=QN=_PSG1]VS3=TUV;O#E\
MW':U-KX^+U-ADLY/T9UG_5%0-_LW,"TY6_NZ_/5%1%14T5%YHJ+XHJ>U%XO<
M5(J[\6O9D:,BLV:TML]]Q3$1/T.G)*)/^Y^01:]LK<^TJXTPT*O+:S(57)E-
M'8SXM>$4@DD\..JN1$$;^([PXE%O.K$A1(L7M8Y*GLWV3Y$FX9W97F\X3#B1
M8[B`:B;7DY[=VSC/BX[&GG*:+$/3NL$R2&(<ULB6R0V/&RF%/25-=OUUCZ1%
M&U$T;\/C%)<5+",^/87CYGH=;.R1H]V.6HX("-#7/?VLJ:HQ]8D=$:KONKYN
M/2+F*"(L"HKKNTZ(TZ+'7<"(R'3H57O7JQ+(,YSG>*C"Q%\55;M`):L5<>R9
M-MA'NR3"G7/\@=!;5*PHE;8+3*)0\G+VRLVILTXS8EO^)0Y`S\2/6<H\B;2"
MKQD(2F?6249^&MHX'2Z:#U*V3N73?SX:IFHPRM:IF)X-*K4ZC4YKR:_7Y9%3
M/WM8786/)`[IRH$V.]#0["&7Q%+AR&->QWUIPE'DE='_`!5B?JKMZ..,-G7Y
M.Z:V7?01*=4-7WBR"]8+M[(LI%8B)M"O"***5ST8H^M)L+&9(4?9N@()TF9+
M.=PF17N:UJNVLW*J:.55XK`38D4[("+'K(\M>L-JI$<#08#N<PYVPV.1'*CG
MHW=S\>.G7B"KJ\P/ABFG,L0L<<MD83V=R_I($4TB-&OE1JZ::-;HIU)O&PD&
M#!B.L9B18;H=4VGCQNW[Y029J17>5Y&J=-WCKHO$D*0VO$<,F%):V7+744BM
M@4\D*JDC<QSJZM`/EHY-FOO*JK,&\,GI3BOD'`RSLQQVR22A3G2XL<<QH8$O
MOA(9"@09$+JY%W.<JMA4SS1YU^I\2JV*61*(*;FUM$==6Y#RC'/)-'8#NW;E
MT8V.]>>Y>(L"(-`Q848$2,)ONBCQA-"$:?8P;$3Y,EQ.1L3UFK.".1Z(K06`
M])-9*7DO*+8!&3_H\2H$T+X\R%(-$E1R)H0$F.1P3A(GL>,C%1?M^D_,&&J_
MK(-!(8W3E\(]H,B[O_%;QEXO9*Q_%;)=%^\I;:NU<W]/;!3G]6GT:N>YK&-1
M7/>Y=&L8U-SWN7V-8U-5XN\S*Q6DRZT?(@[_`'F8]6)Z=1#\$5$?'$XW_B_0
M464-3;7WS!XA?O\`*C`R"%4^-6!7.>B(UDYSXRK[$D?,A4920FR9($EF=-M(
M5<@XRE0+6Q12']Q8SBKJK`C;S1JZN1=$61K72(B)5^N5ZN-'D)8U+GO&,[>@
MYR`,]6M7IKKY2-YZZHD&X6%"1+B6"-(?66D&Q-&:R"^:T5F\#!N2UC!<YJ0_
M,5';D3V\"L`MVB.I%$WJ,>_IM>J#<5&:H$A1Z/Z:^=B.1':.U:BL*QA&+IJP
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MOZC]IB;M2-1VNO!+)S=:K`XSPA=]P^6WL/8_:O/STV-R%1WA_P"YI]7S!9G7
M@VT^:;RRMC?AQLBC-;W[5T]WU$*MD)KS>13>QOTE_!_XO%RF_6:?S.PAI^K_
M`)3^<^/W?]?#_JL<#B#35%YK57UD5>FJ<D5$M/-K]FGM^CKL.K7JRTS*2^N<
M1GOP,?`UI<BLET7<S;"7H,7P4AN(T**-!1H@`QHXF^`P@&T0F)]C6-1/H+*C
MG:]M9121GO;R(%SDU%($J*BM-'*B/8NJ:.;Q*JKE?_DF-R$J+U%Y=R4;-T*X
M'JJZQ[N'H=%U7XF]OW?E[J428UI0!BSX@"C9%M(T>0V2`,W<%\A&C(GB$@7;
M7*BKPCXUE;*]@PQH[BEAN[:M!());5A1(+6K#4CTU5^XRHQJ;^7$SOIUE:/L
M35S[(DU\)BV`*IA6PX$H4"#"CK!:X[W/8UC>JKU1ZN;Y>#Q83Y!&2)A)I'R7
MC<3J$8(2-^$(+%08@M;N5%([35[G+S^>_.:6.20SI##F-1&9O+:5D=%0-U#"
MGZR[I&*O)/-*C;A<W-#M!,B'%)BR@CD1I`7(\)P&:CQ%$].3F/8NJ?,1T4'>
MVDZ0"LI*YJZ.L;B<_HP(FOW!*1=Q7^`@->1>35X@4W6[N8WK3+:PTT=97,\K
MY=I.7[R--+*[IM7]6)&L\&I\RXQ2?M&Z8'K5DQ4U6NMXZ.?7S4T17;!E\I$3
MF\+GM]O%E17$5\.SJ9AX,V,3Q&<#U8[1?!XW::M<GE>U45.2_1QQJNG?8]<P
M_=5=><25IR]W^:^/&'$\.[Q?,X[O.NKNTE8T<:*SW51O<.T]O/Z(LB01@8\<
M1#G,1=!A`%BD,5Z^Q@QM55^SB?\`F!8@(%]T)D'&(LACF%KL4CO5\8BL?Y@R
M;TZK**FB<E8GL^BCYY01W2;&KC=GD%4!GQ<AQKJ=4PA(WF^VJ7:GB:ZZ^8?@
M_B)95\@<N#.`R3$DB75A@D3RN3ZE3P<B\VN147FGTJ-;Y,*R&:J17?R6+9%.
M*KEAO77X-'?R'_!^[&F.V>X9NSY"'.1@0A&\IC%<T8Q"&U7/(1[E1K&,:FJJ
MOAPS\Q+8!!14`6-@L"0-1O%6RDVR\H.$C4(.;?"T;&1='"@_4IWHGS7_`)BX
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MF\/C4N145O($/K$!5V\">88MR-ZKQ1)!7M'N7354TUXF9%`CE-A%E)65D5=%
M&0Q,7GG=K(R2`!F]SJB4]=T\#$^$OQVI[Z*&3&,*1&D"8>/(`]I0G"5J/&41
M&*K2#(U=45/'Z295V4<<N!/CEBRXQ4U88!FJQ[%]O-%\?%.'8;>')(.,)9.-
M6Y_>R"D`K6N&9_@2\I4(UDI/$HU8?[Q-JN<J-:U%<YSET1J)S555>2(B<`LI
MPW#_`"]AG0T<1$<UV<R0+\-ZLY?_`!&.9-R:_P#N+VI_NR?'^?,_,/"(+G4$
MEY).1T\4::41WKN?8P@C:FE0=RZD:B?LSN?ZI?A_0X#)54;_`/(X(-7-<Y/V
MMRQ--&\]5Z_^KC`9?_"YY`W:+HY62J/((.UOL7XDEJKK[$^A#AV+;7Y//C)*
ME37,ZD/%*9[^FZZL53R]X716P8_O&+YE^&U5XC4U6-S8\?>\ABN4DJ;+.Y2R
MY\TR^8\R8=RO(]?%5^KA:W)Z.LO(:H[:*PBC.X*N31213*G7B&T^^)S'I]?%
M9E'Y?V(XKZZQ!-)BV5A]9H)H&E;UX393A&F`$Z/N1.N.9J[VIPF[!L/1VB:H
MF-TSD1?:B+V*:Z<?W'Q#_+5-_0N),L'Y;XY:F`/<.NK\;QILR6[5$00%GM@P
MT=S_`)0K$T]O%HPGY258,@J+JJH9&,EQ[#^]+/O&H2J6-."0U22-,$NY'J=N
MW:N[3B-ZK^3]7'GOAS;6=6"HL)EGJZ:`8("V<@PI':&8\AVHP87D*OM1.+!L
M+!,4?&@&#'6=^&:-(\F0\#9!1QOV3J.[9A6;U5$35W+7GQ_<?$/\M4W]"X_N
M/B'^6J;^A</DTN.T51(*/HD/5U$"`8@MR.Z3RQ(XGN'N3715TUX5KD145-%1
M>:*B^**GM1>"V>(PBVV+%(21:8;&V=[4O*[>>QP]JHQKQ*[5YJUSD:]=7`5K
M]6/98U$P4V(]SQ]0>J."<2[319(7HTT29'?Y2"(UI&.Y*B?2'/;V0J-U61EC
M5WSE:A:BV"CFPY,='?SAY'$Z3@)KW(R.%HN_3B%9?F!7I18\@A/_``H-\ADK
M)9"-\TJ\ZB!E5U`Y_F%7.^.9%TE:-11/8,;&C&-K6#&QJ-8QC4VM8QK=$:UJ
M)R3Z!XR,:09&N80;VHYCV.3:YCVNU1S7(O-.)F9_EG!>:M7=(M\2BM>617KS
M<6;2#U<21!7Q?&3SA\1ZC\HU14T5.2HO)45/8OT&&RN?[/E6/F7:NU=H[:(Y
MR:^S5J<0I?\`P>58?(\-4T-D5="\VG-$1)GCP[]U?_K\\N*88P,O)$1GJ5F<
M?7I</`5-4F7&A!]W8N9SCP&+U"KS)L'S5\:,0\Z=,,LVZNIRM)9W=F1$0T^<
M5$1-RZ:#&W081HC&(C4^:M>>790XY"C=(6JG&K94@3%U=%6=%V38P3?><`@B
M_4].+:TQZ5DF96K*WLJ''[^^A]C&^,IFC]0DABRY"=5VKSS9$N3TV[&O1.7%
MF'*ORT)E=K;6P;3((UY(PR4.YGO8G[7`B&M9]7%A5&U!1PD*-S&)JFKE=PL*
MTKF2+CU"T)10&W<Y8V,U%M)8X-%(L1'A.MZFK$W>Z.]A@*]$:T;FM1>`G&'9
M6P[&TE>MI.&BV%#-JF`@XZ2$Q_75\*Y4LIS'"9%8I-PEW>5/FFR#&Y[\6RDK
M6]Q/C`235W73;M$+):57A!:,:G)IF.#,&G)AD3EPV'GU6N-O5Z"%D('DFX7/
M<Y4:QS+OIL=3$*O\C8LCJB\F/+[RM(-S7C>U'L>Q4<Q[')JUS')JCFN3P7Z!
M7.5&M:BJYRKHB(GBJJO)$3AT+!*QV5R4>H2VS#=IB%:]%VN6=D2L*&6\+O?C
MP&S)+5]YC/'@&09;/3*<D`[JPG/!VU#C[U3FF.TSB'9'.FNG>'<:8Y/Y1K5V
M?22L@Q9T;&LO)N,;X:MI;LW-56P"%JNAS"N\9(FN5R\WL>J[D?39732ZF8FY
M0J9FL6:)KMO<5\QFZ--CZ_>&Y=%Y+HO+Y\.5R_9I4>1YD56_!*PGF1NCE3R^
MSBQ.G\A'H[1--4T6NM*RR:YGUN:L;5$7DJ\EY<,?^FQC_P#KM1W_`#_-//L9
M<:!!BC4LF9,..-%CC3Q>8YG,&-O[J\(R@[W%L1?KU\JE1ECW]V']#%*Z4U"5
ML4J?_P!C*'N5.8!+R+P*II(;(4(2O?M17D-(.5=QY<R25SY$R;)?YB&*YQ'N
MYJO^@O$5C"B(U6$&1J/&]CDT<Q['(K7-<GL7A\K$;"SPB2][BOCT;PEQXY'+
MN<I\7L12J474=[[XHXIW:_K.%ZU1C^91FHFDBAGOQNW?]?\`4E\255*JI[?5
MF<_NI[-+S'\RQ]R(JO6?BUK-B#TUUZMOCP;NC9II_P`3HOLX07XRQD1UU7MI
M5S`A2]$UU7M)9P241-%U\OLX4_XKQKHH[8IO7:OI([]%2=UM1W/CINS3%W&5
M-S8X;VMD2G-Y^9D6/()(>GE7P;[.-E-2Y??$]GIN)W@HKO'DEM;1*RDU54]L
ME.-(=#28C'=_OF367K=F+7_\!C9%KB*B?_EV_P"OAILTM[+-RHJ.["RZ4#%V
M.31=$QBN0,":/5.7?K.>GZ7`H\<0HX`L:((`C:((AL3:P8AL1&#8QJ:(B<D^
MF+3Y-3P;JN-KK'FA0FQRIIU8Y4VGB2&IX$$YA&^Q>#6/Y9W+4:NY_P"',@*O
ME\5Z=?<C8NJ>QC)#/XQEX[7+,<M*5^[8,TJ.JPI#N?\`-+$*E@2_=7]61WSK
M&1H]Y)?Y<2I+4<W>1QOP\\S/*WWGJ1J>'MXKC,5'-+`AD1S5U14=&&O)?;\I
M9]K.AUL$',TR?)##BB^KJ2)#QB9KI[5XZ>"8](M1/:BMR6^2308FQ%73?',>
M.MS>\N;>SBNCD_XAOCQ&N,SL7YA<QB-D1!2`)$QFFD-]TM)CB$.`<AGLDRGR
MI?+D1OA\]5541$3557DB(GBJK[$3AK7VE<QSXQ9C&NFQFN=#!S/+:BDU6,%/
M>?[K?;Q&8/)*(KYM<>WA##;0#%FU47=W-E#$,[B2H`-B[RL1S&Z>/$+M;,<M
M+*KD7,!T,,J6.76Q=>O)`2.`C";=.3$7>[V(O$-T8-X9MA7'M(KVXQDC1+&C
M[MXY$@M4.-!GOV?#BR'BDD^ZQ=4X@]&CR56SZV39#<:G-!Z';ZZ0)S+!T4L&
MRDJGPQ%:W7VJG$)S<2R$+9E?(FO=*+C@$KI`M_2JK`?X@?*2=*5OD4`SQTW)
MO*WGQ$7\*/B]Q6R))FS;NN:^!8CW=O5RNQ]08]).B?'`XS&:\TX`KZ.ABH2L
M,61U,DFG-%N4W=O!8`.-(&57/Y;Y/7&1NO(#N(_43&XVZK-W2,=9SNC=>;H=
MNYS*_N:M.6_<@BK[-.(_7N,?&GIAA2V1\>L'$=<.W="=$DFR78*N%RW1G@(1
M^GZ]OLC]QDS?+6&BRTATD2.T]B3=TK6.DD\]T7H:IH!RE8[3GQ'4^77INE6F
M@R!LBXU'#,DEW[;@G3H%E@L(^[R-"8<;R^83N?$?KY!DLGHUAZPBNLVQEF=?
M?K/D>G1H2-LQ(_R%%TMFB:)PWJRL@DJE2^F=W&4Y(X9H9-^XIHS;1D,EGY_Y
MYT^[1--"<DX;O@=QMJ742]Y+G3>K5$W;XLCNY)NYW[UU>3<1?KX`]V+X^0L:
MM]'`8U1`/(%4ZN5:QD@P'F2`JO7X6NSGX<!4%!2`6.+H`4-5!&H`^;X0=@$Z
M8O.OE3ESXV1P!`Q5W*T(V":KOKVL1$U_T23ZUV'I?37O/5.W[#H^WN>Z_9^G
M_&Y<$(N38#CTM^[63C&=X_4[=?T:_OI%.U47_P`MP0F,_P#^A\":WGTH=[=8
MX]?LZEE7W@T7_5%X=V?YJ?DI;LY[.T_,BHCD5/-IN98I#8QZZ>"/<G/QX1&7
M7Y<R45-=X/S6_+5K6KJJ;5[G*H[M?W$TX:UUM^7@6KXE)^:_Y8JQO+[R!RXI
M/WFKQ15MB6!N'^7X(<P\6PBR:W3T3I%**SBG-#+$V\^LPCF;>:+IQC\7T#.Y
MT\=+#0[08+DT<'5#':CVLL9]9`IR[MOD<,ZL?]U5XBCI/ROR%&S`RRBEY595
M..Q&=JCO+)9"+D5G#)(<W03#1AN?K[$Y\05M2DQ>+.C2Y!PXW"Q@LVL<#J(*
M!-NLDR.QWRY^U.DL>F<QB.U>0:\DH?6*FNDY581Y!A2/S`SVJN<CA31;^RCU
ML27+LA"),T;SK!C$)%\%TT6`IJ.AB-+&EOLM<DG230I;=_8QX@F8T(,\!_*I
M2N*!1<T:PGCQ`62W&XVL>7ZHP#[2;TY?G[%(!2#K^K'3R]52,8Y>>U/;Q`67
M<X^W9'EMM!P\=L-TB6_?V)8$B1DA&PH\;5.H,@9#C*G)X^(2RLH81109D><D
M2BB11S)AM_:SPI(D3WPW0D5-![BL(J>;B%W.77LET:OD0Y2)%QJ,&RD'WHRT
MDH&A[@$Z+O\`AMCE#'\J;Q/Y\0%-D.23'0JZ37$<>P"'U#NM=9T]E?$A"=8@
M1?AE$T6SV)Q"4DW(#^G5\FO:29E.1%8:-)1_6+9!6T2)8S&M>NR3(80XON/;
MHG%6WJQ'%A4UA&KN^O)4T[Z4J*MDY[Y]@<MA'1NO4*52*Q/O)Q0C@+@RG;2V
M"8RHBT9I7X>^)ZKZ*7>^0^GTW]QT54/COXI_1?PMT>PD^@>E^D]+TO<O>>C]
MIY>PW?K.C\/7QX'V70[;3X7;=/H;?^SZ7P]/W/\`3/_:``@!`0,!/R'SD;I!
MI@`A58@8=F`JWN[=+F!B9^^Y.0Q&T],1@`80@`6$XQ,KO^6*B(Q%MDES;1!Q
M^B9JL@B5XLGE!0DT!>&;:94P&Y#3R<+Z=??"O]?G5#"I3#JL"*@>]!S9\&:.
MIJ)G$:PH.7F>.C5N%"`$.+3LUV42B8L^6"'/MI*ZL6;>50T7Q:ZR#-G7+9EB
M6K%<HC0BC\L.@*B)R2CF=*D;E=>&"L+BO]>&"@";QM5,+EA06X`<'!]N#XB^
M(H"N-<&FI;^D!?BX5W2-U[,,$Z[@!<GE5T,:GR"691S3JX\)')HS.E#YLUC(
M*I''BG]%Q0,<O/!8#+<"Z0&9X>:4W_7&YR2P-^FN7+#CW"!I3M=9P*ZW=H@=
MMBYBK*;(#P0:>&[<`'9<$"!`V`'H6:8WOMTB/]1)1M"W3/2Z`>5UN$6IT%OZ
M=I%HDV"KYUTM_,?3'\9#_JQMU5P8.>ZKXRN6Z1`P!12'/AW`0D#SG.S=K8-,
MK+LB@FHL/OYS#)8PAUVS:Z&=MQB_K!#%?]'T%,@57#PDU8)N)VJ@@78`[H=9
M0S02$,,#S45NU6+@,;G\?X-^2DO"&LJS`/Y;.V#ND!)X"1*N=PAC`;\U9^NQ
MH>5Y"VVIM'OI1E(<(Q`2R@Q/B@V6]WLU>M]A?K0&9ZC>,7QX3&#G]D(F6E9"
MJFW^HXVZ#ERSX9J&UE40%HA7-\+P9(Y)X%+?9A549-XBAIJ@IJF\#>8B!;%%
M-?R_M0\Q!K0EU@KZ'7O$]UK)0W:247[9M0?8J;I)RA\@J!Q#15$:<X=3E2U7
M>7@I7W_[Q)*T.'L]6"D@!X.]^DT%[$1/-B;23%G.`)P!VW_SD7-&DG5Q_P#P
ME$!HFX]_N4V<S7]8<#PAA<!2"LAGQ6V;YPBY<<A"R%/=`XM`H"0#"5P<GVS(
M@UU4ISXJA_EJ4(4CZ*+HRLNS*DL8>-@X;,_I'/)D-0-8PUW>WV+D"M&N1Z$8
M;<-69<;Q,YLH<1VRFRBHK.4SKJ]4[9-K/[N55FJO,,P=+O6@S$_F(O:(N(5<
MY!R7&`39)BB7;_V[(,>+9J-S"';?%8]N^K+H_P"6!*R$LXQD.^-[F-Z/'*UA
M0+*X8:/DM@`0/"O8*Q!L*3"K1I<FE/F+(6Q@EPV93'4HIZKBYDZ%H+R!8X*.
MLB=0%)"XX`2N9^W,$[T\=GZ9)`PGLK$U2;'G^G<`%GNS0+<2.<]V0/#\$IH-
M@M?C;CJ.".3MP@GC)[I;96D383W!8M:[7;T)&W4-)Z9^Z[P:EA*]_8E]S_,-
M\KV<)`)0I]..DFF']CP8(CEFK`$23[%-73M>;.S798@3L`93)TP_&;4L<4YT
MP96_*(1J]HJ2)8$P-[1"$H=5P:%S$++EFR9+LO+"^-[4H#2X'*;Y0:,.T$[/
M7(-HO2FST%'J+R%"J^TD^[*HY!@!M*:'T&R[>?)85V`5F08-0C`%[L6M#]0Q
MP@P!XWL@>7;,4,`PG#+W(1+JST+7$>B@%`NT3A"\O8#I2R47X0SAP`>I\;+V
ME(*-GG))2S2M5*8HJ`5#)L@"[^&.ZNCW=-:'-BD!_2!R/`S=Y"<%I=GWSWDZ
M?I.&]T(TR8'"X`^:6K,%$:\/T(C64ZL"Q"8F::?C$%&X(Y`\KTPK-=H-$54L
M'+;H0EN`;(C#`8HDQ("T*`>CMBK%Z5[4BNPB,CJ"*PHEKU:(@'RE$5D^@QS5
MSRJ>W&L`Y%8YW;GQL]%]!W0J^BU>#;(1GC-_82]WBN;#U?L_V9,,?A3B2LM'
M(H$N7RR@I:[30&+K=]90(U*FOWQTHA]=Z!Q7`CF&FVB6IC#U@`H"52VU"V>-
M*`]`IIV']'C)&NN9'L#1.F5^:LRNVWX+7,"D$U`77)N&6'Y"B[]U>518OE<C
MP@1\P>6AX2)G][`\3)!YXH.AN'5(R0;5A+O>R'M[T0B@0TB;$?L<4GQT'@;#
M5`5XD5D*7"=P`M2C#G\6-9;*5TEU/A9N<.4U]LS>6`+P9QJ.ZH/Y;L-((118
ME.OO\8E!`Q$AZ]D;(5@$Z51G[L\]$M]O"3'K(,17?@'V<=J"2:OFM'_#`?2/
MHS:!<'VM5?->H>FXN-HL)IQ:D<Z4^E?3B^B\*6]1[:[H%TY7&;X`#^VG^C;>
M`-%HFZ1)RKP9H<CH%.NL+$!/',W2@_EL-36#4X8$';1&[.8K^G$2H2DY[`/=
M5<U7YVY1Q(QE`%SDE#-&?=*#M6`<$HD+7L4H_$6Q.C+,$H&@@GLC\HK2PM2-
MDVTKJ@:2T//4$9;7C]GE4S.2*)T>3S9E5]IM20HP[[4,?D=,?K@$=L?"@)$$
M/2-'_9S70I]QO1+PT#/H[W[<D/JKE.X.,^C(,"B8B^CQ,S2/,13[!X_WRV>.
M:?"4D/5:;)51TNQ8[NHM))S]QC*R`"$/%'T,8&E7'<8:%=88X:,0'&J8QM,@
M)2F6&FL45PJ^B"(['2/LRI[@UL9XDT"+)O3>+^VZ>VE6#OZGFGRW.*D\LQE\
MX?;["A$SVKT_/C,1A<#;4OTD6.?!=>M];VJ)",==^5G1=$JMAB#6C".;E#_&
M]R;43%4P&_#)B^V\6`<C0"++_"3P!06=EI4WMX6!=T):J]6.<J)$+#49-/)V
MS;ZH.*I!X*3BGFD+&?06%20,CX]$Q-DE47%9/%Z!5#;76@G;3ZLOHOM'#VN-
M7+L7G5FL%?39[+LPIP5C?X)XR"%0`V5^@,?_`)SOWR?<%M!1Z>?:$_7-F?NV
M)3D8MOE,PFUMB4JX"2/]L?3-YJ5+5WL]!6$2=A"1T4C>!,UFC3Z&O`<KU@]P
M!G*I_(PT#&I$9?0F:%Q1US#F4$;WB.G/:RK:0S58#\[&&(ZX71'Q*D/2_$'(
M>(Y\473`1)MUC=5B]BDEJ82YN"K-!+E#BCQ+VB393JWL//2>EF4`/6*VA=01
M$2OK6))H81/,Y`@?8&.V]"=4'$Y`TG[O(G!]#-@A-?SB&5`W0%SQ>2V,E&:_
MB^J1R1!85]1ZN)Y]R9HN(BB(C$=(G(GWV>CZ+++E`@*A3>)[N&J4%07<J_;W
M!Q"N5^4#A/8F-KH2RLUS1@-!V.+C,T\LD:,A6"V'0`ENH@68'C%EB"SX#)5#
M9F.4M9:T)HYX3.![J8HUQ:$V4A]Z^^,"0OM7_3$?<X=7G%=JE8!("O3^OZQS
MJ?P`PY]`X@,*9L?S@T/T`98012H`GB9-QG8]S07.I!:.E3`8Z/R<B';?E6D@
MW+]!)RV!^X3EFR+7WR>P$S'K?;O;+2S-"<(>.="YTE>$+L?HOADCMX#GTO)4
M'D:N7-.'L^VO6KQ<5P5G'1%#7-ISO!Y.JF-M6W-`K0V)"40[&)+[Q\6-N$0:
M838#285?D`^AVGD)%1?O:(XSN@W<I"6('T'<Y5YE#X&J)'$+.>T\M,U7Y))>
M<F7$<7QGKC))&*<0DS@F_IC3#HF4HT1,#U2IV.[U2]2"8_T[@""J'?0O:XX:
M#MD[]-$I%QZAAH]N'X';BGV3PHUFS<6"JA3_`,.!4:F5"Q?[M"@,%"DN13,/
M5/1AN)1%OT/QL?8>KOP(0]Z`;[3?0YW/<W9'8<!:\>^QRK6^X)22`\@N<@^=
M8"5`V;!AF#Y;,%%9+'TNRAC.3>+](3'=D#97@&@00>P#DAO?@90VW"Z7+V;(
MH0;LAT96_L9-$F<K3H#O+K[&=0X2`6SUJ3^E7[,WF,IQ#`W<&(0QW[D%/3:#
MEH/!Y']Q?@,,'+R$W&M;,.$LJ?0:P:Q30G8%=C,V/$*-<6!;/6!:B$.N>Y%1
MUHHDX70UP>X=3C7&B!]F5B"86A2%0MU_EAZK`J(DXTZ*K1V:#P4@S_4O$V$*
MC0R,=X-V+5RV(%/HZ,H4(3F_:96D$YX&9P'E/EI@5;$#`1L@B]-0%R0*-,5\
M-B=H'1,*(ATU]T':D6M#%XJ=$ON_5=%##0&\8Z!%1`)Q(BRI.F%V+?6%T("&
MG($IP;X>UW8@31T-)M$,-B;#B\YL+:8;!JO`G',7V=$4,"+8>"M`FM)VZS$8
M8H5Y"Z&#C9(6Z'1-FHJ1>BO*:\&W(S2#YB^C96#B'T5>Q%&177W@=)[AQ%]"
M]]2+4J.>FW1*_P!``>7.-+6,S:,@:=8EB^JC,CBZP`TKFYM+-LWWW=/G-..0
M?K$TZ.\2D(U;**`F_B"O_.=U\\5HGP?V7LOYO^G4&K.<T?D:.$CS%0$T:#5G
M@[J+=HP6T0#TT>+L5?EW^4G_`%T@W#K"><C"HN,=&UL5JMO(P5*4?.K]VW(M
M$X@9@:0`^$YQYCD&6,PI:L4(Z82$X6F6[J@![&/)13O/OR4+(4IU70W7&U'1
MK!M!61$$1$$1$1V(FD3!%LI.VF>D)!MC2DI4!D[X)@B-2(^G(P*GAU#%ERDE
MS@$XQFT,19!X!`EE4EOH[6!ZNTIA(.4!><NV@'#&)$!GU08MIC<:*JW;*E84
MW;_@#R&(@&%E"H;]X`U!:*T?*ZL&,<FO++N+.)G,-J7VK<P^U>E!.YCFL.VQ
MGM"#@V4C03?V=ULQ!]K@KB<W*U`=XA2^%/;+H/=SC^<GM-T/LI1%.Q-0!ED?
M52O5P\`@@(H6G-#Q.7Y8G^57_EZD0)N#_+16Y-X"8``0!`#T!W!86)#;>38?
MZC*?5``20A[A@.H]?1Z(=)RN5+P<^GP$E_=,N3$Y0N-(86X2"*P_/E16#^MZ
M6Z[C@>Y@-SGTF20XXU;,<>;15ST"P$?\@70$B9]N*O$2\>91P#D/2-]2&%HO
ME,4MI%);(W"$C#,9S["93O&<P`[JX8GI]"B.^/5)F>=HT3'09G]OJM^H<66,
M*/=+;>9%\U8$6O(P.3EV_P"[?L@F117U4M^>4I<FHTJ$!%1]OT7;RA^QT@#'
MR=![!,!"QH[$4FN5KSTB];13&#;XT`CQ%G:=L<P/4O.D>W(B75#VVY1A$T6A
M;]W?G&SU=OO[!%7RD%"#-G!WN&<>!(A0#LR7!DF0]R5?\?73F",==\\3@N:7
M9Z4Y*LBXB2">?KO.<<!6T)2]6U[_`(X+&7P,JG=;,-WZ8P!KHTT`=F9OC#.D
M1CUQO/W!A6`D!B#P<$:#;HY>H*-31R\19N-XE,/6TLJ#$],8K5C/*.I`;F(>
MDY7)2O`/8/P*W::&G=!&?0<0,JZ,-?BDR(,)##9V`B"'HBM%3/;F'@94O47C
M<`+^Y+\25L_!0PQ%G0!$T%'X=)A$FC8NTZ;FB.\Y2&ZLP99>AY#:;&O)**,@
M.L@,A#QHMH8HTD<GC0!?\_)X.$=`9H)2)>^A:&A:GM[U%^')3N4'@L2:=)I'
MUU68X`46.8'B(+0F)$,KBCA%XKUQ38%FJ-70%@^'PIWZ#(D8YU6K)&B1!0I]
M/:-%"Y#=Q0SV0V3NWNOH/1-Q-<Z-TLT`(V@8.-DQB?JJ`M&;B_B3HO3$SK7*
M3*N$W$=]L8+]!^RE@^AICS9_3V,K&XXS&0L[T0\@EICYI4'CL?=@EG%$FQ"`
M":HZN7BW6S6@!86H0SDS0`VC\\-S^/`9-V+!%F?$`W(<1L4*$DPL!7KZR[:Y
ML&]4'*:.2KRQZMYHFM'8*:7$HA4SX`0]T5"""<@">\,KBLY#*E,E2E3-[3AT
M*D=0Y'L=7I<-H-Z%W:G9SQTY_>AL\(KL&S,DJ,($Z<%3?!S<)Q(]W[U)H/C$
MAC1IIB\MJM:GO(7*""DKMYJPKUXN>RGR/:E7TQ)`%2O_`&&R->)M#V`&*;M.
MSF[.9L%/8<,HA"'DYT@CI'8CR)[')<^W`J&RU3U0/6]_P)!F5(`"N*]/99+`
M(W9SN>B)X5QD]W]5YO'*\"B0YAJ;OF/88'V2*.A9L/8'M/$`!`7H@60;`D)A
M9&#5@',9Z:C.';2_GR07$*I@R00`,`=3LE9X%RY<N7+EWI,,9THZB4EQB7O1
M$>8`]N+!P5"4/-:R!\D>*`L2Z'"")L1QP;GEK.PC(,&C(#_@&]/`*KQB00Z#
M5_4Q"ZPV8XT:#@[X2$ORK8HC+CA\4"&-P(OV[`\)KH<),IM16`]X2"Z;`?`A
M:Z!"]X%+-(>^TQ#:47QG2@``V1#G)_3>H!@VJT4<*<!*%#8MUS.3#@6O<+]=
M%VZ'S$>.>RCAY:1RJ8'50VTX`PO.#$00NR'EC+B!E("4N$B^8XCHN7>DPQG2
MCJI"S'H./!T0H!V8>J]-T6"F04K$LSZO%'=DZJWDVZ4=3G22T8@DT@4+2B"\
MRV$3K52_B0^```\#UJI?Q)?""(Y?&Q,-G(Z-6AAHF>@*"(.Q'P;3)OJ@?4J&
M];WA2;"[O%:;2CAEU<T#Z_\`F=Y+O@"X:A>.EC<G>F%$A\`(.73ML[IHGXUL
ME9-VL2XWG)0\;DG\:LB8G0:UW$T$EU`Y>Z4Y)B2N'4[M%7.D&7"E@(V!,,YC
M(V\)$"0)VZX@W@`E5J)K5:"B>`_8$CUC`#:X:))O`OTH,(1F_P`$]?`6+=/!
M&^.HSZ)8G\%LAC0[H=R9;!ZR>`$=S![G;L;5[$(4XSV\N6HL%(!2`V'.??<0
M?8!J]KAGZ*S03[#>LMDP8QJW'4J8&@]F;6EK<JFJW^A<./?0PC(@B9R.=&CQ
MD&E2W$0`&Q#TG<P9'B#CBD`?Z,2UM^\<,)8)ZIMX,=5#L<'`QA(N3<2-6[PG
MSIF5B;$5@%]95-"V$("LP2+W#>(23PQ5)NF-(=0;-OK5P2^UA8,XX6,]4\#2
M`@"'F%?6W6[\!^:'$<H#5?K'2Z2X*@K6#'`C-A]/UW&LVMG*N_KCTWF]CVAK
M]#?4<O`^V^T(D;AG"T:B2@%"Q-IC<'M?W!\DF:,SW.&<^!*A`!MPXQ,Q4#B*
M>KD8:+FH3$Z[62B9]^\:#CN10].PO&4?G53!`SGEI]01C(Z-PB#>!:B<7`#Z
M56<%QK/U,"6V@#829HDM!Q@%WM=H;='.CXCW3?)QP.4D>/0+-==:I7%2EE!5
M@6T';49@-5.3XE!G<(]I(HE<DARX'55"X$V\=P3*%@XP'1R^EB^Q[R2DCO)4
MB'\5(Z;OKNS@AP",@&61P.S6W'*DIR`+7,#?/])_V8I'\]ERCT]>+7>VZ?['
M6L?Q,*YZ?H"/_61[BT-^&$B@$;E2B_+1@-&2[(>;0?NJ0[34,4GL/UFAKH#(
MV504[7;+]F=)TZBP.FU@$T*?S_C54,?,F\G^6(&#JK<4K"FG99^E@C`P0;R,
M](\&)[*E76-\,IF`4`H&("*'PJT65@&E0H';UJ;3HIDMT3C%J"-PHC;T9=A)
M%=&H1IO)55;&I%8"@X`_6IN@@M."1#$U2@<[SEHB?MG^D<0'OYG_`.[?3_O/
M\/ZS_]H`"`$"`P$_(?\`V=?_V@`(`0,#`3\A_P`I4R?+GS)\R?,GS)\R?,GB
M?CSYD^9/_!'_`!C?\Y?_V@`,`P$``A$#$0``$``````````(``!(`)!)````
M`````````````(((((`!`)``!!!```````````!(()(`````````````````
M``````````!``````````````````````!`````!)!))!(``!```````````
M`!(`````)(````````(```<:````````````(``(```````!(`$DF0``````
M`````(`````````!(``DDEP``````````!`````````(```$DDEB````````
M`)```!`````!````EO\`I(`"0``````2````````"````!+;K)<`0``````0
M````"````0````)?OK+$```````"0````````"````!);/))@0``"``"0```
M``"``"0````))9)+,``"""0`0020``"`````"2`!));M=4``""````"22```
M`````"``++O]Y(@`"`00```""2``0``0`220`99;?+$0``20`"`0222`2```
M`"`"0"[IMOZB``````0`00"0"0````2""`1?]+Y@```````0`2```0`````"
M"2`1K;9>``````````````````0``"0`1?MI`````````````"````0`"0``
M`7)+0```````0````````````````";+4``0````"`````0"22220``````-
M&`````````0````""0`200`````"4````"```""```"``200```0```2````
M``2```20``0````````2`2"0```````2```0`20```00"```22``````````
M"2"2`"202"0``````````````?_:``@!`0,!/Q#SF5&\`$:H;2"I6G]!$[P[
MT,'H:T2Z/WVE9T/7M\=.=I?-:J\Q#Z8G4UAPM+I,%M48\0F(FM!$VW7^21P7
MU1UN^+<&XR6T3@6<#$K0U4'/;%.=U#TPQ%4^?7E<7UU^1J:A=>08-'4LD)<(
MR1UHETFC`*92$S"_@#8[PZ^P$)P[,1&"].K!V\%6M8=#C.=M68O`9@%R:("*
M(N+945%+IWH92!X-DUL0OR.\I4_:&+-=:GS9R3^3KDQV#U67&-'&I!J^(D6-
M$]&0&^D2,X;BW%-[Q7,69@,@80>=Q'I1"A4N\/F=NS#$1A3AO'#4E`5-<OZW
M5PPJC@$WVVN3ZS'9YH6,2EPF:$4+W#1&L_%S,+@FB@F<63@RX[0AC(/$VS+I
M?^JF6#]5?3[):%LNJ$&``,6*7-F#W`E>=5_6BFI&N<\S"*P+17?<,Y?6+X-?
M@$;_`*V4;NZL6I0-(ZNR6#M_)HFX(YU@&B%EK\ZI<)[!]R:6.#>P%09():\*
ML(CH2H9HRR+\JX,#!DCT*3',Q-'H1!S%SAJ+KT2B(6/?)"Q:XSQ0YPNPJ^"4
M,1B=[A1ZO(DAZG+LI#E+P9:I9,I1!54\N6U'[#6KX7"NDMPDS3:BL7AI&-@Q
MT.30]]7#P3$#'\C>1*.2<K15_J%`H`5$``JJZ`,VO_'!DF:"@((';(7B@L&"
M`A13;D2!NAJM-4$8L)H@)PA!"J1!P3N"7(POBPB-+`AG:9-(728=;S7QJ'EM
M^@V`Y^0%\"-1(NY.--FW/8PEAHDG!(IPPTM2Q@RJ+<!`.Z<%,6PZ0-VA29*9
M7T[*8T%-*LA=+4'A,9I3CKDED43='BF$FP#SD*"\#!(AD^*$,-\.G\>?%XPK
M9#J]`W"U'X$U+;[B0]N52OB*P'+;D9B01;1E[<U:!4]A(`#1K!W&J1$X*-*6
MJQRX*CJ^`7,-]Y"0/K6GJ6SE<21<0#6T\88F:(8R;'.#_#VT/GF^%0P`N$F8
M57-^!>,1%UW#0Z'TZ&>AL?&W8^6O]A)@(%;`*([0+2DVVD;+%D4HT^TG3IGN
M`Q]MIR%`/CJF)P#3(KLY-<SKZ>H4-B`0(P6S/`B"DBTNBTO_`-L9BX;[(\8H
MAJ#)%Q2Q=RV\(UZW+'0R$9>-HU:D&&3/CB>O;-'K`?Z=O#BYHP;A^_ST2X$+
MBNN\F68P66!35CO+B,$TTERE?'E&H0@:(BA1VJM5?:N#-FDV)ZS;[S1>\"45
M:7`#Z#T=4QDKN>9Z?C\J#27B2@)O`OWH+EGLQ1"$(I$@46&Q!=;>&=$'P;%X
M2Q@<<7X75U!>!UK8J"A/%RH)B#FS%D64N#?O66XPQ:>`/OK^/$Q&--KAFQA,
M,B.]$'E$"A?B$HP>G75M_MBH*CDUXA+>K@`Z^MN=I5VB%@9+0`O)Y+!1VIJ1
MS58SUAL5S3K/)0+JGC31>UB0J`56&,6'7SHZ=N9LK3E);1QQ(-WJ+UFX:KK'
M$(OC;C?RH00W.VWYIYZ@I^N8;4D1,$'@N`O.N34K1F":(58&R4@$L(OZ_`#\
M`@'X'?E(*&]W&2._<+J(D6GUGL4[!IVY!N<#H#!9/#,6SC(I`:"#9!\ZJ=(D
M<DZ*TOR/`)NE2QR<4HYO_4"N@29!/"$1\^/K`);0`=K<Y'AX2#`#[*PXNI(K
MCA8A%'D+JKAU42J'9M%)=>5IF%JB(<5555555JKM5=JOCRC5:NQT6X:<R9*.
M-`O/`U.MS[]K<[Q=E3Z!1@L,="FN*.\DI/J\T3_D>+/O)4)0@@]C;(HQ(T#C
MWJ8I^,*1F6E@&*PBPW`IU*BGC>TU^#C&4XPHY#_&H3%1_AC?,9<MN8!MO4@,
M6([L&%OWITNFX[G]!]'R1"W_`&(6^4P42%;8'$MV<%V@.QU-`6I;N2U#\*#"
M`);O3Z$:G`FP%'[QX!'$L:F`MF%GANZ"6?&+B^J=CCY5A',2EM?B>RJ"_0O]
MC%7RX*!N'5S>X2]GH?Q;8]N8Q3&\U@)LFSYXN5@WG=W\MYB,M@A2F4Q.6<XP
M'D^+4O[)$*B=>!"$#:NDF+69SO2?_LW0(J0>4G9G--`:4Z9-6$_(0&>`A@.:
M4?`U0X-0ZTJ.'BF"'5H,$(U%%X#UX'F_YN^$X0`5R!7)%N540(V'?%ENM')1
MX/HJ=M180UVB-,)LN4HDD.*">LZP\4"5(TH3J4_2$8WM]G<6QT[<#@LE>U@A
M3G&F@9A-_2LBLF2PN?*&U">#SH'"IIZGJ"B=:D(D1`5\W2%D@-.\@0;=97*;
MKX_WBE$BEG&9,A$3&M@5\*;.9$,#]"XI8$J1V&4((*3P&Y:*-(E_H;RXY?Q\
MA%^?LA^+*A`C0#`6'3!,IXEK&+L7!74S#W2Y#%;Y-))F4IT<XXE_QS`C"YZ*
M`2Q;:H1-:K!6R)3G!3.V_LPJ<4=&*%0$`"`(A$1TB.%!Y+5Y-2#I&ZZ-$9T0
MUMG4P2$^42EZD425?CJAR-L;0?[R&T!>#Q/8-\(K8-F"(*%[['_$2#I:"CT%
M\N6'+.H$VPF8^2@N5P#)7UON!Z;F;PI(4N0QW!&ENZ6K#U0.J"#G0\*+Q)D`
M>@O%26?>U!-+8B+V"(:II0$QA.?,EI`AJ*5%74G3-(JO/<GQW[RWX!I"%'-G
M-[;MGWV%M/KZ,QO=EB^\ZTE=QGQ&G1#;SH98(\;EEM@N0`K:,@YPS9>R`?*1
M3_?NE?%B3`Q#`=(760@AH^]':!0'H`\F4%5<%Q2UNV")Q`STSZB/I`3A41\X
M@#*Z"HD,!>77M$))`J8'5Y;N-1%][4&*(2-0/?JR#H!\C=-GA-":`3H4H`0Y
M.:51IX!KLXZNUVK^#K@.(:49N5QZ-03!AAK$,>L3`RO.EL"\S'26<M3*LP"K
MKNHW_JR>Q!7)F;;U'FQ*M40Y42!'!F@V4?$>@O>7R<2BE5=`!?0&@.DGQ8;!
M`2#2XX"0".$XNVR@R05]ZC/N`*A&&O!&I9&/V.RZ.>O_`*L+-=8HBB8@"@B$
M0)L["6D+:9D8"`!07%N;"VG$D%+5V5[3%J;(C[5Y9"E$$^3^`\$@@```[%[P
MLSMWZ;*TP>@4J`UC@RSKTD!4-R0!DDSBJSP\7N!B4%TO@RWAI1G-FG&S[QT+
M&ZTU_!!(1(AP^+5EP1]T[&&(,%$PJS$8LNUP7!DP$GI7B;0%Z5E$`$^=L0T(
M^L-Y%F(T`#&T<]T9XIE)YXRB&4CLEZ)S3R!A>7B\RB>@,K3J!)K")'"939[[
M.V[GL7@6K"6@CLG66D&4X+.$0B$]57:$DN88Q#U&N8IK9%2Z$TS-`25B&ZD>
M-R1WIBH364L!?.\72E&44#(=X0J.MN$!(V>?=<Q4:-%.TG:)"2#&#IN#I&8<
M#ZXTGBKL$&@[M+$6A(`,8E:4".R:'6(\;UH0B=1)I?Y>"HRA.L*)N<K,W80V
MR5B0Y\0YTIFVAU7Q;93BL%DV&4)4P^^&V03M*(/+PUMMAK00LM4;AUB%@#J;
M#<\J7.)&W%ZDI7]6V=Y%N#Z@[0S$$F*V@!/$P4^W?N*[O=E,D1ECS%T]#J1F
MS1MWKQ`"G0[;$6\MNE(`2P.P'.5.OW<2H"Y&#Z9)343=<LZ+:VYC99_'9$R?
ML2(,'H^35J3&6Y:OY+.D!@M,B/D,XS#2;NHP;6J83;>XU`DQ*FZ]OBVAH.R5
MU*Y@U'S8]2@/#?!PI'55_<;`!EGU]#MS#V."`Z(J/>N%T_(>%4[FZL'M%Z##
M3+)M<"*0G1_9YELH#(48I"NTS7PIVNL7!$%BD7M#."BXJHAHNUT>S_:F:7_?
M*>YMFT%!5L;9JN!0##ER8PJ5T!N[2(T-7'OS7S;RBROS!N"F8N!?AB!..5#E
M`[,.CF-A@I='2'D#%1;D+I67R[>.,Y%NG!8-VTZ3P?\`"?9!'WQ`]#!V!+4Z
M0,?`P,[M):2.*K'O7:,:TC7"W'4$%E'Q00?$>G`8FM`]+#?274R?)<)]@1LQ
M'J,"?:J#.B1&<GD6(?CPD2-"GLJJ+1.@(B;-%H@8C"E:1G&=@$X64"NO+H&X
M)N$+9&NVW+PJDG$W&_7IX%]V1,JG'\3C"VW33H&A8(`=$#ZT?H*XX%Y5[/)H
M03KDR/AA<@;#Y\"<4E)YR!BJSF"RCB/A+Q-.&@98MA7L.$D>)FS_`"\$+Z-@
MS7#8'+GO::UOJ:E/(Z5I0Y(TU^XX`%06J)5H5>#CN(@?XNDI+%6TU84.VAII
M:>F]`W?5U0V,O@=*W#QRWD6S?]K/+)^&4/&W%":.)V,T1UHQW9(L?)D=N0@Z
M=,`L^B'P';^;Q'SU)>QNR044CT%$1B;$TB<(XS[<3NW)BM2%B`,YYX7E<(BB
M-,)[;_%CU+0XG`X.OTG@"_)S:@^3?0(%KETM\T,4(O+G0NN:5:U9`6-"'&,B
MN\C;\DUNZUDB7%MI:.*==_O>K4ULB)(*"-,.N(TXH+F+#IH8`$1:_P"%3$5/
MD+A3/9<'0HP-<:"*8*C7>H[71YGD:1+HD,92H-'MM;2#VA!L;UJZ/WP)9P&0
M-`@W)L!@?2>6HZTO'C\@\1L-ZSL)X4DMH-E.?,HRUB+*L<FHJS]O;J2B0PH7
M82$:G1PP)^A`=`(`.#N:I<8A7)9CI5.<MR5<$)A]`('75:L@%"YD7ZE.1?BQ
M5-R%2(&AEFIDYLUTYYV'P*=ZRWU*H[#:`SE,0UK]1O!DF&FVSDG6$O.=UAG.
MMU(*ZE9&#1:Y(D,0MMQ9*NZ'W:51P]K9.*V8CB:1=6466DF1!]?J)&5T&4[R
MTC@>69K47G;UIV2[B/F1#J:7U\1H&$<FZ$-DY4%@3U>RD#>]6O;.J&L9`3(H
MA#T!GI&^E#`HLJ]2\I>:A`Y<"8X&1&WT^HN]N9O(>PB:G_32N\OQIG'6M@[+
M\/&?GEQ"`/N(/F788'!TA@9@@>QM4#L':'KJ?#T7HDBG<E]T)0M40@B,<;UU
M\0:+>6`84'1+[E-@?KFZ!"@DZ?VK_P!$"/Y:R5["L;(/2]4P(4].XV)(Y+QB
M[4!408@G`I\I[T=")-J5-W(^DID;RLUP;62$,21!@3D>CX]0B[4\0@!E-O0C
M@4'87HB<H#82/,VF[>>[Q!:73<R9V9`%,3\1'F.(7A&T%[C]%/4,3QQ;VVA_
M"&>THW0.-*1>/9^M!OH\/H]`[@`D/#$`/`%0`!T%G8#GJ<%`-1`&_:W^J39W
M-)Y(<[1DB+5"J@4B-K<IDL(TVPM,H>-YZ%C,55>%E895:4KTM<81"]O`&B*(
MHHZXR6-A$2"A`10Q$=B/4-[-8]L_1>C83KM#0SP81$`SN<MBFEIBF#,`75(%
M(P&=A<P!#T1`8BZ)H$V8JJJJJJM5=JKM5["F;E%5$"PBB8H>)J;X%\V@J^*6
M[2A=8<>,9'[F(D6+M@61IHWC#5@81*QJJ5/#[@=I;`=%U6P.!J/O8"R['T"#
M"-M.AO"T>,W%:-HC<`Y#9(\$IPZ0/H!`>0!XQ-*FI>L89UL\(6"LBCO7Y@\#
M4/(*T?O3*@ES8P%GY&WJ&A#T$/2U?U8O"@X)@5DP&!N7/SZ`JOR1P9L$>`'7
MHLCE+KS2=]@\8Z26+3\(`H^)_MQJ64!V28Z-:HW&^%A2K!XW.-AKD_S'5OGG
MT<&VQ@L%*)P/CNC3["[\09%P$SD_02'@,'.1H)T`<11A/#&ZKHS<1[A18+K$
M#$'/+.R)+1)X5,L%M!MU=HL"0BS9[E?%P@Q"\:`0`@`"("`8CI,<9C@$!>K/
M#5X6B*(B,1TB<B>DZ.)HF8?*IBD`7%)0C7%]:C[[GZ*D^^@]/,BL<8B*(B,1
MTB<B??B_*0.&;).5YH9$``"8X`%-UV(1X1H0CF_-B*SY,+,%F1U2AH.%K;6I
MX)$C>@^H4OV8TD`D:AE9?!;MV[=NW;_`7EFR@WB;$,1E_HWWBD!)&4.P(8+,
MBS4BCY(`[*HM*5Z(1`D1B6<KT$0L/#<>`RJ@)Q``5QA:KRL5%<#5K$``````
M`(`&@#O("B6C'K.R8P\5P995XI8+C%G&=J8$^@BIU`.42*?2G]O`IDW'_P#D
M(LQ2,*X+`)[NX%<&#%/=0$EA`3778H6=4(E/<"2L%[(/`G750<Q8LZ6W3`8D
MV3&:+,#`)7=VG<OP@?F;=+5$F]W13?!SGDA^CO!4-?KMV_P%Y9LH-XFP'$$N
MM1%JB$$1C@X`>L;D4@-*F8D4;9RBI&:1Y'8A;V:P#I@QX#T',5:TTR&S8`R@
M$5*B2<``'@0,H!%2HDG"(IFD/P;4#E7%);BX"/X@S!R(@B>!^2XW?&T15HN%
MR!]A,]GT#3IY.#^`_P"P=YI4=]T[%M[MRX4OP9SNJZT6B468=GAA#)G)?;:!
M!2R0ZSH!`V+4#^L"\W;1B[K-/2(8([OCW2HN]"0P=P:U0ELKEA>`N/=J%_`>
M*QQ(&`+=]V3-JR811\#U.I6G)-*``KFR""9\PX%H*LA1"5B']-2ODS,I*G^D
MY,^-BX/@1^W(8ER^=^I^Z>LI!OSA!#''-&7:!T3CL(112JE+7:E\PT/';!G3
M>"SN0F*!5!U^X6`8>P7A"^P_3?9UTD&;%_0IKY9.*,:AD1,"GZ-1;5&OF,I`
M)/IN(!8.,48?;5J'.86U0HTID1CH/4T@"6"-"O9(>GJQE1K9FJW0&D2[A8%!
M)>@/)PFO2H+D'N?1(!(!#`(6.5D&``2N6Q9H0$'.EL]]!<@`#S2Y/^$;JMN%
MK=YI<DXAJ6L$C1*B]^Q'=@62*+.T[2S*[@&Y`!VA>CAP143&ZBJC[ZF96.&U
M[>@$(7-,9!?P^4:Q'ED7Q:X@6]^[JA+[H2C:HE$`*XX_:VD)NC(%$973<XFG
M81@W($O?8>J*Q(/7!C*<]TX,KD8Y`P0_,@>;;),/B2`9F>Y,M@`8L`CB'H=@
M-5E#2`/N"2OIE147,5S^\5E61G4+!0MVM,M=6$!PE?:RL01M':M-RY]A7%$4
M%-^.M;I_)%XCX!F1PL]G7HGV`%BM%J``L%&,*H`+W63HY`/7RK8,9C<3M2B&
M'[`+W"X%GF44`77])_H647_>G+C_`%:-KK=5"SV$"/\`JV-EH'`ON!AKI4C(
M3Y,!Z#%PAWXA!Z=QW(&D@$H9`(+84*1^PF06%L<:M3*P#=@9)\2[RL1JQL5:
MAU@E``EOMLMT=,9W@"_PSY(*E73B'+?]-Q#"H+_D,JCS\&"5=F"1!7B"!Z:?
M`F'N%,1NL[CB$'%7[:73S7:)6!ED#>S^$JI2`X1AWQV2%`C-5C9]=J\E<IA1
M85[/"[JE'AS*9_U&<@_YFN=S_4/V_5_M?ZS_V@`(`0(#`3\0_P`I5R_+OS+\
MR_,OS+\R_,OB/CWYE^9?_!#_`!C/\Y?_V@`(`0,#`3\0_P`I(7HK(_-$N(_-
M$')/FB3Y1<O8ESCY1#M2_*IOM2?*+_;MX?,GCY5<WTAT>?CU.F\F<9<O8\_'
M&:[9D[.7QXSI[Z^LWG\8='GY`?67+BY>ER_)D>Z8Z/DQO0R8?*AG:L^5'UV+
,?EA]=%OS"W_&K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g662896g74m92.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g74m92.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0MR4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````Y@```:,````&`&<`-P`T
M`&T`.0`R`````0`````````````````````````!``````````````&C````
MY@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"-8````!````<````#T`
M``%0``!0$```"+H`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``]`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TFRS$ZC7?AU9):]A`M-#]MC"#/TV^YF[9M5;'Z>RG).(;\FVMM;;`
M;+["[<7NYL:]KMOL^@@]'W^KU=F/N9<,A_NN9_A'#?78'LON]7':QU3&,9]G
M_F_YOU?45CIS.H,RRWJ-M5V1Z#=SJ6%C?IV=GOL24VOL%`,[KN7'^?N_.Y_P
MO^9_H_S$W[.QXC??PT?TB[\TRW_"_P"?_I?\(K222G%SCT_&RS3F9.133;7O
M:!=>V7!\OV756>HW\S]%O^@FZ9U_I0I-=F7[G9-S&>J\O/NOL92WU=K&M:[=
M6RFIW\U^CH6I93<;_6IL:PENQS7-+AH=P/M?7XK'R<+JF3@VX>%=C5N-MMT6
M5NASAD&[;^COW5M=8U_J6>G;O]1)3OI+!R,WZSXCL<WMZ<676U4$&RYA<]Y.
M_P!-QJL]S_\``T[/^NO5[[1UKG[+B>/]*L_]X4E.@DLY^5UIC'.^R8AV@F/M
M5G83_P!P5;P\D96'1E`;!?6RP-)F-[0_;N_M)*3)*#[JF?3>UOQ('*BW*QG0
M&VL=/$.!Y,>*2DJ2&R^BPQ78UY(D!K@=)V;M/Y7M3BVLDM#VES7;")$AT;]A
M_E;';TE/_]#N^EV>ED]<>UC[;F9.\UZ;W?H*?296_?L<US6[*O;3Z?\`A/\`
M2HW3<N[+S'7W8MF&XT-'I6EN[1[_`-QSE#I#Z69'5G;6U5U9+M]WJ/<'^QEM
MEMAN<6U^DY_H^S]'7Z/I_P"#1.G=1PNI9KLG!N;?2:&P]L_OO_>AR2G32222
M4I9U=K\;)>VVMVV7'>-ATLM<YCIW>K^?]#8M%4>I4G8<EMME3F!H=Z9`!;O:
MX[I:_P"C_)24V[::KF[+F-L;SM>`X?<Y5OV-T@LV?8<?9L;7M])D;&GU*ZHV
M_P`VRSWL8HX^70,HU#+%PL$L:[;](D^QCV!GA_-_35Y)34/2>E%Q?]CHWE[K
M-WILG>X;;+=VW=ZCV_2L6?TS#P<;$S>F9099T["O930S(;6&-8*<6]C?H5UO
MVY%KW>H_])ZGYZVU"VJJYAKN8VQAY8\!P,:_1<DIRLKI_P!5LA[+<AF+O=O<
MQX<UA)L=^FL:YCF;K++&?SGT]Z'1TSZHM>QU`QMS'`MVVS[O9MD>I[W>VKZ2
MTK.E=+LV"S#H?Z8<VO=6P[0XS8UDM]N_\],WI'2FD%N%0TMU!%3!!T_D_P`A
MJ2FD>E_5BP/8YM%F_P#1O#K-W>S*V^Y[MK]WK7_^"*./TCZL8EV/?2*F78U9
M%+S<XGTQ`W/WV'U]GM_2W>IZ:T/V5TR2?LE)+IW$UM))(<QQ<XM]VYCWM<@_
M\W^B;"P85(8;/6VA@`%FGZ1G[GT?S$E/_]'O.A5>GG=8('L=ER"!#)+&.?LT
MW;MSOTWYGK?VU=8T-ZFYK1M;Z#2`-!)>_<@=-P[67=2=;6ZEF7<7`;FF?:*3
M;5Z>YS6V,96_])LL]7U/T/\`A+ET_`QNGYKL?%:YM8H:8<YSS]-_>QSDE.FD
MDDDI22222FIEX]]ME;ZBV&N:YS7D@>PEWM#6N^GN^FGKMS;&![65;7:B7.!^
M[TU:0?LF/^Z?SOSG?G_3_.24P+L\`G93I_+=_P"DT:FSU:F61&]H=',2)0GX
M=#F.&TF6AOTG?FB&_G(;"T]/:VYEK`UK6O:T.#Y`'T?0/J?YB2FXDL#JSNF-
MOIOOISS9L?MLQ_7`:"[?%@8YNUSGU_HMS/\`P-6[/J_AVUO8Z_,BT0XC*O!(
M/(_G4E.HDJ!Z+B&YUQ?<'.>;#%KV^[8_'W>PM=_-6N_U8J[OJWBEI'VK,G=+
M7G(>YS6';OQ?4?N?9C6;?<R[U4E/_]+U593*<S]IVL=DVE[J][+!0T5-K-K_
M`$Z/6_/NK9[?_!5JI)*:AQLW6,QPYC]&SO\`0[?FJOBVY63??4+[Z_0?&ZRA
MK&N'N9^B>X?I?TE>_?\`Z/8M-))33-&8UNYV6XAH!<&ULDQ]/:-OYWYJK=.M
MS,[&]877T0=I;?CBITB';O2L]VS:[9_76JN>JK^MFQT9$>Y\"ZBHO`CV^GZ6
M4VMWZ3Z'J?X/UO\`1T>JE-_.=F8>,Z\Y%UL$-#*:!:^7N;76[TJF[W,JW;KO
M^#1*:\RZFNX95C&V-#PQ]3&O`<V=EC8]KVN^FKK=VT;H+HU(T$ITE.3GY&7@
M^CNMR;_5<&_J^.+8VC=9ZFP?HO4_P;W?]-6_LV='],,P/\&SF=>W[JMI)*<L
MYUV-U!F-;]IR0\ADMQYK!>6^G8[(KVM8RIN[UO\`T7^?J)))*4DDDDI__]DX
M0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N
M`#`````!`#A"24T$!@``````!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@`Y@&C`P$1``(1`0,1`?_=``0`-?_$`*<``0`!`P4!```````````````(
M!PD*`0(#!08$`0$`````````````````````$```!@(!`P(!!@<&#@D0"P`!
M`@,$!08`!P@1$@DA$Q0Q02(5%A@CU%87MW@Y\%%AE5<9<<%",R24);4VEG>7
M"AJAL='Q,E(TU5B!D>&2LE.ST[0U)G;6-SA95'2$=86V1X<I27D1`0``````
M``````````````#_V@`,`P$``A$#$0`_`,_C`8%!.3\CM^&T)M&9T18*55MH
MQ%2EY6LV'8-:E;C6(A:.9K/'+QU6(>9KSN:<HM43BW0%XBD=;M!01)U`0QXI
MKR0\ZM@:*XV2=`VW0M97U/Q\3O-S;ULEM05ZSM=K3]>F31B&O6$-(2+*+IU:
MDTFYCNW$>7XY(5"^TH0`]0[.H^4/F9?;S5=[,;12(723/DGQ\XSV#C(GK6,<
M2]H_.UKYK8[!>D-FR$L2T1%@:33D`C&:90CA:AT6`PC[@!=76Y_;,4NKW7K/
M@QR"CKFQCW4Z-4M=@U8E9'M42EW4*RN3!EKRV[.C_LU*O6:A4#N7;9UW%$#H
M%$!P*5[=\C?+O7D]KB)J7BEY)[0876?"(L,W7[0T;M-?,/?:)#/SQ4J/*E7C
M^QP8W:10BGX(WIT^E@5T^^-R$]0'@3NH!Z?*,]'B4/0/4>VOF4[>O[Q!']X!
M'TP*%:)\C?+O:T/:Y&\^*3DIIAY7[6ZK\7$VFT,W;NS1;=NBLE:XXRE(AR$B
M7RB@D2)T.L`IF]PI.I0,'U[C\B?+?6XT(*AXK>1^U0MMM2KL\->LS5M]B(E5
M'W36V9]BD3`+1#8_X,Y"B143"`D`P=PE"M1N8W(,.[IP)W8;M[N@_7L=T-T`
M>@@'U#W]#=/WNOK\G7TP*&:<\C7+O9#_`&`TN'BEY):I1I]C4A(!Y8K0T<I7
MR/(L\3+9(7W*-$D0C%2-B'*4QCJ]%2]0``ZB&_=WD8Y<ZO855W2O%/R3W`O/
MV-M"RC&L6=FU7K,<N9,%;#("2DRQ%(]H!Q$Y?H'$"CV]<"MJ/,GD*HFB<W`;
M=B9E$TSG+]>Q_1,QR%,8@^Y7TU/H"/3U*4WIZ@'R8%%]7^1/EM>K-LF#L_BM
MY'ZZC:5.IQ%<L,W9FJ[+8;$Y#F-.P*:M(C2H,$Q+VB4RJA^[YNT0,(:[U\BG
M+;5-18V*C^*WDCN>6=3S&)7JE5L[)I*-&+HBIEIQ14E*ETQ9,13`%"F*0P]X
M=HB/I@<NUO)/O+5M%3L#KQ][DDKK,QZI*'K4]R8Q<WL*WD9`]2HE:<*T]THI
M87P=4T"G;%[U.@"!0$1`->1'D1Y9Z<T'QDVWKWQ2\H-[WO>D"]EME:/J%IJ+
M&W\<'S6+AGR$#L)ZE'3I7\A*.9)9)N9!LBF7X-3X@4%A(W$.BX6^27F%R9VX
MXUYN7Q'<IN(=32JD_/I[5V=;:Q*U@\I$-1<L*T9J6!KCGZPGUOP#<R1UNU4P
M"<@)@=0@?-P9\M-BY;<Q=Z\+MH<,-M\3=FZ8I:VPD0V7;:]/K6NHC;$:O&2A
M(N(BF!HE&;*N5VU.1=\@JF4P`J/0#&"\Q@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@?_T,_C`8%.]JZKI&ZZ'8-9['C'LU2[0V!E.Q;"
MPV.KN'S0#E4%L,S4Y>#G&R*HE`#E1<I@H3J4W4HB`A#QWXK>!#ZEZ\UZZX^0
MZM0U6TEXFCQ)[=L,XQ-:GGR<E,TM>0/;C2DQ0I)\B156">K.(@3%]&X!U#`J
M&7@#P]3W)$[\0T75&NS81W"2D;*-%III!(3M9B@@JY9S4AO*)TA>UP,(`-&<
MHI'&?-VX=A%0#`\DC^THE/U/J[^E:UX$\<!@,!@,!@,!@,!@6A/)MJJR[&WG
MXQIB!V=9M?-->\R*Y9Y^'@%W:+/8D6@K!+*5&R%;/6A%H-R#,1.4Y5BB<2_0
MZ=<"[U^]_0_=_!\^!K@6C=4:GXHQGF%Y([:J^\7TWRSG>+FOZ]?]$*-$$X^I
M:[0M@+1=R0?@'O.G$F_130.@/]9`0,(CWAT"[E@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]'/XP&`P&`P('(_M*)3]3ZN_I6M>!/'
M`8#`8#`8#`8#`?N_=TP+0WDSWI4]0;S\8M<LC&>>O]O\RZY0JN>'8&>MV\V[
M&'31/,J@8OP$>!'G<*P]2AVB'RB'4+O'K_O_`"X&N!CH\?JO9$/])%YH6=>O
MS*%=<\%=7-6T\M&.TX=PZ->F71LWDSH@T67Z(G^@4XF^B/IZ8&1=@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_2R.^56O\`=?(#EML+
M2:_E%F^*51@]>5?9-+T%I775>CMIV&D&BW3.R6N5V1=S/_M"=&TPDB(M8)KW
MLFGL>^'<;N$(0>/!YR&V/N.)9<>O(CRIGX>(B*QMF>U)SHTQ096)VOHV5G&<
M6YMFO[I1)S[00CAX5ZD5L#D@"F==,5$NG<`!E.8#`8$#D?VE$I^I]7?TK6O`
MGC@,!@,!@,!@,!@,"TSY4-7J;F9\9M7L[;,:ZF;]MM]3H79E70;'N&NI"P0Z
M#)M<:BNX,F+6?@7`IN6QRJ)B"R)![@$`'`@X'@.W]TZ?STGD"_CAG^_UZ_X0
M_+@/Y@[?W_SI/('_`!PS_P#:'`M:ZSX$\J;SY6-]^/IUY8^<#"I:DXZU#=$=
ML1M9@/9IF3L-B;PJT&_8GF2M$HYJDY%1,Y53&$WIVAZC@72OY@[?W_SI/('_
M`!PS_P#:'`MS>2W@SRI\:.IM4<AJAY6N:^UY)SR-TO0W51NMC39U]Y%VNX,&
M4B9W\-+/A7+\-W$]HR8D.!A`<#-(K;A9W78!TX4,JX<PL6X75-T[E%EF*"BJ
MAN@`'<<YA$>G[^!W6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP/_3O(>;N][8D=SZ^U96]+)2;:`U_6+[IW8]=H.P)?<=PVW-W>P0,M0=2;3H
MZ)F.IYBKQ,4P<K'F3&CGP3!??3.BFIT"<_C@XL6?AYL;9VJ[9Q[H;%R]@$)*
M!Y:ZV268,=LUUK+)`WJ5VJS]\\5I5SC5'@.%&S#LBW0)G53*42@`!>!P/"7;
M:.M=:EC#;#OU.HX33HK&(&UV.)@/K-V80*#=C]9NVPNE>XP!T)UZ=?7`V*;6
MUBC<([7RNPZ2G>Y=B63BJ<>T0H6:1CSD]Q-ZRA!>_6+ELHF/<4Y$Q`Q?4.H>
MN!$Q']I1*?J?5W]*UKP)XX#`8#`8#`8#`8#`MX<WO_>GP:_65AO_``3/`N'X
M#`M&ZHX]:(@O,-R1Y#PG(&+G]]VSBY0*=:^.Z22!9>F5!I:RNF-Y=+E#WE64
MJ[;$;D((CVF$1'Y0P+N6!CK?Z3!_\#VH?UQ^-_\`^?&.!D$U/_!6L_\`J_#?
MWN;8'H,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_]3*IY-\
M">1.PMMVG=_&+GWNSC99;BE`A8-?*,(78.GW3NOP;&OMY".JTXD"U><NF,<D
M9P#50"K+B=0P=QQP*::N\</,.1O52N/*[R8[KVY"TVQQ-F9ZRUS`0>J:7.O8
M=T1VU0LZT6FK+R<<=5,H*M^\J:I>I3>@X%YK`Q?_`#W:IV;LC;.DUJ30KH_9
M--+[/A#V:(H3W9T#:Y>9E8\6FI$X9H!RT:TV$B`G;64`*LR(;H0P=,"-<#H;
M=$CR6KE3D>/.S:IR(EN6'&C;E)V<O#OIB&UUQOJ>JFL79:VKL]1444VU?<E,
MS<QQS`+IQZF((B(X%Z_1&M-FZV\CE_:[+WK8=XKS?%R`E()W8*O`UD]3C#[5
MM_\`<)FG!&,1^V`3E'W5OPGT`P+LN`P&`P&`P&`P&`'K\WR_PX$6.3_'.0Y`
M-M;N(.]/-?V/65Q&X04VS9)/5"/_`((6Z)R$5]$UFJY2*$-ZAU*("&!1G[JW
M)_\`Z9EU^7K_`.9(\/F`/F3_`(,!]U;D_P#],RZC_P#@K#_Q>!`ND</;BES_
M`-M3<+N:1A]ZN=,UQK:=U-XAN-CLU1),H&855ZB/5L#)BZ*58I@*`B8OK@>M
MY<ZFYE\D-YTWC3H[G'?^,;_6&JX^VV&[U*#BY!SL=\\7"+>GL#-TBH1-5-1,
MJJ`I]H$ZG`>O=@6*_,OP7YU<:N'S'8F_O(QN'E52FF\M.=*?(4"/53JCQM9R
M.PO:)8IF9VHYKR:(JII]/;5,4"F^7`C&7G<Y.B3V?/5S1C2"B3VF*7%*5]M@
M7VR@1HF)(L2B1L'T`$/3H7`FWR7\NND=OZDX\475/E=Y7Z5NVK*N:&VIL6$X
MO3;B1W5-BRCVY++.-SQYTX]T5=JJI[20`3JL.!Y_A9Y8-0\?-S?;_?GEPY9\
MFZ"-6F(8VL+-Q?G(Z*5F'ZC4T=.F>-HY)PDXB014[`*/0WN"`^F!5WQ9_P"D
M7:*I.G=U0/.G?&X-D7]+E3N=SJVR_FHGIYTIH5TX@U-=MWZT"S*UCG9#_''%
MD</>:%4`AO0"X%S/_66_%C^7>X_\QEY_%,!_K+?BQ_+O<?\`F,O/XI@/]9;\
M6/Y=[C_S&7G\4P'^LM^+'\N]Q_YC+S^*8#_66_%C^7>X_P#,9>?Q3`?ZRWXL
M?R[W'_F,O/XI@/\`66_%C^7>X_\`,9>?Q3`][J?_`$A3QG[GVQK'2U/V'L9&
M\[?O=:UO1F]BU1:J]&R-MMTHVA8&.5DY%%)NV^-DGB:0&'J!1.'7TP+WF`P&
M`P&`P&`P&`P&`P&`P&`P&`P&!__5R`?+?H^OZ\+)\L['RW\C%5=WNUZFTGKO
MC?Q*VH2!97#9MJ60JE2@:967:*3!E+65TDHZ?N%5RI_@U%1ZCT*(4;\&VY(O
M8NV]L1J5J\B\HY>:BB;A#Q_.':5>N]>D*Z>\&KRE@UU%Q2IG!7J$U'+-'3KH
M)$R@*9^T5"=P9+>`P&!`Y']I1*?J?5W]*UKP)XX#`8#`8#`8#`8#`8#`8%O&
MA?M&=R?Y#ZQ_?I'`K#%:WJ[?E]8]F);`C'%J=ZFCX!?7)"H_6K&-3F15+8%3
M@L*HLUE.B0%]L.A_7KT],"43U@QDD#-9%DT?M3B`G;/6R+I`PE'J43(KD43,
M(#\G4,#I/L53?R2K/\0Q7XK@/L53?R2K/\0Q7XK@/L53OR2K/\0Q7XI@6JO$
MPAP3M^L.4SGAWK2=K]2B^>')R'VJWV.Q1D7[_>S.P1'YP9BMGD'\VHTI4@51
MF,8W(=%-!`O8")!`>H75?L73?R3K/\0Q7XK@/L53?R2K/\0Q7XK@/L53?R2K
M/\0Q7XK@/L53?R2K/\0Q7XK@/L53?R2K/\0Q7XK@/L53?R2K/\0Q7XK@/L53
M?R2K/\0Q7XK@8_OG!@8.)W%X9%8F%B(Q53RJ<<R*JQ\<S9'4(6W5\0(H=NBF
M8Y0-\PCTZX&11^[K^[Y\!@,!@,!@,!@,!@,!U_=^[^C@,!@,!@,!@,#_ULO3
MR4T*]7;CY7I36>CF7(&]:EWII7>59HRNSEM02K25U%=&=S9V6M7@B*[5A.Q*
M\<4H(.@!F\:++HKC[9S`(6K/"=;^"MMY+\IDM*5SD%K_`)/P4"N&R=/;GO,5
ML2K:9HUDOI[/(5#45BJT_/5,M3>WR2^*,@@9(Y#B':0I`[0#)7P&`P('(_M*
M)3]3ZN_I6M>!/'`8#`8#`8#`8#`8#`8#`MXT+]HSN/\`R'UC^_2.`KY#?SDM
MR-VFZ!Q]B_7H/3H-@Z=>O3ITZ_[.!<.P&`P`X&-%XY*SS,\=_"SR/6-WPVO.
MTMM.O)+R*VMJ;3L9;JG"2NV]=;+M]&8,;E7Y=1U(,F<0QBR.GW8X`CEPDU,4
MI"F,&!4"@>63R9VF^TBL3_A+WC5X&R6^MP$Y9W.YJ$9O6H:8FF<?*V)P11H4
MJC>$8.%'1R=0$Y$NT!ZB&!77F3Y%^>/'KD!:=5Z0\5>V.3>MH2+J[V%W16-G
MU"OPEH<S<"RE)=HTAI%NJ_9'KTFY58*>Z/511N90OT#%P/::=YZ<V-@\6=][
MMNOC*VAKC;FKEFB>M^/\EL^FN[!N=-=HHN[6A9I-`K&$+&*E`ARN2C[O>`$]
M0'`BA1_+1Y-K+<ZG7IOPD[PK<+/6*'B9:QNMS4,S:!C9!\BV>S+@@LR^XC&-
MCF6.7J`F*3H'J.!(?F9Y#^=G'G=+K76C_%CM;DU0T:_"RK;:M8V?3X&)?2,B
M@*DC$)Q3]NJ\06AU0]LYCCT4'U+Z8';:,\@'./9F@>0VU+[XO-IZKV+J:-CG
MFL=02NTJ6^F-W/':K<CV-@Y)%`C:$5BD%3JG.X*)52IB4GTC!@1-A/+MY0Y*
M:A8YYX.-ZL6DE+QC!X]/NF@@1@T>/4&SEZH8[,$P(T05,H/40#H7`B1_I"?)
M/D'4^27C'KM<X@7*Z0&N^7.A-T4*UL[A!(L]M[;9ST:Z;\?(=B!#.H>PO';9
M-L#Y?J@)U`,4.W`OE^/KF!RGY6$VD;DGP1OW"\E)5JZ=06NMZK=O+L,9M.9/
M,DCD(1)%>/&MC'MQ4.J'8J#PH$]2&P+D?S?TOZ7R?(&!9=YD>3;EKQKWM-:H
MU9XL.0G)FF1L5"OV6WJ-=*M%5F:7DTE%';-FP=QKYXB:+.4$U/=.4QC>H%`.
M@B%:]5\YM_WSBYN[?$UP9VU7-CZM!\:JZ!7EV+:W[,4;Q*4B2.@9.68,&:;H
MCDXMSJ^V=`QN@IB;U#`I9PH\D7*GE'M:0UYMSQE[ZXG5AM49>P)[3V);ZS-5
MP)*/3`S6#.P8QS%\9U(F$?;,03`42_2#IZX%G2C>6;FS&Z?WKJ>T;!93_)+>
MMGL\GPGMZ]5@VQ(*F15MM5?NJ2\>TCB1DP762%;]TYW)3&$BI1,(C@50KW//
ME3M77!)ZY<C=NT"!X]<+]2;WV*/'77NGI[<.UIZ].MA.+/M&2C=EIH08:VH\
M92R)N&<<5,RBYE`,!A$H8';[#YN\N$$><').A<N9"/IO$AEQ@F-=ZEN&O];H
M5#<T-LG66MK1/05E:EACV6,N%U>6I8C0(M^3X5TH0J93%#I@5)XW\Z>8&W.3
MNF+:]VH1C4.2G*;F+Q22XY2U1KRU=T[&:+T?L/8%"OIEV;)E<GEC9VG7K?ZY
M^(?`@Z9RHI%*F84C@'QU?F3S)D.-\-KBR\A#+[=V7YO+WXZI/D7#TFFQ$G4-
M40EHN"ZLG3ZN:.=U.+GY5G1S144+ENZ!NI)%'\(J0@B%6&',#D=/^'WD!L.8
MV4Y>[OUSR7V;Q!K^]8AHPK\I8XFM\W6?&&O[5*2';M(EG8S5)^59PNS330-(
M-U%"`41Z`'O6^\.06C_)'$4'D/LK?L%Q^VMLR,U3Q49Q['3U@TS?7#+3T>_>
MQE_E@1<;BB[2M8XZ3="[.<K8RB9?<$"&P*5<T.:7)*(Y2;O'4.\DJ)KCB;5^
M)=IC-<Q<)49R'WXXWQMJ1JEK2L4O)1\C+JQ"$/#BP8!&.&XI/EQ,)C&``P)3
M\]_)GM+B1LJ1H>NN/,%MIK4N/JW(R^2LYL=2DK1E2CK>TJTA$0S(E<FOK2<7
M.[`S<#G12`P#WCTP(D7'SG;4I7U[2)_B]4X?<S6?CQ@:^&RK':*Q+U>P:W0V
M75FJ3FKT![9W%TG&+E-@5!..!BD\-U.N4GK@=3S6Y1\B-GDO-FIDQ:M%3/$+
MQT3W(7:<%4K#(M1K7([?U;:&U]3Y5W[+(\PXUO5(ET^*FNB44UI)-02%,`8'
MU(^<6XL>-VLMD5+2<;;YB_6':U(HC"WVVQIW.SN]!5>O%L[>WU"IT^Q62M[%
MV+;Y46T-&J(&;IIF35=.">Z4,"?W"C?FX+SRSY9ZHVNVD(@6^EN&').(I#N7
M=3C?54WO:J;-JE^UQ%2#Q!JX3AF4]I=.010%)("KR#@_87O'`NH>O[A^?_K8
M'__7R#O,O^>:QZ=VM2]F1_#VL\5WL_QM2U/;=]<J]I<9&]XVI(VNS!?:-M>Y
MTB,63A:H$>UCS139-9)"35.J5TL!0[$P]YXC-+;^T]%V-K=^*/CQT!I^7JL:
MXHUPX2;-MNS).^S!7Z`G-;)RPU:';2L5]7F46*\([<*G7`H=!`PF`+UV`P&!
M`Y']I1*?J?5W]*UKP)XX#`8#`8#`8#`8#`8#`8%O&A?M&=Q_Y#ZQ_?I'`JS$
M[=E7?,:QZ;/7JTG#Q^I&%I2L:;1P6UK/%9CX<[!P^^),V4B2ICW%2]DIBJ>O
M</R8$M<!@,!@,!@,!@,!@,!@6C_+1P'WUSAJ_&&5XT[?UWIS<?%SD;4N0M+G
M]H5>7ME3<3M.$CV&*\C(8XK.!93#-NJ**B9T7"8'(<2_.%J'D7R%\Z7C\V_P
M25Y+\M>'^ZM8<G>9^GN-L[4]:<>']9G$XF[2P*SSP\S)G8G9D&!:.$D56ZGO
M).E$S]IR%.`AEG!Z8#`8&TY"J$.F<`,0Y3$,40Z@8I@$I@$/G`0'`B='<%>)
M,5(4R58:)H*$EKUAL",I;T(5N9S7&&TU'2M^;1BQRF4;)V55XJ9P!1#N$XC\
M^!X'8_C*X+[8@*)6;WQRH$S#ZVK!Z14$"QYV2L;2E73AZK3U'+%1!P^K"KIT
MJH9BN91N8RAA[?I#U#[7WC8X-R>S&.WI+C;K60OL;]DS,Y9Y").$$EJ)%L8:
MG.31JG6.5=5N-C4$F:ADC'0*D7M$.@8'L([@OQ/B-PWG?D7I&EQ^V=C0MC@;
M=<&D>#>0D6=P8(1=L63*D8J#*3LD<W31?.T2D<.4B]ISB'I@4OK_`(LN!-6U
MML+4<#QRH\?K_:5@K%NND`D@Z,E)W"FR#Z5K%O27.Y,Y86B'DI)9=)^@8CD%
M3B83]<"H>PN$&B[CQ#G>%-8@OS3Z:D*^TA(-GKM!A&O*B[C;0RN\98H0'C5Z
MS--M+DP3DSJN$U17=]QU.XQQ$0V0W`WB[&[>6Y!/]55N?WD^CSMI79$JT%:4
M=23R`2K<U/,F1E#QL'+S<6F*2ZK1)(XIG$@#VX'0!XVN$7U]J2S#QYH1IK1S
M1DPUJ^/'&.I!,HNPKVR(:J`902R;>&LKD[YF1R"I6SDPG3[3>N!6C9/%_0NW
MIR>LFR-9UJV3=GU\XU7.R4JS*NXDM?NI5*;7J[DXC].,4E42K"3_`(Y>N!!+
MEAX?>.?)NR5NYQCUSJ2U0J"K*3=0%3IUIB+*S^R:=)BW<G#6J+=@C9:I7TBI
MPTB@LF=@H`&]M3ITP*V:#\<FA]'ZIW'J24D;SO*%WZ+)OMB7W;+1-IL%MA8R
MHP]%B:V_>QD'`I*0476()NW22.F<_P!$3&.)C#@4`Y4>&CC1R-GX6TUITYTE
M-,E+8I-I5&I4RP5^R/KA6*]4GMM7@;-%.D(W8T-"U=H2+FVZA%6JA!.HDN/3
MH$O.+_#:C\79K8MG@KA>[_:=CP&G:;*6?8DDQEYY&E:+I!J;0H`T@S8,5)`Z
M2TE*RCMTOW*N'\LN;H0@$(`2_P`#_]#+!\M&V)C5?%-DVK].XNWB>V[NW36A
MX.%YDP-JM''TDUMNV(U>(?72`J%:M$A)?#R2Z16Y%TVK/WC@*SE(H!W!'?Q-
M^(JQ^.JY[BVO;]WUFSV7>$4P92^D=$ZS/I;BSK9TUDT9,[S7.N5;-95B2:@I
M>P+TXM#&0.<!1`3>@7O\""_*OG-6N-%]U;I^(UK:MR;BVVVEIJO4:N6S5^OV
M<=4H!=!M-6BPW;<%VHE0CVR;IP5!JT(Z6?/G'X-)$?EP*'3_`)8M85GD$CI:
M7TMN)"G1VSJ;HF^;\*?7BNL]?;TO4"-@AM<3+1.[&N4F#=N447DO'QKJ);N.
MA06.40-@>JUWM?5FU?)!:G>KMF:]V2V@.)]?B)Y>@72M7)*#E2[6MO=&3)Z[
M)R)8N0`$S?@5_;4^B/IZ#@7+\!@,!@,!@,!@,!@,!@,"UTELG7^LO(1MJ7V'
M<ZW2XQYIJL,&;^RRS2);.GHRR:_PB"SQ1-,[CV4S'[0'KVE$>F!Z6-V%QU8\
MI9WD"?DYI@\++:T94=&O%M,8631?MY3XX[U1V,A\(+0R(=``"]_=_!ZX$UZ'
MN/5&T5G[;7.Q:==G$6FDM)-ZS/QTNNQ26,)$E72+-=51%)0P=`,8``1],"I.
M`P&`P&`P&`P&`P&`P,;;_2&_\+/#/_\`ZV\<_P#N97`R2<!@,!@,!@,!@,!@
M,!@,!@,!@,!@?__1RPO+AH][R)X:635;7C@7E:A-WJ@.I+32W*-UQ#934?$3
M82!Y1_MILFL11M!.D$G(1"I#)2"A"?(9,H@%LGPJU2$TURWY%Z+GN(MIXI[8
MAM(4^YNF5E\C.P^<C:X4F<N!6#1[`1\ZU7J=;;1\I'^VX=).R/TU#$2%#VEA
M/@9-F!9P\EGBWE><VP]?[+JUHTE%S,!J^]:5L,7O?3*NX81E4;\Z1>.+QKQN
MWL]:5K.U:LY3%2,>',J@!Q*)P#M]0I!5/#9?:AL^OP;3D57IGBDVW%J3D-:*
M;/:[EW>[I_:&I::A5&D8GL$+K]EV])LJS<KUX56(7?$-^!(H)/7`F/0]9ZVU
MIY(;0UUQKRBZ^;SG$VORLVC1ZC7ZFG,R9MK6SND9<L#'1X2;X>\?PRW>IT$?
M7UP+D^`P&`P&`P&`P&`P&`P&!2.Y:$TIL28^T%ZU71+7.BV2:&EYVM1DC(F:
MH"<R+<[MPW,N=)$5#=H"80+U'I@6\830FDU^>]JH2VJZ(K2VFD8Z:;U<]<CS
M0B$PI-BBI)IQQD1:D>G1'L$X%`>W`]MS,UU1-)Z@B'^H:I!ZR?S6U-=-)=_1
MF"-9?R30DXD)6CU[$E:NG#0!'U2,<4QZ^H8%R>-.8\<P.<QC'.R:G,<P]QC&
M,@03&,8?43"(]1'Y\#[<!@,!@,!@,!@,!@,#&V_TAP>EL\,W\/ENXY@'\(B6
M5Z`'[XCTP,DG`T$P!\H@']$0#`T[R?\`&+_VP?[N`,<A"&4,8I4R%,<QQ'Z)
M2E`1,81_>``P(JUWG+Q#MFMMK;@KG(36DOK+1LM*P6W;HTGB&A=?2\(H9&4C
M[(N=,AV3AJJ02B':/<(?1ZX'D[KY'.#>O(#7MGN')?6L1";6JY+MKQV$@^D%
M+13CK';EM3)C%1[Y^C7O?2,07BZ22!3%,`F`0'`Y)+R,<&X;9+34,MR=U5&[
M&?'JZ36LOIP[591>ZQ[.6J3<T@LV)$I.;%'2""K1(ZY5%BJE[0$1Z8'MXGFA
MQ5G=TV'CI#[VUZ_W758Z:E+!KY&9_NQ&M*XQ;R=A]U4R18U5U!1KHCAZW37.
MX:H&]Q0A2@(@'2-^>?#IWI.P<CF?(C6K[1U7O#W6DSLMA-"^K2.P(^8;5YS3
MVKAH@JM*V`9MVDV2;-$USKJJ%!(#]0P/5CRWXXFXZ/>6C+;-9E^.["!>65QL
M^",^G(3ZJCY0\(]%%K$LG<PXD&TVF9D=F1L9X5X4412]T!+@??$<I>/<YM1S
MHZ-VS45=Q,*&39LIK51\=M<(:BG(S/\`:&;AG*23F&:IA((]Y'()JD$_0Q0Z
M#T#I=%<R.+O)J<N%:T)NZB[2GJ&)36R*JTDHY=Q*!WSF,(^$B[=N#V+4D&:J
M!7;<5FQE2"4%!'TP./7O,_BOM?;EET/KG>E!M^WZA]8C8:'#RIEYEC]3+%;S
M!4^]!-I('B5S@1T5LJL+<P]%`+@20/(,$SF34?,TU"%4,=,[E$IRE2]53&*8
MX&*5,!^D(_)\^!H:2CB'03._9$4<D*=L0SI`IW!#B`$.@45`%4AA'T$O4!P(
MI6'G/QGJ>[)#C]8[ZYB=CQUKUW05&RE7M#N#5O\`M.NSUOI='1L4=$/(D+'(
M5:MN9!5)11--LW%,55"&53*(2I4EHQ+VP._:"HLF91!$KA$Z[DI3=G1LB4XJ
M.#BI]$`(`]3>GR^F!`[^='X-_9K[8_GH4^S'YB_O&?7/YNMH_!_FP_.S^8GW
MNOV+[_MI^=W^X/V8[?M)\=Z?`]GT\#__TLA#RH<L^(2\QR(XD\T*M))Z6TAQ
M$J?-F7GXW9TKKRU7ZVCL>XTZC:MUVT@7L5-6"4=OZHJ#@R;GV4W+YFD<@BH!
MB!'OP7Q5.U/NG;6HK9P7C.(W(&]:%U]R%CIMONJS[VF;;HFU3_U=`5ZSV&W.
M5I6JV"ORRR)G,6!2$,<_>8`,3H`9-F`P&!`Y']I1*?J?5W]*UKP)XX#`8#`8
M#`8#`8#`8#`8#`MWU[]I-=/U?XO^_P`&!6[EI9-85C74*^VO4'MTKZU]J#-C
M%L5/96;SCB42)%R1E/BF?X)BX$#F+W#W`'3H/R8$FFADCM6QT"]B!VZ)D2"'
M3L2,F44R]/7IVD$`P/HP&`P&`P&`P&`P&`P*8[)TMJ;<2M$7VGKVJ7Y;5][A
M=GZ]4L\0UE3T_8-<*Y)!VZ!,Y(86,U&%=J`DJ7U#N_H8%3<"R_S'\0ECY9[R
MG-T17D-YJZ`;S<7#QPZVU'L!2(H<8>)0.@+N)C$G+,K55\!^Y;J!C&4#KW=.
M@`$6?]7QNX?_`-NWD?'_`/=%Q_SK@7<N%?$&2X;Z5E-3O^0>[.2;Y_,2TX%Y
MWI8_M%:41D$>Q.(9NSBHHWC$!#Z)#*'`!'J'0/3`QO*QXF>:#)*)ULWU^UAM
M)<AC;0M'+>O+6"'*LYM&O+9<IW3Z+5!L^.D^#8C"69H.S=#@0J0>X)>@X%0X
MOB#Y!>,VNW#_`%CH_8LGLC:'"_5>HJK=-,S^FW%XT9MC5;[8QV]%N,=L\SR'
M7U!;7%I9OGRT<581[52#T,`8'?7[A[SIM[?FYHN5XL&N<OS58\70;[XD[+K.
M+UKK*7I&K];0.P;B_:IS",\E/U:>K;Q:.0B8\_NN"D]H2E'`J!QVX*\HM9\C
MM7U"]:1D;)KSC3R>YH<IIC>*\Q3I&-Y!U#>NC=B:VI^L8J-=2XS+JWS\AL,B
M<HVE$$F*+:,Z**"!B!@4^UWQEYA--+JRWW+KW47&D_-&;R-0>E%YG5C9SL71
M%[G]C%^Q5$90]I6KC:]:HC[`RD/J]PHT9F<-D2-5#F*`D"N%QX[;<TEX5.2$
M=LZD*UFX77DU=.7-BU)'.6LV[H.M]@<\H3D#(4%VM!JO(MU)P>LCJFDDF9U$
M"N3+IE$P%ZB%3=UZEW=LKR2N=G:NXRVN/U!=^'^S]"NN0T([UQ&P4Y:MM$H\
M_6]AOD4+`VM<G!PL=!"Q577;&>$,!`2(9+Z0!1S@CQ]YCZ/NM$VA:.)EAJSC
M0/"G7'!Y6M,[;0"26T[.;:M=7L^UZRX93IV:E'JU=B59<JCPR+QRHY4332%3
MN`0[+@YPLY2T;D]QYCMCZ6<T*G<1Y_E=+R^Z'$[5WT3NA/><ZN\J1*JA$RCF
M?7.#1P"LC\:@B"*A.WZ0],#SFQO&WR*VAR@LVQ[5&[E5K%MYRVE[-+PV_KK7
M(=3BC*T`K3ZN90,%=8]I&0<A9TB"H@W13>^X'<`E+UP+8-3F;IJ#F=J^F\N9
MK<B%=XXWK0D$9G$76QVN\QYJ[K&6E(6MC$-=DP[^:U:H59&3GY%&&GA.[:$^
M(=>JA"A<`M7#+EKRHX8ZVW-I_P",H7)3D_S=L7+RP6Y^#5%[J2H3^M]HU'5B
MKEK**(NR)U.HO8.+!-,JB[0RHK$3$4Q#`B37W=EA/(CQ:H^_*UN+6$9JN[\$
M*6IKV(V1/WJY1NS%*C>>^&6!/:$<_L6D+%>+"TL=KFTX::)V1Z(NG"29%$4`
M^3[8P'W2OJWZI=?%?>*_G%_J+ZM=?%_<0_GMOM5[WL_"]_V;^I__`$D^'Z=O
MP/X7L[/7`__3R_\`F_QQ\>=YC*[R0YWZUTK+Q/'LJ<I![.VZ"+)A36ZLJT<M
MF3M^J\9-92-<S@)&1CWH.FQW1_HI"=0W<'K]%2W#79>W)O?^C;%1+AM_;FFJ
M-)R5IA+&O+3LQI%K,2Z5+=,8M:060BZ@K/@Z`AVS=%-9T0>\3&*7H$RL!@,"
M!R/[2B4_4^KOZ5K7@3QP&`P&`P&`P&`P&`P&`P&!!W<7$.S;`W`XW'1-X635
M5@>U=E57J<+"LGXKL63E9R`?$N71.A%E%0$Q?;]!('0<"$?,'CSMZ@:V@I>V
M<F+GL6/=7^HQ:,++0D:R;-7[Z332:RY%6RQSF<1J@^X0HAT$0]<"X0MHC:<E
MI.LT%ER,N4;;&#M*3=;&2A(@\M),U2`=.'79F."";5N4P`4Y3=X]/7`Z+67&
MK=-)NT)9K-RKO5[A(M1=1]5)&OP[5C,E5;JHD1<N$EE%4B)**`H`E#NZD`.N
M!]?"G:UXVYK^Z3E\E$Y:2BMH7&OL5TV:#,$8F.?F(Q:=B!2E.#=,>T##](0#
MU$1]<"9&`P&`P&`P&`P&`P&`P&`P&`P&`P&!P.6S=X@LU=H(NFSA,R*[=PDF
ML@LD<!`Z:J*I3IJIG`>@E,`@(8&]))-!)-!%--%%%,B2221"II)))E`B:::9
M``J:9"```4`Z``=`P.3`8#`Z!>JUEU-)61U7(%S84&QV2$\O#QZTTBS4`2J-
M$I11N9ZFU.4P@9,%`*(#\F!WI2E(4I"E`A2@!2E*'0I0`.@`4`Z=`#`Z1:KU
MIS.(6=Q78)Q9&K12/:V!:(CU9QLP6!0JS)"6.W,_1:*E6.!DRJ`0P''J'J.!
MM^RE6Z=OV;@.GU)]FNGU/'=/LYW^Y]G^GPW3ZD[_`*7PG]8Z^O;@?__4R@/-
MI"UI[PM8V2P2$O%N]8<@-%[7J+UMJB1W;4TKI0K@G-0!-JZRBTG#JRZL742.
MG+`":@-BF37`HF2+T"$W@BU&V-+S>Z9WEMH3D%9JCHN%X]4VDZ(C9"";4'6Z
M5[=;!</+I%3P-Y_Z_>V%T1!/W$")-TDA3+ZC@9*.`P&!`Y']I1*?J?5W]*UK
MP)XX#`8#`8#`8#`8#`8#`8#`8%O_`,C7_N5JO^5S7G]^TL">,5_YKC?_`*@S
M_P#)T\#[\"*?$BN:KK5(MS34MM>V^$<;(MSR5?/DP349SZTBH,E&IE`I0,@T
M4#M(;^J+Z_/@2LP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!_]7(
M]\L_.=UJ'66V-4TRX;GT5=JO*\;DG6WZ?I!?:*=F8;\N\W3H^@ZJ9N3DC;!L
M!T[B`(JF'>+,JI!,4>\.H1N\'6O>*$!MS?UXU50N9X[_`+K4(Q?;6Y>5NNG.
MNT;Q%EGV:C>/K\4W:,H!L\3D>Q8R2"??[1!'KT`<#),P+`'F_P#(7L;BI5J[
MK?2.QF.H]A+0/YV[%>YB$<R;=:G0%FBH<M&KYC,EX]2PVMP[5`_><HH-4A.'
MJ.!&E/R`\HI_>C;:M;W>F]H5;Y=Z"XO,>/C:%BBP^P*9LC7J$Y.WIPZ7*6>3
ML#N35]YLL0H(HI%'J'3K@7,M$[&VKL3R.7]?:6C);2"\+Q=@8VOM96W0-M-;
M8HNUKATG6ZL$0A(Y$>PH>RK^$^G_``8%V/`8#`8#`8#`8#`8#`8#`8#`A;SK
MUY>]C:<CHW7E=7M,_$7JJ6$(9LJFDLY:Q#\'2W894Q2_U``/KU`!P*?->1G,
M!LV;M_N<RQOAT$40'[2M0[@23*GU_KGS]O7`Y_O)\P?FX;RW7_UF:_\`C,"*
MW$K9W)K6M)MD35>,4];F<AL.TS#M\XD`AS-))X^,9Y&%0=>T=8C)4!("A0$I
M^GH.!<@XM[[?\A:'8+3+5,U+F*S?;%0Y:#%X#X$9"O)QYW1@7``]2JOA3,'S
M&3'IZ"&!)7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`__UK_GGUH&
MVI;36C]M0/+K7O&'4.C=]Z<V+<$[O0YFYO[#L2M[1J<SK"6IS2MQLQ/3EJK\
MHP5%E!(MA3EEU`(JHDF4YRA3?PR;KC>2/)3>VUIOGY;.8&Q6>FJM5#59+2=P
MTKKVGT\+>=ZVL*$1/,FD9)V61EDCMBN$>JAD"JE$1`@]`R1,"F&U-*ZGW?5I
M6E[:U]5;]6IMH1A)QECB&C\CAHFZ1>D;@NHG\4BF#IN0_1,Y>HEP*/I<&^)R
M&Y(;?Z&D*8CMFOH1B,1:T6KA)1FI"QX1,0_+&D<EB%)6,C`]A!T9`SA-+Z('
MP*>H_M*)3]3ZO?I6M6!/'`8#`8#`8#`8#`8#`8#`8#`8#`8$0^&^W[?N2AW&
M>N1X\[Z'V9<*ZS^KF2;%((V-D#$:%433Z@HLFF;H)Q]3=.HX%._'G_@+OC]:
M;<?_`)7$X%P#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_]?(2\J'
M+;C<I<*1QRV70N8J]XT'O;C;REKUPTYQ=M.WM?O9O7%FC;W'0*LNU26@YQE-
M0)G<7(H@'N,U'(F`053*(!0;PH5G7A^2F_;73[CRLF8R&UJZJ.KZEOGBX_X^
MU^@ZIG=J.KX6M$LKI(AMEVB,GY7V6[A?HX;QI3%Z"'4<#)?P&`P('(_M*)3]
M3ZN_I6M>!/'`8#`8#`8#`8#`8#`8#`8#`8#`T'`MU:'VGQ0XXP=MI)>0M:EW
M$A?;187QG_OMEF#N2D%#+1@%08BFH#(2]@G`1[Q`1#`I'PDY+:&U]3]P,;GM
M"LU]W.\B-HV>(;OEG0*/Z_+.8PT9*H^VU4*+5Z1(W9U$#="^H!@30^^KQ6^7
M\]U+^7I_RA]\H_('_(?GP'WU>*P?_K=2_P"V'WXC@/OJ\5?Y;Z7_`&P^_$<!
M]]7BK_+?2_[8??B.`^^KQ5_EOI?]L/OQ'`??5XJ_RWTO^V'WXC@/OJ\5?Y;Z
M7_;#[\1P.YKW+7C?:YR)K5=V_4I6=G9!K%1$8V<._B'\B]5*@T9H>XT33%9P
ML<"$`3!U,(!\HX$B<!@,!@,!@,!@,!@,!@,!@,!@,!@,#__0RU?*E-Z_K/%"
M6FMB[1Y1::KQ;Y16ZUYX=Q,U*[K(Z5DEOA(EJVK\;)R(UF2.422`^WV`F`=1
M`>WJ%L+PMWBY6SEMR52I^TN?N\N+S335%5J>P.;3"V5I2&VBK:%R6.J5>#L;
M..2F#+PI$7/QZ:!5&Y"*)&,)5`P,F#`8#`@<C^THE/U/J[^E:UX$\<!@,!@,
M!@,!@,!@,!@,!@,!@,!@4;><>-%R+MR_?ZDU^[>O%U'+MTO6(I1=PNL<5%5E
M5#-^XZBAS"(B(B(B.!\P\;=`C\NG==CZ=.OV5B>O0`Z?_1L".=TKW'ZJ\C--
MZ.^[UK=Z.S:U>9HUB&!BDSPXUEB#M-LFR!B8K@KX&IRG,)P$O4O3Y^H2,^[9
MH#^1S77^*L3^+8#[MF@/Y'-=?XJQ/XM@/NV:`_D<UU_BK$_BV`^[9H#^1S77
M^*L3^+8#[MF@/Y'-=?XJQ/XM@/NV:`_D<UU_BK$_BV!#?E1JC6E!O/$>0I-$
MJM5?/.2^O6KIY!PS*.<+M@F(]0$%5&R29U$O<#KVB/3K@7-`#I\_7`UP&`P&
M`P&`P&`P&`P&`P&`P&`P&!__T<E[SQ;ANVD.`SNXTC>NQ-"*O-]\>ZI:IS28
MK(\@KKKZT;)BHN]:VX]/48Z1,PW-8ZXJNM#G,"1%/@E43*IE5$V!2+P^VO4U
MCV7MLFO-S^9O:#]"CQIW['R>,=GM:%%M1G6@%=ZU-?*=6F@VY18Y2+@BHHK\
M&*GT>T#"`7]\"D6S>0&A]*O*S';CW5J;4\A='Y8NGL-D[%J%&>6J2.<J16%<
M:V:8C%YIV*AP+[;8JANX0#IU$,#5UO\`T2QV9$Z6>[HU0TW#/1A)J#U4YV'4
MD-C3$0HG[J<I%TI67+9'\>HD'>59)L=,Q?4!Z>N!&I$?_P"2F4_4^KOZ5K5_
MNX$\<!@,!@,!@,!@,!@,!@,!@,!@,!@,!^[]W_5P(G["TM:[/RPT%N>/>PB5
M4UQ4=CQ$\T=/%TIU=W88X[.-^JV)&IT'3?W7O58YEDQ2*3Y#"8,"5X?[O7Y,
M#7`8#`8#`@5S7_PLX??K/Z^_OK'X$]<!@,!@,#S/VUIP-IA[]K:S\'7D5G$^
M[^OHKX:#0;@8RZ\PO\5[48B@4@B<RPD*4`'J(8'=1\C'R[%G*13]G)QD@V1>
M,)&/=(/6+YHX(51NZ9NVQU&[ELNF8#$.0QBF*("`B&!]F!TL=9*[+R,S#Q,_
M"RDO7'"#2PQ<=*L7LC!.W39-ZV:S+%LNJYBW#AFL15,BY2&.D<#``E$!P.ZP
M//*6ZJ)6IK15;/7D[L^@7EJ94Y29CB6EY6(Y^RBI"QM:\9R$LX@6$I)-VRSP
MB(MTEUTTS'`YR@(<5DNE/IOU)]KK57:N-EGHVK5T+!-1T.,]9IA8&\37H8)!
MRW&3FY)<>Q!JAWKJF]"E'`^J*LU;G5W3:$L,',N6(B5ZWBI9A(+LS`<4Q!TD
MT<+*-Q!0!+],`]0Z8'.WG81W)O81I,13J9C4TEI&(;R#1:38(N/ZPJ]8)K&=
M-4UNGT#*$*!OFP.UP&!26;WUI.L["1U/8]KZ_K^RG,;!2S>DS=KAHJQ.&%HD
M)2*K2J,<^=H+*J6"1@WB+)(H"JZ.U5!,INPW0*M"/3U'T`/41'YL"@_WI>,_
MU?\`6WWA-*?5?V`_.M]9?G0I7U?^;+[3?8O\X'QGUU\/]C?MC_<GZR[OA/K/
M^Q>_W_H8'__2RA_-A6JW9N$BJ5CO.^-9'@-W:2N]9V'QGX^.^26ZZ5=Z-=&M
MLI]CI-(CB_6D&_C)V'1.:;;'358I@8@B9-<Z9PBKX9N3=OWCN#?%1M7-_FKR
MCD*+1ZX]DZ+RLX-5#B0WUZXFYI,(R8CW\'!PTO,R\VU;+$29NB@F9N554@&%
M,1`,AO`L->:^O36UX35G'N.X>;-W!5]LK`VW!R1UAQY:;VN&E]60DXREI.I4
M)NW(6?C+[>7K0B;9<KAJU8(B=P8RA^A,""#OB?NB1Y2.J+6N*^ZX^5L_-;CY
MR(UKR:G:&W;URA\;J)KA&%=0%FV@^<+.ZQ>:^DF#%2MG`SA9P81%$Z?<.!=Q
MT3IZT:@\CE_:6;D%NK?I[)Q=@)I@\W,OK=9S36IMJW`/L]5@UQKG735.%`5`
M'H\2>.>I"_AOEZA=CP&`P&`P&`P&`P&`P&`P&`P&`P&`P&!$CD)Q9>;ONE$V
M!`[COFHK30XB?A8Z3I7L`NJSL)VIGHE6.NV7:+*)(&24$IC`HF<`$/H@.!]5
M.X[;!K.N;Y2)+DYN"TS=P*B6)OLLNQ/8Z2*2*B1C5TZHNC)BX,<#*=R@>I0[
M.P>HB%)V7#'<35XT<J\Y^1+E-NX064;*/&XD<$25!0Z*@*2"R0D6*':/<0P=
M!^0<"J.X^.&P]G6=I/UKE%N/53%O#-(M2N4]PS2B7#EL=4RDL<J2C$XOG@*@
M"HF[P^@';VAZ8'T:\X[[`I=2OE<F>3FX+S(W!@5G$6>?78*2U)5*02B_KQEO
MC#%=G'U'N/V_O``_2P*1MN%VXT'#98_.OD8L1!=NLHD=ZW$JY452'.D;W9!9
M/M6*42CW$.7U]2B'H(55W'QQV'LZPQ\U6N4.X=5,F4*TBEH"G.&B48\=-A/W
MRZP)J,5!?.P-^$$PG#J'T>@?1`(7[@T===0W?B\YMG(#9VZ$YGDQK-%FSOJZ
M"S6$,VEVIE'+#HJZ<`X<@H!3]%"D[2A]$1]<"\'@,"'NW-<\Q+!=GLIJ/D+2
MJ'256K,C&LS&MHV<?,W293`\56E7+=VJ[*X4$#%ZB0"A]'M#Y1#9I_77,V`U
M%LBO;FY$T"_;?F+)//-9[!KNJ6%:AJ?67+=L2`B)FMHJ)M)U['+D4,JN8G4_
M>'7OZ``!]&I=>\M:W//W^Y]\U#8]3-!2+<E=@M=Q]>?FDU$1!JZ))M&[15,B
M(]>I.AP/UZ=`^7`Q%N.G&O=NGI^<VO.:$/7#;`TUS\BM=S&O./-E;6ZY[`6L
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MG39)&(<J3;`H)2>57DRUMJ/6M_W9L?FSM)IOCA9(6G9+*M:?H.NYC0FTZ5S*
MU9I&NV6(G67&R\/-;1,AIFS2,O=5GM>M<TM'HN9>,CRJI(_#A&.=W+SI=6K7
M^_+9>.9-1W-1>.7/[2>G=N:]XS6/8=AV\_@N:.LG_%K66T'LUQM@B-JMLRK1
MJ*Q9IU5J>[L36/146,Q%=8I@OZ<MG-NLG(?Q`I;O:*0C2:F-E2]^8-&)G,=%
M;Z#BW<G<2S08(&6^(?1<^J^^!0)WJ&72("8B?MP(7>+>TT;B/LO?M?HNK8O9
M''"!I%=<R7+J@^/3=''+><[MV[;==,DM-[,C9QA)V7>#N"1L!GSJ::-$4HMN
MV$SGM*/<`4MX&:KLS7GOIITRTYLJK<FJ-N;F/-\U]J3>K[W6&UGUE;GG34K:
MR;7G(!G6=C1$N3V#03-K(R'PI$S=A$0`0P*^;WM7D=L?*C:"5$Y'\G=9:V:\
MVM9Z!JE4IFE];3--CM*WVDKO;E?H^5M6GK%*2KB#DT0!K+K/UHV-6/\`3(<W
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M_P#"M_\`X*/YV/ZQ^S7=[W7\U?WCO[']K_D?]3UZ>F!__]/+.Y+;@N&ZM^RO
MCRXZ[QV%QHY`16DJORCLN_ZIKC6>S(:G:\=[)>T*)HSNN;.*]BWLWL)_$OQ(
M=%HH=FU8&4%1,3D`P1-X+:F>ZA\F?).M;]Y3;WY2\M1XMZU=HW2_Z_U)J_6R
MVB75]D?A4*E5M4,VB"\_$W%'L<K2!$U2)N.B93%,82A?<P']'`8$#D?VE$I^
MI]7?TK6O`GC@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0*YK_`.%O
M#[]9_7W]]6&!/7`8#`8#`8#`T^3Y/4/G_P!K`?\`9_WL!Z_N_I^OK\N`_P!C
M]WSX'A;MK'7VR%:BO?*=`6MQ0K=#WZE.)N/1>.*M=(!;WH:S0:YP]V.EX\YA
M]M9,2F[3"4>I1$!#W7^]^[Y<#7`8$5MB<'N(NV]I);JV9QYUA=]GIIQ2:ULL
M5<;2#N3^H6QV<`O.LE1&*L+R`:*"FP7?H.%F1``$#)@`=`D'3:74==U>#I%"
MK$#3*;6(YO$UVK5>*90=?@XQH3VVT?%1,<BW9,&:!/0B:9"E*'R!@4)N?##B
MKL3<L-R#O.A]=6G<L"O5G<=?)B#3=RGUA17#AW1I9^V.?ZJF)NDNG)U89Z\;
MKNXI00,U42$I1`.G^X?PY^H_LS]W/5OV=_-G^9WZD^SB'U9^;7\XGYW/LK\%
MW^Q\+^='_P!(/>[?BOK?^RO=][Z6!__4RH^<7C9LO)#<E%Y4<<.4.PN''*JB
MT)YJA79=)@X:WU_8&K74XI9F])V#2YXZ4;,-86PN%W;!SU%5LHNH`%$#%$@=
MKP+\<LOQ.ONU=_;KY(7_`):<H-S0T'5;;MV\Q,766L12*Z[6D8NDTZIPJBL;
M"PA))87"O:("JJ`#VE'J)@N@8#`8$#D?VE$I^I]7?TK6O`GC@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@0DYI479UI9:5LVK:@6[S>L=NP%\<0`R+
M:-^,;PAR/$T3.')R]B2Z[8$SF*!C$`W7H.!UU-WAS`E[76XJT<5&U?KDC,Q[
M*>G2WQBX-#13ER1-]*`W%H3XD6*!C*`F!@%3M[0]1#`G7\W\'3]_^G@0^VYS
M&K.H+J^I$EK';5C=,6K-T:6K%25D(5<KPACD3:O153*N=+MZ'[0$`'T^7`HM
M`^3&ASZ<BHCHKD0S".E',6H#[7R[8RJK40`ZR`&<?A&YQ'Z)OGP)AZ@W/';D
MI3^Y1%7MU519N7S,(^YPZD/(*JLTA/[Z2)S'!5L<?D,`X&+/"^:CG2[I.^;I
M"DU+L>.I%-WI,S'U#JBYQB''N:U]L1*I49I<9M6QNXB]GM[%01(S;J,G0K%Z
ME`2C@5XAO*5SBL'&*[W"*CXJ7G=9<C*K4-L[,A^.M^^V>L>/-BU9%W0^V9/C
M"[LJ=TD&R%H>BQ*Y3>@@K'E%T0!#TP,A3C-M&.W3H+4VTXJ^U?:#.[TB"GB7
M^EQKN%K%J.]9)J*S$1#/W3Y]$-72@B8&RRRBJ`]2&,(@.!73`8#`8#`8#`8#
M`8#`_]7/XP&`P&`P('(_M*)3]3ZN_I6M>!/'`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8&G3]\>O[OWL!T_AP-<!@<:J9%DE$3AU353.F<`].I#E
M$I@Z_-U`<"'B/!#CJWXP7;B`A79I'2>P%[.ZL40G87Q)E1S;K`:SR[AI.A_9
MC189@WNI"7^M]``/3`HRV\4W&:.U_+4.%LG(*!<V*>:3EFV'#;UN[/9UF3CZ
MZC4V-=G;<#LZS^IL:\W*V;QPI`W;AU.D!%#&.(3ATYI_7F@M8TO3NJ:\A5=>
MZ_@F5<JT$W67<%8QC%($TB*.G:BSIVX4$!,HJJ<RBAS"8PB(X%3,!@,!@,!@
M,!@,!@,#_];/XP&`P&!:%O'E884SDO+:I'2LY(:4J6]ZEQEO&\R6.+1)!;BN
M<,K,Q;%"HG(,D^KK--,$G3PI@[%#!T#I@>/5YZ\-X_R&SEC><B=<-X5IQ?B:
MHYD%)1P""-B8;1M*SR)./P8B#ILD8#&#Y``0]<"8JODOX$H$%5QRHU,W2`2E
M%5Q-K()`8Y@(0HJ*M"$`RAS`4H=>IC"`!ZC@<G\Y3P0_Z4.K?7Y/[K.OG_\`
ML/\`#@<:7DOX$KE$R'*?4RY2JJH&,A-K+%(N@<4UT#F2:&`BR*A1*<@]#$,'
M00`?3`&\E_`HBJ:!^4^IB+K%441;GG%BKK)H]@+*(HF:`JJ1$52]YB@($[B]
M>G4.H:J^2[@4@F=9?E/J=!%,HG466FUD4DR%#J8ZBJC,I$R%#Y1$0`,#<7R5
M\#C`!B\H]5F*8`$IBR[D2F*(=0,409=#%$!Z@(>@X&Q/R7\"514!+E1J94R*
M@I+%2G%E#(J@'44E@(T,*2H`/42FZ&Z?-@:'\F'`E,Z::G*C4R:BQC%034G%
MDU%S$#N.5`AVA3K&*7U$"@(@'K@;S^2S@8F0ZBG*75*::93'444F7!$TR$`3
M'.H<[,"D(0H"(B(@`!ZC@">2S@8J0BB7*75*J:A0.FHG,KJ)J$-ZE.0Y&8D.
M0P?(("(#@;2^2[@4<ZJ1.4^ISJH"0%TB3:QU$!4+WI@LF5F)T14(/<7N`.XO
MJ'4,`IY+^!*(I@MRHU,B*RI4$06G%DA67/U$B"/N-"^ZN<"CVD+U,/0>@>@X
M&\?)5P/#U'E%JP``.HB,NY``#Y>HB++H`=,#8EY+^!*Z95D.4^IW")P$2+-Y
MM9=$X`(E$2*I,SIG`#`(>@CZA@:!Y,.!(JBW#E1J87!4P5,W"<6^(*D)NP%3
M(?">Z5(Q@Z`80[1'TZX&JODPX$H%[W'*C4S=,3%("B\XJ@03G'M(0#JM"%$Y
MS#T`.O41^3`Y/YRG@A\GWH=6=?DZ?6SK\2P.-+R7\"7!/<;\J-3.$Q$Q05;S
MBJZ8F(82G*"B30Y!,0P"`AUZ@(=!P`^2_@2"I4!Y4:F*X.0RI&YIQ8%SI%$"
MF5(@+0%3)D,(`)@#H`CT'`+>3#@2V247<\J-3-D$B]RJ[B<5002+U`.Y595H
M1-,O40#J(@'4<#D_G*>"'R?>AU;U_P#O9U^(X&PGDNX%*^X"7*?4ZOM*&15]
MJ;64]I8G03HJ]C,WMK$`P=Q3=#!U#J&!M-Y,.!)%$D3\J-3$67[@01/.+$67
M["B8_L)&:`HM[9`ZF[0'M#U'TP-RGDMX%I$.JKRFU0BDF43J*K32Z229`^4Y
MU5&92$*'SB(@`8&I?)7P-.4IR<H]5'(<H&(<LPY,0Y#!U*<A@9"4Y#`/4!#J
M`A@;2>2_@2H=5)/E1J915`2E723G%3JH&.7N(5=,K03HF.7U`#`'4/DP"GDO
MX$I&2*KRHU,D98_M(%5G%4S+J]IC^TB4[0HJJ]A1'M+U'H`CT],#D_G*N!X!
MU'E%JL``.HB,NY````ZB(B+(```#Y>OR8&Q+R7<"UTDUT.4VIUT%B%4170FU
MED%DC@!B*HK),SIJIG*("!BB("`^@X&@>2_@494[<O*?4QG"1$U56Y9M87"2
M2PF*BJH@#054TEC)F`AA`"F$H@`CT'H!7R7\"4"E,ORHU,@4YR)$,O.+(E.J
MJ(%22(91H4#*JF'H4H=3&'T`!P.3^<IX(?\`2AU;_&SK\1P-B?DNX%+$]Q'E
M/J=9/J8ON(S:RI.XAA*<O>FS,7N(8!`P=>H"'0?7`JWJ'EMQKWY/2-7TWN:C
M[#L41'$F)*%KLF+F19Q:BWPQ'ZK51%%0&IE_H=X`(=WI@2)P&`P&`P&`P&`P
M&`P&`P/_U\_C`8#`8%G^T>*H++R?G=KJ[KD4-%V_?]2Y26W1WV7CE7$GN:F0
MQXB+<HV\ROQK:L..X%W#0"")U2_+TZX$PS<4-`*<BGFV5:UK=:P/-6M*0M05
M:?2SH_#-[/)6$]K,R,Q%X=ZY7DQ1.J*?02E#J81P/8;)XC<:]L5)W2;EI;7#
MN`>R=<EG"#&G5V,<&>U6QQ5JAS%>,HQ)P1-*8AD#G*!NU4A1(;J4PA@>X3T5
MI),A"%T]J[M(0I"]=?U,1[2AT`.HQ/4?0,#PFO.(?&K5T5.PU0TMKEJPL=[O
MNQY0CVG5V244M.RK;+7:U.457D:H=NT<S\TN=%N3HDW3$$TP`A0``UE^(?&F
M<V-2-J2&E=<*7#7M<O56K#I.GUU%BVB-C.*>ZM";J-3C"LWSARK18_VE52F.
MW`AP((>X?J'V;"XI<<MGT>TZ\MNE];.:S<H1]7YUNRIE;CG:T;(HF0=)MW[2
M,3=-%3)F'HHF8#%'U`<#M":/X[4Z"9-W.K=0P\)"L64:@ZE:=36R#=JS12:-
M2+OGL:0HG[$RAW'-U,/\(X%#]0\/..>EK)MJ56A=9SSC?6UI;9T=&S]1HR98
MI668,FWV?JR2C(3NXU`C0%"`F`C],1Z8%3K5Q!XT7.TZ_N4[I77*\YK*3EI>
MIK-Z?7FC=J]FXX(I^=XT0C2(2)#LPZ%*L!BD-](`ZX'H;5QIX_W.KV2GSNFM
M9K0EK@9BM3*+>CUAHX5BIV/<1<@F@Z0BB+MECM'1P*H00.0P@("`A@<50XQ\
M>Z-5J_3J]IG6:$'6(AC"1"+FD5EZX2CXYN1LV(L[<19UW"A4DP`3G$3&'U'`
MZN`XF<;ZU;K]>(G2^MT[#LMS7'5K76IM<<-7*U4@DJY#"T9*QAF\>5*+1*50
M$BE!4_TS=3#UP/DO_#[C-LM6AK6O2FN71];["@MH5;X.H5Z.!M;JXTEF,4[=
M@TC4@D&:2$TOW-U>Y%03`)BB)0P/3V+2&A/J=^TDM9:DAT))JXBB/G-(IC4$
MEI%$[1+V5%XQ,@N.]4.PH#U,;H`8%&^.7$+COQ^U71]!H5W6=UE:1&2G20GZ
M=2#6N4:2=@EIL7KUB#%1U[+<\H*!#]!+V)E#K\V![QMP]XS--H2>X4-*ZZ+=
MY:FLJ&]=FJ%>-'GKL?*&F&R"<4:-%BDZ*^.(BL4@*&+]$1Z8&NR^'W&?;==0
MJUTTKKEW#MYV$L223&H5Z+6"3K[Y.1C5!<LHU)8R2;I(!.GU[3AZ"`A@5"_,
M;I3Y?S/:MZ_Y/JG_`,T8%/-8</>,VH*HG2Z3I37+2!1E9R9(A(5"O2K@'UAE
M74U)F^+?1JS@4E'[Q0Q"=W:F40*7H`!@;GO#_C/(;-@MN.=*ZY-=:Y4YBE1C
MLE/KR;!.!G9!C)R**T66-!DX<'=QZ8D6.45"%`0`>@C@4TY2\.>.O(C2NP^.
M,A":UUU)[;K"L(RF8*H4=O;V""3UJ_5D8%DJR0<N5$O@!*8Q`Z%*)NH^F!7I
MAJ;CY*K/T(S6FFY)>+<BRDT6%-I+Q:.=E`1%H_3;QJAVCD``?P:@%-Z?)@>:
MI7$OC;K\]Q4K6EM;MS7N[S>P[%\53:X^]^S6!&/0DW+8',8I\$U53C$NU!/M
M2((")0#J.!\]@X@\:+->:#L66TKKE2T:T/85*HY1I]=;-&QK1".J]+_&,$8T
MK60!6,>'*3W2F]L_0Q>@@`X':7GBSQVV+3['1;1IC6KBNVJ)=PLPW:4JM,'*
MK!Z04UR(/&L6FX;*&*/H<A@,'S8':P/'/0M;@X:NQ>F]8IQD!%1T+&IK42K.
M%DV$6S18LR*KJQ1E5U"MT"@8YA$QA]1]1P/+U?B'QII]KO\`=(/2NN$9[9C^
M&DK8LO3JZZ;N7<#'&BHX[-HO&'0CR$9F$#E2`H'-](W4<"F&V.(/''=%MT[.
MMH?6,*ZX];5_.9)1-?J=%6)+*$IMKJAZ];44V7>SC@3LAG0@J`=%&Y1Z>G4`
MKJCI?CU9XA88_5VGY>(DF[EF9W%4RF.VRR2I%&[@J+MG&J)]Q0,8HB4W4H_P
MX'1:WXG<<-4:]I&L*;I?6[2I:]J<!2ZRV?4RN2;U""K,6UAXI)W(O8Q5V_<D
M9-"`=94QE%#=3&$1$<#YX[B'QIBMEVO;3/2VN272YT^ET6==GI]=48+5Z@RM
MRF:X@WBSQ@LFCI!]?)`55DR@HN4Z93B()$Z!IL+B'QIV?'047;M*ZX=,Z[<*
MK>8LC.G5V..G8:9--)^"754:1B9UVR,BR3,HB8136(`E,`E$0P/?#HW2@^GY
MG]6_YOZG_P`T8'A*=Q?XRZKKY*[!ZBU;%Q#B=FI1(DK4ZLX46F+1,O9R0(DY
M?QPJ',XDGZHII`(@0H@4H=``,#R<-QGU%4^5;3>]5<UBI6L--.M7GU[78FLP
M23^+6LX60;&LUC4FLBNX14#V0$4S)@3Y\"5#"7B94SLD9*1TB=@X,T?%8/6S
MPS)T4I3&;.RMU5!;N"E,`B0_0P`(>F!V.`P&`P&`P&`P&`P&`P/_T,_C`8#`
M8#`Q2H>L;?=^5>.:GJFX4]X1W/>Y7.=OIH2\(T4>$ZFE9F/AHD+FHC]BUZBO
M;'#)-&)(N94)`@J>R`E$^!E:X#`8#`8%JKS![!H&ON)$BYN>BI[D+,V2QL:E
MKJD1E6M]J@8^\S[5XQB[A>&M,CY6495&II*J/7"X-U3`*)2I@*HDP,?#:.OK
M#`1L+KU@KR)W=97'$WB[4."VU%J%N-)_^=>O[&9J;5EVKB1B&KO6\ND4JIW*
MTR#%52*(4HF4+Z"&:/5T9-O6:ZWFU!6F4(*(1EU1/[@JR:4>W(_4$_\`5B=V
M4X]?GZX'>X#`8#`QM//Q6N6=RCM<EU=IC9>P=,ZWCJQ=D)G5-Q/&2A]XS6U8
M*%;(VZIQPC.3\!3Z#%KK,O8*=`'DV=9<.C0F!'W7L-M>;Y^T]M*:^W)#<KV_
MDND=DWZTO8.[&K\?P><:5C`9UY;9(-@H<G06SPSB/+%(.Q]R8*)P0`P]P!EF
M8&N`P&`P,36TRO+>M^5K?IHRF&V#LB[\M(NF:HB;AIJYRQ]>\4);B&T3A][:
MQY`G5^PE"KE#V0W=M7D(D*:[Z9>N06354<D.0/>^$V!M'W@-3RL!2MP4UA4O
M%W1]?\W'&QJU>ZNC9>>Q=U,I"7=6!:Y-FB-[V:QB&5D6>S3,SQ/ZN?M2"X$J
MB9"AE&X#`8#`ZV9540AY5=)NZ>*HQKY5-HP4!)\Z43;*G(W9JB8H)NES`!4S
M"(`!Q`>N!@4:NJ7)TE/Y2&JE0WM-24WQZ9KV%E!TW:E.V%K:N1W*J*G-AZUW
M'.2<3$-]];KG]5N7I6TS%&.M]6MU4"@(+%$X9('A^C#A)<SK/K^M72G<7[5O
M2!=\>:_;J_::>U)&,=7TR.ODE5*C<&<=+P=>D+ZV?G*`MT$UU_<5*40-W"%Z
MG`8#`8%B/S7S52KQ.(,^+3;;_85:Y+ZNL;1/758VS:XV/UQ%SZBE]E)N.H49
M)071%J8@#\:07!T_1(HAUP+8>]HC=MQY6[<0US4]U&Y<S_+]I?\`36PT*OL2
M/@VO$QSJ.0.Q0:71=DC6(>I"]<)I+0ZJZ2X2`AWMP.'4`E[X7X*W!OF4FH&I
M;3J%.A^(&L*AR(^WU?NU8:V'ETSV=M)];Y`Z5O;-2VBV(U5Y'_&RK3WTE6RC
M=/WC]@`4,EO`8#`8#`8#`8#`8#`8'__1S^,!@,!@,#C]E'W17]I,%A)V"J!"
M^Z)`'J!!4Z=XD`?FZ],#DP&`P&`P.)5!%<O8NDFL3KU[%2$4+U^8>A@$`P-O
MPK7JB/PR'5OU%`?93ZHB/H(HCV]4^H?O=,#GP&`P&`P-AR%.42G(4Y>O7M,`
M&+\O4!$IO0>@X&P$$06%?V4O?,3L%?L)[PI@/7VQ4Z=XI@/R!UZ8'+_MX&N`
MP&!H/J&!Q^PC[WQ'M)>^"?M`O[9/>!+N[A3]WIW^V)O7MZ].N`3001%0R**2
M0K*"JL*29$Q55-T`5%!*`>XH(!_PAZC@<N`P&`P&!P$:MDA6%-N@07`B*XD1
M3(*PB'016$I0]T1#]_K@;TD4D$P202312+U[4TB%3(7J/4>TA``H=1P.3`8#
M`8'"JV;K]/?016[?^#[J1%.WK\O3O*/3``W;@J"X((@N!/;!8$B`J"?_`'L%
M.WO`G\'7I@:IH(H]_LI))>X<5%/;3(3W#CT[CG[0#N.8`]1'UP.7`8#`8#`8
M#`8#`8#`8'__TL_C`8#`8#`8#`8#`8#`8#`8#`8#`8$>.6]OL6O^+_("\5"2
M5AK34M17RP5^60`AEHV7BJZ_>,'J15"G3%1NX2*8`$!#J&!C':XY'<[.*W%[
MQM<][/S)V)R.IG*FYZ7HF]M!;;AJG((>QM^0&)++:HFXB$C9V(EH%V8JH)++
M+$52`W=Z`("%S.]>7^8H'+RL\6WVK-&V.5O^P[=JNG5W7_+B@;`WG%66$JEB
MLM:F]H:BK<"Y'7]6MZD"5L4%)-Q(L3NTA7;@(B0`ZC7WF]K.SXK12-(X\W2S
M;!O]$Y!7S;NM(2?9OK-IYKQU%^PMD,**4:(V2:E+"S*S8I=K3W?<[PZ].T0E
MEXU^?YO()K:;V<U@]00$0U<-"-H37>[T-GW.J.G(*BZI^XJ@O3Z?-:UOT,9/
MM<LU4W*!QZ^TL<`ZX%RK`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8'__3S^,!@,!@,!@,!@,!@,!@,!@,!@,!@42Y)Q^OI;C]NB,VQ/2-7UE(
M:TN+2_6.(;.7DI!U->#>)SLK'M&<9-.W+QC'F.HF1-HY.8Q0`$SC]$0QO>-_
M'_Q<ZPE/'Q-[,YT\W^2.M%)BL-_'E4.3.N]J4_C&VNBC!P6D/H1Q"<9=641:
M\(M_<-$!:)8%^[K[:9Q],#U&D=`>,J.Y#:OV!KWG1R-GH%QY'-M36H-$/-:N
MFNO([FI\!90V[4+!:E>.49L!\S.V._%BO8;`2)2(408.E1$HB%+O&)6.*EA\
MFWF,E*'L::H&U)ZPR]:H]8URQMDY<Z5345D@OFQ];2IZ++TMS,/;R;J:.BCS
M"R1B_P!DHB`B&!<[\=.I.)^I^57+EA3.4^T.47,Z2A=<N>2$[LRCPU%D*]5R
M-E"T..6C]>Z?U1K!S-G2ZF?JI%>31ENOQ@IC]'`O.X#`8#`8#`8#`8#`8#`8
6#`8#`8#`8#`8#`8#`8#`8#`8#`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g662896g77g14_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g77g14_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-S=G,31?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`+8!O0,!$0`"$0$#$0'_
MQ`"+``$``@,``@,!````````````"`D&!PH%"P$#!`(!`0``````````````
M```````0```&`@(!`P$#"`<#"P,%``(#!`4&!P$(``D1$A,4(146%S%!(B.W
M&'@Y,B2U=[AY"D(T.%%ALK-TM"4U=38W@3,9H5)VMB@1`0``````````````
M``````#_V@`,`P$``A$#$0`_`._C@.!6AVZ[:6)ICHI9]M4X6V!N5_?ZUIBH
MW-\1EN##&;"NZP8[6;!,GI"=_5UJ*&BD8W/!!N!$J3DI91@1%C%C(<NAF@$`
M5NWXCR:Y-E7S:K)WVNNV_!>5@M]U`G8?U@Y4SC2O9<8:V].X_IIV<*'X!:;&
M$^0Y#Y%P.A+J!W^G>P\>GVIFUCLWCW>U:*0$S9X3I$S.W["TT[GB35OLM#VM
M.`A.!-)2`A02)*F![37("AAS@HM4G*"%U'`<!P'`<!P(M[G;<U1HSKA8^RMQ
MK5`8Q!&TH+5'6O`#I184V>#P-<*K:%-V?4:[2^;R%00A1$@"+TB,R:9Z22C1
MA#D$?:9MO=97F_.P>RK>>[>F2E1)8[3-?V_.JWJ75QA<C<JHY6U=,4#=V(M;
M)8LV9)+='Y>)4M7N03!CSG&,9$%P72_LQ>2>YMCNON]+.E-[(:2KZLKTU[M^
M?J2G2SC:;L5UD<3<:ULZ1E%)QRUZKZ61KT-SNH!\U:WJ_!XA9)!X#H=X#@.`
MX#@.`X%0_>#NI9NB^@<TLVDSDS9<UASNO:'K"4KD2=R0P236F\&-ZB='MRLL
MU&O51:.(5ZI"2>$9`W$"?!H#"_46(/7SIBK`;K!_&QKO>^D&Q07(;_C8<%KS
M$VTC90(SWQ/BQT.=!I%A)JK](:$PD2,97ZG)?H^G`[UND/M#4=@E"N\#N=:T
M-^Y6N?V7%[U9D12=L3S]F6EF`A=\1-H*P44"-6$C2BPN*3A]EM>R5!'I*)&E
MP,+NN`X#@.`X#@0RW[W<JKKXU?L+9:UQFKTL:3DLT&@[<>47([3L]^P:E@U:
MQ8HS`Q&N\F=0XP,S`#`HD)2A68'V4YF<!ZX2[+VV>V\GZN\-I+SM1ZLMV<#W
MEECD*L:6PBO:62*%0UK7#:JC<8=&U"T(HP6,!7S3`G+EIY8CSS3#!B&(.N7_
M`$YF_5\;(Q/8C5S8^</%MS/5XZM7Z`6_)LEJ)K+:EM1))@-##8#F465A^E4(
M>X>J3X=#0_)<$2DG)^1FE#-,#ICX#@.!SG]TN_\`LOK/9;3`M;)\]0$JN]1K
M3V0LYV8&C7]^]E^>;*@E4T`9,V2[TZQ^DM=%OQ,G-<F."$'35[$240W@]>,"
M"'AK#[=KHI];LM((56S=>P8:X;CS16FL.VFRL:]@U3]?D4U\K"P)#`T,?IY]
MF(3KLV+G3RQM3(Z*GA46^E8]3@2E]9*4,7V@[AK6/M=J:8"S1JJZ?I&S=HY+
M:RA':C>OON=L&AFK\PLZ\XH]5JKKUQ9(74K_`'6],,.0O@G0UR6."')F$04R
MXK'`V#'.X.S*1-:(K;].&3*JZA2636UNW<[VXT.][2>Q];^OYFW'OU^2UG&*
MEAD)<&N#R8TR'.:X"EF*.>%J<:="4`"@HH)6ZO\`9C.K:@&[LZNBJZJKEMTQ
MK6'3^1O%574HN>,+'&4TH[W\_0-S?S()"$:&6U9"%#*D?`ILK$PG-8;[)OM`
M!Y"MJH.SW:VDG:DB[(O".;OO=VZA:_3BQZ^&RT]5C!K5N%M5<M1UK0E7/UOU
M;%TC7$J[EWW]D1JY-(43L_(6R(C7$"/]\))H;EF7>9<4=@[^Y1O5>LK"EU5,
MFP,CMM2P;!NJ:M7QEI;:^&:H0Q70TH/J=2Z6$9L)/7IU01C"Y$TIBG)H/+/4
M")+R:(/+69W@6;644M0I_P!=J5:+,I:3[HNTZ0R/9A<QU<JJ72U+4B26EPB?
M*JAP^3"YYE9%R((2TL!+&6F,?6]:<)3A*$GW`\1,>W2\*]D%YR*.5$AG;T@%
M<ACC7MB70V1.J*3C6C^F%/7ELW+6=ZC=)N<X5DBN:[D\*-3K1NIBQV1%FE#;
MB<G$%AT"U/,U]CU96EANL<4PYTGE?PV9N416J@+ED67RB.MKXLCBM:62G+6*
M6-0N$F,-"67@P9618"'SXP%??:SL?;=`5!1S#0KZYL-M;`;2533C2MC9E/$S
M%/"`)9-9]Q*H<HOX9=.-\C+JBN'<I*KD.?LY*>>`P7Z>`8R%5FNO;/L4]0C7
MJ3N>7'8:U)/55*1TN&'/D#IF$V%:FZN\5D5#32&=88ZK?,(Y?4U$4"_/"Z0Q
MM67%G=.!6K1-AZ54C4E!_5V=TFPUJ:XK(I1==535E[32"QN,.DV/O$1QK#-M
MBMN[-TIUZ>-5&%XK'+C>CV].]:NDXR%S1L:5O8TY.#LF&CS@(;`SW`7'`<V*
MJKZI![#1TF=3^>J'RR+F9XL9&*F!O2W]>M'Q*M$,-I01KZ\7G,()(']D1NII
MF2#LGX4NQI620`"8^LW:'+ME]PFFAHU4=;D5++$.U\BCDT;;G4/UOL,*U0M]
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MZ+$%E#3@<5`2`!C[+W*6M8.:SLR+U(F=7P^"Y;HY2L!O"/K*BNV<WYV$M>C.
MNC@*P)#2Q$K^S),BK":S%D<DXVY,2REB^4B6>L)J0)H?_DIMK]P7][+\"JY^
M_P#^];^ZS]W_`,7WK\%/=_?)_=#_`!>_%+\-?O1^&?VQ_P")>[]V_F>U]/:]
M/Z7`N'X%*-U=K-M.]ZVGKWU_Z@&;:O5`O^(9?-R3NY6*@-?H)9):0A>OJ1@F
M+E&YD]V+8[$D5%_:R9N;@I&@T>"CS\F^L``PY/>=9]P%3;-=96VE/3O3/:;%
M>-4L=*Q>9*PS106R)W]&XUMLMKE:,?`A8K/B\*LAF0G&F%DHE2%<4!(M(``[
M`AA4!14VM!$^V;K'LPA2L&VVK[TCA=Q(4H!IVJPF)81[]>W_``8!P2C%L#MV
M/A+7%C"'^J+\GIC,`&'`,!_-W1FUXE+ZOVZU>$G2;7ZP+US_``-`><-(TW-7
M;E@'XF:Y3<PK(1*HQ93,4,*(0O(FYY`0I)R`SR/`=7VF6W%4;R:X5MLM3BT\
M<6GS4/+E'G/T%2>OYFTGC:YI7$T;\>#6J7PB1)CT"X@80^1E8-+]1)A8Q!*+
M@.`X#@?0J5)4*52N7*4Z-$C3G*EBQ4<6G2I4J<L1RA2I4'"`40G(*!D0QBS@
M(0XSG.<8QP.-6]-B%/:;MBEO<@\Y1HMJ9*W^/:?,)N#`-5\W0VC4L$XVT=$1
MN,`<8Q'1A/9H)[H<A]O"AQ!@`SQ!X'FK?MF$496LQMNQW037#X2TFNKH:4#*
MAP<#Q#`G;&)D1!\FN4AD+F<4C0IB\9&>J.`'&/'G.`EWI"V,75YJS<_:'V(!
M>HML)MXNK9(FIB-M1DFGD'A`!KT&M&H%9Q-,(IPE=O.V7\]:\IP"+];RL/\`
M?R40WFJ,!N!Q[F=D:H:PVYM+U6WG2FKI'M.$MM*+W15ET674,3-&`(YK;U"0
M].DE#%'VDDT*AV^S%KNI:2`F9,*,R#..!>S#Y?%[!B48GD(?FR4PV:1]GE<3
MDK*J+7,\@C<@;T[LR/36L)R(I4WN;:K+.),#GP,L>,X_+P,CX#@.`X%"5Y=S
M=B+;FLRG-"=0OWK4-'2UPKVW+RGMU,5"TBCLQA%Z)16==/2N+S9^LJ2110,*
M9U5)D:9N0+`B)]T[./5P/!J;<I?O9UEV=Z_[MKR9ZB;80ICC4M>:MESJQ2J0
M5Z^I'0IZIW8JH9DQ^RR6O5Z>8MA1)ZQ*6E,\9.0*RDV5)(S`XEW^(6;4MB61
M0=[1[$/OBCI0?![1CH<YRB/7D%A4,TTC1X@@^TX3/F4TET:58,>V<E4!_)G'
MC@9I2-_6WIOL#6NW]!X$JLBISCT<CAF5(DC7=-/NQQ`Y]4$BR'R6,MZ1)_DM
M2@81B;WA.G4EX]8,<#V7>JVSE2;D:_5ALI1[^&0UQ:D:2O[.<8$)+HSK/(TC
M[%)(AP,8FJ51)[3J&YR2"SG*=:F,!Y%C&!9"07`<!P'`\<[N[5'VET?GYS0,
MK&R-RUW>7AU5IV]K:6IM3&K7%S<EZHPI*B0($9(S3CC!!+++!D0LXQC.>!ZW
MKLZ[!G7L_P!J/Q(8E:XG4>A%[Y%-48RH^0G3S9Q&8)LF.R3TW'!+SEPF@DV4
ML=`:#`T+$6`7I`>I4>L*_91)$,39%;VO*5J\$B3I4+8W)S%CL^/#@>6B9V!E
M0D!,4+WEZ<3BTZ8@L(AF&CQC&,\#L1Z^ZWKWH>T"E.U&ZV7Y3M)MY+H&LD-0
MP-KQ)[$<)<L0KFZC-3:GC19Z<<BEL::G)6<Z&Y-*2EN*EP..."D3`-X&W4W>
MY9]:*44VW!ZX+<UVUO5+414@NF,7+6]\.M0M;BH)2)I-=57PQ`V2.+QE$<H`
M)T5MASS]EEY%D8#/3G.0Z%V5Z:)(S-,BC[F@>F%^;$#TR/+6J)7-CLT.B4I<
MVN;<M3#,3K$"]$>`TDTL0@&%CP(.<XSC/`\GP-1RW7^AI].H[:$[I*HIK9<0
M+0DQ.Q);6T-D<ZBY38M4N3:5'9:\,RQ_9"V]Q6'*"`IE!6"CS1C#X$(6<AXI
M]J#6Q!@MODM7T>B#/%#W#"D+["H$GQ,U4QD:^TY'%"TS@V`Q(E$JES:ID:Y#
M@)PESBG-<#0#.+&=@/J7:RZRG/DXF;GK[19TDL-,ZEV3*E]4P$U[FZ)U1H$C
MV7-GQ0PB7R1(Y(&A,6K"N-.`<4F+"9@02P^`B_!;2ZVMRE5A5+K_`&]K185A
M+XK:KS(E-$.]4O\`9\116N0WQ"TI^D4M[<^FM3M*CG%"0ZKU*<X#D=E.!8%0
M'T@R&S]7]$-=-3:<FM'5[$PR*%V>_/<DM(NP$4:?,6,Y2".L\.<"9+'VN.L,
M$+8<0V/H6DMI0-"%I+0IL`PF\C-$8&SV_5C6-HKB0TZTZYT2U5)+E`%DJJYK
MJ.`-]=R5868G.+6/T+1Q\F..ZLLY&2,)JA,8,(R@"QG&0AS@/X;JOU>%&UWV
M17="CB$(:VV!..&R(UZ..1)EIJ4J)8SPI8%(WY;6%LJJ;$&N25M'[13&Z@$H
M++(48R/@:)F3EUHREJB;Y816F$A:5UH99((OFC13CH0X7-L,VQB9*FR(9?41
MXEUD7&TSQI=5A2+`W)Z(<R%)^#0FA'D)-K*(H]PP]A7TU5*X,E13END>%E>1
M%3B0-]GKVUULI`]X.9QX=4=ANC,C4OI1_N`=STA)BK!HR@9"&TRBBB"BR22R
MR222P%%%%`"64446'`"RRRP8P$!8`XQC&,8QC&,<#6EHTG3-X-3<Q754=8V^
MQL[CEW:&:T8%%9^U-3ME,<CRZ-S=+&IV2(7'*1085[Y0`F>V,0?5Z<YQD/&.
MU9T!#R!3I]K^GHLFAQ48?!S%WBD+9"(J16C*]LD+=Q2%8@2EL94`CLB<DC6H
M]XH+4B7*2B!%%'&A$'CL:PZU!>X5)0Z\T=B15LVH&:NG[%30+#S`6AJ?\2MK
M:X6YX8/FQ9N;91C[23DH1D%D+_ZP#`3?T^!&PF[>L!EN0&KZ6<Z:-MZ_>&&P
MLNCDAE3IK`Q)H;(5=F0"-AA)!`77#G$9:]J']I3^QZVYS5FK2,%J#!F9#(M<
MNOJ@]9KIMW8:&?>R16]<Y;D@DTOF"J,Y4-[`\2]=.W5@9T</BD.;S2724K0J
M5;@Y%.+VM^*F`H7&@3E!"&^X9K?KO7+Y*I-7M"TO`Y).RG`B;R"&5;!XN^3(
MAV5&+74F5.S(Q(5\A*<UIHCE`59AV#C19&/R+.<\#PT'H?5>#"#7E;4W0,0'
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MQ[5=*(0XL.]NHI$IKZ\];G3&$<WEC#%E03=BM*K'18`0I43&,.19KU!EAA>,
MFJQ$&$%A`Z>2PT34-L0B\JUAMMUNZ"=8=-V@EW:3S09(7H3<"$0XLCRC%X-;
M9!'W(DU&N3#Q@9"HD8<X^F,Y#Q-`[%']6FVRBYUJDU)HEM]+V&/;9,X`C$SZ
M_P!\.HTL?@NU*!(7C(&N(3$S)#+.<E!"`.<IG$SU"(P#(=DY!Y"H@E4E.*4I
ME)19Z=008`X@\@X&#"3B3B\B+-*-+%@01!SG`L9\X^G`^W@.`X'-=W-[;R"[
M9R'JFUXE#BRJ)1'6V7;]VK&50B%M3Z^/F/6TT>RNJ?/E#:>PY`1$&`P()S?%
M\G'B#D*P`@!&>,QI@AT>8(?$F9!'8M%VANCT;86PD"5M9F1I2EHFYN1DA]("
MDZ1*4$.,Y^N?&1"SG.<YR'B=#Z1CV_.P+GN1<:IK;.N;0>4/SS6BJ3J"4,*V
M%V4KDI6?++O>U*W);<NI36H*0\MK/-%\-;(2S5/J$6C-+X$B*B?'_L^V::>Q
M:R6QU;=4Z95O\>ZT:CD*8]'B0A.&<S3#>*:,2L(!8DE@`3B1P8E06$QJ80_+
M"$)Y_NF!+W;6^JPUIUTM>W[?,"?#6:*.;)B-%I<N;K8DDER-1'(M5\<9`!,/
MD$CL)Y<"VQ*B+`,1OOB$+'M@&+`2GZDZ,LW6KK6TRH^Y$9S59L`H^,()='U!
MPE"B(N#D)6_$P<\W.18$?!D#J2T#P'.0!$BS@.<AQC/`L3X#@.!\9^N,X\^/
M./RX_-_S_P#TX'&5H8W+Z/:+BT8LM`;'-A=4+?LXNP&E>6,D^P85:ECRJQ*S
MO^/'G8"8_P`5L^/R$L65@?4(E>28G.])F,!R&RMDZOM,J15EMCJPJ1,FXVKJ
MU=(*M&L-&E8[A@KAC`K%UKL09(RA+(5:32`9240Q>6QYP0K)R6/U&8#&.S6C
M8%VWZ6UQV\Z-Q=>/8JE8H[QV]*7RG"58<L@<.5FF6]KY.&=.4`_-UT(_?+7L
M6#"PFK4_O$D8-+7(?`<P<??FF3LK5(V%:6O:'E$0X-RPK/C!J<\/J#Z@_P!(
MH\H6,@,!G](!@<AS]<<"VCI;[&<]=>S.:EM!\RATLVRF2!)(%*Y3@MDU]V)>
MLI6>/V4')PPI6>`V@(M.UR,7DLE*L"D7CR$LH_W`]A-C.,XQG&<9QG'G&<?7
M&<9_)G&?SXSP/G@.`X''7_J+^R=1,79?U<T!)324JE"U/>\4[8%8P',T/<BB
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M$*K",L10#5+X^3%Z<P)P$%@%D)/N&BQ@!8LX"_\`ZX:9L/7;073FB[95#567
M5&N-20><8&HPLR@DC##&E$YL@581F`5%Q]07E"`P(A`,"GP(.<XSC@33X#@5
M'=D6H-M;-7OH9,Z_A+1+&#7R7W_.7%X>+*=86CKFU'JH#&#7^QG*--SBA,GL
M>B=@&"5+T:8)J_(`%DX`-$I7E&!AW57J=M-1TDL&Q=BDDF@1LNI*AJ\E$!DN
MP[_L4Z6UL-"!3AYO?;20O#@YN<;AZNUG>6I&YM:FKXV<-+06)4F29PG2DA`J
M].NKL"=H-+LP*`-SS(+JNWLLOJ5Q"([/N-#HX9=EGN\7AF@=ERR90K#>^SF*
M4U3D/RH^P$1_@F2*48CPY`FR>0'B=I=4+KUPK.77):THM6;(W'9_6JC<0-MV
M-NM".?Z%U%KS7$3D4/9SX"7(RH1/-@KDJS[;E:T20MZ=6K!K<%=A0NPG4@U?
MT%WRFRC0QZO-UV'9:>::HK*UG1ECM]C8)U1MW2C8BQM@K.9[+-LZ0'V@\830
MESB,*3B2IG=T''4*]H.RU9..4&!).HNN386+=5%VZGL<&C5-;$[,WA86;PD#
MK9+_`&['G6%6_?BA3/[5CZX$_8ER!:@H]Z.^RFX"M,O4JFXG"\`U:E0=D-5P
MCK=V1J:`Z`UN3J[5U@.L+W::MX-G;*BDYBL.2P-6<[292T4U7[98DJL"8.J&
MMSD,&":H0+RD3BPPTA(#!JC`!B#INX#@.!7#VP:WSO;/26>T57T%*LMUED\H
MU:_P0=A"K`^55S&+K@4GM-@;Y88I2-:9T>ZX:'1&G*<!_!--/Q@S'G`>!"K6
MC1_;^'[X,MJ38A\AU9579^P:U+8(ME);/6:U]8Y#!2ZXU1U:C-*GNI[?%F&F
MFD29[D+H]I`+UDH9_F)U*T;DI/*#]>Z&F&W%I7SM1=%;PUK>FB:M6@=&Q5@C
M=MI*GL*Q=7ZXM:>6UN-$66P$@4:^L'ZR%<X3L@E>5B96K:&]0`DXL1I.>!$U
M-H)NY6E'2^PK"F3W7C_0NHVY=E4LSMVRMUV1#X-M[<5^3V9U*6ZX;UKQ+[.B
M&L='0J&((V:]H75(%6J-%\`PP@8<!&NE]2]T]@*>D<LI2*[!0O7"<;.MS*^T
MJ_;'RB0V'-:@JK5M%%8_8D<G.Q+Q%VB0QJ9[2S>3R-^"0)*A6NR-(M2IG8A&
M$"D+A-1]&;/UIV0WUN<J%/<AFLNI_7^L]:+JLB\G*TGNQXS56N<0B@F&T8\M
M>F+VYAFZ8VN<G=R4%H4RP+GZD!B8!RS&0KLI;K6[&=.*@N)[JBO:8M?9J^'>
MKZP7SIO?VZ.KJ>J=&U.]L77<T11V_8-@PZ;7+*+[L5Z3,)"XMO1)CFM&\K2S
M2SC&S@=$VFU%Q+6C5>A:)A$`6U=':UK6.,)$"=)2BG#S'7(23#C(4[_-&PI.
MVRV1*I$N5J'%S3%EIURTXTXH``#"'`27X#@5*]I6D]@7>QU_MCJ?EN8]\=1/
MMB2TPI5B"C9[N@#@7@VRM6+(4!$5A;";6:B1`0#/%Z6A^PG5%B)")0,0:QU6
MV8K_`&ZI"*7=7A+DT)7DQQ89C!I$2)%,ZJLR,*<M4_JJ=M9H2U#5+H._E&)5
M)9@`9-+P6>#'MF@SD(B7ROE?7%LBJ[-:?9G=ZHN<IF&)=FU,QA(<L4/]>M'I
M;HGN'#F!*$7S;.HT@_)4@`6'!KQ%QFY%GW2<G!"LS:.WM6=7^Q2<K]5IZCL;
M3_9=NKZU]CE-<M:]]IC3K92]59!-;2QPL)K).AD68-K$IQ:M8RB/+.0.?I7"
M`62I`7@)<RR*1R;QJ1PB9LB&1Q.5LSE&Y/'W,H*AO>&1V3&(G%O5%Y\X$6H3
MFYQ@6/T@"\"#G`L8S@)6=+VW4EJN7+.JG8R4N#[)J[C"V8:-VI)563EUV:RL
MPL%J*Q=7%0/.7"UM=2Q`0*2L"$<NC@4RH(/2F/,$'2#P'`K:[0M^D.A6OI#[
M%&1+8.RUSOV*EU2IW)WI46%;STE%E*X.I10L*$U?5ZB%EYD:W]`M.WI_:]P!
MRDCR'.UKS3"ZG(>\#F,K5V5==H2EUM386WW7]-YM.X94/Y<ED)Y@L8&0QMPQ
M80,Z/'I)0MB<HLL`/(L<",>[-P/KH)9KC7J"V%3*2P,-B[P6G1T3/G$TU;TP
M<9*WQ^?3](S(SBE`YC)&A6I`@()]U8F:B5B\!!@"<9P%F=F2:E]_#*KZP=#5
M[.W]56L,-J]TVRLRK7$6(E<J'#.VRFI]+J^D[>,(G4B0(OC/UE.`3#%64Y@4
M2@859ZH!H6XDDL<99"DY!;-%XO&&4!)))84C+'8S&H^W8`66`./80,[$Q-"+
M&,?T"4R8G\P0_0*_M)*S6=HFRT?WXL9L6AT7U@ECTBZ_(`\I3B$5]VZTGJ&&
M6;N2AI5@"%7'&%20H:JY)-!G(,`/=,>V9[0C0Z0^`X#@.`X%*W;CHM/;:;H7
MNWJ2RISMWM5VMR$QQH`\(TFSM$*CA.5B:R2XTOT_*/?"@#7Q12;ZLMDA`'T>
M@*LTP(02H:\8%L?4T/N2M5BD^,RY$:,;<Y%?$D$5D#<>-ODT)EC:+`3FB6Q!
M[(.0KTI@0C+/*SG&/0(.<AIM#;;SU<;0..Z\72."W3^^W./QSL(KAG3J%1<#
M=_<*9(;NI%&=&`T6'"*?(+;YR407D;BRB"K$$:A.`984B=JU<:WT#OM;JW3R
M2$S_`%@L!;"9?:J^OF96[TOJ_LI=@'5_:ZR2V2TE'P8M%<K2B^\*)H3*?4T*
M%8B/2`L9180A2^,C7(FATC[ZB*<&AX1*&US0GA\EJ$JD&2S2\^?Z(P^?(18^
MH!XQG'UQP.P__3P]FKI<4)4]?&QDJ,<]A-?HJ4X4O-GU7G+G?>N38,AL:51R
ME0/(G2Q:DP,EJ>PXSD]4@^(NS@P?S#0AT^<!P*C>XWLO:^N+6C+G#@-<DVDN
MQ4X5[K'7RWVU!*R7B2`&\6-)D>1>O%?54W*@N3F,6/0H.RE1>H(E81A#U[[*
MW.B3#NZR61.LTG,P?WF:V-/']08LD$\GTG6FNDGECVL-SDT]:ZN2@8L8SGP6
M5Z0!QC&/'`\I&8<1;4X!&Y2TVN5K#6CI`Y1OA<-111;+G6A=>)-)"FA:[+4[
M?ZER(Z1!`:!2H2E*U;4S%JW'"8XM,,/`ZD]H;9J_L`ED)T!U%''T/53I^DKX
MB\I%6ZHO\/\`9&=1EI:'NKM5X`[-AHTK[4-=H0H7:9*RCC2W!?A.A$+(BQC-
M"43BXLT;9E[N[+6N.QN.-"EQ<G%88G:V./L#*B&H5JU)N?:2-K2T-J7(A9_1
M+))+^F,8QC'`QGJVUQ=-Z[P8NSJZF%>BUXJU2],_7!5,E0FIOMX9V36F5;K2
MUC5A#C#Y,RRQHH*6>#)C>S8$O`$)IZ8_(=-_`<!P'`<!P(!7;<=D13L,T.I=
M@DIC?65O5)NO(K%BX6]J/*DCS5B+7HZ!+C'%2B.=D`H^9,G/(0I3R2SOE9P<
M$ST@](3]X#@.!7U<':CH)1MA/E3SO8IA667%3/9F,'K6)V+=<C@YV,>H:>=M
MM,PZ?'PA467^F(EUPC-"#]+(?'UX$B->MIM=-L8BJG6M]S0&XXRVK<-;VKA3
M\E<ET9=\A&/[$ES$+)+]$'W`"Q"RA<TJ17@./.2_'UX'Q>.UFL>LJ5L6;%;"
MTM1A#W@>67\6+-AT!.>L%C]LT3.FDSPVJ70)(_H/)`#,`S^7QP,@IO8&B-B8
MZ=+J"N>K+KBZ8\"57(*JGT6GS2B5&!$,"1<NB[HZ$(5@@`SG!1P@&>,9^G`V
M]P'`@!M=<EDUWM1UKU[#9*:RP^\K_N.(6HS`;VI6"61N,ZJ7//F-K/5+D2E:
MW%H)A&T*[`T9B<T8TP0#$(O(P""?_`<!P'`<!P'`YS-_*L=.MS8Y[[*JI9W%
M9J7>[HPL/935T>1G*BX"_8$G8X3O1$F)&`7]>CGO%MM@ED`P-<T"+<!A&<2>
M<`)X)E+%)V1.M1J&:41:3LI2I*J(&D>8[)HU(&X)I)Q0\>^@=V)]:%F,X_ID
MJ$YOYPBX%0&N]1T-H_9UK=55]UQ$UW6YV=/TQ4:WR=4T($!,(O&7-9?WVU+L
M:2E$%*SE+LG1%NU7/*H[*Y.:EPW$&B/)3^R$7H)&[,U&O&;==NP[VX2.<U.R
M!EVM]MO0,DF[*:K&+!MT4E8E`O!2NR:Q$6%AE:8O(AA4)P*L>HDWW1!Y38>G
M7NUHQ''JN9496VP%-RUMMG7*VD>/"VO;8C?ZUJ.59QCRLB,I(")K?4(_40M;
M5`PF`'Z`XX'2!UF[YLF_FN22?.+(57U\5L]JJHV@I@X_(G.J+MC!)1<B:P%'
M"RJ41"2EB`[1]=GUEK6E65^F(TLX(`F9;5KUY158SVY;9E35!ZTK&*/4UG$L
M>S\)VUBCD?0G.#DN/%]3#1A()R$HDL(SCS1!*+",P80Y#CBC4\L+>+8*2=BU
MY,;I&<RIB5P736G7\`BU-"ZQJE7RDC\ZMPA#+1VY>N0%O#^=CR:F1#3H0B]D
MO``AYK86ZATG!T*Z/QA=8ULV!)F>L*%J)EQDV0VU<<O.^!$(<UIP9]W"/*L?
MR7)3]"T3<2::,0?`?(21^Z5@=8VO,3T?H:0,5H=RG9BL=;(O:Z#D13JQU"T&
MIOLRQK_DR<99@D%*:Z1]6..P!J/P`EV>`8$62(1BXG(3]U2U?JO3:A(#KQ3K
M<-)$(,@,^4[K2R</\WEKF/"R66!+%!(0X6R:7/`AJ5(OZ)0<@(+])))80A$.
M[&R4=E>RCAUL5,[O#/KE6?V!)NS2YHRK4(32HRX9`ZQ+2J%2!((/QY_;Q*?Y
M$M-),P:S1L(RA>#S\DC#I2B$1B\`BD:@L)8&J*PV&L+3%XI&6)$0VLL>CK"@
M(;&9E:6],`M.B;FQO2EDDE`Q@("P8QC\G`R+@.`X#@.`X'+5V,T"?UN;&/>]
M];-9Y6DFSTN:46\<-:DQIC?0%W/BA.R1;;UC;TH1`;X9.%AQ#5/0%@"$"LPA
MS%ZQF&>V&S5J-GD3.K;G!,U2*.2)I/1+D:D"9U8Y`P/2(1*A.<#]:C<VAW;5
M60Y_I%'$F?3R'/`A[I/!Z'I;\5NC_:6%1]1I7N\HGLITTL/X#<RK@S9\]M^F
M^N4PE)*0L1]P0)Q1IGZO'U8(QQ5)$924)AAR1*0$.=G8#7"V-(MBK$T[O0XY
MRF5;A)>J]L`Q*)(@O"D750>3!K29\>1$"<!D)Q-[ZF+&/*!Y2GE"SG&,"R&M
MFR1V-7$WKR[*3DPH1>E*2M%/ZGEP,9R2D?V_`BUD>?2,""%SATT:AFM;NB,\
MDJD*D81X\<#V0/6QOQ7/8UJQ#-@H40".RD)AT-NBL5"CW7FI;BCI2<J90=T"
M+P<8D*4'`6-:H6,87M*I,HQ@.3!`"$F[[O2K]9:9LF_KHE".&U=4\4<YC,I"
MMSC(4;6V%8R%.C3X%@QP>'56,I(@2%>3UBT\H@H(C#`AR'K0MGMJ;1W[V6G&
MXEQ)5S$JE*7[J4=6"U3E011]"H5IZN+Q`H`<_'Q+9*(_+M(U1>,?)<E(@!\$
MEEE@#2@D<TDD@A=:U5%5<_N2VI6UUY4<!;_'RY3-GTS!*(LX>?T$3$T$^M:Y
MK#,A(1H2##3!!`'.<!U-2^#?_BNU0KSJ7U!D3)+>QC=5D=[$VMV$$U$.9-4P
M1^(`P6[L3*4ZLHS);<UHQF1.L6-4$(3SRL'9![A2GY`;7H:C:XULJ&"4=4K*
M%C@E?LQ+0TI\X`-P<U0LY/=I$^*0!#EPD4C<C#%:U0+ZF'&YQCP`(`A#3;'4
M#OVH[/NVGL>4KTFEFNK\P/._=AM2A0E(M27D#(?8EI7$GA&,L9OVCDHEQGQR
M<S&437@M#D19Z@.!AUS,S,T1QG:H]'VMO8V%B;4+,R,K2C3M[4T-#6E*0MK6
MV-Z0LI*A;V]&0`HDDH`2RBP8"'&,8QC@>2X#@.`X#@.!5ML=_-=ZQ?[BNQC^
MS=5.!:3P'`Y@NR#M3V`NI;L'IEUI00:AQ@;T94-X;FR.QB:RBT*EB-6DS9E5
MT(I3,$E?I!9S8R#.:5<E*3@21=Q4"-(`H4D%#P$L.FC;77V31N2:0QC59+HS
M>M!QEJF,@HA*_H)ZP6/!7U;]E8OF#7$E1-[C<:=[DOJ)?G1W+"_DNIX?GY-,
M.P:,(H=VFTNJ6AEA13;6@;BH*O>SN!/,-8GVH#)8C9UVRM%6`\(XO)(1LW&H
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MQ_\`&WT__P`4FP/^"78+@6F<!P'`<!P'`<#P\BCS%+F!\BDI9VV0QF3,[G'Y
M$P/*).XL[XQ/*(YN=F=U;U0#4JYM<D"DPD\DP(BS2AB"+&<9SC@<T%21]]ZP
M-GFOKKL-R<G#4Z[%<CD_6G:L@5J%F(N,DPQ[FNCDO>UHC!9?H'A4-?!#3S1&
M.;$+*0(AJ"/:+":&S&N5;;8TC.:&M=(K'%IHB($D>F@WX<H@TM:%`7*'6+"G
M0.0GLTS@[^02O;U)8@"":5D`LY+,,#D*UUL.M;LBHN3Z:73)&6%]U'5^J1V=
MKW=:@`&IDV-@RE-AKAMOHQ&^@;E4VQ\=2!C5@MP1#+9I)@"@T(<A3$<#1VOE
MVH[WK[$E41YQ@<]C+Z]5]<=5/X!)Y14EO0Y6)JG5?R%&;Z3R3VAV*%E,:+'I
M5(C"C@YS@6?`?9#9[(=,=^-9-I*T691L.R]O5-I=M?``^K#19D6LUV5,%0V7
MA,`02B[$IN6GEX(6>GW5+*I4(Q"]`L^0EIW/S^0;)[DTUUZ.*X:'7*M:D8=S
M-AHX0(PL5V20RR'2'4?5K^((@>]7T=?XJKD#JDSZBG%04C`9C]3C/`U$_O['
M%6)YE$F=6^/QJ-M*]\?GIR.*1-;*R-*4Q8X."LX7I*3HT*,@0\^/R!#X#CSX
MQP,'U.>8?2U=2OO9W)B4A5-);6=4_5;K*)'G\0)*BL8\;#'YLPQ=048H'>6V
M#M@"=IS[(S&6&8$H%C*<XP183ZTHUVLV%J+-VHVM6M\FWCVP7-THNYS0FB5L
M520]O#D5<ZP5F::8=E#7M0M)@"#\EB_\5>??6'"-%[9G`^S=?8ZR*^_#36;5
MEL;Y?O'M@XN4/H&/+P"4L=;,"`K&;"V7LPLDL\2"LZ:9S!K,Y,!X<W4)",H)
M@LF`X%KFBFF%<:':ZQ6AZ_6.,F<25;G,K4M"1Y"?-KIN.7'!<[%MF<K\B-.6
MR&7/@A&8",PS"-&`A(6+VB"^!,/@.`X#@.`X#@8M.8/$+,ADKKNP(XT3"#3F
M.O$3F$5?D93@RR*-R!`>UO3*ZHCL"*5('%O4F%&`S^4(L\#DFC5?2_KCV2!U
MW6H[/#Y2TO1OLPZZ+CDB@Q6HEE8M`OF275Z6OA^<A6VI1)*@/V:(P6#G>-"(
M-"'`P>T$-L;&4%$=EJH?*MEJUS8#E"MLDL(GD=/$BF%6V5%U076"6;"G,H1:
MELD\.?22U)(RQ@R:7@PD6?08+@:-LZO)=W2:?2NE[%2QF%=U'62/*UL7A"0R
ML]_Q5R0X"URID-&$HM;2^U<;:RPJ,!_41N8D@]>""0!`>',)&WW,@;C#U+6Y
M1YZ;'%RCTJBCXE-02"'2Y@6'-<EB<@;SP@4('EA=DQJ<\HP(18$#SX\9X%E?
M3UM!/-0NR.C$416G'U;NG/(SKC>L!$:9AL=)"ZHW?-26HWI\"]E-+H:_`^$H
M/].<J&=:>4/ZX+$`)V?ZE7:::VOMA7VA*9<<V492E>P?8JSV(@0@8M*U9D\R
M5#6K9(/`_2JB5=,\>,<BDHL>VH=%H3#<"RE(R`.?AU=6YD;7!Z>5I#>UM:10
MX.2]2/`"$J1*6(X\\P6?S!`'/C'Y19\8Q]<\"_KK;J^)]:.J[YW(;:P)TD.R
M%ZM2.J.NO6(:;()\I;+*"(B"-#(U*"AJ6^RM@SL`<75;@K(V"%$B$+/ZU41D
M)6:QTQ/X;^(=Y;$R))8&X>S#ZFG^QD]38];:WKRD_LQ.FX#@8C,M=54\R"`U
M-*0O/MFB*,4"]0C`YP'X-BK$MB0S2M-,M3\I%FW^S7STD2=U)`ES)K[4K:8!
M/8VS=@E%8%\5@@B(T13,09X&[/QA"<G!@@Y`(.DG2_4*IM&-=(!KA3J-5F.P
MY(H6/LH>1A52ZR)X^'Y<IO9LZ=<^HYXF4W?SC5BP\8A8!ZPDE>D@HHL`2GX#
M@.`X#@.`X%6VQW\UWK%_N*[&/[-U4X%I/`<#AQTW8E=?Q_8NE7K/N2RBMVMN
MJZEBH?U5.[B;<;_-&V1KA9R(9JJ0QV6(U'N"R+(PYQGSG'C@8KL3>=OZB;6Z
M<[*:[00%FWG+&W8#4*#0#Y)2<$GE%Z0A`OK%2\EBP(Y7$H/9L:1/+J$./`$)
M!OD1?K]>`NSU`TEKK6&I@QV2-\<MR\;!,63+9N^IC'VJ132^+=E1ICI.9)(W
MI[1K7!7'!.RLU.U-HA_$1MI10`E8%D>1!SB[D7[)NK+83M+I/4:&J\ZI;.:L
M0UBM."0E00AA6KNV>R\7ET3A4_8&H`L(HDAE+2@/&YH482`X^TT0L8#A.C+X
M%5\>94T<8&./(RP%)&)G;6=.67C`0!*;D9*3'I"']'&,Y*\_3\N<\#J+_P!*
MQ&7LR6=DMB%&GD0M=,M<:X3I0X%A$X3F%069/\I<\>,^V):E9YRTIC!8QD60
MX#C.?T<8X'8)P*L]X_\`C;Z?_P"*38'_``2[!<"TS@.`X#@.`X#@.!$;>+3:
ML][M<YEK[99S@QX=C&Z35[8L>R$B:T];,5/RZ5Y;,$</44<W2J%/P`*"L@,+
MPI(R<E,S[)YH<A41I;LW.Y8YSW47;4;%$-]-8UQ$5MN.%G%-B"[HB(K`H)L]
M42)7A*<^U_:K'@M6K"E`/+0[94)CP$^``P&.KWF/VIW3:`QBEEB"0V?K96FT
MDRVK?XP<2XDU[0=BU^CB<`KFQG)O&8G1NLVM\Y$Y-+0J'\DGX)JS!(0YR/@0
MRF29,E[2NW`M*F3I2S;GU@5&EIB"DX#%2K4^`'*E1@"0`"-2J.%D9IF<9&8/
M.1"SG.?/`U;LM_[FT?\`\R?1W]L"/@2NWV_G763_`)<5#_X@[@X$#^RL(1Z(
M;+EC#@19L';"C`"QY`849-8J`PL8<_099@!9"(.?H+&<XS].!<KVJ'1RL-L^
MG6WK9*;F/5F`S"](`H?G$E.@KFK]BK&J2.,FMTEE0Q`)98ZDSAI?&IG7J/;3
M-JY4#TB*R,.>!NW:#9JJM1:8DEX6V[9*86A(47%XTT#)6S"U)<Z""EB=>5FR
MEC&KE<NF;N<2D1$I0'8QDWWA^"0#%@,LZM-+[)KS[^[R[AMZ4S>K;!M:C94P
M!-PN:M8:.0F_:%;:JP(XSU82HHBG,`KDRDKTY=Y&,TPS)H4Y)@@N%X#@.`X$
M`]\>R;6SKF;Z2<MC#9Z!/?\`:*.HX$&!Q`R6FADRLDH\2I\`%>WX;65*6>#)
MAH<FG9]7Z!0_`O`3\X#@.`X$(NP32"`[]ZYR"E96YK(9,6QR;K`HZWV(/IEU
M)7;$A&+8%9<74A$6=@YI<19)7)L#`!Q:U"E*/.`G>H(<^&LU[3"7+)SKWL:V
M--=[JZZ.^(/?]9`4DIBGU204`<?NJM4I^23W^I;89Q%.K:L3`&4GR>-.9Z,@
M#@09EJPK26AW;T&HIA2G>W#735?8)%MU*(TH+5-#!#[/61-/2=3S1U0B&B,E
M2R?M:A^1-9Q@E25*D..]`0Y%G`<\G84001VA=E8$Y!"<`MH@'"`F(*3EB.45
M57JA0>(LD!8!'J5!HS#1YQZS31B&+.1"SG(8?IU_,)ZVOXZ:._[T[\";/?'_
M`#D+S_ACU@_Z=D<"GJP2"%;3'TBH@E2D5V94*16E4%@/3*DJFTHB2H2J2#0B
M*/3J"1Y`,`\9",.<XSC.,^.!VJ=R8DM?]@G6-:MKC3->O".'[-5+")&[^TF@
MU?[2SMO@!\`/>UJC!;5'G>8P)@>&ID5'C+QA0`TLL01"SY#5>R>P\)UAK)=8
M<Q)6OCLM4H8Y6E:1_P!*J>7'8\A4EMD,KBOF0OW%SV_2=Z4E$!R068!.4(1Q
MG@`,^0LYZGM")=K'"YKL7LT)JD6]6U@FF47H\HAA7-5411$5DRO]9ZZ5B$:%
M)!*I;3\%*AIQ>AV>LJ%8Q&APGR`+>.`X#@.!%K=?995IYJU<^RR*H+"OA144
M04RH-6U>E+4RZ2ED*$Z<X10S"E.&YE9R5`ESHMP0J$A;$YZ@)!V2\%"#&-#]
M[]?.Q37F*[&:[2@MYCCT66@E$87&)RIA6LR(3$'O$&F[42::)M?&L1X<@'C(
MDRY*,M4F,-3G%F""9G`<"K;8[^:[UB_W%=C']FZJ<"TG@13U]VOCVQ]D;)PJ
M$5]/VZ*ZU6LKH]YM>1!BB.&3VTXXB3*[#C4#;T<F7S0\BO3W%*E6KG%K;T:E
M4<("0Q1@DT00YH[\C:>E.VWL*@I_LLT;N>#ZZ[D,)BLT"9`'[3A[E3-H.N3C
M,@)*(!):S+4JC,^,`]WU"S^?@?3UF5>HVBN>1]DDZ;S_`,-H\ED]-:$1YS(&
M6`,%PL-:+7V6RB/#CVW>VG9$8U,A_I]93"E,R'/@\`LA9?NQM?&-+]=IE=SX
MW?>>1D'-D,J2NR#0@=+5NB:*?L:MZ\:B_5@P8WM]-"8K&'_=FXA0=GQ[?U"K
M^D]-VU)KA9M;;,B3VA:FUZB33S<&6&8"(Z6V58"<(G-$RJAX$-$RU@1A.VQL
M(,X`A"W%G%8#D6>!S22"NYEKY:%@:UVBI-6R^HE:?[(DQX,E%V+5+I@P^!6*
MB]7T,PXM!>$Z_`?/QW`@TL7Z6,\#M6_TZ<$>J@ZB$%SMT,=IO,K]L#8+9='"
MF%0PMLEFF%DE<8E`8VU.,I=6&.I7"01.O&PM&:X+DB(O*D(C3BR_4/`7.:H;
M*PG;[7^O-AZ^:)1'8W8"9]!F,S9`B;9?%9!$92^0>9122(VQQ=VP#O&9A&ER
M$X256I2FB3^X2:86((LA#O>/_C;Z?_XI-@?\$NP7`M,X#@.`X#@.`X#@.!#7
M:WKWTQW?S&5&T>OT)M5ZA8#R8?+UF7J,S^+I50Q&J4##84*=HW-VMK4G#R88
MD)<`I3#,Y$(O(OKP,RU?TVU=TMA;C`-6J2@U,1A[<\/4B)BC><)XE3R$`R@.
M\OE+LI<I5+G0DHP0"U#FM5'%@%D(18#G..!R_P`Y_FF=MO\`?!JS_A*K[@:F
MV6_]S:/_`.9/H[^V!'P)7;[?SKK)_P`N*A_\0=P<""/93_P)[*?_`,*:?_[O
M%.!VO3>J:TO"I'.J+A@<4LVM)Q%DK)+H--F-!(HS(&PY,G&)*Y-+F0H2G^T<
M6`TH?IP82<`!A8@F`"+`03H;IFZT];+0C]RU1J]'4=B0M2-77SY,IA95I$5F
MH&'TA/K1DL^9S!A@*I/C_P"P>U)DIZ?'T*&#'C'`L_X#@.`X&N[?>+"CU36@
M_P!1Q=NF]K,=>31XK*&/"T+:TRZP6V-N2V&1AT<1*D(4#>_2,E,E..R>3@HL
MW(LF`\>K`>NA[NMENXZY8]ID7V#Z.5+K4DBNQ"1^H\^!R4AY'8-I_9[>$N'O
M0"K@L'*-M$4``O<SA%C.19_7_3Z!UQ=;.S_=+=%Y2B+=B6AE.ZR4DAK1U>X[
M8$"F*=W>G"QB)'&D;3%C6TNWK&&>WKX^M<E(S/BIL%#2`_79]?H$%X'`<!P'
M`A)M=UPZ0[ON,<?=H==H1:$JB*4YOC4X,,?8E8+,UGF".-94=@01XC$SPQ#/
M&(SX(EPD>#!B'@OU"%G(;3UHU*UKTX@`JOU@IB#4M!SG`UW<&B&-7QE#Z\G!
MP`U[DSVK-6/\I>S"\8!E8XJE2G(,8#Z_3C&,!Z[?L/\`YHG93_$\F_9)7/`P
MK3K^83UM?QTT=_WIWX$V>^/^<A>?\,>L'_3LC@4_SG_<8O\`WJ4U^U:'\#VK
MES4G4>Q-;R:G[TKB(6O6$Q1X0R6#SED1/\?=20&!.3C.1+BC`E+$2D`3DR@K
M(%"8\`3"A@,"$6`@]KIT[=;VJEFMMRTOK''&FSH\%07#YA,)78MJND`)5`R4
M:37F;3E\R3P3/LB$7@QJ`E/P4(0/7Z,Y#P+,>`X#@.!"_?BY=JJ'UU>;"TUU
MI3[8W>DD\2;&RH%4L20TE9'G9U`EDC^)W5G)P"RP(,^[[(1X&/SYQYP'.,A1
M7GM$_P!1'G&<9Z)&'.,XSC.,W^T9QG&?IG&<9=/&<9QP.=J$[-=A>EW<=%G7
M7GK_`&[5B]=G%$=S<O7;7MHH)]7-UH'YT7KULI6L30I6H:)6B;S%+LE7F83I
M&/!9[A@L#8I5)SP]F$E,/-3)S5)&$JDP@DQ0EP:$_"8\981&D8/!@(#L$F9R
M'UXQC`O'G'`^_@5D[JT;MK(=F-0-G=3XY0TW?-?8ALW")7"[VL><5DVN2&^$
M5/$MCLQ/L)K6S%!ZIE-K4_!Q!Z4D(@J09"/.<9\!N6@I9V`NKM,,;.TEJM"6
M%%%#5<&,I+8"S+!>'Z:`4A]EDD2>:T/7R&/Q]0C]6<N!)RTXHWQCXHPYR((1
MAZ<#7)QHC9*331*7'[KF&_VXDDV'KI",*]AJ.Z%%FFM[[6<5DX#!%SR,1Z.M
MS48D?PEI</`%.5/Q4N3,IR@J/[K]>C=R.TG4W7JGK!5L+^_ZIV5'=[U4=*'E
MR@NG"ZTX9)XPF.>RA>RRRZUY.UOC"SI\YPJR2K/4>G!'D>0N3B<4C<)C,:@T
M*8VZ,0^'L3/%8G'&HDM(U,$<8$!#6RM"$K'I+)1MS<E++#G/^R'R+.<YSG@5
M.0#4>&=YMG7_`&K;JAX_<1HQBL[6+3)0R+52$Z=[%J@Y8KBW4CYR=0EPLQ5+
M\@*8(*H%D:8T]&M4?_N",->ZGV'9QB6R=9=D\E)MM-0I214MV^DL:=/8+5\/
M"NKK]C91P2S5$3NB%!(<RS<8\%K_`))0_2(.`\"&_<+J+(;OHM3?%-MXC=@]
M?HO*U3:E1)\FK;!J9U;U!DZ@1I1?@U>N:@X^VF@'G(@JTYI1?Z2G@=;'6<EJ
MI!UYZ4MU(R1HF%6MFLE--<3E#(+.4#XG;(,S('%PR6/`#TJ\]Y3J<JTYP0'I
ME?NE&A"8`0<!`#KDDFUC#I+9\<U=K.E;-9J_W,VDB^N\ZN:SI;5#-=%4*=FK
M<=Y_-)$S1&N;/>8.\1&P'!S8FHCTJ2I`C;@N0OL\)X$^0V@&G>R*^MK=+[2V
M/K'3VK*PU;LJS[+=%-07S;5FS62*YI0MD5"VLJ%CEE"UTS)TY2^<EJCCQK_4
M$LC.`ASG/C(7(<!P'`<!P'`<!P'`<!P..><_S3.VW^^#5G_"57W`U-LM_P"Y
MM'_\R?1W]L"/@2MWTS@?=;9V09P+!/7+099WISC/M&&[`7$84`S&,^0B,+#D
M6,9_+C'`@GV2?\#]_P"/S#9H<4/'YAEFV7"P&%BQ^00#`"S@6,_3.,^,\#NB
M;,8PVM^,8QC&$*3&,8^F,8P07XQC'YL8X'[N`X#@.`X#@5"]M/523VC-&K;6
M9=RBELZW7N@N01Y,#)G6)>D)3)DRN/8*-E,7RRJ1A2!$4J]2D(<YS@10OIP+
M>N`X#@.`X#@.!ZR_L/\`YHG93_$\F_9)7/`PK3K^83UM?QTT=_WIWX$V>^/^
M<A>?\,>L'_3LC@5!S,H1Y,.3`SC!BJW:32E9%GP'W5%MPPHOU9QC.<!]8\><
M^,^,<#VU'`<!P'`<!P'`BWNL':X>K-U%Z/8K[.U!L-6E4]FSCA$1,N1&FD%G
M'&'#`8W@?"&H2@;5\\.6O[4"G^;CXGO<"O3J'ZB6#K_CTIO"\949L!V![`9.
MD6Q6Q,E5*9`Z%N+X>6Z.<"@KN[!RXD1=*X!#E:MS@I2]J20&F@*3$HT:4+K^
M`X#@.!3#B2//475O9)L+?RZ`RB@I=L3/-I:/*A;Q(OQFF]AW\:S(0:_.<)<8
MT!CQ)%]C)$39'EC6YN&7`EQ]Q2F283&"&$?-"Z#LFN8=8%^;*FIG7<[<27$W
M9LJZ%YR<3$%2E#A)7%!1HXP1IB6#T/"A$,J1.$60"6!5&_I9'@7`CWVI;$2Y
M$QP?1>A7XYFV!VW0NZ:3RQL,SE=1>KS68%#;MLJ!%9P-`]2!(<..QSU9"(YP
M5'&%_I)\9X$@/].@I:JVH[;[31K&L+:]2=Q)JUP1O7JC%:I#4%S1:*VS``".
M.SDTT(ESV[@R9GZ&&%CSCZ^<8#EHVEW2F$)[A]QMZXXM<9+!HUL8_P"O$_B;
M<:,]-,=;Z=:HU4SZ<TI?Z!KS%)#$3W]N%C'D1Y(P_3!@_(=-<8DS!,(]'IE$
M'A#((M*69KDL9?FXP"AO>6)Y1DN+4YI!X]03$ZU$H`/&,_7'GTBQYQG'`U5U
M_73+=`-E[`T7:DT?4T?M^&Q[GZ^T\V?5\9KZ`[3%MZN26KJB^25O9I&MB<+L
M)PSB41W*9"K&FR8XD)TR@\P!60O4Z]-;YOJ9J+5M'69(HU*;%8EUERZ=O$,"
MZ!B`I=;5L3FW)`W1@;VG1O"IA8W.<F(4JA420H4DI@G&%%"'DL(32X#@.`X#
M@.`X#@.`X#@.!QSSG^:9VV_WP:L_X2J^X&K=B`!.G>A*4S'J(5]F>D))X?.<
M9$6&T<J,8"(.<"!GW2`_7'YOIP)/[S?SK;L_R]M;/VVW7P(-=DG_``07Y_Z3
M"_VFPG@=T;;_`.7(/^Q)?^H+X'[>`X#@.`X#@.`X#@.`X#@.`X'K+^P_^:)V
M4_Q/)OV25SP,,TX"(?87UM!`'(A?OSTD/TAQG.?04>\&&"\8^OI++#D6<_FQ
MCSP)H=[1N3NY'8/`L8#\/7'5M*#QY_3`-'/5F1#\_P"U@:C./I]/&,?GX%2,
MH_WBOO[[:&_;)".![:'@.`X#@.`X#@.`X#@.`X#@<XUXN[CO[V=O\1?O&=4N
MJ61Q(Y+$3Q9,1V_O?8$&13%IEKZA%C!*F-ZY5O)",M91H1>9$Z&'8]0`!](2
MUO.ZZ\USI^R+XMM["PUW5L5<Y?*7$0@B5&I4(,82M384,6,K7Z0.9Q*%`1CR
M(]8I+!C^EP.=K3AQ?+W1S;?FS%2-SMO<961)DR9(>)8WU12$:6KF>IJ-CQYH
M<"*1Q%M2B/=!`P'"MY/.-'ZA!P+(2]T?O=NU'[!]Y'Y_4%I(;:O6ZGVC.(-%
MDM,NE6EKS)F&3^GQD(!*A0.=I!F9S^E[1&/K],<#DOJP;FY5^R/DD\J7^<!=
M9]*1*<>Z)6_6&ZKY>]C58'Y]T1ZI['@?J\^<?3/`M[Z?]I4</ETBT"FSZ4,"
M!O<;-UE.6JL"4AAZY0K<)I4F<FB]8CHJNP>Z-!>/J)N,4@QCP2`/`N$VAH!-
MLE4#O7R9^5PF>-;JQV!3%FM8Q$/M4W7!5P'VM;#9%97@].H8Y`G+"HP#/ZY"
M<>5GS@?`NSZNMQ'W>#3B`7!/&%/%+ECKS,:9O^,(O'V:RWG3DB6P6Q_L;(0A
M#]@/;PU?:C>''G)2)>47G.1`SG(6%<!P'`<!P'`<!P'`<!P'`XXI:9E3V?=M
MZD8<!,#>VMR#P'SZ<DH=3JW`4+.,YS^L%@S/JS^3/_)C@:TV#_\`D/0#_,XT
MC_:4?P).[S?SK;L_R]M;/VVW7P(-=DG_``07Y_Z3"_VFPG@=T;;_`.7(/^Q)
M?^H+X'[>`X#@.`X#@.`X#@.`X#@.`X'K+^P_^:)V4_Q/)OV25SP,6TH_F-=:
M_P#&O5O]FR;@3![U/YR6QW\/>K/]D37@5+2C_>*^_OMH;]LD(X'MH>`X#@.`
MX#@.`X#@.`X#@.!SZ;):\;=:>;@7MMAJS0B[;W7;;T4'ENP5"P:7Q2&7I55X
M5]$T-?DVO594\<&B)V%%)Y"FI`0\LPUR5Q)7H\'D9$6+(0AAU?:T[6]CU[4Q
M+MLM:7S4C1?76:M]R(J$MN60R67-M3>,9]8JT4V;%(&YR**0NF*M=!B=PM*Y
M:I5O#J61[Q.4^,Y*"H^$N<6T,MV\]$-AY$TT\_UU=5NSC7YRL5R1Q.)V]K7:
M$Z>K!KN1UW*7HU$P/AD7)D)[0[(2E&53<M2"+&#Z9\!@$AJJP>S6?;`I=)#3
MYVR:[:$[CU_++;B8C5,'G5NWY$X^Q0_66&2U/X:)9)7MMCRM2XX2'')4&#"0
MFC",T/D*,XM.8FNC)"L;FACPF%*%JD;(_J"F-XAKLRE80N\?DK4YC2K65S9%
M:89!Y)X`#`,O./'`OUZFNJ"0[N:/[5[)(S,U#<L^NZK9GUY7M(&=80JCJW6)
MF=B&N;)R\$8=5-06S+Y8\L;L`H(RW-J*&>`H[)2;.0FB&5=H9>0U@/JAN,>Q
M(0X:,28JRZB_=`&^8#@G$UQ<F9?]M%P+)_\`6_L[+5]M8(_J_I][Z\"_/K,T
MS==%=2HC2\PER*P+9?)1/+AO6=M28]&R2FZ;>E+A-9\LCR14$M2GC+:XN06Y
MMP:`LX:!$4,P`#!"`$)_<!P'`<!P'`<!P'`<!P'`XWI+_,V[<?X@]>O\*%:<
M#7&P?_R'H!_F<:1_M*/X$G=YOYUMV?Y>VMG[;;KX$&NR3_@@OS_TF%_M-A/`
M[HVW_P`N0?\`8DO_`%!?`_;P'`<!P'`<!P'`<!P'`<!P'`]9#OZ(0^SCLKR,
M0A9_>P<@^19R+/I+KB`@+#YSYSZ0`QC&,?FQCQP/":4?S&>M?^->K?[-DW`F
M#WJ?SDMCOX>]6?[(FO`J6E'^\5]_?;0W[9(1P/;0\!P'`<!P'`<!P'`<!P'`
M<!P'`U-;E"4;?S,BCUZTU5ES,+8I&M;6:U*_BE@-C:L,"`!BMO12MI=4Z%48
M`L(1&%!`,0<8QG/C@97!J_@=81AMA5:0F(UY#68`RVB)0:-LT2C+468/)A@&
MYA8$3>U(0#'G(LX**#C.<^<_7@1)M7K,Z];RL\-T6_I?K=8MJ95EKUDXE531
M!T?'E<2/`RELD//;,ERA6#(<>#'$"H?C&,>?&,8X$UVQL;F5N;V=G;T32T-*
M)*VM;6V)"$#<VMR$@M*B0-Z%*64F1HD:8H)91180EEEAP$.,8QC'`_;P'`<!
MP'`<!P'`<!P'`<!P'`XWI+_,V[<?X@]>O\*%:<#7&P?_`,AZ`?YG&D?[2C^!
M)K>`83NZV^?1YQE#U^ZPD&X%CQZA*[FO%07D&<9SY"$!6?/GQ]<\"#O9!G__
M`!9<X/\`9-,K,DP.?&<#*.MZ`EFEBQGS@0#"Q9QG'Y\9X'=4G#@*<@(<8"$)
M)00XQCQC&,`#C&,8Q^3&,<#[N`X#@.`X#@.`X#@.`X#@.`X'K']^_P"9QV5_
MQ9.O[.X%P/#:4?S&>M?^->K?[-DW`F#WJ?SDMCOX>]6?[(FO`J:D10CU]:IP
M>/<57K0"4KU9\!R:?<T(`#U"\9](?.?KG\W`]L[P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#D)[$H--]$]]]CMDY[`9](=0]TB
MJGG'XUP"&R*P4%(7/6U?M]6R&%6XT1-N=7^.1:7L+"A<VAY^,8A]\9R88L#!
MG.`U'K,Q23LKVQU004)"IXLUBUIV#A.T-Z[)2N"2F#URX.M/86NU=4]62J8M
MC$OGTNE$P6)S'(:(@:5K;21C,,R(00B"8O;W4UF:Z[L,O8*@KB>6=K;9VNT;
MUYV"=*QBSO/);0\DK2<R:95Y9CW#8\E62)SK&0H)JL;7)6A(4":U*<LTX.`&
MEXR%92A<H[37&*:@:?,$XL./SZP*Z6[`WX97\SC-04/3L0FK',Y@N<Y=+V1@
M1/%D/B:/?9[*QHO>5&JCLB,]L!8Q!#O!"'`0A"'Z8#C`<8_YL8\8_P#TX'SP
M'`<!P'`<!P'`<!P'`<!P'`]>MW=Z<W-JCO?L'L4Y5[.)5K#M7*&&UH_<$0BS
MW+F2O["'$62+S:N;*!'D3BMB9ISA'<.#0M4%!1K$BKV@&9.).``/$]+&G%R[
M>[U:Z7LS5[-XUK#JO/5%SRZY9=%7R)1Z:SMA8'9K@5;5MF0H6U5+G`;Z\@7.
MRE*6)&@0IA!,,P<:268$N_\`46Z:W=`-P\[XQ>OIK96OUL4]`JZM)^@<;=)<
MZ4I.JM7/R=E=)8P,"5<\DU_,(Z_%!`Z`),(1N"8TM1DO!J?W`J2T*U,MGL3V
M5I.OZ?@\W/J*(7!6EDWO>SA$I`P5W`(+6\O:YHM94$C?VYN1/]A2Q0Q@;VUL
M1Y..`,T1YV`$%&C`'L\>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.!\8QC&,8QC&,8QC&,8QXQC&/IC&,8^F,8QP/G@?R``"\>
MD`0@#YSGT@#@./(LY$+/C&,8\B%GSG_ESP/ZX#@.`X#@.`X#@.`X#@.`X#@.
M!\9QC.,XSC&<9QXSC/UQG&?RXSC\^,\!C&,8QC&,8QC'C&,?3&,8_)C&/S8Q
MP/G@?R``"PX`6`(`8\^`@#@(<><YSGP$.,8QYSGSP/ZX#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@48]E_:U:6A6W&KM5M-5P28:_32$K+6V@GCTND:>;U=4Z:\JCHYRFT03-J@#
M(H21!RMU&Y.05Q1F!HB3/2(KT^O@?4\=MDT+[:6_2EI@E:I]36!OMF'V5L(^
MO3X3*$-VTUKRBV0L1C8PEJ2(H1$H!#Y;'TKN:I`:<4L5J,>L'M8QD-S5UW6:
M3V2GEB]#F]8FS-&OMH[45^_V/1$^@+)L)05-MPW:?V/KVXR1O0E60UM#7[2D
M)`/C+3TJDD\LD1`_<P'[:V[I]#[&:;HD1\MLRL8S2%"LVT;W(;GIBQJO;IIK
MP_JS&IKMZK2I,Q)7.?P]9(0!:R#42?)RQP-*+3%G8-+$(/Z8>YO2U5`;VG4\
M'>%&+->8C7<^G-:WG15@UW;CI"[A>@Q>H)%`J]7-:EZG:*SI<8!G:0-V#E`G
M,P"<\L@8L<#63GVCJUNV&I[$-@E]$:US_7G>ZV-@&O9FG994=O0%=JF34+DF
M>5[9)C$JICBB%BF2Y<<I*(7)7%-D`B3O)8@X#/8=W5Z6RN+6K+7%+?\`6Z&K
M];G7<%(@MN@Y_7#S;&L3,>6F6W12[=)$"4<^B(#U28/@L1"T.%A`QIPEF8%@
M,MJ;MSU4NQ)=^:_CFRSG(J.AE=V6KKQ3K-;Z&T+/K.VW4UCK.Q:5KDZ-8EUC
M0V9O!(B4JQ,D+"6''OGX)38R=P-!6/VPIIT9J<+6UMDL/=)1V@U5HQM)6NP%
M5/L+M&N4LMK&;6&[,*B,.B](-C?G1I1-"]N="C%Z0Q(<+TX$+(L`#>G:GO!=
M6F]75@V:L51%;VVIO*>O\:JBIY>J?$K*Z1NM*TF=R6]*%XHZH2.V4\8@<(-*
M)]!H`B<G!(`7JP/TB#PSIW&:KQFE=.+8>6VWI<[;NTBZW)2M=4C4LSN:9R/,
M1C$.DD]AR-FAC>M5E2&*ERW(3L*<$)P`;E@S32\$9\AHEY[W:167/KK"ZGH_
M8V[:CV-U3EFS$7MJJ*3LR>OB<IDE##&"(\CJYBC`WA^(CJQ6X$2Q2!:GS&G%
M,E2*`"$N*,"$8X#WARR,S#35_M=4?>M.7SH+>>Q,C4:JZJW*X362V/6]^-\.
M3O,8K=V>9)-H-`(I6Z)V.>OMD>2<*4GNX4A]U.0,+$[,[H](*[8H')FETN&Y
M6"::],6V;LZ4-25@6JFJK6B2&'DM-T7']@-63*^B9YJ%9C)2H(G,.&]4+*3T
MDC%@(W=EO=M4^NE&7NDU><I-9M^PW7BN[OCDX8:5GEGZ]UXANDQ"MI0^Z)PP
M$(F&'@M1@,-5,Y:U4G`:4,H9QA(3"\#":0>TC5UK;9>ED;O-$\XKG:JH])Y=
M!R($\YEBO8"Z&Z*.D`21A@QD2E[A<I9I4!T2.Y0LI1MB52=C.<$"QP+(>`X#
M@4:;Y=K-GZ9]@^MVNN*O@#]K+-8%6TVV)M5V<I$DG=5M-O;`"UOBDI9R$9V8
MZ.*,5@/3'EU$K)&/"9</(1E^C&<AX1I[@Y*N[1K.U7=(76L:TLJJ";&B?]CG
MITD14M,LK4R$57-=@,X(";B,I8%7)EJ$M*LS))BGY[<JS[F,`]O@;XA7=7I;
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M'T9;NT,:%D='`84Y*%8%V]Q.<C.-",O`PS]E[KM+5D"NR>RY)L!4)5$TU%]C
M9/$[EH*?5S.Y'KY,Y$FBL<NBOHN^H2U4Q@:U]5EIS#DXL*DHQA"H(*$(.,AG
M%8]LVLMP1V^W6`PS:%XE&O"NLPRRH!:QVVDNZ2L=TF'`J.:P"JU,?+EDC@]@
M%)CE"1S&0F3I4A!BA=E(2')G`T++>U9-94MT-#K8E>F%DN'L3ENE&SD%NVLG
MV'VI6[W!Z*LVR))"%\<=E:,V,2Y&Y,3,I"J!E<F-0J<>WD7KSD(9UVX=A-TZ
M-0*K&W5ZGXM?>P]G+;4F**MY:K>TC611NNU6/]LWK,\&1Y4D<<NS4TH&YM:R
M\B]I0Z.Y!><#$((!!EMH]P&I-31'7&3.::YI^OVLU_<=D:4A](4_,;EE,LKQ
MB:(<_P`D&0WPI"MPB71YCF92U7E6),G)2I%(QF@$7@`PCS*^]"G";RI2O*PI
M'8:YJGOG3=RVRA=T5+2EF62K,;CGR+-;$C1UE'(U]LOD>:$SXI^]#@%<F%'7
M,A.WJ2L'+`#+"+M>=Y;_`!*<:R/=T*U=X4M;_6O*]J7ESU1U5N1SE#U8L8V#
M70MYE[9!'-XDDP@%4Q*KV5<I=/ML?H+4D>X%3D1Q"<06*6SW1:/52DC+N2\V
MY;,:>*$A&TTLEM&4K/[4C-.ZYV,4-1"[@N=TCS4,,`B[XC3J%!91X3',"9(>
M<-*$LO(N!&KLT[L*UUQJ.]X]J^LDUB;!UW6](SQ+.VRE9U9.N->9O9_C"ZLV
MJW+%8BD49B[K9E=N*AP9"E2PDDT!J<1AH!&E%F!.479]JTD^W&]>ZSHF61G=
MJ*=?#O"L0)Z^]XMD)FG;'*.H$##CU*E<&=HTY?;9+Z'/P1,Q!RKU>DH6,!8A
MP'`<!P'`YC-KN[^^->MVMAJ#88YJ%((I15ZZF4[&*0E,XGD7VZV)3[(L5?KW
MQ[ID@I0X05697:J8GG*L+4)20"-)GW5`!YQD87':T[+.=JW?O+7TFL"NWAHU
MQOR*57'6E@A$N@[U#2'NGH189K!-Y)+)`Y,=A/ZHR4?**7,I")(4G'@D1>3`
M9%P,&%VDZU#=-K\(&.\GB#:8-MR&W?<S53DH54VW2J@6E"\VO6;%.\A+1O%C
M1I(O"$"#VR2UYI9H$AQ^2C/2&MX7W6Z'2YGN>0.4IM2LV2EJ3CNR*U?;U(69
M7`K'H:6O!,8C-J4VV2*/IWJR8N_S!6F9D64*;*E8Y*TY1!1F#RQ"#RYW<+J,
MU5U9,SF#;?=?3:K+,JNG9#KE-J+F[3LPY67>S<%XI&)Q.H2$BYWE2^UVD)RE
MG$C--)$4D5>^,C*8_!81=V>[>7^I6N\K&@4<D.6N!=:<\VMB^N%EZRW5%=@6
M.TF*[WNF&V1VRN6.K>SQ2HH[(FK),@0";P+T;>4:\A7Y;?0/(:]T\[@UZ6,V
M+*MV;>`SQRBM,*DV`M9+)=);PUSLM5*K6L=_8F>0P5M>I5,V"PJVDV5;9&(P
MG9DPW)Z>$XU.!!`HP2`+4R-SD<RT[OG:*#U7;T#=J>KVWY&76>RE53*EIE]Y
M*UK]5-T"-[BTB(2.HXX^D"2#+7(C#B#B#A8+-P<68``5I:P=H^YICOUT/VYE
M,:X)J2[/&%C2TI8VM\GLD#_5%IRFK3K;B5?6["+*2+"W1+*8^A5I271F<AEI
MER<6#"LE9"9D-D:8]L$^V5WSL[7>9U7$H9KM-D5^+]%+F:USX<\[`)]2[:24
MKL"-U`O/,91^Q*5(W!G^"63ZVA.889[F?`N!";2SNTW*VMGFOT!;(5H_,)+M
M8P;7)(U"JIF-LNMBZDRFA@3!+`ICN'%/DR$;345CO<?1)PJ4AS6O,PZ$92A.
M&+`,A.CKHW`[&=H=A=F8%?,5TGCE6ZB7C+-<;46U$=>H[`D]AM4`B<V97ZOP
MS)0ICH86;F8)R57VC@A=^J,]LO\`HY$%VW`<!P'`K'VXZV(QM]?I]JSJ<%)8
M,\Z*;,Z32BNLQ4#D>Y(-B9!`'W$\22`UZ3%(E<--@^!$),HC,G*!EFX/*R5X
M$$/Z5Z+F"N(!J!")ML$]62LH^-[[H=A)HKB9[?+]E9;OI7)=;S*9G/"R6O9\
M.<XFQ)R"4V3OM<:A.D(`(9?H\Y#P$8Z4KF>(6P0&_P#<UAM%@U_T4V)T0T\S
M&-?R:]6P2([!5>VT\X6=<QX;+D6+/G#!7[`WMY*9OPPMYF"C#\AP>;D6`V+<
M?2BQWHW+H]-+Y=$#`X]5=8=<`AQZ$D$O3?)*IM>.V[&[V0J5\C5(C22I+%DF
M1QTTG(32PB")=X%]`PJP^E^Y=D6V][#VIW)999M78$"ULKVG[5JFA$U>5_3+
M?JK<OX_5^]*JR=[%F*B?O<ML_'RI!A0[(TV4HLIT9:<.`CP&W[(ZLK>VC?('
M+-RMHHU9$C0ZR;R:Q6'BJ*1Q4[.Y0_<=AKV-(105*ML&;*X^;5[?"3C@'.)S
ML>ZJUWJ&(@HH)/`T:MZ5KQM*`V.P[*;FQ>R9B1UYV-UQ:[2*%Z]9KMEKRL[&
M(CI#]:%CL)EIR=38MG.R>'-1!X$:QD:B24YN22`F'Y&`-I;"]/LPN1]O"3Q+
M:IWJY]MC1_5O4)O6LD,=@G-X];K><K3='20.#)84<>G>!W&@7"CSXRHE3:J"
MU*5.`+Q9,]/`P.CND)PJ4^-.1UX5VC4-O9-2W88NB]7T4OKZNFP=644YT^MI
MF$QQQM68N;*R.:IS^<G=5;@O5`"#.#R3C31&X"7NU?6!!-TMM:UOV_+%G:ZK
MZ8HR6US6%.US,+)IU[8[+L26MKE/;65VM5]@163K"WJ$L"!APS@+*39)":8<
M8=ZPE@#0FIW3JOU7L+5)S:=A39/5>FDLWU!2D#<(.M"^M51;DG11QB]9N,R5
MS5Q.<#J<=6A>,+D-+D;N4M`$12<161##'M>NG:S-97+KV?*VVECIKKI]4M^:
M_6E]XZ4-<F^Y*@OZW4-O2`F)D$60B4UG-FMR:4Z(AP-.>B,DY&9E/Y_5B#5L
M.Z2=C*1ANLQ&N.],7KRR->--[?T\5R64:UD3R-6!&+IN4RT9$_JHVHM-I61Q
M>PE"(PV83K3LX<411AXCDIAR40>5'T;V%4<530'3S<-)3T4L+1"MM`-CQV11
MB.VGN:U_7"6:-Z.UJU4)[!A22O[06MMCO9&259;PS@^44/!&1D8R(/%W7T0S
MA\8;_J'6[<0JD-=-HM9-:]?;D@<KH]NM::*E&I5?$5I53Y$9Z.=1$F.MTFBR
M%,GDJ<;<I//P48-$<E,.",@,FE'79*)7WIU#L8EC,V2Z[5KK+"[:M5Z<24::
MJ[.W"K5OGU"T.XM20*XUP7V#`:?GKHK4FC)P0A(3(`A-&89Z0!T'<!P'`JHW
M#ZOHYN)<UT63,;$PU1NX.O*8Z-BB945RN71I^>[?07'%KH;W_P"WT>#E\*DK
M2D-3-OQB\C4)0&_*!_1X$78-T4Q9DKG7^LYI?KW,VJ`Z@;VZV7I(?NCA#,[T
MG._JZ//5LW:-_629V,C\@2/K<K/)(5`=AGA-(`8?X(S[@8^=TK7A9<!GT;V2
MW.C%F2=KZ[K4ZX-;G^&Z]8KMKKRM[3:X^T/UJ68RCM*3J+'LYP00]J3G%(U;
M(TEDIS<E$A,/]98;*V'Z6TFQ#S;+D\;"N,6_$#1_575>-*V:`)5KI![#U.NT
M=[0BY/4XR8:"0-B^6)$1:J/FDD8&F+.#\WU&!&6&'3CIGN:[L71=MY[AQYSW
M=GLZU%GU86]7-"`B5/5`NTFD\@F-2-`*>>;*E+M-6V3R&6.BB1C62`DP[*L`
M$F$X$X0F!L*X.I.Q]L5SE(-O=HFB>2J<:([*:7V(Z5=2Y-8H/%[6O#;+B\Q@
MS2KGDNPT(JH(A:5"2B<#7)0\B![ZE4#UB*X&IY[TNWOL)`MBOWHMSXK/KIM3
M2Z.Z(5A-8#KS^'D)KBGV2RF&TW>4R2%GVE)G.=6/.)-'$@UQQ;JUMZ0LGVTJ
M<(1YQ@-N;0]1LSOB?;A6/$-G#ZZ=]GX1I#$R67,*?5;`!%I[*9A(WJ%V6=&[
M&B$BFU67JEE/V<^-:!<RJ2D@!8^2>$8@9##=?.E-92!]+*\WE##?PK[)Y=V$
MJ(_`Z440*$C#,=<%=&*:8AD=/LN5*8K'V-P6B7(5YZUR.RD`$@XL9V1*,A(_
M97JEK3<?<,O9+8^?SJ10&(:]IZ0J*H*ZF=G4LLAKC()>Z2:V)H]V)5]BQE]E
M8;"0`:6PQJ,*)0@2-@<G84#R#)8:4U5Z=GS6F0:OG&;'_?:)ZFTQN[KW6K0I
MKP]N>1U1M)8T3FM<,KJ^#FSCA0LI-HC@FKWO8\.Q&218"D]KTC#Q=!]/=E:W
MN/7J[5SM''AJ]0M5+`TWMXJ0TJ8Y)+HJ*Q)E'9\[KH:$FQD:BKIF2_1=,64J
M.,>R,)A"\E9%]!!IJ+='^QM.06BFC7C>Z,5Y-:ET&E&@TD?I+K2FG;#/H1/[
M<?K+E4M`QJ+4:5L6?FL#LGPSX)6*`%+46!*<J$YPTX0R-XZ-Y_7T7D=8:D[@
MIJ<JJ\-(Z3T3V;;+`H]':\KE=?TE#I+7K78]6/Q<^AZ*`6-((5-'5&K`M1O#
M66:I"H+)P86#&`_%>W17/9<FV4K#7[<)+26M.UM7ZP0ZU:TDE&H;1FF)%J/"
M(C7=;JXQ8IT^BP&2-2J+P=L#(4XFP]8:<F%E&H38.%Z0RM;U\RB3]]J#:@J+
MSALUR@NND0N&6KG<AO*JZQ=W4#',]>8%(8TD"M,7.$P@^O+ZK^>K,3A`E,RD
MP$8S!Y](=`'`<!P'`<#GXVHZ3[!V8N#=MR_>IA4*U_WYD-'O-T08W6=HFUQ1
MY'2L(BT-3-U47$_602TPA?(`1O)N7+,<5J$(E'J)#[A>!B"4\?ZC=<7^;[8O
M6RT6@NS4)V&V/A.Q$*@MAPL2HFJ'N&:^P.A"2\.:Q\<C),]K6N'G'F.&2D8L
MEK<E"+$(.3!A"';[J;N!>\]A6TL-E<`?)9:^E^X=00ZB]=*3<:@EFQ3I;\&5
M(:X0;+/AULR*%7!-ZM*;R&R..J5A85RHX_WUAV<XP5P,;C/1W:FR=+28[=;:
M98^SZ;Z"4;I[42.+T?'X(X:^12!S.$WN6IL1L#,Y$TVU82&TXF@1N8R\LS<L
M;4!I0"21J<C)#;H>F"?**D0DMEH:F4GLE7FR5$[.TY:>M6F1M:P<N<4&URUF
M9D5V0A[NV8/EMM$H;)TZ$G%%O#.%I`IS\(./TL"#:]J=6%S7ZHNV87=M9&Y/
M:M\=8ML]?,MD\:HP,.C;:\V;:DKL9%93%%";%=#"8[#6N1$LQ#,>M.6K2D6%
M)[CDXX>,!B]]]+!-\EVP4X;#KHL=/=(]/]6XLYL]?)UB^#V+IU<:B[H-<0BU
M\HRB?VMUEI*("E@,`1_5BC0_,R(P(BPL`8*#V,FFIEST7M)L#"K2M.Y87:4&
M.LBN:8_"N'0QBL"#&PIL0,L!43J8.;QAA,/.<CCUKSD]8I5&%!R00`D``K5J
M?ITV,88YK*SW/O<TV05H;3LEA&D,9A>M[=64,KJV%5.KJ:@U]6R`RSIC([>E
M5>,*T1R!"6M9$05>1'?09@_(?W47093VM[EH)8>OUR6;%+NTUG$>>YE.9C,;
M/L6)W+#WZ&O,5V&B3554ELQ3":>'=2Q\-<AJ&(@`$2D(0F%*@_7`9%JOTL$Z
MCN.ADVJZ[V5JMC5%\V&8KJG#54R=B_>NHG8.6RV:JJLGR-OE^%05U>R)U:U;
M`Z+E+O\`!4MPQ`("$W`"PGOJ!IL;JO9&[T_,L`$VQN'M2\[*%-8(WEAS`2G:
MOX+",1`:O+T[?>,9`X<)1\W!:+`L*,`]G'HR(03DX#@.`X#@.`X%5&SG8PZ4
M#M5/Z@;H*EEU9ZX=>UP;Y['+FM(ZNECGH&&2?=BHZWK-"E7I&<M]E9T8D:Q<
M8X%G@^,C3X+R5ZACX'@=8^TQNFNKAVY.W[!0NK>NLB,J8ZLK7ANSS-L-"GD-
MO'@0-\4GSK'8#$C*WGL.>5[>A>2%!2AN3J%V?*L`4ZCT!O..=I_7_+:6E6P4
M=V6B+G5T*LAKIZ1.);)-R94EM1^RC^[E>(ZR4Q8FSWJ82@I>4<U($+,I4NB<
M63DH#B@B&$/YE7:EU_0NFJ^OR0[+1%-6=J2>40J`KD+'.7N62&7P4:X$]C)5
M9,45<K/0OD`$VG?;Z54SD',>`>5P4^,A\A7[NEW7!UE@&S4EB)>NTU=(E=.J
M=,:XB*FEK2%&ZF;)0&'V2LFU_M4=K-.?#F>+P22&R!"C8USJ>]-1("RS2EI@
M$X@W]07;O0LBIBY+XOZZ-=8Y5M9W'!J.89E4SI<<C62V>R6NXG(%$645A+JL
MCEEMT[=9,ZKLM,?;D3TM/9BBE`AYS@W.`Q>]NZ6D:*;+FN,YP@5EZY5]JE4&
MQ,&_#U_F(K^G[K;ED3*OF!D5UU)H&Q1F(1AS7Q$].F7KWDI2G<$YY2Y.E"'`
MN!+J(=G6C4T@=A6,W7Y'T,:J2CX]L;9QK^Q32.K8;3<G'(D[3-EC8^QIN<G-
ML/<(DXI/2@)5'85)O:R#!AI(3`Q;=+M&UET9:M7)!;2^1K(_M78S+#H>[1^.
MOBTN/Q1QCILC=+/D",+6-Q^[T>3J&\L]O(*,?#AN1?QT9H25.20RV2]GFAD/
MO9JUIDNR<*:+F=WZ'1(J,*4$KRUMLRL)O3.L%@\FG!4>,@,0G4M;UA)K>R.K
MHC=%.#B\`(SDP&!!/+@.`X#@.`X#@.`X%/NT?:$NUPV&VOAX*X+G%,Z/Z`AV
MZO92P)W!39CQ8,XF3XU5)5\.SEP3QUJ:U<2@;VYO"U:G49)`:E&#)991_K#(
MZ,[.V86M"':C=Y#0.J]03*3P1BJ:RX%LLU[&U?/,6(SGN;0WK)?&X'$QQ*4,
MZU*:WKTRM*)'A2#R4J%C.0A#;S3VFZ"/]&?O',FQT:=JHS:(J1)7M\:GZJ9*
M[C"5A5BK$-3E1(5LKY^-OS\P#22QF+1H,95!+RGQDW`?7-^U7KYKNJZBNJ5;
M.0I-7-\"DV*F=FEKF4H=9>&#GF)9Z>1#XO&7F:-:6O59(R)":N;TI3">')2\
M2<S'IX%>>Z'=2YZS0ZW,Q\G6QYG)&[=<:DTPK52VXY9$69BEL(KRPI79>P""
M(5@F>V59"HE.2G#+)'#W4YP2J",)#SC@FE<"2U*]O&NSI0E@;%;`W)0L3K-J
MV6=]=ZSD53.EO3QPGSTWQ&+R)*Q**X>*HCUGH+54"=%BA3'&]K=Q(6PHH\:D
M7DWVPP&^NZVDM=VS82V)$K@ED4-6M8ZAS^K`5-(I8[798'[UALG-83Y1#9%!
MF"(0>.GLD;4N+6J,>SC%*="H+4%IE(B$XPF8W]FFBKE7]P6B3L-&4T'H."5M
M9MO.SLPSAB50F"7`C-75E(U["]1=OD*Q',RR!EH@I$B@X:D.4X@!/_5\#$=S
MNT#6O1>?:MP.Z%<D).VDF#G'F%X9H\]N2&&L37&USR=-),F1-:IP.:QNH$39
MA&C*/<\*'`!N4_QRE!I09HN[+=%FW8PK4Y;L="B+X-FJ*LL1#*.3C:2K/<6L
M+R@JY581;`.MD=G+&T83"XZ:\`>AY%@&$WKS@.0G/P'`<!P'`<!P'`@3N[MG
M+M=)+IM5]8Q^,26T=N]LH)1+0FEP78UECM>)661V-=D[&F9E[8M5N46K.&K<
M-Q63PDY=%281V!DA&6,(Q:K]JDFVAN#8TMLHR!0[5G6:P+YK6SK6>=B6-5?4
M$<Z$,<R'.86%JVEA&)#&8%-E+.HPSG%O*Q>(@(#S$V`"%@L))4IVI=>FQ+Q-
MF.G=K*QEZVNZM47;+C\GO4>9VZHV\DHYZL-+(92SL;`]Q:,Y."4\*D"E4!F4
M^2%WQS@B+P']1'M,T!F]7V[<S+LM#TM<T0RQ>2VL^RMGFL#512,SH0BX#)LQ
MV<1B.R=ZC=A'@R5'G!N1*T;Z?^J0&*#<X!P(_3_MXHYF/BUC5[+ZQFVNRW7'
M:&[Y"[N:RV(A=PWC7%XAL><(W&ZD=ZGPK"@+?Y<G1.QSL>W+D1BD@TM*<1ZQ
M\".W7)W2?O9D1M?<\JU#@J!+JG.]J+K2Q&:W1'I323"SR&)Y:FEY:;5K-EBL
MFCD0BDA-!*).@D`F\#N4`*,DQ./!G`E8H[8=>9^/7J4:YVC4L^JNR;RD]3V1
M(9R=;M=RQF21JCY+>)YU8PIPJ@]SG+^JB#(6YI@*L-S:N:A"-2*CQB`#@1_H
M?O;UQVS?=4XY0;M#6:77O>\JK28UK>*VPH1.FF&1LVP4*.05FO8ZZDM>SR7R
M4<21N*1G.>D`RFQ=G"@9*DDTHL)V0OL[T)L*26+%HILS`5KA5D/L6PI<X+RI
M''XD.!U"O,:[4F<1G<B8FJ$6/%ZY<2A$O:Z..#JF;#,>E0,O.<<#:-2[F:XW
MC3LVORLYZO>ZIKM,\KIA)7*OK+B*IK;V&*HIPN<2HO,H='Y<[-IT1<D[@C4(
MD"@EP3'`$E$=ZL8X$):&[O=";FU3C.V4AL=?3\5D4_556&%32,RMWL+\1@FO
M"MLAT>C,+8)$Y6$\NL5:</.`1TIT"E0&_P!9$284<`L+':*OJG=FJMC%U4+8
M,?L^KID4M-CLPC1YQJ!8-L<%32ZHE"=60E<6MV:'5$<E6(E9)"M(I*&4<6`P
M.0X#;O`<!P'`<!P'`I%M2K+[@W;G9=E5%'&PW][3K+,K*O;#L"$RJ8TC$;_U
MOMUXDC7$;?-B:A"M9XW-H5;63R0?+2'+\-RH";W#2O3D*BMG.K+:*DZ"VNMI
MOK[7.!3S:G:CK=,CNJNE\+M2<:W0-_J?9F,.DCON6Q-W8HPY.3A(S7?!\C):
MFAI0I6%"/!IYI@Q'%A+:QNFG<:Z3K<V2LFS->VG;J=;UT!MNV5O5TLOVO]?C
MHIKO1KYKZSP(^VXF&-7M$YC,8M)UKH9)FM+\ML<0$E%A.*$:+`;(9^K?;>G9
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MU;5L5<ZD)']N&]GU<:AF3<@`L$>8[*#2E*@:(K&2R<A%[L(T9V+V$V$ZI8U.
M&MI;++O>/O6MW8LFH5IGTJH9]U'I.>039D#4[6+*XZU*6(HV4P1.T-V'<M,K
M=%DD5ITP1D@-]07#]DVJ]Z[)PO6-WUI>ZI:+8U9V[J?:*,L-SJ98U5K,BZ]C
M\[C"N)/3M!6E]D3'\A%.!'$'IT2C&!)_;R$.!^H(5PV7U'[>S>0;%T4BLC6Q
M-IUMGOO7^_EH3M>CL,S9^$2-BDM4SR95'`6@IG%`W9K<)95:=,R2%:ZI536S
M*32QHS1X+#@.D+@.`X#@.`X#@.`X%%\IJ;8V!]J&[[U3L4B*L[<_0FB'FK9W
M<D(FDJUW(M36B>R^!S6I;770_P",K;RI97]G(59"<*D)YZ<:@X@E3\4\D053
MW=U<;4:XU@[SB)PC7>(6#LSVJ]<%EP_6#5^$6S/-1->%%22-Y;GJT9`QKFE@
MD0F:<OCL4X30Y`ULK<B0(R0EY\AP((2CDO2_N#-R''8Z6610H-O7SL(>]V'V
MKH#8.PU3Z_'Q=UU^3:YAK*/W371$>OF)3$N,H@NF90C0`,.7&&ICDXTQIHQA
MMV,]7^WVODYU:V.U&9M,8)<E9UQM155KTG9%@;.V52)B79NX&BWUMH0VVI4D
M?[LD=BIY&QE'R##D2A)?,J#RB#40/1G@9F_=4M_/4SLN6BLFI"SYYW!:I]BX
M?8%,D82:XHVMJPB,SB(4N&)5E#-WA\A:LYK3X/4(`)C"<'+0C]6`AALGZI=M
MX?:)FS%(3_7=[NJ!=H^U&\57P.U3;"3U7**GV@HV,4JZPR=/D?C*^116SXJF
M8S%J%<W('-$6(7H]><#%D(?NV'ZH]K=CF#L4>)79VOC%:&[6K>BM=M(XRBL0
MF`QJY]695(YU-S%J!Q0+7]#5\G>W%.C:CBU"]U+29,.4$X,"$H8:/W@THOG8
MCL1ZT<S)J;6QQOVOT"?L[8*>CTY?M=GVNM,K,BFR=0-2JQI&PM9GI=[@4986
M].Y@3.;DA4#Q@K!!1F,!:WV(:K;`W_(]*[9UH?JC169J'LV"[BXQ=JN9-4$F
ML?>:NL"JI`UG/<$:7Y^;'AN;YV):D\(S"3QD9*,$#`O.0KP4=1>V"F9/=%&6
M7KV+21\[/B>S95/QIK`'M>![!8R"X3:5+9!-.:]P$4Z;P(PRW+SE8%@SDGX.
M3/`<!T>\!P'`<!P'`<!P*B.S2NIOB^.J[9N(1.335IUPW?2L]FM438'62N;#
M6NR-83.C'&PE+4SHUZW["@\HD;0H<E`2\A1(#3E`\A**,&$(,WEUH[8SK9F<
M;M6>P:<5^Z5'0>Y3$9(]/HU;+=>>Z359],S&$5Q"+\CK^C`PEDQ!.N3K1`*6
MR5:L>DQ04AB<C(`EA&?5SJ*V[VYU.H4S9^9TY2D18^G%_P!*Z&8ZXA-BLEO-
MJS8J&5NYKG_9.)35*SHVEZK@F)IFYP9&]0>%T7B6*A"1B.R0$-]G],.R4YH6
MQ6F4(M9*WV>0%Z>*JTMI#?NY6R[#9R[4*VR[;8HE<+;L$J4'P"G7UY39RC8X
MR2K,:S5QX\F'EE%$""84TT7W3V&N6L]A[]DFL,4G[!IIO9K5(XI4*^TE\4;'
MC94RM2*K6,[Q+HX2[R))'&^$GCD+@<2VF"/.`!&A&6'U<",\UZ1+FLNFJVIZ
M2W-73"EC72:MZSG^0L)4K<U1=S!F=13%IGK0VK6AK*=*J]^M!)U9*@](Y')S
ML`P1CSG(0E(ETXWSN>4=?<^V>>=0XP_Z6[.'64N8J#46PH9)%5Q&M<WIXO")
M;,XVA,/G+M-I7\\*'XK<V-C.'!(5"H\.1#".U+]3.W$0C&G-43^Q-?55<Z6=
MAUQ[,PZ20YSLU/-Y_2=PM.QB]P12%K=8QEGCMKLLIO(DA,0C5FM?PT9I^5>3
MLA`8&$:F=+=S4)$4U66=`M2[[9::H#96D:*L^Q[ZW4DPY>RW@UK8^&,3/6QV
M=3Z1IJ(32+JPH)KF*C7&J<D@4(20&^18"S7JZU-V)U"JBRH)>MC-S['GRSC'
MZBZ;8K1M&](SK55!$6C[*AJ>,W-=38S6=,V(#TVJER8A>E*(:"5($B;(RP9&
M(*U:@ZJNP.AZWT>-B,TT_EMK];-U;/*J&:I.XW`@KR[J+V?9Y2CD:NU'%)$'
M![K*Y8NLDWEL$SHWIMP24,!AN?>%X"V#K7U`F.E^O#[`K+E\6F=J6A>EX['V
MDN@#8Y,];M,\O>P'6=/46KAM>A9>289&0KBD:0Q7@M2JR4-0864(W)80L!X#
M@.`X#@.`X#@0QWDVRE&F5-N-VL^M-M;(Q>*(91)++35*]UBSN%;0&'15VEL@
MGKZ794UAH'-E0(6@8!$-F5J[(Q8])&0^<\"/E#]M&OL\KN`3_9@IHT&.N@B-
M/U"PW:FZ]?V"7737LP8F)ZCEDPUIBUG2,\B*.9S\6C")QPB/"K`(`BPY\>0F
M<^;9ZNQBQSZ?DFQ5),%K)2792KKAYL^&-DV1)&&"@L]Z7+8RM>27=&@::Y-"
M^J#S2@$DM0L*A"P3GU\#`8MV$:)3>'SVP8?N-K/)8/5C6WO=E2MFNNO%[#`F
MAW<#FEF<9<Y)W\::/I'IU3B3(AJA%X6'XP63ZQYQC(:HLGMCT`JUVUB1/VRU
M6.3+MN_2=BJ2>1N>0EXK[((DV.:IV?Y3+`20EO8(UA\;<,(%8O=#]X51#>/`
M#S/`0S7<;L'UQT;>:"9+XF;%&%%_V.O@S*:ZR:-1XF,L;)#)-,)+9,AS(71M
M%]RX\-B2-AYJ?!QV71[0$!!G)^/`12+[HJ/<(-U^SV.4S>TKC_8%,*BAL8DD
M?C[(NKRF7BWI,Z0YH8[9LT#W]S"YPVR)B<$ZB.M"ES=R_LY2,PDHLL`C`E]7
M>VYLHWCV,TGE4)*BS]4U1TQ?592HA\,<RK6JNSE$GBDC<SFHQK1?=QU@%E1!
M2V'DA4+`*$RM*?@98AB*"$TN`X#@.`X#@.`X#@.`X$#.P7=MZT*IM;?`M9+@
MV%KF)LTOE5LO%3/=7-8JEAD.:"7A9*I,DL6;Q!:[-ZLC)P2BF@IP4X$G'ZRP
MXR#U!@5+=I%!RV+5\OV8-C^B-AV^K;5-04KLW=5"-EFV7"9$B9SHA8D;9X;9
M4H*Q&)<XN9K>APJ,3JQKD9Q62L"P'`@E$\[A:GQR>/\`5L@V5HECLB*-\M=Y
M5!'BU80VRR,-,#C;),9JZR-A6/1+DQMD4B<D0.3@H5%E$I42LHXP02QX%P,+
M8>PC1.4U[-K8CFX>M3Y6E:B806#.6NZ*_61F$GRI2M1Q=+*74A^&E8ULE6-J
M@EO(4"+.6FDC`2$8@YQP-:S?M3T,@5DZMUHZ['5BXJ]PF^4.U+S!@G,+=J\7
MM4:"),E<7R7E2,"!I1S*2E&L+"/&#L.C^0:WE^%!8P8#]&Z797K-HA+:;AMZ
M2UJ9'>Y`66X-I:J319DS'HW6593&P5LF>B9`[MJ@;9(7B+IHPV?'":-5(7E&
MGQC&!B$$(=W-WA0BGJ4H_:86H.S<\U+LZN:.L6P-DH0.I7*O::!>KLECK5#W
M(H^Q$T@G<SA,E5@;Y"0QI%"1N5F%D_),-'@O`3RI#;S\4=M=NM2I'#4\1E6N
M""D)]#GE,^G.J>U:9O.'KG%CFI:!2T-9S`Y,$ZBSZR+T>!JRPY2$'!.S[^0`
M":W`<!P'`<!P'`<"K_L1[(GKKV)B<C>-/+ZO2L),MA4:4VE5DAIE!'(_8EBS
MHBOX37CFU3RQ8O*S7Q_>UZ/VU)"`UM+`L![B@&0F>@-NTYO_`$'8+]!ZCLZ7
M0/73;68$*AK=-+,N6F'782*+`'KSVQI>(W7T\EK>I=GV-)B7E*F2*5!PFU66
M9D.,^O`0RY=OOI"V%3TY?MUK>D*JQMP[62,ZYJ_#B!MXYFZ5T4?+?_'O+"(^
M?,BME+`I]LPUS(&F`')V/1P/Q+NPG1%LK%ONI?N-K.EJ-VE:B"-=DF777F(6
MXS5$WI79?%$,AP_Y;%4A;FE<2K4I`&"/3)3`FFA`7GU<#%A=DVF@-MVG2H5W
M0G%UO].M-UL)7WIBGW4>X\_&"4LL<:)!A_SARGCI$P_>1.U$DC-.C.<.8!93
M9]?`WY2VR^O&R#-(Y%K_`'A55U,,/>3(]*GBKIW&IPVQY[*3`6Y;7=9'7%P(
M0J3$1@3R\&"#@TD6#`9$#/G@5PU#W?Z87;=C?1\!D`Y%(7*0;<-2)1&I!$)@
MJ<&C4T4=$IDC+%8F]O$OD"6Z43JO60I(A1*%[PB9%IP2<!`'U!*70_>N*[Y1
M&ZI;%ZFMNF1TEL!,M?)%#[L9FJ-3[[PPZ/Q"1J')SB[:[/!\8RJ13).$3>N,
M`X)32Q@/++'CTX#;:#<#5)TO%5K,V;)4:X;#HOF!64DBM&&*K13'MZ/#DX(C
MH22\#?RW)`VY^2<ER1\@I-^M$#!>/5P/R5UNAJ';\_+JFJ=GZ"LFS#8R=,RX
M!!;;@LJEXXJF5&HE3]B/,CXM=/LY(I)$$XSVO!7CR/QC.,Y"-<8[0=?+0W:J
M;3NAY=6-\E3ZL=@)Q,;.JRX(I,4-626B'VMV11`))'(V2]9RZ23[_&&EG&KT
M>2<(!8"4?@0A%!KO;7N=U`T]NZ;4%8TC0*Y[`X;2,H>D*.:P!K,"YW?<;35S
M;#_A/\D;7`F00Z,NF)L]X,*`4CB8,*_5G)A81!^]V[4V^';LU1J%:&I6R-6Q
MO82?V'5FO6R,L(K<ZK[>FM:,ZI]>ALK$P3EYL!GAKRV(Q',[NXMJ8#B284<$
MD!`_="$D=$-MC-QJ6?YX]PDNL['K:ZKKU[N&NB'P<E2P^SZ0L)ZA#XC;W\UK
M9#G9J>FY"B=T9HTB<?Q'$L(@^H.<Y":'`<!P'`<!P'`C+NI5LNO'3O:NEX`0
MWJ9U;>N5UUK#$SJO"UM:B53BN)'&H^0XN8RC@-Z$UU<B@FGY`+!0,Y%G&?'C
M@<[F['6UV9VWK53VKM:LL"<ZY!U85OJ[+6^/655%<JV39B&1W#>_'VW-);34
M^L*T:/,2EEE,+/&G!D`6[^^I4C3X."K*#]&X>CLUI/7+O`V0MBI(5+7>Z]-M
M7*QIF3,S0?9%CD$UYJPSTE;"`O$?2D2^*,I,Y5C../(493'(2<KU99J8@960
MA52-"6IO16=_,M((#;,V1IS;S0?;>RKYC5_5HY4EM"RU%7TC@\7H&HKFA6KM
M75;75GTW#FQ(O&6JA3RD(?L)%3B>8,X."@L"2]:>R4.:=.[PKO4YC?+.J_L/
MO#:B]J/OK:N`V/+)JT7W2CA4TBFI-O--+1ZNV=8ED!B60J(T@:E"?Y2;*@E0
M:L.S@H)K=LFCFV6W,YH:4:XVBKA*&G*CW*6X;`YJXHA5<T]HEUK2GTA1DZ@<
MK6EHIUB9N[(\+@FA+9FP>5:8)*_V5)8:%VCTWWK8];>KC6;7ZF(=L*AT=LO4
MZ^YI8\XO6$4RM?7S6@AX:\4\VQ9JK%0VX3N[6N)+32$'T*+(QE0F4'B,.&$@
M:8*E=L]W5WVPHBY\90:^=:%`Z]V:02N,>&5!=ETV[)=@%$&:Y*%`W(I0;"(8
MWI1J%)!0`^AR3C$`K)N`<"ZO@.`X#@.`X#@.`X#@.!"'LIHBP-H-`=P==JI3
MM2NR;HU^LJNH0E?',ME9SY+)XXL;6HIQ=C2S2F](-2<'`S1!R$&/KGZ<"BOL
M6ZX>S/8FO3*"K1H@3O4CSH]KM4[42Q6/5-9)6>[:H5B73TB]W614U,K6MR+*
M?AI/N8F8GQE;&Q;D\Y3[`CAGC#Q_85I?)J2U?[WMB+`J^%O$BVHGNO!M-3EH
M:_O=.$M;MD'UXK!]$_NS0V*GV"1QAFK6\+U9R@*IK1I@C<%Z56C":G-"*U/4
M!<F[M;V)(=>FITL"]]<.R>EMO;IM^.;!UC^%^Y[JX:]/%<I6S6Z]XWK#6U0Q
M&;:]Q<38'X9\'.:T3Q@T9ZH:M9DPD)^0CK4V`J*3==%Y5EJA&W9[IG9S<:R=
MAZ8N?:*&6%,4J';QN3MBJSV^UD-.1^$."B)R4H^4FQAJ:@$IURK):$\9HQG@
M"1/;UU\[;;GV#$Y3K[9JB*,L"TVW,@#-'33*L3M[K==UQ^)5_&6-2JF,$D;Z
MWQVQ(([OB)^="519S0F;$HFS*18I.4&!I;;?37L&DT\TZI5IHN";@Z&Z>UQ5
MLB#7LDV&A>NCWL3LM72(A%#Y'>2-NJ>0LBRM*ORUDK6^--K>D0.;N,"E:,XH
MD"8(2DU;;)#9G<SO_>GV*<RQJJ]4=.]5)`,!IZYG77&>=/;\FS`S/>4:)*_8
MKZ/S]F2JE!0,8P:OQC(0"]0`A=7P'`<!P'`<!P'`K+[9M6;:W`U7C]2TNC85
MLQ;ME]6+14DR-[*C[?B*5->D*GLO."O-(4!$M(C[&>,@G`?4>9C``_I9QP*S
MMA]"^QV[-^8=/GEKACEK[5W9'K/M37KS'+"JF!PA)0]=DQ=)*D$@JUNIO\8I
MULH@4`=!*GYUF'V6K:/92)2\X"`@`0MVXU2GFBND54#?(S5E7W[8/=A--A#;
MR)/C:&/QN)/EE7Q9%4S&U[J=ZZL:&PUO;HN>U)`XE,=D+64:,*$*/"H9)Y`>
M`HG3^YMC*=TYV,U/IVS5T,U\<]_M?+/@?[QU:5Y,KK?[ZL]IELVVSHZ[9;KX
M35<[JNU)&E<40@!B4<];&,E,W8^.E]!H6$PGK+MVC[SUR>X!J165AT$/JF>M
M$;-KZ>[+)S9A4$G3R"03-O)4VA^%*1[L]I?&-R!"PO+0W-:U"D-&>$DM,062
M8$ONI/67;G6ZL;JK:\\N5=U`0O@D7T_K64V17E\W725;1>`%L#M'Y9=$0KR'
ML$]C#5(_1]STSFF<G!L:4_LK3S?7@L(0\Z[.LC=[5J_8??\`<5DF609!=;-K
M,IZ\-7TLW()!?.RFS\NM^0PL<EC55-[NTL,B1,T>?EC[@9@TKTJ-1)L`:2,M
MX@EMU2U!NG2L]W?,V>UU@M2QG9K:BSMO8N_1+8%GMA4S.UF((#'15,Y,C=!X
MT::-A0Q(U9E\P<62IR;@G"0&<>O@0MF.@O8]9?8E55OS]IAJNE*/[(''8^&2
M",V+5,/@`-<W>#2R-LZ!LIN.4XVVF\7ZC.?\AE;](9:I)=?7D*4H\H0<I0Q&
MC.FS8"!U_P!9K']SJFK2?TF'M.;]GK(AKNRXDR;][V"W/$J=D:9Y:FE"[6.L
M1GRYE,5`,."-`!*`.,YP0#P&5=:_75N72>RNAD]N?6;6NBH7IIH];6G<KF%1
M6<W2^8WE)%CA5QT9M5Y:T4&C)B&.R4,67*TR-6L7NB->M<#562_DEA$&6[7=
M6FYE^[X6#>K)>+G'Z>EVP_7TZ(FPM-1ZM0@IG605AVK(UH$3_5CL\FN,`NAU
M2A8V\]4;]L!=E)KE\M.E2%$!L&,45V'2?M87;7[)ZLU?9]3UY*'RH]/I$U;2
M-##']6M?Y*IRV3RZ2*;4UFZNU@;!6FSIBC'10<[(?A-N`M23VRPB-$&\^EAM
M<7FH-Q+_`!('!MB.V79#N+?]6$N*=0C/7U>NFZ"MXM)`HU19)Y"66_AN>YIA
M"`'WDBHDS'D(L"R%R/`<!P'`<!P'`<!P'`_.E^+[`/A?'^-^G[?Q?;]C^F+U
M^CVOU?\`]SSY\?[7G\_`_1P'`<#XQZ?(O3Z?/J_2\>//J\8_I>/]KT^/_IP/
MG@.`X#@.`X#@.`X#@.`X#@,^/&?/Y/S^?R>/S^>!]"7XOQR_A>Q\7QGV?B^W
M\?T^<^?;]K]7X]7G\GY^!]_`<!P/C'I^OI\?E_2\>/Z7Y_/C\_`^>`X#@.`X
M#@.`X#@.!]*CX_L&_+]GXWMB]_Y'H]CVO'Z?N^Y^K]OQ^7S].!]@/1Z`>WZ?
M;](?1Z/'H]'C'I]'I_1]/I_)X^GC@?UP'`<!P'`<!P'`<#X#Z?3CT^/3XQZ?
33X]/I\?3QX^GCQP/G@.`X'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g662896g79f34_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g79f34_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG-SEF,S1?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`.P!.P,!$0`"$0$#$0'_
MQ`")``$``@,!`0$!`0``````````!P@&"0H%!`,"`0$!````````````````
M`````!````8#``$#`P`%!P@'"`,``@,$!08'``$("1$2$R$4%3$B%A<Y02.U
M&'BX>5$R)#2VMS@989%STR4U=G%3E%4F5M>8=Z@*$0$`````````````````
M````_]H`#`,!``(1`Q$`/P#OXP-.DF[WNB&T-VTPN;/!E_8=#=3ZY:I>+EM3
MDACD]>.CI)"S.*)<YQT3VH<%#2[PRW6<Q_TF7`"<>P/`RA)P@]I86J0=MQQD
MMY@HJRZKO*!2&3-=J[KRQIA"8LRU]=#G1;3IXL;4'2-,_DDRCNU+$2<[M)<C
M:V8MS;2QF)33M`_6"&:W\BD7Z',XWFM<,MT5-6/2UO&Q:`JK:I%G*_K!1A7S
M7:URD*HJI+L\F0UG'&DV$"-$]N#2>8X*4`4J1&<A<"G0`>/?OD06-E/];,$8
MK*[>>K^KSB/HKJ.E%UW0B#$MDM8ZF8%3:.9LK:SS*=EIS8E,W=E,6,4G2-+F
M),O(&-$,H1OQA"%V>49_!QA?SI"HO;U'=20+BUJZ@KARNBKXRTMMC1-0I98T
MYVA"6#;M*$(VMGESF20O9I`B:'A!IS1#.;BRE!0MA=.>^1:DZ[LV3P%VC-GN
M<6KJTJQH^VKS9&.,J*;JJW;?U$PP>#RMQ6S!!-EJD\^?,!3DN9F)U:6(YZ2`
M<E:40C=%!?O`8#`8#`8#`8#`8&OA[Z^=J>ZMZ=JJ^#XZS5%".4F+L.FI0VMB
MQ&Z'5Q`1R*+=,LTE6J7-0C>76OI$A8G0D:<E+[&^3D%#"+97R"",:G\@$[B%
M0\XR#KJB[7C+_<1=*I9M;$-@K$WT36DWZ=?6XNI:X=`OMBCLUQ4QTZ:,D:?7
MAM8W%J2/@A"4GI0",`0'S6EY+88NB72(JX9+N@2'FVX&*E9YT"^T<RS.JD=G
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MVAVEIAR$P0R]MQ>A!`-7>)=?`KYB-R/-U0V4&P*5=62%!)/W$ID=_P!F$=1M
M,S;3$]\WPNL1Y<Y\952>6%HF(M$V,[?^-;R2AI=#"4,@)[8.%FF"U?XUZ[<+
MF$F#P.>Q-#;(1L*%G5VNYAY>LCF-"2A+4OYY40>%9MA_F$H2Q.@]'HPIM`'[
M_E"%2*W\,"J(QZ?,3_><#7+9;PQT/P\.9P[GA+#[#FZ.^#XBH4W_`'[-U]G2
MI^N2Z4QL6^1P.--;F]8<I-,()1[,-]X9_,?%C9=P0FUH[>?5B&9R%^XY6<1U
M#)XO2"2$$06LWJ51282V;3E@U8K\GG]GS%T@#`6K-0'1UF3D-6M)D!(E!N\#
M-W3QI1EFZ?L6^V,?*SI&[INJ$75,D5\<E16W;@BT\9FB%1EX;Z8NQ?/8RIB;
M7-"80B4)4[BU/1C$\G*%:'>]'!3EAMBP&`P&`P&`P&`P&!KE[LX;AO<CO2R$
MZW3JV>ZKE+RDL)`PH6Q]<[5YSL(AF(NWGY]2'.S<J8H]:A<:9?G<@A/&CV@#
ML!!FQ_0(7Z`\5Z^].AY?<BJX(.0QRVW.7[?1%S&B$5A6_6)O,SY7[REJJEK9
M<Y^W(ZQJ*PUL%VN=D2!B_(B<W1<;M684H$4$))F/CZ:UG,_45).ES`96N^^M
MGKKAQG"Z*I"DL%(57[`[Y41`]$HDJ=*XHD0()MN&YF*DOZBC:C9.OC^,01F3
MXLERKJEEZ.<+E@[ZA8.O7CKIF<G2BT;QT`NU(83)X<31CIT*X6"J4ET?"$<F
M%N.-;8R-X$B<@@E1]S\6S#0^VA/&=955KN;XI/>H&^S:)Y3MNV+^JB!(Z52P
MF9J;5LXBUT#8&:3]-83X@>X-6:.Y7LUG1)V5$XJ%9Q(EZ]26G"6,(C.\0<9K
M>+\_NJ6PN:)@^TMR7`>0IB\=><J1>[ZYD,5KR12"00JP8G''&RX6NK6=-SO-
MG8D\O3RX-SLD6$D*"?>E)-P-V<19$L9B<8C:$#06BC\=961&7'V=''F$M*U-
MJ9`G`R,#<(;>QM`24^M)D9`MDIB?:6#>PAU@9#@,!@,!@,!@,!@,!@,!@,!@
M,!@<8_""UZYY:^+>@3J3JZJEC3P#W9:U62BG')S=I?Y`YU!F];*G"F>D=HH5
M!S6"51%A:RY8S(S!3(UQ-)5&HW--M`K3*`OH@[6\BE?\JV5TW)Q'2&"/W#S/
M=D1GMK,_*:)E8^@I5*ZX;XZVT3%N>+@E;],*;?(I8:Y0WES<P"LAS96\E<\:
M`XJ-)P]9#>'2+U%XU-[(FIMWT](/*)P;57.+WT)1%%,4Y#"7.00XFS9L*(1"
M+-A47FJ2PWUQ1QU\.2MSHC3M9"Q&03[]*U89M`>S.H7M+SATVLNV..D:Z!\A
MTMX]=^+@U["4Z>!01%;MG5#[FV9I$P;=-NVK6>OP3&3&+UQK.8@"O*`V)"`I
MU(0_3C_JGLB7OO`MH6O>L=GT'[)M_K>EY)4**HH?$&>$MU,L]_2:N)G&)>T"
M,F"^:;+H[21["L4F,ZXATWM,A1&IM''A/OEBK:`NC=Q];,A"L43*`][\,-4,
M&MEC^GCS`5).I*X22)Y1PT+P1$E$D7M`AH]NIZ(Y>G0#-().**./"8&W4(@C
M"$8!!&`8=""(.]""((M>H1!%KUT((M;]=;U^G`_K`8#`8#`8#`8#`Y()!"#O
MZW=G66]U;5<'@9'G:@,;?>YH^XJ%/3=9.J>O>?S(?3REH##V4MJI&[I:M1P9
MQ=#9:XHDA4I.^Y83`C"H`%^N9>L^];QM..VR5%9-^XE;U)TS4%KPB2D\M1ZI
M:LJ2GG^W(''U\7?&RREW6+C?#%**Z:U3\C=V(:!<E=5WVS8C3ITBLP*8Q/LK
ML*_.1>HK\E4^+L>GFGQ?7C;=D5U:%!4.33C7TR_LCBY0ZMX0U'-+A+;;HQJ@
M12M0HV\FN)"O04P'!8:<L4-R(+4WCU_TVT1COVVJ\ON$4\R^.>'TL=$N?5%9
M01U9KY5OG/U=7@IW8SH]$'31D8K@=YJ;"8:3$5;()(M;A&^Y>?O:0L/NMWK#
MLQFEW9UP1VZ6*,5ER)V#QY43)S\LJ6'.`)Q"[VB?(JVSH]8M@K?EEJ)S:CK\
M7F,:AF$VGH5Z??W@G!,,M,0&Q'OUQY/8:ICS_P!35##>@1IY>4R4714IC;!.
M72W+OE30YL<6@D$@TK"HC;Y+WM*I4@"K6D[2,B#2IQ4G)4B90I+#W/'A2$JY
MOXMY^I2</[;(99!8:>E?!L;TJD4=CBMX?WF2!KR+/BTXY6Z1&KD[R"-M!QFP
MB&V-1&]@!_F!"Y^`P&`P&`P&`P&`P&`P&`P&`P&!KX>ND?%O5BV&UL^WEQ#!
M7"@)`L5P.$K+%I=C5TW*0-K[&G`R-,6W8@Z!OP6F0N2%1H@M*H^!:H)'KVFC
M#L*8VH/PCS:H;FJVM^CN#>>%]W(6='+9Y3LRYO87]>4QS9EL%.SOJ$TPYFE4
M'?)"QE@?(^N),;'I`H4ISR_0\0]!@5,NO"]-'VDYTS<W/'=O5]\R6HEE:TQ1
MD*J=IKI%:%,Z?04U+4]8TFFDC/5*>)O<H4.LHL1Y5F+$;<E`/2H!:%$DP+-U
MOT9XO(S8BR[+:0<H\I=K>Q2TW*3;+97]1W>P3@Q$6T3$DJ1S%#'9#+V)V^#9
M:21H#E**0-&TYQ:@T@P&M!*;-V+XEXXE@Z%@Z4X29459/,@D5<I&JTJ40)X(
M_2Q-($<H>HB2F>"RX\Z2%)*W0I:>DT4:I`X*0F;%HXSW!^,NLKQ&]GS*'1R=
MS_@CIB?$;.8X"QRN54;9\IT8[*4YQK1$6YV7NSF8H<%B8H?P(P;,,,+"+0=[
M#K>@V*L3&S1AD9XU'&IO8H]'FIO8V%D:4A"!J9F9I2$H&MJ;$"8!:9$WMZ%.
M`DDDL(0%E@T$.M:UK6!ZN`P*F]!]+$4Y8-0U^D_9TD<K067;-KRF5J%)$<JG
MFBBH\C>+8LET,1'E'!7:>Y(P,K:$ST(T>ZF*C/D*1&E&!C+_`.07FR*P:+6!
M)%]ILK/,FV7R9A:EE"79N9GU]`6UH>II;"B")X$?+T-21IED+>I5R0Y&!I+"
MN(*^;[@P).P\%[\F/'3!(FN+K+"E"IV=5-8-9.F:H;>?D261W=`$UF4U#7%R
M98.N0()W:D35EF,3&88%U<%(PI2R-J!!+V'VNGDAY%9H7#)\OL)]+CTR9ULD
M'LJM+*4NL$C+3/SJI>Y+;3&FBAKO5#$RV:F.85"A_)0`_*)E!)?R;3G[+"].
M`P&!4Z[WKB&F8K(F7HIYYGJZ'7++A323,]O.=;0]DM"=-AD;4"E+DW2P]O33
M&4MIT::#-K!`4*B!(4H_>'9)6PA4=RN_PN+K`DMPH[VX&CEURIN>T+A=L6LJ
MBV*W$ZJ0,"F,.$A;)\C<@OR&5;8U0DX7()OW>B=:+V/9>O9@4:YSKGQ-T9)(
MP^3/R$<9VW'J]H6;\YQZ&I/ZK%=)IO65@)(RVRTOH0V!*?R71,E=F>()2=B<
MP$MXU!ZM5^/$K5;."%IE5]<2S2YF._>G.:ZB@54!*9T'&79=S5$D;`R0B`'C
MT\EO\JF453'4T@(D9^G&NAO!R$E_:@'N+=L`M:T,+"N/8OB7=T\U1NO2O"3B
MELB31^:6"F6VE2BHB;R^)E1DB+RB5E'/(P/[_'286S@1*U6C3TP6M+HL0=$%
M>T/$N+J'P[]$-[$T7U?7C]N9LC#DH=HT@M&Q**G"./NJU$8VJW)F)DKHXE-:
MU4WG"(,-)T`8R1;`+>P[WK`NKSVT\],M31E'RRCJ-%1XOR:R'E47J):K(S:]
MT6*WA3'A0?8HT9M4\G'F*!I][]RD0]CW[_=@33@,!@,!@,!@,!@,!@,!@,!@
M,#";*AQUAU]-8&1)'R'#F<8>HN.4QD_221L)#Z@/;53FP+=_5O>DJ92,252'
M]=.?[3`_K!U@?!7M0U94T/8:_K.O(=!H5&6Y*TL4:C,?;&IJ;D",K1)!129*
MG!H8_;KU&8/W&FCWL8Q"&(0MAFGX=I_^5MW_`,$F_P"ZP/I(1I$ON^U2IDWO
M]/?\!!1/N]/T>[XPA]WIZ_RX$.WE?'/G/,4#/.B[:JBG(<$T:4B36U,8O#&@
M]5H&C!HD"V3KD)2U;L'H+X"-C-WKZ^W`C7G[L;B7JTU<EYKZ+YYO)P;"AJ')
MHK*P81+7UN2EB"`:M<PM+@H>$B/0QZU\QA`2][WZ:%@3%:-)U/=,&D5;V?`(
MM,8;*&U4UNK.\,R!2#XU)>P`6(#AD;4-;N@-]IZ1:G$4J1J2RSB3`&@`+097
M"8^LB<-B<6<9$[2]?&HTQL"V5OXP&OTG5,[8E;CY`]FE_P`V:\/)B?:A4,.M
M!&>8+>M:UOTP,GP&!2:SN>+"F?3;O:L=D+#'6)]Y#DU$IWYV8VR:&QJ5+K7C
MLQ]#X"^E`9Y/&9<P`/(<BC5!.A!;RB_4.Q@,`%57/Q*(/W?)*]AO3%BUNWN]
M(7GS[8)D/AT-*3+*SO6SSK6>(G4K4Y@<4='1>-.JLUF:VYL^Z)21GX416RST
MR=:6%F(OQ779$S99XWSE<]I6'K&3]/&,R=$P&LJF8(*(7\QPF#'G(@;.(8*=
MB2=.%`6$>E('!L+^78?:(&!$5=^+Z"5C8U06"SS%AE:FO*TK2N9/JTZ5KNQG
M^3&UK8-D6>5,X7+'DHMRJ.63"86L[J7DYM`I*/'M.:0!.H(^88;2,!@,""X_
MSU7;3;]BWJZM""5V=/M1YH32J1-J%Q=85`HNR(4#37,-6*2SCF.)_G].+VH)
M(V5]VZNR@T[W^TKV!Z5L6Q0-#1T,NO"QZCIV*C.$G*D=H2R'P)D.4@!H8DJ=
MSE"]K1J%7LWK?Q`&(>_77T^N!YU-7KS9T(UJ)#0%NTK<[2VF%:7.M3SB%3U,
MUG&;%L@#@HBCDZ:;CQ[!O80G;+'OT^FL"<1@`8`19@`F`&'81@&'0@"#O7IL
M(@BUO0@[U_)O`^#\.T__`"MN_P#@DW_=8'^;9F<6MA$U-H@BUL(@[0I=Z$'>
MO3>MZV5Z;UO6_K@1'7%!P.I+`M&;UTWIHBWV\.-/,O@[`A2M4243]B+=D#G9
M*9J1!)2))=,6)2WHG<\LL&UP&9(8;[C@C&,)NP&`P&`P&`P&`P&`P&`P&`P&
M`P&`P,6G4Q9*[A,QL"2G#31R#1:0S%_4%@T,PADC+2K>G4XL&Q!T,92%$8+6
MO77KO7Z<#APJ1E5]UO2;R(]@-3?:=LWB!5+J9A$S3E22ON9*)=5R@^M*VK&'
MNP53"UNYD9^W6O3OL@3@Y."@8QF:W[MB#/[?Y%K&PQ-TS@"))0?0L(."^4[T
M74#<C@MDUM,4'\\SN(':-$-QC]'A*@!+<&M;H]*L1B,+V'6Q:W@=#WB9\@CG
MVW2LAB-SH6R&]G<TO".L.J:\1!`E2&28"39L:MV&)=>W2BL[C9B/RK4<5KXB
M#MJ4GU^VT(8;6\!@>0_N"QI8GIU;FM0^.#:T.3@A9$@P%JGA8C1G*4K6F,,U
ML!:AP/+"2`0M>FA#UO>!SAU[T!W59<;>7:NKAZ!5RVP:#YF:I$MG'/B5CKNH
M.M.J^D8M#Y@WU*R/E6QY[61GDJL8Y(`/:9R6.S:GUHHU>HVM&H'@2`^"OV16
MY0L,M2[^M&:NHCV/W:]0FP&R-LB.:2F+TK5#=!Z_C$M7L%-;BCCN1SF03%VB
M@UC:E0.#&CV$K[DPE&>6$,M=V=5Q.,4)5KY9EYT9:4K3\#,D#:HC1$-9(I9E
MC]C6'J;=76?=#JHIL4,"?`V>0.3,8C1G,S@FD3:J7'$G+7$@982DU7OW[8<=
MZ5LA@LU\AMF%#L>H8SSJ77\BDRJJY;:O1K%27-\N6,;Y1L,:H\?3$3^>1/:@
MJ22XB6$+#5Y@D342FT`-IW%QMP`%TVRVC.;'L-BB'2\@A]32>UF"/LDL<X8R
M5I5O[3+B#(O$X4S.<356^JDVV<PE#L!2$("0'FE%E^T+LX#`J+W-V75O!/-,
M_P"D;6VK<6^+DI&B'0AF$`4KM2S)&;MM@570M)L)IBV3S-]&!.5H!9FDY&C5
M)@?A(-%H.1Z,4"_]!3!9U=Y!&YFO/J>PC#GK<;FI89=5O-48<#S%;%2=+PEY
MVMC+$VQ!O.`0X..DXUSFX!..-.'L6QC#^;%Y<0P=TUT3QB%MYAZ^K1&KD-<V
M+5;:EB+/-%342)>*L[@B#&6BC5AUU-0)]H%J1>F,$7H[1@!:V'TV'7)P5U0W
M]M\;\Z]5-[-J-CNFM&64/<:"(9A<:EY`CV2<1M.::,PT]*P3)J7HRC!BV,PH
MD(A?7>\"W.`P&!^19Y!PC@%'%&C3F:)4`+,`,1!VRRSM%'!#O>RC-E&A%[1>
MF_:+6_T;U@?K@,!@,!@,!@,!@,!@,!@,!@,!@/7^3^7>!AECP=ILZO)Y6S_L
MT+%84,E$'>A$;UH_33+&-<PN6R=[]-:-TC7C]O\`TX'$YR.FF%)M\KX*NM'M
MBZ#XE,05?(41H!DI;"J0K9P*7O"'"-"7MRAT\A@4NA&`UO:1>480=[#/0.!<
M;`K)93Q:G*]TP7R(<U,ZU_M*F&8V,7O5#4;]OKIOEH]66Y32NU!80[+4SN#Z
M)V^1128$8B5R;9/H(`]%[#L)Y]OJK>H:5K3H.E).EF-6VU%&V8PU_2^@=J6U
MQ+W\B1>F]PC&YZ9UI9J->D,]#D:U.:09K1A8M:"8L"CKKY!J!9F&S9@K36:=
M!JQMMIH<^9M-=/D@:)Q<+C;9-&*Z\K9`PZ<I-+9,PVB;^,6)RV\O?ZHE!'SI
MO0[88/)O*5RS#X&EF\A.L=N6%&6V.6UX=!50+*K=JH:6)H1;S_/8R-:$MK9X
M=)G!*D").H5GO)RLHMI*7FBV#09/8_>=<,C!=ZB$H9>N_=.D>8V"UWBM)NX4
M,9<:9ZCL-1UD=*6!/MU>Y"@G$P;V]>E;R=^BH*M&4?M<C5$$!0I'T_6CYVW-
MK&L.IH1`&VN+BLJJXU;]D538AA*Q!RS1[W*>C;;06.AGKO!&%ZC[<C>65E^:
M,I3BV5"8(QX-&O+;@!<JP?(?%(K#V2P"(!:,<:"HI>UK/$-LVIYK$[#F5047
M3A-D/<IKEN/"6@2%JW"5QTK1KP,C90%"I(:G*<2]$!#-(1WY53[&&55.8M8M
M5V*L3\P)7JI)1&%ATO:I5U@^.48K2.-OVH`DR0&GY@=/O%9`0%I$#8H5GA)*
M+'H`2QR[<C]=<+L%[DB-L3.4'Z)Z2ILI0S$*$S:ZM%/7;-Z^CSH44J5+3-+3
MV!A3`7;T9LL3@6?L`0`V$`0L(YN;:RMK@\O+@B:6AI0JW-U=7-40A;FQM0$&
M*ES@X+E1A29&B1I2A&&FF""666'8A;UK6]X'&-:/0#CY3>L$O52S2L/%_-3W
M(HIPM#UQ2@A%:<U)-/8IWV&^MBD)?SE.!A!K7"-'`UM,V@&L"$LXXS8PG?`@
M/I2["*)JY?(T+.XR^Q)4XH*YI2MF$@2V46C<TU&)G@$'CC<5H1ZM4O>3P&J!
M!U[4Z,HTP6]:#KU#I=\8O+4AXLX%Y<YEF*Y*XSBL:Q1$S]4A,+/;]V'*G)SG
M$^3MJ@H0BU38AF$F6D)C0[]#""P"U^G`O?@,!@:W>H8XV4ETSR=TU`2CHW)K
M6O:,\OWZD9AC1L]NUW94)F:*"+IRV$>U$\RVKK'8F,YC>#@;<$+8<N0`.^U5
MC*P-D6`P&`P&`P&`P&`P&`P&`P&`P-07E,ZWO.MG3GKC+CYU9(SU?V6\S1,T
M6E(FDF1,O.M&5BU(7:X[V51L_P!R:02%D2O")OCR%2':14[K0[-]P"=EC#7P
M5X<^1'TD;S<DBZ?Z"N!?H*I^Z"L_JB]"[8<7P7H,YZ:%,2F\>CD.UI3^NG1M
MR`M*E#H(`Z%H/KL)'YQZ,NOQL])UKRSU1=LXOKA_I=W)@_*O3%T.!3W:5!7H
M+0A,_--\6)\28<SBUB(@[U#9(XATM^^*V@4C$'>ADA.?F8X/G%Q1J']N\J,`
M5W:/)S4ZJ&R+I/:1KI2@E1@G.RN<W_V:"):XN"<!CG%31;$)&_%_&7K7W@QA
M#573-OP>^ZPA]N5TO,7Q.9MFER0"HO9#HSN!!@TCU&7]$+T-;9'&G8DU$N3#
MT$92@D7T]-AWL)0"(0!!$'>]"#O0@[U^G6];]=;_`.O`PW@KH\/C!ZR*IZ7+
M@MG`/<5CZ_9%:K/^".\I=@2LWT$TC,,WI)'ZAZ)4AU\?NV6E;)($._4HH\X8
M@[`,#4;/_&K*G6PH[,XC?$M1RB8=#5[=MUVR8P5"P2D`*#K2X&NDRH_7\>J5
M/5\ODQE@6$@,D+L]MQCBYM;<27M1K2)O*("48[XT:NAUB5=:<7L&;`G$&;79
M#,9'+8Q3UBN]KKY)<$@O652Y]73BM'LR&SF2V-+G8]2Y1C3-L")<%*2646C;
M_M`]95PT5&H-/XHQ6;9\]@RB\"^F(#1$@=*YC<1;K%0=!&=6'PXZ>HZQ7SA7
M#Y?<P0Z4&O"AX.0-1FR"=;]NA8&"1[QNL$]HMBAG1<F<U5@O$`[$:+#45LZ%
M)F%--.Y9^38EJR6-N;TP?DW!YA!X!-#"N5)RB#4`SMJ4(@G_``EA)MA<&-=R
M15^:+DOJX[!E4AYXN7G%5/3DU7QET11B\)%")#+7MJ8(E7C-$4;T1NNFE&0$
M2$Q*:A),+4EJ-G#%@8:X<=V$X]5/G5CTY,<TE-2<YP^JN>H])'O\1';*N*-M
M%D+-7U=31$HBUL\7>VA3:KQ'&8EI2K2VQI=G9645HU2D3I`MAS!2)7.E$U[4
M8GLV4O,>;W%SFLP/*V0?-;*F;XZ3>SYL:GWL>TFYA84C<W+1&Q"^`*G1>A;T
M#6\#0'YDNKWGIVT5'BEH.2K&Z&IVMEEWD6M.-*C"%$4K!VV!?%N78^\IQZVE
MG]V$EA.>]%B^1OC/J$7K]V:6$(39&1FC+*SQN.-2%CCT>:T#(PLC8G`E;FAG
M:TI2)M;4*8O6@$I420D!8`Z_0$/U]=_7`_1V=FI@:G1^?7)$S,;&VKGAZ>')
M0!(W-+2V)C5KBY+U1N]%IT:)(2,PP>]^@0AWO`EGPZ<JNG65MH_*I>D=5(JS
MCJ5^B/CEJ^2(C2#FV&.'O:Y?UM(&=4'02)A;118TD9^0/R(([K9P=>JD@W07
M%\@G:UY3&_F?QN\#2]LA=\*HPDL3J[IE2P(IDU<<TH[Z^*/$M#"X;$QO?05L
MF"V&-MJ[0BD2$(G`\K98BC2PJ1_RG:G,_P#J59U;Y&UEV[]%1G0V^W[C360)
M[UZ#_+%,Z9S!6R=-I1KWA;@LFT00>A?LV'7K@6X\=G5?1L*Z2G/C<[6G:2Y+
M%8JP#>_*W3P6)NBCQT-0B%^3Q&5,EF1YIT4R(;LJ20K4B=S.;P`3NZ%46L^,
M`PC,.#>!@4![]_U/CC^W]S!_3KY@??TM<UDT7T_Q,X"?R@<XWE-I[S1:#">U
MM1NFFWYS%@3/G2;D/7V7YU"4L?Z]=HH:1I1I$H529%L1>S0%BP*6)_)':M=U
M)<'5TJBD6LFCIG>701M$)'ZZ:5H-(Q<_\[:;:W;T\..G9B.0VO8]W2B$2:6,
MZ06OM1H%J8D:]$7M.`P+(M?D(56C<1-0TW0MC2>*_P!7*F.F9O>"B2P>),M:
MU7?\=L9SA"H$<D!CD]2.Q"%$#'_X,2E,(^,1AIIX=$A*4!`CEY3$M#<D\HWW
M,H4]V#6UD<TTS<,LL*S;QYZ@5Y/+?,FQC_.#CM0-8(R5;5E1]"X@=7I&PH&)
MJ.^?1+7LX_>D@`QM5Y`;<YZZ!\D#O8-663;?,M"=,T4T2>QD4RA2!LY^K:?\
MV\W'N94-@SBH+E4Z2QV6RU;)I"F("F^U0.`STQJQ1L2,`?JV>1L7/+YU&T6G
M($D\ETK\EUIT!S['K(M*%4_`XE#8;S32UIO)$@M&<B3L$*@$43JG%3K6B7)R
M6.CJ2F2I3S%'\V%UJ\[-:.B^&+,ZCJ(C]FWF-PCH!$%N5ND9F2*-6A28YI&'
MI.BDL<6N\*G4:3RZ)C/;G5`H/;W9M&2>'VA-$6`-4/'7DZG;,QS&W[COZP^@
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M:H_,50HM&JX8YOD<^=0Y?,G3?`MTA5F`3B#%ZH\K_P"VT7C<_GO)URUA"+1X
MQL;MFB#RWZ#V',K6@=01Z$2*P(87!H<Y*'",V`:AL1I/CZ,\X\#TE5:V,:)2
M$:0(7<Y&Z'6]14VTW";%8E&&J1JA&1H<%N*%WC&'UA,;VY:G<TDU@Y:=M+<4
MJM8<@7H#20&HUR,T.A'%;+.&%G<!@,#GO\HJ@OF_R+>/SMB=^J2@Y)7]U\,V
M1.%!8OP=13:Z'N$3:EY3)UN];)9(U,95#E#"I7F;`0F./(T:/6C`X%XAA$`0
M@#UL(@[V$6M_IUO6_3>L"&N@Z#K#J&F+`H2XV+4@KRR&,UF>4Y0_MW1K5`&!
M6R2F-N&M?,SRR*/!!+@V+"MZ,3JR`"]=A]P=AX'BKZ]L\$@FGC;[-D@7?KWF
M>/(7:O[.7ZVD)["Y;&H_$P.^V+9N_P#2YJQ`+*9YLDT(9R9Y+TH%L7W)GQAK
M)\D'-VO&KU*LZM@R#3=PEV;/T*'H5E0E""R<R]5R<XI`QW0G3EZ^)EK"]UNP
M(I`(.@IT,@V6I%L(511>![.]>F_TZW_DV'>A!WK?UUL(@[V$0=Z^NMZWO6]8
M$>VO5L(NVMYE4]D,X'R$SMD4L3Z@WOXU`"CO:8E<FU3K^<0/+.N++5HE(/09
M"HD`];^F!LD\+_<DVF"&5>//JV4;>.KN7H\W+(-/G7>R5'4G,`C@M,#N1"89
MO>G"9Q8(2F28%:V(XMR+*5#V+:HS8`WVX#`8#`8#`U:^5OR!G\,48SM=6M:&
M<]?=$/*FJ^3ZN4>TXEWGJE($QUL*5D:W[TM95(TG_F'Q2+6BA!`0EV(`E01A
M#0%SM1Y%$0`YC<9(X6#94SD3Q9-WVT^B$=);<N&7J-N,TG3XJ-]3QZ6.!FRD
M1`M^U(A***#K7H+U"=\"`:_H1V\H_5I_'K08O3\@\_.4=F'?$Z;#%"<B=/&C
M2WJ"<>1YV2C*WM=*S$P'&8B*,T-"SEZ3[V`\X`1AT*^1OM=#P91L&@-&0AHF
M_4UXN"2B^*N>F@A.@0/DV`VDI$[XZMJ+1!;!3E.,.@.C\J"$I,E0)RTVAE#4
M%""%2^+.4DW*%5N31(I:KM:^[7E"^VNH+W>="'(;HN^3:^>1R)0:;K1R2+,@
MC-MT?;M>TEO:R0!``(S#?4+>X&O>MC@7_P"<*FR*[T%U9O']RA=Q_0<J1!V>
MUL-@]3KH2TUG3RQP)]Q&I5N+Q!9(3T0A>],FT#8PA&+TT'1Q@4![]_U/CC^W
M]S!_3KY@3AUGS3%NN:&F=$RN2RN#$28^,O4?L.`JD#?/ZXF\'E3+-X-/X.Y.
M:!T1-THBDJCZ16E-,(-!O9>P#"(`Q!V%2;-\6%5S%#33;!+/L6G$=0<N23C8
MC479JPE)KS1,L0QU*]I$>K'@DN20NP5AD8($9)&8E(X'`--`=\O\SL@)UI;B
M2O:0>I:]QV53)T/EW,7.W+*PAY-9AD)(;S<QV,PQ60)/LVE*;^TKZELE4)P$
M8(:78TY7Q%%Z]^A!3>4>&"J'R#--;L]]7-%(D=Q_2G%]@%H&BH7M^G=9<_)G
MPNO5R23RNN7UXKEV6*)$J&_%QT;<C>M?%[RBC2]';"6;3\8<4M2Q+\D3CT)>
M#-5G5EDUG8O1]`-0*V,K^R15/$JVB4<C25[<H&NL*$LC\AK!"5(?Q+NF/>D(
MQI1C+!H(M![<P\:U?OCQ)IW%+2L*`VXOZIFW6<-LE`V0"3'0>8V13L8HV=P<
M,2F,3>XE*JTE,%C(`*4+DE.6`5C"H(5DG$$#`%K4%**U'/[[14XL:23TZ50B
M:0F1V&L88'%9`M339&\(%BM#'X+%HW"&C;0C>-DHBB6[00ED%[/V>;LTTP*E
MS/Q<4%/XO6D.DC[/#6.$<5/G"$HT@7,S>XVA3"U%`C(NNE3B4S"-0S:M99`2
MGV/+V_24*!Q7K?4L9"@96!!O67!_0DQY;=:J16Y+NIE;K=7.\OD3$]QSFRG9
M9NM*FGI$IE2>#G-=7L-3RZSI,!.1M0">)E\96`3B"%*C,%H0@R'E+B>RE+!6
M&N@B'2"0[F/IB4VMRA5)A%![E[16LGYVE=*O\+O(^@H+%Z<=?RDGM*4O2(#`
MG^Z)3&HRUS@L-^?6@D&I_&-%*U5U2SN_0%VV54O-K%.H_P`L5!,`UV2P4<CG
M<(?JRVJ#(X]"&>:60YP>M9.X1^-G2%>N_%M:LS0PJ%.PJ@A)$3X*B,#CO+31
M"K4LN-/7(_*M@<JU=,49<(6ONF2?1VGH^.P'9(]Q)VCJR:Q_]S#<I1@$AVUB
M.4'Z/2&E[```9[RER:R<ND7`Y@G#[8T]OJS/WL6E+W2.PB#M[M+"HA&(*F.9
M(%6L>BT*CA8H_$4@EAQ*0:YS7B.5+%!QIFO8%M<!@,"(K\HJK>G*9LF@+KBJ
M&:U9;$4<X=-(VO#_`#:YJ<B]:T>E/UK9K>[-:L!:M"K*V$]&M(*/*$$PL(M!
MS\<AS:TN9KDDWBYZPDKC*+4J2-&R[DF\Y!KXC>M>2V\W:%C=52P6_@5732Y)
M8&>6(P"$<:224O#H90AG##9I@4:[@Y@F=VQ^O[BYYD*&NNV.6I"IL[E>S%6O
MC0&/_P!OHJ44W/A`V#;I4ET,I8FAY1F[V06(TI3Z:^,?N"\W+U_T)Y=^(Y:T
MV-7A!!4K;)9S_P!=\U30'OD51VJUI]LMD5C)DQ@0*TREK7#TM97,O18ST9B1
M<0(LWZ%ASAPN'V1Q9?LN\<=_/CG)7FOV0V:\DW"^ZV$[H?EL"H21FTL6"_FE
M=J4UZ!99&G#O9AA1)2P.MDCT8(+-X%;N@:ZLE8LKCH/F]X31+KGF.0GV#0TE
M4"V4W239A'P3.E9ML`B]KZZMY@"8UKR!B]A1QA9VO;L(A8'4IP-VO6W?W,\)
MZ&KM.L8%;D-=%;.KAZ$`,KJ"WXJ,#=8=72U-K0#"'B+/?N"68(!>EB$Q.J`'
M19X,"YN`P&`P(COJ\ZOYFIJR;^NF4HH75E3Q-TF4TDB\6OC0M+65[OA3$^NC
M%SJYJAEI420OU.6+#RB"@B,,"'8<>%?2"T.N+RFGD5Z/95\=GUKLFHES?4+P
M9L\7,_+.E8W"+1/X!?S*6R+*^4+W*E180C&>H`FU[2@;*"%F\"MM^6!9VWBM
M.;.:&M-*.NNG7M5"*395`!GM<);4Q/RSJ]YT$H!HT%?5$P[,<%!HP^U0J`40
M#0Q;$'`Z+:=K7ECPH^/9PU*):-IJVCXR\65=MM/Y8%$UM^TI`82JF<[>"PF;
M52&P;.EZ@M*VH`F&&B&:C;R-[`65K0:V>/:WMJ]K9F'DVZ_CRJ/7[>$<U%N>
M:7>!_<AX]Y./4B<XK7*8H>M%)K6LHLT#U,UI80&B/4!1:T`L!A.@V5X%%NWN
MG9Q3;17M'\X,""Q.W^J'M977+U<J]Z-;FQP+(T*7WG8@`!,VUU'2K.:)U=51
MNM%'G%%)M>[WF>T-G7C\X@@W!7/;54D?=UT[L*1O#E9%_P!U2'U-F=Z7G+Q`
M6SVRY2L-$8H$-S</YEO2[&(#>V$)TP=[^,0QA=_`H#W_`/JM_'IPOU2B>_N6
M?F,W]`%_<RAT0)_>+?TU\ZU644'_`"C,#K^7`_/K>>2<727CTY_CLD?HHVVW
M>D_L6?KX\Z*VE8^P?F^H9-89$&5*49A)IS)*;(7QO;DFV+XUK:E4)C0C).,`
M((CCGDNDDB7UA/"^;SDG*MY]%O\`RY3]Z&VRW'2UZL9+*9=7<,E,NIPB$#.B
M%1V59<+4M#6Z%/SF\$A4HU:MH3D'[V4'X>(V3WO:-0V]=_01$J*F=E]"7LC3
M:=;[D%LQ-&SUW>ULP-OC,!@:UACL5IYA@21F+80%-"?6Y$6VE.:OVGF^P`5>
M\>ODALZ.<U<@)^NJZEQ46M'F6Z+,C_33U:;?8\SGJKFYB'-K#<;#@:=G+=8P
MGD4%TH<F%6%X=U2PM"(E<F;CQE%B">N=?+>Q]!N#RRL]:5Y^=<>8))U37+?#
M>G*^GJ0F*QE;&TJ^`]$2,EA88SSE9B=/-&I8<0H5OK.!+M?['$TUN/*$'[U?
MY:H_-)4GB#[6\'5";.H:+YNG,_HOH!@OVG8Z#IJOI%(:1G;18+7"8@*0D/-D
M,R6%N[8>@;5+2[.J4X!BM.9H6PS:+>4J!+I0M/G5=N-?4FYQ3MF95C=RN5(G
MAJL=EX4G*6*V@H31TEE0J&74CCY;E(V+Y%9_WK*T*3OIZ:P+)K.EI:BX]B'3
MSI5T;@\FDU=UU/7BM;<N6-5?&*XU/2V%2L;[&N!^8S&A@(AB5[_\0.*:U1YA
MY`B$R8XT0`B"F<9\KRV=0"LW"N^?FRR;2L7LNPN(R8M`[\B3]5!=A02JIA;O
M[P6"\=19.CE50N$5C9!QJ\ID(=DP%)P`MJA6FTD/#)F'R53B<-M/P>`\NGO'
M4=D6UU!4LEII]N1ICU?UXKXZ?M1R[I4KNQ+!Y`.0Q@3LZ,A$=$FC0%3J:^I]
M*26\!2H9`8CSQ=5PS+Q%W_<\OD,[9+?01_R.N25P?I(2Z3JO72"W+T>V0^/E
M29H6KD0EM8HF!$V(#T2@U.44W%?;CV6$&\"-ZZ\@#A3\&DLBE_[S;3E<:Y?\
M4!06Z=65$&&KW"R.Q%<QKQJDZR3K(8)[K9(LE:8"V;2-Y7OA!B<"<2-$6>6(
ME8&'R7R!=*6]9G'#I65/IVR0(>]^I>7Y'4T(Z13.M57>&JN6[37+Y6_6L97$
M>0&59%9J0%R!LIC=W,I0S;T%!^1*VB`$JM_D7Z<LVX^%&&K^>8FS1^Z)EV%6
M'0L%F=L(BWV(V1RQ)7"!SAIB\M;X(XH7E@BSK'U;LVN)1!(I(E.*3&IVTSW#
M"&[/`8#`UQ^2[A+^NW3+&=7LG!5?5_/\EU<'(MXIRM?>5U;C0F]"FEY&``CE
M];6.A*_#25OWHPE4WG:,V48:G)U@4HXHZM_K4U<[JIA$CZIZ)IR5+JAZGHIS
M%L+S4-UQL.R7QM++,WLU;"Y2`O\`*1QQ#[B%[6>'8!C&49O07#P-6W1VIOX]
MNBA>4>AF!VD-;/+8QP[R6T=%THU2JR:79!:3,'3T18R?0M;<7/J<X0UVP:">
M[QK9Y0AZV689L,0[)K_HWSHS)!(^/$K/0O/?$BE]LGF;L&PH<K#+NK^E7"(%
M"9HM3@'`;:N8>1'!N6DI9)(S"S@20\104R<XI&/>@J[SK=PKP@BQP?XPNKJV
M8!)7BL;ZJ-Y"(F05-<<0.VWS"'NB8S?S:1Z6%[4MJC?J!6WG%F!$+];T">L"
M`8%?3MXN^KQ]CM!2]1R-?R^-PGON#-A:@]/"G'1Q;+`.PF)J3!-]'"&FK`M\
MP"47L:YE-^?>AGE`&`.SUG>&F0M#4_L#F@>V)\;4+PRO+4L3N#6[-+FF*6MS
MFVKTAAJ5<@7HSP&DG%B$6:6/0@[WK>MX'HX#`8'(#WUTB'R?]6'TI#UX'/Q_
M<26,$4Y<49_W$>ZQZ\B9NA$QTLTO>TD@I[GA;OW*/;LQ(Z23>_J:400,(9>(
M6Q"V(6_40M[WO?\`EWO?KO\`1],"-;AMJ#T364QMNQW,37#X2TF.;D82#YW!
MQ4"&!,UL#&B#ZFN4AD+F<4C0IB];&<I."'6O3UWH/8YZX$\D7/<48O,;#OBD
MG;$E:'5QM+Q^3`3*DBCAP\Z_AWR/<WPB6K4(W2O^D8BA:`2`QQ^<*)>_J#&Y
M61OXQ_<A)\=NQ1YQ[KKCH)1%9A$?&9R^],\HIZL;$:M,SSU+UPV(2C7:?V!'
M`J%J)36'-+FJ.:VE((P],YR0M0H]QA1?L*#<((0AB$,8MB&,6Q"$+?J(0A;]
M1"WO?UWO>]X$']'="UCRI2D]ORX'8UK@T`:PK%)"(O2E^DSVN.`@C,(B3;K?
MRO,PF3X>2@;4A>MB-4':WOT`$8@A^'BNXWL]H=YOY$.T&`I!VIU`Q-[>S5\H
M,$L1<B<UD*/RM?\`-\6^7W:22(19A;G,U@-`,7OH]EC^B;8C`W2X#`IOW['Z
M^>N4+1<K'LTVE6JOM1*VXY;Z5D-E"^MK)J>:1ZP*ME+;$DNMN$U6I[!CS:2%
MA2>BQ_">)M3[T<J!O`@XR!='=%M/CWZCE=7L=07_`$9<3Q(;'K-YD0])5%,V
MG"IU3EC&(=@3.*IC?W*-/C-,T3`N-,6-BE!IH5J!*@#/P,@A/C4JB$S6&.">
MT;L>J9J^[93T;4W+[X^0LZE*WN26.DGD"F2LIJ&"(+2=6:/2>9N;JQL3K)%[
M(S.2OYDZ4/P)`IPME0-&1'G.MB*M@ZY^<(^GFEISD"J2JT:YVV[6[:4RMN2$
M"4(&]L3[0))'-U9*,'P^\M&`H`QF#"(P85LB?CBY]BT#Y>K,X^;2F%\IUS;5
M50YEE#NTK")G#;I@Q]>3=OL;:%@;A/&U,<4F`)VBVW:`,>]BT/7ZN!CI/C@B
M[ES].N5["Z.Z2M.@934)5(QF!3!WJA.;7,+;CVHV-J667Q6I8[-)=)XJ0QI$
MB-=*5[[HY$5LI:4KV:>,T/F7>,JL91`NJ(C9-R7S8\CZ\9:K;['L]V>:[C4T
MBKS2*<T-3RVI$E?UM$897C]!'(*1Q;_MFHQ,6Y("5&RA&".V:$;]=^-F,V]S
MMQ)R;7#`$FKJ!O>DU,HD+C*?PTD:Z"K^*29FM-I.5(D05$U<[SC!YD4?46P$
MD+R9(J6G_P"KZ`,+Q].<UP_J2N&JOI6_2B(&Q>Q:WMN$2Z&#8-OD1L:I98VS
M6#2!.URUAE4,D"9N?&HO9S<[M;@WJBMB",GW>P8`@FOO'75,$=H7)55BW).Y
M=#^M9KVB?*9H_1(]SE-RV!2KW1DD"_)H_"8^SD0X47?SE"1L;DJ`")6`H)(P
MI2PIL#S'[QNUH>Y,DN@5MW?45HQB_.B+]C5JP5W@*J4-#CU2X&+[KK_\5-Z\
ME\(=:ZD8@I=ITJYI4K4"AM1*2505"?1@@EFL^,:PJSDV3\=,<AL9WK:6L=X,
M3Q)99)B)#9*DJ_Y).I3.'%1*E34$"]Z"ZV"N$F5*4QQGT+V=\P]#$,**=9^,
M,3K4+BV<^_G)?(W?^H5#IO%99/6:)N+_`$[PV_2MPCR*NY0=#'2-,-HR)+,#
MOO#WY"O8EX"MD[(1B&$\`2)R'Q79[875\KZ.=7IC!S9>\ZL3DBK4TGKR2.]:
MUS-Z"4TL[P:V)77U:0*'R_9KQ*I&]MQ#2B+$U%K$B<UR<-$CU@3%OQX5HW.-
M4R&$V?<E?2^H.A>A>A(W+(XZ05<Y+EW4LND\MNFNWQOE<!D<=6U_(C)2:E3Z
M`B*>&XA,G&G7@4`$<,+_`.`P&`P-!WE(YQGW/-I(O+1RC$G653>OXLAAO=-$
M1@G8E73?*[&+:@V7,[<4'85MX\])=&.;$?L.SUS26>@$/8`$DC"PU7V=`;JK
MB#V[5<F;YG7%D1IKE\+E#69[T;RPNY&CTI^@^OO3*B=^XE2G,]#4RDLPDS01
M@%K09P:42H*.3J2"%2922<F5)51):E*J2J"Q$J4JI,<$9*E*I(&(!A8PB`8`
M6PBUO6]ZP-;/(=DJ?%%U,R<<S=P4$>._KZ<N9_%TL=%)IS3RQT9)%"EZDG)+
MTX*1#"T5G9RXP]S@8S!A)3.)A[=K6Q&[&`/(\S'*#US;9@O*[0497N<<*9V:
M&^1*KHRE&H4S6H&CT21CI9B9TX=[5V'111F@.HBP[,7QCW>_T"C&(804Q/K+
M*&-FDT:=4+[')&U('U@>VP\"IN>&9U2E+6US0J"][`<E6I#@&`W_`)!?7TWZ
MZP/U=FEJ?VEU8'YM1/+$^MJYF>F=R3@5-SLT.:8U$XMJ],9K9:A&M2'#+,!O
MZ""+>!,'AOZH=>5;8(\4]YR)6MKUX0OTR\<UFR-68><]5^V[&YS'E)]>%(]Z
M432G"S1JH]HS?R+HWOX@[U]J26(.H#`8&@WS/=RS>*IHOX[N4)0)GZKZ:CBY
MPL.PFD7S*.6.8/G$TS>W5QA8O1!.9>$1S)#R=["<->8:K!L&TQ6QAKAJFKH1
M2=<0ZIZW9P,4)@K*F8V)!K?R*!E$^XQ4Y.2G>M#7O3PM,,5K5(_4:A4<,>_T
MX$@ZUZ[]/IK_`*=[T$.M?R[$(6]!"'6OKO>]^FM8&/\`CHYMUY,^I$?3TY;]
M./!/&-@JDM%LJXH1C%U)U?%3QI':V3TY@?@?*HH-<$25DV+0DSC(O>>'W@3&
MEX%[?)WT+.>JKAUXF.69@[14]YCK;+O(C?43/V4LH3G&0@WI%3$7=RO4M)>7
M1:/WHTY7NT:U1XPY8,.PG!&4%H*[KR#U'`895M9QELAE>5Y&VJ(0N*,Q.B&Q
MACK*F`D;T"8&M>XP02P>\TT>]FGG#&:8(1@Q"V&6J%"9&G4K%JI,A1(DRA:N
M7+3RDB)"B1DC4K%JU6>(LA*C1IBA&&FC$$!98=B%O6M;W@:W..:U4>5WI]B[
M8GK8J-\>W)LT<T_#D*=DYQ#9TW?L>4J6:3=B2)K4A`%SK^`K2CVR`$G%[`8K
M+/<M>T0/0T.EC`8#`H'Y!A:5Q7ER-*0A.9I9WER*WOJ(P(1D.")@M%%/D"14
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MYM5J68C[9$`U04$Q46'KHO*E+GF.<AO(Z=KJIR^AC+399K+KYM]]A].12T:;
MN(NDY'1,.M:-U;+6=YLR;2)"ZKXI^>)CB5X;6WVE^Y6:-.G"R',$F?F3M+R(
M40L>75XBC"_<[=#PHAV<U[J*+E="UY(H[,(HU&KSCQ(&'4YHQP>2$96PD)SG
ML[180AW[=!)74G2<PI^5T!350P"/6->G2\PF$;K]LG$P70*NXXQUQ!G2P;`G
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MA$'>O3>MZW]-ZWK`YAIS`_\`D_=:D1T@HUN\8W<EF*#H"M%Z@C?$W8<U4FJU
MT`4F>W2:.4+T0X:,4M.][+1LDB^0CT*(,T(T-I@P"`(0!AV$8!;`,(M>FPB#
MO>A!WK^3>MZP(1Z,Y[K#JJE9[0=Q,YCO!+!:?L5AB,S29\CCPC-`NC<UBCCK
M7RL\PASV02O;59>]#*4DZUOU`(81!Y'B\ZSGTO'8_C7[E<&^2]>\X18DH$L>
MT)(V+LKEAVV8P0CH%F1KRQI7AS6(/:SS=OV$W:1ZT(1OKI5L!8::[1H!?XL^
MLD_*:O[K?&/2SU(Y?PK+EIAYR*K9H::<^3_CUZ<E(A[(+;C5!CK"?E'O:EL,
M&D"(PXDS0`G?`@GHFD$][U\"/H)&X0"QXA(&>QZ3MAB&,B35)<,/4Z<X1.V%
M65Z'E"0.102UA(=^U4A,-*%K?KKT#?\`>*+O]5W-0[NWVFUHH1UWSL^)ZFZQ
MK--H))#18"5((UIL"+$_3:BMK<9D_P"98U`-?%H(STNA"$E&+83CY`^W*]\?
M_,TPO^<(5DH>BE+?"JCK!EW[I1<5S2X1J"O:QC!`=#,&OD+L'W*#@A'I$W$*
M50@B"1O6PY=N?:TL5H46+>_13ZFFO6_3$C*L7H&7I]_(WM2_[?1$4J"%;$(?
MX^MJB8=EM+8F+WHH6RAG?K;&'>@LA@5EF4/LCM6_HKXY*`?'*,O$\8R)KUQ<
M;'ZB.YXY>-5!2.Y:%8'6RDMKW-K8V:.)Q;T842<:L%K1(-F`#?/VET9"O%QR
MO2/*W&M;,#KT19"!!SOPASJVEA"VB>6IK*(7V+-M%_SZ2L*G:3!/TI=E&_54
M;Z%FF_.LV:$(=XQY2:N2:C/BBR3K;.N.Q)*YVMTG>CZ'8I5>-YRS>E<PG#RH
M,U\X&LE2/:-F1;WHMO:R2BPAT+9FQ!;7`U8WZEF/DBZ17>,:E7MW8J,@Z=AD
M_DWO"+JS4:F-5\[^UPC/'\)?DHM:1VE=J8C8W\PL6S6:-A-T(.S#1DB#I3@L
M&A]8PN)US7T;:(?!8+'6>)0^*L*,IO98[&V!`0V,S,UHB=:+3(6]`F`46'7Z
M`A^OKOZX&5X#`8%`>_?]3XX_M_<P?TZ^8$N]&<G07I!RK&5NLPM*K+,IISDZ
M^M;:I>7$P^?QE'.68E@G4<"I<FB1QUXB\R:TB72Y$X-RLO9Z%*H)^)2F).`&
M"._`-%/\7Z/BCXOLUZ3=5456W/5P/#U8#F]2AX@]60^7PB..*:2.Q2UU#,UC
M3.%YCBZJ#%)ZY6()QGZP=^H8S)O&[1DGMMXM=1+KL:B)'>M1=-R2KF&Q=M=4
M2&_*3)@2*%V4\QXIF&\KU^VJLV5,M;AN7X13I&!1]D%9H*D(9S"N%**@-@U_
M9C`7,M2:M+7ZFN6-;6R<Q4WZF783RM?;@VX(]HP:6-(ER\S\4GV(/X\'H'0C
M/3UV$;RCQH4E*:K:J(/L*_FNC0J;$%-ZB9[)3IX3;+;:%O/MV2MCL),KCBUT
M&A42^2+""SV96SN.FHW[,:H9.M:P,5=^,KNDD[Z=GJ2VD]5/_2/2W-KLY22N
M'N2));&^2N86V+&LU=QMX)1M@FV>6C(6U^`\"%\K>C:96K*`)0,D`30M5T5R
M]!.D2JZ7O\BL&O)]3\O4SFI[:J22E1*R(`_N4>=8C(-,[FM;'UD<624Q1\5-
MSHUNC>X-JY,;KY2-F%$F%A'-9\"T'5+_`$G+H[J=N$PI"47I/&Z72>9+9!)+
M`L+I!O*;[=GMJNBTC9\PDTC"2$10_P#1DZ'0"R4Q)28HD@L)TLZBX+;<NHV:
MRX+SM[YZLU9;5>[;',2!(&6KJXG=6G[?4VB3=.S9^R]BN/M(WL&M*?B,]W\W
M[=A5_H7QMT3TC-;.F4ME=U1,N\(57\%N^)5K8HXE$K:::G<7UTK11,$NFAP=
MP+8@HDBL``MJUO2N"<S1+B2L)UH&!YDU\8O/T]M"QK(?99>NFFY[;@=UW53B
M&TUZ>DK;F]7ML";H`.900;<=_P"#Q_=:M)QJ-N5-Y3P-.$MT^^3@*(+#8M@,
M!@,!@,!@,"%NBN?*GZLI"RN>+QBR6959;$77Q27,2G?QFC1K-!,2N36LT$1K
M6_L;B22M;EI7H<B7)RCR]Z&6'>!H*X[L&V*!MF7^,3KJ0KI'>='QO4JYPNM[
M!\'];[DI,IVUQ:>EJ!_S2JV:N++`RS)$`0S=&D`6Z]Y8S#A!LNP*)=P\RSZW
M6JN[YYH?$,"[BY3>EMA<R3Q5O1#;(#SR-`FE!V(8'8-N5476REC:W!.;O9:9
M284I#[?:9L0621:Y^\]'C27M4J9)!6KK)U;C'I*SJB@DVER1U]3KF8B7;0G#
MTG.23*II\G^9*<'9&G5G/#[]`(6C!@:+.?YI:X5MI<\=)M);%U1RM+$58W<6
MB),!'YKI:V_EZ^N2'G[+`6?%K=B'Q.Q(->AB<\9I8P@]`AP+'8'[>/56=$?-
MFS)F(7V2:Z?'78^[#3%:T`E_6U'>=?!@;JM!K]4]R8D,M7I"3MZ]X$R@1>M^
MWZ8$J>:=:?*/(SXR:\>!:51*(5=V'>#6T&:]R7=D,S?5\)C\B4$B]2S5L=9I
M*N^R'O6Q)S%1@@>FQ;W@1+@01T3<J^EH"D<8K$'&R;8GTLCU3T35C.4,QSLR
MYYXI&V0>)%"!Z!2MYJW0E*]0,00$(4YHO=K?I@;HN1J'JCPL<#7%T'U!-29!
M:SDUK^C.W+M3(]+7.<V6>C+3HH/"D^M%J5,9BIRU/%H:U!$6`T9@1!"4:L-U
M@5/XUJRW;<LV;^2CL5D,9^F>@X^3'Z?J9>;I:FX]Y1&IV[0BEV;8P``GL"8%
M&EO4U6E@+,4.1_VV]`"687@;)<"AO;_2UB5BFKCG+EUF0SGN;JYS<(3SG#U8
M=J6B$($96MSSHRRBRP&[;:LIAG,&O4&FA]BY>`I*#1GJ:'0;4>".)JZX)YWC
MM(PA>XRV1JW!RG=S6W(]_/-KNNJ7#`X6%:DS7C$:H4NLC=_7X"1&&!0H"B$H
M!;`3K>PNC@,!@,"@/?O^I\<?V_N8/Z=?,"_V`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P-:ODVX26=GU%&Y!4\C3UCV)S?(C+<Y#N?0-`%$;,0)M`60V4#``1KC5
MEKM9/X61H!>\DU*:`_99@TQ8=A4#B[JM)UC4ZY_?(FKJR\JNE+E4G3E%/(MA
MD5*7E%-_;2F*K23-_,HCKF8#\@PK_J4X-1Y8PC$,!OM"WA8!F#`66'8S!B"`
M`0Z]1"&+>M!#K7^7>]X%1?"6<3+;"\L-Q0LP)]'V=Y#)$363DC%ZL<G?Z[J2
MM8%<$PCP@;VG6-;U8C.I)VK*]2U*A&;O0M[#O`UO7/\`Q?/*9_V/$FO_`.NI
M>!G&!_7"!6E/FXJ;UW[/QWCBZ$5`]/K\HE=_TTD$`?K_`)H0!^NO3Z[W@2;Y
MAOXIWCS_`+*7:/\`3])8$88%=;4_XGO%I_B8<^?T3.,#<O\`_P"@Q.:3P(P2
M]V3'K*LK+K_C>RK[3%EB.3"I.*WY#U$P5NQ`="T>QM"DY&M6:%K8`ITPA"_5
M#O`LJ)4F7[TO1JDZY$X!`O1+DAH#TBY$M#I4D6I#RMB*/2+$QH3"AAWL(P"T
M+6]ZWK`@3IKH^L^2Z0G%]VRM5$Q2%HB`I69I*^[D\XECN>%NA]=PIK#H1SQ,
MIL^G%(4"8L(A;,,V8+6BBS!!#U?%?Q=9D)4SWO7LMI3@[HZL:FP#M%-F;6-?
M*U!(SM.5<\N0@1ON^T,8"1@72I47[1.D@&+9GOTF`88&Y3`8#`8#`U[]U*B7
MJ<<$U@W*"#I?,.VZ\F3<S!'H:\<0I.%V!9\]D7V^A:,`T,:!E3)E"C>OB+5.
M24K>]&*"M;#81@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:B^P_%XZ6K=RCL3C
MF^W'C[K]QC;;$;!DI4.;K(I3HF*,(?2.,'0-1N"UH(DCC'`:^%KD"%8C>6]-
MOXO><6`D!05=6>./RK]")C:YZC[PH6G:1=B=MT](X9I>91.Z[#CRC7P.T<26
MK:\MD6JK3/:(0RCU30@4JPEC$``]:WZX&[>@J&J?F"FZ]H&C(:VP&J*MCJ6,
M0R*M?RC(;VY,(PXX]2J4F'+7-V=%QYJM<M4&&JEJP\T\X8S3!BV'*M<_\7SR
MF?\`8\2?W=2\#.,#]^"/XV];_P"&Q?7]XJFL"2/,-_%.\>?]E+M'^GZ2P(PP
M*ZVI_P`3WBT_Q,.?/Z)G&!V6SZ!0RTX1+JUL6--$R@4]CCS$)E$WY(6N99'&
M9`@/:WIF<TAGZAZ)P0*3"AA^F_:+Z;UOTW@:#6OQG>1_D0D-=<']4T%;',S9
MLPBMJ:[QBMDN<UI!@]XOL8/#[UJ9<9))K!V$H7Q-J5];A*424`"-*#-!]X@F
M"@?%C=$PO2N>H?)7T!#>AYS2+P;)^?>=J8@SA7W*M+S@9!B4JSS&F2N;S,;<
MM%M3&[`V.SX,DMHWO9B=-HWXS"@V=W#$[+;G9!<%,*U3O-8RUZ:I#4KL_#00
MRX(82L.<#H^0->:)HAEE-9BD\Y@?=!*),/,VA<]B0G!/0AG]66G$+BB"29PQ
M6K&C&K7-#PSNZ$]GE$0E#.?M'((;,H^LT%PCDMCC@$2=:B4!T849KUU[BQ`&
M()%P&`P&!$S=1U8-MOOU^`C7WUNR",)(29-7MV>WY>QPM(:D5#B$*2O+BN:X
M%&W1R0DK7%&RD("75>4!2LT>>`!@0EG`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8''O<_\7SRF?]CQ)_=U+P,XP/WX(_C;UO\`X;%]?WBJ:P)!\OHQ&>5[
M@8@>_4I/QSV*J)#Z:U[%!LTI),89ZZU[A>XGZ>F]^G\OZ<"-\"NMJ?\`$]XM
M/\3#GS^B9Q@=K6`P&`P*(]`V,]TUTUQ1&:];8JRH^KN@9U#+S7ZC:$;Y,&:!
M\I7).8L:8[E_"I*=FQYK]J*"J'\IOV"?[;7H7O6@AAEE=M,E*7ITE%7U19MB
MJH*T\21J"4S'H;7C6F<++ZOGEKUW`VF&V"YRAG4N+A-Y'&"M/)DF-:V>/I4)
M9R<\W9YX-!5.Q/)5:$IF')+C6-&WK'%IO?-Z\D7%S\`VC7V8V9(:SYAN:1*F
M=LDR&PGB$,L-CUE-#<O.>53VS>Q(V#/,]2!;*,"37#R?3>2S#BEMI_E*SY4V
M=#V]TC2]Q1=]=JCC]@5%87.#+82*;08DQYN-CBR]\C<N@*M8J7$'N+.X1Y(8
M)O4'+CTJ883_`-A73=3;<'+?)O/,AC-=V/TTJMZ3O]QRJ+ESPFK:BH:.QMUF
MSC%H*I<V=KDE@2>1SQ@:6S\@>-N0%*E2P].J^W`G,"M-IWAV/S#TKQ53S^]R
MKLIRLV#=LN+K%ZAKJK:?=[$#`2.?G2L'.>'SF?-D!B2V!IY$]D*G5([LS<XF
M+DY8&[:@996PF:6^3*(-/,E==;0VAKCL"GYE6[_:<F<"WBEJ_=ZW9(>%5^UL
M5>VFT+6ARB2V>T'-3B46QL/Y02LQM/T4?OW)_G#$Y;Y(Z]K.7WA,%2FY;7@C
M)'O'R.$UM":QA>EI:[MF4S2'5ZM@SDHDC3+)@Z3!U)1"=4+R!"6SA()TDV;\
MRGXPMYS-TZCZ)_>XPN=8SZE;/HBQB:SM2K;&.ASD]1]X=(7%;'B[JWR*O91,
MX3)(]*8/-6Y:F4HG$W98QFD'`+-)$'86AP&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P./*W#-J?+GY53Q:T`2=PXN;@A#]="`GYK;E&C=[W]?>/:O>MZ_1K0<#/
M<#]^"/XV];_X;%]?WBJ:P,_\O7\6/@S^QCV#_MU2>!'.!7BRPZ-ZN\51`_J4
M9Y):8-&']&]F(XA8:M,+W:_6U\:@H._37^=Z>F_I@=J^`P&`P*:]:\LRSHAX
MYZFM=7:LHJR.<+0?[-ALH+KZ/V8V."F3U9.ZE>&=YC$B<6I*:E-C\^4FE&@/
M`84H+!OTWKUU@:\.W/'I<$R@DREZ61RGHZ?W#)."6:_T,0B=1P]\60'D6=VO
M-7N:UW7-E/1E0RZ2RA;8Q&C(S(5?XDHM%]RGV:L*3DB"1N.^.+25-5&/%N,Y
M].Q7D;J:S+3YG@HX'3$.L"7UC8'/,HJQS!>T?H]T=:M8I>JL"U9*[E*V<\:U
M<C3HAN8`KCU>]!,:OQVJVD=92"M+\?8/8=5=A](]81^4N$`CLP:59'4KC:&[
M*K!VBJUQ;2E#<1'[24I&QU+5E*TJA(2I&6=K9A`PG/J;E,WH%VINR(-:DBHF
M_>>9+(Y%4-M1]A8YBE0(IS']Q2PX--8')M:99K`)VPA)"M1[.1+"5B%&K2*T
MYZ8(MAC$+Y#FZ>WZ#OFXNC)+<UF4C'^BH]M:?7L(@4>?$'0(JDT)K:H_%2@"
MC;%`R:F*TA*/4NJ]6:XJ!JEIGM*"$*52_P`+L:D$`K.`MM^KRDD(H"ZN<71;
M-Z9KVT0;A]US]UL!XFM9,LO..8JGN)O4NPVW]H"4[GI6U%EDFI?>42:6$X*O
M%]$5*A8HW;LJ!]X+QL"V#4=9A?'_`,N">K9W%]:&-5L8_P!ZAZS:9RV+UVW@
M#[R-C%OTP+E570;;5MM]-6PCDC@\+>EI_`YZZLRM"E3)(FH@E-0"G4[:V*B!
MB/<4[BB@1:XP9V@B`<I&6'6P!#O83_@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@<=UJ?Q;?*[_`.H>-O[L;%@2#@?7X_P?/YM85O>]A_'^-2Z#`ZUKU^7[_H^I
M2A:%Z_YOQ?;:WKT_3[O^C`SOR]?Q8^#/[&/8/^W5)X$<X%>K'_XL_%/_`(D-
M0_[#V1@=E<TG,-KB.+YA/Y0Q0R)M6TWY6329S2,K"U`5JB41![H[+S2$+<E$
MJ4`!LTXP!0-BU[A:U]<#(42U&Y(TCBW*TJ]O7I2%J!>B/*5(UJ-44`]*K2*B
M!F$*4JD@P(RS`"$`8!:WK>];P/IP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&!QW6I_%M\KO_J'C;^[&Q8$@X'W>/?^-I&_\,^V?[RE78&<
M>7K^+'P9_8Q[!_VZI/`CG`KU8_\`Q9^*?_$AJ'_8>R,#M1.))4DFIU!11Z<\
MHPD\@XL)I)Q)H=@-*-*'H0#"C`"WH0=ZWK>M^F\"@'CC2DQZIKFK9I*+10VH
M.Q.L*UKED(#L"**U\TW)(W:,0YI)V(6DC!$DCYMO;4P?0I(WIR""]!+*`$(;
M`\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<=UJ?Q;?*[_
M`.H>-O[L;%@2#@?=X]_XVD;_`,,^V?[RE78&9>6[>Q^7'B<`M[$`GACJDXD.
M]^H2C3;1IXHTP&M_0(S"@Z"+>OKO6O3`C_`KU8__`!9^*?\`Q(:A_P!A[(P.
MU7`H+X__`/R'K'^WUUS_`+R3L#*^BNLWRJK1K;GJF:8>>ANB+.BTML=%!$<Q
M8JXB<*JF"N+"QR*R++L-_2.Q4;93I+*&]J:TR1M<W%T<#Q!*(T2G4GDA]3SV
MS3M/P"O)'V#)(5Q[.9X2]^M86Q9L#6NS>=&W,QM>UZ-]C;PO97R()@;3K/S!
M8BDJ=&N3[6Z1GC$0`,GM+M;D2DG%J:;<Z4I6NW-\:XL_-"&5V'&FA2X1V:JG
M1%%I,F*4N`1&1AY5,JH)3E_J.O@%L1H=>F]AD$IZIYNA-DE4_++NK:/V>;&E
M4QW"'*4MB=_(C*-F=I$:[K$>S][0)AQ]A7+BM'[+&>C1GG%!&64,00KK5/E,
MX9MCGYCZ617Y"(A6KX_K8H'<WD#$UR!NE2+\DH'&W%F;75Y&%\,9&P;J%,2,
M\P+2(*H>@%;WL(3!8/<7'54QR+2ZQ>G*0B$9G,.2V'"7MXL:,D-\Q@:T]&G(
MF,6/"X&!D,9]S@4,:U)\R<HD7RC&$O0AZ#'#>^^62NI(GR!^]&.FV_.JI:;=
MAY29[CRJ/R1AD#F2BCK.RN*=Y,5N4GD+8=^60IR4PRE+0`2H!VPZUK86W?'Q
MDC#*[R22O#7'H['VQ>]OS\^."1J961F:TIJYS=G=T7FD(6UL;D1`SCSSA@*)
M*`(8Q:#K>\"M<-[BX]L&!S6SX;TM3#[7M;+V!ML&7I9\P%,<)4RQ8E;XH.4K
M52Q.!C12A6M*"VJ5/QIE^A^X@PP/KO03/5EKUK=T&9;-J*;QRQ:^D>W$+#,(
MFY$.[`[_`(AT6LKD)O<4PA$*0)'5N/($(.]A]Y>_3>]>F\"0<!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@<=UJ?Q;?*[_`.H>-O[L;%@2#@?=X]_XVD;_`,,^
MV?[RE78&8^6S^+IQ9_84ZE_WJU!@8!@5]GH=&]B>)Y./ZE&^16O3AZU]-[,0
MU?::U-O0M?76@J"0[WK^77TW],#M2P-<O($E:ZHMKJ'G.QU)<.LV6]3W1=U5
MM3][VLJX:LM(#58J:4U@M6@)0S3]D#EJ]K?TC>8H6LJIL$-8420H2FG!\?1=
M2=$07K^NNUN<Z[C5ZF`H&3\RW#2KU8""KY,IBJR?L]G0.PZVEK\W+XF>[QJ1
M)G)$ZM3F8@`M0.19Q*G1R31)P0E,*[[@;;^>.JT?*E26G(KXY`:N;Y93)]_-
M!!%$/L/M&UIC'_OYS*8&UMLYK.QH[920,O`T(-KDCHR@"E2.B?91P0B>$>,J
MX:[K>[*U.*@M@*7/PI4QX^H-,UB\A.*26S"&[I5++FH29U0F.4<KE<KL".[3
M&'B$`:8DL)I>QI,"3H5S+U)774M'S&IH.LJYE-C=%1[K^PE5S1>7T_T!"JTH
M@$-4I55).#`KFT<ON*RI*A:621,RIN1'L;>$QQ5*R]EMQ81-7_/?D:JOG+F^
MB8U"=Q]BH>U[FC=G;J.[JTC%@W=7<B6RF1U+8%?6#,X8^@K.&)Y&]$_M6RFI
MTDF-)!K20Q044,A8'O\`%'CVO"F7CE=9;<6K]9^YSQQ]`\S212FDB*6C;;2L
MV_X-.&YO8U2QC;5+C'W6#,BLM6XA3H]#^A)B<.C/8$/9YTYTZ%Y`D7#EC3.!
MQJ002G?&2P\H]'.C'.TGY"F7^M%<.GZ^7MC,)I/6V=%#TT:6H"2&?6W#2@LH
M6B!%&;&6%DKS@MT^03QCO\:55^W4)=5^U)%9834]@OJMX9X^\$O[#/VRL;(>
M6YC1KR6F7MC.4SR`(6X1R$AQ4E#3FC*$6,*1])<5]7]IE]'VC+J)@5'OUA4-
MRSSA&Z0=[3BU@CGC56'6K'?UDS&P9/'&4J()X\T1K[IIC+<+[Q6J*.7"4@1_
M=EIM!T"E%%$%EDDEEDDE``4444`)99998=`+++`#6@@``&M:UK6M:UK7I@?W
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#CILDS:CRQ^64\>M!$3..06X.@^O
MMV4GY8BJ@!@O7>]_((2K>M_HUZ:U@2-@>GX[R_G\V3<+U]OX[QE6.;^CU^;\
MATU7!7M_3KV?%]MZ_P`ON]W\GI@99Y;/XNG%G]A3J7_>K4&!@&!7^<_\9?B:
M_P`1"$_[I;7P.U#`UV\;,+59%G=8=!SE$1)[0;>J[BI6%R)Z!^245O5-0#;*
M^8(/7@58CB8<S/!B!:[N^F\"<QV='0\U6([VDZ*#+NANIK:KGH.G>;*0HB*W
M#/+7JBXK?,7SBZ%%.1N.QVGY%5487(OO4%5VHO=G9Z<;72;)#I,G**+3&;$/
M>]AU@2(J[!Y^C=J1#GN?VG`XMT/)D$5^[JM(^JW\YED4N;SEC)&ETB)9T36@
M<)$8B4Z9"G+38M?"2?E2IA:W[=!"?4'9]H4Q>#11E1\^QRY7[?-5I]12ATEM
MZ(J5;&>#55,(3#W1G:E*ZN9RA=)&YJYL4:3M<H:6\HLD6SE)8=[&$/:9?)1R
M$95//=JSRU&JHTO1]/0:\8=%K$`H;I1'J_GB%F/;9#829M)=$,%C:-R>R6\Y
M[<STS'M=ZEEK!_3>PS^S.Z^1Z=LIOI^R+TAT9LAR<X>Q)XN;IW<5)4AL+W"@
M<9<5C.UN+6T2B:)P[/:FQ6>2O<$H=GD%#)ULS`QH'<])PNO7.?WI8M4P)+J]
M[DHZ,I(5-'JTU,G?JHG,LBREF;FIIA35*E]@M[9%3U,B9&]L<`Q]02I*$K4$
M)]JAAZ4Q\@W%4"AE>V%)^DJQ2Q"VHB\SNKW9N>3)"*PXI'%C0@D;M#&Z.IG5
MUD88XJ?$X7$E(0:H0ZV8(\LL)!^RPM%#IA%+"B<9GD%D3-+X5,V%JE$3E4=<
M$SLPR..OJ$AR9GMF=$1AR1P;'-O4EG$G%B$`PL>MZWZ;P,DP&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&!QRV%_%>\MG_\`)'(_]U"%X$E8'L>.?^-@+_#%
MFO\`>?@6!D_EL_BZ<6?V%.I?]ZM08&`8%?YS_P`9?B:_Q$(3_NEM?`[4,"@O
MC_\`_(>L?[?77/\`O).P,:Z8X4B_4G8O/=JV]`8#9%'57S]T5!7J.RTY6>Y%
MV)9DTH5UA[FU,Y*<*=2C(C\">RE"@:DL1`C2@A+'\FQ`#QJCI3IKG?J'H0J#
M5G3L\YYZ9O.!W8?9KW9SM%)U432P4Q5=0R.NS*X(KJ0`G![0GJ9,HBAY#P@2
M%$N`B56T_P!J$2D,7[)\:D,[?Z=:I7=T6BDEI-+Q5==&(5RE6H_;V"W%8%HU
M7)8M/84F+3%EHE<?CT5<1@7:5@$!3\9(B3"C3/0*9R'Q[=@REX+G%UQ%#>CW
M>7'-+<P](PRL>TK3Y6C`)33O[U8S(GU>7`X0:TSVHKJB]CC7J&S:(M?&UHU2
M=,G5%*A#+"N4U?/W9=W78UN#<KE=?QOMSC-SAG&3-9[W"+GLJ6UI3/-M:5]=
MT)K-?0,UD=R0BL5B/\R8[_O%C3&_$148W5,G$W;^Z"^46XOZQH6PZPZ!@$.J
MBXI76W0/D\>5U2/5F+H"4\5;W/T(V6U!YO%9RJ@TE;F:QH>W0UN2NC>J1:).
M0.JXDE9\A)>E`9[RGP1<%.79S5:L_'6:K]CX+Y$WVSFV)N#BK:89:/;O3=7W
MVV0RKB76/-JEQA$/:6=V:CG(T#<>K-+^?[4L*P1)(7-X&H^9<U\;<[T/87X/
M]M*MKAKB<AU&EIKBP`7H3U8]EM*TY$W&J$191H0@WL@KTUKTT'6M8%O<!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<=-JE#9_+GY5V1RU]JZ/;OQY/VE(9
M]#%\07<WLL7(>TW_`+U'I_CZM(,0?70#RM@WO0OI@2-@>WXU"QO'FKF![;K[
MHB">,]2@EAI?ZQ;*OG/2<=<HJA6##ZA*5O+;'EB@DL7H(1)`AZ]=:P,C\N1!
MK1Y;>(WER`),US#B;J&'1M:=KVIW&3QZQZOE3NSIC!:T`:\F/*`J=EAWL>R@
M[WZ>FL#`<"!)&0<^=V^)*)M18EK^H[G#-2VXG7O4?LQ7M)V<[2YX$6'U&%$S
MHEA0C3-Z]@=F!UO>M[U@=G[BXM[0@6NKLN1M;6VI%"]Q<G%40B0($*0H1ZI8
MM6*1E)TJ1,0`0S##!!``&M[WO6M8%#/'*9I]I^V;/;]#,A]V]:]2VY6KH(HX
MDN35I)[>D*2$S-"!0`HXQCFS,T`=FP[8=!5-BU.>#W%F@$(+_P"`P&`P'I_+
M_+^CU_\`;Z>O_7Z8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`TQ^
M3;QA3+J"<P3K+D^P(M4/9E5Q59`-G3QN<7"H>@JB5N(WH=07(G9`C?&TAJ>S
M3%K&_("SUC2J.-ULHTLP.R0U,D\T>:=^/!$4'`M$021*!Z1&VI,^P8G(:=:1
MBW\0W\$;B,>/M=X;BM[^4"/[(A2,.O8,0=_7`WF^,[QT-W!<$L%ZFM@&W?U)
MT'(FV;]'7BH:0L*21O#.WC;8M!8)'0G*-16JJX;5!J1E0;,&<+YCE!V]#.^,
MH,B\DOCYC7D!I^,QY+-W&G+XIJ8$VES;>[&W$.SI5]D)$1S<;IR9E!J<J30.
M7M)XVY^:!FE@7(QZ%H0322A!#0<KYJ\S\)5&0Y\X)IRZ7Q(8)"EMVI.LH)!Z
MJDFRM^PM_61.SVYNL>*$*M>AAJ,"1:(K>]@+$+6M8&S/QK>+>U*:N1R[;[@F
M,&G/5*R%KZZJBN*L`ZG4QR[6[\H(72=DASM($Z1[FUBS,U.46]R(].E]R<K:
M5,7\`A#&&Z^5Q")SMC51F;QB/S&-KAI35T?E+,W2!D6F(51*Y$-6TNJ96@4B
M2+4Y9Q?O+%[#0!%KT$'6]![Y111!19))99)))8"BBB@!+***+#H!9998-:"`
ML`=:UK6M:UK6L#^\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,#Q9*7(38X_E1)0U))48R.I<95/I"E2R)I"-">%E4/*9$84L4-1+ELL2@!0@
MFC)T+0=Z%O6\"B$;\CE+MK0W--[Q^Y:+MYN1%)9]6THY^O5X+89(EWM*[`CD
MVA]=R2!3Z**%Q0S6QW9G-:C7(AEF>X`]C*+#W_\`F3<>_P#W_.O_`->NC_\`
M\28'J1WR)\;2241Z'%7,1''Z6.:-CC)5B0>RZJ;GY^<3P)&Q@:7^S(9$F!<_
MNJLP)*1"6J$J5'""`HL8]ZUL/5L#OGDBLYV^UC)K@1K)]%1E$2R+0>)3^T'.
M(K#TY*LEMEP*SBDN*BSL:C4%G!1N`DRK9)@#-%^P01;#%O\`F3<>_P#W_.O_
M`->NC_\`\28'P./DKY<`F-+BIUX65)C23M,4%KWE_HY[E<G<@%[$F9V@I55S
M8RI%2XWT+"H<EJ!N(]?D4J2"0C-"%MJF76,ZUK"W6W&9HC=E.K"C=9C&6)0%
M8V1=X<@[7&Q@EP`K7$.AT<+/"B/5DFB(5GD#.*]"QA#H)#P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(C8[QKF16?;M/-3LK/GE&QVNY38[
M8-H<R$S0S6FCEJ^&*$CF:F`WNYC@EA#B(PM*8:-/LH.C-!V8#6P^RF+C@-^U
M)6MX5F['NU=6U#X_.H.[+VY<R*W..RAN)=&90>TNQ"1R;U*A&>$6R#BP&@WZ
MZ$'6]8$G;&`(@`$,&AF>[V`V+6A#]FM;'[`[WZB]NM_7T_1@?UZ_R_R8&&6+
M7T0MB"2VM9^QHI)#)NPN,<D;*X$%*$RYL<TXTYP?8<`P):@G8M&$&ZU[R#@`
M,!O0PAWH*!Q?IKDCC<W^JA$_WX6"XT\%DW=DQ@=*VU>G[#RJQ_24FS7I6RZV
M@KNR-MCV0H=QR)W&IWI?LI=MQ4ITZ,TLS86_I&_X3?A=J&PM*_H]5!=UDT))
MP2%"D0&*YG5J]&W2-:R!2N#A]['3E"X&TJ@SX33`^OO*+WZ:V$RJEA21.L/V
M$Y1M$F,5&I490U:T8"RQFZ+(2$Z$>>>=HO>BP!UL1@OIKUW@8S`9HCL"#1&>
M)&2619%,8^SR%+';`C+I"9LR%/2,A80TRR(OQ*5XC4B1Z/T4J0JBP*$Y^A%C
M#H6MZP,OV,&A!!L8=#'H6P`V+6A#T#T]^PAWOU%H/NUZ^GZ/7`_K`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&E]]Y#LBV>_>\+`%:G5=!P]U
MI/D1DAKU2[VQPZ)VPZLC#?09,C/72:`R\B3.<,.<$9!@$1I(D>G+03=;V:#>
M@U5D\P7693W$4+O^"V+&JF:_%!4M01A(Z<77=UL]TUT^E7/A=K')*]J&=Q*5
M43?Q\941@;%+%K>+V#:#TJ=6B.).`K":.PZ[OAVG;"Q,-#SN67-3J+QU&5)U
M$+F&X[!Z`N\F*S&OW>[+)*OJ/S5LJ[E0F&)T[JDE$54IG)S??NE@S4ZE.J*]
M`GB)\BVO8O4LWX>M2!V(3PQ2-@]0=/PJPE!3FB@=C-_8D+<(_7U(1J1?+H2M
MWH27W-:RLQ)H8]-)"*-FA"'W$[T$C^)Q-=-KS^R[4Z`"[[E''$#:_%_'G):Z
M"5H;"F=#RE:Y]#WND*+5*$ZD-MNZ>($A4"]#BSF!22+6A?('`S&A+(E7$UJ=
MG57:/.G3$Y<[E[%L;HRFI_25)2^V(7;D+NM!#A-30Y3N.IS8G6\QJY2TFQ]Q
M3R]<P)26QL2*B%!J4SW%A55@XTDC%.93T2U4=839T"+SG"EC78:5KEQ,K(Y8
ME-J,<:FSFT"T=\:&AI773LXFO(4Y8&5RUL2U4$T\HLX`>#6$,N>1]ZUC9C;R
MV]T4[F6)Y`8YT"1#.=;FC*@R'.\.L4JG%MS]8RB7JH%TR3:<@C[)(F$IB:MM
MC`K5DI23TPRP$J0P>MN')A;58UDS=#4%:4D'`?`C1\*C;+,FV<IB8[U8T*;7
MVI;4S8)2G(+Z'AVCT1B$\8!2!D,4Z,2F$#/$(03M&X79;1T[Q!:[Q5%GWI=\
MCJ7BR`W3'+TYUM1:71B5KK][663?=(=:;*35W4\BC+G*UFY_#782A;+'(@H@
MO1"H17RAT38#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`@OG7]P7[M1_U:_V/_=I^WUL?=?L5_Y;^\K]Y\M_?'^4^3_2_P!J_P!ZWYC\
MO]S_`*1^2^;W_7`G3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g662896g85w60_g.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g85w60_g.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-/6AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:2\^"B`@("`\+W)D9CI397$^"B`@(#PO9&,Z8W)E871O<CX*("`@/&1C
M.G1I=&QE/@H@("`@/')D9CI!;'0^"B`@("`@/')D9CIL:2!X;6PZ;&%N9STB
M>"UD969A=6QT(CYG.#5W-C!?9SPO<F1F.FQI/@H@("`@/"]R9&8Z06QT/@H@
M("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^"B`@("`\
M<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B+SX*
M("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M<SX*("`@
M/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP=&,T>&UP
M0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I061R0VET
M>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@("!)<'1C
M-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R
M0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@("`@27!T
M8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O<F4Z0VE5
M<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X<&%C:V5T
M(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#
M`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`*X`E@,!$0`"$0$#$0'_
MQ`!]```"`@,!``,!````````````"0<(!08*!`$"`PL!`0``````````````
M```````0```'``$#`@$("@,``@,!``$"`P0%!@<(`!$)$A,4(3$5=G?7.0HB
M%I>W&%B86;D:02,743*!0R0E$0$`````````````````````_]H`#`,!``(1
M`Q$`/P"^/A-\)OB[Y6^+OB=R!Y`\3JWHVP:-6[\^NMU?7[7X9W.NX;7]#K,:
MLM&UG0X2#:BU@X1JW`&[5(IBI`8P"<3&$&H?ZX_A7_D7J'[4=]^]?H#_`%Q_
M"O\`R+U#]J.^_>OT!_KC^%?^1>H?M1WW[U^@/]<?PK_R+U#]J.^_>OT!_KC^
M%?\`D7J'[4=]^]?H#_7'\*_\B]0_:COOWK]`?ZX_A7_D7J'[4=]^]?H#_7(\
M*_\`(O4/VH[Y]Z_01VQ\$OY?^4@5K5&<9\,D:NWGS51Q9&/(;6'<"A:2."-#
MUM:8;[4I'I3Y72I4A9F4!P"A@+Z.X@'0;"X_+\>"II5C7IUQ!RUM220Y;">X
MN-MVI&K$@#MRO"3AK"IL)8DL.=H8%0<BM[(IB!O5Z?EZ#[U;\OGX+KS`1MKI
M7#W,+A5YE`7,/9*MM6UV"`E6P*'2%Q&S$3L#N.?(`JF8OK24,7U%$._<!Z#8
M/]<?PK_R+U#]J.^_>OT!_KC^%?\`D7J'[4=]^]?H#_7'\*_\B]0_:COOWK]`
M?ZX_A7_D7J'[4=]^]?H#_7'\*_\`(O4/VH[[]Z_0'^N/X5_Y%ZA^U'??O7Z!
M<G*_P<>*O.><'BOR:E\1:U!Y[R&V#E%6-DK:.@[(Z;W>"S_AUKNGT^/=O'^C
M.Y2,)"WNLL9`AV"[510[<$U3'1,=,P,;_+C_`(*_!?ZH:C^_W5^@=OT!T!T!
MT!T$=ZQK6:X5GEIUC7KG!Y_G5+C_`*3LMKL+KX:.CFYUT6C5$I2$5=/Y*2?N
M$FK)FV36=OG:R;=NDHLH0A@1GR6\F?(39-"Q'/O&G;L"4K.W8SMFOXCL.F5Z
MX6Q#D%N/&62.&C\"'=!?#GDMA>ERT,NF_<2LRHM)LFC5X1.,(L@<Y0K34:9R
M9YCV_E;H#3COR32D/(S@)(GBYRULNFN:9GO";#==XP1%-O\`B6C8W-WVO6&!
MO.2<@H"0440AZBZ?V4TJ$DA((E3*H4(OK?C/>5^BYWQMY#5G`,BM^[\HN`-W
MU'+KUR4SFR53D#E/#"0>HZF3-,HS3C5@M'K)I:)D8M@T9K)2$Y9VH@E*NRG8
MIBL#*?+OC""E`X$TPV)6BZ>/;).3E2F>7N(81G$A;RI8O0LZM1,?C'^+4&.<
M2UOPFHZDC"KV&"BHYZ4D>U1-\&J@B8I0K++^4/C#P2TN[4'AWPH7@>.OQV-:
MQR"L3"NZ9@S$^M<E(JEQM!RW%\4=Y$]KL+N4[F18VS+5N>/0$IPH*)-A7EU7
M`B#IJ9SBPF^[_N6`5V5D%77'9SG57U#57OT-&8Q%[#IKU1O`\?8^\/YEN6;V
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M8;G+_0];S1FN59IFU'C'#XU>JD(;W@<`I!)E]]\N9!'XM\Z4<=_4H`"&`IOD
M$YQ9^C`-*KRLVYI&UDT<$-"R5XE;#!HMHLZ9V<:YBIY61;/8D"I@F=LH!DU$
M?T!^3MV#K%XT,:'Y)L)/S6S=J[XO\UIK/;?Q_F]NIOTQ(LXFXP$0]BHRPV'-
MTK3"T?<H*E/K$6<JC:WMGZT"\4(+91)1(53A&'#3Q/R5?T.KRW(VNL(KC[Q(
MOT^ZX9<;E[<CHZMZU(DP^<VGR+\M;<DFFSU;E+L<XY<2\*U=$5;4EL[[IE"2
M,)FP/RZ`Z`Z`Z`Z!1O.7\2;PC_;]S4_Q^[UT$=?EQ_P5^"_U0U']_NK]`[?H
M#H#H#H#H$I^9O;:O0\]S+'EWD7&V/?I.QP4R\$[)G*/\RJT<C(SE1>2H@218
MUVWV.2C6SA(%$T7R1%6Y_6110A@XYE*_84(>2V^(F(RCR$5<!C8B-JKAQ7IJ
M*=(.4T0/!.XE9LO'G8G$HA[9P54*0ZHF_P#D(G?OW\J_?2LJ]>2<I)O'4C)2
M4@Y6>R$C(/EU'3U^^>.3J.';UXY5,HJJH8QU%#"8PB(B/0>/L'?OV#N/R"/;
MY1__`#\_02[(4"EM,;A-#;:?#2%WDK*M#O\`,$6IB2T3&IE<>F176.J"YA("
M)%3'%(&ITUR%34,H4P=`];Q.^5CC)PUXW/L4VIEIZ-A7U*W7-M,5.G-+'7@A
M["QKZ#9)=9&=;2Y7Z*\6L*A"LS%`IB^DQA[@`=1V/\A\6WK,&FQY1H==MN=N
M6:[MS/M'A4"PAF:/OR+"RLG@-W];EHQ,.[EJ]3071#Y3%](@(@M_F1RWY>9W
MM,#`\>,Y5M.4S>2\?;;.6&4KCQO)4I_?.8%1R^U2K:)=UU^]M[IYEDHY]<0"
MK!:)2_\`])0?27L`+V>\_/)`YS"I6VE2[^TW%':.4!];@4<@KDJPS#-<>EZ6
ME44;37FE!K]L0K!*Y-/I.2B(]Q)W249M3*1;]0_9N`-EX,<AM&W#;>;L-/Z@
MEH.69EK,-4\@9S>6*Y;?(+X,MG9Z$51F2/8I6'*BV%DA'566=BK*RHQ<@^.<
M[!S&JJ`RSH#H%&\Y?Q)O"/\`;]S4_P`?N]=!'7Y<?\%?@O\`5#4?W^ZOT#M^
M@.@.@.@Q<V$N,++A7SL4Y\8N0"#4DTE5HTDN+14(T\@B@LW658E>^@52D4(8
MR?<`,`_*`?S5.0VN[/N&O76\<@;/)VG4#34E!V$9'_I:0"\'(NV"U6@(=/LR
MK\!"/$E4D&;<A$R=A,;U*&.<P0M\O;MW'MW[]NX]N_;MW[?-W[?\]!-;C![B
MUP]EO:SN$)4G]@-!(1QGIB3AP!ZM&$D4T3)@V61/)ME$A1(H+@I">Z)?1W$`
MCREOZU%V:+?6^(7G:\@JH+^,;J`FHL!DCE1.)1.B#@B"PE.9(3D!0`[";_@0
M\MH=P+^PR[VLQBT-`.'AU(N,<K>^LS;"!0]LRGJ/V*90!,4GJ/[93`7U&[=^
M@P!A])3&`.X@41[?_/8._;Y`'Y^@ZQO"IG&'9B[N>?S._P!-MMRUU*@Z;#9D
MW691GZVMJC&2)&KEO[DFZ&S,ZS(S"JQH\"D<&533<+HBFW)Z0Z8^@.@.@.@.
M@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-1_?[J_0.WZ`Z`Z`Z`Z#E'\RWC
MRBL\S6^\I:[*Y'74S[$[LLZP&+"K7"VI:,\.`QD6\0[,IZPM[`_5<G8^V)EV
MB"CHJB9B*I&#F/Z#V'D9%1BC%J2#]2+;N%';>,.]<GCF[I8H$5=(,3*BT1<J
MD#L90I`.8/G'H/'T&]YU8ZQ5K%]*VNJDMT<5BZ01CE%$0(B\5`H).S(.B':N
M0*0#$])P_0]?K+^D4.@U1T)9.5<&C(X6I)&15&.B&IE'0MRO'(_"1K<PA[K@
M4O<*F3Y/4;L'0966A+EG,\U^(1EJ?:XP[2;AG[1RI'R<>]3'WH^6BI2.7*H@
MZ:N2=RJHJ@=)0@AW`P"'0?T?.*FR16Z\9L0V5I+MI%*\9E4YF8?@N42(V0(I
MLRMC%RJ<0`CN+L[9VU7`W82K)&`?E#H)_P#C&GK!/XIMZQ;"\`GOI>L6@"!1
M=`7U=Q;`)@#U_P#U[C\_0"3IJN(%0<MUC&2!8H)+)J"9$QA*"H`0PB*0F#L!
MOF[]!Z.@.@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-1_?[J_0.-N-XJ&?0
MYK!=;%%5F'*LFV!]*NB-TE7*H&%)LW*/=5RY.4AA!-,ICB4HCV[`(@&1K]A@
MK7#L;!6I:/G(231]]A*1;I)XR=)>HQ#&271,8@B10HE,7_[$,`E$`$!#H,ST
M!T&(L$_!U.!F[39I:.@*W6HB2G[#.R[M!A$PL'#,EI&6EI1^Y.FV91T:P;*+
M+K*&*1-,AC&$``1Z#D[\B^NZWSNNV/:9A6*76S\?LNC[,_AJCJ=SI&:O-6>S
M22(0NKT/-YE-W*M'+J*$Q(XEP=0KA9B=,Y&C,5U15#G'M,FD[N]RCU:S+T";
MCIET:7SFSQKB#M5,.Z4,HBPEX1VD@NW2-\HH+I%.R<$_2;JJ)]C"&WW![G;F
MN4E*HQSQE86L8<ES<.0<E1=R'MM@*HD99RLBKW<@L8#)E(4J9BE[?\`&D1D>
M\F)%C%1J(N7\D\;L&3<IBE%9TZ5*BBF!C"!"^I0X=Q$0``^4?DZ#.7.E6*B2
MOT'9&R#21.R2?)`V=HO$%&S@RJ:2J;AN)B#_`-B)@$/G`0^;YNX23LUKQVQK
M4-]CM+EJ$ZC*TW9W!NX5`J#JPM#-A;2,<JG(/55G!1*J*CH10.J/MB)`,`CT
M$E9EQJY"<H(A/259.MPN=1\\7/5-?V"YQ5-I3:?;,B3*U:8.52.IZP2C./=@
MY62CH]X<A3]U!`1Z#H@R7QI<KV?C<TWC(XN=+N#6X[;A^M9K49QM^J"3>NTS
M9LTT728]=_>Z7ID.PB[Y"T]T:.C)ZIR34SMR)Y)@"3E=H`>S3?&#RVMK_:X>
MLP7'6*CMARS98!/2IV5A)70ZO`7[C!7,BR_C]!NFN%,I>B57%+Y#*^RK5I*)
MJ$Q7'*QUJZF_6,0H6)R?QDZ5CG/.@\E(.T465RVBQ]9H;6N1]?I^9SRE59\=
MKI1)&TH1N8YY5X.-1:Z#+(D_4AH9M4'B3SZ;%NE,1K850=OT!T"C><OXDWA'
M^W[FI_C]WKH(Z_+C_@K\%_JAJ/[_`'5^@;;?,DHVF2E4D;O$EL"-.<2CR*AG
MQ@5@UWLH@U;F=RD:8HI2*C-)MV1*IW3**AA$IA[=@V.ITNJT2-7AZ=!1]=B7
M$BZE5(R+2%NP(_?>W\6LW:`84&A5S)`82)%(GZNYO3W$1$*;\LN8#C&RR&7Y
MU2+Y:=YLK%BVSEFA19A]4G3^9.1!O*?38HEC9="*.8WO-VYE#@N0"*@F03'*
M%XXY1ZK'L%9)%)M(J,FJC]NB?W$6[TZ!#.D4E.YO6DDN)BE'N/<`[]!3[R'9
MM=]>X3\CL]SF*<V*XSV=O%(JJ,S^AY=D820C[!+T%IW,1-1S?(2*<PZ::@@D
MJ=\!%!`AC=`FVFWNI:;6V%XH\PWFZU-"L9LY0*9%PP=HJ"F_@9J-6*F]@+)!
M.@,UD(UVFB\8.DSHK)D4()0"(N0'%W&^2T0U9:77%`L4.W51J>CUIP2"T:FF
M5[F$(&S)(+**QIU/TEHQ\F\BG/\`^YL?YP!-UZXCZ'QAGSS%_(IH^.F>MB)[
MA48%07%+B!4'WUM5HC4S]Y3UR%$I3SL>5_!E[>XJ,>'=(0JOL&LXBQE6ZV87
M9>_2D<X9N6LA0(N3LOH,45%?0E982."LO!9+E(9-8'9/;$/1_P`"/005.ZQ?
M;9).992I2+R0>"3WIB]6:-CE%`3*":7J802=E>%333*`%3_Z>P?\!T'[5S0+
MK6S2KV:I.;Z$W>1RS8E;!:SUV3:F$AS%6KUI5DGK)&9,?T@0[N/]D1#TB*0&
M,;H/Z!'CVQSAWL_CKXQUBGM*EL>;-:C7[D_=N2>Q,-=6F&QIB]GLC1BZ1EZY
M;&MEDWC1]'N#E413)\,H4Z10`0:RFFFDF1)(A4TDB%333(4"D33(4"D(0I0`
M"E*4.P`'R`'01!K6QPF1.,^"?0`L==[HVJCF87<%:1U>068/'1I5^N<AB^T5
M9!-/TB)"@0YE!,!4Q[A*"LU#HQ3B=6E8Y*$:,UY%U,'>MBQ;9@V1,X<O5WXJ
M@U2:-VY!.=0QP(4@"(CVZ#"T>\U32:O%76CS+>PU6<(X5AYMHDY39R2#5VX8
MJN68NT&ZB[0SEJ<$U0+[:I0`Y#&()3"&V=`HWG+^)-X1_M^YJ?X_=ZZ".ORX
M_P""OP7^J&H_O]U?H&&[+R\R?)I.J55K/0MXT"U:15<\2H58G8Z0L<8M-6!G
M$34C+LF1WBT6%?:KJ*&2<%2.LN4B(=A,)BA:KH/J8Q2%,<YBD(0HF.<P@4I2
ME#N8QC#V`I2@'<1'YN@AC.^0&::I89JMTB2E9AQ!BL#B3+7II&O.?84!-4&,
M^JR+%K&`Q@$I3*$,J0?6F!R_I=!6CR%^17&/'7E\%=])C9^[72_2K^O93DM.
M-')VJ^S,6R)(3#D7TLX:Q-<J5::+(J2LL[/[+0'"*9"+N7#=NL'&5R@\JVB[
M=KA=IQ#CKCO$Z]O)-HZNMC@;3;M*?;)%-`53^A-EK#>-S+.[6Z41.4B<X,:I
M9(\A"D:22:0"F<+O\8?))E&W.HFBZ:V:XAL,@=)DPA9J5*YSR]R!@`H$SJ]N
MTV:"D@Z-\I(65(SE0[^E$'8`*H@R$0.D8Q3`8AP]1#%,`E,'<!*<ABCV'L)1
M$!`?G#H%;\FO&+G.GK2MXP=Y%XEICQ5>0D()-@JIC=YD51%592>JD:!5J5-/
ME1$3RT$5/U',)W+-X/0(QTG.]%Q:WA0-CI<IGEN5!=2+;R2B3VO6UHV$05E:
M%;V@?0=PC"E_2.#<Y7C8H]G39N;]'H-8J;25T&W1>>YI!3NHZ-.+D:P6=YM%
MN;G=9EV=0B*:+6"@R.W#9(5E"E4=.OAV38!]:ZR28&.`=M&`\,ICQJ<(.,FW
M+,H:I<C<1>04GRM+2@;!%:QE^U;`YE-;S.^+Q@M6%_?XO'Z.>0J\VX!P[9R5
M;(DT7)'R#Q!<'TVVRQ],JMEN$L1VI%56!E[')D8(`Z?&CH2/<23T&C83I?$.
M?AFQO03U!ZS=@[_+T&GI$R[D+FT'+':0]^SNYQL;8H91VW.=LZ;.$@79/42J
M%1>1[Y`%#%-V]I=$WK(;TCZ@Z#$7+#:;8L2N.&5]JC1ZM::I.5E$8!L1/Z)-
M,MUB&D"(B<@O52N5?<5!0_J<!W*8WZ7?H,3QCSS0,DQFHYCHLI4YR3HC3]6X
M::J*<FW9R=7C@*E!+R3&3:MSLII)K_U."IF62.*8'`XF,8`"?N@4;SE_$F\(
M_P!OW-3_`!^[UT$=?EQ_P5^"_P!4-1_?[J_0-G-B60&T$-7-FE)'22@7M=QK
ML9^L?N%1^'*Y&2^']\7I6W_6"XC[P)_H`;T_)T'AUVLZO/1T4YR&^L*38XMR
MX%RC.13>6K\ZP>))IG0?I*,WKAJZ8J)`HW62(/81.4P"!NY0^,GSJ>J%$>5^
M_6QU?++8Y"9E[7.+BLD@X=SA"-UV,6D82G:1;-DB1%$A03``*)BD(`@4H9S*
M\WA,DHL'0J\91:-@R.RINW":*;QZH[>N'BCE\9`A"+.C"OZ3'[=S`4/F#L`!
MRP_F;,2T4UAXU<HVL?)RV-4RGW_(K[*M4%W,9F%AM-DJ=EK%ELADBG)#5NZ!
M$+1JTDKZ&K=\S9(K*$%RCW#E.5LE>1401/.Q`N'7;X1JG(M%WCSU=O2#)F@J
MJZ>&.(AZ02(<3=_D[]!:3-N$7,+D(S3;9?P\Y`Z)`S)2HEE9'+9.F4=ZD<0$
MIS6S60H]1<MP'L8#D=*`'8#!_P`#T#[^(/`+S,XC4W@:'3<LOF5P,452$Q:\
M[VTG.0C$J)DRDA<UO\?`R^?J((-O5[,5:+(HT`2%20D628_HA8ZEZ'7KP\GH
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M%_7T5Y!PW-$)2!#"559$14.D)DQ`2&,`AN^69O7,@SNGYE4B.BUVEPC2$C#/
M5@</5TVX&,L\>K%(D11X]<J'65$I2$]PX^DI2]@`,[:;=5:/#.;'<[+`U.`9
MB0KJ:LDLPA(IN=4?2D15_(KMFI%%3?(0HF]1A^0`$>@S#)ZTDF;21CW*#U@_
M;(/63QJJ1=L[:.DB+MG+=9,3)K(+HJ%.0Q1$#%$!#Y.@]/0*-YR_B3>$?[?N
M:G^/W>N@CK\N/^"OP7^J&H_O]U?H';]!HEAT6M5JWT>BR"ZYK)H"\PE`LFZ1
M5`!"!C59.2?/E3J)E;-$DTRIE$/4=150H%*(`<Q0W1TZ;L6SEZ\63;-&B"SI
MTX6,!$4&[=,RJZRIS=BD322()C"/R``=!$F'[;5.0%,7T&C,YQ*HGL,W`P<I
M.,DH\UD0@7(,7,]%-"N7#@D*Y?D520,X*BN?V3&,D0!#N%3?(=RWE>.E/I.=
M9]4*G>MCWYQ:H.J1.A-WCS-:U2JK&,7&D:'H<7'J-Y"R5VOMI^/8(PK==JM,
MR<NU;"X;(&<.402;D>F\@<`G7EJRHG#-O+22@N)-@;A%1<T8N'!Q,*GP$_BE
MOI%J8$$3B!3/EIE0H`'J%0?5Z@N2[\K7)!*E6>#M_%*`F;`_J]@CXFXX'NT<
M*[6<=Q#MM#R2=.U^KYPM&E;22B:@^U//E$P#N7UF*'J#)\1?,I4S9)GV8\N:
M)N%7YFI03R(99=`Y#9KI8.02]71;M_UQSB2I*,[00-,HJ)FDCR,Q&1T<\]Y1
M9=!IZ%`#6MEXY2W/'6L^W/F#5(JA0.8Q5BA\SXZ9W9UCS#J"MI6H3#;DQL]5
M5B7^DM7R34/52(19.G,U%%`<.9LP@L`7-A86%K4+$UNMP\37:Y`L&\5!5Z`C
M64-!0D6T(";6-B(B-0;1\8P;$#L1%%,B90^8.@JUR+;Q7(GXC@_2$_UUTC5I
M.B--/BX0R[IMB&,HW.`L]TTS3YF.431HJZM:@G#:KLW#AM+S4XY:_`IBBDX<
MMPL3:^.M8\;%1=;KQ$9SU-PFCRKNY\F>,Y)VPVVA6G.Y.0!UINSY^SM4I-2M
M(V;/XU56PN#Q[I-A:6$>Y8O6JCQ9F^9@R^Y76&I5(L%]D#G=PE?@7=A6-'B1
M<[QFV:F=)@S,!@14%V7T@F;U`3](!$>WR]!'^(:5>]0@!L]KS,<^AI-!O(U1
M5:RMYEW,Q3L#'0<.H\D>Q<QGK0]"A#'[@L0X&``#L)@B#F%Q\L^YAB$G720T
MZWRG7("[V//[&[.RA;Q74G#9&49BX%%RT"48-"',W(X)[*I%%4S'+Z@[A<TI
M0*`%*`%*4`*4I0``*`!V```/D``#H/GH%&\Y?Q)O"/\`;]S4_P`?N]=!'7Y<
M?\%?@O\`5#4?W^ZOT#M^@J-R2@,]L%]XZP4W.7:I:9<;Y9:UE-KHZ<>=>*DX
M//+7I\\-@-)"9!*$-7Z`X(0X)+'%ZHBD)?;64'H-[W#9:/A=$@27XM@O4Q?)
MN'RVE42MQL=*Z%K]UL:"K<M=K-?37A(UR[4BV[N2DUSJ,HV)B6CM\[6;,VRJ
MI`\G'/CS&\;:]8:15;C9)ZA/;`ZGJG6;&G'+GHQ)$RBTE$1<NU;MWDA&.7)@
M5*5P!C)G]1O4)E#B(4<\HW'+4]"_\8Y!8Y4I+2K!AR.BU:\Y=7S,PN%KRK4B
M4]]-S-`;R+QBQF;K1[+GD2]2B3+(*2T:H^0;G,\^%15!$+;E%Q[4G)FJRFLU
M2EW&MO7L;9:5IR[O*;E6Y2,.=*3BYVKZ2TJLQ&R,<JF8BZ1TO4F8H@/03)F=
M%VODX#=WD#,V68ZZ$!7Y&Z'7%EG5D8B/90^!Y5+@P?70%B=_8LL\#&ME^15J
ME,$[DZ!GN%<:\GX[Q\H2@0[Y[;+.5N-\U.Y2)K3JNAN6W<R2MNN;M)-TK'MC
MB(M8IDFRA8\H^EHS0+\G0;_I.G9WCE.DM!U2YP%!I<29))Y8+&^*S:G>.1]#
M**CD"E5?S<[)*_\`6TCV2+A\[5$"(HJ'$"]`KO5.46Y\@6DC`9&I;>+>1R#9
MRT_](?Q\<WY.75JX2.DF^IM;F6DO!8'#+%."B3R6;R-J4+V$&<2IV.(>CCAR
M#Y1\.J@VI&1_P^ZC1VCX\Q*56]9J\R[1KS*+BF:6F+%N-`GY!E-:!8P2#XF?
MG:K*.'3@0.Y.(=S%!L^N\O:%O?COLN@Y]&R0VSDM5;?QMS;)+`1DC=QY%WPM
MBR5?)IN,0=.4!DJ-;TGZT\N@HLT:P<2]E`4,P2%?H&#5ZBQD9FT#FLP5.PQ$
M928FE20/T_6G-,&$&WA'1G:9A'N#]!$1.'?O^D/R]!MT>P:1;!E&1Z!6S".:
M-F#)L03"1NT9HD;MD""<QCB5)%,I0[B(]@^4>@]?0'0'0*-YR_B3>$?[?N:G
M^/W>N@CK\N/^"OP7^J&H_O\`=7Z!V_0+5YI:W2\;Y&\/[[H<BX952@5SE#HB
MK..9K2U@L%@2J>>9+5*I3J^S`\E:;U;IW9DHN'BF9%'D@]>$12((F'L$H\><
M;OEDN[GEGR8BT&6YV>#=U_-<N(^;S-?XK9%++M7HYS!O6QU8V9U6WF9MGE]L
MC<3$D'Z*,:R.,3&M#+!=GH*F\P^:&)\'\R2T[:WUB392[]:O4V"J]7F[)-76
MZ'9+.X>EQ(QK):,835A52]EH:0<,VQU!'NH`%,(`G*!X#9[IV^V'F5RSH=(N
M&^7>5A;:WR./;&E,&Q&<C8F/CV)8B"E062U#38Q%@E](VN72!!>3(HXC(Z.(
M8O<&)@"JZ@``'55/V*4H`8YS=@`I2E`.XCV*'8`#Y@#H%D<A/)9G-(M<AB_'
M9K7]_P!V:232!FQ2L/T=BF3RL@[^!(.G:%&$>J2LNP6]1E:]7R/)(!()'BT:
M!BJ]`I+:='Y$9-I2FI\E&>?<JKBR9C,5:S1-CGLQ-F4%+RBL4>!RG([%$VVA
M40J`E!)1^C(!-2Z7Z3Q^J/=,H;.VYUYU&,*Y):CFNYX^SMC`TK7Y:S9ZK::W
M+QY%`25?1\[G#^W'7:$.8!]:C9$?08I_3Z3%$0WPO-'BJM&DD6&X4N:777;L
MF%9@W#R2ODO*/%2(,82'H)&B=N?3,@Y5*DBA\(7NH8`,)0[F`.@GQK\$O_%*
MFTW;<8*9_B+O=CTN_P`=3;+9"6:!XUQ&L3!'3RBYY$LU%:Q7KE-U>-C"W&79
M?$/).4*X;$>J1R:"70,@FM>R>M2$E$V+3L^@)2&?Q45,1LU<J[%OXJ3G824L
ML)'231](H+L7TQ781Z_:I*E*HX9-%ER`9-(YBA'D#R[XIVES26=:Y+X'/N]+
M"2'.FL-KU`DG%\"&=*,98:<BTGU5+*6.>HG16%F"P)JD,4>Q@$.@D7,M;RO:
MJT:YX]I-#U6HDE9&#/:,ZML#=*^2:B%2HRL2>8KK^1CRR4<J<H+("I[B?J+Z
M@`#!W"0N@.@4;SE_$F\(_P!OW-3_`!^[UT$=?EQ_P5^"_P!4-1_?[J_0,GY:
M<@2<8L+LNMD@65GE6L_G5&JT'+6!"H5Y]=M;T>IY32?UMN+MH_:T^F-K7<V:
MTQ*G07^`C4UEBI*G*5(X*01YU8;H6@95JFY8"AN.\\<IFW5C.='RQB[J&>Y=
M>=SW)_Q1@J8:(Y!W.CNXO1M`U;'I:*2FE&KZ*C86&=R19)F@LLD8)=AO.-QA
MGK)G]$CLZVY;1-1CZ8O2*26$IRDE-2VETJFVS,:^@_2NBD-\=I+NSOF,&J#@
M6K\E:EY`BOT8T^,.'UX[^62P[?MV$T67X[3-1H>]TZMO(*=AK?2+T^J]KT>4
MY,V;*!L[Z+MC(IH&Z8?QI?SZK>/C7KZ)5>$!X*3<$E5POAS>XG5OFGQSN6%S
MTTO4Y20=U^W9]>FC)&1>4#3Z+,M+/0K@A'N#$2D6\7/1Z97C43I"\CU5T`43
M%7W"@GC4_(UFO&217SSF53]*QWD'%0+69F,_JN>VC3ZQ?`<J/&:-JQF_U1DZ
MJT_2K/)QK@S'Z8<PDDP`!0DFS59)3H$D[WSUY6<^+3_XQE+*2PW)[,+UFAG-
M7LR+/2KY#H(*KO%M>U.,<-DX.".P2,=S`UU9)KZ.Z3E](%'T=!0-!A9,&M\M
M42QL;"2537<5F6KK4K96#!-`Z2IV29(\R38S<#`15)1$2F(?L<!`W?H,E=]6
MLUZ:`PD1(W9&425=))N7KMP^4;B8S<KMX]766.W;&-W32+Z2E$I._J%,@E#V
M7?8+_IE4HE.L)V3J#RZ)590(1D1\.Z19"W9L/BIAVB945S(LV2*0*""9.Q>X
M@)S"80R60I8.Y:WLNUN;FT?%KHJ49Y5?;4[RJ?O`NS70.0Y7+UR8Z/L$<F39
M"0J@*'*82CT#]/"MS-N4_J:O$1WM6C)5"5H\G+9BKJ3JJ6M^PGZPZ8+NJ?14
MW;([J%;/JVY>.TV:[^4;)$CS`@W3_3,(-/Y"^*XN\;G?-R7VV=A)JWSV62+6
M&%"SKU=!AG^!ZUB\E^L%(C;M#4"TV.:>::62;2CF)^*C$FAVJ`@183$"+ZWX
MB[NU5XMV.R;U!R=NXK4O)*A7(OZ!U2PYS?@RK;3:@T?:5!:!LUNL5H(:,7$(
MANO*'1K$\U9OHP$6[8K$0OSP:XTWOC#F-UK>H7&@Z1I>C:W<MAT+2:%1IG.T
M;Y;[JA#I2,W-5:3M]P8Q3MBTAVT6P:QJC:/8P<<Q:D1,=!1=8+H]`=`HWG+^
M)-X1_M^YJ?X_=ZZ".ORX_P""OP7^J&H_O]U?H&L<@[#3*AA&S7+1JC&WZA4O
M+KY<[A2IAE"R,9:J[4JQ)V*6@GC*R%-`.$9)G&'2[/0^&[F`5.Q0$>@1WEWD
M<XXM\XJ^#;?PJJK/0K=4ZO3K1DF=T3CU'XZ]TIC<,M;PF!%KUJU1V>,BLZN'
M(V)8IS]C0C*RO*-YQVT.@+99N4)C8^2CCS"WB95NO#UY4['5]VDLXKM@A1P"
MSS[>KX[;,TXP/]1<.XVUM7S-W2M9WQ:FQL%#*R\TK%F>K,"*-#.4RA.G$OEC
MQOV#2\ZSO->*LCB:]RR*4Y&Y3/V*G8Q3V%ES5M-OZ1'W*BM:;9I>5<KR3&XG
M<+HI(I2$9#V9DJ]202F"`<&6V"Q-(!D]6]AQ,2R$1+2\=5HA6//9;$6':_$K
ML8!A(/HY!X]5,8B1/6LDB554@**$*;U=!PL^0OE)N>J<C+U9>3W&J;R[XFGJ
MY_DM`N]<<P4K5J0QDW\FU66L;F/!*XOI*0EA>OGK!8Z"2YDTVIBH@7U`M>@U
MJ^3,@YEL_)(EF*DBE,C(14@$9)L#%%0J"L>N5=!P9ZJ*9P(1(1.8`$/^>PAI
MSY\]DWKN1DG;M_(OW"SM\^?+K.7KMVN<5%W#MPX,==9PJH81.8XB81^?H)<J
M]$S27R:\W2=U1"OWVO/&S>N9Z:).NM8"+@44CD<^X"S@'QO<+[B!139>UZG'
MZ)R]!J](T>PT%"Q-H-..53LT:,8]!^S!T*0>E5--PV[&((JD(X.'H/ZTC"8!
M,41*'0>F%SAXA>Z73M,>GQV,M,C#).K9?H.?:Q-?@I1T5L%GDVC&/<S"L&W^
M45EFZ"IDB`8PE[$,`!T499X7&U;TS.;E:=NG,",G8XN4QW0\A<1=[@K588]^
ME(U=^VO$R^%O3IF>0(FYAT5V;AM+HJ&1]0+A\,J'3@MJ>9UR>1SVR:M0F^@L
M:JI9Y"N2]MJT1;EZY%LU5I6XN:L9^V?M(%)-FLNNZ*@5F@0AQ]12E'L&"9<C
MN/,DWKCN.WC&9!K<&TZ\J3EEJ%(=-[2TJQ7![,ZKBR$XHG-MJZ1HJ+\[852L
MP2.*HD](]@D&H72G:#`,K70K96KO5Y+WPCK)4)V+LL`_%LNHU<@RF(9T]CG7
MP[E(Z9_;4-Z#E$H]A`0Z#9>@.@4;SE_$F\(_V_<U/\?N]=!'7Y<?\%?@O]4-
M1_?[J_0-OU[)J3NF<6K)=(92<I0KPP)#6Z%B[!/5A2P0!G3=Q)5R0E:U(Q4N
M:`L+9`S*3:$7*E(1ZZS58#HK*$,&$F..W'ZQ.;8\L&%XY.N[[]&_KTZF<QI4
MHYNGT,O$N8?];%WT(NK8_HIS`L5&WQ@K>P=D@8GI%%,2A[#8-AIYMA93XQE!
MK'%V:;NL98#9U4#3<=<K*U9,;';6$J,.+]G9I]E&MT7K]-0KITD@F14YBD*`
M!FZ_EF8U*<&SU7.:'6;*-8AZ2-AK]0K\-.#3:\DBC`5(9:.CFS_]6(-%NF1F
MP]SX5L4A033*!0[!6;;\5U"S:N-SIKE!]7;=F3[)[*B$Y]!S]/824@+U>Q5Q
M=9([=P(+`DHJ@4Q%'!4U$A$`4*H0.77R0\/^?UD=VG8M*I3B.XX<?(5:I9U(
MVW2\[^/9TC]82,T)HE:86R5?DG;Y8'Z*A&H"LY20.S9F,8&Y>P*[TG.-0XOS
MD7%/;3&L9BY50L@\1JTF9PLS9*KF15C)8CALD=)PBN`^TLF44U/TC(J#V-T$
M4U&BV6\JRR5<9%>&A8Q:6D#+."-R$03]7I3*HJ/91VZ,0P)D^<XE'Y0[=^@U
M(A#J@)DTU%`(F*I_0F<_MI!V]2BGI*/MIE[AW,/8`_YZ#]&Y7!W#<K0JQW9G
M"`-"-DSJN3NA5)\,5NDF4YU%S+>D"%*`B)NP``]!T#\`,5POR*:+H6+<WZ]=
M:]R+S*JQ,Q2'=9L<CGKR;SP3MT9UG)UQ4KV-<V"&FY%!\9P1#_\`I:R?R%*1
MN/<.G?`.)>?\?<34X\1EBOFDY.D#MK"U_7)F,MKBN0;T"G4J\3*-8.%=A7FC
MH!69HK"LHQ.;L@H0A4R$"@W)#QDZ'LVY\AKY7+Y0HRD[;@N&9DP87,+O:'<7
M/8):75OBXV]5$72<)I]`TA4B,-8?BI)I)F@G<@@0ZAG0CT&C1_BHVNWJ7NV:
M_MU/-=;)QTY<8K6(:DPZ@T^N'Y%6&6>4^(L#YU6(.8NM+S:#D"H`K\/&2SE5
M,GJ5,1,H"%^^!W$I[PRRNZY4YM;.\M9O7+5HL5;3LUFEJEV-KA:L11.^J%!"
M)D;)"R$6O'MW3!LR06A6C`54?BP<JJA=OH#H%&\Y?Q)O"/\`;]S4_P`?N]=!
M'7Y<?\%?@O\`5#4?W^ZOT#M^@.@.@.@.@4+Y<\&Y/<M\US/C3QTK<:M"6B[A
M<-?O5DL;.N5*N05.20-68*25[O)J4<RUAE2/_AF+%VJ4L44QP*!BB(4-J_@:
MR[)LITG6^4&M6C:[G3\QN-F;5ZL*OZO1XYY6:I)R#$KJ1=O5[E:48\S,@I%,
MZBVX@0"G0]'<.@Y\[?2XAPF#SB"EK%^K43F,:]VV:@H*TRY84\H[5016LQ6,
M*FG!,GA4S`<.P-DU0.4A^P'Z"<Z?D?)OAUQXC.4MLQV.<Y#R*;NJ%&EL8O&=
MAA$5&;AU5+).,",S.(2NW8B[OZ/37$/CRMB&,"7NM3+!IWB_S""U[GIQKHME
M;J.Z^K;I2P2C-(ZB7QJ%,I]BM:+111(Z:R;9P\ADBJB0P&]L3``_+T'=+7^,
M_&S+'=;T!'/:-$6C-VDJI&:Q.LXM&ZQ+"2:O&LN,G?W)&TJI&+L7RJ2B+AP+
M0J0@4"`!0[!8EH[:OVK9\Q<MWK)X@BZ9O&BR;EJZ:N$RJH.6SA$QTET%TC@8
MARB)3%$!`1#H/1T!T!T!T!T"C><OXDWA'^W[FI_C]WKH(Z_+C_@K\%_JAJ/[
M_=7Z!V_0'0'0'043Y_:KRBSC)(^*XG5"HET"^RDC!SW(36)F`B\+XBT"+@)&
MPW/D'K#&3E6,I:V-3@XU88J':)'1?RHHE>K(-`4$X<_7#SF+/\5(UQ<Z3H*T
MMB&YQNEW;C>PY5OK;5;7SXML!=LY-R2\DW)SD&TS/1R<6Z'HKN9C:QDS&5;0
MU0.P=M57YVB"[(R8.'9>0OC9S@XLR5'Q;2:;'\C^3G#RRW[,N,ERNE3@-G61
MT;/)UO"-%*ZK+G^/(DZ4,<SID9RW.P(#Y,QFIR*F"POCYX2TS@KQ^@LOA19S
M%ZERM+#K=Y1;^VO;[LJT32<?#G4*#A.MU]+NSBFYNWMMB"H8H+++&.%CMQQB
MA\ALEOF+Z7%EEJ7H-?=P,L@'I*Z:"J!58^8BUC%.#29@I)%%XR6`!%%T@0_8
M>W;H.8WAAP&-XZ>4#+D?RDWG*8"KYOJB6"4&O0#EW:;/=;QR`3>9IC#FX_1:
M?T5CC>_GLK=1D,TH1$JK@A7*K5(05$))S[D9!^8/D3!Y-R^SFO47A_1M2OE=
MK_&ZV25EA+;?>6.?HZ#!K<5^6%2EA3K>L7/.Z%6G6H*1E37>UBNIFC$Y9Q(*
MK,U!"YGB+S5WDFA\ZZ+B,%K55\=L1K5*)P_JFP0%YJZE4N@0$TER>KF+0FFL
MXZ^-N/,=H"3'Z"%T@E'_`$D>2+&^XT("J@.TZ`Z`Z`Z`Z!1O.7\2;PC_`&_<
MU/\`'[O701U^7'_!7X+_`%0U']_NK]`[?H#H#H#H,;-0L/8X>5KUAB8V>@)V
M.>P\W!S3!K*0\S$2391G(Q<K&/DEV4A'/V:QTET%B'253.)3%$HB'05?Y$\&
M^+/*JN5:J;;E32?A:7"3-4K25:LMSS-Y'4:SL8V*MN;C*YC8J?*/,QN,1#M6
MDO6UUE822;MD2.&JGLI"0%%;!4.0',K4>"?&.O\`CTOO$*M<..6>:;QI6Z6%
M;+CXY2<KXUJRC:B4/BQ=:9.*SUT<;7'DC8X6Z</#A"01W#>00#T^D`M-R\UK
ME!9^<O%+$L%RKE+&YUG"V]Z/N^GP<,YI.!Z89;BIHA<9R4-/5/(QDJ\?ZE-,
ME%#.F!V$5,1[<5/>6*FD8%.\8*[R@WN+Y"DY6X_Y';GQ%B,=PFZR_'`FS<E7
MN]CRM4M=ZK-]RVL:+K\=Q3NU\AJE5)QE,6F+K<FXSXTA%L',8Y<F];0P;_2/
M#OS4V/CO1HO3-LK^6V#E-QBI''_R$PNHQ#O5=F<1>%:O8;=Q2V2DW2NV8E4=
M\N<VR5_'U:7G91618E<LD'J9G:[)(3AT`Y?PYX^YCICKD"TRZ@2G)^RTJN4_
M2>1YZ37HO4-'-"045"/IN=E(UFB1G(60D.@=_P#"`D#@$44U!.F@B4@6CZ`Z
M`Z`Z`Z`Z!1O.7\2;PC_;]S4_Q^[UT$=?EQ_P5^"_U0U']_NK]`[?H#H#H#H(
M7W/D7A/&6JQMXY!:S1<>J,S86=2B+!?K`QKT;*6>08R,DR@(]=\HF#R6=1\0
MZ7(@F!E#)-U#=NQ1$`BBZ^0'A%G#O-&%]Y5874'VPUR!N6:LK!HE=C'=KIUH
M5;H5NW,F[EZFLVJT\Y=$2:2+@$6;A41(103E,4`\\IY#.#4)8=@JDORNPN-L
MG']I*/\`;89YH,"@^RUK"6.&J$NK=DCN@^@?HZTV%C'K%7$IB.W:20AZS@'0
M3GCFXXYR&I3?1\+T^C:W1',A(1!+7G]DB[/"DF(A4$)6'=/(IRY(REXQ8P%<
M-5O;<(B8/60.X=PSVCZ30,@I4[H^I7&O4"A5A!LYL5OM<HUA:]"MWC]K%M%I
M*4>J)-6B3B1?(HD$Y@`5%2E^<0Z"'M3YE\4<0/<4M=Y"9/G2V?3=#K=W;VNY
M0\2YJ]@U"*EYW.H69;.'!5V4G=H:`>NHQ$Q04=H-%3I@8I#"`:XCS[X3KW?.
M,U+RFPU*_:]!4ZS9A4G6B5UE.7F#T,7A:$_KC%X]05D2752/6)%$('N2"B9B
M(%.</3T&YY1RVXP[KH&CY5C6^Y-I^DY$Y,TTRCTB\0-BLM,63DG,,N,W%1SU
M=TW0:S+-5DLJ!3)(O$S(',54/1T&*S/FGQ'V;2[#C.5<D<8OVM55U8F<_F]8
MT&MR=UCW-0DU86V)C7$'XRKG]6)=`S:0%%)0K)</0L)#"`=!^[GF5Q0:9YK&
MM+\B<?+F6$WN1S#9+V2]P"M8S/18F7B("1I-SED7JC6"LS2;GV30S-<Q5OB'
M21`*)CE`0B*Q>47QT5*`J%JLG-7C?$5R_M)EY3)MWJE7".L:5=E3P<^2-<D?
MG36=PDRD9J[;B(+MURB10A3?)T%W8*<A[/"0UEKTDTF("PQ4?.0<O'K%<,)6
M'EFB+^,DF3@@B1=H^9."*IG#Y#$,`A\_097H%&\Y?Q)O"/\`;]S4_P`?N]=!
M'7Y<?\%?@O\`5#4?W^ZOT#M^@J%SYJ/(Z_<-^0M)XD3IJSR)M6>OX+-)U"=;
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M54K9?6S`SD[46[YL5<Z1`*8!*%-M@XI>36KWWD1=^-U`L"-SY?*</[XTV%3:
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MCG<VI7&:E:2K;ZM4PK%5EC:#,:=L=IF'=LL4K),D6;`R#:,;$3*@91T%"*AP
MF\A4&RR^#A^,N>5J=X<<O^?_`#4R_79;:J`]F]OF=I><G76*8?2XJ%0=2-&J
M]]?[7$*W-W8W;!LW:1`ID;NE#)^T$4H^'WGOE&';CQRJ[W)-$J_(O&^#$Q9[
MIFYTLFE*[R9XP<GLQLFAZ!-,-%N=^);=!T_)UY68?6-)%!B_E:RT15CDS+)D
M4"Y]%\>O):HY]1,[F*S%7.R4'S61G,:U[;.72KC9]^PQU+R%C<;?=(ED2-AX
M'4(^%EF5<DH",CHUJY5@"NF31-%P``'0:`````````=@`/D``#Y@`/\`@`Z#
MYZ!1O.7\2;PC_;]S4_Q^[UT"G_!SROYPYSXK.(M+R7Q7;!R&SR"K.@(UO9*S
MRCX=9]!7=!UL>BOWSN/I^G:Y6KW")QDH[78&)(,4#J*-3*I@9$Z9S`U_^.7R
M3_V1M]_K5\?WW\]`?QR^2?\`LC;[_6KX_OOYZ`_CE\D_]D;??ZU?']]_/0'\
M<ODG_LC;[_6KX_OOYZ`_CE\D_P#9&WW^M7Q_??ST!_'+Y)_[(V^_UJ^/[[^>
M@/XY?)/_`&1M]_K5\?WW\]`?QR^2?^R-OO\`6KX_OOYZ`_CE\D_]D;??ZU?'
M]]_/0'\<ODG_`+(V^_UJ^/[[^>@/XY?)/_9&WW^M7Q_??ST!_'+Y)_[(V^_U
MJ^/[[^>@/XY?)/\`V1M]_K5\?WW\]`?QR^2?^R-OO]:OC^^_GH#^.7R3_P!D
M;??ZU?']]_/0'\<ODG_LC;[_`%J^/[[^>@/XY?)/_9&WW^M7Q_??ST"U^6_+
MCG7.<ZO$_9+)XG=EI-PI.S<J9#.<Z?\`*SAA-2>T2<UPPV.OV.!@K!`;`_J]
9-=4ZKOW,^NXGG3!L\;,#M6IE7BJ*1@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g662896g97i90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g97i90.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0NZ4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@`````````````!*@```ED````&`&<`.0`W
M`&D`.0`P`````0`````````````````````````!``````````````)9```!
M*@`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"1T````!````<````#@`
M``%0``!)@```"0$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``X`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TNRS9!-=MI<7ZUG0;3IN][/I?FJ++VN+`:,AN\P-TZ:[??#_:AYEE
M-;:_5:")?!(<8]W_``:%7U"FH$L`;.I]EG];P2L=PFCO1^QOW-V5ES`][N&@
M.=SY^[Z*K8]F4Y[!=6[:Z02W>(,M$NWV?1^FHC-.32X#Z#P6F6N8?`Z/VN4:
M<P666/K!#JK'UOW,<P;_`&[]N_9ZK?H;+6>Q)#?-;`"270/Y3O\`R2IGJ&&Y
MP;4YUAWACM7MB3'+OI?U%7%N']NV"FO[6!ZV[8>_MW>I]'>CV]3-1#7@21.C
M2=/\Y)5MFFW&O+A4YSMO/TQ_U4(OI-\7?YSO_)+.RL@6^F;&U/`DLWM>>1M]
MFS?^:Y-CVV5ASJ&4-#R-Q:'B8&W66A)3I>DSQ=_G._\`))O39XN_SW?^27.=
M1S:CFVBVO$<YL";&W[H`W-W>E4^OO^:]#/5&NV$MPR:FEM9VY/M:="UOZ!,.
M6(-7LRC#,@$#?5Z!UNV?T&08,:'SC=_.?14F.#WM::KF;A,N<8'D[;8Y<X[J
M5;J64.9AFJL0QA;DPT?R?T"+5FORP,1C,-X@N%9^T`>WO[Z6I>['NHX)@613
MT?ILXEW^>[_R23FAHD$R"/SB>_Q6,VO+]'T7TXOI[@?3;O+2!_Q@KVN:YK-B
ML]/K?5N:YE5;8$-J!'YS=3N<]/!MC(HO_]#T/.R/0%6M8W.L'Z1[F<'\W8RQ
M5AGMW@>I1MELGU7`P=V_V^G^;M]G[Z-U*P5BF;/3EUG^%-4Z_P`EEF]5&7[K
M6-&2X!T>UN1NY_ZS[O\`MS8F\52()7\%Q!$?JV7Y>(W'LRGW,^ST@NMMDD-#
M=7[O;^:G8<@N]XJ-9<=KFN=/IP#2[:YFWU'?X3W*MU0FGH^:?6?+:+'"U]NQ
MPT_[D;'>CM_?]/V*T=Y=2X'VAON_2<RT;?8UNR[_`*"<5B)F4#DOI(J.R`"'
MP_6?IMM:S_P)UB=^0ZMQ:=O!/N#V:#S?^;_PBC..[(EN3[]VTU%S7^YI^@P7
M![J_^M)78["\.8=I=I_.1+CX;V7>Y$UI2!8NV5EOM82X,)G\^VF=/W6L<YZ>
MO)IV#=:)_KO?_P""/8UR3BR@,8UY8#/-KFD\>3]R)M(_PMG_`&X4$N/U#+JK
MS;F.RJZW-(ECNI6T$>UO_:9E+V4_YRK_`&ZC_N;3_P"Y>_\`](*SGY@KS+6?
M;#5M(_1_;651[6_X%V/8ZO\`SU/%KS,D,L9?<<=\Q<S,:\:2.&XW[XV*N=9$
M"M_W;;@],(DB0%#],QZ(6>O96+*K-['`N:]O5,@M(!VDM=]G_>6GBFFFK;Z[
MWE\.<++GW00-16^W\Q%<<AQGZ.GYMK@/NV?])("\N$DAO<BU\_\`4J:,`->O
MD`UIY#+38><I?])F""`09!X*+1],_#_OS4(<<D^9,E%H^F?A_P!^:G+'_]'T
MF^IMC6`V75PY_P#,SKK^>6M>DSTGN#6NN&XP-U;VC0;M2^MJK=3>&MIEP;+K
M.7VL[_\`=;_T8J7J->X,8\.#MI!]?)[_`-DM_.3>(<5:?:NX28@Z_8Z]_3VW
M464^M;5ZC2WU*R`]L_G5N+7;7HGV1L#WNT$3I_<LK,S+\7"RLNTTM%%3K&$O
MLVRV9];:S>VOZ/\`->]&J956'&LQZSO5=[W.&YX;NV;C[:_W6-]B<M;?[/\`
MUCU_M%T!NT4[AZ>HB?3V^YW]93.&#'Z1X@SH1KY'3Z*S&]3P77?9VW@W;S7L
M]\[FG8YO'[X4[P7EL.\OYVUFL_\``?2_M(F]+0`!==[;[\(.B+K61^X[;/\`
M6T4OLC?WW?A_<L^\M<&C=R?WK1_TJ%%M):6F1[3K^EO/?^4_:[^V@EGD=.<^
M][AF9=8)'LKL:&C0?1;Z;D6K'-5;:S99:1/OM(<\R9]S@UJPNH936YUS?7:V
M"/:<S*J(]K?\#13957_8>I4T9N14VZEX?6Z=KAU#+@P=IYI"B$AQ&@"=>I_[
MUG.,\(,B0-*TC_WSN^GYE+T_,JC^SJ/^Y&7_`.Q5O_DDAT^@$'U\HP9@Y5I&
MGC[D^Y=A]O\`Z"Q5#]X_XO\`Z&WO3'B5.IL.)D\#_JFH!<">42@C>=>W_?FI
MRU__TO1L@9!#V5N<SB(TU]3>[7_BD".H[F'<^`9<-PX_E'>OFM))3])M;U$;
MO>\SWD=O`>I^=*G0[/KNWV;K61&W<`)/NW&7._J+YI224_3YR\B/Z/)TTWM\
M?=_FJ=607;O5K-4&&_G2/WO9]%?+J22GZF]:OS_S3_<EZU7G_FG^Y?+*22GZ
MF]>OS_S3_<EZU?G_`)I_N7RRDDI^IO6J\_\`-/\`<EZU7G_FG^Y?+*22GZF]
M:KS_`,T_W)G6,>-K9))'8^/P7RTDDI__V0`X0DE-!"$``````%4````!`0``
M``\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-@`N`#`````!`#A"24T$!@``````
M!P`(``$``0$`_^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!*@)9`P$1``(1`0,1`?_=
M``0`3/_$`.4``0`!!`,!`0`````````````(!`4&!P(#"0H!`0$``@(#`0$`
M`````````````0(%!@,$!P@)$``!!`$"`04("P@/!@,'`@<$`@,%!@$`!P@1
M$A,4%2'2D]-4E)464]15U5875Y<8"1DQD2)2-M;76$'1DK(C,W,T=+1UI;5V
MEE%A,J.S)&-EF'%"@H/#)36!PJ'!8D-$Q"81``$#`@,#!`X(!0,$`@(#``$`
M`@,1!!(%!B%1!S&1$U9!88$B,I+2D],45187&''10F(CE-05\*%35*3BHPBQ
M4J(DP3/A<O%#8__:``P#`0`"$0,1`#\`^^\HIH1I3KJL)2G'+G.=.V4V\@Y5
MJ*P;P0,*XIMTII&4YY/PEXY?WV,=S4[=RG#O*PM7$56DYS_W@^>3/["TY_\`
MW:4<F`+C](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[T
MP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](R
MM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[
MZ>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#
MO3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GT
MC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&
M?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:
M4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"
M?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\
ML9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]
M]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F
M`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5
MKRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?
M3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=
MZ8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D
M96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S
M]]/?:4.],`3Z1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2
MAWI@"?2,K7EC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3
MZ1E:\L9^^GOM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7E
MC/WT]]I0[TP!/I&5KRQG[Z>^TH=Z8`GTC*UY8S]]/?:4.],`3Z1E:\L9^^GO
MM*'>F`)](RM>6,_?3WVE#O3`$^D96O+&?OI[[2AWI@"?2,K7EC/WT]]I0[TP
M!?N.(JM9_P#\QC'_`+5)Q_\`NTH4P!95!;TU^7=2VV6RK*LXQCD6G]G_`.+.
MFW<F#<5N,"08D&4O,+PI*L<O<S]S]GDSJ.V%7:#0JNT4K__0^Y+>"?<A8`IY
MM64Y0TM7<[G=Y,_^S]C&I[("EO9/95SHFWU4!KT2<_#1TI+24:&?(RTD&P<6
M00:,V0\EIPI#N11$J<YJ&F^:G"<8SGE5RJR0DU6:>J=6^#4!Z&CO:VH4+\]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4
MZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T
M=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J4]4ZM\&J_P"AH[VMHE2G
MJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^#5?]#1WM;1*E/5.K?!JO
M^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K:)4IZIU;X-5_T-'>UM$J
M4]4ZM\&J_P"AH[VMHE2GJG5O@U7_`$-'>UM$J4]4ZM\&J_Z&CO:VB5*>J=6^
M#5?]#1WM;1*E/5.K?!JO^AH[VMHE2GJG5O@U7_0T=[6T2I3U3JWP:K_H:.]K
M:)4K]]4ZM\&H#T-'>UM$5HFMNZ;.A.B$U^,%6I"DCGQP(@,D"YG'X#X9C#*7
M&EMKY%<W/.;5R<BTJ3RXTJIJ=ZUOLS,DE!NAD.],X$0^&MS'+C#BA75LY7C&
M<\N,*RWR\G^_4]E2_:`5O[4*J__1^V/B&SG%9-Y/)U_O<ZG[7\;E+/!6]JG^
M2U:_L"&_PX;4*#RJ_P"B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*`_%I:]XXS<W
M95W;*`W2E:KM=(1NZ^ZCU#,[.A284[<:AT0N'MH"I>+>W&AD[+RNXLHW`"-2
M3K<_&0QJQTJ:'?;*1V5!7A[C>)NS5G;6J[P3O$^3*TBE_5VP9]H>OF]E0>N0
MM\MN\%RW,DILV"FJZ58+)"4&SU^N7.0D,OGJD8++ICO.RA>84E6=N;XN/6"\
M]BRV_P`=8$VG>%H&,Q+;V2,B+0V]C]]2(N3BJP6LZ@.1C-V'AFH<AL9,MFRK
MBV!W%-+4PZ38MP8.W8*W(E@X*P<1+U?]:-NT\.#)5HWVPS8*XKB8$1?2+LB4
MDTNV>!;JO:^'S+)A]UJF(8(&=2/@1_1.93HX0('<Z)H5M)W8MUJMD\C<V]4.
MO/6IZ;2:SM[LE/&[)TR<(%ER7$$S>Z`5`<NDG)-MXS(G61>4N.BM"<V5![2E
MEHH31$T1-$31$T1-$31$T1=3[[(S+Q)+S0XX[3C[[[[B&F6&6D9<=>>=<RE#
M;3:$YRI6<XQC&.7.B+0H7%)L,?"RU@8OX[<9!4N][B3"S8&TQAD;2MM(:AV2
MXV(N+D8,649!CZWNA7I)CE9Y\C'3`I0:2&'4N:*:%91MKO=MENZ_+BT"PD3!
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M55EX^"VOCY*)WFD2";#/,%Q@+@3&7$<W*TKD`$&J*&-"^L4WMN=8C7!ZQMT[
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MC`V;#,OK>35LA@1>_P`HP!:@TM91$#=+GG.9SG4%M**5VE<=DQM+<;=6]\`(
M>T"-;T$[4U(O:VL,U@T-@>1V?K8TS88:U[NVJ<FV)&V[YPHKY((@T=$,-+60
M0LDT`)Y394(JDGZS"@1XL2;+;3;E10LTFFQ8I))M%>9#N^X,7PZSM1ITK@&U
M%DM.G0O%14'7SA6S`QW,R+7/6H1CKC#VT65["\:4YO+NF]693;"1V_I<Q9C*
M?3G;)EP>^^LJ>'#8'B*%A;C74/O#0)PD#N5/CF*:<(&P]%BI9>=P\IQ0B@Y4
M7H!JJ)HB:(FB*$W%#OMNMLO-3C]0<V],KL)PI<3W$$J+LE1LA\T7.\/C>U^`
M8!,]&;@0@(\39W=S4J=7F-<>&2!E*<N9?PI@I"Q.Y<2F[E<!W*+BCML'VMH-
MIZ1NE/E[C;;;H[+HN2=R;ENS3(2KP,3;;2?/U2?AB=J'%C-F#R"+2;*!A,*C
M$KZ[F%(`4>-P_K+[O3Y"XE@[?0:J;7*)Q!RG;%I@KW39*(MVVW#3PA;N;;>L
M$3:.Q#\UF[;G<0QE6SS&&7BW2X;(KGX3[CQ**0<+Q=WPS<W;6JG5JL)KV\&X
M-IAZJL<.98F:W5*1>MS*'+-V8IZ:?"D+/,JJT3(C+&8'&%P4:&MM_JS)I,J*
M+JLO%UN#%S:AH^NU;LJ\77<#;_;E1D18BY&J26UO&)LIP:V&>NK<?.8Q=0K!
M9=VWK''`1S<*ZS'1B0W"7'25%#0IH%BD)QF;E63>:L[2`KH38YD;*9EK=7]I
M-[+\\],UR<L-:F(]VB#2-4MM#(3*0*D2+,JAYNN&H>"?)-Z-!CI*!22X6]Z[
MAO#795S<42OUZ]1L?4)N8H\97K379&HBV^(>(9!=)GSIJ"W'K*9B*D!XBZ5R
M0(K]D;$>R.V.Z,^UB5!%%*?10FB)HB:(FB)HB:(FB+&+M50KU3+=2))X@:.N
M-8GZK($"91@I@*PQ1<04\-EQ*V\$-,&*4CG8SCG8QRXSC1%YXSW!-N;96+K+
M2=SH3-KW0V9W/X=;>D`*Q-P,+0=R]N=AMO2;K7<$X(/DK;&.[(+E&HHGJX:L
M3?4E'*ZAUXXIJ%OGADX9C^'Z2F#'[2NQ,3FU6U%)+9(E+-*J%L.WUKWHGI21
MB%622D^QJS+!;G"-BQ075007@GW&V,**<5DA-5+S10FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O,;</C(W:I$P4UB+H1,+8=X['M+4U
M"4J\3]@JZZOQ,;%[)$34W!0EP</W(Q*UC=60/;$BVH@IJ4`$$;06DU:QH5J!
M4FY'&CNO1Y_U!&CZ4;:VMQ=N$.RAVU^YX!3^R-]F>&#;_-X&VB]:EWK%L%W0
MXA"P1H;)BBS&Z^ZWAI#SG*DE`MW#\1=Y33=WRW0J^=8J1Q";#;"5>3=I=PJ`
M+Z]]('A@4+;K/0+%8';4#ZK3O$"0^_%*/#(>#C4,9>8=6M],J*<BBC>^/'B-
MCXW=3.WVW=(L,_M,)9:Y.!2-&W)357;94)KB#V^E[S(;@A69-=J](.W#V;`R
M#!%=)-$1\SA"2ENHZ34*:!5=+^L.W!W7W@CZ=38"LUW;RUQFT4W2[<]MIN7N
MY8BPKKM=NY8;D+(5.A6.$-P]5MS-J38%9">C8$ZF0I_"LY2I!"`%417'IO':
MQ;1$Q=?VRJ=QI%AM8TRU-0=GM$;+5E'$/3=JJ'-0P(=YJ4@,/+4Z^CD%DN.O
M,9GHB1#93EM'/:)0*6^YV\VY-%W2I=$RY3(BN3<-MX"5?I>D72PP,IN%N#<Y
M2CC5XU52M!#VT*%&#"/0"["@B,M<@7F%9E`3&L/N2HH**+AOU@=FV\*V=:W,
M7MA*LW![>Z2W`16X^9J<U!052GK+M]L['U6`FKM;")V9W'W$J!C!!'2J9%:Y
M&^A1E.'W8JIPUJMCTSBCW8G-W-J]I)R0VX9E+36[M9[834]F=][,_&N5Q'#%
M@"NOA/2<2Q38XLG>R6YEK*)DX`H$($S_`+93KXC<J*!>BVBA-$31$T1-$31$
MT1-$31$T1-$47]B_XZ:_MF5_KI.I/*/I5G^!W%*#4*J__]/[8^(?\F3?Y!7[
MW.I^U_&Y2WP>ZMZU/\EJU_E^&_PX;4*#RK])JU>+M,/=28D5ZUU^`LM6A9Q:
M59.CJ]<)&J2UFB1U85A"19F2HT0\]C*<YRL!KDSCDSRD6GI+A7X>I>+A860V
MJK)$77:?2=O8</"#F6PZ%MW$W2`J=+YS!C3A%6"KNXT]&D`.J6+(QLP6(8A\
M=];69J=Z*X/<-FQA%]^,Y[;>"<O")-^:&FU*D,XCYDV9J%CE9:*C.N]CQ$G/
MS^W\&;)OBCLNRA<2*Z6IY;*%85**C3PM\/B84*NIVIJR86.W!C-U@(_`Y.&A
M-PX:I#4*)M0ZNM=*W(QU)#:B6>171HCVTL83T>,)TJ=Z+K!X7MD(&BV';VF4
M:*H,#8@8@5Q5088CS(HNM6"2MU2FX?K;,@"-,5.X2STL`XXPZVV>KGK;<3RI
MRJ453:>&/8:ZR^)VS[:04I+YLF+>\<MR2&=,L29>ESR)*12$>,W)J9FMNX0I
MMHA+K+;\<TM*,*YV5*G>BUV5P1;$'[D8W%/BI@A`M.C:A!T<<T"&IE87#L;=
MB15QK_J_%1%O%W"C`]J*ZT+-.2[Q@J(8#+*FU1\>H5B-$6RZAPY[1;?V^.N-
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MP-X>MD)`^6D<U(8"8GK2S9"9>!L5DK<X/:0B[/.9+@9>O3D9*5LEV4M\W(DL
MQKHK9)LL>4\A;Y9+CA*E5CW#QLR2[82#*+'GEV@:/'FCI(Z9DI%]R,,@),65
M$D3I(@Z)L2IJJ14B_*".,214I&"'//N%C,O()4JT`\+FQ<2:!*05)=K,S&NR
M#P\]4[7=:I87')B4E)R:R?8*Y8XN:E$SDU-%%G)*?>2:2^IU_#B\\[1*K/:!
MM3M]M:,6'0JT-713&8P)3#!4B6V)$0;+PU?KD3B2,,[$J=:&)=:C(@/H(R-;
M=6@5AI*U8R456PM$31$T1-$31%#C>FORLAOA2)&:I=WN]616ZN+M[ZF/3P;5
M-W*'W>JY]ILT_.0^6@JL.BH("?R6:O"#8:.EXMO*L'O!GE(7FC9*?Q9TV*V6
MW)VZVXW=G;'LQ';,W#<*DM-6L,O<;B*JFV^Z$-Q5E=4ER`V;?%[F5:QQ49'R
M;;V8.;GVNL#/+=;<)7"ML/*M'27#OQJTZG;M;7P0._ED`N6VN\NVYMY;D+61
M*.S&R>\G$#O=LI:XO+QC1.$[HQ<"JN9(%2MXU%OBV<IZ%2%MDV*3=CV5W?MF
MVC\'6*4$-N`U;>*29GBYKATW)K\B\495N('XIS9R\EVFOM[B6;$K)@9K=@BB
M4]A$$,+;:4XZSRE"SZ7"W@J@D!>ZWLSO;:-X:CNGOU>[F6]ZWI$N-2<FMT+#
MP\4JP(SD*)W(D2:&]"1XY8>7T5;+3L<^H-XS+.B<O+R+-^#.`WNV1W/F]JM\
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M_P"5.^:D>+T1/76O^5.^:D>+T1/76O\`E3OFI'B]$7:Q;H,AS#31+BEY0XOD
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MU"I@3LP53)*%CLJ02I5Y"HFPT=`357"I\0/`6*OP=7GHU`!V69>"K>#>Q@9!
M:EJ>*ZHN2(7EU:LO.NOK6XM:U95DH6(#[%<,4>\`5!4G%2/BWBR(V5HLO=:'
M,`N'S^X]I/2+,TV;@I1ADZP[NV4MYM+V&W79@C*TYQE.$E-2KXC:OAP;D7Y9
M&W]>3)E08E:)/3%FX*?@`-P3=U0HEU["^>L,7<62(EVT9_X3'EJQW%9QHHJL
MFL->V>M5IA[I/PK9]EA.Q\"2&>V1DE)K<PY8JPU.`!D#QME9JED>7)1*)%DI
M$5)+44)ADA67,DJK:C;?8-J//;Q2(+,?,E57$BTY&ENH,(V_ODQNQ4.E0ZI>
M>;7-P[4=,BXQR)0<8ZODSE6<:*:K$H#9#AKJDQ"V&J58ZK3E?9?"C):M6?<*
M`/3$/L4X/-<.)B+$&Y+U-B-V\@0V(@O+\8,!#ABM,(''::22I4@?76O^5.^:
MD>+T4)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B+M=MT&SAE3A+F
M,/M8?;Y!G\\K>5N-XSGD1W,\YO/<SW=$75ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>
MB)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B)ZZU_RIWS4CQ>B+*DJPI*5)[N%8PK&?
M]V<<N/\`^&B*,&Q?\=-?VS*_UTG4GE'TJS_`[BE!J%5?_]3[8^(?\F3?Z.O]
MZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JCWQ!<0,QLX>R+"UF*GVHC;'<#>2
MW*EI4V,<Q3=NIBCP\E%5[J<=(I?LDHNZ8<841T8S6!<X7SNDQE%V,Q=GLT7&
M]Y9R#L$\U%K(+C),3OA;=I)>I`BC5>S[@C-28YI"S9>ITG;R3MJI$$=WFL+E
M6YB'<%+;YW,9:(&5GDRZG*K='WH<#MV*G2]^6D<E?^BO\3Q%[ER54H;KM.V\
M&N>Z5QHT!4!V+L9)P$='WG:B7W;9?M;(D7ZS1<A$QD`6#S%BLI/<Z(EKF,N9
M0B"QM3M-`/\`YHI$CB!L&(G_`.*K,MH^(OXT3@7LUU$-"'\.>UN^G)@M9TD(
M7?97<`"3KV5]$*,6/$(IB>A?PAI3ZG594E&.3&#F8>SMQ$*S),78V80>>JU/
M!<7]KDZBV>;1ZV'9[)&<.UAIHXTW.R$&/!\2*I]5=39LL5_MEV5J(M7,<-:`
M8=2<O+3;.6N?E:9,8KR[-O\`)4$II6@J:?S651_$M<IV4X?PX&G0<B%OL"2P
MS*B%SA,=6;#2)K*]TA32#(Z'*4&'4A3'HCIQA'23A%LN\SG)QF,`[_;R?P%/
M2$F.@\+^"IG:XUS)HB:(FB)HB:(FB*")?$%=X/B:M6TI5CJ>8$_<2H@UR+DX
M:I)F8^!*HNS"YR/Q,3&_-%/0N6F[D2_$8'KTP<6^DY#(I*0N8LBG=HB\R-IZ
MHA7%"=>Z?&;4U-%JL4[+35>AJ49+;L5N)<@<-3$1O!%,6N&KVU$A8I<5PL:7
M%CRY(XU]H<EQYA3R'B+T;LZY=NM6%ROF1,?/(@Y9<(?/X=S!`RZ0"%1IDUAA
M27LQ(QF$+)YF<*Z%*N3/+HBTKM3N!9+#<YFN3\Q72FP:77)`6.CK%"VR67(C
M&'Q,[8").KU^`A08F96@9;([J5%+)ZPI+`@Z&FUD4AM$31%Y';L<7?$W46=T
M2Z5`UB5:3N/N?M/ML[9:D2U#YW"I>X-<<JU=CGXFUIG[<F9V7@;W*2[B04M@
MG0@:</,I>RV["L`.R587..#=ZY57>2_;>SD,'4HK8'BXWUVP,FMN\+%D`]@S
MMK7Z`&)()LZD3\?/0>X"_6+"D,O#$Y%ZHZE.7<9)14>YG''O_MSN#?-I%XJ$
MK-QN\3%4V^G6:TT/*6ZC-TRGCV)IF)DK+%P3]VJU[E.F*=ZPQ&-!6&):=Z-6
M7'%DH**0M7X@]Z6N)2K;3V-#J*X?N)&;?S+%@I4&$<TW)<,FX>^/.59:?<IV
M!'N[-AJ8[*1&,F`+A>L+RO!'1KQ*B@HO1;10FB)HB:(FB)HB:(FB)HB\R.*G
MC!W1V)X@HJG0850)VPBZ5MM<[^_+QYRIJ+@+B%Q7`V.R,2[4F/'@Q-*/VJK\
MR<HAG+;<*%*8RKGNM+9*0%J:B\<>^Y6W.SU^GO4NP/;N2EK6]7XFIF@%P`>W
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MT"S>D\3-X.O=^%MTA(L479+;**O6Z9S=`KE5DZF0Y;^(%J:BMQ`9W<(\QDN+
MI^V$9ALJKIEHZ2(40<RMH$H5*)446B*=QQ[Y2J*^Q/1<(FU568VM@-UZY!TB
M3>A<2VY._<-46XU,B9/-S$$4_M+<H=^*7T3N'Y]_&'&U#*YNH4T"SNS\6V]=
M/J2IQMZA[B24QP:[P<2;<;3H,6-(V]GJY5-EI^L>MC%@W"'3)T"/*O<BK_LG
M'IDX)3&$L+6RX\]*B@7J[$?SY/\`1C_\/*T4*/?$3>['MSMBJR5/DQ-D[A[*
MTYE6(K$X0V#N/O3M_MW-.QT0HH-L^89A;20H)M;F&\EX;Y^%)Y4Y*0O/:]<7
M?$]0!-RU6&&@(J:IP&[(T;&&TIM4>0U6>%[>K??;V7D)$*\&C@7R=<H$.3(0
MG6'P1PR3F,/I=;:>Q"F@V*:UJW0N]6H]<BW1[#';BV2Z;?5<B6N5$:[)K<;?
MMS8REYD2Y"FR\IMN?-CQIV5`!#SK[V27A5%,\W+C.94+3Q7$GN3%[3;V6C,Q
MMY:I[;'B0V+V<BI^M1$BU5IJ"O:>&%BU2&0")PTE$GUG=J8PUA)2VQ'4-(Y7
ML,Y6Z2FT+)^#'B+O._<7.L;@"5V/M5,I.TGK:!7Q2Q&6+O98NS%6$UD<TTLL
M2`LX$;'S4,.]_#M1,FQE:W,KPO1"**>(?\QE_P"C"_X@+HH6DM_+M,[:;%;T
M[C5U(2[!0-I=QKM!(DF'"8Y<S5:=,SL8D\9IX9T@)1H",.H2XVI:.7&%)SGE
MP10S3Q+<0E:W`O=,ME*2NOQ5LX-1:;;SH2NP,@BE;\\0,KM7<IK<2OXW")-C
M9,YN(-`@VXP8G+2@VSC61T$=$DIH%@-+XX=R;F\1+=9I<32(N4N&XTI,BU9Z
M9L,7P_R`&T5MVPN,[2";W!VPJF1U?NL]#6NP0@<D[$SL='D.!,A/$)S"FG.I
M4;-[H[NVS8&=W4FHL8FT$5J2L%7CK`Q!5NHEK!9E'FU@&5&9NEAS!N88;Y<R
M`PI^>;R=$CG94F5!&VBD'MA9C[KMKMY<I5D0>3MM&J5FD6(]MYH!D^>@(^5,
M9":)(*(;$;(*5AM+CKB\(QC"EJSRYR4+9BO_`,,Q_:9?]5#T11PXB[]:-O:7
M79*H*<1*SVYVV],=<&@D620:C+9:08>3<BX=TP)DN32&^KH>>OF)5^%E*N3D
MT4A0F/XSM^*0#:!]R]OH6&LE3D96`,2PU$X@9"[M<'6U^\$)MZ'B-O5FG6;+
M+;OW=07*ADR/2(^T,R<4XCK#L*:#>K$7QL;Q#[8W6\+-I/24O:S=2$9D8JG8
MF(&Q[_;0;=;PEVJ)EAV=R/6;:PN4N^V#<K"`S0*X@ZKO]"W*$R!;2A"4%5,#
M=/<?=O;S9Z%L,8[%,[B2,K,1<?6;_2\V>VW*P/1%H=IU#JE,VAO799<].RP`
MI#YJ9I8<7`L&&FI:;9(=$E1LKVE*L59#@PZRV6QBUL,K*'9?R4R.0IM.7F6B
M5,C*(;:<SE*7,MMY7C'+S4\O)@H5ZD?XJ*_LQ']<-T10WXE]S-X:9-4&L;+Q
M0L[;+;7-U96*A"8,>68G+-38FND5&#EC"[!6QJ]5I:7F>ADS^LMN#,*PM"T9
M3G.BD4[*BA)\;>]*MO;.3&56"C-QB]N.'R1VM"L$4R9#W.Z;AWCB)]=BQA*O
M;IJ5]76MMMD'B@F"<`G,D#/*=1T:T\V%-!57U?&!N=8V8*3J9,05';K7"-5M
M&-7:M7+$W:=KW=V:A2"+!5;NYNCZI.VV!C+:.#9X2Q(@SXBR+6VPT\&QA]\E
M%*C<_=6];=E[.MCOU1\*;L6V-3W&C[#&&EW%DK<V\U.@1$KS:?.D1%+!3)R1
MK22\L3@)LRH4%*A!5/R3$J%)_10I)L?Q#/\`)-_O,:(HR[&?QLS_`&S*_P!=
M*U)Y1]*L[P>X%)_4*J__U?MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO
M\.&T53RK'[QM9M_N0]"D7:M"3[U?49V4LA\X?H6)%V.?D0",`EBID8F1?AQ%
MD!DX=$?6*TIQM66T9Q(<16A57-:ZF(*W-;+;6L6T6]MTV-Q;0Y:VS@\VIPYP
ME$G>HJ-A+8^IMPM8SK<U%PXS3C2T*93AK&4(2K*LYG$ZE*[$P-KBIM^M683A
MUV8`JY-.!HP0<`5-`6%;`LE.L',R\3&,0<04#.-2B9R.3#P0R`0VAR6F1`4]
M7:2AGE1IC=6M=JCHV4IAV*[C[*[9AV2M6V.K:XF<J%7@:57W8:<L4,`'4ZNY
M).UZOOPD7+B0<G&0ZY<G+#10S^$=+G'W,8Y&)U"*["IP-J#3:%:0^'?9B/KD
MO4@J)'C0$V;`2!H;1TREUHJJ%MG5545(=I=I0+-7+:2N-:!>&:`SR]`EO&<X
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MN2#E*M38"*\$/)3ZS5P1Z140<<6M`A\NI_*<#,NJPVZ]S4JSC&<Z(HN\+M>(
MB[E>I)4F?+=K5.G/3!<="7J%HXUE5*VIPJO1`5W/>;BCZI%*$!ZL`.V40,VW
M(3#KYQJ,-$4U]$31%C+-+IPY`1;%3K+!4;8Y:X1Q+,#%MD`6V?"E8R=M(3R!
M4N"V.:C9TX<LYO*226#'VW%J2ZYA1%C06RVSD9!XK$;M-MI'UI,!:*FFO!42
MK"0::M=TQJ+I6L1+$4V!B`MZ(8/$H'T?5I#`C.'T.=$CFE-3O7&Q;*;-6]Y9
M%LVDVRM#[A<P>X]8J%59MYPZPL0PL^:MR2BB5J+G!:['MF.9SSR6P1TN95AE
MO"2BJN,-M9MC75`KK^W-#@E1<LU/QBH:H5^,5'3K$'(UAB:!4%'L9$EF:U+E
MQZ"6^:\D$IYC"NB<6A1*K/-$31$T1-$31$T1-$31$T181/;9[;VJ1-F+1M]2
M+)+24"JK2,I/52!F)$^L+#LL<NN&FR`!!)4"N/N<PQD-:E#Y9EC$<SFE/X61
M6.!V+V2JJ"VJOL[M96VY"1A9@]N!V^J4.@V7K=E1<Z[*%HCX@=),C`7!M,L$
M^OG.BR:<%-*2_C"]$JNX#939J*%E`8O:3;*-"G(NRP<T&!0JJ&++PET;B&;C
M#R@X\4VS(1=L9KP"9,=W"V3T@CX?2O#+?-*:G>JTW:;:N3#5'26V>W\A'K:M
M;"P3:97"PULWRTQ]XO#*A7XUQA35SNL0),2J<IY)&4%:+(Z1]M#B2BJ#[3;5
MBN0+HNV>WXSM5E(:<J[@],KC+E;FZY4S*%7IB!6W&I5#RD#19$B%"('RV\+$
MON!M*2.M3>2+8&B)HB:(FB*,%CAXF=P?&3D7'3,:[(((=CY4(:1!<?CY%J0`
M?<$,:>86\$>*T^RK*><V\VE:<X4G&<$6N#-D]F9&1/F)#:/;$Z6E8^7B9.4,
MH55*D9*+L$A9I:>C3SGXE9)D?-RMUF22V7%*;)(EC7',*64_E934[U1*V!V(
M6VEI>RFTBVD19<&EM6W%.4VF%D#IR3/B$HS#93B+-DK-)$/#_P`4X_($N*3E
M;[N5DJ=ZRA[;C;PB6F9\BATQ^=L1=>D+!-/5>#=EIT^HDQ9M3-F9)8*C),NL
M&083L<X^M:PG0V%,Y0IIO*2BJM8FSFT0`DC'@[5[<!`3$79H.7"$H]8&$E(6
MZM0S-RB)$9F+0R=%VUFNQZ),=U*FCT@#X?2YAAOFD6VHC^?)_HQ_^'E:(L;E
M(>)G!F@IJ+CI@-B1AYAD24"&D!F9:O2P4_`2C3!;3S3<C!SL8,:&_C&'1BQV
MWFU)<;2K!%C4_MIMQ:VI9BT[?TFRLSRR')QF?JL%,-3+A=6D:,6N6;D0"42*
MRJ3,%P[F7L+RN**>$SRL.K;42J[D[>4!-5>HJ:-3TTDGG=8IR:S"XJK_`#RT
MGKZ:O8"[)=YYR,/9YS.>5W&%_P#%W=$6.?$;LGUA9?Q/;6]:<[`Z0GXOJEUA
MSU51!M5?GO=D=(KU;;K,:D#ES_V:8\;#/,PPUS"5.]7R*VRVW@I9$_";?4B'
MG6\1R6YJ*J<#'RR$Q%?]4HE*)$0!DQ.(NJX[,'QA?\!'_P#;HYK/X&B56R@_
MYC+_`-&%_P`0%T18W,0\388F4@)^+CIR"G(XV'FH68"&DXF8B9,9T*2BY2--
M:?#D(Z0#?6T^PZA;3K2U)4G*<YQHBL\S1J38W)%VPTZK3SLPQ6199R9K\3*.
M2@U*G#+-31Y%9PCZC6*E9)$B0C$.Y4D`Y]Q]C#;JU+R16&3V<VBFY")EIG:O
M;B7E8".A8>"DY.CU@^0A8FMDEF5V+B32HMTF.CH`L]]T)AE2&A7'G%-)2I:L
MY)572M[<;>4T*4CJA0Z958^;YW;0%;J\'!A2_/P1A?:@L8"*Q(<[!;O+TJ5\
MO2K_`!L\I%E$?'@1(`45%!"1L9&B#1\='1XS(8$>`&R@8,((,9#8XH@H[:6V
MVVTI0A"<)3C&,8QHBORO_P`,Q_:9?]5#T18W)0\3,H$;EXN.E6P)$&8!;D@A
MCD!2T6^DJ-E!$E-.I&D8XI&'&'T<UUES&%(5C..71%CLCMQMY,'8DY:ATR4D
MDVB,NZ9"1J\&:=BZ0H<''P]OP62"Z_BT1(%8C6!I#G=;89CAD(<2EAK""*PR
M6Q^RLS(S$Q,;0;72LM80IJ-GY22V_J9TC.1UC`F(NP@3!I42Z3)A3T98I`8U
MIY2T%,'$-NX4AYS"BFIWJJ-V<VBDX:&KLEM7MQ(5^N2),Q7H(VCUDN&@I8T<
MT,R4AHQ^+<"BY$L21(:=?80AUQM]Q*E92M6,E%5L1MMMEM#32$---(2VVVVE
M*&VVT)PE"$(3C"4(0G&,8QC')C&B*[2/\5%?V8C^N&Z(L;(AXDN2CIDJ+CB9
M>(9/'B94@(9Z2BV)7`R9-B..<:44$S))#9P^EI24O8:1S\9YJ>0BQT';C;R+
M/BI2,H=,CI."'`#@Y$&KP8A\,)%#6H*+%BC!P6R(X>-#O4VT.AE2$LM3!R48
MPDLC#A%B:.'O8)H9\-K8_:!L0EN*9)%1MI2T#$,P3H+\(T^PF%PTZW#/Q@RQ
M4JQG`ZQVLM\W+:.0IJ=ZRDO;3;B0*J9Q^W])--H3+(]%,+JL$252V!U`+'8J
M9#P"WJXRPN+%RA(>64IR,UG&,=&CD*%FVB*2;'\0S_)-_O,:(HR[&?QLS_;,
MK_7BM2>4?2K.\'N!2?U"JO_6^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E
M^&_PX;15/*M/[K24B'80V@Y`T5I4*.XIL8I]A"EY.D4Y7E#3B4Y7E*<8Y?N\
MF,:D*IY5K+MZ<]V97TB9X[15J=Z=O3GNS*^D3/':)4[T[>G/=F5](F>.T2IW
MIV].>[,KZ1,\=HE3O3MZ<]V97TB9X[1*G>G;TY[LROI$SQVB5.].WISW9E?2
M)GCM$J=Z=O3GNS*^D3/':)4[T[>G/=F5](F>.T2IWIV].>[,KZ1,\=HE3O3M
MZ<]V97TB9X[1*G>G;TY[LROI$SQVB5.].WISW9E?2)GCM$J=Z=O3GNS*^D3/
M':)4[T[>G/=F5](F>.T2IWIV].>[,KZ1,\=HE3O3MZ<]V97TB9X[1*G>G;TY
M[LROI$SQVB5.].WISW9E?2)GCM$J=Z=O3GNS*^D3/':)4[T[>G/=F5](F>.T
M2IWIV].>[,KZ1,\=HE3O3MZ<]V97TB9X[1*G>G;TY[LROI$SQVB5.].WISW9
ME?2)GCM$J=Z=O3GNS*^D3/':)4[T[>G/=F5](F>.T2IWIV].>[,KZ1,\=HE3
MO3MZ<]V97TB9X[1*G>G;TY[LROI$SQVB5.].WISW9E?2)GCM$J=ZI)"UR<8`
M;)&3DNV)'B$G%.)..<4@81E;[Z\(0ZI:\I:;SGDQC.<_L:)4[U%='&S`Q89N
M+@[8X>:C(K$R?&P=A8L8C`CTI%@,,.2)!5??"+#'F&2)%9@H@$<TAQU92A5"
MDE%.W>LC'XNX%.5XF%WR#PU(2K!+Y3S!`@,/'7J]T9FR'NB33KH\40_M^:6[
MC#:GA!U-X>0EQ:4Y)4[U:QN-W;DU0R0[#="LG5B3MX&6$J<1(P<$29ZPEQKB
M9CF2+<#$1[\B2XQEQGJ[2V6UK.0H3!*E5<EQB5^-,!;6N]NQQ"KV(7()>2A4
M=)4H6DG,#D#N2B6D!V46\B=6*6\VVPI2<DX99Z9Y@E3O7ZUQH;>.,P!>;/;6
M`+2W67*W($*6R).9LL`]:$#12E2O2GR$5!B/ND"M(44\XPI@1LHA33+A-JK8
M/BJ9M\7-R51S8)#$;C;X(-F4G78OIY_<7<.P;<1<;*.A]M)BQ(^5AFB"WVL&
M/,C$93D?K+*Q\DJ=ZIR>+^MQ#KX%C/ML7,1+U$&LPH4@Q.`P2[S6;-:6CUR<
M?+929!0X-+E>F*0UA9"1<."M/MOL*<)MWJYM<6%9=D@H/M"]LV&0`K<B-7B6
MW!9GJ]PMD?4*PI\,B6;R*U,FRK#[;[N4#-C.<KKK;N,M8)4[U(#MZ<]V97TB
M9X[114[UYP7WZR.FT6\W2DFT*[2!E.MEBJI9[$W%(8.)KTP9$/F,H=Y74-$N
MB96G"OPL85W>[KPC-^.V4Y1FV:93)D-P^2UN)(2X/8`XQO<PD`BH!+:BJ^H]
M/_\`%[/]09#DF?0ZIM(X;ZSAN&L='(2T31MD#21L):'4)&RH6)_:F43Y-KYZ
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MXF7&174<)<`YP<QV$;\.PFFX&NZIV+KW7_$K5D5M/)::GL9;EK26L+968B.1
MN(@AM>0$BE>6@VJ2VY[NY^ZU>K]IV'W')`@C]K]QI""G(XE[HYBT&NT]5#&9
M#D9.*8%60V-+CK>/%):`PZXK+3170/->ZY?F%EFUE;9CEUP);*9@<QPK0@]F
MA`([8(!!V$57S!FV59CD.97N3YQ:N@S*WD+)&$@EKARBK20>P002"*$$@K!5
M6GCB3+`M8I=.>A<1521*O)LD.+(N2)%?2Y=C8EQ<B:PP1&RR%LQP1`[HY)3C
M;SIC0K:QW.ZL=LWE;$L$EOO&2(,P!VT>DJ'IT=/1P'8),0Q,S%PVMBYU^J13
MLHY(#(@Z^_9B\.2#RVF5KPL@HL=`S01*]M:8$F^/X$.3']7:066V[,GA&$3T
M8:*82=:\EC1C#3DV`:'$@P<J^@=3KBG,M`CMJ2TI+F2XVJ:MWE;"8/XN#K7+
M1LP+!!4<+<*K^KLW!R,<W89:E1>X,.])%3[;\OED9B8H8QV361V,$]:4.AA'
M1OD-BRHJ*<NU7_:EWB4"NAL3N,\"1MT)#R!<9/JD0#;3*6$HV-?;"DL`DH:&
MCV$G'=%AD9M*&QF4<J<=Q9*BG+M7K2-_-A_Y!K_IIU"LHS[&?QLS_;,K_7BM
M2>4?2K.\'N!2?U"JO__7^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*M);O\`Y2@_V&-_7Y/4A4=RK56BA-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$5JF)V$KPF#Y^8BH,'+R!\&S$@)&"9?<2M3;&"37F&<O
M.);5G">=SLX3GDQW,ZJ^1D8Q2/#6[R:?]5P7%U;6<?2W=S'%%6E7N#17=4D"
MO:79%3$3.A-R4)*1TS'/*<0T?%&C2`3JV5J:=2V4(Z\PM33B<I5C"LY2K&<9
M[NC'LD:',<'-W@U"F"XM[J,36T[)(3R.:X.!IL.T$C8KCJRYDT1-$31%88VU
M5B9+4!$6.!E3D-+?6'&S$><6AAMB+*<>4.*0Z\EIL:<"<4K..3#9C"L]QUO*
MB*O[5B^L=4[2`ZWU_LKJO7!^L=J=E]M]F]#TG2=?[%_[SH>3I.J_PO)T?X6B
M(_*Q8SS@Y,D`.^UV9TK#Y@[3S?;9SL9#=(TXXE:.UY)E8XO+C'6'T*;1SEXS
MC1%7Z(FB+O%%?-(;%&2E;SN<X;2IQMK&<X3E>>5QY;;:?P4Y^[G&B+7&.$W:
MM+1#"-G=O6VRV1!B4MQ]:;R\.`YET%A:T/I7ED-[\-I/+S6UXPI.,9QC."FA
M639X?ZLIQEU6WE1RL:5%G!\Y:KV4CRX4G.30D@PCK',:)'EK-($I4G&.1XUY
M?_$XK.24*L^.&#;I/,Y-J*'CF1>81'_95O\`!B%2:9AR-Q_#_P`R?DD)<<;_
M`.%WFX2O"DXPG1*%!>&2DCPW8+VWU:D8_)$Z4[B47!G/D%60L$R:)(?=)RXZ
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MGYZ+#XW3X6Z-]F#^7DI\P?$SVI%XG^I<D?5`<++BN:AS>C*N12N3.]4^GN(3
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M]/ST6'QNGPMT;[,'\O)3Y@^)GM2+Q/\`4GV0?"M[+O3\]%A\;I\+=&^S!_+R
M4^8/B9[4B\3_`%)]D'PK>R[T_/18?&Z?"W1OLP?R\E/F#XF>U(O$_P!2?9!\
M*WLN]/ST6'QNGPMT;[,'\O)3Y@^)GM2+Q/\`4N7V0'"SAO#O2;T<S*U(QGXZ
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MOOEK!A1J+)A5$R,A+(W%30]@.B2(61=`$9JN8V(C19"$>!'E`49+4^SAY$>V
MZ$SCJYY:%;^QC(V,CC8&QM```%``-@``V`#L!>-ODDED?+,\OE<XEQ)J22:D
MDG:23M)/*=JU"]L1Q"&1]A>-W/C7+457MJA8"=9D36&`K#1X:Y]LR3\<B,ZN
MT/*6.R#N*1C#Z3FQE+>;:Y^&$V5=FY=%,V'XB8^>L5LN6Y,!+6$RI6Z#@G(R
M2FV8\,V;>H9$:0Z`0PD,9\?%=D6LF):?<$ZZE8[.&L=5039V%<U;`[O.;<PU
M9(NPSMY0YNK*SNX`MJLD69FPW"9-EJT5%1S#;P2`Q5NCM$HREI8D>.['!Y2(
M:3A1.SVE=X[8O=H*7J1WQDKQ&PUFIT_.1#DI/']L#0-;?KYD(T6[+"LLQ2&2
ME*PRL9;<@4VR:1ALA"^E)O4HNSRO8T^&8\9HJT4SQNX,/C_8PU_TTZA<BC/L
M9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J__0^V/B&_)DW^CK_>JT^U_&Y69X*WK4
M_P`EJU_E^&_PX;15/*HE\7=QD=OZ[/7*)%".DH&IA%!B2/3X!?><G"1L()R,
MXT_AOD?SG\%6,\N/_P!-8+4V:SY)D.99K;1L?<0LJT.KA)+@-M*&FWL+9M&9
M':ZEU5DV17LTD=K<R%KG,IC`#7.[W$"*[.R%`K/$Y>P"IR)F8W;\4\<^P0$*
M?SK"Q'O3E:WHSM44X4PX^\G+,F.Y@H5ETL)E#S?,?-:;<Z1GSWX@YS#)>6UW
M!9-F:^6.-WXH:9(K_P!3)().QX.-C2^-H<*/E:UV)OK8X3:=N(<OO;&ZS)]N
MZ.&:5GX)>(I\K_<&AI`&V-P,<CFQRN+78HX'N;@?20?%)?Y^,$FTPVW\)#O,
M[11Y9\L9+K8C)K<J5+!+DBR&36@4UR,8B2%(STV',N/,IRM24J4OBL^(N=WM
MO'=BULH;4BR:YSW/HR2Z>YKGN(<&]$P,<1WU:N:*D`D\V8<(=-Y;=S6!OLRN
M+YKLR>UD;8P9(K&-KVQM!87]/(9&`][3"UYP@D!N-O<5VY5B@FF8>`K,*;+;
M5-6!<EDT3!H,U*;3V7<7$U`Q,C9&963BHMR#ZIAI`)2,.8<><)QT/5W>@[B3
MG]]9M9:V5O#+)EHEQ8FXFR/LY;GI(V.E#WL88\%!&\5Q.=)WO1NRL?!O2F5Y
MB]][F5W<00YP80S"[`^*/,8++HII&0&..202])B,L9PX6,B./I67</BIMP,(
M4.6NAR4U`0]H.))<7(,XF1ZKM3M9>Q'\##2CSS#]HEKD:"RXA*V^E0UA"%*2
MM*^U%Q'S2&TDCE-E)=PQ2N).(8Q#9V=PTT#R09GSR1M(!%0V@)!!Z,_![)+B
M_AEA&8Q6%S/;L:T!AZ(W&89A:.&)T8!%O':Q2N:2'82_$X`M+:KZ1M]*DJN7
M%!5K!MUJ.W)B(XY<X_#UXFTS^];98)8+)[#V;!!,T@8,]25(YY;3J.1*4HPF
M_OWG4D^72VT5OTUW:VKL+ND+(C-)?@M<T.!Z2,6[&2&HJ\.%``*<7PNTY#:Y
MO#>3W?06%[>M+V"(2S-MX<J+7M>6$=#,;M\L((-(W,-22ZM,1Q:W0>C/SST-
M1!)Y\&J6&)")*FTADPMBV<SNN_&IR^\&*[,@<WJJG7C@FE-*RXTT\\A`SU'\
M3,V9D[[UUI9MO2R&5C29,)CEL?7"S:6@O;X!+I(P0<36O>!&_EBX+Y#)J&/+
MF7^8ORYLEQ#(YK8L398<S_;@_8'.$3__`+`UL4K@X!KWQL<Z6/*=E=^K#8;;
M8(6=<!FHL]_=VSA"1KS\G;*F#39>G]2A9()GD0Y&R(-LRU'82TVZMP3..5SI
M>1K*Z,U?F&:9S<9==/CDAFDO)&@.)E@;#)`&LD')@<V>D9H#5AVNQ=[@N(W#
M_*LCT[:9O8Q30W-O%E\3RYH;#<NN(KHODB/*96.MJRC$X4E&QN'OXE2O'-O\
M^;%1$948MER?OVRE:$F(V(@"Q'VMTZIP'S4I7ZV/-[@QQ3MFBC>):>P(]+,A
M1BD)`PZ0K+1&5^L81O\`XVKPI9S*\4>^L)O#N%M_,RL14ZO7#@X"/G;-MW%6
M*>*FQMN.#>X$4^KP>W^Y$B?:=XK%*[^S4<!&(#7#O%Y`R*47U=X<Z*"E?X[*
M*:O#[?MQKM7[-';MP<)`;CT*;J=7N05;:*;@&[).;-;5[HS@<0LJ3F\%@0$O
MN*_%-D-&$MD)`Z3GX4I2$P1NY$6_-0B:(FB+27$?4]T;UL7N=4=E;N1MSNE.
MU8P.G6\1(N"XV1Z1EYT80PMDAN&+FP&G@&I)"%/Q:R<%LXZ5E&JR8RQW1D"2
MFRO)7M]I686A[2\$LKM7S_UKB/\`K+=]&=G>"Z`C;+M=OQM;:8V2WLWA1+B.
MSCU,K<T.+5YBV];5)CHAU*%5F;;*7)/6$9P9;B"'W2(L[3K3.;R[S%^GXGD7
M]H[\9Y`HYN")\8V4JXLF8Z0MH,;',:`Q^-FQ3Y?;6]J,U>T&UN!^&T5V'$]K
MNX'1N#`:G"X.)Q-PN^F&.8+&CP1CSLR9PX8S!LDH=D14@6TPAL@Y0@_(.+DM
MY.7,MH_`1SN1/<QC6YK6U6:(FB)HB:(O##BRM^Y>\FSL)7>)B0#V*JCW$IBN
MR#S7#]N>UB%J`<1<L4Z^XO\`+;@&5J>:DG!^A+C1@$/I0^@A#F$H4RK0\XN+
MR[M&Q9D!!#ZQ2O1/V`!V%V(N(->R`*]GM+Y4XA9KJ+4.00V6LF-RS+?WC`7"
MRN1AC:V;HINF?.Z-^*E'1M8';0\&@+3DO!]N!N]MYM#L;2MCP`]U]O9#B)L%
M*MTJYLON>TF#VK-W-EQ9#<D/<KUFBJ>8I^,Y2$,)CG,QW.Y"TYRC*%\N37-]
M;VMC!91B6V-P6N/1OV,+S5^/$&\FWDV=E=_AQG6I\JR+3&5Z;LVWN2/S9\4L
MGJESWELZY<'SBXZ1L1[VK@.C/1_;&RA]JM;NOIQ-$31%0R4G&PP!<K,2`,5%
M@,K).DI(M@$`(=O'*M\LPIQH<=E&/NJ6K"<?[=$7G^QP\4*.O-UM0G$%5@)"
MTR%PDVHEE$6TW#-LR%C*FG\,*O&4DR=`JX%>0"9AMCL60IXIZT*;3@1@BHC-
MA:=-2U=K58XD:X-=E$!S]8?B8H"<LL7<ZYLBS5F[?7TB77F@E3,AT%FFFC$%
M-S0X@HV<H2TLIXBL@>SU`OE"B1J_Q0,HA$4MF&B[!88LX2;Z*/W0)L0%]@3+
M!;H(Q%@B'YH.KXE4(?;9=:>$SE)"NKC$4V=I3X*,K\+1!+_3[F7"5R+=AG(&
M7;)DCZL`(%!O3A`#L]/FI`5:`S1V7$OO,M-(:'RZMYMQ2B+;NB*SV&1=AX"<
MEF$-NO1</)R++;O.Z)QT()\EM#G,4E?1K6UC&>3.,\GW,Z(H8U7C`(3`Q+ET
MJF'YMV3@(F5>KR<L"M&VI&X,W"CMQT;)7Z-"SFI[>D.9?<G78_)A83;Y(F'R
MNSB+G!<:`%MDZG$5ZI`I)L9=+R^3(VKE$8C;-N]#;;&.1V!(-QR0)%CY=LL?
M+W4V#2'4MB+*8;?);(LUE^)!-7MK$1.HK9(\[NI!;81M;!+-$NM3=E+A(TP2
M=M+3G:(QX-HR.Q,QR<,Q:6XAQ2LN/_P3CI%B2^-6`%K(MBDZ69'J=BJS($1R
MK"$24AVZ2,R/7F@6!0'9&5$9`@W')1]D;ECWWQVTMOLK=)8(I3T.W^O,$_/H
MC'(H;%BMD&(.^4V24ZU5+-*U9XTK#+:6!7#38=UQ#2''\)94C.7.=E24D6::
M(FB)HB:(O''=+ZS>UT/<W<:C@5S:@H&F7NW50(HZ4F>NDB5VP2$0,^9T-D99
MZT\R&E3G,0E//SGDQC'<U\RY[QIU7E>>9SEEMD%L^VM[N:)CBV8ES8Y',:XD
M/`J0`339N7VOI7_C/HO/=,:<SN\U-?QW=Y86\[V-=`&M?+$R1S0'1EP#7.(%
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MKN7$X/<08P`2\BA:VKMH!!T7B/\`\<=/:6TGF6HLCU:\SVC<;VW3H@Q[.3`Q
MT;&D2N)`C!!#W49L+@1ZI9QR9SCEQGDSG'+CNXSR?LXS_LU]#+Y$31$T1-$3
M1$T1-$31$T1-$4VQ?YL/_(-?]-.H7(HS[&?QLS_;,K_7BM2>4?2K.\'N!2?U
M"JO_T?MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RK16]`HQL\
M,*8.P6,]`BI>')9;?8=3B1DE82XRZE;:\85C&>3.,]W&JOCCE8Z.6,.C/*"`
M0?I!V*T<TL$K)H)7,E;R.:2"/H(VA:;<K\"[TN'82(<P_EU3_21H:^F4^<F4
M?4[SF<])EZ21@A><\O.?QAS/X>.77";*S=BQ6D1Q5KWC=M78S79MJ_OCO=WW
M+M7.W,LQ9@P9A.,-*4>X4HSHQ3;LI&2P4Y&=Z-FQ6.>H%5L,0]"E1O4`WRHP
MU:X$@BO%]:AS<2$:YDN&<"?<0*7RKPVO*FE<Y6%)SA6<9Z=[DN77UJ^TD@P1
M.<QWX9,;JL=B8<3"TFCMM#4';4$$K(9;J3.,LO8[^&ZZ2=K)&`3-;,W#*W`\
M890X`N;LQ`!PH"""`JR!IM6K,7#0\)!QP0$!!C5J)1U=#[XD$(TEEF,P83TQ
MCHW,3RJPMQ72*SE2N56<YURV659=E]M:VMI9L9#!"(F;*EL;10,Q&KB-]2:G
M::E<&8Y[G&;7E]?7^82R7-S<.GD.(@.E<:F3"VC0ZO(0!04`H``JC%4J^,IS
MBMP&,H;':1G$/'8RAH3#6!6T\@WX+8V&&^CQCN(YB>3DY,:Y/VW+MG_H0[`!
MX#>04H.3D%!3=04Y%Q_O.;FM<UN=I)/XK]I=7$?"Y75-3V:FO*5WIKT`ES#J
M8.'2[ASI<.)C`L.8=Z<PKI,+PQSL.=9D2'.7EY>>^XK[JU9S86-D'8A9Q8JU
MK@;6M7&O)RU<X_2YQY25QG,\R+2PYA.64I3I'4I1K:4KR86,;3<QHY&BG'-<
MKRFDCJ@8;+",BY0SF+!RTC((F0`LI;RQS$Y#!5EEKDQ_!LYYB>1/<T]1L<(9
MZG%@%-F!M.];A;LI]EO>C<W8-B#-,S#S(,QGZ0XJGI'U[]V-VVM>^?WSM[N^
M-3M7>#"PT8XX]&Q,9'O/(PV\Z"`*(XZVE:G$H<6PTVI:,.+RK&,YSCESG/W<
MZO#:6MNYSX+:-CB*$M:`2.7;0#LJEQ?WUVUK+J]EE8TU`>]S@#2E0"30T`'T
M+$AMJ=M!JV-4,42JE5D4`6+:AI.$`F`E1X($1%AB/HE635%LC1E?`&1AW*^:
MP".WC\!EO">PNHN9>U>V!\,W73MN*&;7VECN-01=0KQ$,TX($!&BN-QCT<L)
M"QHZ*%8;SA&,H9&:1CD2VC&%2BO%8I]8I@A8%5A`((,XQL\D:/:Z%EPAB-CH
M0/"4<N<-#1L%#A@",(YK(8`;`S"&V&6FTD62ZA$T1-$31%%C;_A1J>WO$MNQ
MQ-QULMLC9MVJZ'6I*K2.('U8A0Q"8D[+T2H.&%FUDNFQF5<I!;R$H>4GF_@I
M5C$6V26-IFN89S"UWKMS3&2:C8R-@H.QWL3.[4]E=^;,KF>QM<ND+?5X:X=F
MW:Y[MI[.U[OY;E*?677031$T1-$31%`S=K8_B#W[A<4;>"'X8+7M^BU1]@'C
M67=]H*2&;C7Y<9I:RJ];89\R3S$&HPE73LC(?<<YS+J4-YS@;NQS"_9T%XRU
M?;XP:?B@[*[G#;0[Z5KL*\JU!IC5VJ[;]KU#;9'<92)VR!H-\QPPEX&V.5A+
ML#AMQ!H<35K@`KELMM)Q&[)P]5V^IL9PQUO:J)L;9<C!Q3F]\O.,04I/8D;2
MF&E[799AUV<)&>(<%64I0S9#J4J;Z)O\.]E:9C9,BMX6VK;4.V@=*30FKJ%S
MCMY:5V5[07-IK3^L=,V]CE&709)#D,<U7,;ZZ]X8Y^*7`^61Y+R"XM+JM#B`
M1A&V<.LVO3TT1-$6(7NE0NX=7D*C8$97%R+T44YR"Q9V6RX28`GHLCJ4Y'2\
M,;@:4C&7,LEBD#NX3S7&UHSE.2+2`7";MI'-6$0(^U-1MH3/IFH=PJ`,B2TS
M4-'U\-I0!U<*8P%6(F'#:CQ.3J>,#)R2T3E;N7"*][<<.U5VVFV)R*E91UZ.
MZI'P@+0<%%Q495XV$D86+K20(Z*9;4*)F5?*Z1K+&</Y2AM+0R>KY(K)!\).
MT]=B("M1GK&S4JPNINP=3Q(@(A(]^G21TM%.#88B69%EIP^>EUO#H(2)GMDG
M"&D8;"ZH19/MQP\43:V:@YNK/2K3T!49NF``K'JX<4F,LEG;M\X2D"#K4.T(
M=)S@[+KW5N@'6IG"\M9=6ZXX1;WT1=PX[9;R!GB!A6GN<A;YF'<C(3S%9STV
M&&2'<I5R<WN(5W<_[-$5:Q2J\,PR,-+4L<8?+"F!V!)-IAA0S[A(V66FZ^EM
MO(Y+JG$<W&.8M658Y,YSG1.ZB:57D.8=1+4M#J<-)PXD232YA++K#[.,+Q7\
M*QAI\5I:?Q5MISCNIQR$[J[5U&%=<R\[.5!QY3B'5.K8EEN*=:9<';<RM4!E
M67&QWEH3GEY<(7E..YG.-$[JZ\TR`5C"53%-RG#66,)R+*9QAC*V7<LXQFO\
MG19<';5S?N<Y"<_=3CD)W56(KH#>,I;LU90G*UKRE';2<96ZM3KJ\X3!XQE;
MCB\J5G[N59SG/=SHG=7/L$/X4US]U.>\>B=U.P0_A37/W4Y[QZ)W4[!#^%-<
M_=3GO'HG=3L$/X4US]U.>\>B=U0LG_J^^#.R3LU8I[8G:^7G)^6DIJ9E7X^4
M4_)RLH8\=(R#RN<WSG33'UN*SS4\N5?<Q]S6"DTSD$LCY9,KB,CB230[234G
ME[)6[V_$;7-K!!;6^IKEEO&P-:T$4:UH`:!LY```K3]G#P._J\;4^CI7QNJ>
MZNG?9$7,?K7-\3M?]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=K_K5=
M>,/)3[.'@=_5XVI]'2OC=/=73OLB+F/UI\3M?]:KKQAY*?9P\#OZO&U/HZ5\
M;I[JZ=]D1<Q^M/B=K_K5=>,/)7-OZM[@<6KFYX?-IF\<BL\]R.E^;^"E2L)_
M`6M7*O..3'<Y.7..7DQW=/=73OLB+F/UI\3M?]:KKG'DKA]G#P._J\;4^CI7
MQNGNKIWV1%S'ZT^)VO\`K5=>,/)3[.'@=_5XVI]'2OC=/=73OLB+F/UI\3M?
M]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=K_K5=>,/)3[.'@=_5XVI]
M'2OC=/=73OLB+F/UI\3M?]:KKQAY*?9P\#OZO&U/HZ5\;I[JZ=]D1<Q^M/B=
MK_K5=>,/)7-/U;W`XI+BL\/FTR<HQC.$*CI?G.<JDIREOFK4GE3C/+GESC')
MC/[/<T]U=.^R(N8_6GQ.U_UJNN<>2N'V</`[^KQM3Z.E?&Z>ZNG?9$7,?K3X
MG:_ZU77C#R4^SAX'?U>-J?1TKXW3W5T[[(BYC]:?$[7_`%JNO&'DI]G#P._J
M\;4^CI7QNGNKIWV1%S'ZT^)VO^M5UXP\E/LX>!W]7C:GT=*^-T]U=.^R(N8_
M6GQ.U_UJNO&'DI]G#P._J\;4^CI7QNGNKIWV1%S'ZT^)VO\`K5=>,/)7/[-[
M@<Z/"_H^;3<N5J1T79TOTF,)2G.%Y_#YG,5E7)C\+EY<9[FGNKIWV1%S'ZT^
M)VO^M5USCR5M':7A0X=MB9N1LFT&V=&H$[+Q2H.2E(`0]@LN(66*>N/=<=P]
M_P!NLP)IS.,<G*IM/^S7<LLERK+973V-@R*4MH2!MI4&G.`L1G.K]3ZAMH[/
M.L[FN;9K\8:\B@<`0#L`VT)'=6_>JM^7!_?)]K:RBUJG;3JK?EP?WR?:VB4[
M:=5;\N#^^3[6T2G;3JK?EP?WR?:VB4[:YK":3A&<2("^>CGYPC)?*WGG*3S%
M\X1..?C">7N<N.3..[HE.VN'56_+@_OD^UM$IVTZJWY<']\GVMHE.VG56_+@
M_OD^UM$IVTZJWY<']\GVMHE.VG56_+@_OD^UM$IVU-`;^;#_`+/\`U_TTZA7
M49]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57__2^V/B&_)DW^CK_>JT^U_&Y69X
M*WK4_P`EJU_E^&_PX;15/*M);O\`Y2@_V&-_7Y/4A4=RK56BA-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T16
M:QN2+->G7HAQ;4LU#2CD6ZB.S+K;D4`OJ"<1$I*"5*+03A.<#X>9R_G',YZ.
M=SL$4$Y7>#B/:J5GCH"EWPZ8A@!2XFQF[>S)$W858OT*P8=&NF;;T:'=`Q!&
MD1O99%7!F4=7<D48(`2U($$6T\V#>FW!77"3+A1"HO=K;J%A4P%$!9);IY5V
MCX"Y,-D7RIV>/M`#%=,=-(F@6\AIRSAX=UMA+B5$6-PV]?$)-LP$HC:UR+`)
MS3&IF*E-M=Q1)?#LH+>)"TK'>D)2,<C&8G-0&`1EX)]*'Y@8A2G$=$R21?@N
M]?$*_BOE/;6N#`D6+;&+EF?BUW%<DR@[DJV9MSD>*Y)C=A-T`^'%C2SI'&`E
MM*5*HRH<D`,@BFOHB:(FB)HB:(OG$WK^M/O].WDW:J,)ODS'0M5W-OE;B(_X
MJJ^9U"+@[5*QD>'ULO;DHLKJH@J$=(ZZXXOF\Y2E9SG.?E#4&L>+,&?9W!EF
M94RUEY,V(='9FD0D<(Q5[,?@4\+OO^[;5?H%I#A%P6O=)Z7O<XT]BS>;+K9\
MYZ>^%9GPL=*:,F#!5Y<:,`:/L@"BUE]KGNE\OS/S15;]&6L1[[<9_:?^W8^C
M6Q?!G@+U;_R,Q].GVN>Z7R_,_-%5OT9:>^W&?VG_`+=CZ-/@SP%ZM_Y&8^G3
M[7/=+Y?F?FBJWZ,M/?;C/[3_`-NQ]&GP9X"]6_\`(S'TZ?:Y[I?+\S\T56_1
MEI[[<9_:?^W8^C3X,\!>K?\`D9CZ=/M<]TOE^9^:*K?HRT]]N,_M/_;L?1I\
M&>`O5O\`R,Q].GVN>Z7R_,_-%5OT9:>^W&?VG_MV/HT^#/`7JW_D9CZ=/M<]
MTOE^9^:*K?HRT]]N,_M/_;L?1I\&>`O5O_(S'TZ?:Y[I?+\S\T56_1EI[[<9
M_:?^W8^C3X,\!>K?^1F/IT^USW2^7YGYHJM^C+3WVXS^T_\`;L?1I\&>`O5O
M_(S'TZ?:Y[I?+\S\T56_1EI[[<9_:?\`MV/HT^#/`7JW_D9CZ=/M<]TOE^9^
M:*K?HRT]]N,_M/\`V['T:?!G@+U;_P`C,?3I]KGNE\OS/S15;]&6GOMQG]I_
M[=CZ-/@SP%ZM_P"1F/IT^USW2^7YGYHJM^C+3WVXS^T_]NQ]&GP9X"]6_P#(
MS'TZ?:Y[I?+\S\T56_1EI[[<9_:?^W8^C3X,\!>K?^1F/IT^USW2^7YGYHJM
M^C+3WVXS^T_]NQ]&GP9X"]6_\C,?3I]KGNE\OS/S15;]&6GOMQG]I_[=CZ-/
M@SP%ZM_Y&8^G7T`<*^X&X^Z&R=4NNZ$&W#S\NUAZ.-2PB/<MM<6,,_$W!^"0
M.,F`7,(>5R,80A#N&^L-MM,O-HQ]'</,UU'G.F;2]U/9"',"2`[8#*P4PRE@
M`#,6W8-CJ8V@,<T+XIXNY!I'36MLPRO1>9&?*F@%S:EPMY23CMQ(23*(Z`XC
M5S<71O<Y['$R(UO"\Q31$T1-$31$T1-$31$T1-$31%-L7^;#_P`@U_TTZA<B
MC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J_]/[8^(;\F3?Z.O]ZK3[7\;E9G@K
M>M3_`"6K7^7X;_#AM%4\JU!NPJ#:G!GI8LX7+4(PI2V!Q%C(82;(YZ1UXDT7
MH\X5SN7N<W&,8SR_[(<YK&ESW`-'*3L`0,=(]K&-+GG8`!4D]H+5V"J;G*DX
MEY+*DC8,4G`T5G*1,XY<%*QVORX&SC[B_P#A_P!^J]-%4CI6UPXN4>#O^CM\
MBMZO.`"8'T+\/@GPO^W_`/;M<JY]-4<=7Y925QUO^:_]I&?]S^!TG_;_`/W;
M^&_@_P`+\'E_![OW-3TD?>=^WON3:-O9V;]FW8HZ&7\7\)W>>%L/>[:=]NV[
M-O97?T=:\KG/1P'OIJZXMB='6O*YST<![Z:)L3HZUY7.>C@/?31-B='6O*YS
MT<![Z:)L3HZUY7.>C@/?31-B='6O*YST<![Z:)L3HZUY7.>C@/?31-B='6O*
MYST<![Z:)L3HZUY7.>C@/?31-B='6O*YST<![Z:)L3HZUY7.>C@/?31-BQVV
MVG;.A5F<N=TM)%8JE:C29>>L$TU%`1<5&B(RX0686_+(;:;0G')CN\JE9PE.
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M<IC;R/N!!=WKT>-*SE89%`5+14>9T61BS1NTL98:>02RM/.[O1D,KY.8\TI>
M2ER?-(,MM\YEL9&Y7,\L9*1WCG#E#3V2*'NM<.5K@.C'F>7RW\^5QW;#F$3`
MY\8\)K3R$CL`U'<+3R.%<*-W_P"'R/W,<VA+O<HW>F0AC"H]%?>(C0,E\JF0
M96Q#//5Z'EE,Y;=ZH64R_EI]I>$YPXC.<G%I#44V2#4,>6N.5%Q`=5H<ZG*Y
MD9(D>RM1C8US:M<*]Z5T)-39'%FQR1]^!F(:"6T<0*\@<\`L:ZE#A<X&A!IM
M"W(WZKNH0ZT=-.-.(2XVXV!'+0XA>,*0M"TRN4J0I.>7&<=S.-:V0YI+7"C@
M=H6=!:X!S34%<^CK7E<YZ.`]]-0FQ.CK7E<YZ.`]]-$V+4-MWKV>I%U'HEBE
M;4#+D5L>V9*S"1F8EB#>E#HETH@U4XE3>0GP%K>3S,YPSR*3SN16$DV*P37$
MMP]P,FU&&V>X*5@4TN3/9I$EV17TQGJPJ4$GY0A3`<;,Q#%P!=-CE*S(@M.9
M40PUA.=%*O$EOOL="6BX5.<LMDB)"D$5P2;),KJ,QV2[+6Y:X,-!D"GDND-1
M-6A7CY(C+:!0!?X1UU*4N902BXJW^X?5@2QT??#9=R&'&>.C8Z,%5)LNFUJ?
MMP@9`Q4@(F.*7`U:2>=ZVL=L/J)"2E,Y9=P@BRBN;F[.VV5%A*];961E#H$F
MT!"IA%#Y,KX<D/$D2HKI9`[!`J2S1E)RA6<K'+&(3C+!+#KA-BM$EO/LI"V"
M:J\U9[!%S4+*@PJQ"*ZI_,E)2<179F."AU`%F8D9"1'LK*!@T?\`>DK8)RTR
MML=Q:2C8@.]NP<G(AQ0&X!)1T@2","TU$\YLO$H7&1T8:P3UC`KD/)R\P,",
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M;7YEUK'<R2?C_P!J$X__`-C2B;.VOSI6?*COW*/;&IIVDV=M<<]14GG9>-R[
ME:N=RLLY3S>1/-SSNLY5E>5<O+W.3DY.[HFQ<.0+V0KP+7C]$V=M.0+V0KP+
M7C]$V=M.0+V0KP+7C]$V=M.0+V0KP+7C]$V=M.0+V0KP+7C]$V=M<E)`Y$<Q
MTS.>;^'SF&<8POG*[B.0C/*GF\G=SR9Y>71-BX\@7LA7@6O'Z)L[:<@7LA7@
M6O'Z)L[:<@7LA7@6O'Z)L[:<@7LA7@6O'Z)L[:<@7LA7@6O'Z)L[:FD-_-A^
M3[G0-<G@TZA749]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57__4^V/B&_)DW^CK
M_>JT^U_&Y69X*WK4_P`EJU_E^&_PX;15/*H8<<4/*V';3<F#@X\N5F);:B9`
MC8T!E9)AQI*9EM@45AO"G'GWG%8PE.,9SG.=:OK:UN;[2&I+.S@=+=26<K6,
M:*N<XM(``&TD]@+=N&M]9Y9Q!T;F&87+(;&',8'R2/(:UC6O!+G$[``-I)7E
MA';-;F1L_8#)FE6"4@8@:F4E<<T"](>LFTVTFZ^UH#48*QEO&)1^S56N24E@
M3'(HH-W+6,.?_P!SQ:#2NH(+V]EN\IGDLHFP080TNZ6SLKRT:&`4[\RPQ2RX
M.5[#A`=]KZ.NM=:3NLMRV"QSZVAS&=]U=!Y>&=!F.8Y=F#S(XU_#$%Q/!!TG
M)'(W&2W[%\=KF\;CNW!T7M*3'QFR!TU9(J/C(VQUU@I$[O2PI[%?K4Q+760?
M.,VW@"O_`+4U)J9C!YK#;*L-MMLX[CK#53G9#-;Z9<RWRA\DK&L;+$#TE^*]
M'$]\[BYUK&_\$2EL39\+#A:UBQ[,TT,UFJ;>[UHR6[U!'%!(^1\$Y:8<K-.F
MGBCM6!C;Z:/_`-AT`=.^U+I!C<^17Y[;A%BJ>]3PVT$JW(34G6X*C4^U4B=D
M4HDO6&R0+>\UAD[$$D&QW58ER+/*?2IW`4.&,.\X[G&4X[K\A%]EFK'1Z7D$
M\LD4=O!-;R.[_I98Q?2OE;AEGPSOD>X5Z.!D;'.<=BQT>J799G.@F2ZWA-M!
M%/-=W-O=PL)CZ&"8Y7#'"_'!:AUK'#&PAO2W,LLC&,%"I*;<;9#[<[N6`6O1
MLV-2V=E]K*_%%R$C,2D;B2KT[?P28V-=E"RQP'!H=(+SXHN&6>D?R^IOI7W%
MKW[(=/LR+4]['8V\S<I&4V<;'.<][,<4ERTL87N<&D,Z-SF,PMJ[&1B>XGRK
M5.K)=4:*RV;,[NW?GSL^S":1K&11OP30V;VO>(VM<\.EZ9K)),3L+.C#L$;6
MM\]A)'B)D-ULW8X??RW5F/AKQ*VR@4R?WGC(0J3K]2XKW+13*W:86Q1NW_31
M6[0M;KH$:,&W9U/XC'AS.HB%-/;]LHO+5,&PTOB!I]3X=:)3[`3*%P-VIZKY
MN9+V;</<*2F2W:[=2;LY<ZR8;!2<CMZ1.%-+%ZQ:.:,M0C&!D-,-8U&S:BBU
ML:_Q!5BS\,B;`?Q#&RT_2MHH?=>+W;F+BU$.;D#;>!8N(CN;$1+5VS-$461F
M9EC$'V<4%,U1]5BR;)%C99DTVHO7O5$31$T1-$31$T1:UW@VFH^^NV=QVDW'
MBD3-,N\2J*F`\X9R\UELA@^-E`%DL$L,2T'+!L&ANK;<2R6.VO*5<WDS5[&O
M:YCAWI%%9KBQP<T[0OFNV0X#&]QN*@_@EW,WRM-VV/X2U&;HQM+7%XCXJP8L
M]J&7)UT0)JQ%'U0<SM$!;A2BI%_#P;A3&!S37RL^>Y4;F?5>;9-,2<LL36(4
M[,D-J]VWD\*68"FQK)'Q-`91HVV^,461V.8QM'KER*2&O89),UNSZ&,)KRN:
MUYJZI/T8[OTR\S5'A*MM.UD%H*;@VY>MUVS8VUE):C18A:'*M4KB$5$^I;ZC
M&PLJ='(#<S',/C,/,.O-N(S>M;35=]IC-+31&96UIJ=X9T,MPUSHFTE890X,
M#G`NA$C&N`)8]S7T.%8?(9\IMLVM)\\M7SY8TNQL80''O7!A&(@'"_"XM.QP
M!:=A4`:5LIO=`V^J0<M`;QB,@\4RMRIG;\L<VV;75ZK"RQ!3=MG^).?$GK)?
MK;U%QF184JRF*=4_V`XUG#;F&OG;1FC.)%EQFMLWU9IPW,<4`=-FS+US;>:1
MUAT0$-CTXIT;G>J87VP<YL7K;G])*:^OYUJ31]QH/-+/)<R]7DDC9%%9O@:Z
M6C;N*5^*80EK&R8'73BR?O7O%LQG1MJO6C7UDO"5U/X?RR[@932",MKZ!3Z%
MN,I=YN>9EU#:VEJ;PK[N,*QGD_9U9F#$WI`2RNVFPT[7+_T578L+L!&.FRO)
MW5!B<X<2Z3>;QOS282IQFZ5OBI@(^S`2=X/+A2)"/0$B4A:TY"6*$()2O#CW
M_<L+&0MS^%3EI*$L^L66L(LURG*])9G?S.R*WD8YL3VQ-#PUV+"^4/C>!R#O
M7!Q`[TXB2[SFZTS+EV99AJ3+[*(9O.QP,C72$M);3$R,M>TGE/?-+03M%*4\
M\ZY1-\HZ\#U6#N)LW)R3Q\G+)DM[BQ61.F:41+6>0K430FI8EIG.7%&O.`\C
M?)SFTN+RC&O9KW--,R92^_NK*&.VC#6LP60<7=AD37ON<()V!C0_;V2!4KRR
MUR_/F9DVRM[J5\[R7.Q75`WLND<UL&(@;<3BWZ`30*7])XQ.&BE1T8P'Q.R4
MNT^&$QD8C:'=.?&,--:/=;<:ZM5,$X.+4&^\C#?1.N,H0K*.BZ/&O-LTX=:[
MS26X=+H*&,AQ-1=6L9`&$=F:E!5H-:@$D5Q56^9?KC1^7QPMCUC*\81L-O</
M!)K_`/Y5J:$CD)%-E*+=[/'CPK@0;<K*;T1YK'*;_P#<`Z/?VD&I":&*)4!'
M,5P\HIH)DUIMQ;.74X?PIO.<.)6VC4W\)M?RW!B@TP]AV=Z9[<X:D@8B913$
M02`:;*$=Z03L3>)&C(X1)+G[7#;M$,VVE":`1FM*@&E=M1R@@2NK-CAKA6Z_
M;:Z7F0K]IA(JQP1ZA3`E&PTV`/)QA:@I`<0\3)(12%Y:?:;>;YW-6A*L9QCS
MZ]L[G+KV[R^\CP7<$KXWMJ'87L<6N%6DM-'`BK20>4$A;K:74%]:VU[:OQ6T
MT;7L-"*M>`YIH0"*@@T(!'9`*P^Z;/;<;AG-R5RK34V8TD!#;SLC,"X2B,C+
MM#!HZ("1$9RAN,W%F6E8RG.',&<J^<IIC+75785@*X=]GS6R&BJH\^DS%ER;
MERSV_+D@_<`JN!9SY%[M_I9"5FF*;'J?,>4X4I]MU[I,/$DK>(HBUO<CATW#
M@XS>"S[-3,1.;B],,63'2,B_8CRMTDS6UG8MT4](U*95+OPU;F41[!8[S4+!
M!IZNX$24R#DBV3M>CASW#F2*Y7-L[S`D7ZK6*_R+%G19H%A;44[8MG9X0V-?
MM#AT!.DQE\+7A.!AVI`622<TZ\\C#C1%A%=O&RM:F,%U3;?<..OM6$@J2$XQ
M?I4R/=J3,W`7`Z/'EIVWFK=K<(V]'-G-$1R"ECO-A!-OC-*RR19?MQ2=A=]1
M6IF%J]UK5@A#=O;PN5>N=M??*Z`^35$$PL^FTF8DXT%R%E8%EQQ`QL0V*H=E
MH)8PZ62+=PO#9L['.&D0U9-A#3(L6(:-BK3;!WHL2/M0-WC>Q&E3;H40['6V
M,'.94PTCD<:PC.,M94VHBW8<TX^$8PRI:7GA2&FE()<#6EQQI:$*08TT^Z*O
M"LXY'$H6IO/X6$YSCDT10,%VOXC$Q::]%8'KE58DJ47&Q)4M7<%.1\%9AI*U
MO6C$+UB.<NL\:(&0R1&=6B#HX8MPH020/=8419N!M%N)9`["'N8(!94O6'9Q
M<>-./0$E"]C4O=ZS3\VB)C1Q$LB"YVPF1X][!+6"32,%-+RMA2%+(K8%4.*\
MELLA^W/03L=#U<6&BQ#:6]'G3$+M':`)LDQ*J^;G$5-;P`PQK24J'<S&ONH<
M;:1ET=)%S]4N+!;!9"[F6T4U(41$<(P335MDK9`GVMQ"S5.1B&Q8*1N:1#XU
M:<OD!P3B$+CB'&GH9PBFMHB:(FB)HB:(OGOXC97C+;WYW<13-K>,.5J:+]9$
MUV2IT=9':J=$8D7L!%5]P6R##KB7F.3+.4-H3E&<<F,:^5-5:2XFW>I,[N<L
MS"\;E\ES(Z,-EN`T,+CA`#1A`IV!LW+[YT#J_@I9Z*TM:YW!DYS>.QB;,9(K
M4OZ0,`=C+^^+J\I=MWK2W;''C\CO'/Z*M?YU:P'N5Q;]IWWGKKR5M_OQP`_M
MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?F;-.V./'Y'>.?T5
M:_SJT]RN+?M.^\]=>2GOQP`_MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR
M4]^.`']MD?F;-.V./'Y'>.?T5:_SJT]RN+?M.^\]=>2GOQP`_MLC\S9IVQQX
M_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?F;-.V./'Y'>.?T5:_SJT]RN+?
MM.^\]=>2GOQP`_MLC\S9IVQQX_([QS^BK7^=6GN5Q;]IWWGKKR4]^.`']MD?
MF;-.V./'Y'>.?T5:_P`ZM/<KBW[3OO/77DI[\<`/[;(_,V:=L<>/R.\<_HJU
M_G5I[E<6_:=]YZZ\E/?C@!_;9'YFS3MCCQ^1WCG]%6O\ZM/<KBW[3OO/77DI
M[\<`/[;(_,V:=L<>/R.\<_HJU_G5I[E<6_:=]YZZ\E/?C@!_;9'YFS3MCCQ^
M1WCG]%6O\ZM/<KBW[3OO/77DI[\<`/[;(_,V:=L<>/R.\<_HJU_G5I[E<6_:
M=]YZZ\E/?C@!_;9'YFS7JI]7\%Q4/1,W-[T9N]9H[I!@L91]X0BW]QW9AO#.
M,RT6Z7)EF5^O9Y>[A]U]HE:5=&.C*E/X]?X69+Q$RN:\&I<S+LG^RR4ODE+R
M!M8Y^%T;!V0ZH<:X6`DO7S?QYS[A#FT>7MT7E4?O#LQS6PCBMVQ@GO9&1@LE
MD/V2W"Y@ICD(`C7I+KVM?,Z:(FB)HB:(FB)HB:(FB)HB:(FB)HBFV+_-A_Y!
MK_IIU"Y%&?8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55_]7[8^(;\F3?Z.O]ZK3[
M7\;E9G@K>M3_`"6K7^7X;_#AM%4\JT=OA:*W47WYZSL1[41#UGM.3EY`J1'9
M`CQBI)Q]U[`9#:>A80A2\YYN5=W/^[77O+RVR^TN+Z]F$=I$PN>X\C6@5)/:
M`7:L,OO<VO[3+,NMG37\[PR-C?">]QHUHY-I/(H_9WXV7QT_++U#&!JK$79Y
M7;<OS45:P.B,P4QS^N\U;$P](,(&2G.77UOMI0G.5IQG$'56G!CKG,'>VS+@
M]]__`$R%HC?]#RYH8.5Q<T`&H6>&A=8'HZ:=N>_O)+4=Z=MQ"'&6+EV&(,>7
MD]ZT,<7$!IITYW_V3P]7V,S-0PJTC"F0+G;,SU4\<Z4>@Q%X,ZYU093\TPL/
M"'EMKZTG+7)TGX.J^]NFL=BS]Z@K<M#HSBV.#GF-O?4PBL@+*.(.,8?"V*XT
M#K(QYE(--W-+-[FS##WS"R,2N&&N)U(B)26@CHSCKAVJZO[S;0"IL"B)NA-8
MJA3`5DY]O<PJ$,))ZB.)(I[9YPQ3Y^,CH;5CGJ)2IK&.D3E..P_4>01B^+\Z
MM1ZLX-E_%9^&XG"&NV["7=Z!REP+?"!"ZD>C]5S'+!%IN]<;QA=!2&3\5K6X
MW.9WO?-#._)&P,(>>](*KXW=+;&8F&*]$'4J4G"H@>?&B8ZUO&GDPA;3!`LL
M.,-,.N/QY`Q+3J'4XRA33J%XSS5)SGGM\ZR>ZNF6-KFMO)>.B$@8V1CG&-P!
M#P`22T@@@C800>0A=:ZTWJ&QL9,SO<BNX<O9.872/BD8QLK26NC+G``/:YKF
MEIVAS7-.T$"^$V>IQJLM&1U?`5T)QF6R9HX575P6VRY,O*'9-O/0AM$)=?<_
MX6TN84O.,*QG.36$[B[Q[#72V!"A8B&)&/PE0)`\M)/,&I6TM]*A'FY)39&%
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M#"]I/-/!-:V[+NZB,5JZ,R![P6L+`Y["\.-&E@<Q[2ZM`YC@35IIZ`U^XU*U
M0,):*[&P\Q7[)$1L]!2P4E,.ARD-,!LR$9(B.=?QT@QH1"'6U<G=0K&=<RXN
MXK;'UG;6)LLS<XK:RD1EPL333%@M<?&J"LLZPP@5IAF9G1G&Y23:9:!92A+[
MJ\)2RC&.XA/(2JRGM.*^#@/GTQ[?T4=Q5';PO5NI]C,]4YW/ZKVK.]6Y_+SN
M?T':71<[E[O+R<O+HIJJ?M.*^#@/GTQ[?T4=Q.TXKX.`^?3'M_1.XM#UOBBV
M:M>\UHV&AX]#NX-/C>TIH%QR60,RA.65/,)=[54[EY@<L=U6<MX;QA]"<JPY
MRHQMEYHO/K#3-CJRY@:,GN),+'5VGEH:4Y"0X#;7O2:4H5KEKJO)[S/[S3<$
MI.9P,Q.%-@WBM>4`@G93:!R[%IASB"X6F-Y+M0H[8P63/LL29!;C[F5K;N9/
MKLZ\PN7&F:K9K#'C8,M@T?EIU@I3&9!ADIQ8[O,6AWF[.W2FN7Z;RO-ILZ++
M>"1LEM;R76&1@.$LEBC<^D1=L<W%T;BT![:@MKK[M1Z19GN89='E0?-*PLGG
M9;U8\C$'1R/#:R`;0ZF,!Q+30@TVS5]BN%7HV)RJ</VUHB5&LFM$@P9L<ZB2
MCN4=@UP=3HSS,D-A&<)=6C#W(K.>7.%<N==O]8ZX#WVV8:CO7.#2TATSG#"[
M:16I&$[@:<RSEGIG218RXLLBM`VH((B#=K=@-*`XAO.WG65";*</0(S`H?#_
M`+5#-"KAW!5-5QE)`JJ_FN*AL"EXSUL9N/74(M:$(6E'/!95G&5(QG71?K#5
M<CGN?J2])=CK^-)0])TF.HQ4.+I9*[.1[AR%=MFF-.,#6LR*T`;AI^$RHP8,
M-#2HP]&RG;:#V%LZ,]6X:-CX>)J$3'Q<2")&QL>(5+,B@QX+#8H88S*#\(:'
M&':2A"<=Q*4XQC6!GFFN9IKFXD+YY'%SG$U+G.-22>R2223O69BBB@BB@AC#
M86-#6@;``!0`#L`#8%'3=7B<A=J-P`JO+[;C%5U^M1LV]8QYJ7R3B4-7>#LU
ML.*R3C!<H16=OY0\;E>0AQ(3J591R)RKB7)W%B-FXTZO!R9@XNQUJ+BH'-N9
MM$F1,PHCXTI1FZ$198"#CDWDC,Q(1HUYY5$.O"1SJPU8%(*;=;=R16V;XAME
MJ7NAN%63.'^(),HF*^!%S=8`BE2TT)![>+W,M1(SLU+UP5$/MK$5&(94@<P@
MA!F!&FV,*91S"*B!XA.'C(DI,5WAO+C)G;MAD$)3U1B*^F,='I6Y&YC@$9*C
MVID4R(@%T24;+Q'O$,8DG4*'P^ESI\$6?TG=G8/<ZTPU78V+BQ3):IIW6BI.
M=C*B=$X1'2\!!!=.7`V^Q/Q-S0U8(TAD8EI@MH0EOERAU*FD$5E8XD=E:)<Y
MNKU_9H%?:5CHM9@K#MKZOJA;:NU5R%EZFR;(XMD$@53K\W()$=(_^WK'#?6T
M1E>'FFRCN*]U_C)VLLDM&1(.VMO9S)MPIC<@:J,8C!X6?N,'08^>?)1?W5+C
M\6J?;$(;90Z:(ZR^EYAM3*TX)W%*;M.*^#@/GTQ[?T3N*U0MPIUD`Q*UT6MS
M\6HN3CTR4+/F2H"CX63+A9@+!@,J^/DN)F(]\0EOG<]@EAQI>$K0I."GN*H3
M9*TL0@],7"*!$4<@HQ,Q(Y$&7%OOBR:"",2>6651Q(KK;^%9QEEQM25\F4YQ
M@H[BM-?W#V\MF'%59ZG65+($+*NYK]J=F<-1=ECTRU=DG,QTR3A`$_%+P2$]
MGD;*'SAQK*D9Y=%/<5Q5:ZFE,BI0-?2F'*:!EU*G#\)BS7Q03F`Y'.93D!*>
M"DQGD-N\U:FB&EXQS7$YR4=Q<?6ZH=;ZAU.N]>[4[#ZEV\;UOMKL7UD['ZMV
MKTW:GJ[_`-_U?DZ7J7\/S>B_"T3N*J,L-=CVD$'Q$."PX4""V\9+28S2S9,T
M>-C0T./22$**D)$MH=AO&>>Z^ZA",94K&,D[BJNTXKX.`^?3'M_1.XJ<:=@3
M&U/!PL24T@@H5;HTI*/MI*!*>!.&4MJ14E)`9H[C+J,YYS;J%(5C"DYQ@G<5
M1VG%?!P'SZ8]OZ)W%8'YJ$9>=:==B1W$+4E;#DIA#C*L9[K:T.%X<2I'W.17
M=_VZZSKRT8XM==1APY07"H_FNXRPOI&M?'8S.814$,<01O!HNKMZ!\KA?2S?
MMS4>O67]Y%XS?K5OVW,?9T_B/^I.WH'RN%]+-^W-/7K+^\B\9OUI^VYC[.G\
M1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/\`J3MZ!\KA?2S?MS3UZR_O
M(O&;]:?MN8^SI_$?]2YHL%?2KE41"+QR*QS<RZ,8Y<ISC&>5)N,\J<YY?]_)
MW>YIZ]9?WD7C-^M/VW,?9T_B/^I<.WH'RN%]+-^W-/7K+^\B\9OUI^VYC[.G
M\1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/^I.WH'RN%]+-^W-/7K+^\
MB\9OUI^VYC[.G\1_U)V]`^5POI9OVYIZ]9?WD7C-^M/VW,?9T_B/^I=K,O#D
MNI9'=BR'E\N$,L26'G5YQC*LX0VV4I:LX3C.>YC[F-69=VLC@R.YC<\]@.!/
M_55DL;V)CI);*5L8Y26N`'TDBB[296*CVL+/;`$0^\P*P\6:Z,G)3[J4,L-*
M<);0X^0K\!".[E6<]S'+KL+J;-R[6RA76T.M##N-.(2XVXV^^MMQM>,*0M"T
MO92M"TYY<9QW,XT39N7+IF/(VO"D>-T2HW+BDH5>7$H&'6II>&W4I??5EMS+
M:'<(<QA[.4+RTXE7)GDSS58S]S.-$V;D<*%:;6ZZ,.VTVA3CCCC[Z&VVT8RI
M:UK4]A*$(3CESG/<QC1-FY<4&!N*>0VP,XL=S#+Z$$/+4PZIII_#3R4OYRVY
MEA]"\)5R9YBTY^YG&B;-R['#`VF5+=$&:2UTCKI#A!*$H:2C&5=)E3^&T-MX
M3E65=S[O=SR:)LW)TS'D;7A2/&Z)4;EUK,#;4RAQ@9M9#F66$+(>0I]U+3K^
M6F4J?QEQS##"UY2GESS$*S]S&=$V;EV=,QY&UX4CQNB5&Y.F8\C:\*1XW1*C
M<G3,>1M>%(\;HE1N7)1`V<(Y`&4\U/(K.'BL\]7.5GGYYSV<8SR9QCDQR8[F
MB5&Y<>F8\C:\*1XW1*C<G3,>1M>%(\;HE1N3IF/(VO"D>-T2HW)TS'D;7A2/
M&Z)4;DZ9CR-KPI'C=$J-RFD-_-A_V/X!KN?_`"TZA749]C/XV9_MF5_KQ6I/
M*/I5G>#W`I/ZA57_UOMCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T
M53RJ(7&35)>\TF\TZ`0PY-6;;.3A8M!3Z1AUG'YF!QTO$*PI++>7%XY59QGD
MQK7]69;=9QIC/LJL@TW=Q:R1LJ:#$YI`J>P*]E;7H/.;+3VM=+9YF3G"PM+V
M*60M&)V!CP74'9-!L"\X8SA=W*@;!-3XJ8&3R#,P1M:"<E%"-'UG;G=+;B;I
M-3*6MDC`62Z51EJ4M27&FCB.:K/-SSD^56_#O/[*^N[V,0R%DL;HFE^$.BM;
MNUDMX3L.&L%N:G:!(ZAV;1[G=\7M*9CEEAELQN81)!*V=XCQ%D][E]]%=7#:
M%N/#=78``(<Z)E1MV&[9V0WM-;E8N3CX$M-LKY55+G'9^)&S6HYS>6;O3$@\
MQ"UR+;G95FO'HSEUD,51,CG+CG,YRE8[1TAJZ5MS;7$$+A<P&%TAD8.B:;Z2
MX#B&1,$CQ&X;6L9CEJYU*DKI#B!H"!]G>6ES<L=97+;AL0AD=T[QED5H6`RS
MR&&,S,(#72R"."C6XJ`&YC[#;I1U@JT^T'`FXVPF3BHH3%G>8=W!$D]QK+<7
M'GU.PN6H,L*.FF>1)"GL*.2ZG"L-X0^OL,T9J."]RZ];%"_]NE<6-Z4@W+7W
M4LY)K'2-S6R-V.Q5D#A7#1YZDG$;2%UEN<9:Z>XC_=X&-D=T`(LG1V,%L`*2
MUE:]\3JE@;2(L-,1=&WOV.X=-QML+A7CI*6'=BPY0NQSI`EMF38DQF5VOB:<
MY41*D2`,!@Z#LT4T0Q,Y2TZ[&,H8Y$<Y36+Z/T+GVGLTL9KBY:;=LAED+9I'
M,<'VC(#"V$M#<4<K`YL^QQB:&4%2T<?$'BAI;5N1YG;VEDYMV^%L$+76T39&
MF._DN1<NN6O<_!+!(YC[:KFMG<Z2KJ!YCM?>%W=2]TOB-AW]M*M=+/N?3=XZ
MS4+;;7@80ZG3^+KQ4/AYBT%+;E!XZ]A;KQ3T.\.4^!@:1/;/P.T,TT;[)7DV
MKYY6TSN&JT/"L6E.U->DFG+5Q2656RQEGBX2/34MV-N+3`0^W1DE#]:K(!FX
M-F+P=-/B8)8C3)HKF$%H9R0_%>VI7;M7PX6>L;D[*6P?;8>KOUZS7F];GVZ0
M*H<0].&W:&W_`,R58AJ339&WOTV%JU[W59)JL8'8I2)=A9>6>FU.SPH)I0GE
M4+(1-G-\3=M[[$WQ1M_*=XC*)NM5*A9[I'V=HS9NKW.CV</:CK<R(/%#6.M`
M0!66U&+='E)=MA9,IAM]P@545[B+34!PH7:/O%PFB=A*`)`YNSM\#AH>S5P2
M.F*S(;,\--*"VH@,GQ\ZZZBK7+:PV;4+,#!5TL^`BAL8ZD<\[&J[.5%)C@QV
MQO&T]+N-4N8:8](=CJ04(QT*<*+"@=G=LJRY*J,8PQ'&/NYA4B&9!8'C>U`2
MUAHP*XSC`FJ*8VJHFB+Y`N+0+=>ZWEB.<X6=^R('>3<^5N&Y-6'VHW/$EAIV
M[IF!X8.M/S-=(`<=VLS;SL5\@0H4$^_NV23;Z2(D0EJUW0UJ^VXA:ASJ]RSU
M%P@Z:*Y[P![F5A(8YAQ^NO;;6[VN=L$`M8L0P/:,SJ&5LNE\KL8+[U@=)T;X
MN^.$'\3O@[O?5PZ60%HV](9GT[YI/U`<+4M.S/#QM"19:9([?S0-+C*Z9592
M$G:R2%BJ=)5Q3F:W:`HZSUZ-GPX=N0#!DF&9`0,IIHE&'D+QK99&M9(]C'AS
M`2`0"`0#L-#M%>7;MWK"@DAKG-HXBI'+3M5&S9VEOW5%*:(FB)HBZ2&UO,NM
M-D/"+<0I*"1TL*>85G')AQI)3!(^5I^[CGMK3_MQG5V.#'M<Z,.:#R&M#VCA
M(/,055[2YKFAY:3V12H^BH(YP5%ZU\-S+\I<;=4K*5$7"X0<K&2TR%6:-$V0
MQ1P+H>>AN$'!0,_'./-KSA)`Y`Y;#CCCC;^%N*7K?LLUDT0Y;EV9V^++;>5K
MF,+YI(FX78ML,DDC'"O*US7,<``6D`!:;?Z7?TM]?9?-2^GC<USPV)DAJ*;)
M&,8YII]IKFN!)(<"25Y<A\/C;%]M%(KMPR`WM_%E6+<E$]:MYGCZS6HE)B3Y
MAMY,P17WGF\B.8$"6:PV?AI2DDH1E2V_>YM6L_9['-+N`RNNY!';!D%D&RRO
MIA9MCQ@;1C?@)945830'QN+3;QF=YE]O+T;;9ADG+YKHF.-M:NV/P$[#A9B`
M?0]\!4C;])X\.'@,055`VNXBYI<D;"UA8L?<IIV7-E"!CB@6GJ^K<A:!T\Q"
MN1_F-#H<+3A*L-+4O&M9GPKUK-)(S-]09+&&-?)5T,>`-!`-'^K`G_\`7:XA
MA)!<`%GLOXAZ4B8QV69+FKW.+64$KRXN()%6=.:?3L%7<M"2MZ1GUC6V#M;3
M*QFUN]DF.OL@>&98BX.1-DG9EBI*AF2,2-M3.MDSSUS!1'(4P^1()>0XTA27
M6<N:G/P5S\W;HYL]RMCZOQG$]K6X#+C\&+HZ,Z)^,@AK""'$%KJ;'%Q6R7U<
M/BRC,'-HW#WK7.=B$>'PI,=7=(W!4$O!!%016>5'M0MZI=0NX`1T:#<:O`6H
M..E$C)DP!;#$B2XX4BD(DP-)PK)F$/8:>=:PXG/-6I/(K/D>:6$F59GF.5RR
ML?+;3R1%S:X7&-Y87-J`<)(J*@&G*`=B]+R^\9F-A8YA'&YD<\+)`UU,30]H
M<`ZA(J`:&A(KR$J[EQ$4>O+AT9'FN9PTG+A80Q"\I808VQC*GFUJSAE$@0E'
MXN'W,8_XU<O07<5O34JJAL9I-9KR6@PUQPC286-PV+'N#1H3@`R,#<U@-P.&
M#:4TG&$9:$93G'-:1A)%!VC;P[M'U6J+N>Q+<MN#*-PO;T6[72HH.M$[A6!4
M/.*`.577`I"'9K*`9*6>ZQAX@V>:8>0*V.4V&19_M5NX1<K/`Q-KV)7MT)=*
M5*6*0DY.`-1AJU!6DFBP]7EWB:X`,\?8:F^^2-E3BT]40\TA;K6>=DBU^K<>
M\B/OQ6-A88,D*PUR*A+B-5I1*ECL2`%R?=<BHZHKZBL><G7%!X2^H+K(Y1!#
M[#CF$Y(MG;.E1V\L0=&[C;)1]>=@V:K86G9BM9"3)RLQ,S$S*9YA,%#9R=ZR
M0&9`]*$(:*[13AQI;*\/%$4D"*94"\2F"*O7G<S8ZA9=>8>/P[)CJ6V[EHYY
M(^'248=90O'/5GD6A*L<F4XS@BOIB"G!"FP"&1#G!GT!E$C*-'&*4TI(Y#X:
M"0UELLO9PI36'FLN)QE.%IY>=@BA51N$"8V]'&"B-V\S0\.YM\[62[70Q"IJ
M#]29>-LTB"D^KV2H!$P]XM#19LLS@1ITI;HZG'G'A>G>(KKMSPE?%\^`XW?^
MO,!4JSU5;`E8(A<'2%JF+M-2EA/ZO:R6#2)`NZ<IK+S3F#5Q4<XI:714+T1:
MYSP02L>B.C(?<P\<:3*'B;+/18+M;DH;;RIA79S;FIUL4>4DTN^K1J:,*A67
M!U*'J3CZG.>:IC!2LY@^$(R$,26WN;EW"IU<XXUBJ&IP#E5837515=<?NI3D
M)"G9REXP;.2&W41T4RUT"(_'3E"S2N\/D_5:]`Q,-N!%#R41N`U<R)CU(-QD
MT7XF7MGS!VQ6KRT\+9SVW>UW999#[:CU+Y0\I7^"1:T<X,)4F"`K3^\TJ%%L
MPE;C32(&NGQ\W@^O[@RUV5,0$C)76<&@7CV)9;&49&*Z,M/6\*SRY8T15K7!
MFT4W)+L5XBIDJ2)F"\--T-P6#C79V[4ZU'-0T"=<I@:,&1!5PFN-8;7AS%?)
M'#<6ZR'A#Q%LW:_8*2V[OYEW,O;=F29!6^'<#=JZHZ4=<M-SC[<R^;8,V.1=
MD!(3JCS(X[HZN8LM]UM;72N-K(I)Z(OGVW^X3N-2Z[X;MVNI[!5R4JT]N);I
M&M2K^]M'C7I:`?FS,PTL]&ELI+C'92.PV^H9WE<'RYT:LYRG.<_+>I^#.H,Z
MU%G>;0SM;#<7,DC11AV.<2.64'D[07WAH;_D)H/3NC=+Y%>3R&[M+&&)]&2T
MQM8`X;(G`T=45!(-*A:B^A-QZ?JZ5?Y^=O\`Q>L'\!=2_P!TSF9Z9;5\SW#O
M^K+XDWH4^A-QZ?JZ5?Y^=O\`Q>GP%U+_`'3.9GID^9[AW_5E\2;T*?0FX]/U
M=*O\_.W_`(O3X"ZE_NF<S/3)\SW#O^K+XDWH4^A-QZ?JZ5?Y^=O_`!>GP%U+
M_=,YF>F3YGN'?]67Q)O0I]";CT_5TJ_S\[?^+T^`NI?[IG,STR?,]P[_`*LO
MB3>A3Z$W'I^KI5_GYV_\7I\!=2_W3.9GID^9[AW_`%9?$F]"GT)N/3]72K_/
MSM_XO3X"ZE_NF<S/3)\SW#O^K+XDWH4^A-QZ?JZ5?Y^=O_%Z?`74O]TSF9Z9
M/F>X=_U9?$F]"GT)N/3]72K_`#\[?^+T^`NI?[IG,STR?,]P[_JR^)-Z%9=0
MN![C=+N=:8GMJ*YMU$*EA%'WD?>:K31%68:7TN9D:*@4)F#BA%(QEML=2',K
MY.12>ZK'-;\"-4,GA?'F+(GAX(?L&"AKB!9*75'**"M:<G*.GF'_`"<X=.L;
MMAMI;H&-PZ'`^DE13`>DB#*.Y'8C2E=AY#[F2^S:[+2]OZ9;KS8;8FI%22[)
M89-D4:?NX$Q0;K0I..(,C5"+AL$@W-?(6C+\@EIGDZ?)*\%H^I\GL;G+<LL[
M&[S*6[N(V`.ED#0]YWG"!W*U=3PG.=5Q^"]09I:9QG.8YG89-!E]I-(7-MX2
MXQQ@]AN(D]LT#65)P,8VC1H`7A)W5BQZ]'0'%9N#`0];KD17P8R.CYU8[>8G
M,;E!S0YNX9<?_"(#=92.\.^,T*]AI*/X-*LY.G;6'Q#;L6YI79VS+@&G8^\.
MF7^'V@WAVY@[6?B6"D52VY4A5)>)FUV)4M.V"(9KIU0'3R-K+>5C*74*0IE*
M%E`/-5:FL7"EN7+.6AR$XG+Y456BXKMI"X(:SC$HPN,CHIJ(?/'W(%D#!(T.
M&$8$<4ZE[`C70D*)QS%-J=M2'#9WJK)WA:W$G8FPPA/$G>GXRPTB(J+\?),6
M.2!22/6X:$L,T^VO<%DHO-I/"*.('R\G"%%88PM3&"$%J)4;EL%>Q%C;W=F]
MR([=VU1=?L%JKUJDMO@LS+4243!UVMU]\0DINU-C/BS#=;96_C(6,<Q#;&,=
M#UA!)1792BUS<^$NR66)W'C(3>>2HS6X\YF5E0ZM`3D;7\B/A7&)E`#:X#N$
M$#(/V"&F(8>1*QEAXQ4'AU?\(4M3:BG%R;%F5NV(OMKW2-N:-WYZ&K0]SVBN
M]:KHIEJ6U%YI,'>*]>:BW'`VJ%B@H>^"SX;Q!;6%./9Z=E\=:4LN9("`.17R
M:V0GIR_V>[R&XC\H%+P943`4>=AI.5IE:>D*,1499?8R+<$Q)1<T8[@TP3&!
ME/<W+>'DKST^"BO)L6*0W"P/#2)TD/?#V"'YRL3X!`%?CV2HB2@J^[#&2("9
M$N7B69(DTLLT+"0T@1JY$QE`C@[_`$2"$U6]MKJ&QMC0*S019,B8%K`+D<+(
M%LH8)>%ZV20,AYM#CN,K'8>2USLJ4I?,YRL\[.=%!V[5GVB)HB:(FB)HB:(F
MB*;8O\V'_D&O^FG4+D49]C/XV9_MF5_KQ6I/*/I5G>#W`I/ZA57_U_MCXAOR
M9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RJ/G$5N6WM9&3=Q/8R3"U>
MFD6.2'%A8*4E'AP'9-XAL'MA#;:GEM,<B&U/M-\[]G'+G.L=G&:6^295F&;W
M;'NMK:)TC@P`N+6BI#02T$[JN`[:R^G\DN]2Y[E.G["2-EY>3LA8Z0D,#GG"
M"XM:]P;4[2&N.X%1'&XVJB88J.#B)\D_-.HUM$#;I-'P_($;AR5<B*W30T.%
M-_\`_8KD;6$V0P[EL4;#F5K(PA.58U"/B3D,LI@BMKMTWJMO,UH8RKC<OB9%
M`VL@_'Q31AS31C*U,E`2M_EX-ZI@@%U/>V#+;UZ[MG.,DE&-LHYY)[IU(3_Z
MP9;RECVXI'X0&Q%Q`5T.XNPHQZ-;D:5<@&'X46?L)9M%H`B:/&DW$VBJ?M`1
M,DU+K;&G@%]([&#23'5,I)0M;&>DUV)M>9?;OMVSY3?L88A)*YS(V^KM,[K>
MLS3*'T$C34Q-E;@I("6'$NI;\+<VNX[IUKGV522-N'0PM;),XW;VVS+NENYM
MN8P70O&%L[X'=)6)S6R#"JU7%O6<ED@#BR1L@N0[-K00U%K73WHA%A,JI+E1
MR^PPR4*%.Q[[3SQ2PVT(;Z;ERRI#BN8ZZR7I)(&1W#YR_!$T,VW!Z5T)Z&K@
M"&R-<UQ>6``8JX"UQZXX7ZDZ&*YEFM([818YWND-+0&%MPT7-&$M<^%['-;&
M)"2[!3I`YHJ*UQ4`6RSU*MQ5<LG17B+/F:Y8RJ#4QZZ9'1<4Q)R9+C^<JDQ&
MXYXID%_+HB<-2#R&%<F5ISF^7ZTR[,LPRRPMK"\PWD;GQ2F,")S6,#WDG'C`
M:2V-U6"DK@P[2%QYKPXS?)LISK-;S-,NQY?,R*>!LKC.U\DACC:!T?1N+PUT
MK<,AQ0M=(-@(6T!=V0#6G'F)ZK9:;E)>%RX[$5D9"Y2`D2XB:#843&-8)=BY
M0!\=[H^<E#S#B,YYR%8QN"\]JL&M7%%M]2ITZKV.XU\.R`5:KW-<$-31Y>6-
MKMUNB-NJD7"@0U9D";`78KRZU%"!@))->-(9;2UG+[//FA45732>*O;7<:17
M%TN]U:<)361[BR\U501(R0K+\-4K"]+1$U(5P2'FF(J&OT&_(I$??<BTS`>#
M$L*)92M0A359#=]_J[MW#,3UIFHYF/*E'H43$+16[;(ER@L/*6(T,2%J-8G)
MDER/K\&8>3EL=21@A77W<H:;4K`"J56JV^.O8QZ.E99C<>%(`B9&2C%/#[:R
MCZI=Z%DKM$S1=289HZR+O"PI>VT_DV0AD'@"#Q!+[SR&&E.:82BWU7=SVK;$
MLSM:E:]-1#Y,D&S(`05=>&67#R9D-*C87B*QR/1\K'OCNISW4.M*3GNXU"BJ
MO?K7,?\`E7^G:][UZ)5/6N8_\J_T[7O>O1*KQ+XD_KG-P-B[CN5'PO#A&VZD
M;;7,_;^0M)]BIT&2[:`C+7'@AD18M5FB`5V`VA2[^&\H<5%U[J4R7GHSF0\X
MW),TML_U-<:3LVR,S>.X;%^*UT<;L45M+TK97#`80+J.-TE0!*V6/:Z-R[V8
M6,N6Y1#G5PYCK)\1?WA#WBCY68"P=\)#T+G!E*EA8[D<%[$T/=DO<"C4R^1H
M28R.NU4KMN`C9JJUH29CPK)$!S(H,L(T"0T+)B,&I;?;2XM*'4JQA2L8Y<Y)
M=([-BROUKF/_`"K_`$[7O>O1156&S;J"4N$-LEMG:K6X&.PQUR7F8NK1X#"R
MB&@Q&5$$QS:%$FFD-L,-)Y7'WW$-H2I:DISQ3SP6L,MQ<S,CMV-)<YQ#6M`Y
M2YQ(``[))H%RPPS7,L<%O$Z2=Y`:UH+G.)Y```22>P`HZ1G&_`35@B18B!*.
MI<UN*UM/'[@IBMM&07[RX\X!D7U1(-:W`:A69Y&(QPQV+;RDU7.Z+J6,F:\]
MM^+&B+O73>'=KFO2:E='C#6BK'#H/6.]>#WPZ'OND:#%BK%TG2M<P;:_0FHX
M]-W.J9;0-RV&A>#4/:TS-@!<"W""97!HC+A+A(DZ/HB'F5/K7,?^5?Z=KWO7
MKT=:;5/6N8_\J_T[7O>O1*J*E7XRY.P\0VX.Q)>WI,"%M_#8EB]QI&*K>*X7
M_P!HT<IE2\UMJ,%1@;IE84F0>=ST*^5I/1$]7WV^T,ZST=D^JX\WAEDNY2P6
M[0>D&VE>7$=M!X`&T4<<3,6G6>KVW6I\STX_+)(V6T>(SN(P'96G)0;*_:)V
M&H&%V'4@'UA,_/;OE0-3I$?9]HQV&A&;2%`U>.LDB=C/*5801;&J#"75$Y7S
M&N5OI'4H2\EW/3MM)V:3A0^UT['>7^9"#4#CB,3JNC:WL1N,;7N$O9.V@)+2
MWO2XX%G$=MQGC[6RL#-DS13I&T#W'LO:'N8.C[`V5-,5>^`$VZGNPBU1PQ$2
MN&'6H?+G9#L/25R03#+F1E].)%M2#3+;+J.9RI7E')E.<9RA;:E>7YEE=YET
MTC+D8@#X8#L))V["YK2:C;M%>7L@T]`L<QM;Z)CH#A)'@G#44V<C21L[1W=@
MA97ZUS'_`)5_IVO>]>L8N_5/6N8_\J_T[7O>O1*J*V\&\W$-4-PP\T>J^M='
M]6(C#\?%[<PLB\];2<[B3*\NRC-><ZM#KBZ:P`6I+N7!C92.QA&.LY7HI6`6
M3B)XKT'K.@:$!F)C1+EU2(QLC*9*MSE7"VPDXB=(D'Q27ZT#>FK-*,@PRQL2
M8;@KB'7WWQ"F6B+(K/Q`<3,)N+N$##;:9FZ6VZK.WAQ.VD:]'&AT7;J:L=V;
M=(A!'9T>4N-YR'"0SI[#`[^.5\)DY*58=(J9KB.XEY..N0Y&T(\'(P.<"1)X
MVWA!)$JMK;'<>R%R\(,=5B(S.9*S5:,!!3AV0P([-(&*;>(0ALDBR[;WB4W7
MG;7!1ETV_<K%=EJ*U,%S9&TDY#LQ=WD;E$5V*ICQ4Q7>@61AN6=9=4M#25]0
MZ^A?5#$('(L*LW%9O5`V@[`>WIZJ/,7.HUZ"FK#LG,,.P(=C%K\&?(%L1\`.
M3(MP=Q"D6$!*0E^8=D1%`E*8Z#!)%50_%/O^[*9]8]G?5V!CA(><L9I.V4JO
MLV-,NM>I\W#!2#$`0%,R==BC3;&HP9#C9$:/AKJK7,67DBF9ZUS'_E7^G:][
MUZ**K3L7Q1TH\1HD^PPM8<)`8F8\&TURMPYTM`R+*"X"=AFG(]UN7C;,"YT@
M'5ENO/.-OC*;08&8,.4KMA.*7;>PC,%Q>X-'='+DBHL)QV,K0R3B!I^=K27@
M5/Q;:3`#92LGX%);RI@ED1UYM:FD+7@FU4@7%AMJ>J&:'OE-4_-B+,'8;BJN
M4H5*&G%88D70HXH4,D@AEP8=.7,];+:6RQEQQ.4Z)5<#.+3;`4U0*-P:0>XT
M"5*%$1L=5#(T*+!L59JQLB9+-@8BV!!YFUC,\[+W*ZM#Z&L..#NH217P;B1I
M,A)1T/#W.FSLI)G-QXX$+&U22)0^HWLTCK#0X"E,XCCE-M%XS^&*M]G#J4]*
MWSB*@3Q/4]AY]J=G8:I-<MB>B#K77JO#1MGB:E@K-CGZV>\$H:1AX?(3F2%Y
M4VZRWEIU;:6217'R*Z(XCZ`MUEA.X^VV2",MH8&SZEI)<=6K"7&,#J#P]UD+
M&<**:RGI`V\X6_AM&<*T455UK6^5;N1;H%5MU,GS60!I1P6+CJL4]B.+:%?'
M,2AN-SEP=8T@,[SD\N$M%CKSR((94LI6:^M<Q_Y5_IVO>]>BBJBI:^-'AVIM
MEG:K:-S@8RQ5^4,BIJ/Q0KL5@.2#>4T6/@F-I),>]AIU.<<YEQ;>?_=SG&O/
M<PXJ:#RJ^N\MO\]Z.]@D+'MZ&X=A<TT(JV(M-#V02-Q7K>4\#>*F>9989QE6
ME^ERVYB;)$_UFS;B8X5:<+YVN%1V'-!'9"Q_Z>W"S\K87S=[A_F%KI_&/AOU
MB_Q[KT*R'R\<8^J'^78_J4^GMPL_*V%\W>X?YA:?&/AOUB_Q[KT*?+QQCZH?
MY=C^I3Z>W"S\K87S=[A_F%I\8^&_6+_'NO0I\O'&/JA_EV/ZE/I[<+/RMA?-
MWN'^86GQCX;]8O\`'NO0I\O'&/JA_EV/ZE<V^/KA;;5ST;N`<O(I/X6W&X*\
M<BTJ0K\%=!4GEYJL\F>3EQGNX[NGQCX;]8O\>Z]"GR\<8^J'^78_J5P^GMPL
M_*V%\W>X?YA:?&/AOUB_Q[KT*?+QQCZH?Y=C^I3Z>W"S\K87S=[A_F%I\8^&
M_6+_`![KT*?+QQCZH?Y=C^I3Z>W"S\K87S=[A_F%I\8^&_6+_'NO0I\O'&/J
MA_EV/ZE9]MWQ4;'[KSOJQ0=R(2;L"F5/L1!$!-5XPY#>%+=3&(M%=A4RC[3:
M,K6T-EUU+:<KRG"<9SC,Y'Q#T9J2\_;\GSQDEZ14,<R2(NIRX>E8S$1RD-J0
M-M*+7=3\).(VCLN.;:ATS+#EH=0R-DAF:VO(7]!))@!-`'/PM)(`-31;UZ\1
M_P"!YH)XC6ZKS>I6)W'<ZO;=Q;<I;I1B(C#G31DE=@O26,*BH&9ML@XYB-BC
MWPA@8"M&EO/KPVTAH=6%+Y<X2HE2598?>W;2?CX.3B]PZ.^+9`8Z0A$O2L$$
M8<-+.-LQ_-C3LC2+)!!+F&>A<:0\DCE:4C#F,IPV*>^5ZSN55,$QXWK/7E*E
M*W/W$`AM<:['D5>K%0@=@G<2C;:HUN-BR;$&EQQ;J<?PW+CEPE>4E%2K+G>W
M;1&9;!&X='!1"2;4/(OR4K!1@K<@_&P\LTR.9(9&%/0H*?$_A!UNM8==Z+*L
M.H6A+8I[Y=DIO/MS#0LM83[]3$Q$'$%3TF4+(PDBIB)#0.IXM`L=UHPK&<F,
MH;0RVXXZZ^TVA*EN(2IL45*K!=UZ49.35:9MU:3/UZ;%KDM$$NQH1[$T;&UZ
M5$!8',:87(+?$M<?A*Q^E;Z<E+'.Z=*VTMB5*L9O$%MA&QEK-D[W6HP6C.2*
M[,U)#,1TG'Y`BVY<AQN,,`8F909Z+YKPRA6GVBTYY1\N9SG38I[Y5,QO?MQ7
ML73$W=ZU&.[>D#B6\0O`K4A%%FUD>X`"HCLC=?DR)*NDI(%0(V0HG*7&FL+=
M:<;0V)WVQ<T;U;?.1<1,(M\$H*>DXR(AL8&;Z[)&3%T$V\C<B1?4NU'0B;B>
MR%@K#/54J<PXIS#/*YIL3OE:WN(/;`?$QDJX1XF*^QUB8ZY!GB9!:7"/V47I
M<$PS65.2==%>."0GG+.$9<='PXAM:DMB=\L]@[K$V1R=:@I,"3769XJL3N!Q
M&,XCI\(0$TR,=6L5"%D##R+.5\S*DI4OFYSSDJ3@HJ5?>O$?^!YH)XC1*E<U
MR12\(PKJW(VCHT\T$%'X.%*5^%E(Z<K5RJSW5<N>3N<O)C&B5*X=>(_\#S03
MQ&B5*=>(_P#`\T$\1HE2G7B/_`\T$\1HE2G7B/\`P/-!/$:)4IUXC_P/-!/$
M:)4J:`W=&'S_`.`U_P!-.H5U&?8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55_]#[
M8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JC#Q3;?&;GU^S48<
M@F-1;:$97<S#,8[*ICE23DJ/DG(:"`\%*8P[A71],USOQL<O+K$:@RG]]R/-
M<F]8Z+UJ!\>/#BPXQ3%AJW%3=B%=X6?TIGWNOJ?(=1^J=/ZE=1S='BP8^C<'
M8<>%^&M*5PNIN*@^-P8$1DI/S4-:9$*3D+`Y:(1XFG/&LPDN#N)4+S5&R&,3
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M:C8@\M>VYQ/<[:&86MV#MGL`5MU-"2W:$I.)B=N*]MY!COP3H:XYD*6E9^TR
MJB$E$I>>MLR:.ZII#;*1FPFV^<[C"<HS>G])1Y%=Q7/KQF$5A%;1@MPX0U[Y
M)GUQ&IF>YI(`:&B-K:NV$:SJS7LVJ+":R_;!;F;-)KV5P>7!Y?''#;QTP-H+
M:)CVAQ<XO,KG49M#O.'>7@`WTN-O@RJW&UN2%B=QU7A^=ND2J>(?BFK[Q+R0
ML*F6<L$=,D#G1&_(1TM#+C61)$\`U[$FTXIAHC<PX+S[:I!T[@)OU`G&K=5]
MZI%%F2S,5]04OM.Q)41C;FRP=":L6W<5`,6N.MD3`D6FALE@H;L*FHJ/?4(*
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MN3]SCO-"/%ZA10[D[+D_<X[S0CQ>B4.Y?-!Q`?5[?6.;D[AU&:!VSVQE&S;-
M.3^XC[EUC"J9/';GBA`;K&33TI7(&[,`V1ELF")'#CSG1J`!`!C+?D125(Q&
ME;2]RK56?YQG4T<V77%K2(1@B42-=.UD,F,X!:]$Z(O+29#*Z=P`!81D<XGM
MKS)LML;!CX[N*:KRZF#`1&3(W#WQFQA]*T8&",$FCE[]\/E+W;J>S&WM7W;0
MW)7ZN028.8/BW#)5HH.*+*"KCQTJ[$P^).>56&`^TR&Q1V'Y+IUM-I:4C&LU
M(8S)(8@1%B-`=I`KLKVZ<JQK0["W'X=!6G)7LT[55N3LN3]SCO-"/%ZHIH=R
MP'<':1.Y0$(#(2%QJ9E;L(]JK]EJ\?'ERL-.B1DK$L%(CK``=#2+*P9DAI;;
MS?.1TF'6'&26V7F]9UCI+)]=:;S'2V>B;]KNNC+NBD?#('12LGC<R1A#FELD
M;';-AIA<"TD'*Y)G%[D&9V^:V&#UJ(.`Q-#VD/8Z-[7-<""',<YI![!WJ)D)
MP"R,!N3'W]JQU6<)B-W,[L.;L6"@N+XH+8IQ3X^:1,VR-C`(6%K*(4KL9Y(9
M*@RH%CH<@MOO*=;\YTKP>N-'ZNM,WRC7.8#2%M!@BRMP#H@XP=$]TD[GF20/
ME,EV\%H)N7EY<0`U;GF_$`9YD=]89CIZU?G,^$&Z%6EC62L>WHXF@,:]L<;+
M9KZG#;@Q@;:J>/9<G[G'>:$>+U[8O-Z'<NMV'D7FW&EQ\EA+B%(5EIDUAS&%
M8Y,Y;>8PV\TOD^XI*L*Q^QG5FN+7!PI4;P".8U![JAS<0+36AW5'\QM6JIWA
M_JUC%(&E`MS%I):+9)ZKN?NT#@Y@]ME@L.02Q:\-E@D,C-)6TI.4J2TC&<<F
M,<FQV.J<QLI&/9':=Z00?5+5Q:6DD%M8MC@2:$$4J2L%=Z>LKJ-[7/N34$$>
MLW`!!H"'4DV@@#80>0*!BN#NP&W:QB+I5X@*;4(UZ9<+;M6XDK(71U//=%@*
MST9)0N$R0[3V$O)=(,`<0STPKRGNAQZZ>(-C%E-G*R\AFS2Y>&!I@@8V'L&2
M78#WA(-"&MD&+"]H;B7F@T5>R9C<QOM98LO@87DB69SI>6C(]M.^H=M2YFS$
MQQ.%4=(W;XF,J%BQ.!4ZF2H8[8L621MI:78K#[@$@E@DFR/)BWA(X@YP-HIY
M?2',#NDOJ8>=;ZLMF.F=&4DFEXJ.N(7$EP$[`Z@<VH$8Q`N`QEH%(W$,:'M!
MQBUCGVJZQQ1\.VP2``-)B?05!H2_O32N$..UX!<XM)&$[,A-^N,4P6$43P:V
M2&:DY"&%D>@066;7PYA=*PF0[$.=KHTL2VS:WGB!U2`#`"@"&2"TJ'*<8P=Q
MHOAXUUR6\1HY',:\BH`#RSI=F(![F@]&`TACR_&US&$.8'96'56MW"`'0SV-
M<6UI4EN+H]M"6-)[\DC&T-PN:YU6N+9QT?-PG:53YNTU<RO6:8JU?E;%`-BR
M*D0<[(1(A<O#HR:*,9E$9(/.,XRZVV[R(_"2E7+C'E&:06EKF>8VMA<]-8QS
MR-CDV=_&UY#'["1WS0';"1MV$A>CY?+<W%A8W%Y!T5V^%CGLV]X]S07-V@'O
M7$C:`=FT+*>RY/W..\T(\7KH+MT.Y.RY/W..\T(\7HE#N4$J!0^-*N5*K5N6
M.DI"SCMU)-MM\H5#SD+*X(L.2+8:"/-OSMDC)6,JKD9'L"M\\!>`Y@C*R#GP
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M`!#J:DY1Q<HB)&OEPZVF:TIM@IEP=;$RIAMR60>XGG9*=JR@/A7I0,4Q",@7
M%<</U5E#1)Y9;KD:WG<%,E$%%DANF&AV`?=2?9-<><66IN0ST3S2FF%-$H=R
MM:N#[;CL.,KR(.RXCX@`&/";*PQ+-]#%V2SW&*48%-Q$G%2/9]JM+IN&R!W6
M'E#LLOMNC=,R\2AW+I7P;[:*"F8MN%M8T7-Q[D05'!D*%%;BER]5GD"-]!&H
M>=>9E:<&O!CZWI!3"$BK?6(R*P.2AW++`^&NIA7AJ_M1UJ7-L'SLF.V^0^^$
M.;9+4W<9=3&'0E&M!/S3"%MAX?ZB/GI7&F4/DENODH=RM-BX5:?:5(Q,M7H@
M4=RS8CHW$D^F+B`[7ES,C'14?F/4*&RQUPQ(S^$Y-89.>8P_U?HFFB4.Y<Y/
MA5HTP6^_(Q%F+#(OLIN<Y"E909#8N\\B1"GY]`AL62MLZ4@9%4<A>%\^.&3T
MD?D0MQ\ETE#N684O8R"H<VN>@(R>;,54Z[34H(2I;6(>LQL;$Q_3K:!8,D2<
M!0XR4Y+=(;%4EU0J!U%FY))0[EM'LN3]SCO-"/%Z**'<O'/=OZK?=/<[=+<3
M<1CBR16Q;O=;+:`JXKAVC)A5>`FI<L\""7+KW2C5RRX<-]`V2E#L*(RWTF6T
M95E./%<XX*9/G.:YCFUQF#A-<S/D(P.V%[B:;)@-E:5H*[E]1::_Y-9CIK3V
M2:?@TP'Q65K'"'>L`8NC8&EU#;.IB()IB=2M*FE5KW['[=?]<QK_`-,L7^E_
M6-^`61>TG>([TRS?S:YOU4;^9;^D3['[=?\`7,:_],L7^E_3X!9%[2=XCO3)
M\VN;]5&_F6_I$^Q^W7_7,:_],L7^E_3X!9%[2=XCO3)\VN;]5&_F6_I$^Q^W
M7_7,:_\`3+%_I?T^`61>TG>([TR?-KF_51OYEOZ1?N/J?-V59Y$\9;:L\F<\
MF.&2+SGDQC.<YY,;O_<QC'+G_=I\`LB]I.\1WID^;7-^JC?S+?TB_/L?MU_U
MS&O_`$RQ?Z7]/@%D7M)WB.],GS:YOU4;^9;^D3['[=?]<QK_`-,L7^E_3X!9
M%[2=XCO3)\VN;]5&_F6_I$^Q^W7_`%S&O_3+%_I?T^`61>TG>([TR?-KF_51
MOYEOZ12-X:?JUV=F;JNZ;J;K9WW?C<QY5/AW-L!=O(F`F0WW7US$DR);[6JR
M.IST61V7>@89<;RM:7<Y3A&:T_P6TSDN9V^9SN=<R0D.8UP(8'@U#G`O?BPT
MJT;!7:0[934M:?\`)75>J,DN,DRZR&7Q3@MED;())'1D4+&.$471AP)#G"KB
M-C2W;7TY4T0K.5*:=RI6<YSG+:^7.<]W.?N:]B7S>L=GJ9$6ER">G8?$HFL3
M*K!&,DL+>$9DUPLS7<$$#*2I@E*(ZP$)0EU*DI=4E>,86A&<$4>"^"O8<]P9
M9M1F"D"0X\".R[8['A+,6RT`.X.RZ@Y!;'6A(QEM64.)RWG"W&>C?===6HIQ
M%;0D]DZK(5<JL-"R(#1%%W"H+4@*O."AHO<]Z/-MI;8^6NS<GFRD6P2C/08:
M96G*&T(:5E&B56O)_@]V6L[DL[-UJ;-<GK`1;)A2K!.-]=LIC3C<A,H2T4A$
M<1)K?6X2V)@<<A>4<]M6&!L,J*<1"J3.$798[KZGJG(8>DJY`U0HIN6EDFYA
M*U7(^HQ`S!F7U%!K9K8&1%K96A;J"'5KSEQ25H448BLS*V$V],W#?W2?@35W
M(F3AYAX_K\EAA<E7XEB#ABL`]-U5M8,4TME.$)2E>'W,KPK*L9P2II18U:N%
MG;"[!SH]KB9^838YD2:/+=E31#,G1KES>CL(,CD!O.XC?C`DDLY>RZZVRXRU
MA?1##(:40.(7.]\+FT^X\G9Y>U5Z6,,N,E5Y6Q=!-S0;!Y=.BGX>OK2.P2AD
M/(0C^?PV,-N+SRX4K*''4.*('$461*V$V]7)0TLJ!-R;`M0#4<O)\EE+7JO<
MW+[`NK3E[//=C[&2^O&?_?9(<:7SD9QA)*JG<X?J"5B8[3C)66=GHR6B9,H\
MU_)1(LN)<(]UU9`K8KBI,<#<*<8;-5E1BFI-U+CKF$,="2I6=52@0-)]8<5J
M+)`19Y]5FEFE$R!C3DNN&AH%;PR#7R,`L*CH$;'0L\QG"TJ7A.%+5G)16JRW
MH'_87?!K_:T1?N1R,<G*P]CG8YR>5I>.=CESCEQRI[N.7&=$7YT#_L+O@U_M
M:(G0/^PN^#7^UHB=`_["[X-?[6B)T#_L+O@U_M:(G0/^PN^#7^UHBFL+_-A_
MY!K_`*:=0N11GV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_]'[8^(;\F3?Z.O]
MZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JB[Q5[@2&V5;M-X!:=.54Z`;8416
M#WX]D]V.<EB,,./LH>RSTW183E>$+SC'[&=8;46:NR+(<WSED`D=:V[Y`TF@
M=@!-*T-*[Z%;#I'(FZGU3D&G7W)A9>W4<)>!B+`]P;B#:BM*\E17>H4TGC'=
MLES$K4S$24($]7=O<$2(\P;)/B[A7F3I<0[3G!<##)2/"GWD-#I65XSS<\[+
M:<=S&CY3Q+AO\UCR^[RXPPF"VJX.+B+FX?`PP$81LC=<,#GU[9:%Z9G_``9N
M<KR*;-K#.!<7#;J]PL+0P.LK2.ZD%R'8G=]*RTD+8Z4KL#BJXWC`Y)Z/"A(*
MQ3D%,KVX;CIAJ0-&?91>U;F-ODR$?U8E3:8I>WO*EM*^<^A]Q7.1T6,.<TO$
MBW]=ABM,LDFLY3:AKP2"/6/6P2YN$TP>K;!7O@YQJ,-'<$'!V[.77,]_G<5O
MF,`OB^(@.!-IZ@0UC\;:](+W:XBC"QHH['5M7(\8,`#2RYM#L\18&=N&;F*-
MT,\Q53YHW:@W=J*K35G?$2D<B4K\:0MK#K*'L(95SF\+YJ%<L_$C*H<IENQ$
M]U\+`3@8'B%TCK-UXR(2ENPOC:XBK0ZC35H-`>"VX.9[<9]#8&>-N6.S0VKG
M8XS<,B9F+<NDG,`?M$<SV!V%Q;5PHXMJX;.H_$!5[]99.FPEADW+)#!FE'B*
M4<@9>88\2&L*`"UJ2DK$#-FMB$9SA'\*O',YR>56-@R?5V39UF%QE5G.3?Q,
M<7-H0.\<UDN%W9Z.1P8[DVG94;5J6H=`ZCTWE5IGF86P&53R-:QV(%PZ5CI8
M2]H\'IHF.D9M/>@XJ'8M#QW%Y>%TE,Y)5`;%EL%-VXN.W\%$W24-'L2=R+1F
MI`0<B05!@D14K%R">F>RV@IE8RLJ2K&6UXUIL'$:_=E`O+C)(OW">UM9[:-D
MSG"7UJ;H6QN)B:6/8[OG4#P6FH/>E>BW7!_*FY^<OM=2S_M-M?7MM>320-:Z
M'U&W]9?*QK9GB2.1G>M#C&X/%".^:KJ[Q;S!-THU=@08V2C[M#;12X.";A*"
M6(IC=9R>0LJ(C&(4X,T.ECPO6I++I#"L,*SA&.?R)SV'<1'29MD]C964$D%W
M%9/;65S92+PR;6,$;FN;`&8Y:N:</)MV+J,X1,BR'4.:9CF=U%<V$^91OPP-
M=`TY>(2&R2&9CFNNC+T<&%CQC`Q=[M5]A>)^4C4R/QFL=CDYO=BH->`HYEMN
M9TM(4YYYNS2#HN("-=9!'0L=;"&\/$OX<5C#7*GDSW;377JXG]X+5D4GKDMM
M$VWZ6=SW0$B5Q'1-(:.]+0,3W5/>U"QM_P`,/6C:^Z=])/%^W07DS[OH+5D;
M+D`P,#NG>"]U'AY=AC80*OH:B4?:DG[HG>=D>,UZ(O(:G>G:DG[HG>=D>,T2
MIWIVI)^Z)WG9'C-$J=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWKYU^+CZS#
MC:VGW!W<QM\]2!JO2+]=Z'!524`D'[&:S08Z=L4[906"Q'W;?'4VEQ419K2^
M(<*VB)MP48(R.>._(ZQ6G\QFSG5U]IB\L76EM#*T^LES9(_5G10/-PYC2'MI
M(^XB$5"YPM))00UP`R.9VD5AD=KF\%R)II&'\*A8[I@^1HB#C5IJQL3\>P`S
M-802#7WVVZNMIM^WU$MD^*;6IVT4VL6*:KB94DU,!+34(#)24+@S.&,EXBC"
M5L=+E".DZ/G<W'+R:RJQY/;69=J2?NB=YV1XS114[U@&XN["-MX>/D9#UEG9
M"<FQ*W6JS7R@>W++/%BG2.(V,<GYJ!@1EC0\48:^\:<(,P((ZXMW'-QC.OZI
MU1D>C,AO]2ZCO6V^3VV#'(02`9)&11MV=E\LC&`FC07`N+6U(RF3Y1?Y]F5M
ME66QX[R7%05IL:TO<=_>L:YU`"XTHT.<0#">$XVMQIS=F.K+8?9T.7ODC9HN
ME'4RT&2,2W@%Y]V<D>(BO[@S6QOK%D3HY1JNC,%%O"YR$E_)V<)3YAIKC`_5
MNMK')<ER)DFD[F$OCO3<P!SP(7/+Q;&03X1*Q\`#8G-<&^L-EZ(@'>\TX?,R
M73>89CF682,SN`,<8>BEP''+&UK,?1X`3%*V<O?(PL/_`*[HNE-1Z+]J2?NB
M=YV1XS7MZ\PJ=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWIVI)^Z)WG9'C-$
MJ=Z=J2?NB=YV1XS1*G>G:DG[HG>=D>,T2IWIVI)^Z)WG9'C-$J=Z=J2?NB=Y
MV1XS1*G>G:DG[HG>=D>,T2IWJ)D5Q@=I;AW*@9JUK2_3)-^)(.9F4Y7*G)OD
MAM\('$B2+<4PX6;+F5U2>E):'PW8$JP]E`KR\E-3O77+<:]1`:*D01[?,5]B
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M)B-A)BKMX=;<=L4=+6BD;?/K99).`>!=BMQ;JB+?4\E(O(.X[A_E0\TR4[5<
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M:#VE]#Z>_P"-.NM2Y%E.H+'-LI99WD#)F-DEN`\->`X!P;:N:'4.T!SAN)6(
M_:=[!_!O>GT!2_TB:QOS!:.]F9GYN#]2LQ\IO$7VUDOGKK]&GVG>P?P;WI]`
M4O\`2)I\P6CO9F9^;@_4I\IO$7VUDOGKK]&GVG>P?P;WI]`4O](FGS!:.]F9
MGYN#]2GRF\1?;62^>NOT:?:=[!_!O>GT!2_TB:?,%H[V9F?FX/U*?*;Q%]M9
M+YZZ_1K]Q]9[L(G/*FN;U)SR9QRX@:9C/)G&<9QRXW%^YG&>3/\`NT^8+1WL
MS,_-P?J4^4WB+[:R7SUU^C7Y]IWL'\&]Z?0%+_2)I\P6CO9F9^;@_4I\IO$7
MVUDOGKK]&GVG>P?P;WI]`4O](FGS!:.]F9GYN#]2GRF\1?;62^>NOT:E%LGQ
M$[=<0$*;+[?RTFDF)<PW-5J?:9CK-#)=<6@0DP$0^1$>`.PWSFB!B'V>7\!:
MDNI4C'HND-<Y!K6UEN,GF>)HS1\4@#965Y"6AS@6N[#FN<.P2'`@>1<0.&.J
MN&U]!::AMXW6\PK%/"7/@DH!B:USFL<'-K1S7L:[[0!:0XZ/D^,W-+EY]N_T
M6R#UL:WWFK5N;K;@)9,RY4;;:JTCEB)F7B"EY,Q4"N8MCI.G)YK+*%<J5+W"
MJ\_P[BME[;<4M+W9L153IH-I[:8B)&40N>:`C8=:@"%"=55(@RLP^O+K^,*R
MX..2AME:'%=QUG#A000L2M'&/7ZA"T*1E:[8DDW*CT?<"2%`.BS`X>#M]4O]
MN4(@I^0C#2S(X7;8]OK#X8D<IY8R%D-.$(1A53A5FB>/7:Z813WAJSNJV/=Z
M5:+Y$/O0];ST,)5%VU@]N2&'N1!P9Y!=)/9;;Z)26U-X40MAO.7,*IA.U7<3
MB_B90!-@BZS8'*UBW-5PAYXN'[:&%8V_OMXDI)V/;F\Q;;2':-D5M;A[;6&"
MDFJ5U=.,N%%.57>4XJX_&W]>W&KE9D9*,L(>X<@+7YZ>"K=P?!VV+=&G9`"&
M':GQ'P&D!$*6L@L13;F11^8HHUAC*JG#MI55\)Q($R4O"1\C5V8@:9.J(392
M[<HDQ?K<Q"C!DQD0N!$+F1,STRA#;C&<H5%Y1(.Y80I;+1118-GC@I\<;*QU
M@J5X&+%:%E(AN(7`R3TW`F4N#OKC[,>=/0TLS,5V"G4]L!X'=P"MI6>E6C/+
MA53A*K-QN+.4J[$4]4*:=<';50ML[13ZUDTH2RDRV[+]U#KJIF/CV)A8-?CC
MJL&'(/L-DK;+E6$(YV>;AQ5`WMJQP/&0N1G)L@V(YU(B*C>]P!C87&3[%.U*
MN[L/;6UXR)!=G!Q'$3BVE'X6M227%-.BMA\_#3KJJ85*_;^\)OU6$LXB"!1R
MI"PQ[:%/+6EWU?L<M75FL+SA&5"2*XK)#.>3NLNI[N?NY*I%%FG3O^S.^$7^
MWHB=._[,[X1?[>B)T[_LSOA%_MZ(OW)!&>3E?>SS<<U/*ZO/-QRYSR8Y5=S'
M+G.B+\Z=_P!F=\(O]O1$Z=_V9WPB_P!O1$Z=_P!F=\(O]O1$Z=_V9WPB_P!O
M1$Z=_P!F=\(O]O1%-87^;#_R#7_33J%R*,^QG\;,_P!LRO\`7BM2>4?2K.\'
MN!2?U"JO_]+[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JCYQ
M$;>B;EA2]0EGV&86S4YZOR>43T+#R.!#WI-DA0G:A*5(7T3WX+G1+1SN7'=S
MC.,8_-LLMLZRR_RF\+A:W$3HWX31V%PH:$@@'=L*RN19U>:<SO*\^R\,-]9S
MLECQBK<3#48@""14;0"/I44E<']"0=)28)3T5(24^7:>MQU[J33@4^5?H?<=
M,D"AYY]E#@=@@AD,H<2ZTD5'1Y0K/(K&K'AYI\37%Q"9XYY)W38FO`+9#<LN
ML3:M([V2-H:""`P82#RK=QQ;U8ZWM+2X%K-;16S;?"]A(?"VSEL<#R'@T=#,
M\N+2UQD.($#8N0?")38\0$4.6/85')I21"\7VG++;]1"+H]$Y4MU2VG<EHOL
M@T5SD9Z1M:.;T:T<_,Q</\C@BACBFN08_5\+L;<0]7,Y9RLH<0N)0^HV@BF$
MBJB?BQJ:YFN)I[>R<)?6L3>C<&GUL6HDV"0$839PNCH1A<'5Q-=18L+P60+C
M\]'S-@R94GJU`U:MPC%XK#2P!(G:(G9]<Q)J43E@RQ-5Z3,P,\E*64*(RM32
ME(;YF.CX:Y8Y][!=74S\L-O'#%&'4PAED;+&_O:.E$3WX7`!H+JEI(;3+S<9
MLZ;'EUS8V-M'G3;N:XGE+*XW29DW,A%'W]6P&:.+&TDN(9A#P'.Q;=I/#[!4
M&P3-B@#4X(F<RBE@&7JMOQ(+L[)LS4Z0"$B09Y")B79P0ZMY3RD+RI+71MJR
MC.SY1I?+,EO;J^LG38Y<?>N?5C3(\22%K:#:]XQ$N+J&H;A::+2L_P!;YUJ3
M+;'+,R9;]'!T='M921XAC,4(>XD][%&<#0T-!%"_$X!RUS&\%NWH@L`#*'FV
ML*M9K@\6)9[[33A$0U3#GAH"N.B"Y!&<A`2+&07E&$8>>*PTMUU>&D)Q@K?A
MKIV**RAN'W-S%;]$&-E>UPZ.%L@CB(#&CHVF5SZ4Q.?A+G$-`&T77&75\TV9
M7%G'9V<]WTYD=!&YCC+<.A=-.'.D>X2O;`R.M2QL>-K&-+W$WR"X3J971&`H
MXUWH!"]N2P</WFH.9!QM9<IZ[5$4;.'480(,?8GQG49PK+@*4-XRE6,K5W+/
M0>1V,;(H'3X&NM7-JX'#ZG/)<0M'>^"'2N81MK&`VH()./S'BEJ;-)I)[IEK
MTCV7K7T8X8_W"UAM;ESN_/?.9`R1I%*2ESJ$$-%59.%FIVN*,A):1*S%25RL
M-VDP!MP:V,-(R5G(03*"%,(-Z)0:7$8ZLXG"30\YRI@AM><JS>_T/DV96TMI
M<R7'JTEU+</:)*!SI35[7"E,-?`(I(SE8]I)*X<JXF:CR>\@S"SBM/7(K&&U
MC>Z+$YC(&EL;FDNKBH?Q`28I=@DC<T`+>GJ\?Y1!_P"IZU[[:W%>>43U>/\`
M*(/_`%/6O?;1*)ZO'^40?^IZU[[:)1/5X_RB#_U/6O?;1*)ZO'^40?\`J>M>
M^VB47@?NO]35Q'[@72CV0/BWVZ8>JLX%,%6!5:1'2,D^1(+G;'(R-6=W7LD!
M.3TU<S92Q2!+Y#2)>2GBQG&QXYD49&,TWES]/:BSG/3>/N8KN"@AD#0(YPZ7
M#<![0'.P1OCA;"?P\$+2:N<\N[^:W;,SRJQRWU9L3X9:F1I-7Q496(M)H*O:
MYY>.^K(:4`;3V4V'V4LNSVT5&VQF;K!W<REQ3D*S84R$%`CN13)YCD%$1\09
M<[0<#$UF$='C`TDR1Y610VU/$.NY6M66D>'R/>U@:"XF@K05/(*U-!R"I6/:
MTAK07$D`;32I[9[96W/5X_RB#_U/6O?;5%-%8;'ME!W2-5"7.$J-HA5O-DJC
M9*T0C:6RF,*ZN:&:!/!R49(BY7G+)`SS3[6<_@JQRYY>G?Y?89K9SY?FEC#<
MV$HH^*5C9(W@$&CF/!:X5`-"#M`*Y[>XN+2:.XM9WQW##5KFN+7`[P001W"M
M,QW!IM3#248;#&3\;7("Y)W!K.T0^XE'^*F`NV)ARP*M##3B%WV3/587W9/#
M)TV2&V>[ST,I;0VTC1[+A1P]RW6/O]8:;CAU3T;8Q*R29K&M;;MM6AEL)/58
MR+=C80YD+78!2NTUV276VJ)\CN-.39JY^4RGOVN;&7O_`!NGHZ8L,Q:9OQ2T
MR82^CB*@*0GJ\?Y1!_ZGK7OMKT1:I1/5X_RB#_U/6O?;1*)ZO'^40?\`J>M>
M^VB43U>/\H@_]3UKWVT2B>KQ_E$'_J>M>^VB43U>/\H@_P#4]:]]M$HGJ\?Y
M1!_ZGK7OMHE$]7C_`"B#_P!3UKWVT2B>KQ_E$'_J>M>^VB46%%;*TDTN8D#*
M3M<6?84$(GS2D[?/ESB"\PF2D3!+I"WI-!.:U&])AY2\+[/&Y>7H&N:4KID=
MC*%+\F9:A;42F4X=2G,BQMT;S4OR,A,/XQUEYWDP]+RQ12_QB277<_AN+5DH
MHN6=CZ*H=L55$VJR*U(,R[0V6MN\CMRH\E-3(\FVSE_HT2#$Q9)$M#V,=(DD
M\EW"L+?=4HI620E`"K,6)!UN.IM?A0,.I!AX26IT3%AI??=*>2)'@2`X@^'B
M7UN*PA&.<M:E9[N<YT2BNOJ\?Y1!_P"IZU[[:**)ZO'^40?^IZU[[:)1:YC^
M'_;R),%D(NC;;1QP33+`90)=+%>%8'LB+@TRPMF01EII-I9;D.;CDQDMIMS/
M*IM&4E*H'N&O:L@5`+^W.UCP;:Q5-BNNTAQA"0E-.##I:6?E"0VBF$D=!R=#
MDOE(RG+^<N9)1;!A:&Q78P2%@AZS%Q8*%I%"#L58:9;RZZX0^YG&);G.$%$O
M+=><7E3CSJU+6I2U*SDHHKIZO'^40?\`J>M>^VB43U>/\H@_]3UKWVT2B>KQ
M_E$'_J>M>^VB43U>/\H@_P#4]:]]M$HGJ\?Y1!_ZGK7OMHE$]7C_`"B#_P!3
MUKWVT2B\N-R/JI-H]R]P;QN'-[X<2T=+WFVV&V2,;`;G;;#P$878)4J4>C((
M<O;62*&A(Y970B-N$D+;'0A*G%YQSL^:YAPITEFE_>9C=PR.N9Y7/<?P_"<2
M3RQ$TV[*DFG97NN2_P#(77F0Y1EF26$-B+*T@CA95L]<,;0T%V&X:,1`JXAH
M!))`'(L*^QMV.^7SBL^=3:_]$^NG\&M%?VTG^UZ)9/YF^(_]*P\6X_4I]C;L
M=\OG%9\ZFU_Z)]/@UHK^VD_VO1)\S?$?^E8>+<?J4^QMV.^7SBL^=3:_]$^G
MP:T5_;2?[7HD^9OB/_2L/%N/U*?8V['?+YQ6?.IM?^B?3X-:*_MI/]KT2?,W
MQ'_I6'BW'ZE<T?4U;(+5S4[^\56,\BL_A[K[6-IY$IRK/X3FU*4\N<8[F.7E
MSGN8Y<YQC3X-:*_MI/\`:]$GS-\1_P"E8>+<?J5P^QMV.^7SBL^=3:_]$^GP
M:T5_;2?[7HD^9OB/_2L/%N/U*?8V['?+YQ6?.IM?^B?3X-:*_MI/]KT2?,WQ
M'_I6'BW'ZE3^V"X>:5PY;?A[?45Z2DAVWWBY:TVV9AI6YVDUQ]]UDNR3``D0
M*8L%A_JXS;0S#++*<82CGJ<6O=M.Z7R72MI)9Y-:"-CW8GNV8GGL%Q`'(-@`
M``VT%22?*-::ZU'K[-&9IJ*\QR,9@C8VHCB;V0QKG.(Q':YQ<YSC2IH&@;KZ
MH[^.-YZ'X_6P+3J)U1W\<;ST/Q^B45,U!#I,+EFAHEN1(#!!-D,$13<@6!'D
M'/1P3Q/3)*+%`)EB7&6N5265$NJ3C'/7G)2JGJCOXXWGH?C]%%$ZH[^.-YZ'
MX_1*)U1W\<;ST/Q^B43JCOXXWGH?C]$HJ<6)9";4R&Q'",K(++6T*_',-K+D
M"WCSRE(:=0E1!IQ+CSR\XYSCKBEJSE2LYR4T55U%[F8<YX?-RK*.3M`#G\J<
M)5G.6^L])A/(KN*SCFYSRXQGEQG111<>J._CC>>A^/T2BZ!HML-E(XC4>*.C
M+BD,#$1[#*5.N*==4EIIU*$Y<=6I2LXQW59SG/=SHI7?U1W\<;ST/Q^BBB=4
M=_'&\]#\?HE$ZH[^.-YZ'X_1*+DH%Y.$9RL///3S\<V0`7G&.52>1>$$JRVK
ME3_PJY%<G)GDY,XT2BX]4=_'&\]#\?HE$ZH[^.-YZ'X_1*)U1W\<;ST/Q^B4
M3JCOXXWGH?C]$HG5'?QQO/0_'Z)132&_FP_\@U_TTZA<BC/L9_&S/]LRO]>*
MU)Y1]*L[P>X%)_4*J__3^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*H=\:=EFZ;0+_:ZV;V=/U[:Z6EH<_JPAG4Y`+MAX8CJI[!01'1.IQGF
M.MK0K[F<9QK7-89A=Y5I74&96$O1WL%I(]CJ-=A<UI(-'`M-#V""-X6W\/LJ
ML,]UUI/)LU@Z7+;F_ACE9B<W$QSP'#$PM<*CLM<".P5YR[?\26Y[FX;$992D
M3<*,WM]ME(1;D=$0^'-PW+WMQM_?[DR4#&Y.RVS-6PQ+87/0+A8N4H2G&4KU
MY9DFO=0NSQEOF$@FM&BVM',+6,K<^L6MM<S@M9BV23/`CJ&580`!0KW#4O"O
M2+=,27>50FWOW&\OV2!\DM+(6E]>6=J6ODP5,5O$3+0R4D!<2:M5T^D7NA8)
MV$D(#LB.@9Q>S:GX,E8KN8]FU*WQ3/ICY/U?*))<DFJ.&O"WN5+"QTX;3A+K
MV<]GW[U%>WEI/9=%'9S&QK&:'")OW#I,+^C))<+=AJ[8TM`:*.=7J?"_2.6Y
M=?VV9=/+F-N,SI*T.&,V_P"T]#CCZ9K6AANY!1NUX>2XDL91+<55R'VX+(#A
MF&CG-J8HL"WO3,<?9Q;I8>'">WFC)DRM-5&.K)P(15>>:)6A`XZG%)4@1+7.
M:PN>(^:LR&5\5J!,<M8YLYD:Z43RY7)?,>Z(0MB<UIB<'D!K22"(@VK4L^#N
M12ZIABGOG&W&<R-?;")[('6L.=PY9)$V<W+YV/>V9KHP2]X:"'3%]'G>^TF^
M<EN)<INI&5AN-"B1K.D&=5*Y69)E4FR`5*;<*AW8L!#3$A(F=..X(Z4RVTGF
M/9;<6A*MRTSK"XSS-;O+)<N$<4;9<,F/OGFWE;#(2PL:`'.=B:6.>T#8XM<0
M#YUK3A[::8R*PSJ#-S+/,^#'#T?>QMNH'W,0;*)'DEC&X'MD;&YSCB8'-#B(
MM,;_`.Z<1M]"M&[CNRMIW(V\V8GX:PR5<I^"*19KY:I2/L#;<?`UH*-.ATU:
M%+.$9,"))2L1S^$=3G^#\Z9K74=MDEHV7/C)F-_8V,D<KHH*V\MQ,]L@#8XF
MM<SH8WR,:^-[JL/?.![WU^7AMI"]U+?O@TL(<HRO,\TAEA9/<X;J"SMXWPDO
MFG>]DOK$L<4CHI6,(D;WK".^R0#?O<>VVS;N1AK#.1M5G(CAPS.,CPU#?JL=
M)[FSUP@+<#8W3XLF]-S,E(0C84,J-SD$8]K/7>C:6GG]^'6>?9GF>1SVE]-'
METT65](`RW,+7W<D\<[92YAN!(YT8C@,7X;)`>FPM(KBKGASI;)<FU-:W^66
M\N<6\V=]$72W@N'QV$-M-;/@#)&VAB8R4RW(G`EDA</5\3VFF3(WNO.V,589
M.P2\GN>PC=&^5#!-J(JU:%JU9V_*6WVIE&WNVK4D21+-FMX-,)'5&A="EUQ8
M;659<[XU=G&GK:^N+VYDS%@S&Y@K,88A#%;&F/\`]:U#R7APZ1[FF*/"'.,3
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ME&FI6W13`@L;9Y63K$87)3X(@#3`0@LL<ZX^AEI"&VDKYB4IQCDQFEC#RE;1
MT4)HB:(FB)HB\R=X.(C="N;["55F[,U';_MBDUZ`B6(VM25GW8O-NW:E**[5
M:\I^')D8FO52OQI!LR\GE-;6PQA#[*3F,YU>\S*[COVQ";!;8FM`HTND>Z0L
MPMV5`:`2[L\FT8@OKS0O"S1V:\.9\Y?D#K[5'J]U/-(7SQV^6V=KEK+P7,])
M6LDFNIGLAM6FD)#I"8Y'6\M-LS'%G+QEYW!J*:?!**IUD!@PZZY/3?KR1%N[
MD[.4)=RG(?%71%P];FAMTW)"'6R87@T8#EYZ5]::"VE?(BMA7&6^J+9GH.J0
M-FC5[!U/<E`<%;@)*9DMT[D58H6(V?AXT7+DH=)M6>(&!*>9$>6$LU*B6V,<
MW"X[-%?HS@+]M*T_Z?\`6OU5[%7M3Q?G[G;A4>F,4D6-=L6&(VX5TPZ:'W`V
MWFV=K3+W.R$Y`KK[@+]-@[9&KJCT@Z2#C,V0PTWAQ65(S*HIRZA0FB)HB:(H
M];E[\#;>W4*C+B.N24\'2FH`E9"6@\3-ZLU@J$9F7SR],-#!SH(""'FD.<QL
MQ6<YP[@=DDBW369T>T5NOV81D@86Q0<3.C#E(RV4P/+@#R#+)+>>3*"&FR,)
M7C]A6,XT17S1$T14IS)!`1@XABX\M\4AD4]#+)*P2'6EH8,0.2E8[ZQG%87A
M#F,H5E/(K&<9SHB@KMKOUO\`31\;'6O;HJ/(L<17I#"CJA8QQ*?(.;ET7:N8
MCCC6T1K4EUP)Z<LS#.<(4@4;ER3T'*V,1<P>)3>(6LCE';2RQ4HY5XA\?!M;
MNR7$V\JW05<]69Y5?JYJU&%U+)=K<)#CV4,@E,L($5D=3I)%+?;2S2MQHU>L
MDW%$0TI*"O.%`$@.Q;N,L&DB-%]G.G2O4FI)@=)+;:##F4-O)PT44WS2'"+.
MM$31$T1-$31$T1>(.^'UG-QVWWBW.V^B++LBB.I-YLM5&:E76G)1C$%*DQK@
MTDI-M&Y)`5X93;Z<MMJ0ZE2<I3G&<8^8=3<4^(.6:ASK+LNRJ)]C!<R,8XV\
MKB6M<0"7!X!.SE`7W#HG@!PRSW2&FLZS;,KQF97=E%+(T7$3`'/8'&C71$@;
M=@).SLK5GVMVX?PGV"^^W^>FL'\8N)WL:'\M-Y:VGY:N$/M>]_-0^B3[6[</
MX3[!??;_`#TT^,7$[V-#^6F\M/EJX0^U[W\U#Z)/M;MP_A/L%]]O\]-/C%Q.
M]C0_EIO+3Y:N$/M>]_-0^B3[6[</X3[!??;_`#TT^,7$[V-#^6F\M/EJX0^U
M[W\U#Z)3NX&>-&T\3]BO%=F@JC-#5B'CYA=HH#K.8R"=,*=$%A[&TJ:E,X)G
M\-/.`Y;5AQ74W^5"D)6XUZ?PPU[JO5&87]AJ')3'&R(/;*R-T;6FM,#@]QJ7
M5JW":C"ZH(VCPSCCPDT7H'*<HS73&?.=-+.8W02R-E>\8<721F-C:".E'XA3
MOV4<'4:[TCU[6OFA-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$4VQ?YL/\`R#7_`$TZA<BC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J_
M_]3[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\JTKO-!5RPR&8
MJR*!*CI&O(!/AI.'Q,1TB`\7(I>9-%>2X(2,^E:D+:<0I*L8[N,XSKBN+>WN
MX);6[@9+;2-+7,>T.:YIY0YI!!![((H5S6MW=6%U;WMC=207L3@YDD;G,>QP
M-0YKVD.:X':""".PM)&;5[22*#VY"$IIR)3)69-!E#CR42.3I9F?.R>EX1>"
M\F3H[9KO2<[I"T)>5RN8PK'0ER+))Q,V?)K5XDKCQ11G%B>)'8JM[[%(!(:U
MJ\!Q[X564@U/J2U-NZVU'?1NAP]&6SRMP8(S"S!1XPX87&)M*88R6"C20NKX
MI=GLBH!S7Z3D)O$/AL/U`C>JHQ7B#RX#"!^I]$G$&7*%.A\F/^V<)=4WS<N+
MSFO[!D71B']DM.B&"C>ACI^$7.CV8:?AE[RS_L+G%M"XUM[UZHZ9UQ[S9ATY
MZ6KO6)L1Z9K&S5..OXK8XVR[?Q&L8'5#6TL(&PFRL?-3TXF+KI1$]$@5Y8IU
M-CB8Z*K@-:'J6:W!B*`QB,KQT",@<D).<CO-XYF4\S\'73ATEIZ"[O;P93`Y
M\T38J.CC+61-B$/11C#WD3HP&N8.]<-A%-BR5SKW5MS89=EYSZZ9%;3/F#F2
MRM?).^=UST\KL?XDS)G%[)3W[7;0<6U9I&4/;J$DY&:AF*_$3$PEE$O+1E18
M`DY1`Z4H'3(GBLM%')80C&$8=6K"<8QC')R:RMOEF76EQ/=VN7P174M,;V,:
MU[Z<F)P`+J=BI-%@;O.<WO[2UL+[-[F:Q@),<<DKWQQEVUV!CG%K*DDG"!7L
MJS0>T.S59Z#U;K=&KW59)$R-V'M[%Q/5Y=L(N-;E6.H!#]#)(CCWQ\/IY'<,
M/.(PKFK5C/5L]/9!E^#U#([.##)C'1PQLH\-<P/&%HH\-<YN(;<+G"M"0N]F
M&K=59MTG[KJC,+G'$8G=+<328HR]LAC.-YJPO8QY8>]QM:ZE6@BM&VRVJ#2X
M@.*J0B'28LQU`U'"82X7"3)MBA2G$M#)PLF(L$D0<*O/*H<Q]QYO*7%J5GEC
MR7)X@X193;-!<QQI$P5=&]TL9-&\K)'.D8>5KW.>*.)*X)=1ZAG+73Y_>O<&
M2-!=-*:-EB;#*T5=L;)"QD4@Y'Q,;&ZK&@#]-VTVLDD-MR,75#VV9MZS,H-I
M`12&K(0YTQ%@;2^,XE$V^]CGK+QR/J5W<KSG4RY-E$X:V?*;9[1,91BB8:2D
MU,HJW_["=I?X1/940:BU!:N<ZUSZ\C<ZW$!+9I6DP-%!":.%8@-@C\`#8`LK
MZA"^[_\`=1??ZR2PU!O3J$+[O_W47W^B4&].H0ON_P#W47W^B4&].H0ON_\`
MW47W^B4&].H0ON__`'47W^B4&]>+F\'U:/U:DG;Z[$[D\3%II\G1W:N>!09?
M?2!B#`8UD6'J]9`PJULF7Z%B3:[!QL.(L*0#>4@1#[#J9)\HPCHY/EUCD&;9
MCGF4VS8<TN[9UO*\5=CB=)+*1A<2UK^DFD<)6@2#%0/PAH';OKRZS*QM<NO9
M3)90S"5C:4H\-8P&HH2W#&P8"2S97#4DGU@VHV@V\V:H,#MO3)V237J]VHX,
MY,-R4M*%FSLU(V*:D#SR%X4\5)3<N20O"$MLMY=YC3;;24(3D9)'RO?)(:O<
M22=Y)J3SKIM:UK6M;L:``/H'(MA]0A?=_P#NHOO]44T&].H0ON__`'47W^B4
M&].H0ON__=1??Z)0;TZA"^[_`/=1??Z)0;TZA"^[_P#=1??Z)0;UKN0V6V<E
MKQ$[D24;#'7:#4^]$3I,(<ZZ`:2$-&/2[`BG^SL3RHH)D3$AEG)R1&4,8=PT
MA*,=9UG;/G9=.@:9V\AW&E*TY*T`%:5ILK1;3:ZVU79:=O=)VF?3QZ>N*"2%
MI`#V->Z01EU,?0](]TO0XNB,KG2%A>XN.53DK0JP*DVRWZ%KP:U<Q!<YS(D5
M2^Y^`E\\H=I2OPL=S&>7NZS.793FN;RFWRG++BZG`J6PQOD<!OHP.-%H&;Y]
MD6GX&W6?9W:65LXT#[B6.%I.X.D<T$[>2JPR"W;V%L\FQ"5[?';^9FRL\T:&
MCYJ,)ER%=)EKFL1C<CDYY7/QR<B6\Y_"3G[BD\N7S'16L,HMWW>::6S""T;R
MR/@E:P;*[7EN$=T[]Q6%R?B!H34%PRTR366675V[DCBN8GO.VFQ@?B/<'9&\
M+9O4(7W?_NHOO]:PMPH-Z=0A?=_^ZB^_T2@WIU"%]W_[J+[_`$2@WIU"%]W_
M`.ZB^_T2@WIU"%]W_P"ZB^_T2@WJPR-(H<L\>1)/@&OR<:/$'OOP9*WB8X3M
M7(@KCG/POFB9G#>BSC.%-=:=YN<<]7*2@WJ^(C(%I"&FIQ#;;:$H;;1$%(0A
M",82A"$)5A*4)3CDQC'<QC1*#>N74(7W?_NHOO\`1*#>G4(7W?\`[J+[_1*#
M>G4(7W?_`+J+[_1*#>G4(7W?_NHOO]$H-Z=0A?=_^ZB^_P!$H-Z=0A?=_P#N
MHOO]$H-Z=0A?=_\`NHOO]$H-Z=0A?=_^ZB^_T2@WIU"%]W_[J+[_`$2@WIU"
M%]W_`.ZB^_T2@WIU"%]W_P"ZB^_T2@WIU"%]W_[J+[_1*#>HZS?"CPJV*9E[
M!8.'G8&P3T[)GS,W/36R6WLG,3<O)E.FR4O+21]<?.D)*2,?6\^^\M;KKJU*
M6K*LYSK&29+DTKWRRY3;.E<223$PDD[222VI).TD\JV*#6&K;6&&VMM4YC';
M1M#6-;<S-:UK11K6M#P&M```````H%;/H<<'WZL7#=\PFV7YKZK^PY'[&M/,
MQ^2N7WWUIUOS3\U/Z1/H<<'WZL7#=\PFV7YKZ?L.1^QK3S,?DI[[ZTZWYI^:
MG](GT..#[]6+AN^83;+\U]/V'(_8UIYF/R4]]]:=;\T_-3^D3Z''!]^K%PW?
M,)ME^:^G[#D?L:T\S'Y*>^^M.M^:?FI_2+9&WNS.S.U.99.UVW.V^V")_`2I
M[.WNWM<IF)M40D_,3B8368R,[3S'YDB,#Y?Y_0=9=YG)SU\O;M;"QLL?J5E%
M#BI7`QK*TK2N$"M*FE>2I6+S+/,ZSGH?WC-[J[Z.N#II9)<.*F+#C<[#BPMK
M2E:"O(%L/HAO*_\`D.?MZ[2Q:=$-Y7_R'/V]$3HAO*_^0Y^WHB=$-Y7_`,AS
M]O1$Z(;RO_D.?MZ(N26!,I7G)O-SC&,H3U9W//SE6,9QRXSR)Y$YSGN_[-$7
M'HAO*_\`D.?MZ(G1#>5_\AS]O1$Z(;RO_D.?MZ(G1#>5_P#(<_;T1.B&\K_Y
M#G[>B+ET`G,PKKOX>59QE'5G>XG&$YPKG<O)GG9SG')^QR:(N/1#>5_\AS]O
M1$Z(;RO_`)#G[>B)T0WE?_(<_;T1.B&\K_Y#G[>B)T0WE?\`R'/V]$7)3`F,
M(YIO.SE/*K'5G<<Q7.5CF]W/X7X.,9Y?]^B+CT0WE?\`R'/V]$3HAO*_^0Y^
MWHB=$-Y7_P`AS]O1$Z(;RO\`Y#G[>B)T0WE?_(<_;T131&_FP_\`(-?]-.H7
M(HS[&?QLS_;,K_7BM2>4?2K.\'N!2?U"JO_5^V/B&_)DW^CK_>JT^U_&Y69X
M*WK4_P`EJU_E^&_PX;15/*H6\<W:?Q8;F=C=>[6^*:;[.[,ZQVCUSFS/0=2Z
MI_W/6>?R<SF?A<OW-:MKCUCW.U-ZIC]9]2EPX*XL6$TPTVUW4VK>.&7JGQ$T
M7Z_T?J7[C!CZ3#@PXQ7%B[W#3EKLIRKS!O4M=^=+Q6TD+N+,4JM;@V3=^F)"
M(D0NCB-OMO:(PX'T]RD8P\RE2&Y4_).-ABY*>(<$=ZL,\E/-UX]G%SF];JVT
MS:7TN4V][+>P82YM&6UM;C#6=S'.@==22D,9C<XL=T<;P*+Z$T]9:?I97FM+
M_*X,^N\M@RVZQM8^LEY>W9#J6S)&-NF6,,`,L@C:QLC.EE8359E4828L>Y-@
MF9@*;73[P=Q`-@X:,M8A9Z0CJK-5@>R!O&-Q0T6,*EUR+R(A+_3I4GG9;Y^,
MY3++.[O\^OKJZAF.5WC\R#:.F:7870R1"5I<&!@%3#@`=B!%<-5@\[S"QRO2
MN66-C/;C/,OCR8OJVW<UF)EQ%<&!P:9'2.=A%QTA+,!!H'4*EUP^Q.(C9+:M
MMT<P>1.V_ITM.8D'373W9^2K<65,D'9D''24&/'K6IU"N3FKSG')C[FO3M$6
MWJND=.-<QS9WV4#Y,1<7&1\3#(78B3B+JU'8/8"\3XEWOKNOM8.9(QUK'F5S
M'%@#0P0LGD;$&8`&EH8`&D5J*;2MQ:VE:.FB)HB:(FB)HB:(FB)HB^,7C6F-
MLK+N%:WF+:1%HWWW3O\`:ZS?E.GQT77:E<XR>E*2%;&0SCXPX#=B'W!BY2TE
M%MLF(VH]514\Q39P6-9X>R17O$O49M;^2ZCMBV[=:S'I81@C9;ODZ)PHVQ8^
MQ>Q[`:.G=>R.Y65SFIFR0:2RGIK5L+I`8!-&,$AJYTH;C!J;DMN6EKCR1B!@
MY"OK#X8+#"V;AYV;D($V7/""V_KM9)=L27D6-B<I@+=0L\98\/ND+S8H>R09
M8A^<.O)46PYE+CB<X6K:9(WQ2/BD;21I((W$&A'<*P0<U[6O::M<*CZ#M"WO
MJBE-$31$T1-$6%;D6"3J>W]VM$,#B2EJ]59Z:C@,MO.X*,C8PDL=K+(Z%OO8
MRXUCE0C'.7_PXSCEY<9W2^76>;ZDR'*LPN.BL;F\BCD?4#"Q[VM<:G8-AY3L
M'+0THM8UKFV89#I#4^=Y3:B;,[2PGFB802'21QN<T$-[YPJ!5HVNY`16H\0[
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M`<=5"B@Z<Q7ZB_:#D0;\F/$1,],7H&VV%LEE3"0I*NP,.R<.Z[UIE#X[;2QU
M=93A9%(RJES,A6*X?8@41=@-@8<N=C$9RI$=,DQX[TF"A6<YRI`AJUMXS^SA
M.B*_:(FB*E."&D@C(XUKI@SQ2`BV>>XWTHQ32V'VND:6VZWTC3F<<Y*DJQR\
MN,XSHB@KMKMAQ25D^-'L5S*)#D(BO(N10LU`G#%S<5N718Q<I$*,B6)2,=)V
M.J)@IC>&W$.&'H=96E]2L"$V+F#4>,&,K(\6/86NT,5>(KN'1CJ:EJ+LC5N@
MI%RT1:"HA0_JX!MC&]C*8=:6^Y/+(=P(L9W!ZB*6^V@MN"HU>%O93IEJ9%>3
M*$$9!R2O&325`8+3&NE!,F-QJF4O--E2&&G4J1DT[*<F/D6=:(FB)HB:(FB)
MHB^>GB#XC.*R(WTW>AZ@#Q:IK$/N-;X>#]6J!N617%1T5.&QX[D`3'QRP2X5
MU(W.%>95EIUC*5HSE.<:^4]4P\5GZCSQV4YC?MRSUJ3H@U\@:&8CAP@"E*<E
M-E%]]Z$M>!HT7I;]^R[)'YR;"$S&06Y>9#&TNQESJXZGOJ[:UKM6G_I.<9_D
M7&A\W>ZWO7K`^K<9_:F9><E^I;9ZM_QW]E9!XMMY2?2<XS_(N-#YN]UO>O3U
M;C/[4S+SDOU)ZM_QW]E9!XMMY2?2<XS_`"+C0^;O=;WKT]6XS^U,R\Y+]2>K
M?\=_960>+;>4GTG.,_R+C0^;O=;WKT]6XS^U,R\Y+]2>K?\`'?V5D'BVWE+T
MA^KJW1XC=R+'N6C=1G=-BG0D+`K;^.2L6N`FG+'*&2&(S%/>L@PJBP$`1IG:
MB6^>EI61.7"5.)RKU?A2SB)'F.9C5-U+)E?1"G3%SGB2O>]&7`4:6XL?**X.
M1?/W'^'A)'E&1.T3:6L>>&=]?5.C$9A#1CZ8,)[[$8^B.PTZ3E`V>JNO<U\L
MIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBFV+_`#8?
M^0:_Z:=0N11GV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_UOMCXAOR9-_HZ_WJ
MM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RJU62B1%H.://)DF7F1$!I2&\*VUEI
MMY]Y*E)>#(7ES*R%<N>=C')C'<_VE!%5C_Q05KRZ<\Y`][-351A"?%!6O+IS
MSD#WLTJF$)\4%:\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJ
MF$)\4%:\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJF$)\4%:
M\NG/.0/>S2J80GQ05KRZ<\Y`][-*IA"?%!6O+ISSD#WLTJF$)\4%:\NG/.0/
M>S2J80HV2WU;'!-.2P4[+<.VTYTM'',R@1KVVNWG2,20Y;IS9Z4IJB6U&9+?
M4XMQ2<K<5G\/*N3')5C6QRON(VAL[F8"X;'%E2<)(VEM23A.RI.S:KESG1MB
M<\F,.Q`$[`[DJ!R`[!MY=BWW7^'_`&ZJ<+'5RJ@.5FO1`^!(F!KXL'#0L6(E
M2EI%CHN.A1@0ATJ7G.$--I3C.<]S4JM%>/B@K7ETYYR![V:FJC"$^*"M>73G
MG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5
M,(3XH*UY=.><@>]FE4PA:;L/`UPSVMS+MAVTK\FM1YLHYTT+7FT/2<CV;B0D
M2&F(9IL@XU,0.EUY>%..(;YJLY2I6,[?8\0-;Y:S!9:JOHV]&UG_`-KS1C,>
M%@))(:WI'EK10`FH%0*:5?<-=`9G)TM]I#+WOZ1TA_!8*R/P8WN#0`Y[A&P.
M<X$D-H30FN=5+AGVEH,=V11Z^/3XO.4J6!68VO08KJT85A+KS,;!C(?>_"SR
MK7A2\YSG.<\N<ZP.9YSF^=7'K6<9G<75S_W2R/D<.T"\D@=H;%L>5Y)D^1VX
MM,FRNWM+7_LAC9&WZ2&``GMG:LJ^*"M>73GG('O9K'562PA/B@K7ETYYR![V
M:53"$^*"M>73GG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*
M"M>73GG('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG
M('O9I5,(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,
M(3XH*UY=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,(3XH*UY
M=.><@>]FE4PA/B@K7ETYYR![V:53"$^*"M>73GG('O9I5,(3XH*UY=.><@>]
MFE4PA:F)K@+)#[272\I:>=;3E2V<JRE"U)QG.<,8QR\F/]FE4PA=/8`?LI/[
MMKQ.E4PA.P`_92?W;7B=*IA"=@!^RD_NVO$Z53"$[`#]E)_=M>)TJF$*L`K`
M!1.&7'C,)RR4YRH<9PKE9%>?1CE4.K')E;>.7N?<TJF$*C[`#]E)_=M>)TJF
M$)V`'[*3^[:\3I5,(3L`/V4G]VUXG2J80G8`?LI/[MKQ.E4PA.P`_92?W;7B
M=*IA"K!ZP`Z,>\IXS"A667&\)<9PG.7"F6%87C(^<YQA#F>3DSCNZ53"%1]@
M!^RD_NVO$Z53"$[`#]E)_=M>)TJF$)V`'[*3^[:\3I5,(3L`/V4G]VUXG2J8
M0G8`?LI/[MKQ.E4PA5BJP!B/;*Z8SI%F/CY3TC/,YC;([B<XQU?G<[*G<\O=
MY.3D[FE4PA4?8`?LI/[MKQ.E4PA.P`_92?W;7B=*IA"=@!^RD_NVO$Z53"$[
M`#]E)_=M>)TJF$)V`'[*3^[:\3I5,(5876`&$!*0\9G)(:2%\YQG.,+R^0UG
M".0?'(GFM8^[RYY>7NZ53"%1]@!^RD_NVO$Z53"$[`#]E)_=M>)TJF$)V`'[
M*3^[:\3I5,(3L`/V4G]VUXG2J80G8`?LI/[MKQ.E4PA2N'QR#L8_V,M8^\A.
MH5E&;8S^-F?[9E?Z\5J3RCZ59W@]P*3^H55__]?[8^(;\F3?Z.O]ZK3[7\;E
M9G@K>M3_`"6K7^7X;_#AM%4\JR#1$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$4<3OYZ9_2B/^JO1%2Z(FB)HB:(KG$?SY/]&/_P`/*T16S1$T1-$31$T1
M7,/^8R_]&%_Q`71%;-$31$T1-$31%<U?_AF/[3+_`*J'HBMFB)HB:(FB)HBN
M<C_%17]F(_KANB*V:(FB)HB:(FB*2;'\0S_)-_O,:(HR[&?QLS_;,K_7BM2>
M4?2K.\'N!2?U"JO_T/MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T
M53RJ(?%Y;=UH24VO:VOKVY<TQ49$S>&[JV]4D9DNO4*8K`SM3L?33$-FQQ-J
MBIZ22N&$Q('E*&2ZT&O+.'6N6,-.+$1N7#*7`MP@[-IIVE:*HO<Z:X@Y>I3)
M6Z:*FQ<=])664LN^0]8]0;13-K@MNLP]I&<"ALY1*N2BHUF/,ZY&E(*<;2PZ
MAU6!PAE12M!S]E!B+Z&M*G?R;*+3<F%NQ7MBMOE8DN(9\F2(XBI":*CK)O7:
M[YG<2/:G(G8@(P@>2FK8)5WW8EC#0#F40!A66EEM.9*<R];O2]W)V-W=5"'!
MC=KNSOK7L?QR*\[RN<1ID+ND+`2NY49:\W_AQ3!NUHNR#1XSZMN0"[D-#XBU
MX$35"K8A29=L;.!7<J7AW.%9Y=&X-FP4H?\`JC^DHZA-:C_HM3M63B<$ID;>
M%.[YE2;/%;9-X#ZJZ]<%'/;8-\.D+O'\4BX_#N6,4W%BR17QXY..H(D^5AI/
M6,<FK496FSP:=VM*JM9,(=WU<5>Y2M/_`(58_GB:KFS4)#FSV^LS<%P/&9MR
MB;$>W!DIJ2W"*W`J,?LO('$Q>"2X]+L9$R:X64?Z($$93G1/M-NXY\=X7'8*
M;#]:G\0,`)=6CAV>6NS_`/"V7$R/$*)Q0V`$TO=$O:Z;W`WK,@U.$69<!"MU
MW:G`P<8KG+R&U7).3E8XF$:Y,#8DABUL<KV5<D'!@')6@4C'TIJ3AJ?^BD)P
M3OSQ.R,$];I"W2-R=$K[EJ<NDKO+*334XNHU]<HT=G>,HD@20Q*Y(R2S!\R"
M2[G/5TXSS]4EIB-.3N?_``N2&N`5K7N__/\`_"EWKC7*FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(HXG?STS^E$?]5>B*ET1-$31$T17.(_GR?Z,?_AY6B*V:(FB)HB:(FB*YA_S
M&7_HPO\`B`NB*V:(FB)HB:(FB*YJ_P#PS']IE_U4/1%;-$31$T1-$31%<Y'^
M*BO[,1_7#=$5LT1-$31$T1-$4DV/XAG^2;_>8T11EV,_C9G^V97^O%:D\H^E
M6=X/<"D_J%5?_]'[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\
MJH+#>*_5R,#S#[S"NIX.4M+.5,MC<]]O+CCN5)0C"<CJSGE[F,8Y=0XAK2YQ
M`:!4D\@"EK7/<UC&DO)H`!4DGD`'9)5GQNI4<XQG#YN<9QC.,X"7G&<9[N,X
MSA7=QG4\NT<BJ30T/*J%S>?;]DGJ3LOT1G/%;ZHXEM!/2'8)R$CH%/8=YYF`
MGNBQR<KG1+YO+S5<G"ZXMVR=$Z=@EJ!0N%:NKAV5KWV%U-]#3D*[#;6Z?%T[
M+:0P4<<0:XMHS#C-:4HW$W%_VXFUI4*N^-2I>S'>9+[[7,NO4)\:E2]F.\R7
MWVB5"Z'-WJ2R\..Z>^T07EU(C#C&$/%*9;R\\D=I3F%O9::3E2L)QGFIQRY[
MFJ.DC:]D;G@/=6@)%305-!V:#::<@7(V.1\<LK(W&)E,1`)#:F@Q'D%3L%>4
M[%W_`!J5+V8[S)??:NN.H3XU*E[,=YDOOM$J$^-2I>S'>9+[[1*A/C4J7LQW
MF2^^T2H3XU*E[,=YDOOM$J$^-2I>S'>9+[[1*A/C4J7LQWF2^^T2H3XU*E[,
M=YDOOM$J%12>\U!A8V0F9F6[)B(D$N3E9630V!&QD:`PX4=(2!Q3S0H0(0K2
MG'77%);;;3E2LXQC.=$J%8B>(_9L*!@K29>((2L6A^O#5FQDRD6Q`V(FW.BL
M50>"EW3DQ\N_9WS641Z!W'%&J>1AG"\K3RQ44#JC"?\`YY.=3MJ10U"RKXU*
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M*,S'-#<][I4&OOYQT2N;T;C`S:>[R_=YS6>YI1,05%VV!^,YX-6E$Q!.VP/Q
MG/!JTHF()VV!^,YX-6E$Q!.VP/QG/!JTHF()VV!^,YX-6E$Q!5IEBC'D`I0M
M[E'"2PYRM*QR.8()<SR=WNXYKN.[I1,05%VV!^,YX-6E$Q!.VP/QG/!JTHF(
M)VV!^,YX-6E$Q!.VP/QG/!JTHF()VV!^,YX-6E$Q!2I'SRL,9Q]S++>?OH3J
M%91FV,_C9G^V97^O%:D\H^E6=X/<"D_J%5?_TOMCXAOR9-_HZ_WJM/M?QN5F
M>"MZU/\`):M?Y?AO\.&T53RJ('&=7)&W4#<:LP[!A4Q-[162/B`P"E!$GRSX
M5@Q&QZ7\/,)Z*0.Z-EU"UX:=:6I#GX"E8UKVKK"?,]*ZCR^U8]UU-93-8UIP
MESS&[`VM1L<ZC2":$$AVPE;9H'-+7)-=:/S:^DC98V^96SY'/;B:R,2MZ1]*
M':QE7-(!<UP#F]\`O,N95O[5HNP2<C+[F1%<:)V\AHT/*F6B.QY;=#9B&JP,
M5-%W)]U%O>K!<J)(8Q'BI6^Z1@\AY2F%8\ANCK7+K:^N)[K,(K$.MF-;L!P/
MN[%D+62.G)$QB,S)?PV`N+^F>\EA7T!8CAOG%YEMI:V64SYH67LKW;2WI8[#
M-);A\D3;4`VPG;;R0_C2$,;&;>)@$@-_KU4WH%F$V2?@;P<IZ1VQ62]TXSMJ
M-IM=E^)%\./-,:,1E=DC:O8(!HI:GL/8-(3E;F7.>K7=L<MU9'="_O;*\>3)
M:5-09G01/S0M:YP=_P#:V&2V#SBQ=(X5=6I6-S/.=!S6)RK+<QR^,-BOPT4<
M+=EU/'D8<]K2TT@?<0WCHP&X>B8<+0W"%35H3B($CH5W+&\3A-@-B")@.7E3
M"V:@8O>+;B8D(=@F7F'90J!C-L&3`%%YZ51CW7,XQAMQ6$TL(M<QP6CL&:F2
M=["]KWN<(7>O6KW,!>\O,;+0/C+^^QNZ79A<:<N:S\,9KJ_9TF1B*VCD;$Z.
M-K3<M_;+Z)DI;'$(VS27YBF$?>B)O0;2YHK>H>#XC`)J%DU&[EG)3(U"1.C#
M9YM<:^LC<O=6-L8#C9_61!P44!N$7S%)4RUTC;_-R[CE3V[6SUW#=VEP9LP>
M.D@<YCI!A-;N\;*TAU6AOJWJYH1A%6OH7;1T+[,.%UQ87]H(,IC)BN6,D;"0
M\4L,O?`\%F%SGF\-T*@ASJ/CJ&&AUZ]6^(B08CY&5BMX"S8ARP2E;(2?'^M,
M-.6#9M^/0C,JY*,,KCD;A82V\EI(@F>564!CAKRUC"/R_7,[()[FVS1TT1D?
M$<3>FCDDL2WP\8&'UF@=3`SE(B9$<*V6/->&-M)<VUG>9(RWG$,<[<#_`%>6
M*',P\GHQ&3C-E5S2XR2#8'3R3M#UL[>%O<J4W7V[B;.S:Y';>,K%`FKU7*"=
M96).V`DB[P1>Z+@L54"HV6L`E0W*^*PLA@1;S^(HHQKH'12"F7?H"TZ?U2V]
M;IZWT;<=.3'08J=JM:+Y1OO53>WGJ`/J/2OZ.O+@Q'!6NVN&E:]E1XHFWV[`
MK<BS9J]Q*1\:/#;C"WUJ4LE^O<@_+'[K;(G;$ESCL=>JL=O+%4ZIQ-D=M*:F
M9D^6AU%`Y6MTUH1WL[%U%,C@T<W+QM.]';G+L#\M"2E>B!R;78UV^R+E&-K-
MN"-TPIJTJ3AJ=.KV_1-MB\OLY4+A(.$,<C*&TI@TKL12TU5$T1-$31$T1:AW
M[V7J/$1L_?=E[RA_-9OL+V6:Z-GD("*%,%EH:49;5G#)+D3-QXQ6&7<*8?RS
MT;J5MJ6G-7L$C',)(!'*-A';!WJS'%CFO`!(W\B^;;;#@UWCWIWKC/J]]V]_
M2+)L=PH'O[E'1PX)C"YR%EIYH1$-&J)6027*,,G-)$)D77,1CIARV4N"/.1Q
M'GN63RW6H\PTW(ZEAEKL3*;"<45O(!R[&Q].^.-HV-939C8Q[=MO&1P91:YP
MQO\`[5X*.KR#"^5I^DNZ)KGGE<ZOV7.:?J;CH\.)CP8N/9P,!&AC1X(Z5+6D
M<,-A`XS*5NJ6XO#3+:4XRI659Y.[G.=>B+4%6:(FB)HB:(FB)HB:(FB)HB:(
MH+B5KBGC=SMRI1XVSR-)5('.45@"Q5%U&8U=]$D4KBXFQV!T7M7U%W"F11FI
M-E@+!E7!PM+3*&.M$5+9Q>,UYLDZ/$<S,$Q4.<B/KLS1F*V)9:WO%83A85MN
M<E@I'%1G-L.K]?>PKM$QQ8[+JT)P^TP1=K:.-&0@)1Z<B(^/LA[U6`$9J\]6
MT"C(@I2ZQYYSW7YM`H<%9D`QTN<L1/;#`DJT"WUE8CF&"*4NT;VXA&WM>>W8
M&9#O[F)3,^*.U$LML\DU)8BD<R#E9J*RYB%P-SU,DK2M?*K*6\YRV@BV1HBZ
MGV&"F'AB66B!B&G&"!WVT.L/L.HRVZR\TYA3;K3K:LI4E6,X5C/)G1%H/;+:
MR0HDI3'A168B,`I-]A;'$Q4F2S!.S4E<JQ,U>08KC#K<'VFF+:DFWSVQT%+;
MRTRZXMMME+9%':H;4\1E1@*JW4VO4YL22I*Y"NMS=6,6-'05-@(VXB$CK3)1
M/4[E<X0R1RS'GLJ6Y)I-?7TZC!%D5SBMMN*I`&WT(?<BV:E`,[4NR\0,9`8M
M;[=)E8(N^1I=O%+!00]9CXQ+L2A+#K9$3AT<TD%:UL&$5SA*/Q9'!6*/O5S:
MF69O9.XU_#(C-;KT<UN3(-&BB20ZHTJ4EANL'/\`2"92ZEAN.RVM60WD+CU$
M622NUV_$`36H+;W<!F-J(Q<$F7:CH2$`$$&EK9N;/VX:MPT@82Y78*'"F(,&
M/:P3(."@`M-,MN92_P!,184/2^-EV+.:D]QXQJ3(K<PZ,J$#K0S(=@+E>NP3
M")"39DLK<BV&GAB&\@8&4&\.K!#S^'>A(KCG;SB<BS[8W6K2:&#)E;PO0)I\
MQ7)(P=^9F+T;2"Y=R3CY,DIH8:4C<133><-QV6\)*:<91T&"*7-'$L0%4A0;
M8:J2L`8JAI"0<6,X\;EA]YL8HAP-@49PI\-+:G5(;0G+F59Y,:(LKT1?/)Q!
M_6;;A;?[Z;OT.!WQC8B)I6X]PJ8D2K;VH'*B\5V<-B'HY1AU%,+*4"0&MK+B
MWG5+RGEYZN7ES\IZIUIQ4M-1YY:Y3F#AED=U(V(=%:FC&N(`J^,N-*<KB3O*
M^^]"<(^#>9Z+TMF.>9`'YO<6$,DKO6+UN)[XVN)PQSA@K6M&@`=@!:?^UDW9
M_6"C/FSHWZ/-8'W\XR^TG>9L_1+;/@KP&ZN-_,YA^H3[63=G]8*,^;.C?H\T
M]_.,OM)WF;/T2?!7@-U<;^9S#]0GVLF[/ZP49\V=&_1YI[^<9?:3O,V?HD^"
MO`;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W\XR^TG>9L_1)\%>`W5QOYG,/U"?:R
M;L_K!1GS9T;]'FGOYQE]I.\S9^B3X*\!NKC?S.8?J$^UDW9_6"C/FSHWZ/-/
M?SC+[2=YFS]$GP5X#=7&_F<P_4)]K)NS^L%&?-G1OT>:>_G&7VD[S-GZ)/@K
MP&ZN-_,YA^H3[63=G]8*,^;.C?H\T]_.,OM)WF;/T2?!7@-U<;^9S#]0GVLF
M[/ZP49\V=&_1YI[^<9?:3O,V?HD^"O`;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W
M\XR^TG>9L_1)\%>`W5QOYG,/U"?:R;L_K!1GS9T;]'FGOYQE]I.\S9^B3X*\
M!NKC?S.8?J$^UDW9_6"C/FSHWZ/-/?SC+[2=YFS]$GP5X#=7&_F<P_4)]K)N
MS^L%&?-G1OT>:>_G&7VD[S-GZ)/@KP&ZN-_,YA^H3[63=G]8*,^;.C?H\T]_
M.,OM)WF;/T2?!7@-U<;^9S#]0GVLF[/ZP49\V=&_1YI[^<9?:3O,V?HD^"O`
M;JXW\SF'ZA/M9-V?U@HSYLZ-^CS3W\XR^TG>9L_1)\%>`W5QOYG,/U"?:R;L
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M<SI5?6N2SYI=9587&=6;+?-'Q@R1L=C:UW9`/_45=A/>XG4Q'\^=26N266>Y
MI:Z<S&2[R..9PAFD9@<]@Y"6U[@=1N(`.+&5P#*=9181-$31$T1-$31$T1-$
M4VQ?YL/_`"#7_33J%R*,^QG\;,_VS*_UXK4GE'TJSO![@4G]0JK_T_MCXAOR
M9-_HZ_WJM/M?QN5F>"MZU/\`):M?Y?AO\.&T53RK0V_%DJM1<*LMM64'#P56
MS*2DFV9AD<*-$)DW2'G!VXB2)=Z%*%*SS.7.<<F,)Y<=WJWU]:Y;9W.87TPC
MLX6%[W$$AK6BI-`"=@W`E=S+<LOLYS&RRG++<RYC<2-CC8"`7/<:-:"X@"IW
MD!1N<WUV%>P\T[8</)8J==OSC:Y!;J<UFR%QS-7E&DYJBL$/RY\B*@0=OG%N
M//-I0USE)QG!NU?IA^-KLUB(;;17)%''\*4M$+QWNTO<Y@8T5>7.:`VI"V9G
M#_6T?1O9D4[2Z]FLP0Y@_'@:\W$9[[O1&QDAD>:1M:UY+Z`K]SO]L3AV`:S8
MB.2RBBFQ)'6S,@9',FWZR.J1D<5'J$&M5B%<!R@YT9:"T9:5C"^YI[Y:9Q63
M?W9G_L-#F'"_#1TAB&)V'#'^*#'20M(>,)`.Q/AUK,LS)_[#)_ZCW-D;CBQX
MFQ"=V!F/'*.A<V6L37@QD/!+=JNK^\VR0K5H>(MD:PU3,/9LRW;?%(3%=7>)
M%>P[E4)CIU-&AO#9PUTF<%-+8_C4J1CLOU1IV-N8ODSJW:VTKTM7@8*$@UWT
M<US=E>_!9X0(73CT1JZ5^41Q:<O'/OZ=`!&X])4-<*;-E6.:^KJ?AN;)X!#E
M?$[@;9+M;E&3)I5;VAL%.5[%EC^TDM9&0;S<L=A_SG`+J2,L\O38'5AWF]'G
M"M=P9QE9S)V3B_B_=`VIBQ#'2F+DWX2'8?"PG%3#M6..GL[;DS=0G*I_V0OP
MB;"<%<1;R_\`;C!9B\'&"RN(47Y);A;50Q)`4Q8XF*,$B)"?+$DKW7`218&)
M+<`E9LA@J-:=9B(PYI;)!*L899=3E"U85C.-9+:L/W$:W"VJ?:%?9L<2\R;7
M";@&\U>ZXXT74@NBZY:17$1N4/UP3IT=*<C.1F^>GG+QRXTVIW$`W"VJE94&
M"B['$R4W*0K-DC88"]UPR5D:Z1CE'G@8\>-<++A7\?\``4VA3"OV%9TVIW%>
MIB?IE>C#9J?=7!PT<SDB0EIBSQ49&`#ISA*GS3S89@45G"E8QE2UI3RY^[HF
MQ8P1NKLP(J:25<ZV,JM@1LK8DD;C51E4!%S+8CL/)36'`4YB@)5J084,\_T;
M;Z7V\HRK"T\LT*=Q<'-V=E&HQZ:=NU8:AAHJ-G2)9S<BIHC&(.9DG(>(F7CU
M!8%:BI67:6*,0I>&7R4Y:0I2\93I0IW%F`$O4Y41D^+03)`D(2X.:!8XTP1]
MM:<+0XR0/"N,NH6A6,XRG.<9QGEU";%6=-!^YTKZ9#]X=%&Q>?NZOUH7`_LS
M?K)MS?+I8@9ZIOD!S+H+#\F`B1CG5M3<<"H.O.'2K\$MA]DAP9AT9<@(3&L.
MO2@[P2..VFBO;F2SLY&S7;)1&YC"'/;(YK'MC+6U<'EDD;@TC$6O8X"CFD\L
ML,D$++B=A9`YA>'.[UI8"YI<":`M#FN:36@+7#E!4[H.PTRS0L/9*_DF9@+!
M%Q\W"2\=8`"H^5B)41D^-D@26H-39`9P1"'6G$YRE:%8SCN9UR+C[BPR#VFV
M1K5^L^ZE?VOB8?<BZ"-`6R\@8AA[1806,AY9"E9ENN8-+$;5'L*PVI>484TG
M/)RXY=<38(6R/F;$T3.Y7`"IV`;3RG8`-O8`W*YED<QL;GN,;>05V#EY!V.4
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M2VR,*,TI:UJSC"4ISG/<T4[%:4W?;A0<&>F3:R'91(^0KS^+7$\R;`ECH.,C
MC8O'8W..$+D;-',(<;PI&73F$\O*ZC"B;%5E6BC!2;<*6Z\/+O"L',QCMBCT
M'OA$R8T*T8P)F#Z=X7$L:P.MQ*<H;=?;2O*<N(Y2C8KSTT'[G2OID/WAT38G
M30?N=*^F0_>'1-BP&0W/VQBCBXV2W`IL8>$^X,7'2-_K`AP3[2LI<&+%()9?
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MC">I\N%8SR\N>7N_[/\`:38N/3,_BE>=I]K:)L3IF?Q2O.T^UM%.Q<.<+["_
MYRW[5T4;$YPOL+_G+?M71-B<X7V%_P`Y;]JZ)L7+*@_P>:P3C.$_A<I32N57
M+GNIQ@-/-3R<G<[O=_9_8P38N/.%]A?\Y;]JZ)L3G"^PO^<M^U=$V)SA?87_
M`#EOVKHFQ.<+["_YRW[5T38G.%]A?\Y;]JZ)L4U!OYL/_(-?]-.H7(HS[&?Q
MLS_;,K_7BM2>4?2K.\'N!2?U"JO_U/MCXAOR9-_HZ_WJM/M?QN5F>"MZU/\`
M):M?Y?AO\.&T53RJ(W&)4I6^TVZTN#4(B8M&VLE"1JCWECA)-D%3`[&2GVVG
MW&F,.+QSE80K.,?L9U@-599<YUIK/,ILRT75Q;21LQ&C<3FD"I`-!OV%;3H;
M.K/3FL],9]F`>;&SO8I9,`!=A8\$X02`30;`2/I7G3&\*FX,#/S=@CS:Q(/C
M3L3+5@0R2/$8(AZ'N?MY8:/5CW6XLQ0##E,HG1..(0\EDY_[BT<Y>O+X.&^=
MV5[=WT$MN][9F/B:YSF@LM[NVEMX7'`["#!;X20'!LCN0BI7MUUQBTSF.6V&
M67,%W'&^WDCG<UC'%LMW87L-W<,!D;C(NKO$UI+2Z)G*TT:KJK83>HQN3C)5
MZJG,6NOD525F2[2<076H=>[TS>F7A$-5(1=GD!JZ<AA#CB0,O&_PKO-QE6NP
M=%ZLE%Q;W+K9[+F`PO>9G%T3/77W`+:0MZ5PB<&@D1XI.^=3:NF.(^@H'6EW
M9LO(Y+*Y;<1Q-MV!L\HRV*T(<3<N$#'3,+RT&;#%WC*FBN,CPWWF3JNX=<-]
M4R5.;;[@46C%.RAI>98VXWR6NP,_-CDP#*:\3%-E#C_P+IJ^GZ9:5<S",KYY
M]!9Q<9;GEC-ZLXFPN;>W)>YV-T]P^X;)(#&.B+`6M[TR'%B(-*5ZMKQ3T]:9
MQIG-+?UQ@&:V=W=M$;6]&RUM([5T,3FS'IFR%KW]\V(8,#2,6(#:8FTUM8WC
MS:7'H9=/:W*F=U&#<2AN9]P^7V8CMI/5AV%S$=2P(*L9P[!>#O\`@Z-OHN7G
M*QL<6FLS9JG]Q<^(Y6,P?>!V-W2%S[%MET1CP8<((,F/I.3"W#6I6GSZSR63
M0W[.V.<9V<JBR\LZ-O0AD6:/S'IQ+TF+$X.;$8^BY<3\=*`PV%X6]Z3MHK74
M#*KMW9[79$Q-A)O=TDCH^T`7^M[#M;(VUBLA(KY6(IJZ7N+D["++*.(&(BKA
M*XR,T^ZEQ_T"HJO*U<9WA8WC45'ST1MGL>?(-7_=_=LN$GI]1L)(R=^5Q#KI
MU1L835`CS95Z@3.[HDNVIF58BS7Y>S-.H2_F,D'50H5]VRX3]R:CO]MW?DY:
M#HE>D6;I9`YRQU^0D)"Z2%)XE(*W33,=7Z<*IFS3EOWR0<.T(>%70HEXT=L)
M+K0.$*[".RBSR!V/WTCZW++L\UF_R@/$Q`[UU.L6K<NP3L<SMK'(!3"[7=L3
M\-*]4E]MWD9D`GE,NM2LR`,2\8PX\LD94=C<BP"N\->_54L=ZL-0@=H*)-A1
MUPL>V)M6E#L5N/MUBX2]@MDH.@!0I=8P=&;90NXNUY$H6ZXO"W!8F)4@!UQQ
M;82H18UNEP1[B8NC$IL[).0-2K<UM%88(#US@7ILTBC7O@L=D!Q/6+:^21&.
MLTCA=>?2Q(GR\>5-8&*=0M9CJ8R<6_\`CE129X.-H[ILQ19ZG7'`#;@#VV<0
M(B+20]&GDT_83:2CST['R1@D69(!ES=:>#2O((#3JH]1#([#9"66X)JBE]JJ
M+X[^+R3M%TO.8M6P.]J8'>;=>2M5]KB=L]PXVS1<Q>%65-,B*Y%6.GCG/E;7
M'WF3+B<"/-!RVYY%D7A+H60U)UO05L;;B/J+.I\L.7SMA%Q%<G"UKW,;ZN7-
MD:277[V6EN6`C9;LM68AWX6;U'+TVE,KL67HN8S(8G0[26M)Z4!S2`!;!T\N
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M6QP<X[`.'%1N%)';'+5@Q!%D^Y?"O![E3UPG#[.</ZXLS3)L:4&1,Q8F9.K;
M;5H1X*+.F<1(I,>O;S!2W61FGBW"6TNKS@5G.B+%I?@WC9',\AB[D#C6>2W5
M-G4G1,Q/$R*-S40/.=<=F+F4,Q+1ST"W@AYEAH4YG.$X%'6G+JB+/1>'`&*J
MFYE'KUD9K-:W3D)HB<8@ZM'!EQT?/3RGCHZ%Y2W(=G.*62]"-N/@D80V@5S"
M.B&ZLZ1:^;X*JLJ-?C9.Q!S_`$K.83M.<I$&7,.TV/D]EB*Q5SBV2!1S&82(
MV6%#6OH4,$Y->=2PSG',415)'!I7")=$TY96EG+B"H@XQRJA+D2$G[S9W@D)
M!F1Q)H(&E#7F!HMQY72\\-CE5C.<H2V12+VFV_:VMV_K]#8,$.8@,2:67P(M
MR&!0S(S,C+-"!Q[\E-&-#`(/PPA9)IA;R6\.$/O/K<<41;%T1>!&_/!IQH7K
M>S=BX57;C;,JKV/<*VRM:,.W2;`.-KY4V8N%.-`5`.*`,-C>B==8RI70K7E'
M.5S>7/S'J7@MG6=:@SG-H[MC8[BYDD`V;`YQ([.Y?<NB?^16B]-Z0TSD-S'<
M.N;2QAB>1&ZF-C`'4W@.J`>R-JU-]`GCN^3':GYW6OS=UA/@%GO]\S_Q\I;/
M\TNA?Z-QYMR?0)X[ODQVI^=UK\W=/@%GO]\S_P`?*3YI="_T;CS;D^@3QW?)
MCM3\[K7YNZ?`+/?[YG_CY2?-+H7^C<>;<GT">.[Y,=J?G=:_-W3X!9[_`'S/
M_'RD^:70O]&X\VY/H$\=WR8[4_.ZU^;NGP"SW^^9_P"/E)\TNA?Z-QYMR?0)
MX[ODQVI^=UK\W=/@%GO]\S_Q\I/FET+_`$;CS;D^@3QW?)CM3\[K7YNZ?`+/
M?[YG_CY2?-+H7^C<>;<GT">.[Y,=J?G=:_-W3X!9[_?,_P#'RD^:70O]&X\V
MY2CX2."#B0K&Z@=OWA?C=JX>L--2485ME>T3L_8Y#!"$KKY3N8L0>,A"1^7K
MBG$$X(9Y6,-XZ3+B-ETEP4S7)\]L\TN<\D@BA.+\$@/>:CO,52`QWVZ@AS>]
MIMJ-%XC?\C]+Y]I:_P`DRO3[+VXN1@(N6'HHP0?Q<.PND::='A<TM=1^+O<+
MO:Y2N<I2N:E/+G.>:G'(G'+^QC'=Y,:^DE\6K\T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31%-L7^;#_R#7_33J%R*,^QG\;,_P!LRO\`7BM2>4?2
MK.\'N!2?U"JO_]7[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\
MJCQQ&[A@[8QLU<Y:.1(1%6IC]AD61XF,DI5T6/>DWGV0,23@S*G5-L_@(6\T
MWSL]U6.7.=8[.,TM\DRK,,WNV/=;6T3I'!@!<6M%2&@EH)W5<!VUE]/Y)=ZE
MSW*=/V$D;+R\G9"QTA(8'/.$%Q:U[@VIVD-<=P*B_5.+3;^VV<.K#`HB##JA
M3;:R=/UNM1\9A=Z(@Q(*JK>0:01BWJ+L0;3HF&LH2X]A*759SC&=;RW7^0YG
MF$671F6*5]K!,'2!K6?^P8VQPUQD]/BE8"RE`7`!Q*W#.>%.JLERF?.)1!-!
M'?75L60E[Y/_`%&RNFN`#&UOJV&"1S9,52UI)8`#3LE>+/;2(GAX%UV))4>Y
M36XN5"AJR["2B[PNY-1743EEM94V*]2"FREK0VAI;S&$Y7SE]':YU]IRVO66
M3K@N+S`&/;@,;_6.G#,+L8V`V[P\D``N90FIPTL^%6L+W+I<Q99M8(Q=&2-P
MD$L?JGJQDQL$9VN%U&8P"2X-DJ&T;BNAG$[MR#62Y]^2J2Y`*@/[C/4P1%)/
MN#D&/3U7E;`80,F3%R)RZ^G+K:AS'0W4XRM#ZF<=+KL2ZUT]#E\MZ^^89V61
MNC`V2)TYC$'K%&M;(6.=T>T%KRP\H>6]\NI#PWU;<9M!EL>62"VDS(60NG13
MLMA*;GU0%SGQ-D8P3=ZX/B;(T]ZZ,/[Q9W`;MU6SR!L-!RM)D9R+&'*EH(4>
MO$R\2V0EO*<2((^'7AEMK=2ASE[B',\W.<9SC69LLYRK,)YK6SOXI+R-H+XP
M]I>P&GA-!)%*T.X[#M6NYEIW/<HMH+[,,JGBR^9[FQRNC<V.0MKX#W-`<"`2
M-XVC8M(@\9%/*ILI=#*/8H88*LU*X1<+)5.CN3EJKUXFO5VMG5MN)L<I%$.&
M3><#+')+%)8<4GI&TX6C*M1AXCY/)E5QFTN77L4;+>&=D;VQ&2:*XDZ*)T09
M,]A+I.]+7O8]I(Q-`()W^XX/:AASVSR&#-\MGEDN[FVDE8^<16\UI%TT[)S)
M;QR`-B[\/9')&X`X7$M(%^-XJ*T+882#&ITI*BS@FVA35DC:Y1UP0:MW294*
MAC&)+GPYU;LL7#/(6L8$@<;'-6\XAO//QW)=<Y9'?6EG'8W4L<S;4B5@BZ-O
MKI>VW#L4S9*O+'`EL;FLV%[@-JQT'#'.ILLO\PES.QAEMWWS3`\SB9W[:V-U
MVYN&W="!&V5I`?*Q\FUK&N<*&MKO$Y5I,>5+M4(%M6-&6@JF-/;D8VMC&YBS
M1KQ+$S%PZH&VV/!#D*XPGIW'.B94EY"F5NIPYE'-8ZTRJX9<RYC$_+8X[@P`
MW4ELP/E82)&,Z.XEJ8R!B)PM(<"TN&*G!F?#?/+26SAR>:+.)9;1MT18Q7DA
MB@D#3%))TUK!02@G`UN)P+7![6'"';Q[?(]SX/T'&>UM;>O/:IV^1[GP?H.,
M]K:)5.WR/<^#]!QGM;1*IV^1[GP?H.,]K:)5.WR/<^#]!QGM;1*KQ9XB_KEY
M382][BP;/"T/;:5M];'*,5<"KC7JP0_8FY*Y0H;;D.S1K.@9%BE]O9SJ3*R$
MD,Q@+,D7A@0YO+./R/,[/4&I)])Y?(1G,=TV`MD!C87.BMIL8D<`PQ!EW"'2
M8L(>71UQ,<!W<PL9\LRF'.KD#U%\)E!:0]V$/ECPEH[X/+H7D,I4MPNY'`KU
M]H^Y@M_I5/O<-$!BP]UJU?ML4-+5J+"E1XVR1(DR"Q)AI;?2)(,BFI2\UA:\
M-N8RGG9Y.76073.S8LI[?(]SX/T'&>UM%%4[?(]SX/T'&>UM$JG;Y'N?!^@X
MSVMHE4[?(]SX/T'&>UM$JG;Y'N?!^@XSVMHE5!.R<<]J%W%H=/IVQ5>LT%N4
M99!Z58)FW5RGS-I$JS[@I$Q7JH13Y?$A$60L=U$*\L]C#S:4ER'9D>\P8[MD
M.FH765W<W.9X)8`W&UL9>UI?MHY^(4+01C&$T\%F-X+1B7YH\30QQ6N)CR<)
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M'L;M^R@C?K;N&::<>1"1UGE^IPID[(J#V_JR<QH4=$VR:D$&,ES@I*21`*@\
MK*$(7S\OM8;ROF$]7N_0.>Q`&7H6U<&BKCM)+&BE&G82\<QKRMK#=0V#ZX,9
MH*G8-E`2>SVOXVT]'FK$0XTVYF,AFLN-H7EIV"B\.MY6G"LMN82PM.'$<O)G
MDSG'+^SK2B*$BJS=5V=OD>Y\'Z#C/:VH2J=OD>Y\'Z#C/:VB53M\CW/@_0<9
M[6T2JQ.>W9J]6S(8L4E4(;,7&-2YN#XN,8RV`^Q.E,.-84+RE//#5B0<0RUS
MWE-ANJPC.$9SHE5EG;Y'N?!^@XSVMHE4[?(]SX/T'&>UM$JG;Y'N?!^@XSVM
MHE52G6@D((PQ,-&FJ$%()2$#`1+II>6&ENX%#:=;9;<*(RCF-I4M"<KSC&<X
MQW=$JM*5?BOVJM^'U1$I#*2AF&*#4NHMN(F19U^IQH+T(L*/,3).8L-T`BW6
M&\]9;/<PC+?1K:<<*=JN`G%!M01#+G2+/2XL%B"'LAJY*+B64!0SYT3#KD5F
M,L$1AD>'/S#<:\6*^0&B2:(&Z7+HQ"6B56T86\"V&,$F(D>%(`-0M32W:V,$
M0VMEUP<D4P`X`8^//"*96R0,0TT^.\VIMQ"5I4G!1573M\CW/@_0<9[6T2J=
MOD>Y\'Z#C/:VB53M\CW/@_0<9[6T2J=OD>Y\'Z#C/:VB53M\CW/@_0<9[6T2
MJ=OD>Y\'Z#C/:VB546;7QF\.%,LLY5+-N1'1=AKTF7$S,<FB7LO`4B&\IDH;
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MKJ.KN&>N="VUI>:JR!UK:SO+&/$D,K2X"N$F&20-)%2`["7`.PUPFFX.M+]B
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M]B%\V8[S1*]I.M+]B%\V8[S1*]I32&[HP_\`(-?]-.H5U&?8S^-F?[9E?Z\5
MJ3RCZ59W@]P*3^H55__6^V/B&_)DW^CK_>JT^U_&Y69X*WK4_P`EJU_E^&_P
MX;15/*HN<5-%>W*@+-1&S7(K%NH)E>S+HCU2>([,D[+#=:ZDDD+!>6,.<[H^
MF:YWW.=C[NL1J#*?W[(\UR;UCHO6H'QX\.+#C%,6&K<5-V(5WA9_2F?>Z^I\
MAU'ZIT_J5U'-T>+!CP.#L./"_#6E*X74W%0;&X.EQ4U*3\'<G1)`JV-6Z-1(
M5!Z1#!+C=R:=>J]'&-,62-(D(F'BJ4+$=&VZ*M;.,.I6US<-9T*/A@RVN[B]
ML\YPSNN1.W%#B:US;J"XB:X"5A<QC(&0T#F$M[X%M,*]2EXV27EA:9;F&G2^
MV99&V>67&!SVOL;FTF>TF"0,DEDNI+G$6R`.[PM?7&JN*X3)2($BD#7KI#HI
M.VN&R2*2^H9[-`(W.44IP-JU,N)[<%W+<0C&'L=3<$2O/3I7EM/);<.);6*V
M$>>-,T?JNTP;#ZL;NM6B8'\071`[[O"P'OP<(X;SC%#>S7CI=,N%O-Z]5K;D
M8AZX+##1QMR/PG6+2:M_$;(6CHRT..&-<(%JDV)VH2MF;!J0%2JE<@95JKX)
MDIV8B.'N5V5]8G6T61*XF-CU6`HI<:XEQ9+B&L(*;1A:G,4WAG?7#+S*[G,V
MLRQEM#%&\1`OD>S+'V'2D=+WC&]*]YB-2XAH$C0"79U_&C++23+L[L\E?)G4
ME[<3S1F<MCABESF/-.@!,%)'O$,<8G!`8TO)A<X@-WAMAP^N[;76?MB)UR88
ME$6G$?'KKKHIL>NYV0&U3O6)A^7D^LL=J!8P.R*.`TEG.,/8(<0AW&WZ>T:W
M(,VO<R%^)62";"WHZ.;T\K9I*O,CZC&WO6L;&`WPP]P#AY]J[B*[560Y=DSL
MJ,$D)M\;Q+B:_P!5@?;PX8Q%'A/1O.-TCYG%U>C,;'.8=817![,X!I4?9-R2
MSV*0'0X(!5:I;M7>(K&WRY^3B@W72[195)FR[-*C'/G?A-)2`AIH9O*U.ZUZ
MVX93]#E,%_J(O9:-MXV]%#T),5MTCV-),TOXCI7LD=)R4C#6QMJ7+;KSC5;&
MXSZYRK2`CDS!]Y,_I[GU@-GO!#'(X!MO!^$V".2)L6QQ,SGOE>&ABN=:X0FZ
M^36I-VS]J3U,1M/'U2POTU+<U"U_;*VV>7+@QI#$VZ2V-<:G8&H4WHUM-Y0)
MAY;;N%)8:[&7\-(K*2PN'9H)+VT%FV&4P@21QVDTKS&'=(32>&0024(%&!Y:
MZH8WJ9KQGN,SBS6T9DCH<NOCF+[B$7),4LU_;01ME<SH0TNMKB%UU%B#G5D,
M;7,H9'WJV<,)UECR`QKB3#D$[BWB\]J#U@A4D$+>"&7BXF-+&L(#S)(;;.$=
M(^HB.-QGFEQ[[>,-X[>9:!=?POB9G'1/=?W%QC$1Q-%P07,81*T@M`I5Q=%)
MR2P/;1JZ&3<5695<QSRZ>Z>)N5VEIT;IA@>ZT:0V1[70/!:XFM&!D\7+!<QN
MJY2FZJ3Y._X)SO=>BKR!.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y._P""<[W1
M$ZJ3Y._X)SO=$7S$\0G`O]8QN/N#5IH'9.F3S$Q:YFQ;IH]>]OF*-:9#<L,2
M%W/.GG#CH2WLQLA&"Y@&V1HR1(&HT7!J:4].8D$(Q&E;6^RW5F?9MG;HWY;-
M:4A,=3+TC73-9;/:X81;&,QO>]IZ3IGRT;A#",CG$UI=9)EUEE^-MY'/WX=3
M!@(C)E:0:F4/#VM:1AP-94U+J_0?P\5[=&O[*;=5_=L5A-^@*^W!3"@'FI#I
MA(<HF-KI,D:".-&D6(NLC!NRJ@VT!=IK?ZLG#'1XUFI.CZ1_1`]%B.&O+2NR
MM-E:<M.RL:W%A;C(QT%:<E>S3M5Y%N?JI/D[_@G.]U12G52?)W_!.=[HB=5)
M\G?\$YWNB)U4GR=_P3G>Z(G52?)W_!.=[HB\2=UOJ^N-61WIJ5MVNWYJH%0V
MPB)FK[%%S,0\#-[/523B*M#!1:HQFN3`5I)@Q:WRX?>=5U]U]6<H#3R(QZCE
M^KM-,RRXM[_)Y#<SN:Z<--6S/!>XFN(%@<7<@'>@?:Y5JMQD^9NNHY+>\:(X
MP1'4;6`@`"E#6E.[7L*6U\V,XMZ/!`/<..X-?3*0U$,7,Q5E0^+%7K<F3LUS
MO%NE0ZG(P4_6Z^NV3]ESEA_!XS[.<MM$$J'8Y7=>M,ST_=2O&=6,G1NF&$MV
MF.(-8Q@+PYKG8&MVC"0=I#<1V9&:US&)@-C.W$&;0>1SB7.)H00*D[QN)H%K
MZ,V9^LKF`*U:YK>6B5^_@DUP@B,[3DB*DN*8@K;'SD1.TV"VW'JQD@879AB'
M'$.FJP;%MN,F)8Z!@?MR9CHJ-\]O%E<S[0AU#A&.N)A:6O=)C``:0-C>]<06
MUJ7<+;;/'!DC[I@F%-E=E*$$%H;3LU[.T;#2@&U=J]CN*ZI[OU^\VF[;<G56
M4!D?C<CH^)9/M]QEGQK%B'(:MY6V,1-Y!@'BXII@-HJ.CFV(W.&!!VWNKM]"
M_P`SR&XRZ:UM[2<7#2.A))#&"K:]X)2VKJ/))#G5=M<2*GLV]KF$=RR62:,Q
MD''0=\X[:;<(-!LV5`V;`.13LZJ3Y._X)SO=:FLLG52?)W_!.=[HB=5)\G?\
M$YWNB)U4GR=_P3G>Z(M%7[8MVZVN6N+,Y+PDL30@Z4!@0$`H3#0DK/3CB946
M7C95DD$R6.`?RH3`1[*H["4$]&^ZC1%NL&)5'!!QXHI21@11PQTK2^ZM+`S2
M&&L+=<PIQQ>&T8Y5*SG.<]W/=T15752?)W_!.=[HB=5)\G?\$YWNB)U4GR=_
MP3G>Z(M`5[A9VFJLA#24%5I4$BOQX\3#I[;L#XX,:/N(#NI@-H8DUUG#+EVB
MQ2E8SC/*D=+>.1O+B5D5&CA-VD:"$`'@+,&P"(!&"9!MMO!(8AH^?8M[$,V4
M'*LD)CU7)C$NK'.Z3)RLYPO#?(W@BW+3J/&4.LQ-1K4:2'"0@ZQP!E].]EM#
MK[Q3W(I>.:VA9#ZU);;PAEE.<(:0AM*$)(LFZJ3Y._X)SO=$3JI/D[_@G.]T
M1.JD^3O^"<[W1$ZJ3Y._X)SO=$3JI/D[_@G.]T1.JD^3O^"<[W1%X^;M?5:[
MJ[G[H[B;BC\6*:X)>+I9;2#7<\.D;,*K\?-RY<A'P2IA6Z4:N75#A/MCY*4.
MPHG+?29;1E64X\5SC@ID^<YMF.;7&8.$US,^0C`[87N)ILF`V5I6@KN7U%IK
M_DUF.FM/9)I^#3`?%96L<(=ZP!BZ-@:74-LZF(@FF)U*TJ:56O?L>]VOURD?
M^F.,_2]K&_`+(O:3O$=Z99OYM<WZJ-_,M_2)]CWNU^N4C_TQQGZ7M/@%D7M)
MWB.],GS:YOU4;^9;^D3['O=K]<I'_ICC/TO:?`+(O:3O$=Z9/FUS?JHW\RW]
M(GV/>[7ZY2/_`$QQGZ7M/@%D7M)WB.],GS:YOU4;^9;^D4O>#_@-G.&.W6:Y
MV[=K&\DO*0K$+6W,;5L[>YJC3K[SDX0VH6Y6I$H],L889Y5(9RPVVO"<JPZK
M&-NT;PNR71V92YK;RF6[,98TD.&`$]]2LCQ4@`5V$"H[)7FW$WCIG7$?)K7(
MWY?ZG8-FZ20"1LG2EH[P&D,1`:232I!-#2K0O0CJI/D[_@G.]UZ<O"TZJ3Y.
M_P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D[_@G.]T1.JD^3O\`@G.]
MT1.JD^3O^"<[W1$ZJ3Y._P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D
M[_@G.]T1.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y._P""<[W1$ZJ3Y._X)SO=
M$3JI/D[_`()SO=$3JI/D[_@G.]T1.JD^3O\`@G.]T1.JD^3O^"<[W1$ZJ3Y.
M_P""<[W1$ZJ3Y._X)SO=$3JI/D[_`()SO=$3JI/D[_@G.]T134&_FP_\@U_T
MTZA<BC/L9_&S/]LRO]>*U)Y1]*L[P>X%)_4*J__7^V/B&_)DW^CK_>JT^U_&
MY69X*WK4_P`EJU_E^&_PX;15/*OTZU5R,3*+D)J.#;@UQC4R\02VVQ%.3+K3
M4:W(OJSAD-9.7VU8PXI.4MN(6KD0M*LD7&U6RLT>#+LMOG8RN0(3L>,1*2Q;
M08N#)>2$AH:/:6ZK&29.:FI`<((5K"R##"&F&4+=<0A1%CU*W9VRW',D`*!?
M*M<BHN`IMK.16ID*80U6-Q(\V5HEB0^"Z\P1!VZ.C2'H\IM2V"D,.9;5GF*Y
M%$5=<-QJ'M^PZ3=[=`54=BN6NWO/3DD-'-MU>BQ[$K<I]:B%HPF*K,:2V^:]
M_P``[2\*5G&,Z(LTT1-$5EC['`RTK/P<;+@'3%6)`#LD:*2V\9"%2D:/,1P\
MDPA65B.FQ1;1#:5XQE;3B58[F=$54#*Q\FN0;`+:*7%2#D5(I:SG.1)!E@<E
MT1WEQCD=0P6VK/)RXY%XT17#1%992QP,(=6XR7EP(V0N$T_7*L&82VP18)X6
MNS]N(B(II:L*-/9K%6DCU-(Y58%"><Y.:VK."*WQMWJ,Q5:Y>8FQ14G3[>+5
M3JO9`"D%Q$\#>'HP>HF19@_2-%BV%V:$P*XG.4.8?1G&>3/+HBN$)8X&RM2+
MT!+@3#41-2U<DW(\ELE`$]!%K`F8@I32E89/C#6E-/-9Y%-K3G&<<NB*]:(F
MB+J??9%8>)(<2TP.TX^\ZK_A;9:1EQQQ7)RYYJ$)SG.B*P,7&K$RE>@V)Z,<
MF;76Y:XUN*ZTVF0FJM`D5@.;GH\164OD1D45=(ELAW">:TN182KDRXGE(NG-
MWJ*55A"[%%-+NL_(U6I-O%(9<L5CB(BRV"3A8AMWF+-D0H.FRI;C2,94D>/?
M<_X6U9T176"G82T0D/9JS,15BKEBBH^=K]@@I`27A)V$EQ&9"*F(>5CWB`).
M*DP"&WQR&'%LO,K2M"LISC.2*ZZ(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBC!L9_&S/]LRO]>*U)Y1]*L[P>X%)
M_4*J_]#[8^(;\F3?Z.O]ZK3[7\;E9G@K>M3_`"6K7^7X;_#AM%4\J\EN)S@U
MJ^\&]F[DJ7Q`4VFV2P!REMCXHX1]ZV4N+W#V,I/"U9GV98.7B2(""8CPQ9'*
M'%&#FG20Z5-1W,R8;<&@&Q%Z"<3T/4Y3:Q)5OOH>V0=>W`VHL<-<I%F0,CPK
M?&[E59-/B"XZ)F:]*R:;?8R!H9L<0X0Y;T@CJCS16&7$U"+R:J7U8^SN\V[.
MYF[]<XQ2=W9^8J^ST-)R$0,988N$E:55:D)4[TW+PFYW8EXGI'-#;SS9G$W$
MN1QLG'EB%=:4XU;$:4HH6WJ_]631MK(*\5*6WP@01M[HSBEVSK+KFW:X^9@9
M#BM@%,>HE(DYG<F=,70MO8RO/'P];4I:W#W9$M9>,DJ2VQ5["E4=H^I\J,];
M;%9`-TH:($E)S?R5A(5.T`BPZV)O=N1%;B1L-D.,OL)7[)&[2F@O]@,R<<2,
ML@US!S)<:EN*2Q(MJ;J_5D5C<_<JZ;E9W7L-;F;AN!%;@$2(`$[(6%;L0R>@
M&M2I<I?"*H56XA4BMN-2!!Q9H8;:&5$O9Z1QR`Z@HBT6']5#0]P(^T3-:WPI
M;U.W#8'K]CA*)LZ-7J,^/0WZ#7TQ5=#JNYT83"=+-;5NHL"L%/DFD&E88=!<
M2A29Q=I%U57ZG3;&0CR+$UO43:82Z1$/-L035((KNV\P<^Q7D`6(RO4R^5>=
M,:13(MJ+"RW+#'I#;%P265T+J26,[E"E1NGP"L;VD[>RMYW*.BY.F4Z/H<DW
M7(^2D&IZ#@YZQUV+D<RMHL4E,,VJ1X<=T]Q*+)GOK*43B_&R"4H6,P.N,5*J
M5$8OZKO8VBW`&:LG$-7A[32[1PH;E"AV>APJAQX392K;F;&5Z*GQ'K@U)'5O
MB%G+TRY=>:4,BS3K)^>1KM+"`YQ$]A%UF_4Z;6PFW-2VMEN)&W5T6NU>D-Q<
MM7Z\%6908+8^0JELAI:))S/R&(5JF66W;KRT=A*U=G$;JOYRI_$2QUEC[2A;
MOVU^K3H++^Z6X<3NP.4WO]MQNU#1,SMC7)RCP5.@=^(>4:RUME`B[F3])&V_
MC@YY,J%'%QI[ZYI*#L')3A(Z1<>2BE8[>_JBZ;N#.'34KN/`PS)PV_*TURI;
M-0L%5(Z2WRV!5L8TB)@LVTT<"M;4/"#6&J`8RI^.ER99U9;SLGTXK&BK)?ZH
MG;*3)OQ8NX"ZZ7<;]NA=(25K>WM?BI_;P;</=:O[IQ4+2YAN26[$>H!\`EF*
M?90VEEU>"$,MJ1A&8Q=I%;1_JHMJJ3)1UO=OM<&,:J55VI"18-MC;E`07:UU
MW-<7+4,:_P"XMPG*?=)^?W;$R"0B1("!E6'RNJNX.RT-.*J*Q;9_5H;9[>";
MW)>XA(B<BXW9S<+8O<L,#;H")'K!MW>V:W=EK-<8T>YRD8NT?%Y4H#)3+8@7
M:09C1K_/><4IT75IL1:7GOJJ*,3NG9X:\[Q;,U?;W;J)W[L-541"QYVX\8CC
M:V])V/V^+M0LWBNURGU?;"Z5J7Q0112SEN&`Y:8>&6YEL><6SD_@*%Z#\(/`
M:'P@S^9"HW:KR,.9MYM_MY/1H.URZY)V`?;JGQ-1A+`9->OTVR#-.,P`KKS8
M08T>\MPM;@RR2$%,5+JJ5Z$ZJB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*,&QG\;,_VS*_UXK4GE'TJSO![@4G]0
MJK__T?MDXAOR9-_H[G[Q6GVE9G@K>E3_`"6K7^7X;_#AM%4\J\M^)W@&!WNO
M._5C-WGK-+^-'U;BPC'VE8NM$D;G#[!T`"/K%@S+A+IJ[)*[&AC9:::)5;`K
M%(0V$`K<2<Y<.I38BGCQ&T*G[G;=`TF[7=-`AR=SMF+>W--S[]8D##]HMVJ9
MO0/7XF;"G*Y*QLA/M[=+&ZR$6V6&RXX2WA66>;FH-$7ES&_5<\.5JF;I>MH-
MX=HQ-I9FFS441"4VAUJ8!I;EOA-Q+G2[7`;D5+<6'+AW8[:/B';4U@CIF)6'
M<BY/\%;4:2/;$>R-J+=5>^K,V=.V7NM&AK?`3-;WAW/$WJ78`:OBU0Y$43L$
MSM)6JM"F6FZW*7FJ#7E%OS==25,'(C62DBCJRVG#ZF(U18=0?JZMNN&3<>)W
M_NW$368,:NRMML$M89NK16WJD=?VMG*Y/2,?8IK<0^G5"9D(8+$S/R@T0DDA
M,4K(ZHX59J7F*HI1%W5OZI2IU,F!,B=S(\IJ"&H[3E5M&WLQ==O;&92K)7K*
MF8M58M^Z<U(R<G+E5$1*\,R0H@?:]C6&P.N>>R.Q]I%K0SZIW;O;]NH/V[B6
MKD5#0%TW*L=.>MVWT'"J8MVXVVVSM<GB`NL;BQM2E9&LT_ATQ*1(;\43'"OJ
M*),"-$&P.EB)["+--K_JE:YL'$;?S=1W?[<N&Q\40YMK,WZ&M,36ZYV*FGW"
MN1Q`=#W.J?1U(7=."G9*28+5(-D0-MDHI*6DI:*PQUV41;6W#^KBHN[^ZKN^
M(6[)S<?*6V'W$K=3"A`9S;B4CA7A;?&5FTA,SPS-^V]LM\M5WEY<=+HBI@*\
MEA)?9:;2Z[`=04HBT0)]2EMDQD!!^YK5E#?H4GMQ<(ZS[81DB%9H&8WCK.[3
M\HRV+:XY<3;X$6L8K,#(+46F&K<E(B-,K25C+4XSN4465M_5&0F)X"X2&^\Y
M:+0WTYTXW<J()/4NV6"=&-D;O)V"GHMD?UD&U;BV:<M.04&(8%F"@W$Y7U#&
M2&+L44K+:7]6IM]LKM!*5PW=:.,BH>?`W!L]CW1KTA9:#.A5.K[MQC\QNQ3+
MEN4=4)$J'#W4)D42(2X(40NNP9+K#O9>.E8B3R(L1&^IZVYRY*N36Y*;$LVK
MUFI".3&VD$8^@:L[4V?:DBU2[I,X1B9W'W`$L*):VS.$C9GI@?+RF&$*0TRQ
MHK?+?5([3BL5*-.W9C0)J1N,:8K)U/:A7=V)>,*NU]G*I9LUN^U.V6H&S`,L
M&RH8DHR40/5AR%N<P3&66,[D5#(?5-;5/[=;@T"O;UUP%YN8A";G?)W;:J7W
M<"M2U6WGN'$C"Q%EM%HM)IRXIVL[J",RH<WDDB5'&`D77DCNNBD,7:173;OZ
MN?93<SAQO.WM/X@:3NI1=P.(G?C?B-M='@(.WTRKS&[W#'=^'>&J=8;5N#=$
M+'VH"O8DW$DO2KQN'(X9K.6\JP2EB-:T1:$H7U2E7)CMQ[EN]O!L8S88G<GA
M\D)14)6X[<.KUIWAMX=)K:)N+W6LEG-HATY;=R)6["6>V*<%ALF%!BN8;0LA
M#H[%N"A>MG"CPV*X6Z1*;<QEIB9^H/28DO`1X%.)K94$6F+%A)-),H7;K2?8
MFI<*&!*6X:M9B)-9SB7^I/@Q\94FNU2MW7O<W;?:V.CIC<[<&D;<Q,Q*Y@HF
M4O=L@:A'2DVF(EK!F'CC;`?'C&RN(&`/-R.TI3W5`GWN;T;+BDQ2O(BQ><XA
M-@JQ(R,/9-\-H*]+Q$[ZK2T7.;ETN)D8NSYKE=N/JY(@GS0Y(4[ZHV^)E>IN
MI21V;*"$\SH265KFAW(K[4MV]J;_`%Z9MM$W-V]NM4KI4N#8+-4KI6['7H(Z
MOJ?1/!S,U#R1D;&%0BQG,%MONH6-EM6',)YN>10[D5XLEZI--@%6NWW&JU6K
M(%(.79;)88F#@$`B11DZ48J8DRQ8Y(HT)'$&..9<YB!6''<YPVA2L0BNLW.P
ME9B3IZR3$57X.+8R5)S4W("143'#)RE*B#I$]X<,1A*E8QE;BTIQG..[HBL$
MEN1MW#5Z;MLQ?:7$U2LRI$%9+-)6F#!KU?FQ)5J"*AYN:*.:C8F5&FWT!N#O
MN-O(+6EG*<.9PG2B*_RT["0+83LY,14,U)RL=!1SDM("1S<A-S!*`HB'"68\
MRDJ5E#'$M##MY4\^ZK"4)4K.,:(L6JVZ^UMYD"(FD[DT&XR@O:76HVK7&NV&
M0&[%S")F.L!Q,B60SV3FRQV"><G'09D!N?S>G:YTT.Y%ET9+1<V&B1AI*/EX
M]UTIAL^,,'/#<?!+?`-904(XZPMT,X9QEU.%<K;K:D*Y%)SC$(KAHB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*,&QG\;,_P!LRO\`7BM2>4?2
MK.\'N!2?U"JO_]+[?-\HIZ1KIB&D95E0[F,8QC_^E6-3V59G9"VK2C!#ZA6B
M0GVR!U0<8VEQM6%8PXP&TP^RO&,YYCS#S:D.(S^$A:<ISC&<9U"JO/?>;@:M
M^YNY&^UR"W!C``MW$MBPR92`)EYW;9%BVKVTVBL-BVLG!;!`*H=NC!MO>U2G
MW1YAF;0L8/"`^@<=>L';`BE?Q0[$-<2FREJV?5:RZ,_83JE(AV\",3+'P9-5
MN$#:N<('F0B5K[5'AG`'LH)95U8MS'+G&<I5`-#5%#_;/ZM@;;:_A7AC>F6E
MV8^%N-;!@'ZH4$''P!</N]M[MI&`.BW?F=6HNREZK-9/;)9*'G%4*).2U'NH
M;;'DNJ*(M$R/U/T[AX#%3XH4T4.!CZX!5/5C9?,7,55N/KBXBT,0\U&;LQRV
MHBZ3#KLH0`IK(C!I13R$**+)*=G'O"+8^Y7U54-N#M-NSM4O=>-P+N/?YBY1
M1]IVN7<`*LQ)PN]M;&Z6M.[B0\3*W2&K^]*PQYX7LMW(\'&LN#K8&::;C%R(
MLTH_U<3E)EN(\\7?2<<$WSBM]8&KQ8-5*AA=I*SN_:Z]8(&DP8X=X5'2U$VU
MCJPR!'Q^!@7$(/DLAOQ[1RAVF+DV(HN3?U.]LO%HM\Q8-^:Y6D![Y;D[D;>R
M$#M.1)&,0&ZO#]MUMH[&ACE[DB*I8NR=AC9AC;8)I^0Q5XY+:E/&*)=0W.+M
M(I$;<_5D(IEV3<IO>9BTMYCJC"9KB=L\QL(%`U_A\XB=B;)#0C,AN#8W8T'<
MX_>X"WV-M:B&I.SPA!+B,]HL]F075["*MVJ^K>D=L=L3MN\[SP=B;?8VB:PT
M9M`Z/2[`C:_=R?W37'[CTA6YYN+G`$`S3-9B@V)"*S$5N,"#><D$,\BF+;6B
M+JS]7S=*QM??JO7]Z#+;/6HF@M#1<W&RT'1)IBO[MSE\GK#NI#DVRV2&X]RE
M(*U.1A!F2X[!L9!Q0:D-X84\IBVA%KH;ZI)0Z[<1](5U1UWD&BI8_&UN4%0\
M6)7MQ(4:ETYW&Y&5PE"*^,/JYT61D]LB%@X@%I0Z@LE.SCY-B*U;E?4]AWVM
M;AU&/WY&K%=W`H4Q2TQ#&T#9L=4RS+GFS@6>K1S&Y,5'!2SU=CXNH2V5LN*D
MJ:"J,:6$AQIP<'=I%OFN_5Z'5VBNU%.\,?,$/[N.;HFN3>V\F35)U6=N+_0!
M1['3!-T06BK1'&7AB<'FP3(YQJ7K\0]@?G!-YU&+;R(H_(^IZ4PV@S._\-8[
M,%,;5RT3/[B[&MW]L1[;_:[??:VRFDPTMNHR`[,[F#;QBS,LX-U,%^?@L&$!
ME9+6AF<7:1;#V9^J[D=J]PCMP)7B#=N9KJ=N`8P5_;0J-<A:_0N%3>7AF,KH
M,B;N;8241EI(W,B[$2VG"&L$5H<=3;JEM%B075%*(L0$^J3F1XH`'/%%.)*;
MF=GIB2-;HMBD5/L[04QFEO5:-)MV\MKGQJ1O+%!"!7N,/D)1,O!1X44`N)$!
M"2/./M(NXKZHD%QVL.A[Z)"5"R9<Q,YSM@0<]9CQ]F2=JJ6](&F[FO2#RMN9
M`UZ6A%EO'/@\_J[+C:^<4IC[2+6>?JD-S8F[[?PE>WNKWQ5UY.P$Q(RS],+"
MF(D_93AONVR5UK->J+-H+CL5OB.N,Z'8KH-DQM,V*^6.^^V8$P;*,7:VHI9U
MOZOF5HVSVW.W5*W>KPUKH>[%\W++OEIVGE+4W90KOLAO1LDQ5#X;XVH>>6-4
MXG>!3L:05.&]"/&MB9:RAS+C<8MI-$6HP?JDV8PZ8+8XE+H>U-[-[K[=%"3%
M3:9;3;KW,6^1JUQ-=I]NII-UJM3C+?F*DJQ:UV(>RQ$7'`$EL@!H%S.+M(MW
MO\`AOK?/6J/WA;C56"#XG(4U+-"-?D^AXA]SN)/<L%@>0)W$<CXR.H\AQ"IP
M0@`$(NPDP`CQ9*&VPQ@(Q=I%IFS?5/B6+8BV;+.[RPKKEHEP['FQS6S;4V(#
M:TUG>NG2=SQ75;D!9)N1=>W=':'D^O-DC+@!,KR^US669Q;:T19Q!?5H,0)N
M_#[&])C@.[H>_@E5BT4=T,':T+>*_@WJMU",##O3,;-;8[;O13.&(3(P;CYK
MQA(I<:DGJ[<8N38BTUOY]3^7OU7=X!)3B)CZ_:]Z;*[8+/80-EG3(P80V\SU
MXE:G'P1&[;<DNH2AQL<IT(B4?2LN+02O*U9:0/(?2FQ%M/;SZLDFB;A5^^/[
MX#67,/N!2[R_%2FUY/0MDTJW-6KM"JYSN:_'TZ\W5G"8RR38X;N)>,`C&<B-
M=0QEZ,2+"]Q_JHYN^S<?)"[_`-7@XR'VQMVTT)7BMBI&V1U=K%JF=O)A1%45
M8][2WJ68"JA(8&CX;,?5XAI;*H.(AGF7G2YQ=I%BD)]3J;"0+T6/Q'`]H,E6
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M>3A6%)SCNXQG[N.3_P#7ETY?I2I!J%H`O:ZQ1!)#U4L$U`H)<4Z\Q&'/LB/.
MJ3S.E=#PO(KCN$]S"E(RK'<[NI^D*U6E6W-.W<_8W"LV/_G-Y_\`HZ5[2FC4
M]3=W/E"LWAF_%:5[2B@3U-W<^4*S>&;\5I7M)0+]Q3MW.7N[@V;./Y=O'_T<
MZ5[24&]<O4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S>
M<(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R
M@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.
MW:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O
M">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW
M4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$
M:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\
MX1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE
M`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=
MNU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>
M$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?N
MI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*!9O.$>(
MTK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[=KY0+-Y
MPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\)ZG;M?*
M!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=2@WA/4[
M=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1I7[J4&\
M)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;SA'B-*_=
M2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4"S><(\1
MI7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV[7R@6;S
MA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X3U.W:^4
M"S><(\1I7[J4&\)ZG;M?*!9O.$>(TK]U*#>$]3MVOE`LWG"/$:5^ZE!O">IV
M[7R@6;SA'B-*_=2@WA/4[=KY0+-YPCQ&E?NI0;PGJ=NU\H%F\X1XC2OW4H-X
M3U.W:^4"S><(\1I7[J4&\+CFG;M_L;@V;'_SV\__`$<:5[24&]?GJ;NY\H5F
M\,WXK2O:2@3U-W<^4*S>&;\5I7M)0)ZF[N?*%9O#-^)TKVDHU5;>V=OF\M,V
MBTS\R&A;:\A&GO=16MM>5H6Z&VIL9YQ&<\N%+3G./V,Z5W!*M"WU78`>"#;'
M90E/,3A/<QC&.Y_LQJ.3Z54G$>TLCT1?_]3[^-$7%7['_#_\7_\`+4CNJ#W%
MP\%JW.HYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3
MG3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!
M:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)
MX+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.
M9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%IS
MIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M
M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\
M%ISIS)X+3G3F3P6G.G,G@M.=.9/!:<Z<R>"TYTYD\%ISIS)X+3G3F3P6G.G,
;G@M.=.9<D_=_]S_X?NZ@]U2.XN>JJ4T1?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g662896g97j81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g662896g97j81.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0L:4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````:0```+T````&`&<`.0`W
M`&H`.``Q`````0`````````````````````````!``````````````"]````
M:0`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"'T````!````<````#X`
M``%0``!18```"&$`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``^`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5)`P\RG,J-E4C:XL>QPAS7-^DRQOYKD=)2/(R*L:A]]S@RNL%SG'
MP"I=,IOML?U/+!9=>W;323_-T_2:P_\`"V?SER&/\KYFXZ].PW^WPNN;^=_*
MIQ_^G:M5)2DDDDE+`@ZA.AV$L_2#4#Z8\OWO[*F"")&H/!24NDDDDI22222E
M))))*?_0]#SL:^B_]I8#=UP`&30/\,P>'_=BO_!._P"MH61GCJ;:\/IS],AN
M_(N&AJJX<W^3D6?S;6H/5LG-JSWFBQP;CTMN-0/M<`_:^1_:2ZC8UACIWZ`W
M5NS<BROVES0WV;C_`,(Y59<[`>Y<3>(@5_G+/!Z6P.6D>#45,7?[FG%ZG9HI
MJQZ64TM#*ZP&L:.P"(LRW/NHP,,UM];*R&L#6N/)V[['I.ZRP=,KS0S?9:0Q
MM0/Y^H<V?[*?]ZQ`D$T8P]R6GZ/_`'WKBL^[Y#1`NY<`\_Y1=-)9EF=U/&Q;
MK\JBL;&M<PL<2)+@PUO'TMS934=6O^U5T95;&"VLVM?6XNAH&_\`2-<T?FI?
M>L0D(RXHF5?-&4?G/!'B3]WF02*D!?RRB?E'%*G45?&=M?9CG_!&6_U7>YO^
M:L\=5ZC9CNSJ<9AQ&R0USCZCFCZ3]!L:JW4\S(R<S"Q^FV&BWJ5<ONB2RIDV
M.VC_`$GTO\S^6@.;QD7'B.@,1P\/N"9X82AQ)^[3NC0WXC=\'`.*7'PO0I+G
M^FNQ6=395C];MRW`O9=BW.%FYS0[=L=M9Z3JGMWI^D==ZCU%]9]+&94Y[FO;
MZI]6&C5S*=GO3AGCH#H22`!Z_E_N?WD2Y>0L@V(@$F7ZO?BZ3_N.^DN?P/K-
M;D9-^/?2VHM;:[&<"2'FDN:]FH_D_P#5HF/U[)M_8VZI@_:;;#=!/MV!KAZ?
M^=^<B.8QD6#X;?UHP_[M1Y;*"01MX_U93_[B3N)+!KZUU?.MN?TO$JMQ,9YK
M+K;"U]I'TO1TV5_]<3LZWGY/5+L3$KH]/&L%=E=MA;<\`Q;;0V-FVMON_P#.
MTO?AI5ZGACH?5_=5]WR:[:#BEZH^G^\__]'T5^&ZSJMEC]IILQC4X3[M7:^W
M]U5,7I&57B9;;=KK[*_0IUD;`#MU_-W.*MC_`)>)_P"Z@_\`/CEH*I'E\624
MI$&XSR#?]_TR_P#06Q+-.`C$$48P.W[CD-Z;FV7XY?9Z#,6AK&/K(<[U(VV^
MU[7-VH)Z+F"F[':YNUEK;\9Y.I=&UX?#?;_Y-;J2)Y'"=^+K^E^]'@_[U`YK
M(-N'IT['B<K(KZOF8=]-M559<UH8&N))<'!SG3]%C-H4:>DVX^4QU36MHNI]
M/*:#KN(U>R1^\M=)./*0,A.1E*<:J4JXO23+]W^OZD#F)`&,1&,3?I&WJ'"X
MC,/K-6$[IK&U.K,M;D%Q'L=]+]''FJF1AY-O4*ZNFN:W*Z0QGIV/G8\.'Z6J
MS;N<W=^;_P!>9_PBZ#,RJL/&LR+?HL$QXG\U@_K.5'H&/8W&?F7_`,_FO]5W
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ME]WCP\%RX?W>WDH<S(2X^&/'7S:V?$ZO_]+T4?\`+Q_\*#_SXY:"K?JG[1)G
M];]$2-8]/=_VW_.*RHL4:X]0;G(Z+\AOAT(J(&JDD&PY3236&6-_=<2PC^W%
MF[_,0SE9(T^QVN/\EU4?>^UCO^@I5C:0[\BG&J==>\5UMY<53??UFW2C&JH_
MEWV;O_`Z&N_\^JE9CX-64QW6LIV1<3^C;8QS,<'^1[?1_K;[/^,24JNN[KN0
MV^YIKZ929JK=S:?WG?R?_5?^D6ZF$0-O':.(3I*4DDDDI22222E))))*?__9
M`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`
M<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(``V
M`"X`,`````$`.$))300&```````'``@``0`!`0#_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"`!I`+T#`1$``A$!`Q$!_]T`!``8_\0`L0`!``$%`0$!````````````
M``D%!@<("@0!`P$!``$%`0$!``````````````4!`P0'"`8""1```00!!`$#
M`00'!0<%`````P$"!`4&`!$'"!(A$Q0),4$B%3(C,[0U=19")+8W=U%A4D-C
M<[4V=A>W.1$``@$#!`$#`00$#`8#`````0(#`!$$$@4&!R$Q$P@B05$R%$(C
MM#=A<8%BLC-S=!4U=;5RLR06-G:A4E/_V@`,`P$``A$#$0`_`._C2E-*4TI3
M2E-*5&9V4SS(NQ')]=U-XEG.'5QYC)O+^4QO(T*#$K#`++K#/$J,+#HB.8IQ
M^;4D6C@Q?)CF/\KR`(ON-_)2I%L6QZ%B6,X[BE:226NQFBJ,>@%FE^1,)"I:
M^/6Q22S^+?>DO!&:I'[)Y.55V]=6B;DFE5W5*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI7__0[^-*4TI32E-*5IYV[[!R^)<:K\+P9"6/+W(J
MI58E6P1_*GU<>8;X#KY(@T>1\I\I_P`>O8K=C2]W(CFA(W5R--1N?PBJU<?5
M;KY%X'P)!VB"G<BY6HK;.[KW$DD=-=[A(]'&EJKG%@4Z'>BO\G?(DO*;?Q>Q
MK*.^H_P52MH-?%*:4II2FE*I1;'X4E@9Z#$"47VX4QJJT*D=NK8LGS<OLR%1
M/PNW\"?=XK^'2E572E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?_T>\'`^2,
M%Y/JI%W@.3UF45<.>>LERJTCW)&GQT8XD<XC#"<3E&1KV*YJ-(-S7L5S515J
M05\$4J]]4I32E8UY<Y3QGAK`KO/LJ-M!J@H.%`&1C)MW;R$<VNI:YKM_.7.,
MW;?96B$UY7[#&]R552Q`%*TNZE<69-R-E=EVTYD&LC)\J(8G'5.<9&Q:.B()
MT0%O#BG5S@1E@.^/6-7=?C>4A5>\[")=D8`>VOI2I&]6:4TI32E-*4TI7FEQ
M(\Z,:)*&A8YV*,@W;INB_8J*FRM<U4W14V5%3=/73TI5I4UG(K+1V*W!7$*@
MU-26!?ML8:>7Z@COL67&:U47_B1J_P"Y75/D7I5[:I2FE*:4II2FE*:4II2F
ME*:4II2FE*:4K__2ZJ^5,&ROIER6_GGB*`6?P]D\V/$Y,P*-ND.H25+<1SHT
M<0T!75JO>JULK94@2R+'=_=SM$2^I$@TM^+[*K4CF`YYB_)F)4V:X?9#M*&\
MBMD1C-5J'CD3\,F!/`USUB6,`Z.$<3EW&1JIZILJV2"I(/K5*NF7+BP(LF=-
MD!B0H4<TN7+DE8&/%BQQN-(D',16C$$(F*YSG*B-:BJOIJE*BOALL.]_.WYA
M(%+#UMX@L'BC!(A8H\RMW*UR-?NC"/D7GLL(5NR/A5*-8OLGD^3[_P#5+_/-
M*E3``$4`8T8(H\:.(8(\<`V"```F(,00B&C1B$(;4:UK41&HFR:L4K]=*4TI
M32E-*4TI32E6-G]*6SI'S8"N'<4;EM*TP_0OE'V(8#%_ZK![M3[R,;]VJ@^:
M54<-R0.58_"MAJU#.18\X351?8G`V:=FR?HM?NA&I]O@]NA%C2KHU2E-*4TI
M32E-*4TI32E-*4TI32E-*5__T^^JSK*ZZKI]/;P8MG56D21`L:Z<`<F'.A2Q
M.!)BRHY6N&8!PO5KFN145%T]*5%C-CY/T%Y36T@LM+_K+R-;>,N"UQ9LG#K0
MK7.08&D,UK+6`%GZDC_XE`'[;W..%'LO^)5_GBJU<W9'F*Q[`Y+C/6;@&YC6
MP<RCPK7/LQK#*>IA8U)!'L6PGS`*G]PCP"MDV*-5'O<X4--RO*'5$72"[TK?
M7BWC7&N(L&H<"Q2.HJNDC>#Y!$;\RTL#+[MA;V!&HGNS;"4YSW?V6(J#8C1L
M8U+3,6))JE9!U2E-*4TI32E-*4TI32E-*5KI@,W^E.5LPP%Z^U!LD=;TPEW\
M&N:-DT80?<J?ELIS7KZ^L9$^Y=?9\J#]M4'J:V+U\56FE*:4II2FE*:4II2F
ME*:4II2FE*__U.T3MOSGEW!V+8K98=$I3V%_?28$@UW%DS0`B1(#Y+F@CQID
M)??,9[/QN>Y&M:J>*JY%;S'\GNX^3]/<;XWG\5Q<1\[-S6C9LA'D542,N0JH
M\?U,Q7ZBQ``(TDD%=X]&];['V-O.]8F_SY"XN+C*ZB%E0EF<+Y9E?P`#X`!)
M(-["QQ-P!SD3M"'/N'.:\=QV1\NC2:"'!ASJQMA7AEBCV03"E3Y18]K52SQ3
MQB@<,HU1ST1'#1VO)_&;Y&\B[5WSD'%.:X>'!ON/`)X#`CQ:T5PDR.DDDGUH
M7C9=-B5+W7Z+UZ#N[IK9^`[7L_(.,9.3+M<TIBE$K))I<J6B961$^E@K@WN`
MP6Q^JU4N_P`3PWH+QI<7>!>.3\@Y[?@IZRURP0RFCU8!EFDC_'K705=6U8A>
M3T8]BGF'$XF[&L8W9OR.[DR>G^#P[OM4$$O(\S)6#&24,4'TEY96561F6-%L
M`&`]R2.]UN#XGIOKF'LCE,FW;A++'LV-`99FCL&/D*D:LP8*78WN5/T(]K&Q
M%V=3^R?)',F;99BN=0,=BCI,?6T"M563:Z8"='MHE<>-(2393&.8K9:^35:C
MFO8GK]J+J;XS_(#GW:_+^3<;YEA8$:8>#[R^S%)%(LBS)$R-KE<$?6;BP(*C
MSZBO?=W=1\2X!QW9-ZXWDY;MDY7MGW9$D0HT32!ETQH;_2+&Y!!]/2MM<^Y3
MX^XNC5TO/<G@8V&V,<%;\MDLY9I(K!/D^Q'@QI4A[([3L\W^'@Q7M1517)OT
M[S;LC@_7./@Y/->10X$64S+%K#LTA0`OI6-78A0RZC:PU*";L+Z.XQPOE',I
MLJ#C.S2Y<D"J9-)50@8D+=G95!:QL+W-C8>#58P[-<5Y`HH^2X;=1+^DDE.`
M4^'[K6>_&(HS@*&0,,B.83OM81C7;*B[;*BK*<5Y=QOF^S0<@XIN\6;L\C,H
MD2X&I#9E*L%96!]590;$&UB"<#?^/;UQ?<I=HW_;Y,7<44$HUKV874@J2K`_
M>I(O<>H(JE9WRCQ]QE#!-SO+*G'!2E<D0,PSRSYB#V]QT*KB#DV4Q@E5/-PA
M/:Q53=4W3>-YGV-P?KS%AS.9\FQ<".2^A9&)DDMZF.%`TL@7QJ*(P6XN1<5F
M\:X;RGF$\F/QK9)\MTMJ*`!$OZ:Y&*QH3]@9@38VO8U0N/N=>)>4Y9J_!,UK
M;RQ`$DDE8Z/95-FL83VL+(%6W<&MG'CB<]J.>P;FM\DW5-TU#<'[EZQ[(R9<
M+AG+L?,ST0N8BLL,V@$`L(LB.*1E!(NRJ0+BY\BI+E'6W..%P1Y7)>/38V(S
M!1)JCECU$7"F2%Y$#&QL"P)L;>AJC2>S'`L20>)(Y1Q<<B*8L<X_DG?X&"]P
MRL\F1W,=XO:J;HJHOW+J)R/D'TMBSS8T_8VW+/&Y5AK8V9201<*0;$>H)'W5
M(1=0=F3Q13Q<,S3$ZA@=(%P1<&Q:_I]_FLA8=R%@_(,0\W"<JH\FCQ',9,6I
MG@E&A/+Y^TV;%:Y)4-3()RL]UC/-&JK=TU[GBO.>'<XQILOB')</<8(B`_LR
M*[1DWTB1`=<>JQTZU&H`D7%>6W_BO(^+3Q8_(MDR<.5P2GNH5#@6OH;\+VN+
MZ2;7`-JHF?<R<8<7^RW.\SJ,?D2!*<$`KI$VU-';Y)\@=16`FVCXZN8K4>@?
M!SD\455]-1'-NUNN^NO:7F?+,7!GD74L9+23,OGZA!"LDQ6X(#:+$C2"3XJ1
MXQP'F/,O</&N/SY42-8N-*1AO'TF61DC#>02-5P/)%O-4;!NPG#/)%@RHP[/
MJBSMC(Y8]7)#94EC+\/+S;"A7T&KDS2,:U7*T37N1B*[;Q]=17#>\NI^?YR;
M7Q3FV+D;FP.F%UEQY7MZB./)CA>0@`DA`QT@M;3YK/Y)U;V!Q+%;.W_C$\."
MMM4BF.:-;^FMX7D5`?2[$"_CU\5@;LKFM1PMFE7S;D,A\'%\.QD<Z\>!GNSK
M:6LZ?4U^.U$=SA,E7F1+9,C!:I&C&-KS%5@1$?KV_*^5;3PSCVX<@WF4C#A'
MA5\N[MX2-`;79CX%R`!=F(4$B$XAQ/=N;<AV_CNRQ@YLY/EO"1HHN\CGS947
MR;`DFRJ"Q`,?-%W3^H3V>L;>9UJXDI:3$J\[XHIC*ZGF"`]'_(2-/S3D*RJ\
M6L+AD=J(\,8`5:PB*HD<YCEY5P^V.[^PI\J7@/&8H=L1K!M*,!]MFGR62%GM
MZJBK8'\-R#76.;U%T5USCXL787*)IMT=;E=;J3]EUQ\5'F5+^C.S7(/U6!%;
M'=<>S7<__P"=L3X2[/\`#$>E@YJ')/RO.*^BEU884R@QNYR9S7W%58W>&WL<
MXZIL5!1W@,)YF/<]_P"B[W?!.P.UO^\=LXCV%Q18H<L2Z,A8V0*T<3R_C1I(
M)`0FBRE64L"2?0^`Y_UWU)_V7N?,.N>7---AF+7CM(KEEEECA_JW6.>,@OKN
MP96"D`#U&Y68=N>M>`9+;8?F/,>&T.341V1;>GF3)"RZ^2\`I*`D>Q&,-ID"
M=JN;Y*K579=E143:FZ=F\!V7/R=KW7E.+#N$+6=&8W4D`V-@1>Q'B_CT/FM3
M[5U=V#OFWXNZ[3Q/+GVZ9;I(JC2P!(N+D&UP?-O/J/%7+QOV(X2Y>E7$/C7D
MG&LODX_`9:70ZN29?RRN(1PFS);Y((XQ`4C517;[)MZ^FI#8><\1Y1)E1;!O
M^/E20)KD"$_0I-M1N!87^VH[D'`^8<6CQ9>0\?R,6.=]$9<#ZV`OI6Q))M]E
M4'"NV'7'D;)Z_#,)YAPS(LHMG2&5=+"L'I,L"18Y99Q0DD`".29D8#R>#'*Y
MS6*J(NRZP]I[)X)ONX0;5M'*,2?<9;Z(U;ZF(!8A;@`FP)L#>P-JS=WZRY_L
M&W3[MO'%,N#;8K:Y&7Z5!(4%K$D"Y`N?%R+U=6=\[\1\997A^#YWF]9C>59]
M(%%Q&HFAL7EN#GGQZL+&'BPI$.(AK"4P372"":YR^B^B[2.\\RXSQ_<MKVC>
M=WC@W+-8"%&#7<E@@\A2JW8@`L0"?Y:C=EX7RCD6V;KO&R[/)D;;@J6G=2MH
MP%+FX+!FLH).D,;5XLY[#\+\:YSC/&F<Y]58[G.8BK38WCTN/:%E68KBUDT=
M61IHD"3"C,G6T,H!J8H_)XU^Y-]6=XYSQ/8-XV_8-XWJ.#>,H(8HF#DN'<QH
M;JI4:G4J-1%R#5[9N!\NY#LVX\AV;9)9]FQ"XEE4H`AC02.+,P8Z48,=(/@B
MK^S3.<-XYQ^9E>>9/1XCCD#Q25<Y!8QJR"PA$<HH[#22#0\N0K5001^12N]&
M-<OIJ:W;>-JV+"EW+>=PAQ<!/5Y&"+<^@N2+L?L47)/@`FH3:-FW;?\`.BVS
M9=NFRMP?TCB0NUAZFP!LH^UC90/)(%:[83WIZG<AY/%P[%.9Z&7D,^8"OKX5
ME593C8+&?)+[$6%76>34-/56$J4?9@AA.]Q'N:UJ*KFHOAMI[BZUWS<(]KVW
ME<+9SL%572:(,Q-@JO+&B,2?`"L220!ZBO>;QTQV=L.W2;MN?$IUP$0LS(\,
MI10+EG2&1W4`>264``$FP!J^.7^T/`7`LB+!Y8Y+H\4LYH!RXU*@+:]OWPRE
M>$4YU!C5=<W08!3">UAW@:)RL<B.7Q=M+\H[#X7PQXX>2\@AQLAP"([/))I)
ML&]N)7D"D@@,5"FQ\^#4-Q7KCF_-HY9N,<>FR<=&*F2Z1Q:@+E?=E:.,L`02
MH8L+CQY%6H/NQU7-@<SDL7,^,$P^OMJZBGS1Q[Q]G"N+B):3ZFNE8PVI7*02
M;.'1S2QVNA)[S(AE;O[;]HY>VNN6V:7?UY7CG:TE6-FM)K5W#LBF+1[P+K'(
M5O']01B+Z3:3;J#LI=[BX\W$LD;K)$\BJ3'H:-&1783:_9(1I(PQ$GTETO;4
M+__5ZW/J-?\`HOCC_P!T6W_B6:X*^>G_`(CP'_49O^2*ZQ^)W_D/+?[E%_S3
M6`,C\N`>;^!^5HWG&QS,,'P*VMU&TC0>T;'*[&LUC^#?+Y)FP2,G[*BI[\AJ
MHB*B;:1W[5TEV_TOV5CWCV'==GVV:>P(72V+%B9ZV%];>V5R;>?UDJD`$"MH
M;3I[/Z[[+X3-9]VP-RS8HKVO<3R9&(U_T1K!A_X$(^TUD[FP[.P/;O!>*HKV
MS\3PA\8=T@WH2(9C!CR7,"(5-V-617QX]=OLJ(<>WKOMK8?;TR]X?*'AG6N.
MXFXSLY09%C=&``R\XW]!JB6/%_@D2WF]>.Z[C/5W17).:S*8M\W$,8KBS`DG
M'Q1;U^EV>?\`X&^RU>GI\B)V>Y^1$1$1,R1$3T1$3D&-LB)]R)J_\6`!\B>[
M0!X_Z[_<TJUWP2>F^L"3Y_Z3]A:J+S;#)V3[;57%$288>-X572JJPF1GH\44
M\.$6ZR2;LJO]L[[%T>L?LB+[@&_9^EJ*[?Q)._\`Y.[;UIBY;+Q_:('AE=#=
M49(VGRI/MLQE,6(WB^J-?3UJ0Z[R$ZCZ-S>;3XZG=]QE61%86+!G$4"?9<",
M/D#^:Y_BJM]!<OGXYD_(_">0*Z-,BR9-Y!AD<NT:YI)+*'*8;=U\7&(UL5R-
M1$7QC$5=_NEOA-RG-V'D7/>HM\)CRXY&R(XR?P3X[C&S$^XL0(2``/$3GS]D
M=\G=AQMVV?B?8>U@/CNBPNX_2BF7WL9OXA^L%S]LBCQ]N),2H8_9[MSE`LY/
M+DX[`GY)-=6-DE`1^-XO.2KI*`)PJQ\2.]Q@K(<+P>]%,YKF$?YIK'C&RP?(
MGY0<BCYE/+)L4$^5(80Y4G%PY/9Q\966Q126C,I32S7E92LCZQ[G?-SEZ<Z+
MV9^-Q1INLL6.GN:0P$^0GN33D&X9A9]`:X'ZL$,BZ3)!BW67B#!LWI\^PS'Y
M.-W--$L88X\&UG'JYH[.(:$4DV)9EGD]X(3N\'!('U7\2.V37?/&_CUU;P[E
M^U<UXGLDFW[MB12H%CFD:&02HT;&1)C(=2JQTE&3S^+585R7O7<'.^2<=S^,
M<@W1,O;\AXV+/&BR(8V#@(T806)47#*W\W3<U$7PG8<'UW(&;%YV@.L<>?#L
MV4X61[R0]+K\Z`Y'-2B*$['+!:5$<1R#W7_;LNOR]ZBSNGL#F_+I>YL(S[$8
MI1`H7(8_F/S"GQ^7*L#[>L78Z?/WVKNGL3%[&R^,<>3K7)$6ZB2,RDM"H]GV
MF_\`V!4_7I-E&K^2]9VZ5TTU_-><YWB%7=UW$]77Y;':>:\FRULF<*9CM!(,
MKWBL[F+#$(Q6H]WM^UYN<BN9Y[G^)&TY;=N\RYGQ;;LN#K/'@S5#2$_U3R*^
M+C,UR)9TC".XU'3HU,PU)KUI\A=PQUZ\XWQK?LW'EYO-+C-I0#^L5"L\ZBP,
M<3.6538:M6D`Z6TT7K+@M;V9YES_`#CE,1KV)!'^?2JI\LPHTJRN9I05,$Y(
MY8\E:JIA12-$$?@S80VN_5HK'Q'QZX;M_P`A>U^;<P['C?-Q85_,O"78(\L\
MA6&-BI5_9AC1@B+I6R1JWT`HTCW!R3+Z?X!QCCG"W7&GD/LK(%!98XD!E<!@
MR^Y*[*69KGZG8?59EK7=7A7#>(I.!9QQK"=B);&RF0Y<*MES&B!:5;8MC57%
M6XAB%KI0MGH_VWM9Y,&YC6N\W.E_EQU'Q3J_(X5S'K_$.URSY#H\<3R!5FA"
M2PSPDL6B<?4&T,%NL;*JMK+1WQZ["W_G4/)N.<OR!G)%$C*\BH2T<FJ.2*2P
M`D4^"-0)L75B5T@8@^JKFUUD?7WJG+E&]L6<"=F=U&%Y,$:W'A6/&BD\&N\%
M;&_J>6C45%V]ST5/7?=?=W)=PY%U5TYNV6P$FZ84.9,H\`ROAP/Z>E@9Y+?Q
MU&_';8<':.QNU\.!+_X?,V-$Q\D1C*F4B_\`#[*7_BK<6/F&:=:NDG7^SZ]\
M.S>8+2=CG'+9F.XY77%H98V6X?+RG(<U/$Q>%/L)C9=_X(][&^"/G-<KO%J(
MNZ4W3=N`]1\)R.$<6?=,EX,75%$KN;30--+.5A5F;5):Y`M>0&]A6GGVK:.P
MNX><8_.N5IM6,F1E:997C07AG6&+'#3,JKIBO8$WM&1:YK$?6[ZBW)_+78_&
MNO\`R)PK7<?6%T[*(EFTTK(:_(L=L<>Q*ZRMH;"CO(0CL<<=,H7"(@2-]YK]
M]F^+O,<"[TY#R;GF!PK?>)QX,\WO*]S*LL310R36:.10?(320=)&H'[+'U/8
M'0G'.+\`W#G&P\ODSH(?99++$T4JRSQPW62-B/!DU`C4#I(^VXC3YNR#B;%O
MJ)<GWO.6*6V;\6P<[RC^J,7HVL?:6?RL-EPZ3XK27N-,7X612(DA^\T/ZL3O
MT_V;M!<NS>-;=WER',YAMLN7QU,R;WH8_P`;W@98[7DB_#*48_K%\*?7\)Z$
MX=@\GW+H;CF%PW<XL/DCX4/LS2?@2TZM)>T<OXH@ZC]6WEAZ?B$MG3+(.HN=
M8GS-E76+BC(^-9=72CQ_+'9.-XYEC'FUMI8UC8GMYIF4-T9A(I?/8@2H]$\F
MJU6KKICJG-ZQWC;>5;CU]QN?`DCB$<WN@AF#*[)IM/.MK@W\J;^HM:N7^VL'
MM+9MTXEMG8O)L?<(I)O=A]DW52KHCZKX\#7L1;PPMZ&]ZY\L)Q?.,4PBO[)X
M7,/&+QQRO14AI(!.<^CNG5XLDQ>T(YKE1\&7*KI$<R/1HT>@AJKO>V3B3:=N
MW?;=H@Y]M,I5L#<HXR0/ZN32)87/\TE65K^+Z1YUVKN?>-RV;<]XGZ^W>(,N
MX;9)(`3XDCU&*9!]S*&5EM<VU-XT7J2[M?RO2\X<S_3TY3HE"V)F#<-L)40)
M5,E3=#Y/I8>04A"*B*\U)=QI$5SMOQ*+R3T5%UO[LGDF)R_E?1_(\,CVLKV&
M*@WT2#+C62,G[XY`R'[[7KGKK'C.7P[B7>W&LT'W<3WU#$6UQG#D:*0#[I(R
MKC[M5O6JY]1#_P#0WJ]_(>$__O#-M9G>/[\>N_['`_W">L/H?]Q/8_\`;[A_
MM^/5K?4AOLBYJ[G\7=<4MI%9C4*=QSB4*/YJL(62\GVL!)^3$`B>)9`JVXAQ
MV^2.\&1G>.WN/\H[OG-SN6=K<>X(,EH\!'Q85'Z(ERW75*1]I"NBB][!3;\1
MO)=`86!Q#J3DG/ORJR;BZ94['](Q8:-IA!^P%T=C:URXO^$6DJ3Z:W4J-"Q<
M=/@]O0W6*V=%;Q,KK,KO"9!83*.5'F*MM^:R;.EE"M3Q]Y+6PAHU'*D?V$\?
M'?@Z#ZSCBV]<79Y8<O&DC=9DFD,C-&0WUZR\9#D?4!&+7^C1XMSV?D'VA)-N
M39>\Q3XF3'(C0O#&(E612OT:`DBE`?H)D-[#7K\WB'[.`+PEWYRCDCL/Q;+Y
M3XVR')9MU35]JI`T^2XM*IAUU(E3+(U]792<*$H`O@R/P.?$1A48U["IS%V"
MC<1[HW'?N<\=;<=AGR&D17N$EA,86/0Q^AS`-*F-O!*6:P(:NI^NG7F'2.W<
M?X)R1=MY!!CK'(R6+Q3"0O)K4?6@R#J82+YL]UN5*UN-!SOZ60>)<HY7B84]
MV-6.<8'*R#B;\OO7VPN0J:@Y&;AXEPI;S^FXXCT-]>[/;+_I\SA^+G^^-J:V
MG#O/QT7C.X\EBVD_D'S,<RX>F36,E(\KV!['N>T`8Y,CSK_+-:Q.M0*U/-LO
MR3?D^V\9EW<?XA'AY(BS=4>@XLDN+[Y_,>W[I(DCQ_&C\RH-PNAB:__6Z\/J
M$4ES<X7QZE/46=JL?*+)9"5L"7.4"%JOU2F2*(OM(3VW>/EMOXKM]BZX;^<F
MT;MNW$N##:]KR,DQ[C+J]J-Y--X?&K0IM>QM?UL;>E=2_%K<=OV_D'*3GYT,
M`?#CT^XZI>TGFVHB]KB]O2XIV6XNG9CU9XXM8-7-DY-Q[CN&3F0`1#ELG5T^
MCJJB_@MAM&LA'@(H))4\?)C8B[I]NGR!ZYS>5_'#@6Y8>VS2<AV/`P)!&J,T
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M^7V(JZ\[T>V\\*[:^1'+<WCV:<?&P]TFC4PRCWV3.]Q(HSH^II=-ETW\'5Z`
MFICM!=MY-U[TYQ[&WC&$T^3@QN1(A]I6Q=#.XU>`E[F]ON]36/.`>M?)?+KL
MPY%F<A9-Q3;R+V5#-.%16J6^02;%1W5V8CQW^,R`PDE2`._YK#%5?T5'Z^%Z
M2^/_`&#V@>4\\R^<[AQK='S71I!CS>_DO+:?(8D9.(RQZVC/Z:N]_0Q^?5=G
M]N<0X*-AXI!Q;#WO!7&5PAFC]J!8[Q0@`P9"E]*N/T2JV]0_CPW/&N>]8>Q.
M%9$V;D/(L1),'(;/*HM!:>_95UQ)G5&50IS!S+UZ6?PG'7R><CG>Z,BINNVL
M/=NO^:_';O;B._+EYV_8WN1Y4V8F--JEBG>2#,CD`?(/N^V9#=I&)UHY%S:L
MC;^7<9[CZJY#M1Q\7:9]#P1XS31VCDB5)<9T)2$>WKT>`B@:64'Q>KBS[$>3
MNK78*RY5Q3%I>1X9<6EU9121(TLM62KR(A)%EC5L>``SZ>37R3?W9Y&JUZ!$
M1ON;$&V=YKQ?L/XX=X;AV5QKCDN?Q/+R,B5"B.T)ARB6EQ)FC5C`\3M^J9@0
MP2.0:[.@B^,;[P_N?J[$X3O>])B<@QX8HV#,HD$D`"QY$0<CW5=1^L"FXU.A
MTW5CM=PUV@SCF?D2LH:_B6;C&&!K[.1DV06)K&T=%E"@O)6QX\YM?3UL)QYW
M@SP(TY3,55:UB-54Z7ZH^17,.V>=;=LN#UC-MW$T@E;+R96EF*.L9,2K((H(
MHRTFE=+"1W4DJ$`)&DN?]-\<Z^XKF;GE<XCS.0-+&N/!&(XPREP)&9-<LCZ4
MN;J452`"6N`=5>H_$L#)^3N4*SDG`%GTQL:MQ1OZGQTJ#C39&0P@*>KESXC7
MP+1L5Y/;,!S#L3=6N39=<U_&#K'"Y%V)V+MW/^$&;:7V^<)^;Q39)&RHUU0O
M(@,<P0MI>,K(HN5(K=?>?.<G9^'<.S.)<H]K<%S(BWY><79%@<Z9%1K/'J"Z
ME<%";`@U7NJL+,>'>?LQXGNZB^-B&0FO*!TPM9,?3FG4BRI=%>.DL`L1H;2H
M$46Z*U'?*8C]O!$2;^-F'RKJKNWE76>[[7FOQ?.?(QB[12&!I,?6^-D%PN@+
M-`'2XL#[R:K:;"+[KR-@Y[UAL/-]OSL9=]Q5AFTB1!*$FTK-#IU:KQRE6^VW
MMMIOJN;&QL?)G2OE[(I)\&LLKPNW#+J@3(PY3(5U2.FI+IIL.ZCPYL>#=PO;
M:AXQF.5/(C/'9PS)XW8$["^)':.^Y$W#LC<^)92O"KH'$<^.9-<$D<ZI(L>1
M'8"2)U)%W6UFCE'I-V;B'R%X+M4,7)(<+D,#+(RL5+Q3:-,J/$SHSPO<E)%(
M'A6O</'7LY'R7ECNGEV*X]C''MGBV)X_(.A)D])4F#`/8K$987-[<$A5\)JQ
M886_'B":IW)Y^'N*_9N7SWD'9GRVY1QK8N.\&R-MXS@NUY)-;QQM+H$L^3.8
MXH_H11[<"`R$:].LO9<?B>S\(^/>Q;UNN\\IAS=[RE%D32KN(]12*&(.[_4Q
M.N5B$'TZM(6YI'=W'*KE;(,?ZBT,D<>ZQ#$,"7BV5(;^H'GU97W$9,8MY`AO
M6NK,UPVTBB]_;VX]A&AD*YD?WGL[M[#ZBBY#UEL_$=B95S-GAA7$+V`9<>$0
MB)CZ*)(QZ^`'"$D*#7.?5W:S\1[$W'E&\HS;=NCRC+"W)7WI?=]U1^D8Y/4>
M24+@`L16!.$>Z_9/ISC$7A'E_KSD^4U^+?,B8LMH6[Q&\KX'RG$^$"Y7'LGJ
M,GQZ(5[FPR1V-:P3T:PY!-&Q-#<1[:Y[U9MT?$>4<'R,F'&U+#K,D,BK>^D/
M[4J2Q*;Z"H\`@!RH4#H/F/4'7W:^XR\QXKSO&QI\G2TV@1SQLVFVHQ^["\,K
M"WN!C<D$E%8L3X>GT7E/FOZA%=V//Q-E>+X=97?(607E@:NM#XYCC+CC?*<?
MK*\F3S:RJAV,PUA-CB:UC&%(YZO036-<K;/5T?(^6]W0<\?C63C[5)-DR2,5
M<Q1:\6:-%]UD168LRBP`)N3I`!M>[5DXUQ#HN?@"<GQ<G=HX<6*-0R"671EP
MRNPA5W95"JS7)(``&HDB]K\CV^7\*?4=SWF67PYF7(-!09IE,IM-#H[)D2\C
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M\C=8NS7%'(>/W&/PL]N(%;$->4LV$:'.9CRFJ;Z#'L`Q_DGH+H4>4/;=ONB:
MCO1=M:IZ)X<^^]?=@\;WS"E@BS9553)&RE6]JZ2*&`N8Y`KC[+J+UMKOSFB;
M!V+UWR;8<Z*>7"B9V$<BL&7W;/&Q4FPEC+(?MLQM4<O''$_.6,\_<2<>9+@V
M:J/CWG*AC^TS&[B35P#KFU`R\FP;-M>@#4LI*ADEAT?\=PMS-5&D<Y=%;#QO
ME^W\UXSL>X;/EZ<'>(Q;VG**??C]QE?38QG0&#7TD?6/!)._=_Y/PW<>$<HW
MW;]YP]6?LTAN98P[#\O+[:LFJXD&LH5MJ!^@^5`$BW?[$<KN>_G6:WJ,8R&U
MJ8E+PT*7:5M+93JZ*6+S3F,J2.1-BQBQ@$CQCL(1'.16,>UR[(J+K>G=6V;E
ME=U=?Y6+M\\F,L6""ZQLR@C/G)!8`@$`@FY\`@GP:T)T?NFV8G2'8>+E[C!%
ME/-GE4>1%8@X$`!"D@D$@@6'D@@>17K^ICUJY7#RQB?:?ARDM+\M3&QK^HPX
M[7DMK['<GPV>LK'\K6JC`-*G5+X8HPB/:,J17P_(JH,C?&YW_P`!Y(G)=M[&
MXMB23-&L7NB)2\D4L#7BFT`$LA4("0#H,=VLK"UKX\]A<8?C&Y]:\LS(X%E:
M7VC*P2.6&==,L.LD!7U%R`2NL266[*;W3A7U.>:N2[+"<$P[JY/7.[J]HJW(
M;1\O)+G'H5<6PC1[RTC4<:CJIU>!D-Y"^Y+LO9@(WR*\[45=2.T_(/EG(,C:
M=GVKKM_\8EFC65[RO$JE@)'$8C1E&FYN\NF.UV+@&HW=_CKQ#CV/O&];MV0G
M^"PPR/$@$4<K.%)C0R&1U8ZK+9(M4E[*$)%5WFSO?8XEEW*7#G8#J%:9EBT#
M*LC@89*6(^31YEBD.?*B8_='@9#0V,`A)]8HS_-A2"HQQU8@AO8OEF<M[DGV
MS<^1<6YMUA)E;<F3*L!M>.>%6*Q2%98V4EDLWN(QL6L%4CSA<0Z6Q]SVOC?+
M.#]J18FY/C1-D#5:2"9E#2QAHI%8!7NOMR*+A;EF#>(?0]<.7WX98<^NX6RH
M/%0.0Z=!X8Z#DWG8X[+6\M3E"5@%O$Q&EBPAU9+HC&M4T]B#(XB%1O+R\#Y0
M=JGYH>)Y(XV,Y+0:9?JB/N.2#;W/9C"B(SD`:I!I8MJMU6W/^*C=X.$#E^,>
M3-@27GU0_1*OMH`1?V_?D9C,,<$G3$2RA=-__]?M>[7<Q9-PGQQ4Y3B<:KDV
MECFE1C[DMP&DQ1PSUEW;R7($!XSW$,E,@=_-/%A7.39R-5.>ODMVIR'J'@6V
M<DXSCXTFY3[M!C'WU9T"-%D3O]*LA);V`GXA978BS`$;AZ2X%L_8G+,W9=\F
MF3"BV^6?]4P5BPDAB7R58`#W=?H;E0#X)%;'P)*S(,*8K$&LN)'DJ-%\D8IP
ML*K$=LGDC?+;?9-];\PL@Y>'B917298E>WK;4H-K_P`%ZU+DQ#'R<B`-<([+
M?[[$B_\`\5Z]9-6*:4II2FE*:4II2FE*:4II2O/+EQH$63.FG%%APXYI<N2=
M[1ACQHXW&.<Q'*C1B")BN<Y?1$3?2E0P=7/E<^]T<MY@DA>^GH3Y%EL?WV+X
MB!($[%<+KBHJJY)<6KD,*U?1/*$Y?3T362_TQA:K4T^L:J4TI32E-*4TI32E
M-*4TI32E-*4TI7__T.P7ZA_^2N,?ZHTO^$\VUQ;\ZOW2<=_]CQ_V+<*Z8^*W
M[PMY_P!&E_:<2MWZ/^"T_P#*Z_\`=`Z[!V?_`"C:_P"[1?T%KG/<?\PSO[9_
MZ1JJ:D:PZ:4II2FE*:4II2FE*:4II2H^?J!<Z!P'C=>,:2:C<NY(C%CSD`5$
M/588PB"M9!D:JN&M\]JP1(Y-B!^2J*BC35V);G4?04J\>BG#1.*^&HUU;QG1
M\JY*)%RBU&5BL/"IT`]F+U96JC7M<&OD/E/:]$>,TT@U_0U25M36^P54UNKJ
MW5*:4II2FE*:4II2FE*:4II2FE*:4K__T>P7ZA_^2N,?ZHTO^$\VUQ;\ZOW2
M<=_]CQ_V+<*Z8^*W[PMY_P!&E_:<2MWZ/^"T_P#*Z_\`=`Z[!V?_`"C:_P"[
M1?T%KG/<?\PSO[9_Z1JJ:D:PZ:4II2FE*:4II2FE*:4K$G-7,N)<&X-89IE4
MA'*-'1J.E"4;++(KE[%6-65XWKNNZ_C.796@`UQ'(NR(OTJEC84J*#KKQ9EW
M;WF>XYOY6&LK":FZ'*G!(QZ5MQ90T$:GP>I`;W&_D-1%42S$W<J@\6/522'$
M2^["-0J^M5J;E$1$1$1$1$1$1$V1$3T1$1/1$1-8U4K[I2FE*:4II2FE*:4I
MI2FE*:4II2FE*__2[!?J'_Y*XQ_JC2_X3S;7%OSJ_=)QW_V/'_8MPKICXK?O
M"WG_`$:7]IQ*W?H_X+3_`,KK_P!T#KL'9_\`*-K_`+M%_06N<]Q_S#._MG_I
M&JIJ1K#II2FE*:4II2FE*:4K6CGWM/QIP'7G#;369!FQ8ZDJL&J)(G6AGO:O
MQY%Q(1I14%6]^VYC-<5[=U"(RM5J?:(S^GI2HW\$XGYH[RYX+DWE.9,QWC&+
M(>.$4(R18:UHY+5-CN`5TE2^2$4?A(LBH1GN-57O,5GM:O%EB&D?BJOI4R^*
MXKCV$8]58IBE5$I,?I(C(5;6PF*P(`L57.<YSE<4\@Y7.(4I'.*8KG/>YSG*
MJXY))N?6J5<&J4II2FE*:4II2FE*:4II2FE*:4II2FE*_]/NJY9XDQ+F?&8V
M*9DEE^61+N!?`?52V0I;)T`4N,U$,2/)9[,B'.,$B>'EX$56N:]&N37?9O6'
M&.V>/8_&N5C(_P`.BRX\E3"XC<21AU'U%7&EDDD1A:^EB5*L`P]CPCG.^=?[
MQ-O>P&+\Y)CO"PD4NI1RK>@93=61&7S:ZBX*W!R4$(XX11PM1@0#&$3$551@
MQ-1C&HKE5RHUK43U7?6P(HHX(HX8EM$BA0/N`%@/Y!7D9)'ED>60W=B23]Y/
MDU^FKE?%4VV);!@F)1Q($^R8HU#$LY\BLAG:A&^ZQ\Z-7VI8[U%OX+[!$\MD
M5$3=44K$MAS;7XLJIR'A>>X0(>Z&N7X](RW%T7;R8YM]A*Y`T`B-^Q908KV^
MODUJ(JZ^M-_0BJ7KY6]D^O\`:A]^-S-QL%FS55EIEU+2'3R5[418MS+@245%
M&NZ>&Z)LJ^BINT-_]35:^6793K]4B]Z5S-QL5FWEM6Y=371=O)K/V%/+GGWW
M>GIX[[;K]B*J-#G]$TK!&8?4(Z^X\C@8],R7/[!5008^.4$J'&?(<[Q:-\W(
MTIMV*[T\@#/O_91=?8B<_P`%+5@ZVY=[L=BD=5<5\;3.'<0FN<-^363SU5HZ
M(]O[5N47D>`=0_HJCJ:!\ICMT0CD1=OK3&GXC<U6LC<._3[PS&IX<MYCN2<I
M9<0_SY-:?W_Z2;.>Y2%)/;.\K3*B>]^)7RU"`J*J$C.^W7RTI/A184O4A4>.
M"(`$6*`,:+&"./&C1QL"".`+&C"``1M:,01#:C6M:B-:U$1$VU:JE?MI2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2O_4[^-*4TI32E-*4TI4-?>[^+7G_>-^
M\0]9$7H*J*BYU?I4Q70O]K5?RXG^'J[6-+5#ZU*AJS2FE*:4II2FE*:4II2F
4E*:4II2FE*:4II2FE*:4II2O_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
